<SEC-DOCUMENT>0000944809-20-000033.txt : 20200731
<SEC-HEADER>0000944809-20-000033.hdr.sgml : 20200731
<ACCEPTANCE-DATETIME>20200731085241
ACCESSION NUMBER:		0000944809-20-000033
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200731
DATE AS OF CHANGE:		20200731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OPKO HEALTH, INC.
		CENTRAL INDEX KEY:			0000944809
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752402409
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33528
		FILM NUMBER:		201063807

	BUSINESS ADDRESS:	
		STREET 1:		4400 BISCAYNE BLVD.
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33137
		BUSINESS PHONE:		305-575-4181

	MAIL ADDRESS:	
		STREET 1:		4400 BISCAYNE BLVD.
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33137

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Opko Health, Inc.
		DATE OF NAME CHANGE:	20070621

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	eXegenics Inc
		DATE OF NAME CHANGE:	20040505

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXEGENICS INC
		DATE OF NAME CHANGE:	20011114
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>opk-20200630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:58648600-8b9a-4bda-ba8d-a94f5b914ae0,g:b952a604-1bee-438c-aa3f-da7449f6ab9c,d:a969b45ba09947e9a03ce421f700f5b3--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:opk="http://www.opko.com/20200630" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>opk-20200630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180L2ZyYWc6ZmI2ZjUyNjgwNjRkNGZkOTkxMjFhNTdiY2QxZDc5MzYvdGFibGU6OTc1MTYyYjYyODhiNDdlY2IwYTE3NjMwOGM1ZDE2MzYvdGFibGVyYW5nZTo5NzUxNjJiNjI4OGI0N2VjYjBhMTc2MzA4YzVkMTYzNl8yLTEtMS0xLTA_f5398f5e-36fa-4b42-abc7-400b6537d2c8">0000944809</ix:nonNumeric><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180L2ZyYWc6ZmI2ZjUyNjgwNjRkNGZkOTkxMjFhNTdiY2QxZDc5MzYvdGFibGU6OTc1MTYyYjYyODhiNDdlY2IwYTE3NjMwOGM1ZDE2MzYvdGFibGVyYW5nZTo5NzUxNjJiNjI4OGI0N2VjYjBhMTc2MzA4YzVkMTYzNl8zLTEtMS0xLTA_8fd300d5-3815-42bf-8806-b4cbb91e5cab">false</ix:nonNumeric><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180L2ZyYWc6ZmI2ZjUyNjgwNjRkNGZkOTkxMjFhNTdiY2QxZDc5MzYvdGFibGU6OTc1MTYyYjYyODhiNDdlY2IwYTE3NjMwOGM1ZDE2MzYvdGFibGVyYW5nZTo5NzUxNjJiNjI4OGI0N2VjYjBhMTc2MzA4YzVkMTYzNl80LTEtMS0xLTA_892c355d-b408-4867-b400-1c8d28efb4fb">2020</ix:nonNumeric><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180L2ZyYWc6ZmI2ZjUyNjgwNjRkNGZkOTkxMjFhNTdiY2QxZDc5MzYvdGFibGU6OTc1MTYyYjYyODhiNDdlY2IwYTE3NjMwOGM1ZDE2MzYvdGFibGVyYW5nZTo5NzUxNjJiNjI4OGI0N2VjYjBhMTc2MzA4YzVkMTYzNl81LTEtMS0xLTA_8d313225-1f10-4747-831e-bee87e7d8437">Q2</ix:nonNumeric><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180L2ZyYWc6ZmI2ZjUyNjgwNjRkNGZkOTkxMjFhNTdiY2QxZDc5MzYvdGFibGU6OTc1MTYyYjYyODhiNDdlY2IwYTE3NjMwOGM1ZDE2MzYvdGFibGVyYW5nZTo5NzUxNjJiNjI4OGI0N2VjYjBhMTc2MzA4YzVkMTYzNl82LTEtMS0xLTA_cd1b40c6-2db6-4987-b38c-c9a26e3fe59c">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ic8a18f692161417a9aeed6b519fbe23c_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfNS0wLTEtMS0xOTcx_2a78596e-2e9b-4170-8b5c-be1bf9f61bd7">us-gaap:AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="ic3ca2bc91b8f4fdfb88ca44ddd58ce7d_D20180101-20181231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNS0wLTEtMS0xOTc1_d0d7ef42-df32-41f0-99db-db4b4d4334f1">us-gaap:AccountingStandardsUpdate201807Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i8cf69adbd58647c68a8b7b7475028534_D20190201-20190228" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182Ny9mcmFnOmMyZGJmZDdkYTQ1MDRkMDdhM2I4MDEyOGU0N2E3ZTM1L3RhYmxlOmIzMzJlNDY0NGQ3YTQyMzE4ZTFjZTlkMTMwM2Y4M2JjL3RhYmxlcmFuZ2U6YjMzMmU0NjQ0ZDdhNDIzMThlMWNlOWQxMzAzZjgzYmNfMy0xLTEtMS0w_7ac067cb-0597-4b5d-95c3-d100bb116a4d">0.2367424</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic3ca2bc91b8f4fdfb88ca44ddd58ce7d_D20180101-20181231" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184Mi9mcmFnOmNlMmExOGExZGViNzRkMDE4MWJkYmU3MTgyM2RjMTkyL3RhYmxlOmQwNmZmMGNjMzJjZDRlNzA5N2EyMTQ0YjNlODdmMDQyL3RhYmxlcmFuZ2U6ZDA2ZmYwY2MzMmNkNGU3MDk3YTIxNDRiM2U4N2YwNDJfMS0xLTEtMS0w_4c9b00ee-47c4-4d5c-a1c9-da2a9efd9090">0.01</ix:nonFraction><ix:nonFraction unitRef="lawsuit" contextRef="icded229365d849a8885db0145859da11_D20180907-20180907" decimals="INF" name="opk:NumberOfDerivativeLawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184OC9mcmFnOjU1MDFiODg0OGU3MDQzNDM5MGExZmNkZjJiZTg1N2E4L3RleHRyZWdpb246NTUwMWI4ODQ4ZTcwNDM0MzkwYTFmY2RmMmJlODU3YThfMTI3_68047e18-4c2a-4abd-8547-5f1643e77d90">12</ix:nonFraction><ix:nonNumeric contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMzM2L2ZyYWc6ZmRiYWRlNzhkMDAxNGFiZTkzMWRhZDg3NzI0YmM1OTgvdGFibGU6NmFhMmM3NDkzODllNGE3MWI5MjJlYTBmODYzODI5ZjIvdGFibGVyYW5nZTo2YWEyYzc0OTM4OWU0YTcxYjkyMmVhMGY4NjM4MjlmMl8wLTMtMS0xLTE5ODc_623da3fb-fb6b-40af-a46b-7882ab84721d">us-gaap:PropertyPlantAndEquipmentNet</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="opk-20200630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic45ce08a007f4d38ae03538fab205183_I20200720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5698d6f1fc1940309b63ded417c158e4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5492a302d8ca4a85901a3a7b73505049_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia2b0d7b56e4e464a9d12b6d4962aea9f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e422d827f1b4988be46200738452fe0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717fe99763b443568a4e4ea66cbaafd2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia322ccb5ede0412f84ec2408b2552856_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i440a8d7180944369aae265f885c6d28a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e6c1f5b817d47bf874e9f6b12b917c4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ee6bb1db084cdfb8f79401b5096546_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c4c5128c354e2dade223d90ca95718_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dca3ea038b14e008a2d1981f1feded6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd98b19d90454faca4fb220c3e3f056a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7395bc7d5fc44e6cb1075481b8adb1cf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92dec2859b504d4dbeb247bd54453c0e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8173ffa4f57449388f4402918c710024_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a60d3075b9948199e8195d7f913ac6c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id895905b1a694b509baac821f4b07cc9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b81bddf69248d2a9dca49367b845fb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43dc309a84a34c9da443f4b8fb4f46d6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b6ee414e2b14aa2b7779dae646fa43d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if81665549a744db4b9e3cbd8460e29b6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5a9e0119604e449787b4ccd42bbfe0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4af5a56db0c24f5d8ef4a585500444b2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i143f61f3bd52487bbac948c8fad1648c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1df47745364a0b99f41d53769dcdec_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i936bc210908045ebb32428a797e622c9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64a03ce9a44446aba8fd3973415e1804_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e72a60ac3204f79a58324d7ac06d70b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fd219acb38f4ebd979473ebe1345577_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52609be761ba4470bb6b72bcdc9ed16e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e9d6032dccc43d39b3c75fc3e207e87_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21eeb8671f80463cbbd4d25c43812904_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3925554062df4071b663e93f01c6d247_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie00bd5bfbe0747e98efecb5d0d36c2eb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9409bbd3d79a4f199dc0914b6a6a6232_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a18f692161417a9aeed6b519fbe23c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14e0f7cf90b845618c2da998b2ec9256_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ca894201f24ceb996ca85bc139745f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cc1ebc6dac04ccbb4e43babd6ec58f5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5051d9d5fe094597bf4e37ba100c22fd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73abe1462fc54ccca6f449fcd66ad85f_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cdf44d9233e47f7b9bf249aff94b19c_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89218e50948c4507b1df814b142d514e_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib353496e520042c2b547d13887f30ff4_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i077eb15fd51d4b74985ebd93f8f78daa_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9acb0e76a853407e8a654c3be8ff1fee_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67bbc9625fd1467492f28cf2d894d765_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5715c6fc274f75937803500c320ab9_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc58805b460451388796d3179b73858_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47c7b4841e944d8c8219ea505de34c81_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6096decc24534d73b84d8382fa7cfddd_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44cab2f05311498cb261057427e71187_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7adf54fa64417e87f3555d5bf0773d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if62bbfa990154581b6b8060ab7f25983_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic97107d2cf63436bbd19e901d052161a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb67fadb72846cdba88dedab4956840_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d4687ed998d4bc89b441e1a77865855_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i280cba37fbf24b4683f965f0f7b346d8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic493611ea31741d8bb485d6a0d53db9f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f0723faaa34d11aa00d312f4c86b4e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf70df459fcd4df1abd8e73dbfafd943_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida9ba4776d674e048a8f35590863e24a_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c9c6b69f3bc46868fad995b8c409262_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ca2bc91b8f4fdfb88ca44ddd58ce7d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee436d2fd7ff45f3915d1e32dcd70904_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd4ae6fdd629444197cc9a625cdcfc9f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dfc05b578db438c821384cc836c5a4c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5497d158e29a4207b882cb978b473faa_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d185d0856f4299a62fe26f4513d5f8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>opk:employee</xbrli:measure></xbrli:unit><xbrli:unit id="test"><xbrli:measure>opk:test</xbrli:measure></xbrli:unit><xbrli:context id="id7248978ab134af9bb5051c652bb74f7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="opk:COVID19TestTypeAxis">opk:SerologyAntibodyTestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i137e26f6947848af8470ae5fd8e6bab1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="opk:COVID19TestTypeAxis">opk:DiagnosticMolecularTestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id2fe9bfd426d4e56a5b3bcbcaf3b2286_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5e57cbd6ab542d79a08167f6ec07985_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52f6774dfd1f4573beee75bf01ef821c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:DistributionToHealthcareProvidersCOVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i998e2997494745b2998bd29dda7de21f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:DistributionToHealthcareProvidersCOVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b70e317a90e423daaa6fcc619c8eb46_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:DistributionToHealthcareProvidersCOVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34113ca72899471b80fa537db298faf5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5f22aa17f4f4f80a5186830a870ac40_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a9fcdf9701e4978a7f6f9fdbae12895_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8597cb5f4cd4e56a0b43a5aaa79edf0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c925c357ef94419a653f6179d8cd427_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id483c700016445cf875194cf5a6fd62b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf9292e3f244c65ab4a6e78952c669e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i287a64693aa543c9b39361bdcfae9f34_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ecb6c47f6db44edbbe0ea91612ccfd1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ec9c63dd2d444eba263c0dabc7144b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6a40facfada4fc5a367a7dcaf4f0135_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf92eadea438478cb1b5f0aa51c40f56_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">opk:AutomobilesandAircraftMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i542ee96b497e4c8e81ce12f68616f43a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">opk:AutomobilesandAircraftMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16be18cc629345ec9ee57120942f2250_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i741090abba6940d68c835c82f65dc928_D20191231-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-31</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic59039c688094e9385f6da64420c81a7_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede87b24ecb34c16881dd3d454c04ad4_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c116f9b15604e95aba107054937c166_D20191231-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-31</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>opk:segment</xbrli:measure></xbrli:unit><xbrli:context id="i2cf990d401b84d509ca83830387dfec4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703dda2862bf49c082b5e9c7749b1af2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ae1d925ca624ccfa017da2775100740_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4825a57053b245fdb80ca8d81b3e823e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c6cd428f6b456c8d5b3acae79fbf66_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94eb82a852ec42fbb84bb7e84f189cd8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f1de219854f4356843dae3ee1cd6115_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d2610a4d4b94c94af040534c9ec37b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaca125106e0d4865a167a745ed415e38_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00247b06c5ee4f84af09a0224926e806_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a3ad80fd03a4bd898db95dcf64037d2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b9d57f64db42caaea9671412bed643_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ccef43c91b649af897f72ba0ca5d9aa_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64d57f02fcfa4a818269328b1928521f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8cd1bd900ad44d581af60988c19e099_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:ProductRegistrationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3e7a27b8c6642a990135286515905fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:ProductRegistrationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04069b5f0be245a5b667f48793383f5c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i135e6bd0ecae45b790948a4ae8040c83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i230b30ca3eb04af49f4ca4734faacd44_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i882f8261760b4d6aa3a96e6fa3284bfb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied7d8e97b2b945238ba32720ff6e8c0f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ecfd46843994ca2aa33b2267b51858d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1497918852414fb6ac3b2f71effa85a6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da706af1baa4c159c9bbb8d4c1030fd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11f6b9bd556843b1aafd7e182d59c3cb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:CovenantsNotToCompeteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8408841c1a734a08b778637e70249682_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5adb35b4c9f34a37aeb9549a65e96e46_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f61b01165e24fc98421d859fadcd8b2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i179802b429d44dda9f21192ac337df1a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18db37a30a74d9c9ee748531acedbae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ea760e341c847f4a25f3b37d6b09d32_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b56c73c8d84a5e8fb1fa551b3eddd3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i483bd6c64a9c49c2b324993790f590ee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i798edede7d9340b38166a915bb9c5868_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b2f66f652b94502a75f85a54c4c3ef4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd4a728fcd14faf998c1ab9c30b3b83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33fff5e9ff6341f0bb92ec8ca48cb6e0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd9cb4e1c5bf46f7811c43a8af57ec52_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94fa7a9bd57a4f9bb8aa3d9c5b228336_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i771f4bcba7074c7bbbdffdd2ad65b477_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f6803f62e7447adadce391b33061cba_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79658e603527497182db4f569fcc87f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i986492897965401d95c6a703c55c6e77_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93c9c6bb19df4ae99dc27947a8f03121_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4fc9634e3a348bab19da19df297d2c9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:PharmsynthezMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40c56be3936e42218c130b6171df7087_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b1d2bd1b0014409b092ff4aa9f8efb5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NonInvasiveMonitoringSystemsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1aa8cc835a1411f9161a88fefd51afb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecfe4462c2ee470cb896cbcb8858c7f9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:InCellDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5822595b03740f291e2481860949888_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:BioCardiaInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i323d8d5a5c3f438bb251f37e63e4c809_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:XeneticBiosciencesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d3ef7c1241144ff931d3374e709b07e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f4e2d31d1d5424882ae14d6cb9c371c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe9c0975275d45f6898ff7d4f683e8e3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:PhioPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09cc35711f9348d9b1b3f52011a7e368_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:VBIVaccinesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79df6dd0e9984686893d9cfc9fe6d27f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ChromaDexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if01ceaf264f64e64b9647bf4a84dac24_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:MabVaxTherapeuticsHoldingsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94995994c21b4facabf08492a51c559a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:EloxxPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84662a74a01c4b2d941452c7e6b5ee4a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90446d4596a146d88429e4a98be0564f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6747d466c09424e9a50661e16dd7503_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f02e4f9fd574e05a785e3c62f223eb4_I20200225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c119d6e22ac4137a2e112127278f9af_D20200225-20200225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-25</xbrli:startDate><xbrli:endDate>2020-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8195e9a3e7ae435da153c7711a07ccb8_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i628701cad23a4cacaed112b486d72676_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>opk:day</xbrli:measure></xbrli:unit><xbrli:context id="i3d0c8459b0d1480baa745356d20f4dc6_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0022ff1fff4fa7ba8b28cb480d9e7b_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c71fc44fe84471c8a385354d7db5b4d_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i888c9ebcddbc498c8ab5222fdd77b5af_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81c329c54b3b47abb5e4773dc4152952_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d8ef11ad99488aa65782d224ee68dd_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9c15a8bce54e078a65dfcda71e2b93_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib386889486af4a37ada3615b1c1421e7_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8a7a241ec2b494485438af91f368462_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i870ca847a91146ff97990a7c7cdd8e63_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2d51166e124a23a7ecda07a40b9b8c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c32717a26d40d88eae1ea4982913d6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a737d9667b94ccdbd7e9b723c6dcf66_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8df4da0e504a6a9b34701d6f7d3cd7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45d70386f33c4ae487d8d292158b179c_I20181108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i268d6c6d9d5e407ea296ba2214d356e1_D20190220-20190220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-20</xbrli:startDate><xbrli:endDate>2019-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac1e5f5cb1464cb9905c5e33a1c7fede_I20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41911bac43624dd190e89f282a2ee86a_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i640328d25f104a07a644f3c84408a24d_I20130130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i612e5c755b184a3585408a4ff760d866_D20130130-20130130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-30</xbrli:startDate><xbrli:endDate>2013-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4631f4b114e54a1fbc1288a82a9c2663_D20130101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d898ee3d254a1aa7701dbf13c49fa2_D20130101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d496a3b69364f4b9c89244789d4e32d_I20190201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7f7c5a48e684b00b4e6a9dad87deb6f_D20130101-20130131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e81f5b8d06047b19aa7e48cbf98af16_I20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i743fcf96590e44c695952271c01375ce_I20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fbb22c04f364ad5afd2e52f45a360e6_I20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie499e8a5b1e1470ab749b6aa2325157c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie73fdab1754844eeac2a5f34832d8a31_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a682eabf2f34c8a9917e7ba7e3c88ff_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6e118592a94347b7f4c1050e6a8489_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORThereafterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9339ecd27304a0184566aff4167b7d7_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i034c1dc338af428faed94254148230d8_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24807c0e885b473087a1ad68767cb2f9_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i047b3aa3c79c430db33cc3494843fe01_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1f11282fee4ec6b1d277f48503edb2_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i764a079c978a4ea0b66bc026841d4844_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="institution"><xbrli:measure>opk:institution</xbrli:measure></xbrli:unit><xbrli:context id="i8dbeb3eb23de47a1b6f04ae8eeb9574b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:JPMorganChaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc44f46b59e54e81a86a9fb4fb093caf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:JPMorganChaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6559fae108574d0aa1c9714fb3e24788_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ItauBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8b5e2d07aba47b7a77c8a56814325cd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ItauBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48c73acda48c4111a5af1047ccf8cc87_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BankOfChileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i779d609c655f49bd9d3e70d6c46b21fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BankOfChileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76e8733ec84b470fb842fdfb15d41f7c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BiceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10ec51989518476483634a001fbac0a7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BiceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icee7b550c55b456e9633769b30d100c7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BbvaBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia45c0ca28d4645e1bf8bb43d0dd8fabe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BbvaBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide21bf3a408f483c9f82c34a363accc8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63a721c51927453b93d7de9c83a24c60_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c7a5f9bb26d4ad3b5047c54208133b5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:EstadoBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8f740cc35344458b1021626127aa9e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:EstadoBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ae1a5c41df24314a8823e0cba821c20_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57693f69122442efb5a7d809f56b6b3c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04e2700b7f6495590aab83734460c88_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ScotiabankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c490f5f8dd9456c9a903914580ff1b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ScotiabankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0c00ea5e5ee42868078230022479853_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:Corpbanca1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac4d242acca94e6b92d84518bdbd23d7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:Corpbanca1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846f414c67b44a778a4b2f8c9669725b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BancoDeSabadellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b422715f43443c9f03f43e7a9abfff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BancoDeSabadellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id96b2ea0a8c14dadb89a084344dce841_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BilbaoVizcayaBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6906c76a48dc48c48a3dfb34cdf030b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BilbaoVizcayaBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic444558faa604456a69c0ea677b33c92_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBank2MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83f9b1ef620641e998c7c8c1895e255a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBank2MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8a9e82eefe34a719b632c3dd6b4c0bb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05425f68234a4c09943873aa2d16cc00_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95fecc4a436340768768e918eea21ff8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">opk:NotesPayableAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf8f60d813964c65a753ded4929b4ce1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">opk:NotesPayableAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbc9ba99b84443e38237727e48a82f23_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b21a3e7a57d4609b0d409b6ba20c32c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45a19ae7054d4411b573ae861b1aadf1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6281d7b057a416cab5bb28eeef12716_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cf69adbd58647c68a8b7b7475028534_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350765d31f054cb4a900a05635ea70c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idef84b903bff4b0ea60e0666075a8447_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c611772672a47c8984d0140e9dff6e2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic564593128ce4e4b84460058baeb14cf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531ede9f4ddd48268654c99511a06679_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i432215f275164d1b94ffc495a44a8c93_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ff069d8c2354606be4fd434fa345d89_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if458b89b3f2b4390bb62734646f1a224_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c6bc5e253b4fe2a84e3f5d4fb9d30e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f5503e95ced4126b68fbce3f56c2973_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i889906dfb28744f396261bd2650c45b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie329f1da30bf41b49d879864c1d2d60b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7e565fc549d442ca4eb00695a5c82db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c5e6af0a8a040aaa94190167dea56ab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i466da00a6f1e4da59279c84d5c12fe30_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76725fac2d244963b0e9b87c1b59c414_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156c35b6196a4d9cba4e041a0cb57b3b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8680556422af45dd8dfa9ce4d3edc1ba_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a53eb2f2d054cc998864517435338b1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia730eb3f2de947f1ae2828ca66e4a318_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdc50b58341940828f8595408b7a269e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e0ac6f1d4cb4c66b971c20cf8aeca20_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if667381c8f554ff082c1a91219f79181_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aca251d226f472f9def2eed58862fb1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aaa36a9c3b240c480e7a180e04210a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80bdef2e23504d6fb04d750584ece882_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9b681e985234321b995bee7faf1aa60_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee03a450fc9448c1b8e2ea08fdc41417_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c1ec4036db94ff8ab2eaaeed0d02080_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1b1f708d7d402caa5805034a48ad80_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia293f36717934081b9f1213686122a51_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f3753e96f434c02990e62a093e23382_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib875afce9dcb4394b143601b365f6f9f_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccf1d6fe84ba4e54b2f9cc386683e187_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69d3efc364ab4dcb8a44ddd5b86d234d_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie55e61c7727f4127be76e9ba93be973f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d3673e8cc554f419eeaf0ebe4a24185_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03aeaa43340c459c8da023f93e0228ea_D20191029-20191029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-29</xbrli:startDate><xbrli:endDate>2019-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dbdeb0b817643be9cbd2dfa9e9606f9_I20191029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec908835f0b2426ca21f5664f890c7b2_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3cfd08ad6df4811a785c595816354c4_D20191029-20191029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:MembersofSeniorManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-29</xbrli:startDate><xbrli:endDate>2019-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39377d350ed8459c9f4a6c8173298ce4_I20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:XeneticBiosciencesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">opk:OPKOTransactionSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9973ed8023248deb54e5d88777adf34_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">opk:SharesReceivedUponClosingofXeneticTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0f5d9e5d0c94731921acdcd9d79d299_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:ChiefTechnicalOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">opk:FederalTradeCommissionFilingFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i043083dceb38404bb2b35a4fd84c56dc_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">opk:FederalTradeCommissionFilingFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bfdb219056b42969ad222d49e930c2e_I20181108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6302ffbd2069456f9a5cc3c3c7a1e7a5_D20190220-20190220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-20</xbrli:startDate><xbrli:endDate>2019-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e3a3664d4aa4479ab2f7ff77d256120_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65bd6c4d55ac4253a96252cdeb1cebf6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ChromadexCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i651485904eaf48cf9b0d0e4ae12aa57c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NIMSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib51423d67fdf443e92d5bbdd0177b903_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1752740ed5f481c9bd06120be92363d_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8fff2811a6f4c0c9d1e13125eac0f56_D20170401-20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0bd41509ea64c85ab834813ae267e3d_D20170401-20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a7333b8434e44f483b8888bb05796ca_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04269715161949f5a492269ba0ca5d33_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69978c473ccc4f789665ee256ad80248_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesAWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c13820530324de6a22fce865f5cabb2_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesBWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i513914a206464308b0f07a3fdec68ace_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesCWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ad66425a0b64ba89a7212677580e0de_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesBWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0abeab516404b459edcdfb5578edb3c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesAWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397e015eed2e471682652c5cde1df638_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesCWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i202231196f75401e854be2d8baec5847_I20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MuseumofScienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostandMrPfennigerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c3cb92761b94bb7b621e130359abbc8_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MuseumofScienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostandMrPfennigerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i1996c6025aa74093ba775cca607f2ad3_I20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:FrostRealEstateHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>opk:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i45906ae2d8ff43e28d1650b504a4b3c5_D20181227-20181227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-27</xbrli:startDate><xbrli:endDate>2018-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4107320ea8b40a4941b1ec675d93864_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icded229365d849a8885db0145859da11_D20180907-20180907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-07</xbrli:startDate><xbrli:endDate>2018-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i287de0999fc24a5cb5546c28ae66980f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd5de3ee3106459b8b1aaab7a6b137d4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f7c56771ab4b20b7d3fa3715695ba7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e55f87c472d4233942a0970f859291b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fb7acf8a79143cfb95180991f377710_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia071dd1966f14fa29801b16850ffc8ea_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6668a10b9952410e9af8b9a573c3e502_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7313b7ad75404a70aedcc5983ef98116_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d2333fa91a41edb9d18575c207b357_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic673a0ad279b49569adc8053d136c9ed_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i357cf1c7f87349e9a4ad4f30e32145c1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2604b5fdeede46d09d8201be1e143102_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c6c923d99b4f72ba76f4043d93e5b7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafbe4baeeb164e489598f3e93202ba13_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7fba9e8f0b849fca41dd97146435305_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd71af6f0ead42e3977e6816580c5b93_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c056955493c4da89ecda0e8ec4dfeba_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i089a4e13e63742a3bf748b525008d6b6_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7a45f8733e649d5a143646e955ce1f8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbef2a22641441ef8b13514f0f8eebc1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic702ce3d60b840edaa4bec0798d18d2e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01e46e792ea463fb3ad976ee43f07a4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i387d466a792a4a228b1f3c6bc7fc4238_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id67bcee65e014a2a88bd297922d60030_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ba957ba45c4cb99119dded44d3d424_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7922e995a9b44dc296c267b40bfec5f5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0a4001228bb4c458e9d188609ce4c92_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa95a3813d3b4948b9efc4c7b0d46611_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fdb6f9b86ce4bbb9158e2c6d20fc489_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f98c06a3c1e4ad896eadb86f6436385_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2327c5e5ccd74c11bba8c2252aa98414_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6569a37c094481dbbbf19ebad7e7881_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic15d90a4230749868f5b5c698ace3ce2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e3522057538446ea1d251088ff7d6f5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fa68b3c3ee24bd292852c6f5f85587c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ac0c06819a046cfa71bf39ddbd390fc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3e2e61832ff4501874806792daa7e45_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia335908fb412465eaee57977f0412a4d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d636303815c49c8a2406f9aaa62f932_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:BioReferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b958666966849daa4cbbd1cef96fbf6_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2fe40f321844ae6bf4ae91cb7dc8144_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85584120b6ae40969ed88e8fc454cbac_D20171012-20171012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-12</xbrli:startDate><xbrli:endDate>2017-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ba1de7824543edbdd98ac438e809ef_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="opk:MilestoneAxis">opk:PhaseTwoInitiationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d78de3ebc6453598709f12f3820f35_D20171012-20171012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="opk:MilestoneAxis">opk:RegulatoryAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-12</xbrli:startDate><xbrli:endDate>2017-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie228af85f95c497a87274c2e14523168_D20171012-20171012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="opk:MilestoneAxis">opk:SalesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-12</xbrli:startDate><xbrli:endDate>2017-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eed0ec839c8449599c9e800686ae3ce_D20171012-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-12</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61fa984d891a47d58311053b2676c0d2_D20200505-20200505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-05</xbrli:startDate><xbrli:endDate>2020-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27932b492e774f8db8526aebe560cf2c_D20200505-20200505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:SalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-05</xbrli:startDate><xbrli:endDate>2020-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36465446b239476682a20c709bd20264_D20160501-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:ViforFreseniusMedicalCarePharmaLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">opk:DevelopmentandLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e8caee7a4340afab2963d15be9c425_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:ViforFreseniusMedicalCarePharmaLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">opk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aca0bd3383748acb9d44a211a37ecaf_D20160501-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:ViforFreseniusMedicalCarePharmaLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">opk:ExclusiveOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40db44cde7914640bc267bc5d3ca1d33_D20191021-20191021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-21</xbrli:startDate><xbrli:endDate>2019-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bb57ae1dccc4112800dea209c9b6318_D20150101-20150131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic54c6d599fea4f00a596b9e77dc46c21_D20150101-20150131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090a78b5b12948a8bc788af6634489b5_D20150101-20150131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4935e51954e74cb4802f926d08c79c4e_D20150101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a4105b8a0d43d798aa66064542811f_D20101201-20101231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:TesaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-12-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if83c5551238f479bbacf93c87bc5c2a9_D20101201-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:TesaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-12-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i080c53c4c6124f38aaee94f9fcbb0577_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:TesaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1c90b9bdb34bb583bd46dc1902301f_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:TesaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i284f86e01b904662b657fa1db96fa2a3_I20130331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:PhioPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic884ff99f6fc4caabe0eb0adf1366e62_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i851a20819c20437db63c3ed7b80d94a3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d2c67981041400a9c26389895519dc2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81434e108329422e88ec3e2303f45ee8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f0b42571364216bc7c04e7377e706e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba6b13bf7a9415ab5f66ca96f8d16e1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68fb7f858bc4413a97b4525dd5797a6f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafd6856e572145f7aa974629ed727822_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08298c5ab2f84fd5ae3f88f51ad3bb30_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62426df8ac264ca2861d073dca037333_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8519b57ec414786acb984d55ce68d04_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9de6620da22b4ec5be9f72a4e769a2c8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b15741ac49b49afb0e5f05f9ae67e48_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc753fb5d2a648f29daaac8bb88bc64f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b1215e9556046579114216aeac09f0a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f46c52a8ad4493da6d40440badaf26c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4e1eb15dab448d6b2ea94c22565bff4_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53552ab0d0f048c0902d204716895bdd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i285f40a66d974262a93473c2fc344b4e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba1e15ab2b34df19c53cd26a28891e9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22026731d58f47f6bd0ff0c6f70fcf10_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecdbfdd262384e3da2176a1036fa1472_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2db64897d6404c58a431674a58d3c3b4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i127c96f883e447a49aa692832a21189b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7935d8cd6d2c4a9eb100d80e225fb6b1_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77b768751f6a4284aa23055c0a54e8e7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a6eba59724c47faa438965d96def811_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb999c735a4342efba32032318fe7b05_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23194842f3d84a37bd807bed4100a22e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd9f71d8ea54fb3b4a6d84cc0903e51_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89565ed2865e40509a73fa94d9ac6df0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc09bfbf0b54937b5e5c7c9ad9f5556_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i536a503a71bf40b38d8e2df97401bda3_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief7ca9e930b14261a5d0126d1359cce0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i467d69f1593b4e59aeba2ae8185b03a5_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95137661f82444ed8ade5d61a8c2693c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78ab453f6db84127938a7075db98d34c_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaccfccfe524e46b09fdc3bb72135977e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a53a1a90634b7198030c3447c9898c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i176405a326bc43a0a55b9bc8ac1d8bf2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf8ef541025e44ee8cf8686ede2517a7_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i254cd6a34e0a4624a06cd9c4a34e9913_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e8982b6568f486980128a9f7513ec32_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63bb2b62077c41bc8668fc1ce4d89ec0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i198a3844c0c0490abcbc066a7dd24dc8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56bcff9a57b427f8621c4e8187ca9c3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e68ebe729e346baaedc4e909e8155d6_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie634e2306c8a4bebb90dffbe2e414e0e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibccc990af11146938643e532d4826cb5_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7027219b6b1045408436c1bb1b2f5a53_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0871f5c7e8b94f5781f08a92001c6cea_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0460fea90284226bde4999b97d0ed81_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4da1a32fe2164419974b9faaefa37a49_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a29626ff724abb9ad4cee99f7898d9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e418fb903dd4587b64cfae8429ade02_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if216b4c1ff0547679dcc2abcaf82d5dd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i914a917d0c624130b4baa7ce8b4d021d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66aa17bc991b4212b0639a733b595a8a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1af19639eaec49a2970b68e53aa71655_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a58a1bdfc547f5961d72ff32ddb242_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d16a24c094b4ab6964f823f0e7ca361_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15f1fa750fa04018a4f1850d6bf7a8bd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba985ea2bc4348dcabba2e4c00d34207_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f619314d9249319d7a90de7f3e4587_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc2adb4a7c142589c1a8c280a393746_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b6d1653ea794637b798906498b50d0e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da3b5d4af3d4ef9b385a90d5a8722bc_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i309155533c28422e82b808d1dc76e743_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9bcd23670e4f6185473829764ef0a9_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cfb0c9e22cd4f7eb6a00d4ace862685_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a15f6d7c0e345db8249158f70fc4ed4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c3c30dd034436bb8769e07c7ddefc9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e6d29b56e2343b0a824d97674db5c75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e4767da5b9c440090362640bac1a2e0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfcc5f95aa934dfa95991eb13af1680d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50b1c18c29b2480badccb24aa75ca3bd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:A4KscoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d3de83d9ad4ba99bcdfa4b49b82318_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:A4KscoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia969b45ba09947e9a03ce421f700f5b3_1"></div><div style="min-height:42.75pt;width:100%;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WASHINGTON, DC 20549</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:150.00pt;"><tr><td style="width:1.0pt;"></td><td style="width:148.00pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODcx_794c93cb-0831-4b1d-9264-7639c53865a7">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:150.00pt;"><tr><td style="width:1.0pt;"></td><td style="width:148.00pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.856%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.144%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6NmFiMDdjZGJiYzYzNDBkOWI1NjZhODNjN2U3YTU5ZTEvdGFibGVyYW5nZTo2YWIwN2NkYmJjNjM0MGQ5YjU2NmE4M2M3ZTdhNTllMV8wLTAtMS0xLTA_6222afff-cb77-423d-9bee-6493264c3bae">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xMzQ_0612012e-2da5-48f4-804a-dbf29f3daeaf">June 30, 2020</ix:nonNumeric>.</span></div><div style="text-align:center;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.856%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.144%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MGI1NmU3M2M4MjJiNDdhZDgzZTU3NjllMzMwZjg3MDUvdGFibGVyYW5nZTowYjU2ZTczYzgyMmI0N2FkODNlNTc2OWUzMzBmODcwNV8wLTAtMS0xLTA_bff69622-9886-437f-a39e-da41e413cfdb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</span></div><div style="text-align:center;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission file number <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODcy_3ab6961e-fe44-4d10-abae-857a17bf062e">001-33528</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:150.00pt;"><tr><td style="width:1.0pt;"></td><td style="width:148.00pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODcz_42937110-fa96-4b2b-8bdc-be2d2fb3462f">OPKO Health, Inc.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:150.00pt;"><tr><td style="width:1.0pt;"></td><td style="width:148.00pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt;"><tr><td style="width:1.0pt;"></td><td style="width:238.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:28.00pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:238.75pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MGNlZmJiYTI4NjQ1NGQxMGI2YTYwZThhYmZjOWRjNGYvdGFibGVyYW5nZTowY2VmYmJhMjg2NDU0ZDEwYjZhNjBlOGFiZmM5ZGM0Zl8wLTAtMS0xLTA_2a041ec6-e61f-4db5-8d66-2b19ffe356a8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MGNlZmJiYTI4NjQ1NGQxMGI2YTYwZThhYmZjOWRjNGYvdGFibGVyYW5nZTowY2VmYmJhMjg2NDU0ZDEwYjZhNjBlOGFiZmM5ZGM0Zl8wLTItMS0xLTA_cbc5acde-45df-486e-93ac-c51008df9355">75-2402409</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:228.75pt;"><tr><td style="width:1.0pt;"></td><td style="width:100.00pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:22.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:100.00pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV8wLTAtMS0xLTA_3d217c5c-e6d7-4ee2-b00d-efb5f67015a2">4400 Biscayne Blvd.</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV8xLTAtMS0xLTA_e0d8856a-3aa1-4a9d-a6e2-a51284398450">Miami</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV8xLTEtMS0xLTA_17785b8b-1f65-4b12-ac2c-ac4ea7a28639">FL</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV8xLTItMS0xLTA_3d25f682-7f33-485e-832d-c67fa2317887">33137</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of Principal Executive Offices) (Zip Code)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV80LTAtMS0xLTA_e7a933b0-b2d6-40f5-a3a3-ee1529c847e5">(305)</ix:nonNumeric>&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV80LTEtMS0xLTA_28654c9b-f6ad-45f8-bc59-c5f893b1b69a">575-4100</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Registrant&#8217;s Telephone Number, Including Area Code)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;margin-top:9pt;margin-bottom:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:31.235%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.382%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.383%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6OWY3OTVjZDU4NjBhNDA3YThiZGIwZDIyOTNkZTRkZDMvdGFibGVyYW5nZTo5Zjc5NWNkNTg2MGE0MDdhOGJkYjBkMjI5M2RlNGRkM18xLTAtMS0xLTA_369c362f-2442-49bb-9820-ff9f1cb16f71">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6OWY3OTVjZDU4NjBhNDA3YThiZGIwZDIyOTNkZTRkZDMvdGFibGVyYW5nZTo5Zjc5NWNkNTg2MGE0MDdhOGJkYjBkMjI5M2RlNGRkM18xLTEtMS0xLTA_a1b5871f-da33-47c6-b8f0-aa0d9b022178">OPK</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6OWY3OTVjZDU4NjBhNDA3YThiZGIwZDIyOTNkZTRkZDMvdGFibGVyYW5nZTo5Zjc5NWNkNTg2MGE0MDdhOGJkYjBkMjI5M2RlNGRkM18xLTItMS0xLTA_ba7bcf67-278e-46f4-89b0-d7dac2015c67">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;margin-top:9pt;"><span><br/></span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#253;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;<ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODc0_7bd67c5b-60a0-4a67-88b5-0ff0400c513a">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#168;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;NO</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#253;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;<ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODY5_2291d305-98b4-4ef6-8d7c-59e70ae68656">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#168;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;NO</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:18.321%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:49.315%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.415%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.949%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6NTYxYTcxOGQ2MzIyNDkzYmIwN2M5MTc3Y2FhNGEyOWUvdGFibGVyYW5nZTo1NjFhNzE4ZDYzMjI0OTNiYjA3YzkxNzdjYWE0YTI5ZV8wLTAtMS0xLTA_36ae4f0c-a8b2-494d-9943-b611e6afcf10">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">x</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#168; </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6NTYxYTcxOGQ2MzIyNDkzYmIwN2M5MTc3Y2FhNGEyOWUvdGFibGVyYW5nZTo1NjFhNzE4ZDYzMjI0OTNiYjA3YzkxNzdjYWE0YTI5ZV8xLTMtMS0xLTA_15b6894a-a31e-4f2e-ba2e-852f9191804f">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6NTYxYTcxOGQ2MzIyNDkzYmIwN2M5MTc3Y2FhNGEyOWUvdGFibGVyYW5nZTo1NjFhNzE4ZDYzMjI0OTNiYjA3YzkxNzdjYWE0YTI5ZV8yLTMtMS0xLTA_83d92366-1d55-4c22-b38b-3aba32dfc410">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#168;</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act):&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODcw_890f99a2-622b-4ba4-818f-3c6e822aff3c">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;YES&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#253;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;NO</span></div><div style="text-align:center;margin-top:9pt;"><span><br/></span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of July&#160;20, 2020, the registrant had <ix:nonFraction unitRef="shares" contextRef="ic45ce08a007f4d38ae03538fab205183_I20200720" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODMy_865f64ba-a689-4a2c-95aa-795c8760144b">669,831,024</ix:nonFraction> shares of Common Stock outstanding.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.641%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:62.860%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.762%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-45pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_16">Item&#160;1.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_16">Financial Statements</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:29.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_19">Condensed Consolidated Balance Sheets as of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_19">June</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_19"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_19">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_19">, 2020 and December 31, 2019 (unaudited)</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_19">7</a></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:47.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_25">Condensed Consolidated Statements of Operations for the three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_25">and s</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_25">i</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_25">x </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_25">months ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_25">June</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_25"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_25">30</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_25">, 2020 and 2019 (unaudited)</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_25">8</a></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:47.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_28">Condensed Consolidated Statements of Comprehensive </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_28">Income (</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_28">Loss</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_28">)</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_28"> for the three and six months ended June 30, 2020 and 2019 (unaudited)</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_28">9</a></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:47.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_31">Condensed Consolidated Statements of Equity for the three and six months ended June 30, 2020 and 2019 (unaudited)</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_31">10</a></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:47.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_34">Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2020 and 2019 (unaudited)</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_34">12</a></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:47.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_37">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_37">14</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-45pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_109">Item&#160;2.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_109">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_109">45</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-45pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_127">Item&#160;3.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_127">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_127">63</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-45pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_130">Item&#160;4.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_130">Controls and Procedures</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_130">64</a></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_133">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-45pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_136">Item&#160;1.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_136">Legal Proceedings</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_136">65</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-45pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_139">Item&#160;1A.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_139">Risk Factors</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_139">66</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-45pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_142">Item&#160;2.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_142">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_142">66</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-45pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_145">Item&#160;3.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_145">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_145">66</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-45pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_148">Item&#160;4.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_148">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_148">67</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_151">Item&#160;5.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_151">Other Information</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_151">67</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_154">Item&#160;6.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_154">Exhibits</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_154">67</a></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_157">Signatures</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_157">68</a></span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements,&#8221; as that term is defined under the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;), Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).  Forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects, including the potential impact of the COVID-19 pandemic on our businesses, operating results, cash flows and/or financial condition.  You can identify forward-looking statements by the fact that these statements do not relate strictly to historical or current matters.  Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.  Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.  Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements.  These factors include those described below and in &#8220;Item 1A-Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2019 and this Quarterly Report on Form 10-Q, and described from time to time in our other filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;).  We do not undertake any obligation to update forward-looking statements, except to the extent required by applicable law.  We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.  These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance.</span></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risks and uncertainties, the occurrence of which could adversely affect our business, include the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our business may be materially adversely affected by the recent coronavirus (COVID-19) outbreak;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we have a history of losses and may not generate sustained positive cash flow sufficient to fund our operations and research and development programs; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our need for, and ability to obtain, additional financing when needed on favorable terms, or at all;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">adverse results in material litigation matters or governmental inquiries, including, without limitation, pending class action and derivative lawsuits which followed the now settled lawsuit against the Company and its Chairman and Chief Executive Officer by the SEC;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the risks inherent in developing, obtaining regulatory approvals for and commercializing new, commercially viable and competitive products and treatments; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our research and development activities may not result in commercially viable products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success of our relationship with Pfizer in connection with the development of hGH-CTP (Somatrogon); </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">that we may fail to obtain regulatory approval for hGH-CTP or successfully commercialize </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and hGH-CTP;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">that we may not generate profits or cash flow from our laboratory operations or substantial revenue from </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and our other pharmaceutical and diagnostic products; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to build a successful pharmaceutical sales and marketing infrastructure;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability and our distribution and marketing partners&#8217; ability to comply with regulatory requirements regarding the sales, marketing and manufacturing of our products and product candidates and the operation of our laboratories; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the performance of our third-party distribution partners, licensees and manufacturers over which we have limited control;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our success is dependent on the involvement and continued efforts of our Chairman and Chief Executive Officer; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">integration challenges for acquired businesses;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">availability of insurance coverage with respect to material litigation matters; </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in regulation and policies in the United States (&#8220;U.S.&#8221;) and other countries, including increasing downward pressure on healthcare reimbursement;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to manage our growth and our expanded operations;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">increased competition, including price competition;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changing relationships with payors, including the various state and multi-state Blues programs, suppliers and strategic partners; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">efforts by third-party payors to reduce utilization and reimbursement for clinical testing services;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to maintain reimbursement coverage for our products and services, including the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> test; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to timely or accurately bill and collect for our services;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the information technology systems that we rely on may be subject to unauthorized tampering, cyberattack or other data security or privacy incidents that could impact our billing processes or disrupt our operations;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to obtain and retain new clients and business partners, or a reduction in tests ordered or specimens submitted by existing clients;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to establish, and perform to, appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to maintain the security of patient-related information;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain and maintain intellectual property protection for our products; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to defend our intellectual property rights with respect to our products; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to operate our business without infringing the intellectual property rights of others; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to attract and retain key scientific and management personnel; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the risk that the carrying value of certain assets may exceed the fair value of the assets causing us to impair goodwill or other intangible assets;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to obtain and maintain regulatory approval outside the U.S.; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">legal, economic, political, regulatory, currency exchange, and other risks associated with international operations. </span></div><div style="padding-left:54pt;margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I. FINANCIAL INFORMATION</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to the &#8220;Company&#8221;, &#8220;OPKO&#8221;, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;ours&#8221;, and &#8220;us&#8221; refer to OPKO Health, Inc., a Delaware corporation, including our consolidated subsidiaries.</span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_16"></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Item 1. Financial Statements</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OPKO Health, Inc. and Subsidiaries</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(In thousands, except share and per share data)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:65.935%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.666%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.667%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMy0xLTEtMS0w_6bfccb24-d879-4074-b895-4b6555365970">21,612</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMy0zLTEtMS0w_e436bca4-f2f7-440d-bc31-945f543d9a61">85,452</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNS0xLTEtMS0w_f3507350-b74b-4d2f-b830-fd4ea7942bad">214,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNS0zLTEtMS0w_57de302c-ef6d-4cc8-92d1-a4c49bfd1290">134,617</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNi0xLTEtMS0w_5377de72-c5a4-475c-87d0-82a2b879be0a">72,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNi0zLTEtMS0w_57131b63-0d75-4e4e-be1d-4817e07852e4">53,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets and prepaid expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNy0xLTEtMS0w_c3007a7a-236c-49ad-bfc6-e0d3bb08c484">51,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNy0zLTEtMS0w_9a85a18c-bdfa-4953-8436-e65feada7886">50,542</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfOC0xLTEtMS0w_7438ffa1-3a79-462e-bf4a-8597dd1e0c93">360,054</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfOC0zLTEtMS0w_a43e5966-6750-4a32-9696-023704aae313">324,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, plant and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfOS0xLTEtMS0w_03cf8f50-694c-42a6-89a3-3cc0f6e15dae">130,540</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfOS0zLTEtMS0w_30ba4a39-6db0-4514-b84e-ca36994fbfe6">127,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTAtMS0xLTEtMA_a6d05044-024b-47a5-965f-e6258ed192da">499,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTAtMy0xLTEtMA_d33f01a5-17aa-4263-877d-9e34851cb697">528,962</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In-process research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:InProcessResearchandDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTEtMS0xLTEtMA_f2e7e847-0cbc-4dca-b66a-63812cde1191">590,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="opk:InProcessResearchandDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTEtMy0xLTEtMA_a7b3db14-7302-4319-a593-c2950026ac25">590,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTItMS0xLTEtMA_31f6efbf-9d09-4661-ac78-bf70e93e2eec">671,599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTItMy0xLTEtMA_2336b767-9933-4c73-b1ac-2cf7f0bb65ca">671,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTMtMS0xLTEtMA_32039d9e-d5fc-4f59-a4a6-4cc569dc8ce4">26,260</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTMtMy0xLTEtMA_d2e5c8c6-4f63-439c-85ac-d893f3f65f59">20,746</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTQtMS0xLTEtMA_9f988151-4755-49f1-9ecc-430cc72e73c0">38,469</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTQtMy0xLTEtMA_68706dd1-6318-4ab3-b3c9-8812280bc994">39,380</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTUtMS0xLTEtMA_946b4b6d-a100-4f3a-ac4e-d7268d99c851">7,487</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTUtMy0xLTEtMA_019943fd-562b-4f08-9923-bd6a028930f9">6,888</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTYtMS0xLTEtMA_775861b8-3587-43e4-998f-4181dbb60816">2,323,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTYtMy0xLTEtMA_00ff467f-cc99-49e6-b396-e4833be3b3f0">2,309,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTktMS0xLTEtMA_460ffa72-0d98-49da-b3db-527b7b715509">44,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTktMy0xLTEtMA_1e9671aa-ff7e-49d1-8fbe-dbc21d82b56d">62,537</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjAtMS0xLTEtMA_539a3b26-11f8-407a-9123-8fd233113020">210,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjAtMy0xLTEtMA_1b5c42a3-b057-40dd-a458-749fab1c117b">164,925</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current maturities of operating leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjEtMS0xLTEtMA_2dc8f983-6711-4e8d-92b9-6f50730eb54a">10,298</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjEtMy0xLTEtMA_a3a5b900-548d-49e8-821f-6be3d600a301">12,038</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of lines of credit and notes payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LinesOfCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjMtMS0xLTEtMA_761d3200-8443-4475-bfd4-79bd8b1ffeaa">14,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LinesOfCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjMtMy0xLTEtMA_8efe2425-6fdd-4e45-8bcb-67f77cf81614">9,619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjQtMS0xLTEtMA_8a3c9624-c336-4ac6-b7bc-3235cfa63fed">279,543</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjQtMy0xLTEtMA_e93c653e-775e-4719-b50e-f7b044c2ba58">249,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjUtMS0xLTEtMA_f545a34c-1115-4e65-a192-0fb57fa4d6c3">28,759</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjUtMy0xLTEtMA_4a616054-02f9-496b-bc83-8f66fad5e73b">27,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjYtMS0xLTEtMA_e5942124-afea-44b0-9352-3bcdf7500ca4">216,457</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjYtMy0xLTEtMA_34c7ef95-6db6-487d-a988-02788ab85420">211,208</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjctMS0xLTEtMA_fccadba5-3e86-448c-8852-002cdc69c85d">118,979</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjctMy0xLTEtMA_8834df18-78f2-400c-8b5c-fbcbc8372646">118,717</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjgtMS0xLTEtMA_83299a99-5e44-4a47-b9f4-231865fc9ff3">91,653</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjgtMy0xLTEtMA_a2c42889-c01e-4788-83cb-13e9ab9c5e98">87,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjktMS0xLTEtMA_80d5c2d9-f3ce-4997-a8c5-296c1337e5ff">455,848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjktMy0xLTEtMA_7ceb7e90-1343-4f06-9d2d-411b9c18d9aa">445,394</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzAtMS0xLTEtMA_4a179842-4c2f-4a48-b7b3-1b1c48bd9b70">735,391</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzAtMy0xLTEtMA_9e3176c5-68fb-40f5-a018-9c2255815927">694,513</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Common Stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3MTk_43ef1d72-023e-4503-a6db-827aee7abe97"><ix:nonFraction unitRef="usdPerShare" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3MTk_b9f1ee86-488a-460c-8d47-2dfa75621994">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3MzU_400c70a8-f0e1-49b3-9335-7829ef9f6751"><ix:nonFraction unitRef="shares" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3MzU_fb20e6fa-5cca-4820-b63b-4f76df010ed3">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3NDg_b084ee6a-a238-497a-a0f1-06309753e965">670,378,701</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3NjE_14d24c0a-d31b-461b-a3cf-e36b9bc7f19f">670,378,701</ix:nonFraction> shares issued at June 30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMS0xLTEtMA_822bf45a-3489-40f5-87cb-c2418e9b1b6a">6,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMy0xLTEtMA_20d4b527-09ab-465b-bbf5-9befcaf4c1ec">6,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Treasury Stock - <ix:nonFraction unitRef="shares" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmRjZWJhOWFkM2RiYTQ3MTJhZmFmYzljMzkxMTFlYTlhXzIxOTkwMjMyNTU2NDc_5e21263a-46a5-42fd-b686-75791a05d5ee"><ix:nonFraction unitRef="shares" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmRjZWJhOWFkM2RiYTQ3MTJhZmFmYzljMzkxMTFlYTlhXzIxOTkwMjMyNTU2NDc_e0d63b81-2235-44d8-9126-afa011c4ade5">549,907</ix:nonFraction></ix:nonFraction> shares at June 30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzctMS0xLTEtMA_6c7f592e-e4e6-42ff-9f4c-89ed81a83a62">1,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzctMy0xLTEtMA_fe1c207a-2ad0-412c-b6cd-0fd414a21f67">1,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzgtMS0xLTEtMA_9b49ad17-0133-4a9b-b2a5-43890d4527c5">3,147,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzgtMy0xLTEtMA_b0569b22-e4f9-4fa7-92b0-8bbe2e91dbf2">3,142,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzktMS0xLTEtMA_04c0853f-89d5-4bc6-addb-25b32e618152">25,752</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzktMy0xLTEtMA_71f808b0-e325-4378-870c-04e056ac2da1">22,070</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDAtMS0xLTEtMA_4132b7c4-2043-45dc-991f-ca04999340d3">1,537,848</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDAtMy0xLTEtMA_e74ae5b5-79cc-4c99-99b2-301d352d38db">1,511,077</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total shareholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDMtMS0xLTEtMA_68eaa09e-12e6-40f8-adb2-d6dec1dacdbc">1,588,343</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDMtMy0xLTEtMA_a58e5357-954e-4e78-9151-785d2b2e8ac8">1,614,759</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDQtMS0xLTEtMA_17f6c183-e828-4189-a3ff-569e39d3d093">2,323,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDQtMy0xLTEtMA_6feb6927-6cc6-45dc-bb76-1c01f5d6c832">2,309,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="padding-left:13.5pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OPKO Health, Inc. and Subsidiaries</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(In thousands, except share and per share data)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:49.023%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.702%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia2b0d7b56e4e464a9d12b6d4962aea9f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMy0xLTEtMS0w_5cee1a8b-3aca-4bef-9a3c-f2bef9f4f3b7">250,971</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e422d827f1b4988be46200738452fe0_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMy0zLTEtMS0w_ba369b00-036b-4bcc-aed5-e5ac5720b67a">178,458</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i717fe99763b443568a4e4ea66cbaafd2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMy01LTEtMS0w_792b3c7b-86a8-44c3-b329-439c6a94919c">421,811</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia322ccb5ede0412f84ec2408b2552856_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMy03LTEtMS0w_aa027de1-4379-4441-9663-d34e2ff463ad">357,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i440a8d7180944369aae265f885c6d28a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNC0xLTEtMS0w_c9f0989e-df43-4ba2-af26-17d1fe2eaa5b">29,356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e6c1f5b817d47bf874e9f6b12b917c4_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNC0zLTEtMS0w_1f101bfa-4c4a-47ef-a3ad-7590c09e5b8e">28,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3ee6bb1db084cdfb8f79401b5096546_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNC01LTEtMS0w_1b042f1c-ea07-4430-a287-e2a50c41a896">60,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c4c5128c354e2dade223d90ca95718_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNC03LTEtMS0w_54359ca6-e3ca-48cf-8a83-34d57aef0e3f">53,981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from transfer of intellectual property and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3dca3ea038b14e008a2d1981f1feded6_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNS0xLTEtMS0w_63a3abfe-e947-479b-a062-dd6841bd42cc">20,880</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd98b19d90454faca4fb220c3e3f056a_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNS0zLTEtMS0w_ae0c2e27-c321-4078-96d8-82f0e49ca441">19,230</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7395bc7d5fc44e6cb1075481b8adb1cf_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNS01LTEtMS0w_ca20f210-eab3-4fa8-9d39-7cecc4e0cc3c">30,433</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92dec2859b504d4dbeb247bd54453c0e_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNS03LTEtMS0w_df74d2ae-1eec-4c6c-be76-0bc8073f4fc4">37,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNi0xLTEtMS0w_9fe6d97e-c27d-4d76-818e-d41e56e80bce">301,207</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNi0zLTEtMS0w_14ec141f-a9b8-4104-9801-343cd3627be7">226,368</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNi01LTEtMS0w_744d9b48-6570-4484-8bca-1d09c68240cf">512,674</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNi03LTEtMS0w_2a636e80-8fcb-4a25-b46c-5952727e4c11">448,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia2b0d7b56e4e464a9d12b6d4962aea9f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOC0xLTEtMS0w_ee6c7c43-1b15-4ec8-a24e-cf4dfb628525">144,794</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e422d827f1b4988be46200738452fe0_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOC0zLTEtMS0w_9a0bf0b0-cad1-4e3c-848b-62684138f6b6">130,078</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i717fe99763b443568a4e4ea66cbaafd2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOC01LTEtMS0w_8942a1f6-e63e-41f0-a7ad-605c631a102d">267,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia322ccb5ede0412f84ec2408b2552856_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOC03LTEtMS0w_5614ad4f-ba40-4d59-a139-885c23148444">259,981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of product revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i440a8d7180944369aae265f885c6d28a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOS0xLTEtMS0w_c21a1ea5-b1c5-46a1-8625-bd9fcacc3fa5">17,857</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e6c1f5b817d47bf874e9f6b12b917c4_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOS0zLTEtMS0w_8464bf57-55a8-4803-b960-89a29d4690fa">14,145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3ee6bb1db084cdfb8f79401b5096546_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOS01LTEtMS0w_6ba3c255-9e12-42a7-9e51-86cfd322c82f">35,229</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c4c5128c354e2dade223d90ca95718_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOS03LTEtMS0w_ea24ed7d-595d-4672-a8ce-7ef1fceca0e0">28,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTEtMS0xLTEtMA_516ae421-619d-418e-9f72-feffe21a3730">77,721</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTEtMy0xLTEtMA_2251ff68-fe02-4165-a082-1aa3fdb2f49c">88,475</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTEtNS0xLTEtMA_80622c4f-f1f5-4859-8b96-8eb3e379feda">153,852</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTEtNy0xLTEtMA_ea81ea53-dd3f-472e-8bf0-4f8bf0f6ff65">183,633</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTItMS0xLTEtMA_d75bd3ef-f16e-4012-b9e7-f81e632abc59">17,608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTItMy0xLTEtMA_339a31fb-9510-4186-ba0d-f24c368a8a47">28,286</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTItNS0xLTEtMA_9d3d54cb-651a-4346-9be0-f05ff6bc6c25">39,369</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTItNy0xLTEtMA_fa68c3e0-c837-4d34-9783-312a0155bca2">64,816</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTQtMS0xLTEtMA_058af295-8fc3-4228-a1f6-a76780194260">1,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTQtMy0xLTEtMA_f561ceeb-ed9b-4a2c-8b01-99428e675c6b">3,775</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTQtNS0xLTEtMA_c587e228-f8c9-452b-987d-35bb26568120">251</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTQtNy0xLTEtMA_e384fd93-5172-48f1-ba7c-42d718ed0f80">1,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTUtMS0xLTEtMA_7bb10a31-0abb-4e6f-ade2-1204006f7234">14,937</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTUtMy0xLTEtMA_9d20767a-d982-4543-90fa-0149bdf2e2cc">16,419</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTUtNS0xLTEtMA_d618217f-95ec-4d71-8b9d-932ca31d60c8">29,874</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTUtNy0xLTEtMA_fb422219-f02b-47a8-a2bc-ff1834cd6218">32,981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset impairment charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTYtMS0xLTEtMA_f6943955-16ce-4fc0-98f3-5d3630680e7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTYtMy0xLTEtMA_70804a7a-8c26-403c-8d16-e90408691822">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTYtNS0xLTEtMA_91d33715-c8ea-41bc-8e73-d6e2ba1786cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTYtNy0xLTEtMA_656e62d3-4023-4c72-9789-dd78393f33c3">655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTctMS0xLTEtMA_824e228b-0465-4cff-b73f-d747be42550b">274,028</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTctMy0xLTEtMA_f6317fbc-f9d6-433a-abc1-1a6d565ab216">273,628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTctNS0xLTEtMA_de2c18bc-364e-42aa-b4ba-a45c0b1a937b">526,255</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTctNy0xLTEtMA_d5f56c35-b71d-47f8-8389-747186bb2c44">571,397</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTgtMS0xLTEtMA_e1aa3c25-8794-4374-96ba-686a5eb1acd2">27,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTgtMy0xLTEtMA_5452eded-23c9-4ad9-881c-bf2c5496431f">47,260</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTgtNS0xLTEtMA_90516898-4da8-4d4a-83b9-3bb9e7be9a05">13,581</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTgtNy0xLTEtMA_7d633e88-87a6-4861-868a-1ed1cbfa113c">122,577</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income and (expense), net:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" name="opk:InterestIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjAtMS0xLTEtMA_f200c7ee-ef81-4969-a809-d649c6629bb7">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" name="opk:InterestIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjAtMy0xLTEtMA_0804351e-e212-410e-85b3-be9e83cfb1d9">572</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" name="opk:InterestIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjAtNS0xLTEtMA_b1d474de-fdaf-4857-8841-54ab3441d5d4">147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="opk:InterestIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjAtNy0xLTEtMA_1e7448cb-6f0e-44a8-9946-9376eb63e589">1,127</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:InterestExpenseNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjEtMS0xLTEtMA_a729a27e-4ea8-4352-9f41-28e6fa557a42">5,474</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="opk:InterestExpenseNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjEtMy0xLTEtMA_f65f61d2-95bc-4012-82c4-9f6e37e12d8a">5,501</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:InterestExpenseNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjEtNS0xLTEtMA_29833e97-8969-4b66-b886-230458b868d1">10,970</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="opk:InterestExpenseNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjEtNy0xLTEtMA_7f1c8182-5a62-41f2-942a-c185d3d56c77">10,257</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value changes of derivative instruments, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjItMS0xLTEtMA_cb51c65b-0f39-44b7-bcff-1c10f8385e48">13</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjItMy0xLTEtMA_0771eed3-798c-4c12-aa6d-6551f419e9b6">388</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjItNS0xLTEtMA_c53ca282-f3c8-4532-bb99-d3904a59f701">608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjItNy0xLTEtMA_6f414b2d-e602-49c1-8773-05cd52f3c6cf">27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjMtMS0xLTEtMA_3bf3fab7-666d-4073-ade5-8b1905c80236">18,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjMtMy0xLTEtMA_b7e7ec19-9194-4976-8dfc-50b7cbd1785f">5,874</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjMtNS0xLTEtMA_1bdaa63c-0678-4398-904b-72f909072c3e">5,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjMtNy0xLTEtMA_893cb547-d3c1-470f-996c-80c1b68934aa">4,897</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income and (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjQtMS0xLTEtMA_f89d2cf3-34a6-48b8-8175-ce2d4535e309">12,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjQtMy0xLTEtMA_39e4d445-fc1e-4f3f-a1a0-63f6d617e2be">11,191</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjQtNS0xLTEtMA_cec3dd1e-fd9f-4fe1-8b2c-983e1b63cb2e">4,325</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjQtNy0xLTEtMA_79b85590-02ca-4664-8d9b-7d0eb2f8009b">14,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes and investment losses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjUtMS0xLTEtMA_06f403b0-adb3-410b-8190-05e20f896ba7">39,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjUtMy0xLTEtMA_59f452ef-cfcc-4da3-9726-56f90cbd23b6">58,451</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjUtNS0xLTEtMA_aeae1bce-9eef-42d0-8e96-2bff89162f3d">17,906</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjUtNy0xLTEtMA_104b7730-88e7-4a06-85f1-ebff0082aae1">136,577</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax provision</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjYtMS0xLTEtMA_96e37877-8815-4a29-943f-23742e5f1691">6,028</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjYtMy0xLTEtMA_b2209e94-508b-40db-95cf-07e39073461e">1,084</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjYtNS0xLTEtMA_c957074b-7331-4bc6-9097-55406c327092">7,200</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjYtNy0xLTEtMA_ea50c39e-3402-4e86-8f1a-3ad1ab52c02c">1,866</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) before investment losses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjctMS0xLTEtMA_aade9bd3-2819-439c-bb30-cb94d9a17159">33,892</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjctMy0xLTEtMA_9f0aca5c-7850-43a6-a9c6-a436bd1eba70">59,535</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjctNS0xLTEtMA_b992ecca-3cac-47f9-a53d-89ec9ee71f04">25,106</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjctNy0xLTEtMA_362eb43a-a8e6-4d07-b85d-153d86f6b63c">138,443</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from investments in investees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjgtMS0xLTEtMA_020cfc87-9f1d-4398-b335-790c20f6678f">189</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjgtMy0xLTEtMA_e8bedaea-ee95-40b9-83be-e03a14ce87e2">271</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjgtNS0xLTEtMA_b7ce60e2-4cc9-441c-bc77-91f1f7c95ff4">323</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjgtNy0xLTEtMA_a3b1b46e-7999-4419-ba13-862a0c3c7403">2,125</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjktMS0xLTEtMA_a7258ebd-9691-43a3-a94a-911f98f7d82f">33,703</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjktMy0xLTEtMA_71211027-62eb-4849-bd81-3870079b69f7">59,806</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjktNS0xLTEtMA_daac8ccd-f771-4cce-991c-18cbd6376121">25,429</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjktNy0xLTEtMA_9e1a32b4-af6f-452c-8a83-9a68857753f3">140,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) per share, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMzktMS0xLTEtMA_242e6bd8-2277-4db1-bc07-97a8a1fb17bd">0.05</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMzktMy0xLTEtMA_c2f85fe3-f401-4943-b9d0-5259710f5638">0.10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMzktNS0xLTEtMA_5671ee78-0513-4609-ab63-e9c464bd20f4">0.04</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMzktNy0xLTEtMA_baa621af-a327-41a4-861b-134e7a78aae1">0.24</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNDEtMS0xLTEtMA_9a3e7171-04ed-4203-9272-7e772acf6b6f">640,578,794</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNDEtMy0xLTEtMA_3e778f66-b0f0-4cae-914c-c7a7c748262a">586,351,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNDEtNS0xLTEtMA_aedf7632-d2de-496e-8f97-3f0873399c22">640,578,794</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNDEtNy0xLTEtMA_bd158ef7-5f9f-4f73-a658-ccb68433c737">586,347,645</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OPKO Health, Inc. and Subsidiaries</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(In thousands)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:49.023%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.702%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfMi0xLTEtMS0w_32672c85-5769-4793-86ea-611eaade2689">33,703</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfMi0zLTEtMS0w_f7c96cf6-a525-4fc0-a7fe-0dce9704bf9c">59,806</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfMi01LTEtMS0w_2b72c4e1-33e1-49b5-87a5-ff8a129b5be9">25,429</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfMi03LTEtMS0w_4f9e12f6-b6a1-460d-be10-01bae0d05e65">140,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in foreign currency translation and other comprehensive income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfNC0xLTEtMS0w_5b324f50-41b4-4c82-8ae3-35484d43b28c">4,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfNC0zLTEtMS0w_6e3c526c-821d-423b-9d97-fe332f5c74b2">2,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfNC01LTEtMS0w_fb1c6177-0479-4290-8042-0c2e94b7b8ef">3,682</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfNC03LTEtMS0w_a6c78f00-1a1d-4352-9989-69e9f029888e">220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfOS0xLTEtMS0w_d6fbfbdd-ff27-4cf9-9164-b5ce20d402dc">38,138</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfOS0zLTEtMS0w_8fb46d4e-4fea-4410-93c5-d0037adc97b2">56,928</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfOS01LTEtMS0w_2652d88b-3050-4871-9b9e-ecf6b3a6a507">29,111</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfOS03LTEtMS0w_d8fb012f-987d-4648-8d03-ef4b47f778f2">140,788</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(In thousands, except share and per share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and six months ended June 30, 2020</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.567%;"><tr><td style="width:1.0%;"></td><td style="width:29.195%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:6.152%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.934%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:7.573%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollars</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollars</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2a60d3075b9948199e8195d7f913ac6c_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi01LTEtMS0yNzM_a0ae4cfc-13ff-4d13-af5c-6142625d1b43">670,378,701</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a60d3075b9948199e8195d7f913ac6c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi03LTEtMS0yNzM_e0435d7b-e088-41f2-9ce2-58acdf14d30d">6,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="id895905b1a694b509baac821f4b07cc9_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi05LTEtMS0yNzM_a76051c2-5fcb-48e3-89cb-2b7a9f104124">549,907</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id895905b1a694b509baac821f4b07cc9_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi0xMS0xLTEtMjcz_71ace562-565c-4c66-a9c5-7f84b9015ce5">1,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i25b81bddf69248d2a9dca49367b845fb_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi0xMy0xLTEtMjcz_7aa5e1cd-d530-4397-8253-41d3a8b473ba">3,145,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i43dc309a84a34c9da443f4b8fb4f46d6_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi0xNS0xLTEtMjcz_52ca3c30-8b26-4583-b949-0a48a9795e3d">30,187</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2b6ee414e2b14aa2b7779dae646fa43d_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi0xNy0xLTEtMjcz_b810707d-ee06-46f8-bb1f-eae2a051ae63">1,571,551</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if81665549a744db4b9e3cbd8460e29b6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi0yMS0xLTEtMjcz_ca2e908e-c36b-4b02-8a72-a814164fd739">1,548,619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation expense</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a5a9e0119604e449787b4ccd42bbfe0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMy0xMy0xLTEtMjcz_2457200f-2325-40b5-ada0-3bcc8e93c494">1,586</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMy0yMS0xLTEtMjcz_942a337d-ce4a-4a00-9197-74dd05611d1a">1,586</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4af5a56db0c24f5d8ef4a585500444b2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfNy0xNy0xLTEtMjcz_e76c22f8-f1af-40a7-b74a-2c37bb3b131d">33,703</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfNy0yMS0xLTEtMjcz_19ebd750-9510-4c00-80f5-9c9029ccd2ab">33,703</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i143f61f3bd52487bbac948c8fad1648c_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOC0xNS0xLTEtMjcz_7da30dae-c053-42a1-a553-e9cd6c110f2a">4,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOC0yMS0xLTEtMjcz_4f7b9f5b-8760-43c8-b9ea-67ced3b3ba33">4,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9d1df47745364a0b99f41d53769dcdec_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS01LTEtMS0yNzM_920e25e4-2e1c-4518-a788-5d29b1cdf56b">670,378,701</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d1df47745364a0b99f41d53769dcdec_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS03LTEtMS0yNzM_4c8a9e54-0f8a-4af4-9ad1-351f364c3be9">6,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i936bc210908045ebb32428a797e622c9_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS05LTEtMS0yNzM_cb3a6386-8646-4db6-8793-6858d692810f">549,907</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i936bc210908045ebb32428a797e622c9_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS0xMS0xLTEtMjcz_b9e17360-06a2-4f07-a2bb-715229bc1427">1,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64a03ce9a44446aba8fd3973415e1804_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS0xMy0xLTEtMjcz_5192cc4d-1018-4eee-93d9-d2668e97f1ed">3,147,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4e72a60ac3204f79a58324d7ac06d70b_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS0xNS0xLTEtMjcz_2ecc24e5-45be-4714-979d-86e9e346c35e">25,752</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fd219acb38f4ebd979473ebe1345577_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS0xNy0xLTEtMjcz_19b233fa-af51-43ff-bcfc-a01b90f891cf">1,537,848</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS0yMS0xLTEtMjcz_829d7df2-cebe-47a1-9834-6b8aee0de021">1,588,343</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.567%;"><tr><td style="width:1.0%;"></td><td style="width:29.195%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:6.152%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.934%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:7.573%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollars</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollars</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i52609be761ba4470bb6b72bcdc9ed16e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi01LTEtMS0w_50df40eb-cd15-4859-b65b-96bd27772ffe">670,378,701</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52609be761ba4470bb6b72bcdc9ed16e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi03LTEtMS0w_db88ea6c-ee71-4712-910e-a9a448fad599">6,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i7e9d6032dccc43d39b3c75fc3e207e87_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi05LTEtMS0w_1f69b42b-2c28-4a2b-8e50-215bfc3b6cc1">549,907</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7e9d6032dccc43d39b3c75fc3e207e87_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi0xMS0xLTEtMA_ee3d86f8-e8a4-423f-8ea6-56d92fcd7494">1,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21eeb8671f80463cbbd4d25c43812904_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi0xMy0xLTEtMA_bb75305d-c2a7-45a1-a03a-127010551262">3,142,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3925554062df4071b663e93f01c6d247_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi0xNS0xLTEtMA_3d161e92-ee7c-414c-86a0-f06d71f2e39e">22,070</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie00bd5bfbe0747e98efecb5d0d36c2eb_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi0xNy0xLTEtMA_1d596aa2-5235-44f9-941d-be90edeec31f">1,511,077</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi0yMS0xLTEtMA_d11fcb82-a9f0-4c69-99cb-c6e901d831c8">1,614,759</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation expense</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9409bbd3d79a4f199dc0914b6a6a6232_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMy0xMy0xLTEtMA_9e330a79-8fd9-44ee-a1fc-d096d4ef5df6">4,037</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMy0yMS0xLTEtMA_4f2102e6-ab19-4e71-82f8-41cb735ab777">4,037</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfNS0wLTEtMS0xOTcx_2a78596e-2e9b-4170-8b5c-be1bf9f61bd7">Adoption of ASC 326</span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i14e0f7cf90b845618c2da998b2ec9256_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfNS0xNy0xLTEtMA_b0c3fe19-c865-448d-9467-295d8b70a888">1,342</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if1ca894201f24ceb996ca85bc139745f_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfNS0yMS0xLTEtMA_2a303b0f-c58e-439d-92ce-6f3937dc3e08">1,342</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0cc1ebc6dac04ccbb4e43babd6ec58f5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfNy0xNy0xLTEtMA_095dd9bc-ec71-4536-bdff-b3245eaf3b5f">25,429</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfNy0yMS0xLTEtMA_f81611cd-a9fa-44b5-9cc2-14130ce715f8">25,429</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5051d9d5fe094597bf4e37ba100c22fd_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOC0xNS0xLTEtMA_72eb4b56-24a1-4d8e-8972-d8f52147d14a">3,682</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOC0yMS0xLTEtMA_ab094556-dc48-443f-bf08-ca771aea8b8a">3,682</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9d1df47745364a0b99f41d53769dcdec_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS01LTEtMS0w_292cfdf7-4312-40ca-8e7c-4e81f3e10660">670,378,701</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d1df47745364a0b99f41d53769dcdec_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS03LTEtMS0w_b746dd04-9432-4f6f-b339-6a4e06956b01">6,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i936bc210908045ebb32428a797e622c9_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS05LTEtMS0w_1a8c5eee-00fc-42e9-a618-5b491c1c92d7">549,907</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i936bc210908045ebb32428a797e622c9_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS0xMS0xLTEtMA_fae09d0a-9ec2-410c-9264-5d836faaff78">1,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64a03ce9a44446aba8fd3973415e1804_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS0xMy0xLTEtMA_a375f187-d116-45e9-b90b-c8cf2c2802a3">3,147,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4e72a60ac3204f79a58324d7ac06d70b_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS0xNS0xLTEtMA_400aaa93-be72-48fb-97ca-d07adaf0c38b">25,752</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fd219acb38f4ebd979473ebe1345577_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS0xNy0xLTEtMA_7486c5c3-f3ea-4e50-a3f5-4539a5fb4593">1,537,848</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS0yMS0xLTEtMA_56ce07b5-41db-4d9d-b504-21a602a7afc8">1,588,343</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(In thousands, except share and per share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">six months ended June 30, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.567%;"><tr><td style="width:1.0%;"></td><td style="width:29.195%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:6.152%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.934%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:7.573%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollars</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollars</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i73abe1462fc54ccca6f449fcd66ad85f_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi01LTEtMS0yODM_091fda67-3769-4f49-88d6-ec955d84261e">616,150,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73abe1462fc54ccca6f449fcd66ad85f_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi03LTEtMS0yODM_7537be58-b4e8-4533-ae49-348b5a96a68c">6,162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i1cdf44d9233e47f7b9bf249aff94b19c_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi05LTEtMS0yODM_9b47ab9b-4099-4772-aa82-848525fdc8b4">549,907</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1cdf44d9233e47f7b9bf249aff94b19c_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi0xMS0xLTEtMjgz_7aad77b8-95b8-4907-a6dc-afa40744cc17">1,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89218e50948c4507b1df814b142d514e_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi0xMy0xLTEtMjgz_e8e003a5-3893-44f7-bc30-e0869fa7594c">3,058,509</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib353496e520042c2b547d13887f30ff4_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi0xNS0xLTEtMjgz_a4a2da4f-7439-41e4-a3d1-6582ef53c8ab">23,229</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i077eb15fd51d4b74985ebd93f8f78daa_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi0xNy0xLTEtMjgz_f578e62c-33f9-44d6-a6e8-80251ece9daa">1,276,914</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9acb0e76a853407e8a654c3be8ff1fee_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi0yMS0xLTEtMjgz_5e474e71-8e6f-4856-870c-5547a4a68ff3">1,762,737</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation expense</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67bbc9625fd1467492f28cf2d894d765_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMy0xMy0xLTEtMjgz_0334b1cd-da39-49b0-9461-74023eb84cd2">3,122</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMy0yMS0xLTEtMjgz_9b2c8d0c-a016-4aa3-98c3-0440b5637293">3,122</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec5715c6fc274f75937803500c320ab9_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfNy0xNy0xLTEtMjgz_1dcc347f-09b5-4945-a293-3fd450153a7c">59,806</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfNy0yMS0xLTEtMjgz_33f0a5cb-68be-46ae-a11f-10a47f5fbbe7">59,806</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cc58805b460451388796d3179b73858_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOC0xNS0xLTEtMjgz_949bc2b6-0cf3-4f2b-8999-2078615b618d">2,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOC0yMS0xLTEtMjgz_f3ed3f07-4382-40d5-be23-20b568202bf9">2,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i47c7b4841e944d8c8219ea505de34c81_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS01LTEtMS0yODM_3407ebf9-a9cb-4adf-b16a-996931f3b847">616,150,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i47c7b4841e944d8c8219ea505de34c81_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS03LTEtMS0yODM_b713efe4-74ad-41e2-8be5-46ca44f43429">6,162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i6096decc24534d73b84d8382fa7cfddd_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS05LTEtMS0yODM_29240266-97d3-4cdb-9aba-80477a1fb99e">549,907</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6096decc24534d73b84d8382fa7cfddd_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS0xMS0xLTEtMjgz_8a3748dc-66f5-4564-9a94-8a0a57d7dcde">1,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44cab2f05311498cb261057427e71187_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS0xMy0xLTEtMjgz_974f5779-b430-498b-bf62-1d369a918647">3,061,631</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7a7adf54fa64417e87f3555d5bf0773d_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS0xNS0xLTEtMjgz_593e6a40-9cc2-47ce-9e08-8d085394b0c8">20,351</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if62bbfa990154581b6b8060ab7f25983_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS0xNy0xLTEtMjgz_b1b5646f-c738-4f81-b659-f32dd5d992c3">1,336,720</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic97107d2cf63436bbd19e901d052161a_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS0yMS0xLTEtMjgz_5d330f26-2d6b-43c6-bec6-02e247b58cac">1,708,931</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.567%;"><tr><td style="width:1.0%;"></td><td style="width:29.195%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:6.152%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.934%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.343%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:7.573%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollars</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollars</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5fb67fadb72846cdba88dedab4956840_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi01LTEtMS0w_4b2840fa-254e-4eef-a9d0-68bbdd7ab8fb">586,881,720</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fb67fadb72846cdba88dedab4956840_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi03LTEtMS0w_4a49d1b1-a9cd-4e4c-832b-4b549c14ec72">5,869</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i1d4687ed998d4bc89b441e1a77865855_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi05LTEtMS0w_96c96957-c550-4ef2-9218-9d551bf9a445">549,907</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d4687ed998d4bc89b441e1a77865855_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi0xMS0xLTEtMA_f7563e43-73cb-44f6-9f3e-62dfafdf76fe">1,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i280cba37fbf24b4683f965f0f7b346d8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi0xMy0xLTEtMA_c4281bf9-3f9f-4ca7-b519-c19e2cbadf21">3,004,422</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic493611ea31741d8bb485d6a0d53db9f_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi0xNS0xLTEtMA_de81ab3c-810b-4499-a125-0fa781d720e2">20,131</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i00f0723faaa34d11aa00d312f4c86b4e_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi0xNy0xLTEtMA_6eeb17b9-9970-475a-ad53-ab244acf2719">1,197,078</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf70df459fcd4df1abd8e73dbfafd943_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi0yMS0xLTEtMA_0c064413-2ba2-4c49-aa89-77fa27bb5c4b">1,791,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation expense</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida9ba4776d674e048a8f35590863e24a_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMy0xMy0xLTEtMA_880e250d-fd5c-4b6b-895c-91858ccfa586">7,579</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMy0yMS0xLTEtMA_5961bd36-32a1-4cd4-9972-2b3102c834d4">7,579</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of Common Stock options and warrants</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1c9c6b69f3bc46868fad995b8c409262_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNC01LTEtMS0w_86b5da38-17b1-44c3-9bfa-1a5a3f6964af">19,232</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ida9ba4776d674e048a8f35590863e24a_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNC0xMy0xLTEtMA_958cb6bc-ca57-4ee5-bf04-0e85914143ac">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNC0yMS0xLTEtMA_833224f9-92f2-4049-b673-2b60d0b519d6">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNS0wLTEtMS0xOTc1_d0d7ef42-df32-41f0-99db-db4b4d4334f1">Adoption of ASU 2018-07</span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iee436d2fd7ff45f3915d1e32dcd70904_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNS0xMy0xLTEtMA_f03faa82-7793-4bc1-96e6-de80822444a2">926</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd4ae6fdd629444197cc9a625cdcfc9f_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNS0xNy0xLTEtMA_c38f0c5b-9562-40b3-8cb9-55cf8e2060d8">926</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9dfc05b578db438c821384cc836c5a4c_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNS0yMS0xLTEtMA_165680dc-2730-49b6-a151-02a20c93a167">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 convertible notes including share lending arrangement</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1c9c6b69f3bc46868fad995b8c409262_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNi01LTEtMS0w_87edb908-a2d8-4a11-9d81-4eb4eaa0720a">29,250,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c9c6b69f3bc46868fad995b8c409262_D20190101-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNi03LTEtMS0w_7793b50e-2005-4138-b2c5-4ba280d72619">293</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida9ba4776d674e048a8f35590863e24a_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNi0xMy0xLTEtMA_91bfd227-1895-4b88-a0a5-11fb2bb8fe1e">50,559</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNi0yMS0xLTEtMA_f1d3caa6-f9d6-43b3-8147-ba6e4350d7af">50,852</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5497d158e29a4207b882cb978b473faa_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNy0xNy0xLTEtMA_f0332cf8-8e69-4774-ba77-5e2ac2721d4d">140,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNy0yMS0xLTEtMA_b8192a96-a59a-4d33-9d5f-97a284e56850">140,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i00d185d0856f4299a62fe26f4513d5f8_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOC0xNS0xLTEtMA_84ba104f-89a7-4d60-a43f-a6104c455bb1">220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOC0yMS0xLTEtMA_c1250f7f-ca53-49fb-a8a6-7c27ae923952">220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i47c7b4841e944d8c8219ea505de34c81_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS01LTEtMS0w_11767ebb-ff47-478f-87b6-9b88c4b22c10">616,150,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i47c7b4841e944d8c8219ea505de34c81_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS03LTEtMS0w_0bc191d4-0b48-4411-bc09-0d9740fac658">6,162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i6096decc24534d73b84d8382fa7cfddd_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS05LTEtMS0w_950534c9-2d8f-4159-ad39-7b5b613c4b36">549,907</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6096decc24534d73b84d8382fa7cfddd_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS0xMS0xLTEtMA_5842036e-f2fb-4e5e-bbeb-0cc8b04cf108">1,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44cab2f05311498cb261057427e71187_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS0xMy0xLTEtMA_9ceb1b0d-e30f-4c65-b83a-bb288173edf6">3,061,631</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7a7adf54fa64417e87f3555d5bf0773d_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS0xNS0xLTEtMA_4fc1a639-3f83-4d7e-b89c-abe24507c0b6">20,351</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if62bbfa990154581b6b8060ab7f25983_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS0xNy0xLTEtMA_388cf84a-bdf8-4c75-b0bf-00d03fb6ea66">1,336,720</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic97107d2cf63436bbd19e901d052161a_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS0yMS0xLTEtMA_ee12f75f-8d48-4d47-abf6-b7b67b55380b">1,708,931</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_34"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OPKO Health, Inc. and Subsidiaries</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(In thousands)</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:67.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.662%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.664%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMy0xLTEtMS0w_b86600e1-9f1e-4b5e-8d0f-87eb7e27a060">25,429</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMy0zLTEtMS0w_88801fe1-1a99-4687-947a-1d55e815738b">140,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNi0xLTEtMS0w_9baa15e7-c5f7-4df5-8b34-ba0473e4700e">44,318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNi0zLTEtMS0w_237cddb8-22ea-4129-9c8e-a20f55407c3c">47,477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNy0xLTEtMS0w_87fed4b4-5c29-438f-bfbf-a97ff806257e">5,022</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNy0zLTEtMS0w_8fa70bc8-318e-4ec7-ae66-f0fa36ebeca8">2,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of deferred financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfOC0xLTEtMS0w_ff20b8b0-d89d-4851-a60d-64bdbc99933a">411</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfOC0zLTEtMS0w_729f9a08-533e-49e1-9898-883a3a067072">308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses from investments in investees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTAtMS0xLTEtMA_690def50-0c62-43af-810c-6b36a624839b">323</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTAtMy0xLTEtMA_faede164-a9a2-4d9a-b04f-da2ed1047282">2,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation &#8211; employees and non-employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTEtMS0xLTEtMA_c0576a83-13d9-4bc8-9e79-63ab1fdd7a41">4,037</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTEtMy0xLTEtMA_3f719ccf-1648-4e4d-a314-965be708e457">7,579</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Realized loss on disposal of fixed assets and sales of equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTUtMS0xLTEtMA_4a8d8aea-b93b-4e00-b850-bcf0c0231702">156</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTUtMy0xLTEtMA_ae7220b9-e094-447f-b41f-aba2f4189718">220</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of equity securities and derivative instruments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTgtMS0xLTEtMA_e85439de-17fc-420c-822c-0bd0410ecd65">6,515</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTgtMy0xLTEtMA_36af5c21-4702-4fd3-97c9-f517d461c67c">5,431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjAtMS0xLTEtMA_16be821e-3c8c-4c46-9134-4454b9bc59d6">251</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjAtMy0xLTEtMA_8869d320-9ad6-43cf-9c8d-76357ddaab18">1,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impairment of assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjMtMS0xLTEtMA_f31a5812-9e33-4cfc-a97f-ad9103f76b7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjMtMy0xLTEtMA_1d24ecd0-b80a-4cc5-a80b-86add0e0d4e5">655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax provision</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjQtMS0xLTEtMA_f7119b61-ddea-44de-9240-4a316aefdc58">1,028</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjQtMy0xLTEtMA_61eb132c-27af-499d-9568-622f5dd861dd">168</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjYtMS0xLTEtMA_d1a64508-a637-4890-b5e1-e573f33c37f0">81,539</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjYtMy0xLTEtMA_13dbffbd-7167-4a4f-a0e7-0b281b85345d">4,398</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjctMS0xLTEtMA_74cc4124-f595-4d75-a77b-82beb308818c">21,905</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjctMy0xLTEtMA_b0571a97-6986-453c-a1bb-2f5cf36c3910">6,225</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets and prepaid expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjgtMS0xLTEtMA_d7367001-b1d6-43fd-aa1a-a15b562a7c3d">2,619</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjgtMy0xLTEtMA_b323219e-17a6-465b-88c9-3d92d4de3b54">2,476</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjktMS0xLTEtMA_dbe46d7b-5254-4881-a5cb-007c166fc0fa">61</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjktMy0xLTEtMA_bbb2c033-038e-4d97-9035-c1d7720699e2">136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzAtMS0xLTEtMA_4f0b75d1-54c6-4015-8d21-fbc16d46f23f">16,753</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzAtMy0xLTEtMA_b36c5e1b-0472-4c4d-ab23-a237510069f8">12,887</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency measurement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="opk:IncreaseDecreaseinForeignCurrencyMeasurement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzEtMS0xLTEtMA_e8d93d01-bd1c-4880-b49e-2973809397df">2,077</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" name="opk:IncreaseDecreaseinForeignCurrencyMeasurement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzEtMy0xLTEtMA_41543b7d-f56d-4944-837d-b145e8d18469">131</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzItMS0xLTEtMA_1ece1936-1412-4cc3-8dcf-a349b43568cc">4,026</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzItMy0xLTEtMA_994b0d90-97f1-42d6-9c25-509b6ca114ba">37,015</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzMtMS0xLTEtMA_95530a4b-43d6-4da4-bfa0-afed52f0534a">47,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzMtMy0xLTEtMA_c29febe9-0b29-437e-aea8-9fcc9e59c2b0">2,095</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzYtMS0xLTEtMA_16950523-d443-4dbc-ab37-8f3a6d582ad7">57,793</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzYtMy0xLTEtMA_35be3eb7-9f61-4577-bfcf-0f4477f7ab4e">102,619</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments in investees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzgtMS0xLTEtMA_6fefe7c1-dcd5-467c-9ac6-0822dc51ce45">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzgtMy0xLTEtMA_71f3466f-e274-441b-a665-0e3fb2103a43">1,200</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from the sale of property, plant and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDMtMS0xLTEtMA_387a064c-1871-41f5-a118-98c2afc73454">65</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDMtMy0xLTEtMA_2b852d23-e797-4b2e-b5a9-d4ff84595c0b">309</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDUtMS0xLTEtMA_17fed21b-acc6-4e7e-89bd-81b70f385880">17,149</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDUtMy0xLTEtMA_d37b7f94-a036-4b89-8ad0-8084b0173869">6,432</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDYtMS0xLTEtMA_0d1d5d85-bcbb-47a5-b40e-53568825911f">17,084</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDYtMy0xLTEtMA_88c4c075-61fd-40c5-b789-5220ac44fd23">7,323</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of convertible notes, including to related parties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDgtMS0xLTEtMA_0905e6e4-e58a-482d-be51-ef663f08fb75">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDgtMy0xLTEtMA_052d5d36-8d43-4203-8e65-b6b4c2831c7f">200,293</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDktMS0xLTEtMA_96701ed6-83f6-4d01-a562-865f330446b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDktMy0xLTEtMA_fdfc41cf-0577-4d78-b68b-774807164cbd">7,762</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from the exercise of Common Stock options and warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTEtMS0xLTEtMA_30c96c72-c0d2-45b2-93e0-1078f15cc510">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTEtMy0xLTEtMA_d149f55f-ceee-4bf1-9ad5-9b5afe82fe97">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Borrowings on lines of credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTQtMS0xLTEtMA_dc2c1e7f-cd6b-4762-bfe5-5bc1194c6a1a">393,651</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTQtMy0xLTEtMA_f775cd85-80a4-4481-99ec-587eea39fe28">39,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayments of lines of credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTUtMS0xLTEtMA_359fd982-9240-4204-a99f-29aafd495247">382,374</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTUtMy0xLTEtMA_6f9efd1b-c8db-4b6c-af07-a05b1bb8f8c2">78,824</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Redemption of 2033 Senior Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfSeniorDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTgtMS0xLTEtMA_27093993-5467-4c2a-a57c-c08d1c4fdb48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTgtMy0xLTEtMA_fd6b62c3-e68e-4d11-8154-34135051a299">28,800</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTktMS0xLTEtMA_60d9c0a2-4a2f-4367-a493-8c87e89184d5">11,277</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTktMy0xLTEtMA_ef7e23f6-e55b-453d-b1be-c5cf187544bd">124,599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjAtMS0xLTEtMA_e5ec5201-942d-4a92-861b-15156b8deed1">240</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjAtMy0xLTEtMA_c012895b-cefc-4765-894a-b9d529421727">15</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjEtMS0xLTEtMA_57b00bf4-5587-4f09-9523-4e195f7fa4bc">63,840</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjEtMy0xLTEtMA_57a55e31-ad53-43ec-b7ce-bdd120dc6355">14,642</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjItMS0xLTEtMA_b32b52e0-6c0d-41c6-aaf3-d127a8dd318c">85,452</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf70df459fcd4df1abd8e73dbfafd943_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjItMy0xLTEtMA_08d54877-d1bc-4f94-bea2-4d2d0ffdbc3e">96,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjMtMS0xLTEtMA_c675e793-0930-4880-b607-1c17b8862e8a">21,612</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic97107d2cf63436bbd19e901d052161a_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjMtMy0xLTEtMA_9f67399b-1690-43bf-84d3-576de2063bcb">111,115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SUPPLEMENTAL INFORMATION:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjUtMS0xLTEtMA_573ad887-1cd8-49f7-846b-11caa5b4dac1">5,578</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjUtMy0xLTEtMA_331c14fb-7662-4b4a-b7af-8cda00b284e0">5,411</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes paid (received), net of refunds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjYtMS0xLTEtMA_f3ba26d4-b2f1-43e4-8263-96cb706e3108">208</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjYtMy0xLTEtMA_accffb0d-a301-41e6-8bd4-5163cc8d6fed">2,132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets due to adoption of ASU No. 2016-02</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjctMS0xLTEtMA_a0a0f68b-27b9-41f9-a769-39319228c2a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjctMy0xLTEtMA_d85f2adf-c637-4f6e-b52a-75ed0e867dc4">29,640</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities due to adoption of ASU No. 2016-02</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="opk:OperatingLeaseLiabilityInitialRecognitionUponAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjgtMS0xLTEtMA_9574f7e0-83c0-4277-980e-320a2d0b7cfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="opk:OperatingLeaseLiabilityInitialRecognitionUponAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjgtMy0xLTEtMA_cd8f170f-04af-41e9-a513-31b66fe1cc99">30,049</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash financing:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:60.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares issued upon the conversion of:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:78.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock options and warrants, surrendered in net exercise</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="opk:CommonStockWarrantsNetExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNzQtMS0xLTEtMA_5bf023e7-8709-436f-8381-56b78957bfc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" name="opk:CommonStockWarrantsNetExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNzQtMy0xLTEtMA_6d779613-c0d6-483c-9c3a-375a6cc0e62f">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OPKO Health, Inc. and Subsidiaries</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_40"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 1 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180MC9mcmFnOjFiYTRiZmQ2MjQ5YTRmODI5NzQzNjJmYTkyYzRhOTViL3RleHRyZWdpb246MWJhNGJmZDYyNDlhNGY4Mjk3NDM2MmZhOTJjNGE5NWJfMjkxMQ_a402ef2f-2e8e-4fd0-8307-a0b025f69ea8" continuedAt="i6f700cc0e7b54163b123bd55c2d7591c" escape="true">BUSINESS AND ORGANIZATION</ix:nonNumeric></span></div><ix:continuation id="i6f700cc0e7b54163b123bd55c2d7591c"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets.  Our diagnostics business includes BioReference Laboratories, Inc. (&#8220;BioReference&#8221;), one of the nation&#8217;s largest full service laboratories with a core genetic testing business and an almost <ix:nonFraction unitRef="employee" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-2" name="opk:NumberofSalesEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180MC9mcmFnOjFiYTRiZmQ2MjQ5YTRmODI5NzQzNjJmYTkyYzRhOTViL3RleHRyZWdpb246MWJhNGJmZDYyNDlhNGY4Mjk3NDM2MmZhOTJjNGE5NWJfMzY1_f7dac456-9dac-48e2-a4d0-929f7dabd234">300</ix:nonFraction>-person sales and marketing team focused on driving growth and leveraging new products, including the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> test.  Our pharmaceutical business features </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, an FDA-approved treatment for secondary hyperparathyroidism (&#8220;SHPT&#8221;) in adults with stage 3 or 4 chronic kidney disease (&#8220;CKD&#8221;) and vitamin D insufficiency (launched in November 2016); OPK88004, a selective androgen receptor modulator which we are exploring for various potential indications; and OPK88003, a once weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists (phase 2b).  Our pharmaceutical business also features hGH-CTP, a once-weekly human growth hormone that recently successfully completed a phase 3 trial and for which we have partnered with Pfizer Inc. (&#8220;Pfizer&#8221;).  We are incorporated in Delaware, and our principal executive offices are located in leased offices in Miami, Florida.   </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Through BioReference, we provide laboratory testing services, primarily to customers in the larger metropolitan areas across New York, New Jersey, Florida, Texas, Maryland, California, Pennsylvania, Delaware, Washington, DC, Illinois and Massachusetts, as well as to customers in a number of other states.  We offer a comprehensive test menu of clinical diagnostics for blood, urine and tissue analysis.  This includes hematology, clinical chemistry, immunoassay, infectious&#160;diseases, serology, hormones, and toxicology assays, as well as Pap smear, anatomic pathology (biopsies) and other types of tissue analysis.  We market our laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate established pharmaceutical platforms in Ireland, Chile, Spain, and Mexico, which are generating revenue and from which we expect to generate positive cash flow and facilitate future market entry for our products currently in development.  In addition, we have a development and commercial supply pharmaceutical company and a global supply chain operation and holding company in Ireland.  We own a specialty active pharmaceutical ingredients (&#8220;APIs&#8221;) manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development activities are primarily performed at facilities in Woburn, MA, Waterford, Ireland, Kiryat Gat, Israel, and Barcelona, Spain.</span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_43"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 2 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0MTY_38fbd8d7-6098-47eb-a08f-a2641762d806" continuedAt="i9a2f1c001ae74e589f15ebc776db312e" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i9a2f1c001ae74e589f15ebc776db312e" continuedAt="i187d33daf8154f118e150a66f59ce38e"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQzNjg_08ba94b7-b061-462e-893b-eff6ab0388b7" continuedAt="i90056b9ad929422b86181c0dc866a5e9" escape="true">Basis of presentation</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i90056b9ad929422b86181c0dc866a5e9">.  The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all information and notes required by GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company&#8217;s results of operations, financial position and cash flows have been made.  The results of operations and cash flows for the three and six months ended June 30, 2020 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2020 or any other future periods.  The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</ix:continuation>  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQzNzM_9a836212-8117-4a94-9c81-d4eb2fcaad7a" continuedAt="ifa8f0f041e514f67a61d4d2654e64a32" escape="true">Principles of consolidation</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ifa8f0f041e514f67a61d4d2654e64a32">.  The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and of our wholly owned subsidiaries.  All intercompany accounts and transactions are eliminated in consolidation.</ix:continuation>   </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODc1OA_5d6063ad-60de-4f78-9fd5-4863f57cace8" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of estimates</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from these estimates.</span></ix:nonNumeric></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i187d33daf8154f118e150a66f59ce38e" continuedAt="i1ad6ee151ab44b43a2dbce40d6c906c9"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Impact of COVID-19</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.   As the disease caused by SARS-CoV-2, a novel strain of coronavirus, COVID-19 continues to spread and severely impact the economy of the United States and other countries around the world, we are committed to being a part of the coordinated public and private sector response to this unprecedented challenge. In response to the COVID-19 pandemic, BioReference Laboratories is accepting specimens for two types of COVID-19 testing, diagnostic molecular testing and serology antibody testing, from healthcare providers, clinics and health and hospital systems throughout&#160;the U.S., to promote earlier diagnosis of the coronavirus, assess a patient&#8217;s immune response to the virus and aid in limiting spread of infection. In addition to its robust nationwide COVID-19 testing offering, BioReference has partnerships with the&#160;New York State&#160;Department of Health, the New York City Health and Hospital Corporation (NYC&#160;Health + Hospitals), the&#160;State of New Jersey, the&#160;State of Florida&#160;and the cities of&#160;Detroit&#160;and&#160;Miami, among others,&#160;to provide COVID-19 testing. BioReference performed approximately <ix:nonFraction unitRef="test" contextRef="id7248978ab134af9bb5051c652bb74f7_D20200401-20200630" decimals="-2" format="ixt:numdotdecimal" name="opk:COVID19NumberOfTestsPerformed" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODc2MQ_f7a650e8-f88f-4934-9fe7-4c12b08f48cc">331.6</ix:nonFraction>&#160;thousand serology antibody tests and <ix:nonFraction unitRef="test" contextRef="i137e26f6947848af8470ae5fd8e6bab1_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="opk:COVID19NumberOfTestsPerformed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODc3Nw_18173e2d-d4ae-49fd-b4fe-01416c3b1871">2.2</ix:nonFraction>&#160;million diagnostic molecular tests for COVID-19 during the three months ended June 30, 2020, which represented <ix:nonFraction unitRef="number" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="3" name="opk:COVID19PercentOfTotalTestVolume" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODc5MA_36491a4e-3299-4b88-a6c4-cb6173a05e7a">28.1</ix:nonFraction>% of BioReference&#8217;s total test volume during the second quarter of 2020. For serologic antibody testing, BioReference has partnered with the State of New York, New York City and a number of employers and government agencies with the capacity to perform up to <ix:nonFraction unitRef="test" contextRef="id7248978ab134af9bb5051c652bb74f7_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="opk:COVID19TestsPerformedPerDay" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODc5Nw_855db79a-a441-48d6-9903-d87202783bac">400,000</ix:nonFraction> tests per day and for diagnostic molecular tests, BioReference has the capacity to perform more than <ix:nonFraction unitRef="test" contextRef="i137e26f6947848af8470ae5fd8e6bab1_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="opk:COVID19TestsPerformedPerDay" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODgwNg_e612f196-9539-4e6c-a91f-3156d3e21bdf">50,000</ix:nonFraction> tests per day. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have put preparedness plans in place at our facilities to maintain continuity of operations, while also taking steps to keep colleagues and customers healthy and safe. In line with recommendations to reduce large gatherings and increase social distancing, we have, where practical, transitioned many office-based colleagues to a remote work environment.&#160;</span></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Beginning in March 2020, BioReference experienced, and continues to experience, a decline in routine clinical and genomics testing volumes due to the COVID-19 pandemic. Excluding COVID-19 test volumes, for the three months ended June 30, 2020, volumes in our diagnostics segment were down <ix:nonFraction unitRef="number" contextRef="id2fe9bfd426d4e56a5b3bcbcaf3b2286_D20200401-20200630" decimals="3" sign="-" name="opk:ChangeInTestingVolumePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODgxNA_f870254a-c7e4-477b-9a40-9c1a3e8a819f">46.5</ix:nonFraction>% as compared to volumes in the second quarter of 2019. Additionally, sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> have not increased in accordance with its expected growth trajectory as a result of challenges in onboarding new patients due to the COVID-19 pandemic. Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, a significant reduction in physician office visits, the cancellation of elective medical procedures, customers closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home or shelter-in-place policies, all of which have had, and may continue to have, an adverse impact on our operating results, cash flows and financial condition, including continued declines in testing volumes. It is also possible that we will experience an adverse impact on cash collections as a result of the impact of the COVID-19 pandemic.&#160;As stay at home orders and other restrictions have been lifted, we have seen our routine clinical and genomic testing volumes trending towards normalization with prior periods, however should stay at home orders or other restrictions be reenacted, we could see our routine testing levels decline. We also continue to see a substantial need for COVID-19 testing by our existing clients and expect new clients as infection rates for the virus continue to increase across the country.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, in response to the COVID-19 pandemic, the CARES Act was signed into law. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding the prior and future utilization of net operating losses, temporary changes to the prior and future limitations on interest deductions, temporary&#160;suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property, and the creation of certain payroll tax credits associated with the retention of employees.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have received, or expect to receive a number of benefits under The CARES Act including, but not limited to:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We received approximately $<ix:nonFraction unitRef="usd" contextRef="ib5e57cbd6ab542d79a08167f6ec07985_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODgyMQ_6d90f4e9-3eeb-47bb-8cba-d95156382441">14</ix:nonFraction>&#160;million under The Centers for Medicare &amp; Medicaid Services (CMS) Accelerated and Advance Payment Program, which provides accelerated payments to Medicare providers/suppliers working to provide treatment to patients and combat the COVID-19 pandemic, and the amounts advanced are loans which will be offset against future claims and must be repaid. These loans are initially recorded as contract liabilities included in Accrued expenses and are recognized in Revenue from services when earned;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are eligible to defer depositing the employer&#8217;s share of Social Security taxes for payments due from March 27, 2020 through December 31, 2020, interest-free and penalty-free;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We received approximately $<ix:nonFraction unitRef="usd" contextRef="i52f6774dfd1f4573beee75bf01ef821c_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODgzNA_22af2b0f-d514-441c-9564-4ceb9dae3a4c">6.2</ix:nonFraction>&#160;million during the three months ended June 30, 2020 from the initial tranche of funds that was distributed to healthcare providers for related expenses or lost revenues that are attributable to the COVID-19 pandemic. We recognized the $<ix:nonFraction unitRef="usd" contextRef="i998e2997494745b2998bd29dda7de21f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODg0OA_5cd0518c-af51-4d43-9faa-3514ff627296"><ix:nonFraction unitRef="usd" contextRef="i8b70e317a90e423daaa6fcc619c8eb46_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODg0OA_7aee46fd-185c-4069-b1d5-fdc478055613">6.2</ix:nonFraction></ix:nonFraction>&#160;million grant in other revenues for the three and six months ended June 30, 2020;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">U.S. Department of Health and Human Services (HHS), will provide claims reimbursement to healthcare providers generally at Medicare rates for testing uninsured patients; and</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i1ad6ee151ab44b43a2dbce40d6c906c9" continuedAt="i2c824895a9fe4b74aa49eea2217de2d8"><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Clinical laboratories are provided a one-year reprieve from the reporting requirements under the Protecting Access to Medicare Act (&#8220;PAMA&#8221;) as well as a one-year delay of reimbursement rate reductions for clinical laboratory services provided under Medicare that were scheduled to take place in 2021.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the pandemic began in the U.S., we have invested, and expect to continue to invest, in testing capabilities and infrastructure to meet demand for our molecular and antibody testing for COVID-19. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NDI_e56f6da5-6b38-4840-8cce-9354745d9151" continuedAt="i6b096c8fa5504d23aed3fbf9896403ef" escape="true">Cash and cash equivalents</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i6b096c8fa5504d23aed3fbf9896403ef">.  Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase.  We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents.  These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.</ix:continuation> </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NDM_c395b13b-0491-427d-8458-d72b4037adc3" continuedAt="i491cf443014f4a918d613d6968508299" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Inventories</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Inventories are valued at the lower of cost and net realizable value.  Cost is determined by the first-in, first-out method.  We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value.  Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which is used in our testing laboratories.  Inventory obsolescence expense for the six months ended June&#160;30, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjg2OQ_6641f582-1af1-4f80-a964-4e9eca1a0246">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjg3Ng_4b773b47-78fa-459d-9280-b1531986f736">1.3</ix:nonFraction> million, respectively.</span></ix:nonNumeric></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:continuation id="i491cf443014f4a918d613d6968508299" continuedAt="i15c47f608376414ab55702ced24b25e6">Pre-launch inventories</ix:continuation></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i15c47f608376414ab55702ced24b25e6">.  We may accumulate commercial quantities of certain product candidates prior to the date we anticipate that such products will receive final U.S. FDA approval.  The accumulation of such pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever.  This risk notwithstanding, we may accumulate pre-launch inventories of certain products when such action is appropriate in relation to the commercial value of the product launch opportunity.  In accordance with our policy, this pre-launch inventory is expensed.</ix:continuation>&#160;&#160;</span></div><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NzA_5ede7702-9257-4ae8-ab77-0d2d9ca96e0b" continuedAt="i21908de0b79a4639806592e1f472abf4" escape="true"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill and intangible assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting.  Refer to Note 4.  Goodwill, in-process research and development (&#8220;IPR&amp;D&#8221;) and other intangible assets acquired in business combinations, licensing and other transactions was $<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-8" format="ixt:numdotdecimal" name="opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMzg4Mw_27fae88e-4c6a-4a89-b653-2d473e6ddc79"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-8" format="ixt:numdotdecimal" name="opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMzg4Mw_61955bef-14ad-414f-987f-d561e48facc0">1.8</ix:nonFraction></ix:nonFraction> billion at both at June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values.  Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill.  At acquisition, we generally determine the fair value of intangible assets, including IPR&amp;D, using the &#8220;income method.&#8221;</span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill was $<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTY0OTI2NzQ3NTAzMg_ad9da6e4-722a-4e56-97b5-7d32c60f0eca">671.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfNDY0NA_d1e144be-bdbf-4712-a44d-24e7eae58009">671.9</ix:nonFraction> million respectively, at June&#160;30, 2020 and December&#160;31, 2019. Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.  We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing.  Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net intangible assets other than goodwill were $<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfNTI3NA_784c143d-1622-4966-983f-0d127a78471c"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfNTI3NA_d3b58c6a-9c75-4ff7-bf56-e86ebd400c3d">1.1</ix:nonFraction></ix:nonFraction> billion, including IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="i34113ca72899471b80fa537db298faf5_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfNTI5Nw_2409e55a-4027-4e77-9108-1a9b5b266f85"><ix:nonFraction unitRef="usd" contextRef="ia5f22aa17f4f4f80a5186830a870ac40_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfNTI5Nw_3d19217c-4996-421c-91bc-e6731d1978ff">590.2</ix:nonFraction></ix:nonFraction> million, at both June&#160;30, 2020 and December&#160;31, 2019.  Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products and IPR&amp;D.  Considering the high risk nature of research and development and the industry&#8217;s success rate of bringing developmental compounds to market, IPR&amp;D impairment charges may occur in future periods.  Estimating the fair value of IPR&amp;D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon obtaining regulatory approval, IPR&amp;D assets are then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.  If the project is abandoned, the IPR&amp;D asset is charged to expense.  Finite lived intangible assets are tested for impairment when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.  The testing includes a comparison of the carrying amount of the asset to its estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i2c824895a9fe4b74aa49eea2217de2d8" continuedAt="i46a069d77a164aabad5609d679595dc2"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i21908de0b79a4639806592e1f472abf4" continuedAt="ib9f02c6f21bd4d59baf9d196f89ac84a">We believe that our estimates and assumptions are reasonable and otherwise consistent with assumptions that marketplace participants would use in their estimates of fair value.&#160; However, if future results are not consistent with our estimates and assumptions, including as a result of the COVID-19 global pandemic, then we may be exposed to an impairment charge, which could be material.&#160; </ix:continuation></span></div><div style="text-indent:22.5pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib9f02c6f21bd4d59baf9d196f89ac84a">We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from <ix:nonNumeric contextRef="i0a9fcdf9701e4978a7f6f9fdbae12895_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfODA3NQ_a44c927a-c529-4fef-a0c0-f67b7c14a9f9">3</ix:nonNumeric> to <ix:nonNumeric contextRef="ic8597cb5f4cd4e56a0b43a5aaa79edf0_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfODA4MQ_a79fa8a2-1690-4a7c-aac1-0e6eaa52218b">20</ix:nonNumeric> years.  We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up.</ix:continuation>  Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfODMwMg_befd390c-3e58-41cd-a6a1-06b7cb35efab">29.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfODMwOQ_185444cf-1ed2-43db-9cb4-a24c2a29f0aa">33.0</ix:nonFraction> million for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0ODI_46a31dc0-3837-4824-a510-d05567810dc7" continuedAt="i9bd11ef4323846748aea1599cbdf757e" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair value measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments.  Investments that are considered equity securities as of June&#160;30, 2020 and December&#160;31, 2019 are predominately carried at fair value.  Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest applicable to such debt.</span></ix:nonNumeric></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i9bd11ef4323846748aea1599cbdf757e">In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates.  The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts.  Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.</ix:continuation>  Refer to Note 8.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NDU_2329c62b-c49a-4460-83ba-f5830ba0c825" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contingent consideration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense.  Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability.  Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions.  The assumptions used in estimating fair value require significant judgment.  The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.</span></ix:nonNumeric></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ1MDA_42a026fb-7329-40be-aca9-42ab9f620c2e" continuedAt="ibfa1c7c292454b05a85c3858a9e0616d" escape="true">Derivative financial instruments</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ibfa1c7c292454b05a85c3858a9e0616d">.  We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges.  For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At June&#160;30, 2020 and December&#160;31, 2019, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognize all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations.</ix:continuation>  Refer to Note 9.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NDg_50d2521d-1301-4713-8fcf-60d523dcd63c" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Property, plant and equipment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Property, plant and equipment are recorded at cost or fair value if acquired in a business combination.  Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases.  The estimated useful lives by asset class are as follows: software - <ix:nonNumeric contextRef="i2c925c357ef94419a653f6179d8cd427_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE2MDY_cd3cbcb4-9a57-43a7-ba56-622f931ed9ee">3</ix:nonNumeric> years, machinery, medical and other equipment - <ix:nonNumeric contextRef="id483c700016445cf875194cf5a6fd62b_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE2NTc_ec2b4c8d-a5c0-4749-a64e-de5f27011f3c">5</ix:nonNumeric>-<ix:nonNumeric contextRef="i7bf9292e3f244c65ab4a6e78952c669e_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE2NjA_e07800bc-7c7e-43b0-83b1-4efe67bddbab">8</ix:nonNumeric> years, furniture and fixtures - <ix:nonNumeric contextRef="i287a64693aa543c9b39361bdcfae9f34_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE2OTU_3604818e-ae40-4b8d-b032-30d0033661a1">5</ix:nonNumeric>-<ix:nonNumeric contextRef="i4ecb6c47f6db44edbbe0ea91612ccfd1_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE2OTg_ec213c38-5896-4cb7-b612-7d7ba3bebf5c">12</ix:nonNumeric> years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - <ix:nonNumeric contextRef="ic3ec9c63dd2d444eba263c0dabc7144b_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE4MTM_6f26875c-4125-4ce0-a90e-db06feedfdc0">10</ix:nonNumeric>-<ix:nonNumeric contextRef="if6a40facfada4fc5a367a7dcaf4f0135_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE4MTY_d8c1c616-c204-4609-b262-eee596315f0b">40</ix:nonNumeric> years, and automobiles - <ix:nonNumeric contextRef="ibf92eadea438478cb1b5f0aa51c40f56_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE4NDQ_9f4e2c8f-6143-438e-b133-f93c9a9d2e20">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i542ee96b497e4c8e81ce12f68616f43a_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE4NDc_47f7d5cd-2052-489e-8201-7cbb6f9a59c7">5</ix:nonNumeric> years.  Expenditures for repairs and maintenance are charged to expense as incurred.  Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE5NjE_43a56985-de47-40f0-bf55-0032e73dc79f">14.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE5Njg_e0fc45ff-758c-4c5d-b06e-e8bf42554854">14.5</ix:nonFraction> million for the six months ended June 30, 2020 and 2019, respectively.  Assets held under finance leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheet and are amortized over the shorter of their useful lives or the expected term of their related leases.</span></ix:nonNumeric></div><div style="text-indent:22.5pt;margin-top:9pt;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NTk_ce86143a-3a7b-450f-9fa4-e47b83648ea9" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Impairment of long-lived assets.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span></ix:nonNumeric></div><div style="text-indent:22.5pt;margin-top:9pt;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0MTI_b4cd1190-823b-4ae5-951a-a360f6517a61" continuedAt="i3eec6816471149388aec35ef3626b12c" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income taxes.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are accounted for under the asset-and-liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those </span></ix:nonNumeric></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i46a069d77a164aabad5609d679595dc2" continuedAt="icdf6a03cf48545c99efaf13bb85d3227"><ix:continuation id="i3eec6816471149388aec35ef3626b12c"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.  We periodically evaluate the realizability of our</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">net deferred tax assets.  Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">adjustment.  Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate in various countries and tax jurisdictions globally.&#160; For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.&#160; For the three and six months ended June 30, 2020, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.</span></div></ix:continuation><div style="text-indent:22.5pt;margin-top:9pt;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQzNzE_c62b0197-068a-49d3-8f15-6e9ef45bd554" continuedAt="i7da6386f0df944f6b0dd025631aad221" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue recognition</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;Topic 606&#8221;).  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.  </span></ix:nonNumeric></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i7da6386f0df944f6b0dd025631aad221" continuedAt="ia60f9a36fb99491aaab050d7307dea55">We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.  At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct.  We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.</ix:continuation>  For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 12.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0MDU_16d9796f-94da-4c86-a78a-db669ff6629e" continuedAt="i9c5be3cfaa1641abbf25f53451c4d450" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Concentration of credit risk and allowance for credit losses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable.  Substantially all of our accounts receivable are with either companies in the healthcare industry or patients.  However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span></ix:nonNumeric></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i9c5be3cfaa1641abbf25f53451c4d450">While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.</ix:continuation>   At June&#160;30, 2020 and December&#160;31, 2019, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were <ix:nonFraction unitRef="number" contextRef="i16be18cc629345ec9ee57120942f2250_D20200630-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTY5ODk_4b8c77a0-1187-488d-a44a-54bdc319104d">11</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i741090abba6940d68c835c82f65dc928_D20191231-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTY5OTY_574a9d83-4f9a-4e52-8d13-0c2ecb5aa1c9">6</ix:nonFraction>%, respectively, of our consolidated Accounts receivable, net. At June&#160;30, 2020, receivable balances (net of explicit and implicit price concessions) due directly from states, cities and other municipalities, specifically related to our real-time reverse-transcription polymerase chain reaction (real-time RT-PCR) assay to detect the 2019 novel coronavirus disease (COVID-19), were <ix:nonFraction unitRef="number" contextRef="ic59039c688094e9385f6da64420c81a7_D20200630-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTczNjQ_0c722028-2757-4821-8de6-082aa1cb83e2">37.6</ix:nonFraction>% of our consolidated Accounts receivable, net. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk.  At June&#160;30, 2020 and December&#160;31, 2019, receivables due from patients represented approximately <ix:nonFraction unitRef="number" contextRef="iede87b24ecb34c16881dd3d454c04ad4_D20200630-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTc1OTk_c10735b0-d4ef-4338-9bca-f803e4676e30">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i8c116f9b15604e95aba107054937c166_D20191231-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTc2MDY_43144d35-a30d-4e93-9e89-1a6c9ee8bb0e">2.5</ix:nonFraction>%, respectively, of our consolidated Accounts receivable, net.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0Nzk_7dcab28c-5440-4da9-bb13-8a20df3cac37" escape="true">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer&#8217;s ability to pay.  Actual results could differ from those estimates.</ix:nonNumeric>  The allowance for credit losses was $<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTgwNjI_9651c058-eb51-489c-90d5-05bb75d537e1">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTgwNjk_2b5ae3d8-d777-4348-ba91-6c89ea325b64">1.9</ix:nonFraction> million at June&#160;30, 2020 and December&#160;31, 2019, respectively.  The credit loss expense for the six months ended June 30, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTgxNDk_6dedfa4d-cef5-403e-9ee5-c8c833523093">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTgxNTY_f0a88957-71fc-40e0-8eea-6c2a272f880f">0.2</ix:nonFraction> million, respectively.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQzNzk_ba3f9a08-c5a5-43aa-a24b-5ca8985a5ae0" continuedAt="if12d4fbf229245e1b8f275a9f47a21e9" escape="true">Equity-based compensation</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="if12d4fbf229245e1b8f275a9f47a21e9">.  We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award.  We record excess tax benefits realized from the exercise of stock options as cash flows from operations.</ix:continuation>  For the six months ended June 30, 2020 and 2019, we recorded $<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTg2NTg_01fdb479-80df-4e0c-975f-1e8b8a90c6ff">4.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTg2NjU_45d6594f-ac2f-4b3e-925f-ca7d8997a863">7.6</ix:nonFraction> million, respectively, of equity-based compensation expense.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0Mjc_e70d831f-06db-41cf-bb2d-002b1a4bc996" continuedAt="i7525d4ee848f45b5a0836f5797730a22" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expenses.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses include external and internal expenses.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  Research and development </span></ix:nonNumeric></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="icdf6a03cf48545c99efaf13bb85d3227"><ix:continuation id="i7525d4ee848f45b5a0836f5797730a22"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">employee-related expenses include salaries, benefits and equity-based compensation expense.  Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.  We expense these costs in the period in which they are incurred.  We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received.  As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility and which have no alternative future use.  For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed.  Once the development process has been completed the asset will be amortized over its remaining estimated useful life.</span></div></ix:continuation><div style="text-indent:22.5pt;margin-top:9pt;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NzM_7389613c-e86c-41ea-b4a0-aa94607ec8e7" continuedAt="i5e0d97bf412b4c1cb22a3aaec2146332" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Segment reporting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Our chief operating decision-maker (&#8220;CODM&#8221;) is Phillip Frost, M.D., our Chairman and Chief Executive Officer.  Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis.  We manage our operations in <ix:nonFraction unitRef="segment" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjA2ODg_1d6b79b5-d47e-4c6a-888c-36163887a94b">two</ix:nonFraction> reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span></ix:nonNumeric><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5e0d97bf412b4c1cb22a3aaec2146332"> product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of clinical laboratory operations through BioReference and point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense or income taxes.</ix:continuation>  Refer to Note 14.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><ix:continuation id="ia60f9a36fb99491aaab050d7307dea55"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Shipping and handling costs.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not charge customers for shipping and handling costs.  Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.</span></ix:continuation></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0MzM_4ad59a4b-b74e-4472-a1be-5e31b7e54d72" continuedAt="i18a30fd5883c4e9b9f679cf18b0ca563" escape="true">Foreign currency translation</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i18a30fd5883c4e9b9f679cf18b0ca563">.  The financial statements of certain of our foreign operations are measured using the local currency as the functional currency.  The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods.  Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss).</ix:continuation> </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0MDc_fff3dae5-fa9d-4adc-84bf-d5960c72fa7e" continuedAt="ic9881a86e79f4cef841c32afcc79bee5" escape="true">Variable interest entities</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ic9881a86e79f4cef841c32afcc79bee5">.  The consolidation of a variable interest entity (&#8220;VIE&#8221;) is required when an enterprise has a controlling financial interest.  A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.</ix:continuation>  Refer to Note 5.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NTU_a79b16f9-f423-4c06-b955-0e85cc6809dd" continuedAt="iba4996e525354757b8b9686203ff1941" escape="true">Investments</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="iba4996e525354757b8b9686203ff1941">.  We have made strategic investments in development stage and emerging companies.  We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees.  For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations.  Refer to Note 5.  For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value.</ix:continuation>  Refer to Note 5.</span></div><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQzODU_0ee4483d-31f7-4d34-98b2-fd52cb1ad78c" escape="true"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently adopted accounting pronouncements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221; which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables.  This may result in the earlier recognition of allowances for losses.  The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2019, with early adoption permitted.  The adoption of ASU 2016-13 on January 1, 2020, did not have a significant impact on our Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 3 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfODI0NjMzNzIxMzE0Mw_c10b2735-49a8-44f1-9f9d-948a5bf43030" continuedAt="i96efe85ebddf4cc3bc8d3327e43b2148" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i96efe85ebddf4cc3bc8d3327e43b2148"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic income (loss) per share is computed by dividing our net income (loss) by the weighted average number of shares of our common stock par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTY3_10a35126-c6b7-4c49-8671-bf797e9744d1">0.01</ix:nonFraction> per share (&#8220;Common Stock&#8221;) outstanding during the period.  Shares of Common Stock outstanding under the&#160;share lending&#160;arrangement entered into in conjunction with the 2025 Notes (as defined in Note 6) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.  Refer to Note 6.  For diluted earnings per share, the dilutive impact of stock options and warrants is determined by applying the &#8220;treasury stock&#8221; method.  The dilutive impact of the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes (each, as defined herein and as discussed in Note 6) has been considered using the &#8220;if converted&#8221; method.  For periods in which their effect would be antidilutive, no effect is given to outstanding options, warrants or the potentially dilutive shares issuable pursuant to the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes in the dilutive computation.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A total of <ix:nonFraction unitRef="shares" contextRef="i2cf990d401b84d509ca83830387dfec4_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTIwOA_7c7e79f3-94ea-41fb-a985-c995328504fe">69,505,513</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i703dda2862bf49c082b5e9c7749b1af2_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTIxNQ_728098a4-8b7d-4041-afaa-02fa8664d9c7">68,933,402</ix:nonFraction> potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the three months ended June 30, 2020, and 2019, respectively, because their inclusion would be antidilutive. A total of <ix:nonFraction unitRef="shares" contextRef="i9ae1d925ca624ccfa017da2775100740_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMjU4Ng_53318939-1e90-49fb-90f4-a5e14fb6564b">69,347,867</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4825a57053b245fdb80ca8d81b3e823e_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMjU3MA_cc04c328-f4d8-4bb7-bc5a-96b239951b6e">61,760,134</ix:nonFraction> potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the six months ended June 30, 2020, and 2019, respectively, because their inclusion would be antidilutive.  A full presentation of diluted earnings per share has not been provided because the required adjustments to the numerator and denominator resulted in diluted earnings per share equivalent to basic earnings per share.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June 30, 2020, and 2019, <ix:nonFraction unitRef="shares" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA0Nw_7f963648-5a5d-4974-98e1-ee47915cbf35"><ix:nonFraction unitRef="shares" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="INF" format="ixt-sec:numwordsen" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA0Nw_bb4ecfbe-6da0-4c00-a09e-73e3884c779b">no</ix:nonFraction></ix:nonFraction> Common Stock options or Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="INF" format="ixt-sec:numwordsen" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA3Nw_3661093c-1ea8-4e0d-923e-2cd052c561f9"><ix:nonFraction unitRef="shares" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA3Nw_3aef9b82-753f-463d-908b-2ddc62b95e14">no</ix:nonFraction></ix:nonFraction> shares of Common Stock.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2020, <ix:nonFraction unitRef="shares" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA1OA_a901f3db-789b-4276-8b39-f7baa6dea840">no</ix:nonFraction> Common Stock options or Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA4OA_3d4c853d-a647-44a6-9239-fa6513a593af">no</ix:nonFraction> shares of Common Stock.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2019, <ix:nonFraction unitRef="shares" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMTIwOQ_83b5bc4d-5ef3-417c-afc5-a1ab459ba54e">24,877</ix:nonFraction> Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMTIxNw_a25aad8e-7f6a-4eff-9b5c-01dec65c4001">19,232</ix:nonFraction> shares of Common Stock.  Of the <ix:nonFraction unitRef="shares" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMTIzMg_51495de9-1807-4716-8cbf-10d21f4c5875">24,877</ix:nonFraction> Common Stock options and Common Stock warrants exercised, <ix:nonFraction unitRef="shares" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="opk:SharesSurrenderedInLieuOfCashPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMTIyNQ_b29b696b-6112-43f4-9986-147fbb1dee93">5,645</ix:nonFraction> shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.</span></div></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 4 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMTEwOA_d63919ba-1e3d-4224-977d-eac3b9d260eb" continuedAt="i7ef713a0925b49638cd20b24f82d9ec3" escape="true">COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS</ix:nonNumeric></span></div><div style="margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i7ef713a0925b49638cd20b24f82d9ec3" continuedAt="i4be38b51c34342c490ea4b21017b38e1"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMTA4OA_cd5f1f19-e069-47d2-b6c4-967f010b5c3e" continuedAt="i2cc5748e70cc41d7b827e86f6f4c94c7" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:65.935%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.666%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.667%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMi0xLTEtMS0w_8207e639-14f8-4750-8c43-e50dc7ca1142">215,925</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMi0zLTEtMS0w_00e19fe8-75c5-41d8-9357-9f970ec4d076">136,551</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: allowance for credit losses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMy0xLTEtMS0w_e54f5383-1c07-4d55-8f85-d4927328568a">1,573</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMy0zLTEtMS0w_7e152999-ea48-4c88-9ca4-220fdfc0b706">1,934</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNC0xLTEtMS0w_72a509d3-9b71-40d7-be96-412d54b0a212">214,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNC0zLTEtMS0w_77d0f427-ea53-45c2-94ab-66af6f46a099">134,617</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories, net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consumable supplies</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherInventorySupplies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNi0xLTEtMS0w_1cc52a48-cf52-4ea4-9766-631590cc665a">41,298</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherInventorySupplies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNi0zLTEtMS0w_4ec405d7-ce2b-4d00-ad37-8b93c4098a68">23,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNy0xLTEtMS0w_17d88d02-3bde-4c6d-a4cd-df7a32b5cdd8">24,259</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNy0zLTEtMS0w_84221811-233e-4f62-b4ca-ad250801aa9d">25,142</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfOC0xLTEtMS0w_231231f4-7797-4bb4-9952-78c730aea072">4,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfOC0zLTEtMS0w_b2ecad33-dd22-40b8-99ea-eb87c1f67386">3,238</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfOS0xLTEtMS0w_7b1f019e-ec45-4619-908e-8b743eee3dc1">5,826</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfOS0zLTEtMS0w_c5078fa1-1861-49a6-8612-d9e879ac862b">4,586</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: inventory reserve</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTAtMS0xLTEtMA_8c73a595-829e-4fee-95a1-4f47c56884fd">3,129</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTAtMy0xLTEtMA_09b57170-bf54-42d8-a96c-e332416fbfa4">2,537</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTEtMS0xLTEtMA_8f8ab59f-5d94-4760-978a-bc08f472b95c">72,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTEtMy0xLTEtMA_8da62643-a274-4b90-9cae-d20382b02851">53,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets and prepaid expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes recoverable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:TaxesRecoverableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTMtMS0xLTEtMA_02e943f9-0d47-48bd-841b-1f7662957e06">12,135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="opk:TaxesRecoverableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTMtMy0xLTEtMA_8dd64c9c-2d6e-492c-abab-55e09808669b">19,808</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Supplies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTQtMS0xLTEtMA_62204d6e-6931-498e-a77e-c5d1c025f159">12,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Supplies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTQtMy0xLTEtMA_f7af0c93-d054-4784-8211-344741542602">8,147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTgtMS0xLTEtMA_80f94b18-d580-43e4-a208-fb9148be56b1">6,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTgtMy0xLTEtMA_9b584065-32ef-4e51-a06c-ff0b5e5bacc5">3,486</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other receivables</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTktMS0xLTEtMA_ce145e09-c653-41fe-9ad0-e1c05909a164">661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTktMy0xLTEtMA_50ffe29d-7d9b-40a9-9f87-703b7020a253">3,262</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjAtMS0xLTEtMA_ab2a44b8-6267-44cd-a3c4-bfb087e0ea3a">19,056</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjAtMy0xLTEtMA_8129a711-2d88-427c-89f8-2f1bcb5619c5">15,839</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjEtMS0xLTEtMA_3313f26f-054e-4970-ab5a-391231eded57">51,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjEtMy0xLTEtMA_02920415-3e33-473c-bdf3-c96ccb09313a">50,542</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Customer relationships</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94c6cd428f6b456c8d5b3acae79fbf66_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjMtMS0xLTEtMA_a99e4a2b-8535-4c2d-be07-ab8be3ef5d34">445,144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94eb82a852ec42fbb84bb7e84f189cd8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjMtMy0xLTEtMA_fcf28d5c-5837-4cd5-b51d-71b47cd9c514">445,408</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Technologies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f1de219854f4356843dae3ee1cd6115_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjQtMS0xLTEtMA_75390492-1454-4e68-87ab-6e6b7b6bdc56">296,251</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d2610a4d4b94c94af040534c9ec37b2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjQtMy0xLTEtMA_1907161e-9670-4fc2-9409-74a9f483aa5c">296,246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade names</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaca125106e0d4865a167a745ed415e38_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjUtMS0xLTEtMA_b0f7d8f5-4567-4936-aa54-f6b5899856a1">49,771</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i00247b06c5ee4f84af09a0224926e806_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjUtMy0xLTEtMA_8b469284-0142-443f-9843-c08d5d4c6c57">49,786</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Covenants not to compete</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a3ad80fd03a4bd898db95dcf64037d2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjctMS0xLTEtMA_99bf6b9c-f06a-4c00-b582-955caa807710">16,318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i57b9d57f64db42caaea9671412bed643_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjctMy0xLTEtMA_59c698b2-e077-4df3-bae1-578599f3ee4b">16,318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Licenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ccef43c91b649af897f72ba0ca5d9aa_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjgtMS0xLTEtMA_f848133b-44df-44c9-8c7b-63c9bedaf00d">5,766</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64d57f02fcfa4a818269328b1928521f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjgtMy0xLTEtMA_14318670-c803-4fd8-8932-d87d9b09e194">5,766</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product registrations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8cd1bd900ad44d581af60988c19e099_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjktMS0xLTEtMA_65d796e4-3620-4687-8da2-55921d66207d">7,109</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3e7a27b8c6642a990135286515905fa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjktMy0xLTEtMA_a9b97b71-a5cc-4607-a88b-521e5a9269e7">7,578</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i04069b5f0be245a5b667f48793383f5c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzAtMS0xLTEtMA_0e69a5ee-f9a2-44ba-a500-31466b72dc0e">6,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i135e6bd0ecae45b790948a4ae8040c83_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzAtMy0xLTEtMA_7fc980b9-2856-434d-8c7c-e00055f9ad07">6,094</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzEtMS0xLTEtMA_c342367f-71a0-4179-98c4-695577cef303">327,334</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzEtMy0xLTEtMA_66e2156f-8f8f-49be-bdf4-344305b20e83">298,234</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzItMS0xLTEtMA_bb844b44-13b9-4d68-8802-0b99a80989ec">499,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzItMy0xLTEtMA_896c030d-0712-4438-95ad-1a99d5145dfe">528,962</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory received but not invoiced</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:InventoryReceivedNotInvoicedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzQtMS0xLTEtMzU2Mg_e3f63970-55b5-4c2c-95e9-d417d0858391">49,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="opk:InventoryReceivedNotInvoicedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzQtMy0xLTEtMzU2Mg_89e6db37-a81a-4997-a383-8b270bec5886">13,751</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and Contingencies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:AccruedCommitmentsandContingenciesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzQtMS0xLTEtMzU0MA_5978ba02-139e-4c21-b929-2691c5e8d6ab">38,668</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="opk:AccruedCommitmentsandContingenciesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzQtMy0xLTEtMzU0MA_1807199f-08ae-4a00-88df-0346d76e8c92">38,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzUtMS0xLTEtMA_aeb3b67c-b2f1-4519-9eff-925f0af6ee13">34,086</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzUtMy0xLTEtMA_b9505fac-466f-4602-91f9-e1c51fee3b0b">33,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzctMS0xLTEtMzU1Mg_02addf7f-e9d4-4189-b5db-df4da3dd123c">16,570</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzctMy0xLTEtMzU1Mg_c76ae447-806a-4ffa-aa4a-1e749eeb723d">19,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:AccruedClinicalTrialsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzctMS0xLTEtMA_5fd1635c-2167-4989-954c-ac1ec4bcbee4">6,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="opk:AccruedClinicalTrialsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzctMy0xLTEtMA_7f8ac80f-1655-47f5-8194-e55cb8147edb">8,122</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzktMS0xLTEtMA_a8afe25f-b333-4695-8429-1edd59bbc72d">2,375</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzktMy0xLTEtMA_c13ba25b-0af6-4632-b7f0-bbf1b43eab4b">2,375</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases short-term</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDAtMS0xLTEtMA_9d75a96f-3bbb-46fa-97e7-a017b35149d3">2,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDAtMy0xLTEtMA_3cd0ed13-2146-49a0-89e9-efe042736264">2,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDItMS0xLTEtMA_62dae26e-ecaf-4685-859b-fa636c8d6825">4,009</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDItMy0xLTEtMA_d6f7c3df-6720-42e4-a603-865d4808c0e2">1,333</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDQtMS0xLTEtMA_0b882250-1ada-46e7-ad24-01dee0bb9218">56,884</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDQtMy0xLTEtMA_d30251cb-d9f9-458e-afaa-1d06b8a0fc19">45,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDUtMS0xLTEtMA_11e752eb-8c75-4505-b3e5-8c55187edc44">210,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDUtMy0xLTEtMA_69f54ac1-fa4a-4163-93b2-627fd8d1b48c">164,925</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i4be38b51c34342c490ea4b21017b38e1"><div style="margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i2cc5748e70cc41d7b827e86f6f4c94c7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:65.935%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.666%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.667%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Line of credit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDktMS0xLTEtMA_92e4b5bf-e1ce-401d-866a-d2130c8d6e61">51,489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDktMy0xLTEtMA_e37b128c-fa6b-47da-b362-d3faa7cb769b">44,749</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTAtMS0xLTEtMA_19ad2b0e-59c4-4b26-83ac-b931803e1c3e">7,559</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTAtMy0xLTEtMA_0f012fef-7ff1-4a6b-b050-8b9e5611e053">7,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgages and other debts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTItMS0xLTEtMA_2d72a1ce-3df1-483f-897c-746d367f82a9">4,201</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTItMy0xLTEtMA_f0dfba9d-a3f1-470d-8714-3c0c5770f8f3">3,906</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases long-term</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTMtMS0xLTEtMA_054ea014-902f-4cce-a676-7db48df902f5">2,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTMtMy0xLTEtMA_cecd9d6e-93ac-4a2f-95e2-78e1a488ccc9">4,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTQtMS0xLTEtMA_82d3799a-4401-4609-be39-ce61f9cb2f94">1,170</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTQtMy0xLTEtMA_16313edf-8c96-448b-bb79-820a03615192">2,571</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTUtMS0xLTEtMA_f2494799-db86-46c2-9bf3-ad6d25c8aa98">24,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTUtMy0xLTEtMA_5c123ed6-8e90-402e-9049-11241581e771">25,224</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTYtMS0xLTEtMA_3f71d8c2-21cc-41f2-bca6-bb74f9aac5fe">91,653</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTYtMy0xLTEtMA_5887ef32-614a-4ecb-af75-5ac186a2922c">87,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:22.5pt;margin-top:9pt;"><span><br/></span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our intangible assets and goodwill relate principally to our completed acquisitions of OPKO Renal, OPKO Biologics, EirGen Pharma Limited (&#8220;EirGen&#8221;) and BioReference.  We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives.  The estimated useful lives by asset class are as follows:  technologies - <ix:nonNumeric contextRef="i230b30ca3eb04af49f4ca4734faacd44_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1NjcyMQ_a337f835-270d-4d37-ba64-4b495333683f">7</ix:nonNumeric>-<ix:nonNumeric contextRef="i882f8261760b4d6aa3a96e6fa3284bfb_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1NjcyNw_d0fe2183-e1e9-4c66-aa59-3c85d572e14d">17</ix:nonNumeric> years, customer relationships - <ix:nonNumeric contextRef="ied7d8e97b2b945238ba32720ff6e8c0f_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1NjczMw_9dfdba16-e927-482e-8f91-74f8eb4bee0f">7</ix:nonNumeric>-<ix:nonNumeric contextRef="i9ecfd46843994ca2aa33b2267b51858d_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1NjczOA_464db8ef-9d4b-45c3-b9d8-6f6262306091">20</ix:nonNumeric> years, product registrations - <ix:nonNumeric contextRef="i1497918852414fb6ac3b2f71effa85a6_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc0NA_64af5312-15e0-4d53-9b89-149f0e12f4ac">7</ix:nonNumeric>-<ix:nonNumeric contextRef="i0da706af1baa4c159c9bbb8d4c1030fd_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc0OQ_c5025749-3c06-4994-b7d3-9343f0cfa797">10</ix:nonNumeric> years, covenants not to compete - <ix:nonNumeric contextRef="i11f6b9bd556843b1aafd7e182d59c3cb_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc1NQ_86a26781-d0b0-4ba1-aca9-e7f5c97bff61">5</ix:nonNumeric> years, trade names - <ix:nonNumeric contextRef="i8408841c1a734a08b778637e70249682_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc2MA_ef469664-14bb-44dd-9aca-6af9c0734fd9">5</ix:nonNumeric>-<ix:nonNumeric contextRef="i5adb35b4c9f34a37aeb9549a65e96e46_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc2NQ_3f1ebfbf-8a38-4278-8ed0-d1d1a0272802">10</ix:nonNumeric> years, other <ix:nonNumeric contextRef="i4f61b01165e24fc98421d859fadcd8b2_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc3MQ_1362bf04-4184-4409-831a-fff0499c8ac7">9</ix:nonNumeric>-<ix:nonNumeric contextRef="i179802b429d44dda9f21192ac337df1a_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc3Ng_926a35e4-f6ad-4212-a942-cd4e34018f81">13</ix:nonNumeric> years.  We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred.  Our goodwill is not tax deductible for income tax purposes in any jurisdiction in which we operate.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in value of the intangible assets and goodwill during the six months ended June 30, 2020 were primarily due to foreign currency fluctuations between the Chilean Peso, the Euro and the Shekel against the U.S. dollar.  </span></div><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMTEwMQ_62915faa-1f94-44c5-8fb7-76f5fa075999" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the changes in Goodwill by reporting unit during the six months ended June 30, 2020.</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:49.537%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.666%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:13.666%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.667%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign exchange and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30th</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceuticals</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rayaldee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic18db37a30a74d9c9ee748531acedbae_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNC0xLTEtMS0w_adb4ac57-36d3-463a-8199-21754eec5016">85,605</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ea760e341c847f4a25f3b37d6b09d32_D20200101-20200630" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNC01LTEtMS0w_749a9368-5a8f-4ec8-a193-038ea1530e40">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52b56c73c8d84a5e8fb1fa551b3eddd3_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNC03LTEtMS0w_3eda7bdd-a5e5-4672-8412-9476a6e37a07">85,705</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPKO Chile</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i483bd6c64a9c49c2b324993790f590ee_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNi0xLTEtMS0w_d430a7cd-32c6-4527-95a5-64f0d73f402a">4,348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i798edede7d9340b38166a915bb9c5868_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNi01LTEtMS0w_59d5ba1d-729d-4d91-bf44-ec7d391dc6de">450</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b2f66f652b94502a75f85a54c4c3ef4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNi03LTEtMS0w_383ce595-c3ae-4977-8a76-cf5a9794854c">3,898</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPKO Biologics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cd4a728fcd14faf998c1ab9c30b3b83_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNy0xLTEtMS0w_d1f184bc-5514-4ddd-828a-23b9a629fc7d">139,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i33fff5e9ff6341f0bb92ec8ca48cb6e0_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNy01LTEtMS0w_89479d64-68e2-47bc-995c-e57085969525">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd9cb4e1c5bf46f7811c43a8af57ec52_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNy03LTEtMS0w_5bd11f6e-e7ea-4f6a-9001-cd2a0d33e2c6">139,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPKO Health Europe</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94fa7a9bd57a4f9bb8aa3d9c5b228336_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfOC0xLTEtMS0w_62c5dfb4-31be-414e-b75a-2a046381c1d2">7,394</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i771f4bcba7074c7bbbdffdd2ad65b477_D20200101-20200630" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfOC01LTEtMS0w_a43f397b-dff8-444a-b3f3-c2591e2a26a4">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f6803f62e7447adadce391b33061cba_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfOC03LTEtMS0w_ee1c822a-c9c5-480b-babd-66ed36ddf11e">7,403</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BioReference</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79658e603527497182db4f569fcc87f7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTQtMS0xLTEtMA_1d54bede-ec5e-4aa2-9ddc-28eaf16ea36b">434,809</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i986492897965401d95c6a703c55c6e77_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTQtNS0xLTEtMA_5d5581cb-ab48-4a8b-a87e-64b31d0c2ce1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93c9c6bb19df4ae99dc27947a8f03121_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTQtNy0xLTEtMA_7b99b53b-2863-4f54-9984-f0245364d1bf">434,809</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTctMS0xLTEtMA_74ddae7a-df7a-4ecb-864c-8287fc7796aa">671,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTctNS0xLTEtMA_9590ead7-817f-4f30-a12b-120b91facfac">341</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTctNy0xLTEtMA_48ba26cb-1903-4229-8eb3-9f0d4515ce4f">671,599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 5 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:InvestmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDc4OQ_f6732116-86e9-4a9f-9b45-c6e618c10a7c" continuedAt="i50f94eccf5af4ff5b9c868cc7dd54380" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i50f94eccf5af4ff5b9c868cc7dd54380" continuedAt="i2f1440c7bd6f43939ca6a96e45dbd0b7"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments</span></div><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:InvestmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDgxNw_38dd2f91-f4c7-4f64-98fc-d6444b5071b4" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June&#160;30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:51.460%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.533%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.535%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment type</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment Carrying Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Underlying Equity in Net Assets</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity method investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" name="opk:EquityMethodInvestmentExcludingVariableInterestEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfMi0yLTEtMS0w_07590cf4-9dc2-4650-89c5-383b581d16a1">561</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfMi00LTEtMS0w_f34de138-757e-4eda-9e52-d2c86dd9cfa2">2,370</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable interest entity, equity method</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" name="opk:EquityMethodInvestmentVariableInterestEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfMy0yLTEtMS0w_e043e614-429a-4d90-8d16-db994e01de69">836</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfNC0yLTEtMS0w_36272ade-d2b2-42e1-87c3-2c68af681230">24,777</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfNS0yLTEtMS0w_561bed32-ccab-4c6c-bcc1-727787c9d5fd">35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants and options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" name="opk:StockOptionandWarrantInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfNi0yLTEtMS0w_534d6356-9f8f-479b-a268-6e0dbc08514c">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total carrying value of investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfNy0yLTEtMS0w_e2abf96e-0e1d-447a-b521-c8ab09bdf750">26,260</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;">Equity method investments</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our equity method investments consist of investments in Pharmsynthez (ownership <ix:nonFraction unitRef="number" contextRef="ib4fc9634e3a348bab19da19df297d2c9_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjkx_740cdd31-f996-483a-a209-6faa23fe4014">9</ix:nonFraction>%), Cocrystal Pharma, Inc. (&#8220;COCP&#8221;) (<ix:nonFraction unitRef="number" contextRef="i40c56be3936e42218c130b6171df7087_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMzI5_0cd1fdbd-e734-413b-8c68-5ebd7b85ab3b">5</ix:nonFraction>%), Non-Invasive Monitoring Systems, Inc. (&#8220;NIMS&#8221;) (<ix:nonFraction unitRef="number" contextRef="i4b1d2bd1b0014409b092ff4aa9f8efb5_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMzgy_c67e1dd9-fa6a-4c74-b76f-305e169fc3e5">1</ix:nonFraction>%), Neovasc, Inc. (&#8220;Neovasc&#8221;) (<ix:nonFraction unitRef="number" contextRef="ia1aa8cc835a1411f9161a88fefd51afb_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDE0_06b2a5bc-d09e-439c-8ed2-47f75d54dc61">2</ix:nonFraction>%), InCellDx, Inc. (&#8220;InCellDx&#8221;) (<ix:nonFraction unitRef="number" contextRef="iecfe4462c2ee470cb896cbcb8858c7f9_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDQ4_a71314fe-23c9-45b5-9682-b54cee5a2c65">29</ix:nonFraction>%), BioCardia, Inc. (&#8220;BioCardia&#8221;) (<ix:nonFraction unitRef="number" contextRef="ie5822595b03740f291e2481860949888_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDg0_90c44e03-3211-4ca2-abab-ae37a34ab699">2</ix:nonFraction>%), and Xenetic Biosciences, Inc. (&#8220;Xenetic&#8221;) (<ix:nonFraction unitRef="number" contextRef="i323d8d5a5c3f438bb251f37e63e4c809_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNTMy_632131d4-6ef5-4e49-930b-01fbb6e46131">3</ix:nonFraction>%).  The aggregate total assets, liabilities, and net losses of our equity method investees as of and for the six months ended June 30, 2020 were $<ix:nonFraction unitRef="usd" contextRef="i7d3ef7c1241144ff931d3374e709b07e_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNjUx_8fe99f24-8228-4a7e-a760-dbf31c65e757">79.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7d3ef7c1241144ff931d3374e709b07e_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNjU1_28fd09fb-5d86-4a32-8a58-e1302334f087">32.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i9f4e2d31d1d5424882ae14d6cb9c371c_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNjYz_da4ff28c-e7a8-4e99-96f2-63177a9fcd6f">26.6</ix:nonFraction> million, respectively.  We have determined that we and/or our related parties can significantly influence control of our equity method investments through our board representation and/or voting power.  Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Condensed Consolidated Statement of Operations.  The aggregate value of our equity method investments based on the quoted market prices of their respective shares of common stock and the number of shares held by us as of June&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTI2OQ_951342b2-4290-413a-8603-81b151a95d8b">7.9</ix:nonFraction> million.  </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Equity Securities</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our equity securities consist of investments in Phio Pharmaceuticals (&#8220;Phio&#8221;) (ownership <ix:nonFraction unitRef="number" contextRef="ibe9c0975275d45f6898ff7d4f683e8e3_I20200630" decimals="4" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTM4Mg_852752fe-9cde-49f9-a2cf-9526d9f862a9">0.02</ix:nonFraction>%), VBI Vaccines Inc. (&#8220;VBI&#8221;) (<ix:nonFraction unitRef="number" contextRef="i09cc35711f9348d9b1b3f52011a7e368_I20200630" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTQxNA_b45c523a-bd96-4369-88cf-e6cfa4d900c1">3</ix:nonFraction>%), ChromaDex Corporation (&#8220;ChromaDex&#8221;) (<ix:nonFraction unitRef="number" contextRef="i79df6dd0e9984686893d9cfc9fe6d27f_I20200630" decimals="3" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTQ1Ng_f62a0db4-5848-47d7-b7c5-de0976afa064">0.1</ix:nonFraction>%), MabVax Therapeutics Holdings, Inc. (&#8220;MabVax&#8221;) (<ix:nonFraction unitRef="number" contextRef="if01ceaf264f64e64b9647bf4a84dac24_I20200630" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTUwOA_83b19f60-56d6-4de1-926a-b8b87b039725">1</ix:nonFraction>%), and Eloxx Pharmaceuticals, Inc. (&#8220;Eloxx&#8221;) (<ix:nonFraction unitRef="number" contextRef="i94995994c21b4facabf08492a51c559a_I20200630" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTU1Ng_1583bd52-2fe0-486d-86ff-cd64a3390772">3</ix:nonFraction>%).  We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of these investments.  Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have readily determinable fair value. Equity securities without a readily determinable fair value are adjusted to fair value when there is an observable price change. <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDgxOA_bf1f7950-efbe-41ee-8834-78d836795bce" continuedAt="i74f33c2f89484080809cdcc7c4c54858" escape="true">Net gains and losses on our equity securities for the six months ended June 30, 2020 were as follows:</ix:nonNumeric></span></div><div style="margin-top:14pt;margin-bottom:5pt;"><ix:continuation id="i74f33c2f89484080809cdcc7c4c54858"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:76.592%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.706%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.502%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity Securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net gains and losses recognized during the period on equity securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjkxNmJhYmU2NTMwYjQwYmVhODkxOGFhZjQzYzUxODIwL3RhYmxlcmFuZ2U6OTE2YmFiZTY1MzBiNDBiZWE4OTE4YWFmNDNjNTE4MjBfMi0yLTEtMS0w_57a9419c-a2a0-4df4-8739-aa44a6e16337">5,907</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Net gains and losses realized during the period on equity securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjkxNmJhYmU2NTMwYjQwYmVhODkxOGFhZjQzYzUxODIwL3RhYmxlcmFuZ2U6OTE2YmFiZTY1MzBiNDBiZWE4OTE4YWFmNDNjNTE4MjBfMy0yLTEtMS0w_b3a71732-ca77-4585-a274-0f0ce1eef5da">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized net gains recognized during the period on equity securities still held at the reporting date</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjkxNmJhYmU2NTMwYjQwYmVhODkxOGFhZjQzYzUxODIwL3RhYmxlcmFuZ2U6OTE2YmFiZTY1MzBiNDBiZWE4OTE4YWFmNDNjNTE4MjBfNC0yLTEtMS0w_7381bd79-10a0-43d4-b009-b7aacadd3786">5,907</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sales of investments</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statement of Operations.  We did not have significant sales activity during the six months ended June 30, 2020 and 2019.  The cost of securities sold is based on the specific identification method.  </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Warrants and options</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to our equity method investments and equity securities, we hold options to purchase <ix:nonFraction unitRef="shares" contextRef="ie5822595b03740f291e2481860949888_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjYyNg_66cb8140-bc43-49ab-bff2-3058c589a888">47</ix:nonFraction> thousand additional shares of BioCardia, <ix:nonFraction unitRef="shares" contextRef="ie5822595b03740f291e2481860949888_I20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjY2MQ_8c82ea08-de5c-41a3-b6c5-f59dc694e694">33</ix:nonFraction> thousand of which were vested as of June&#160;30, 2020, and <ix:nonFraction unitRef="shares" contextRef="i40c56be3936e42218c130b6171df7087_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjY5OQ_75963950-7967-4018-bf93-d2e72859e279">33</ix:nonFraction> thousand, <ix:nonFraction unitRef="shares" contextRef="iecfe4462c2ee470cb896cbcb8858c7f9_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjcwMw_57a40e39-694e-4744-a4d2-37b87326febd">0.7</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i323d8d5a5c3f438bb251f37e63e4c809_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjcwNw_2f02f019-9cb0-4e1e-a4fc-199486df25a0">40</ix:nonFraction> thousand and <ix:nonFraction unitRef="shares" contextRef="ibe9c0975275d45f6898ff7d4f683e8e3_I20200630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjcxNA_3da1b462-1bf2-4f83-9024-73a0428c7c3a">404</ix:nonFraction> </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i2f1440c7bd6f43939ca6a96e45dbd0b7"><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">warrants to purchase shares of COCP, InCellDx, Inc., Xenetic, and Phio, respectively.  We recorded the changes in the fair value of the options and warrants in Fair value changes of derivative instruments, net in our Condensed Consolidated Statement of Operations.  We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheet.  See further discussion of the Company&#8217;s options and warrants in Note 8 and Note 9.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments in variable interest entities</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have determined that we hold variable interests in Zebra Biologics, Inc. (&#8220;Zebra&#8221;) based on our assessment that Zebra does not have sufficient resources to carry out its principal activities without additional financial support.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We own <ix:nonFraction unitRef="shares" contextRef="i84662a74a01c4b2d941452c7e6b5ee4a_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMzQ3Ng_d436ca9d-5d3b-4c74-8391-e1fea5e6895d">1,260,000</ix:nonFraction> shares of Zebra Series A-2 Preferred Stock and <ix:nonFraction unitRef="shares" contextRef="i90446d4596a146d88429e4a98be0564f_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="opk:SharesReceivedAsGift" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMzUyNg_d8b1c489-94f8-4e94-a103-2d006847c9d4">900,000</ix:nonFraction> shares of Zebra restricted common stock (ownership <ix:nonFraction unitRef="number" contextRef="if6747d466c09424e9a50661e16dd7503_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMzU4MA_c05acf9c-4f2b-45fa-860a-d8ef16b2c2e4">29</ix:nonFraction>% at June&#160;30, 2020).  Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs.  Dr. Richard Lerner, M.D., a member of our Board of Directors, is a founder of Zebra and, along with Dr. Frost, serves as a member of Zebra&#8217;s Board of Directors.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related parties&#8217; investment, as well as our investment combined with the related parties&#8217; investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra.  Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebra&#8217;s economic performance and have no obligation to fund expected losses.  We determined, however, that we can significantly influence control of Zebra through our board representation and voting power.  Therefore, we have the ability to exercise significant influence over Zebra&#8217;s operations and account for our investment in Zebra under the equity method.</span></div></ix:continuation><div id="ia969b45ba09947e9a03ce421f700f5b3_64"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 6 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTY0NTA_78b96ca1-517c-4ab3-9428-7d0ef3c1fccf" continuedAt="i0d518f67eea245a3bd08854fa7179c61" escape="true">DEBT</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i0d518f67eea245a3bd08854fa7179c61" continuedAt="iea6c73b79f5c4bd29dff8b0028158113">&#160;</ix:continuation></span></div><ix:continuation id="iea6c73b79f5c4bd29dff8b0028158113" continuedAt="ibeb4c02af05e414194bb0f230353a8ea"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i7f02e4f9fd574e05a785e3c62f223eb4_I20200225" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMjEw_f3e01ee0-f303-4df8-9f2b-7e5980d0982f">100</ix:nonFraction> million.  Borrowings under the line of credit will bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="i7f02e4f9fd574e05a785e3c62f223eb4_I20200225" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMjgz_9ec6b80c-adb4-431b-b1cf-8b1c8ece123b">11</ix:nonFraction>% per annum and may be repaid and reborrowed at any time.  The credit agreement includes various customary remedies for the lender following an event of default, including the acceleration of repayment of outstanding amounts under line of credit.  The line of credit matures on February 25, 2025. The line of credit also calls for a commitment fee equal to <ix:nonFraction unitRef="number" contextRef="i7c119d6e22ac4137a2e112127278f9af_D20200225-20200225" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNjQx_d8a00a10-2f84-4392-82c8-5cd2f0e85a7f">0.25</ix:nonFraction>% per annum of the unused portion of the line. As of June 30, 2020, no funds were borrowed under the line of credit.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, we issued $<ix:nonFraction unitRef="usd" contextRef="i8195e9a3e7ae435da153c7711a07ccb8_I20190228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzg4_d706506a-696e-409e-b6f5-94cf2af40ed5">200.0</ix:nonFraction> million aggregate principal amount of Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in an underwritten public offering.  The 2025 Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="i628701cad23a4cacaed112b486d72676_I20190228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTUz_6a674beb-1e43-4b60-8943-f97f0a94237e">4.50</ix:nonFraction>% per year, payable semiannually in arrears on February&#160;15 and August&#160;15 of each year.  The notes mature on February&#160;15, 2025, unless earlier repurchased, redeemed or converted.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders may convert their 2025 Notes into shares of Common Stock at their option at any time prior to the close of business on the business day immediately preceding November&#160;15, 2024 only under the following circumstances:  (1)&#160;during any calendar quarter commencing after the calendar quarter ended March&#160;31, 2019 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at least <ix:nonFraction unitRef="day" contextRef="i3d0c8459b0d1480baa745356d20f4dc6_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU1Ng_615631b4-2768-44c6-993c-79b8b8adde84">20</ix:nonFraction> trading days (whether or not consecutive) during a period of <ix:nonFraction unitRef="day" contextRef="i9c0022ff1fff4fa7ba8b28cb480d9e7b_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTYyMA_90288559-4ad3-4f45-8ce7-55fcd8b22bee">30</ix:nonFraction> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="i7c71fc44fe84471c8a385354d7db5b4d_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTc1Mw_cd02f455-b200-4290-be48-1780b841df1f">130</ix:nonFraction>% of the conversion price on each applicable trading day; (2)&#160;during the <ix:nonFraction unitRef="day" contextRef="i888c9ebcddbc498c8ab5222fdd77b5af_D20190201-20190228" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTgyNw_0756921b-a287-4ee5-8dcc-86a6932de2a6">five</ix:nonFraction> business day period after any <ix:nonFraction unitRef="day" contextRef="i81c329c54b3b47abb5e4773dc4152952_D20190201-20190228" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTg2MA_efd9a04b-c91e-4ab0-aa6b-7139acb09000">five</ix:nonFraction> consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of 2025 Notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i34d8ef11ad99488aa65782d224ee68dd_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMjA1MQ_ad998d88-b18e-4a47-a327-9881255ec9ff">98</ix:nonFraction>% of the product of the last reported sale price of our Common Stock and the conversion rate on each such trading day; (3)&#160;if we call any or all of the 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4)&#160;upon the occurrence of specified corporate events set forth in the indenture governing the 2025 Notes.  On or after November&#160;15, 2024, until the close of business on the business day immediately preceding the maturity date, holders of the 2025 Notes may convert their notes at any time, regardless of the foregoing conditions.  Upon conversion, we will pay or deliver, as the case may be, cash, shares of our Common Stock, or a combination of cash and shares of our Common Stock, at our election.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial and current conversion rate for the 2025 Notes is 236.7424 shares of Common Stock per $1,000 principal amount of 2025 Notes (equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i8195e9a3e7ae435da153c7711a07ccb8_I20190228" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMzAyNw_866494b6-f879-44ac-9018-165e49bb0056">4.22</ix:nonFraction> per share of Common Stock).  The conversion rate for the 2025 Notes is subject to adjustment in certain events, but will not be adjusted for any accrued and unpaid interest.  In addition, following certain corporate events that occur prior to the maturity date of the 2025 Notes or if we deliver a notice of redemption, in certain circumstances the indenture governing the 2025 Notes requires an increase in the conversion rate of the </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="ibeb4c02af05e414194bb0f230353a8ea" continuedAt="ic8a83f852d214050bb702a645cbfbce6"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2025 Notes for a holder who elects to convert its notes in connection with such a corporate event or notice of redemption, as the case may be.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not redeem the 2025 Notes prior to February&#160;15, 2022.  We may redeem for cash any or all of the 2025 Notes, at our option, on or after February&#160;15, 2022, if the last reported sale price of our Common Stock has been at least <ix:nonFraction unitRef="number" contextRef="ifd9c15a8bce54e078a65dfcda71e2b93_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMzgzOQ_a2b25524-ea99-40d0-b114-5cd835057688">130</ix:nonFraction>% of the then current conversion price for the notes for at least <ix:nonFraction unitRef="day" contextRef="ib386889486af4a37ada3615b1c1421e7_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMzkwNg_d8e1e497-519b-47a3-9b34-f97acdc61ba3">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="day" contextRef="id8a7a241ec2b494485438af91f368462_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMzk2Mg_229708ca-6f75-4e4d-a3c0-1954780010c7">30</ix:nonFraction> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide a notice of redemption at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="ifd9c15a8bce54e078a65dfcda71e2b93_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNDE5MQ_a4fb6789-de71-4e13-97ed-2381adc8a764">100</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.  No sinking fund is provided for the 2025 Notes.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we undergo a fundamental change, as defined in the indenture governing the 2025 Notes, prior to the maturity date of the 2025 Notes, holders may require us to repurchase for cash all or any portion of their notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i7c71fc44fe84471c8a385354d7db5b4d_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNDYxNg_6315f2d0-cb21-4bbd-9634-111ce7692258">100</ix:nonFraction>% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.  The 2025 Notes are our senior unsecured obligations and rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2025 Notes; equal in right of payment to any of our existing and future liabilities that are not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the issuance of the 2025 Notes, we agreed to loan up to <ix:nonFraction unitRef="shares" contextRef="i8195e9a3e7ae435da153c7711a07ccb8_I20190228" decimals="INF" format="ixt:numdotdecimal" name="opk:DebtInstrumentConvertibleDebtMaximumSharesIssuable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNTQwNg_249f0d1c-9661-4a61-8292-f67ba64b2855">30,000,000</ix:nonFraction> shares of our Common Stock to affiliates of the underwriter in order to assist investors in the 2025 Notes to hedge their position. As of&#160;June&#160;30, 2020, a total of&#160;<ix:nonFraction unitRef="shares" contextRef="i870ca847a91146ff97990a7c7cdd8e63_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNTU2Mg_22403393-0a7d-43d0-90de-154b67ac5dc4">29,250,000</ix:nonFraction> shares were issued under the&#160;share lending&#160;arrangement. We will not receive any of the proceeds from the sale of the borrowed shares, but we received a one-time nominal fee of $<ix:nonFraction unitRef="usd" contextRef="i870ca847a91146ff97990a7c7cdd8e63_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="opk:ProceedsFromConvertibleDebtConversionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNTc0MQ_de1b9393-df34-47cc-80c8-2722a855ebef">0.3</ix:nonFraction> million for the newly issued shares. Shares of our Common Stock outstanding under the&#160;share lending&#160;arrangement are excluded from the calculation of basic and diluted earnings per share. See Note 3.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As required by ASC 470-20, &#8220;Debt with Conversion and Other Options,&#8221; we calculated the equity component of the 2025 Notes, taking into account both the fair value of the conversion option and the fair value of the&#160;share lending arrangement. The equity component was valued at&#160;$<ix:nonFraction unitRef="usd" contextRef="i8195e9a3e7ae435da153c7711a07ccb8_I20190228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNjIxMQ_e426c05a-ce44-4089-8e4e-870b5fdb7ee0">52.6</ix:nonFraction> million&#160;at issue date and this amount was recorded as Additional paid-in capital, which resulted in a discount on the 2025 Notes. The discount is being amortized to Interest expense over the term of the 2025 Notes, which results in an effective interest rate on the 2025 Notes of <ix:nonFraction unitRef="number" contextRef="i8d2d51166e124a23a7ecda07a40b9b8c_I20200630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNjQ4Ng_6d530c43-d749-45ba-bf53-75046fb4c3ad">11.2</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTY0NjI_6dd8a311-5fb2-49e6-9926-9e058df53b21" continuedAt="i7af18101736942e79d3cebf8f8be1d04" escape="true"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth information related to the 2025 Notes which is included in our Condensed Consolidated Balance Sheet as of June&#160;30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:51.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.985%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 Senior Notes</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt Issuance Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6c32717a26d40d88eae1ea4982913d6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMS0xLTEtMS0w_8b1a6957-faa1-479c-9df1-efece6b3f253">200,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6c32717a26d40d88eae1ea4982913d6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMS0zLTEtMS0w_6e85e988-21f1-4549-91ce-61207643b63d">46,774</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if6c32717a26d40d88eae1ea4982913d6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMS01LTEtMS0w_38dca37b-a985-4a55-b074-f64d7a5d297e">5,086</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6c32717a26d40d88eae1ea4982913d6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMS03LTEtMS0w_569ee474-f0ae-4cf8-a542-83a3b099d2d6">148,140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount and debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a737d9667b94ccdbd7e9b723c6dcf66_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMy0zLTEtMS0w_c8ee39f1-6247-4015-ba93-04c529865371">3,497</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a737d9667b94ccdbd7e9b723c6dcf66_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMy01LTEtMS0w_b8b81cf9-195b-410f-8dea-73c288a7ec97">381</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a737d9667b94ccdbd7e9b723c6dcf66_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMy03LTEtMS0w_1cd769cf-ea5b-4795-8cac-7773f0615d89">3,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c8df4da0e504a6a9b34701d6f7d3cd7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfNS0xLTEtMS0w_ce470814-9df7-4ebc-96cc-1eea9ad51e95">200,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c8df4da0e504a6a9b34701d6f7d3cd7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfNS0zLTEtMS0w_29fb4f6f-826f-433e-8a18-e91fa8778e98">43,277</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c8df4da0e504a6a9b34701d6f7d3cd7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfNS01LTEtMS0w_145b35d2-f13e-4309-9562-99c31954de72">4,705</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c8df4da0e504a6a9b34701d6f7d3cd7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfNS03LTEtMS0w_fafb82f2-9f26-4437-a848-f8a6d7af1465">152,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 8, 2018, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i45d70386f33c4ae487d8d292158b179c_I20181108" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNjg0NA_86b15262-04e2-46cf-a133-1598c8ffc9f1">60</ix:nonFraction> million.  The credit agreement was terminated on or around February 20, 2019 and we repaid the $<ix:nonFraction unitRef="usd" contextRef="i268d6c6d9d5e407ea296ba2214d356e1_D20190220-20190220" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNjkzNA_c03ce600-a600-4a06-96d8-24b60c8775d9">28.8</ix:nonFraction> million outstanding thereunder from the proceeds of the 2025 Notes offering. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, we issued a series of <ix:nonFraction unitRef="number" contextRef="iac1e5f5cb1464cb9905c5e33a1c7fede_I20180228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzA0Nw_2dd9e151-debd-4d1d-a3de-1694b8c83a96">5</ix:nonFraction>% Convertible Promissory Notes (the &#8220;2023 Convertible Notes&#8221;) in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="iac1e5f5cb1464cb9905c5e33a1c7fede_I20180228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzE0Nw_595ea9d6-1f8d-4bb7-babf-510e1af84071">55.0</ix:nonFraction> million.  The 2023 Convertible Notes mature <ix:nonNumeric contextRef="i41911bac43624dd190e89f282a2ee86a_D20180201-20180228" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMjE5OTAyMzI3MjA2NA_2573cbed-50fc-42f1-9008-dfe70089267f">five years</ix:nonNumeric> following the date of issuance.  Each holder of a 2023 Convertible Note has the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iac1e5f5cb1464cb9905c5e33a1c7fede_I20180228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzUxMA_879029f9-80b0-45d4-90f2-f6baead8ca79">5.00</ix:nonFraction> per share.  We may redeem all or any part of the then issued and outstanding 2023 Convertible Notes, together with accrued and unpaid interest thereon, pro rata among the holders, upon no fewer than <ix:nonNumeric contextRef="i41911bac43624dd190e89f282a2ee86a_D20180201-20180228" format="ixt-sec:durday" name="opk:DebtInstrumentConvertibleConversionNoticeThresholdMinimum" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzcxMg_810e8530-e616-4704-acf4-13a225abe2a4">30</ix:nonNumeric> days, and no more than <ix:nonNumeric contextRef="i41911bac43624dd190e89f282a2ee86a_D20180201-20180228" format="ixt-sec:durday" name="opk:DebtInstrumentConvertibleConversionNoticeThresholdMaximum" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzczOA_07cfcaf9-81e0-4895-9828-248c12e51096">60</ix:nonNumeric> days, notice to the holders.  The 2023 Convertible Notes contain customary events of default and representations and warranties of OPKO.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Purchasers of the 2023 Convertible Notes included an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer.  </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="ic8a83f852d214050bb702a645cbfbce6" continuedAt="i467b0c9d4dba49cd9e29613d4c6bf19b"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2013, we entered into note purchase agreements with respect to the issuance and sale of our <ix:nonFraction unitRef="number" contextRef="i640328d25f104a07a644f3c84408a24d_I20130130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfODE5OQ_96ecc9c4-7733-4476-8750-042df8e26d0a">3.0</ix:nonFraction>% Senior Notes due 2033 (the &#8220;2033 Senior Notes&#8221;) in a private placement exempt from registration under the Securities Act.  We issued the 2033 Senior Notes on January&#160;30, 2013.  The 2033 Senior Notes, which totaled $<ix:nonFraction unitRef="usd" contextRef="i640328d25f104a07a644f3c84408a24d_I20130130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfODQxNg_ed7cdb63-0c2b-458f-a4e1-764ff2da672b">175.0</ix:nonFraction> million in original principal amount, bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="i640328d25f104a07a644f3c84408a24d_I20130130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfODQ3OA_8956db83-a951-45a2-b491-e3205905d33e">3.0</ix:nonFraction>%&#160;per year, payable semiannually on February&#160;1 and August&#160;1 of each year.  The 2033 Senior Notes mature on February&#160;1, 2033, unless earlier repurchased, redeemed or converted.  Upon a fundamental change, as defined in the indenture governing the 2033 Senior Notes, subject to certain exceptions, the holders may require us to repurchase all or any portion of their 2033 Senior Notes for cash at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i612e5c755b184a3585408a4ff760d866_D20130130-20130130" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfODkwMg_334a9365-e82c-47a2-a640-170eea0b4f54">100</ix:nonFraction>% of the principal amount of the 2033 Senior Notes being repurchased, plus any accrued and unpaid interest to, but not including, the related fundamental change repurchase date.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From 2013 to 2016, holders of the 2033 Senior Notes converted $<ix:nonFraction unitRef="usd" contextRef="i4631f4b114e54a1fbc1288a82a9c2663_D20130101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTE0Mw_861ad359-439c-4fb5-9a2e-5c5b3a26653b">143.2</ix:nonFraction> million in aggregate principal amount into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i21d898ee3d254a1aa7701dbf13c49fa2_D20130101-20161231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTE5Nw_62642ba8-290a-4810-9dcd-87906c3af3a8">21,539,873</ix:nonFraction> shares of Common Stock. On February 1, 2019, approximately $<ix:nonFraction unitRef="usd" contextRef="i3d496a3b69364f4b9c89244789d4e32d_I20190201" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTI1OQ_200b6c6e-379b-485d-9a03-5858f6db2be7">28.8</ix:nonFraction> million aggregate principal amount of 2033 Senior Notes were tendered by holders pursuant to such holders&#8217; option to require us to repurchase the 2033 Senior Notes as set forth in the indenture, following which repurchase only $<ix:nonFraction unitRef="usd" contextRef="i3d496a3b69364f4b9c89244789d4e32d_I20190201" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTQ4MQ_c24d85e8-9073-4ddf-821e-ebedbece9b11">3.0</ix:nonFraction> million aggregate principal amount of the 2033 Senior Notes remained outstanding.  Holders of the remaining $<ix:nonFraction unitRef="usd" contextRef="i3d496a3b69364f4b9c89244789d4e32d_I20190201" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTU4NA_1120650d-3eff-4481-b57e-879e573ee390">3.0</ix:nonFraction> million principal amount of the 2033 Senior Notes may require us to repurchase such notes for <ix:nonFraction unitRef="number" contextRef="ie7f7c5a48e684b00b4e6a9dad87deb6f_D20130101-20130131" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTY3Mw_31ae1d5e-255c-4672-8394-76e2414a2acc">100</ix:nonFraction>% of their principal amount, plus accrued and unpaid interest, on February 1, 2023, on February 1, 2028, or following the occurrence of a fundamental change as described above.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of the 2033 Senior Notes, include, among others: (i) rights to convert the notes into shares of our Common Stock, including upon a fundamental change; and (ii) a coupon make-whole payment in the event of a conversion by the holders of the 2033 Senior Notes on or after February 1, 2017 but prior to February 1, 2019.  We determined that these specific terms were embedded derivatives.  Embedded derivatives are required to be separated from the host contract, the 2033 Senior Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument.  We concluded that the embedded derivatives within the 2033 Senior Notes met these criteria and, as such, were valued separate and apart from the 2033 Senior Notes and recorded at fair value each reporting period.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For accounting and financial reporting purposes, we combined these embedded derivatives and valued them together as one unit of accounting. In 2017, certain terms of the embedded derivatives expired pursuant to the original agreement and the embedded derivatives no longer met the criteria to be separated from the host contract and, as a result, the embedded derivatives were no longer required to be valued separate and apart from the 2033 Senior Notes and were reclassified to additional paid in capital. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2015, BioReference and certain of its subsidiaries entered into a credit agreement with JPMorgan Chase Bank, N.A. (&#8220;CB&#8221;), as lender and administrative agent, as amended (the &#8220;Credit Agreement&#8221;).  The Credit Agreement provides for a $<ix:nonFraction unitRef="usd" contextRef="i6e81f5b8d06047b19aa7e48cbf98af16_I20151130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTE2MDk_f64de7e2-887d-4e9e-83d5-42737edae46a">75.0</ix:nonFraction> million secured revolving credit facility and includes a $<ix:nonFraction unitRef="usd" contextRef="i743fcf96590e44c695952271c01375ce_I20151130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTE2NjE_b519a662-9508-435a-9d5d-efc7c62ac9ba">20.0</ix:nonFraction> million sub-facility for swingline loans and a $<ix:nonFraction unitRef="usd" contextRef="i9fbb22c04f364ad5afd2e52f45a360e6_I20151130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTE3MDM_a86a0f25-b186-460c-916f-a35eadffb0d5">20.0</ix:nonFraction> million sub-facility for the issuance of letters of credit. The Credit Agreement matures on November 5, 2021 and is guaranteed by all of BioReference&#8217;s domestic subsidiaries.  The Credit Agreement is also secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference.  Availability under the Credit Agreement is based on a borrowing base composed of eligible accounts receivables of BioReference and certain of its subsidiaries, as specified therein.  As of June&#160;30, 2020, $<ix:nonFraction unitRef="usd" contextRef="ie499e8a5b1e1470ab749b6aa2325157c_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTIyNTk_436e3e95-8328-49f1-84a8-83c54e2fe05e">15.3</ix:nonFraction> million remained available for borrowing under the Credit Agreement. Principal under the Credit Agreement is due upon maturity on November 5, 2021. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At BioReference&#8217;s option, borrowings under the Credit Agreement (other than swingline loans) will bear interest at (i) the CB floating rate (defined as the higher of (a) the prime rate and (b) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) for an interest period of one month plus <ix:nonFraction unitRef="number" contextRef="ie73fdab1754844eeac2a5f34832d8a31_D20151101-20151130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTI3Mjc_20ee8a0d-6e3a-4afe-a8e1-8d38b791be80">2.50</ix:nonFraction>%) plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="i4a682eabf2f34c8a9917e7ba7e3c88ff_D20151101-20151130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTI3NjA_98c9e4c8-a311-4176-ac41-8a4b5e511aa6">0.35</ix:nonFraction>% for the first 12 months and <ix:nonFraction unitRef="number" contextRef="i3d6e118592a94347b7f4c1050e6a8489_D20151101-20151130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTI3OTE_1e87627d-9bd9-4031-817b-f6fea624f463">0.50</ix:nonFraction>% thereafter or (ii) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="ie9339ecd27304a0184566aff4167b7d7_D20151101-20151130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTI5MzI_16ba851b-ce1a-448e-862d-72749798b151">1.35</ix:nonFraction>% for the first 12 months and <ix:nonFraction unitRef="number" contextRef="i034c1dc338af428faed94254148230d8_D20151101-20151130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTI5NjM_f7a6d31d-f270-4f05-a17a-3233456e5357">1.50</ix:nonFraction>% thereafter.  Swingline loans will bear interest at the CB floating rate plus the applicable margin.  The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee of <ix:nonFraction unitRef="number" contextRef="i24807c0e885b473087a1ad68767cb2f9_D20151101-20151130" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTMxNzU_33ad8e7f-c6c3-4b97-840d-fa6d8317f3ca">0.25</ix:nonFraction>% of the lending commitments.  </span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2020, BioReference and certain of its subsidiaries entered into Amendment No. 11 to the Credit Agreement, which amended the Credit Agreement to provide that the fixed charge coverage ratio requirement set forth in the Credit Agreement would not be tested for the quarter ended December 31, 2019, with respect to availability calculated on January 29, 2020 and January 30, 2020, subject, in the case of testing for the quarter ended December 31, 2019, to (i) there having been no event of default occurring and (ii) availability under the revolving facility exceeding <ix:nonFraction unitRef="number" contextRef="i047b3aa3c79c430db33cc3494843fe01_D20191001-20191231" decimals="INF" name="opk:LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTM3OTI_f0f69783-b737-465f-8de3-686f4db58424">10</ix:nonFraction>% of the total revolving commitment, for at least <ix:nonNumeric contextRef="idd1f11282fee4ec6b1d277f48503edb2_D20191001-20191231" format="ixt-sec:durday" name="opk:LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTM4NDM_9a3e2040-7d5b-4eca-8db9-6ffb7422384d">30</ix:nonNumeric> consecutive days for the period ended December 31, 2019, excluding December 18, 2019. The other terms of the Credit Agreement remain unchanged.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-indent:22.5pt;"><span><br/></span></div><ix:continuation id="i467b0c9d4dba49cd9e29613d4c6bf19b" continuedAt="ib3c5430801064b61bca5840675594665"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of June 30, 2020, $<ix:nonFraction unitRef="usd" contextRef="ie499e8a5b1e1470ab749b6aa2325157c_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTQwMTQ_ddee10df-ef50-43d3-a111-e7877588d9f4">51.5</ix:nonFraction> million outstanding under the Credit Agreement was included within Other long-term liabilities.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement contains customary covenants and restrictions, including, without limitation, covenants that require BioReference and its subsidiaries to maintain a minimum fixed charge coverage ratio if availability under the new credit facility falls below a specified amount and to comply with laws and restrictions on the ability of BioReference and its subsidiaries to incur additional indebtedness or to pay dividends and make certain other distributions to the Company, subject to certain exceptions as specified therein.  Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of BioReference to meet its debt service obligations.  The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement and execution upon the collateral securing obligations under the Credit Agreement.  Substantially all the assets of BioReference and its subsidiaries are restricted from sale, transfer, lease, disposal or distributions to the Company, subject to certain exceptions. As of June&#160;30, 2020, BioReference and its subsidiaries had net assets of approximately $<ix:nonFraction unitRef="usd" contextRef="i764a079c978a4ea0b66bc026841d4844_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTUzNzA_f81c89c9-327d-4240-b874-147cf209ae41">913.2</ix:nonFraction> million, which included goodwill of $<ix:nonFraction unitRef="usd" contextRef="i764a079c978a4ea0b66bc026841d4844_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU0MDE_287b5b79-c2a2-48b6-bc62-330b3d6da7b0">434.8</ix:nonFraction> million and intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i764a079c978a4ea0b66bc026841d4844_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU0Mjk_49370c12-7c3b-41d1-93ea-8adb54d7e664">345.9</ix:nonFraction> million.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the Credit Agreement with CB, we had line of credit agreements with <ix:nonFraction unitRef="institution" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="opk:DebtInstrumentsNumberofFinancialInstitutions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU1MTY_2c94def4-3e0d-4943-88a9-2800061dc1a1"><ix:nonFraction unitRef="institution" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="opk:DebtInstrumentsNumberofFinancialInstitutions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU1MTY_38cb1654-5045-4841-ad6e-340c43252666">eleven</ix:nonFraction></ix:nonFraction> other financial institutions as of both June&#160;30, 2020 and December&#160;31, 2019 in the U.S., Chile and Spain.  These lines of credit are used primarily as a source of working capital for inventory purchases.</span></div><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTY0NjQ_bb2157f6-3d2b-4615-873a-254b3bd58439" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:38.675%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.096%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.096%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.096%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.101%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(Dollars in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance Outstanding</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lender</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest&#160;rate&#160;on<br/>borrowings at <br/>June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Credit&#160;line<br/>capacity</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">JPMorgan Chase</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i8dbeb3eb23de47a1b6f04ae8eeb9574b_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMi0yLTEtMS0w_c025e021-dd28-48b1-8014-b4139e6fcf21">3.67</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8dbeb3eb23de47a1b6f04ae8eeb9574b_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMi00LTEtMS0w_1224e89a-8c36-4820-bdbb-d7f6cffe0f10">75,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8dbeb3eb23de47a1b6f04ae8eeb9574b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMi02LTEtMS0w_4baee7fc-9dcb-4623-85cf-c589cd214977">51,489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc44f46b59e54e81a86a9fb4fb093caf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMi04LTEtMS0w_69a0d46f-f214-4c67-9db9-94eb07ce876e">44,750</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Itau Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6559fae108574d0aa1c9714fb3e24788_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMy0yLTEtMS0w_5fb21f8d-5a8f-4896-9c16-962f989560df">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6559fae108574d0aa1c9714fb3e24788_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMy00LTEtMS0w_5ded93cb-f5cc-4939-adc0-8487270cd5c5">1,810</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6559fae108574d0aa1c9714fb3e24788_I20200630" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMy02LTEtMS0w_63a51379-7552-4aa2-841f-e3d447951e3a">530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8b5e2d07aba47b7a77c8a56814325cd_I20191231" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMy04LTEtMS0w_54f4c291-d8a4-4570-9ab3-7e52c0725584">472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bank of Chile</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i48c73acda48c4111a5af1047ccf8cc87_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNC0yLTEtMS0w_76eae41f-b283-48a2-916e-3816b8d0416d">6.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48c73acda48c4111a5af1047ccf8cc87_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNC00LTEtMS0w_211ad0c5-588e-492e-84b2-e04fdf0b2ad0">3,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48c73acda48c4111a5af1047ccf8cc87_I20200630" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNC02LTEtMS0w_ce80aa98-cb0f-4769-af1e-d4f41fb33445">865</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i779d609c655f49bd9d3e70d6c46b21fe_I20191231" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNC04LTEtMS0w_6a8e89e3-8966-4903-ac7f-a0f901991757">851</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BICE Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i76e8733ec84b470fb842fdfb15d41f7c_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNS0yLTEtMS0w_4af42e52-3970-4855-a6ad-94a593fcd151">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76e8733ec84b470fb842fdfb15d41f7c_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNS00LTEtMS0w_0e59535a-492c-4ba5-90a2-c20994f834e2">2,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76e8733ec84b470fb842fdfb15d41f7c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNS02LTEtMS0w_672df65e-7f24-439f-ab9e-a5e8ecbf85f1">1,019</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10ec51989518476483634a001fbac0a7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNS04LTEtMS0w_80e02f6b-3028-4d33-bbc9-82270eb6c4fc">1,429</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BBVA Bank</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="icee7b550c55b456e9633769b30d100c7_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNi0yLTEtMS0w_57c4bf9a-8c8d-49f8-9511-885ad8252777">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icee7b550c55b456e9633769b30d100c7_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNi00LTEtMS0w_90eada39-4015-4e63-be96-68b54a2650e7">3,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icee7b550c55b456e9633769b30d100c7_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNi02LTEtMS0w_72b25906-ddae-455a-87f5-f9fc9b065f92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia45c0ca28d4645e1bf8bb43d0dd8fabe_I20191231" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNi04LTEtMS0w_259a4ac6-f985-4c0f-8a1e-f33b36024237">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Security Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ide21bf3a408f483c9f82c34a363accc8_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNy0yLTEtMS0w_2ca5763c-a95e-433b-b3ec-8b860b58fe4e">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ide21bf3a408f483c9f82c34a363accc8_I20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNy00LTEtMS0w_ed1db3e5-6939-4da7-8ab1-aa33c5bcda53">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ide21bf3a408f483c9f82c34a363accc8_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNy02LTEtMS0w_2e6c1cae-c3bb-4fc2-a06b-e093b13e6831">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i63a721c51927453b93d7de9c83a24c60_I20191231" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNy04LTEtMS0w_abb862a9-40c9-403c-b707-cee79d199191">588</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estado Bank</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3c7a5f9bb26d4ad3b5047c54208133b5_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOC0yLTEtMS0w_606e5b75-2f01-4b93-84e3-de3693f474a8">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3c7a5f9bb26d4ad3b5047c54208133b5_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOC00LTEtMS0w_797a8e53-c684-4160-8166-cbc38fa5f0d6">3,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3c7a5f9bb26d4ad3b5047c54208133b5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOC02LTEtMS0w_29537078-9544-498d-8490-e8fd8f831dec">1,974</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f8f740cc35344458b1021626127aa9e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOC04LTEtMS0w_9e65345b-885c-4f34-a7c7-b5a683987600">1,365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Santander Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3ae1a5c41df24314a8823e0cba821c20_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOS0yLTEtMS0w_bb225838-ecca-4c9d-93a9-ae75ae997436">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ae1a5c41df24314a8823e0cba821c20_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOS00LTEtMS0w_3c0c3569-d408-4952-ac52-0f4b4b4f4ce2">4,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ae1a5c41df24314a8823e0cba821c20_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOS02LTEtMS0w_1a96b3b5-2199-4512-aa8c-ad0577204e88">2,648</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i57693f69122442efb5a7d809f56b6b3c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOS04LTEtMS0w_123d9caf-a699-4991-9fcb-e420b4a5e34e">1,943</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Scotiabank</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id04e2700b7f6495590aab83734460c88_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTAtMi0xLTEtMA_a9a01dde-5081-4210-9b44-a4c380855927">5.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id04e2700b7f6495590aab83734460c88_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTAtNC0xLTEtMA_98336b87-e466-4442-b983-1148a1dbf9ec">1,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id04e2700b7f6495590aab83734460c88_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTAtNi0xLTEtMA_1887fc7b-bfcf-417d-9efb-cabd17c03669">1,095</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c490f5f8dd9456c9a903914580ff1b4_I20191231" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTAtOC0xLTEtMA_5a32b681-9266-4699-a561-1075055b9b26">668</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corpbanca</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic0c00ea5e5ee42868078230022479853_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTEtMi0xLTEtMA_5cd63307-8c93-4f1a-a661-60fa22b30bd7">5.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0c00ea5e5ee42868078230022479853_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTEtNC0xLTEtMA_421cc1e3-b8e0-4ca5-8a13-036d0b40d88d">3,917</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0c00ea5e5ee42868078230022479853_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTEtNi0xLTEtMA_40c1b689-b28b-4f91-a86b-ce04b986fa08">3,917</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac4d242acca94e6b92d84518bdbd23d7_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTEtOC0xLTEtMA_768ad890-5341-47ea-a4ab-b8598c6eadec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Banco De Sabadell</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i846f414c67b44a778a4b2f8c9669725b_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTItMi0xLTEtMA_b9e347fb-f4f9-4d0f-8993-3144c9f26955">1.30</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i846f414c67b44a778a4b2f8c9669725b_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTItNC0xLTEtMA_c624c8f4-6557-4d9d-9585-33d3f858add2">337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i846f414c67b44a778a4b2f8c9669725b_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTItNi0xLTEtMA_500321ea-5758-4fb7-840e-ef89688a1659">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0b422715f43443c9f03f43e7a9abfff_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTItOC0xLTEtMA_e3995dee-d966-43d3-9035-dc399a84f585">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Banco Bilbao Vizcaya</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id96b2ea0a8c14dadb89a084344dce841_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTMtMi0xLTEtMA_33d63ae3-6a85-4da7-8576-e929c54afa60">1.70</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id96b2ea0a8c14dadb89a084344dce841_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTMtNC0xLTEtMA_c28a94ad-a4bc-4eb4-9515-d4abdeb12b14">337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id96b2ea0a8c14dadb89a084344dce841_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTMtNi0xLTEtMA_af02964b-2f2f-4386-b564-aa60587b3b9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6906c76a48dc48c48a3dfb34cdf030b1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTMtOC0xLTEtMA_085ef4b8-2bae-48d9-8e9f-438cf8757b54">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Banco Santander</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic444558faa604456a69c0ea677b33c92_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTQtMi0xLTEtMA_dc148102-65d9-4604-a582-7a3924d7c425">1.82</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic444558faa604456a69c0ea677b33c92_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTQtNC0xLTEtMA_d05e18b2-259d-4014-aa9c-c21cd151d089">561</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic444558faa604456a69c0ea677b33c92_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTQtNi0xLTEtMA_8900a97c-8722-47ae-83d9-4da764638f9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83f9b1ef620641e998c7c8c1895e255a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTQtOC0xLTEtMA_640e4a61-ea20-4dc0-b43a-1d7a1759e88d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTUtNC0xLTEtMA_6b5a494c-5cfb-466c-b54b-db524ca87876">101,312</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTUtNi0xLTEtMA_32235ca2-d31b-4da2-869d-fdade49f9589">63,537</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTUtOC0xLTEtMA_0e1ad276-640e-415a-8c02-19c2996ea3af">52,077</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020 and December&#160;31, 2019, the weighted average interest rate on our lines of credit was approximately <ix:nonFraction unitRef="number" contextRef="id8a9e82eefe34a719b632c3dd6b4c0bb_I20200630" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU5MDU_11340d07-0e74-467c-bf17-66d0d77a8690">4.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i05425f68234a4c09943873aa2d16cc00_I20191231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU5MTI_7a18561c-559f-49d7-9d24-8e3e79ee6780">4.0</ix:nonFraction>%, respectively.</span></div><ix:continuation id="i7af18101736942e79d3cebf8f8be1d04"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020 and December&#160;31, 2019, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the Credit Agreement and amounts outstanding under lines of credit described above) as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:58.263%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.501%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.503%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of notes payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95fecc4a436340768768e918eea21ff8_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMS0xLTEtMS0w_ccbd5f2c-4316-417d-a5fa-df9571fe867a">2,415</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf8f60d813964c65a753ded4929b4ce1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMS0zLTEtMS0w_dfa7ca13-4615-42ba-aa8e-b6c2ce6a0a68">2,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95fecc4a436340768768e918eea21ff8_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMi0xLTEtMS0w_6a6ab215-47d4-4827-b602-71461da98187">4,936</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf8f60d813964c65a753ded4929b4ce1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMi0zLTEtMS0w_6463b916-01b6-4fdf-91e6-bd484a3b5315">4,723</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95fecc4a436340768768e918eea21ff8_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMy0xLTEtMS0w_903fab77-a3df-4f3a-8683-02d6373d1a06">7,351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf8f60d813964c65a753ded4929b4ce1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMy0zLTEtMS0w_83274e5c-a6e6-4cf0-9589-82a4d0df7ca6">7,217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation></ix:continuation><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib3c5430801064b61bca5840675594665">The notes and other debt mature at various dates ranging from 2020 through 2024, bearing variable interest rates from <ix:nonFraction unitRef="number" contextRef="ifbc9ba99b84443e38237727e48a82f23_I20200630" decimals="3" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTYyNzA_ef9938b3-48c2-4d76-9b8b-45e9e70ebdcf">0.7</ix:nonFraction>% up to <ix:nonFraction unitRef="number" contextRef="i9b21a3e7a57d4609b0d409b6ba20c32c_I20200630" decimals="3" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTYyNzk_e568f2e1-7d51-498f-8775-c289e169d14d">3.8</ix:nonFraction>%.  The weighted average interest rate on the notes and other debt was <ix:nonFraction unitRef="number" contextRef="i45a19ae7054d4411b573ae861b1aadf1_I20200630" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTYzNTI_23c88cae-10d5-4166-b65d-5af1ea7e56d3"><ix:nonFraction unitRef="number" contextRef="ib6281d7b057a416cab5bb28eeef12716_I20191231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTYzNTI_564140af-02aa-484c-a629-48942bdd637a">2.6</ix:nonFraction></ix:nonFraction>% and 2.7% on June&#160;30, 2020 and December&#160;31, 2019. The notes are partially secured by our office space in Barcelona.</ix:continuation>  </span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_70"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 7 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183MC9mcmFnOjIzZTM3YzdjMWVlYTQ4MTVhOWM0MmEyOGM3MTI2MzhlL3RleHRyZWdpb246MjNlMzdjN2MxZWVhNDgxNWE5YzQyYTI4YzcxMjYzOGVfMTY0_cea5b9e6-fbea-4435-8a03-1494d2e551f9" continuedAt="i55a6c4851dd04d4bb2cc0d1bb4bc0d96" escape="true">ACCUMULATED OTHER COMPREHENSIVE LOSS</ix:nonNumeric></span></div><ix:continuation id="i55a6c4851dd04d4bb2cc0d1bb4bc0d96"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183MC9mcmFnOjIzZTM3YzdjMWVlYTQ4MTVhOWM0MmEyOGM3MTI2MzhlL3RleHRyZWdpb246MjNlMzdjN2MxZWVhNDgxNWE5YzQyYTI4YzcxMjYzOGVfMTcw_bb9294b2-e89e-421f-8ae0-3e9c7ef1ebe6" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the six months ended June 30, 2020, changes in Accumulated other comprehensive loss, net of tax, were as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:84.530%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.470%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i350765d31f054cb4a900a05635ea70c4_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183MC9mcmFnOjIzZTM3YzdjMWVlYTQ4MTVhOWM0MmEyOGM3MTI2MzhlL3RhYmxlOmY3MDE3ZDkzOWZkMzQ2NTJhYzVmNTk3ZjE5OTFjMWM3L3RhYmxlcmFuZ2U6ZjcwMTdkOTM5ZmQzNDY1MmFjNWY1OTdmMTk5MWMxYzdfMS0xLTEtMS0w_eaa32baf-2c6c-47f9-8e58-b9f5f4122795">22,070</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other comprehensive loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idef84b903bff4b0ea60e0666075a8447_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183MC9mcmFnOjIzZTM3YzdjMWVlYTQ4MTVhOWM0MmEyOGM3MTI2MzhlL3RhYmxlOmY3MDE3ZDkzOWZkMzQ2NTJhYzVmNTk3ZjE5OTFjMWM3L3RhYmxlcmFuZ2U6ZjcwMTdkOTM5ZmQzNDY1MmFjNWY1OTdmMTk5MWMxYzdfMi0xLTEtMS0w_8f86d5c0-da60-4168-8657-a55992906cc3">3,682</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1c611772672a47c8984d0140e9dff6e2_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183MC9mcmFnOjIzZTM3YzdjMWVlYTQ4MTVhOWM0MmEyOGM3MTI2MzhlL3RhYmxlOmY3MDE3ZDkzOWZkMzQ2NTJhYzVmNTk3ZjE5OTFjMWM3L3RhYmxlcmFuZ2U6ZjcwMTdkOTM5ZmQzNDY1MmFjNWY1OTdmMTk5MWMxYzdfNS0xLTEtMS0w_5ef8243e-5a7f-488d-aebd-b0f1165b364f">25,752</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 8 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjc3Mw_12301279-a664-413d-98f2-f1444daafdfd" continuedAt="i67ce0793537042cf909a09ef9b3111a1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i67ce0793537042cf909a09ef9b3111a1" continuedAt="id943ab52e5b04bb58452c8c439a62d16"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record fair values at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.  We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we had equity securities (refer to Note 5), forward foreign currency exchange contracts for inventory purchases (refer to Note 9) and contingent consideration related to the acquisitions of CURNA, OPKO Diagnostics and OPKO Renal that are required to be measured at fair value on a recurring basis.  In addition, in connection with our investment and our consulting agreement with BioCardia, we record the related BioCardia options at fair value as well as the warrants from COCP, InCellDx, Xenetic and Phio.</span></div><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjc1Mg_a0bcb422-184c-4c92-bc49-ba048b328e8e" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial assets and liabilities measured at fair value on a recurring basis are as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value measurements as of June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNS0xLTEtMS0w_bea683b7-ef39-4d96-a07f-a733a9ef4383">24,777</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic564593128ce4e4b84460058baeb14cf_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNS0zLTEtMS0w_59838927-3bde-4550-972f-17e26f7d9c15">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i531ede9f4ddd48268654c99511a06679_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNS01LTEtMS0w_45ce8db4-64df-426f-82a1-7175964556b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNS03LTEtMS0w_f312f1f7-5be7-498a-afcf-417846709f8d">24,777</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options/warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNi0xLTEtMS0w_c06f03db-fdec-4f9c-b985-5398096fb7fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic564593128ce4e4b84460058baeb14cf_I20200630" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNi0zLTEtMS0w_3d60bd80-6299-4efe-a11e-5647730ec877">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i531ede9f4ddd48268654c99511a06679_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNi01LTEtMS0w_4eb16e7f-59b9-46a0-82f4-38af07ffb8ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNi03LTEtMS0w_cabc4e03-3fd1-411e-ac65-4b857339fc24">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i432215f275164d1b94ffc495a44a8c93_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNy0xLTEtMS0w_bb5eb861-78f9-44e0-acf4-6af9bbacbde9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ff069d8c2354606be4fd434fa345d89_I20200630" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNy0zLTEtMS0w_6d508376-3832-4b9a-b89e-e38ecc75d1ff">215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if458b89b3f2b4390bb62734646f1a224_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNy01LTEtMS0w_7af85c2f-3cc5-44fd-86b3-ac434568a1d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic8c6bc5e253b4fe2a84e3f5d4fb9d30e_I20200630" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNy03LTEtMS0w_ee1578ad-c0f5-472f-8aea-c92d6e19b271">215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfOC0xLTEtMS0w_257c4f7b-3012-446f-a515-73e3d52d0102">24,777</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic564593128ce4e4b84460058baeb14cf_I20200630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfOC0zLTEtMS0w_c612675f-c27e-476b-9249-fe7a9fb96c5d">266</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i531ede9f4ddd48268654c99511a06679_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfOC01LTEtMS0w_5d5083c6-af43-41f5-b641-24bad94fe083">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfOC03LTEtMS0w_fa6198c4-da79-4982-a614-ade9941942c3">25,043</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTMtMS0xLTEtMA_f68e28e1-5167-4553-9b57-9fabb8f4dc3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic564593128ce4e4b84460058baeb14cf_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTMtMy0xLTEtMA_185e4171-49cb-419f-b144-20e40158ef4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i531ede9f4ddd48268654c99511a06679_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTMtNS0xLTEtMA_c9847e3a-dfe4-4060-894c-22a846753aca">9,934</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTMtNy0xLTEtMA_cc658e31-9e94-4f53-9acf-e4159dddf809">9,934</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTQtMS0xLTEtMA_b7e3f534-6db3-4623-887b-8915fe7d9159">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic564593128ce4e4b84460058baeb14cf_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTQtMy0xLTEtMA_0e6e3b6f-7bfb-4b29-ab66-e37d39969030">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i531ede9f4ddd48268654c99511a06679_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTQtNS0xLTEtMA_aa0f0dce-936b-4896-9a56-8bdfb023b99b">9,934</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTQtNy0xLTEtMA_da049013-2966-4d69-8c49-9e9976cacde4">9,934</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value measurements as of December&#160;31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNi0xLTEtMS0w_200571e0-362f-4d0a-8dff-77e4076dcf9b">18,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNi0zLTEtMS0w_31e6c977-0876-4f35-8bfb-a49cca3a7f21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f5503e95ced4126b68fbce3f56c2973_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNi01LTEtMS0w_1b43a3e8-a332-43e1-bebf-203414b4137e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNi03LTEtMS0w_da187b0d-e80a-47bf-a77b-7f5c2bfe7924">18,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options/warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNy0xLTEtMS0w_9a6b10cd-0da8-4577-a151-2b2505a14c5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNy0zLTEtMS0w_81d9ff59-7ec9-4762-a58a-f0341873acc5">120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f5503e95ced4126b68fbce3f56c2973_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNy01LTEtMS0w_3ba52d26-62e3-46c3-8a78-2d4aad67779c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNy03LTEtMS0w_352e5c8c-b8cd-4909-b05c-d0346257bfff">120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i889906dfb28744f396261bd2650c45b2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOC0xLTEtMS0w_1d9cb264-0bba-48fb-8553-cdf70dd7046a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie329f1da30bf41b49d879864c1d2d60b_I20191231" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOC0zLTEtMS0w_0dff7f49-a7f0-44ea-a7f8-dcbdb4af83b4">133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7e565fc549d442ca4eb00695a5c82db_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOC01LTEtMS0w_bcd6d4fd-531e-4084-880d-137084eddfa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c5e6af0a8a040aaa94190167dea56ab_I20191231" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOC03LTEtMS0w_0889733b-b6d3-4f37-aa72-e455cfcfa4c5">133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOS0xLTEtMS0w_a1572b95-7cca-4ad7-a8dc-fa3bcbc5fecf">18,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOS0zLTEtMS0w_0bea9d26-179b-4ba4-8e7e-2d2a538d99df">253</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f5503e95ced4126b68fbce3f56c2973_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOS01LTEtMS0w_c76f49fb-f6e9-4747-8745-46591a7620b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOS03LTEtMS0w_1ed743fe-99a7-46fd-b9c8-d4fc18d0df64">19,123</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTQtMS0xLTEtMA_9ed1a0fe-37c3-46a8-9de6-0886fec3c9b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTQtMy0xLTEtMA_62c2bafc-40fd-4864-b5da-33e0131ebe19">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f5503e95ced4126b68fbce3f56c2973_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTQtNS0xLTEtMA_53d72810-cd1c-4c3a-abe0-2364571c41c8">9,683</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTQtNy0xLTEtMA_7299cbd1-1c51-40be-bab4-3b4c7698e7a7">9,683</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTUtMS0xLTEtMA_5e4d125a-39e1-4e59-b6bb-54f103d603fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTUtMy0xLTEtMA_a668efbf-a9db-4e91-83d5-e9b9232dd53d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f5503e95ced4126b68fbce3f56c2973_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTUtNS0xLTEtMA_86333679-3b13-4a80-952e-30ffb87efe1b">9,683</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTUtNy0xLTEtMA_b5cf1f6d-6be0-4bb0-be34-c319080b2d26">9,683</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no transfers between Level 1 and Level 2 and no transfers to or from Level 3 of the fair value hierarchy.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, the carrying value of our other financial instrument assets approximates their fair value due to their short-term nature or variable rate of interest.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjc2Nw_51cc3f6d-482d-49af-b89e-a9a99a7ed054" continuedAt="i1ed9ee57a74145d5a99aa560fdd3b9c1" escape="true"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjc3MA_70d563a3-d11f-4219-acc1-e01bb7eee8a1" continuedAt="if45247740b93446a8cc725c8f7974eb7" escape="true">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of June&#160;30, 2020:</ix:nonNumeric></ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="id943ab52e5b04bb58452c8c439a62d16"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i1ed9ee57a74145d5a99aa560fdd3b9c1"><ix:continuation id="if45247740b93446a8cc725c8f7974eb7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:78.498%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.502%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent<br/>consideration</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i466da00a6f1e4da59279c84d5c12fe30_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOmYwNzljZWVkZTAxNjRjZDY5ZDI5MDNhNzFmZTcyYWYxL3RhYmxlcmFuZ2U6ZjA3OWNlZWRlMDE2NGNkNjlkMjkwM2E3MWZlNzJhZjFfMi0xLTEtMS0w_758326fe-2bec-4bd6-bac6-efa9d581b150">9,683</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in results of operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76725fac2d244963b0e9b87c1b59c414_D20200101-20200630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOmYwNzljZWVkZTAxNjRjZDY5ZDI5MDNhNzFmZTcyYWYxL3RhYmxlcmFuZ2U6ZjA3OWNlZWRlMDE2NGNkNjlkMjkwM2E3MWZlNzJhZjFfNS0xLTEtMS0w_dabeb3a9-e31c-4e1f-a43d-0971bc90cca8">251</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i156c35b6196a4d9cba4e041a0cb57b3b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOmYwNzljZWVkZTAxNjRjZDY5ZDI5MDNhNzFmZTcyYWYxL3RhYmxlcmFuZ2U6ZjA3OWNlZWRlMDE2NGNkNjlkMjkwM2E3MWZlNzJhZjFfOS0xLTEtMS0w_761b61f4-b627-4745-84a3-6abecc9a7de1">9,934</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></ix:continuation></ix:continuation></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair values of our financial instruments have been determined by using available market information and what we believe to be appropriate valuation methodologies.  We use the following methods and assumptions in estimating fair value:</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contingent consideration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; We estimate the fair value of the contingent consideration utilizing a discounted cash flow model for the expected payments based on estimated timing and expected revenues.  We use several discount rates depending on each type of contingent consideration related to OPKO Diagnostics, CURNA and OPKO Renal transactions. As of June&#160;30, 2020, of the $<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjQ5MA_0da6ab40-a4b3-43ba-bfd1-a2463e47c432">9.9</ix:nonFraction> million of contingent consideration, $<ix:nonFraction unitRef="usd" contextRef="i8680556422af45dd8dfa9ce4d3edc1ba_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjUyMg_af4daa63-ffc2-4c01-8452-b34ec9e062dc">2.4</ix:nonFraction> million was recorded in Accrued expenses and $<ix:nonFraction unitRef="usd" contextRef="i3a53eb2f2d054cc998864517435338b1_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjU2Mg_5b46ae76-78b3-4f56-a8e0-a4097758e5d2">7.6</ix:nonFraction> million was recorded in Other long-term liabilities.  As of December&#160;31, 2019, of the $<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjYyOA_678cec40-5362-43b9-b836-d0e471d8aa1f">9.7</ix:nonFraction> million of contingent consideration, $<ix:nonFraction unitRef="usd" contextRef="ia730eb3f2de947f1ae2828ca66e4a318_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjY2MA_f1b069e5-a017-4793-8680-7bbff147f78d">2.4</ix:nonFraction> million was recorded in Accrued expenses and $<ix:nonFraction unitRef="usd" contextRef="icdc50b58341940828f8595408b7a269e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjcwMA_87486a0c-fcc8-4aa4-8de1-664af38b310d">7.3</ix:nonFraction> million was recorded in Other long-term liabilities.</span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 9 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RleHRyZWdpb246MjA3NDcxYmIxZjcyNGUwNWIyZDQ4OWFiY2NmYTUwNDVfMTE4Mw_fd9ca6ff-56c5-417d-bf92-36ba28e0ce86" continuedAt="ia473a574aff74c6a98760e579b868446" escape="true">DERIVATIVE CONTRACTS</ix:nonNumeric></span></div><ix:continuation id="ia473a574aff74c6a98760e579b868446"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RleHRyZWdpb246MjA3NDcxYmIxZjcyNGUwNWIyZDQ4OWFiY2NmYTUwNDVfMTE5Mg_94a16682-ff6e-4d37-9e1a-e02062893b33" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair values and the presentation of our derivative assets (liabilities) in the Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:35.591%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.722%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Component</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative financial instruments:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock options/warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e0ac6f1d4cb4c66b971c20cf8aeca20_I20200630" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjFhNGY5MWFkOWI5NzQ1MDJhNjI3ZjI3YjJhYmVlNjg5L3RhYmxlcmFuZ2U6MWE0ZjkxYWQ5Yjk3NDUwMmE2MjdmMjdiMmFiZWU2ODlfMy0zLTEtMS0w_b73cd2d9-6d25-4319-af1b-3b4bc03b3dec">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if667381c8f554ff082c1a91219f79181_I20191231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjFhNGY5MWFkOWI5NzQ1MDJhNjI3ZjI3YjJhYmVlNjg5L3RhYmxlcmFuZ2U6MWE0ZjkxYWQ5Yjk3NDUwMmE2MjdmMjdiMmFiZWU2ODlfMy01LTEtMS0w_77061015-85e5-425d-b620-c03912eabb86">120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses.  Unrealized (losses) on forward contracts are recorded in Accrued expenses.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0aca251d226f472f9def2eed58862fb1_I20200630" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjFhNGY5MWFkOWI5NzQ1MDJhNjI3ZjI3YjJhYmVlNjg5L3RhYmxlcmFuZ2U6MWE0ZjkxYWQ5Yjk3NDUwMmE2MjdmMjdiMmFiZWU2ODlfNS0zLTEtMS0w_27368bef-0e45-4797-af6c-41f92f3794cd">215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7aaa36a9c3b240c480e7a180e04210a9_I20191231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjFhNGY5MWFkOWI5NzQ1MDJhNjI3ZjI3YjJhYmVlNjg5L3RhYmxlcmFuZ2U6MWE0ZjkxYWQ5Yjk3NDUwMmE2MjdmMjdiMmFiZWU2ODlfNS01LTEtMS0w_3215eeff-379e-4827-8210-569c20a5cdf4">133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We enter into foreign currency forward exchange contracts in an effort to mitigate the effects of exchange rate differences arising from inventory purchases on letters of credit.  Under these forward contracts, for any rate above or below the fixed rate, we receive or pay the difference between the spot rate and the fixed rate for the given amount at the settlement date.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To qualify the derivative instrument as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At June&#160;30, 2020 and December&#160;31, 2019, our derivative financial instruments did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognize the changes in Fair value of derivative instruments, net in our Condensed Consolidated Statement of Operations.  <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RleHRyZWdpb246MjA3NDcxYmIxZjcyNGUwNWIyZDQ4OWFiY2NmYTUwNDVfMTIwMA_856bb133-860d-46dd-8429-bcefd16122f6" continuedAt="i343f0af7ef284c19a7b1c628635ed39b" escape="true">The following table summarizes the losses and gains recorded for the three and six months ended June 30, 2020 and 2019:</ix:nonNumeric></span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i343f0af7ef284c19a7b1c628635ed39b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:51.508%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.257%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.257%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:9.257%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.261%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative gain (loss):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock options/warrants </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i80bdef2e23504d6fb04d750584ece882_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNC0xLTEtMS0w_ea677c85-9d2d-4255-b46e-a90ed61c7cf9">7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib9b681e985234321b995bee7faf1aa60_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNC0zLTEtMS0w_af039d97-c2c9-4a42-bb5d-fab21826acad">392</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iee03a450fc9448c1b8e2ea08fdc41417_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNC01LTEtMS0w_6ff678ac-e433-4d36-8d49-292328142c2a">69</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5c1ec4036db94ff8ab2eaaeed0d02080_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNC03LTEtMS0w_59270cb4-6aa7-47c3-b99c-6829983d6c9a">24</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifc1b1f708d7d402caa5805034a48ad80_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNi0xLTEtMS0w_84a32433-3218-4be1-9d52-61138142d0f9">6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia293f36717934081b9f1213686122a51_D20190401-20190630" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNi0zLTEtMS0w_db8f1823-e24b-4e90-b4dc-4f8300ebf71c">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f3753e96f434c02990e62a093e23382_D20200101-20200630" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNi01LTEtMS0w_f165f329-dbdb-466e-a8c3-8b73ec564d78">677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib875afce9dcb4394b143601b365f6f9f_D20190101-20190630" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNi03LTEtMS0w_35741cb6-02f9-4a54-b2cc-aaf1a5f64439">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iccf1d6fe84ba4e54b2f9cc386683e187_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNy0xLTEtMS0w_e04a3d1b-f31b-49b1-90b8-6780627dd13a">13</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i69d3efc364ab4dcb8a44ddd5b86d234d_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNy0zLTEtMS0w_c0f84f52-5a84-498f-be4b-359582dd14e4">388</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie55e61c7727f4127be76e9ba93be973f_D20200101-20200630" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNy01LTEtMS0w_c8c0e814-d9ed-4d2a-a94f-7beec9ade86b">608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d3673e8cc554f419eeaf0ebe4a24185_D20190101-20190630" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNy03LTEtMS0w_5e50a1d3-4787-4f99-b25b-eab9641f1bd1">27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:center;"><span><br/></span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_79"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 10 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjE5OTAyMzI2NDI2OA_92909887-7f62-4d9a-a531-9e25382e9100" continuedAt="ieeaf5be4d5144042ba08c7dd05b2f932" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="ieeaf5be4d5144042ba08c7dd05b2f932" continuedAt="i6a17dff2329a4328bb360f29a8998c0e"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i7f02e4f9fd574e05a785e3c62f223eb4_I20200225" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjMy_f3e01ee0-f303-4df8-9f2b-7e5980d0982f">100</ix:nonFraction> million.  Borrowings under the line of credit will bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="i7f02e4f9fd574e05a785e3c62f223eb4_I20200225" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMzA1_9ec6b80c-adb4-431b-b1cf-8b1c8ece123b">11</ix:nonFraction>% per annum and may be repaid and reborrowed at any time.  The credit agreement includes various customary remedies for the lender following an event of default, including the acceleration of repayment of outstanding amounts under line of credit.  The line of credit matures on February 25, 2025.  The line of credit also calls for a commitment fee equal to <ix:nonFraction unitRef="number" contextRef="i7c119d6e22ac4137a2e112127278f9af_D20200225-20200225" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjY0_d8a00a10-2f84-4392-82c8-5cd2f0e85a7f">0.25</ix:nonFraction>% per annum of the unused portion of the line.  As of June 30, 2020, no funds were borrowed under the line of credit.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 29, 2019, we issued <ix:nonFraction unitRef="shares" contextRef="i03aeaa43340c459c8da023f93e0228ea_D20191029-20191029" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfODE1_856b010b-38fb-414f-af0b-c88085f8646d">50</ix:nonFraction> million shares of our Common Stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3dbdeb0b817643be9cbd2dfa9e9606f9_I20191029" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfODU5_89961562-e086-492b-bae6-3ee7baee131e">1.50</ix:nonFraction> per share in an underwritten public offering (the &#8220;Offering&#8221;), resulting in net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="i03aeaa43340c459c8da023f93e0228ea_D20191029-20191029" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfOTgz_71dd9ba8-ccea-46cd-9833-f6fd228ec338">70</ix:nonFraction> million, after deducting underwriting commissions and offering expenses.  In November 2019, pursuant to an option the Company granted the underwriters, we issued an additional <ix:nonFraction unitRef="shares" contextRef="iec908835f0b2426ca21f5664f890c7b2_D20191101-20191130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMTE1NA_78697797-632a-4d53-a858-1842a1e304c9">4,227,749</ix:nonFraction> shares at the public offering price, less underwriting discounts and commissions, resulting in net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="iec908835f0b2426ca21f5664f890c7b2_D20191101-20191130" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMTI5Nw_1270c83a-1324-45d8-b3ae-5a90fe64ce10">6</ix:nonFraction> million. Drs. Frost and Hsiao and Mr. Steven Rubin, members of OPKO&#8217;s senior management purchased an aggregate of <ix:nonFraction unitRef="shares" contextRef="id3cfd08ad6df4811a785c595816354c4_D20191029-20191029" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMTQwNg_ebcbd69b-acda-460b-afb0-7ff6d2e61990">2,415,000</ix:nonFraction> shares of Common Stock in the Offering. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 1, 2019, OPKO Pharmaceuticals, LLC entered into an assignment agreement with Xenetic Biosciences, Inc., as amended from time to time (the &#8220;Assignment Agreement&#8221;), pursuant to which Xenetic acquired all of OPKO Pharmaceuticals&#8217; right, title and interest in and to that certain Intellectual Property License Agreement (the &#8220;IP License Agreement&#8221;), entered into between The Scripps Research Institute and OPKO Pharmaceuticals, regarding certain patents for novel CAR T platform technology and through which the Scripps Research Institute granted an exclusive royalty-bearing license in exchange for royalties, subject to the terms of the IP License Agreement.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Assignment Agreement and the IP License Agreement, Xenetic issued to OPKO Pharmaceuticals <ix:nonFraction unitRef="shares" contextRef="i39377d350ed8459c9f4a6c8173298ce4_I20190301" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjIxOA_24351297-3f1b-4d3a-8044-dd3558c37aea">164,062</ix:nonFraction> shares of Xenetic common stock (the &#8220;OPKO Transaction Shares&#8221;). In connection with the Assignment Agreement, OPKO Pharmaceuticals entered into a voting agreement pursuant to which OPKO Pharmaceuticals agreed, among other things, to vote </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i6a17dff2329a4328bb360f29a8998c0e" continuedAt="ida03c91ff86d4a709df35d4deb7eb5ae"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">its shares in Xenetic in favor of the transactions contemplated by the Assignment Agreement, and a lock-up agreement with Xenetic which restricts OPKO Pharmaceuticals&#8217; sale or transfer of any of the OPKO Transaction Shares as provided therein and as otherwise required by law. The Assignment Agreement and the obligations thereunder took effect on July 19, 2019, after Xenetic satisfied certain closing conditions, including obtaining stockholder approval and securing certain financing.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company owns approximately <ix:nonFraction unitRef="number" contextRef="ib4fc9634e3a348bab19da19df297d2c9_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjk3Nw_f8463704-fe41-427f-9dd7-63664679fe1c">9</ix:nonFraction>% of Pharmsynthez and Pharmsynthez is Xenetic&#8217;s largest and controlling stockholder. Dr. Richard Lerner, a director of the Company, is a co-inventor of Xenetic&#8217;s technology and received <ix:nonFraction unitRef="shares" contextRef="ia9973ed8023248deb54e5d88777adf34_I20200630" decimals="INF" format="ixt:numdotdecimal" name="opk:RelatedPartyTransactionShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMzE2NA_8a2f4e51-4b1e-4b9e-bd17-5907e9ea9cd8">31,240</ix:nonFraction> shares of Xenetic upon the closing of the Xenetic transactions described above.  Adam Logal, our Senior Vice President and Chief Financial Officer, is a director of Xenetic.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, we paid the $<ix:nonFraction unitRef="usd" contextRef="if0f5d9e5d0c94731921acdcd9d79d299_D20190301-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMzM3MA_11b26942-0ef4-4248-99e9-1f1bd239c643">125,000</ix:nonFraction> filing fee to the Federal Trade Commission (the &#8220;FTC&#8221;) in connection with filings made by us and Dr. Jane Hsiao, our Vice Chairman and Chief Technical Officer, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (&#8220;HSR Act&#8221;) relating to her purchases of Common Stock.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, Dr. Phillip Frost, our Chairman and Chief Executive Officer, paid a filing fee of $<ix:nonFraction unitRef="usd" contextRef="i043083dceb38404bb2b35a4fd84c56dc_D20190201-20190228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMzc1MQ_11d84d61-16c7-44e0-bdf9-4214f970177c">280,000</ix:nonFraction> to the FTC under the HSR Act in connection with filings made by us and Dr. Frost, relating to his purchases of Common Stock.&#160; We reimbursed Dr. Frost for the HSR filing fee.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 8, 2018, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i1bfdb219056b42969ad222d49e930c2e_I20181108" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNDU5OQ_97c43608-675b-4915-9767-cb8fde5e2040">60</ix:nonFraction> million.  Borrowings under the line of credit bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="i1bfdb219056b42969ad222d49e930c2e_I20181108" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNDY2Nw_55e40123-004b-4532-98ed-3a97556d546d">10</ix:nonFraction>% per annum and could have been repaid and reborrowed at any time.  The credit agreement included various customary remedies for the lender following an event of default, including the acceleration of repayment of outstanding amounts under line of credit.  The line of credit would have matured on November 8, 2023.  We repaid approximately $<ix:nonFraction unitRef="usd" contextRef="i6302ffbd2069456f9a5cc3c3c7a1e7a5_D20190220-20190220" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTAwOQ_2f5dbe28-64f9-4ceb-9637-2af4a9db9728">28.8</ix:nonFraction> million that was borrowed in 2019 and terminated the line of credit on or around February 20, 2019.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, we issued the 2023 Convertible Notes in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="iac1e5f5cb1464cb9905c5e33a1c7fede_I20180228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTE5Ng_595ea9d6-1f8d-4bb7-babf-510e1af84071">55.0</ix:nonFraction> million.  Refer to Note 6. Purchasers of the 2023 Convertible Notes included Dr. Hsiao and an affiliate of Dr. Frost.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We hold investments in Zebra (ownership <ix:nonFraction unitRef="number" contextRef="i5e3a3664d4aa4479ab2f7ff77d256120_D20200101-20200630" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTM1MQ_1f6b21be-1bdf-4f52-8d8c-9a26a518b96c">29</ix:nonFraction>%), Neovasc (<ix:nonFraction unitRef="number" contextRef="ia1aa8cc835a1411f9161a88fefd51afb_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTM2NQ_424c6b79-a107-457f-8c40-831c39dc9771">2</ix:nonFraction>%), ChromaDex Corporation (<ix:nonFraction unitRef="number" contextRef="i65bd6c4d55ac4253a96252cdeb1cebf6_I20200630" decimals="3" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTM5Mw_109f25bf-956f-4da0-a094-2b0a3243bedf">0.1</ix:nonFraction>%), MabVax (<ix:nonFraction unitRef="number" contextRef="if01ceaf264f64e64b9647bf4a84dac24_I20200630" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTQwNg_83b19f60-56d6-4de1-926a-b8b87b039725">1</ix:nonFraction>%), COCP (<ix:nonFraction unitRef="number" contextRef="i40c56be3936e42218c130b6171df7087_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTQxNw_0cd1fdbd-e734-413b-8c68-5ebd7b85ab3b">5</ix:nonFraction>%), NIMS (<ix:nonFraction unitRef="number" contextRef="i651485904eaf48cf9b0d0e4ae12aa57c_I20200630" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTQyOA_6f0e3bac-946f-4ee9-929f-93bdd561d41f">1</ix:nonFraction>%), Eloxx (<ix:nonFraction unitRef="number" contextRef="i94995994c21b4facabf08492a51c559a_I20200630" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTQ0MA_1ea5a234-77a3-4f7e-9d53-b0e22f158b93">3</ix:nonFraction>%), and BioCardia (<ix:nonFraction unitRef="number" contextRef="ie5822595b03740f291e2481860949888_I20200630" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTQ2MA_4919ed37-7c73-4754-b40b-04c49d9238d5">2</ix:nonFraction>%).  These investments were considered related party transactions as a result of our executive management&#8217;s ownership interests and/or board representation in these entities.  See further discussion of our investments in Note 5.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, we invested an additional $<ix:nonFraction unitRef="usd" contextRef="ib51423d67fdf443e92d5bbdd0177b903_D20180201-20180228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTczNg_bdcf17c7-fc3a-47f9-a312-feefdfd7fb91">1.0</ix:nonFraction> million in COCP for a convertible note, which was converted into <ix:nonFraction unitRef="shares" contextRef="ia1752740ed5f481c9bd06120be92363d_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="opk:DebtInstrumentConvertibleSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTc5Ng_75a3062f-797f-4977-a697-5d2a039f28db">538,544</ix:nonFraction> shares of its common stock in May 2018. In April 2017, we invested an additional $<ix:nonFraction unitRef="usd" contextRef="ie8fff2811a6f4c0c9d1e13125eac0f56_D20170401-20170430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTg4MA_99caee7b-7f33-4eb7-8a8e-6371bcd48334">1.0</ix:nonFraction> million in COCP for <ix:nonFraction unitRef="shares" contextRef="ia0bd41509ea64c85ab834813ae267e3d_D20170401-20170430" decimals="INF" format="ixt:numdotdecimal" name="opk:EquityMethodInvestmentSharesPurchasedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTg5NQ_669f2085-f28e-4fad-9815-649062b09016">138,889</ix:nonFraction> shares of its common stock.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017, we invested an additional $<ix:nonFraction unitRef="usd" contextRef="i0a7333b8434e44f483b8888bb05796ca_D20171101-20171130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTk3Mg_dcfa1618-d097-4f3c-bfdc-fa06443dbb99">3.0</ix:nonFraction> million in Neovasc for <ix:nonFraction unitRef="shares" contextRef="i04269715161949f5a492269ba0ca5d33_D20171101-20171130" decimals="INF" format="ixt:numdotdecimal" name="opk:EquityMethodInvestmentSharesPurchasedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTk5MA_8edeb0cb-8fee-4118-b242-e86c85973c71">20,547</ix:nonFraction> shares of its common stock, <ix:nonFraction unitRef="shares" contextRef="i69978c473ccc4f789665ee256ad80248_I20171130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjAyMQ_ec2401f3-e7c9-4f92-8a98-d7b26a2a2930">20,547</ix:nonFraction> Series A warrants, <ix:nonFraction unitRef="shares" contextRef="i7c13820530324de6a22fce865f5cabb2_I20171130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjA0Mw_3e9da12e-2dbb-450d-96f4-95bbbc27cafa">20,547</ix:nonFraction> Series B warrants and <ix:nonFraction unitRef="shares" contextRef="i513914a206464308b0f07a3fdec68ace_I20171130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjA2OA_11306243-d394-41be-beff-2e59e34d1f10">8,221</ix:nonFraction> Series C warrants, after adjusting for a 1-for-100 reverse stock split in 2018. In April 2018, we exercised the Series B warrants in a cashless exercise and received <ix:nonFraction unitRef="shares" contextRef="i3ad66425a0b64ba89a7212677580e0de_D20180401-20180430" decimals="INF" format="ixt:numdotdecimal" name="opk:ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjIzNw_728ed83c-725a-469d-93d6-beb043f01e51">10,690</ix:nonFraction> shares of Neovasc common stock. In the first quarter of 2019, we exercised the Series C warrants for $<ix:nonFraction unitRef="usd" contextRef="ib0abeab516404b459edcdfb5578edb3c_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjM0MQ_96e81a2e-c4cf-42cc-937d-9b00eca93973">1.2</ix:nonFraction> million and exchanged the Series A warrants and received a total of <ix:nonFraction unitRef="shares" contextRef="i397e015eed2e471682652c5cde1df638_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="opk:ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjQwNA_34139627-e2c9-4ea0-999e-a484cc65b394">22,660</ix:nonFraction> additional shares of Neovasc common stock.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2016, we entered into a Pledge Agreement with the Museum of Science, Inc. and the Museum of Science Endowment Fund, Inc. pursuant to which we agreed to contribute an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i202231196f75401e854be2d8baec5847_I20161130" decimals="-5" format="ixt:numdotdecimal" name="opk:RelatedPartyTransactionFutureContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjY0MQ_3e9d82a4-5580-4a3c-8dea-32497890df8c">1.0</ix:nonFraction> million over a <ix:nonNumeric contextRef="i6c3cb92761b94bb7b621e130359abbc8_D20161101-20161130" format="ixt-sec:durwordsen" name="opk:RelatedPartyTransactionFutureContributionTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMzg0ODI5MDcwNzAyNA_0896059f-c64f-4e09-a169-bd0ab9d92b87">four-year</ix:nonNumeric> period for constructing, equipping and the general operation of the Frost Science Museum.  Dr. Frost and Mr. Richard Pfenniger serve on the Board of Trustees of the Frost Science Museum and Mr. Pfenniger is the Vice Chairman of the Board of Trustees.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We lease office space from Frost Real Estate Holdings, LLC (&#8220;Frost Holdings&#8221;) in Miami, Florida, where our principal executive offices are located.  Effective August 1, 2019, we entered into an amendment to our lease agreement with Frost Holdings.  The lease, as amended, is for approximately <ix:nonFraction unitRef="sqft" contextRef="i1996c6025aa74093ba775cca607f2ad3_I20190801" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNzIwMw_155e57a3-08be-4da2-8751-313362dc6ceb">29,500</ix:nonFraction> square feet of space.  The lease provides for payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i1996c6025aa74093ba775cca607f2ad3_I20190801" decimals="-3" format="ixt:numdotdecimal" name="opk:OperatingLeasesMonthlyPaymentsYearOne" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNzI3OA_c5ecabf7-d344-4253-8d31-0d207b72e9d9">89</ix:nonFraction> thousand per month in the first year increasing annually to $<ix:nonFraction unitRef="usd" contextRef="i1996c6025aa74093ba775cca607f2ad3_I20190801" decimals="-3" format="ixt:numdotdecimal" name="opk:OperatingLeasesMonthlyPaymentsYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNzMzMg_342baff2-c857-43dd-af5a-0846aa6ada58">101</ix:nonFraction> thousand per month in the fifth year, plus applicable sales tax.  The rent is inclusive of operating expenses, property taxes and parking.   </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">BioReference purchases and uses certain products acquired from InCellDx, a company in which we hold a <ix:nonFraction unitRef="number" contextRef="iecfe4462c2ee470cb896cbcb8858c7f9_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNzU3MA_a71314fe-23c9-45b5-9682-b54cee5a2c65">29</ix:nonFraction>% minority interest.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We reimburse Dr.&#160;Frost for Company-related use by Dr.&#160;Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr.&#160;Frost.  We reimburse Dr. Frost for out-of-pocket operating costs for the use of the airplane by Dr. Frost or Company executives for Company-related business.  We do not reimburse Dr.&#160;Frost for personal use of the airplane by Dr.&#160;Frost or any other executive.  For the three and six months ended June 30, 2020, we reimbursed approximately $<ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMTY0OTI2NzQ0OTg3NQ_ed8ac9f5-2a1e-44b3-b410-06738a9e7d87">0</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfODA1OQ_50b5a76d-3fd2-4a0c-b4b0-070738ce2aae">94</ix:nonFraction> thousand, respectively, for Company-related travel by Dr. Frost and other OPKO </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ida03c91ff86d4a709df35d4deb7eb5ae">executives. For the three and six months ended June 30, 2019, we reimbursed approximately $<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjE5OTAyMzI2NDI4MA_bc8b0179-9520-40c8-9e4a-2b491e0bc295">122</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjE5OTAyMzI2NDI5NQ_22bbdb65-8725-4075-8969-069f05333851">160</ix:nonFraction>&#160;thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives.</ix:continuation> </span></div><div style="margin-top:9pt;"><span><br/></span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_85"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 11 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfODk3OA_db7141fc-8dcf-4e1b-84ce-f3f906b53915" continuedAt="i1fa3d54a50404f43b058cc01a58b662d" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i1fa3d54a50404f43b058cc01a58b662d" continuedAt="i5c777cae08cf49de9b4c68692754ec2b"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with our acquisitions of CURNA, OPKO Diagnostics and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events.  As a result, as of June 30, 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMjQ1_de34d844-42e7-473a-aa74-f9bd38f29189">9.9</ix:nonFraction> million as contingent consideration, with $<ix:nonFraction unitRef="usd" contextRef="i8680556422af45dd8dfa9ce4d3edc1ba_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMjgy_662c9c0d-ed35-48fd-be31-e01f08f43b95">2.4</ix:nonFraction> million recorded within Accrued expenses and $<ix:nonFraction unitRef="usd" contextRef="i3a53eb2f2d054cc998864517435338b1_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMzIy_4c44bf64-05a9-46b5-b645-30e4d06f8250">7.6</ix:nonFraction> million recorded within Other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets.  Refer to Note 4.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 3, 2019, BioReference reported that Retrieval-Masters Creditors Bureau, Inc. d/b/a American Medical Collection Agency (&#8220;AMCA&#8221;), had notified BioReference about a data security incident involving AMCA (the &#8220;AMCA Incident&#8221;).  AMCA informed BioReference that an unauthorized user had access to AMCA&#8217;s system between August 1, 2018 and March 30, 2019.  AMCA advised that AMCA&#8217;s affected system may have included patient name, date of birth, address, phone, date of service, provider, and balance information, as well as credit card information, bank account information (but no passwords or security questions) and email addresses that were provided by the consumer to AMCA.  AMCA  advised BioReference that no Social Security Numbers were compromised, and BioReference provided no laboratory results or diagnostic information to AMCA.  BioReference notified patients and provided notice to the Office of Civil Rights of the AMCA Incident. BioReference had been named in at least <ix:nonFraction unitRef="lawsuit" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="opk:NumberOfClassActionLawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMTQzOQ_3fd587b4-b637-495e-bce6-6fa5274e1b71">two</ix:nonFraction> class action lawsuits against AMCA and other defendants in connection with the AMCA Incident. In April 2020, the class action lawsuits against BioReference were dismissed without prejudice. The Office of Inspector General and Office for Civil Rights (&#8220;OCR&#8221;) of the Department of Health and Human Services, as well as the attorney generals&#8217; offices from certain states have contacted BioReference to request additional information relating to the AMCA Incident.  It is not possible at this time to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to whether the class action lawsuits or other lawsuits will be filed or refiled, and/or the lack of resolution of significant factual and legal issues.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As previously disclosed, on September 7, 2018, the Securities and Exchange Commission (the &#8220;SEC&#8221;) filed a lawsuit in the Southern District of New York (the &#8220;SEC Complaint&#8221;) against a number of individuals and entities (the &#8220;Defendants&#8221;), including the Company and its CEO and Chairman, Dr. Phillip Frost.  The SEC alleged, among other things, that the Company (i) aided and abetted an illegal &#8220;pump and dump&#8221; scheme perpetrated by a number of the Defendants, and (ii) failed to file required Schedules 13D or 13G with the SEC.  On December 27, 2018, the Company announced that the Company and Dr. Frost entered into settlement agreements with the SEC, which upon approval of the court would resolve the SEC Complaint against each of them.  The settlement was approved by the court in January 2019.  Pursuant to the settlement, and without admitting or denying any of the allegations of the Complaint, the Company is enjoined from violating Section 13(d) of the Exchange Act and paid a $<ix:nonFraction unitRef="usd" contextRef="i45906ae2d8ff43e28d1650b504a4b3c5_D20181227-20181227" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLegalSettlements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMzQwMQ_2f420352-4974-4941-a9db-557b9c616107">100,000</ix:nonFraction> penalty.  Liability under Section 13(d) can be established without any showing of wrongful intent or negligence.  </span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Following the SEC&#8217;s announcement of the SEC Complaint, we were named in several class action lawsuits, more than a dozen derivative suits, and other litigation relating to the allegations in the SEC Complaint among other matters.  On June 26, 2020, The Amitim Funds, the lead plaintiff in the class action lawsuits  filed a Stipulation of Settlement  in the Southern District of Florida of behalf of itself and the remainder of the class, which, if approved, will provide for the settlement of and release of the class action claims against the Company and Dr. Frost for $<ix:nonFraction unitRef="usd" contextRef="if4107320ea8b40a4941b1ec675d93864_D20200501-20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMjE5OTAyMzI2Njg0Mw_947bd67e-80f1-468f-a572-9d68381ed2bd">16.5</ix:nonFraction>&#160;million. We reached agreement with our insurance carriers with respect to claims made in the class action and derivative lawsuits and we expect insurance coverage for a significant portion of the settlement amounts.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The settlement remains subject to certain terms and conditions including court approval. The Company is also in advanced negotiations to settle the derivative suits. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2017, the Civil Division of the United States Attorney&#8217;s Office for the Southern District of New York (the &#8220;SDNY&#8221;) informed BioReference that it believes that, from 2008 to 2012, BioReference had, in violation of the False Claims Act, improperly billed Medicare and TRICARE (both are federal government healthcare programs) for clinical laboratory services provided to hospital inpatient beneficiaries at certain hospitals.  In April 2019, the SDNY also informed BioReference that it believes that BioReference provided physicians subsidies for electronic health record systems prior to 2012 that violated regulations adopted by HHS in 2006 which allowed laboratories to provide these donations under certain conditions.  BioReference and the SDNY are in negotiations to resolve the matter.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October&#160;11, 2019, GeneDx received a letter from the Centers for&#160;Medicare&#160;and Medicaid Services (&#8220;CMS&#8221;), notifying GeneDx of CMS&#8217; determination to suspend Medicare payments to GeneDx, which suspension became effective on September&#160;27, 2019 (the &#8220;CMS Letter&#8221;).  The CMS Letter specifically stated that the foregoing suspension may last for up to </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i5c777cae08cf49de9b4c68692754ec2b"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">180 days from the effective date and may be extended under certain circumstances.  CMS advised that it suspended payments due to possible overpayments to GeneDx in connection with reimbursement claims for genetic testing services based on a diagnosis of family history of cancer, which testing CMS has alleged is not covered by Medicare under the applicable provisions of the Social Security Act on the basis that such testing is not reasonable and necessary for the diagnosis or treatment of illness or injury.  On or around February 3, 2020, we were notified that CMS was lifting the payment suspension.  CMS noted, however, that the decision to lift the payment suspension should not be construed as a positive determination regarding GeneDx&#8217;s Medicare billing.  There can be no assurance that CMS and other governmental payor programs will not seek to recoup payments from us, suspend reimbursement or seek overpayment damages from GeneDx.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may receive inquiries, document requests, Civil Investigative Demands (&#8220;CIDs&#8221;) or subpoenas from the Department of Justice, OCR, CMS, various payors and fiscal intermediaries, and other state and federal regulators regarding investigations, audits and reviews.  In addition to the matters discussed in this note, we are currently responding to CIDs, subpoenas, payor audits, and document requests for various matters relating to our laboratory operations.  Some pending or threatened proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material.  Settlements of suits involving the types of issues that we routinely confront may require monetary payments as well as corporate integrity agreements.  Additionally, qui tam or &#8220;whistleblower&#8221; actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act&#8217;s requirements for filing such suits.  Also, from time to time, we may detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians, among other things.  We may avail ourselves of various mechanisms to address these issues, including participation in voluntary disclosure protocols.  Participating in voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action.  The Company generally has cooperated, and intends to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to other litigation in the ordinary course of business.  While we cannot predict the ultimate outcome of legal matters, we accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss.  It&#8217;s reasonably possible the ultimate liability could exceed amounts currently estimated and we review established accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information.  To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.  Because of the high degree of judgment involved in establishing loss estimates, the ultimate outcome of such matters will differ from our estimates and such differences may be material to our business, financial condition, results of operations, and cash flows.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, we were committed to make future purchases for inventory and other items in 2020 that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating approximately $<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfODk3NA_e6852a3f-2428-4db1-8ae2-90fd8b84251f">154.2</ix:nonFraction> million.</span></div></ix:continuation><div id="ia969b45ba09947e9a03ce421f700f5b3_91"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 12 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTUzMDc_d2762e2d-af52-41f0-b9ea-fcd7ad2ef182" continuedAt="if2c5b848e929424e8230d3e1ceb0d1fd" escape="true">REVENUE RECOGNITION</ix:nonNumeric></span></div><ix:continuation id="if2c5b848e929424e8230d3e1ceb0d1fd" continuedAt="i8bf3138c04754ecc8f09f754ae4c46f4"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We generate revenues from services, products and intellectual property as follows:</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from services</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance obligations are satisfied.  Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs.  Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following are descriptions of our payors for laboratory services:</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Healthcare Insurers.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules.  Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the third-party payors, are recorded upon settlement.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Government Payors.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Reimbursements from government payors are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid.  Revenues consist of amounts billed, net of contractual </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i8bf3138c04754ecc8f09f754ae4c46f4" continuedAt="id7e974850ee34c82a61861c8eadd3cf7"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the government payors, are recorded upon settlement.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Client Payors.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Client payors include physicians, hospitals, employers, and other institutions for which services are performed on a wholesale basis, and are billed and recognized as revenue based on negotiated fee schedules.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Patients.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients.  Insured patients (including amounts for coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers.  Collection of billings from patients is subject to credit risk and ability of the patients to pay.  Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions.  Implicit price concessions represent differences between amounts billed and the estimated consideration that we expect to receive from patients, which considers historical collection experience and other factors including current market conditions.  Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered.  Actual amounts are adjusted in the period those adjustments become known. For the six months ended June 30, 2020 and 2019, revenue increases (reductions) due to changes in estimates of implicit price concessions for performance obligations satisfied in prior periods of $<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMzY2NQ_fcc9bba1-ae22-4651-a6de-82d965214d29">0.2</ix:nonFraction> million and $(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMzY3Mg_143851a2-8c9e-4673-97ec-5e2cb91a6808">14.3</ix:nonFraction>) million, respectively, were recognized.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third-party payors, including government programs, may decide to deny payment or recoup payments for testing they contend were improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received.  Our revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payors in interpretations, requirements, and &#8220;conditions of participation&#8221; in various programs.  We have processed requests for recoupment from third-party payors in the ordinary course of our business, and it is likely that we will continue to do so in the future.  If a third-party payer denies payment for testing or recoups money from us in a later period, reimbursement for our testing could decline.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As an integral part of our billing compliance program, we periodically assess our billing and coding practices, respond to payor audits on a routine basis, and investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements, as well as overpayment claims which may arise from time to time without fault on the part of the Company.  We may have an obligation to reimburse Medicare, Medicaid,&#160;and third-party payors for overpayments&#160;regardless of fault.  We have periodically identified and reported&#160;overpayments, reimbursed payors for&#160;overpayments&#160;and taken appropriate corrective action.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are also considered variable consideration and are included in the determination of the estimated transaction price for providing services.  These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and our historical settlement activity, including an assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved.  Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. As of June&#160;30, 2020 and December&#160;31, 2019, we had liabilities of approximately $<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="opk:AccruedExpensePayorOverpaymentReimbursementLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfNjE5OQ_9fa07b17-16f9-44c5-a2a1-e60ea5f19b30">21.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-5" format="ixt:numdotdecimal" name="opk:AccruedExpensePayorOverpaymentReimbursementLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfNjIwNg_aaeaa075-1fc4-42cf-b343-259f00ead834">27.3</ix:nonFraction> million, respectively, within Accrued expenses and Other long-term liabilities related to reimbursements for payor overpayments.</span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMjE5OTAyMzI3MzUxNw_eb473d58-9455-4c5c-8648-d774e158f639" continuedAt="i620aea89b93e4c79ba128d956627dd32" escape="true">The composition of Revenue from services by payor for the six months ended June 30, 2020 and 2019 was as follows:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="id7e974850ee34c82a61861c8eadd3cf7" continuedAt="i7f13e3c643e141eda1a6573290e90605"><ix:continuation id="i620aea89b93e4c79ba128d956627dd32"><div style="text-align:center;margin-top:14pt;margin-bottom:10pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.035%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.035%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.035%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.039%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June&#160;30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June&#160;30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Healthcare insurers</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i287de0999fc24a5cb5546c28ae66980f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMi0xLTEtMS0w_8fb7619d-7003-4aff-9f5b-99d8e57b5031">84,082</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd5de3ee3106459b8b1aaab7a6b137d4_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMi0zLTEtMS0w_28b4b406-dc08-40e3-a967-2e720eb6f833">106,278</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2f7c56771ab4b20b7d3fa3715695ba7_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMi01LTEtMS0w_ecba4ca4-e31e-4709-8aba-dc3f9b4ab0bf">183,232</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e55f87c472d4233942a0970f859291b_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMi03LTEtMS0w_16356cdb-a7c0-4cb3-aa2f-68f2e2ed4192">211,207</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government payers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fb7acf8a79143cfb95180991f377710_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMy0xLTEtMS0w_334fea8b-8576-409d-9f63-0c24213a7508">15,886</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia071dd1966f14fa29801b16850ffc8ea_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMy0zLTEtMS0w_7ad4a716-aa40-472e-acea-f5db8d652ea7">28,634</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6668a10b9952410e9af8b9a573c3e502_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMy01LTEtMS0w_655dd318-2d82-4d57-9996-1b17c398faa8">42,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7313b7ad75404a70aedcc5983ef98116_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMy03LTEtMS0w_30f855dd-dd09-42db-aaa3-84e848c0c58e">59,037</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Client payers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic8d2333fa91a41edb9d18575c207b357_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNC0xLTEtMS0w_657d1cf8-a6c2-4e22-8646-101cd17302e7">141,090</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic673a0ad279b49569adc8053d136c9ed_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNC0zLTEtMS0w_334abf97-ce02-478b-a9e8-917948944380">38,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i357cf1c7f87349e9a4ad4f30e32145c1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNC01LTEtMS0w_86087644-00d6-4267-9327-f09b1235898d">180,191</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2604b5fdeede46d09d8201be1e143102_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNC03LTEtMS0w_c984225b-2e59-4532-a8e3-11be482efb23">76,559</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patients</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i98c6c923d99b4f72ba76f4043d93e5b7_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNS0xLTEtMS0w_e3f68f6f-6d0f-4819-ac08-6346a10f26dc">9,913</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafbe4baeeb164e489598f3e93202ba13_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNS0zLTEtMS0w_c9c9c529-783c-48bb-8cb9-d4c90ad17ca0">5,445</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7fba9e8f0b849fca41dd97146435305_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNS01LTEtMS0w_6c006596-19c9-4b5e-ba46-4afc53df5e6a">15,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd71af6f0ead42e3977e6816580c5b93_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNS03LTEtMS0w_ad71ce9c-c871-42d6-ac7d-5326d1d0ffa7">10,546</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia2b0d7b56e4e464a9d12b6d4962aea9f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNi0xLTEtMS0w_313291fe-d5a6-4370-a006-0174614bbdc4">250,971</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e422d827f1b4988be46200738452fe0_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNi0zLTEtMS0w_2c46b322-49c4-4c2e-8c60-d27bc97dbb2b">178,458</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i717fe99763b443568a4e4ea66cbaafd2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNi01LTEtMS0w_0c59e9a2-3e16-465e-a78d-135f8f7f602a">421,811</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia322ccb5ede0412f84ec2408b2552856_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNi03LTEtMS0w_ec93acdb-0783-4f27-93bb-767c95215049">357,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Client payers include cities and states for which BioReference provides COVID-19 testing services.</span></div></ix:continuation><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from products</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue from product sales when a customer obtains control of promised goods or services.  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns.  Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, &#8220;Sales Deductions&#8221;) as well as estimated product returns which are all elements of variable consideration.  Allowances are recorded as a reduction of revenue at the time product revenues are recognized.  The actual amounts of consideration ultimately received may differ from our estimates.  If actual results in the future vary from our estimates, we will adjust these estimates, which would affect Revenue from products in the period such variances become known.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is distributed in the U.S. principally through the retail pharmacy channel, which initiates with the largest wholesalers in the U.S. (collectively, &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Customers&#8221;).  In addition to distribution agreements with </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Customers, we have entered into arrangements with many healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue for shipments of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> at the time of delivery to customers after estimating Sales Deductions and product returns as elements of variable consideration utilizing historical information and market research projections. For the three and six months ended June 30, 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfODI5Nw_645c2a0c-71ae-4b95-8a22-4e585698e13b">8.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTY0OTI2NzQ1NzA3OQ_b30c03f5-ca06-4ff2-a4e5-22e83720bdbd">18.6</ix:nonFraction>&#160;million, respectively, in net product revenue from sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  For the three and six months ended June 30, 2019, we recognized $<ix:nonFraction unitRef="usd" contextRef="i0c056955493c4da89ecda0e8ec4dfeba_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfODMwNA_5b7ed3f8-bfc3-496b-b2bf-ce68a4e7b493">5.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i089a4e13e63742a3bf748b525008d6b6_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTY0OTI2NzQ1NzE1Nw_dc6a7534-dc4f-4a7e-bc24-1f7864f9f736">11.5</ix:nonFraction>&#160;million, respectively, in net product revenue from sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </span></div><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="opk:ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTUzMDU_a6fb5e9e-a27c-4fac-a28a-8e7f0c55a3b8" continuedAt="i71a5dab086cb4c6b9cdc3368cfbe823a" escape="true"><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents an analysis of product sales allowances and accruals for the three and six months ended June 30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:47.558%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.617%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.588%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.588%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.593%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Governmental </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia7a45f8733e649d5a143646e955ce1f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMS0yLTEtMS0zMTgx_07d6dc86-4c14-47da-bac4-259b00ef33c3">2,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icbef2a22641441ef8b13514f0f8eebc1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMS00LTEtMS0zMTgx_dd18ca10-50be-4659-8cb5-5127d7ced814">6,199</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic702ce3d60b840edaa4bec0798d18d2e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMS02LTEtMS0zMTgx_f12a3b0c-4297-4034-aeaf-80805323244c">3,332</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic01e46e792ea463fb3ad976ee43f07a4_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMS04LTEtMS0zMTgx_2f97152f-36f9-41a2-a422-9f9d115fe72a">12,394</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i387d466a792a4a228b1f3c6bc7fc4238_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMi0yLTEtMS0zMTgx_1c839d02-e9a7-4016-bb74-21b3cbc2072f">4,468</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id67bcee65e014a2a88bd297922d60030_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMi00LTEtMS0zMTgx_ca71f2b2-e30f-4b4a-895f-687b7d823e7a">9,073</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66ba957ba45c4cb99119dded44d3d424_D20200401-20200630" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMi02LTEtMS0zMTgx_87d5b1d6-3a8e-4f0c-88f7-2e2927498948">686</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMi04LTEtMS0zMTgx_1790ebd0-a802-4218-a649-a22852109581">14,227</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i387d466a792a4a228b1f3c6bc7fc4238_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNC0yLTEtMS0zMTgx_52c9bb08-66b1-4a15-a2eb-48127cc50c84">4,441</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id67bcee65e014a2a88bd297922d60030_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNC00LTEtMS0zMTgx_40a0e60a-7fe9-42bf-a44f-05ba9f7addc3">8,273</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i66ba957ba45c4cb99119dded44d3d424_D20200401-20200630" decimals="-3" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNC02LTEtMS0zMTgx_2831bfdc-f2ae-4180-8785-5a3443feba52">188</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNC04LTEtMS0zMTgx_7437e0c3-e5de-47f9-8704-eda0cc22f9c4">12,902</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7922e995a9b44dc296c267b40bfec5f5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNS0yLTEtMS0zMTgx_6a9599c5-b316-43bd-b962-90e38436bfaf">2,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0a4001228bb4c458e9d188609ce4c92_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNS00LTEtMS0zMTgx_0a0d3f8f-9b61-4d6d-a87c-d6297272483b">6,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa95a3813d3b4948b9efc4c7b0d46611_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNS02LTEtMS0zMTgx_ffc1aeca-872b-40d4-a58e-d9752cc78ad8">3,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fdb6f9b86ce4bbb9158e2c6d20fc489_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNS04LTEtMS0zMTgx_86799839-70c2-40b8-b3fb-60305ad87790">13,719</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNy04LTEtMS0zMTgx_1e778853-c018-4320-a658-7fa06c661287">22,876</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Provision for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales allowances and accruals as a percentage of gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630" decimals="2" name="opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfOC04LTEtMS0zMTgx_26ef282b-80e9-4b90-bd91-b9d5db91c0c2">62</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i7f13e3c643e141eda1a6573290e90605" continuedAt="i9c2c99e90cac4b658bc4eecb824f946a"><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><ix:continuation id="i71a5dab086cb4c6b9cdc3368cfbe823a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:47.558%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.617%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.588%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.588%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.593%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Governmental </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0f98c06a3c1e4ad896eadb86f6436385_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMS0yLTEtMS0w_40437988-f161-4982-a504-749ca93f4ed1">3,194</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2327c5e5ccd74c11bba8c2252aa98414_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMS00LTEtMS0w_320c935f-4945-4d5a-b5ac-923091df437b">5,841</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id6569a37c094481dbbbf19ebad7e7881_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMS02LTEtMS0w_9733fb22-8bca-49cb-882c-659ebc7be601">2,751</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic15d90a4230749868f5b5c698ace3ce2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMS04LTEtMS0w_aae966bf-a2b2-45dd-b6bd-146b1de79c7e">11,786</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3e3522057538446ea1d251088ff7d6f5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMi0yLTEtMS0w_bb9c1e2f-42a7-4daa-a8bd-e725f4ac0241">9,293</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa68b3c3ee24bd292852c6f5f85587c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMi00LTEtMS0w_104e006b-8459-40cd-9316-77855676de51">16,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ac0c06819a046cfa71bf39ddbd390fc_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMi02LTEtMS0w_e1a16c93-a982-46ca-bb40-193401cba9f3">1,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMi04LTEtMS0w_ae608ea6-4f7f-43de-b25f-3ca17bf9db3b">26,963</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3e3522057538446ea1d251088ff7d6f5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNC0yLTEtMS0w_a2a1ee7c-0025-4919-957f-a11b2ae2484c">9,597</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa68b3c3ee24bd292852c6f5f85587c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNC00LTEtMS0w_a772ec59-9a06-4bd1-b7b9-94a024ab777d">15,123</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0ac0c06819a046cfa71bf39ddbd390fc_D20200101-20200630" decimals="-3" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNC02LTEtMS0w_7f7de239-6403-44ca-8ed6-6811207e3bcd">310</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNC04LTEtMS0w_775abadb-ee8c-44e3-b23b-340393a75540">25,030</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7922e995a9b44dc296c267b40bfec5f5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNS0yLTEtMS0w_174a85aa-b621-4a82-a949-7d4d8d08dbca">2,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0a4001228bb4c458e9d188609ce4c92_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNS00LTEtMS0w_caf7b807-c399-4b1f-966a-1300e583c0d1">6,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa95a3813d3b4948b9efc4c7b0d46611_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNS02LTEtMS0w_f428d769-2bc5-4a60-a26b-3f19c3002fc9">3,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fdb6f9b86ce4bbb9158e2c6d20fc489_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNS04LTEtMS0w_8c6fc0ef-0799-4beb-8f25-c81c8bee0cf9">13,719</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNy04LTEtMS0w_e12f8158-c46e-4ba0-95c1-164f1fdaf0db">45,559</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Provision for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales allowances and accruals as a percentage of gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630" decimals="2" name="opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfOC04LTEtMS0w_bbce13a5-f155-4abb-b8a0-100f1fb40034">59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></ix:continuation></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues.</span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from intellectual property</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements.  The terms of these agreements typically include payment to us for one or more of the following:  non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products.  Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For research, development and/or commercialization agreements that result in revenues, we identify all material performance obligations, which may include a license to intellectual property and know-how, and research and development activities.  In order to determine the transaction price, in addition to any upfront payment, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract.  We constrain (reduce) our estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract.  When determining if variable consideration should be constrained, we consider whether there are factors outside of our control that could result in a significant reversal of revenue.  In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue.  These estimates are re-assessed each reporting period as required.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upfront License Fees:  If a license to our intellectual property is determined to be functional intellectual property distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement.  The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.  If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Development and Regulatory Milestone Payments:  Depending on facts and circumstances, we may conclude that it is appropriate to include the milestone in the estimated transaction price or that it is appropriate to fully constrain the milestone.  A milestone payment is included in the transaction price in the reporting period that we conclude that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods.  We may record revenues from certain milestones in a reporting period before the milestone is achieved if we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We record a corresponding contract asset when this conclusion is reached.  Milestone payments that have been fully constrained are not included in the transaction price to date.  These milestones remain fully constrained until we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period.  We adjust our estimate of the overall transaction price, including the amount of revenue recorded, if necessary.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and Development Activities:  If we are entitled to reimbursement from our customers for specified research and development expenses, we account for them as separate performance obligations if distinct.  We also determine whether the research and development funding would result in revenues or an offset to research and development expenses in accordance </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i9c2c99e90cac4b658bc4eecb824f946a" continuedAt="i37bac0ea1dfe4b68bf7b8bcca4984a66"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">with provisions of gross or net revenue presentation.  The corresponding revenues or offset to research and development expenses are recognized as the related performance obligations are satisfied.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales-based Milestone and Royalty Payments:  Our customers may be required to pay us sales-based milestone payments or royalties on future sales of commercial products.  We recognize revenues related to sales-based milestone and royalty payments upon the later to occur of (i) achievement of the customer&#8217;s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to our intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other Potential Products and Services:  Arrangements may include an option for license rights, future supply of drug substance or drug product for either clinical development or commercial supply at the licensee&#8217;s election.  We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the inception of the contract and revenue is recognized only if the option is exercised and products or services are subsequently delivered or when the rights expire.  If the promise is based on market terms and not considered a material right, the option is accounted for if and when exercised.  If we are entitled to additional payments when the licensee exercises these options, any additional payments are generally recorded in license or other revenues when the licensee obtains control of the goods, which is upon delivery.</span></div></ix:continuation><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i37bac0ea1dfe4b68bf7b8bcca4984a66">For the three and six months ended June 30, 2020, revenue from transfer of intellectual property principally reflects $<ix:nonFraction unitRef="usd" contextRef="ie3e2e61832ff4501874806792daa7e45_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTQ5NzU_d307dce7-710c-4e67-bd42-ea326ef6ad34">13.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia335908fb412465eaee57977f0412a4d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTY0OTI2NzQ1NzMwOA_76399cb3-caf7-4943-9b44-5ec6e9d02068">22.7</ix:nonFraction> million of revenue, respectively, related to the Pfizer Transaction (as defined below).   In addition, revenue from the transfer of intellectual property and other for the three and six months ended June 30, 2020 includes a $<ix:nonFraction unitRef="usd" contextRef="i5d636303815c49c8a2406f9aaa62f932_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMjE5OTAyMzI3MzM2OQ_99be7ece-31c9-4a61-a039-196b29f90656">6.2</ix:nonFraction>&#160;million grant received by BioReference from the CARES Act. For the three and six months ended June 30, 2019, revenue from the transfer of intellectual property principally reflects $<ix:nonFraction unitRef="usd" contextRef="i6b958666966849daa4cbbd1cef96fbf6_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTQ5ODI_c22c4715-9ac2-47f3-9085-259478d3c6e0">18.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia2fe40f321844ae6bf4ae91cb7dc8144_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTY0OTI2NzQ1NzU0Ng_e9e4906b-cd58-4711-bd72-e9c38f5a22d2">35.6</ix:nonFraction> million of revenue, respectively, related to the Pfizer Transaction.  Refer to Note 13 for discussion of the Pfizer Transaction. Total contract liabilities included in Accrued expenses and Other long-term liabilities was $<ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTUxNzY_677c0260-3479-4747-94ad-a2028a8d9a97">17.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTUxODM_97f4d72e-81a0-4021-b8a4-ae929420dc9a">21.8</ix:nonFraction> million at June&#160;30, 2020 and December&#160;31, 2019, respectively.  The contract liability balance at June&#160;30, 2020 related primarily to accelerated payments received as part of the COVID-19 Aid, Relief, and Economic Security (CARES) Act.</ix:continuation>  Refer to Note 2.</span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_94"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 13 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="opk:StrategicAlliancesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTU0Nzk_4ce44a7f-567f-4333-8817-783b543721ad" continuedAt="i3746675652e8435f8401c9c231d513f3" escape="true">STRATEGIC ALLIANCES</ix:nonNumeric></span></div><ix:continuation id="i3746675652e8435f8401c9c231d513f3" continuedAt="icfeaec1a650e4bf58a7cd9ce4586eac2"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Japan Tobacco Inc.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 12, 2017, EirGen, our wholly owned subsidiary, and Japan Tobacco Inc. (&#8220;JT&#8221;) entered into a Development and License Agreement (the &#8220;JT Agreement&#8221;) granting JT the exclusive rights for the development and commercialization of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Japan (the &#8220;JT Territory&#8221;).  The license grant to JT covers the therapeutic and preventative use of the product for (i)&#160;SHPT in non-dialysis and dialysis patients with CKD, (ii)&#160;rickets, and (iii)&#160;osteomalacia (the &#8220;JT Initial Indications&#8221;), as well as such additional indications as may be added to the scope of the license subject to the terms of the JT Agreement (the JT Additional Indications&#8221; and together with the JT Initial Indications, the &#8220;JT Field&#8221;).  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the license, OPKO received an initial upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i85584120b6ae40969ed88e8fc454cbac_D20171012-20171012" decimals="-6" format="ixt:numdotdecimal" name="opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfODM5_a382e991-a609-45e8-8b96-dcdac31d7588">6</ix:nonFraction> million and received another $<ix:nonFraction unitRef="usd" contextRef="i12ba1de7824543edbdd98ac438e809ef_D20180901-20180930" decimals="-6" format="ixt:numdotdecimal" name="opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfODYz_a6d37a0f-1b6e-4a9e-b743-d9d9ecf70d03">6</ix:nonFraction> million upon the initiation of OPKO&#8217;s phase 2 study for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in dialysis patients in the U.S. in September 2018 (the &#8220;Initial Consideration&#8221;). OPKO is also eligible to receive up to an additional aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i96d78de3ebc6453598709f12f3820f35_D20171012-20171012" decimals="-6" format="ixt:numdotdecimal" name="opk:ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTA3OA_77d04e9b-af20-424a-bcbe-e608a268b9ee">31</ix:nonFraction> million upon the achievement of certain regulatory and development milestones by JT for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the JT Territory, and $<ix:nonFraction unitRef="usd" contextRef="ie228af85f95c497a87274c2e14523168_D20171012-20171012" decimals="-6" format="ixt:numdotdecimal" name="opk:ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTE5NQ_483de098-af07-4240-b662-d212cded3939">75</ix:nonFraction> million upon the achievement of certain sales based milestones by JT in the JT Territory.  OPKO is also entitled to receive tiered, double digit royalty payments at percentages ranging from low double digits to mid-teens on net sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">within the JT Territory.  JT will, at its sole cost and expense, be responsible for performing all development activities necessary to obtain all regulatory approvals for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Japan and for all commercial activities pertaining to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Japan.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The JT Agreement provides for the following:  (1) an exclusive license in the JT Territory in the JT Field for the development and commercialization of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">; and (2) at JT&#8217;s option, EirGen will supply products to support the development, sale and commercialization of the products to JT in the JT Territory.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Initial Consideration will be recognized over the performance period through 2021, when we anticipate completing the transfer of license materials specified in the JT Agreement and our performance obligation is complete.  Payments received for regulatory, development and sales milestones are non-refundable.  The milestones are payable if and when the associated milestone is achieved and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, <ix:nonFraction unitRef="usd" contextRef="i7eed0ec839c8449599c9e800686ae3ce_D20171012-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMjU1Nw_9378d8a5-d728-4490-a802-690fb253b32d">no</ix:nonFraction> revenue has been recognized related to these milestones.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="icfeaec1a650e4bf58a7cd9ce4586eac2" continuedAt="id07e79a606534c11802fd38e2cbc13cb"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vifor Fresenius Medical Care Renal Pharma Ltd</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2016, EirGen and Vifor Fresenius Medical Care Renal Pharma Ltd (&#8220;VFMCRP&#8221;), entered into a Development and License Agreement (the &#8220;VFMCRP Agreement&#8221;) for the development and commercialization of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (the &#8220;Product&#8221;) worldwide, except for (i) the U.S., (ii) any country in Central America or South America (excluding Mexico), (iii) Russia, (iv) China, (v) Japan, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, and (x) Taiwan (the &#8220;VFMCRP Territory&#8221;).  The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the &#8220;VFMCRP Field&#8221;), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with CKD and vitamin D insufficiency/deficiency (the &#8220;VFMCRP Initial Indication&#8221;).</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective May 5, 2020, we entered into an amendment to the VFMCRP Agreement (the &#8220;VFMCRP Amendment&#8221;), pursuant to which the parties agreed to exclude Mexico, South Korea, the Middle East and all of the countries of Africa from the VFMCRP Territory. In addition, the parties agreed to certain amendments to the milestone structure and to reduce minimum royalties payable. As revised, EirGen is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i61fa984d891a47d58311053b2676c0d2_D20200505-20200505" decimals="-6" format="ixt:numdotdecimal" name="opk:CollaborativeArrangementMaximumMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMjE5OTAyMzI3MjA0Nw_83ad256d-2d7a-46ab-a1c9-d97fa8753ee5">20</ix:nonFraction>&#160;million in Regulatory Milestones and $<ix:nonFraction unitRef="usd" contextRef="i27932b492e774f8db8526aebe560cf2c_D20200505-20200505" decimals="-6" format="ixt:numdotdecimal" name="opk:CollaborativeArrangementMaximumMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMjE5OTAyMzI3MjA2MA_1a477170-58ec-4a97-ad2b-5ed17a90519a">210</ix:nonFraction>&#160;million in Sales Milestones tied to launch, pricing and sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the VFMCRP Agreement, as amended, EirGen granted to VFMCRP an exclusive license in the VFMCRP Territory in the VFMCRP Field to use certain EirGen patents and technology to make, have made, use, sell, offer for sale, and import Products and to develop, commercialize, have commercialized, and otherwise exploit the Product.  EirGen received a non-refundable and non-creditable initial payment of $<ix:nonFraction unitRef="usd" contextRef="i36465446b239476682a20c709bd20264_D20160501-20160531" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMzg5MA_13ccdbcb-13b6-4c02-a5b5-56adc57758d8">50</ix:nonFraction> million, which was recognized in Revenue from the transfer of intellectual property and other in our Consolidated Statement of Operations in 2016.  EirGen also received a $<ix:nonFraction unitRef="usd" contextRef="i80e8caee7a4340afab2963d15be9c425_D20180701-20180731" decimals="-5" format="ixt:numdotdecimal" name="opk:CollaborativeAgreementAdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfNDA1Ng_7720e27d-f52a-4f90-814f-16f34feb8446">2.0</ix:nonFraction> million payment triggered by the approval of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Canada for the treatment of SHPT in adults with stage 3 or 4 CKD and vitamin D insufficiency in July 2018. EirGen is also eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i61fa984d891a47d58311053b2676c0d2_D20200505-20200505" decimals="-6" format="ixt:numdotdecimal" name="opk:CollaborativeArrangementMaximumMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfNjU5NzA2OTc4MzU2NA_83ad256d-2d7a-46ab-a1c9-d97fa8753ee5">20</ix:nonFraction>&#160;million in regulatory milestones (&#8220;Regulatory Milestones&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="i27932b492e774f8db8526aebe560cf2c_D20200505-20200505" decimals="-6" format="ixt:numdotdecimal" name="opk:CollaborativeArrangementMaximumMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfNjU5NzA2OTc4MzYwNA_1a477170-58ec-4a97-ad2b-5ed17a90519a">210</ix:nonFraction>&#160;million in Sales Milestones tied to launch, pricing and sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;Sales Milestones&#8221;), and will receive tiered royalties on sales of the product at percentage rates that range from the mid-teens to the mid-twenties or a minimum royalty, whichever is greater, upon the commencement of sales of the Product within the VFMCRP Territory and in the VFMCRP Field.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We plan to share responsibility with VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan.  EirGen will lead the manufacturing activities within and outside the VFMCRP Territory and the commercialization activities outside the VFMCRP Territory and outside the VFMCRP Field in the VFMCRP Territory and VFMCRP will lead the commercialization activities in the VFMCRP Territory and the VFMCRP Field.  For the initial development plan, the companies have agreed to certain cost sharing arrangements.  VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in the VFMCRP Territory in the VFMCRP Field except as otherwise provided in the VFMCRP Agreement.  The first of the clinical studies provided for in the development activities commenced in September 2018.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted to VFMCRP an exclusive option (the &#8220;Option&#8221;) to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the U.S. solely for the treatment of SHPT in dialysis patients with CKD and vitamin D insufficiency (the &#8220;Dialysis Indication&#8221;).  Upon exercise of the Option, VFMCRP will reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the U.S.  VFMCRP would also pay EirGen up to an additional aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i1aca0bd3383748acb9d44a211a37ecaf_D20160501-20160531" decimals="INF" format="ixt:numdotdecimal" name="opk:CollaborativeArrangement.MaximumMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfNjg0OQ_24d717f6-7d92-4b25-a861-b2c6811abc5b">555</ix:nonFraction> million of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the U.S. for the Dialysis Indication.  To date, VFMCRP has not exercised its option.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payments received for Regulatory Milestones and Sales Milestones are non-refundable.  The Regulatory Milestones are payable if and when VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  We account for the Sales Milestones as royalties and Sales Milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met.  </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pfizer Inc.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2014, we entered into an exclusive worldwide agreement (the &#8220;Pfizer Agreement&#8221;) with Pfizer for the development and commercialization of our long-acting hGH-CTP (Somatrogon) for the treatment of growth hormone deficiency (&#8220;GHD&#8221;) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (the &#8220;Pfizer Transaction&#8221;).  </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="id07e79a606534c11802fd38e2cbc13cb" continuedAt="i6734e71d613e4dc18d7a163c2f9f2dcc"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2020, we entered into an Amended and Restated Development and Commercialization License Agreement (the &#8220;Restated Agreement&#8221;) with Pfizer, effective January 1, 2020, pursuant to which the parties agreed, among other things, to share all costs for Manufacturing Activities, as defined in the Restated Agreement, for developing a licensed product for the three indications included in the Agreement.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 21, 2019, we and Pfizer announced that the global phase 3 trial evaluating Somatrogon (hGH-CTP) dosed once-weekly in prepubertal children with GHD met its primary endpoint of non-inferiority to daily Genotropin&#174; (somatropin) for injection, as measured by annual height velocity at <ix:nonNumeric contextRef="i40db44cde7914640bc267bc5d3ca1d33_D20191021-20191021" format="ixt-sec:durmonth" name="opk:CollaborativeArrangementAnnualHeightVelocityatPointinTime" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfODQyNQ_86becc3d-2b41-4b14-964a-8bc404b3be65">12</ix:nonNumeric> months.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Pfizer Transaction, as restated, we received non-refundable and non-creditable upfront payments of $<ix:nonFraction unitRef="usd" contextRef="i0bb57ae1dccc4112800dea209c9b6318_D20150101-20150131" decimals="-5" format="ixt:numdotdecimal" name="opk:CollaborativeArrangementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfODU4Ng_7a15805c-4a93-4be5-aaf9-84af0108120e">295.0</ix:nonFraction> million and are eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i0bb57ae1dccc4112800dea209c9b6318_D20150101-20150131" decimals="INF" format="ixt:numdotdecimal" name="opk:CollaborativeArrangement.MaximumMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfODYzNw_8598c98c-e16a-4b42-ae48-f5afe029d4fc">275.0</ix:nonFraction> million upon the achievement of certain regulatory milestones.  Pfizer received the exclusive license to commercialize hGH-CTP worldwide.  In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of hGH-CTP for adult GHD with percentage rates ranging from the high teens to mid-twenties.  Upon the launch of hGH-CTP for pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both hGH-CTP and Pfizer&#8217;s Genotropin&#174;.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement with Pfizer will remain in effect until the last sale of the licensed product, unless earlier terminated as permitted under the Pfizer Agreement.  In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Pfizer Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period.  If the Pfizer Agreement is terminated by us for Pfizer&#8217;s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions.     </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized the non-refundable $<ix:nonFraction unitRef="usd" contextRef="i0bb57ae1dccc4112800dea209c9b6318_D20150101-20150131" decimals="-5" format="ixt:numdotdecimal" name="opk:CollaborativeArrangementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfOTk0Mg_cafc2c91-3d8f-4adc-91ba-8b97d13dc752">295.0</ix:nonFraction> million upfront payments as revenue as the research and development services were completed and as of June 30, 2020, we had no contract liabilities related to the Pfizer Transaction.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Pfizer Transaction includes milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i0bb57ae1dccc4112800dea209c9b6318_D20150101-20150131" decimals="INF" format="ixt:numdotdecimal" name="opk:CollaborativeArrangement.MaximumMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTAyMDE_834f110e-ca4b-4aa4-b4d0-b2da2e80f1f4">275.0</ix:nonFraction> million upon the achievement of certain milestones.  The milestones range from $<ix:nonFraction unitRef="usd" contextRef="ic54c6d599fea4f00a596b9e77dc46c21_D20150101-20150131" decimals="INF" format="ixt:numdotdecimal" name="opk:CollaborativeArrangementMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTAyNzU_e1e6b27d-155f-4253-acb7-3fef69d6c88d">20.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i090a78b5b12948a8bc788af6634489b5_D20150101-20150131" decimals="INF" format="ixt:numdotdecimal" name="opk:CollaborativeArrangementMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTAyODE_d4a52348-156c-424d-9c78-466db5fe969e">90.0</ix:nonFraction> million each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets.  The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  To date, <ix:nonFraction unitRef="usd" contextRef="i4935e51954e74cb4802f926d08c79c4e_D20150101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTA2MDI_0a43837d-97b1-4f05-865f-32fb2af3922b">no</ix:nonFraction> revenue has been recognized related to the achievement of the milestones.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">TESARO</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2009, we entered into an asset purchase agreement (the &#8220;NK-1 Agreement&#8221;) under which we acquired VARUBI&#8482; (rolapitant) and other neurokinin-1 (&#8220;NK-1&#8221;) assets from Merck.  In December 2010, we entered into an exclusive license agreement with TESARO, Inc. (&#8220;TESARO&#8221;), in which we out-licensed the development, manufacture, commercialization and distribution of our lead NK-1 candidate, VARUBI&#8482; (the &#8220;TESARO License&#8221;).  Under the terms of the license, we received a $<ix:nonFraction unitRef="usd" contextRef="if7a4105b8a0d43d798aa66064542811f_D20101201-20101231" decimals="-5" format="ixt:numdotdecimal" name="opk:LicenseandCollaborationAgreementsProceedsasUpFrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTExNjA_0825da0b-fc1d-4dae-adee-77c5ad95e179">6.0</ix:nonFraction> million upfront payment from TESARO and we received $<ix:nonFraction unitRef="usd" contextRef="if83c5551238f479bbacf93c87bc5c2a9_D20101201-20180930" decimals="-6" format="ixt:numdotdecimal" name="opk:CollaborativeArrangementMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTEyMDc_ade390cc-76c9-4e3c-8091-b663ef74205e">30</ix:nonFraction> million of milestone payments from TESARO upon achievement of certain regulatory and commercial sale milestones and we are eligible to receive additional commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="if7a4105b8a0d43d798aa66064542811f_D20101201-20101231" decimals="INF" format="ixt:numdotdecimal" name="opk:CollaborativeAgreementAdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTEzOTU_55fe5214-8dfd-489e-9bab-71301a97e87a">85</ix:nonFraction> million if specified levels of annual net sales are achieved.  The sales based milestone payments will be recognized as revenue in full in the period in which the associated sales occur. For the six months ended June 30, 2020 and 2019, <ix:nonFraction unitRef="usd" contextRef="i080c53c4c6124f38aaee94f9fcbb0577_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTE1OTg_45db6fa7-4c0b-4a62-808a-8fe3bb7da810"><ix:nonFraction unitRef="usd" contextRef="i5b1c90b9bdb34bb583bd46dc1902301f_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTE1OTg_c03440e8-dac9-44a7-8252-8df9fb222e0e">no</ix:nonFraction></ix:nonFraction> revenue was recognized related to the achievement of the milestones under the TESARO License. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the TESARO License, TESARO was also obligated to pay us tiered royalties on annual net sales achieved in the U.S. and Europe at percentage rates that range from the low double digits to the low twenties, and outside of the U.S. and Europe at low double-digit percentage rates until the later of the date that all of the patent rights licensed from us and covering VARUBI&#8482; expire, are invalidated or are not enforceable and <ix:nonNumeric contextRef="if7a4105b8a0d43d798aa66064542811f_D20101201-20101231" format="ixt-sec:duryear" name="opk:CollaborativeAgreementPeriodfromFirstCommercialSale" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTIxMjU_76fa8ba2-cbc8-49b3-953f-35334f5fca09">12</ix:nonNumeric> years from the first commercial sale of the product.  TESARO announced in 2018 that it had elected to suspend further distribution of Varubi IV.  In June 2018, TESARO assigned its rights and obligations under the agreement to TerSera Therapeutics LLC (&#8220;TerSera&#8221;) pursuant to an asset purchase agreement.  Under the asset purchase agreement, TerSera is responsible for VARUBI in the U.S. and Canada and TESARO was permitted to continue to commercialize VARUBY&#174; in Europe and the rest of the world though a sublicense with TerSera.  In September 2019, TESARO informed us and TerSera that it intends to stop selling VARUBY</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the TESARO Territory and that it intends to withdraw its marketing authorization for VARUBY</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Europe.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The term of the license with TerSera will remain in force until the expiration of the royalty term in each country, unless we terminate the license earlier for material breach of the license or bankruptcy.  TerSera has a right to terminate the license at any time during the term for any reason on <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" format="ixt-sec:durwordsen" name="opk:CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTMxNTQ_8aefad29-8b4b-4d1d-943c-1aaa01900f48">three months</ix:nonNumeric>&#8217; written notice.  </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i6734e71d613e4dc18d7a163c2f9f2dcc"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pharmsynthez </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2013, we entered into a series of concurrent transactions with Pharmsynthez, a Russian pharmaceutical company traded on the Moscow Stock Exchange, pursuant to which we acquired an equity method investment in Pharmsynthez (ownership <ix:nonFraction unitRef="number" contextRef="ib4fc9634e3a348bab19da19df297d2c9_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTM0Mzg_740cdd31-f996-483a-a209-6faa23fe4014">9</ix:nonFraction>%).  We also granted rights to certain technologies in the Russian Federation, Ukraine, Belarus, Azerbaijan and Kazakhstan (the &#8220;Pharmsynthez Territories&#8221;) to Pharmsynthez and agreed to perform certain development activities.  We will receive from Pharmsynthez royalties on net sales of products incorporating the technologies in the Pharmsynthez Territories, as well as a percentage of any sublicense income from third parties for the technologies in the Pharmsynthez Territories.  </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Phio Pharmaceuticals Corp.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2013, we completed the sale to RXi Pharmaceuticals Corporation (now known as Phio Pharmaceuticals Corp.) of substantially all of our assets in the field of RNA interference (the &#8220;RNAi Assets&#8221;) (collectively, the &#8220;Asset Purchase Agreement&#8221;).  Pursuant to the Asset Purchase Agreement, Phio will be required to pay us up to $<ix:nonFraction unitRef="usd" contextRef="i284f86e01b904662b657fa1db96fa2a3_I20130331" decimals="INF" format="ixt:numdotdecimal" name="opk:EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTQyODE_acdab066-68dd-4213-bead-3cc752af3875">50.0</ix:nonFraction> million in milestone payments upon the successful development and commercialization of each drug developed by Phio, certain of its affiliates or any of its or their licensees or sublicensees utilizing patents included within the RNAi Assets (each, a &#8220;Qualified Drug&#8221;).  In addition, Phio will also be required to pay us royalties equal to: (a)&#160;a mid single-digit percentage of &#8220;Net Sales&#8221; (as defined in the Asset Purchase Agreement) with respect to each Qualified Drug sold for an ophthalmologic use during the applicable &#8220;Royalty Period&#8221; (as defined in the Asset Purchase Agreement); and (b)&#160;a low single-digit percentage of net sales with respect to each Qualified Drug sold for a non-ophthalmologic use during the applicable Royalty Period.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have completed strategic deals with numerous institutions and commercial partners.  In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements.  At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products.</span></div></ix:continuation><div id="ia969b45ba09947e9a03ce421f700f5b3_100"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 14 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90ZXh0cmVnaW9uOmYwOTQ4OWJhY2RiNzQ3MGRhMDRkNTQwMjQ1ZjBhZDUxXzEwMDU_069b7b12-2fb8-4759-a8af-d3073901c971" continuedAt="i3b0e8e32e8b447c895eb5eee9abc8aa7" escape="true">SEGMENTS</ix:nonNumeric></span></div><ix:continuation id="i3b0e8e32e8b447c895eb5eee9abc8aa7" continuedAt="i8de9998a829247f2956b373c7abd57e5"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We manage our operations in <ix:nonFraction unitRef="segment" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90ZXh0cmVnaW9uOmYwOTQ4OWJhY2RiNzQ3MGRhMDRkNTQwMjQ1ZjBhZDUxXzUw_450e2493-567b-4a6c-8516-d93a68d42f52">two</ix:nonFraction> reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of our clinical laboratory operations through BioReference and our point-of-care operations.  There are <ix:nonFraction unitRef="usd" contextRef="ic884ff99f6fc4caabe0eb0adf1366e62_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90ZXh0cmVnaW9uOmYwOTQ4OWJhY2RiNzQ3MGRhMDRkNTQwMjQ1ZjBhZDUxXzQ0MQ_c58b8db2-887e-4bc5-957e-71da9482afe6">no</ix:nonFraction> significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is <ix:nonFraction unitRef="usd" contextRef="ic884ff99f6fc4caabe0eb0adf1366e62_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90ZXh0cmVnaW9uOmYwOTQ4OWJhY2RiNzQ3MGRhMDRkNTQwMjQ1ZjBhZDUxXzU2Nw_96cd310b-2d65-411a-8389-fd27026cceb9">no</ix:nonFraction> inter-segment allocation of interest expense and income taxes.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90ZXh0cmVnaW9uOmYwOTQ4OWJhY2RiNzQ3MGRhMDRkNTQwMjQ1ZjBhZDUxXzk5OA_356ad894-c398-4f81-9fcf-d0e5f8dab984" continuedAt="i2328fae6093c4aec91ef2452c2fa67a7" escape="true">Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i8de9998a829247f2956b373c7abd57e5" continuedAt="ib51854478c3e48348db6256170998c28"><ix:continuation id="i2328fae6093c4aec91ef2452c2fa67a7" continuedAt="idc2a684a300e4b2589c02beed7dce3aa"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.035%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.035%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.035%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.039%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from services:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851a20819c20437db63c3ed7b80d94a3_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMtMS0xLTEtMA_bbcb8d36-46c7-46b5-a1c5-e73c8be25a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d2c67981041400a9c26389895519dc2_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMtMy0xLTEtMA_880035f6-2bd7-48c5-8caa-9e2b1f7b765f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i81434e108329422e88ec3e2303f45ee8_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMtNS0xLTEtMA_3fdac6fc-bd0f-481d-bd0e-7fd46eafa91e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44f0b42571364216bc7c04e7377e706e_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMtNy0xLTEtMA_74f8571b-043c-4651-a894-7d1c003aba93">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ba6b13bf7a9415ab5f66ca96f8d16e1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQtMS0xLTEtMA_50e77dd0-9f73-4984-b31d-4f961d452561">250,971</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i68fb7f858bc4413a97b4525dd5797a6f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQtMy0xLTEtMA_02ea13f3-cf4c-4858-946d-2689b28caa6e">178,458</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafd6856e572145f7aa974629ed727822_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQtNS0xLTEtMA_4e745f04-8f20-4bcd-a0cc-4feebaa34479">421,811</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i08298c5ab2f84fd5ae3f88f51ad3bb30_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQtNy0xLTEtMA_43750b06-dd4f-4bd9-8084-c1ccafa15b61">357,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i62426df8ac264ca2861d073dca037333_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzUtMS0xLTEtMA_e9bf4c98-2b00-46ee-a011-a86002b55be8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8519b57ec414786acb984d55ce68d04_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzUtMy0xLTEtMA_5edde8e4-94c1-4be8-8663-8b457a2da5a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9de6620da22b4ec5be9f72a4e769a2c8_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzUtNS0xLTEtMA_ba3a6e67-a6c7-4ad0-a944-70a4ec242c62">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b15741ac49b49afb0e5f05f9ae67e48_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzUtNy0xLTEtMA_2f5bc1ae-95e4-431c-a56e-e7545adca286">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia2b0d7b56e4e464a9d12b6d4962aea9f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzYtMS0xLTEtMA_82238f6b-f5a5-455f-b05e-9168454b8f66">250,971</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e422d827f1b4988be46200738452fe0_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzYtMy0xLTEtMA_0ec7273a-5b4b-4423-96d0-6f234df450db">178,458</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i717fe99763b443568a4e4ea66cbaafd2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzYtNS0xLTEtMA_f162eb93-2d1f-4c96-9a4c-206702e88f23">421,811</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia322ccb5ede0412f84ec2408b2552856_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzYtNy0xLTEtMA_461cfa9d-8ec5-42a3-aed8-76795743824d">357,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from products:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc753fb5d2a648f29daaac8bb88bc64f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzgtMS0xLTEtMA_73c4e6de-75d3-434e-babe-197bc1901adc">29,356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b1215e9556046579114216aeac09f0a_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzgtMy0xLTEtMA_fec05f62-d41b-46db-8a06-4939f8beaad6">28,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f46c52a8ad4493da6d40440badaf26c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzgtNS0xLTEtMA_7b6990ed-9cc8-4360-93a9-d792be4fde86">60,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if4e1eb15dab448d6b2ea94c22565bff4_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzgtNy0xLTEtMA_1462152f-110d-41be-b623-cf069ff397ad">53,981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i440a8d7180944369aae265f885c6d28a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzExLTEtMS0xLTA_a3958ca4-b403-4930-9cbf-5b486cebfd28">29,356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e6c1f5b817d47bf874e9f6b12b917c4_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzExLTMtMS0xLTA_5ce2055e-ddfb-4a8a-8481-b90058b83bb2">28,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3ee6bb1db084cdfb8f79401b5096546_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzExLTUtMS0xLTA_4a7572a4-c336-47aa-9574-75cd5e9cd2aa">60,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c4c5128c354e2dade223d90ca95718_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzExLTctMS0xLTA_335bf5be-9185-438b-b759-69c69e94004d">53,981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from transfer of intellectual property and other: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53552ab0d0f048c0902d204716895bdd_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzEzLTEtMS0xLTA_3a100af8-9903-41be-9e05-caa96c2a1c62">14,686</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i285f40a66d974262a93473c2fc344b4e_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzEzLTMtMS0xLTA_ac335591-878d-4b3b-9b9d-6dfc0eb782d3">19,230</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifba1e15ab2b34df19c53cd26a28891e9_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzEzLTUtMS0xLTA_2967d093-0c6d-408b-9ad9-265160e89091">24,239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i22026731d58f47f6bd0ff0c6f70fcf10_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzEzLTctMS0xLTA_5a3b457c-24d1-43b3-83a6-8dd6e22b12c2">37,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecdbfdd262384e3da2176a1036fa1472_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE0LTEtMS0xLTA_88c8233e-8ec5-42f8-957f-99be248e48b7">6,194</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2db64897d6404c58a431674a58d3c3b4_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE0LTMtMS0xLTA_30a1bb87-71ca-40bf-9ff7-a90eed8a63d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i127c96f883e447a49aa692832a21189b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE0LTUtMS0xLTA_2f924f8c-5613-4efe-b42e-172ac14e57f2">6,194</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7935d8cd6d2c4a9eb100d80e225fb6b1_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE0LTctMS0xLTA_3fd1c7f7-052a-42ab-b7b2-06ef89ff96aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77b768751f6a4284aa23055c0a54e8e7_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE1LTEtMS0xLTA_9a6d916d-98df-411e-9669-81329195f754">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a6eba59724c47faa438965d96def811_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE1LTMtMS0xLTA_b171960f-3eb8-47b2-9244-8070487df846">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb999c735a4342efba32032318fe7b05_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE1LTUtMS0xLTA_765b5dd6-18a3-4612-8be5-48dfa30f2a8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i23194842f3d84a37bd807bed4100a22e_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE1LTctMS0xLTA_fd31b0ef-13d1-4fde-85b3-168570438861">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3dca3ea038b14e008a2d1981f1feded6_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE2LTEtMS0xLTA_7b21a68c-d539-4731-bab7-4bab8c3b6c94">20,880</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd98b19d90454faca4fb220c3e3f056a_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE2LTMtMS0xLTA_328f8edb-5680-47d9-8ce8-63dd2b69b8d1">19,230</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7395bc7d5fc44e6cb1075481b8adb1cf_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE2LTUtMS0xLTA_7d76165a-c7e3-4ebe-a0e9-3f5ee6efe5fc">30,433</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92dec2859b504d4dbeb247bd54453c0e_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE2LTctMS0xLTA_c242e509-cea2-4e83-8faa-f884b4fc5487">37,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating loss:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9dd9f71d8ea54fb3b4a6d84cc0903e51_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE4LTEtMS0xLTA_61221bfe-8e6d-4426-abdb-65ab1011221b">5,996</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i89565ed2865e40509a73fa94d9ac6df0_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE4LTMtMS0xLTA_1f88c06c-497a-4e8a-9249-423e45c6f0b8">8,556</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1fc09bfbf0b54937b5e5c7c9ad9f5556_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE4LTUtMS0xLTA_6d1dea82-cb03-453c-8ad7-cf0bb20c95ae">20,121</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i536a503a71bf40b38d8e2df97401bda3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE4LTctMS0xLTA_321bdaa9-92d2-4a8f-83ae-a59f85c06297">38,033</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief7ca9e930b14261a5d0126d1359cce0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE5LTEtMS0xLTA_70d2547d-e354-40a3-a73c-97d137b95ff4">40,935</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i467d69f1593b4e59aeba2ae8185b03a5_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE5LTMtMS0xLTA_74656f7f-1152-4373-b79c-49f9867e13f3">28,013</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95137661f82444ed8ade5d61a8c2693c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE5LTUtMS0xLTA_544751df-cb3d-409e-a1d1-177ec3cde080">22,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i78ab453f6db84127938a7075db98d34c_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE5LTctMS0xLTA_8a3cd9ab-4ac0-4f98-a5e3-dd7efc305341">61,582</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaccfccfe524e46b09fdc3bb72135977e_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIwLTEtMS0xLTA_a9978980-87d8-41f4-b405-39366c973f35">7,760</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i70a53a1a90634b7198030c3447c9898c_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIwLTMtMS0xLTA_64f27e7c-6677-420c-82ed-ec5e0a6d6936">10,691</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i176405a326bc43a0a55b9bc8ac1d8bf2_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIwLTUtMS0xLTA_86a5e6d5-2e9d-485b-8370-e5d0d6bb0e2e">16,263</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibf8ef541025e44ee8cf8686ede2517a7_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIwLTctMS0xLTA_ed742626-472d-4528-af55-7580e9428766">22,962</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIyLTEtMS0xLTA_4ee32f13-ff99-4f05-8c0d-376be9f8ac8b">27,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIyLTMtMS0xLTA_83f0ac6a-6cae-4d69-b9f0-9dc44e46e781">47,260</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIyLTUtMS0xLTA_d4a6eb1f-b708-4bc8-9c11-7e2365244fd1">13,581</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIyLTctMS0xLTA_6d762f17-1a75-4f2d-8281-ff227cd8b9b7">122,577</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9dd9f71d8ea54fb3b4a6d84cc0903e51_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI0LTEtMS0xLTA_535638bd-dd1a-4480-92a2-94641b8950b1">7,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89565ed2865e40509a73fa94d9ac6df0_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI0LTMtMS0xLTA_5d6cbc04-8c03-4972-be05-6678bf77f3aa">7,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1fc09bfbf0b54937b5e5c7c9ad9f5556_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI0LTUtMS0xLTA_c602f9e4-56e3-4d48-bf3e-4c1c64eca438">14,240</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i536a503a71bf40b38d8e2df97401bda3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI0LTctMS0xLTA_a27ab96e-9316-4f47-9f35-3186fc4782eb">14,908</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief7ca9e930b14261a5d0126d1359cce0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI1LTEtMS0xLTA_190ee9eb-1160-46a0-ae0e-8246667eca16">15,147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i467d69f1593b4e59aeba2ae8185b03a5_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI1LTMtMS0xLTA_8f0b893e-887f-4ed9-b93e-fa8974226194">16,260</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95137661f82444ed8ade5d61a8c2693c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI1LTUtMS0xLTA_ede72d9e-7131-4f3d-bb52-23de26c208cf">30,019</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78ab453f6db84127938a7075db98d34c_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI1LTctMS0xLTA_b1486135-9701-4719-98a6-ab7daca3c5d9">32,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaccfccfe524e46b09fdc3bb72135977e_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI2LTEtMS0xLTA_72fdfd3d-5b64-4398-82ad-c1ac4117ea87">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i70a53a1a90634b7198030c3447c9898c_D20190401-20190630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI2LTMtMS0xLTA_0fd477f4-e740-47b0-93c5-9167e1592e94">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i176405a326bc43a0a55b9bc8ac1d8bf2_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI2LTUtMS0xLTA_1bfcf6ff-e314-4118-8d99-b87666e61f08">59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibf8ef541025e44ee8cf8686ede2517a7_D20190101-20190630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI2LTctMS0xLTA_2873f147-2c45-4d7b-82a8-84d15457677d">39</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI3LTEtMS0xLTA_694921e3-c527-43b8-a0d8-8ea6b90d3826">22,266</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI3LTMtMS0xLTA_7533fb01-3591-4043-ad89-1919195c25d1">23,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI3LTUtMS0xLTA_009f3e77-b250-4d42-a430-aff525f564f1">44,318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI3LTctMS0xLTA_9331eda8-6c12-4ff4-a398-9bbe24fc946c">47,477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from investment in investees:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9dd9f71d8ea54fb3b4a6d84cc0903e51_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI5LTEtMS0xLTA_4e84622e-8682-4f35-9baa-a6abfd954f36">189</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i89565ed2865e40509a73fa94d9ac6df0_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI5LTMtMS0xLTA_535b7ecf-348c-4b95-8528-7b96bc3338e3">271</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1fc09bfbf0b54937b5e5c7c9ad9f5556_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI5LTUtMS0xLTA_7fecc4ce-6d3b-4cbc-8159-4914fb2b093d">323</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i536a503a71bf40b38d8e2df97401bda3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI5LTctMS0xLTA_598be7a7-ef3d-4b81-aabb-ff0faa660c72">2,125</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief7ca9e930b14261a5d0126d1359cce0_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMwLTEtMS0xLTA_6cf8fc22-dd55-4a30-9d2f-ca67c3dddf87">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i467d69f1593b4e59aeba2ae8185b03a5_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMwLTMtMS0xLTA_b86d905c-e940-4877-bbf8-2652880541b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95137661f82444ed8ade5d61a8c2693c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMwLTUtMS0xLTA_37b89727-1758-4d1c-81e6-14354d798ed2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78ab453f6db84127938a7075db98d34c_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMwLTctMS0xLTA_c19f2e37-9770-4c45-9b49-7e53cc207ddd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaccfccfe524e46b09fdc3bb72135977e_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMxLTEtMS0xLTA_7e3ec725-3cc5-4eb6-8707-5bc563346d97">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i70a53a1a90634b7198030c3447c9898c_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMxLTMtMS0xLTA_d1b8bb8c-3265-4ef7-b2c8-be0a9d95d128">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i176405a326bc43a0a55b9bc8ac1d8bf2_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMxLTUtMS0xLTA_4adb6c78-ef0d-41c0-b356-71513063ea03">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibf8ef541025e44ee8cf8686ede2517a7_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMxLTctMS0xLTA_1382c2a8-503c-44d8-9b9f-51dc8263f9ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMyLTEtMS0xLTA_1bb2f258-f09c-4b21-af46-f01ed7b3ebeb">189</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMyLTMtMS0xLTA_088390b2-276c-4d98-8bab-59b16eb9a7b0">271</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMyLTUtMS0xLTA_e29279f9-d446-4b46-99c1-2af51b235e39">323</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMyLTctMS0xLTA_c1ca37cc-ce81-474b-993b-549c4110e391">2,125</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i254cd6a34e0a4624a06cd9c4a34e9913_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM0LTEtMS0xLTA_ed487868-0e03-4b7b-84c8-86ea3c21038c">265,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e8982b6568f486980128a9f7513ec32_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM0LTMtMS0xLTA_032b63cb-686e-4853-9c72-31b78a46f7bc">184,310</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i63bb2b62077c41bc8668fc1ce4d89ec0_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM0LTUtMS0xLTA_3564c779-c141-4d99-bab6-d728090743ec">446,761</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i198a3844c0c0490abcbc066a7dd24dc8_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM0LTctMS0xLTA_7d27e205-a0e9-4b06-aadb-3c780586aad1">369,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ireland</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id56bcff9a57b427f8621c4e8187ca9c3_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM1LTEtMS0xLTA_caedd6f2-2e50-4ab5-87c4-d54c242e3c65">16,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e68ebe729e346baaedc4e909e8155d6_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM1LTMtMS0xLTA_fb492ecc-3085-4739-8466-7c12475208e3">22,174</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie634e2306c8a4bebb90dffbe2e414e0e_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM1LTUtMS0xLTA_cffaea35-ff1f-4cec-817e-a429d6a2f8c0">28,749</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibccc990af11146938643e532d4826cb5_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM1LTctMS0xLTA_3e426c18-69a6-4c64-bdf4-0eaf0c9777f2">42,707</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chile</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7027219b6b1045408436c1bb1b2f5a53_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM2LTEtMS0xLTA_fd91e759-96c3-4ac2-8c9a-b3a7aa193813">11,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0871f5c7e8b94f5781f08a92001c6cea_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM2LTMtMS0xLTA_b854bf7f-5121-4e4c-9ed0-8db3e7ba4c63">9,051</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia0460fea90284226bde4999b97d0ed81_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM2LTUtMS0xLTA_98c11730-433c-464f-8c34-b0f3dde08ae9">22,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4da1a32fe2164419974b9faaefa37a49_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM2LTctMS0xLTA_047c02e8-ee9f-4a17-b83a-39cc44141a30">16,915</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spain</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i62a29626ff724abb9ad4cee99f7898d9_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM3LTEtMS0xLTA_0e9b7a2b-5922-448e-bd17-fdb871844125">4,136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e418fb903dd4587b64cfae8429ade02_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM3LTMtMS0xLTA_0079bb2c-c750-4528-b3b1-da29b8af4462">4,876</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if216b4c1ff0547679dcc2abcaf82d5dd_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM3LTUtMS0xLTA_1181fba6-fd17-4558-9cf5-46e9df1f6a6a">8,292</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i914a917d0c624130b4baa7ce8b4d021d_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM3LTctMS0xLTA_303bccf7-169a-4644-9754-fb1a42b81763">9,294</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Israel</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66aa17bc991b4212b0639a733b595a8a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM4LTEtMS0xLTA_9d8a9b0b-0ede-4d0e-9d98-067ff9abef07">1,183</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1af19639eaec49a2970b68e53aa71655_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM4LTMtMS0xLTA_e0a50261-4716-492e-b15a-ec7df3ca25cb">3,768</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i06a58a1bdfc547f5961d72ff32ddb242_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM4LTUtMS0xLTA_43eb2280-d855-4ff5-a388-363e0248548d">2,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d16a24c094b4ab6964f823f0e7ca361_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM4LTctMS0xLTA_7ca47ac7-e21e-4ade-95cb-82005a67a5e1">6,884</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mexico</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15f1fa750fa04018a4f1850d6bf7a8bd_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM5LTEtMS0xLTA_2182760b-7f42-48ce-a4b7-7dee4f0291cd">1,866</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba985ea2bc4348dcabba2e4c00d34207_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM5LTMtMS0xLTA_b1c23eeb-5352-40d0-86e0-285943aad916">2,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9f619314d9249319d7a90de7f3e4587_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM5LTUtMS0xLTA_fab79f4d-8c43-47e1-8d9f-d5db15751d40">3,708</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcc2adb4a7c142589c1a8c280a393746_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM5LTctMS0xLTA_9ab8586b-ff5a-4d88-8497-47ccaae5e78c">3,589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b6d1653ea794637b798906498b50d0e_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQwLTEtMS0xLTA_bc9b1b90-0fa5-4393-ad15-fc0fd96f9227">133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7da3b5d4af3d4ef9b385a90d5a8722bc_D20190401-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQwLTMtMS0xLTA_b6541094-9ef9-48aa-97dd-5b57ab6876e0">131</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i309155533c28422e82b808d1dc76e743_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQwLTUtMS0xLTA_ea4c0308-ad99-4db4-b64f-6c3179554f56">272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a9bcd23670e4f6185473829764ef0a9_D20190101-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQwLTctMS0xLTA_246624b2-e6c2-4585-9685-84b5fc76bc87">228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQxLTEtMS0xLTA_1b587317-137a-4bcf-aefb-768bf1532079">301,207</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQxLTMtMS0xLTA_60b7b881-3e93-40a3-8c28-cb12fc337e27">226,368</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQxLTUtMS0xLTA_e403ea7f-04d6-45e4-aaa1-733b61ddd7ad">512,674</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQxLTctMS0xLTA_e3fc0e8d-1867-4113-aca4-083fde7aec82">448,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="ib51854478c3e48348db6256170998c28" continuedAt="i2af1f22d3ae14db49c9dce4281d9b90e"><ix:continuation id="idc2a684a300e4b2589c02beed7dce3aa"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.114%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.077%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cfb0c9e22cd4f7eb6a00d4ace862685_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzItMS0xLTEtMA_97b0db5e-b66c-4101-aa65-aa9015059320">1,148,151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a15f6d7c0e345db8249158f70fc4ed4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzItMy0xLTEtMA_6731f5a3-779f-46fa-8ddb-3e4f24974043">1,174,639</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31c3c30dd034436bb8769e07c7ddefc9_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzMtMS0xLTEtMA_a697b2f8-301d-4180-ad33-19ebd67f06bc">1,121,202</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3e6d29b56e2343b0a824d97674db5c75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzMtMy0xLTEtMA_c5505cc8-8664-4d53-9de1-8fadf7cd98a4">1,035,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e4767da5b9c440090362640bac1a2e0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzQtMS0xLTEtMA_0e213a9c-1ee6-4cd5-9de0-42e64df99595">54,381</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icfcc5f95aa934dfa95991eb13af1680d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzQtMy0xLTEtMA_37f25105-822b-4bbe-8c48-51e728842b37">99,521</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzUtMS0xLTEtMA_45ba8d1b-3d2d-4aa2-a24c-db78280921a6">2,323,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzUtMy0xLTEtMA_23c3f890-2e1b-4a93-b742-58bb00a875e7">2,309,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cfb0c9e22cd4f7eb6a00d4ace862685_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzctMS0xLTEtMA_c6ae6625-2f62-4f0e-afac-8d8dae459966">236,790</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a15f6d7c0e345db8249158f70fc4ed4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzctMy0xLTEtMA_ed19c44c-eb29-4e3f-8f17-7f8079167f0e">237,131</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31c3c30dd034436bb8769e07c7ddefc9_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzgtMS0xLTEtMA_be256663-1e36-4e71-ac90-d74ce4d02202">434,809</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3e6d29b56e2343b0a824d97674db5c75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzgtMy0xLTEtMA_65123c39-42ac-4e2c-96b6-972bc255d9a1">434,809</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e4767da5b9c440090362640bac1a2e0_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzktMS0xLTEtMA_a02eb0b0-3b16-4f18-a572-12be142e2779">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icfcc5f95aa934dfa95991eb13af1680d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzktMy0xLTEtMA_ec81aaf7-eff5-415a-9629-a1dbccd7222e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzEwLTEtMS0xLTA_6f81049c-0d91-4d27-9f1f-4fda1c89ecd7">671,599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzEwLTMtMS0xLTA_bf1e7cca-5ffe-4530-bbb2-db65d9991f16">671,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div style="padding-left:72pt;"><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2af1f22d3ae14db49c9dce4281d9b90e">No customer represented more than 10% of our total consolidated revenue during the six months ended June 30, 2020 and 2019. As of June&#160;30, 2020 and December&#160;31, 2019, no customer represented more than 10% of our accounts receivable balance.</ix:continuation> </span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_103"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 15 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzIwODg_2f352f84-4d68-40fa-918d-41fd78bedb31" continuedAt="i83c3b618f7124582ac612a2e8755fc79" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i83c3b618f7124582ac612a2e8755fc79" continuedAt="i485eecc294354f8b9979f4e8fb192ae6"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have operating leases for office space, laboratory operations, research and development facilities, manufacturing locations, warehouses and certain equipment.  We determine if a contract contains a lease at inception or modification of a contract.  Our leases generally do not provide an implicit interest rate, and we therefore use our incremental borrowing rate as the discount rate when measuring operating lease liabilities.  The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment.  We used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.  Many of our leases contain rental escalation, renewal options and/or termination options that are factored into our determination of lease payments as appropriate.  Variable lease payment amounts that cannot be determined at the commencement of the lease are not included in the right-to-use assets or liabilities.  </span></div><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="opk:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzIwODQ_e2096ca8-6100-4129-a2a8-2f70529b0b1a" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of June 30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:31.431%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:28.938%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.982%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.450%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classification on the Balance Sheet</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzItNC0xLTEtMA_32aa088c-dc10-4684-bb20-8e47bb87d448">38,469</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzItNi0xLTEtMA_2b1d9ead-06c5-4f4a-8751-babe3da5488a">39,380</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzMtNC0xLTEtMA_b3d20e3f-c092-4144-a6e7-04445989a599">5,395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzMtNi0xLTEtMA_f52f6d68-3039-426b-bc03-550f0776c120">6,789</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current maturities of operating leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzctNC0xLTEtMA_cf7f1521-ae99-4e72-9be6-a56ac37ccd1b">10,298</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzctNi0xLTEtMA_c949e409-8e45-4eb3-ba3a-37352a3ca7f3">12,038</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current maturities of finance leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzgtNC0xLTEtMA_1b6cb47e-450b-4a93-b402-c942036c7d20">2,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzgtNi0xLTEtMA_1627d0df-80c5-4efc-8526-fb1ce721c987">2,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzEwLTQtMS0xLTA_2e097eb4-060d-4139-adda-c37e753b8972">28,759</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzEwLTYtMS0xLTA_aeea2e47-45a7-4bbc-9667-4206862057d9">27,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzExLTQtMS0xLTA_0e6c2382-671d-4d6c-99ea-4f1c4fde613e">2,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzExLTYtMS0xLTA_40dbd547-93d1-42a4-8164-82ec71eda2ea">4,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE0LTQtMS0xLTA_ae1806d0-1326-4125-adba-f6ff4139c671">5.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE0LTYtMS0xLTA_bb7e931c-a8fb-4e78-af57-3d2f2e5299ef">5.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE1LTQtMS0xLTA_f39d815c-d35a-4eec-83d9-cea1b9f0ce0d">2.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE1LTYtMS0xLTA_65e08b56-43ec-4a2f-9bf5-ea7500da786c">2.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average discount rate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE3LTQtMS0xLTA_2d9af1c9-4005-4a24-a507-85c0fa120394">6.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE3LTYtMS0xLTA_d66dba2b-557e-4e85-9eb0-17447330696b">6.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE4LTQtMS0xLTA_3bfedb68-7f53-4d92-a0ba-ad3b98e3df4f">3.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE4LTYtMS0xLTA_82b5fb1b-5a89-4167-ae75-f5a32723d9eb">3.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><ix:continuation id="i485eecc294354f8b9979f4e8fb192ae6"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzIwODE_b01099d6-5858-404b-94c0-73427f91682a" escape="true"><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzIwODY_d14a4567-df0c-416d-ba9a-f6402e327183" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of June 30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 1, 2020 through December 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzEtMS0xLTEtMA_e14d5483-440b-4a67-908b-a664b5a04c0a">6,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzEtMy0xLTEtMA_bd670897-3e81-4d72-bce9-ae5b9ad18659">1,404</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzItMS0xLTEtMA_ea86c1f3-0010-49e2-be92-e6ebc030a41f">7,479</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzItMy0xLTEtMA_5c867825-f54e-41af-ae10-5f411b23c31f">2,186</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzMtMS0xLTEtMA_a9754ec7-392c-4b5d-8602-b603bf25adc7">6,506</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzMtMy0xLTEtMA_a0df7854-3ceb-49bd-b269-068cc6009fa1">1,175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzQtMS0xLTEtMA_b5ede7d1-4ee1-4663-8ddd-0463c9cd6cf3">5,845</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzQtMy0xLTEtMA_9f23b295-61b5-4713-9181-52179aa6994a">590</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzUtMS0xLTEtMA_d3755230-6cc1-4385-b950-e2acf4599e41">4,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzUtMy0xLTEtMA_3427558d-1bd3-46e1-b122-41886ae40fce">249</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzYtMS0xLTEtMA_1e3b1e02-4054-46c8-b415-6a9cc7d21f4b">17,374</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:zerodash" name="opk:FinanceLeaseLiabilityPaymentsDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzYtMy0xLTEtMA_f82d1c80-c950-4fe7-90ae-7fc7829b0060">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted future minimum lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzctMS0xLTEtMA_fd40f229-103a-49d1-ad07-6cf34732da84">48,479</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzctMy0xLTEtMA_e0f8b597-815b-44de-8c5c-ac1fcb4e3c36">5,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Difference between lease payments and discounted lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzgtMS0xLTEtMA_9648f476-3ce8-470e-ba18-91ca3747f301">9,422</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzgtMy0xLTEtMA_77eaa1df-9c36-4737-a427-4f55efa41ec0">209</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzktMS0xLTEtMA_e050da19-91e7-4820-9d6e-92c5a796c5e8">39,057</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzktMy0xLTEtMA_6d2c673c-2fba-4354-b358-617b259ac1ea">5,395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expense under operating leases and finance leases was $<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE2Mjg_6a59082e-420a-47f1-bbf6-02aface6340d">9.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE2MzU_7cda103b-b19a-4aca-962b-879bae9510cc">1.2</ix:nonFraction> million, respectively, for the six months ended June 30, 2020, which includes $<ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE2ODA_b6d7750a-bf55-46d6-bfba-128987f9aa31">1.6</ix:nonFraction> million of variable lease costs. Expense under operating leases and finance leases was $<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE3NjI_bb63592b-dc00-43ff-8c64-b0d03e93a86d">9.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE3Njk_f3c48ff3-ed6f-48bf-9d42-afbb4c850ceb">2.0</ix:nonFraction> million, respectively, for the six months ended June 30, 2019, which includes $<ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE4MTQ_1a961622-43a7-4729-a7e2-2bcdb4375a36">1.7</ix:nonFraction> million of variable lease costs. Operating lease costs and finance lease costs are included within Operating loss in the Condensed Consolidated Statement of Operations. Short-term lease costs were not material.  </span></div><ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzIwNzk_392fda85-acbe-4d6a-98cb-bfd0d80cb5eb" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental cash flow information is as follows:</span></div><div style="margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.700%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.931%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash out flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzItMS0xLTEtMA_882fd0cc-7189-4cee-8b85-f0f8feec0325">9,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzItMy0xLTEtMA_ae0aefea-a45e-4f2d-a90b-77996258e93f">10,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash out flows from finance leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzMtMS0xLTEtMA_15b69ceb-e789-41a1-a1fe-0869eba97151">86</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzMtMy0xLTEtMA_c784f547-97b5-4cfc-9e4e-f76ef204401f">234</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing cash out flows from finance leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzQtMS0xLTEtMA_df9c24c0-3cba-41f4-a9c3-3b644566c031">1,026</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzQtMy0xLTEtMA_6359a35a-39f4-4a42-b440-bf367dbe539b">1,590</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="opk:PaymentsForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzUtMS0xLTEtMA_200d14cc-ba4f-4ce2-a2b7-cb0f62fc3a8a">10,916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="opk:PaymentsForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzUtMy0xLTEtMA_acb05852-0b5f-47ba-8c5e-b8f3e92466fa">12,628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_106"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 16 <ix:nonNumeric contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDYvZnJhZzo5MDBhM2FlOWM4MGY0MGZhOGE4OGIwOTFmOTMzMzY5ZC90ZXh0cmVnaW9uOjkwMGEzYWU5YzgwZjQwZmE4YTg4YjA5MWY5MzMzNjlkXzEyMjY_333ddd31-0314-441b-a38d-2f9b0a35c770" continuedAt="i478e51958f6e490eaa50b48434c59ebd" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i478e51958f6e490eaa50b48434c59ebd"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered.  In July 2020, we received a favorable Medicare appeal decision from Novitas Solutions Inc. (&#8220;Novitas&#8221;) for previously denied Medicare claims for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> tests we performed during 2019. As a result of the favorable appeal, Medicare will reimburse us for such </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> tests for patients who meet defined criteria. Due to a prior non-coverage determination by Novitas, no revenue was previously recognized for these </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> tests and therefore we recognized $<ix:nonFraction unitRef="usd" contextRef="i50b1c18c29b2480badccb24aa75ca3bd_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDYvZnJhZzo5MDBhM2FlOWM4MGY0MGZhOGE4OGIwOTFmOTMzMzY5ZC90ZXh0cmVnaW9uOjkwMGEzYWU5YzgwZjQwZmE4YTg4YjA5MWY5MzMzNjlkXzIxOTkwMjMyNjE0Mjc_4e238346-fd02-4b50-ba1e-54f7aa19c18f"><ix:nonFraction unitRef="usd" contextRef="i56d3de83d9ad4ba99bcdfa4b49b82318_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDYvZnJhZzo5MDBhM2FlOWM4MGY0MGZhOGE4OGIwOTFmOTMzMzY5ZC90ZXh0cmVnaW9uOjkwMGEzYWU5YzgwZjQwZmE4YTg4YjA5MWY5MzMzNjlkXzIxOTkwMjMyNjE0Mjc_9c632883-a762-42f6-87cb-0ebfcb6a67a1">10.9</ix:nonFraction></ix:nonFraction>&#160;million for the previously denied </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> tests as a component of Revenue from services for the three and six months ended June 30, 2020.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have reviewed all subsequent events and transactions that occurred after the date of our June&#160;30, 2020 Condensed Consolidated Balance Sheet, through the time of filing this Quarterly Report on Form 10-Q.</span></div></ix:continuation><div style="text-indent:22.5pt;margin-top:9pt;"><span><br/></span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_112"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OVERVIEW</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">You should read this discussion together with the unaudited Condensed Consolidated Financial Statements, related notes, and other financial information included elsewhere in this Quarterly Report on Form 10-Q together with our audited consolidated financial statements, related notes, and other information contained in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 (the &#8220;Form 10-K&#8221;).  The following discussion contains assumptions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under &#8220;Risk Factors,&#8221; in Part I, Item&#160;1A of the Form 10-K and in Part II, Item 1A of this Quarterly Report on Form 10-Q and as described from time to time in our other filings with the Securities and Exchange Commission.  These risks could cause our actual results to differ materially from those anticipated in these forward-looking statements.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets.  Our diagnostics business includes BioReference Laboratories Inc. (&#8220;BioReference&#8221;), one of the nation&#8217;s largest full service laboratories with a core genetic testing business and an almost 300-person sales and marketing team to drive growth and leverage new products, including the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> test.  Our pharmaceutical business features </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, an FDA-approved treatment for secondary hyperparathyroidism (&#8220;SHPT&#8221;) in adults with stage 3 or 4 chronic kidney disease (&#8220;CKD&#8221;) and vitamin D insufficiency (launched in November 2016), OPK88004, a selective androgen receptor modulator which we are exploring for various potential indications, and OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists (phase 2b).  Our pharmaceutical business also features hGH-CTP, a once-weekly human growth hormone injection for which we have partnered with Pfizer and successfully completed a phase 3 study in August 2019.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate established pharmaceutical platforms in Spain, Ireland, Chile and Mexico, which are generating revenue and from which we expect to generate positive cash flow and facilitate future market entry for our products currently in development.  We have a development and commercial supply pharmaceutical company, as well as a global supply chain operation and holding company in Ireland, which we expect will play an important role in the development, manufacturing, distribution and approval of a wide variety of drugs with an emphasis on high potency products.  We also own a specialty active pharmaceutical ingredients (&#8220;APIs&#8221;) manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products. </span></div><div style="text-indent:22.5pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#160; </span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_115"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RECENT DEVELOPMENTS</span></div><div><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020, we announced that the Japan Phase 3 clinical trial met its primary and secondary objectives, and demonstrated that the efficacy and safety of Somatrogon administered weekly was comparable to GENOTROPIN&#174; for injection administered once-daily as measured by annual height velocity after 12 months of treatment in treatment-na&#239;ve Japanese pre-pubertal children with GHD. The findings were consistent with the results previously reported in the Phase 3 global study.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RESULTS OF OPERATIONS</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Impact of COVID-19</span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As the disease caused by SARS-CoV-2, a novel strain of coronavirus, COVID-19 continues to spread and severely impact the economy of the U.S. and other countries around the world, we are committed to being a part of the coordinated public and private sector response to this unprecedented challenge. In response to the COVID-19 pandemic, BioReference is accepting specimens for two types of COVID-19 testing, diagnostic molecular testing and serology antibody testing, from healthcare providers, clinics and health and hospital systems throughout&#160;the U.S., to promote earlier diagnosis of the coronavirus, assess a patient&#8217;s immune response to the virus and aid in limiting spread of infection. In addition to its robust nationwide COVID-19 testing offering, BioReference has partnerships with the&#160;New York State&#160;Department of Health, the New York City Health and Hospital Corporation (NYC&#160;Health + Hospitals), the&#160;State of New Jersey, the&#160;State of Florida&#160;and the cities of&#160;Detroit&#160;and&#160;Miami, among others,&#160;to provide COVID-19 testing. BioReference performed approximately 331.6 thousand serology antibody tests and 2.2 million diagnostic molecular tests for COVID-19 during the three months ended June 30, 2020, which represented 28.1% of BioReference&#8217;s total test volume during the second quarter of 2020. For serologic antibody testing, BioReference has partnered with the State of New York, New York City and a number of employers and government agencies, with the capacity to perform up to 400,000 tests per day and for diagnostic molecular tests, BioReference has the capacity to perform more than 50,000 tests per day. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have put preparedness plans in place at our facilities to maintain continuity of operations, while also taking steps to keep colleagues and customers healthy and safe. In line with recommendations to reduce large gatherings and increase social distancing, we have, where practical, transitioned many office-based colleagues to a remote work environment.&#160;</span></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Beginning in March 2020, BioReference experienced, and continues to experience, a decline in routine clinical and genomics testing volumes due to the COVID-19 pandemic. Excluding COVID-19 test volumes, for the three months ended June 30, 2020, volumes in our diagnostics segment were down 46.5% as compared to volumes in the second quarter of 2019. Additionally, sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> have not increased in accordance with its expected growth trajectory as a result of challenges in onboarding new patients due to the COVID-19 pandemic. Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, a significant reduction in physician office visits, the cancellation of elective medical procedures, customers closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home or shelter-in-place policies, all of which have had, and may continue to have, an adverse impact on our operating results, cash flows and financial condition, including continued declines in testing volumes. It is also possible that we will experience an adverse impact on cash collections as a result of the impact of the COVID-19 pandemic.&#160;As stay at home orders and other restrictions have been lifted, we have seen our routine clinical and genomic testing volumes trending towards normalization with prior periods, however should stay at home orders or other restrictions be reenacted, we could see our routine testing levels decline. We also continue to see a substantial need for COVID-19 testing by our existing clients and expect new clients as infection rates for the virus continue to increase across the country.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, in response to the COVID-19 pandemic, the CARES Act was signed into law. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding the prior and future utilization of net operating losses, temporary changes to the prior and future limitations on interest deductions, temporary&#160;suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property, and the creation of certain payroll tax credits associated with the retention of employees.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have received, or expect to receive a number of benefits under The CARES Act including, but not limited to:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We received approximately $14 million under The Centers for Medicare &amp; Medicaid Services (CMS) Accelerated and Advance Payment Program, which provides accelerated payments to Medicare providers/suppliers working to provide treatment to patients and combat the COVID-19 pandemic, and the amounts advanced are loans which will be offset against future claims and must be repaid;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are eligible to defer depositing the employer&#8217;s share of Social Security taxes for payments due from March 27, 2020 through December 31, 2020, interest-free and penalty-free;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We received approximately $6.2 million during the three months ended June 30, 2020 from the initial tranche of funds that was distributed to healthcare providers for related expenses or lost revenues that are attributable to the COVID-19 pandemic;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">U.S. Department of Health and Human Services (HHS), will provide claims reimbursement to healthcare providers generally at Medicare rates for testing uninsured patients; and</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Clinical laboratories are provided a one-year reprieve from the reporting requirements under the Protecting Access to Medicare Act (&#8220;PAMA&#8221;) as well as a one-year delay of reimbursement rate reductions for clinical laboratory services provided under Medicare that were scheduled to take place in 2021.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020, we took certain temporary actions to manage our workforce costs including reduced hours for employees whose work was significantly impacted and temporary furloughs for non-essential employees with diminished work requirements. Substantially all of our furloughed employees have returned, and in the second quarter of 2020 we hired approximately 2,000 additional employees to support COVID-19 testing and the continued increase to normalized levels of routine clinical and genomic testing.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the pandemic began in the U.S., we have invested, and expect to continue to invest, in testing capabilities and infrastructure to meet demand for our molecular and antibody testing for COVID-19. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FOR THE THREE MONTHS ENDED JUNE 30, 2020 AND 2019</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated income (loss) from operations for the three months ended June 30, 2020 and 2019 is as follows:  </span></div><div style="text-align:center;margin-top:11pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:510.75pt;"><tr><td style="width:1.0pt;"></td><td style="width:264.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:1.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,513&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">676&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from transfer of intellectual property and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,650&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">301,207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">226,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74,839&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">162,651&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,754)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,608&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,678)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent Consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,775)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,937&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,482)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">274,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">273,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(47,260)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. The following presents the financial measures that management considers to be the most significant indicators of the Company's performance. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Diagnostics </span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:50.046%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.645%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,513&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from transfer of intellectual property and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257,165&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144,783&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129,802&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,712&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,610)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,785&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">327&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent Consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,915&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,798&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(883)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">216,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,759&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,935&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28,013)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,948&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Revenue from services for the three months ended June 30, 2020 increased by approximately $72.5 million compared to the three months ended June 30, 2019, primarily due to the positive impacts of increased COVID-19 testing volumes. Revenue from services further benefited from the successful appeal of previously denied Medicare claims for the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> test resulting in approximately $10.9 million of incremental revenue.  In addition, Revenue from transfer of intellectual property and other for the three months ended June 30, 2020 included a $6.2 million grant received by BioReference from the CARES Act. BioReference performed approximately 331.6 thousand serology antibody tests and 2.2 million diagnostic molecular tests for COVID-19 during the three months ended June 30, 2020, which represented 28.1% of its total testing volume for the second quarter of 2020. Additionally, BioReference experienced $5.6 million of higher net reimbursement on our genomic testing due to a test mix shift of increased whole exome sequencing. This was partially offset by the negative impacts of:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Reduced clinical test volumes and genomics test volumes at BioReference of $68.3 million and $13.6 million, respectively, exclusive of COVID-19 test volumes. The decline in volume reflects the negative impacts from the COVID-19 pandemic, principally from referring physician office closures and stay-at-home guidance throughout states in which we predominately operate, and declines in routine clinical and genomics testing, which declined 46.5% versus the Company's normal daily levels.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt;">$1.0 million from lower net reimbursement on our clinical testing resulting from the latest negative impact of the PAMA price reduction that went into effect January 1, 2020 and were partially offset by improved operational procedures and a flattening of our denial rate.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimated collection amounts are subject to the complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, and require us to consider the potential for retroactive adjustments when estimating variable consideration in the recognition of revenue in the period the related services are rendered.  For the three months ended June 30, 2020 and 2019, revenue increases (reductions) due to changes in estimates of implicit price concessions for performance obligations satisfied in prior periods of $9.0 million and $(5.9) million, respectively, were recognized.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The composition of Revenue from services by payor for the three months ended June 30, 2020 and 2019 was as follows:</span></div><div style="margin-top:14pt;margin-bottom:10pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:65.935%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.666%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.667%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June&#160;30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Healthcare insurers</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,082&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,278&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government payers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,634&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Client payers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141,090&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,101&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patients</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Client payers include cities and states for which BioReference provides COVID-19 testing services.</span></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Cost of revenue for the three months ended June 30, 2020 increased $15.0 million compared to the three months ended June 30, 2019.  Cost of revenue increased $44.9 million due to labor and material costs to produce COVID-19 testing volumes during the three months ended June 30, 2020, which was partially offset by an overall reduction in other clinical and genomic test volumes, and to cost reduction initiatives, which resulted in per patient encounter efficiency gains at BioReference.</span></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, general and administrative expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Selling, general and administrative expenses for the three months ended June 30, 2020 and 2019 were $57.7 million and $62.3 million, respectively.  The decrease in selling, general and administrative expenses in our diagnostics segment was primarily due to $2.0 million of expenses incurred in the second quarter of 2019 in connection with certain legal matters, and to decreased expenses at BioReference due to the enactment of cost reduction initiatives. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The following table summarizes the components of our research and development expenses: </span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.862%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.570%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and Development Expenses</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">External expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PMA studies</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development employee-related expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,163&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other internal research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,565&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,785&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development for the diagnostic segment relates to the development of testing services for our clinical and genomics testing at BioReference and the development of the Claros Analyzer, a diagnostic instrument system to provide rapid, high performance blood test results in the point-of-care setting. The increase in research and development expenses for the three months ended June 30, 2020 was primarily due to an increase in research and development expenses related to the development of clinical and genomics testing services. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contingent consideration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Contingent consideration for the three months ended June 30, 2020 and 2019 was $35 thousand and $91 thousand of expense, respectively.  Contingent consideration for the three months ended June 30, 2020 and 2019 was attributable to changes in assumptions regarding the timing of achievement of future milestones for OPKO Diagnostics in both periods, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">potential amounts payable to former stockholders of OPKO Diagnostics in connection therewith,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> pursuant to our acquisition agreement in October 2011.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization of intangible assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Amortization of intangible assets was $9.9 million and $10.8 million, respectively, for the three months ended June 30, 2020 and 2019.  Amortization expense reflects the amortization of acquired intangible assets with defined useful lives. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our estimates and assumptions in testing goodwill and other intangible assets are consistent with assumptions that marketplace participants would use in their estimates.  However, if actual results are not consistent with our estimates and assumptions, including as a result of the COVID-19 global pandemic, we may be exposed to an impairment charge that could be material.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Pharmaceuticals</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt;"><tr><td style="width:1.0pt;"></td><td style="width:265.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:1.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">676&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from transfer of intellectual property and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,686&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,544)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,910&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,868)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,881&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,406&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,199)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,051&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,029&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,978)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent Consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,866)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,942&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,022&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(599)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,038&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,466&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,428)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,996)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,556)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The increase in revenue from products for the three months ended June 30, 2020 compared to the three months ended June 30, 2019 was primarily attributable to an increase in sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which were $8.6 million for the three months ended June 30, 2020, compared to $5.7 million for the comparative period in 2019.  However, sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> have not increased in accordance with its expected growth trajectory as a result of challenges in onboarding new patients due to the COVID-19 pandemic. Revenue from transfer of intellectual property for the three months ended June 30, 2020 and 2019 principally reflected $13.9 million and $18.2 million, respectively, of revenue related to the Pfizer Transaction. </span></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Cost of revenue for the three months ended June 30, 2020 increased $3.4 million compared to the three months ended June 30, 2019.  Cost of product revenue increased primarily due to an increase in sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in 2020 and changes in product mix during the period.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, general and administrative expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Selling, general and administrative expenses for the three months ended June 30, 2020 and 2019 were $12.0 million and $15.2 million, respectively.  The decrease in selling, general and administrative expenses was primarily due to decreased expenses at our pharmaceutical subsidiaries and a decrease in equity-based compensation expense. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Research and development expenses for the three months ended June 30, 2020 and 2019 were $14.1 million and $25.0 million, respectively.  Research and development expenses include external and internal expenses, partially offset by third-party grants and funding arising from collaboration agreements.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  We track external research and development expenses by individual program for phase 3 clinical trials for drug approval and premarket approval (&#8220;PMA&#8221;) for diagnostics tests, if any.  Internal expenses include employee-related expenses such as salaries, benefits and equity-based compensation expense.  Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the components of our research and development expenses: </span></div><div style="margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:62.421%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.423%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.424%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and Development Expenses</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the three months ended June&#160;30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">External expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Manufacturing expense for biological products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(309)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,426&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase III studies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,297&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Post-marketing studies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Earlier-stage programs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,964&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development employee-related expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,753&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other internal research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,931&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third-party grants and funding from collaboration agreements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,051&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,029&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The decrease in research and development expenses for the three months ended June 30, 2020 was primarily due to a decrease in research and development expenses related to hGH-CTP, a once-weekly human growth hormone injection for which we have partnered with Pfizer and successfully completed a phase 3 study in August 2019. Ongoing expenses on the hGH-CTP program support Open Label Extension studies that will continue until market launch in most countries, as well as the preparation of applications for marketing approvals.  Research and development expenses for the pharmaceutical segment for the three months ended June 30, 2020 and 2019 included equity-based compensation expense of $0.3 million and $0.4 million, respectively.  The COVID-19 pandemic has impacted our ongoing and prospective clinical trials. We expect that Research and development expenses will increase in the future if and when these clinical trials commence or resume. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2020, we entered into a Restated Agreement with Pfizer, effective January 1, 2020, pursuant to which the parties agreed to share all costs for Manufacturing Activities, as defined in the Restated Agreement, for developing a licensed product for the three indications included in the agreement. This resulted in a reversal of certain previously accrued costs for manufacturing expenses for biological products in the second quarter of 2020. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contingent consideration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Contingent consideration for the three months ended June 30, 2020 and 2019 was $1.1 million of expense and $3.9 million reversal of expense, respectively.  Contingent consideration for the three months ended June 30, 2020 and 2019 was primarily attributable to changes in assumptions regarding the timing of achievement of future milestones for OPKO Renal, and potential amounts payable to former stockholders of OPKO Renal in connection therewith, pursuant to our acquisition agreement in March 2013.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization of intangible assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Amortization of intangible assets was $5.0 million and $5.6 million, respectively, for the three months ended June 30, 2020 and 2019.  Amortization expense reflects the amortization of acquired intangible assets with defined useful lives.  Our indefinite lived IPR&amp;D assets will not be amortized until the underlying development programs are completed.  Upon obtaining regulatory approval by the U.S. FDA, the IPR&amp;D assets will be accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our estimates and assumptions in testing goodwill and other intangible assets, including IPR&amp;D, for impairment are consistent with assumptions that marketplace participants would use in their estimates.  However, if actual results are not consistent with our estimates and assumptions, including as a result of the COVID-19 global pandemic, we may be exposed to an impairment charge that could be material. If we are unable to successfully develop hGH-CTP, or changes in projections and assumptions negatively impact our forecast of net cash flows, we may be exposed to a material impairment charge related to the IPR&amp;D for hGH-CTP.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Corporate</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt;"><tr><td style="width:1.0pt;"></td><td style="width:265.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:1.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,945)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(228)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(200)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,760&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,691&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,931)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,760)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,691)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,931&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating loss for our unallocated corporate operations for the three months ended June 30, 2020 and 2019 was $7.8 million and $10.7 million, respectively, and principally reflects general and administrative expenses incurred in connection with our corporate operations. The decrease in operating loss for the three months ended June 30, 2020 was primarily attributable to a decrease in legal fees incurred during that period compared to the three months ended June 30, 2019. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Other</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest income</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Interest income for the three months ended June 30, 2020 and 2019 was not significant as our cash investment strategy emphasizes the security of the principal invested and fulfillment of liquidity needs.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest expense</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Interest expense for the three months ended June 30, 2020 and 2019 was $5.5 million and $5.5 million, respectively.  Interest expense was principally related to interest incurred on the 2025 Notes, the 2023 Convertible Notes, the 2033 Senior Notes, and BioReference&#8217;s outstanding debt under its credit facility.    </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair value changes of derivative instruments, net</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Fair value changes of derivative instruments, net for the three months ended June 30, 2020 and 2019, was $13.3 thousand and $0.4 million of expense, respectively.  Derivative income for the three months ended June 30, 2019, principally related to the change in fair value of warrants to purchase additional shares of Xenetic.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other income (expense), net</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Other income (expense), net for the three months ended June 30, 2020 and 2019, was $18.2 million of income and $(5.9) million of expense, respectively.  Other income for the three months ended June 30, 2020 primarily consisted of net unrealized gains recognized during the period on our investment in VBI.  Other expense for the three months ended June 30, 2019 primarily consisted of net unrealized losses recognized during the period on our equity securities.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income tax provision</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Our income tax provision for the three months ended June 30, 2020 and 2019 was $6.0 million and $1.1 million, respectively, and reflects quarterly results using our expected effective tax rate.&#160; For the three months ended June 30, 2020, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Loss from investments in investees</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  We have made investments in certain early stage companies that we perceive to have valuable proprietary technology and significant potential to create value for us as a shareholder or member.  We account for these investments under the equity method of accounting, resulting in the recording of our proportionate share of their losses until our share of their loss exceeds our investment.  Until the investees&#8217; technologies are commercialized, if ever, we anticipate they will report net losses.  Loss from investments in investees was $0.2 million and $0.3 million for the three months ended June 30, 2020 and 2019, respectively. </span></div><div style="margin-top:9pt;"><span><br/></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FOR THE SIX MONTHS ENDED JUNE 30, 2020 AND 2019</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated income (loss) from operations for the six months ended June 30, 2020 and 2019 is as follows:  </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:11pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:510.75pt;"><tr><td style="width:1.0pt;"></td><td style="width:264.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:1.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,462&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,449&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from transfer of intellectual property and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,057)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">512,674&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">448,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">302,909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">288,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">153,852&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183,633&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29,781)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,369&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,447)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent Consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(780)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,874&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,107)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset impairment charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(655)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">526,255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">571,397&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45,142)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,581)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(122,577)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108,996&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Diagnostics </span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:50.046%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.645%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,462&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from transfer of intellectual property and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">428,005&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,656&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">267,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,974&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,436&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129,787&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,351)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(73)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent Consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">583&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(515)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,831&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,764)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">405,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">418,931&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,729)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(61,582)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Revenue from services for the six months ended June 30, 2020 increased by approximately $64.5 million compared to the six months ended June 30, 2019, primarily due to the positive impacts of increased COVID-19 testing volumes. Revenue from services further benefited from the successful appeal of previously denied Medicare claims for the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> test resulting in approximately $10.9 million of incremental revenue.  In addition, revenue from the transfer of intellectual property and other for the three months ended June 30, 2020 included a $6.2 million grant received by BioReference from the CARES Act. BioReference performed 331.6 thousand serology antibody tests and 2.3 million diagnostic molecular tests for COVID-19 during the six months ended June 30, 2020, which represented 13.6% of its total volume for that period. Additionally, BioReference experienced $3.4 million of higher net reimbursement on our genomic testing due to a test mix shift of increased whole exome sequencing. This was partially offset by the negative impacts of:</span></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Reduced clinical test volumes and genomics test volumes at BioReference of $78.3 million and $14.8 million from reduced clinical test volumes and genomics test volumes, respectively, exclusive of COVID-19 test volumes. The decline in volume reflects the negative impacts from the COVID-19 pandemic, principally from referring physician office closures and stay-at-home guidance throughout states in which we predominately operate, and declines in routine clinical and genomics testing, which declined 28.8% versus the Company's normal daily levels.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">$0.5 million from lower net reimbursement on our clinical testing resulting from the latest negative impact of the PAMA price reduction that went into effective January 1, 2020 and were partially offset by improved operational procedures and a flattening of our denial rate</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimated collection amounts are subject to the complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, and require us to consider the potential for retroactive adjustments when estimating variable consideration in the recognition of revenue in the period the related services are rendered.  For the six months ended June 30, 2020 and 2019, revenue increases (reductions) due to changes in estimates of implicit price concessions for performance obligations satisfied in prior periods of $0.2 million and $(14.3) million, respectively, were recognized.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The composition of Revenue from services by payor for the six months ended June 30, 2020 and 2019 was as follows:</span></div><div style="margin-top:14pt;margin-bottom:10pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:65.935%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.666%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.667%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June&#160;30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Healthcare insurers</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183,232&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">211,207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government payers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Client payers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patients</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Client payers include cities and states for which BioReference provides COVID-19 testing services.</span></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Cost of revenue for the six months ended June 30, 2020 increased $8.0 million compared to the six months ended June 30, 2019.  Cost of revenue increased $47.2 million due to labor and material costs to produce COVID-19 testing volumes during the six months ended June 30, 2020, which was partially offset by an overall reduction in other clinical and genomic test volumes, and to cost reduction initiatives, which resulted in per patient encounter efficiency gains at BioReference.</span></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, general and administrative expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Selling, general and administrative expenses for the six months ended June 30, 2020 and 2019 were $110.4 million and $129.8 million, respectively.  The decrease in selling, general and administrative expenses in our diagnostics segment was primarily due to expenses of $12.6 million incurred during the six months ended June 30, 2019 in connection with certain legal matters, and to decreased expenses at BioReference due to the enactment of cost reduction initiatives. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The following table summarizes the components of our research and development expenses: </span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.862%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.570%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and Development Expenses</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June&#160;30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">External expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PMA studies</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development employee-related expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other internal research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development for the diagnostic segment relates to the development of testing services for our clinical and genomics testing at BioReference and the development of the Claros Analyzer, a diagnostic instrument system to provide rapid, high performance blood test results in the point-of-care setting.Research and development expenses for the six months ended June 30, 2020 was consistent with the comparative period in 2019. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contingent consideration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Contingent consideration for the six months ended June 30, 2020 and 2019 was $68 thousand and $583 thousand of expense, respectively.  Contingent consideration for the six months ended June 30, 2020 and 2019 was attributable to changes in assumptions regarding the timing of achievement of future milestones for OPKO Diagnostics in both </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">periods, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">potential amounts payable to former stockholders of OPKO Diagnostics in connection therewith,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> pursuant to our acquisition agreement in October 2011.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization of intangible assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Amortization of intangible assets was $19.8 million and $21.6 million, respectively, for the six months ended June 30, 2020 and 2019.  Amortization expense reflects the amortization of acquired intangible assets with defined useful lives. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span><br/></span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Pharmaceuticals</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt;"><tr><td style="width:1.0pt;"></td><td style="width:265.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:1.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,449&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from transfer of intellectual property and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,251)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,669&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,802)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,292&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,713&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,670&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,563)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,069&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,467)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent Consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">448&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(265)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,043&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,343)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset impairment charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(655)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129,504&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24,714)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,121)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38,033)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,912&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The increase in revenue from products for the six months ended June 30, 2020 compared to the six months ended June 30, 2019 was primarily attributable to an increase in sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which were $18.6&#160;million for the six months ended June 30, 2020, compared to $11.5&#160;million for the comparative period in 2019.  Revenue from transfer of intellectual property for the six months ended June 30, 2020 and 2019 principally reflected $22.7&#160;million and $35.6&#160;million, respectively, of revenue related to the Pfizer Transaction. </span></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Cost of revenue for the three months ended June 30, 2020 increased $6.6&#160;million compared to the six months ended June 30, 2019.  Cost of product revenue increased primarily due to an increase in sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in 2020 and changes in product mix during the period.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, general and administrative expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Selling, general and administrative expenses for the six months ended June 30, 2020 and 2019 were $26.7&#160;million and $30.2&#160;million, respectively.  The decrease in selling, general and administrative expenses was primarily due to decreased expenses at our pharmaceutical subsidiaries and a decrease in equity-based compensation expense. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Research and development expenses for the six months ended June 30, 2020 and 2019 were $32.6&#160;million and $58.1&#160;million, respectively.  Research and development expenses include external and internal expenses, partially offset by third-party grants and funding arising from collaboration agreements.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  We track external research and development expenses by individual program for phase 3 clinical trials for drug approval and premarket approval (&#8220;PMA&#8221;) for diagnostics tests, if any.  Internal expenses include employee-related expenses such as salaries, benefits and equity-based compensation expense.  Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the components of our research and development expenses: </span></div><div style="margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:62.421%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.423%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.424%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and Development Expenses</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June&#160;30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">External expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Manufacturing expense for biological products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,728&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase III studies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,339&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,580&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Post-marketing studies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,122&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">603&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Earlier-stage programs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,568&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,159&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development employee-related expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,268&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other internal research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,577&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,972&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third-party grants and funding from collaboration agreements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(377)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,069&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The decrease in research and development expenses for the six months ended June 30, 2020 was primarily due to a decrease in research and development expenses related to hGH-CTP, a once-weekly human growth hormone injection for which we have partnered with Pfizer and successfully completed a phase 3 study in August 2019. Ongoing expenses on the hGH-CTP program support Open Label Extension studies that will continue until market launch in most countries, as well as the preparation of applications for marketing approvals.  Research and development expenses for the pharmaceutical segment for the six months ended June 30, 2020 and 2019 included equity-based compensation expense of $0.9 million and $1.1 million, respectively.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contingent consideration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Contingent consideration for the six months ended June 30, 2020 and 2019 was $0.2 million and $0.4 million of expense, respectively.  Contingent consideration for the six months ended June 30, 2020 and 2019 was primarily attributable to changes in assumptions regarding the timing of achievement of future milestones for OPKO Renal, and potential amounts payable to former stockholders of OPKO Renal in connection therewith, pursuant to our acquisition agreement in March 2013.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization of intangible assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Amortization of intangible assets was $10.0 million and $11.4 million, respectively, for the six months ended June 30, 2020 and 2019.  Amortization expense reflects the amortization of acquired intangible assets with defined useful lives.  Our indefinite lived IPR&amp;D assets will not be amortized until the underlying development programs are completed.  Upon obtaining regulatory approval by the U.S. FDA, the IPR&amp;D assets will be accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Asset impairment charges</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Asset impairment charges were $0.7 million for the six months ended June 30, 2019 and is related to an impairment charge to write down our intangible assets at FineTech down to their estimated fair value.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Corporate</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt;"><tr><td style="width:1.0pt;"></td><td style="width:265.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:1.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:78.25pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(72)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(148)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,746&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,614&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,868)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(411)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(504)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,263&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,962&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,699)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,263)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,962)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,699&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating loss for our unallocated corporate operations for the six months ended June 30, 2020 and 2019 was $16.3 million and $23.0 million, respectively, and principally reflects general and administrative expenses incurred in connection with our corporate operations. The decrease in operating loss for the six months ended June 30, 2020 was primarily attributable to a decrease in legal fees incurred for the six months ended June 30, 2020, compared to the six months ended June 30, 2019. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Other</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest income</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Interest income for the six months ended June 30, 2020 and 2019 was not significant as our cash investment strategy emphasizes the security of the principal invested and fulfillment of liquidity needs.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest expense</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Interest expense for the six months ended June 30, 2020 and 2019 was $11.0 million and $10.3 million, respectively.  Interest expense was principally related to interest incurred on the 2025 Notes, the 2023 Convertible Notes, the 2033 Senior Notes, and BioReference&#8217;s outstanding debt under its credit facility.    </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair value changes of derivative instruments, net</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Fair value changes of derivative instruments, net for the six months ended June 30, 2020 and 2019, was $0.6 million and $27 thousand of income, respectively.  Derivative income for the six months ended June 30, 2020, principally related to the change in fair value on foreign currency forward exchange contracts at OPKO Chile.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other income (expense), net</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Other income (expense), net for the six months ended June 30, 2020 and 2019, was $5.9 million of income and $(4.9) million of expense, respectively.  Other income for the six months ended June 30, 2020 primarily consisted of net unrealized gain recognized during the period on our investment in VBI, offset by net unrealized loss recognized during the period on our investment in Eloxx. Other expense for the six months ended June 30, 2019 primarily consisted of net unrealized losses recognized during the period on our equity securities.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income tax provision</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Our income tax provision for the six months ended June 30, 2020 and 2019 was $7.2 million and $1.9 million, respectively, and reflects quarterly results using our expected effective tax rate.&#160; For the six months ended June 30, 2020, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Loss from investments in investees</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  We have made investments in certain early stage companies that we perceive to have valuable proprietary technology and significant potential to create value for us as a shareholder or member.  We account for these investments under the equity method of accounting, resulting in the recording of our proportionate share of their losses until our share of their loss exceeds our investment.  Until the investees&#8217; technologies are commercialized, if ever, we anticipate they will report net losses.  Loss from investments in investees was $0.3 million and $2.1 million for the six months ended June 30, 2020 and 2019, respectively. </span></div><div style="margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, we had cash and cash equivalents of approximately $21.6 million.  Cash used in operations of $57.8 million for the six months ended June 30, 2020 principally reflects general and administrative expenses in connection with our corporate operations and research and development activities.  Cash used in investing activities for the six months ended June 30, 2020 primarily reflects capital expenditures of $17.1 million.  Cash provided by financing activities primarily reflects net borrowings on our lines of credit.  We have not generated sustained positive cash flow sufficient to offset our operating and other expenses, and our primary sources of cash have been from the public and private placement of equity, the issuance of the 2033 Senior Notes, 2023 Convertible Notes and 2025 Notes and credit facilities available to us.  However, as a result of the significant increase in testing volumes resulting from the COVID-19 pandemic, and if our routine clinical and genomic testing volumes continue to trend towards normalization with prior periods, we anticipate generating cash from operations.  We are unable to predict how long the demand will continue for COVID-19 related testing or or whether further restrictions will be placed on elective procedures or stay at home orders will be reinstated and accordingly, the sustainability of the cash flow is uncertain.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $100 million.  Borrowings under this line of credit will bear interest at a rate of 11% per annum and may be repaid and reborrowed at any time.  The credit agreement includes various customary remedies for the lender following an event of default, including the acceleration of repayment of outstanding amounts under line of credit.  The line of credit matures on February 25, 2025. As of June 30, 2020, no funds were borrowed under this line of credit.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 29, 2019, we issued 50 million shares of our Common Stock at a price of $1.50 per share in an underwritten public offering, resulting in net proceeds to the Company of approximately $70 million, after deducting underwriting commissions and offering expenses.  In November 2019, pursuant to an option the Company granted the underwriters, we issued an additional 4,227,749 shares of Common Stock at $1.50 per share, resulting in proceeds of approximately $6 million after deducting underwriting commissions.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, we issued $200.0 million aggregate principal amount of the 2025 Notes in an underwritten public offering.  The 2025 Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on February&#160;15 and August&#160;15 of each year.  The notes mature on February&#160;15, 2025, unless earlier repurchased, redeemed or converted.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders may convert their 2025 Notes into shares of Common Stock at their option at any time prior to the close of business on the business day immediately preceding November&#160;15, 2024 only under the following circumstances:  (1)&#160;during any calendar quarter commencing after the calendar quarter ended on March&#160;31, 2019 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2)&#160;during the five business day period after any five consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our Common Stock and the conversion rate on each such trading day; (3)&#160;if we call any or all of the 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4)&#160;upon the occurrence of specified corporate events set forth in the indenture governing the 2025 Notes.  On or after November&#160;15, 2024, until the close of business on the business day immediately preceding the maturity date, holders of the 2025 Notes may convert their notes at any time, regardless of the foregoing conditions.  Upon conversion, we will pay or deliver, as the case may be, cash, shares of our Common Stock, or a combination of cash and shares of our Common Stock, at our election.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The current conversion rate for the 2025 Notes is 236.7424 shares of Common Stock per $1,000 principal amount of 2025 Notes (equivalent to a conversion price of approximately $4.22 per share of Common Stock).  The conversion rate for the 2025 Notes is subject to adjustment in certain events but will not be adjusted for any accrued and unpaid interest.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 8, 2018, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the aggregate principal amount of $60 million.  The credit agreement was terminated on or around February 20, 2019 and we repaid the $28.8 million outstanding from the proceeds of the 2025 Notes offering.  Borrowings under the line of credit bore interest at a rate of 10% per annum.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 1, 2019, holders tendered to us approximately $28.8 million aggregate principal amount of 2033 Senior Notes pursuant to such holders&#8217; option to require us to repurchase the 2033 Senior Notes as set forth in the indenture, following which repurchase only $3.0 million aggregate principal amount of the 2033 Senior Notes remained outstanding.  Holders of the remaining $3.0 million principal amount of the 2033 Senior Notes may require us to repurchase such notes for 100% of their </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">principal amount, plus accrued and unpaid interest, on February 1, 2023, on February 1, 2028, or following the occurrence of a fundamental change as defined in the indenture governing the 2033 Senior Notes.   </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the total commitments under our Credit Agreement (as defined below) with CB and our lines of credit with financial institutions in Chile and Spain were $93.1 million, of which $63.5 million was drawn as of June&#160;30, 2020.  At June&#160;30, 2020, the weighted average interest rate on these lines of credit was approximately 4.2%.  These lines of credit are short-term and are used primarily as a source of working capital.  The highest aggregate principal balance at any time outstanding during the six months ended June 30, 2020 was $63.5 million.  We intend to continue to draw under these lines of credit as needed.  There is no assurance that these lines of credit or other funding sources will be available to us on acceptable terms, or at all, in the future.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 5, 2015, BioReference and certain of its subsidiaries entered into a credit agreement with JPMorgan Chase Bank, N.A. (&#8220;CB&#8221;), as lender and administrative agent, as amended (the &#8220;Credit Agreement&#8221;).  The Credit Agreement provides for a $75.0 million secured revolving credit facility and includes a $20.0 million sub-facility for swingline loans and a $20.0 million sub-facility for the issuance of letters of credit.  The Credit Agreement matures on November 5, 2021 and is guaranteed by all of BioReference&#8217;s domestic subsidiaries.  The Credit Agreement is also secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference.  Availability under the Credit Agreement is based on a borrowing base comprised of eligible accounts receivables of BioReference and certain of its subsidiaries, as specified therein.  As of June&#160;30,&#160;2020, $15.3 million remained available for borrowing under the Credit Agreement. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, in a transaction exempt from registration under the Securities Act, we issued the 2023 Convertible Notes in the aggregate principal amount of $55.0 million.  The 2023 Convertible Notes mature five years from the date of issuance.  Each holder of a 2023 Convertible Note has the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock, par value $0.01 per share, at a conversion price of $5.00 per share of Common Stock.  We may redeem all or any part of the then issued and outstanding 2023 Convertible Notes, together with accrued and unpaid interest thereon, pro ratably among the holders, upon no fewer than 30 days, and no more than 60 days, notice to the holders.  The 2023 Convertible Notes contain customary events of default and representations and warranties of OPKO.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 12, 2017, EirGen, our wholly-owned subsidiary, and JT entered into the JT Agreement granting JT the exclusive rights for the development and commercialization of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Japan.  The license grant to JT covers the therapeutic and preventative use of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for (i)&#160;SHPT in non-dialysis and dialysis patients with CKD, (ii)&#160;rickets, and (iii)&#160;osteomalacia, as well as such additional indications as may be added to the scope of the license subject to the terms of the JT Agreement.  In connection with the transaction, OPKO received an initial upfront payment of $6 million, and OPKO received another $6 million upon the initiation of OPKO&#8217;s phase 2 study for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in dialysis patients in the U.S. in September 2018.  OPKO is also eligible to receive up to an additional aggregate amount of $31 million upon the achievement of certain regulatory and development milestones by JT for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the JT Territory, and $75 million upon the achievement of certain sales based milestones by JT in the JT Territory.  OPKO will also receive tiered, double digit royalty payments at rates ranging from low double digits to mid-teens on sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> within the JT Territory.  JT will, at its sole cost and expense, be responsible for performing all development activities necessary to obtain all regulatory approvals for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Japan and for all commercial activities pertaining to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Japan.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2016, EirGen, our wholly-owned subsidiary, partnered with VFMCRP through a Development and License Agreement (the &#8220;VFMCRP Agreement&#8221;) for the development and commercialization of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Europe, Canada, Mexico, Australia, South Korea and certain other international markets (the &#8220;VFMCRP Territory&#8221;).  The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the product in human patients, provided that initially the license is for the use of the product for the treatment or prevention of SHPT related to patients with CKD and vitamin D insufficiency/deficiency (&#8220;VFMCRP Initial Indication&#8221;).  Effective May 5, 2020, we entered into an amendment to the VFMCRP Agreement (the &#8220;VFMCRP Amendment&#8221;), pursuant to which the parties agreed to exclude Mexico, South Korea, the Middle East and all of the countries of Africa from the VFMCRP Territory. In addition, the parties agreed to certain amendments to the milestone structure and to reduce minimum royalties payable. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have received non-refundable and non-creditable payments of $52 million to date and are eligible to receive up to an additional $230 million pursuant to the terms of the VFMCRP Amendment upon the achievement of certain regulatory and sales-based milestones tied to sales and reimbursement levels.  In addition, we are eligible to receive tiered royalties on sales of the product at percentage rates that range from the mid-teens to the mid-twenties or a minimum royalty, whichever is greater, upon commencement of sales of the product.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the arrangement, the companies will share responsibility for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan.  For the initial development plan, the companies have agreed to certain cost sharing arrangements.  VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the product for the VFMCRP Initial Indication in the VFMCRP Territory except as otherwise provided in the VFMCRP Agreement.  EirGen also granted to VFMCRP an option to acquire an exclusive license to use, import, offer for sale, sell, distribute and commercialize the product in the U.S. for treatment of SHPT in dialysis patients with stage 5 CKD and vitamin D insufficiency (the &#8220;Dialysis Indication&#8221;).  Upon exercise of the Option, VFMCRP will reimburse EirGen for all of the development costs incurred by EirGen with respect to the product for the Dialysis Indication in the U.S.  VFMCRP would also pay EirGen up to an additional aggregate amount of $555 million upon the achievement of certain milestones and would be obligated to pay royalties on sales of the product at percentage rates that range from the mid-teens to the mid-twenties or a minimum royalty, whichever is greater, upon commencement of sales of the product.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020, we announced that the Japan phase 3 clinical trial met its primary and secondary objectives, and demonstrated that the efficacy and safety of Somatrogon administered weekly was comparable to GENOTROPIN&#174; for injection administered once-daily as measured by annual height velocity after 12 months of treatment in treatment-na&#239;ve Japanese pre-pubertal children with GHD. In October 2019, we and Pfizer announced that the global phase 3 trial evaluating Somatrogon (hGH-CTP) dosed once-weekly in prepubertal children with GHD met its primary endpoint of non-inferiority to daily Genotropin&#174; (somatropin) for injection, as measured by annual height velocity at 12 months.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2014, Pfizer and OPKO entered into a worldwide agreement for the development and commercialization of our long-acting hGH-CTP for the treatment of GHD in adults and children, as well as for the treatment of growth failure in children born small for gestational age.  Under the terms of the agreements with Pfizer, we received non-refundable and non-creditable upfront payments of $295 million in 2015 and are eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones.  Pfizer received the exclusive license to commercialize hGH-CTP worldwide.  In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of hGH-CTP for Adult GHD with percentage rates ranging from the high teens to mid-twenties.  Upon the launch of hGH-CTP for Pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both hGH-CTP and Pfizer&#8217;s Genotropin&#174;.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2020, we entered into Amended and Restated Development and Commercialization License Agreement (the &#8220;Restated Agreement&#8221;) with Pfizer, effective January 1, 2020, pursuant to which the parties agreed to share all costs for Manufacturing Activities, as defined in the Restated Agreement, for developing a licensed product for the three indications included in the Agreement.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with our acquisitions of CURNA, OPKO Diagnostics and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events, including up to an additional $19.1 million in shares of our Common Stock to the former stockholders of OPKO Diagnostics upon and subject to the achievement of certain milestones; and up to an additional $125.0 million in either shares of our Common Stock or cash, at our option subject to the achievement of certain milestones, to the former shareholders of OPKO Renal.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that the cash and cash equivalents on hand at June&#160;30, 2020, cash from operations and the amounts available to be borrowed under our lines of credit are sufficient to meet our anticipated cash requirements for operations and debt service beyond the next 12 months.  We based this estimate on assumptions that may prove to be wrong or are subject to change, and we may be required to use our available cash resources sooner than we currently expect.  If we acquire additional assets or companies, accelerate our product development programs or initiate additional clinical trials, we will need additional funds.  Our future cash requirements, and the timing of those requirements, will depend on a number of factors, including the impact of the COVID-19 pandemic on our business, the approval and success of our products in development, particularly our long acting hGH-CTP for which we expect to submit for approval in the U.S. this year and in Europe and Japan thereafter, the commercial success of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, including the launch of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> by Vifor expected later this year, BioReference&#8217;s financial performance, possible acquisitions, the continued progress of research and development of our product candidates, the timing and outcome of clinical trials and regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing, our success in developing markets for our product candidates and results of government investigations, payor claims, and legal proceedings that may arise, including, without limitation class action and derivative litigation to which we are subject, and our ability to obtain insurance coverage for such claims.  We have not generated sustained positive cash flow and if we are not able to secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical trials or research and development programs or possible acquisitions or reduce our marketing or sales efforts or cease operations.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, the rapid development and fluidity of the&#160;COVID-19 pandemic makes it very difficult to predict its ultimate impact on our business, results of operations and liquidity.  The pandemic presents a significant uncertainty that could </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">materially and adversely affect our results of operations, financial condition and cash flows, including due to a continued negative impact on non-COVID-related diagnostics testing services provided by BioReference in our diagnostics segment. Further, deteriorating economic conditions globally have resulted in a challenging capital raising environment, which could materially limit our access to capital, whether through the issuance and sale of our common stock, debt securities or otherwise, as well as through bank facilities and lines of credit.  Events resulting from the effects of COVID-19 could negatively impact our ability to comply with certain covenants&#160;in the Credit Agreement or require that we pursue alternative financing. We can provide no assurance that any such alternative financing, if required, could be obtained on acceptable terms or at all. The combination of potential disruptions to our business resulting from&#160;COVID-19 together with and volatile credit and capital markets could adversely impact our future liquidity, which could have an adverse effect on our business and results of operations.  We will continue to monitor and assess the impact&#160;COVID-19 may have on our business and financial results.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides information as of June&#160;30, 2020, with respect to the amounts and timing of our known contractual obligation payments due by period.  </span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:22.522%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.572%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.985%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.985%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.838%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.985%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.985%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.990%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual obligations<br/>(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining six&#160;months ending December&#160;31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Open purchase orders</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">153,623&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">506&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154,164&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,392&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,938&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,856&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,121&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">581&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">247&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,394&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2033 Senior Notes, 2025 and 2023 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">207,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">210,067&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,994&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgages and other debts payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,209&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">739&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,983&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lines of credit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,048&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest commitments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">283&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,016&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,997&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,145&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,749&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">548,910&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preceding table does not include information where the amounts of the obligations are not currently determinable, including the following: </span></div><div style="text-indent:-4.5pt;padding-left:31.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">- Contractual obligations in connection with clinical trials, which span over two years, and that depend on patient enrollment.  The total amount of expenditures is dependent on the actual number of patients enrolled and as such, the contracts do not specify the maximum amount we may owe. </span></div><div style="text-indent:-4.5pt;padding-left:31.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">- Product license agreements effective during the lesser of 15 years or patent expiration whereby payments and amounts are determined by applying a royalty rate on uncapped future sales.</span></div><div style="text-indent:-4.5pt;padding-left:31.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">- Contingent consideration that includes payments upon achievement of certain milestones including meeting development milestones such as the completion of successful clinical trials, NDA approvals by the FDA and revenue milestones upon the achievement of certain revenue targets all of which are anticipated to be paid within the next seven years and are payable in either shares of our Common Stock or cash, at our option, and that may aggregate up to $149.1 million.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CRITICAL ACCOUNTING POLICIES AND ESTIMATES </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no material changes to our critical accounting policies and estimates described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, that have a material impact to our Condensed Consolidated Financial Statements and related notes.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently adopted accounting pronouncements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221; which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables.  This may result in the earlier recognition of allowances for losses.  The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2019, with early adoption permitted.  The adoption of ASU 2016-13 on January 1, 2020, did not have a significant impact on our Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of doing business, we are exposed to the risks associated with foreign currency exchange rates and changes in interest rates.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Foreign Currency Exchange Rate Risk &#8211; We operate globally and, as such, we are subject to foreign exchange risk in our commercial operations as portions of our revenues are exposed to changes in foreign currency exchange rates, primarily the Chilean Peso, the Mexican Peso, the Euro and the New Israeli Shekel.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we do not speculate in the foreign exchange market, we may from time to time manage exposures that arise in the normal course of business related to fluctuations in foreign currency exchange rates by entering into offsetting positions through the use of foreign exchange forward contracts.  Certain firmly committed transactions may be hedged with foreign exchange forward contracts.  As exchange rates change, gains and losses on the exposed transactions are partially offset by gains and losses related to the hedging contracts.  Both the exposed transactions and the hedging contracts are translated and fair valued, respectively, at current spot rates, with gains and losses included in earnings.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our derivative activities, which consist of foreign exchange forward contracts, are initiated to economically hedge forecasted cash flows that are exposed to foreign currency risk.  The foreign exchange forward contracts generally require us to exchange local currencies for foreign currencies based on pre-established exchange rates at the contracts&#8217; maturity dates.  As exchange rates change, gains and losses on these contracts are generated based on the change in the exchange rates that are recognized in the Condensed Consolidated Statements of Operations and offset the impact of the change in exchange rates on the foreign currency cash flows that are hedged.  If the counterparties to the exchange contracts do not fulfill their obligations to deliver the contracted currencies, we could be at risk for currency related fluctuations.  Our foreign exchange forward contracts primarily hedge exchange rates on the Chilean Peso to the U.S. dollar.  If Chilean Pesos were to strengthen or weaken in relation to the U.S. dollar, our loss or gain on hedged foreign currency cash-flows would be offset by the derivative contracts, with a net effect of zero.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not engage in trading market risk sensitive instruments or purchasing hedging instruments or &#8220;other than trading&#8221; instruments that are likely to expose us to significant market risk, whether interest rate, foreign currency exchange, commodity price, or equity price risk.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest Rate Risk &#8211; Our exposure to interest rate risk relates to our cash and investments and to our borrowings.  We generally maintain an investment portfolio of money market funds and marketable securities.  The securities in our investment portfolio are not leveraged, and are, due to their very short-term nature, subject to minimal interest rate risk.  We currently do not hedge interest rate exposure.  Because of the short-term maturities of our investments, we do not believe that a change in market interest rates would have a significant negative impact on the value of our investment portfolio except for reduced income in a low interest rate environment.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, we had cash and cash equivalents of $21.6 million.  The weighted average interest rate related to our cash and cash equivalents for the six months ended June 30, 2020 was less than 1%.  As of June&#160;30, 2020, the principal outstanding balances under BioReference&#8217;s Credit Agreement with CB and our Chilean and Spanish lines of credit was $63.5 million in the aggregate at a weighted average interest rate of approximately 4.2%.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our $3.0 million aggregate principal amount of our 2033 Senior Notes has a fixed interest rate of 3%, our $55.0 million aggregate principal amount of our 2023 Convertible Notes has a fixed interest rate of 5%, and our $200.0 million aggregate principal amount of the 2025 Notes has a fixed interest rate of 4.50%, and therefore are not subject to fluctuations in market interest rates.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk.  To achieve this objective, we may invest our excess cash in debt instruments of the U.S. Government and its agencies, bank obligations, repurchase agreements and high-quality corporate issuers, and money market funds that invest in such debt instruments, and, by policy, restrict our exposure to any single corporate issuer by imposing concentration limits.  To minimize the exposure due to adverse shifts in interest rates, we maintain investments at an average maturity of generally less than three months.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Controls and Procedures</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Disclosure Controls and Procedures </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) as of the end of the period covered by this Quarterly Report on Form 10-Q.  Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the Securities and Exchange Commission.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.  Based on this evaluation, management concluded that our disclosure controls and procedures were effective as of June&#160;30, 2020.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes to the Company&#8217;s Internal Control Over Financial Reporting </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no changes to the Company&#8217;s internal control over financial reporting that occurred during the calendar quarter covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II. OTHER INFORMATION</span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_136"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Legal Proceedings</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are, from time to time, party to various legal proceedings arising out of our business. During the reporting period, covered by this Quarterly Report on Form 10-Q, except as set forth below, there have been no material changes to the description of legal proceedings set forth in our Annual Report on Form 10-K for the year ended December 31, 2019. The following should be read in conjunction with the information provided in Part I, Item 3 of such Annual Report.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On June 26, 2020, The Amitim Funds, the lead plaintiff in the class action lawsuit against the Company and Dr. Frost,  filed a Stipulation of Settlement (the &#8220;Stipulation&#8221;) in the Southern District of Florida of behalf of itself and the remainder of the class, which, if approved, will provide for the settlement of and release of the class action claims against the Company and Dr. Frost that were previously disclosed in the Annual Report for $16.5 million. We reached agreement with our insurance carriers with respect to claims made in the class action and derivative lawsuits and we expect insurance coverage for a significant portion of the settlement amounts. The lead plaintiff also filed a Motion for Preliminary Approval of Settlement and a Notice of Dismissal on June 29, 2020.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The settlement remains subject to court approval. </span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;See Note 11 to the interim unaudited condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q for information regarding the status of other legal proceedings involving the Company.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1A. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Risk Factors </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except as set forth in this Item 1A, there have been no material changes to our risk factors as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business has been, and may continue to be, materially adversely affected by the recent coronavirus disease 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(COVID-19) outbreak.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The outbreak of the coronavirus disease 2019 (COVID-19) has evolved into a global pandemic. The novel coronavirus originating in Wuhan, China has spread to many regions of the world, including the U.S. and Europe. The extent to which this coronavirus impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning the virus and the actions to contain the spread of or to detect, prevent, or treat COVID-19, among others.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Severe respiratory symptoms, infections, deaths, and widespread quarantine measures related to the pandemic have disrupted healthcare delivery in key markets in which our laboratory business currently operates, including New York, New Jersey, Texas, Florida, and California. Since late March 2020, the Company experienced, and may continue to experience, a material decline in testing volumes due to the COVID-19 pandemic.  In addition to declining volumes, it is possible that, as a result of the COVID-19 pandemic, we may experience supply chain disruptions, including shortages, delays and price increases in testing equipment and supplies, which could materially adversely impact our business. It is also possible that the Company will experience an adverse impact on cash collections as a result of the impact of the COVID-19 pandemic.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The spread of COVID-19, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on our business.  Such restrictions may present challenges in connection with our laboratory business, our ability to successfully commercialize </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, our ability to manufacture pharmaceutical products in </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ireland, Mexico, Spain, Chile and Israel</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and our ability to continue clinical development of our product candidates. Further, if the spread of the coronavirus pandemic continues and our operations are adversely impacted, our ability to meet performance obligations under contracts may be impacted.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">COVID-19 could disrupt our operations due to absenteeism by infected or ill members of management or other employees, or absenteeism by members of management and other employees who elect not to come to work due to the illness affecting others in our office or laboratory facilities, or due to quarantines. Supplies used in our diagnostic testing and research laboratories could be disrupted or we could see prices increase if the manufacturers or suppliers of such items experience absenteeism due to illness of their employees or due to local quarantines, limiting our ability to provide diagnostic testing services, supply sufficient product for our clinical or commercial plans or satisfy our contractual obligations.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The regulatory framework governing laboratories, diagnostic and pharmaceutical&#160;companies may be affected as governmental authorities divert resources to respond to the&#160;COVID-19 outbreak, which may have an unanticipated and unforeseen impact on our operations. It is possible that the timing of regulatory submissions and approvals for our products, including hGH-CTP, will be adversely impacted or delayed. With respect to our ongoing and planned clinical trials, restrictions and efforts to avoid further spread of COVID-19 may present challenges to the conduct of these trials consistent with normally applicable approaches and good clinical practice standards, and although regulators including the FDA have offered guidance applicable during the COVID-19 pandemic allowing for flexibility of standards in certain areas and alternate methods of meeting trial oversight obligations (for example, via remote monitoring), the potential impact of these challenges cannot be fully predicted at this time.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The anticipated economic consequences of the COVID-19 pandemic have adversely impacted financial markets and the deteriorating economic conditions globally have resulted in a challenging capital raising environment, which could materially limit our access to capital, whether through bank facilities and lines of credit, the issuance and sale of our common stock, debt securities or otherwise. Our inability to obtain capital when and if needed, could have a material adverse impact on our operations. </span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_142"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_145"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;3. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Defaults Upon Senior Securities</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Mine Safety Disclosures</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not Applicable.</span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_151"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;5. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Other Information</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div id="ia969b45ba09947e9a03ce421f700f5b3_154"></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;6. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibits</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:17.501%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.499%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a101viforlicagmtamend.htm">Exhibit 10.1</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="a101viforlicagmtamend.htm">Amendment to Development and Lic</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="a101viforlicagmtamend.htm">ense Agreement between EirGen Pharma L</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="a101viforlicagmtamend.htm">td. </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="a101viforlicagmtamend.htm">and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="a101viforlicagmtamend.htm">Vifor Fresenius Medical Care Renal Pharma Ltd</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="a101viforlicagmtamend.htm">.,</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="a101viforlicagmtamend.htm"> dated May </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="a101viforlicagmtamend.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="a101viforlicagmtamend.htm">, 2020</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="a101viforlicagmtamend.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a102pfizerlicagmtamend.htm">Exhibit 10.2</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a102pfizerlicagmtamend.htm">Amended and Restated Development and Commercialization License Agreement by and between Pfizer Inc. and</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a102pfizerlicagmtamend.htm"> OPKO Ireland Ltd., dated May 12, 2020.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a102pfizerlicagmtamend.htm"> </a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex311.htm">Exhibit&#160;31.1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex311.htm">Certification by Phillip Frost, Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex311.htm">June</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex311.htm"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex311.htm">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex311.htm">, 2020.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex312.htm">Exhibit&#160;31.2</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex312.htm">Certification by Adam Logal, Chief Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex312.htm">June</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex312.htm"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex312.htm">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex312.htm">, 2020.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex321.htm">Exhibit&#160;32.1</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">**</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex321.htm">Certification by Phillip Frost, Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex321.htm">June</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex321.htm"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex321.htm">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex321.htm">, 2020.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex322.htm">Exhibit&#160;32.2</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">**</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex322.htm">Certification by Adam Logal, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex322.htm">June</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex322.htm"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex322.htm">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="opk-6302020xex322.htm">, 2020.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit 101.INS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit 101.SCH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit 101.CAL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit 101.DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit 101.LAB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit 101.PRE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit 104</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="text-indent:-22.5pt;padding-left:22.5pt;margin-top:3pt;"><span><br/></span></div><div style="text-indent:-22.5pt;padding-left:22.5pt;margin-top:3pt;"><span><br/></span></div><div style="padding-left:22.5pt;margin-top:3pt;"><span><br/></span></div><div style="padding-left:22.5pt;margin-top:3pt;"><span><br/></span></div><div style="text-indent:-27pt;padding-left:27pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;vertical-align:top;">*</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">&#160;Pursuant to Item 601(b)(10)(iv) of Regulation S-K, portions of this exhibit have been omitted because such portions are both not material and would likely cause competitive harm to the Company if publicly disclosed.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">The Company will supplementally provide a copy of an unredacted copy of this exhibit to the U.S. Securities and Exchange Commission or its staff upon request.</span></div><div style="text-indent:-27pt;padding-left:27pt;"><span><br/></span></div><div style="text-indent:-27pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">**&#160;Furnished herewith.</span></div><div style="padding-left:22.5pt;margin-top:3pt;"><span><br/></span></div><div style="padding-left:22.5pt;margin-top:3pt;"><span><br/></span></div><div style="margin-top:3pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><div id="ia969b45ba09947e9a03ce421f700f5b3_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ia969b45ba09947e9a03ce421f700f5b3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:20.693%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.213%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.094%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: July 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPKO Health, Inc.</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;Adam Logal</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adam Logal</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Senior Vice President and Chief Financial</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officer</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a101viforlicagmtamend.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie855f78c50874d059442d3d515f5d2b9_1"></div><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMENDMENT AGREEMENT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> to Development and License Agreement effective as of 8 May 2016 (&#8220;the Agreement&#8221;) between EirGen Pharma Limited, West Side Business, Old Kilmeaden, Waterford, Ireland (&#8220;OPKO&#8221;) on the one part and Vifor Fresenius Medical Care Renal Pharma Ltd, Rechenstrasse 37, 9014 St. Gallen, Switzerland (&#8220;VF&#8221;) on the other part.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Background</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Parties have now agreed to amend the Agreement with effect as of 5 May 2020 as set out in this Amendment Agreement.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The Parties have agreed to insert a new Section 1.48&#58; &#8220;Middle East&#8221; shall mean Algeria, Bahrain, Egypt, Golan Heights, Iran, Iraq, Iraqi Kurdistan, Israel, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Palestinian territories, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, United Arab Emirates, and Yemen.</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The Parties have agreed to amend Section 1.43 as follows. </font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 1.43 is hereby amended to exclude the following jurisdictions from the Territory&#58; Mexico, South Korea, the Middle East and all countries of Africa (&#8220;Excluded Countries&#8221;).</font></div><div style="text-indent:-2.25pt;padding-left:40.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The Parties have agreed to insert a new Section 2.4&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.4&#160;Territory</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">VF agrees, ***, to promptly transfer to OPKO, if any, all results, analyses, reports, Product data, technology, know-how, regulatory applications or filings, and other information in whatever form developed or generated regarding past and ongoing clinical, development or regulatory activity concerning the Product in the Excluded Countries. </font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The Parties have agreed to delete and replace the existing Section 5.2 with the following new Section 5.2&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Milestone Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">As additional consideration for the rights under the Patents, OPKO Trademarks, and OPKO Technology granted to VF in this Agreement, VF shall pay non-refundable and non-creditable milestone payments to OPKO in the amounts and upon the occurrence of the events set forth below.  Each such payment shall be made within *** Business Days of the achievement or occurrence of the milestone event.  Each milestone payment will be payable only one time.  For purposes of clarity, more than one of the Net Sales and regulatory approval milestones may be met during the same Agreement Year and, in that case, each such milestone would be payable.  For example, if during one Agreement Year there were Net Sales of the Product in the Territory of ***, and it was the first Agreement Year in which Net Sales of the Product in the Territory exceeded ***, *** and ***, then VF would owe all of the ***, the *** and the *** milestone payments and no similar milestone payments would be due in any following Agreement Year if the Net Sales in the Territory exceeded ***. </font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Milestone</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Milestone Payment</font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">First New Drug Approval in *** for the</font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">treatment of secondary hyperparathyroidism in </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** patients with vitamin D insufficiency&#160;***</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">First New Drug Approval in *** for the</font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">treatment of secondary hyperparathyroidism in </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** patients with vitamin D insufficiency&#160;***</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">First New Drug Approval in *** for the</font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">treatment of secondary hyperparathyroidism in </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** patients with vitamin D insufficiency&#160;***</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">First New Drug Approval in *** for the</font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">treatment of secondary hyperparathyroidism in </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** patients with vitamin D insufficiency&#160;***</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">First Commercial Sale in ***.&#160;***</font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8232;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***&#160;***&#59; </font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">and ***, then the milestone owed and payable to OPKO </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">will be equal to that corresponding pro rata percentage *** between *** and *** that is obtained. For example, *** obtained is ***, OPKO shall be entitled to a *** milestone payment of ***.  *** per day. For the avoidance of doubt, OPKO shall be entitled to receive the milestone payments described herein based on *** irrespective of any additional dosage provided in a ***.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div><font><br></font></div></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***&#58;</font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">if *** &#47; Daily Dose&#160;***&#59;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">and ***, then the milestone owed and payable to OPKO </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">will be equal to that corresponding pro rata percentage of the *** that is obtained. For example, if the *** obtained is ***, OPKO shall be entitled to a *** milestone payment of ***.</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***&#58;</font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">if *** &#47; Daily Dose&#160;***&#59; </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">and if the ***, then the milestone owed and payable to OPKO </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">will be equal to that corresponding pro rata percentage *** between *** that is obtained. For example, if the *** obtained is ***, OPKO shall be entitled to a *** milestone payment of ***.  </font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">First time aggregate Net Sales of the Product </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in the Territory exceed ***  </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in an Agreement Year&#160;***</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">First time aggregate Net Sales of the Product </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in the Territory exceed ***  </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in an Agreement Year&#160;***</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">First time aggregate Net Sales of the Product </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in the Territory exceed ***</font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in an Agreement Year&#160;***</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">First time aggregate Net Sales of the Product </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in the Territory exceed ***  in an </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Agreement Year&#160;***</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The Parties have agreed to delete and replace the existing Section 5.4 with the following new Section 5.4&#58;</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">5.4&#160;Minimum Royalty</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Beginning on the first day of the first Calendar Quarter after the Product First Commercial Sale, for the periods set forth in the table below, VF shall be obligated to pay OPKO a minimum royalty (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Minimum Royalty</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">extent the aggregate Royalty Payments due for the applicable period are below the following amounts, ***</font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Minimum Royalty</font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The first *** consecutive Calendar Quarters </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">beginning on the first day of the first Calendar Quarter after the Product First </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Commercial Sale, and each *** consecutive Calendar Quarter </font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">thereafter&#160;***</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:36pt;"><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For purposes of clarity, if the total Royalty Payments due under Section 5.3 with respect to each Minimum Royalty period are greater than the applicable Minimum Royalty for the same period, no Minimum Royalty amount shall be payable by VF with respect to such period.  To the extent that the total Royalty Payments due under Section 5.3 with respect to a period are less than the Minimum Royalty for the same period, VF shall pay OPKO the difference between the total Royalty Payments and the Minimum Royalty.  The calculation for the first period to determine if anything is due under this Section 5.4 is made after *** Calendar Quarters based on the total Royalty Payments due under Section 5.3 with respect to such *** Calendar Quarters when compared to the Minimum Royalty of ***.  Thereafter, the calculation for subsequent periods is made for periods of *** Calendar Quarters each, comparing Royalty Payments due under Section 5.3 with respect to the period to the Minimum Royalty of ***.  The Minimum Royalty obligation under this Section 5.4 shall terminate as of the end of the applicable *** Calendar Quarter period ending immediately prior to the Calendar Quarter in which&#58;  (a) a Competitive Product comes on the market in at least *** Major Countries and there is a Royalty Payment Reduction in *** country or (b) the Royalty Term expires for a Product in at least *** Major Countries.</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The Parties have agreed to delete and replace the existing Section 8.1 with the following new Section 8.1&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">8.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;VF Efforts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Subject to the terms and conditions of this Agreement, VF agrees to use Commercially Reasonable Efforts to (a) commence the regular commercial distribution, use, and sale of the Product in the Field in each Major Country as soon as commercially practicable, and (b) continue diligently thereafter to commercialize, market, promote and sell the Product in the Field in the Territory </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">for each indication for which the Product has received Regulatory Approval in the Territory.</font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** if it is determined, by mutual agreement of VF and OPKO through the JSC, that *** in such country or another country.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Except as expressly amended herein, the Agreement shall remain in full force and effect.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">In Witness Whereof,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> the Parties have caused this Amendment Agreement to be executed by their duly authorised representatives as of the dates listed below.</font></div><div style="text-align:justify;"><font><br></font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.784%;"><tr><td style="width:1.0%;"></td><td style="width:44.572%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.854%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:44.574%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EirGen Pharma, Ltd.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Vifor Fresenius Medical Care Renal Pharma Ltd</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">&#47;s&#47; Steven D. Rubin   </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Print name&#58;    Steven D. Rubin</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Title&#58;   Director</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Date&#58;   May 4, 2020</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">&#47;s&#47; Christoph Springer   </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Print name&#58;   Christoph Springer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Title&#58;   Chief Strategy Officer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Date&#58;   05-May-20</font></div><div><font><br></font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">&#47;s&#47; Adam Logal   </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Print name&#58;    Adam Logal</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Title&#58;   Director</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Date&#58;   May 4, 2020</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">&#47;s&#47; Oliver P. Kronenberg   </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Print name&#58;   Oliver P. Kronenberg</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Title&#58;   Group General Counsel</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Date&#58;   05-May-20</font></div><div><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a102pfizerlicagmtamend.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i39b99448049f4e83bf0c947d9bb4e4b9_1"></div><div style="min-height:126pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">CONFIDENTIAL</font></div><div style="text-align:right;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">EXECUTION VERSION</font></div><div style="text-align:right;margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION LICENSE AGREEMENT</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Amended and Restated Development and Commercialization License Agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is entered into as of May 12, 2020 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment Execution Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and is made effective as of January 1, 2020 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), by and between Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York 10017 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Pfizer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and OPKO Ireland Ltd., an entity organized and existing under the laws of Ireland (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">OPKO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Pfizer and OPKO are referred to herein individually as a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and collectively as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#8221;</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">RECITALS</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, OPKO and Pfizer are parties to that certain Development and Commercialization Agreement, dated December 13, 2014 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Original Execution Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), as amended by those certain letter agreements between OPKO and Pfizer dated as of December 13, 2018 and December 19, 2018 (as amended, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Original Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), whereby, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">inter alia</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, OPKO granted an exclusive license of Licensed Technology owned or otherwise Controlled by OPKO in the Territory to Pfizer (each as defined therein)&#59; and</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, OPKO and Pfizer now wish to amend and restate the Original Agreement in its entirety to make such changes as set forth herein, with the effect that the Original Agreement shall be superseded and replaced in its entirety by this Agreement. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the mutual covenants and agreements provided herein, the Parties hereby agree that the Original Agreement is superseded and replaced in its entirety by this Agreement as of the Amendment Effective Date as follows&#58;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.&#160;DEFINITIONS.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">AAA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 11.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Accounting Standards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means GAAP and International Financial Reporting Standards or other applicable international accounting standard in use, in each case as applicable and consistently applied by the relevant Person.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Additional Pediatric Indication</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.10.3(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:126pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, as of any point in time and for so long as such relationship continues to exist with respect to any Person, any Person that controls, is controlled by or is under</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">2</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_4"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">common control with such Person. A Person shall be regarded as in control of another Person if it (a) owns or controls at least fifty percent (50%) of the equity securities of the subject Person entitled to vote in the election of directors or (b) possesses, directly or indirectly, the power to direct or cause the direction of the management or policies of any such Person (whether through ownership of securities or other ownership interests, by contract or otherwise)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> where an entity owns a majority of the voting power necessary to elect a majority of the board of directors or other governing board of another entity, but is restricted from electing such majority by contract or otherwise, such entity will not be considered to be in control of such other entity until such time as such restrictions are no longer in effect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">AGHD</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">,&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Adult Growth Hormone Deficiency</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means growth hormone deficiency in adult patients, whether as a result of adult onset or childhood onset causes. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in the Preamble. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Amendment Execution Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Applicable Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any law (including common law), statute, rule, regulation, order, judgment, or ordinance of any Governmental Authority, including those concerning environmental, health, and safety matters.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Approved CRO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.11(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Approved Indication</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, with respect to a Licensed Product, a specific human disease or condition for which the treatment or prevention has received Regulatory Approval.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Approved</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Vendor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.11(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Audited Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.8.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Auditing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.8.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Auditing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.7.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.16.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Bankruptcy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Code</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.17.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Bankruptcy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Event</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.18.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Binding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Obligation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, with respect to a Party, (a) any oral or written agreement or arrangement that binds or affects such Party&#8217;s operations or property, including any assignment, license agreement, loan agreement, guaranty, or financing agreement, (b) the provisions of such Party&#8217;s charter, bylaws, or other organizational documents, or (c) any order, writ, injunction, decree, or judgment of any court or Governmental Authority entered against such Party or by which any of such Party&#8217;s operations or property are bound.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.19.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Biosimilar</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means a pharmaceutical product which, with respect to a Licensed Product (a) has been licensed as a biosimilar or interchangeable product by the FDA pursuant to Section 351(k) of the Public Health Service Act (42 U.S.C. &#167; 262(k)), as may be amended, or any subsequent or superseding law, statute or regulation, (b) has been authorized as a similar biological medicinal product in the EU pursuant to Directive 2001&#47;EC&#47;83, as may be amended, or any subsequent or superseding law, statute or regulation, or (c) has otherwise </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">3</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">achieved analogous regulatory approval based upon reference to a Licensed Product from another applicable Regulatory Authority. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.20.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">BLA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means a Biologics License Application for Regulatory Approval filed with the FDA in the United States pursuant to Section 351(a) of the Public Health Service Act (42 U.S.C. 262(a) or any successor statutes or regulations), or any foreign equivalent thereof. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.21.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Brief</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 11.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.22.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Business</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Day</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means a day other than a Saturday, Sunday or bank or other public holiday in New York, New York.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.23.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Calendar</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Quarter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30 and December 31.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.24.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">CDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.18</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.25.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Chairperson</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.26.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical Data Package</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.4.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.27.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical Dataset</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.4.3(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.28.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Investigator</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the principal investigator at each Site.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.29.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Investigator</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Meeting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.2.2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.30.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.2.1(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.31.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Registries</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.3.4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.32.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">CMC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the chemistry, manufacturing and control information required for the submission of a BLA.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.33.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Commercialize</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means all activities required or directed to market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize a pharmaceutical product or device, including activities ***. When used as a noun, &#8220;Commercialization&#8221; means any and all activities involved in Commercializing.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.34.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Commercially</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Reasonable</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Efforts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, with respect to the efforts to be expended by a Party with respect to any objective, subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, those reasonable, good faith efforts and resources to accomplish such objective as such Party and its Affiliates would normally use to accomplish a similar objective under similar circumstances, in each case taking into account all Relevant Factors in effect at the time such efforts are to be expended. With respect to any efforts relating to the Development, Regulatory Approval and&#47;or Commercialization of a Compound or Licensed Product, generally or with respect to any particular country in the Territory, such Party will be deemed to have exercised Commercially Reasonable Efforts if such Party has exercised those efforts normally used by such Party and its Affiliates, in the relevant country, with respect to a compound, product or product candidate Controlled by such Party and&#47;or its Affiliates which is of ***, in each case taking into account all Relevant Factors in effect at the time such efforts are to be expended***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.35.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Compliance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the adherence by the Parties in all material respects to all Applicable Laws, in each case with respect to the activities to be conducted under this Agreement.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">4</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.36.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Compound</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any human growth hormone (hGH) polypeptide ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.37.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Confidential</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.38.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, with respect to any Intellectual Property Right or material (including any Patent Right, Know-How or other data, information or material), the ability (whether by sole, joint or other ownership interest, license or otherwise) to, without violating the terms of any agreement with a Third Party, grant the relevant license or sublicense or provide or provide access or other right in, to or under such Intellectual Property Right or material. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.39.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Cost</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">of Goods Sold</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">COGS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, for Genotropin Products or Licensed Products, as the case may be, as reasonably determined on a *** basis, (a) with respect to product Manufactured by the Party reporting Net Sales, the Manufacturing Cost of such product&#59; (b) with respect to product purchased by the Party reporting Net Sales from the other Party, the Manufacturing Cost of such product&#59; (c) with respect to product purchased by the Party reporting Net Sales from a Third Party, such Party&#8217;s cost of acquisition of such product&#59; and (d) with respect to product Manufactured by the Party reporting Net Sales and sold to a Third Party, the Manufacturing Cost of such product, together in the case of (a), (b), (c) and (d) with other costs incurred by such Party and allocable to such product in accordance with Accounting Standards, including the costs of quality assurance and storage. For clarity, Pfizer agrees to allocate all aforementioned costs on a *** basis consistent with its internal accounting policy, such that *** are only applied as a reduction of Net Sales in that same *** (i.e., *** apply only to Net Sales in the *** and are not applied to reduce the Net Sales in the *** or ***). </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.40.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">CRO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means a contract research organization.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.41.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">CRO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.11(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.42.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">CTA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means a Clinical Trial Application submitted to a Regulatory Authority, the submission and approval of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.43.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">CTP Technology</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any Intellectual Property Rights, compositions, compounds or products including or relating to or directed towards the fusion with or conjugation of a polypeptide to at least one C-terminal peptide (CTP), or fragment thereof sufficient to increase the half-life of the polypeptide.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.44.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Data Management Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.5.2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.45.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Develop</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Developing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means to discover, research or otherwise develop a process, compound, device or product, including conducting non-clinical and clinical research and development activities. When used as a noun, &#8220;Development&#8221; means any and all activities involved in Developing.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.46.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Development Budget</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.47.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.48.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.1(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.49.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Device</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means a proprietary delivery system for subcutaneous delivery of any Compound.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.50.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">DG44 Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 8.4.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">5</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.51.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Diligence Issue</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.10.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.52.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Disclosed Third Party Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 8.3.11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.53.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Disclosing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.54.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">EMA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the European Medicines Agency and any successor agency or authority thereto.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.55.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">EU Regulatory Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the first approval of an MAA for a Licensed Product in the EU.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.56.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the *** as of the Original Execution Date and to the extent *** following the Original Effective Date, ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.57.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means that period beginning on the *** on termination of this Agreement in its entirety or termination of this Agreement for the *** as permitted pursuant to ***. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.58.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">European Union</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">EU</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">E.U.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the member states of the European Union, as may exist from time to time, which as of the Original Execution Date include Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom and all other countries that accede to the European Union during the term of this Agreement. For clarity, ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.59.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Existing Trials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.60.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">FDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the United States Food and Drug Administration and any successor agency or authority thereto.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.61.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Field</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means all human therapeutic uses of human growth hormone (hGH) for long-lasting (not daily) administration.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.62.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Financial Disclosure Form</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.2.1(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.63.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">First Commercial Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, on a Licensed Product-by-Licensed Product and country-by-country basis, the first sale by Pfizer or an Affiliate or permitted sublicensee of Pfizer to a Third Party in such country or for end use or consumption of such Licensed Product in a country, after such Licensed Product has been granted Regulatory Approval (for clarity, including Price Approval) by the appropriate Regulatory Authority(ies) for such country. A First Commercial Sale excludes any sale or other distribution for use in a clinical trial or other Development activity, promotional use (including samples), or for compassionate use or on a named patient basis.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.64.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Force Majeure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.65.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Franchise Gross Profit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means *** applied on a *** basis in the Territory in the applicable calendar year (prorated for any partial calendar year).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.66.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Franchise Net Sales</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means *** in the Territory in the applicable calendar year (prorated for any partial calendar year).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.67.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">GAAP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means United States generally accepted accounting principles, consistently applied.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">6</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.68.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Genotropin</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 1.70</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.69.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Genotropin Divestment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the event upon which *** in which case, any and all ***. For the purposes of this definition, divestment shall include any transaction that ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.70.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Genotropin Products</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the pharmaceutical products listed on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule&#160;1.70</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Genotropin</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) *** in the first *** following the First Commercial Sale of Licensed Product for PGHD.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.71.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Good Clinical Practices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">GCP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means all applicable good clinical practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials, including, as applicable, (a) the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (&#8220;ICH&#8221;) Harmonised Tripartite Guideline for Good Clinical Practice (CPMP&#47;ICH&#47;135&#47;95) and any other guidelines for good clinical practice for clinical trials on medicinal products in the EU&#59; (b) the Declaration of Helsinki (2004), as last amended at the 52nd World Medical Association General Assembly in October 2000, and any further amendments or clarifications thereto&#59; and (c) the equivalent Applicable Laws in any relevant country, each as may be amended and applicable from time to time and, in each case, that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.72.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Government Official</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means (a)&#160;any elected or appointed government official (e.g., a member of a ministry of health), (b)&#160;any employee or Person acting for or on behalf of a government official, Governmental Authority, or other enterprise performing a governmental function, (c)&#160;any political party, candidate for public office, officer, employee, or Person acting for or on behalf of a political party or candidate for public office, and (d)&#160;any employee or Person acting for or on behalf of a public international organization (e.g., the United Nations). For clarity, healthcare providers employed by government-owned hospitals will also be considered Government Officials.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.73.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Governmental Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any court, agency, department, authority or other instrumentality of any national, state, county, city or other political subdivision.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.74.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">HSR Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.75.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">HSR Filing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means filings by OPKO and Pfizer with the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act) with respect to the matters set forth in this Agreement, together with all required documentary attachments thereto.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.76.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">IDMC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.77.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">IDMC Charter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.78.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">IND</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means an Investigational New Drug Application submitted under the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder, or an analogous application or submission with any analogous agency or Regulatory Authority outside of the United States for the purposes of obtaining permission to conduct clinical trials.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.79.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Indemnified Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 10.4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">7</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.80.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Indemnifying Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 10.4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.81.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Informed Consent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.82.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Infringement Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.6.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.83.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Intellectual Property Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means all copyrights, trade secrets, trademarks, moral rights, Patent Rights, Know-How and any and all other intellectual property or proprietary rights now known or hereafter recognized in any jurisdiction.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.84.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Invoicing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.85.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">IRB</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means institutional review board.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.86.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.87.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means that period beginning on the ***, and ending on termination of this Agreement in its entirety or termination of this Agreement for the ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.88.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Japan Regulatory Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the first approval by a PMDA for a Licensed Product in Japan.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.89.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">JDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.90.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Joint Developed IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.1.2(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.91.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any invention, discovery, development, data, information, process, procedure (including training procedures), method, technique, material (including any chemical, biological material or other compositions of matter), technology, result, cell line, compounds, probe, sequence, device or other know-how, but not any Patent Rights.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.92.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Liability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 10.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.93.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">LIBOR</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the rate of interest per annum determined on the basis of the rate for deposits in U.S. Dollars for a period of thirty (30) days as published by the Wall Street Journal. If the thirty (30) day LIBOR has been permanently discontinued, then it will be replaced by a comparable or successor quoting service mutually agreed to by the Parties and the definition of &#8220;LIBOR&#8221; as used herein shall be deemed to be referring to such quoting service.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.94.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Licensed Activities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.5.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.95.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Licensed hGH-Specific Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means those certain Licensed Patent Rights, the claim(s) of which claim, recite, pertain to or are directed to a human growth hormone (hGH) polypeptide ***. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.96.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Licensed Know-How&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">means any</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Know-How that (a) is Controlled by OPKO or any of its Affiliates as of the Original Effective Date or comes into the Control of or is developed by OPKO or any of its Affiliates during the Term (other than through the grant of a license by Pfizer) to the Compound or Licensed Products&#59; and (b) is directed to any Compound or Licensed Product or to the Development, Manufacture, Commercialization or use of any of the foregoing.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:138%;"> </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.97.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Licensed OPKO Core Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means those certain Licensed Patent Rights including (a) at least one claim that claims, recites, encompasses or is directed to a human growth hormone (hGH) polypeptide ***. Without limiting the foregoing, Licensed OPKO Core </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">8</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Patents include the Patent Rights set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 1.98(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> as it may be updated by OPKO from time to time. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.98.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Licensed Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any Patent Right that (a) is owned by OPKO as of the Original Effective Date (including the Patent Rights listed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 1.98</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">) or comes into the Control of OPKO during the Term (other than through the grant of a license by Pfizer) and (b) (i) claims or recites any</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Compound or Licensed Product (including the composition of matter thereof) or Licensed Know-How, (ii) claims a method of making any Compound or Licensed Product, or (iii) claims a method of using any Compound or Licensed Product. For the avoidance of doubt, Licensed Patent Rights shall include ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.99.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Licensed Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any pharmaceutical product containing one or more Compounds. The Licensed Product may be used with or accompanied by a Device.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.100.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Licensed Product CMC Activities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means those activities set forth in the Development Plan under &#8220;CMC Development&#8221; and relating to the Licensed Product.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.101.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Licensed Technology</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means Licensed Patent Rights and Licensed Know-How.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.102.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Litigation Conditions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 10.4.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.103.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">MAA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means Marketing Authorization Application.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.104.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Major EU Country</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any of France, Germany, Italy, Spain or the United Kingdom. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.105.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Major Market Country</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any of ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.106.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Manufacture</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Manufacturing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing on, release, ship or store a compound, device or product or any component thereof. When used as a noun, &#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved in Manufacturing a compound or product or any component thereof.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.107.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Manufacturing Activities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.2(f)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.108.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Manufacturing Cost</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means*** </font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.109.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">MEDDEV Guidelines</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means those guidelines published by the European Commission promoting a common approach by manufacturers and notified bodies involved in the conformity assessment procedures according to the relevant annexes of the Medical Device Directive and other applicable EU directives, and by the competent authorities charged with safeguarding public health.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.110.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Medical Device Directive</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the directive 93&#47;42&#47;EEC, as amended from time to time.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.111.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Monitoring Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.112.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Net Sales</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, with respect to a Genotropin Product or a Licensed Product, gross amounts invoiced for sales by Pfizer and its Affiliates and sublicensees of such Genotropin Product or Licensed Product to Third Parties in the Territory, less in each case (i) bad debts and uncollectable invoiced amounts relating to sales of Licensed Product that are actually written off </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">9</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">in accordance with GAAP, consistently applied throughout Pfizer and its Affiliates, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> any such amounts shall be capped at up to *** of Net Sales per Pfizer Year and any subsequently collected amounts will be included in the current Net Sales or Gross Profit calculation, as the case may be, (ii) sales returns and allowances actually paid, granted or accrued, including trade, quantity and cash discounts and other adjustments, including those granted on account of price adjustments, returns, rebates, chargebacks or similar payments granted or given to wholesalers or other institutions, (iii) adjustments arising from consumer discount programs or other similar programs, (iv) customs or excise duties, valued-added taxes, sales taxes, consumption taxes and other taxes (except income taxes) or duties relating to sales, any payment in respect of sales to the United States government, any state government or any foreign government, or to any other governmental authority, or with respect to any government-subsidized program or managed care organization, each to the extent not already reflected in the amount invoiced, and (v) freight and insurance for the Licensed Product to the extent included in the amount invoiced. Net Sales shall be calculated by Pfizer using a method of value allocation consistent with the method used with Pfizer&#8217;s other collaborations. Net Sales shall be determined from books and records maintained in accordance with the Accounting Standards, as consistently applied by Pfizer with respect to sales of the Genotropin Product or Licensed Product.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.113.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the *** described in ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.114.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">means those activities set forth in the Development Plan under &#8220;CMC Development&#8221; and relating to the ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.115.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">New Trials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.116.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Notice of Dispute</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.13.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.117.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OLE Studies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means all ongoing and completed open label extension studies for the Licensed Product set forth in the Development Plan (as it may be amended from time to time, including amendments for additional open label extension studies), ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.118.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.119.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Developed IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.1.2(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.120.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Indemnified Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 10.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.121.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Prosecuted IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.1(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.122.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Review Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.8.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.123.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Third Party Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any agreement between OPKO (or any of its Affiliates) and any Third Party that could give rise to a Third Party&#8217;s claim on or otherwise relates to OPKO&#8217;s ownership of OPKO&#8217;s right, title or interest in or to any Licensed Technology necessary for the Development, Manufacturing or Commercialization of Licensed Products.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.124.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Original Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">has the meaning set forth in the Recitals.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.125.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Original</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means January 28, 2015. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.126.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Original Execution Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in the Recitals. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.127.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Partial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.5.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.128.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; and &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; have the meaning set forth in the Preamble.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">10</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.129.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Patent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any and all (a) issued patents, (b)&#160;pending patent applications, including all provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon, (c) patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor&#8217;s certificates, (e) other forms of government-issued rights substantially similar to any of the foregoing and (f) United States and foreign counterparts of any of the foregoing.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.130.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means all of the payments made by Pfizer and&#47;or its Affiliates to OPKO and&#47;or its Affiliates pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> of this Agreement, including without limitation the upfront payment, regulatory milestone payments, royalty payments, profit share payments and any adjustments.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.131.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pediatric O&#38;E Study</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means that certain Trial entitled &#8220;A Phase 3, Randomized, Multicenter, Open-Label, Crossover Study Assessing Subject Perception of Treatment Burden with Use of Weekly Growth Hormone (Somatrogon) Versus Daily Growth Hormone (Genotropin</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:138%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">) Injections in Children with Growth Hormone Deficiency,&#8221; as the same may be amended from time to time in accordance with requests, requirements or other instructions received from any applicable Regulatory Authority.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.132.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pending Phase III PGHD Study</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means that certain Trial entitled &#8220;Phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin&#174; - therapy in pre-pubertal children with growth hormone deficiency,&#8221; as the same may be amended from time to time in accordance with requests, requirements or other instructions received from any applicable Regulatory Authority.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.133.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision or department or agency of a government.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.134.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.135.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Developed CTP IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.136.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Developed IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.1.2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.137.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Indemnified Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.138.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Prosecuted IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.139.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Quarter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means each of the four (4) thirteen (13) week periods (a) with respect to the United States, commencing on January 1 of any Pfizer Year and (b) with respect to any country in the Territory other than the United States, commencing on December 1 of any Pfizer Year.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.140.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Review Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.8.2.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.141.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Year</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the twelve (12) month fiscal periods observed by Pfizer (a) commencing on January 1 with respect to the United States and (b) commencing on December 1 with respect to any country in the Territory other than the United States.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">11</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.142.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">PGHD</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">,&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pediatric Growth Hormone Deficiency</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means growth failure in pediatric patients due to an inadequate secretion of endogenous growth hormone. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.143.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pharmacovigilance Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.14.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.144.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Phase III Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means a human clinical trial of a compound or product for an indication on a sufficient number of subjects that is designed to establish that the compound or product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with the compound or product in the dosage range to be prescribed, and to support Regulatory Approval of the compound or product for such indication or label expansion of the compound or product. For clarity, the term &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Phase III Clinical Trials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; includes early access and compassionate use programs.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.145.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Phase IV Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">a human</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> clinical trial conducted after Regulatory Approval of a product, designed either (a) to extend or expand the label of indications for which that product is approved or (b) to obtain additional information regarding the risks, benefits and optimal use of that product.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.146.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">PMDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the Pharmaceuticals and Medical Devices Agency, Japan and any successor agency or authority thereto.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.147.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Post-Amendment Effective Date Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.2(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.148.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, in any country or jurisdiction where a Governmental Authority authorizes reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of *** pricing approval ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.149.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Profit Share Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means one or more of the *** as the context may require.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.150.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">PSGA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">,&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pediatric Short for Gestational Age</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means growth failure in children born small for gestational age who fail to manifest catch-up growth by age two (2) years.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.151.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Quality Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.6.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.152.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Receiving Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.153.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.154.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, as relevant, each or all regulatory, technical, medical and scientific licenses, registrations, authorizations and approvals (including approvals of BLAs, supplements and amendments, pre- and post- approvals and Price Approvals) necessary for offering for sale, marketing and sale of a pharmaceutical product and&#47;or device in a regulatory jurisdiction. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.155.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, with respect to a particular country, ***, or jurisdiction, the Governmental Authority having responsibility for granting a specific Regulatory Approval in such country, ***, or jurisdiction. For clarity, Regulatory Authority shall, as applicable, include any notified body with respect to any Device. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.156.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Exclusivity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Licensed Product in a country, Region, or jurisdiction in the Territory, other than a Patent Right, including orphan drug </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">12</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">exclusivity, pediatric exclusivity, rights conferred in the European Union under Directive 2001&#47;EC&#47;83, or rights similar thereto in other countries or jurisdictions in the Territory.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.157.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, with respect to a Licensed Product for any particular indication in any particular jurisdiction, regulatory applications and submissions (and any supplements or amendments thereto), and any notifications, communications, correspondence, registrations, drug master files, Regulatory Approvals and&#47;or other filings made to, received from or otherwise conducted with a Regulatory Authority, including BLAs and INDs, as applicable, that relate to such Licensed Product in such jurisdiction. Regulatory Materials also include presentations, responses, and applications for Regulatory Approvals.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.158.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Milestone</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.159.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Milestone</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.160.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Relevant</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Factors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means all relevant factors that may affect the Development, Regulatory Approval or Commercialization of a Compound or Licensed Product, including (as applicable)&#58; actual and potential issues of safety, efficacy or stability&#59; product profile ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.161.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.162.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Representatives</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, with respect to a Party, such Party, its Affiliates, its sublicensees and each of their respective officers, directors, employees, consultants, contractors and agents.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.163.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.7(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.164.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Residual</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Knowledge</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means knowledge, techniques, experience and Know-How that (a) are, or are based on, any Confidential Information Controlled by the Disclosing Party and (b) are incidentally and unintentionally retained in the unaided memory of any authorized Representative of the Receiving Party after having access to such Confidential Information. An individual&#8217;s memory will be considered to be incidentally and unintentionally unaided if the individual has not intentionally memorized the Confidential Information for the purpose of retaining and subsequently using or disclosing it. In no event, however, will Residual Knowledge include any knowledge, techniques, experience and Know-How to the extent (at any time, for such time) within the scope of any issued, valid and enforceable patent claim Controlled by the Disclosing Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.165.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Responsible Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.166.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Royalty</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, with respect to any particular Licensed Product in any particular country in the Territory, the period (a) commencing, on a country-by-country and Licensed Product-by-Licensed Product basis, on the First Commercial Sale of such Licensed Product in such country and (b) expiring on the date of the earlier of (x) the *** anniversary of the First Commercial Sale of such Licensed Product in a country, and (y) the commencement of the *** Profit Share Term, *** Profit Share Term ***. For the avoidance of doubt, the Royalty Term for a given Licensed Product in a given country in the Territory, if not previously expired, will expire immediately upon expiration or termination of this Agreement. On a Licensed Product-by-Licensed Product and country-by-country basis, the royalty rates for the Royalty Term *** within such country. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.167.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Safety Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.8.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.168.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">sBLA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.10.3(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">13</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.169.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Site</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.2.1(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.170.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">SOPs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.171.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Specimens</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.172.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Statistical Analysis Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.5.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.173.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Subject</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.174.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Subject Recruitment Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.175.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Supply Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.6.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.176.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.177.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.5.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.178.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Territory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means all countries of the world other than countries in any *** that have been terminated under this Agreement pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. For clarity, Territory includes each of the remaining *** under this Agreement (which until the termination of a ***, includes ***).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.179.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Third</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any Person other than Pfizer, OPKO or their respective Affiliates.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.180.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Third Party Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 10.4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.181.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Third Party Infringement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.182.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trademark</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any trademark, trade name, service mark, service name, brand, domain name, trade dress, logo, slogan or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.183.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Transition</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;2.8.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.184.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Treaty</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;5.7.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.185.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means all clinical trials, including methodology and non-interventional trials, whether initiated prior to or following the Original Execution Date, to be conducted pursuant to the Development Plan.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.186.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trial Database</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.5.3(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.187.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trial Master File</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.188.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">United States</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">U.S.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the United States of America and all its territories and possessions. For clarity, the United States of America includes Puerto Rico.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.189.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Upfront</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.190.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the *** comprised of the ***.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.191.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means that period beginning on the *** and ending on termination of this Agreement in its entirety ***.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">14</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.192.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">U.S. Regulatory Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the first achievement of Regulatory Approval of a BLA for a Licensed Product for an Approved Indication.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.193.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Valid Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, with respect to a particular country, a claim of a Licensed Patent Right that&#58; (a) is (i) issued or, (ii) as to a claim in a pending patent application which claim was filed in good faith, has been pending for a period of *** years or fewer from its first office action&#59; (b) has not been held permanently revoked, unenforceable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal&#59; and (c) has not expired or been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. For clarity, any pending claim in an application in any country that has not been granted within *** years from its first office action shall not be included as a Valid Claim until such claim is granted and the provisions of (b) and (c) above are satisfied. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.194.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">VAT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.7.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.195.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Vendor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means any Third Party with whom a Party may contract for the procurement of services, equipment, tools, materials and&#47;or supplies.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.196.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Vendor Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.11(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.197.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Vendor Oversight Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">1.198.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Interpretation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Except where the context expressly requires otherwise, (a)&#160;the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&#160;the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;, (c)&#160;the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;, (d)&#160;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any Person shall be construed to include the Person&#8217;s successors and assigns, (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) the word &#8220;days&#8221; shall mean calendar days, (h) all references herein to Articles, Sections, Exhibits or Schedules shall be construed to refer to Articles, Sections, Exhibits or Schedules of this Agreement, and references to this Agreement include all Exhibits and Schedules hereto, (i) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (j) provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (k) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (l) the term &#8220;or&#8221; shall be interpreted in the inclusive sense commonly associated with the term &#8220;and&#47;or&#8221; unless the context dictates otherwise because the subjects of the conjunction are mutually exclusive. </font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">LICENSES.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Exclusive License Grant</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to the terms of this Agreement, including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, as of the Original Effective Date, OPKO hereby grants to Pfizer an </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">15</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">exclusive royalty-bearing license (even as to OPKO and its Affiliates) under the Licensed Technology to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, and have Commercialized Compounds and Licensed Products in the Territory. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Non-Exclusive Grant-Back License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to the terms of this Agreement, as of the Original Effective Date, Pfizer hereby grants to OPKO and its Affiliates a fully-paid non-exclusive sublicense, with the right to sublicense, under the Licensed Technology and Pfizer&#8217;s rights in any Pfizer Developed IP to Develop and have Developed Compounds and Licensed Products (including any Device used with or that accompanies Licensed Products) in the Territory, solely to the extent necessary for performance by OPKO of its obligations pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 2.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Articles 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> of this Agreement. The foregoing sublicense is further sublicenseable to the extent useful or reasonably necessary for OPKO to fulfill its obligations hereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Sublicenses for Pfizer Development and Commercialization. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.3.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Pfizer may not sublicense the rights granted under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> in whole or in part without the prior written consent of OPKO&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> Pfizer may, subject to the requirements of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, without the prior written consent of OPKO&#58; </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">***</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">***</font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">In the event that Pfizer or its Affiliates need to grant a sublicense reasonably required for Pfizer to perform its obligations under this Agreement in connection with the Development, Manufacture and Commercialization of Licensed Products throughout the Territory, and the sublicense is not specifically permitted under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Sections 2.3.1(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">2.3.1(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, then OPKO agrees to not unreasonably withhold its consent to such sublicense. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.3.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">With respect to a permitted sublicense, (i) the relevant Third Party sublicensee(s) must be reasonably capable of assisting Pfizer in exploiting the market opportunity in the Territory for the Licensed Product based on the Development planned for the Licensed Product at the time of sublicense and must agree in writing to assume Pfizer&#8217;s obligations with respect to the Licensed Product hereunder, (ii) Pfizer shall provide OPKO not less than *** days&#8217; prior written notice of such sublicense and shall promptly respond to any reasonable inquiries by OPKO with respect thereto, and (iii) Pfizer shall provide to OPKO no fewer than *** days after execution a copy of each such sublicense, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> Pfizer may redact confidential information from such sublicense agreement that is not reasonably necessary to demonstrate Pfizer&#8217;s compliance with the obligations set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Notwithstanding anything to the contrary, the prior written consent of OPKO shall be required for sublicenses to any Third Party that includes a right of Commercialization of any or all of the Major Market Countries.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.3.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Pfizer shall remain fully responsible to OPKO for the performance of all such permitted sublicensees, including if it has delegated Development, Manufacturing or Commercialization activities to, or otherwise contracted with, a Third Party Manufacturer, as if Pfizer had not so delegated and&#47;or contracted with respect to such responsibilities. Sublicensees shall not have a right to further sublicense other than to their Affiliates.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Pfizer shall not have any rights to grant any sublicenses under the Licensed Technology except as otherwise granted in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">16</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Licenses to Pfizer Developed IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. To the extent any of the Pfizer Developed IP relates to or is directed to CTP Technology or any derivatives, variants or improvements thereof (such Intellectual Property Rights, collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Developed CTP IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) and is useful outside of its use in connection with the Licensed Products, then upon the request of OPKO and subject to the terms and conditions of this Agreement, Pfizer and OPKO shall negotiate in good faith to seek to agree upon commercially reasonable terms for an exclusive or non-exclusive (at the option of OPKO) licensing arrangement with respect to such Pfizer Developed CTP IP&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> neither Party will have any obligation to enter into any such licensing arrangement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Direct Licenses to Affiliates</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer may, from time to time, request that OPKO grant licenses directly to Affiliates of Pfizer by giving written notice, upon receipt of which OPKO agrees to enter into and sign a separate direct license agreement with such designated Affiliate of Pfizer. All such direct license agreements shall be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by Applicable Laws in the country in which the direct license will be exercised. The Parties further agree to make such amendments to this Agreement that are necessary to conform the combined terms of such direct licenses and this Agreement to the terms of this Agreement. All costs of making such direct license agreement(s), including OPKO&#8217;s reasonable attorneys&#8217; fees, under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall be borne by Pfizer.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Right of Reference</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO hereby grants to Pfizer a &#8220;Right of Reference,&#8221; as that term is defined in 21 C.F.R. &#167; 314.3(b) (or any analogous Applicable Law recognized outside of the United States), to all data Controlled by OPKO or its Affiliates that relates to any Compound or Licensed Product, and OPKO shall provide a signed statement to this effect, if requested by Pfizer, in accordance with 21 C.F.R. &#167; 314.50(g)(3) (or any analogous Applicable Law recognized outside of the United States).</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:138%;"> </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">No Implied Rights&#59; Retained Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Except as expressly provided in this Agreement, neither Party shall be deemed to have granted the other Party (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any Intellectual Property Rights or information Controlled by such Party. For the avoidance of doubt, OPKO retains the right to use the Licensed Technology in order to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, and have Commercialized products other than Licensed Products, on its own or with any other party throughout the world, and to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized products incorporating the CTP Technology in connection with any polypeptide or other compound which is not a Compound. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Transfer Activities.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.8.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Transition Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO shall cooperate with and provide timely assistance to Pfizer to ensure the smooth transition and to facilitate the transfer of the Licensed Technology to Pfizer, including taking the actions specified in a transition plan to be agreed by the Parties (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Transition Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). If there is an inconsistency between the Transition Plan and this Agreement, the terms of this Agreement shall prevail.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.8.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Initial Disclosure and Knowledge Transfer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. As soon as reasonably possible, *** after the Original Effective Date, OPKO shall *** transfer to Pfizer true, accurate and complete copies of all Licensed Know-How and material documentation related to Licensed Patent Rights, in each case to the extent developed by OPKO on or prior to the Original Effective Date, by download of digital files to a secure website or e-room designated and controlled by Pfizer. To the extent that any material Licensed Know-How *** as of the Original Effective Date, OPKO shall have *** such Licensed </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">17</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Know-How in a reasonably organized and complete form, and *** to Pfizer. Such Licensed Know-How shall include information to assist Pfizer to develop processes and procedures, including training, to Manufacture the ***.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">2.8.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Continuing Disclosure and Knowledge Transfer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. On a ***, or more frequently at the reasonable request of a Party during the Term, each Party shall provide the JDC a written summary of all Know-How and Patent Rights that it develops to the extent such Know-How and&#47;or Patent Rights are or are to be licensed or assigned to the other Party. During the Term, each Party shall make appropriate personnel available to the other Party at reasonable times and places and upon reasonable prior notice for the purpose of assisting the other Party to understand and use such Know-How and Patent Rights.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">DEVELOPMENT AND COMMERCIALIZATION.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Development.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Generally</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to the terms and conditions of this Agreement, each of OPKO and Pfizer shall Develop Licensed Products in accordance with the amended and restated development plan attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (as the same may be further amended from time to time in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). The Development Plan, which is effective as of the Amendment Effective Date, replaces, in its entirety, the former Development Plan attached to the Agreement at the Original Execution Date, as such Development Plan may have been amended prior to the Amendment Effective Date. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Development Activities for PGHD</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The Parties acknowledge and agree that, as further set forth in the Development Plan and to the extent relating to the Development of Licensed Products for PGHD, OPKO will be responsible for conducting all activities, including all clinical and associated regulatory activities, as set forth in the Development Plan, subject to oversight by the JDC&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, notwithstanding the foregoing, Pfizer will be responsible for (i)&#160;conducting ***, as set forth in the Development Plan, (ii)&#160;conducting the CMC Activities, including the Licensed Product CMC Activities and ***, as set forth in the Development Plan, (iii)&#160;supplying Licensed Product and Genotropin to OPKO for use in connection with OPKO conducting its activities under the Development Plan, as may be set forth in the Supply Agreement and the Quality Agreement and (iv)&#160;preparing, seeking, submitting and maintaining all regulatory filings for the BLA and all subsequent supplemental filings and Regulatory Approvals for all Compounds and Licensed Products as further set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Further, notwithstanding any provision of this Agreement to the contrary, (A) *** over (1) all regulatory submissions and decisions in connection with any Trial for which it is serving as regulatory sponsor in accordance with the Development Plan, and (2) all regulatory submissions and decisions for the BLA and all subsequent supplemental filings and Regulatory Approvals for all Compounds and Licensed Products in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, and (B) *** shall have sole control over all regulatory submissions and decisions in connection with any Trial for which it is serving as regulatory sponsor in accordance with the Development Plan.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">18</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Allocation of Costs and Expenses for PGHD. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">As between the Parties, the following costs for the Development of Licensed Products for PGHD shall be allocated as follows&#58; </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Pre-Amendment Effective Date Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Subject to the remainder of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer and OPKO hereby acknowledge that, as of the Amendment Execution Date, Pfizer has invoiced OPKO for all costs and expenses incurred by Pfizer prior to the Amendment Effective Date with respect to the Development of Licensed Products under the Development Plan for which OPKO is responsible and OPKO has paid for all such costs and expenses.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Post-Amendment Effective Date Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to the remainder of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, with respect to the period of time occurring after the Amendment Effective Date (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Post-Amendment Effective Date Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), the Parties shall equally share all costs (including costs incurred by Pfizer in conducting the Manufacturing Activities as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.2(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">) of Developing a Licensed Product for PGHD in accordance with the Development Plan&#59;</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Post-Marketing Commitments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to the remainder of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, following the Post-Amendment Effective Date Period, the Parties shall equally share all costs of conducting any *** for a Licensed Product for PGHD ***&#59; </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Notwithstanding any provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> to the contrary, the Parties shall equally share all costs of *** in accordance with the Development Plan, including all costs of the ***&#59;</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The Parties shall equally share all costs associated with conducting the *** in accordance with the Development Plan&#59; </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Manufacturing Activities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Division of Manufacturing Activity Costs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. With respect to Developing a Licensed Product for PGHD in accordance with the Development Plan, all costs incurred by Pfizer during the Post-Amendment Effective Date Period in connection with Pfizer (A)&#160;*** for use by OPKO in connection with conducting its activities under the Development Plan and (B)&#160;*** ((A) and (B) collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Manufacturing Activities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), shall be equally shared by the Parties. </font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Calculation of Manufacturing Activity Costs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer shall calculate its costs incurred in conducting the Manufacturing Activities as follows (A) Licensed Products will be supplied by Pfizer in connection with the Development Plan and Development Budget *** and (B) the Licensed Product CMC Activities shall be provided at ***&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> in no event shall OPKO be obligated to *** for such activities.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Costs to be Reimbursed to Pfizer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The Parties shall equally share all costs incurred by Pfizer in connection with ***.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Allocation of Costs and Expenses for AGHD. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">As more fully set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.10.3(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the Parties *** in preparing and submitting a sBLA for a Licensed </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">19</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Product for AGHD in the United States&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, *** (which ***) for inclusion in such submission. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Allocation of Costs and Expenses for Additional Pediatric Indication. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">As more fully set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.10.3(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, if the JDC approves an amended Development Plan and corresponding amended Development Budget for the Additional Pediatric Indication, then the costs of Developing such Licensed Product for the Additional Pediatric Indication shall be shared equally by the Parties.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Estimated Budget.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> The amended and restated budget attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> sets forth the cost anticipated to be incurred in connection with the implementation of the Development Plan (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Development Budget</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), and replaces, in its entirety, the former Development Budget attached to the Agreement at the Original Execution Date, as such Development Budget may have been amended prior to the Amendment Effective Date. The Parties acknowledge and agree that (a) ***  and (b) the Development Budget *** under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, except as expressly set forth therein. The Parties shall update the Development Budget as necessary based on any amendments to the Development Plan approved by the JDC pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Invoicing and Payments.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Invoicing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. No later than *** after the end of each Calendar Quarter during which a Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Invoicing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) has incurred any costs that are the responsibility of the other Party under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or, to the extent applicable, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Responsible Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), the Invoicing Party shall submit to the Responsible Party an invoice setting forth the amounts (or the portion of such amounts, as applicable) for which the Responsible Party is responsible. Each invoice shall be accompanied with reasonable supporting explanation for such invoiced amounts. The Responsible Party shall pay all undisputed amounts invoiced within *** of receipt of such invoice. Any adjustments with respect to any previously submitted invoice by the Invoicing Party shall be reflected in the next such invoice delivered by the Invoicing Party to the Responsible Party, such adjustments to be made in a manner consistent with the internal accounting policies of the Invoicing Party. At the end of each Calendar Quarter, or as otherwise agreed by the JDC, each Party shall submit to the JDC a report setting forth the status of the costs and expenses incurred by the Party in respect of its activities under the Development Plan in comparison to the related budget for such activities as set forth in the Development Budget. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Invoice Disputes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If a Party reasonably and in good faith disputes any invoice (or portion thereof) submitted by the other Party, then the disputing Party shall notify the Invoicing Party in writing of such dispute within *** of the disputing Party&#8217;s receipt of the relevant invoice and the disputing Party shall only be obligated to pay to the Invoicing Party the undisputed portion of such invoice. A written notice of dispute may also include a request for any additional information or supporting documentation that the disputing Party reasonably and in good faith believes is necessary to determine whether it is responsible for the invoiced amounts. The Invoicing Party shall reasonably and in good faith respond to such request in writing within *** of receipt thereof with the requested information and documentation or an explanation as to why such requested information and documentation is not available. The Parties shall resolve such payment dispute in accordance with the dispute resolution provisions set forth in </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">20</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Sections 11.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">11.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If, following final resolution of such dispute, it is determined that the disputed amounts were properly owed to the Invoicing Party, then the disputing Party shall pay such disputed amounts (plus interest calculated pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.6(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">) to the invoicing Party within *** of final resolution of such dispute. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Interest</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. With respect to amounts due under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> that are not paid when due, such amounts shall accrue interest (i) if such amount is *** past due, at a rate equal to the thirty (30) day U.S. Dollar *** and (ii) if such amount is more than *** past due, at a rate equal to the thirty (30) day U.S. Dollar ***.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Payment ***.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Funding of ***&#59; Withdrawals</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to the balance of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, if, *** (or portion thereof) delivered by Pfizer in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, then upon the written request of Pfizer, ***. If OPKO fails to pay Pfizer for any undisputed invoice (or portion thereof) within *** days of OPKO&#8217;s receipt of such invoice as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, then (i) (A) if the *** Pfizer may upon written notice to OPKO *** which amount shall bear interest in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.6(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> through the date *** and (B) following any *** and receipt of written notice from Pfizer of such ***, then, consistent with the first sentence of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.7(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the *** to Pfizer and, *** Pfizer&#8217;s and OPKO&#8217;s rights and responsibilities with respect to *** and payment shall be as set forth in subclause (i) hereof. Upon Pfizer&#8217;s receipt of any payment from *** for amounts *** pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.7(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer shall ***.   </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Remittance of ***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Within sixty (60) days following ***, if any.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Changes to the Development Plan. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">During the Term, any changes or other amendments to the Development Plan (excluding any country-specific appendices required by Applicable Laws or any changes made in response to any communications with any Regulatory Authorities that require a submission to a Regulatory Authority, an IRB or other ethics committee, each of which shall be added to and implemented in the Development Plan in accordance with Applicable Law or instructions from Regulatory Authorities, as applicable) shall require the JDC&#8217;s approval, subject to the tie-breaking provisions and limitations on tie-breaking authority set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If the JDC agrees to change or otherwise amend the Development Plan so that a Party shall perform new Development or Manufacturing activities, then the Parties shall meet and discuss, in good faith, an appropriate allocation of costs with respect to such activities and shall amend the Development Budget to reflect the agreed to allocation of costs.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Approvals Under the Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party will be responsible for obtaining all necessary Regulatory Approvals or other approvals as may be required for the implementation of those parts of the Development Plan allocated to them as their responsibility (including as required by Applicable Law) prior to commencing any Trial, and each Party will reasonably cooperate with the other Party in such regard.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Sponsor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Sponsorship and Responsibilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. During the Term for the Development of the Licensed Product for PGHD, OPKO will be the regulatory </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">21</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">sponsor of a Trial in all countries in the Territory where any Trial is conducted as specified in the Development Plan, except (i) to the extent that the JDC has determined that Pfizer should be the regulatory sponsor or (ii) with respect to the *** in which case Pfizer will be such regulatory sponsor, and except as otherwise provided herein, OPKO (or Pfizer where relevant) will have all responsibilities of such regulatory sponsor as specified under Applicable Laws and OPKO and Pfizer will have such other responsibilities as are described in the Development Plan.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Compliance with the Development Plan and Applicable Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. During the Term, OPKO shall use Commercially Reasonable Efforts to perform its obligations under the Development Plan and this Agreement in compliance with all Applicable Laws and obligations imposed by any Regulatory Authorities (including GCP) and the terms of this Agreement. During the Term, Pfizer shall use Commercially Reasonable Efforts to perform its obligations under this Agreement in compliance with all Applicable Laws and obligations imposed by any Regulatory Authorities (including GCP) and the terms of this Agreement.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Approved CROs and Approved Vendors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Approved CROs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Except as otherwise provided herein, OPKO may delegate any of its responsibilities described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> to one (1) or more CROs determined by the JDC (an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Approved CRO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) pursuant to a written agreement between OPKO and such Approved CRO (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">CRO Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). Each CRO Agreement will enable OPKO to comply with the terms hereof, including, but not limited to, in respect of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.10(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the terms pertaining to ownership of intellectual property and publications and treatment of Confidential Information.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Approved Vendors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Except as otherwise provided herein, OPKO will be permitted to contract with one or more Vendors determined by the JDC (an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Approved Vendor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) pursuant to a written agreement between OPKO and such Approved Vendor (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Vendor Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). Each Vendor Agreement will enable OPKO to comply with the terms hereof, including, but not limited to, in respect of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.10(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the terms pertaining to ownership of intellectual property and publications and treatment of Confidential Information.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Responsibility</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. For clarity, OPKO will remain responsible for all its obligations under this Agreement, including if it has delegated such to an Approved CRO and&#47;or contracted with an Approved Vendor (except to the extent any Vendor Agreement has been assigned to Pfizer or a Third Party designee of Pfizer), as if OPKO had not so delegated and&#47;or contracted with respect to such responsibilities.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Applicability to Pfizer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The terms of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall also apply to Pfizer in circumstances where Pfizer is a regulatory sponsor of a Trial, ***.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Reporting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. During the conduct of the Development Plan, at JDC meetings and as otherwise requested by a Party, each Party shall provide the other Party with updates in writing with respect to its progress under the Development Plan. Each such update shall include a summary of activities under the Development Plan performed by the reporting Party since the previous JDC meeting or request, including (as applicable) a </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">22</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">summary of&#58; results, information, and data generated, activities planned with respect to Development going forward (including updates regarding regulatory matters and current and future Development or regulatory plans and activities), challenges anticipated, timeline adjustments, budget updates required by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and updates regarding intellectual property issues relating to any Compound or Licensed Product.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.1.13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Retained Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Except for Development activities for which OPKO is responsible under the Development Plan or as otherwise expressly set forth in the Development Plan, Pfizer shall have sole authority over and control of the Development of Compounds and Licensed Product. *** acting in good faith, ***, then Pfizer shall have the right to provide OPKO with written notice thereof, including an explanation of the basis for Pfizer&#8217;s belief. If OPKO, acting in good faith, reasonably disputes the contents of Pfizer&#8217;s notice, OPKO shall have the right to deliver to Pfizer a Notice of Dispute within thirty (30) days after Pfizer&#8217;s written notice. Upon Pfizer&#8217;s receipt of such Notice of Dispute, the Parties shall comply with the dispute resolution provisions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Sections 11.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">11.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> ***. If (i) *** (ii) OPKO does not deliver to Pfizer a Notice of Dispute within thirty (30) days after receipt of Pfizer&#8217;s written notice or (iii) the dispute resolution process results in the confirmation *** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> OPKO *** in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Governance of Development Activities&#59; Notifications to the JDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.2.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Joint Development Committee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The Parties hereby establish a joint development committee (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">JDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) to oversee and coordinate the overall conduct and progress of the activities set forth in the Development Plan. The JDC will continue to operate during the term of the Development Plan and ***. The JDC shall provide a forum for sharing the activities conducted, progress against timelines and results achieved under the Development Plan. Each Party, through its representatives on the JDC, shall be permitted to provide advice and commentary with respect to activities performed pursuant to the Development Plan. The JDC may establish other committees, including a joint manufacturing committee to oversee activities. Each Party shall take such advice and commentary into good faith consideration. More specifically, the JDC shall, subject to the provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.1.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#58;</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">oversee, review and coordinate activities and budgets pursuant to the Development Plan, CMC and supply activities for clinical supply and related regulatory strategy, including (i) discussing and making suggestions in response to any notifications described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and (ii) discussing the reports submitted by each Party to the JDC in accordance with this Agreement and otherwise monitoring the costs incurred by each Party in the conduct of their respective activities under the Development Plan&#59; </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">review and approve amendments and modifications to the Development Plan as contemplated herein&#59; </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">exchange and review Development, regulatory, Manufacturing and Commercialization updates and information, as well as disclosures of developed intellectual property&#59; and </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">perform, or delegate to a Party (in the JDC&#8217;s discretion), such other duties as are specifically assigned to the JDC under this Agreement.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">23</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.2.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Membership</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The JDC shall be composed of *** employees from each of Pfizer and OPKO (or such other equal number as the Parties may agree) ***. The JDC shall have at least one (1) representative from each Party with relevant decision-making authority, such that the JDC is able to effectuate decisions within the scope of its authority. Any member of the JDC may designate a substitute to attend JDC meetings upon prior written notice to the other Party. The chairperson of the JDC shall be an employee of Pfizer (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Chairperson</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). The Chairperson will be responsible for arranging meetings of the JDC, setting the agenda for such meetings and organizing and overseeing such meetings. Ad hoc guests who are subject to written confidentiality obligations commensurate in scope to the provisions in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> may be invited to the JDC meetings, as mutually agreed, so long as the number of guests is reasonable and does not disrupt or delay JDC activities. Each Party may replace its JDC members with other of its employees, at any time, upon written notice to the other Party. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.2.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Meetings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. During the performance of the Development Plan pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the JDC shall meet, in person (at a location mutually agreeable to the Parties), by teleconference, or by video-teleconference, at least one (1) time per ***.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.2.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Notifications to be Provided to the JDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Trial Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. With regard to both New Trials and Existing Trials, OPKO shall *** summarize for the JDC for its review and input, including status and any issues related to (i) standard operating procedures, (ii) clinical sites and investigators, (iii) a subject recruitment plan, (iv)&#160;the investigator&#8217;s brochure, (v) case report forms and a data management plan (and compliance therewith), (vi) an auditing plan, (vii) a monitoring plan (and compliance therewith), (viii) IND and CTA submissions and approvals, (ix)&#160;IRB approvals, and (x) reporting mechanisms. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Unusual or Unforeseen Events</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party will promptly notify the JDC of any unforeseen or unusual events that occur in connection with the implementation of the Development Plan, including any events that may affect any of the timelines set forth therein or that may have a material impact on the success of any BLA submissions hereunder by Pfizer.</font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Urgent Safety Measures or Serious Breaches</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If either Party becomes aware of (a)&#160;any urgent safety measures taken by a Clinical Investigator to protect Subjects against any immediate hazard or (b)&#160;any serious breaches of the Development Plan or any Applicable Laws (including GCP guidelines), such Party will immediately inform the JDC.</font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Regulatory Inspections</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party will promptly notify the JDC within *** of any inspection by any Governmental Authority, including any Regulatory Authority, in connection with Manufacture or any Trial. Each Party will promptly forward to the JDC copies of any inspection findings relating to Licensed Product or this Agreement that a Site receives from any Regulatory Authority and each Party will have a right to comment on any proposed responses related to such inspections to be made to any Governmental Authorities before such responses are made. </font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Government Investigations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party will promptly notify the JDC upon learning of any investigations by any Governmental Authority involving any Third Party conducting activities with respect to </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">24</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">the Development Plan, including any Approved CRO or Approved Vendor.</font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Notification of Error</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If either Party learns of an error or omission in the conduct of the activities under the Development Plan that could call into question the validity, or otherwise compromise the quality and&#47;or integrity, of part or all of any of such activities, or other activities conducted in connection therewith, such Party will inform the JDC in writing within *** hours of such Party learning of such error and&#47;or omission. The members of the JDC will discuss in good faith a remediation plan to address such error within *** days of such written notification. Such remediation plan will not be effective unless and until approved by the JDC in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If the JDC approves such remediation plan, the JDC will provide the responsible Party with written notice thereof, specifying the dates on which, and the detail with which, such responsible Party will be required to update the JDC of its progress with respect thereto.</font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(v)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Compliance with Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. With respect to each of the foregoing </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Sections 3.2.4(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">-</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the Party responsible for notifying the JDC will notify the Person to whom notice is required to comply with all Applicable Laws.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.2.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Decision-Making&#59; Limitations on JDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">General</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Decisions of the JDC shall be made by consensus, with the representatives of each Party having collectively one (1) vote in all decisions. Notwithstanding the creation of the JDC, each Party shall retain the rights, powers and discretion granted to it hereunder, and the JDC shall have only such rights, powers and discretion as are specifically assigned to it in this Agreement, and such rights, powers and discretion shall be subject to the terms and conditions set forth herein. Without limiting the generality of the foregoing, the JDC shall have no power to amend, modify or waive compliance with this Agreement, or take any action which, under the terms of this Agreement, requires the consent or agreement of either or both of the Parties, without having received such consent or agreement. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Final Decision-Making Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In the event that the JDC is unable to reach a consensus decision on a matter that is within its decision-making authority within *** Business Days after it has met and used its best efforts to reach consensus with respect to such decision then, except as expressly provided to the contrary in this Agreement, including in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Sections 3.1.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">3.10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, such decision shall be made by the representatives of Pfizer unilaterally, and provided that Pfizer shall not have power to unilaterally resolve a dispute&#58; ***. For all purposes under this Agreement, any decision made pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall be deemed to be the decision of the JDC.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Except as contemplated by the Development Plan or pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer shall have the sole authority over and control of all regulatory plans and strategies in respect of Compounds and Licensed Products and will own, have sole authority for, and be responsible for preparing, seeking, submitting and maintaining all regulatory filings for the BLA and all subsequent supplemental filings and Regulatory Approvals for all Compounds and Licensed Products, including preparing all reports necessary as part of a </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">25</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">regulatory filing, Regulatory Approval or Regulatory Exclusivity. To the extent requested by Pfizer from time to time, OPKO shall cooperate with Pfizer and take such reasonable actions to assist Pfizer in making regulatory filings and seeking and maintaining Regulatory Approval and Regulatory Exclusivity. With respect to regulatory activities of OPKO contemplated by the Development Plan&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.3.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Communications with Regulatory Authorities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. With respect to Trials conducted by OPKO, OPKO shall promptly provide Pfizer access to a copy of any written communication received by OPKO or its representatives from any Regulatory Authority with respect to any Compound or Licensed Product. OPKO will have primary responsibility to respond to such communications&#59; however, if any planned written responses or meetings with Regulatory Authorities relates to information that may affect any of the timelines set forth in the Development Plan or that may have a material impact on the success of any BLA submission by Pfizer, then OPKO shall also notify Pfizer in advance of all such responses or meetings with the Regulatory Authorities, whether in person or by telephone or videoconference and Pfizer shall be entitled to attend and, if appropriate and permitted under Applicable Law, participate in all such meetings with Regulatory Authorities, whether in person or by means of telecommunication&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> where such communications concern the CMC Information, Pfizer will have primary responsibility to prepare responses to such communications as described further in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. During the preparation and submission of BLAs, to the extent practical, and provided that Pfizer will not be required to incur a substantive delay, OPKO shall be provided with prior notice as reasonably practicable of all proposed communications and meetings by Pfizer with Regulatory Authorities and afforded the opportunity to promptly comment on such communications (and Pfizer shall reasonably take into account such comments) and attend such meetings (unless the Parties shall reasonably determine that such participation would decrease the likelihood of obtaining any requisite Regulatory Approval)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> notwithstanding anything set forth above, Pfizer will have the sole decision making authority and responsibility with respect to any such communications and meetings with Regulatory Authorities. During the preparation and submission of BLAs, OPKO will provide reasonable support in the preparation of the relevant sections related to OPKO&#8217;s clinical activities (including Modules 1 and 2) and provide support to the rapid response team for queries. Each Party will promptly provide the JDC with access to copies of all regulatory communications and, in circumstances during the Trials conducted by OPKO where such communications require a response that pertains to the CMC Information, OPKO will provide Pfizer with a copy of such communication promptly (and in no event more than *** Business Days) following receipt thereof so that, after having considered any OPKO comments thereto, at Pfizer&#8217;s discretion, Pfizer can provide OPKO with the relevant response, which OPKO will submit to the applicable Regulatory Authority in whole without any changes, additions or deletions, except with respect to translations to local language required by Applicable Law or with Pfizer&#8217;s consent, not to be unreasonably withheld. For clarity, during preparation and submission of the BLAs, if Pfizer receives any correspondence from any Regulatory Authorities, including that relates to the CMC Information, Pfizer will provide OPKO a full and complete copy, of such communication.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.3.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Approval of Regulatory Filings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. During the Trial activities set out in the Development Plan (other than Trial activities with respect to the ***), OPKO will be the sponsor of all INDs and CTAs and will have responsibility to submit any report or filing to any Regulatory Authority under such IND or CTA. However, if any such report or filing includes any information that may affect any of the timelines set forth in the Development Plan or that may have a material impact on the success of any BLA </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">26</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">submissions by Pfizer, OPKO shall provide the JDC with a copy of all such reports or filings prior to its intended date of submission and the JDC shall have the right to review, modify and approve all such reports or filings. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.3.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">INDs and CTAs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.3.4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> below, OPKO will be responsible for preparing, submitting and maintaining the INDs and CTAs required by Applicable Law to conduct each Trial *** and Pfizer will reasonably cooperate with OPKO in such regard. OPKO will maintain any INDs and CTAs prepared and submitted in connection with the Trial during the Term until transferred to Pfizer, pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">In all countries where the Sites are located, Pfizer will prepare and provide to OPKO the CMC information required for all INDs and CTAs and any updates to this information after having considered any OPKO comments thereto. OPKO will submit the CMC information to the Regulatory Authorities as provided by Pfizer without any modification thereto, except with respect to translations to the local language as required by Applicable Law.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.3.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical Trial Registries</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, from and after the Original Effective Date, OPKO will be responsible, in consultation with Pfizer, for registering, maintaining and updating any registries pertaining to any Trial *** to the extent required by any Applicable Laws, including without limiting the foregoing, www.clinicaltrials.gov, www.clinicalstudyresults.org, and EUDRACT (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical Trial Registries</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) in all countries in the Territory.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">For clarity, OPKO will ensure that the information on all Clinical Trial Registries is correct, consistent and in compliance with Applicable Law.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.3.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">IND</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, OPKO will be responsible for opening and maintaining the IND and subsequent amendments for Trials *** set out in the Development Plan.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.3.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory Exclusivity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer shall use Commercially Reasonable Efforts to obtain all applicable Regulatory Approvals and Regulatory Exclusivities in each Major Market Country.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Cooperation by the Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.4.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Generally.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Each Party will, upon request, cooperate with and assist the other Party in preparing and maintaining any INDs, CTAs and BLAs for the Licensed Product, and any other submissions and&#47;or communications with the Regulatory Authorities. Such cooperation will extend to consultation by telephone or at the cooperating Party&#8217;s normal business location and the provision of information Controlled by a Party, but will not include submissions to any Regulatory Authority for the other Party. Notwithstanding anything to the contrary herein, each Party will provide the other Party with reasonable advance notice of any assistance that it needs in connection with such submissions.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">27</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">For clarity, upon Pfizer&#8217;s request, OPKO will participate in any meetings with any Regulatory Authorities in connection with any BLA for the Licensed Product. In addition, at scheduled time intervals specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, OPKO will provide Pfizer with copies of and access to the Clinical Data Package or portions thereof for use by Pfizer in connection with preparing and maintaining BLAs for the Licensed Product, and any other submissions and&#47;or communications with the Regulatory Authorities. Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article&#160;3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer will be solely responsible for all such interactions with the Regulatory Authorities in all countries in the Territory, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> Pfizer shall provide OPKO with a copy of any BLA reasonably in advance of filing to enable OPKO to comment thereon, and Pfizer, at its sole discretion, shall reasonably take into account such comments.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.4.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical Data Package.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> The &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical Data Package</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; is defined as all information in OPKO&#8217;s possession or control, and all information available through access provided to Pfizer that can be obtained by OPKO using Commercially Reasonable Efforts including all non-clinical trial and clinical trial data that relates to the Development of any Compound or Licensed Product, including provision of the following to Pfizer by OPKO (a) the definitions and attributes that comprise the Clinical Data Package, (b) the data quality management and validation processes that underlie the clinical trials in the Clinical Data Package and any database in which such Clinical Data Package is maintained, (c) the methodologies that have been utilized in converting source data into output (derived) data in connection with the Clinical Data Package, (d) the relevant statistical analysis assumptions or plans for the clinical trials in the Clinical Data Package, (e) audit history of the clinical trials in the Clinical Data Package and the database in which it is maintained, (f) all data, including appropriately de-identified subject-level records, raw datasets, compiled data (derived statistical data sets) and trial master files (including other documentation as determined by Pfizer clinical data management, including versions of medical coding dictionaries used, statistical programs to produce tables, listings, and figures, Statistical Analysis Plan, Data Management Plan, statistical programming plan and other Trial Master File documents) and (g) all databases, including the safety database and non-clinical and clinical databases used for development through the clinical trials.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.4.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Transfer of the Data Package. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Clinical Datasets</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. A &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical Dataset</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; is defined as a dataset that consists of identifier-stripped versions of all study data at the time of transfer. OPKO will transfer Clinical Datasets in the form of SAS Export&#47;Transport file format (XPT) files.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Ancillary Documents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In order to make use of the Clinical Datasets, Pfizer will also need the following ancillary documents, which OPKO will provide, as they become available, as Portable Document Format (PDF) files&#58;</font></div><div style="text-indent:36pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">An electronic data dictionary consisting of all versions of the case report forms used in the study, annotated with the variable names and corresponding datasets&#59; and </font></div><div style="text-indent:36pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> Other documentation as determined by Pfizer clinical data management, including versions of medical coding dictionaries used, statistical programs to produce tables&#47;listing&#47;graphs (TLGs), raw and </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">28</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">derived datasets, SAP, Data Management Plan, statistical programming plan and other Trial Master File documents.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Test Data Transfer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Within *** months after study initiation, OPKO will transfer a set of test data to Pfizer. Pfizer will perform certain qualification steps to determine if the transmission meets Pfizer requirements in content and process and if the data will load successfully into the target Pfizer database. OPKO will work with Pfizer if changes are needed in the data formatting or transmission process to ensure data quality and usability. OPKO will transfer additional sets of test data if needed after such changes are made and again if there are any changes in the study variables or data collection tools during the study.  </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Data Cleaning and Validation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. After each transfer of a Clinical Dataset, Pfizer and OPKO will collaborate to ensure that the data meets appropriate quality standards. This may include data queries from Pfizer that OPKO will investigate and resolve. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Transfer Schedule</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The anticipated content and timing of data transfers will be agreed to by the JDC and documented in a data transfer plan.</font></div><div style="padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.4.4.&#160;Collaboration on Preparations for BLA Regulatory Submissions.</font></div><div style="padding-left:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">At the request of the JDC, OPKO will provide to Pfizer all information required for Pfizer to meet its responsibility for BLA&#47;MAA regulatory submissions including&#58;</font></div><div style="text-indent:36pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Modules M1, M2 or equivalents&#59;</font></div><div style="text-indent:36pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Integrated Safety Database (mapped to CDISC)&#59;</font></div><div style="text-indent:36pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Pre-inspection Visits and Interviews with OPKO during inspections&#59;</font></div><div style="text-indent:36pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Rapid response to queries from regulatory authorities&#59;</font></div><div style="text-indent:36pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(v)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Clinical Dataset Transfer (test and final transfers)&#59; and</font></div><div style="text-indent:36pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(vi)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Complete Study Reports for all Phase 1, 2 and 3 Trials.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer&#8217;s Right to Cross Reference</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Upon Pfizer&#8217;s written request, OPKO will provide each applicable Regulatory Authority with a letter of authorization for each Regulatory Authority to access any submissions of INDs or CTAs to any Regulatory Authorities made by, or on behalf of, OPKO hereunder in connection with reviewing any regulatory submission or application to any Regulatory Authority made by or behalf of Pfizer or any Third Party designated by Pfizer.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical Supply of Licensed Product&#59; Manufacturing for Clinical Supply</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.6.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Supply of Licensed Product&#59; ***&#59; Assignment of *** Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. For the conduct of all Existing Trials and as set forth in the Development Plan, OPKO shall be responsible for the supply of requisite quantities of Licensed Product. The Parties acknowledge and agree that OPKO may use *** to supply or have supplied to OPKO such quantities of Licensed Product. In addition, at any time that Pfizer may request, OPKO shall assign all of its rights, title and interests in and to the *** Agreement. In the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">29</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">event of such an assignment, Pfizer shall thereafter be responsible for the supply of requisite quantities of Licensed Product in all Existing Trials.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.6.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Supply of Licensed Product for Trials. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Except as otherwise set forth in the Development Plan, for the conduct of any Trials initiated following the Original Execution Date that are conducted by ***, *** will supply or have supplied to *** such quantities of Licensed Product *** that are necessary for *** to conduct the activities that it is responsible for under the Development Plan as provided in (a) a Supply Agreement containing customary terms to be mutually agreed upon by the Parties (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Supply Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> all (i) Licensed Product will be supplied by *** in connection with the Development Plan and Development Budget *** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> in no event shall *** for such Licensed Product and (ii) *** will be supplied by *** at *** and (b) a quality agreement reasonably acceptable to each Party in form and substance (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Quality Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;).</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">*** shall also supply Licensed Product and ***. OPKO will provide the JDC at each JDC meeting with quarterly reports regarding inventory of Licensed Product and the reasonably anticipated needs for Licensed Product to ensure that Pfizer can supply OPKO with such quantities of Licensed Product at such times as required by OPKO to conduct all activities required to be conducted by OPKO under the Development Plan in compliance with the timelines set forth therein. For clarity, any use of Licensed Product that is not described in the Development Plan will be Pfizer&#8217;s sole right and responsibility and OPKO will have no rights or obligations with respect thereto. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.6.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Diligence</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If Pfizer is responsible for providing clinical supply of Licensed Product in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.6.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer shall use Commercially Reasonable Efforts with respect to the Manufacture of such Licensed Product to permit the Parties to perform their respective Development obligations in the Development Plan and hereunder without unnecessary expense or delay.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.6.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Use of Licensed Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO will (i)&#160;only use Licensed Product supplied by *** as agreed by the Parties, Pfizer or such Third Parties designated by Pfizer as a supplier of Licensed Product in connection with conducting activities under the Development Plan, and (ii)&#160;only use Licensed Product, and provide Licensed Product to permitted Third Party transferees, for the sole purpose of conducting activities under the Development Plan, and in accordance with the terms of this Agreement. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.6.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Complaints Related to Licensed Product, Devices and&#47;or Compounds</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. As may be further set forth in the Supply Agreement and Quality Agreement, each Party will promptly forward to the JDC any complaints that it receives related to any Compound, Device or Licensed Product. OPKO shall notify Pfizer if it receives any complaints that may impact product safety, quality purity and effectiveness of any Compound, Device or Licensed Product used or to be used in connection with activities conducted under the Development Plan, including any Trials in respect thereof, which could result in a product recall. OPKO will respond to any complaints of which OPKO becomes aware relating to any Compound, Device or Licensed Product&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> Pfizer will provide reasonable cooperation in connection therewith. Notwithstanding the foregoing, if a complaint pertains to the Manufacturing, appearance or general physical characteristics of any Licensed Product or other processes at any Manufacturing facility, Pfizer will be solely responsible for responding to such complaint.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.6.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Recall of Licensed Products Prior to Regulatory Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If the Licensed Product is recalled prior to Regulatory Approval in any jurisdiction in the Territory, OPKO will be responsible for the operational execution of such recall in </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">30</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">connection with the activities it has conducted under the Development Agreement (but not in connection with Licensed Product being Commercialized by Pfizer or any other Licensed Product, for which Pfizer will be responsible at its expense). Pfizer will cooperate with OPKO in connection therewith. The costs for such a recall will be at Pfizer&#8217;s expense, unless such recall and&#47;or costs were based on the material breach of this Agreement, intentional misconduct, gross negligence or negligence by OPKO and&#47;or any Third Party conducting activities on behalf of OPKO, in which case, OPKO will bear the expense of any such recall.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory Filings and Other Data. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.7.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Transfer of Regulatory Filings and Other Data.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> At Pfizer&#8217;s request following such time as Regulatory Approval is granted to Pfizer, its Affiliates and&#47;or sublicensees, for an Approved Indication in AGHD, PGHD or the Additional Pediatric Indication, for any Licensed Product in the ***, as applicable, or at such earlier time, as Pfizer may reasonably request, OPKO shall, as permitted under Applicable Laws, (i) promptly transfer to Pfizer or a designated Affiliate of Pfizer all such Regulatory Materials and right, title and interest in such Regulatory Materials, as requested by Pfizer, and (ii)&#160;thereafter provide such support and assistance to Pfizer or such Affiliate in connection with such matters regarding such Regulatory Materials as may be reasonably requested by Pfizer or such Affiliate from time to time. OPKO shall provide such Regulatory Materials in a format reasonably requested by Pfizer or such Affiliate. All Regulatory Approvals for Licensed Products for which Regulatory Approval has been granted shall be obtained and held in the name of Pfizer or a designated Affiliate of Pfizer, and Pfizer or such Affiliate shall maintain all right, title and interest in and to all such Regulatory Materials.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.7.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Submitting and Maintaining Regulatory Approvals. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Notwithstanding anything in this Agreement or the Development Plan to the contrary, Pfizer shall have sole authority for and be responsible for promptly preparing, seeking, and submitting and for maintaining all regulatory filings and Regulatory Approvals for such Licensed Product in such jurisdiction for such Approved Indication. To the extent requested by Pfizer from time to time, OPKO shall cooperate with Pfizer and take such reasonable actions to assist Pfizer in making regulatory filings and maintaining Regulatory Approval for such Licensed Product.</font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Commercial Supply of Licensed Product&#59; Manufacturing for Commercial Supply.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.8.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Supply of Licensed Product. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">During the Term, Pfizer shall have the exclusive right to Manufacture Licensed Products for Commercialization itself or through one or more Affiliates or Third Parties selected by Pfizer in its sole discretion. Pfizer shall use Commercially Reasonable Efforts with respect to the Manufacture of Licensed Products as necessary to perform its Commercialization obligations hereunder.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.8.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Capacity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In the event that the materials and&#47;or Manufacturing capacity required to Manufacture the Licensed Products is not sufficient to meet current or anticipated demand, Pfizer shall notify OPKO of such shortage and *** meet to discuss the shortage, including the proposed measures Pfizer intends to take to address such lack of capacity.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.8.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Safety Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. From and after the Amendment Effective Date, unless otherwise agreed in writing by the parties, Pfizer shall create and adhere to a </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">31</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">commercially reasonable plan to maintain an inventory of Licensed Product to seek to meet anticipated demand (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Safety Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). On a *** basis,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Pfizer shall provide OPKO updates as to the status of the Safety Stock. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Commercialization Activities.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.9.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">General</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to its diligence obligations, Pfizer shall have sole and exclusive control over all matters relating to the Commercialization of Licensed Products, including sole and exclusive control over (a) pricing of Licensed Products and (b) the negotiation of Licensed Product pricing with Regulatory Authorities and other Third Parties. *** Pfizer will use Commercially Reasonable Efforts to seek Regulatory Approval, including Price Approvals, if required, for Licensed Products in each Major Market Country. *** Pfizer will use Commercially Reasonable Efforts to Commercialize the Licensed Products in the Major Market Countries ***. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.9.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Branding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer or its designated Affiliates or sublicensees shall select and own all Trademarks used in connection with the Commercialization of any and all Licensed Products. OPKO and its Affiliates shall use Commercially Reasonable Efforts to not register or use, anywhere in the world, any Trademark which is confusingly similar to any Trademark used by or on behalf of Pfizer, its Affiliates or sublicensees in connection with any Licensed Product.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.9.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Progress Reporting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. During the first *** following the date upon which the JDC is disbanded pursuant to the provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer shall provide OPKO with written reports, on the ***, summarizing Pfizer&#8217;s activities to Commercialize Licensed Products and providing any other information as OPKO might reasonably request regarding the Commercialization of Licensed Products. Any information or written report provided by Pfizer to OPKO pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.9.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall be deemed to be Pfizer&#8217;s Confidential Information and subject to the provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Thereafter, Pfizer shall continue to provide such reports ***. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Diligence.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.10.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Exceptions to Diligence Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Notwithstanding any provisions of this Agreement to the contrary&#58; (a) if Pfizer, an Affiliate or sublicensee of Pfizer, OPKO or a Third Party generates any safety, tolerability or other data reasonably indicating, as measured by Pfizer&#8217;s safety and efficacy evaluation criteria and methodology, or signaling that a Licensed Product has or would have an unacceptable risk-benefit profile, Pfizer may take any and all actions it deems necessary or appropriate in its sole discretion to appropriately address such concerns, including putting on hold or ceasing Development or Commercialization of any effected Compound or Licensed Product, or terminating this Agreement in its entirety&#59; and (b) in such event, Pfizer shall not be in breach of this Agreement or any obligation hereunder as a result of Pfizer taking such actions so long as Pfizer is using Commercially Reasonable Efforts to address and, to the extent practicable, remedy the safety issue in order to permit continued Commercialization. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.10.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Assertion of Pfizer Diligence Obligation Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.9.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, if OPKO reasonably believes that Pfizer is not using Commercially Reasonable Efforts with respect to its obligations to Commercialize a Licensed Product in accordance with this Agreement, then OPKO shall promptly provide to Pfizer written notice documenting in reasonable detail the reasons for such assertion. Promptly upon Pfizer&#8217;s receipt of any notice of a potential alleged diligence failure (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Diligence Issue</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) pursuant </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">32</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.10.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer and OPKO will meet and discuss the specific nature of such Diligence Issue and seek to identify an appropriate corrective course of action. If, no later than *** days after Pfizer&#8217;s receipt of such notice, (a) the Parties have not reached consensus regarding whether Pfizer has failed to satisfy its obligations pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Sections 3.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">-</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">3.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, and (b) the Parties have not agreed upon an appropriate corrective course of action for such Diligence Issue,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">then such Diligence Issue will be escalated and resolved pursuant to the provisions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.10.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Diligence Obligations for Additional Indications</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">AGHD</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Upon receipt of the first Regulatory Approval (excluding any required Price Approvals) of a Licensed Product for PGHD in the United States, *** be required to support the filing and subsequent Regulatory Approval by way of a supplemental BLA (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">sBLA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) for a Licensed Product for AGHD in the United States and, if the FDA is willing to grant such meeting, attend and participate in such meeting, and ***. Without limiting the foregoing, ***&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> *** for AGHD. In the event that Pfizer determines that it will, or is otherwise required to, file a sBLA for AGHD in the United States, ***. The Parties *** incurred by Pfizer in preparing and submitting such sBLA. Except as expressly set forth in this Section, *** obligation *** unless such additional activities are agreed to by the Parties in writing, in which case, the *** (unless otherwise agreed to in writing). </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Additional Pediatric Indication</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">The Parties shall work together to identify one additional pediatric indication other than PGHD (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Additional Pediatric Indication</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) ***. If the Parties are *** on an Additional Pediatric Indication before December 1, 2020, *** following identification of the Additional Pediatric Indication, *** shall *** for such Additional Pediatric Indication that ***. </font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Promptly following submission to the JDC, the *** Licensed Product for the Additional Pediatric Indication. In connection therewith, the representatives of each Party to the JDC shall act reasonably and in good faith.</font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">*** shall be shared equally by the Parties. Additionally, the Parties acknowledge and agree that </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Articles 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> of this Agreement contemplate that, except for the ***, OPKO shall be designated as the regulatory sponsor for all Trials set forth in the Development Plan.  If the amended Development Plan approved by the JDC provides that Pfizer will be designated as the regulatory sponsor for any Trials set forth in the Development Plan, then such Development Plan will state Pfizer&#8217;s obligations as the regulatory sponsor. Notwithstanding any provision of this Agreement to the contrary, including any decision-making authority at the JDC, the amended Development Plan including the Additional Pediatric Indication shall provide that Pfizer will control the preparation, submission, pursuit and maintenance of all regulatory filings for the BLA and all subsequent supplemental filings and Regulatory Approvals for the Licensed Product for the Additional Pediatric Indication in each Major Market Country.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">33</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">If the *** an amended Development Plan or corresponding amended Development Budget for the Additional Pediatric Indication (provided Pfizer has complied with its obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section&#160;3.10.3(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.10.3(b)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">), ***.</font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(v)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Notwithstanding any provision of this Agreement to the contrary but in all cases subject to, and without limitation of, the obligation to act reasonably and in good faith in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.10.3(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, in no event ***.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Expedited Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Any dispute or disagreement arising between Pfizer and OPKO in respect of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> may be referred by either Party for resolution through expedited arbitration in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Genotropin Products</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer shall have the exclusive right to Develop, Manufacture and Commercialize Genotropin Products itself or through one or more Affiliates or Third Parties selected by Pfizer in its sole discretion. For clarity, and notwithstanding anything in this Agreement to the contrary, Pfizer shall have no diligence obligations with respect to the Development, Manufacture and Commercialization of Genotropin Products. ***.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Existing Trials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Except as otherwise set forth in the Development Plan, OPKO shall continue to conduct all Trials initiated prior to the Original Execution Date (such trials, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Existing Trials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) in accordance with the protocol, standard operating procedures and other development plans established by OPKO with respect to such Existing Trials prior to the Original Execution Date, subject to oversight by the JDC. OPKO shall keep Pfizer apprised of the progress of all such Existing Trials, engage with Regulatory Authorities, and otherwise perform its Development obligations as provided for in and in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will provide access to all documents and electronic information currently held by OPKO or OPKO&#8217;s CROs and other Vendors, related to all Existing Trials and any completed Trials, and to facilitate site visits by Pfizer. OPKO will undertake specific actions requested by Pfizer to remediate incomplete documentation and make amendments to current SOPs if, in Pfizer&#8217;s opinion, these changes are required to meet regulatory requirements or will have a material impact on the success of any BLA submissions by Pfizer.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">New Trials. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Subject to the terms hereof, OPKO shall (and with respect to the ***) conduct all Trials initiated following the Original Execution Date (such trials &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">New Trials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) in accordance with the protocols, standard operating procedures and other development plans specified by the JDC and set forth in the Development Plan or as otherwise approved by the JDC.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pharmacovigilance and Safety Information Exchange.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.14.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">The safety reporting units from each of the Parties will meet and will, within *** days of the Original Effective Date, agree upon the timing for establishing a written agreement for exchanging adverse event and other safety information relating to (a) the Licensed Products, and (b) adverse events attributable to CTP Technology used in other products (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pharmacovigilance Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). The Pharmacovigilance Agreement will ensure that adverse event and other safety information is exchanged upon terms that will permit each Party to comply with Applicable Laws and requirements of Regulatory Authorities. This Pharmacovigilance Agreement will be established in advance of the earlier of (1) the first Regulatory Filing in any country in the Territory and </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">34</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(2) the start of any clinical trial under an IND or CTA sponsored by Pfizer related to the Licensed Products.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.14.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Following the Original Execution Date and until such time as the Pharmacovigilance Agreement is executed, within *** Business Days of providing any notification to the JDC pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the notifying Party shall provide a copy of such notification to the other Party. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.14.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO agrees to manage pharmacovigilance obligations for the&#160;Licensed Products in compliance with global requirements, until such time that these obligations and all needed legacy data can be transferred to Pfizer, as established in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.14.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">3.14.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO agrees to provide the JDC aggregate clinical safety data relating to the Licensed Products for the purposes of assessing potential benefit and risk. The frequency and format for this exchange, including responsible parties, shall be established by the JDC. </font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">TRIAL ACTIVITIES AND RESPONSIBILITIES.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">SOPs. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Subject to the terms hereof, for New Trials ***, OPKO will conduct, or ensure that each Approved CRO conducts, all such New Trials in accordance with standard operating procedures (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">SOPs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), access to electronic copies of which will be provided by OPKO to the JDC for review prior to the initiation of each New Trial at a time to be determined by the JDC. For Existing Trials, OPKO will provide access to electronic copies of all current SOPs within ninety (90) days following the Original Effective Date. Pfizer, from time to time, may request OPKO to make amendments to current SOPs if, in Pfizer&#8217;s opinion, these changes are required to meet regulatory requirements or will have a material impact on the success of any BLA submission by Pfizer. In the event of any updates to existing SOPs, or in the event that any Trial *** is not being conducted in compliance with the SOPs (as updated from time to time), OPKO shall take all such actions as may be necessary to bring such Trial into compliance with the then-current SOPs as promptly as is practicable. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Sites and Clinical Investigations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.2.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Selection of Sites and Investigators.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">The JDC will approve the study sites to conduct each Trial *** as proposed by OPKO.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will enter, and each Approved CRO will enter, into an agreement with each study site&#59; such an agreement will be substantially in the form to be agreed upon by the Parties within *** days following approval by the JDC of the Development Plan (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical Trial Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) (upon execution of the Clinical Trial Agreement, such study site will be deemed a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Site</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), and will provide that any Trial *** may be freely transferred or assigned to Pfizer or a designee of Pfizer without any negotiation of the CTA necessary. If a study site requires any material changes to such form Clinical Trial Agreement, OPKO will inform the JDC and seek JDC approval of such change, and the JDC will not unreasonably withhold such approval. For clarity, each Clinical Trial Agreement will specify reasonable terms, consistent with industry standards for similar agreements, and will expressly require during the period which it is effective the applicable Site and Clinical Investigator to comply with the terms hereof as if such Site and Clinical Investigator were a Party hereto, including the terms </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">35</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">pertaining to ownership of intellectual property and publications, treatment of Confidential Information and that the Site, the Clinical Investigators and other personnel working on any Trial at each Site have (i) GCP and other appropriate training and experience to conduct such Trial(s), including training with respect to the Development Plan&#59; (ii) access to an adequate number of subjects that satisfy the criteria in the Development Plan to meet subject enrollment requirements for such Trial(s)&#59; (iii) any licenses, certifications and&#47;or accreditations required by Applicable Laws&#59; and (iv) understand the Development Plan and their obligation to comply therewith and all Applicable Laws in conducting such Trial(s). Any such representations and warranties will be made for the benefit of OPKO and Pfizer as third party beneficiaries.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">The Clinical Trials Agreements will also provide that the Clinical Investigators, any sub-investigators (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">e.g.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, research fellows, residents and associates) and any others required by Applicable Law at each Site complete the financial disclosure document with respect to Pfizer and OPKO, and such financial disclosure document will be substantially in the form to be agreed upon by the Parties within *** days following approval by the JDC of the final Development Plan (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Financial Disclosure Form</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). For clarity, if any of the foregoing individuals do not complete such Financial Disclosure Form, such individuals may not participate in, or do any work in connection with, any Trial.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.2.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Obligations During Trial Conduct.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">From and after the Original Effective Date, OPKO will conduct meetings with the Clinical Investigators (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Clinical Investigator Meeting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), of which the JDC will be provided with reasonable advance notice and in which Pfizer will have the right (but not the obligation) to attend and participate (at Pfizer&#8217;s cost). Minutes of Clinical Investigator Meetings will be made available to the JDC upon request.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will provide the JDC with copies of all communications relevant to any Trial *** and provided to all Sites, and upon request of the JDC, provide the JDC with copies of any other communications between OPKO and any individual Sites and&#47;or any Affiliate or Approved CRO and any individual Sites.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">If OPKO terminates a Site, OPKO will inform the JDC with the reason for such termination and if reasonably practicable, such notice will be provided reasonably in advance of such termination.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will meet its CRO Trial Site Monitoring and Vendor Oversight responsibilities as established by the JDC as specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Subjects and Informed Consent.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.3.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Subject Recruitment Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO will comply with the subject recruitment plan for each Trial ***, which will be established by OPKO and communicated to the JDC, for approval by the JDC not to be unreasonably withheld, within a reasonable period of time after the Original Effective Date not to exceed ninety (90) days (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Subject Recruitment Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) in recruiting subjects to participate in such Trial. For clarity, prior to engaging in any recruiting activities, OPKO will ensure that the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">36</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">applicable IRBs and&#47;or other ethics committees approve any related materials and activities as required by the JDC and all Applicable Laws.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.3.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Informed Consent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO will prepare the informed consent document for use in each Trial ***. OPKO will ensure that the informed consent of each subject participating in any Trial be obtained in accordance with all Applicable Laws, including completion of the informed consent document&#59; such informed consent document for such Trial will be substantially in the form to be agreed upon by the Parties within *** days following approval by the JDC of the Development Plan (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Informed Consent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) (upon obtaining such Informed Consent, a prospective subject will be deemed a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Subject</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). For clarity, the Informed Consent document that each Subject signs will expressly state that each Subject understands that Pfizer is providing support for such Trial and will authorize disclosure of data and results related to such Trial to Pfizer for any purpose, subject to all Applicable Laws. For clarity, OPKO will be required to obtain Pfizer&#8217;s prior written consent (which shall not be unreasonably withheld) for any subsequent material amendments to the form initially agreed upon by the Parties or for translations of such form. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.3.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Inclusion and Exclusion Criteria. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Neither OPKO nor any of its Representatives will provide a waiver for any exclusion or inclusion criteria related to a Trial *** as specified in the Development Plan. Any changes to the exclusion or inclusion criteria will be subject to an amendment to the Development Plan to be approved by the JDC pursuant to the terms of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Investigator&#8217;s Brochure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO will prepare and maintain the investigator&#8217;s brochure for the Licensed Products. OPKO will, promptly following receipt of written notice from Pfizer of the need for the most recent version of the investigator&#8217;s brochure, provide Pfizer with such version of the investigator&#8217;s brochure.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Data Collection and Data Management. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.5.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">CRF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. From and after the Original Effective Date, OPKO will be responsible for preparing the CRF for each Trial *** in accordance with the Development Plan. OPKO will provide the JDC with access to electronic copies of the CRFs for review by the JDC. A CRF is to be completed for each Subject and will be in electronic form, validated and in compliance with all Applicable Laws.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.5.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Data Management Plan. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will comply with the data management plan to be agreed upon by the Parties within *** Business Days following approval by the JDC of the Development Plan (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Data Management Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). For clarity, the Data Management Plan will provide Pfizer the right to review the Development Plan, and OPKO will agree to make modifications requested by Pfizer if they are considered by Pfizer to affect any of the timelines set forth in the Development Plan or may have a material impact on the success of any BLA submissions hereunder by Pfizer. The Data Management Plan will be agreed upon by the Parties prior to recruitment of Subjects for any future Trial. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">During the Term, with respect to any data collected in connection with any Trial, OPKO will ensure that such data is held in one or more appropriate facilities with information security protections (including in accordance with all Applicable Laws) including&#58; (i)&#160;unique accounts for all </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">37</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">operators&#59; (ii)&#160;cancellation of an account when an employee or other personnel terminates employment&#59; (iii)&#160;deactivation of an account when an employee or other personnel ceases working on the Trial&#59; (iv)&#160;required password changes at frequent intervals&#59; and (v)&#160;regular backups of electronic data.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.5.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trial Database.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will promptly update the applicable trial database for the data collected from each Site for each Trial *** (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trial Database</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) upon receiving data for any such Trial from any Site, and OPKO will ensure that the Sites, promptly following receipt thereof, provide data in connection with such Trial to OPKO. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will provide the JDC with access to electronic copies of such data requested by the JDC at JDC meetings and in accordance with Applicable Laws.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">If, at any time following the Original Effective Date, OPKO decides to change the format of the database for any such Trial, OPKO will so notify Pfizer and the Parties will cooperate to ensure that the format that OPKO selects permits Pfizer to incorporate the data from such Trial into its relevant systems and is in compliance with all Applicable Laws.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will provide SAS datasets to Pfizer in accordance with specifications as defined by Pfizer in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#58; (i) at such times as Pfizer may reasonably request such SAS datasets&#59; (ii) if a safety signal is identified&#59; and&#47;or (iii) if a request is received from any Regulatory Authority.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will maintain each Trial Database in accordance with all Applicable Laws, including ensuring that information included in such Trial Database is accurate and up-to-date.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.5.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trial Master File</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Promptly following the Original Effective Date, OPKO will establish and maintain a trial master file (to the extent they not already established and maintained for any applicable Trial) for any Trials *** in the format as agreed upon by the JDC (each a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trial Master File</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). Notwithstanding anything to the contrary herein, OPKO will not be permitted to delegate its rights and obligations pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> to any Third Parties without the prior approval of the JDC, except OPKO may delegate its rights and obligations pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> to any of its Affiliates provided that OPKO retains accountability following such delegation.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.5.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Source Data Verification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. From and after the Original Effective Date, OPKO will be responsible for source data verification of data records according to OPKO&#8217;s SOPs related to the Monitoring Plan and Vendor Oversight Plan to be agreed as specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 4.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. At Pfizer&#8217;s request, OPKO will provide Pfizer with copies of any OPKO reports relating to source data verification and other types of Trial audits.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.5.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Statistical Analysis</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. From and after the Original Effective Date, except as may otherwise by determined by the mutual agreement of the JDC without reference to the tie-breaking provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.2.5(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, OPKO will perform any statistical analysis required in accordance with the statistical analysis plan for the Trial ***, a draft of which for any applicable Trial will be attached as an agreement to the Development Plan upon mutual agreement of the Parties (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Statistical Analysis Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">38</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Specimens</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Unless otherwise requested by Pfizer, from and after the Original Effective Date, OPKO (or its designated CRO) will test, store, or manage all biological samples and&#47;or associated slides or blocks (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Specimens</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Audits. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.7.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">From and after the Original Effective Date, OPKO will conduct quality oversight inspections and audits of the facilities and services of any CRO or other applicable Third Parties in accordance with its SOPs and pursuant to a quality assurance audit plan (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Auditing Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), and OPKO will provide Pfizer with copies of all audit reports.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.7.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Notwithstanding the foregoing, Pfizer will have the right, but not the obligation, to co-audit with OPKO any sites (including any Sites), facilities and services of any CRO or other applicable Third Party pursuant to the Auditing Plan. OPKO will provide the JDC with written notice of any upcoming audits to enable Pfizer to so participate. If Pfizer chooses to co-audit pursuant to the foregoing sentence, Pfizer will provide OPKO with advance written notice thereof, and OPKO will cooperate with Pfizer with respect to such audit. For clarity, Pfizer&#8217;s participation in any auditing activities will not relieve OPKO of its obligations hereunder and Pfizer will be limited to acting in a supporting capacity in any such audit. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.7.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">From and after the Original Effective Date, Pfizer will conduct quality oversight inspections and audits of the manufacturing facilities for any Licensed Products in accordance with its internal policies.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Monitoring and Vendor Oversight</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. From and after the Original Effective Date, OPKO will monitor each Trial***, and share information with the JDC pertaining to monitoring such Trial, in accordance with the monitoring plan for such Trial to be agreed upon by the Parties within ninety (90) days following the Original Effective Date (each a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Monitoring Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). Within *** days following the Original Effective Date the Parties also will enter into a vendor oversight plan mutually agreeable to the Parties (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Vendor Oversight Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">IRBs and Other Ethics Committees.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.9.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will be responsible for obtaining the approval of the IRBs and other ethics committees required prior to commencing, and during, the Trial *** at every Site.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.9.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will ensure that IRBs and such other relevant ethics committees have current registrations and accreditations as required by Applicable Law, and OPKO will provide all ethics committees, including all IRBs, and Regulatory Authorities, with all necessary documentation prior to, and during the course of, each Trial *** as required by Applicable Law.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.9.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">From and after the Original Effective Date, OPKO will be solely responsible for responding to all queries from the IRBs and other ethics committees ***&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (a) Pfizer will make itself reasonably available to assist with any such queries, and (b) if such query relates solely to the CMC Information, Pfizer will prepare the applicable response and provide OPKO with a copy thereof.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.9.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">The ultimate responsibility for fulfillment of all pharmacovigilance obligations resides with the IND or CTA holder and&#47;or the marketing authorization holder according to relevant Applicable Laws. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">39</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Independent Data Monitoring Committee (&#8220;IDMC&#8221;)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO will establish an IDMC for each Trial *** if not already established, which will be governed by a charter substantially in the form to be agreed upon by the Parties within *** days of the Original Effective Date (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">IDMC Charter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). For clarity, the IDMC Charter will specify the number of members of the IDMC, the qualifications of such members, the experience of the chairman of the IDMC, details regarding open and closed sessions, including who can attend any such sessions, and information that the IDMC may share with the Parties, including that efficacy will not be disclosed to either Party until the IDMC has approved such data. OPKO will communicate any decision of the IDMC to the JDC within five (5) Business Days of such decision. OPKO will ensure that the IDMC is provided with all information and data that it requires as specified in the IDMC Charter, and Pfizer will reasonably cooperate with OPKO in such regard. OPKO will ensure that all members of the IDMC have any licenses, certifications and&#47;or accreditations required by Applicable Laws&#59; and understand the Development Plan and their obligation to comply therewith and all Applicable Laws in conducting such Trial(s). Any such representations and warranties will be made for the benefit of OPKO and Pfizer as third party beneficiaries. OPKO will ensure that each member completes the Financial Disclosure Form. For clarity, if any of the foregoing individuals do not complete such Financial Disclosure Form, such individuals may not participate in the IDMC. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Environmental Health and Safety.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.11.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">In conducting each Trial ***, OPKO will comply with all Applicable Laws, including those relating to environmental, health and&#47;or safety matters. For clarity, OPKO will be solely responsible for establishing material and specimen handling guidelines and for ensuring use of controls, including appropriate personal protective equipment, that minimize potential worker exposure, obtaining the material safety data sheets and providing the appropriate training for workers who will potentially be exposed to any Compound, Device or Licensed Product.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.11.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO will promptly notify the JDC, in writing, of any worker claims of suspected occupational illnesses related to working with any Compounds, Devices or Licensed Products, or of any known facts or circumstances which could lead to such claims, regardless of whether such claims are received during the Term or any time thereafter. After termination of this Agreement for any reason, or expiration of this Agreement, each Party will promptly notify the other Party of any worker claims of suspected occupational illnesses related to working with any Compounds, Devices or Licensed Products during the Term, of which it has knowledge.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">4.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trial Reports&#59; Safety or Efficacy Data</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. With respect to each Trial ***, OPKO shall provide Pfizer with access to all clinical data (in a format required by Regulatory Authorities), the Trial Master File and a &#8220;topline&#8221; report, an &#8220;interim study&#8221; report, if available, and a final complete study report, as well as any other reports as required by the Development Plan. In the event that there are any additional safety or efficacy data pertaining to any Trial *** that come into the possession of OPKO after providing Pfizer with the final complete study report, OPKO will prepare and promptly provide Pfizer with a supplement to such report. </font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">PAYMENTS.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Upfront Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The Parties hereby acknowledge that, within *** days of the Original Effective Date, Pfizer made a one-time non-refundable and non-creditable payment to OPKO of Two Hundred Eighty-Five Million U.S. Dollars ($285,000,000) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Upfront Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;).</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">40</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory Milestone Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer shall pay to OPKO the amounts set forth below within *** days following the first occurrence of each event described below (each event, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory Milestone</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; and each payment, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Regulatory Milestone Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), which amounts shall be non-refundable and non-creditable against any other payments due under this Agreement.</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%;"><tr><td style="width:1.0%;"></td><td style="width:62.716%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:33.284%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Regulatory Milestone</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Regulatory Milestone Payment</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">First achievement of *** of a Licensed Product for an Approved Indication in ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">First achievement of *** of a Licensed Product for an Approved Indication in ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">First achievement of *** of a Licensed Product for an Approved Indication ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">First achievement of *** of a Licensed Product for an Approved Indication in ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">First achievement of *** of a Licensed Product for an Approved Indication in ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">First achievement of *** of a Licensed Product for an Approved Indication ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">First achievement of *** of a Licensed Product for an Approved Indication in ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For the avoidance of doubt&#58; (a) each Regulatory Milestone Payment shall be payable only once upon first achievement of the applicable Regulatory Milestone and only on the first occurrence of the corresponding Regulatory Milestone, regardless of the number of Licensed Products achieving such Regulatory Milestone&#59; (b) a Regulatory Milestone satisfied by a sublicensee or Affiliate of OPKO shall be deemed to have been achieved by OPKO for the purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; and (c) to the extent any ***, which trigger a Regulatory Milestone, Regulatory Milestone Payments shall be payable in respect of each such *** as provided above. In addition, and for greater clarity, milestones shall not be paid on ***. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Royalty Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.3.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Royalties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to the provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> ***, Pfizer shall pay to OPKO royalties in the amount of the marginal rates set forth below of the aggregate Net Sales resulting from the sales of all Licensed Products in the Territory during each Pfizer Year of the applicable Royalty Term for each Licensed Product (pro-rated for any partial Pfizer Year). Each marginal royalty rate set forth in the table shall apply only to that portion of the Net Sales of a given Licensed Product in the Territory during a given Pfizer Year that falls within the indicated range.</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Annual Worldwide Net Sales</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Marginal Royalty Rate</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Worldwide Net Sales up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Worldwide Net Sales above ***, up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Worldwide Net Sales above ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">At such time as there is a commencement of the *** Profit Share ***, such that royalties are no longer payable with respect to such *** pursuant to the provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Pfizer&#8217;s payment obligations under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> with respect to those *** which remain eligible for payment of royalties shall then be calculated based upon </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">41</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the applicable table set forth below rather than the table set forth above for purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (pro-rated for any partial Pfizer Year).</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Royalties payable only for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#58;</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Annual Net Sales in the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Marginal Royalty Rate</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in the *** up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in the *** above ***, up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in the *** above ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Royalties payable only for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#58;</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Annual Net Sales in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Marginal Royalty Rate</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** above ***, up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** above ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Royalties payable only for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Annual Net Sales in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Marginal Royalty Rate</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** above ***, up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** above ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Royalties payable only for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#58;</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Annual Net Sales in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Marginal Royalty Rate</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** and *** up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** and *** above ***, up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** and *** above ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">42</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Royalties payable only for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#58;</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Annual Net Sales in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Marginal Royalty Rate</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** and *** up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** and *** above ***, up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** and *** above ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Royalties payable only for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#58;</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Annual Net Sales in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Marginal Royalty Rate</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** and *** up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** and *** above ***, up to and including ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Annual Net Sales in *** and *** above ***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.3.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. For each of the *** consecutive *** with respect to which royalties are payable pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, OPKO shall receive *** for such period for all countries in the Territory&#58;</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Year</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">At such time as there is a commencement of the *** Profit Share Term, such that royalties are no longer payable with respect to such *** pursuant to the provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Pfizer&#8217;s payment obligations under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall be calculated based upon the applicable table set forth below rather than the table set forth above for purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. For clarity, the tables set forth below are intended only to provide for alternative *** amounts payable under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> for the *** months for which *** are payable (as compared to the table set forth above), and shall not be construed to require the payment of any additional amounts of royalty payments beyond such *** month time period.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">*** payable only for ***&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Year</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">*** payable only for ***&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">43</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Year</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">*** payable only for ***&#58;</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Year</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">*** payable only for ***  and ***&#58;</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Year</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">*** payable only for *** and ***&#58;</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Year</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">*** payable only for *** and ***&#58;</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%;"><tr><td style="width:1.0%;"></td><td style="width:60.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Year</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">*** Period</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Profit Share Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.4.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Subject to the provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer shall pay to OPKO gross profit payments in the amount of the marginal rates set forth below of the aggregate Franchise Gross Profit in *** with respect to Licensed Product and Genotropin Product in *** during the *** Profit Share Term***, as applicable, determined as set forth below, based on the percentage of annual Franchise Net Sales attributable to Licensed Product in ***. Each marginal gross profit payment rate set forth in the table shall apply only to that portion of the Franchise Net Sales that falls within the indicated range. Franchise Gross Profits for partial calendar years shall be determined by prorating the annual aggregate </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">44</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">thresholds for the relevant ***. An example calculation of gross profit payments under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> is set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.4.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Subject to the caveat in the following sentence, in addition, if there is a ***, which *** occurs not later than the *** anniversary of the commencement of the Profit Share Term ***, then following the occurrence of such *** and continuing until the ***, each threshold dollar amount set forth in the left-hand-most column of the table set out below in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> applicable to *** shall be reduced by an amount equal to *** which were realized in *** during the *** period immediately preceding the occurrence of such ***. Notwithstanding the foregoing, the reductions in threshold dollar amounts contemplated by the prior sentence shall not be applicable in the event that (i)&#160;Pfizer directly or indirectly *** with respect to, ***, including through the effectuation of an *** agreement ***  (ii)&#160;there is a subsequent ***, and (iii) such *** period prior to the date of *** that were equal to at least *** of the worldwide Net Sales of the *** for the same *** period. If, however, (i)&#160;Pfizer directly or indirectly acquires, or obtains rights with respect to, ***, including through the effectuation of an *** agreement ***, (ii)&#160;there is a subsequent ***, and (iii) such *** period prior to the date of *** that were less than *** for the *** period, then following the occurrence of such *** and continuing until the ***, each threshold dollar amount set forth in the left-hand-most column of the table set out below in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> applicable to *** shall be ***. </font></div><div style="padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">*** Profit Share&#58;</font></div><div style="padding-left:4.5pt;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.634%;"><tr><td style="width:1.0%;"></td><td style="width:23.870%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.147%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.983%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#d9d9d9;text-align:left;vertical-align:top;border-top:3pt double #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">Annual Aggregate ***  Franchise Net Sales</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#d9d9d9;text-align:left;vertical-align:top;border-top:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">Less than or equal to *** of Annual Aggregate *** Franchise Gross Profit is Attributable to Licensed Products</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#d9d9d9;text-align:left;vertical-align:top;border-top:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">More than *** of Annual Aggregate *** Franchise Gross Profit is Attributable to Licensed Products</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales up to and including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales above </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, up to and including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales above </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, up to and including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales above </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">45</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8232;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">*** Profit Share&#58;</font></div><div style="padding-left:4.5pt;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.634%;"><tr><td style="width:1.0%;"></td><td style="width:23.870%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.147%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.983%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#d9d9d9;text-align:left;vertical-align:top;border-top:3pt double #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">Annual Aggregate ***  Franchise Net Sales</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#d9d9d9;text-align:left;vertical-align:top;border-top:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">Less than or equal to *** of Annual Aggregate *** Franchise Gross Profit is Attributable to Licensed Products</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#d9d9d9;text-align:left;vertical-align:top;border-top:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">More than *** of Annual Aggregate *** Franchise Gross Profit is Attributable to Licensed Products</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales up to and including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales above </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, up to and including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales above </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, up to and including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales above </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Profit Share&#58;</font></div><div style="padding-left:4.5pt;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.634%;"><tr><td style="width:1.0%;"></td><td style="width:23.870%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.147%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.983%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#d9d9d9;text-align:left;vertical-align:top;border-top:3pt double #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">Annual Aggregate *** Franchise Net Sales</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#d9d9d9;text-align:left;vertical-align:top;border-top:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">Less than or equal to *** of Annual Aggregate *** Franchise Gross Profit is Attributable to Licensed Products</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#d9d9d9;text-align:left;vertical-align:top;border-top:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">More than *** of Annual Aggregate *** Franchise Gross Profit is Attributable to Licensed Products</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales up to and including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales above </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, up to and including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales above </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, up to and including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;border-left:3pt double #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;margin-top:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Annual Aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Franchise Net Sales above </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:3pt double #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Royalty and Profit Share Payment Adjustments, Statements and Payments.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.5.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Adjustments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The following adjustments shall be made, on a Licensed Product-by-Licensed Product and country-by-country basis, to the royalties payable pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and the gross profit payments payable pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#58;</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">No Adjustment for OPKO Third Party Agreements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 3.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, OPKO shall be solely responsible for (i) all obligations (including any royalty or other obligations that relate to the Licensed Technology) under its agreements with Third Parties that are in effect as of the Original Effective Date or that OPKO enters into during the Term, and (ii) all payments to inventors (other than inventors that are Representatives of Pfizer) of the Licensed Technology, including payments under inventorship compensation laws. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">46</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Third Party Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If Pfizer, in consultation with OPKO, reasonably (i) determines it is necessary or reasonably useful to obtain a license from a Third Party in order to Develop, Manufacture, Commercialize or use a Licensed Product in a *** in the Territory and to pay a royalty or other consideration under such license (including in connection with the settlement of a patent infringement claim), or (ii) is or becomes subject to a final court or other binding order or ruling requiring any payments, including the payment of a royalty to a Third Party holder of Patent Rights in respect of sales of any Licensed Product in a *** in the Territory, then, without limiting OPKO&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the amount of Pfizer, its Affiliates or its sublicensee royalty payments under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> with respect to Net Sales for such Licensed Product in such ***, as well as gross profit payments under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> with respect to Franchise Gross Profits in such ***, shall each be reduced by *** of the amounts payable and actually paid to Third Parties pursuant to any such Third Party license or such order, such reduction to continue until all such amounts have been expended, provided the reduction shall not exceed *** of the amounts payable to OPKO in any Calendar Quarter.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.5.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Cumulative Royalties and Gross Profit Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The obligation to pay royalties and&#47;or gross profit payments under this Agreement shall be imposed only once with respect to any sale of any Licensed Product.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.5.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Royalty and Gross Profit Payment Statements and Payments. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Within *** days of the end of each Calendar Quarter, Pfizer shall deliver to OPKO a report setting forth, for the most recent Pfizer Quarter ending during such Calendar Quarter, the following information, on a Licensed Product-by-Licensed Product, Genotropin Product-by-Genotropin Product, country-by-country, and Territory-wide basis&#58; (a) Net Sales of each Licensed Product and Genotropin Product, (b) Franchise Gross Profits with respect to each Licensed Product and Genotropin Product, (c) the basis for any adjustments to the royalty or gross profit payment payable for the sale of any such Licensed Product and Genotropin Product and (d) the royalty or gross profit payment due hereunder for the sale of each such Licensed Product or Genotropin Product. No such report shall be due for any Licensed Product or Genotropin Products (i) before the First Commercial Sale of a Licensed Product in the *** or (ii) after the Royalty Term and Profit Share Term for such Licensed Product has terminated in *** in the Territory. The total royalty and gross profit payment due and payable for the sale of all Licensed Products during a Pfizer Quarter shall be paid within *** days following the end of such Calendar Quarter. Any adjustments with respect to the calculation of any amount of royalties and&#47;or gross profit which were included in a previously submitted report delivered pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.5.3(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall be reflected in the next such report delivered by Pfizer to OPKO, such adjustments to be made in a manner consistent with the internal accounting policies of Pfizer.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">*** shall be paid as follows&#58; At the end of the *** period in respect of which a *** is payable, Pfizer shall pay to OPKO within *** days after the end of the *** period in question, and assuming the difference is a positive number, the difference between (i) the applicable *** and (ii) the aggregate amount of all the royalties due and payable to OPKO for the *** period actually paid to OPKO in such period.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">47</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">With respect to amounts due or otherwise payable to *** by *** in connection with this Agreement, *** in connection with this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Taxes and Payments.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.7.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Taxes and Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. It is understood and agreed between the Parties that any payments made under this Agreement are exclusive of any value added or similar tax (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">VAT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), which shall be added thereon as applicable. Where VAT is properly added to a payment made under this Agreement, the Party making the payment will pay the amount of VAT only on receipt of a valid tax invoice issued in accordance with the laws and regulations of the country in which the VAT is chargeable. In addition, in the event any payments made by Pfizer pursuant to this Agreement become subject to withholding taxes under the Applicable Laws or regulations of any jurisdiction or Governmental Authority, Pfizer shall&#58; (i) deduct and withhold the amount of such taxes for the account of OPKO to the extent required by Applicable Laws or regulations and such amounts payable to OPKO shall be reduced by the amount of taxes deducted and withheld&#59; (ii) pay the amounts of such taxes to the proper Governmental Authority in a timely manner&#59; (iii) transmit to OPKO an official tax certificate or other evidence of such tax obligations together with proof of payment from the relevant Governmental Authority of all amounts deducted and withheld sufficient to enable OPKO, in OPKO&#8217;s good faith opinion, to claim such payment of taxes&#59; and (iv) cooperate with OPKO in any way reasonably required to obtain available reductions, credits and&#47;or refund of such taxes. Any such withholding taxes required under Applicable Laws or regulations to be paid or withheld shall be an expense of, and borne solely by, OPKO. In order to assist Pfizer in its cooperation referred to in clause (iv) of the foregoing sentence, OPKO shall provide Pfizer with a valid Form W-8BEN-E, Certificate of Status of Beneficial Owner for United States Tax Withholding and Reporting (Entities), certifying that OPKO is the beneficial owner of the Payments within the meaning of the tax treaty in force between Ireland and the United States (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Treaty</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.7.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Currency</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. All amounts payable and calculations under this Agreement shall be in United States dollars. As applicable, Net Sales, Gross Profits and any royalty or gross profit payment deductions shall be translated into United States dollars at the exchange rate used by Pfizer, in the ordinary course, for public financial accounting purposes. If, due to restrictions or prohibitions imposed by national or international authority, a given payment cannot be made as provided in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.7.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the Parties shall consult with a view to finding a prompt and acceptable solution. If the Parties are unable to identify a mutually acceptable solution regarding such payment, then Pfizer may elect, in its sole discretion, to deliver such payment in the relevant jurisdiction and in the local currency of the relevant jurisdiction.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.7.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Method of Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each payment hereunder shall be made by electronic transfer in immediately available funds via either a bank wire transfer, an ACH (automated clearing house) mechanism or any other means of electronic funds transfer, at the Party to whom payment is due&#8217;s election, to the bank account as set forth below or as designated by such Party in writing to the other Party at least *** days before the payment is due&#58;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">48</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.461%;"><tr><td style="width:1.0%;"></td><td style="width:49.515%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.485%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.301%;"><tr><td style="width:1.0%;"></td><td style="width:48.632%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.368%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="padding-left:4.5pt;padding-right:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">***</font></div></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Inspection of Records.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.8.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Record Keeping</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party shall keep and shall cause its Affiliates and sublicensees to keep books and accounts of record setting forth gross sales of the Licensed Product and Genotropin Products, Net Sales, expenses, and COGS on a *** basis sufficient to enable the calculation of amounts payable hereunder to be verified, as well as books and records of the costs and expenses associated with Development activities. Each Party and its Affiliates and sublicensees shall maintain such records during the Term and for a period of at least *** after the final payment has been made under the Agreement.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.8.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Audits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party, upon *** days&#8217; prior notice from the other Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Auditing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), shall permit an independent certified public accounting firm of nationally-recognized standing selected by the Auditing Party and reasonably acceptable to the other Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Audited Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) to examine, at the Auditing Party&#8217;s sole expense, the relevant books and records of the Audited Party and its Affiliates as may be reasonably necessary to verify calculation of and the amounts reported by the Audited Party in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the payment of royalties and gross profit payments hereunder, and to confirm the costs and expenses of each Party associated with Development activities. An examination by either Party under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.8.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall not occur more than *** in any calendar year and shall be limited to the pertinent books and records for any calendar year ending not more than *** before the date of the request. The accounting firm shall be provided access to such books and records at the Audited Party&#8217;s or its Affiliates&#8217; facility(ies) where such books and records are normally kept and such examination shall be conducted during the Audited Party&#8217;s normal business hours. The Audited Party may require the accounting firm to sign a reasonably acceptable non-disclosure agreement before providing the accounting firm with access to the Audited Party&#8217;s or its Affiliates&#8217; facilities or records. Upon completion of the audit, the accounting firm shall provide both Pfizer and OPKO a written report disclosing any discrepancies in the reports submitted the Audited Party and, in each case, specific details concerning any discrepancies. No other information shall be provided to the Auditing Party.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.8.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Overpayments&#47;Underpayments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If, after conducting an audit pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.8.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the applicable accounting firm concludes that additional royalties or gross profit payments were due to OPKO, then Pfizer will pay to OPKO the additional royalties or gross profit payments within *** days of the date Pfizer receives such accountant&#8217;s written report. Further, if the amount of such underpayments exceeds more than *** of the amount that was properly payable to OPKO, then Pfizer shall reimburse OPKO for </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">49</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO&#8217;s out-of-pocket costs in connection with the audit. If the accounting firm concludes that Pfizer overpaid royalties or gross profit payments to OPKO, then OPKO shall refund such overpayments to Pfizer within *** days of the date OPKO receives such accountant&#8217;s written report.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Notwithstanding any provision of this Agreement to the contrary, all reports and financial information of Pfizer, its Affiliates or its sublicensees which are provided to or subject to review by OPKO under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall be deemed to be Pfizer&#8217;s Confidential Information and subject to the provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">5.10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">No Guarantee of Success</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer and OPKO acknowledge and agree that nothing in</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">this Agreement will be construed as representing an estimate or projection of (i) the successful Development or Commercialization of any Licensed Product under this Agreement, (ii) the number of Licensed Products that will or may be successfully Developed or Commercialized under this Agreement, (iii) anticipated sales or the actual value of any Licensed Products that may be successfully Developed or Commercialized under this Agreement or (iv) the damages, if any, that may be payable if this Agreement is terminated for any reason. Pfizer makes no representation, warranty or covenant, either express or implied, that (A) it will successfully Commercialize or continue to Commercialize any Licensed Product in any country, (B) if Commercialized, that any Licensed Product will achieve any particular sales level, whether in any individual country or cumulatively throughout the Territory, or (C) Pfizer will devote, or cause to be devoted, any level of diligence or resources to Developing or Commercializing any Licensed Product in any country, or in the Territory in general, other than is expressly required under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">INTELLECTUAL PROPERTY.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Ownership and Inventorship.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.1.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pre-Existing Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to the licenses granted pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, and except for the Intellectual Property Rights assigned to Pfizer pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, each Party shall retain all right, title and interest in and to any Intellectual Property Rights that are Controlled by such Party prior to the Original Effective Date, or that are Controlled by such Party on or after the Original Effective Date and are outside the scope of this Agreement. For the avoidance of doubt, as between the Parties, OPKO shall retain sole and exclusive ownership and all right, title and interest in and to all Licensed OPKO Core Patents and the CTP Technology.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.1.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Developed Intellectual Property. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">As between the Parties, except for Licensed OPKO Core Patents, Pfizer shall own all right, title and interest in and to any Intellectual Property Rights conceived by Pfizer or its Affiliates, subcontractors or sublicensees in the course of conducting Pfizer&#8217;s activities and rights under this Agreement, and that do not name any inventors having an obligation of assignment to OPKO at the time such intellectual property is conceived, discovered, developed or otherwise made (collectively herein, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Developed IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;).</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">As between the Parties, OPKO shall own and retain all right, title and interest in and to any Intellectual Property Rights conceived, developed or otherwise first made or reduced to practice by OPKO or its Affiliates, subcontractors or sublicensees in the course of conducting OPKO&#8217;s activities and rights under this Agreement, and that do not name any inventors having an </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">50</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">obligation of assignment to Pfizer at the time such intellectual property is conceived, discovered, developed or otherwise made (collectively herein, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Developed IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Except for the Licensed OPKO Core Patents, the Parties shall jointly own all Intellectual Property Rights conceived, developed or otherwise first made or reduced to practice during the course of the Development, Manufacturing or Commercialization of the Compound or Licensed Products hereunder, and that name any inventors having an obligation of assignment to Pfizer and any inventors having an obligation of assignment to OPKO at the time such intellectual property is conceived, discovered, developed or otherwise made (collectively herein, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Joint Developed IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">For the avoidance of doubt, OPKO Developed IP and OPKO&#8217;s rights in and to any Joint Developed IP shall be deemed and treated as Licensed Technology licensed by OPKO under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> of this Agreement to the extent such OPKO Developed IP and Joint Developed IP relate to Licensed Product. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">For purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, inventorship shall be determined in accordance with applicable United States intellectual property laws, regardless of the country in which such intellectual property is conceived, discovered, developed or otherwise made. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">With regard to intellectual property conceived, discovered, developed or otherwise made or reduced to practice during the course of the Development, Manufacturing or Commercialization of the Compound or Licensed Products, each Party shall promptly notify the other Party of any such intellectual property of which it becomes aware, and the Parties shall confer in a timely manner in order to take such actions as may be reasonably necessary to protect such intellectual property, including but not limited to filing for patent protection.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Trademarks</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.2.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">All Trademarks filed in the Territory shall be owned by Pfizer, and applications for registration of such Trademarks shall be filed and prosecuted by Pfizer with reasonable assistance from OPKO, if necessary. All costs of the filing of applications for registration of Trademarks in the Territory shall be borne solely by Pfizer.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.2.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Effective as of the Original Effective Date, OPKO hereby transfers, releases and assigns to Pfizer, all right, title and interest in and to the Trademark LAGOVA and any associated trademarks, logos, copyrights and domain names related thereto, together with (1) the goodwill associated therewith, and (2) all common law rights in the marks and associated Intellectual Property Rights, for its own use and behalf and for the use and behalf of its successors, assigns, licensees and other legal representatives.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Patent Prosecution and Maintenance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.3.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Prosecution and Maintenance of Licensed OPKO Core Patents and OPKO Developed IP. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">51</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">First Right to File, Prosecute and Maintain</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to Pfizer&#8217;s rights set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.1(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> below, OPKO shall have the first right, but not the obligation, to file, prosecute and maintain the Licensed OPKO Core Patents and the OPKO Developed IP (together, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Prosecuted IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) throughout the world, using outside patent counsel, patent agents and an annuity service of OPKO&#8217;s choice that are reasonably acceptable to Pfizer. For avoidance of doubt, nothing herein shall be construed to give OPKO the right to use Pfizer&#8217;s Confidential Information in prosecuting OPKO Prosecuted IP or in connection with such prosecution, or prosecute Licensed hGH-Specific Patents (except as otherwise provided with respect to certain continuations, continuations-in part and divisionals pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.2(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">), without Pfizer&#8217;s prior written consent. At least forty-five (45) calendar days prior to the applicable date for national stage filing of any international patent application filed under the Patent Cooperation Treaty that is a OPKO Prosecuted IP, OPKO shall provide Pfizer with a list of countries and regions into which OPKO intends to file such national stage applications. This list shall include at least the Major Market Countries. Pfizer may request that OPKO file such national stage applications in one or more additional countries. Except as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.1(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, OPKO shall retain the sole right and responsibility for prosecuting, maintaining and defending the OPKO Prosecuted IP filed under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO shall be responsible for *** and Pfizer shall be responsible for *** of direct out-of-pocket costs incurred in such activities&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> if Pfizer provides a written request to OPKO that OPKO file the OPKO Prosecuted IP in a jurisdiction outside the Major Market Countries, *** shall be responsible for *** of direct out-of-pocket costs (including any required translation costs) incurred in such activities. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Review and Comment.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> OPKO shall keep Pfizer advised on the status of the prosecution and maintenance of all Licensed Products and Compounds of the OPKO Prosecuted IP in the ordinary course of patent prosecution and in such manner as OPKO or OPKO&#8217;s counsel and&#47;or management is informed. OPKO shall provide quarterly docket reports as well as updated docket reports as requested by Pfizer for all Licensed Product and Compounds of the OPKO Prosecuted IP. For the Major Market Countries, and any other countries or patent offices specifically requested in writing by Pfizer, OPKO shall allow Pfizer a reasonable opportunity and reasonable time to review and comment regarding substantive communications from the relevant patent offices or Governmental Authorities and drafts of any responses or other proposed substantive filings before any such filings are submitted to any relevant patent offices or Governmental Authorities, and OPKO shall consider in good faith any reasonable comments offered by Pfizer in preparing any final filings to be submitted to any relevant patent offices or Governmental Authorities.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Election to Not Prosecute or Maintain</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If OPKO at any time abandons or declines to continue prosecution or maintenance of the patents and applications in a particular country for any Licensed Product and Compounds of the OPKO Prosecuted IP, OPKO shall provide Pfizer with forty-five (45) days prior written notice to such effect, and OPKO shall have no responsibility with respect to the prosecution or maintenance of the applicable Patent Right and no responsibility for any expenses incurred in connection with such Patent Right after the end of such forty-five (45) day period. If Pfizer gives written notice to OPKO before the end of such forty-five (45) day period that Pfizer elects to </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">52</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">continue prosecution or maintenance, (a) OPKO, upon Pfizer&#8217;s request, shall make reasonable efforts to timely execute such documents and perform such acts, at Pfizer&#8217;s expense, as may be reasonably necessary to permit Pfizer to prosecute and maintain such Patent Right at its sole expense, (b) Pfizer shall keep OPKO advised on the status of the prosecution and maintenance of all such Patent Rights annually and at other times as reasonably requested by OPKO, and (c) it is agreed that Pfizer may use internal patent counsel, filing clerks and paralegals employed by Pfizer for such activities, including for coordination of worldwide filings of such Patent Rights, for prosecution before the European Patent Office, and for direction of instructing U.S. outside counsel and ex-U.S. patent agents, including providing draft applications and responses, and that Pfizer may employ its preferred patent agents and&#47;or members of the &#8220;Pfizer Legal Alliance&#8221; to conduct such activities as required for U.S. and ex-U.S. prosecution. If Pfizer does not give written notice to OPKO before the end of such forty-five (45) day period that Pfizer elects to continue prosecution or maintenance of such Patent Right, OPKO shall be entitled to allow such Patent Right to lapse. For avoidance of doubt, nothing herein shall be construed to give Pfizer the right to use OPKO&#8217;s Confidential Information in prosecuting OPKO Prosecuted IP or in connection with such prosecution without OPKO&#8217;s prior written consent.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Patent Term Restoration and Extension</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to Pfizer&#8217;s rights as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.2(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, OPKO shall have the exclusive right, but not the obligation, to seek patent term extensions, supplemental protection certificates and the like available under Applicable Law, including 35 U.S.C. &#167; 156 and applicable foreign counterparts, in any country in the Territory in relation to Licensed Product and Compounds of the OPKO Prosecuted IP. OPKO and Pfizer will cooperate in connection with all such activities. OPKO will give due consideration to all suggestions and comments of Pfizer regarding any such activities, but in the event of a disagreement between the Parties, OPKO will have the final decision-making authority&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> OPKO will seek (or will allow Pfizer to seek) to extend, including through the use of supplemental protection certificates and the like, any OPKO Prosecuted IP at Pfizer&#8217;s request unless, in OPKO&#8217;s reasonable legal determination, such OPKO Prosecuted IP may not be extended under Applicable Law without limiting OPKO&#8217;s right to extend any other Patent Right.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">European Patents with Unitary Effect and Jurisdiction of European Unified Patent Court</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO shall have the exclusive right, but not the obligation, to determine in relation to the OPKO Prosecuted IP whether any Patent Right sought in Europe shall be obtained as a national patent of a European state, or as a European patent with unitary effect, including whether to validate a European patent as a national patent or a patent with unitary effect. Where OPKO has the first or sole right to enforce any Patent Right under this Agreement, unless such right to enforce has passed to Pfizer, OPKO shall have the sole right, at any relevant time in the prosecution or enforcement of such Patent Right, to determine whether to subject such Patent Right to the jurisdiction of the Unified Patent Court, including with respect to any infringement or nullity action, and with respect to any decision whether to opt-in or opt-out of such jurisdiction. OPKO and Pfizer shall cooperate in connection with all such activities, taking such action in Pfizer&#8217;s name if so required. OPKO, its agents and attorneys will give due consideration to all suggestions and comments of Pfizer regarding such </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">53</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">determinations, but in the event of a disagreement between the Parties, OPKO shall have the final decision-making authority.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">For the avoidance of doubt, OPKO shall have no obligations to Pfizer with regard to the prosecution and maintenance of OPKO Prosecuted IP as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Subsections 6.3.1(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">-</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, and Pfizer shall have no rights with regard to the prosecution and maintenance of OPKO Prosecuted IP as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Subsections 6.3.1(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">-</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, to the extent such OPKO Prosecuted IP does not claim or otherwise impact Intellectual Property Rights associated with the Compounds and&#47;or the Licensed Products.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.3.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Prosecution and Maintenance of Licensed hGH-Specific Patents and Pfizer Developed IP.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">First Right to File, Prosecute and Maintain</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Subject to OPKO&#8217;s rights set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.2(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> below, Pfizer shall have the first right, but not the obligation, to file, prosecute and maintain the Licensed hGH-Specific Patents and Pfizer Developed IP (together, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Prosecuted IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) throughout the world, using outside patent counsel, patent agents and an annuity service of Pfizer&#8217;s choice that are reasonably acceptable to OPKO. It is agreed that Pfizer may use internal patent counsel, filing clerks and paralegals employed by Pfizer for such activities, including for coordinating worldwide filings of such Patent Rights, for prosecution before the European Patent Office, and for directly instructing U.S. outside counsel and ex-U.S. patent agents, including providing draft applications and responses. It is also agreed that Pfizer may employ its preferred patent agents and&#47;or members of the &#8220;Pfizer Legal Alliance&#8221; to conduct such activities as required for U.S. and ex-U.S. prosecution. For avoidance of doubt, nothing herein shall be construed to give Pfizer the right to use OPKO&#8217;s Confidential Information or prosecute Licensed OPKO Core Patents in prosecuting Pfizer Prosecuted IP or in connection with such prosecution without OPKO&#8217;s prior written consent. At least forty-five (45) calendar days prior to the applicable date for national stage filing of any international patent application filed under the Patent Cooperation Treaty that is a Licensed hGH-Specific Patents or Pfizer Developed IP, Pfizer shall provide OPKO with a list of countries and regions in which Pfizer intends to file such national stage applications. This list shall include at least the Major Market Countries. OPKO may request that Pfizer file such national stage applications in one or more additional countries. Except as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.1(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer shall retain the sole right and responsibility for prosecuting, maintaining and defending the Pfizer Prosecuted IP filed under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. *** shall be responsible for *** of direct out-of-pocket costs incurred in such activities. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Review and Comment.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> Pfizer shall keep OPKO advised on the status of the prosecution and maintenance of all Pfizer Prosecuted IP in the ordinary course of patent prosecution and in such manner as Pfizer or Pfizer counsel and&#47;or management is informed. Pfizer shall provide quarterly docket reports as well as updated docket reports as requested by OPKO. For the Major Market Countries, and any other countries or patent offices specifically requested in writing by OPKO, Pfizer shall allow OPKO a reasonable opportunity and reasonable time to review and comment regarding substantive communications from the relevant patent offices or Governmental Authorities and drafts of any responses or other proposed substantive filings before any such filings are </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">54</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">submitted to any relevant patent offices or Governmental Authorities, and Pfizer shall consider in good faith any reasonable comments offered by OPKO in preparing any final filings to be submitted to any relevant patent offices or Governmental Authorities. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Election to Not Prosecute or Maintain</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If Pfizer makes a decision to abandon or declines to continue prosecution or maintenance of the patents and applications in a particular country for any Pfizer Prosecuted IP, Pfizer shall provide OPKO with forty-five (45) days prior written notice to such effect, and Pfizer shall have no responsibility with respect to the prosecution or maintenance of the applicable Patent Right and no responsibility for any expenses incurred in connection with such Patent Right after the end of such forty-five (45) day period. If OPKO gives written notice to Pfizer before the end of such forty-five (45) day period that OPKO elects to continue prosecution or maintenance, (a) Pfizer, upon OPKO&#8217;s request, shall make reasonable efforts to timely execute such documents and perform such acts, at OPKO&#8217;s expense, as may be reasonably necessary to permit OPKO to prosecute and maintain such Patent Right at its sole expense and (b) OPKO shall keep Pfizer advised on the status of the prosecution and maintenance of all such Patent Rights annually and at other times as reasonably requested by Pfizer. If OPKO does not give written notice to Pfizer before the end of such forty-five (45) day period that OPKO elects to continue prosecution or maintenance of such Patent Right, Pfizer shall be entitled to allow such Patent Right to lapse. For avoidance of doubt, nothing herein shall be construed to give OPKO the right to use Pfizer&#8217;s Confidential Information in prosecuting Pfizer Prosecuted IP or in connection with such prosecution without Pfizer&#8217;s prior written consent. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Certain Continuations or Divisionals of Licensed hGH-Specific Patents Filed by OPKO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If OPKO believes that there is subject matter in a Licensed hGH-Specific Patent which can form the basis of a patent application which would be considered a Licensed OPKO Core Patent or a Patent Right unrelated to the Compound or Licensed Product, and OPKO wishes to file a continuation, continuation-in-part or divisional application relating to such subject matter, OPKO shall communicate this to Pfizer and provide a copy of such application to Pfizer prior to the filing of this application, and after the application has been filed all official correspondence and draft responses thereto at least ten (10) Business Days before such responses are intended to be filed. Pfizer shall have the opportunity to comment on this application and the draft responses,&#160;and such comments shall be reasonably considered and addressed by OPKO. After communication with and review by Pfizer, OPKO shall have the sole right, but not the obligation to prosecute such applications throughout the world claiming priority to, or the benefit, of a Licensed hGH-Specific Patent as outlined above, provided that the claims are not directed toward the Compound or any Licensed Product.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Patent Term Restoration and Extension</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Upon any Regulatory Approval, Pfizer shall have the exclusive right, but not the obligation, to seek, in OPKO&#8217;s name if so required, patent term extensions, supplemental protection certificates and the like available under Applicable Law, including 35 U.S.C. &#167; 156 and applicable foreign counterparts, in any country in the Territory in relation to the Pfizer Prosecuted IP. OPKO shall have no right to seek patent term extensions, supplemental protection certificates and the like as provided in </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">55</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.1(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> unless (i) Pfizer, in its reasonable discretion, determines not to seek such patent term extensions, supplemental protection certificates and the like in relation to the Pfizer Prosecuted IP, or (ii) the applicable time period to seek such patent term extensions, supplemental protection certificates and the like in relation to the Pfizer Prosecuted IP has lapsed or expired. Pfizer and OPKO will cooperate in connection with all such activities. Pfizer will give due consideration to all suggestions and comments of OPKO regarding any such activities, but in the event of a disagreement between the Parties, Pfizer will have the final decision-making authority&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> Pfizer will seek (or will allow OPKO to seek) to extend, including through the use of supplemental protection certificates and the like, any Pfizer Prosecuted IP at OPKO&#8217;s request unless in Pfizer&#8217;s reasonable legal determination such Pfizer Prosecuted IP may not be extended under Applicable Law without limiting Pfizer&#8217;s right to extend any other Patent Right.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">European Patents with Unitary Effect and Jurisdiction of European Unified Patent Court</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer shall have the exclusive right, but not the obligation, to determine in relation to the Pfizer Prosecuted IP whether any Patent Right sought in Europe shall be obtained as a national patent of a European state, or as a European patent with unitary effect, including whether to validate a European patent as a national patent or a patent with unitary effect. Where Pfizer has the first or sole right to enforce any Patent Right under this Agreement, unless such right to enforce has passed to OPKO, Pfizer shall have the sole right, at any relevant time in the prosecution or enforcement of such Patent Right, to determine whether to subject such Patent Right to the jurisdiction of the Unified Patent Court, including with respect to any infringement or nullity action, and with respect to any decision whether to opt-in or opt-out of such jurisdiction. Pfizer and OPKO shall cooperate in connection with all such activities, taking such action in OPKO&#8217;s name if so required. Pfizer, its agents and attorneys will give due consideration to all suggestions and comments of OPKO regarding such determinations, but in the event of a disagreement between the Parties, Pfizer shall have the final decision-making authority.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.3.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Liability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. To the extent that a Party is obtaining, prosecuting or maintaining a Patent Right or otherwise exercising its rights under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, neither such Party, nor any of its Affiliates, employees, agents or representatives, shall be liable to the other Party in respect of any act, omission, default or neglect on the part of any such Affiliate, employee, agent or representative in connection with such activities undertaken in good faith.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.3.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party shall provide the other Party with all reasonable assistance and cooperation in the patent prosecution and extension efforts in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.3.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, including by providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution or extension applications.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.3.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Status Updates</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party shall provide the other Party with a written status update on the Licensed Patent Rights, including any updates to the list in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 1.98</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, at least once every ***, or earlier upon the reasonable request of the other Party. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Enforcement and Defense of Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">56</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.4.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Notification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party will promptly notify the other Party in writing of any actual, potential, suspected or threatened infringement, misappropriation or other violation by a Third Party of any Licensed Patent Right of which it becomes aware (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Third Party Infringement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;).</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.4.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:138%;vertical-align:top;"> </sup></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Except as otherwise provided in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.4.2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer will have the sole right, but not the obligation, to institute litigation or take other steps to remedy Third Party Infringement of any Licensed Patent Rights other than Licensed OPKO Core Patents, and any such litigation or steps will be at Pfizer&#8217;s expense&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> any recoveries resulting from such litigation or steps relating to Third Party Infringement, after deducting Pfizer&#8217;s out of pocket expenses (including counsel fees and expenses) in pursuing such claim, will be deemed Net Sales of Licensed Products during the Royalty Term and Franchise Gross Profit during the Profit Share Term. Pfizer will not, without the prior written consent of OPKO, enter into any compromise or settlement relating to such litigation that (i) admits the invalidity or unenforceability of any Licensed Patent Right or Pfizer Developed CTP IP, (ii) requires Pfizer to abandon any Licensed Patent Right or Pfizer Developed CTP IP, or (iii) amends the claim. In order to establish standing, OPKO, upon request of Pfizer, agrees to timely commence or to join in any such litigation, at Pfizer&#8217;s expense, and in any event to cooperate with Pfizer in such litigation or steps at Pfizer&#8217;s expense. OPKO will have the right to consult with Pfizer about such litigation and to participate in and be represented by independent counsel in such litigation at OPKO&#8217;s expense. Pfizer will keep OPKO reasonably apprised of the status of such litigation and shall provide to OPKO all relevant communications, notices and&#47;or documents in a timely fashion. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Except as otherwise provided in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.4.2(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, OPKO shall have the first right, but not the obligation, to institute litigation or take other steps to remedy Third Party Infringement of any Licensed OPKO Core Patents and any such litigation or steps will be at OPKO's expense. OPKO will keep Pfizer adequately informed, consult with and work closely with Pfizer, and reasonably consider all recommendations of Pfizer, regarding any such litigation. OPKO will not, without the prior written consent of Pfizer enter into any compromise or settlement relating to such litigation that (i) admits the invalidity or unenforceability of any Licensed Patent Right or Pfizer Developed CTP IP, (ii) requires Pfizer to abandon any Licensed Patent Right or Pfizer Developed CTP IP, or (iii) amends the claim. In order to establish standing, Pfizer, upon request of OPKO, agrees to timely commence or to join in any such litigation, at OPKO's expense, and in any event to cooperate with OPKO in such litigation or steps at OPKO's expense. As noted above, Pfizer shall consult with OPKO regarding such litigation and have the right to participate in and be represented by independent counsel in such litigation at Pfizer's expense. OPKO will keep Pfizer fully apprised of the status of the litigation and shall provide to Pfizer all relevant communications, notices and&#47;or documents, and proposed filings, in a timely fashion. If OPKO decides not to institute litigation or take other steps to remedy Third Party Infringement of any Licensed OPKO Core Patent Right (relating to the Compound or Licensed Product), or if OPKO fails to institute litigation or otherwise take steps to remedy Third Party Infringement within thirty (30) days of its receipt of notice of infringement or such earlier time as required to meet a </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">57</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">deadline in the relevant jurisdiction for instituting such litigation, then Pfizer has the second right, but not the obligation to institute such litigation or take other steps to remedy such Third Party infringement at Pfizer's expense. OPKO will have the right to consult with Pfizer about such litigation and to participate in and be represented by independent counsel in such litigation at OPKO&#8217;s expense. Pfizer will keep OPKO reasonably apprised of the status of such litigation and shall provide to OPKO all relevant communications, notices and&#47;or documents in a timely fashion.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.4.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Election to Not Enforce or Defend</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If Pfizer fails to institute litigation or otherwise take steps to remedy Third Party Infringement within *** days of its receipt of notice, then OPKO will have the right, but not the obligation, upon *** prior notice to Pfizer, at OPKO&#8217;s expense, to institute any such litigation&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> OPKO will only have the foregoing right if Pfizer would not be required (by Applicable Law or otherwise) to join such litigation as a party and such litigation would not involve a Patent Right covering a then-existing Licensed Product. Pfizer will have no obligation to cooperate with OPKO in any such litigation. Neither Party will incur any liability to the other Party as a consequence of any litigation initiated or pursued pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.4.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or any unfavorable decision resulting therefrom, including any decision holding any Licensed Patent Right invalid or unenforceable.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.4.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Other Actions by Third Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party will promptly notify the other Party in the event of any legal or administrative action by any Third Party involving any Licensed Patent Right or Pfizer Developed CTP IP of which it becomes aware, including any nullity, opposition, revocation, interference, reexamination or compulsory licensing proceeding. Pfizer will have the first right, but not the obligation, to defend against any such action involving any Licensed Patent Right, in its own name (to the extent permitted by Applicable Law) or OPKO&#8217;s name, and any such defense will be at Pfizer&#8217;s expense. OPKO, at Pfizer&#8217;s request, agrees to join in any such action at Pfizer&#8217;s expense and in any event to cooperate with Pfizer at Pfizer&#8217;s expense. If Pfizer fails to defend against any such action involving a Licensed Patent Right, then OPKO will have the right to defend such action, in its own name, and any such defense will be at OPKO&#8217;s expense. Pfizer shall keep OPKO reasonably apprised of the status of such Actions and shall allow OPKO a reasonable opportunity and reasonable time to review and comment regarding substantive communications and shall give due consideration to any reasonable comments offered by OPKO.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Allegations of Infringement&#59; Third Party Licenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.5.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Notification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If the Development, Manufacture, Commercialization or use of any Compound or Licensed Product, the practice of any Licensed Technology, or the exercise of any other right granted by OPKO to Pfizer hereunder (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Licensed Activities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) by Pfizer or any of its Affiliates or permitted sublicensees or the practice of any Licensed Technology by OPKO is alleged by a Third Party to infringe, misappropriate or otherwise violate such Third Party&#8217;s Patent Rights or other Intellectual Property Rights, OPKO will notify Pfizer in writing promptly upon becoming aware of such allegation. Additionally, if OPKO determines that, based upon the review of any Third Party Patent Right or other Third Party Intellectual Property Rights, it may be desirable to obtain a license from such Third Party with respect thereto so as to avoid any potential claim of infringement by such Third Party against either Party or their respective Affiliates or sublicensees, then OPKO will promptly notify Pfizer of such determination.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">58</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.5.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Option to Negotiate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If Pfizer determines, in its reasonable discretion, that, in order for Pfizer, its Affiliates or permitted sublicensees to engage in the Licensed Activities, it is necessary to obtain a license under one or more Patent Rights or other Intellectual Property Rights Controlled by a Third Party, then Pfizer will have the right, but not the obligation, to negotiate and enter into a license or other agreement with such Third Party. All amounts payable under any such license or agreement with a Third Party will reduce Pfizer&#8217;s royalty and gross profit payment obligations under this Agreement as and to the extent provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.5.1(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer shall provide OPKO with a copy of all such Patent Rights, shall keep OPKO reasonably apprised of the status of such negotiations, and shall provide to OPKO copies of all relevant communications and&#47;or documents in a timely fashion.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Third Party Infringement Suits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.6.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Notification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party will promptly notify the other Party in the event that any Third Party files suit or brings any other action alleging patent infringement by Pfizer or OPKO or any of their respective Affiliates or sublicensees with respect to the Development, Manufacture, Commercialization or use of any Compound or Licensed Product or the practice of Licensed Technology (any such suit or other action referred to herein as an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Infringement Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.6.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In the case of any Infringement Claim against Pfizer (including its Affiliates or sublicensees) alone or against both Pfizer and OPKO (including its Affiliates), Pfizer will have the right, but not the obligation, to control the defense of such Infringement Claim, including control over any related litigation, settlement, appeal or other disposition arising in connection therewith. OPKO will cooperate with Pfizer and will have the right to consult with Pfizer concerning any Infringement Claim and to participate in and be represented by independent counsel in any associated litigation in which OPKO is a party at OPKO&#8217;s own expense. If Pfizer elects to control the defense of any Infringement Claim then Pfizer will continue to have the right to control using counsel of its own choice and will bear *** of its own attorneys&#8217; fees incurred in investigating, preparing or defending such Infringement Claim. In the case of any Infringement Claim against OPKO alone, Pfizer will have the right to consult with OPKO concerning such Infringement Claim, and Pfizer, upon request of OPKO, will reasonably cooperate with OPKO at OPKO&#8217;s expense (but Pfizer will have no obligation to join any Infringement Claim or associated litigation).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Orange Book Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer will have the sole right, but not the obligation, to submit to all applicable Governmental Authorities patent information pertaining to each Licensed Product pursuant to 21 U.S.C. &#167; 355(b)(1)(G) (or any amendment or successor statute thereto), any similar statutory or regulatory requirement enacted in the future regarding biologic products, or any similar statutory or regulatory requirement in any non-U.S. country or other regulatory jurisdiction. Pfizer shall keep OPKO reasonably apprised of the status of such submissions and shall provide to OPKO all relevant communications, notices and&#47;or documents regarding such submissions in a timely fashion.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">6.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Biosimilar Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Notwithstanding any provision of this Agreement to the contrary, each Party shall, within three (3) Business Days after receipt thereof, give written notice to the other of any notice received from a Third Party of an application for FDA approval under the Biologics Price Competition and Innovation Act of 2009 (or any amendment or successor statute thereto) of a Biosimilar Product, or any certification under a similar statutory or regulatory requirement in any non-United States country in the Territory, claiming that a </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">59</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Licensed Patent Right covering any Product is invalid or that infringement will not arise from the Development, Manufacture or Commercialization of a proposed Biosimilar Product by a Third Party. Upon the giving of such notice, Pfizer shall have the first right but not the obligation, to bring an infringement action against such Third Party in connection with such certification, with the rights and obligations of the Parties as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer shall notify OPKO at least ten (10) Business Days prior to the date set forth by statute or regulation with respect to the first response to be made by the BLA holder, of its intent to exercise, or not exercise, this right, and, if Pfizer does not exercise this right, the Parties will have the rights and obligations as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Any infringement action against a Third Party arising under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall be governed by the provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 6.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">CONFIDENTIALITY.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Definition</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Confidential Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means, with respect to each Party, all Licensed Know-How or other information, including proprietary information and materials (whether or not patentable) regarding or embodying such Party&#8217;s technology, products, business information or objectives, that is communicated by or on behalf of the Disclosing Party to the Receiving Party or its permitted recipients, on or after the Original Effective Date, but only to the extent that such Licensed Know-How or other information in written form is marked in writing as &#8220;confidential&#8221; at the time of disclosure, and such Licensed Know-How or other information disclosed orally or in non-tangible form is (a) identified by the Disclosing Party as &#8220;confidential&#8221; at the time of disclosure and (b) within thirty (30) days thereafter, the Disclosing Party provides a written summary of such Know-How or other information marked as &#8220;confidential&#8221;. Notwithstanding the foregoing, information disclosed orally or in non-tangible form that is not subsequently summarized in writing shall be treated as Confidential Information if the circumstances of the disclosure or the nature of the information would reasonably be expected to be confidential. Confidential Information does not include any Licensed Know-How or other information that (a) was already known by the Receiving Party (other than under an obligation of confidentiality to the Disclosing Party) at the time of disclosure by or on behalf of the Disclosing Party, (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party, (c) became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party, other than through any act or omission of the Receiving Party in breach of its obligations under this Agreement, (d) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to the Receiving Party or (e) was independently discovered or developed by or on behalf of the Receiving Party without the use of any Confidential Information belonging to the Disclosing Party. The terms and conditions of this Agreement will be considered Confidential Information of both Parties.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Obligation&#59; Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Except to the extent otherwise expressly authorized by this Agreement, the Parties agree that, during the Term and for *** thereafter, each Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Receiving Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) receiving any Confidential Information of the other Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Disclosing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) hereunder will&#58; (a) keep the Disclosing Party&#8217;s Confidential Information confidential&#59; (b) not disclose, or permit the disclosure of, the Disclosing Party&#8217;s Confidential Information&#59; and (c) not use, or permit to be used, the Disclosing Party&#8217;s Confidential Information for any purpose other than as expressly permitted under the terms of this Agreement. For clarity, use of the Disclosing Party&#8217;s Confidential Information for the purpose of invalidating Licensed Patent Rights is not a purpose expressly permitted under the terms of the Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Disclosure to Party Representatives</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Notwithstanding the provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">60</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to the Receiving Party&#8217;s Representatives who (a) have a need to know such Confidential Information in connection with the performance of the Receiving Party&#8217;s obligations or the exercise of the Receiving Party&#8217;s rights under this Agreement and (b) have agreed in writing to non-disclosure and non-use provisions with respect to such Confidential Information that are at least as restrictive as those set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Disclosure to Third Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Notwithstanding the provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.4.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to Governmental Authorities (a) to the extent desirable to obtain or maintain Regulatory Approvals for any Compound or Licensed Product within the Territory, and (b) in order to respond to inquiries, requests or investigations relating to any Compound, Licensed Product or this Agreement&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.4.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to outside consultants, contractors, advisory boards, managed care organizations, non-clinical and clinical investigators, and bona fide potential or actual sublicensees, collaborators, partners or permitted assignees, in each case to the extent desirable to Develop, register or Commercialize any Compound or Licensed Product&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> the Receiving Party will obtain the same confidentiality obligations from such Third Parties as it obtains with respect to its own similar types of confidential information&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.4.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">in connection with filing or prosecuting Patent Rights or Trademarks as permitted by this Agreement&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.4.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">in connection with prosecuting or defending litigation as permitted by this Agreement&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.4.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">in connection with posting results of and other information about clinical trials to clinicaltrials.gov or PhRMA websites&#59; or</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.4.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to the extent necessary or desirable in order to enforce its rights under this Agreement.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If a Party deems it reasonably necessary to disclose Confidential Information belonging to the other Party pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 7.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, then the disclosing Party shall to the extent possible give sufficient advance written notice of such disclosure to the other Party and take such measures to ensure confidential treatment of such information as is reasonably required by the other Party, at the other Party&#8217;s expense. If reasonably practicable under the circumstances, the disclosing party shall give the other Party sufficient advance notice of the text that such Party will have the opportunity to seek, at its own cost, an appropriate protective order or other remedy or waive compliance with the provisions of this Agreement. If a Party seeks a protective order, the other Party agrees to cooperate. If the Party seeking the protective order fails to obtain the protective order or waive compliance with the relevant portions of this Agreement, the other Party will disclose only that portion of information concerning the Compound or Licensed Product that its legal counsel determines it is required to disclose.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">SEC Filings and Other Disclosures</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Either Party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of such Party&#8217;s legal counsel, to comply with Applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange Commission or any equivalent governmental agency in any country in the world. Before disclosing this Agreement or any of the terms hereof pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure, with the disclosing Party providing as much advanced </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">61</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">notice as is feasible under the circumstances, and giving consideration to the comments of the other Party. Further, if a Party discloses this Agreement or any of the terms hereof in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, such Party shall, at its own expense, seek such confidential treatment of confidential portions of this Agreement and such other terms, as may be reasonably requested by the other Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Residual Knowledge Exception</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Notwithstanding any provision of this Agreement to the contrary, Residual Knowledge shall not be considered Confidential Information for purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Announcements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Except as may be expressly permitted under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, and except for OPKO&#8217;s press release which shall be in the form of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Exhibit C</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> attached hereto, neither Party will make any public announcement regarding this Agreement without the prior written approval of the other Party. For the sake of clarity, nothing in this Agreement shall prevent Pfizer from making any scientific publication or public announcement with respect to any Licensed Product under this Agreement&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, except as permitted under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer shall not disclose any of OPKO&#8217;s Confidential Information in any such publication or announcement without obtaining OPKO&#8217;s prior written consent to do so.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Publications</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.8.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Publications by Pfizer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. During the Term, Pfizer shall submit to OPKO for review and approval any proposed academic, scientific and medical publication or public presentation that contains OPKO&#8217;s Confidential Information or relates to a Compound or Licensed Product. Such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing OPKO&#8217;s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to OPKO no later than *** before submission for publication or presentation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Review Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). OPKO shall provide its comments with respect to such publications and presentations within *** of its receipt of such written copy. The OPKO Review Period may be extended for an additional *** in the event OPKO can, within *** of receipt of the written copy, demonstrate reasonable need for such extension, including for the preparation and filing of patent applications. Pfizer will comply with standard academic practice regarding authorship of scientific publications and recognition of the contribution of other parties in any publication governed by this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.8.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For the sake of clarity, Pfizer&#8217;s obligation to submit any publication to OPKO for review and approval under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.8.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall not apply to any publication that does not contain OPKO&#8217;s Confidential Information or relate in any manner to the Compound or Licensed Product.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">7.8.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Publications by OPKO. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">During the Term, OPKO shall submit to Pfizer for review and approval any proposed academic, scientific and medical publication or public presentation that contains Pfizer&#8217;s Confidential Information or relates to a Compound or Licensed Product. Such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing the Pfizer&#8217;s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than *** days before submission for publication or presentation (the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">62</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Review Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). Pfizer shall provide its comments with respect to such publications and presentations within *** days of its receipt of such written copy. The Pfizer Review Period may be extended for an additional *** days in the event Pfizer can, within of receipt of the written copy, demonstrate reasonable need for such extension, including for the preparation and filing of patent applications. OPKO will comply with standard academic practice regarding authorship of scientific publications and recognition of the contribution of other parties in any publication governed by this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.8.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For the sake of clarity, (x) OPKO shall not include in its academic, scientific and medical publications and public presentations any pre-clinical and clinical data and results relating to a Compound or Licensed, including without limitation any such data and results provided to Pfizer under this Agreement, without Pfizer&#8217;s prior written consent, such consent not to be unreasonably withheld and (y) OPKO&#8217;s obligation to submit any publication to Pfizer for review and approval under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 7.8.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall not apply to any publication that does not contain Pfizer&#8217;s Confidential Information or relate in any manner to the Compound or Licensed Product.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">REPRESENTATIONS, WARRANTIES AND COVENANTS.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Mutual Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each of OPKO and Pfizer hereby represents and warrants to the other Party, as of the Original Execution Date, as of the Original Effective Date and as of the Amendment Execution Date that&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.1.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.1.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite action under the provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any of its shareholders or other holders of its voting securities or voting interests&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.1.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.1.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">this Agreement has been duly executed and is a legal, valid and Binding Obligation on each Party, enforceable against such Party in accordance with its terms&#59; and</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.1.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">the execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of or default under any Binding Obligation. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Mutual Covenants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each of OPKO and Pfizer hereby covenants to the other Party that&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.2.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">from the Original Effective Date until the expiration or termination of this Agreement, it will perform its obligations under this Agreement in compliance in all material respects with Applicable Laws&#59; and</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.2.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">with respect to any Licensed Products, payments or services provided under this Agreement, such Party has not taken and will not during the Term take any action, directly or indirectly, to offer, promise or pay, or authorize the offer or payment of, any money or anything of value in order to improperly or corruptly seek to influence </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">63</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">any Government Official or any other person in order to gain an improper advantage, and has not accepted, and will not accept in the future, such payment.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO hereby represents and warrants to Pfizer, as of the Original Execution Date and as of the Original Effective Date  that&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:138%;"> </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">except as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 8.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, OPKO and its Affiliates own all right, title and interest to the Licensed Technology, all of which is clear of any claims, liens, charges or encumbrances, including under any OPKO Third Party Agreement, that would prevent OPKO from granting the rights it is granting to Pfizer hereunder or conflict with the grant of those rights&#59; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO (including as necessary through appropriate licenses granted to OPKO by its Affiliates) has the full right, power and authority to grant all of the right, title and interest in the licenses and other rights granted or to be granted to Pfizer, Pfizer&#8217;s Affiliates or Pfizer&#8217;s sublicensees under this Agreement&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 1.98</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> sets forth a true and complete list of all Patent Rights that are a part of the Licensed Technology owned or otherwise Controlled by OPKO or its Affiliates that relate to the Compounds or Licensed Products, or their manufacture or use, including in the case of Patent Rights that are licensed to OPKO, the name of the owner(s) and licensor(s) and the agreement(s) providing OPKO with Control, (b) each such Patent Right remains in full force and effect and (c) OPKO or its Affiliates have timely paid, including within any extension or grace periods, all filing and renewal fees payable with respect to such Patent Rights&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to its knowledge, it has made available to Pfizer all material scientific and technical information and safety and efficacy information in its possession with respect to the Compounds and Licensed Products&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to its knowledge, no Third Party has challenged or threatened in writing to challenge the inventorship, Control, right to use, scope, validity or enforceability of any Licensed Patent Right (including, by way of example, through the institution or written threat of institution of interference, derivation, post-grant review, opposition, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority)&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">it has complied with all Applicable Laws, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the Licensed Patent Rights&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">except as expressly disclosed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 8.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, to its knowledge, OPKO and its Affiliates have independently developed all Licensed Know-How or otherwise have a valid right to use, and to permit Pfizer, Pfizer&#8217;s Affiliates and Pfizer&#8217;s permitted sublicensees to use, the Licensed Know-How for all permitted purposes under this Agreement&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO and its Affiliates have obtained, from all inventors of Licensed Technology, valid and enforceable agreements assigning to OPKO each such inventor&#8217;s entire right, title and interest in and to all such Licensed Technology&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">except as disclosed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 8.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, to its knowledge, other than ordinary course governmental rights that apply to research performed with federal state or local </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">64</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">institutions, no Licensed Technology is subject to any funding agreement with any government or Governmental Authority&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">except as expressly disclosed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 8.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, neither OPKO nor any of its Affiliates are party to or otherwise subject to any agreement or arrangement which limits the ownership or licensed rights of Pfizer or its Affiliates with respect to, or limits the ability of Pfizer or its Affiliates to grant a license, sublicense or access, or provide or provide access or other rights in, to or under, any Intellectual Property Right or material (including any Patent Right, Know-How or other data or information) as related to the Compound or Licensed Product, in each case, that would, but for such agreement or arrangement, be included in the rights licensed or assigned to Pfizer or its Affiliates pursuant to this Agreement&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> there are no OPKO Third Party Agreements, other than the OPKO Third Party Agreements disclosed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 8.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Disclosed Third Party Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), true and complete copies of which have been made available to Pfizer, pursuant to which (a) any Third Party has any right, title or interest in or to, or any license or covenant not to sue under, any Licensed Technology licensed hereunder, or (b) rights granted by or to OPKO or its Affiliates conflict with any right or license granted to Pfizer or its Affiliates hereunder&#59; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to its knowledge, neither the Compound, nor the Development, Manufacture or manufacture and use of the Compound as conducted by OPKO prior to the Original Execution Date infringes any then-issued Patent Right of a Third Party&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to its knowledge, the parties to the Disclosed Third Party Agreements are in compliance in all material respects with all Disclosed Third Party Agreements except to the extent such noncompliance would not conflict with any right or license granted to Pfizer or its Affiliates hereunder&#59; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to its knowledge, OPKO, its Affiliates and all other Third Parties that have conducted or have otherwise provided materials, support or services for any ongoing Trials are and have been in material compliance with all Applicable Laws, including, where applicable, compliance with GCP, and are and have been in material compliance with any other agreed upon quality standards, in each case at every stage during the said Trials (including protocol and database development, Trial site feasibility and initiation, subject enrollment, Trial study conduct, analysis and reporting) and have not been the subject of any regulatory enforcement action by any Regulatory Authority, or of any circumstances that would give rise to any such Third Parties being the subject of any regulatory enforcement action by any Regulatory Authority&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO is not, and, to its knowledge, no (a) current licensor or (b) clinical research investigator, institution or other Third Party acting on behalf of OPKO in connection with a Trial under a written agreement for services or rights related to Licensed Product (in each case, as applicable) is debarred by any Regulatory Authority or the subject of debarment proceedings by any Regulatory Authority and, in the course of the Development of any Compound, OPKO has not used, and, to its knowledge, (i) no current licensor nor (ii) any clinical research investigators, institutions or other Third Parties acting on behalf of OPKO in connection with a Trial (in each case, as applicable)&#160;has used, any employee or consultant that is debarred by any Regulatory Authority or, to OPKO&#8217;s knowledge, is the subject of debarment proceedings by any Regulatory Authority&#59;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">65</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.16.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to its knowledge, there is no (a) claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to its knowledge, threatened against OPKO or any of its Affiliates or (b) judgment or settlement against or owed by OPKO or any of its Affiliates, in each case in connection with the Licensed Technology, any Compound or any Licensed Product or relating to the transactions contemplated by this Agreement&#59; and</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.3.17.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a) Invitrogen and its successors have no claim on or other interest in the MOD-4023 cells or any use thereof, (b) other than the license that is in place between OPKO or its Affiliates and Invitrogen or its successor relating to DG44 Materials, no additional license is required from Invitrogen or its successors in order to permit the use of the DG44 Materials or the MOD-4023 cells in commercial bioproduction applications, including for commercial production of Licensed Products, and (c) the only further Third Party intellectual property license that needs to be put in place in order enable the use of the DG44 Materials or the MOD-4023 cells in commercial bioproduction applications, including for commercial production of Licensed Products, without infringing the Intellectual Property Rights of any Third Party is a license for use of these materials in commercial bioproduction applications to be obtained from Lawrence Chasin and Gail Urlaub Chasin.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Reference to &#8220;its knowledge&#8221; in any of the above provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means actual knowledge of senior management of OPKO and its Affiliates or other employees of OPKO and its Affiliates responsible for patent matters after reasonable and due inquiry.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Covenants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In addition to the covenants made by OPKO elsewhere in this Agreement, OPKO hereby covenants to Pfizer that, from the Original Effective Date until expiration or termination of this Agreement, other than in connection with the Agreement&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.4.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">it shall not, and shall cause its Affiliates not to, incur or permit to exist, with respect to any Licensed Technology related to the Compound or any Licensed Product, any lien, encumbrance, charge, security interest, mortgage, liability, assignment, grant of license or other Binding Obligation that is or would be inconsistent with the licenses and other rights granted to Pfizer or its Affiliates under this Agreement&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.4.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">it will (a) not enter into any OPKO Third Party Agreement that adversely affects (i) the rights granted to Pfizer, Pfizer&#8217;s Affiliates or sublicensees hereunder or (ii) OPKO&#8217;s ability to fully perform its obligations hereunder&#59; (b) not amend or otherwise modify any OPKO Third Party Agreement (including any Disclosed Third Party Agreement) or consent or waive rights with respect thereto in any manner that (i) adversely affects the rights granted to Pfizer or Pfizer&#8217;s Affiliates or sublicensees hereunder or (ii) OPKO&#8217;s ability to fully perform its obligations hereunder&#59; (c) promptly furnish Pfizer with true and complete copies of all amendments to the Disclosed Third Party Agreements and OPKO Third Party Agreements, relating to a Trial and related amendments executed following the Original Effective Date&#59; (d) remain, and cause its Affiliates to remain, in compliance in all material respects with all OPKO Third Party Agreements relating to a Trial (including Disclosed Third Party Agreements)&#59; and (e) furnish Pfizer with copies of all notices received by OPKO or its Affiliates relating to any alleged breach or default by OPKO or its Affiliates under any OPKO Third Party Agreement relating to a Trial (including and Disclosed Third Party Agreement) within five (5) Business Days after receipt thereof&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.4.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">where OPKO&#8217;s or its Affiliates&#8217; ownership of all right, title and interest to the Licensed Technology is based upon or depends on a sequence of historical transfers </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">66</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">of title to any of the Licensed Technology (i.e. chain of title to the Licensed Technology) being valid, effective and free from defects and other problems, if at any time there is a potential defect with the validity or effectiveness in such transfers or other problems in such chain of title, then OPKO and its Affiliates shall, at their expense, with urgency and diligence make any and all corrections and clarifications, including preparing any documents and obtaining any necessary Third Party signatures and consents, as may be necessary, including filing such documents in any patent office as appropriate, to remedy any such problems and to restore such chain of title&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.4.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">it will not enter into or otherwise allow itself or its Affiliates to be subject to any agreement or arrangement that limits the ownership or licensed rights of Pfizer or its Affiliates with respect to, or limits the ability of Pfizer or its Affiliates to grant a license, sublicense or access, or provide or provide access or other rights in, to or under, any existing Licensed Technology or material (including any Patent Right, Know-How or other data or information) as related to the Compound or Licensed Product, in each case, that would, but for such agreement or arrangement, be included in the rights licensed or assigned to Pfizer or its Affiliates pursuant to this Agreement&#59; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.4.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">unless otherwise agreed by the Parties, it will maintain valid and enforceable agreements with all Persons acting by or on behalf of OPKO or its Affiliates under this Agreement that require such Persons to assign to OPKO their entire right, title and interest in and to all Licensed Technology as related to the Compound or Licensed Product&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.4.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO and its Affiliates shall, at their sole expense, timely satisfy in full any and all obligations owed to Israel&#8217;s Office of the Chief Scientist within the Ministry of Economy (&#8220;OCS&#8221;), including in relation to any grants OCS previously provided to OPKO or its Affiliates, in each case relating to the Licensed Products and&#47;or the Development thereof&#59; and</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.4.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Promptly following the Original Effective Date, OPKO shall obtain, at its cost and expense, a license for commercial bioproduction applications to utilize the DG44 cell line materials used by OPKO and its Affiliates in relation to the Licensed Products (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">DG44 Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), which license shall be obtained in such a manner that it extends to each of Rentschler, Pfizer and any designee of OPKO in the event of a termination of this Agreement or a *** hereunder. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.5.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">***  </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.5.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">***  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Compliance with Law and Ethical Business Practices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In addition to the other representations, warranties and covenants made by each Party elsewhere in this Agreement, each Party represents and warrants or covenants and agrees, as applicable, with the other Party that during the Term&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.6.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">it is licensed, registered, or qualified under all Applicable Laws to do business, and has obtained such licenses, consents, authorizations or completed such registrations or made such notifications as may be necessary or required by Applicable Law to provide any products, goods or services encompassed within this Agreement, and </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">67</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">providing such products, goods or services is not inconsistent with any other obligation of such Party&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.6.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">in conducting its activities hereunder, such Party will and will cause its Affiliates and, to the extent of its legal right to do so, use reasonable efforts to cause its other Representatives to comply in all material respects with all Applicable Laws and accepted pharmaceutical industry business practices, including, to the extent applicable to such Party and each of its Affiliates and other Representatives&#58; the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301, et seq.), the Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b), the Civil Monetary Penalty Statute (42 U.S.C. &#167; 1320a-7a), the False Claims Act (31 U.S.C. &#167; 3729 et seq.), comparable state statutes, the regulations promulgated under all such statutes, and the regulations issued by the FDA&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.6.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">with respect to any products, payments or services provided under this Agreement, it has not taken and will not during the Term take any action directly or indirectly to offer, promise or pay, or authorize the offer or payment of, any money or anything of value in order to improperly or corruptly seek to influence any Government Official or any other person in order to gain an improper advantage, and has not accepted, and will not accept in the future, such payment&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.6.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">it complies with the laws and regulations of the countries where it operates, including anti-bribery and anti-corruption laws, accounting and record keeping laws, and laws relating to interactions with healthcare professionals or healthcare providers and Government Officials&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.6.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to its knowledge, it and each of its Affiliates has been and will, for the Term, be in compliance with all applicable global trade laws, including those related to import controls, export controls or economic sanctions, and such Party will cause each of its Affiliates to remain in compliance with the same during the Term&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.6.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">to its knowledge, except to the extent permissible under United States law, neither it nor any of its Affiliates has, on its own behalf or acting on behalf of any other Person, directly or indirectly engaged with, and will not for the Term, directly or indirectly engage in any transactions with, or otherwise deal with, any country or Person targeted by United States, European Union, United Kingdom or other relevant economic sanctions laws in connection with any activities related to such Party&#8217;s interaction with the other Party, including those contemplated under this Agreement&#59; and </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.6.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">it is, as between the Parties, solely responsible for ensuring Compliance by it and its Affiliates.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Representation by Legal Counsel</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption shall exist or be implied against the Party which drafted such terms and provisions.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">8.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Disclaimer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. THE REPRESENTATIONS AND WARRANTIES OF EACH PARTY IN THIS AGREEMENT ARE IN LIEU OF ANY OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">68</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">TERM AND TERMINATION.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The term of this Agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) will commence on the Original Execution Date and end as follows&#58; (a) if the Royalty Term expires prior to the initiation of a Profit Share Term, the Term shall terminate at end of the Royalty Term&#59; (b) if a Profit Share Term begins prior to the expiration of the Royalty Term, the Term shall terminate *** in the Territory, unless, in either case of (a) and (b), this Agreement is terminated earlier as permitted in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Termination for Uncured Material Breach</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Either Party may terminate this Agreement for cause at any time during the Term by giving written notice to the other Party in the event that such other Party commits a material breach of its obligations under this Agreement and such material breach remains uncured for *** days (or *** days for any payment breach) from the date of receipt of such notice by the breaching Party&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> if any breach is not reasonably curable within *** days and if the breaching Party is making a bona fide effort to cure such breach, such termination shall be delayed for a time period to be agreed by both Parties in order to permit the breaching Party a reasonable period of time to cure such breach. If the breaching Party disputes in good faith that it has materially breached one of its obligations under this Agreement, termination shall not take effect pending resolution of such dispute pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> so long as Commercialization of Genotropin Products and Licensed Products continues in at least all countries in which Commercialization was ongoing as of the date of receipt of written notice of breach by the breaching Party. If, as a result of the application of such dispute resolution procedures, the breaching Party is determined to be in material breach of one or more of its obligations under this Agreement, then if the breaching Party fails to complete the actions specified to cure such breach within *** days (or *** days for any payment breach) after such ruling, then the complaining Party may terminate this Agreement upon written notice to the breaching Party.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Termination at Will</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Upon delivery of at least *** prior written notice to OPKO, Pfizer shall have the right to terminate this Agreement for any reason (a) in its entirety or (b) with respect ***. For clarity, termination by Pfizer of the last remaining *** under this Agreement shall be deemed to be termination of this Agreement in its entirety.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Termination for a Bankruptcy Event</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.4.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Termination Right</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Each Party shall have the right to terminate this Agreement in the event of a Bankruptcy Event with respect to the other Party. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Bankruptcy Event</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; means the occurrence of any of the following&#58; (a) the institution of any bankruptcy, receivership, insolvency, reorganization or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code, as amended, or under any similar laws or statutes of the United States or any state thereof (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Bankruptcy Code</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), where in the case of involuntary proceedings such proceedings have not been dismissed or discharged within ninety (90) days after they are instituted, (b) the filing of an insolvency proceeding or making of an assignment for the benefit of creditors or the admittance by a Party of any involuntary debts as they mature, (c) the institution of any reorganization, arrangement or other readjustment of debt plan of a Party not involving the Bankruptcy Code, (d) appointment of a receiver for all or substantially all of a Party&#8217;s assets, or (e) any corporate action taken by the board of directors of a Party in furtherance of any of the foregoing actions.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.4.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Rights to Intellectual Property. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">All rights and licenses granted under or pursuant to this Agreement by OPKO are, and shall otherwise be deemed to be, for </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">69</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101 of the Bankruptcy Code. The Parties agree that Pfizer, as licensee of intellectual property under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that in the event of a rejection of this Agreement by OPKO in any bankruptcy proceeding by or against OPKO under the Bankruptcy Code or foreign equivalent, (a) Pfizer shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in Pfizer&#8217;s possession, shall be promptly delivered to it upon Pfizer&#8217;s written request therefor, and (b) OPKO shall not interfere with Pfizer&#8217;s rights to intellectual property and all embodiments of intellectual property, and shall assist and not interfere with Pfizer in obtaining intellectual property and all embodiments of intellectual property from another entity. The term &#8220;embodiments&#8221; of intellectual property includes all tangible, intangible, electronic or other embodiments of rights and licenses hereunder, including all compounds and products embodying intellectual property, Licensed Products, filings with Regulatory Authorities and related rights, and Licensed Technology.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Effects of Expiration or Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.5.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Partial Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In case of termination of this Agreement, not in its entirety, but with respect to only ***, by Pfizer pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Partial Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221; and *** in which such Partial Termination occurs, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), then the effects of termination described under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall only apply to the ***, and this Agreement shall remain in full force and effect in accordance with its terms in *** of the Territory. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.5.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Termination by OPKO for Uncured Material Breach or Bankruptcy Event&#59; Termination by Pfizer at Will</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In the event that OPKO terminates this Agreement pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, or Pfizer terminates this Agreement in whole or in part pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, the following will apply in respect of the *** or Agreement, as the case may be.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Effective upon the date of termination for the Agreement or each ***, Pfizer hereby grants to OPKO a fully ***, non-exclusive, perpetual, irrevocable, sublicenseable right and license under (i) the Pfizer Developed IP and (ii) any other Patent Rights and Know-How Controlled by Pfizer and its Affiliates as of the effective date of termination that is necessary to continue the Development, Manufacture and Commercialization of Compounds and Licensed Products, in each case, to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, and have Commercialized Compounds and Licensed Products&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> upon request of OPKO, the Parties shall negotiate in good faith ***. Neither Party will be obligated to enter into any transaction described in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.5.2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, and neither Party will have any liability to the other for failure to do so. *** OPKO shall be responsible for any royalties or other payments payable to Third Parties with respect to the use by OPKO and its Affiliates and sublicensees of any Patent Rights or Know-How licensed to OPKO under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.5.2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Marks</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. To the extent that Pfizer is Commercializing any Licensed Product under any Trademark that is neither (i) used for any other products in Pfizer&#8217;s portfolio, nor (ii) confusingly similar to any other trade mark used for any </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">70</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">other products in Pfizer&#8217;s portfolio, Pfizer shall, upon OPKO&#8217;s request, assign such Trademark to OPKO. As part of the termination transition plan, the Parties shall reach agreement on commercially reasonable terms for procedures and obligations to address functional areas in which each Party&#8217;s respective Licensed Product activities inside and outside of the Territory following termination of *** may have an impact on one another, including pharmacovigilance, coordination of brand messaging and coordination on any further Development efforts.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Transition. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Prior to the effective date of any termination or partial termination of this Agreement, the Parties shall negotiate in good faith and agree upon an outline and estimated schedule for transition of Intellectual Property Rights and Licensed Products to OPKO, to be reflected in a commercially reasonable termination transition plan and, if appropriate, a transition agreement, to seek to minimize any disruption to the Development or Commercialization of the Licensed Product (including therapy and coverage for patients, patient support activities, and pharmacovigilance reporting). The termination transition plan, and any transition agreement, shall provide for undertaking Commercially Reasonable Efforts for development and regulatory activities, support in commercialization activities, and such other matters as the parties may agree, including, if appropriate, a governance structure to allow for decision-making to be made on transition issues. Pfizer shall use diligent efforts to cooperate with OPKO or its designee to effect a smooth and orderly transition, which transition shall not exceed ***, except with respect to supply of Licensed Product which shall continue for the period contemplated herein.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Ongoing Trials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In the event of&#58; (x)&#160;a termination of this Agreement in its entirety, with respect to ongoing clinical trials and investigator-initiated trials involving a Licensed Product or related Device supported, directly or indirectly, by Pfizer or its Affiliates&#59; or (y)&#160;in the event of a termination of this Agreement in part by Pfizer pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, with respect to those ongoing clinical trials and investigator-initiated trials involving a Licensed Product or related Device supported, directly or indirectly, by Pfizer or its Affiliates that relate only to a country or countries that are located in the *** so terminated&#59; the Parties will, with respect to such trials&#58;</font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Within *** days of the date of the notice of termination, Pfizer will provide OPKO with a list of ongoing clinical trials and investigator-initiated trials involving a Licensed Product or related Device supported, directly or indirectly, by Pfizer or its Affiliates. The trial listing shall include material details of the trials such as protocol summary, dates, sites, budget expended and estimated budget remaining, number of patients, current enrollment and safety issues. Pfizer shall promptly answer any questions of OPKO as to the status or details of any such trial. Prior to the date of termination, OPKO will notify Pfizer as to any trial for which OPKO wishes to assume responsibility and, Pfizer shall, at OPKO&#8217;s cost and expense for activities after termination, complete such Trial. Notwithstanding the foregoing, Pfizer may prematurely suspend or terminate any such Trial if (A) a priori protocol defined stopping rules are met for safety or efficacy or (B) unacceptable safety signals are observed by Pfizer or a data and safety monitoring board with respect to the Licensed Product that present an unacceptable risk to patients participating in such trials.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">71</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">With respect to any ongoing Trials involving a Licensed Product for which OPKO has notified Pfizer prior to the effective date of termination that it wishes to assume responsibility (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, with ***, OPKO shall be required to assume responsibility for such Trial and the provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.5.2(d)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall apply to such Trial) (A) each Party shall cooperate with the other Party to facilitate the orderly transfer to OPKO of the conduct of such Trials as soon as reasonably practicable after the effective date of termination, (B) until such time as the conduct of such Trials has been successfully transferred to OPKO, Pfizer shall continue such Trials, (C) between the effective date of termination and the date on which the conduct of such Trials has been successfully transferred to OPKO, OPKO shall be responsible for, and shall reimburse Pfizer with respect to, all costs and expenses reasonably incurred by Pfizer in the conduct of such Trials, and (D) following the date on which the conduct of such Trials has been successfully transferred to OPKO, OPKO shall be solely responsible for all costs and expenses of such ongoing Trials.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Assignment of Filings and Marketing Approvals.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> At OPKO&#8217;s option, which shall be exercised by written notice to Pfizer, to the extent permitted under Applicable Laws, Pfizer shall assign or cause to be assigned to OPKO or its designee (or to the extent not so assignable, Pfizer shall take all reasonable actions to make available to OPKO or its designee the benefits of), at no cost to OPKO, any and all regulatory filings made with and all Regulatory Approvals obtained from the Regulatory Authorities in the Territory specifically relating to the Licensed Products, including, without limitation, any BLAs, MAAs, PMDAs, Price Approvals and third-party reimbursement approvals, in all such cases, only to the extent it is legally permissible to so transfer such items.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Transfer of Know How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer shall promptly provide to OPKO, at no cost to OPKO, all Know-How, materials, and other development data specifically relating to the Licensed Products, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> Pfizer shall be entitled to retain copies of such items for legal archival and regulatory purposes. Pfizer shall&#160;deliver to OPKO (i) all clinical data and information in Pfizer&#8217;s possession or control relating solely to Licensed Product, including for clarity, manufacturing data, if any (subject to the proviso at the end of this sentence), in the same form in which Pfizer maintains such data and (ii) in the same form in which Pfizer maintains such items, copies of all reports, records, regulatory correspondence and other materials in Pfizer&#8217;s possession or control relating solely to the clinical development of Licensed Product, including, if applicable, any information contained in the global safety database established and maintained by Pfizer.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Rights of Reference.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> Pfizer shall grant to OPKO a &#8220;Right of Reference,&#8221; as that term is defined in 21 C.F.R. &#167; 314.3(b) (or any analogous Applicable Law recognized outside of the United States), with respect to development data and regulatory filings transferred to OPKO pursuant to clauses (e) and (f) above.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Supply of Licensed Product.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">72</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">In the event of a termination of a *** or this Agreement in its entirety, except to the extent that Pfizer continues to supply Licensed Product to OPKO following a partial termination pursuant to subsection (ii) below, Pfizer shall continue to supply OPKO after the effective date of termination with OPKO&#8217;s requirements of clinical and commercial quantities of Compound and Licensed Products, pursuant to a supply agreement to be negotiated in good faith by the Parties on &#8220;commercially reasonable terms,&#8221; which agreement will remain in effect until the earlier of (a) the *** anniversary of the effective date of termination, and (b) such time as OPKO or a Third Party manufacturer engaged by OPKO is capable of supplying OPKO with its requirements of clinical and commercial quantities of Compound and Licensed Products (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Supply Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> OPKO must use its commercially reasonable best efforts to supply or have supplied by a Third Party, Compound and Licensed Products as soon as reasonably practicable after the effective date of such termination. In addition, Pfizer shall assign any Third Party contracts to which it is a party relating to the supply or Commercialization of Licensed Product to OPKO and use Commercially Reasonable Efforts to cause such Third Parties to continue to supply to OPKO the same supplies and services then utilized in the Development, Manufacture and Commercialization of the Licensed Product. In the event Pfizer is restricted from assigning such Third Party contracts, Pfizer shall use Commercially Reasonable Efforts to maintain such Third Party Agreements for the benefit of OPKO until the end of the Supply Period. Solely for purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Subsection 9.5.2(h)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> &#8220;commercially reasonable terms&#8221; means, with respect to clinical supplies of Compound and Licensed Products, *** prior to the *** of effective date of termination, *** for the ***, and *** after the *** of the effective date of termination, to be set forth in the supply agreement between the Parties. Prior to termination of the supply term, if requested by OPKO, Pfizer shall cooperate with OPKO in building a reasonable safety stock of Licensed Products.</font></div><div style="text-indent:42.75pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">In the event of a termination of this Agreement in part by Pfizer pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, Pfizer may elect, in its sole discretion, to continue to supply OPKO after the effective date of termination with OPKO&#8217;s requirements of clinical and commercial quantities of Compound and Licensed Products, pursuant to a supply agreement to be negotiated in good faith by the Parties on &#8220;commercially reasonable terms,&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (A) Pfizer shall provide notice to OPKO of its decision with regard to post-termination supply, pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Subsection 9.5.2(h)(ii</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">), no fewer than *** days prior to the effective date of termination, and (B) ***. Solely for purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Subsection 9.5.2(h)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> &#8220;commercially reasonable terms&#8221; means, with respect to clinical supplies of Compound and Licensed Products, *** for such supplies, and with respect to commercial supplies means Pfizer&#8217;s ***.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Existing Inventory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Notwithstanding anything in this Agreement to the contrary, except in the event of termination by OPKO for Pfizer&#8217;s uncured material breach, Pfizer and its Affiliates shall have the right to continue to sell their existing inventory of Licensed Products for a period not to exceed *** days </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">73</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">after the effective date of such termination, and OPKO shall continue to receive royalties and gross profit payments with respect to such sales.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.5.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Termination by Pfizer for Cause or Bankruptcy Event. </font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Partial Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In the event that Pfizer terminates this Agreement pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> with respect to any Licensed Product *** in the Territory&#58; (i) all licenses granted under this Agreement by OPKO to Pfizer with respect to such Licensed Product in such *** shall become fully ***, perpetual, irrevocable *** and (ii) except as otherwise expressly provided herein, all other rights and obligations of each Party with respect to such Licensed Product in such *** shall cease.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Complete Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In the event that Pfizer terminates this Agreement in its entirety pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, (i) all licenses granted under this Agreement by OPKO to Pfizer shall become fully ***, perpetual, irrevocable *** and (ii) except as otherwise expressly provided herein, all other rights and obligations of each Party with respect to such Licensed Product in such *** shall cease.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.5.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Confidential Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Following any termination of this Agreement, each of Pfizer and OPKO shall, upon request of the other Party, return or destroy all Confidential Information of such Party, disclosed to it pursuant to this Agreement, including all copies and extracts of documents, as promptly as practicable following receipt of such request, except that one (1) copy may be kept for the purpose of complying with continuing obligations under this Agreement.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.5.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Accrued Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Expiration or termination of this Agreement, in whole or part, for any reason (i)&#160;shall be without prejudice to OPKO&#8217;s right to receive all royalties and Profit Share Payments accrued under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Sections 5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> prior to the effective date of such termination and any other payments due hereunder that have accrued prior to the effective date of such termination, (ii)&#160;shall be without prejudice to any other remedies that either Party may otherwise have, and (iii)&#160;shall not release a Party hereto from any indebtedness, liability or other obligation incurred hereunder by such Party prior to the date of termination or expiration.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">9.5.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Survival</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing hereunder prior to such expiration or termination. Without limiting the foregoing, the following sections, together with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 9.5.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> and any sections that expressly survive, shall survive expiration or termination of this Agreement for any reason&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Sections 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Definitions), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Licenses to Pfizer Developed IP), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Payments), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">5.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Inspection of Records), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">5.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (No Guarantee of Success), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">6.1.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Pre-Existing IP), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">6.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Developed IP), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Confidentiality), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">9.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Effects of Expiration or Termination), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">10.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Limitation of Liability), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">10.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Indemnification by Pfizer), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Indemnification by OPKO), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">10.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Procedure) and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (Miscellaneous).</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">LIMITATION OF LIABILITY, INDEMNIFICATION AND INSURANCE.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Limitation of Liability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. EXCEPT WITH RESPECT TO LIABILITY ARISING FROM A BREACH OF </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">ARTICLES 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> AND </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, FROM ANY WILLFUL MISCONDUCT OR INTENTIONALLY WRONGFUL ACT, OR TO THE EXTENT SUCH PARTY MAY BE REQUIRED TO INDEMNIFY THE OTHER PARTY UNDER THIS </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">ARTICLE 10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, IN NO EVENT WILL EITHER PARTY OR ITS REPRESENTATIVES BE LIABLE UNDER THIS </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">74</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">AGREEMENT FOR ANY SPECIAL (ONLY AS RESPECTS INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR LOST PROFITS OR REVENUE), INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, OR LOSS OF PROFITS OR REVENUE SUFFERED BY THE OTHER PARTY OR ANY OF ITS REPRESENTATIVES. Without limiting the generality of the foregoing, &#8220;consequential damages&#8221; will be deemed to include, and neither Party will be liable to the other Party or any of such other Party&#8217;s Representatives or stockholders for, any damages based on or measured by loss of projected or speculative future sales of the Licensed Products, any Regulatory Milestone Payment due upon any unachieved Regulatory Milestone under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, any unearned Net Sales or Franchise Net Sales, any unearned royalties or gross profit payments under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.3 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or any other unearned, speculative or otherwise contingent payments provided for in this Agreement or other speculative costs or savings related to the Development or Commercialization of Licensed Products. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Indemnification by Pfizer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Pfizer will indemnify, defend and hold harmless OPKO, each of its Affiliates, and each of its and its Affiliates&#8217; employees, officers, directors and agents (each, an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Indemnified Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) from and against any and all liability, loss, damage, expense (including reasonable attorneys&#8217; fees and expenses) and cost (collectively, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Liability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) that the OPKO Indemnified Party may be required to pay to one or more Third Parties to the extent resulting from or arising out of&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.2.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">the negligence or willful misconduct of Pfizer or its Affiliates or sublicensees in connection with this Agreement&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.2.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Manufacture, Development, Commercialization or use of any Licensed Product by, on behalf of, or under the authority of, Pfizer (including by any OPKO Indemnified Party), other than (i) claims by Third Parties relating to patent infringement arising out of the exercise of rights under the Licensed Patent Rights, (ii) claims by Third Parties relating to misappropriation of trade secrets arising out of the exercise of rights under the Licensed Know-How, or (iii) claims for which OPKO is required to indemnify Pfizer pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#59; or </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.2.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">the material breach by Pfizer of any of its representations, warranties or covenants set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, except, in each case, to the extent caused by the breach, negligence, recklessness or intentional acts of OPKO or any OPKO Indemnified Party. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Indemnification by OPKO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO will indemnify, defend and hold harmless Pfizer, its Affiliates, sublicensees, contractors and, distributors, and each of its and their respective employees, officers, directors and agents (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Pfizer Indemnified Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) from and against any and all Liabilities that the Pfizer Indemnified Party may be required to pay to one or more Third Parties to the extent resulting from or arising out of&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.3.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">the negligence or willful misconduct of OPKO or its Affiliates in connection with this Agreement&#59; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.3.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">the material breach by OPKO of any of its representations, warranties or covenants set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Article 8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, except, in each case, to the extent caused by the breach, negligence, recklessness or intentional acts of Pfizer or any Pfizer Indemnified Party&#59; or</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.3.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO&#8217;s misappropriation of trade secrets, proprietary materials, and&#47;or patentable subject matter, in each case owned or Controlled by a Third Party in relation to </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">75</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">the Development or Manufacture of the Licensed Product at any time prior to the Amendment Effective Date. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Procedure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.4.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party will notify the other Party in writing in the event it becomes aware of a claim for which indemnification may be sought hereunder. In the event that any Third Party asserts a claim or other proceeding (including any governmental investigation) with respect to any matter for which a Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Indemnified Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) is entitled to indemnification hereunder (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Third Party Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), then the Indemnified Party shall promptly notify the Party obligated to indemnify the Indemnified Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Indemnifying Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) thereof&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> no delay on the part of the Indemnified Party in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced thereby.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.4.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The Indemnifying Party shall have the right, exercisable by notice to the Indemnified Party within ten (10) Business Days after receipt of notice from the Indemnified Party of the commencement of or assertion of any Third Party Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> (a) the Indemnifying Party has sufficient financial resources, in the reasonable judgment of the Indemnified Party, to satisfy the amount of any adverse monetary judgment that is sought, (b) the Third Party Claim seeks solely monetary damages and (c) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party and the Indemnified Party, the Indemnifying Party shall be solely obligated to satisfy and discharge the Third Party Claim in full (the conditions set forth in clauses (a), (b) and (c) above are collectively referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Litigation Conditions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). Within ten (10) Business Days after the Indemnifying Party has given notice to the Indemnified Party of its exercise of its right to defend a Third Party Claim, the Indemnified Party shall give notice to the Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnified Party reasonably so objects, the Indemnified Party shall continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until such time as such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn, the Indemnifying Party shall be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. During such time as the Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party shall cooperate, and shall cause its Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of the Third Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or appeals as may reasonably be requested by the Indemnifying Party. In the event that the Indemnifying Party does not satisfy the Litigation Conditions or does not notify the Indemnified Party of the Indemnifying Party&#8217;s intent to defend any Third Party Claim within ten (10) Business Days after notice thereof, the Indemnified Party may (without further notice to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party&#8217;s expense (including reasonable, out-of-pocket attorneys&#8217; fees and costs and expenses of enforcement or defense). The Indemnifying Party or the Indemnified Party, as the case may be, shall have the right to join in (including the right to conduct discovery, interview </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">76</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">and examine witnesses, and participate in all settlement conferences), but not control, at its own expense, the defense of any Third Party Claim that the other Party is defending as provided in this Agreement.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.4.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Settlement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, enter into any compromise or settlement that commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified Party shall have the sole and exclusive right to settle any Third Party Claim, on such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but shall not have the right to settle such Third Party Claim to the extent such Third Party Claim involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnified Party shall not make any admission of liability in respect of any Third Party Claim without the prior written consent of the other party, and the Indemnified Party shall use reasonable efforts to mitigate Liabilities arising from such Third Party Claim.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">10.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Insurance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party further agrees to obtain and maintain, during the Term, commercial general liability insurance, including products liability insurance (or clinical trials insurance, whichever is applicable), with reputable and financially secure insurance carriers (or pursuant to a program of self-insurance reasonably satisfactory to the other Party) to cover its indemnification obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 10.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, as applicable, in each case with limits of not less than *** per occurrence and in the aggregate. Insurance shall be procured with carriers having an A.M. Best Rating of A-VII or better. All deductibles&#47;retentions of the named insured shall be the sole responsibility of the named insured. Products liability and&#47;or clinical trials coverage shall be maintained for *** following termination or expiration of this Agreement. </font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">MISCELLANEOUS.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">HSR Filing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each of OPKO and Pfizer will, by January 7, 2015 (or such later time as may be agreed to in writing by the Parties) file with the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice any HSR Filing required of it under the HSR Act, and shall request early termination in such filing. The Parties will cooperate with one another to the extent necessary in the preparation of any such HSR Filing. Each Party will be responsible for its own costs, expenses and filing fees associated with any such HSR Filing&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> Pfizer will be solely responsible for any fees (other than penalties that may be incurred as a result of actions or omissions on the part of OPKO) required to be paid to any Governmental Authority in connection with submitting any such HSR Filing. Notwithstanding the foregoing, nothing in this Agreement shall obligate, or be construed to obligate, Pfizer (i)&#160;to dispose, transfer or hold separate, or cause any of its Affiliates to dispose, transfer or hold separate any assets or operations, or to commit or to cause OPKO or any of its Affiliates to dispose of any assets&#59; (ii)&#160;to discontinue or cause any of its Affiliates to discontinue offering any product or service, or to commit to cause OPKO or any of its Affiliates to discontinue offering any product or service&#59; or (iii)&#160;to make or cause any of its Affiliates to make any commitment (to any Governmental Authority or otherwise) regarding its future operations or the future operations of OPKO or any of its Affiliates, and OPKO shall not agree, commit or consent to any of such restrictions with respect to itself or any its Affiliates, or permit any of its Affiliates to do so, in each case without the prior written consent of Pfizer.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Termination upon HSR Denial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. In the event that the Parties make an HSR Filing under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, this Agreement will terminate (a) at Pfizer&#8217;s election, immediately upon </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">77</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">notice to OPKO, in the event that the United States Federal Trade Commission or the United States Department of Justice seeks a preliminary injunction under the HSR Act against OPKO and Pfizer to enjoin the transactions contemplated by this Agreement, or (b) at the election of either Party, immediately upon notice to the other Party, in the event that the United States Federal Trade Commission or the United States Department of Justice obtains a preliminary injunction under the HSR Act against OPKO or Pfizer to enjoin the transactions contemplated by this Agreement. Notwithstanding the foregoing, this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> will not apply in the event that Pfizer reasonably determines that an HSR Filing is not required.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Other Government Approvals</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each of OPKO and Pfizer will cooperate with the other Party and use such Party&#8217;s Commercially Reasonable Efforts to make all registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications, authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated hereby.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Neither this Agreement nor any interest hereunder shall be assignable by a Party without the prior written consent of the other Party, except as follows&#58; (a) a Party may assign its rights and obligations under this Agreement by way of a sale of itself or of the portion of its business to which this Agreement relates, through a merger, sale of assets and&#47;or sale of stock or ownership interest provided that the assignee shall expressly agree to be bound by such Party&#8217;s obligations under this Agreement and that such sale is not primarily for the benefit of its creditors, or (b) such Party may assign its rights and obligations under this Agreement to any of its Affiliates, provided that the assignee shall expressly agree to be bound by such Party&#8217;s obligations under this Agreement and that such Party shall remain liable for all of its rights and obligations under this Agreement. In addition, either Party may assign its rights and obligations under this Agreement to a Third Party where such Party or its Affiliate is required, or makes a good faith determination based on advice of counsel, to divest a Licensed Product in order to comply with Applicable Law or the order of any Governmental Authority as a result of a merger or acquisition, provided that the assignee shall expressly agree to be bound by the Party&#8217;s obligations under this Agreement. Each Party shall promptly notify the other Party of any assignment or transfer under the provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. This Agreement shall be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> shall be void.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Further Actions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further ministerial, administrative, or similar acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto the other Party its rights and remedies under this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Performance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. To the extent that the performance of a Party&#8217;s obligations hereunder is adversely affected by the other Party&#8217;s failure to perform its obligations hereunder, the impact of such performance failure will be taken into account in determining whether such Party has used its requisite efforts (which may be Commercially Reasonable Efforts) to perform any such affected obligations as required by this Agreement.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">78</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Force Majeure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party shall be excused from liability and from the performance of its obligations or the obligations of its Affiliates and&#47;or sublicensees under this Agreement to the extent that such performance is prevented in whole or in part by Force Majeure and the non-performing Party promptly provides written notice of such Force Majeure to the other Party. Such excuse shall be continued so long as the condition constituting Force Majeure continues and the non-performing Party takes Commercially Reasonable Efforts to remove the condition. &#8220;Force Majeure&#8221; shall include conditions beyond the control of the Party or its Affiliates and&#47;or sublicensees, including an act of God, voluntary or involuntary compliance with any regulation, Applicable Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, or storm, or like catastrophe. Each Party shall notify the other Party promptly in writing following the occurrence or after becoming aware of the occurrence of any Force Majeure, whereupon the Parties shall promptly co-operate so as to mitigate the effects of such Force Majeure and the Party suffering the Force Majeure shall be obliged to use reasonable efforts to overcome the circumstances thereof. In the event a Party suspends its performance for a period of three (3) or more months due to a Force Majeure, the Parties shall consult in good faith to develop and implement a plan for mitigating the same.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each communication and document made or delivered by one Party to the other Party under this Agreement shall be made in the English language. All notices, consents, approvals, request or other communications required hereunder given by one Party to the other shall be in writing and made by (a) personal delivery, (b) first class certified mail with return receipt requested or (c) next-day delivery by major international courier with confirmation of delivery. Notices will be deemed given either upon receipt or as of the date of certified delivery by a reputable delivery service, whichever is earlier.</font></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">To Pfizer&#58;</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Chief Counsel, Global Innovative Pharma Business</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Pfizer Inc.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">235 East 42</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:138%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> Street</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">New York, New York 10017-5755</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font><br></font></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">with a copy to&#58;</font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Vice President, GIP Global Medicines Development Group</font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Rare Disease Lead</font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Pfizer Inc.</font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">400 Campus Drive</font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Collegeville, PA 19426</font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(484) 865-0226</font></div><div style="padding-left:72pt;text-align:justify;"><font><br></font></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">To OPKO&#58;</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Steven D. Rubin</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Executive Vice President</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO Health, Inc.</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">4400 Biscayne Boulevard</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Miami, Florida 33137</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">(305) 575-6015</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">srubin&#64;opko.com</font></div><div style="padding-left:72pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">79</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">with a copy to&#58;</font></div><div style="padding-left:72pt;text-align:justify;"><font><br></font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Kate Inman </font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">General Counsel </font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">OPKO Health, Inc. </font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">4400 Biscayne Blvd.</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Miami, FL 33137 </font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Office&#58; 305.575.4138 </font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">kinman&#64;opko.com</font></div><div style="padding-left:108pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and a copy to&#58;</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Asher Rubin</font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Hogan Lovells US LLP</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">100 International Drive, Suite 2000</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Baltimore, MD 21202</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Office&#58; 410.659.2777</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">asher.rubin&#64;hoganlovells.com</font></div><div style="padding-left:108pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. No amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized representative of each Party.</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized representative of the waiving Party. The waiver by either Party of any breach of any provision by the other Party shall not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same shall not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement shall be construed as if such clause or portion thereof had never been contained in this Agreement, and there shall be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Export Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed upon or related to OPKO or Pfizer from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Dispute Resolution</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Except as otherwise set forth in this Agreement, if any dispute or disagreement arises between Pfizer and OPKO in respect of this Agreement, they will follow the following procedures in an attempt to resolve the dispute or disagreement&#58; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.13.1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">The Party claiming that such a dispute exists will give notice in writing (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Notice of Dispute</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) to the other Party of the nature of the dispute. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">80</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.13.2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Within thirty (30) days of receipt of a Notice of Dispute, a representative of each of the Parties who is at least a senior vice president level or higher will meet at a mutually agreed-upon time and location (which may include by teleconference) for the purpose of resolving such dispute. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.13.3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">If, within a further period of sixty (60) days, the dispute has not been resolved, or if, for any reason, the meeting described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.13.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> has not been held within thirty (30) days of initial receipt of the Notice of Dispute, then the Parties agree that (i) *** or if such dispute is not expressly stated to be resolved through expedited arbitration in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, ***, and (ii) *** or if such dispute is expressly stated to be resolved through expedited arbitration in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, then ***. </font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notwithstanding any provision of this Agreement to the contrary, either Party may immediately initiate litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement. The provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 11.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall survive for *** from the date of termination or expiration of this Agreement.</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Expedited Dispute Resolution</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The following disputes will be finally settled by binding arbitration in accordance with the procedures set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Schedule 11.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#58; (a) any dispute relating to the existence of a Development Limitation referred by a Party for expedited arbitration in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.13.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#59; and (b) any other dispute hereunder that a Party has the express right to refer for resolution through expedited arbitration in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. This Agreement, and all claims arising under or in connection therewith, shall be governed by and interpreted in accordance with the substantive laws of the State of New York, without regard to conflict of law principles thereof.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.16.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Jurisdiction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. Each Party to this Agreement hereby (a) irrevocably submits to the exclusive jurisdiction of the state courts of the State of New York or the United States District Court for the Southern District of New York for the purpose of any and all actions, suits or proceedings arising in whole or in part out of, related to, based upon or in connection with this Agreement or the subject matter hereof, (b) waives to the extent not prohibited by Applicable Law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such action brought in one of the above-named courts should be dismissed on grounds of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;">forum non conveniens</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or should be transferred to any court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced in or by such court and (c) agrees not to commence any such action other than before one of the above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such action to any court other than one of the above-named courts, whether on the grounds of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;">forum non conveniens</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> or otherwise.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.17.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">No Jury Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. THE PARTIES EXPRESSLY WAIVE AND FOREGO ANY RIGHT TO TRIAL BY JURY.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.18.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. This Agreement, together with its Exhibits, sets forth the entire agreement between the Parties as to its subject matter and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter, including, without limitation, that certain Confidential Disclosure Agreement by and </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">81</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">between the Parties, dated *** (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">CDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), which is hereby terminated as of the Original Effective Date. The Parties acknowledge and agree that, as of the Original Effective Date, all Confidential Information (as defined in the CDA) disclosed by a Party pursuant to the CDA shall be considered Confidential Information of such Party and subject to the terms set forth in this Agreement. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.19.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Independent Contractors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The Parties are independent contractors under this Agreement. Nothing herein contained shall be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act, or failure to act, of the other Party. Neither Party shall have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. The Parties acknowledge and agree that neither Party owes the other any fiduciary or similar duties or obligations by virtue of the relationship created by this Agreement. Without limiting the foregoing, the Parties also acknowledge and agree that if a court of competent jurisdiction or an arbitrator should determine that, notwithstanding the terms of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Section 11.19</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">, such fiduciary or other obligations exist, the Parties hereby waive such duties and obligations and agree not to assert or rely upon such duties or obligations in connection with any dispute arising out of or relating to this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.20.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">No Third Party Rights or Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. No provision of this Agreement shall be deemed or construed in any way to result in the creation of any rights or obligations in any Person not a Party to this Agreement. However, either Party may decide, in its sole discretion, to use one or more of its Affiliates to perform its obligations and duties hereunder, provided that such Party shall remain liable hereunder for the performance by any such Affiliate(s) of any such obligations.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.21.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Headings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. The descriptive headings of this Agreement are included herein for ease of reference only and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.22.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same document. Counterparts may be signed and delivered by facsimile or PDF file, with the same effect as if delivered personally.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">11.23.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">OPKO Parent Co. Guaranty</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">. OPKO Health, Inc., a corporation formed under the laws of Delaware with offices at 4400 Biscayne Blvd., Miami, Florida 33138, and a parent company of OPKO (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Guarantor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), (i) hereby unconditionally guarantees the due and punctual payment and performance of all of OPKO&#8217;s obligations and commitments under both (a) this Agreement, with respect to OPKO&#8217;s obligations and commitments arising following the Amendment Effective Date and (b) the Original Agreement, with respect to OPKO&#8217;s obligations and commitments arising following the Original Execution Date but prior to the Amendment Effective Date and (ii) without limiting the foregoing or being limited thereby, hereby further covenants to procure and cause OPKO and its Affiliates to take such actions that may be necessary or useful to support and duly complete the performance of OPKO&#8217;s obligations and commitments under both (a) this Agreement, with respect to OPKO&#8217;s obligations and commitments arising following the Amendment Effective Date and (b) the Original Agreement, with respect to OPKO&#8217;s obligations and commitments arising following the Original Execution Date but prior to the Amendment Effective Date, with respect to each, including in relation to Pfizer&#8217;s exercise of its rights under this Agreement and the Original Agreement (collectively, (i) and (ii) the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Parent Guaranty</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;). This Parent Guaranty is an irrevocable guaranty of payment </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">82</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">and performance (and not just of collection) and shall continue in effect notwithstanding any extension or modification of the terms of this Agreement, any assumption of any such guaranteed obligations by any other party or any other act or event that might otherwise operate as a legal or equitable discharge of Guarantor. Guarantor hereby waives all its rights to subrogation arising out of any payment or performance by Guarantor under this Parent Guaranty. The obligations of Guarantor hereunder shall be absolute and unconditional, and shall not be affected by or contingent upon (I) the liquidation or dissolution of, or the merger or consolidation of OPKO with or into any corporation, or any sale or transfer by OPKO or all or any part of its or their property or assets, (II) the bankruptcy, receivership, insolvency, reorganization or similar proceedings involving or affecting OPKO or (III) any modification, alteration, amendment or addition of or to the Agreement. Guarantor hereby waives all suretyship defenses and protest, notice of protest, demand for performance, diligence, notice of any other action at any time taken or omitted by Pfizer and, generally, all demands and notices of every kind in connection with this Parent Guaranty, and OPKO&#8217;s obligations hereby guaranteed, and which Guarantor may otherwise assert against Pfizer. This Parent Guaranty shall continue to be effective or shall be reinstated, as the case may be, if at any time payment or performance of any of the obligations of OPKO under this Agreement is rescinded or must otherwise be restored or returned by Pfizer upon the insolvency, bankruptcy or reorganization of OPKO or otherwise. Guarantor acknowledges that each of the waivers set forth in this Parent Guaranty is made with full knowledge of its significance and consequences and under the circumstances the waivers are reasonable and not contrary to public policy. If any of said waivers is determined to be contrary to any applicable law or public policy, such waivers shall be effective only to the extent permitted by law.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#91;Signature page to follow&#93;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">83</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this Agreement as of the Amendment Execution Date.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PFIZER INC.</font></div><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font><br></font></div><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font><br></font></div><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Suneet Varma   </font></div><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;  Suneet Varma</font></div><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;  Global President, RD BU</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">OPKO IRELAND LTD.</font></div><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font><br></font></div><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font><br></font></div><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; J. Gaul   </font></div><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;  J. Gaul</font></div><div style="padding-left:6.75pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;  Director</font></div></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">As a party to this Agreement solely with respect to &#8232;the provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 11.23</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">OPKO HEALTH, INC.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Steven D. Rubin&#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;  Steven D. Rubin</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;  Executive Vice President - Administration</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 1.36</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8211; Compounds </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 1.56</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8211; ***</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule&#160;1.70</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8211; Genotropin Products</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 1.86</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8211; ***</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 1.98</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8211; Licensed Patent Rights</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 1.190 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8211; ***</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 3.10.3(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8211; ***</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8211; Example Profit Share Calculation</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 8.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8211; OPKO Disclosure Schedule</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 11.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8211; Expedited Dispute Resolution</font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Development Plan</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Development Budget</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit C</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Press Release</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 1.36</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8211; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Compounds</font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">*** </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 1.56 &#8211; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each of the following countries&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 1.70 - Genotropin Products</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Genotropin products sold by Pfizer and its Affiliates under various trademarks in various jurisdictions worldwide&#58;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 1.86 &#8211; ***</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each of the following countries&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8232;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 1.98 - Licensed Patent Rights</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a) - Licensed hGH-Specific Patents</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">U.S. Patents and Applications</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patents and Applications Outside of U.S.</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> (b) - Licensed OPKO Core Patents </font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">U.S. Patents and Applications</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patents and Applications Outside of U.S.</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 1.190 &#8211; ***</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">*** </font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 3.10.3(b) &#8211; Additional Pediatric Indications</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 5.4 &#8211; Example Profit Share Calculation</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 8.3 &#8211; OPKO Disclosure Schedule</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">***</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_31"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 11.14 &#8211; Expedited Dispute Resolution</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Any dispute that is referred to resolution in accordance with the procedures set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 11.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> will be submitted to fast-track, binding arbitration in accordance with the following terms&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Arbitration will be conducted in New York, New York under the rules of the American Arbitration Association (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">AAA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;) in effect at the time of submission for the resolution of commercial disputes in the most expedited manner permitted by such rules. The Parties will mutually select, within ten (10) days of a dispute being referred to arbitration as set forth herein, a single arbitrator to resolve such dispute. If the Parties, acting in good faith, are unable to agree on an arbitrator during such ten (10) day period, then the Parties will promptly request that the AAA select the arbitrator within ten (10) days following the Parties making such a request of the AAA. The arbitrator will be a professional in business or licensing *** (ii) *** with applicable Regulatory Authorities and (iii) ***. Additionally, the arbitrator shall not be or have been an employee, consultant, officer, director or stockholder of either Party or any Affiliate of either Party and not have a conflict of interest under any applicable rules of ethics. The cost of the arbitration will be borne equally by the Parties. Except in a proceeding to enforce the results of the arbitration or as otherwise required by Applicable Law, neither Party nor any arbitrator may disclose (a) the existence, content or results of any arbitration hereunder, (b) the content of any Brief submitted by a Party pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Paragraph 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> hereof or (c) the content of any response to a Brief submitted by a Party pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Paragraph 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> hereof, with respect to (a)-(c), without the prior written agreement of each Party.</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">*** after such matter is referred to arbitration (provided that, if an arbitrator has not been selected within such *** period, then within *** following the selection of an arbitrator), each Party will provide the arbitrator with a proposal and written memorandum in support of its position regarding the dispute at issue, as well as any documentary evidence it wishes to provide in support thereof (each a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:138%;">Brief</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#8221;), and the arbitrator will provide each Party&#8217;s Brief to the other Party after it receives it from both Parties.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">Within *** after a Party submits its Brief to the arbitrator as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration: underline;">Paragraph 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> hereof, the other Party will have the right to respond thereto. The response and any material in support thereof will be provided to the arbitrator and the other Party.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">The arbitrator will have the right to meet with the Parties as necessary to inform the arbitrator&#8217;s determination and to perform independent research and analysis. Within *** of the receipt by the arbitrator of both Parties&#8217; responses (or expiration of the *** period </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">if any Party fails to submit a response), the arbitrator will *** in writing&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;text-decoration: underline;">that</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> ***.</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_34"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit A &#8211; Development Plan</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">&#91;See attached.&#93;</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="padding-left:13.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:10pt;"><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><div id="i39b99448049f4e83bf0c947d9bb4e4b9_37"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit B &#8211; Development Budget</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">&#91;See attached.&#93;</font></div><div style="text-align:center;"><font><br></font></div><div style="padding-left:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">***</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div><font><br></font></div></div><div style="padding-left:9pt;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit C &#8211; Press Release</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:180%;">OPKO and Pfizer Enter into Global Agreement for </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:180%;">OPKO&#8217;s Long-Acting Human Growth Hormone (hGH-CTP)</font></div><div style="text-align:center;"><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.8pt;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%;">hGH-CTP in global clinical development for the treatment of pediatric and adult growth hormone deficiency (GHD)</font></div><div style="text-indent:-18pt;padding-left:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%;padding-left:13.8pt;">hGH-CTP has potential to reduce dosing frequency of human growth hormone to single weekly injection from current standard of daily injection</font></div><div style="text-indent:-18pt;padding-left:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%;padding-left:13.8pt;">OPKO to receive upfront payment of $295 million and eligible to receive up to an additional $275 million upon achievement of regulatory milestones</font></div><div style="text-indent:-18pt;padding-left:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%;padding-left:13.8pt;">Pfizer to obtain exclusive license to commercialize hGH-CTP globally </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">Miami, FL, and New York, NY, December &#91;XX&#93; - OPKO Health, Inc. (NYSE&#58;OPK) and Pfizer Inc. (NYSE&#58; PFE) announced today that they have entered into a worldwide agreement for the development and commercialization of OPKO&#8217;s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by 2 years of age. hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. hGH-CTP is currently in a global phase 3 trial in adults and a global phase 2 trial in children and has orphan drug designation in the U.S. and Europe for both adults and children with GHD. </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">Under the terms of the agreement, OPKO will receive upfront payment of $295 million and is eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. Pfizer will receive the exclusive license to commercialize hGH-CTP worldwide. </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">In addition, OPKO is eligible to receive initial royalty payments associated with the commercialization of hGH-CTP for Adult GHD which is subject to regulatory approval. Upon the launch of hGH-CTP for Pediatric GHD, which is subject to regulatory approval, the royalties will transition to gross profit sharing for both hGH-CTP and Pfizer&#8217;s Genotropin. </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">OPKO will lead the clinical activities and will be responsible for funding the development programs for the key indications, which includes Adult and Pediatric GHD and Pediatric SGA. Pfizer will be responsible for all development costs for additional indications as well as all post-marketing studies. In addition, Pfizer will fund the commercialization activities for all indications and lead the manufacturing activities covered by the global development plan.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">&#34;We believe this collaboration will help advance our commitments to patients with Adult and Pediatric Growth Hormone Deficiency as we believe Pfizer&#8217;s strengths, expertise and presence in the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">human growth hormone space makes them the ideal partner for our hGH-CTP program. Our collaboration enables full alignment between Pfizer and OPKO to optimize development and potentially bring an innovative treatment to patients. We believe that the global growth hormone market is currently valued at more than $3 billion, and believe that hGH-CTP has the potential to be the best in class long-acting growth hormone product. Our long acting human growth hormone is our most advanced product candidate utilizing our CTP technology to extend the half life of a broad range of therapeutic peptides and&#160;proteins. By reducing the number of injections, our technology can improve patient compliance,&#8221; said OPKO's CEO,&#160;Phillip Frost, M.D.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">&#8220;This agreement strengthens Pfizer&#8217;s commitment to rare diseases, and we are pleased to work with OPKO to help provide a potential next-generation therapy for patients with Adult and Pediatric Growth Hormone Deficiency,&#8221; said Geno Germano, Group President, Pfizer Global Innovative Pharma (GIP). &#8220;Long-acting growth hormone is the first innovation in the GHD space in 20 years. hGH-CTP would be complementary to our existing Genotropin franchise, and could potentially provide an option that could improve patients&#8217; adherence to treatment with once weekly dosing.&#8221;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">The transaction is subject to customary Hart-Scott-Rodino approval and is expected to close during the first-quarter 2015. </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:180%;">About hGH-CTP </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">hGH-CTP is a novel, long-acting recombinant human growth hormone analog being developed by OPKO for the treatment of children with growth failure due to inadequate endogenous growth hormone secretion, and adults with growth hormone deficiency (GHD) of either childhood or adult-onset etiology. hGH-CTP is intended to reduce the burden of daily injection therapy by requiring only weekly injections potentially improving compliance and treatment outcomes. OPKO&#8217;s proprietary technology allows the company to extend the hormone&#8217;s half-life without the use of polymers, encapsulation techniques, or nanoparticles. This technology is based on a natural peptide, the C-terminal peptide (CTP) of the beta chain of human chorionic gonadotropin (hCG). OPKO has an ongoing pivotal Phase 3 clinical trial in adults for hGH-CTP and a Phase 2 clinical trial in pediatric patients. hGH-CTP has been granted orphan drug designation in the U.S. and Europe for both adults and children with growth hormone deficiency.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:180%;">About OPKO Health</font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration: underline;">http&#58;&#47;&#47;www.OPKO.com</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:180%;">Pfizer and Rare Diseases</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">Rare diseases are among the most serious of all illnesses and impact millions of patients worldwide, representing an opportunity to apply our knowledge and expertise to help make a significant impact in addressing unmet medical needs. The Pfizer focus on rare diseases builds on more than a decade of experience and a global portfolio of 22 medicines approved worldwide that treat rare diseases in the areas of hematology, neuroscience, inherited metabolic disorders, pulmonology, and oncology.</font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:180%;">About Pfizer Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.&#160;Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration: underline;">www.pfizer.com</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">.</font></div><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:180%;">SAFE HARBOR STATEMENT</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%;">&#91;This press release contains &#34;forward-looking statements,&#34; as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as &#34;expects,&#34; &#34;plans,&#34; &#34;projects,&#34; &#34;will,&#34; &#34;may,&#34; &#34;anticipates,&#34; &#34;believes,&#34; &#34;should,&#34; &#34;intends,&#34; &#34;estimates,&#34; and other words of similar meaning, including statements regarding expected benefits of hGH-CTP), whether the collaboration with Pfizer will be successful, whether OPKO's clinical trials for adult and pediatric growth hormone deficiency will support marketing approval, whether hGH-CTP will be successfully developed or commercialized, expectations regarding the product, its efficacy, safety and market potential, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;"> </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:138%;">CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.  OMISSIONS ARE IDENTIFIED AS &#91;***&#93;</font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:138%;">PFIZER DISCLOSURE NOTICE</font><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;">&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;">The information contained in this release is as of December &#91; &#93;, 2014. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;">This release contains forward-looking information about an agreement between Pfizer and OPKO for the development and commercialization of hGH-CTP that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements include, among other things, those regarding </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;">hGH-CTP</font><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;"> and the collaboration, including their potential benefits and market potential, as well</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;">as those about the anticipated timing of the closing of the transaction. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results&#59; whether and when biologics license applications may be filed in any jurisdictions for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;">hGH-CTP</font><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;"> for any indication&#59; whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted&#59; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;">hGH-CTP</font><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:138%;"> in any such indications&#59; risks relating to the satisfaction of conditions to closing the transaction in the anticipated timeframe or at all&#59; and competitive developments.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">A further description of risks and uncertainties can be found in Pfizer&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Information That May Affect Future Results&#8221;, as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">www.sec.gov</font><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">www.pfizer.com</font><font style="background-color:rgb(255,255,255, 0.0);color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:180%;">Contact&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:180%;">&#93;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%;"> &#8232;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:138%;"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>opk-6302020xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iaff04022cacc441eb1350508eef28495_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">CERTIFICATIONS</font></div><div style="margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">I, Phillip Frost, certify that&#58;</font></div><div style="text-indent:-27pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt;">I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(3)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(4)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.34pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-27pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(5)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.165%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; July 31, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Phillip Frost, M.D.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phillip Frost, M.D.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>opk-6302020xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i2fbc18d653224a9cb7d3d9bbb880e3c1_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">CERTIFICATIONS</font></div><div style="margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">I, Adam Logal, certify that&#58;</font></div><div style="text-indent:-27pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt;">I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(3)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-27pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(4)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.34pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-27pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(5)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:24.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%;"><tr><td style="width:1.0%;"></td><td style="width:59.526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.474%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; July 31, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Adam Logal</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adam Logal</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>opk-6302020xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i7e519d1626cb48fa99a0ab083c6d7755_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 906 of the Sarbanes-Oxley Act of 2002, I, Phillip Frost, Chief Executive Officer of OPKO Health, Inc. (the &#8220;Company&#8221;), hereby certify that&#58;</font></div><div style="margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">The Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.165%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; July 31, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Phillip Frost, M.D.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phillip Frost, M.D.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>opk-6302020xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i49a5ed00b98a4dabaea1dae66a01235b_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Exhibit 32.2</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 906 of the Sarbanes-Oxley Act of 2002, I, Adam Logal, Chief Financial Officer of OPKO Health, Inc. (the &#8220;Company&#8221;), hereby certify that&#58;</font></div><div style="margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">The Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:58.761%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.239%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; July 31, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Adam Logal</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adam Logal</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>opk-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:58648600-8b9a-4bda-ba8d-a94f5b914ae0,g:b952a604-1bee-438c-aa3f-da7449f6ab9c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:opk="http://www.opko.com/20200630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.opko.com/20200630">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="opk-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="opk-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="opk-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="opk-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVERPAGE" roleURI="http://www.opko.com/role/COVERPAGE">
        <link:definition>0001001 - Document - COVER PAGE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFEQUITY" roleURI="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessandOrganization" roleURI="http://www.opko.com/role/BusinessandOrganization">
        <link:definition>2101101 - Disclosure - Business and Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessandOrganizationDetails" roleURI="http://www.opko.com/role/BusinessandOrganizationDetails">
        <link:definition>2402401 - Disclosure - Business and Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.opko.com/role/EarningsLossPerShare">
        <link:definition>2106103 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareNarrativeDetails" roleURI="http://www.opko.com/role/EarningsLossPerShareNarrativeDetails">
        <link:definition>2407403 - Disclosure - Earnings (Loss) Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainFinancialStatementCaptions" roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions">
        <link:definition>2108104 - Disclosure - Composition of Certain Financial Statement Captions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainFinancialStatementCaptionsTables" roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables">
        <link:definition>2309301 - Disclosure - Composition of Certain Financial Statement Captions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainFinancialStatementCaptionsDetails" roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails">
        <link:definition>2410404 - Disclosure - Composition of Certain Financial Statement Captions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainFinancialStatementCaptionsNarrativeDetails" roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails">
        <link:definition>2411405 - Disclosure - Composition of Certain Financial Statement Captions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails">
        <link:definition>2412406 - Disclosure - Composition of Certain Financial Statement Captions - Changes in Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.opko.com/role/Investments">
        <link:definition>2113105 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.opko.com/role/InvestmentsTables">
        <link:definition>2314302 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofInvestmentsDetails" roleURI="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails">
        <link:definition>2415407 - Disclosure - Investments - Summary of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.opko.com/role/InvestmentsNarrativeDetails">
        <link:definition>2416408 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" roleURI="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails">
        <link:definition>2417409 - Disclosure - Investments - Schedule of Net Gains and Losses on Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.opko.com/role/Debt">
        <link:definition>2118106 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.opko.com/role/DebtTables">
        <link:definition>2319303 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.opko.com/role/DebtNarrativeDetails">
        <link:definition>2420410 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofNotesDetails" roleURI="http://www.opko.com/role/DebtScheduleofNotesDetails">
        <link:definition>2421411 - Disclosure - Debt - Schedule of Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtLinesofCreditDetails" roleURI="http://www.opko.com/role/DebtLinesofCreditDetails">
        <link:definition>2422412 - Disclosure - Debt - Lines of Credit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNotesPayableandOtherDebtDetails" roleURI="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails">
        <link:definition>2423413 - Disclosure - Debt - Notes Payable and Other Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLoss" roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLoss">
        <link:definition>2124107 - Disclosure - Accumulated Other Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossTables" roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables">
        <link:definition>2325304 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossDetails" roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails">
        <link:definition>2426414 - Disclosure - Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.opko.com/role/FairValueMeasurements">
        <link:definition>2127108 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.opko.com/role/FairValueMeasurementsTables">
        <link:definition>2328305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" roleURI="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
        <link:definition>2429415 - Disclosure - Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsLevel3ReconciliationDetails" roleURI="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails">
        <link:definition>2430416 - Disclosure - Fair Value Measurements - Level 3 Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2431417 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeContracts" roleURI="http://www.opko.com/role/DerivativeContracts">
        <link:definition>2132109 - Disclosure - Derivative Contracts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeContractsTables" roleURI="http://www.opko.com/role/DerivativeContractsTables">
        <link:definition>2333306 - Disclosure - Derivative Contracts (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeContractsBalanceSheetComponentDetails" roleURI="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails">
        <link:definition>2434418 - Disclosure - Derivative Contracts - Balance Sheet Component (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeContractsDerivativeGainsLossesDetails" roleURI="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails">
        <link:definition>2435419 - Disclosure - Derivative Contracts - Derivative Gains (Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.opko.com/role/RelatedPartyTransactions">
        <link:definition>2136110 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.opko.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2437420 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.opko.com/role/CommitmentsandContingencies">
        <link:definition>2138111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.opko.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2439421 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.opko.com/role/RevenueRecognition">
        <link:definition>2140112 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.opko.com/role/RevenueRecognitionTables">
        <link:definition>2341307 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://www.opko.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>2442422 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionScheduleofDisaggregationofRevenueDetails" roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails">
        <link:definition>2443423 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails">
        <link:definition>2444424 - Disclosure - Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicAlliances" roleURI="http://www.opko.com/role/StrategicAlliances">
        <link:definition>2145113 - Disclosure - Strategic Alliances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicAlliancesDetails" roleURI="http://www.opko.com/role/StrategicAlliancesDetails">
        <link:definition>2446425 - Disclosure - Strategic Alliances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.opko.com/role/Segments">
        <link:definition>2147114 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.opko.com/role/SegmentsTables">
        <link:definition>2348308 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsNarrativeDetails" roleURI="http://www.opko.com/role/SegmentsNarrativeDetails">
        <link:definition>2449426 - Disclosure - Segments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsOperationsandAssetsInformationDetails" roleURI="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails">
        <link:definition>2450427 - Disclosure - Segments - Operations and Assets Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.opko.com/role/Leases">
        <link:definition>2151115 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.opko.com/role/LeasesTables">
        <link:definition>2352309 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseAssetsandLiabilitiesDetails" roleURI="http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails">
        <link:definition>2453428 - Disclosure - Leases - Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseLiabilityMaturityDetails" roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails">
        <link:definition>2454429 - Disclosure - Leases - Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseLiabilityMaturityDetails_1" roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1">
        <link:definition>2454429 - Disclosure - Leases - Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.opko.com/role/LeasesNarrativeDetails">
        <link:definition>2455430 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCashFlowInformationDetails" roleURI="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails">
        <link:definition>2456431 - Disclosure - Leases - Lease Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.opko.com/role/SubsequentEvents">
        <link:definition>2157116 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.opko.com/role/SubsequentEventsDetails">
        <link:definition>2458432 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="opk_CovenantsNotToCompeteMember" abstract="true" name="CovenantsNotToCompeteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_ProductRegistrationsMember" abstract="true" name="ProductRegistrationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_OperatingLeasesMonthlyPaymentsYearOne" abstract="false" name="OperatingLeasesMonthlyPaymentsYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_AccruedExpensePayorOverpaymentReimbursementLiability" abstract="false" name="AccruedExpensePayorOverpaymentReimbursementLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_CollaborativeArrangement.MaximumMilestonePayments" abstract="false" name="CollaborativeArrangement.MaximumMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_JPMorganChaseMember" abstract="true" name="JPMorganChaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_SantanderBank2MemberMember" abstract="true" name="SantanderBank2MemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_TaxesRecoverableCurrent" abstract="false" name="TaxesRecoverableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_CollaborativeArrangementMilestonePayment" abstract="false" name="CollaborativeArrangementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_AccruedClinicalTrialsCurrent" abstract="false" name="AccruedClinicalTrialsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_FrostRealEstateHoldingsLLCMember" abstract="true" name="FrostRealEstateHoldingsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_GovernmentPayersMember" abstract="true" name="GovernmentPayersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_AccruedCommitmentsandContingenciesCurrent" abstract="false" name="AccruedCommitmentsandContingenciesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_CollaborativeArrangementMaximumMilestonePayments" abstract="false" name="CollaborativeArrangementMaximumMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" abstract="true" name="LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_EstadoBankMember" abstract="true" name="EstadoBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_RegulatoryAndDevelopmentMember" abstract="true" name="RegulatoryAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_InterestIncomeNonoperating" abstract="false" name="InterestIncomeNonoperating" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_EloxxPharmaceuticalsMember" abstract="true" name="EloxxPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_NotesPayableAndOtherLongTermLiabilitiesMember" abstract="true" name="NotesPayableAndOtherLongTermLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_PharmsynthezMember" abstract="true" name="PharmsynthezMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" abstract="true" name="PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" abstract="true" name="EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_DrFrostandMrPfennigerMember" abstract="true" name="DrFrostandMrPfennigerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_NumberOfDerivativeLawsuits" abstract="false" name="NumberOfDerivativeLawsuits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="opk_ScotiabankMember" abstract="true" name="ScotiabankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived" abstract="false" name="ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_NewCreditAgreementMember" abstract="true" name="NewCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_ItauBankMember" abstract="true" name="ItauBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_GovernmentalMember" abstract="true" name="GovernmentalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_DiagnosticMolecularTestMember" abstract="true" name="DiagnosticMolecularTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_OperatingLeasesMonthlyPaymentsYearThree" abstract="false" name="OperatingLeasesMonthlyPaymentsYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_BioCardiaInc.Member" abstract="true" name="BioCardiaInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_DevelopmentandLicenseAgreementMember" abstract="true" name="DevelopmentandLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" abstract="false" name="DebtInstrumentConvertibleConversionNoticeThresholdMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_ClientPayersMember" abstract="true" name="ClientPayersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" abstract="false" name="CompositionOfCertainFinancialStatementCaptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="opk_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" abstract="true" name="FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="opk_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_StrategicAlliancesTextBlock" abstract="false" name="StrategicAlliancesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="FinanceLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_NotesDueFebruary12033Member" abstract="true" name="NotesDueFebruary12033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_BbvaBankMember" abstract="true" name="BbvaBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_NumberofSalesEmployees" abstract="false" name="NumberofSalesEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="opk_BiceBankMember" abstract="true" name="BiceBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_CollaborativeArrangementUpfrontPayment" abstract="false" name="CollaborativeArrangementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_ZebraMember" abstract="true" name="ZebraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_OPKOBiologicsMember" abstract="true" name="OPKOBiologicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_CollaborativeArrangementMilestonePaymentReceived" abstract="false" name="CollaborativeArrangementMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_COVID19TestTypeDomain" abstract="true" name="COVID19TestTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_COVID19TestsPerformedPerDay" abstract="false" name="COVID19TestsPerformedPerDay" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="opk_PhioPharmaceuticalsMember" abstract="true" name="PhioPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" abstract="false" name="ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold" abstract="false" name="CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_DebtInstrumentRollForward" abstract="true" name="DebtInstrumentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_InProcessResearchandDevelopment" abstract="false" name="InProcessResearchandDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_SalesReturnsMember" abstract="true" name="SalesReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" abstract="true" name="FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_SharesReceivedUponClosingofXeneticTransactionMember" abstract="true" name="SharesReceivedUponClosingofXeneticTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_NumberOfClassActionLawsuits" abstract="false" name="NumberOfClassActionLawsuits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="opk_RayaldeeMember" abstract="true" name="RayaldeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_RelatedPartyTransactionFutureContributions" abstract="false" name="RelatedPartyTransactionFutureContributions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_SerologyAntibodyTestMember" abstract="true" name="SerologyAntibodyTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_DistributionToHealthcareProvidersCOVID19Member" abstract="true" name="DistributionToHealthcareProvidersCOVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" abstract="false" name="StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_BioReferenceMember" abstract="true" name="BioReferenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_MuseumofScienceIncMember" abstract="true" name="MuseumofScienceIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract" abstract="true" name="SharesIssuedintheConversionofStockandDebtInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_DebtInstrumentsNumberofFinancialInstitutions" abstract="false" name="DebtInstrumentsNumberofFinancialInstitutions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="opk_ViforFreseniusMedicalCarePharmaLtdMember" abstract="true" name="ViforFreseniusMedicalCarePharmaLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_TesaroMember" abstract="true" name="TesaroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_NeovascMember" abstract="true" name="NeovascMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_InterestExpenseNonoperating" abstract="false" name="InterestExpenseNonoperating" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_SalesRevenueMember" abstract="true" name="SalesRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_HealthInsurersMember" abstract="true" name="HealthInsurersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_SeriesCWarrantMember" abstract="true" name="SeriesCWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_COVID19NumberOfTestsPerformed" abstract="false" name="COVID19NumberOfTestsPerformed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="opk_OpkoChileMember" abstract="true" name="OpkoChileMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_EquityMethodInvestmentSharesPurchasedInPeriod" abstract="false" name="EquityMethodInvestmentSharesPurchasedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_ChargebacksDiscountsRebatesAndFeesMember" abstract="true" name="ChargebacksDiscountsRebatesAndFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays" abstract="false" name="LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_SharesSurrenderedInLieuOfCashPayment" abstract="false" name="SharesSurrenderedInLieuOfCashPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_ProceedsFromConvertibleDebtConversionFee" abstract="false" name="ProceedsFromConvertibleDebtConversionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_EquityMethodInvestmentVariableInterestEntity" abstract="false" name="EquityMethodInvestmentVariableInterestEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_FederalTradeCommissionFilingFeesMember" abstract="true" name="FederalTradeCommissionFilingFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_DebtInstrumentConvertibleSharesIssued" abstract="false" name="DebtInstrumentConvertibleSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_Corpbanca1Member" abstract="true" name="Corpbanca1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_AutomobilesandAircraftMember" abstract="true" name="AutomobilesandAircraftMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_CommonStockWarrantsNetExercised" abstract="false" name="CommonStockWarrantsNetExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_InventoryReceivedNotInvoicedCurrent" abstract="false" name="InventoryReceivedNotInvoicedCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_PatientsMember" abstract="true" name="PatientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_MabVaxTherapeuticsHoldingsInc.Member" abstract="true" name="MabVaxTherapeuticsHoldingsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_XeneticBiosciencesInc.Member" abstract="true" name="XeneticBiosciencesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_A4KscoreMember" abstract="true" name="A4KscoreMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_InCellDxIncMember" abstract="true" name="InCellDxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member" abstract="true" name="CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" abstract="true" name="LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_IncreaseDecreaseinForeignCurrencyMeasurement" abstract="false" name="IncreaseDecreaseinForeignCurrencyMeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_NonInvasiveMonitoringSystemsInc.Member" abstract="true" name="NonInvasiveMonitoringSystemsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_VBIVaccinesIncMember" abstract="true" name="VBIVaccinesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_A5ConvertibleNotesMember" abstract="true" name="A5ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_StockOptionandWarrantInvestments" abstract="false" name="StockOptionandWarrantInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_CocrystalMember" abstract="true" name="CocrystalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" abstract="false" name="ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="opk_SeriesBWarrantMember" abstract="true" name="SeriesBWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_ExclusiveOptionMember" abstract="true" name="ExclusiveOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment" abstract="false" name="LicenseandCollaborationAgreementsProceedsasUpFrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_COVID19TestTypeAxis" abstract="true" name="COVID19TestTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" abstract="false" name="AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="opk_RelatedPartyTransactionShares" abstract="false" name="RelatedPartyTransactionShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_EquitySecurityFVNIOwnershipPercent" abstract="false" name="EquitySecurityFVNIOwnershipPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" abstract="false" name="CollaborativeArrangementAnnualHeightVelocityatPointinTime" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_ChangeInTestingVolumePercent" abstract="false" name="ChangeInTestingVolumePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="opk_MembersofSeniorManagementMember" abstract="true" name="MembersofSeniorManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_NIMSMember" abstract="true" name="NIMSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_OPKOTransactionSharesMember" abstract="true" name="OPKOTransactionSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_SecurityMember" abstract="true" name="SecurityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_EirGenPharmaLimitedMember" abstract="true" name="EirGenPharmaLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" abstract="false" name="ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_CollaborativeAgreementPeriodfromFirstCommercialSale" abstract="false" name="CollaborativeAgreementPeriodfromFirstCommercialSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" abstract="false" name="DebtInstrumentConvertibleConversionNoticeThresholdMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_SantanderBankMember" abstract="true" name="SantanderBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" abstract="false" name="IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_RelatedPartyTransactionFutureContributionTerm" abstract="false" name="RelatedPartyTransactionFutureContributionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" abstract="true" name="EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_BankOfChileMember" abstract="true" name="BankOfChileMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_ChiefTechnicalOfficerMember" abstract="true" name="ChiefTechnicalOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_DrFrostMember" abstract="true" name="DrFrostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_EquityMethodInvestmentExcludingVariableInterestEntity" abstract="false" name="EquityMethodInvestmentExcludingVariableInterestEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived" abstract="false" name="EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_SharesReceivedAsGift" abstract="false" name="SharesReceivedAsGift" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_ConvertibleSeniorNotesDue2025Member" abstract="true" name="ConvertibleSeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_CollaborativeAgreementAdditionalMilestonePayment" abstract="false" name="CollaborativeAgreementAdditionalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" abstract="false" name="DebtInstrumentConvertibleDebtMaximumSharesIssuable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" abstract="false" name="AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_BilbaoVizcayaBankMember" abstract="true" name="BilbaoVizcayaBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_ChromaDexMember" abstract="true" name="ChromaDexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="opk_OPKOHealthEuropeMember" abstract="true" name="OPKOHealthEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_BancoDeSabadellMember" abstract="true" name="BancoDeSabadellMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_PaymentsForLeases" abstract="false" name="PaymentsForLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_LondonInterbankOfferedRateLIBORThereafterMember" abstract="true" name="LondonInterbankOfferedRateLIBORThereafterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_DiagnosticsMember" abstract="true" name="DiagnosticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="opk_COVID19PercentOfTotalTestVolume" abstract="false" name="COVID19PercentOfTotalTestVolume" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="opk_TransferOfIntellectualPropertyAndOtherMember" abstract="true" name="TransferOfIntellectualPropertyAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_SalesMilestonesMember" abstract="true" name="SalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption" abstract="false" name="OperatingLeaseLiabilityInitialRecognitionUponAdoption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage" abstract="false" name="LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="opk_ChromadexCorporationMember" abstract="true" name="ChromadexCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" abstract="false" name="IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_PhaseTwoInitiationMember" abstract="true" name="PhaseTwoInitiationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember" abstract="true" name="LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="opk_SeriesAWarrantMember" abstract="true" name="SeriesAWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>opk-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:58648600-8b9a-4bda-ba8d-a94f5b914ae0,g:b952a604-1bee-438c-aa3f-da7449f6ab9c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.opko.com/role/COVERPAGE" xlink:type="simple" xlink:href="opk-20200630.xsd#COVERPAGE"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/COVERPAGE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1b60002d-4940-4c77-8a62-5c21922a94df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9cc2e8a3-9720-426a-aa0c-e227c8a18232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1b60002d-4940-4c77-8a62-5c21922a94df" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9cc2e8a3-9720-426a-aa0c-e227c8a18232" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_93a649fd-cf04-4485-8129-277e9ba545fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1b60002d-4940-4c77-8a62-5c21922a94df" xlink:to="loc_us-gaap_Liabilities_93a649fd-cf04-4485-8129-277e9ba545fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_23e018ec-795a-43d0-8fcf-ffae8fe776ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8723d70d-8f59-49a8-a7d2-b3c5b915dad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_23e018ec-795a-43d0-8fcf-ffae8fe776ef" xlink:to="loc_us-gaap_AssetsCurrent_8723d70d-8f59-49a8-a7d2-b3c5b915dad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b47c6283-fbfe-4056-b576-c7cbcfbfb01d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_23e018ec-795a-43d0-8fcf-ffae8fe776ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b47c6283-fbfe-4056-b576-c7cbcfbfb01d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5eec126a-56a0-4a40-b882-0b02ae9de117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_23e018ec-795a-43d0-8fcf-ffae8fe776ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5eec126a-56a0-4a40-b882-0b02ae9de117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InProcessResearchandDevelopment_5a08ec09-045c-45db-b0a4-c5bc8eb3a4a3" xlink:href="opk-20200630.xsd#opk_InProcessResearchandDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_23e018ec-795a-43d0-8fcf-ffae8fe776ef" xlink:to="loc_opk_InProcessResearchandDevelopment_5a08ec09-045c-45db-b0a4-c5bc8eb3a4a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_935528c3-32bd-4bf7-bffc-51a07b909381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_23e018ec-795a-43d0-8fcf-ffae8fe776ef" xlink:to="loc_us-gaap_Goodwill_935528c3-32bd-4bf7-bffc-51a07b909381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_54e25b1e-a5ec-4ea4-babb-c861ffae7657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_23e018ec-795a-43d0-8fcf-ffae8fe776ef" xlink:to="loc_us-gaap_LongTermInvestments_54e25b1e-a5ec-4ea4-babb-c861ffae7657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_068b5fa4-77eb-4fa9-80b7-b35526cb7c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_23e018ec-795a-43d0-8fcf-ffae8fe776ef" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_068b5fa4-77eb-4fa9-80b7-b35526cb7c7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_51167ae9-6eaa-4ff2-ac4a-a371a8b7209c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_23e018ec-795a-43d0-8fcf-ffae8fe776ef" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_51167ae9-6eaa-4ff2-ac4a-a371a8b7209c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_2a7d5368-28e4-4d70-aa3a-d3181c83ecc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_62554508-3e92-4f8e-8c5b-62642ac86a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_2a7d5368-28e4-4d70-aa3a-d3181c83ecc2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_62554508-3e92-4f8e-8c5b-62642ac86a6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_6d1524fb-968f-4f13-9218-90a3aa8cd924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_2a7d5368-28e4-4d70-aa3a-d3181c83ecc2" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_6d1524fb-968f-4f13-9218-90a3aa8cd924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_de0ea0dd-0c0d-49a5-9f7d-20c9a6d5b941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_2a7d5368-28e4-4d70-aa3a-d3181c83ecc2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_de0ea0dd-0c0d-49a5-9f7d-20c9a6d5b941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4c70a0af-aa4d-4343-9625-f1629b9569c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_2a7d5368-28e4-4d70-aa3a-d3181c83ecc2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4c70a0af-aa4d-4343-9625-f1629b9569c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_da91207f-922f-426e-8364-09e6f069bfd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_0eaf4da5-8bd4-4dd6-b759-b1fb3e586f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da91207f-922f-426e-8364-09e6f069bfd0" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_0eaf4da5-8bd4-4dd6-b759-b1fb3e586f58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c5622444-36cf-48e1-871f-8a44d0b5809e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da91207f-922f-426e-8364-09e6f069bfd0" xlink:to="loc_us-gaap_LiabilitiesCurrent_c5622444-36cf-48e1-871f-8a44d0b5809e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_649cc4c9-c07d-4c98-b9cc-247f0b897a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_62187274-0c5a-4542-ab3c-e215b329bb1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_649cc4c9-c07d-4c98-b9cc-247f0b897a3e" xlink:to="loc_us-gaap_AccountsPayableCurrent_62187274-0c5a-4542-ab3c-e215b329bb1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a81d83dc-5845-4985-a86e-95326ae47407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_649cc4c9-c07d-4c98-b9cc-247f0b897a3e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a81d83dc-5845-4985-a86e-95326ae47407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_1c9013ec-c4c3-4be7-968b-1973c99f8b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_649cc4c9-c07d-4c98-b9cc-247f0b897a3e" xlink:to="loc_us-gaap_LinesOfCreditCurrent_1c9013ec-c4c3-4be7-968b-1973c99f8b1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cc49d097-a491-47e1-8a20-3ddfe4a4daa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_649cc4c9-c07d-4c98-b9cc-247f0b897a3e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cc49d097-a491-47e1-8a20-3ddfe4a4daa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d00dcce-e8ce-4446-983a-034dcdff3871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f8a84e0f-489c-423d-a7e7-9513d6c3f928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d00dcce-e8ce-4446-983a-034dcdff3871" xlink:to="loc_us-gaap_CommonStockValue_f8a84e0f-489c-423d-a7e7-9513d6c3f928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_10336207-ac19-4cce-9408-a7c24b70ffd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d00dcce-e8ce-4446-983a-034dcdff3871" xlink:to="loc_us-gaap_TreasuryStockValue_10336207-ac19-4cce-9408-a7c24b70ffd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_01af3887-9279-4e7f-8eb0-bc059cc0ddbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d00dcce-e8ce-4446-983a-034dcdff3871" xlink:to="loc_us-gaap_AdditionalPaidInCapital_01af3887-9279-4e7f-8eb0-bc059cc0ddbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7cadf434-b4c2-49ed-8895-2bd01dfcaeca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d00dcce-e8ce-4446-983a-034dcdff3871" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7cadf434-b4c2-49ed-8895-2bd01dfcaeca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9b81b4be-209b-4328-b774-a585adb94323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d00dcce-e8ce-4446-983a-034dcdff3871" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9b81b4be-209b-4328-b774-a585adb94323" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0e64a2d0-892e-45ed-992b-0fede4197968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_71ae77f7-da33-4407-a636-0d230ccd4809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e64a2d0-892e-45ed-992b-0fede4197968" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_71ae77f7-da33-4407-a636-0d230ccd4809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e5070e46-c782-4802-9532-c16cf4b4ba72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e64a2d0-892e-45ed-992b-0fede4197968" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e5070e46-c782-4802-9532-c16cf4b4ba72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1968474d-a24f-49d1-9ffb-7bde8d3985e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e64a2d0-892e-45ed-992b-0fede4197968" xlink:to="loc_us-gaap_InventoryNet_1968474d-a24f-49d1-9ffb-7bde8d3985e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a079be0c-7c52-4f28-ac18-ed98e643d7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e64a2d0-892e-45ed-992b-0fede4197968" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a079be0c-7c52-4f28-ac18-ed98e643d7a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9504a12c-7868-4ec8-bd5b-17875bd7c01b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c379cd81-0f85-44b1-82e8-dc70b21e0a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9504a12c-7868-4ec8-bd5b-17875bd7c01b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c379cd81-0f85-44b1-82e8-dc70b21e0a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_286d98c0-45f4-4962-be43-0c9775332744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9504a12c-7868-4ec8-bd5b-17875bd7c01b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_286d98c0-45f4-4962-be43-0c9775332744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_28628ba9-f7e6-442b-8af9-e6acd61c01be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9504a12c-7868-4ec8-bd5b-17875bd7c01b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_28628ba9-f7e6-442b-8af9-e6acd61c01be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_89f4827d-b9f4-482c-b633-4823dbeb11f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9504a12c-7868-4ec8-bd5b-17875bd7c01b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_89f4827d-b9f4-482c-b633-4823dbeb11f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0b7c8e23-5e8f-4014-a125-ca194af8b326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9504a12c-7868-4ec8-bd5b-17875bd7c01b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0b7c8e23-5e8f-4014-a125-ca194af8b326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3abfbebc-e709-4303-8625-cb17a624317f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9504a12c-7868-4ec8-bd5b-17875bd7c01b" xlink:to="loc_us-gaap_AssetImpairmentCharges_3abfbebc-e709-4303-8625-cb17a624317f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e58c1334-90f8-4578-a892-b3cdd54bfb02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3dbe3150-fdfd-490f-b49f-65c7170db01d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e58c1334-90f8-4578-a892-b3cdd54bfb02" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3dbe3150-fdfd-490f-b49f-65c7170db01d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6f6a2492-9f2b-433a-abc5-eedd10ec260f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e58c1334-90f8-4578-a892-b3cdd54bfb02" xlink:to="loc_us-gaap_OperatingExpenses_6f6a2492-9f2b-433a-abc5-eedd10ec260f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5c7ef42d-e3ab-4fc3-b920-cda361124e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8496ca31-cfe1-41b5-9f24-f8fc76e0e7a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5c7ef42d-e3ab-4fc3-b920-cda361124e7d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8496ca31-cfe1-41b5-9f24-f8fc76e0e7a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5e16da6e-3a1d-4d65-beff-2145e4b72c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5c7ef42d-e3ab-4fc3-b920-cda361124e7d" xlink:to="loc_us-gaap_OperatingIncomeLoss_5e16da6e-3a1d-4d65-beff-2145e4b72c9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cdefcc71-440b-453a-8914-52eeab7360cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_d7797d25-da1a-4165-bdee-9b090a897125" xlink:href="opk-20200630.xsd#opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_cdefcc71-440b-453a-8914-52eeab7360cd" xlink:to="loc_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_d7797d25-da1a-4165-bdee-9b090a897125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b3e497b8-a57b-4895-accf-c74f32eb80ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_cdefcc71-440b-453a-8914-52eeab7360cd" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b3e497b8-a57b-4895-accf-c74f32eb80ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_4c15a942-9ba0-40fc-8006-e339f940e904" xlink:href="opk-20200630.xsd#opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ea639ad8-d557-4c5e-9a6f-0fa711cbddf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_4c15a942-9ba0-40fc-8006-e339f940e904" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ea639ad8-d557-4c5e-9a6f-0fa711cbddf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4f9097c2-28a9-4e2b-ae79-5815ef456c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_4c15a942-9ba0-40fc-8006-e339f940e904" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4f9097c2-28a9-4e2b-ae79-5815ef456c68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_977d0a92-46e1-4078-9be6-a44f05e21c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestIncomeNonoperating_4e6c4ea0-3c00-47ed-b857-a63fa6e8e995" xlink:href="opk-20200630.xsd#opk_InterestIncomeNonoperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_977d0a92-46e1-4078-9be6-a44f05e21c26" xlink:to="loc_opk_InterestIncomeNonoperating_4e6c4ea0-3c00-47ed-b857-a63fa6e8e995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestExpenseNonoperating_a25c0a65-ffb9-4a9f-a3d2-2f73ae423f88" xlink:href="opk-20200630.xsd#opk_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_977d0a92-46e1-4078-9be6-a44f05e21c26" xlink:to="loc_opk_InterestExpenseNonoperating_a25c0a65-ffb9-4a9f-a3d2-2f73ae423f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_80de9773-26a6-4d0d-a9ac-1506d1e8e51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_977d0a92-46e1-4078-9be6-a44f05e21c26" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_80de9773-26a6-4d0d-a9ac-1506d1e8e51d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cb5ee23b-9f31-4b41-b102-9ab61e72eeb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_977d0a92-46e1-4078-9be6-a44f05e21c26" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cb5ee23b-9f31-4b41-b102-9ab61e72eeb8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_de98cdbe-cef9-4729-9b19-4da94adc603c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f6aade15-257b-494c-85fb-f9e38e2c2049" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_de98cdbe-cef9-4729-9b19-4da94adc603c" xlink:to="loc_us-gaap_ProfitLoss_f6aade15-257b-494c-85fb-f9e38e2c2049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_dd22c84d-8e1f-474a-a97f-515788f4aa2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_de98cdbe-cef9-4729-9b19-4da94adc603c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_dd22c84d-8e1f-474a-a97f-515788f4aa2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="opk-20200630.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f7ed91f7-720e-4d10-a6ae-d4f7a26bafa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_ProfitLoss_f7ed91f7-720e-4d10-a6ae-d4f7a26bafa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fe9f7217-47d6-4a0d-bf31-5b289e099506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fe9f7217-47d6-4a0d-bf31-5b289e099506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_36b9ae4f-56ef-46be-81a1-ce52e7f60c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_PaidInKindInterest_36b9ae4f-56ef-46be-81a1-ce52e7f60c8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4de4dcbd-c067-446f-9f81-2a9836520c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4de4dcbd-c067-446f-9f81-2a9836520c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f4100041-0884-4e74-891f-f07c7635c04e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f4100041-0884-4e74-891f-f07c7635c04e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_372a74c0-091b-472b-872d-7b50bb542911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_ShareBasedCompensation_372a74c0-091b-472b-872d-7b50bb542911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_ee4f5221-7f4f-42e0-b6e6-c0d873732c2c" xlink:href="opk-20200630.xsd#opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_ee4f5221-7f4f-42e0-b6e6-c0d873732c2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a5423cdb-f6c8-460e-8395-0530c22886df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a5423cdb-f6c8-460e-8395-0530c22886df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c72e137a-5d51-4d52-a807-c0708f658a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c72e137a-5d51-4d52-a807-c0708f658a99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e2d2a3f1-ad6c-4d85-814f-7ab193e77492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e2d2a3f1-ad6c-4d85-814f-7ab193e77492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b6065e29-69a3-4473-b2a4-2572bf79aa31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b6065e29-69a3-4473-b2a4-2572bf79aa31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8d576b9-fdb5-4a2a-a3c5-bc942b130712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8d576b9-fdb5-4a2a-a3c5-bc942b130712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_369e7bb6-4496-4174-9201-378c0d202356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_369e7bb6-4496-4174-9201-378c0d202356" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_dfa0189c-2a01-4669-9665-21e299d574b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_dfa0189c-2a01-4669-9665-21e299d574b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement_e5f5bd61-a54f-4312-ab6b-1ae9dac4b07b" xlink:href="opk-20200630.xsd#opk_IncreaseDecreaseinForeignCurrencyMeasurement"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement_e5f5bd61-a54f-4312-ab6b-1ae9dac4b07b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5c1cce63-14d6-4ae0-a25e-3b351a84bf7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5c1cce63-14d6-4ae0-a25e-3b351a84bf7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_72d433a7-4d35-4d54-b521-aee8eecf06e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_72d433a7-4d35-4d54-b521-aee8eecf06e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_be8533c0-8b0f-4acf-a4a5-862b1207e8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_AssetImpairmentCharges_be8533c0-8b0f-4acf-a4a5-862b1207e8bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_7202a107-a4a3-4cd3-8e10-743b03e088be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc11aacf-814f-4db2-86d9-687b2e4df75f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_7202a107-a4a3-4cd3-8e10-743b03e088be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34cc93e4-c0df-4611-aec5-b2a4e93961b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a70a56ce-f0d2-4aef-a705-71a430411775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34cc93e4-c0df-4611-aec5-b2a4e93961b1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a70a56ce-f0d2-4aef-a705-71a430411775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_2e6eccbc-03f2-4b92-8253-a00f0bcfae80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34cc93e4-c0df-4611-aec5-b2a4e93961b1" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_2e6eccbc-03f2-4b92-8253-a00f0bcfae80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_a71749cc-69fb-4e9e-a106-affcd0aef119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34cc93e4-c0df-4611-aec5-b2a4e93961b1" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_a71749cc-69fb-4e9e-a106-affcd0aef119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_82587440-c46b-442e-810b-690475fca174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34cc93e4-c0df-4611-aec5-b2a4e93961b1" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_82587440-c46b-442e-810b-690475fca174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_2d65d8da-3f5d-4a39-a292-6d62235b1e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34cc93e4-c0df-4611-aec5-b2a4e93961b1" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_2d65d8da-3f5d-4a39-a292-6d62235b1e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9da79e1e-a658-4706-8c1b-b5abfb13772b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34cc93e4-c0df-4611-aec5-b2a4e93961b1" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9da79e1e-a658-4706-8c1b-b5abfb13772b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64309700-c8b3-4864-b51a-197315ee94b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4806da3b-d3e8-48a0-a50b-9fe8396c7ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64309700-c8b3-4864-b51a-197315ee94b0" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4806da3b-d3e8-48a0-a50b-9fe8396c7ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_68582c97-a056-46f9-bcfd-d6d6b9c068f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64309700-c8b3-4864-b51a-197315ee94b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_68582c97-a056-46f9-bcfd-d6d6b9c068f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_12a77230-940f-4cd8-b52f-b7d82a7d88c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64309700-c8b3-4864-b51a-197315ee94b0" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_12a77230-940f-4cd8-b52f-b7d82a7d88c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5bd5ec16-36dd-449d-9d03-9079f473f8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7e18253-b561-45a9-88bf-cd1b7a870524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5bd5ec16-36dd-449d-9d03-9079f473f8a7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7e18253-b561-45a9-88bf-cd1b7a870524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e3f16bf-e2b8-474a-8622-c2d04147a5eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5bd5ec16-36dd-449d-9d03-9079f473f8a7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e3f16bf-e2b8-474a-8622-c2d04147a5eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e042b5f4-b79c-4c5c-ac04-946f8a576eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5bd5ec16-36dd-449d-9d03-9079f473f8a7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e042b5f4-b79c-4c5c-ac04-946f8a576eef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b8403531-a6b5-4f17-acd7-a744e7092298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5bd5ec16-36dd-449d-9d03-9079f473f8a7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b8403531-a6b5-4f17-acd7-a744e7092298" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/BusinessandOrganization" xlink:type="simple" xlink:href="opk-20200630.xsd#BusinessandOrganization"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/BusinessandOrganization" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/BusinessandOrganizationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#BusinessandOrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/BusinessandOrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="opk-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="opk-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="opk-20200630.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/EarningsLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#EarningsLossPerShareNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/EarningsLossPerShareNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptions"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsTables"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_aa158870-2b4a-4970-a646-aad92f518236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_000f9667-0f63-4bee-9630-5fa989b0c2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_aa158870-2b4a-4970-a646-aad92f518236" xlink:to="loc_us-gaap_LongTermLineOfCredit_000f9667-0f63-4bee-9630-5fa989b0c2dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4698055b-0235-4d90-a4d7-ae3bc69146fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_aa158870-2b4a-4970-a646-aad92f518236" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4698055b-0235-4d90-a4d7-ae3bc69146fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fa02f284-17cb-46d1-a939-f436a80312eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_aa158870-2b4a-4970-a646-aad92f518236" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fa02f284-17cb-46d1-a939-f436a80312eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4cb055bf-955a-4aeb-9a28-b11dd00e600f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_aa158870-2b4a-4970-a646-aad92f518236" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4cb055bf-955a-4aeb-9a28-b11dd00e600f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f9cfc184-5428-42c1-83fa-9ca33718d556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_aa158870-2b4a-4970-a646-aad92f518236" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f9cfc184-5428-42c1-83fa-9ca33718d556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_77579e25-1910-4d27-adc7-55a402098a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_aa158870-2b4a-4970-a646-aad92f518236" xlink:to="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_77579e25-1910-4d27-adc7-55a402098a02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04a2ea74-50af-4441-801a-653eb48063ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TaxesRecoverableCurrent_07c50004-3d80-4dbb-a33a-9ad402b69b88" xlink:href="opk-20200630.xsd#opk_TaxesRecoverableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04a2ea74-50af-4441-801a-653eb48063ad" xlink:to="loc_opk_TaxesRecoverableCurrent_07c50004-3d80-4dbb-a33a-9ad402b69b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_83a980ea-415c-4244-bf50-f8ca498ec5ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04a2ea74-50af-4441-801a-653eb48063ad" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_83a980ea-415c-4244-bf50-f8ca498ec5ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_98ff6615-3666-4a09-aac8-e00402a2900c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04a2ea74-50af-4441-801a-653eb48063ad" xlink:to="loc_us-gaap_Supplies_98ff6615-3666-4a09-aac8-e00402a2900c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_68f5da33-6e88-431c-951b-9836eef9fc18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04a2ea74-50af-4441-801a-653eb48063ad" xlink:to="loc_us-gaap_PrepaidInsurance_68f5da33-6e88-431c-951b-9836eef9fc18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7a62f88a-2117-46b9-819c-2f34c0201fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04a2ea74-50af-4441-801a-653eb48063ad" xlink:to="loc_us-gaap_OtherAssetsCurrent_7a62f88a-2117-46b9-819c-2f34c0201fbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c9fcc5fb-6962-4b18-b12c-71af055c4d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_01371001-2089-47bb-b702-a8e83fa9fecd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_c9fcc5fb-6962-4b18-b12c-71af055c4d91" xlink:to="loc_us-gaap_OtherInventorySupplies_01371001-2089-47bb-b702-a8e83fa9fecd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_bdd2b990-a829-46c5-81bf-fd8728e579ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_c9fcc5fb-6962-4b18-b12c-71af055c4d91" xlink:to="loc_us-gaap_InventoryFinishedGoods_bdd2b990-a829-46c5-81bf-fd8728e579ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_9dfcf421-f7d2-4ca4-850c-4ece94de40c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_c9fcc5fb-6962-4b18-b12c-71af055c4d91" xlink:to="loc_us-gaap_InventoryWorkInProcess_9dfcf421-f7d2-4ca4-850c-4ece94de40c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_c7d2cd58-7896-4191-ac8b-5ea5db827d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_c9fcc5fb-6962-4b18-b12c-71af055c4d91" xlink:to="loc_us-gaap_InventoryRawMaterials_c7d2cd58-7896-4191-ac8b-5ea5db827d66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_574c6c06-35d2-4672-b052-eb4338be2f4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_c9fcc5fb-6962-4b18-b12c-71af055c4d91" xlink:to="loc_us-gaap_InventoryValuationReserves_574c6c06-35d2-4672-b052-eb4338be2f4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5742127c-4273-4b90-990a-ced1bde12c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_42ebe660-cfad-499d-8d7d-397e29819ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5742127c-4273-4b90-990a-ced1bde12c3d" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_42ebe660-cfad-499d-8d7d-397e29819ce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_db8a1e0f-9f1a-4ac6-a0ea-d50917d73455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5742127c-4273-4b90-990a-ced1bde12c3d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_db8a1e0f-9f1a-4ac6-a0ea-d50917d73455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedCommitmentsandContingenciesCurrent_c003cb08-5791-422e-b1f9-1a0e43712d5c" xlink:href="opk-20200630.xsd#opk_AccruedCommitmentsandContingenciesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5742127c-4273-4b90-990a-ced1bde12c3d" xlink:to="loc_opk_AccruedCommitmentsandContingenciesCurrent_c003cb08-5791-422e-b1f9-1a0e43712d5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bf754b67-952b-4ae9-859c-56335aa870db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5742127c-4273-4b90-990a-ced1bde12c3d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bf754b67-952b-4ae9-859c-56335aa870db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_91754268-a8c5-4903-83e0-bee9d69ed29f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5742127c-4273-4b90-990a-ced1bde12c3d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_91754268-a8c5-4903-83e0-bee9d69ed29f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InventoryReceivedNotInvoicedCurrent_927c422b-b0f1-4fb8-974d-ce98e3a1d246" xlink:href="opk-20200630.xsd#opk_InventoryReceivedNotInvoicedCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5742127c-4273-4b90-990a-ced1bde12c3d" xlink:to="loc_opk_InventoryReceivedNotInvoicedCurrent_927c422b-b0f1-4fb8-974d-ce98e3a1d246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f646bb69-cffe-403c-af01-c879ec7ca690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5742127c-4273-4b90-990a-ced1bde12c3d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f646bb69-cffe-403c-af01-c879ec7ca690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f6d761f2-4655-41f2-8b7a-0228707dde79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5742127c-4273-4b90-990a-ced1bde12c3d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f6d761f2-4655-41f2-8b7a-0228707dde79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedClinicalTrialsCurrent_2380145b-8408-4b65-8eff-3b277966aa3c" xlink:href="opk-20200630.xsd#opk_AccruedClinicalTrialsCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5742127c-4273-4b90-990a-ced1bde12c3d" xlink:to="loc_opk_AccruedClinicalTrialsCurrent_2380145b-8408-4b65-8eff-3b277966aa3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6ba758e1-6d9a-4b6d-814f-c4632ada7a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_155581bb-97a9-4c4e-b53d-167e7e6c3aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_6ba758e1-6d9a-4b6d-814f-c4632ada7a4d" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_155581bb-97a9-4c4e-b53d-167e7e6c3aa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0cc02009-1b59-4267-a222-051ff835f549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_6ba758e1-6d9a-4b6d-814f-c4632ada7a4d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0cc02009-1b59-4267-a222-051ff835f549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5263364f-c2b5-400e-b97d-257c8bed295d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f9a7b78f-aa8a-45dd-b656-ac04960b1a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5263364f-c2b5-400e-b97d-257c8bed295d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f9a7b78f-aa8a-45dd-b656-ac04960b1a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4020ed9c-e0f2-4f92-b5d3-cdb65fae62d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5263364f-c2b5-400e-b97d-257c8bed295d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4020ed9c-e0f2-4f92-b5d3-cdb65fae62d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/Investments" xlink:type="simple" xlink:href="opk-20200630.xsd#Investments"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/Investments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/InvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_6c159469-4618-436d-b1eb-f41dc17adc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity_456c7df2-d1ec-46c3-add6-c90e55d432ca" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentExcludingVariableInterestEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_6c159469-4618-436d-b1eb-f41dc17adc1d" xlink:to="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity_456c7df2-d1ec-46c3-add6-c90e55d432ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentVariableInterestEntity_f20538a1-f795-44ca-b873-2166dc79e4d6" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentVariableInterestEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_6c159469-4618-436d-b1eb-f41dc17adc1d" xlink:to="loc_opk_EquityMethodInvestmentVariableInterestEntity_f20538a1-f795-44ca-b873-2166dc79e4d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_70e01efa-cbba-4928-a43d-eb9db367b2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_6c159469-4618-436d-b1eb-f41dc17adc1d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_70e01efa-cbba-4928-a43d-eb9db367b2dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockOptionandWarrantInvestments_e7010ff0-c12b-416f-8bfd-b650e5b4839d" xlink:href="opk-20200630.xsd#opk_StockOptionandWarrantInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_6c159469-4618-436d-b1eb-f41dc17adc1d" xlink:to="loc_opk_StockOptionandWarrantInvestments_e7010ff0-c12b-416f-8bfd-b650e5b4839d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c7bc51b5-1a53-47e3-9202-fbaa9d950413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_6c159469-4618-436d-b1eb-f41dc17adc1d" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c7bc51b5-1a53-47e3-9202-fbaa9d950413" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/InvestmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e956af20-4c91-4f0b-a212-81ebfa9eb23a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_3e10781e-6b3e-4464-858d-440a48627704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e956af20-4c91-4f0b-a212-81ebfa9eb23a" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_3e10781e-6b3e-4464-858d-440a48627704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_09e3a7c8-f990-4847-ad2c-1230931a4c64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e956af20-4c91-4f0b-a212-81ebfa9eb23a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_09e3a7c8-f990-4847-ad2c-1230931a4c64" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/Debt" xlink:type="simple" xlink:href="opk-20200630.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/DebtTables" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/DebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtScheduleofNotesDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d9f99921-d36e-459b-89c7-5eff101f7847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_93f58d5b-df9b-44e3-a861-c46c71eeb197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d9f99921-d36e-459b-89c7-5eff101f7847" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_93f58d5b-df9b-44e3-a861-c46c71eeb197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_25b47920-dc86-4d04-b8c2-bf269c0ad4cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d9f99921-d36e-459b-89c7-5eff101f7847" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_25b47920-dc86-4d04-b8c2-bf269c0ad4cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_95abfa95-996f-4448-b65b-f9f1f4f8845c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5d2e929a-1fb7-4b64-b0d8-0722950279d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95abfa95-996f-4448-b65b-f9f1f4f8845c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5d2e929a-1fb7-4b64-b0d8-0722950279d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c5e5479e-5f0a-497f-b3b9-7dd31a2e13df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95abfa95-996f-4448-b65b-f9f1f4f8845c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c5e5479e-5f0a-497f-b3b9-7dd31a2e13df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_3127a7fc-3ff3-4b91-a64d-79fa32fb6a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95abfa95-996f-4448-b65b-f9f1f4f8845c" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_3127a7fc-3ff3-4b91-a64d-79fa32fb6a9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtLinesofCreditDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtLinesofCreditDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/DebtLinesofCreditDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtNotesPayableandOtherDebtDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_af8ca9c0-5856-494e-bd37-5fb96552b4a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_af3495ef-2c7f-404f-928e-cbfba0a64990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_af8ca9c0-5856-494e-bd37-5fb96552b4a7" xlink:to="loc_us-gaap_LongTermDebtCurrent_af3495ef-2c7f-404f-928e-cbfba0a64990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_804f4cc2-c689-4650-91ca-0f3c26df5d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_af8ca9c0-5856-494e-bd37-5fb96552b4a7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_804f4cc2-c689-4650-91ca-0f3c26df5d62" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="simple" xlink:href="opk-20200630.xsd#AccumulatedOtherComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="simple" xlink:href="opk-20200630.xsd#AccumulatedOtherComprehensiveLossTables"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#AccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ced0092d-60db-4ef7-a86a-16c73148cd06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a28d0297-7b4e-4f2a-8dd5-86a9afde6bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ced0092d-60db-4ef7-a86a-16c73148cd06" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a28d0297-7b4e-4f2a-8dd5-86a9afde6bd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_a381f530-6e4d-4375-9fb2-f37cf901f126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ced0092d-60db-4ef7-a86a-16c73148cd06" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_a381f530-6e4d-4375-9fb2-f37cf901f126" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_da30c839-af46-496b-b93e-47a5053350a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ced0092d-60db-4ef7-a86a-16c73148cd06" xlink:to="loc_us-gaap_DerivativeAssets_da30c839-af46-496b-b93e-47a5053350a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_64166fff-ee9b-4301-8497-39b68237e7c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4deb3a39-0dcc-41e7-bc69-2ffdf6c6840b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_64166fff-ee9b-4301-8497-39b68237e7c5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4deb3a39-0dcc-41e7-bc69-2ffdf6c6840b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsLevel3ReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContracts" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContracts"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/DerivativeContracts" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContractsTables"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/DerivativeContractsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContractsBalanceSheetComponentDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContractsDerivativeGainsLossesDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="opk-20200630.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/RelatedPartyTransactionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="opk-20200630.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CommitmentsandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CommitmentsandContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognition" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognition"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/RevenueRecognition" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionTables"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/RevenueRecognitionTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionScheduleofDisaggregationofRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/StrategicAlliances" xlink:type="simple" xlink:href="opk-20200630.xsd#StrategicAlliances"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/StrategicAlliances" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/StrategicAlliancesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#StrategicAlliancesDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/StrategicAlliancesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/Segments" xlink:type="simple" xlink:href="opk-20200630.xsd#Segments"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/Segments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#SegmentsTables"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/SegmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SegmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/SegmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SegmentsOperationsandAssetsInformationDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/Leases" xlink:type="simple" xlink:href="opk-20200630.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesTables" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesLeaseLiabilityMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b69c0ef3-aa06-4cd3-a1ec-6f11e236c90f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_f4933867-296f-4c17-b3fe-db4ee9099d1f" xlink:href="opk-20200630.xsd#opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b69c0ef3-aa06-4cd3-a1ec-6f11e236c90f" xlink:to="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_f4933867-296f-4c17-b3fe-db4ee9099d1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bbabecfe-91c1-463d-8d03-44cba0ab1c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b69c0ef3-aa06-4cd3-a1ec-6f11e236c90f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bbabecfe-91c1-463d-8d03-44cba0ab1c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_31257de7-e59f-45ce-8e83-537c78a05d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b69c0ef3-aa06-4cd3-a1ec-6f11e236c90f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_31257de7-e59f-45ce-8e83-537c78a05d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bbb70462-7091-421e-afbc-bf2bde47a2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b69c0ef3-aa06-4cd3-a1ec-6f11e236c90f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bbb70462-7091-421e-afbc-bf2bde47a2b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b3246c8d-f97b-4603-abb1-687f865916ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b69c0ef3-aa06-4cd3-a1ec-6f11e236c90f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b3246c8d-f97b-4603-abb1-687f865916ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eeb26103-0613-4fb1-bfd2-f61d7e9489bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b69c0ef3-aa06-4cd3-a1ec-6f11e236c90f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eeb26103-0613-4fb1-bfd2-f61d7e9489bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d4e0ac8c-2751-4312-814e-b5d7508b3bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ad164359-756d-4f9d-a85e-091fa302ff30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d4e0ac8c-2751-4312-814e-b5d7508b3bab" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ad164359-756d-4f9d-a85e-091fa302ff30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_65bef52e-421e-41d5-81a2-90878f6b9a58" xlink:href="opk-20200630.xsd#opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d4e0ac8c-2751-4312-814e-b5d7508b3bab" xlink:to="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_65bef52e-421e-41d5-81a2-90878f6b9a58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d7524fa3-d163-4861-a5c8-bfe7e5641b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d4e0ac8c-2751-4312-814e-b5d7508b3bab" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d7524fa3-d163-4861-a5c8-bfe7e5641b7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a69f1fb7-1815-4223-92d3-1e7580279688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d4e0ac8c-2751-4312-814e-b5d7508b3bab" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a69f1fb7-1815-4223-92d3-1e7580279688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_b58d3c73-454d-4482-acf9-d45ec06025d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d4e0ac8c-2751-4312-814e-b5d7508b3bab" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_b58d3c73-454d-4482-acf9-d45ec06025d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d5530142-b845-4e5a-a0a6-2e840c9369c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d4e0ac8c-2751-4312-814e-b5d7508b3bab" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d5530142-b845-4e5a-a0a6-2e840c9369c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesLeaseLiabilityMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fd81a1ac-a359-4f2c-97a5-3c12ac85bf21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ecdc81d4-4a8b-47f3-a169-9b72c00bd214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fd81a1ac-a359-4f2c-97a5-3c12ac85bf21" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ecdc81d4-4a8b-47f3-a169-9b72c00bd214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e2ac5969-ce77-41e0-add2-471d765cf38a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fd81a1ac-a359-4f2c-97a5-3c12ac85bf21" xlink:to="loc_us-gaap_OperatingLeaseLiability_e2ac5969-ce77-41e0-add2-471d765cf38a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_eb745b40-85a5-4f20-915f-c30b53f4cefd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_6aa12357-0f3b-4eed-8e71-173228beecac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_eb745b40-85a5-4f20-915f-c30b53f4cefd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_6aa12357-0f3b-4eed-8e71-173228beecac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_64f3d9fc-c083-48bd-9a8e-f3b37169b7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_eb745b40-85a5-4f20-915f-c30b53f4cefd" xlink:to="loc_us-gaap_FinanceLeaseLiability_64f3d9fc-c083-48bd-9a8e-f3b37169b7eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesLeaseCashFlowInformationDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_PaymentsForLeases_c708d0ec-d88c-4dcf-bc8f-b6544e0059d5" xlink:href="opk-20200630.xsd#opk_PaymentsForLeases"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_fdbdaf00-4e69-4331-85d5-86047fd78fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_opk_PaymentsForLeases_c708d0ec-d88c-4dcf-bc8f-b6544e0059d5" xlink:to="loc_us-gaap_OperatingLeasePayments_fdbdaf00-4e69-4331-85d5-86047fd78fbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_15573784-8c8e-499c-8524-836391065633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_opk_PaymentsForLeases_c708d0ec-d88c-4dcf-bc8f-b6544e0059d5" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_15573784-8c8e-499c-8524-836391065633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_b345e785-05bd-48a6-bc1a-d2054b98a60c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_opk_PaymentsForLeases_c708d0ec-d88c-4dcf-bc8f-b6544e0059d5" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_b345e785-05bd-48a6-bc1a-d2054b98a60c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SubsequentEvents" xlink:type="simple" xlink:href="opk-20200630.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>opk-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:58648600-8b9a-4bda-ba8d-a94f5b914ae0,g:b952a604-1bee-438c-aa3f-da7449f6ab9c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.opko.com/role/COVERPAGE" xlink:type="simple" xlink:href="opk-20200630.xsd#COVERPAGE"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/COVERPAGE" xlink:type="extended" id="i5c9dabc1fa5c409fb41dda2079665c58_COVERPAGE"/>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i5b04b7a519ce4dcf9917e92722793f93_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="iae4a7615f0374599b43f2c7523ffdb8d_CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i8eaddc5c1a0043a7bc5eb7c4bcfe77ff_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c4c8a360-6601-4ad1-8f2b-6078a80dc903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_RevenuesAbstract_c4c8a360-6601-4ad1-8f2b-6078a80dc903" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_809748fb-a90f-4075-92b6-8a102eff5baf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c4c8a360-6601-4ad1-8f2b-6078a80dc903" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_809748fb-a90f-4075-92b6-8a102eff5baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0dec4383-f25c-4844-9157-c86b92041ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0dec4383-f25c-4844-9157-c86b92041ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b8310a55-1ba3-4224-8da4-c60168021a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b8310a55-1ba3-4224-8da4-c60168021a24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7c885534-56ee-4826-9ea4-8e1928954e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7c885534-56ee-4826-9ea4-8e1928954e80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_714ed1e8-1d20-4080-870e-367cb4a7e506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_714ed1e8-1d20-4080-870e-367cb4a7e506" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9706d438-4ea6-440d-9e68-063060490ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9706d438-4ea6-440d-9e68-063060490ac8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4b84cfff-94d3-406e-835b-4bfaa7795f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_AssetImpairmentCharges_4b84cfff-94d3-406e-835b-4bfaa7795f6c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_694219e2-3d22-4b4a-94c0-8fe91c85cced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_OperatingExpenses_694219e2-3d22-4b4a-94c0-8fe91c85cced" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c73dcd41-7a1d-4b59-aa6c-2a6fc7eb687d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_OperatingIncomeLoss_c73dcd41-7a1d-4b59-aa6c-2a6fc7eb687d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestIncomeNonoperating_abdbac11-e55c-46ae-a438-54337228c37b" xlink:href="opk-20200630.xsd#opk_InterestIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:to="loc_opk_InterestIncomeNonoperating_abdbac11-e55c-46ae-a438-54337228c37b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestExpenseNonoperating_23061984-5a33-4d84-aa0a-feb55c13c8f0" xlink:href="opk-20200630.xsd#opk_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:to="loc_opk_InterestExpenseNonoperating_23061984-5a33-4d84-aa0a-feb55c13c8f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_7635d446-a3bb-48ae-be7f-82bbe26f7e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_7635d446-a3bb-48ae-be7f-82bbe26f7e9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_31d6df2d-e269-45ec-81eb-00b833cc00ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_31d6df2d-e269-45ec-81eb-00b833cc00ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bb68cb87-c76f-4e7a-bc62-df3cdf8cf8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bb68cb87-c76f-4e7a-bc62-df3cdf8cf8ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c6949fa8-79ca-4920-9cf0-0052e82d6da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c6949fa8-79ca-4920-9cf0-0052e82d6da9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_25189acb-9ef7-4d0f-a0e7-f25fd8263092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_25189acb-9ef7-4d0f-a0e7-f25fd8263092" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_37e10be6-b1d9-4d79-a89e-ee5efb99fbab" xlink:href="opk-20200630.xsd#opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_37e10be6-b1d9-4d79-a89e-ee5efb99fbab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dc98842d-b233-4726-b920-cfae6866d441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dc98842d-b233-4726-b920-cfae6866d441" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b24de358-fbdd-4c02-8dd6-31af5f6fffcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_ProfitLoss_b24de358-fbdd-4c02-8dd6-31af5f6fffcc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6e849435-eb0e-4ab9-9b22-948f388cdf79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_EarningsPerShareAbstract_6e849435-eb0e-4ab9-9b22-948f388cdf79" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_745a0ec6-bdd0-4856-8391-d621ee79126c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6e849435-eb0e-4ab9-9b22-948f388cdf79" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_745a0ec6-bdd0-4856-8391-d621ee79126c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_abb12d92-5805-4a1a-8a45-dd4a373309d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_abb12d92-5805-4a1a-8a45-dd4a373309d2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7ec50802-0b44-467e-8b23-d589e152c729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_StatementTable_7ec50802-0b44-467e-8b23-d589e152c729" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5fdb3f61-0b78-4678-a8ac-6d139145f7a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7ec50802-0b44-467e-8b23-d589e152c729" xlink:to="loc_srt_ProductOrServiceAxis_5fdb3f61-0b78-4678-a8ac-6d139145f7a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5fdb3f61-0b78-4678-a8ac-6d139145f7a0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5fdb3f61-0b78-4678-a8ac-6d139145f7a0" xlink:to="loc_srt_ProductsAndServicesDomain_5fdb3f61-0b78-4678-a8ac-6d139145f7a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_44c3c00f-c69e-4f04-ac9a-905e6c09ecbb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5fdb3f61-0b78-4678-a8ac-6d139145f7a0" xlink:to="loc_srt_ProductsAndServicesDomain_44c3c00f-c69e-4f04-ac9a-905e6c09ecbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_fe4c0408-f9b7-41d1-b4d1-b4590a4249b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_44c3c00f-c69e-4f04-ac9a-905e6c09ecbb" xlink:to="loc_us-gaap_ServiceMember_fe4c0408-f9b7-41d1-b4d1-b4590a4249b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3de89032-5582-49d2-a0d3-a6b984b646b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_44c3c00f-c69e-4f04-ac9a-905e6c09ecbb" xlink:to="loc_us-gaap_ProductMember_3de89032-5582-49d2-a0d3-a6b984b646b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_86432e3b-34be-4741-a919-d67f163ef608" xlink:href="opk-20200630.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_44c3c00f-c69e-4f04-ac9a-905e6c09ecbb" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_86432e3b-34be-4741-a919-d67f163ef608" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended" id="i907d07acb90243338f4cffad13be16b2_CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:roleRef roleURI="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="opk-20200630.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended" id="i8fd652e04d824c00ae01b511c29e6870_CONSOLIDATEDSTATEMENTSOFEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d12c23df-d400-4d57-ace1-2468af8da8d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d12c23df-d400-4d57-ace1-2468af8da8d4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_929738b5-56ee-48fa-8f24-c2c13c5815a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_SharesIssued_929738b5-56ee-48fa-8f24-c2c13c5815a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20a61e72-a74a-4165-a6cd-ff2079b20277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20a61e72-a74a-4165-a6cd-ff2079b20277" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a3045994-5b82-4309-9dc7-b7597e8cc9a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a3045994-5b82-4309-9dc7-b7597e8cc9a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b14b098-583c-4bab-b341-79abe53427b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b14b098-583c-4bab-b341-79abe53427b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6c38b8b0-bd03-459e-843c-9d58a50789cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6c38b8b0-bd03-459e-843c-9d58a50789cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1d2af96e-4b86-4568-ac53-28359cbd620f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1d2af96e-4b86-4568-ac53-28359cbd620f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b7c28cb0-9e5e-40cc-97b3-ee5f33c26565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b7c28cb0-9e5e-40cc-97b3-ee5f33c26565" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b09d78ed-4831-4b3e-b489-c49db8c81cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_NetIncomeLoss_b09d78ed-4831-4b3e-b489-c49db8c81cf3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59ddda71-2504-422a-b027-9fe547a12fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59ddda71-2504-422a-b027-9fe547a12fe1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_d72c2613-7d1c-4b4e-a6cb-787d1bcdd0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ce9c52ab-2bf2-44ec-95ec-79df0ce62cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_4a850f44-53c6-4acd-b68f-c8bbc24f0e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d12c23df-d400-4d57-ace1-2468af8da8d4" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_4a850f44-53c6-4acd-b68f-c8bbc24f0e23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_80ed3686-794a-41aa-9df3-6359d6285e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d12c23df-d400-4d57-ace1-2468af8da8d4" xlink:to="loc_us-gaap_StatementTable_80ed3686-794a-41aa-9df3-6359d6285e61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c748737e-1d64-41cb-ae73-054309352750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_80ed3686-794a-41aa-9df3-6359d6285e61" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c748737e-1d64-41cb-ae73-054309352750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c748737e-1d64-41cb-ae73-054309352750_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c748737e-1d64-41cb-ae73-054309352750" xlink:to="loc_us-gaap_EquityComponentDomain_c748737e-1d64-41cb-ae73-054309352750_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c748737e-1d64-41cb-ae73-054309352750" xlink:to="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ee979a79-93fc-420e-af3d-020db10ea247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:to="loc_us-gaap_CommonStockMember_ee979a79-93fc-420e-af3d-020db10ea247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_16c9fc55-7cd5-4662-ad8c-2e3db0e68355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:to="loc_us-gaap_TreasuryStockMember_16c9fc55-7cd5-4662-ad8c-2e3db0e68355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d24a8ab2-228e-4013-9e69-ae2d7f28586a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d24a8ab2-228e-4013-9e69-ae2d7f28586a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_393235e1-4554-4a03-84a6-15e7349a9d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_393235e1-4554-4a03-84a6-15e7349a9d7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2f65bbb4-2739-40b0-9d9a-bc0a6a5282f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:to="loc_us-gaap_RetainedEarningsMember_2f65bbb4-2739-40b0-9d9a-bc0a6a5282f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d81dbe2-0fc7-4013-88ea-a9bd2d439bec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_80ed3686-794a-41aa-9df3-6359d6285e61" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d81dbe2-0fc7-4013-88ea-a9bd2d439bec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8d81dbe2-0fc7-4013-88ea-a9bd2d439bec_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d81dbe2-0fc7-4013-88ea-a9bd2d439bec" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8d81dbe2-0fc7-4013-88ea-a9bd2d439bec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77905d76-b170-4e31-9cc3-7730283d9787" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d81dbe2-0fc7-4013-88ea-a9bd2d439bec" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77905d76-b170-4e31-9cc3-7730283d9787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1de22fd9-7f43-4355-ae73-d60f095fc84b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77905d76-b170-4e31-9cc3-7730283d9787" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1de22fd9-7f43-4355-ae73-d60f095fc84b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="if99c15960c744ee789f771d595940dbc_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.opko.com/role/BusinessandOrganization" xlink:type="simple" xlink:href="opk-20200630.xsd#BusinessandOrganization"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/BusinessandOrganization" xlink:type="extended" id="ibcbefc309f524f439f207214fe01254d_BusinessandOrganization"/>
  <link:roleRef roleURI="http://www.opko.com/role/BusinessandOrganizationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#BusinessandOrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/BusinessandOrganizationDetails" xlink:type="extended" id="ib0468859eac94fe9a311fafdeb5b96d0_BusinessandOrganizationDetails"/>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="opk-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="ib8a3be84a5e847808f093b72725b832f_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="opk-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i9ed6cda11cf04e0c8bb470262dacc8c4_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i84a68778a9684237ba10fe5af680a676_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:href="opk-20200630.xsd#opk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19NumberOfTestsPerformed_89901fce-7e31-4ded-a144-45d2d9c3bb63" xlink:href="opk-20200630.xsd#opk_COVID19NumberOfTestsPerformed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_opk_COVID19NumberOfTestsPerformed_89901fce-7e31-4ded-a144-45d2d9c3bb63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19PercentOfTotalTestVolume_d23fcde4-622f-4b20-b0eb-504ad8f889d6" xlink:href="opk-20200630.xsd#opk_COVID19PercentOfTotalTestVolume"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_opk_COVID19PercentOfTotalTestVolume_d23fcde4-622f-4b20-b0eb-504ad8f889d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestsPerformedPerDay_1892d211-3a54-40fd-a4c2-fdb9d3828366" xlink:href="opk-20200630.xsd#opk_COVID19TestsPerformedPerDay"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_opk_COVID19TestsPerformedPerDay_1892d211-3a54-40fd-a4c2-fdb9d3828366" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChangeInTestingVolumePercent_17802d8d-ace7-40c5-bfec-653e990c1374" xlink:href="opk-20200630.xsd#opk_ChangeInTestingVolumePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_opk_ChangeInTestingVolumePercent_17802d8d-ace7-40c5-bfec-653e990c1374" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_838fb405-50b9-45d8-99ef-95f760611f25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_838fb405-50b9-45d8-99ef-95f760611f25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed535878-e51a-45a3-8469-2c7d220ead0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed535878-e51a-45a3-8469-2c7d220ead0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_0102e3e1-9fb9-4bce-8650-0db14d6b3cb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_InventoryWriteDown_0102e3e1-9fb9-4bce-8650-0db14d6b3cb8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_232e18a6-e9dd-412b-a78b-8d5a826a41bb" xlink:href="opk-20200630.xsd#opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_232e18a6-e9dd-412b-a78b-8d5a826a41bb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ea23ed4a-5646-4f7e-a134-c4eee4163c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_Goodwill_ea23ed4a-5646-4f7e-a134-c4eee4163c76" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8a073c40-ac1c-43cc-b08e-83e675120352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8a073c40-ac1c-43cc-b08e-83e675120352" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d1e7f3ba-fbe9-4e7e-9dcc-f27ca15ab14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d1e7f3ba-fbe9-4e7e-9dcc-f27ca15ab14d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d95a448b-5dcc-44ae-a570-0478f8b6c4de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d95a448b-5dcc-44ae-a570-0478f8b6c4de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_643bd5fb-5c3d-467c-8f14-068fa539a539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_643bd5fb-5c3d-467c-8f14-068fa539a539" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f6d78fc7-03d5-46bf-8f98-5967c7b59722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_Depreciation_f6d78fc7-03d5-46bf-8f98-5967c7b59722" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6b56651f-b59d-4cdf-8283-955818f30b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6b56651f-b59d-4cdf-8283-955818f30b1c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_baa1d90b-7361-4cec-b5dd-db8309f90e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_baa1d90b-7361-4cec-b5dd-db8309f90e64" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_28b16a42-50f0-4228-9334-5bbb39acc6d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_28b16a42-50f0-4228-9334-5bbb39acc6d0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5320bc4a-85d5-47cc-84ea-562988ef80f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5320bc4a-85d5-47cc-84ea-562988ef80f4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b03bfaf2-9c99-4d9d-afe2-cd1ddd749c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_NumberOfReportableSegments_b03bfaf2-9c99-4d9d-afe2-cd1ddd749c6f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:href="opk-20200630.xsd#opk_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8fd47cf5-0add-4a7f-b703-14519433b1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8fd47cf5-0add-4a7f-b703-14519433b1f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8fd47cf5-0add-4a7f-b703-14519433b1f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8fd47cf5-0add-4a7f-b703-14519433b1f6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8fd47cf5-0add-4a7f-b703-14519433b1f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11028392-e943-4f23-91e7-33bb49130212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8fd47cf5-0add-4a7f-b703-14519433b1f6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11028392-e943-4f23-91e7-33bb49130212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5fe0c718-81f0-4fd4-aa59-1ccea07a9512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11028392-e943-4f23-91e7-33bb49130212" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5fe0c718-81f0-4fd4-aa59-1ccea07a9512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_478ef007-185f-4631-9bcb-655a31b43cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_478ef007-185f-4631-9bcb-655a31b43cb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_478ef007-185f-4631-9bcb-655a31b43cb6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_478ef007-185f-4631-9bcb-655a31b43cb6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_478ef007-185f-4631-9bcb-655a31b43cb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_478ef007-185f-4631-9bcb-655a31b43cb6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_07095143-4472-493a-8b34-2ce47550a66e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_07095143-4472-493a-8b34-2ce47550a66e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_0b9b93d2-b6f3-4cb3-b77d-c93515222a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_0b9b93d2-b6f3-4cb3-b77d-c93515222a4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3b07bb48-ee46-4c9e-8b78-144f3fd89616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3b07bb48-ee46-4c9e-8b78-144f3fd89616" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_c19f696f-e329-4e56-b3c1-4de8c68d4ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_c19f696f-e329-4e56-b3c1-4de8c68d4ae3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AutomobilesandAircraftMember_23ae3a29-9016-4d9a-a2ff-89d45d4aad0d" xlink:href="opk-20200630.xsd#opk_AutomobilesandAircraftMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:to="loc_opk_AutomobilesandAircraftMember_23ae3a29-9016-4d9a-a2ff-89d45d4aad0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_77c05984-a3f7-43be-a1b1-d4adb24424ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_77c05984-a3f7-43be-a1b1-d4adb24424ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_77c05984-a3f7-43be-a1b1-d4adb24424ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_77c05984-a3f7-43be-a1b1-d4adb24424ac" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_77c05984-a3f7-43be-a1b1-d4adb24424ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d475fa2f-30b7-479b-95cc-0a936d0f2002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_77c05984-a3f7-43be-a1b1-d4adb24424ac" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d475fa2f-30b7-479b-95cc-0a936d0f2002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_c520d437-2613-4560-92b0-c138e7a3a412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d475fa2f-30b7-479b-95cc-0a936d0f2002" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_c520d437-2613-4560-92b0-c138e7a3a412" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_213bbf98-2544-4057-839d-8e2517c29c62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d475fa2f-30b7-479b-95cc-0a936d0f2002" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_213bbf98-2544-4057-839d-8e2517c29c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2635bc3f-6955-4c04-a552-c64f201e7602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d475fa2f-30b7-479b-95cc-0a936d0f2002" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2635bc3f-6955-4c04-a552-c64f201e7602" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6a9d878b-c415-447a-9b7a-69de82af3e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6a9d878b-c415-447a-9b7a-69de82af3e6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a9d878b-c415-447a-9b7a-69de82af3e6b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6a9d878b-c415-447a-9b7a-69de82af3e6b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a9d878b-c415-447a-9b7a-69de82af3e6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0d1e6156-028e-41f2-88fc-633b91ff5df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6a9d878b-c415-447a-9b7a-69de82af3e6b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0d1e6156-028e-41f2-88fc-633b91ff5df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b662b676-afa2-4d59-89a8-0c0d5ecc258d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0d1e6156-028e-41f2-88fc-633b91ff5df3" xlink:to="loc_us-gaap_AccountsReceivableMember_b662b676-afa2-4d59-89a8-0c0d5ecc258d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f5c59a12-b2c9-4910-8eda-1466c2e5f0d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_srt_RangeAxis_f5c59a12-b2c9-4910-8eda-1466c2e5f0d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f5c59a12-b2c9-4910-8eda-1466c2e5f0d3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f5c59a12-b2c9-4910-8eda-1466c2e5f0d3" xlink:to="loc_srt_RangeMember_f5c59a12-b2c9-4910-8eda-1466c2e5f0d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b44db8d-f1f9-421b-9a1c-979d24ae10fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f5c59a12-b2c9-4910-8eda-1466c2e5f0d3" xlink:to="loc_srt_RangeMember_1b44db8d-f1f9-421b-9a1c-979d24ae10fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_461c3ff0-d633-4ff7-b3eb-f8f2a9281499" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b44db8d-f1f9-421b-9a1c-979d24ae10fc" xlink:to="loc_srt_MinimumMember_461c3ff0-d633-4ff7-b3eb-f8f2a9281499" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4d1a9c9-cc05-4ee5-a294-b926cf5550b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b44db8d-f1f9-421b-9a1c-979d24ae10fc" xlink:to="loc_srt_MaximumMember_a4d1a9c9-cc05-4ee5-a294-b926cf5550b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestTypeAxis_09e5b85d-379b-4d5e-960b-21b4857932cf" xlink:href="opk-20200630.xsd#opk_COVID19TestTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_opk_COVID19TestTypeAxis_09e5b85d-379b-4d5e-960b-21b4857932cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestTypeDomain_09e5b85d-379b-4d5e-960b-21b4857932cf_default" xlink:href="opk-20200630.xsd#opk_COVID19TestTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_opk_COVID19TestTypeAxis_09e5b85d-379b-4d5e-960b-21b4857932cf" xlink:to="loc_opk_COVID19TestTypeDomain_09e5b85d-379b-4d5e-960b-21b4857932cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestTypeDomain_b3831f01-262d-45ed-976e-7a1a1f605703" xlink:href="opk-20200630.xsd#opk_COVID19TestTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_opk_COVID19TestTypeAxis_09e5b85d-379b-4d5e-960b-21b4857932cf" xlink:to="loc_opk_COVID19TestTypeDomain_b3831f01-262d-45ed-976e-7a1a1f605703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SerologyAntibodyTestMember_7a4ddcd5-1c97-4e12-8c2d-5fa3b9674604" xlink:href="opk-20200630.xsd#opk_SerologyAntibodyTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_COVID19TestTypeDomain_b3831f01-262d-45ed-976e-7a1a1f605703" xlink:to="loc_opk_SerologyAntibodyTestMember_7a4ddcd5-1c97-4e12-8c2d-5fa3b9674604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticMolecularTestMember_b8345b19-edb0-4912-90d0-02bfc161e063" xlink:href="opk-20200630.xsd#opk_DiagnosticMolecularTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_COVID19TestTypeDomain_b3831f01-262d-45ed-976e-7a1a1f605703" xlink:to="loc_opk_DiagnosticMolecularTestMember_b8345b19-edb0-4912-90d0-02bfc161e063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3ffb0585-c73e-4e08-90e4-b7ee0de5c004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3ffb0585-c73e-4e08-90e4-b7ee0de5c004" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3ffb0585-c73e-4e08-90e4-b7ee0de5c004_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3ffb0585-c73e-4e08-90e4-b7ee0de5c004" xlink:to="loc_us-gaap_SegmentDomain_3ffb0585-c73e-4e08-90e4-b7ee0de5c004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b899cfb0-0d4d-432e-890a-09f206dfcf18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3ffb0585-c73e-4e08-90e4-b7ee0de5c004" xlink:to="loc_us-gaap_SegmentDomain_b899cfb0-0d4d-432e-890a-09f206dfcf18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember_07b594d0-6206-49d8-b6de-cd24fca5a4db" xlink:href="opk-20200630.xsd#opk_DiagnosticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b899cfb0-0d4d-432e-890a-09f206dfcf18" xlink:to="loc_opk_DiagnosticsMember_07b594d0-6206-49d8-b6de-cd24fca5a4db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_edb7f0f9-ad34-4144-a894-ac4f75c5dc45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_srt_ProductOrServiceAxis_edb7f0f9-ad34-4144-a894-ac4f75c5dc45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_edb7f0f9-ad34-4144-a894-ac4f75c5dc45_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_edb7f0f9-ad34-4144-a894-ac4f75c5dc45" xlink:to="loc_srt_ProductsAndServicesDomain_edb7f0f9-ad34-4144-a894-ac4f75c5dc45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2507f82c-3a9c-4799-b5d8-68987ccd15e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_edb7f0f9-ad34-4144-a894-ac4f75c5dc45" xlink:to="loc_srt_ProductsAndServicesDomain_2507f82c-3a9c-4799-b5d8-68987ccd15e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_4588edd7-3a12-4536-97f6-974e4d1a8177" xlink:href="opk-20200630.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2507f82c-3a9c-4799-b5d8-68987ccd15e7" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_4588edd7-3a12-4536-97f6-974e4d1a8177" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_95c854d6-f689-45ef-95cf-c81dd8b57abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_DebtInstrumentAxis_95c854d6-f689-45ef-95cf-c81dd8b57abf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_95c854d6-f689-45ef-95cf-c81dd8b57abf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_95c854d6-f689-45ef-95cf-c81dd8b57abf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_95c854d6-f689-45ef-95cf-c81dd8b57abf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_16b2c628-02f4-427c-a04d-83fa90bc727a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_95c854d6-f689-45ef-95cf-c81dd8b57abf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_16b2c628-02f4-427c-a04d-83fa90bc727a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member_c68d1130-3ecc-492a-88c3-e825eee359c4" xlink:href="opk-20200630.xsd#opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_16b2c628-02f4-427c-a04d-83fa90bc727a" xlink:to="loc_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member_c68d1130-3ecc-492a-88c3-e825eee359c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DistributionToHealthcareProvidersCOVID19Member_0b965b49-043e-45de-bf38-38fef5c6b99e" xlink:href="opk-20200630.xsd#opk_DistributionToHealthcareProvidersCOVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_16b2c628-02f4-427c-a04d-83fa90bc727a" xlink:to="loc_opk_DistributionToHealthcareProvidersCOVID19Member_0b965b49-043e-45de-bf38-38fef5c6b99e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="opk-20200630.xsd#EarningsLossPerShare"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/EarningsLossPerShare" xlink:type="extended" id="i534f704e62df44268b8d8a11d8fd507c_EarningsLossPerShare"/>
  <link:roleRef roleURI="http://www.opko.com/role/EarningsLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#EarningsLossPerShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/EarningsLossPerShareNarrativeDetails" xlink:type="extended" id="i0b56006e25534418b6829c9388e856f8_EarningsLossPerShareNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bea510a0-7e37-4b69-8905-a7829501b043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bea510a0-7e37-4b69-8905-a7829501b043" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d4918c57-1acb-46db-bf4e-77a293f92e44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d4918c57-1acb-46db-bf4e-77a293f92e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_8af523dc-7f9d-4112-9739-c746175f7866" xlink:href="opk-20200630.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:to="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_8af523dc-7f9d-4112-9739-c746175f7866" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_b6468fdc-8a72-4ff9-980e-d69b0e591a1d" xlink:href="opk-20200630.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:to="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_b6468fdc-8a72-4ff9-980e-d69b0e591a1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesSurrenderedInLieuOfCashPayment_186d1931-801d-4d4d-923e-0c5e8042fd51" xlink:href="opk-20200630.xsd#opk_SharesSurrenderedInLieuOfCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:to="loc_opk_SharesSurrenderedInLieuOfCashPayment_186d1931-801d-4d4d-923e-0c5e8042fd51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_25ce60ff-9a8d-4617-9222-5f919de566a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_25ce60ff-9a8d-4617-9222-5f919de566a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_511765d9-7212-44f4-a518-8f989d93421c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_25ce60ff-9a8d-4617-9222-5f919de566a0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_511765d9-7212-44f4-a518-8f989d93421c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_511765d9-7212-44f4-a518-8f989d93421c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_511765d9-7212-44f4-a518-8f989d93421c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_511765d9-7212-44f4-a518-8f989d93421c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fe5746e1-3214-4a42-9630-7296086854ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_511765d9-7212-44f4-a518-8f989d93421c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fe5746e1-3214-4a42-9630-7296086854ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7852446c-1863-45c3-b06b-9c742e5e8c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fe5746e1-3214-4a42-9630-7296086854ff" xlink:to="loc_us-gaap_CommonStockMember_7852446c-1863-45c3-b06b-9c742e5e8c0e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptions"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions" xlink:type="extended" id="i83d02dfc9d54456d9a32d8681b421c28_CompositionofCertainFinancialStatementCaptions"/>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsTables"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables" xlink:type="extended" id="ie8d898ab3c64486eb14ef964a2b11924_CompositionofCertainFinancialStatementCaptionsTables"/>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="extended" id="ief89aee4787e455aa283f8fed28f51cb_CompositionofCertainFinancialStatementCaptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetAbstract_aa85f27c-5593-4e3e-8cbc-436658457c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_AccountsReceivableNetAbstract_aa85f27c-5593-4e3e-8cbc-436658457c8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_74d284c3-d587-427c-b091-3c285b525c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_aa85f27c-5593-4e3e-8cbc-436658457c8e" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_74d284c3-d587-427c-b091-3c285b525c00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3a82703e-fbea-4295-929f-c6d7d8db976f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_aa85f27c-5593-4e3e-8cbc-436658457c8e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3a82703e-fbea-4295-929f-c6d7d8db976f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_07ccae87-a15c-4e2d-87fc-afee53b34684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_aa85f27c-5593-4e3e-8cbc-436658457c8e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_07ccae87-a15c-4e2d-87fc-afee53b34684" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_e204bd85-ad20-428c-8231-eabfe5451190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_OtherInventorySupplies_e204bd85-ad20-428c-8231-eabfe5451190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_e8e0f2a3-1094-44ed-a149-388e7264938d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_InventoryFinishedGoods_e8e0f2a3-1094-44ed-a149-388e7264938d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_b20e151f-b7df-415e-aac3-26ef3907026c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_InventoryWorkInProcess_b20e151f-b7df-415e-aac3-26ef3907026c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_8aa31d3c-5194-4cd5-bfa8-7b32e06054ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_InventoryRawMaterials_8aa31d3c-5194-4cd5-bfa8-7b32e06054ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_03d9ec7c-9ed4-49b0-bf54-247260d9a22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_InventoryValuationReserves_03d9ec7c-9ed4-49b0-bf54-247260d9a22a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_711681b8-be9b-48c9-a48f-9110fa6d6421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_InventoryNet_711681b8-be9b-48c9-a48f-9110fa6d6421" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TaxesRecoverableCurrent_37401a36-657a-4698-bab3-a40817cf16d8" xlink:href="opk-20200630.xsd#opk_TaxesRecoverableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_opk_TaxesRecoverableCurrent_37401a36-657a-4698-bab3-a40817cf16d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_cdab3529-50d3-458d-8fdd-1324759bb3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_us-gaap_Supplies_cdab3529-50d3-458d-8fdd-1324759bb3b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_ec0a057c-f109-43ba-941e-a1774ef9a5be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_us-gaap_PrepaidInsurance_ec0a057c-f109-43ba-941e-a1774ef9a5be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_8ab70079-d175-41e6-9591-f7d2b19951ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_8ab70079-d175-41e6-9591-f7d2b19951ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_66d99dc3-3cad-400a-86ae-62b4a56522a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_us-gaap_OtherAssetsCurrent_66d99dc3-3cad-400a-86ae-62b4a56522a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2af4ca3c-c627-4dff-a4aa-fdfbc5d071d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2af4ca3c-c627-4dff-a4aa-fdfbc5d071d9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b1491579-dfaa-4d1e-85d1-3d8c9910fb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b1491579-dfaa-4d1e-85d1-3d8c9910fb1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_de4edd9c-07b2-4cde-8bbf-68bd56a1885d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b1491579-dfaa-4d1e-85d1-3d8c9910fb1a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_de4edd9c-07b2-4cde-8bbf-68bd56a1885d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_546d4727-ea66-4134-bfe9-19e7eb7227b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b1491579-dfaa-4d1e-85d1-3d8c9910fb1a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_546d4727-ea66-4134-bfe9-19e7eb7227b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f83e7965-b704-45b2-8467-b73aea16dfa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b1491579-dfaa-4d1e-85d1-3d8c9910fb1a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f83e7965-b704-45b2-8467-b73aea16dfa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InventoryReceivedNotInvoicedCurrent_329d6f3b-88e1-477e-a578-b73244c5b356" xlink:href="opk-20200630.xsd#opk_InventoryReceivedNotInvoicedCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_opk_InventoryReceivedNotInvoicedCurrent_329d6f3b-88e1-477e-a578-b73244c5b356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedCommitmentsandContingenciesCurrent_9c6e0b09-d206-4e36-860b-247efe48ae40" xlink:href="opk-20200630.xsd#opk_AccruedCommitmentsandContingenciesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_opk_AccruedCommitmentsandContingenciesCurrent_9c6e0b09-d206-4e36-860b-247efe48ae40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_556ec7cf-e60a-4489-a8d4-a1f52a610d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_556ec7cf-e60a-4489-a8d4-a1f52a610d28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_91dcd91b-3b9f-412a-a415-71797ef6de5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_91dcd91b-3b9f-412a-a415-71797ef6de5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedClinicalTrialsCurrent_f7cb12a9-d3b3-4bd6-9508-693580c64def" xlink:href="opk-20200630.xsd#opk_AccruedClinicalTrialsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_opk_AccruedClinicalTrialsCurrent_f7cb12a9-d3b3-4bd6-9508-693580c64def" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_3cee56da-fc3a-49f7-85fc-ab72d5a55a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_3cee56da-fc3a-49f7-85fc-ab72d5a55a8d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_241fd4a9-0692-40b6-8638-05517e4f2ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_241fd4a9-0692-40b6-8638-05517e4f2ad6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f2c4e251-2186-4187-91fe-9ae6c64185cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f2c4e251-2186-4187-91fe-9ae6c64185cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_05b70946-b636-41af-9631-29213d83cafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_05b70946-b636-41af-9631-29213d83cafb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_52231c4e-3d85-4bf2-b1cd-4d335f4695a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_52231c4e-3d85-4bf2-b1cd-4d335f4695a1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_abcfec9d-a9d3-4ddc-9cc0-b4fd320cb3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_LongTermLineOfCredit_abcfec9d-a9d3-4ddc-9cc0-b4fd320cb3ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4da6c87f-4a98-443b-aba4-846d405157a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4da6c87f-4a98-443b-aba4-846d405157a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c38ee701-9c23-42ca-9a37-4ca71133b3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c38ee701-9c23-42ca-9a37-4ca71133b3b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_28e4cac7-cf44-420a-8840-3f9026431b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_28e4cac7-cf44-420a-8840-3f9026431b78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5efc3fe5-99e1-4067-9cba-dd186f0c34f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5efc3fe5-99e1-4067-9cba-dd186f0c34f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_fde6a189-d6c8-4a58-9fbc-5e6a856a633c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_fde6a189-d6c8-4a58-9fbc-5e6a856a633c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_27ba1bbf-1d68-41e0-b1f7-f16a7f0e6660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_27ba1bbf-1d68-41e0-b1f7-f16a7f0e6660" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_85d51f30-d417-403e-a400-cebf51980e96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_85d51f30-d417-403e-a400-cebf51980e96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0ef80fe-2768-48dd-954f-d9611ff2d722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_85d51f30-d417-403e-a400-cebf51980e96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0ef80fe-2768-48dd-954f-d9611ff2d722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0ef80fe-2768-48dd-954f-d9611ff2d722_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0ef80fe-2768-48dd-954f-d9611ff2d722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0ef80fe-2768-48dd-954f-d9611ff2d722_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0ef80fe-2768-48dd-954f-d9611ff2d722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_9e480e42-8ad3-4abc-b956-c305d5edda24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_9e480e42-8ad3-4abc-b956-c305d5edda24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d25db772-a732-4844-b4fe-6e8c1ad5bc5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d25db772-a732-4844-b4fe-6e8c1ad5bc5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_66ec89db-a65a-4f24-a269-79f72d7168e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_TradeNamesMember_66ec89db-a65a-4f24-a269-79f72d7168e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_6133320a-6415-46ea-89d5-7533e571f7b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_6133320a-6415-46ea-89d5-7533e571f7b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_44a73cae-3955-42a4-b666-b1295e41373f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_LicensingAgreementsMember_44a73cae-3955-42a4-b666-b1295e41373f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProductRegistrationsMember_e722d300-82da-4d5b-8921-333c27a97ff7" xlink:href="opk-20200630.xsd#opk_ProductRegistrationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_opk_ProductRegistrationsMember_e722d300-82da-4d5b-8921-333c27a97ff7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1982953a-efa6-4c0e-b58b-d3c2a05fbe3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1982953a-efa6-4c0e-b58b-d3c2a05fbe3d" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails" xlink:type="extended" id="ie72e75d468574331a3280ed3a3798582_CompositionofCertainFinancialStatementCaptionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_db99a4f4-c277-4c67-8d7b-e909c13e590c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8915bf82-3969-4bb8-8bfd-1536779b22b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_db99a4f4-c277-4c67-8d7b-e909c13e590c" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8915bf82-3969-4bb8-8bfd-1536779b22b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_3e8d11d0-55fc-4a9e-920d-929fda7adf5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_db99a4f4-c277-4c67-8d7b-e909c13e590c" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_3e8d11d0-55fc-4a9e-920d-929fda7adf5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_58194d7f-e963-4cb5-9d24-ab8d6d41ff02" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_3e8d11d0-55fc-4a9e-920d-929fda7adf5e" xlink:to="loc_srt_RangeAxis_58194d7f-e963-4cb5-9d24-ab8d6d41ff02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_58194d7f-e963-4cb5-9d24-ab8d6d41ff02_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_58194d7f-e963-4cb5-9d24-ab8d6d41ff02" xlink:to="loc_srt_RangeMember_58194d7f-e963-4cb5-9d24-ab8d6d41ff02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7332ac46-9e50-437b-b4ff-da6894bef4d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_58194d7f-e963-4cb5-9d24-ab8d6d41ff02" xlink:to="loc_srt_RangeMember_7332ac46-9e50-437b-b4ff-da6894bef4d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7c350da1-164c-421b-99da-28d117e1c510" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7332ac46-9e50-437b-b4ff-da6894bef4d2" xlink:to="loc_srt_MinimumMember_7c350da1-164c-421b-99da-28d117e1c510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ffd921b-26ed-4915-8d8e-7b978168d1f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7332ac46-9e50-437b-b4ff-da6894bef4d2" xlink:to="loc_srt_MaximumMember_7ffd921b-26ed-4915-8d8e-7b978168d1f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bc995521-23e5-47c2-9a96-44934c38716f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_3e8d11d0-55fc-4a9e-920d-929fda7adf5e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bc995521-23e5-47c2-9a96-44934c38716f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc995521-23e5-47c2-9a96-44934c38716f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bc995521-23e5-47c2-9a96-44934c38716f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc995521-23e5-47c2-9a96-44934c38716f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bc995521-23e5-47c2-9a96-44934c38716f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_38056fad-31c2-41a5-8477-6f1c87c5f427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_38056fad-31c2-41a5-8477-6f1c87c5f427" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_a8b040c7-828a-4a88-ab04-2c0b3351fc97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_us-gaap_CustomerRelationshipsMember_a8b040c7-828a-4a88-ab04-2c0b3351fc97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_97ab0d3b-a95e-4478-a4b1-8bd0db733e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_us-gaap_ProductMember_97ab0d3b-a95e-4478-a4b1-8bd0db733e9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CovenantsNotToCompeteMember_1acffc4f-cc21-47d6-a827-13abe6130808" xlink:href="opk-20200630.xsd#opk_CovenantsNotToCompeteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_opk_CovenantsNotToCompeteMember_1acffc4f-cc21-47d6-a827-13abe6130808" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_2e058d6b-b476-44ab-b875-b2855eb16c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_us-gaap_TradeNamesMember_2e058d6b-b476-44ab-b875-b2855eb16c29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_2a483d1e-fde8-4228-b61a-20ebc8d7d01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_2a483d1e-fde8-4228-b61a-20ebc8d7d01c" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" xlink:type="extended" id="i78b90dba70794b4aae311ed45b85b3df_CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_88146fce-829f-46c6-80eb-43ad537feae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_64d004a8-5aa8-4d87-857c-786a19272731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_88146fce-829f-46c6-80eb-43ad537feae1" xlink:to="loc_us-gaap_GoodwillRollForward_64d004a8-5aa8-4d87-857c-786a19272731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f4b05bda-9b9b-4773-94f9-90a2666b51fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_64d004a8-5aa8-4d87-857c-786a19272731" xlink:to="loc_us-gaap_Goodwill_f4b05bda-9b9b-4773-94f9-90a2666b51fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_b55a775e-e421-4ee6-9d73-3cf20763449a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_64d004a8-5aa8-4d87-857c-786a19272731" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_b55a775e-e421-4ee6-9d73-3cf20763449a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_65a154f1-da52-475f-ae75-e08dff7731c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_004225c8-f042-4a95-9c58-d02e217bc5a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_88146fce-829f-46c6-80eb-43ad537feae1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_004225c8-f042-4a95-9c58-d02e217bc5a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_35749cbb-d831-4cd4-b0d4-5b574ebce1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_004225c8-f042-4a95-9c58-d02e217bc5a6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_35749cbb-d831-4cd4-b0d4-5b574ebce1dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_35749cbb-d831-4cd4-b0d4-5b574ebce1dc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_35749cbb-d831-4cd4-b0d4-5b574ebce1dc" xlink:to="loc_us-gaap_SegmentDomain_35749cbb-d831-4cd4-b0d4-5b574ebce1dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d5f63a24-114a-4aa6-80e3-3b999490ff5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_35749cbb-d831-4cd4-b0d4-5b574ebce1dc" xlink:to="loc_us-gaap_SegmentDomain_d5f63a24-114a-4aa6-80e3-3b999490ff5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmaceuticalMember_983b0046-73c4-4c78-b902-d13525578ff9" xlink:href="opk-20200630.xsd#opk_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d5f63a24-114a-4aa6-80e3-3b999490ff5d" xlink:to="loc_opk_PharmaceuticalMember_983b0046-73c4-4c78-b902-d13525578ff9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember_1e9be080-3c1b-4a7b-a52a-125703d97dca" xlink:href="opk-20200630.xsd#opk_DiagnosticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d5f63a24-114a-4aa6-80e3-3b999490ff5d" xlink:to="loc_opk_DiagnosticsMember_1e9be080-3c1b-4a7b-a52a-125703d97dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_96c66614-0fe4-4cdd-9b39-c1f00d5c90b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_004225c8-f042-4a95-9c58-d02e217bc5a6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_96c66614-0fe4-4cdd-9b39-c1f00d5c90b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96c66614-0fe4-4cdd-9b39-c1f00d5c90b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_96c66614-0fe4-4cdd-9b39-c1f00d5c90b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96c66614-0fe4-4cdd-9b39-c1f00d5c90b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_96c66614-0fe4-4cdd-9b39-c1f00d5c90b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EirGenPharmaLimitedMember_f973aecc-9724-4ad1-b772-d43c43a4a88f" xlink:href="opk-20200630.xsd#opk_EirGenPharmaLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:to="loc_opk_EirGenPharmaLimitedMember_f973aecc-9724-4ad1-b772-d43c43a4a88f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OpkoChileMember_43f52597-b35e-4fbb-af18-5a8cfff494a2" xlink:href="opk-20200630.xsd#opk_OpkoChileMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:to="loc_opk_OpkoChileMember_43f52597-b35e-4fbb-af18-5a8cfff494a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOBiologicsMember_ca0fbd42-4ac9-4448-8eee-7f675687ef95" xlink:href="opk-20200630.xsd#opk_OPKOBiologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:to="loc_opk_OPKOBiologicsMember_ca0fbd42-4ac9-4448-8eee-7f675687ef95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOHealthEuropeMember_c9c886f0-5f02-4367-8b0f-5ab0c562a2b7" xlink:href="opk-20200630.xsd#opk_OPKOHealthEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:to="loc_opk_OPKOHealthEuropeMember_c9c886f0-5f02-4367-8b0f-5ab0c562a2b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember_9c4226b1-f454-418f-9f86-b925cd45fe73" xlink:href="opk-20200630.xsd#opk_BioReferenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:to="loc_opk_BioReferenceMember_9c4226b1-f454-418f-9f86-b925cd45fe73" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/Investments" xlink:type="simple" xlink:href="opk-20200630.xsd#Investments"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/Investments" xlink:type="extended" id="i3d18225a49a84a1a945354bb920f45fb_Investments"/>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/InvestmentsTables" xlink:type="extended" id="ifbf3a32b312d47d8a604554dbdad2a89_InvestmentsTables"/>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended" id="ibfe582ac448242d2a793d7a45751fb23_InvestmentsSummaryofInvestmentsDetails"/>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/InvestmentsNarrativeDetails" xlink:type="extended" id="i5cc62f7ee67a4baaa690675da1446645_InvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3db4e6bc-0431-4ecd-b769-bd1fb123b11b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3db4e6bc-0431-4ecd-b769-bd1fb123b11b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9db798df-4bfe-4742-bcd9-c5d94b704e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_Assets_9db798df-4bfe-4742-bcd9-c5d94b704e6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_190a7744-036b-4cd1-8b11-cf91a93ece7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_Liabilities_190a7744-036b-4cd1-8b11-cf91a93ece7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7abfaa7c-8951-4bde-8c8e-9e5813898297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_ProfitLoss_7abfaa7c-8951-4bde-8c8e-9e5813898297" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_f4d9b4d3-a23f-45e0-b2c2-8d3bd44ac946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_f4d9b4d3-a23f-45e0-b2c2-8d3bd44ac946" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquitySecurityFVNIOwnershipPercent_89f78c71-4ce9-4ff4-aef3-6642c0ead85e" xlink:href="opk-20200630.xsd#opk_EquitySecurityFVNIOwnershipPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_opk_EquitySecurityFVNIOwnershipPercent_89f78c71-4ce9-4ff4-aef3-6642c0ead85e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4f798f5d-bdec-4532-b15e-4dddd98a07a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4f798f5d-bdec-4532-b15e-4dddd98a07a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested_3cc226e3-34a2-401c-bc15-75bc39e1d6b7" xlink:href="opk-20200630.xsd#opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested_3cc226e3-34a2-401c-bc15-75bc39e1d6b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_b12dda57-b04a-4e61-a1c4-b326f15c7064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_b12dda57-b04a-4e61-a1c4-b326f15c7064" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedAsGift_607bcee2-218f-413c-9272-421c15bfc162" xlink:href="opk-20200630.xsd#opk_SharesReceivedAsGift"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_opk_SharesReceivedAsGift_607bcee2-218f-413c-9272-421c15bfc162" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae3245df-6223-4c83-b75d-c8002a2af7d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae3245df-6223-4c83-b75d-c8002a2af7d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8a916ddc-2cf2-4760-983e-d4dc9a7e4315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae3245df-6223-4c83-b75d-c8002a2af7d9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8a916ddc-2cf2-4760-983e-d4dc9a7e4315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8a916ddc-2cf2-4760-983e-d4dc9a7e4315_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8a916ddc-2cf2-4760-983e-d4dc9a7e4315" xlink:to="loc_us-gaap_ClassOfStockDomain_8a916ddc-2cf2-4760-983e-d4dc9a7e4315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d0e6a4bb-fa15-4a0e-9395-ebe5f9427d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8a916ddc-2cf2-4760-983e-d4dc9a7e4315" xlink:to="loc_us-gaap_ClassOfStockDomain_d0e6a4bb-fa15-4a0e-9395-ebe5f9427d75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_0be583de-c177-4817-8269-4e8cd0a5634d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d0e6a4bb-fa15-4a0e-9395-ebe5f9427d75" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_0be583de-c177-4817-8269-4e8cd0a5634d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_526a7f10-279e-406b-8e96-3cc019de5518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d0e6a4bb-fa15-4a0e-9395-ebe5f9427d75" xlink:to="loc_us-gaap_RestrictedStockMember_526a7f10-279e-406b-8e96-3cc019de5518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e1a80245-e1cb-4b6d-a9c1-8bcda4e083fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae3245df-6223-4c83-b75d-c8002a2af7d9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e1a80245-e1cb-4b6d-a9c1-8bcda4e083fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e1a80245-e1cb-4b6d-a9c1-8bcda4e083fa_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e1a80245-e1cb-4b6d-a9c1-8bcda4e083fa" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e1a80245-e1cb-4b6d-a9c1-8bcda4e083fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e1a80245-e1cb-4b6d-a9c1-8bcda4e083fa" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember_f63ffec2-119a-4fff-9874-afd0adca2d02" xlink:href="opk-20200630.xsd#opk_PharmsynthezMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_PharmsynthezMember_f63ffec2-119a-4fff-9874-afd0adca2d02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CocrystalMember_870b83da-0a5f-4cc8-bb50-8dc35acb8cf3" xlink:href="opk-20200630.xsd#opk_CocrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_CocrystalMember_870b83da-0a5f-4cc8-bb50-8dc35acb8cf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NonInvasiveMonitoringSystemsInc.Member_8e1e23fd-ba3a-4347-83ca-9d49067a0326" xlink:href="opk-20200630.xsd#opk_NonInvasiveMonitoringSystemsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_NonInvasiveMonitoringSystemsInc.Member_8e1e23fd-ba3a-4347-83ca-9d49067a0326" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NeovascMember_2d31d299-1987-4a97-b270-cac4cbf5716a" xlink:href="opk-20200630.xsd#opk_NeovascMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_NeovascMember_2d31d299-1987-4a97-b270-cac4cbf5716a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InCellDxIncMember_8ab3e2d7-7f82-4528-9246-1754325a570b" xlink:href="opk-20200630.xsd#opk_InCellDxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_InCellDxIncMember_8ab3e2d7-7f82-4528-9246-1754325a570b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_f8b0ed40-43ed-4696-8579-22881c3528e5" xlink:href="opk-20200630.xsd#opk_BioCardiaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_BioCardiaInc.Member_f8b0ed40-43ed-4696-8579-22881c3528e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_XeneticBiosciencesInc.Member_db84220c-4f0b-4dbf-8b0a-ec925f003ecf" xlink:href="opk-20200630.xsd#opk_XeneticBiosciencesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_XeneticBiosciencesInc.Member_db84220c-4f0b-4dbf-8b0a-ec925f003ecf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhioPharmaceuticalsMember_e9bd82a9-195e-4007-ad6c-f1a609d88283" xlink:href="opk-20200630.xsd#opk_PhioPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_PhioPharmaceuticalsMember_e9bd82a9-195e-4007-ad6c-f1a609d88283" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_VBIVaccinesIncMember_bdb49acc-e884-4c83-91f2-27acc727fc56" xlink:href="opk-20200630.xsd#opk_VBIVaccinesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_VBIVaccinesIncMember_bdb49acc-e884-4c83-91f2-27acc727fc56" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromaDexMember_e2f4f73e-929b-482e-a685-ea8ff885eb54" xlink:href="opk-20200630.xsd#opk_ChromaDexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_ChromaDexMember_e2f4f73e-929b-482e-a685-ea8ff885eb54" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MabVaxTherapeuticsHoldingsInc.Member_aa725fc3-87ea-4216-9624-1742cb68c136" xlink:href="opk-20200630.xsd#opk_MabVaxTherapeuticsHoldingsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_MabVaxTherapeuticsHoldingsInc.Member_aa725fc3-87ea-4216-9624-1742cb68c136" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EloxxPharmaceuticalsMember_2434212b-e6fc-44a5-8b80-f3f08c402871" xlink:href="opk-20200630.xsd#opk_EloxxPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_EloxxPharmaceuticalsMember_2434212b-e6fc-44a5-8b80-f3f08c402871" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ZebraMember_81b34bf9-75e4-4db7-8af4-ab4f6f547cb5" xlink:href="opk-20200630.xsd#opk_ZebraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_ZebraMember_81b34bf9-75e4-4db7-8af4-ab4f6f547cb5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_cd4577cb-b396-46d8-852a-9017b3602381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae3245df-6223-4c83-b75d-c8002a2af7d9" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_cd4577cb-b396-46d8-852a-9017b3602381" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_cd4577cb-b396-46d8-852a-9017b3602381_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_cd4577cb-b396-46d8-852a-9017b3602381" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_cd4577cb-b396-46d8-852a-9017b3602381_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_584f4e5d-c2ff-4de7-98ab-855bef4f5780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_cd4577cb-b396-46d8-852a-9017b3602381" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_584f4e5d-c2ff-4de7-98ab-855bef4f5780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_f9d55af7-f14a-4aaa-8604-fcb41128601f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_584f4e5d-c2ff-4de7-98ab-855bef4f5780" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_f9d55af7-f14a-4aaa-8604-fcb41128601f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" xlink:type="extended" id="i70062b1337d54e32895e40bdcecea9c1_InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"/>
  <link:roleRef roleURI="http://www.opko.com/role/Debt" xlink:type="simple" xlink:href="opk-20200630.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/Debt" xlink:type="extended" id="i98b94ba5d5f64f3199f2193735dd5b5a_Debt"/>
  <link:roleRef roleURI="http://www.opko.com/role/DebtTables" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DebtTables" xlink:type="extended" id="ia1b6f56e184640339a2bcdc24cd303e0_DebtTables"/>
  <link:roleRef roleURI="http://www.opko.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DebtNarrativeDetails" xlink:type="extended" id="i531b25a3111343fca09c5321aa78ecd5_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_45408dcc-d54d-40bf-9cf3-163bd4cc7d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_45408dcc-d54d-40bf-9cf3-163bd4cc7d21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e0a28b21-0636-4dff-a1ac-ebbda329803e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e0a28b21-0636-4dff-a1ac-ebbda329803e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d128ba73-e318-4c1b-970f-dd3e41ff89df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d128ba73-e318-4c1b-970f-dd3e41ff89df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_06b4c43f-ee86-43db-825b-7206a176e41e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_06b4c43f-ee86-43db-825b-7206a176e41e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6a1c2ad1-20a0-4674-bc14-d7dd6c64d59e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6a1c2ad1-20a0-4674-bc14-d7dd6c64d59e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_ab2cc3c0-5f43-49bf-8a8c-421bda4b3abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_ab2cc3c0-5f43-49bf-8a8c-421bda4b3abe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_b344394e-e158-4d56-b17a-29f74910a5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_b344394e-e158-4d56-b17a-29f74910a5d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_cf42c9bc-33d0-45bf-9c30-a9853f2ae249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_cf42c9bc-33d0-45bf-9c30-a9853f2ae249" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3c5f6cbf-b8da-413e-97aa-ae3efff6c5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3c5f6cbf-b8da-413e-97aa-ae3efff6c5db" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f31beb34-bff8-4485-9472-1c891229f9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f31beb34-bff8-4485-9472-1c891229f9b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_abbcb2f1-0302-4ab5-a7cc-7636e9e8fb71" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_abbcb2f1-0302-4ab5-a7cc-7636e9e8fb71" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b602e607-f728-4fd8-8067-4070d9921ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b602e607-f728-4fd8-8067-4070d9921ba2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromConvertibleDebtConversionFee_346abce0-2a75-47cd-81c0-70a0f382b7f0" xlink:href="opk-20200630.xsd#opk_ProceedsFromConvertibleDebtConversionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_ProceedsFromConvertibleDebtConversionFee_346abce0-2a75-47cd-81c0-70a0f382b7f0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_80ca9190-cf62-44ed-ba50-c16f7f8b77a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_80ca9190-cf62-44ed-ba50-c16f7f8b77a7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9db37a6a-1c4a-4642-8632-913f570bfcec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9db37a6a-1c4a-4642-8632-913f570bfcec" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_29ee6974-9f51-4560-84a7-9b3523af55e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_29ee6974-9f51-4560-84a7-9b3523af55e8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_ad5d9723-03f9-4aa5-8749-ca0710cfe183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentTerm_ad5d9723-03f9-4aa5-8749-ca0710cfe183" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_f2c6a187-4d4f-4950-a0f0-bdf70c5cd1e7" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_f2c6a187-4d4f-4950-a0f0-bdf70c5cd1e7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_ba389e46-83ec-4a16-a28a-88a0e75be825" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_ba389e46-83ec-4a16-a28a-88a0e75be825" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2139d68d-88d4-4b89-91ce-44bfb40b278e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2139d68d-88d4-4b89-91ce-44bfb40b278e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_f28f2617-ec8f-4df8-b2ad-479ec12788e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_f28f2617-ec8f-4df8-b2ad-479ec12788e5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e47af8e1-e5e8-4294-83f3-7083c07752b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LongTermDebt_e47af8e1-e5e8-4294-83f3-7083c07752b5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_02e2118e-39f1-42ad-b1ee-c3045ddc1454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_02e2118e-39f1-42ad-b1ee-c3045ddc1454" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ce124920-d0e5-4608-8f3f-9a5bd91967cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ce124920-d0e5-4608-8f3f-9a5bd91967cb" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_272da164-9787-4803-bb4a-8b674e7ff74e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_272da164-9787-4803-bb4a-8b674e7ff74e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage_5c555273-1378-4a4c-be7b-4bb5502eb283" xlink:href="opk-20200630.xsd#opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage_5c555273-1378-4a4c-be7b-4bb5502eb283" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays_d077a6bc-da01-47da-808b-4bfcadb08c79" xlink:href="opk-20200630.xsd#opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays_d077a6bc-da01-47da-808b-4bfcadb08c79" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_d3e76148-d4ab-472e-a49c-4d713262b3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LongTermLineOfCredit_d3e76148-d4ab-472e-a49c-4d713262b3f0" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0d975cb-81e5-434a-9ec7-e1785325a7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_StockholdersEquity_a0d975cb-81e5-434a-9ec7-e1785325a7cf" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_53f6ce74-1488-4171-a62c-3f29a8f321df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_Goodwill_53f6ce74-1488-4171-a62c-3f29a8f321df" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd0fc65d-a982-484f-8745-14d7a30df19c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd0fc65d-a982-484f-8745-14d7a30df19c" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentsNumberofFinancialInstitutions_500a842b-79bd-4d8e-9ade-26e921a1dcef" xlink:href="opk-20200630.xsd#opk_DebtInstrumentsNumberofFinancialInstitutions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_DebtInstrumentsNumberofFinancialInstitutions_500a842b-79bd-4d8e-9ade-26e921a1dcef" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_0f1c5490-db18-4bd8-a2a0-4741c242f76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_0f1c5490-db18-4bd8-a2a0-4741c242f76b" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_744a861f-c4d5-4ecb-9839-634102f1d013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_744a861f-c4d5-4ecb-9839-634102f1d013" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2ae734b-fc32-4801-82f2-28b6c8defbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2ae734b-fc32-4801-82f2-28b6c8defbf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e2ae734b-fc32-4801-82f2-28b6c8defbf6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2ae734b-fc32-4801-82f2-28b6c8defbf6" xlink:to="loc_us-gaap_RelatedPartyDomain_e2ae734b-fc32-4801-82f2-28b6c8defbf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8be75901-60a6-4839-bb74-bbc2d15fbbf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2ae734b-fc32-4801-82f2-28b6c8defbf6" xlink:to="loc_us-gaap_RelatedPartyDomain_8be75901-60a6-4839-bb74-bbc2d15fbbf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DrFrostMember_2ee0f819-802c-4a81-91c2-8c7470492eda" xlink:href="opk-20200630.xsd#opk_DrFrostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8be75901-60a6-4839-bb74-bbc2d15fbbf8" xlink:to="loc_opk_DrFrostMember_2ee0f819-802c-4a81-91c2-8c7470492eda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_17ff36d6-7165-41f8-a8eb-8e5e242d5c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_StatementClassOfStockAxis_17ff36d6-7165-41f8-a8eb-8e5e242d5c8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_17ff36d6-7165-41f8-a8eb-8e5e242d5c8d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17ff36d6-7165-41f8-a8eb-8e5e242d5c8d" xlink:to="loc_us-gaap_ClassOfStockDomain_17ff36d6-7165-41f8-a8eb-8e5e242d5c8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3ff7557a-44a6-4e78-af96-2b726f73a2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17ff36d6-7165-41f8-a8eb-8e5e242d5c8d" xlink:to="loc_us-gaap_ClassOfStockDomain_3ff7557a-44a6-4e78-af96-2b726f73a2d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_01a97d68-46c4-401e-8baf-80282cc449ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3ff7557a-44a6-4e78-af96-2b726f73a2d3" xlink:to="loc_us-gaap_CommonStockMember_01a97d68-46c4-401e-8baf-80282cc449ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6c0e0897-d6af-4609-a07f-a2664d427196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_VariableRateAxis_6c0e0897-d6af-4609-a07f-a2664d427196" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6c0e0897-d6af-4609-a07f-a2664d427196_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_6c0e0897-d6af-4609-a07f-a2664d427196" xlink:to="loc_us-gaap_VariableRateDomain_6c0e0897-d6af-4609-a07f-a2664d427196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_6c0e0897-d6af-4609-a07f-a2664d427196" xlink:to="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_4728d3ec-007d-4c08-add1-4cb8a6758506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_4728d3ec-007d-4c08-add1-4cb8a6758506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_fb858177-8194-411f-8138-0a50b6f6d08a" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_fb858177-8194-411f-8138-0a50b6f6d08a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORThereafterMember_bee286f5-1156-455a-9ce4-40b28d3b0004" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORThereafterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORThereafterMember_bee286f5-1156-455a-9ce4-40b28d3b0004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_f295ab27-ef15-479f-bf7a-1fe4e4ba6e58" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_f295ab27-ef15-479f-bf7a-1fe4e4ba6e58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember_8075721d-925f-4b11-8785-524e357a3a7c" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember_8075721d-925f-4b11-8785-524e357a3a7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c2838c37-bf5d-44a1-82c3-467669a72abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_CreditFacilityAxis_c2838c37-bf5d-44a1-82c3-467669a72abe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c2838c37-bf5d-44a1-82c3-467669a72abe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_c2838c37-bf5d-44a1-82c3-467669a72abe" xlink:to="loc_us-gaap_CreditFacilityDomain_c2838c37-bf5d-44a1-82c3-467669a72abe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_c2838c37-bf5d-44a1-82c3-467669a72abe" xlink:to="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_fd5c6e91-7a88-4b43-aec1-58080e2e2eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:to="loc_us-gaap_LineOfCreditMember_fd5c6e91-7a88-4b43-aec1-58080e2e2eec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2d40b3f5-1652-430c-bba0-9cb67657c97f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2d40b3f5-1652-430c-bba0-9cb67657c97f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_fae6c95a-cd49-4b99-9130-c1fb345fea4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:to="loc_us-gaap_BridgeLoanMember_fae6c95a-cd49-4b99-9130-c1fb345fea4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_39d6bf3c-f4bd-4be2-a7c7-c1dfd011ec26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:to="loc_us-gaap_LetterOfCreditMember_39d6bf3c-f4bd-4be2-a7c7-c1dfd011ec26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_77d91a73-4c80-4fef-baeb-7e27f55a9c06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_77d91a73-4c80-4fef-baeb-7e27f55a9c06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_77d91a73-4c80-4fef-baeb-7e27f55a9c06_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77d91a73-4c80-4fef-baeb-7e27f55a9c06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_77d91a73-4c80-4fef-baeb-7e27f55a9c06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77d91a73-4c80-4fef-baeb-7e27f55a9c06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_6e64bdf9-1378-453c-8014-9024a5d65a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:to="loc_us-gaap_UnsecuredDebtMember_6e64bdf9-1378-453c-8014-9024a5d65a6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_4a9f9895-24eb-4388-b389-24c2e6559ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:to="loc_us-gaap_LineOfCreditMember_4a9f9895-24eb-4388-b389-24c2e6559ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d3025166-d7a5-4087-b157-e1c9cbebd869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:to="loc_us-gaap_ConvertibleDebtMember_d3025166-d7a5-4087-b157-e1c9cbebd869" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_c5159c6f-8cf4-4f54-b854-7405a80b6b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:to="loc_us-gaap_SeniorNotesMember_c5159c6f-8cf4-4f54-b854-7405a80b6b95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_cd407291-f343-40f1-84fc-e3aafff9c51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_cd407291-f343-40f1-84fc-e3aafff9c51c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1c5f825-a624-4d1e-9675-bf1f1063c220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1c5f825-a624-4d1e-9675-bf1f1063c220" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1c5f825-a624-4d1e-9675-bf1f1063c220_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1c5f825-a624-4d1e-9675-bf1f1063c220" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1c5f825-a624-4d1e-9675-bf1f1063c220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1c5f825-a624-4d1e-9675-bf1f1063c220" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NewCreditAgreementMember_2ad8f7d6-80ea-4ba7-b68a-e44ee27c83cf" xlink:href="opk-20200630.xsd#opk_NewCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:to="loc_opk_NewCreditAgreementMember_2ad8f7d6-80ea-4ba7-b68a-e44ee27c83cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConvertibleSeniorNotesDue2025Member_201e9b84-c318-458e-885e-69e3a780b96b" xlink:href="opk-20200630.xsd#opk_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:to="loc_opk_ConvertibleSeniorNotesDue2025Member_201e9b84-c318-458e-885e-69e3a780b96b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A5ConvertibleNotesMember_a13fe50b-dcae-4f4f-a422-c82ecb973d5e" xlink:href="opk-20200630.xsd#opk_A5ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:to="loc_opk_A5ConvertibleNotesMember_a13fe50b-dcae-4f4f-a422-c82ecb973d5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesDueFebruary12033Member_e166bffd-baa2-42ec-9b0c-caef3e672109" xlink:href="opk-20200630.xsd#opk_NotesDueFebruary12033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:to="loc_opk_NotesDueFebruary12033Member_e166bffd-baa2-42ec-9b0c-caef3e672109" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e80651f7-54c9-4457-8403-d15768ea3aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e80651f7-54c9-4457-8403-d15768ea3aa5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e80651f7-54c9-4457-8403-d15768ea3aa5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e80651f7-54c9-4457-8403-d15768ea3aa5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e80651f7-54c9-4457-8403-d15768ea3aa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_483e35b1-ae74-46c4-b67b-e98bfa4353ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e80651f7-54c9-4457-8403-d15768ea3aa5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_483e35b1-ae74-46c4-b67b-e98bfa4353ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_02fc58d5-68fc-4493-8b50-9328ac60b5fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_483e35b1-ae74-46c4-b67b-e98bfa4353ab" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_02fc58d5-68fc-4493-8b50-9328ac60b5fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_3e8ad7d0-5551-45e1-a447-ef3fd60ff9b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_483e35b1-ae74-46c4-b67b-e98bfa4353ab" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_3e8ad7d0-5551-45e1-a447-ef3fd60ff9b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_62d9c7b8-49e1-46a7-9379-e9eb1f37baf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_483e35b1-ae74-46c4-b67b-e98bfa4353ab" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_62d9c7b8-49e1-46a7-9379-e9eb1f37baf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8dfab7a0-43d6-4857-b527-da89451ae521" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_srt_RangeAxis_8dfab7a0-43d6-4857-b527-da89451ae521" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8dfab7a0-43d6-4857-b527-da89451ae521_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8dfab7a0-43d6-4857-b527-da89451ae521" xlink:to="loc_srt_RangeMember_8dfab7a0-43d6-4857-b527-da89451ae521_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d57a8b0-8328-4994-a430-8e9f36fb0338" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8dfab7a0-43d6-4857-b527-da89451ae521" xlink:to="loc_srt_RangeMember_0d57a8b0-8328-4994-a430-8e9f36fb0338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f6c26e06-8f30-4e44-b19b-e15476b760d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d57a8b0-8328-4994-a430-8e9f36fb0338" xlink:to="loc_srt_MinimumMember_f6c26e06-8f30-4e44-b19b-e15476b760d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c812369-e76e-4554-b470-52b63a8b61a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d57a8b0-8328-4994-a430-8e9f36fb0338" xlink:to="loc_srt_MaximumMember_5c812369-e76e-4554-b470-52b63a8b61a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e6e6b2a0-99c2-44c5-aa4f-fee661e3a51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e6e6b2a0-99c2-44c5-aa4f-fee661e3a51f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6e6b2a0-99c2-44c5-aa4f-fee661e3a51f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6e6b2a0-99c2-44c5-aa4f-fee661e3a51f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6e6b2a0-99c2-44c5-aa4f-fee661e3a51f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4317df3e-e13c-471a-b4ca-1de93bdd2f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6e6b2a0-99c2-44c5-aa4f-fee661e3a51f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4317df3e-e13c-471a-b4ca-1de93bdd2f84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember_86866d7b-5081-4108-82f7-9e188efad247" xlink:href="opk-20200630.xsd#opk_BioReferenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4317df3e-e13c-471a-b4ca-1de93bdd2f84" xlink:to="loc_opk_BioReferenceMember_86866d7b-5081-4108-82f7-9e188efad247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOHealthEuropeMember_66b44902-2815-4f07-9ce7-0920de8daf18" xlink:href="opk-20200630.xsd#opk_OPKOHealthEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4317df3e-e13c-471a-b4ca-1de93bdd2f84" xlink:to="loc_opk_OPKOHealthEuropeMember_66b44902-2815-4f07-9ce7-0920de8daf18" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtScheduleofNotesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="extended" id="i12bba4c0ac06412b81a752ee171a2067_DebtScheduleofNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8da5a301-46f4-4100-a0ad-decbb268ddaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:href="opk-20200630.xsd#opk_DebtInstrumentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8da5a301-46f4-4100-a0ad-decbb268ddaa" xlink:to="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_91ec706c-9404-4387-aea4-ef4524e72a00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_91ec706c-9404-4387-aea4-ef4524e72a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0df5bc12-2d2e-4523-b9fa-f5f1877ae789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_91ec706c-9404-4387-aea4-ef4524e72a00" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0df5bc12-2d2e-4523-b9fa-f5f1877ae789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8c6d5fb0-ea1f-4459-bcd1-26496c452750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_871b14c4-ad5e-4d99-835a-649cafd57244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_871b14c4-ad5e-4d99-835a-649cafd57244" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3137d77c-fd14-4438-860e-ec77f10b06d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_871b14c4-ad5e-4d99-835a-649cafd57244" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3137d77c-fd14-4438-860e-ec77f10b06d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_f1a4a234-4228-4e76-8fcc-dd18c7c8b2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_871b14c4-ad5e-4d99-835a-649cafd57244" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_f1a4a234-4228-4e76-8fcc-dd18c7c8b2c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a059c2e7-be92-45e0-913c-7ba7215622c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract_c353f31d-f0f1-437a-a7ca-bbbba92dbffa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:to="loc_us-gaap_DeferredFinanceCostsNetAbstract_c353f31d-f0f1-437a-a7ca-bbbba92dbffa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c5daa0f4-5415-4177-b99f-7e5a3ea9d7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_c353f31d-f0f1-437a-a7ca-bbbba92dbffa" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c5daa0f4-5415-4177-b99f-7e5a3ea9d7c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7c98713b-686f-4c09-8bbe-63bdb28bb331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_c353f31d-f0f1-437a-a7ca-bbbba92dbffa" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7c98713b-686f-4c09-8bbe-63bdb28bb331" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cb2d903b-3b95-4c72-8c4c-16ca555b0b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAbstract_ea2a45af-1e36-4d40-9e5f-c85ba7c58698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:to="loc_us-gaap_LongTermDebtAbstract_ea2a45af-1e36-4d40-9e5f-c85ba7c58698" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0b455962-5646-4d2b-8892-0ae0aa126331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAbstract_ea2a45af-1e36-4d40-9e5f-c85ba7c58698" xlink:to="loc_us-gaap_LongTermDebt_0b455962-5646-4d2b-8892-0ae0aa126331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_051343ba-0e78-42e4-a40b-2ab00b04e841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAbstract_ea2a45af-1e36-4d40-9e5f-c85ba7c58698" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_051343ba-0e78-42e4-a40b-2ab00b04e841" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0406a719-8033-4e24-9b7c-755eba0a0987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6f1ef4c7-65c3-4598-890e-ea5f641121a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8da5a301-46f4-4100-a0ad-decbb268ddaa" xlink:to="loc_us-gaap_DebtInstrumentTable_6f1ef4c7-65c3-4598-890e-ea5f641121a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4601e748-1133-4a0d-b439-13560da85545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1ef4c7-65c3-4598-890e-ea5f641121a8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4601e748-1133-4a0d-b439-13560da85545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4601e748-1133-4a0d-b439-13560da85545_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4601e748-1133-4a0d-b439-13560da85545" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4601e748-1133-4a0d-b439-13560da85545_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e52d4003-79f2-42c0-ad87-8b89d182fc26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4601e748-1133-4a0d-b439-13560da85545" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e52d4003-79f2-42c0-ad87-8b89d182fc26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7aeea4cd-3237-4c9c-bf2e-005aa60b6059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e52d4003-79f2-42c0-ad87-8b89d182fc26" xlink:to="loc_us-gaap_SeniorNotesMember_7aeea4cd-3237-4c9c-bf2e-005aa60b6059" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtLinesofCreditDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtLinesofCreditDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DebtLinesofCreditDetails" xlink:type="extended" id="if6fcd7215e794b87b864d041c1998d01_DebtLinesofCreditDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_a8b6a613-2316-4bb5-a5de-b164d484f777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_eb7248cc-31c6-43dc-9427-bcb870bbb144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a8b6a613-2316-4bb5-a5de-b164d484f777" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_eb7248cc-31c6-43dc-9427-bcb870bbb144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e06deba3-69e9-4e77-a196-1357a0a36e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a8b6a613-2316-4bb5-a5de-b164d484f777" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e06deba3-69e9-4e77-a196-1357a0a36e52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_24ce9d47-d019-473f-93ca-d60de63c8bec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a8b6a613-2316-4bb5-a5de-b164d484f777" xlink:to="loc_us-gaap_LineOfCredit_24ce9d47-d019-473f-93ca-d60de63c8bec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_62a67fd0-4607-4360-98c9-e081a9811338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a8b6a613-2316-4bb5-a5de-b164d484f777" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_62a67fd0-4607-4360-98c9-e081a9811338" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_911821e0-2a18-412e-bb2f-8acbf2ad3ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_62a67fd0-4607-4360-98c9-e081a9811338" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_911821e0-2a18-412e-bb2f-8acbf2ad3ab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_911821e0-2a18-412e-bb2f-8acbf2ad3ab4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_911821e0-2a18-412e-bb2f-8acbf2ad3ab4" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_911821e0-2a18-412e-bb2f-8acbf2ad3ab4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_911821e0-2a18-412e-bb2f-8acbf2ad3ab4" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_JPMorganChaseMember_613a2b44-a1e7-40a9-8645-83b6a3b385c7" xlink:href="opk-20200630.xsd#opk_JPMorganChaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_JPMorganChaseMember_613a2b44-a1e7-40a9-8645-83b6a3b385c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ItauBankMember_9be43a17-49f0-4161-a4b4-84a037852ea5" xlink:href="opk-20200630.xsd#opk_ItauBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_ItauBankMember_9be43a17-49f0-4161-a4b4-84a037852ea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BankOfChileMember_4e649d8d-0f54-4ae7-a255-1542b2f4fadb" xlink:href="opk-20200630.xsd#opk_BankOfChileMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_BankOfChileMember_4e649d8d-0f54-4ae7-a255-1542b2f4fadb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BiceBankMember_6114bf09-93d3-4bed-ab6a-fedbb2a01323" xlink:href="opk-20200630.xsd#opk_BiceBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_BiceBankMember_6114bf09-93d3-4bed-ab6a-fedbb2a01323" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BbvaBankMember_5f7854ba-423a-4620-af89-e81b591c8633" xlink:href="opk-20200630.xsd#opk_BbvaBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_BbvaBankMember_5f7854ba-423a-4620-af89-e81b591c8633" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SecurityMember_c5bc91ae-407d-4b79-add3-4f22161ecc0b" xlink:href="opk-20200630.xsd#opk_SecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_SecurityMember_c5bc91ae-407d-4b79-add3-4f22161ecc0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EstadoBankMember_d464f8ef-7941-4f59-89ab-d635f48cfc93" xlink:href="opk-20200630.xsd#opk_EstadoBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_EstadoBankMember_d464f8ef-7941-4f59-89ab-d635f48cfc93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBankMember_efbb02aa-e670-48b3-98fa-dfccc9a2cb28" xlink:href="opk-20200630.xsd#opk_SantanderBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_SantanderBankMember_efbb02aa-e670-48b3-98fa-dfccc9a2cb28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ScotiabankMember_a88ca397-a1b7-4bba-8413-67b4ab9d39c6" xlink:href="opk-20200630.xsd#opk_ScotiabankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_ScotiabankMember_a88ca397-a1b7-4bba-8413-67b4ab9d39c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_Corpbanca1Member_d155f400-b13f-43a1-9f8c-e63e0ae5d4b8" xlink:href="opk-20200630.xsd#opk_Corpbanca1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_Corpbanca1Member_d155f400-b13f-43a1-9f8c-e63e0ae5d4b8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BancoDeSabadellMember_109a7e75-56ea-4aee-b5c4-fd71d89b17b3" xlink:href="opk-20200630.xsd#opk_BancoDeSabadellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_BancoDeSabadellMember_109a7e75-56ea-4aee-b5c4-fd71d89b17b3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BilbaoVizcayaBankMember_09285760-ca6c-470b-a555-f0bbd752698e" xlink:href="opk-20200630.xsd#opk_BilbaoVizcayaBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_BilbaoVizcayaBankMember_09285760-ca6c-470b-a555-f0bbd752698e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBank2MemberMember_2bc95c68-baa0-44fa-b88e-48fe16ec7e37" xlink:href="opk-20200630.xsd#opk_SantanderBank2MemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_SantanderBank2MemberMember_2bc95c68-baa0-44fa-b88e-48fe16ec7e37" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtNotesPayableandOtherDebtDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="extended" id="ida2122edc0504e24bab17807112be393_DebtNotesPayableandOtherDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_192a74ef-0a79-43cb-9f73-66871ab11357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_143fe5c5-228b-44ce-ac79-d0f8ed2f55a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_192a74ef-0a79-43cb-9f73-66871ab11357" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_143fe5c5-228b-44ce-ac79-d0f8ed2f55a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9eaeb635-38f8-4cf2-aece-10c877a327e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_143fe5c5-228b-44ce-ac79-d0f8ed2f55a4" xlink:to="loc_us-gaap_LongTermDebtCurrent_9eaeb635-38f8-4cf2-aece-10c877a327e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_eec52490-19ab-43eb-8196-d1c8908c250e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_143fe5c5-228b-44ce-ac79-d0f8ed2f55a4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_eec52490-19ab-43eb-8196-d1c8908c250e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6ed809c6-3f50-4720-84ca-195cc3a31655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_143fe5c5-228b-44ce-ac79-d0f8ed2f55a4" xlink:to="loc_us-gaap_LongTermDebt_6ed809c6-3f50-4720-84ca-195cc3a31655" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bd1bab92-8e80-4d6e-852d-1775bc5488ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_192a74ef-0a79-43cb-9f73-66871ab11357" xlink:to="loc_us-gaap_DebtInstrumentTable_bd1bab92-8e80-4d6e-852d-1775bc5488ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_38e057be-e286-4bd9-85de-4174d3059628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bd1bab92-8e80-4d6e-852d-1775bc5488ed" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_38e057be-e286-4bd9-85de-4174d3059628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_38e057be-e286-4bd9-85de-4174d3059628_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38e057be-e286-4bd9-85de-4174d3059628" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_38e057be-e286-4bd9-85de-4174d3059628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_96d35fe3-92e5-46ac-9ab5-88de3c892012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38e057be-e286-4bd9-85de-4174d3059628" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_96d35fe3-92e5-46ac-9ab5-88de3c892012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember_76089745-dc62-456a-9a7d-296220229f27" xlink:href="opk-20200630.xsd#opk_NotesPayableAndOtherLongTermLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_96d35fe3-92e5-46ac-9ab5-88de3c892012" xlink:to="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember_76089745-dc62-456a-9a7d-296220229f27" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="simple" xlink:href="opk-20200630.xsd#AccumulatedOtherComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="extended" id="ic26ef02c188d4ac19cd7cf487cff40bc_AccumulatedOtherComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="simple" xlink:href="opk-20200630.xsd#AccumulatedOtherComprehensiveLossTables"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="extended" id="i5dd4e26bd5be41e78e3811059effe5ef_AccumulatedOtherComprehensiveLossTables"/>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#AccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i1a9db8592de44631aec579de5b188f07_AccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0ebfb0b4-9632-42a2-9cdf-42ac392a3c16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_289a6d5b-9782-409f-88ec-753ee21813ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0ebfb0b4-9632-42a2-9cdf-42ac392a3c16" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_289a6d5b-9782-409f-88ec-753ee21813ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c15ae0c5-e6df-4641-bf19-dfb94d02fb7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_289a6d5b-9782-409f-88ec-753ee21813ea" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c15ae0c5-e6df-4641-bf19-dfb94d02fb7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_9d4ba352-d11a-4bfe-9ce9-be1ccb714b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_289a6d5b-9782-409f-88ec-753ee21813ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_9d4ba352-d11a-4bfe-9ce9-be1ccb714b03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b4abd3af-982d-4e80-9765-dd14180fea49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e8750519-9574-430c-a686-41acabe7b477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0ebfb0b4-9632-42a2-9cdf-42ac392a3c16" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e8750519-9574-430c-a686-41acabe7b477" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a705dfdd-4c89-4602-b844-ea44748e50a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e8750519-9574-430c-a686-41acabe7b477" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a705dfdd-4c89-4602-b844-ea44748e50a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a705dfdd-4c89-4602-b844-ea44748e50a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a705dfdd-4c89-4602-b844-ea44748e50a3" xlink:to="loc_us-gaap_EquityComponentDomain_a705dfdd-4c89-4602-b844-ea44748e50a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_333159c9-9d86-499b-84c6-974ed1896f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a705dfdd-4c89-4602-b844-ea44748e50a3" xlink:to="loc_us-gaap_EquityComponentDomain_333159c9-9d86-499b-84c6-974ed1896f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5c7a23b0-2bdd-4a61-973b-4a34273ff7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_333159c9-9d86-499b-84c6-974ed1896f23" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5c7a23b0-2bdd-4a61-973b-4a34273ff7b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/FairValueMeasurements" xlink:type="extended" id="i93307bd22d2a40a4841f2407fc146d2f_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/FairValueMeasurementsTables" xlink:type="extended" id="icf03392ff3a0435f9738d7fda255a765_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended" id="icc2c623d4f5940ae977a5281418d5e0c_FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dc68236-3fc1-48f3-8922-0b1f47fae060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dc68236-3fc1-48f3-8922-0b1f47fae060" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c5bb0679-7d45-458a-948e-8154bf1f07e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c5bb0679-7d45-458a-948e-8154bf1f07e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_700fac7d-5344-48f8-bddb-5e80212ea460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_700fac7d-5344-48f8-bddb-5e80212ea460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_46717f11-2390-4f74-8c99-dfe5badaec69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:to="loc_us-gaap_DerivativeAssets_46717f11-2390-4f74-8c99-dfe5badaec69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2bec454a-1436-4a52-ab0e-6cead7ac43f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2bec454a-1436-4a52-ab0e-6cead7ac43f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6e9f715d-1237-4bd6-9a6a-1324f7666393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dc68236-3fc1-48f3-8922-0b1f47fae060" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6e9f715d-1237-4bd6-9a6a-1324f7666393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a880fe0d-809c-454c-b4c8-0c8f4dd0ffe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6e9f715d-1237-4bd6-9a6a-1324f7666393" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a880fe0d-809c-454c-b4c8-0c8f4dd0ffe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_170eb3b0-649d-431f-9a1e-67affc2c1eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6e9f715d-1237-4bd6-9a6a-1324f7666393" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_170eb3b0-649d-431f-9a1e-67affc2c1eb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cabd462-602f-4ae8-b16d-1cb87c72d232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dc68236-3fc1-48f3-8922-0b1f47fae060" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cabd462-602f-4ae8-b16d-1cb87c72d232" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c8697f81-011f-47e0-bfff-1eb30e95fb1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cabd462-602f-4ae8-b16d-1cb87c72d232" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c8697f81-011f-47e0-bfff-1eb30e95fb1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c8697f81-011f-47e0-bfff-1eb30e95fb1f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c8697f81-011f-47e0-bfff-1eb30e95fb1f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c8697f81-011f-47e0-bfff-1eb30e95fb1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3dd39407-ce14-4526-a0ab-9d6ebc52212e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c8697f81-011f-47e0-bfff-1eb30e95fb1f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3dd39407-ce14-4526-a0ab-9d6ebc52212e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_da1be0bb-7ef3-4afa-8147-81d26cd3b393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3dd39407-ce14-4526-a0ab-9d6ebc52212e" xlink:to="loc_us-gaap_ForwardContractsMember_da1be0bb-7ef3-4afa-8147-81d26cd3b393" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_72021263-8fec-4454-b1b1-aee643bff1bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cabd462-602f-4ae8-b16d-1cb87c72d232" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_72021263-8fec-4454-b1b1-aee643bff1bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_72021263-8fec-4454-b1b1-aee643bff1bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_72021263-8fec-4454-b1b1-aee643bff1bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_72021263-8fec-4454-b1b1-aee643bff1bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_362aeb2d-8b7c-443b-be5f-e6ffa9b51d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_72021263-8fec-4454-b1b1-aee643bff1bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_362aeb2d-8b7c-443b-be5f-e6ffa9b51d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7067a4c0-5015-4837-bf29-3c4934b7056f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_362aeb2d-8b7c-443b-be5f-e6ffa9b51d3b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7067a4c0-5015-4837-bf29-3c4934b7056f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f04620b0-f6f3-471b-8966-a33b93b81515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_362aeb2d-8b7c-443b-be5f-e6ffa9b51d3b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f04620b0-f6f3-471b-8966-a33b93b81515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0e165bc0-b6a6-4b90-b6b5-ffd7bc31188f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_362aeb2d-8b7c-443b-be5f-e6ffa9b51d3b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0e165bc0-b6a6-4b90-b6b5-ffd7bc31188f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsLevel3ReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails" xlink:type="extended" id="i372e45b1fc7546bfbe849afd03ebd09a_FairValueMeasurementsLevel3ReconciliationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_0a083107-ec9c-40fa-b9d5-38926a777bda" xlink:href="opk-20200630.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db95081a-b4da-48ba-a6bc-110c3acdf409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_0a083107-ec9c-40fa-b9d5-38926a777bda" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db95081a-b4da-48ba-a6bc-110c3acdf409" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_68e0921d-e31b-4ce4-817f-de08bf2dd104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db95081a-b4da-48ba-a6bc-110c3acdf409" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_68e0921d-e31b-4ce4-817f-de08bf2dd104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b1e3d3df-0cec-4d71-86d5-2ac1efbead77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db95081a-b4da-48ba-a6bc-110c3acdf409" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b1e3d3df-0cec-4d71-86d5-2ac1efbead77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6518c874-da69-44d1-8433-343f8ebd1946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_3305c0ca-e8cd-4dfe-b108-fddf34094ad8" xlink:href="opk-20200630.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_0a083107-ec9c-40fa-b9d5-38926a777bda" xlink:to="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_3305c0ca-e8cd-4dfe-b108-fddf34094ad8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_56348b2b-a727-433c-8fd0-2d11a7f0e2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_3305c0ca-e8cd-4dfe-b108-fddf34094ad8" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_56348b2b-a727-433c-8fd0-2d11a7f0e2ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56348b2b-a727-433c-8fd0-2d11a7f0e2ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_56348b2b-a727-433c-8fd0-2d11a7f0e2ad" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_56348b2b-a727-433c-8fd0-2d11a7f0e2ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a7120ca6-4f0e-46ab-9570-66096f517461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_56348b2b-a727-433c-8fd0-2d11a7f0e2ad" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a7120ca6-4f0e-46ab-9570-66096f517461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ContingentConsiderationMember_5c007013-1b45-4e82-a695-2f79df0acc3f" xlink:href="opk-20200630.xsd#opk_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a7120ca6-4f0e-46ab-9570-66096f517461" xlink:to="loc_opk_ContingentConsiderationMember_5c007013-1b45-4e82-a695-2f79df0acc3f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i4c1a878cde504aaea63754e4d4d39067_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f45023a-ddf9-45cf-bef0-d4259bbdc023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e2c64d74-7e78-41d0-90ac-f11070868786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f45023a-ddf9-45cf-bef0-d4259bbdc023" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e2c64d74-7e78-41d0-90ac-f11070868786" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4445c607-2a71-486b-9868-14a7ce783098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f45023a-ddf9-45cf-bef0-d4259bbdc023" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4445c607-2a71-486b-9868-14a7ce783098" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2d086b5f-3845-4bd8-a301-7e8e19aae496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4445c607-2a71-486b-9868-14a7ce783098" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2d086b5f-3845-4bd8-a301-7e8e19aae496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2d086b5f-3845-4bd8-a301-7e8e19aae496_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2d086b5f-3845-4bd8-a301-7e8e19aae496" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2d086b5f-3845-4bd8-a301-7e8e19aae496_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4e0f42b0-9fb5-455c-9ae3-bce70f38802e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2d086b5f-3845-4bd8-a301-7e8e19aae496" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4e0f42b0-9fb5-455c-9ae3-bce70f38802e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_caffdeae-97f8-4c36-bdc7-d6941ca1e20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4e0f42b0-9fb5-455c-9ae3-bce70f38802e" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_caffdeae-97f8-4c36-bdc7-d6941ca1e20d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0990b35f-c87e-4477-8dfe-253245ef2c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4e0f42b0-9fb5-455c-9ae3-bce70f38802e" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0990b35f-c87e-4477-8dfe-253245ef2c88" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContracts" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContracts"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DerivativeContracts" xlink:type="extended" id="ice94b4b9a2594c1dbf8356c7a57d9ef6_DerivativeContracts"/>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContractsTables"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DerivativeContractsTables" xlink:type="extended" id="iabd01444db5c4fdab71c10b5ee94b4af_DerivativeContractsTables"/>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContractsBalanceSheetComponentDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails" xlink:type="extended" id="i3159ff530e65422a9f72e7376a657f65_DerivativeContractsBalanceSheetComponentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_83d4a57e-6bbe-4b71-bb28-79569e95ffa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_be9b153c-5b57-4f1c-a1dd-f436d165335d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_83d4a57e-6bbe-4b71-bb28-79569e95ffa7" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_be9b153c-5b57-4f1c-a1dd-f436d165335d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_f53b7810-eb4a-442b-983c-679708a31929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_83d4a57e-6bbe-4b71-bb28-79569e95ffa7" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_f53b7810-eb4a-442b-983c-679708a31929" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_741c8bc1-a4c7-43bc-8391-826592644340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_f53b7810-eb4a-442b-983c-679708a31929" xlink:to="loc_us-gaap_HedgingDesignationAxis_741c8bc1-a4c7-43bc-8391-826592644340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_741c8bc1-a4c7-43bc-8391-826592644340_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_741c8bc1-a4c7-43bc-8391-826592644340" xlink:to="loc_us-gaap_HedgingDesignationDomain_741c8bc1-a4c7-43bc-8391-826592644340_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_cec7aaa8-a906-4e3d-ad8b-868dc0d0a148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_741c8bc1-a4c7-43bc-8391-826592644340" xlink:to="loc_us-gaap_HedgingDesignationDomain_cec7aaa8-a906-4e3d-ad8b-868dc0d0a148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_19a6449a-1e32-46fa-bb98-1fd3033b80e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_cec7aaa8-a906-4e3d-ad8b-868dc0d0a148" xlink:to="loc_us-gaap_NondesignatedMember_19a6449a-1e32-46fa-bb98-1fd3033b80e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_685be12b-a065-4f31-b1b9-5af84fd9f5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_f53b7810-eb4a-442b-983c-679708a31929" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_685be12b-a065-4f31-b1b9-5af84fd9f5bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_685be12b-a065-4f31-b1b9-5af84fd9f5bc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_685be12b-a065-4f31-b1b9-5af84fd9f5bc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_685be12b-a065-4f31-b1b9-5af84fd9f5bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_11e18bf2-f293-4c3a-b31d-bb2dadfa47e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_685be12b-a065-4f31-b1b9-5af84fd9f5bc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_11e18bf2-f293-4c3a-b31d-bb2dadfa47e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_8033c738-e15e-4a86-81fc-b93620d03011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_11e18bf2-f293-4c3a-b31d-bb2dadfa47e4" xlink:to="loc_us-gaap_StockOptionMember_8033c738-e15e-4a86-81fc-b93620d03011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_d9d13fad-09bd-4c88-a41e-0bad29b76dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_11e18bf2-f293-4c3a-b31d-bb2dadfa47e4" xlink:to="loc_us-gaap_ForwardContractsMember_d9d13fad-09bd-4c88-a41e-0bad29b76dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6a3e4a0f-bc89-4052-ad64-5bfed67f5f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_f53b7810-eb4a-442b-983c-679708a31929" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6a3e4a0f-bc89-4052-ad64-5bfed67f5f6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6a3e4a0f-bc89-4052-ad64-5bfed67f5f6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6a3e4a0f-bc89-4052-ad64-5bfed67f5f6e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6a3e4a0f-bc89-4052-ad64-5bfed67f5f6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_693fe8ea-43f0-4eee-b81c-1608f7f6b304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6a3e4a0f-bc89-4052-ad64-5bfed67f5f6e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_693fe8ea-43f0-4eee-b81c-1608f7f6b304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_de5a009c-f0d6-4d69-a099-24725c2e52e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_693fe8ea-43f0-4eee-b81c-1608f7f6b304" xlink:to="loc_us-gaap_InvestmentsMember_de5a009c-f0d6-4d69-a099-24725c2e52e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_8bb3b5f8-694c-45df-b1d1-1fdf45faad94" xlink:href="opk-20200630.xsd#opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_693fe8ea-43f0-4eee-b81c-1608f7f6b304" xlink:to="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_8bb3b5f8-694c-45df-b1d1-1fdf45faad94" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContractsDerivativeGainsLossesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails" xlink:type="extended" id="i12e6524ffed441a4a48ed95f3f2cd39e_DerivativeContractsDerivativeGainsLossesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aa78034a-6de5-435e-8ec8-4ed660e3ad60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_8eb9ec0d-4982-403f-9560-fc625099bddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aa78034a-6de5-435e-8ec8-4ed660e3ad60" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_8eb9ec0d-4982-403f-9560-fc625099bddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2906601b-d9fe-4cd7-9fb2-7ce193066acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aa78034a-6de5-435e-8ec8-4ed660e3ad60" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2906601b-d9fe-4cd7-9fb2-7ce193066acf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e294f261-92c8-4a79-9d63-8af2e736ffa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2906601b-d9fe-4cd7-9fb2-7ce193066acf" xlink:to="loc_us-gaap_HedgingDesignationAxis_e294f261-92c8-4a79-9d63-8af2e736ffa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e294f261-92c8-4a79-9d63-8af2e736ffa0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_e294f261-92c8-4a79-9d63-8af2e736ffa0" xlink:to="loc_us-gaap_HedgingDesignationDomain_e294f261-92c8-4a79-9d63-8af2e736ffa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8ace32bb-06d8-4844-bfe3-ba6f3443df47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_e294f261-92c8-4a79-9d63-8af2e736ffa0" xlink:to="loc_us-gaap_HedgingDesignationDomain_8ace32bb-06d8-4844-bfe3-ba6f3443df47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_50abe0ac-73a6-47da-83f0-9b3452e43046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8ace32bb-06d8-4844-bfe3-ba6f3443df47" xlink:to="loc_us-gaap_NondesignatedMember_50abe0ac-73a6-47da-83f0-9b3452e43046" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_aedfbaff-7cfc-4ab3-9cda-2340e88722d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2906601b-d9fe-4cd7-9fb2-7ce193066acf" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_aedfbaff-7cfc-4ab3-9cda-2340e88722d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_aedfbaff-7cfc-4ab3-9cda-2340e88722d2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_aedfbaff-7cfc-4ab3-9cda-2340e88722d2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_aedfbaff-7cfc-4ab3-9cda-2340e88722d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_da1554ed-966c-4af7-a79a-2a4039ed8f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_aedfbaff-7cfc-4ab3-9cda-2340e88722d2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_da1554ed-966c-4af7-a79a-2a4039ed8f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_e673959b-ea6b-4b56-9c7a-f26169f69216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_da1554ed-966c-4af7-a79a-2a4039ed8f2e" xlink:to="loc_us-gaap_StockOptionMember_e673959b-ea6b-4b56-9c7a-f26169f69216" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_8a6e62a2-308c-48b0-9304-791a93ee41f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_da1554ed-966c-4af7-a79a-2a4039ed8f2e" xlink:to="loc_us-gaap_ForwardContractsMember_8a6e62a2-308c-48b0-9304-791a93ee41f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="opk-20200630.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/RelatedPartyTransactions" xlink:type="extended" id="i440394d2c7c14291aa1687bb4527f5c4_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.opko.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="if03bb33a136845499322fcdc48e4b8e5_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1f8c0e1d-6fc3-4fc8-9d49-76b0e933ba1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1f8c0e1d-6fc3-4fc8-9d49-76b0e933ba1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5242f476-fdb5-4322-bb1c-de55c7d2596a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5242f476-fdb5-4322-bb1c-de55c7d2596a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_7933ce52-8367-4b65-a968-6544bcb07006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_7933ce52-8367-4b65-a968-6544bcb07006" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ac226c23-f1eb-41ee-9ba4-c3a274229657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ac226c23-f1eb-41ee-9ba4-c3a274229657" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_81998f8e-6739-49ff-aefe-5fe0a59b24f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_81998f8e-6739-49ff-aefe-5fe0a59b24f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5665064f-5c20-469f-87ed-5a4255fb7c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5665064f-5c20-469f-87ed-5a4255fb7c05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_137a65ef-7205-44aa-9466-6ef765f80199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_SharesIssued_137a65ef-7205-44aa-9466-6ef765f80199" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a1abc1a4-1428-40c2-932a-995d61080398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a1abc1a4-1428-40c2-932a-995d61080398" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionShares_6c477af9-01bd-4631-bd1c-1552547eb9ee" xlink:href="opk-20200630.xsd#opk_RelatedPartyTransactionShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_RelatedPartyTransactionShares_6c477af9-01bd-4631-bd1c-1552547eb9ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_50d612b3-7212-4dd1-ab41-6b1b642dfbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_50d612b3-7212-4dd1-ab41-6b1b642dfbd1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_27dfacf4-b671-41c8-8e80-62c4eccdaa2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_27dfacf4-b671-41c8-8e80-62c4eccdaa2b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ab7ea324-657e-4253-999d-f17cbe57797c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ab7ea324-657e-4253-999d-f17cbe57797c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_67702ee4-49a3-4428-918c-abce51063020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_67702ee4-49a3-4428-918c-abce51063020" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquitySecurityFVNIOwnershipPercent_7ff87fc6-1070-4b64-a3b8-14d2fb4cb2d7" xlink:href="opk-20200630.xsd#opk_EquitySecurityFVNIOwnershipPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_EquitySecurityFVNIOwnershipPercent_7ff87fc6-1070-4b64-a3b8-14d2fb4cb2d7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ccd593a5-8c84-4255-8529-1b93d4c0f15c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ccd593a5-8c84-4255-8529-1b93d4c0f15c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleSharesIssued_9b507908-8438-4adc-a239-0f98542f6488" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_DebtInstrumentConvertibleSharesIssued_9b507908-8438-4adc-a239-0f98542f6488" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentSharesPurchasedInPeriod_714a7d93-c799-45dc-835b-41cdaac7e5c3" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentSharesPurchasedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_EquityMethodInvestmentSharesPurchasedInPeriod_714a7d93-c799-45dc-835b-41cdaac7e5c3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_61e52f5e-9836-46f2-b368-cef6710f13af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_61e52f5e-9836-46f2-b368-cef6710f13af" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2bf66dda-0c0f-4bf4-9c10-6fd305e7dc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2bf66dda-0c0f-4bf4-9c10-6fd305e7dc52" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived_4a97a66e-dc54-43a9-89da-448ad9a8df4d" xlink:href="opk-20200630.xsd#opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived_4a97a66e-dc54-43a9-89da-448ad9a8df4d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_6ba04ef2-fac7-4a19-bbeb-e120b2385ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_6ba04ef2-fac7-4a19-bbeb-e120b2385ba8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributions_2b4cd8bf-1435-489a-b94e-958ea9b5d039" xlink:href="opk-20200630.xsd#opk_RelatedPartyTransactionFutureContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_RelatedPartyTransactionFutureContributions_2b4cd8bf-1435-489a-b94e-958ea9b5d039" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributionTerm_12272936-b4db-44a9-b94b-2a42c6f3c9d2" xlink:href="opk-20200630.xsd#opk_RelatedPartyTransactionFutureContributionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_RelatedPartyTransactionFutureContributionTerm_12272936-b4db-44a9-b94b-2a42c6f3c9d2" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_5c44eaa8-0f8f-4c53-aa21-5be22c75bec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_5c44eaa8-0f8f-4c53-aa21-5be22c75bec0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearOne_be90c4eb-f457-4724-90de-ee7c3f18c4f2" xlink:href="opk-20200630.xsd#opk_OperatingLeasesMonthlyPaymentsYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_OperatingLeasesMonthlyPaymentsYearOne_be90c4eb-f457-4724-90de-ee7c3f18c4f2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearThree_f266a121-67fd-473a-8eda-514b1ed1343e" xlink:href="opk-20200630.xsd#opk_OperatingLeasesMonthlyPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_OperatingLeasesMonthlyPaymentsYearThree_f266a121-67fd-473a-8eda-514b1ed1343e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_2b2c175c-5eef-461f-917f-e17d57d6c52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_2b2c175c-5eef-461f-917f-e17d57d6c52e" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0d1689fd-c643-4a57-84f3-b27a4f63e4c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_srt_CounterpartyNameAxis_0d1689fd-c643-4a57-84f3-b27a4f63e4c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0d1689fd-c643-4a57-84f3-b27a4f63e4c0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0d1689fd-c643-4a57-84f3-b27a4f63e4c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0d1689fd-c643-4a57-84f3-b27a4f63e4c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a92313ee-7ad6-471a-ad16-ede041492501" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0d1689fd-c643-4a57-84f3-b27a4f63e4c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a92313ee-7ad6-471a-ad16-ede041492501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MembersofSeniorManagementMember_4ca10ee4-bbe7-4c27-bf16-9b3d5d46b37a" xlink:href="opk-20200630.xsd#opk_MembersofSeniorManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a92313ee-7ad6-471a-ad16-ede041492501" xlink:to="loc_opk_MembersofSeniorManagementMember_4ca10ee4-bbe7-4c27-bf16-9b3d5d46b37a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dd7c9114-2616-4aee-9025-10f3574d1204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dd7c9114-2616-4aee-9025-10f3574d1204" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dd7c9114-2616-4aee-9025-10f3574d1204_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd7c9114-2616-4aee-9025-10f3574d1204" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dd7c9114-2616-4aee-9025-10f3574d1204_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c7d0468-b53d-4f13-9b66-949127f62bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd7c9114-2616-4aee-9025-10f3574d1204" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c7d0468-b53d-4f13-9b66-949127f62bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_8c8ca818-76e8-49c7-950e-cc98e462e2f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c7d0468-b53d-4f13-9b66-949127f62bf2" xlink:to="loc_us-gaap_IPOMember_8c8ca818-76e8-49c7-950e-cc98e462e2f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_86fb6fd6-cc93-4f05-862b-c91ae0848179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c7d0468-b53d-4f13-9b66-949127f62bf2" xlink:to="loc_us-gaap_OverAllotmentOptionMember_86fb6fd6-cc93-4f05-862b-c91ae0848179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_35b4284e-20e1-47f7-b7b9-d460a58eebb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_CreditFacilityAxis_35b4284e-20e1-47f7-b7b9-d460a58eebb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_35b4284e-20e1-47f7-b7b9-d460a58eebb3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_35b4284e-20e1-47f7-b7b9-d460a58eebb3" xlink:to="loc_us-gaap_CreditFacilityDomain_35b4284e-20e1-47f7-b7b9-d460a58eebb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_447da1aa-d578-4b7b-9af2-804219c11627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_35b4284e-20e1-47f7-b7b9-d460a58eebb3" xlink:to="loc_us-gaap_CreditFacilityDomain_447da1aa-d578-4b7b-9af2-804219c11627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_cf41db91-45f7-437d-8b5d-1a2ae0048bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_447da1aa-d578-4b7b-9af2-804219c11627" xlink:to="loc_us-gaap_LineOfCreditMember_cf41db91-45f7-437d-8b5d-1a2ae0048bc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c4dbedf5-4621-466b-90d8-321ae3efbebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_447da1aa-d578-4b7b-9af2-804219c11627" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c4dbedf5-4621-466b-90d8-321ae3efbebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d6488d21-0efc-4c8d-be1a-dae11582cfb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d6488d21-0efc-4c8d-be1a-dae11582cfb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d6488d21-0efc-4c8d-be1a-dae11582cfb3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d6488d21-0efc-4c8d-be1a-dae11582cfb3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d6488d21-0efc-4c8d-be1a-dae11582cfb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_af4bb51f-cfd3-4aaf-ada6-258c948a492f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d6488d21-0efc-4c8d-be1a-dae11582cfb3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_af4bb51f-cfd3-4aaf-ada6-258c948a492f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SeriesAWarrantMember_617be38a-b66f-4612-aefd-c065c34f9216" xlink:href="opk-20200630.xsd#opk_SeriesAWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_af4bb51f-cfd3-4aaf-ada6-258c948a492f" xlink:to="loc_opk_SeriesAWarrantMember_617be38a-b66f-4612-aefd-c065c34f9216" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SeriesBWarrantMember_a8466718-4002-4b53-a64a-1ff9e627aec3" xlink:href="opk-20200630.xsd#opk_SeriesBWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_af4bb51f-cfd3-4aaf-ada6-258c948a492f" xlink:to="loc_opk_SeriesBWarrantMember_a8466718-4002-4b53-a64a-1ff9e627aec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SeriesCWarrantMember_311e6cba-5951-4fa8-b5fa-4c8d766f2e10" xlink:href="opk-20200630.xsd#opk_SeriesCWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_af4bb51f-cfd3-4aaf-ada6-258c948a492f" xlink:to="loc_opk_SeriesCWarrantMember_311e6cba-5951-4fa8-b5fa-4c8d766f2e10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7dbabda6-28df-42be-8172-2d7d048b58a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_DebtInstrumentAxis_7dbabda6-28df-42be-8172-2d7d048b58a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7dbabda6-28df-42be-8172-2d7d048b58a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7dbabda6-28df-42be-8172-2d7d048b58a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7dbabda6-28df-42be-8172-2d7d048b58a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5c8c3ae6-3bc7-435d-9713-7bed1e806862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7dbabda6-28df-42be-8172-2d7d048b58a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5c8c3ae6-3bc7-435d-9713-7bed1e806862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NewCreditAgreementMember_6aecae40-e6d6-40f6-a26d-a8a8c7d8fb02" xlink:href="opk-20200630.xsd#opk_NewCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c8c3ae6-3bc7-435d-9713-7bed1e806862" xlink:to="loc_opk_NewCreditAgreementMember_6aecae40-e6d6-40f6-a26d-a8a8c7d8fb02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A5ConvertibleNotesMember_78b0c2c4-2a55-4d1b-a191-7edac55a542a" xlink:href="opk-20200630.xsd#opk_A5ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c8c3ae6-3bc7-435d-9713-7bed1e806862" xlink:to="loc_opk_A5ConvertibleNotesMember_78b0c2c4-2a55-4d1b-a191-7edac55a542a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_991f3de5-7274-4a52-8855-b4e0eb862b13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_991f3de5-7274-4a52-8855-b4e0eb862b13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_991f3de5-7274-4a52-8855-b4e0eb862b13_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_991f3de5-7274-4a52-8855-b4e0eb862b13" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_991f3de5-7274-4a52-8855-b4e0eb862b13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c121e020-e953-446c-b3ef-90cbb1017031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_991f3de5-7274-4a52-8855-b4e0eb862b13" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c121e020-e953-446c-b3ef-90cbb1017031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_459cb703-0856-4ddf-9515-c3197817356a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c121e020-e953-446c-b3ef-90cbb1017031" xlink:to="loc_us-gaap_UnsecuredDebtMember_459cb703-0856-4ddf-9515-c3197817356a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_bbcb682e-a616-44db-a8ed-43877428a670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c121e020-e953-446c-b3ef-90cbb1017031" xlink:to="loc_us-gaap_LineOfCreditMember_bbcb682e-a616-44db-a8ed-43877428a670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1b44e2fa-6f5c-4249-bbbf-05789df14244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c121e020-e953-446c-b3ef-90cbb1017031" xlink:to="loc_us-gaap_ConvertibleDebtMember_1b44e2fa-6f5c-4249-bbbf-05789df14244" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c063daf6-2a12-4382-8591-3045f89417cc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_dei_LegalEntityAxis_c063daf6-2a12-4382-8591-3045f89417cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c063daf6-2a12-4382-8591-3045f89417cc_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c063daf6-2a12-4382-8591-3045f89417cc" xlink:to="loc_dei_EntityDomain_c063daf6-2a12-4382-8591-3045f89417cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b4e32946-93c4-4f3a-be74-c85ba61e0f26" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c063daf6-2a12-4382-8591-3045f89417cc" xlink:to="loc_dei_EntityDomain_b4e32946-93c4-4f3a-be74-c85ba61e0f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_XeneticBiosciencesInc.Member_2dea9503-60ec-4528-9bb1-46bbbfbe8026" xlink:href="opk-20200630.xsd#opk_XeneticBiosciencesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b4e32946-93c4-4f3a-be74-c85ba61e0f26" xlink:to="loc_opk_XeneticBiosciencesInc.Member_2dea9503-60ec-4528-9bb1-46bbbfbe8026" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MuseumofScienceIncMember_59618a60-0782-48d2-acc3-317f3b0eb309" xlink:href="opk-20200630.xsd#opk_MuseumofScienceIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b4e32946-93c4-4f3a-be74-c85ba61e0f26" xlink:to="loc_opk_MuseumofScienceIncMember_59618a60-0782-48d2-acc3-317f3b0eb309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_49508327-0545-472f-9f6d-6d05d7f208dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_StatementClassOfStockAxis_49508327-0545-472f-9f6d-6d05d7f208dd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_49508327-0545-472f-9f6d-6d05d7f208dd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_49508327-0545-472f-9f6d-6d05d7f208dd" xlink:to="loc_us-gaap_ClassOfStockDomain_49508327-0545-472f-9f6d-6d05d7f208dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fea2d099-d115-479e-92d7-21fd921e1de3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_49508327-0545-472f-9f6d-6d05d7f208dd" xlink:to="loc_us-gaap_ClassOfStockDomain_fea2d099-d115-479e-92d7-21fd921e1de3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7f8e75c2-3c5c-4193-90ef-4b2ad0c78629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fea2d099-d115-479e-92d7-21fd921e1de3" xlink:to="loc_us-gaap_CommonStockMember_7f8e75c2-3c5c-4193-90ef-4b2ad0c78629" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_718ee82e-cdc9-4b4f-b5b3-cfca2f7f5753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_718ee82e-cdc9-4b4f-b5b3-cfca2f7f5753" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_718ee82e-cdc9-4b4f-b5b3-cfca2f7f5753_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_718ee82e-cdc9-4b4f-b5b3-cfca2f7f5753" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_718ee82e-cdc9-4b4f-b5b3-cfca2f7f5753_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1d851abb-cb33-451e-9a58-f963f580076a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_718ee82e-cdc9-4b4f-b5b3-cfca2f7f5753" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1d851abb-cb33-451e-9a58-f963f580076a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOTransactionSharesMember_035ec9e0-7763-4ac7-a9b8-3b08e8fd0d9d" xlink:href="opk-20200630.xsd#opk_OPKOTransactionSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1d851abb-cb33-451e-9a58-f963f580076a" xlink:to="loc_opk_OPKOTransactionSharesMember_035ec9e0-7763-4ac7-a9b8-3b08e8fd0d9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_8982208b-2236-4b4d-b7e2-a99ea66e5382" xlink:href="opk-20200630.xsd#opk_SharesReceivedUponClosingofXeneticTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1d851abb-cb33-451e-9a58-f963f580076a" xlink:to="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_8982208b-2236-4b4d-b7e2-a99ea66e5382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FederalTradeCommissionFilingFeesMember_cb9a7f56-f865-4338-b600-4215119b2bd3" xlink:href="opk-20200630.xsd#opk_FederalTradeCommissionFilingFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1d851abb-cb33-451e-9a58-f963f580076a" xlink:to="loc_opk_FederalTradeCommissionFilingFeesMember_cb9a7f56-f865-4338-b600-4215119b2bd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dcd81428-dcee-4082-abd1-39f86c849683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dcd81428-dcee-4082-abd1-39f86c849683" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_dcd81428-dcee-4082-abd1-39f86c849683_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dcd81428-dcee-4082-abd1-39f86c849683" xlink:to="loc_us-gaap_RelatedPartyDomain_dcd81428-dcee-4082-abd1-39f86c849683_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dcd81428-dcee-4082-abd1-39f86c849683" xlink:to="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_5133677d-1124-47be-9d35-65f8c6639bae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_srt_AffiliatedEntityMember_5133677d-1124-47be-9d35-65f8c6639bae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c042d27b-8de3-41b3-944a-0fa695215a51" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_srt_DirectorMember_c042d27b-8de3-41b3-944a-0fa695215a51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_a8c9b7a9-3164-4534-a247-91be49e26cd1" xlink:href="opk-20200630.xsd#opk_SharesReceivedUponClosingofXeneticTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_a8c9b7a9-3164-4534-a247-91be49e26cd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChiefTechnicalOfficerMember_8e0cebd7-fd15-477b-84f3-653ecf07c17e" xlink:href="opk-20200630.xsd#opk_ChiefTechnicalOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_opk_ChiefTechnicalOfficerMember_8e0cebd7-fd15-477b-84f3-653ecf07c17e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_3e04dbb2-ed12-46c3-967e-ed7e00579b15" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_srt_ChiefExecutiveOfficerMember_3e04dbb2-ed12-46c3-967e-ed7e00579b15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_515ec82f-151c-474e-b02b-a85c481cb766" xlink:href="opk-20200630.xsd#opk_BioCardiaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_opk_BioCardiaInc.Member_515ec82f-151c-474e-b02b-a85c481cb766" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DrFrostandMrPfennigerMember_2919351a-18ad-4582-89c8-d012c15c2520" xlink:href="opk-20200630.xsd#opk_DrFrostandMrPfennigerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_opk_DrFrostandMrPfennigerMember_2919351a-18ad-4582-89c8-d012c15c2520" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FrostRealEstateHoldingsLLCMember_495cd339-c062-46cd-b0f4-5e73ae9a43cb" xlink:href="opk-20200630.xsd#opk_FrostRealEstateHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_opk_FrostRealEstateHoldingsLLCMember_495cd339-c062-46cd-b0f4-5e73ae9a43cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1663b917-c037-4a38-94bf-d066596f4595" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1663b917-c037-4a38-94bf-d066596f4595" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1663b917-c037-4a38-94bf-d066596f4595_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1663b917-c037-4a38-94bf-d066596f4595" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1663b917-c037-4a38-94bf-d066596f4595_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1663b917-c037-4a38-94bf-d066596f4595" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember_63d7ff0c-bf06-46e2-bfe3-6031de28bb50" xlink:href="opk-20200630.xsd#opk_PharmsynthezMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_PharmsynthezMember_63d7ff0c-bf06-46e2-bfe3-6031de28bb50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ZebraMember_b7ef4c8a-2f44-4c03-a3df-12115bd4aacf" xlink:href="opk-20200630.xsd#opk_ZebraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_ZebraMember_b7ef4c8a-2f44-4c03-a3df-12115bd4aacf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NeovascMember_52092066-70af-41a3-aeb6-3f9b770945b2" xlink:href="opk-20200630.xsd#opk_NeovascMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_NeovascMember_52092066-70af-41a3-aeb6-3f9b770945b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromadexCorporationMember_c16d723e-b6a0-4667-a64e-15e80dcdf9e7" xlink:href="opk-20200630.xsd#opk_ChromadexCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_ChromadexCorporationMember_c16d723e-b6a0-4667-a64e-15e80dcdf9e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MabVaxTherapeuticsHoldingsInc.Member_ca8b507c-0d99-4c49-823f-ed0314893f81" xlink:href="opk-20200630.xsd#opk_MabVaxTherapeuticsHoldingsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_MabVaxTherapeuticsHoldingsInc.Member_ca8b507c-0d99-4c49-823f-ed0314893f81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CocrystalMember_ee02f5df-8baf-4a4b-915b-57b8fad1a52e" xlink:href="opk-20200630.xsd#opk_CocrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_CocrystalMember_ee02f5df-8baf-4a4b-915b-57b8fad1a52e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NIMSMember_bd0faea3-32db-4045-8b10-77b8b7d3168c" xlink:href="opk-20200630.xsd#opk_NIMSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_NIMSMember_bd0faea3-32db-4045-8b10-77b8b7d3168c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EloxxPharmaceuticalsMember_55df64c5-e892-4390-9e76-21820d1c9916" xlink:href="opk-20200630.xsd#opk_EloxxPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_EloxxPharmaceuticalsMember_55df64c5-e892-4390-9e76-21820d1c9916" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_fffc65b0-cd5f-4815-bc71-d0154228c08b" xlink:href="opk-20200630.xsd#opk_BioCardiaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_BioCardiaInc.Member_fffc65b0-cd5f-4815-bc71-d0154228c08b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InCellDxIncMember_8bbb2d29-71a6-47e7-b585-3e1c87d0c9c9" xlink:href="opk-20200630.xsd#opk_InCellDxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_InCellDxIncMember_8bbb2d29-71a6-47e7-b585-3e1c87d0c9c9" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="opk-20200630.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CommitmentsandContingencies" xlink:type="extended" id="i8854e780d4924adf9520d113f62c8454_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.opko.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i14ca45a0d2e4474a978f2e91e9aee61a_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9a0df51e-9201-419c-a5ef-7521a684aa8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9a0df51e-9201-419c-a5ef-7521a684aa8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NumberOfClassActionLawsuits_55233a50-c1cf-428b-901e-8e6169e7aa13" xlink:href="opk-20200630.xsd#opk_NumberOfClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_opk_NumberOfClassActionLawsuits_55233a50-c1cf-428b-901e-8e6169e7aa13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_7f8d6ec2-7a1d-4312-863a-978edd10ee49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_7f8d6ec2-7a1d-4312-863a-978edd10ee49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_98e37e4f-4cba-455d-84ef-0ab2870df46e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_98e37e4f-4cba-455d-84ef-0ab2870df46e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NumberOfDerivativeLawsuits_cea79c2f-e41b-4797-a929-87edd2c7979a" xlink:href="opk-20200630.xsd#opk_NumberOfDerivativeLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_opk_NumberOfDerivativeLawsuits_cea79c2f-e41b-4797-a929-87edd2c7979a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_255998b2-b95b-40c0-a422-bcac71012e98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_us-gaap_PurchaseObligation_255998b2-b95b-40c0-a422-bcac71012e98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8985ac0c-a472-42b2-a927-d377135ce16d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8985ac0c-a472-42b2-a927-d377135ce16d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7b434124-091c-4b8a-b314-06eb8551f953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8985ac0c-a472-42b2-a927-d377135ce16d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7b434124-091c-4b8a-b314-06eb8551f953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7b434124-091c-4b8a-b314-06eb8551f953_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7b434124-091c-4b8a-b314-06eb8551f953" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7b434124-091c-4b8a-b314-06eb8551f953_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7a1ea16d-2d66-45ce-9e3a-412d37f6a3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7b434124-091c-4b8a-b314-06eb8551f953" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7a1ea16d-2d66-45ce-9e3a-412d37f6a3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_2472a375-4fdb-44ba-b916-907321067322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7a1ea16d-2d66-45ce-9e3a-412d37f6a3ec" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_2472a375-4fdb-44ba-b916-907321067322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4db3b49d-da85-425e-b40a-6b816f2d0e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7a1ea16d-2d66-45ce-9e3a-412d37f6a3ec" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4db3b49d-da85-425e-b40a-6b816f2d0e7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_aea5028c-b300-47f6-9c60-3ca2aa5f5c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8985ac0c-a472-42b2-a927-d377135ce16d" xlink:to="loc_us-gaap_LitigationStatusAxis_aea5028c-b300-47f6-9c60-3ca2aa5f5c24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_aea5028c-b300-47f6-9c60-3ca2aa5f5c24_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_aea5028c-b300-47f6-9c60-3ca2aa5f5c24" xlink:to="loc_us-gaap_LitigationStatusDomain_aea5028c-b300-47f6-9c60-3ca2aa5f5c24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_d80e84d2-9da6-4539-aeb1-45d491ea0f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_aea5028c-b300-47f6-9c60-3ca2aa5f5c24" xlink:to="loc_us-gaap_LitigationStatusDomain_d80e84d2-9da6-4539-aeb1-45d491ea0f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_c5dd24c0-28f7-43cd-a13e-96a335d5c3be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_d80e84d2-9da6-4539-aeb1-45d491ea0f18" xlink:to="loc_us-gaap_SettledLitigationMember_c5dd24c0-28f7-43cd-a13e-96a335d5c3be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognition" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognition"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/RevenueRecognition" xlink:type="extended" id="i9bd60b95906a445c885f64987136125c_RevenueRecognition"/>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionTables"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/RevenueRecognitionTables" xlink:type="extended" id="i156de699712248f1b8b29f185d1341b9_RevenueRecognitionTables"/>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" id="i0bf87b9022fe485a8a9fccabad763ebe_RevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_8580d6c7-75d8-460f-946b-3bc02398a4ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_8580d6c7-75d8-460f-946b-3bc02398a4ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability_dcb80fcb-5d84-446d-9298-6a198715cfc7" xlink:href="opk-20200630.xsd#opk_AccruedExpensePayorOverpaymentReimbursementLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:to="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability_dcb80fcb-5d84-446d-9298-6a198715cfc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_389ba4b1-b145-42d0-a584-dc6df5192c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_389ba4b1-b145-42d0-a584-dc6df5192c42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c2ebb08-ed03-4f0e-a8b8-fa42a051e48c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c2ebb08-ed03-4f0e-a8b8-fa42a051e48c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d5ea2ad2-5635-49d2-b885-2f5ab03b9e66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d5ea2ad2-5635-49d2-b885-2f5ab03b9e66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7aad485f-db36-49b9-a330-cb10c97eb7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7aad485f-db36-49b9-a330-cb10c97eb7a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b946e318-5a0a-4157-bf2e-4c99327ab44c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7aad485f-db36-49b9-a330-cb10c97eb7a8" xlink:to="loc_srt_CounterpartyNameAxis_b946e318-5a0a-4157-bf2e-4c99327ab44c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b946e318-5a0a-4157-bf2e-4c99327ab44c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b946e318-5a0a-4157-bf2e-4c99327ab44c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b946e318-5a0a-4157-bf2e-4c99327ab44c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ca0d9d4-8f46-4fea-ac5c-af0dcd898825" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b946e318-5a0a-4157-bf2e-4c99327ab44c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ca0d9d4-8f46-4fea-ac5c-af0dcd898825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember_686d648c-aacd-4565-867c-aeedf3a50e53" xlink:href="opk-20200630.xsd#opk_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ca0d9d4-8f46-4fea-ac5c-af0dcd898825" xlink:to="loc_opk_PfizerMember_686d648c-aacd-4565-867c-aeedf3a50e53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember_a93c1a57-c86e-4829-9d78-137322484ab3" xlink:href="opk-20200630.xsd#opk_BioReferenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ca0d9d4-8f46-4fea-ac5c-af0dcd898825" xlink:to="loc_opk_BioReferenceMember_a93c1a57-c86e-4829-9d78-137322484ab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_aff71a83-b688-4ce5-80dd-aa1e5486a5e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7aad485f-db36-49b9-a330-cb10c97eb7a8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_aff71a83-b688-4ce5-80dd-aa1e5486a5e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aff71a83-b688-4ce5-80dd-aa1e5486a5e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_aff71a83-b688-4ce5-80dd-aa1e5486a5e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aff71a83-b688-4ce5-80dd-aa1e5486a5e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcf2a5ab-61be-4c22-8b72-552c3c7cd986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_aff71a83-b688-4ce5-80dd-aa1e5486a5e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcf2a5ab-61be-4c22-8b72-552c3c7cd986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b0c3baed-ecab-4626-9cdd-7eab5fc1f1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcf2a5ab-61be-4c22-8b72-552c3c7cd986" xlink:to="loc_us-gaap_ProductMember_b0c3baed-ecab-4626-9cdd-7eab5fc1f1b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4877da9-85eb-4f99-9b0a-33d6c3a7ec88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7aad485f-db36-49b9-a330-cb10c97eb7a8" xlink:to="loc_srt_ProductOrServiceAxis_a4877da9-85eb-4f99-9b0a-33d6c3a7ec88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4877da9-85eb-4f99-9b0a-33d6c3a7ec88_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a4877da9-85eb-4f99-9b0a-33d6c3a7ec88" xlink:to="loc_srt_ProductsAndServicesDomain_a4877da9-85eb-4f99-9b0a-33d6c3a7ec88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4a927d4b-bc16-40e2-9f2e-5af63d68b2f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a4877da9-85eb-4f99-9b0a-33d6c3a7ec88" xlink:to="loc_srt_ProductsAndServicesDomain_4a927d4b-bc16-40e2-9f2e-5af63d68b2f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RayaldeeMember_7fc9cb78-8d38-42ae-bb6a-97c9dfcece7b" xlink:href="opk-20200630.xsd#opk_RayaldeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4a927d4b-bc16-40e2-9f2e-5af63d68b2f1" xlink:to="loc_opk_RayaldeeMember_7fc9cb78-8d38-42ae-bb6a-97c9dfcece7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_9648e8e2-5a4d-41f0-b425-814099bafc91" xlink:href="opk-20200630.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4a927d4b-bc16-40e2-9f2e-5af63d68b2f1" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_9648e8e2-5a4d-41f0-b425-814099bafc91" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionScheduleofDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="extended" id="i5f69d2ce137048288e4c7d7cb2a108b4_RevenueRecognitionScheduleofDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a7b19381-ba16-4d08-9ff7-814f3efd4779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4ba22c27-065e-45ed-85cc-8e95e8cc9546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a7b19381-ba16-4d08-9ff7-814f3efd4779" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4ba22c27-065e-45ed-85cc-8e95e8cc9546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b1e24cf8-3a82-460e-85f8-7a5c8618ea62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a7b19381-ba16-4d08-9ff7-814f3efd4779" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b1e24cf8-3a82-460e-85f8-7a5c8618ea62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cfcca94f-0401-46a5-b123-177cf6b3e8c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b1e24cf8-3a82-460e-85f8-7a5c8618ea62" xlink:to="loc_srt_ProductOrServiceAxis_cfcca94f-0401-46a5-b123-177cf6b3e8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfcca94f-0401-46a5-b123-177cf6b3e8c1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cfcca94f-0401-46a5-b123-177cf6b3e8c1" xlink:to="loc_srt_ProductsAndServicesDomain_cfcca94f-0401-46a5-b123-177cf6b3e8c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cc6396a4-1f9b-41c5-ba64-52dac0e19d6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cfcca94f-0401-46a5-b123-177cf6b3e8c1" xlink:to="loc_srt_ProductsAndServicesDomain_cc6396a4-1f9b-41c5-ba64-52dac0e19d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cc6396a4-1f9b-41c5-ba64-52dac0e19d6d" xlink:to="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_HealthInsurersMember_7f2d3b37-8ba7-4cc6-bd2f-8c4e558791b8" xlink:href="opk-20200630.xsd#opk_HealthInsurersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:to="loc_opk_HealthInsurersMember_7f2d3b37-8ba7-4cc6-bd2f-8c4e558791b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentPayersMember_3fd1bc2e-e457-4990-81cd-0169e49d68a8" xlink:href="opk-20200630.xsd#opk_GovernmentPayersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:to="loc_opk_GovernmentPayersMember_3fd1bc2e-e457-4990-81cd-0169e49d68a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClientPayersMember_2bf58d58-b41a-498c-bed0-bf4c83059dc0" xlink:href="opk-20200630.xsd#opk_ClientPayersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:to="loc_opk_ClientPayersMember_2bf58d58-b41a-498c-bed0-bf4c83059dc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PatientsMember_ca2cf938-bbb9-49dd-aaac-ce3cd34f70e4" xlink:href="opk-20200630.xsd#opk_PatientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:to="loc_opk_PatientsMember_ca2cf938-bbb9-49dd-aaac-ce3cd34f70e4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" xlink:type="extended" id="i4006d23be1dc4c7681b86e3f17385520_RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_73c51042-b0ed-4253-ad61-4c40a7f7634d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9fe0696c-af6d-4e5b-9bc8-1d938af3e4fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_73c51042-b0ed-4253-ad61-4c40a7f7634d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9fe0696c-af6d-4e5b-9bc8-1d938af3e4fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_be1b0dac-c912-4bad-b101-aafae81e837e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9fe0696c-af6d-4e5b-9bc8-1d938af3e4fa" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_be1b0dac-c912-4bad-b101-aafae81e837e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fafed431-20e9-4728-994c-6a3831ed3077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9fe0696c-af6d-4e5b-9bc8-1d938af3e4fa" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fafed431-20e9-4728-994c-6a3831ed3077" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_d13d59ef-fdab-459d-9301-ee9833392348" xlink:href="opk-20200630.xsd#opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9fe0696c-af6d-4e5b-9bc8-1d938af3e4fa" xlink:to="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_d13d59ef-fdab-459d-9301-ee9833392348" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_71f1bb1c-0c06-4268-a804-0758071a579e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c3ffc959-7c8c-4e66-aa62-08eb04a07e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_73c51042-b0ed-4253-ad61-4c40a7f7634d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c3ffc959-7c8c-4e66-aa62-08eb04a07e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_980beefd-f0a0-4891-bb51-27c80d289174" xlink:href="opk-20200630.xsd#opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_73c51042-b0ed-4253-ad61-4c40a7f7634d" xlink:to="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_980beefd-f0a0-4891-bb51-27c80d289174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d21bc2d1-af83-4b92-b183-4aaad6973572" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_73c51042-b0ed-4253-ad61-4c40a7f7634d" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d21bc2d1-af83-4b92-b183-4aaad6973572" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6dd63245-863c-41d3-94a7-130e13ff013e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d21bc2d1-af83-4b92-b183-4aaad6973572" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6dd63245-863c-41d3-94a7-130e13ff013e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd63245-863c-41d3-94a7-130e13ff013e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6dd63245-863c-41d3-94a7-130e13ff013e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd63245-863c-41d3-94a7-130e13ff013e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa32c265-3cce-48b3-af59-6929b1a23337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6dd63245-863c-41d3-94a7-130e13ff013e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa32c265-3cce-48b3-af59-6929b1a23337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChargebacksDiscountsRebatesAndFeesMember_a36b7ab9-ead1-4d72-847a-9d4313d9c120" xlink:href="opk-20200630.xsd#opk_ChargebacksDiscountsRebatesAndFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa32c265-3cce-48b3-af59-6929b1a23337" xlink:to="loc_opk_ChargebacksDiscountsRebatesAndFeesMember_a36b7ab9-ead1-4d72-847a-9d4313d9c120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentalMember_13cd24c5-c561-4554-bd58-fce748b62a1e" xlink:href="opk-20200630.xsd#opk_GovernmentalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa32c265-3cce-48b3-af59-6929b1a23337" xlink:to="loc_opk_GovernmentalMember_13cd24c5-c561-4554-bd58-fce748b62a1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesReturnsMember_be96cd66-2332-4f0a-8fba-69a5b9b90e10" xlink:href="opk-20200630.xsd#opk_SalesReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa32c265-3cce-48b3-af59-6929b1a23337" xlink:to="loc_opk_SalesReturnsMember_be96cd66-2332-4f0a-8fba-69a5b9b90e10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8d5a9f81-196e-4322-ab39-7eee414f4037" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d21bc2d1-af83-4b92-b183-4aaad6973572" xlink:to="loc_srt_ProductOrServiceAxis_8d5a9f81-196e-4322-ab39-7eee414f4037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8d5a9f81-196e-4322-ab39-7eee414f4037_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8d5a9f81-196e-4322-ab39-7eee414f4037" xlink:to="loc_srt_ProductsAndServicesDomain_8d5a9f81-196e-4322-ab39-7eee414f4037_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b15b185-8cf1-49e5-b174-e26b626f84c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8d5a9f81-196e-4322-ab39-7eee414f4037" xlink:to="loc_srt_ProductsAndServicesDomain_2b15b185-8cf1-49e5-b174-e26b626f84c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RayaldeeMember_7f476d21-e321-447c-9b58-382f53a369f7" xlink:href="opk-20200630.xsd#opk_RayaldeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b15b185-8cf1-49e5-b174-e26b626f84c0" xlink:to="loc_opk_RayaldeeMember_7f476d21-e321-447c-9b58-382f53a369f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/StrategicAlliances" xlink:type="simple" xlink:href="opk-20200630.xsd#StrategicAlliances"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/StrategicAlliances" xlink:type="extended" id="i50125ce3f1844c7597a66dc610dbb8f0_StrategicAlliances"/>
  <link:roleRef roleURI="http://www.opko.com/role/StrategicAlliancesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#StrategicAlliancesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/StrategicAlliancesDetails" xlink:type="extended" id="i65bc1e729cdc4ee99c71ff80f29b30f6_StrategicAlliancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_ad3edd5a-7d02-4b37-aa53-53ec1474dbe5" xlink:href="opk-20200630.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_ad3edd5a-7d02-4b37-aa53-53ec1474dbe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_90abf4c6-02df-482a-bd74-896d3536846f" xlink:href="opk-20200630.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_90abf4c6-02df-482a-bd74-896d3536846f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b66cd5d4-194d-4253-b897-3c80f24048d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b66cd5d4-194d-4253-b897-3c80f24048d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMaximumMilestonePayments_44db65db-78c8-4dad-8f93-aa9a7a907575" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementMaximumMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementMaximumMilestonePayments_44db65db-78c8-4dad-8f93-aa9a7a907575" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_55df449a-2378-4115-82c8-441d9dc7ef41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_55df449a-2378-4115-82c8-441d9dc7ef41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeAgreementAdditionalMilestonePayment_1f6b3f87-396e-41c3-847f-89d9369a585a" xlink:href="opk-20200630.xsd#opk_CollaborativeAgreementAdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeAgreementAdditionalMilestonePayment_1f6b3f87-396e-41c3-847f-89d9369a585a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangement.MaximumMilestonePayments_09eef97e-b924-4e18-9707-a521195cb393" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangement.MaximumMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangement.MaximumMilestonePayments_09eef97e-b924-4e18-9707-a521195cb393" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_b0edf185-d9ec-49af-a3a8-c7c57f29e3bf" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_b0edf185-d9ec-49af-a3a8-c7c57f29e3bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementUpfrontPayment_890babfe-c07b-4164-8d28-d98a02b59492" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementUpfrontPayment_890babfe-c07b-4164-8d28-d98a02b59492" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMilestonePayment_08a30f31-fe8c-41f7-8a1f-9c5904da1551" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementMilestonePayment_08a30f31-fe8c-41f7-8a1f-9c5904da1551" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment_46a292f9-d468-44bf-9341-95bc949f80cf" xlink:href="opk-20200630.xsd#opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment_46a292f9-d468-44bf-9341-95bc949f80cf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMilestonePaymentReceived_805b2e9d-569f-4f13-a562-a017099a44ef" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementMilestonePaymentReceived_805b2e9d-569f-4f13-a562-a017099a44ef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeAgreementPeriodfromFirstCommercialSale_00442b3e-61c0-41a8-910a-8abded34b081" xlink:href="opk-20200630.xsd#opk_CollaborativeAgreementPeriodfromFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeAgreementPeriodfromFirstCommercialSale_00442b3e-61c0-41a8-910a-8abded34b081" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold_d69f76f7-4e56-4aa1-befe-cc0f003cdc29" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold_d69f76f7-4e56-4aa1-befe-cc0f003cdc29" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_07cde8fa-adff-46e1-854b-be28b4d1083d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_07cde8fa-adff-46e1-854b-be28b4d1083d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived_25b95d26-0142-4c17-b283-3f7226205171" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived_25b95d26-0142-4c17-b283-3f7226205171" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d8d2538-a24a-4af0-b1fa-10c5df0e97d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_srt_ProductOrServiceAxis_4d8d2538-a24a-4af0-b1fa-10c5df0e97d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d8d2538-a24a-4af0-b1fa-10c5df0e97d2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4d8d2538-a24a-4af0-b1fa-10c5df0e97d2" xlink:to="loc_srt_ProductsAndServicesDomain_4d8d2538-a24a-4af0-b1fa-10c5df0e97d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_759dcc88-61c1-496d-a5bf-c23ee8c6165e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4d8d2538-a24a-4af0-b1fa-10c5df0e97d2" xlink:to="loc_srt_ProductsAndServicesDomain_759dcc88-61c1-496d-a5bf-c23ee8c6165e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryMilestonesMember_cdcf4aa2-106a-4038-997a-fef61e9088c5" xlink:href="opk-20200630.xsd#opk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_759dcc88-61c1-496d-a5bf-c23ee8c6165e" xlink:to="loc_opk_RegulatoryMilestonesMember_cdcf4aa2-106a-4038-997a-fef61e9088c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesMilestonesMember_f41810b5-7a87-4b3b-b647-e8017ebcf8a4" xlink:href="opk-20200630.xsd#opk_SalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_759dcc88-61c1-496d-a5bf-c23ee8c6165e" xlink:to="loc_opk_SalesMilestonesMember_f41810b5-7a87-4b3b-b647-e8017ebcf8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneAxis_ad970937-cc7e-4e26-b97f-134e6a68341a" xlink:href="opk-20200630.xsd#opk_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_opk_MilestoneAxis_ad970937-cc7e-4e26-b97f-134e6a68341a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneDomain_ad970937-cc7e-4e26-b97f-134e6a68341a_default" xlink:href="opk-20200630.xsd#opk_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_opk_MilestoneAxis_ad970937-cc7e-4e26-b97f-134e6a68341a" xlink:to="loc_opk_MilestoneDomain_ad970937-cc7e-4e26-b97f-134e6a68341a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneDomain_98c65a37-d9cb-4805-b8d5-0c1b05dee16f" xlink:href="opk-20200630.xsd#opk_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_opk_MilestoneAxis_ad970937-cc7e-4e26-b97f-134e6a68341a" xlink:to="loc_opk_MilestoneDomain_98c65a37-d9cb-4805-b8d5-0c1b05dee16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhaseTwoInitiationMember_1c7d97cc-c15f-470a-8800-86f1aa0264fe" xlink:href="opk-20200630.xsd#opk_PhaseTwoInitiationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_MilestoneDomain_98c65a37-d9cb-4805-b8d5-0c1b05dee16f" xlink:to="loc_opk_PhaseTwoInitiationMember_1c7d97cc-c15f-470a-8800-86f1aa0264fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryAndDevelopmentMember_98abeac8-8883-4fe3-b6cc-653f2ea52874" xlink:href="opk-20200630.xsd#opk_RegulatoryAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_MilestoneDomain_98c65a37-d9cb-4805-b8d5-0c1b05dee16f" xlink:to="loc_opk_RegulatoryAndDevelopmentMember_98abeac8-8883-4fe3-b6cc-653f2ea52874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesRevenueMember_1be9688d-d56b-4817-b751-10c7ff6a8db3" xlink:href="opk-20200630.xsd#opk_SalesRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_MilestoneDomain_98c65a37-d9cb-4805-b8d5-0c1b05dee16f" xlink:to="loc_opk_SalesRevenueMember_1be9688d-d56b-4817-b751-10c7ff6a8db3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fa433b8-954f-4ac4-82fb-79a6e830d3cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fa433b8-954f-4ac4-82fb-79a6e830d3cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7fa433b8-954f-4ac4-82fb-79a6e830d3cc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fa433b8-954f-4ac4-82fb-79a6e830d3cc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7fa433b8-954f-4ac4-82fb-79a6e830d3cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b9e764ff-b23e-45b2-9e72-a32468b6be2f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fa433b8-954f-4ac4-82fb-79a6e830d3cc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b9e764ff-b23e-45b2-9e72-a32468b6be2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember_00104da2-8ed1-4a7e-a71e-815e82cbfe84" xlink:href="opk-20200630.xsd#opk_PharmsynthezMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9e764ff-b23e-45b2-9e72-a32468b6be2f" xlink:to="loc_opk_PharmsynthezMember_00104da2-8ed1-4a7e-a71e-815e82cbfe84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhioPharmaceuticalsMember_15bf02e6-15b2-4ce1-bd05-daa594fbd17c" xlink:href="opk-20200630.xsd#opk_PhioPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9e764ff-b23e-45b2-9e72-a32468b6be2f" xlink:to="loc_opk_PhioPharmaceuticalsMember_15bf02e6-15b2-4ce1-bd05-daa594fbd17c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fe5a9a7f-9739-442d-bdfa-d089e3cf1c10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_srt_RangeAxis_fe5a9a7f-9739-442d-bdfa-d089e3cf1c10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe5a9a7f-9739-442d-bdfa-d089e3cf1c10_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fe5a9a7f-9739-442d-bdfa-d089e3cf1c10" xlink:to="loc_srt_RangeMember_fe5a9a7f-9739-442d-bdfa-d089e3cf1c10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7813c88c-165a-40ad-a587-46c71af806f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fe5a9a7f-9739-442d-bdfa-d089e3cf1c10" xlink:to="loc_srt_RangeMember_7813c88c-165a-40ad-a587-46c71af806f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff4ee2d4-f306-4b97-9325-81889fb0f11c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7813c88c-165a-40ad-a587-46c71af806f1" xlink:to="loc_srt_MinimumMember_ff4ee2d4-f306-4b97-9325-81889fb0f11c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_46e88c5e-a5f1-442e-b7ce-8f78d9ead7ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7813c88c-165a-40ad-a587-46c71af806f1" xlink:to="loc_srt_MaximumMember_46e88c5e-a5f1-442e-b7ce-8f78d9ead7ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_161c6c32-4195-4cba-a4ba-8d0b6124fa78" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_srt_CounterpartyNameAxis_161c6c32-4195-4cba-a4ba-8d0b6124fa78" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_161c6c32-4195-4cba-a4ba-8d0b6124fa78_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_161c6c32-4195-4cba-a4ba-8d0b6124fa78" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_161c6c32-4195-4cba-a4ba-8d0b6124fa78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_161c6c32-4195-4cba-a4ba-8d0b6124fa78" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_faa07aae-9baa-4070-96a0-b9b72544048c" xlink:href="opk-20200630.xsd#opk_ViforFreseniusMedicalCarePharmaLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:to="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_faa07aae-9baa-4070-96a0-b9b72544048c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EirGenPharmaLimitedMember_d2dc4e4a-a4bb-4583-9694-89a613b1614b" xlink:href="opk-20200630.xsd#opk_EirGenPharmaLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:to="loc_opk_EirGenPharmaLimitedMember_d2dc4e4a-a4bb-4583-9694-89a613b1614b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember_0778a6e1-b7b8-4760-8770-4ad71688ab85" xlink:href="opk-20200630.xsd#opk_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:to="loc_opk_PfizerMember_0778a6e1-b7b8-4760-8770-4ad71688ab85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TesaroMember_43a38393-7793-43c6-9111-7875e9dd12ca" xlink:href="opk-20200630.xsd#opk_TesaroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:to="loc_opk_TesaroMember_43a38393-7793-43c6-9111-7875e9dd12ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cb1a1b2c-9623-4759-a447-c4ea1124727b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cb1a1b2c-9623-4759-a447-c4ea1124727b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1a1b2c-9623-4759-a447-c4ea1124727b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cb1a1b2c-9623-4759-a447-c4ea1124727b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1a1b2c-9623-4759-a447-c4ea1124727b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cb1a1b2c-9623-4759-a447-c4ea1124727b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DevelopmentandLicenseAgreementMember_dc25cba8-93cc-42ab-af05-1bc90e4086b8" xlink:href="opk-20200630.xsd#opk_DevelopmentandLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:to="loc_opk_DevelopmentandLicenseAgreementMember_dc25cba8-93cc-42ab-af05-1bc90e4086b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryMilestonesMember_51bbd392-6270-4c79-8f43-6632691891b9" xlink:href="opk-20200630.xsd#opk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:to="loc_opk_RegulatoryMilestonesMember_51bbd392-6270-4c79-8f43-6632691891b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ExclusiveOptionMember_39f351f8-7982-4462-bc53-1c8a2e1cefd4" xlink:href="opk-20200630.xsd#opk_ExclusiveOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:to="loc_opk_ExclusiveOptionMember_39f351f8-7982-4462-bc53-1c8a2e1cefd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a232c504-4cd7-42a1-978a-84597daa85ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:to="loc_us-gaap_ProductMember_a232c504-4cd7-42a1-978a-84597daa85ae" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/Segments" xlink:type="simple" xlink:href="opk-20200630.xsd#Segments"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/Segments" xlink:type="extended" id="iadcedb7e4c9e42058d1757a7cb02f58d_Segments"/>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#SegmentsTables"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SegmentsTables" xlink:type="extended" id="ife770076eacc4e36bb17e4aedf43205a_SegmentsTables"/>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SegmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SegmentsNarrativeDetails" xlink:type="extended" id="ib4f3a849192e45d4874ecdb9bd99ed23_SegmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d0dc4109-7e8e-4417-b674-9f7d40390c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_a204b35e-32de-4e8d-965a-fe73fdae93a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d0dc4109-7e8e-4417-b674-9f7d40390c76" xlink:to="loc_us-gaap_NumberOfReportableSegments_a204b35e-32de-4e8d-965a-fe73fdae93a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0b4cc35e-b477-47b5-ada1-da42cd151278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d0dc4109-7e8e-4417-b674-9f7d40390c76" xlink:to="loc_us-gaap_Revenues_0b4cc35e-b477-47b5-ada1-da42cd151278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a7565853-ddd4-4268-8c00-c29e8f61082f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d0dc4109-7e8e-4417-b674-9f7d40390c76" xlink:to="loc_us-gaap_InterestExpense_a7565853-ddd4-4268-8c00-c29e8f61082f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aec87e04-de7f-4e5d-b507-a4ef3866ef84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d0dc4109-7e8e-4417-b674-9f7d40390c76" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aec87e04-de7f-4e5d-b507-a4ef3866ef84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_761fa174-d2d4-4461-a211-d361dac6c23b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aec87e04-de7f-4e5d-b507-a4ef3866ef84" xlink:to="loc_srt_ConsolidationItemsAxis_761fa174-d2d4-4461-a211-d361dac6c23b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_761fa174-d2d4-4461-a211-d361dac6c23b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_761fa174-d2d4-4461-a211-d361dac6c23b" xlink:to="loc_srt_ConsolidationItemsDomain_761fa174-d2d4-4461-a211-d361dac6c23b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_306c5ac9-8997-44fa-b4f8-73dda8716125" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_761fa174-d2d4-4461-a211-d361dac6c23b" xlink:to="loc_srt_ConsolidationItemsDomain_306c5ac9-8997-44fa-b4f8-73dda8716125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_4b85c3c9-6507-470e-80a3-6ba4fa9d3ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_306c5ac9-8997-44fa-b4f8-73dda8716125" xlink:to="loc_us-gaap_IntersegmentEliminationMember_4b85c3c9-6507-470e-80a3-6ba4fa9d3ef2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SegmentsOperationsandAssetsInformationDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails" xlink:type="extended" id="ia165cfc317b94cc190cc1a0b67a2c74b_SegmentsOperationsandAssetsInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f49eeda2-6d91-4c1c-8ae3-c03ada670c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f49eeda2-6d91-4c1c-8ae3-c03ada670c47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_06578a75-3dee-44d9-ac3f-63e60dc5d3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_OperatingIncomeLoss_06578a75-3dee-44d9-ac3f-63e60dc5d3cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_80011476-40e2-4a40-9856-ae31c22b689a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_80011476-40e2-4a40-9856-ae31c22b689a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_c864e754-8779-4de0-a661-89fa8270618e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_GainLossOnInvestments_c864e754-8779-4de0-a661-89fa8270618e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0e561a77-2720-4865-8375-b2cdb358f8c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_Assets_0e561a77-2720-4865-8375-b2cdb358f8c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_211e2f1a-bc66-48bc-86c5-64754d5cddee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_Goodwill_211e2f1a-bc66-48bc-86c5-64754d5cddee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_06477713-0d9a-4c38-9176-ec7c17a948eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:to="loc_srt_ProductOrServiceAxis_06477713-0d9a-4c38-9176-ec7c17a948eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06477713-0d9a-4c38-9176-ec7c17a948eb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_06477713-0d9a-4c38-9176-ec7c17a948eb" xlink:to="loc_srt_ProductsAndServicesDomain_06477713-0d9a-4c38-9176-ec7c17a948eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5d17559-62ed-4d62-b8ec-032f58683383" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_06477713-0d9a-4c38-9176-ec7c17a948eb" xlink:to="loc_srt_ProductsAndServicesDomain_a5d17559-62ed-4d62-b8ec-032f58683383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_54811510-68dd-4d55-be84-9cbdbac705ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5d17559-62ed-4d62-b8ec-032f58683383" xlink:to="loc_us-gaap_ServiceMember_54811510-68dd-4d55-be84-9cbdbac705ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_197c5ae6-ea33-4a70-ae6e-657ad6a7154b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5d17559-62ed-4d62-b8ec-032f58683383" xlink:to="loc_us-gaap_ProductMember_197c5ae6-ea33-4a70-ae6e-657ad6a7154b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_441d85a4-c519-4e8a-a39a-1ce3b1b6d498" xlink:href="opk-20200630.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5d17559-62ed-4d62-b8ec-032f58683383" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_441d85a4-c519-4e8a-a39a-1ce3b1b6d498" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4948aa6c-f77a-400b-b00f-16f6f95b348c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4948aa6c-f77a-400b-b00f-16f6f95b348c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4948aa6c-f77a-400b-b00f-16f6f95b348c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4948aa6c-f77a-400b-b00f-16f6f95b348c" xlink:to="loc_us-gaap_SegmentDomain_4948aa6c-f77a-400b-b00f-16f6f95b348c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5a80b4be-3d58-4423-b0fd-508c486f40f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4948aa6c-f77a-400b-b00f-16f6f95b348c" xlink:to="loc_us-gaap_SegmentDomain_5a80b4be-3d58-4423-b0fd-508c486f40f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmaceuticalMember_79c019fd-eeba-48da-955f-97d9a1d47d70" xlink:href="opk-20200630.xsd#opk_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5a80b4be-3d58-4423-b0fd-508c486f40f5" xlink:to="loc_opk_PharmaceuticalMember_79c019fd-eeba-48da-955f-97d9a1d47d70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember_cd4dfa83-a14b-440b-afc5-d85d12c1d056" xlink:href="opk-20200630.xsd#opk_DiagnosticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5a80b4be-3d58-4423-b0fd-508c486f40f5" xlink:to="loc_opk_DiagnosticsMember_cd4dfa83-a14b-440b-afc5-d85d12c1d056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_571bc078-b5b0-4509-970a-8004e4019294" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:to="loc_srt_ConsolidationItemsAxis_571bc078-b5b0-4509-970a-8004e4019294" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_571bc078-b5b0-4509-970a-8004e4019294_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_571bc078-b5b0-4509-970a-8004e4019294" xlink:to="loc_srt_ConsolidationItemsDomain_571bc078-b5b0-4509-970a-8004e4019294_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9b768047-49a0-4296-8503-f12e7487cff3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_571bc078-b5b0-4509-970a-8004e4019294" xlink:to="loc_srt_ConsolidationItemsDomain_9b768047-49a0-4296-8503-f12e7487cff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_183a445e-586e-4e03-a0df-1e3bd90bec37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_9b768047-49a0-4296-8503-f12e7487cff3" xlink:to="loc_us-gaap_OperatingSegmentsMember_183a445e-586e-4e03-a0df-1e3bd90bec37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_dc050b70-86b4-4d73-b92f-ef7e7a3827b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_9b768047-49a0-4296-8503-f12e7487cff3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_dc050b70-86b4-4d73-b92f-ef7e7a3827b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8d0e3ed4-25d1-4c69-a32a-c9c74ffd0c98" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:to="loc_srt_StatementGeographicalAxis_8d0e3ed4-25d1-4c69-a32a-c9c74ffd0c98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8d0e3ed4-25d1-4c69-a32a-c9c74ffd0c98_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8d0e3ed4-25d1-4c69-a32a-c9c74ffd0c98" xlink:to="loc_srt_SegmentGeographicalDomain_8d0e3ed4-25d1-4c69-a32a-c9c74ffd0c98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8d0e3ed4-25d1-4c69-a32a-c9c74ffd0c98" xlink:to="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b83f0704-f11a-479f-a3dc-6df25d45fa3d" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_US_b83f0704-f11a-479f-a3dc-6df25d45fa3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_1c392acb-ff68-4849-9fd0-41984d072d8e" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_IE_1c392acb-ff68-4849-9fd0-41984d072d8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CL_22502600-1821-4d61-8413-0ba4b39735c1" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_CL_22502600-1821-4d61-8413-0ba4b39735c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_b8f05e4d-0944-4c0b-8b58-b695a2266e48" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_ES"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_ES_b8f05e4d-0944-4c0b-8b58-b695a2266e48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IL_3bc54086-5c77-4c51-8422-2e15c58e97fb" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_IL_3bc54086-5c77-4c51-8422-2e15c58e97fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_67d06557-5f64-494f-ada7-d1e1d2eb757f" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_MX_67d06557-5f64-494f-ada7-d1e1d2eb757f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OtherCountriesMember_5fdbaf91-2ba4-4e67-9e3c-d1e306186694" xlink:href="opk-20200630.xsd#opk_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_opk_OtherCountriesMember_5fdbaf91-2ba4-4e67-9e3c-d1e306186694" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/Leases" xlink:type="simple" xlink:href="opk-20200630.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/Leases" xlink:type="extended" id="i54bbb5fdddea446ead990601d176c934_Leases"/>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesTables" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/LeasesTables" xlink:type="extended" id="i621d009856994f98a9f8f533b67c2115_LeasesTables"/>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesLeaseAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="extended" id="i1be4bc9c3b574f46a3002be7e438a779_LeasesLeaseAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesLeaseLiabilityMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails" xlink:type="extended" id="i527a8d2cb35749adb1612336f814b596_LeasesLeaseLiabilityMaturityDetails"/>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i06f1232bec5d4321a49ca8bf2e9396aa_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesLeaseCashFlowInformationDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails" xlink:type="extended" id="ia1938440e3154e539983fa4660f1e492_LeasesLeaseCashFlowInformationDetails"/>
  <link:roleRef roleURI="http://www.opko.com/role/SubsequentEvents" xlink:type="simple" xlink:href="opk-20200630.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SubsequentEvents" xlink:type="extended" id="i9e0c31d8ab0a48b2b8da29d2f520a9fb_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.opko.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SubsequentEventsDetails" xlink:type="extended" id="i693c6ed8ab154464b88e143c534c0c0a_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ac0f3b4c-4503-40ca-9764-6e1dac52c0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a12a921c-539f-43b4-be0c-3c223d88939a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_ac0f3b4c-4503-40ca-9764-6e1dac52c0f6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a12a921c-539f-43b4-be0c-3c223d88939a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b90b4917-5c23-4b11-9730-3c9cae881f28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_ac0f3b4c-4503-40ca-9764-6e1dac52c0f6" xlink:to="loc_us-gaap_SubsequentEventTable_b90b4917-5c23-4b11-9730-3c9cae881f28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8e988bb-8975-4b91-a1f6-fac9b307a2aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b90b4917-5c23-4b11-9730-3c9cae881f28" xlink:to="loc_srt_ProductOrServiceAxis_b8e988bb-8975-4b91-a1f6-fac9b307a2aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b8e988bb-8975-4b91-a1f6-fac9b307a2aa_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b8e988bb-8975-4b91-a1f6-fac9b307a2aa" xlink:to="loc_srt_ProductsAndServicesDomain_b8e988bb-8975-4b91-a1f6-fac9b307a2aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31c9973a-7bb7-4aa5-a09f-b393efd5ba76" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b8e988bb-8975-4b91-a1f6-fac9b307a2aa" xlink:to="loc_srt_ProductsAndServicesDomain_31c9973a-7bb7-4aa5-a09f-b393efd5ba76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_eb2e25af-afb9-4c32-8888-882c1f86e678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_31c9973a-7bb7-4aa5-a09f-b393efd5ba76" xlink:to="loc_us-gaap_ServiceMember_eb2e25af-afb9-4c32-8888-882c1f86e678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_808a46d2-12e1-4e61-89e6-03b4ffc45a0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b90b4917-5c23-4b11-9730-3c9cae881f28" xlink:to="loc_srt_LitigationCaseAxis_808a46d2-12e1-4e61-89e6-03b4ffc45a0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_808a46d2-12e1-4e61-89e6-03b4ffc45a0a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_808a46d2-12e1-4e61-89e6-03b4ffc45a0a" xlink:to="loc_srt_LitigationCaseTypeDomain_808a46d2-12e1-4e61-89e6-03b4ffc45a0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4113b958-7ce8-4bd1-a3a0-1c8c9becefe7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_808a46d2-12e1-4e61-89e6-03b4ffc45a0a" xlink:to="loc_srt_LitigationCaseTypeDomain_4113b958-7ce8-4bd1-a3a0-1c8c9becefe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A4KscoreMember_ba6b607c-6768-4144-b71a-8a665ec8dd24" xlink:href="opk-20200630.xsd#opk_A4KscoreMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4113b958-7ce8-4bd1-a3a0-1c8c9becefe7" xlink:to="loc_opk_A4KscoreMember_ba6b607c-6768-4144-b71a-8a665ec8dd24" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>opk-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:58648600-8b9a-4bda-ba8d-a94f5b914ae0,g:b952a604-1bee-438c-aa3f-da7449f6ab9c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_6e8bf985-b9e1-4305-8bed-5c0263402b66_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of real estate property (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_aadfce9d-7d8d-4bb6-9900-bb1c15b2df04_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_55f54aed-e541-4424-b23e-ed454894fa2e_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lines of credit and notes payable</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquitySecurityFVNIOwnershipPercent_a1990ef7-3106-4ddc-b356-1121966ad183_terseLabel_en-US" xlink:label="lab_opk_EquitySecurityFVNIOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_opk_EquitySecurityFVNIOwnershipPercent_label_en-US" xlink:label="lab_opk_EquitySecurityFVNIOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Security, FV-NI, Ownership Percent</link:label>
    <link:label id="lab_opk_EquitySecurityFVNIOwnershipPercent_documentation_en-US" xlink:label="lab_opk_EquitySecurityFVNIOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Security, FV-NI, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquitySecurityFVNIOwnershipPercent" xlink:href="opk-20200630.xsd#opk_EquitySecurityFVNIOwnershipPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquitySecurityFVNIOwnershipPercent" xlink:to="lab_opk_EquitySecurityFVNIOwnershipPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6dd80f48-b452-4c09-b3d5-f1912525aaf7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NumberOfDerivativeLawsuits_c06d78d2-a565-4986-9166-fb8af368f696_terseLabel_en-US" xlink:label="lab_opk_NumberOfDerivativeLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of derivative lawsuits (at least)</link:label>
    <link:label id="lab_opk_NumberOfDerivativeLawsuits_label_en-US" xlink:label="lab_opk_NumberOfDerivativeLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Derivative Lawsuits</link:label>
    <link:label id="lab_opk_NumberOfDerivativeLawsuits_documentation_en-US" xlink:label="lab_opk_NumberOfDerivativeLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Derivative Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NumberOfDerivativeLawsuits" xlink:href="opk-20200630.xsd#opk_NumberOfDerivativeLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NumberOfDerivativeLawsuits" xlink:to="lab_opk_NumberOfDerivativeLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_72011a44-168d-4835-aa42-c6c8e28f4549_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14060d04-c8ae-41ff-ab45-706085273eb3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_a40aa856-7543-4dd4-bf3b-22a8b3544ef4_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_7aa9a42d-5862-49ce-aced-33f7779fd491_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_e12a3284-33b7-487a-8561-f71f4874eadd_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_3c72c608-6a5e-40c3-823f-62af3debc585_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swingline</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_f77322cb-cbf5-488e-b2a4-9c5ed9c60e33_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PharmaceuticalMember_5bf4f20a-ebd9-450b-a5e7-942451f50753_terseLabel_en-US" xlink:label="lab_opk_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_opk_PharmaceuticalMember_label_en-US" xlink:label="lab_opk_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_opk_PharmaceuticalMember_documentation_en-US" xlink:label="lab_opk_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmaceuticalMember" xlink:href="opk-20200630.xsd#opk_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PharmaceuticalMember" xlink:to="lab_opk_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_5abd0902-ec91-47ac-9107-33529834af89_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_494ae90d-c138-4c73-a0ed-f4f631c0e8e5_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CL_a0cfbf6f-60e7-4c1e-ab50-389882a13dbf_verboseLabel_en-US" xlink:label="lab_country_CL" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chile</link:label>
    <link:label id="lab_country_CL_label_en-US" xlink:label="lab_country_CL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHILE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CL" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CL" xlink:to="lab_country_CL" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RegulatoryAndDevelopmentMember_844a077b-fb18-4757-b98a-da03a6e88f14_terseLabel_en-US" xlink:label="lab_opk_RegulatoryAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and Development</link:label>
    <link:label id="lab_opk_RegulatoryAndDevelopmentMember_label_en-US" xlink:label="lab_opk_RegulatoryAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory And Development [Member]</link:label>
    <link:label id="lab_opk_RegulatoryAndDevelopmentMember_documentation_en-US" xlink:label="lab_opk_RegulatoryAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryAndDevelopmentMember" xlink:href="opk-20200630.xsd#opk_RegulatoryAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RegulatoryAndDevelopmentMember" xlink:to="lab_opk_RegulatoryAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d8ba1387-06a4-4c50-932a-09cf529e033c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Accumulated Other Comprehensive Loss, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_08bf1873-4909-4114-8bec-78233a7bad5e_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_84c89285-b75c-44e9-ac72-194627664607_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_31affdd6-68b0-4eb8-8bd1-46ee6a258c83_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for inventory obsolescence</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived_df27a6cd-9f47-4f9d-aa60-5048f16397df_terseLabel_en-US" xlink:label="lab_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received upon exercise of warrant (in shares)</link:label>
    <link:label id="lab_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived_label_en-US" xlink:label="lab_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Of Warrant, Number Of Securities Received</link:label>
    <link:label id="lab_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived_documentation_en-US" xlink:label="lab_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Of Warrant, Number Of Securities Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived" xlink:href="opk-20200630.xsd#opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived" xlink:to="lab_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_261611bc-64aa-49d9-a82f-22760b17fd0d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement paid to related party for travel</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_f783e4c4-ad5a-44fa-ac5a-bbf5d7127185_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SeriesAWarrantMember_ec0563bc-ab3b-4fa4-b5a5-b2c5d0ff8270_terseLabel_en-US" xlink:label="lab_opk_SeriesAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrant</link:label>
    <link:label id="lab_opk_SeriesAWarrantMember_label_en-US" xlink:label="lab_opk_SeriesAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrant [Member]</link:label>
    <link:label id="lab_opk_SeriesAWarrantMember_documentation_en-US" xlink:label="lab_opk_SeriesAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SeriesAWarrantMember" xlink:href="opk-20200630.xsd#opk_SeriesAWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SeriesAWarrantMember" xlink:to="lab_opk_SeriesAWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_13bf4939-ae99-445e-89ab-5b4d48ce70b2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_42eede0d-551d-424e-8bd3-206e78798015_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FederalTradeCommissionFilingFeesMember_f0cd57af-937d-4abd-8d27-23a17262b301_terseLabel_en-US" xlink:label="lab_opk_FederalTradeCommissionFilingFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Trade Commission Filing Fees</link:label>
    <link:label id="lab_opk_FederalTradeCommissionFilingFeesMember_label_en-US" xlink:label="lab_opk_FederalTradeCommissionFilingFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Trade Commission Filing Fees [Member]</link:label>
    <link:label id="lab_opk_FederalTradeCommissionFilingFeesMember_documentation_en-US" xlink:label="lab_opk_FederalTradeCommissionFilingFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Trade Commission Filing Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FederalTradeCommissionFilingFeesMember" xlink:href="opk-20200630.xsd#opk_FederalTradeCommissionFilingFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FederalTradeCommissionFilingFeesMember" xlink:to="lab_opk_FederalTradeCommissionFilingFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_46bbcc3a-34ea-4053-8880-d25a74d7f957_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ab4a87e-8fa2-41f9-8724-6dd1aec41a4f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_6dacba8a-a57e-4460-992f-b4699e5de56c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ChromaDexMember_accd1418-7810-4fd6-a554-2db28d83e789_terseLabel_en-US" xlink:label="lab_opk_ChromaDexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChromaDex</link:label>
    <link:label id="lab_opk_ChromaDexMember_label_en-US" xlink:label="lab_opk_ChromaDexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChromaDex [Member]</link:label>
    <link:label id="lab_opk_ChromaDexMember_documentation_en-US" xlink:label="lab_opk_ChromaDexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChromaDex.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromaDexMember" xlink:href="opk-20200630.xsd#opk_ChromaDexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ChromaDexMember" xlink:to="lab_opk_ChromaDexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember_0b032ed8-c50b-4c91-befb-380ef8be74c6_terseLabel_en-US" xlink:label="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VFMCRP</link:label>
    <link:label id="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember_label_en-US" xlink:label="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor Fresenius Medical Care Pharma Ltd [Member]</link:label>
    <link:label id="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember_documentation_en-US" xlink:label="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor Fresenius Medical Care Pharma Ltd [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:href="opk-20200630.xsd#opk_ViforFreseniusMedicalCarePharmaLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:to="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_98ae5a9e-60d6-4e99-86e4-a26bffa71eb5_terseLabel_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment from development and license agreement</link:label>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_label_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Development And License Agreement, Upfront Payment</link:label>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Development And License Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:href="opk-20200630.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:to="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_40eb11f1-e9c5-4136-9135-db3b6f5420a9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_d40e2ae1-959d-493c-8b83-715581ff395f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DERIVATIVE CONTRACTS</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_InventoryReceivedNotInvoicedCurrent_8c55a8c2-4ff3-4b74-9eb4-429a967e4cbc_terseLabel_en-US" xlink:label="lab_opk_InventoryReceivedNotInvoicedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory received but not invoiced</link:label>
    <link:label id="lab_opk_InventoryReceivedNotInvoicedCurrent_label_en-US" xlink:label="lab_opk_InventoryReceivedNotInvoicedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Received, Not Invoiced, Current</link:label>
    <link:label id="lab_opk_InventoryReceivedNotInvoicedCurrent_documentation_en-US" xlink:label="lab_opk_InventoryReceivedNotInvoicedCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Received, Not Invoiced, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InventoryReceivedNotInvoicedCurrent" xlink:href="opk-20200630.xsd#opk_InventoryReceivedNotInvoicedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_InventoryReceivedNotInvoicedCurrent" xlink:to="lab_opk_InventoryReceivedNotInvoicedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_b09a7124-2d1a-436c-bcb0-5144be4d15af_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_134bbb77-a54f-4d13-add5-64ec7d3fde4b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 convertible notes including share lending arrangement</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e58b3065-a97e-4d15-a9ab-e2f590c55d3f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability_c09115b6-bde7-4881-8b8f-41226a7ae506_terseLabel_en-US" xlink:label="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overpayment reimbursement liability</link:label>
    <link:label id="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability_label_en-US" xlink:label="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expense, Payor Overpayment Reimbursement, Liability</link:label>
    <link:label id="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability_documentation_en-US" xlink:label="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expense, Payor Overpayment Reimbursement, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:href="opk-20200630.xsd#opk_AccruedExpensePayorOverpaymentReimbursementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:to="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b31ea8ad-10a5-4418-ada1-f975ead25a6f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_XeneticBiosciencesInc.Member_e47b7698-3c8f-45a8-91e8-444c4fdc16b1_terseLabel_en-US" xlink:label="lab_opk_XeneticBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenetic Biosciences, Inc.</link:label>
    <link:label id="lab_opk_XeneticBiosciencesInc.Member_3c38c85c-6c45-4453-b818-58cd1987f12d_verboseLabel_en-US" xlink:label="lab_opk_XeneticBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenetic</link:label>
    <link:label id="lab_opk_XeneticBiosciencesInc.Member_label_en-US" xlink:label="lab_opk_XeneticBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenetic Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_opk_XeneticBiosciencesInc.Member_documentation_en-US" xlink:label="lab_opk_XeneticBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenetic Biosciences, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_XeneticBiosciencesInc.Member" xlink:href="opk-20200630.xsd#opk_XeneticBiosciencesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_XeneticBiosciencesInc.Member" xlink:to="lab_opk_XeneticBiosciencesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_0dd2a160-005d-4dea-a45c-9f7534ed4505_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of convertible notes, including to related parties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ce6cfea0-b7d6-4fe0-9a98-03f3d9db459f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6e405b4d-5693-4d42-aa7a-097845f5add0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ExclusiveOptionMember_162fb153-be03-4181-9828-358b8c5335e1_terseLabel_en-US" xlink:label="lab_opk_ExclusiveOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Option</link:label>
    <link:label id="lab_opk_ExclusiveOptionMember_label_en-US" xlink:label="lab_opk_ExclusiveOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Option [Member]</link:label>
    <link:label id="lab_opk_ExclusiveOptionMember_documentation_en-US" xlink:label="lab_opk_ExclusiveOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ExclusiveOptionMember" xlink:href="opk-20200630.xsd#opk_ExclusiveOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ExclusiveOptionMember" xlink:to="lab_opk_ExclusiveOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_8f77f880-7173-4ba6-b73c-6bbe92e4a082_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c799c29a-b332-467f-b872-0606ac9cec0f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b8cdd4da-bb86-4106-8a92-c553f72a4b5d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_943df09c-7f96-4cf8-a530-1e9d75cd87ec_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_70941be4-f6e5-4c85-a9be-a1445b95ddfd_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_ace30b0f-8ec2-4e91-bf64-d15c0dae702c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_362d3ac3-23b2-4190-8534-60c5c0ef90f6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_66f1a989-bb09-4194-a3ea-3025ae878eab_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SantanderBank2MemberMember_e94b5f92-432c-454b-9ad5-d986597da3a7_terseLabel_en-US" xlink:label="lab_opk_SantanderBank2MemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banco Santander</link:label>
    <link:label id="lab_opk_SantanderBank2MemberMember_label_en-US" xlink:label="lab_opk_SantanderBank2MemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Santander Bank2 [Member] [Member]</link:label>
    <link:label id="lab_opk_SantanderBank2MemberMember_documentation_en-US" xlink:label="lab_opk_SantanderBank2MemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Santander Bank2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBank2MemberMember" xlink:href="opk-20200630.xsd#opk_SantanderBank2MemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SantanderBank2MemberMember" xlink:to="lab_opk_SantanderBank2MemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_7ebdd4c5-083b-491f-9089-bdd1c2b0f9ca_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_961ff87c-33b3-4a76-8dfa-e261d3650710_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_ec750e2e-bf24-4ff1-995e-6af8d8bfa0d1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ab740f83-79bb-4c3a-956f-41aba8c0f122_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_df49c1cf-8805-40b6-a423-b8fd8ea59819_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_b5c3ae36-3f5a-4bff-b70d-02cb9a0023d4_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_2fedf802-2c8a-45a4-82cd-ad3dbdbd2b31_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_bb234f85-1a96-4800-9beb-82f278f452f6_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CocrystalMember_8b06835b-3e64-4f72-a936-e20c16984361_terseLabel_en-US" xlink:label="lab_opk_CocrystalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cocrystal</link:label>
    <link:label id="lab_opk_CocrystalMember_85a6fe1c-c6e6-4ebc-b2da-277984ebf4de_verboseLabel_en-US" xlink:label="lab_opk_CocrystalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COCP</link:label>
    <link:label id="lab_opk_CocrystalMember_label_en-US" xlink:label="lab_opk_CocrystalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cocrystal [Member]</link:label>
    <link:label id="lab_opk_CocrystalMember_documentation_en-US" xlink:label="lab_opk_CocrystalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cocrystal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CocrystalMember" xlink:href="opk-20200630.xsd#opk_CocrystalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CocrystalMember" xlink:to="lab_opk_CocrystalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fa7b74ba-f40c-4ce6-bcce-2b9395d2ee34_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_c7e53544-1714-48da-b08f-dfb57b11c436_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash out flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0fdd3cd2-2d1d-4e1a-af18-854ab2f0ad11_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_87eaa3ed-19ea-4841-b7b7-5bbcb2dde455_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_444ea08c-f317-46cd-9747-9824f62ca97a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_b60d95f4-7350-4d08-96b0-1f32a5cbbe5c_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_75871455-88a9-4664-84c7-cd2b2de51dbf_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NumberOfClassActionLawsuits_5bfa49f3-3f2b-4c66-a9aa-def85e1dd5c1_terseLabel_en-US" xlink:label="lab_opk_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of class action lawsuits (at least)</link:label>
    <link:label id="lab_opk_NumberOfClassActionLawsuits_label_en-US" xlink:label="lab_opk_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:label id="lab_opk_NumberOfClassActionLawsuits_documentation_en-US" xlink:label="lab_opk_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NumberOfClassActionLawsuits" xlink:href="opk-20200630.xsd#opk_NumberOfClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NumberOfClassActionLawsuits" xlink:to="lab_opk_NumberOfClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8f413463-d692-47dc-b828-5d87bb2f3eb8_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_61d7b942-6559-41d0-bdba-e646f6c81a06_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_68a20511-5f7d-4d3a-a913-674cc5b586c4_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_46ea5a86-e2ff-4377-b257-8168115bc32f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_44fdf7ae-7007-4cb0-b9a2-06c92da2f435_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ChangeInTestingVolumePercent_cac707e8-36fd-4be0-868a-d2f372e8d37c_terseLabel_en-US" xlink:label="lab_opk_ChangeInTestingVolumePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in testing volume (as a percent)</link:label>
    <link:label id="lab_opk_ChangeInTestingVolumePercent_label_en-US" xlink:label="lab_opk_ChangeInTestingVolumePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Testing Volume, Percent</link:label>
    <link:label id="lab_opk_ChangeInTestingVolumePercent_documentation_en-US" xlink:label="lab_opk_ChangeInTestingVolumePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Testing Volume, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChangeInTestingVolumePercent" xlink:href="opk-20200630.xsd#opk_ChangeInTestingVolumePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ChangeInTestingVolumePercent" xlink:to="lab_opk_ChangeInTestingVolumePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AccruedCommitmentsandContingenciesCurrent_158116e9-79d7-4dcb-8f0e-4be5b63307a5_terseLabel_en-US" xlink:label="lab_opk_AccruedCommitmentsandContingenciesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_opk_AccruedCommitmentsandContingenciesCurrent_label_en-US" xlink:label="lab_opk_AccruedCommitmentsandContingenciesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Commitments and Contingencies, Current</link:label>
    <link:label id="lab_opk_AccruedCommitmentsandContingenciesCurrent_documentation_en-US" xlink:label="lab_opk_AccruedCommitmentsandContingenciesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Commitments and Contingencies, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedCommitmentsandContingenciesCurrent" xlink:href="opk-20200630.xsd#opk_AccruedCommitmentsandContingenciesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AccruedCommitmentsandContingenciesCurrent" xlink:to="lab_opk_AccruedCommitmentsandContingenciesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold_ba40f89f-38fe-4c65-94c6-2cf0c66e461f_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written termination threshold</link:label>
    <link:label id="lab_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold_label_en-US" xlink:label="lab_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Termination, Written Notice Threshold</link:label>
    <link:label id="lab_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Termination, Written Notice Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold" xlink:to="lab_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_19b40905-8949-4de2-aa3e-0dde305fbaa8_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_8bd3f679-040c-475f-b7b6-6b703d9d9e81_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_56a7a662-80f1-4893-98fd-3ee70d818010_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_7119b3e5-7dd2-4a8b-b605-47edcdf7abbe_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_fc43286e-fb32-4b55-8de0-1702b56b9936_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f5d4dda1-f3b6-417f-97c0-7a2c3a9d2d93_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_54836760-09bb-4d5c-85ef-445b2c9e7f2f_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Beginning and Ending Balances of Level 3 Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d8949818-6507-476a-b0f6-07419fe32e9a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RayaldeeMember_41b26adb-d508-4086-b8fc-3f2e25f1c829_terseLabel_en-US" xlink:label="lab_opk_RayaldeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rayaldee</link:label>
    <link:label id="lab_opk_RayaldeeMember_label_en-US" xlink:label="lab_opk_RayaldeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rayaldee [Member]</link:label>
    <link:label id="lab_opk_RayaldeeMember_documentation_en-US" xlink:label="lab_opk_RayaldeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rayaldee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RayaldeeMember" xlink:href="opk-20200630.xsd#opk_RayaldeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RayaldeeMember" xlink:to="lab_opk_RayaldeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f8f0f318-c66f-4c94-9d13-fa71ce8d7310_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e17c191e-278d-4be3-ab09-d12615bd83f5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementMilestonePayment_03874834-956c-4ca2-bb62-08402628e3f7_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Each milestone payment</link:label>
    <link:label id="lab_opk_CollaborativeArrangementMilestonePayment_label_en-US" xlink:label="lab_opk_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:label id="lab_opk_CollaborativeArrangementMilestonePayment_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMilestonePayment" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementMilestonePayment" xlink:to="lab_opk_CollaborativeArrangementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_GovernmentalMember_b30e3cb3-44ac-4e58-8602-bbf3dea8d765_terseLabel_en-US" xlink:label="lab_opk_GovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Governmental</link:label>
    <link:label id="lab_opk_GovernmentalMember_label_en-US" xlink:label="lab_opk_GovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Governmental [Member]</link:label>
    <link:label id="lab_opk_GovernmentalMember_documentation_en-US" xlink:label="lab_opk_GovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Governmental [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentalMember" xlink:href="opk-20200630.xsd#opk_GovernmentalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_GovernmentalMember" xlink:to="lab_opk_GovernmentalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DiagnosticsMember_0b3e3478-0f2f-4463-a25c-2c03b1879dac_terseLabel_en-US" xlink:label="lab_opk_DiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostics</link:label>
    <link:label id="lab_opk_DiagnosticsMember_cfd8c783-168a-4728-94dc-f0b29a399b7d_verboseLabel_en-US" xlink:label="lab_opk_DiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostics</link:label>
    <link:label id="lab_opk_DiagnosticsMember_label_en-US" xlink:label="lab_opk_DiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostics [Member]</link:label>
    <link:label id="lab_opk_DiagnosticsMember_documentation_en-US" xlink:label="lab_opk_DiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember" xlink:href="opk-20200630.xsd#opk_DiagnosticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DiagnosticsMember" xlink:to="lab_opk_DiagnosticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_98317c28-5d1e-481f-a073-cb9e880b7821_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_18b261c3-0156-445e-a30f-fc41aebf2e95_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_5e71215d-f95a-4f1c-a181-cd82d2c6ab0f_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_8f943f86-733b-4cb9-84f0-d4b183e9048a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d1563c32-2858-48eb-af67-a014d8ade779_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_216d3fd2-2783-4b12-a148-84157850c02b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_95f99cd2-5ad0-4c27-b8f1-b9ca2c7c52b6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementMaximumMilestonePayments_3c674282-d0ac-4ddf-ba7e-8fdcdbdefa07_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payments</link:label>
    <link:label id="lab_opk_CollaborativeArrangementMaximumMilestonePayments_label_en-US" xlink:label="lab_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payments</link:label>
    <link:label id="lab_opk_CollaborativeArrangementMaximumMilestonePayments_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementMaximumMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:to="lab_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d42456cb-bd53-442c-a757-8ce0f7513554_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_dbb4e1d5-4b9b-4c8a-93fa-70456c13d6ff_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9cc0dac0-a63b-4f2a-bded-52268cbec9d8_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d6c02033-ee2c-4135-837d-ca444ddcd73c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementMilestonePaymentReceived_cef85efc-68d7-448f-a694-ed9da0c7ac0b_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received</link:label>
    <link:label id="lab_opk_CollaborativeArrangementMilestonePaymentReceived_label_en-US" xlink:label="lab_opk_CollaborativeArrangementMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment Received</link:label>
    <link:label id="lab_opk_CollaborativeArrangementMilestonePaymentReceived_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMilestonePaymentReceived" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementMilestonePaymentReceived" xlink:to="lab_opk_CollaborativeArrangementMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_31e8b417-d494-4157-a20f-66e36bbbe7f1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash out flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_64a40014-3970-45c9-97a1-f98d3bca2366_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CommonStockWarrantsNetExercised_5bf729bf-98d9-4177-b48e-f742f4dad625_verboseLabel_en-US" xlink:label="lab_opk_CommonStockWarrantsNetExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock options and warrants, surrendered in net exercise</link:label>
    <link:label id="lab_opk_CommonStockWarrantsNetExercised_label_en-US" xlink:label="lab_opk_CommonStockWarrantsNetExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Net Exercised</link:label>
    <link:label id="lab_opk_CommonStockWarrantsNetExercised_documentation_en-US" xlink:label="lab_opk_CommonStockWarrantsNetExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants net exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CommonStockWarrantsNetExercised" xlink:href="opk-20200630.xsd#opk_CommonStockWarrantsNetExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CommonStockWarrantsNetExercised" xlink:to="lab_opk_CommonStockWarrantsNetExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Supplies_9517d8b6-6a85-4905-a238-bafae51574c2_terseLabel_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_Supplies_label_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Supplies" xlink:to="lab_us-gaap_Supplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_e0d81510-e60c-4baa-81c6-0c48adeb60f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_93f0c47d-5b78-48b0-820d-1dc4692f2108_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d4167882-5542-40fa-87d0-4874d1c3e490_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NonInvasiveMonitoringSystemsInc.Member_afb5b081-b911-4294-831f-4f7a40df7074_terseLabel_en-US" xlink:label="lab_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Invasive Monitoring Systems, Inc.</link:label>
    <link:label id="lab_opk_NonInvasiveMonitoringSystemsInc.Member_label_en-US" xlink:label="lab_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Invasive Monitoring Systems, Inc. [Member]</link:label>
    <link:label id="lab_opk_NonInvasiveMonitoringSystemsInc.Member_documentation_en-US" xlink:label="lab_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Invasive Monitoring Systems, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:href="opk-20200630.xsd#opk_NonInvasiveMonitoringSystemsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:to="lab_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1983b19-8949-4b5b-ad69-656c220dba8c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_8760b90a-475c-4ca6-8184-55c0773cf252_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction amount</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2831359f-f783-40e8-9cff-445d77f7492a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_c44ea046-1e60-4410-a70c-4eb5a31d939f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_caca48c6-9cd3-469a-95e4-3021330df98b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_622ce0db-913f-4cbf-b0b6-970c649f7290_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_COVID19TestTypeAxis_a2393699-b379-45e8-82b8-ba8e53b6416d_terseLabel_en-US" xlink:label="lab_opk_COVID19TestTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Test Type [Axis]</link:label>
    <link:label id="lab_opk_COVID19TestTypeAxis_label_en-US" xlink:label="lab_opk_COVID19TestTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Test Type [Axis]</link:label>
    <link:label id="lab_opk_COVID19TestTypeAxis_documentation_en-US" xlink:label="lab_opk_COVID19TestTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Test Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestTypeAxis" xlink:href="opk-20200630.xsd#opk_COVID19TestTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_COVID19TestTypeAxis" xlink:to="lab_opk_COVID19TestTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_7fc3aaff-3c36-467e-aef0-537707a7ce10_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_e3d2a201-2eb3-487a-9ed8-f8e9bb43c546_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_40fe7f05-7e5d-4c81-98e7-ef2cd4551eb3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_759077c4-0c25-4925-a82a-c541f2b01976_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_8dc3ed7f-6a3a-40f2-8894-07bb1f993be5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_COVID19PercentOfTotalTestVolume_77c90ab3-8ef5-4fa5-a3d7-f731f9118af3_terseLabel_en-US" xlink:label="lab_opk_COVID19PercentOfTotalTestVolume" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total test volume (as a percent)</link:label>
    <link:label id="lab_opk_COVID19PercentOfTotalTestVolume_label_en-US" xlink:label="lab_opk_COVID19PercentOfTotalTestVolume" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Percent of Total Test Volume</link:label>
    <link:label id="lab_opk_COVID19PercentOfTotalTestVolume_documentation_en-US" xlink:label="lab_opk_COVID19PercentOfTotalTestVolume" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Percent of Total Test Volume</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19PercentOfTotalTestVolume" xlink:href="opk-20200630.xsd#opk_COVID19PercentOfTotalTestVolume"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_COVID19PercentOfTotalTestVolume" xlink:to="lab_opk_COVID19PercentOfTotalTestVolume" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0843d2e3-54d2-4aa6-ac4c-97e33601f62a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e0c03a53-b82c-47e0-b94a-62c6c859d58b_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_40c1c9c1-79fc-4281-a3b1-55f676a07083_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ClientPayersMember_cd6dd2ca-7280-4550-b6cb-9300f43421af_terseLabel_en-US" xlink:label="lab_opk_ClientPayersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client payers</link:label>
    <link:label id="lab_opk_ClientPayersMember_label_en-US" xlink:label="lab_opk_ClientPayersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Payers [Member]</link:label>
    <link:label id="lab_opk_ClientPayersMember_documentation_en-US" xlink:label="lab_opk_ClientPayersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Payers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClientPayersMember" xlink:href="opk-20200630.xsd#opk_ClientPayersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ClientPayersMember" xlink:to="lab_opk_ClientPayersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_75352845-1807-498f-b10f-a265bbc29431_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SeriesCWarrantMember_51c581fd-f294-4f97-ac38-6e16c203826c_terseLabel_en-US" xlink:label="lab_opk_SeriesCWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Warrant</link:label>
    <link:label id="lab_opk_SeriesCWarrantMember_label_en-US" xlink:label="lab_opk_SeriesCWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Warrant [Member]</link:label>
    <link:label id="lab_opk_SeriesCWarrantMember_documentation_en-US" xlink:label="lab_opk_SeriesCWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SeriesCWarrantMember" xlink:href="opk-20200630.xsd#opk_SeriesCWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SeriesCWarrantMember" xlink:to="lab_opk_SeriesCWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_d9076d56-9579-4895-b19b-2751a157ed8d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_12c01c1e-b31f-4019-a3ce-fe5d00e58212_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b87b8ace-8308-49be-90fb-a1e6aaad7d0b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141bbfad-e218-4a9c-afec-3ac62f398e4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_4fc67132-cb7e-4507-9997-6aefea17e28f_terseLabel_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum conversion notice</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_label_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Notice Threshold, Minimum</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_documentation_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Notice Threshold, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:to="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_84fbbf2f-e5e0-4996-8979-cec433be7a82_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fbccd562-80aa-4d4d-bd4c-e1423eafcdb7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_730562eb-f0f2-4932-b2d1-a7baedf2fced_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNetAbstract_1202e5d8-c8a6-4655-8f0d-921c1ac7eeb8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract" xlink:to="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_b78df591-6758-4703-8d31-28eda94af457_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_94c014d7-e599-44fe-b6d7-91a5e1f7fd53_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IL_34bc4840-018a-4454-856b-c3c9ff60b86e_verboseLabel_en-US" xlink:label="lab_country_IL" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israel</link:label>
    <link:label id="lab_country_IL_label_en-US" xlink:label="lab_country_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ISRAEL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IL" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL" xlink:to="lab_country_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PfizerMember_4747369c-c0bd-481a-a29f-09cddda69baa_terseLabel_en-US" xlink:label="lab_opk_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_opk_PfizerMember_label_en-US" xlink:label="lab_opk_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_opk_PfizerMember_documentation_en-US" xlink:label="lab_opk_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember" xlink:href="opk-20200630.xsd#opk_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PfizerMember" xlink:to="lab_opk_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentsNumberofFinancialInstitutions_bfea7732-20ed-4dbe-af89-316844be9a9c_verboseLabel_en-US" xlink:label="lab_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financial institutions</link:label>
    <link:label id="lab_opk_DebtInstrumentsNumberofFinancialInstitutions_label_en-US" xlink:label="lab_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments, Number of Financial Institutions</link:label>
    <link:label id="lab_opk_DebtInstrumentsNumberofFinancialInstitutions_documentation_en-US" xlink:label="lab_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financial institutions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:href="opk-20200630.xsd#opk_DebtInstrumentsNumberofFinancialInstitutions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:to="lab_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_652c3262-4861-4e0b-819e-209a97b92a03_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3c6876e8-746f-48b8-89e3-19dc3c212185_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e2f30bd5-ae38-45ea-98ee-f4fcf4a656ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_853f94a3-9cc3-4516-b22b-0c74f388cb88_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ProceedsFromConvertibleDebtConversionFee_012495e2-df74-4c41-b45e-ce2323575758_terseLabel_en-US" xlink:label="lab_opk_ProceedsFromConvertibleDebtConversionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds one-time nominal fee</link:label>
    <link:label id="lab_opk_ProceedsFromConvertibleDebtConversionFee_label_en-US" xlink:label="lab_opk_ProceedsFromConvertibleDebtConversionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Convertible Debt, Conversion Fee</link:label>
    <link:label id="lab_opk_ProceedsFromConvertibleDebtConversionFee_documentation_en-US" xlink:label="lab_opk_ProceedsFromConvertibleDebtConversionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Convertible Debt, Conversion Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromConvertibleDebtConversionFee" xlink:href="opk-20200630.xsd#opk_ProceedsFromConvertibleDebtConversionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ProceedsFromConvertibleDebtConversionFee" xlink:to="lab_opk_ProceedsFromConvertibleDebtConversionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4ef6081d-318f-4209-a01e-43c1bb5cd162_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4dbe7f8d-7e9d-4482-84cd-6a52b09d7ec6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_934cd65c-fc1d-45cb-8d70-b4ba17c5bcd0_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_d59869c3-42a0-4667-8eee-af62276384e3_terseLabel_en-US" xlink:label="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due after Year Four</link:label>
    <link:label id="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="opk-20200630.xsd#opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1ecdc469-4b2b-4bd8-b689-c1ed1cf35eee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption period one</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_93fec3e5-1c1b-4692-803b-7ba1fbdab889_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_JPMorganChaseMember_9b4ac247-d923-4ca9-8c45-bc9380f3e81d_terseLabel_en-US" xlink:label="lab_opk_JPMorganChaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JPMorgan Chase</link:label>
    <link:label id="lab_opk_JPMorganChaseMember_label_en-US" xlink:label="lab_opk_JPMorganChaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JP Morgan Chase [Member]</link:label>
    <link:label id="lab_opk_JPMorganChaseMember_documentation_en-US" xlink:label="lab_opk_JPMorganChaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JP Morgan Chase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_JPMorganChaseMember" xlink:href="opk-20200630.xsd#opk_JPMorganChaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_JPMorganChaseMember" xlink:to="lab_opk_JPMorganChaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ea403139-f22e-4117-bdd9-661af7881340_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fff71332-ed86-4268-bd9b-0e621e1a6c14_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_03c45146-9122-45fb-bb74-f0f0333f9978_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_dbd27ec5-5295-4283-a00c-4869015d3674_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_c10924c6-8432-4ae3-9b69-bc0f6848e04f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_79b9cd75-551b-4cae-a7f1-0787d17ea84d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_db422887-136a-496d-af6a-b0320fbf8039_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_82843c6c-6089-467f-8801-240d5479de32_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_380bef18-b465-4244-b7de-4795d4bcf12f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_9fa5bc89-18be-4c30-8016-d9391baa9a8c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160;Balance Outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1f56e57b-6191-40fd-bd1d-a835b6562717_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PhaseTwoInitiationMember_482665e9-c8fa-4382-a2e6-adf5f1b4e1e7_terseLabel_en-US" xlink:label="lab_opk_PhaseTwoInitiationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Two Initiation</link:label>
    <link:label id="lab_opk_PhaseTwoInitiationMember_label_en-US" xlink:label="lab_opk_PhaseTwoInitiationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Two Initiation [Member]</link:label>
    <link:label id="lab_opk_PhaseTwoInitiationMember_documentation_en-US" xlink:label="lab_opk_PhaseTwoInitiationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Two Initiation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhaseTwoInitiationMember" xlink:href="opk-20200630.xsd#opk_PhaseTwoInitiationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PhaseTwoInitiationMember" xlink:to="lab_opk_PhaseTwoInitiationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_51a57579-4baa-471d-81be-e085085e4268_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_ES_182481ab-01c8-4ec6-9f10-40e12de1960f_verboseLabel_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spain</link:label>
    <link:label id="lab_country_ES_label_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_ES"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_A4KscoreMember_0e54ca1e-eb78-41f6-8289-4e30c21b773a_terseLabel_en-US" xlink:label="lab_opk_A4KscoreMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4Kscore</link:label>
    <link:label id="lab_opk_A4KscoreMember_label_en-US" xlink:label="lab_opk_A4KscoreMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4Kscore [Member]</link:label>
    <link:label id="lab_opk_A4KscoreMember_documentation_en-US" xlink:label="lab_opk_A4KscoreMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4Kscore</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A4KscoreMember" xlink:href="opk-20200630.xsd#opk_A4KscoreMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_A4KscoreMember" xlink:to="lab_opk_A4KscoreMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_55e38852-b6b8-42e4-9b06-04eb6f54094f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_c590ca63-14f2-463c-bd93-ab2e33cfaa5d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_7efa60eb-22b0-487a-b39d-4bec259491ef_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_7ed4ee64-8afd-4cca-8cbd-55f67a0756be_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_332b225b-e70b-4fca-82c9-ec89d6723486_verboseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CovenantsNotToCompeteMember_c0f06a68-4a4d-4546-85bc-588e48f1d307_terseLabel_en-US" xlink:label="lab_opk_CovenantsNotToCompeteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants not to compete</link:label>
    <link:label id="lab_opk_CovenantsNotToCompeteMember_label_en-US" xlink:label="lab_opk_CovenantsNotToCompeteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants Not to Compete [Member]</link:label>
    <link:label id="lab_opk_CovenantsNotToCompeteMember_documentation_en-US" xlink:label="lab_opk_CovenantsNotToCompeteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants not to compete.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CovenantsNotToCompeteMember" xlink:href="opk-20200630.xsd#opk_CovenantsNotToCompeteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CovenantsNotToCompeteMember" xlink:to="lab_opk_CovenantsNotToCompeteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_e8d9707d-a612-4f0e-a9a0-05227164abd6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses:</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_6a60d519-7cbb-4c29-a3d8-0f14c52c0b93_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Risk [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_7b2a5672-0fcc-42bd-99e9-24f7b6b7ed42_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e4b866a6-a5a7-4bad-ae4a-11193b55d705_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bc036c32-0a4c-4745-bdb0-3b964e4d9b7c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_da0b135f-e1a7-4aeb-a13f-55e261d28200_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative gain (loss)</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_7682d610-f74f-4149-bd66-ceccf7868f7d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_fc87ed25-54cf-4f93-aaca-d82db95de7fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption period three</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_2140ec23-db39-4cf7-a089-820d057fb66a_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_37f73847-5ad7-4b01-b54a-17c4a2706600_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_30eaa637-1d68-4923-9366-6b82335701ff_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_db7b46f2-1459-46c6-943e-411b99880e8f_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_33d316b8-16bd-4557-bf0f-7f874db71a8d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_cd5e3558-64d5-4d3c-aa83-d91255fdbb3f_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest rates</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_3c4d66a4-f92c-4114-98fc-699cda27a668_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_18895d8d-5f27-493b-b99c-d5846acec065_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_COVID19TestTypeDomain_d1df757a-9ba6-4705-b3b6-b9f30ebd2521_terseLabel_en-US" xlink:label="lab_opk_COVID19TestTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Test Type [Domain]</link:label>
    <link:label id="lab_opk_COVID19TestTypeDomain_label_en-US" xlink:label="lab_opk_COVID19TestTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Test Type [Domain]</link:label>
    <link:label id="lab_opk_COVID19TestTypeDomain_documentation_en-US" xlink:label="lab_opk_COVID19TestTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Test Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestTypeDomain" xlink:href="opk-20200630.xsd#opk_COVID19TestTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_COVID19TestTypeDomain" xlink:to="lab_opk_COVID19TestTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_afee8a95-3553-491d-8ddf-7656a9bdd2be_negatedTerseLabel_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits or payments made</link:label>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_label_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Doubtful Accounts Receivable, Decrease, Credits Or Payments</link:label>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_documentation_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Doubtful Accounts Receivable, Decrease, Credits Or Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:href="opk-20200630.xsd#opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:to="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5c28526d-2d32-4e87-ab7f-0560bcf0573a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_fbcff61d-f17b-4854-b435-1b6d29798e04_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lines of Credit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4ed02fa9-d799-416d-a60a-e9ee90e767a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0f720d05-145a-4549-a663-48ad539f73d6_negatedLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NumberofSalesEmployees_f5bcff73-81f1-49fa-b732-d800177b6018_terseLabel_en-US" xlink:label="lab_opk_NumberofSalesEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sales employees</link:label>
    <link:label id="lab_opk_NumberofSalesEmployees_label_en-US" xlink:label="lab_opk_NumberofSalesEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Sales Employees</link:label>
    <link:label id="lab_opk_NumberofSalesEmployees_documentation_en-US" xlink:label="lab_opk_NumberofSalesEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Sales Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NumberofSalesEmployees" xlink:href="opk-20200630.xsd#opk_NumberofSalesEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NumberofSalesEmployees" xlink:to="lab_opk_NumberofSalesEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dc877428-3cf9-48b0-b70a-7d78a4d66131_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9468edfe-4bca-4344-87ef-a0a5d75ed279_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NotesDueFebruary12033Member_557d50cd-6b8a-4735-8139-4bfb9e9ef9ee_terseLabel_en-US" xlink:label="lab_opk_NotesDueFebruary12033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due February 1, 2033</link:label>
    <link:label id="lab_opk_NotesDueFebruary12033Member_label_en-US" xlink:label="lab_opk_NotesDueFebruary12033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due February 1, 2033 [Member]</link:label>
    <link:label id="lab_opk_NotesDueFebruary12033Member_documentation_en-US" xlink:label="lab_opk_NotesDueFebruary12033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due February 1, 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesDueFebruary12033Member" xlink:href="opk-20200630.xsd#opk_NotesDueFebruary12033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NotesDueFebruary12033Member" xlink:to="lab_opk_NotesDueFebruary12033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9bdd80f2-607e-4b52-97a6-84dc0463246f_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BbvaBankMember_5a93ba98-5d6a-4ed8-a3e1-2ad56c270202_verboseLabel_en-US" xlink:label="lab_opk_BbvaBankMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BBVA Bank</link:label>
    <link:label id="lab_opk_BbvaBankMember_label_en-US" xlink:label="lab_opk_BbvaBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BBVA Bank [Member]</link:label>
    <link:label id="lab_opk_BbvaBankMember_documentation_en-US" xlink:label="lab_opk_BbvaBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BBVA bank.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BbvaBankMember" xlink:href="opk-20200630.xsd#opk_BbvaBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BbvaBankMember" xlink:to="lab_opk_BbvaBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_d675aea6-72a4-4ab1-a224-4e18d9eba2e8_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_49148242-c357-46fd-8384-ed6d3304409b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_cb83d58b-c265-426b-85ea-d4d7c07945d7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cash Flows</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_f39f274c-dd09-4568-8fab-96a470747a59_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, net</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_beafd5f2-9c9c-4777-bd00-2d9e73a226ea_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4e4620ac-b483-423b-ace7-3bd92e6291d4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f2adb2ee-ca21-4022-b382-2cdc2edfa275_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember_6609f5cd-109e-41fa-8ffa-87a06a7e551b_terseLabel_en-US" xlink:label="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received Upon Closing of Xenetic Transaction</link:label>
    <link:label id="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember_label_en-US" xlink:label="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received Upon Closing of Xenetic Transaction [Member]</link:label>
    <link:label id="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember_documentation_en-US" xlink:label="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received Upon Closing of Xenetic Transaction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:href="opk-20200630.xsd#opk_SharesReceivedUponClosingofXeneticTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:to="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SantanderBankMember_87bd39bc-b806-4448-a31d-0dc1e0d66996_terseLabel_en-US" xlink:label="lab_opk_SantanderBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Santander Bank</link:label>
    <link:label id="lab_opk_SantanderBankMember_label_en-US" xlink:label="lab_opk_SantanderBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Santander Bank [Member]</link:label>
    <link:label id="lab_opk_SantanderBankMember_documentation_en-US" xlink:label="lab_opk_SantanderBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">santander Bank.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBankMember" xlink:href="opk-20200630.xsd#opk_SantanderBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SantanderBankMember" xlink:to="lab_opk_SantanderBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OPKOTransactionSharesMember_75c23d78-28f2-4c30-bfbc-c8daca9fceaa_terseLabel_en-US" xlink:label="lab_opk_OPKOTransactionSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Transaction Shares</link:label>
    <link:label id="lab_opk_OPKOTransactionSharesMember_label_en-US" xlink:label="lab_opk_OPKOTransactionSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Transaction Shares [Member]</link:label>
    <link:label id="lab_opk_OPKOTransactionSharesMember_documentation_en-US" xlink:label="lab_opk_OPKOTransactionSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Transaction Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOTransactionSharesMember" xlink:href="opk-20200630.xsd#opk_OPKOTransactionSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OPKOTransactionSharesMember" xlink:to="lab_opk_OPKOTransactionSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5c985766-587a-44af-9c13-07519816151e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_fb6109f6-5167-4bd6-9a2e-20c5c6b89153_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_6dde59e5-0673-4009-bef8-522b602ddacb_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENTS</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_9eadad46-a6fd-4a3e-97cb-355f05cf85e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Converted debt amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_a818019f-c285-4182-92f1-1d2df82e7848_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, underlying equity in net assets</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Underlying Equity in Net Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:to="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_c06dad49-9788-4c3d-9c23-1f483093b51f_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net gains and losses realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_3b5430de-08ac-47bf-ac10-1306e48228f4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash out flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangement.MaximumMilestonePayments_13e7f9d8-6010-42bd-9059-18bc71a81dc5_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangement.MaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment to be received</link:label>
    <link:label id="lab_opk_CollaborativeArrangement.MaximumMilestonePayments_label_en-US" xlink:label="lab_opk_CollaborativeArrangement.MaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement. Maximum Milestone Payments</link:label>
    <link:label id="lab_opk_CollaborativeArrangement.MaximumMilestonePayments_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangement.MaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement. Maximum Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangement.MaximumMilestonePayments" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangement.MaximumMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangement.MaximumMilestonePayments" xlink:to="lab_opk_CollaborativeArrangement.MaximumMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_9f6ff043-446a-4300-a121-c79ce89b900d_terseLabel_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment from development and license agreement</link:label>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_label_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Development And License Agreement, Milestone Payment</link:label>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_documentation_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Development And License Agreement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:href="opk-20200630.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:to="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_8d130a89-a4a4-4fca-9be1-f94e78a2ebe4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_282f2701-eee5-467c-ab4d-81f72075f81b_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets of equity method investees</link:label>
    <link:label id="lab_us-gaap_Assets_7e1ccb4a-e538-483b-8573-63555c28e693_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_aa30c2eb-6652-4af3-938e-a7a4a0c3312c_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_TransferOfIntellectualPropertyAndOtherMember_56755dfb-7a12-4d38-8869-c54cdf1a865b_verboseLabel_en-US" xlink:label="lab_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from transfer of intellectual property and other</link:label>
    <link:label id="lab_opk_TransferOfIntellectualPropertyAndOtherMember_b1715bbb-a351-46ca-8f88-9216d6c59e8d_terseLabel_en-US" xlink:label="lab_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of intellectual property and other</link:label>
    <link:label id="lab_opk_TransferOfIntellectualPropertyAndOtherMember_label_en-US" xlink:label="lab_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Intellectual Property And Other [Member]</link:label>
    <link:label id="lab_opk_TransferOfIntellectualPropertyAndOtherMember_documentation_en-US" xlink:label="lab_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Intellectual Property And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:href="opk-20200630.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:to="lab_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORThereafterMember_7058caf7-db95-4c0a-963e-ac250ab79b14_terseLabel_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORThereafterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR Thereafter</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORThereafterMember_label_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORThereafterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), Thereafter [Member]</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORThereafterMember_documentation_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORThereafterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), Thereafter [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORThereafterMember" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORThereafterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LondonInterbankOfferedRateLIBORThereafterMember" xlink:to="lab_opk_LondonInterbankOfferedRateLIBORThereafterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_95f55272-7a2d-4da6-a170-b026120320b7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c91525a1-c6e0-43b1-b874-aeb5e25b7d10_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on converted debt (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_a63a11f3-bb63-4422-994f-61d5f1728d29_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_54d79236-d41f-4447-9520-119755b58ee9_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_Corpbanca1Member_916ed611-18bc-418e-94f8-2e67eb7c32b6_terseLabel_en-US" xlink:label="lab_opk_Corpbanca1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corpbanca</link:label>
    <link:label id="lab_opk_Corpbanca1Member_label_en-US" xlink:label="lab_opk_Corpbanca1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corpbanca1 [Member]</link:label>
    <link:label id="lab_opk_Corpbanca1Member_documentation_en-US" xlink:label="lab_opk_Corpbanca1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corpbanca1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_Corpbanca1Member" xlink:href="opk-20200630.xsd#opk_Corpbanca1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_Corpbanca1Member" xlink:to="lab_opk_Corpbanca1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_42693096-7e0b-4cda-8fa8-e7b19497c27d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ec7a7635-ece3-4be1-8f27-80a52c59d046_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_d7626164-ce7e-465c-87ba-a836e1c080d9_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Frost</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_93a6c308-6ddd-496e-aae1-21585bcf123e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_f5726452-89eb-41ec-af30-bf74c821b941_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage notes and other debt payables</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, by Current and Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_b205439f-7291-4bee-a5fd-54bc722ba9c8_terseLabel_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR, First 12 Months</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_label_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), First Twelve Months [Member]</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_documentation_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), First Twelve Months [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:to="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_0c303460-df26-439d-b26e-3217ae60a7f0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of credit risk and allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_981c15b0-e892-4e45-b5c6-210665707afd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_03d4a193-47d9-4424-b8cb-8f9d4e9d9c88_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inter-segment allocation of interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OtherCountriesMember_365033b1-171b-4dc8-986a-e2185f955ad3_terseLabel_en-US" xlink:label="lab_opk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_opk_OtherCountriesMember_label_en-US" xlink:label="lab_opk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_opk_OtherCountriesMember_documentation_en-US" xlink:label="lab_opk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OtherCountriesMember" xlink:href="opk-20200630.xsd#opk_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OtherCountriesMember" xlink:to="lab_opk_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5b10f35d-3b58-46ec-9eb3-8a9d99a86d37_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_MilestoneAxis_152ab60f-4007-4307-9e90-bacd03424709_terseLabel_en-US" xlink:label="lab_opk_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_opk_MilestoneAxis_label_en-US" xlink:label="lab_opk_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_opk_MilestoneAxis_documentation_en-US" xlink:label="lab_opk_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneAxis" xlink:href="opk-20200630.xsd#opk_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_MilestoneAxis" xlink:to="lab_opk_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_65100a56-4f09-4cb2-b121-d0d8ce5dc78b_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d49fb40f-7537-4b9d-92e0-6c5e272a57ae_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_e7dcc432-46ec-4621-9591-09697bbf168e_terseLabel_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_documentation_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="opk-20200630.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_78f7bf39-233d-4ff2-8639-ffc94966ff82_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gains recognized during the period on equity securities still held at the reporting date</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_667fa1e7-c1e9-4305-ac5c-2e3741ecf1cf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_22ba2c3c-b310-41d3-aa12-1953ac64e527_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Gains and Losses on Equity Securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_117e8a96-4444-4da3-adc8-e677e0156f01_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ZebraMember_c368208b-245f-47dd-950d-b9f25ef062ed_terseLabel_en-US" xlink:label="lab_opk_ZebraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zebra</link:label>
    <link:label id="lab_opk_ZebraMember_label_en-US" xlink:label="lab_opk_ZebraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zebra [Member]</link:label>
    <link:label id="lab_opk_ZebraMember_documentation_en-US" xlink:label="lab_opk_ZebraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zebra [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ZebraMember" xlink:href="opk-20200630.xsd#opk_ZebraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ZebraMember" xlink:to="lab_opk_ZebraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_cfe19f13-861b-4a0c-bcbd-420fa5ff7329_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_65b67705-5611-47a1-92b8-b858cc109459_negatedLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (liabilities) of equity method investees</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e9110706-652a-4360-9156-7b3a54c20054_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cb1cbc69-b697-4868-a707-388d041b9f29_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Difference between lease payments and discounted lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_374d26d4-691b-4973-b44c-c5fd86077b80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_344c22b0-7175-4b6a-adb6-d3b669a84e4c_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_066fc117-778d-4f53-87ae-c0e4df439c94_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ItauBankMember_a7ab8475-93b3-4612-9830-ea8dc169b1a3_verboseLabel_en-US" xlink:label="lab_opk_ItauBankMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Itau Bank</link:label>
    <link:label id="lab_opk_ItauBankMember_label_en-US" xlink:label="lab_opk_ItauBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Itau Bank [Member]</link:label>
    <link:label id="lab_opk_ItauBankMember_documentation_en-US" xlink:label="lab_opk_ItauBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Itau.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ItauBankMember" xlink:href="opk-20200630.xsd#opk_ItauBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ItauBankMember" xlink:to="lab_opk_ItauBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_56f314cd-8712-4344-8ca8-5571fc88003e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_52619abe-c6fb-48de-b636-9b63a42ff00c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets for identical assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DrFrostMember_f96c123a-20d0-4b82-b9b8-fbdad04ea045_terseLabel_en-US" xlink:label="lab_opk_DrFrostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Frost</link:label>
    <link:label id="lab_opk_DrFrostMember_label_en-US" xlink:label="lab_opk_DrFrostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Frost [Member]</link:label>
    <link:label id="lab_opk_DrFrostMember_documentation_en-US" xlink:label="lab_opk_DrFrostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Frost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DrFrostMember" xlink:href="opk-20200630.xsd#opk_DrFrostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DrFrostMember" xlink:to="lab_opk_DrFrostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_29704e9d-18da-431b-85fd-a1c8b37f6146_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_de181d64-7a6a-43c6-af82-83d99c573111_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentConvertibleSharesIssued_f6d5cf7e-339a-4814-a5ed-3459c558be55_terseLabel_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received after conversion (in shares)</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleSharesIssued_label_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Shares Issued</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleSharesIssued_documentation_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleSharesIssued" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentConvertibleSharesIssued" xlink:to="lab_opk_DebtInstrumentConvertibleSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82427ba6-58ee-4a05-8a00-6e16ac3ff58f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e5541b79-0cc0-4960-90b6-10e4ded59655_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_fc11dd95-c110-49e8-8108-13e1605dd02f_terseLabel_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales</link:label>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_label_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Doubtful Accounts, Provision For Allowance As Percent Of Gross Sales</link:label>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_documentation_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Doubtful Accounts, Provision For Allowance As Percent Of Gross Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:href="opk-20200630.xsd#opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:to="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4f6a1bd5-120f-40ab-87c8-76d8e677c968_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d6868e97-2343-4688-8056-c74e37ffd1c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_89d6c10b-2a9c-4ecb-b01c-36d9d8da7f93_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_6aedfce2-40dc-445f-afec-f4882d6180da_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a6d4a20f-fbb0-414c-bdd9-7c730f00e15b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_7b2eeb38-cd42-4bca-9a89-4f918dc9deda_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_d2b62944-f346-4145-9a7f-97b52da4ff85_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9a9416bb-0c52-4632-8add-762d4d160803_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_a11a87a7-30b1-4a0a-ae62-79e7d85f0c21_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_9715b92b-5c7d-4cba-810f-09e13513c1e7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Stock Split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_9c94b117-e8a4-4d73-a0ed-fd51037c4505_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_992f5d34-dcbc-483b-8200-99e0a0d02ec7_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_9ea65b99-af84-48ec-b05e-6a0cea09edbc_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_b23636ef-9ce7-4aaa-9325-bc84e23d9bdb_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_8f01e824-8d32-46dc-b273-48c318ba99df_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_403dae59-bbef-49e2-b332-2dff50c0738b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_12c42a39-b04c-412b-82c8-3d537f96b911_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributions_301e1442-d1fe-4e26-b8e5-9abfba862a8a_terseLabel_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party future contribution</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributions_label_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Future Contributions</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributions_documentation_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Future Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributions" xlink:href="opk-20200630.xsd#opk_RelatedPartyTransactionFutureContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RelatedPartyTransactionFutureContributions" xlink:to="lab_opk_RelatedPartyTransactionFutureContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PatientsMember_40abb071-d183-49c6-af4c-fab548b02a88_terseLabel_en-US" xlink:label="lab_opk_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients</link:label>
    <link:label id="lab_opk_PatientsMember_label_en-US" xlink:label="lab_opk_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:label id="lab_opk_PatientsMember_documentation_en-US" xlink:label="lab_opk_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PatientsMember" xlink:href="opk-20200630.xsd#opk_PatientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PatientsMember" xlink:to="lab_opk_PatientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_29951106-83a6-43ac-b53e-1483872cdbf2_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, Medical and Other Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_67a2f9e8-e8bd-40ee-8092-0250970109c1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_98c5e9ae-6274-468a-be23-831138b0deb0_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_34c51edc-3c72-4aa6-b918-076f7666a51e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88e52803-e61a-4c53-b179-fa575cefdc31_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_51f2bcd1-0b82-4344-9b53-447fe08fc182_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_68b04a93-8a66-46f5-bc83-393771a4356f_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EloxxPharmaceuticalsMember_49369238-2d6a-42f0-9b87-f51aaba3a49f_terseLabel_en-US" xlink:label="lab_opk_EloxxPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eloxx Pharmaceuticals</link:label>
    <link:label id="lab_opk_EloxxPharmaceuticalsMember_label_en-US" xlink:label="lab_opk_EloxxPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eloxx Pharmaceuticals [Member]</link:label>
    <link:label id="lab_opk_EloxxPharmaceuticalsMember_documentation_en-US" xlink:label="lab_opk_EloxxPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eloxx Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EloxxPharmaceuticalsMember" xlink:href="opk-20200630.xsd#opk_EloxxPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EloxxPharmaceuticalsMember" xlink:to="lab_opk_EloxxPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PhioPharmaceuticalsMember_0d18ad38-0722-4e8e-b374-db0fda3898f9_terseLabel_en-US" xlink:label="lab_opk_PhioPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phio Pharmaceuticals</link:label>
    <link:label id="lab_opk_PhioPharmaceuticalsMember_label_en-US" xlink:label="lab_opk_PhioPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phio Pharmaceuticals [Member]</link:label>
    <link:label id="lab_opk_PhioPharmaceuticalsMember_documentation_en-US" xlink:label="lab_opk_PhioPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phio Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhioPharmaceuticalsMember" xlink:href="opk-20200630.xsd#opk_PhioPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PhioPharmaceuticalsMember" xlink:to="lab_opk_PhioPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_GovernmentPayersMember_e02d5bba-f1ba-4bb5-8109-a1e801570980_terseLabel_en-US" xlink:label="lab_opk_GovernmentPayersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government payers</link:label>
    <link:label id="lab_opk_GovernmentPayersMember_label_en-US" xlink:label="lab_opk_GovernmentPayersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Payers [Member]</link:label>
    <link:label id="lab_opk_GovernmentPayersMember_documentation_en-US" xlink:label="lab_opk_GovernmentPayersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Payers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentPayersMember" xlink:href="opk-20200630.xsd#opk_GovernmentPayersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_GovernmentPayersMember" xlink:to="lab_opk_GovernmentPayersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ee3c364a-e361-44f2-9155-68277031eeb5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_060083ad-099e-43a4-ac44-3b94b97f4670_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9d3090c1-5a42-4bb5-b3e6-e926acdbcb70_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operations and Assets for Operating Segments and Geographic Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BioCardiaInc.Member_2b5a5600-93c0-40d0-b947-970a95b23013_terseLabel_en-US" xlink:label="lab_opk_BioCardiaInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCardia, Inc.</link:label>
    <link:label id="lab_opk_BioCardiaInc.Member_label_en-US" xlink:label="lab_opk_BioCardiaInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCardia, Inc. [Member]</link:label>
    <link:label id="lab_opk_BioCardiaInc.Member_documentation_en-US" xlink:label="lab_opk_BioCardiaInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCardia, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member" xlink:href="opk-20200630.xsd#opk_BioCardiaInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BioCardiaInc.Member" xlink:to="lab_opk_BioCardiaInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_0498c434-76f5-487e-9a92-cdca73cb525c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a54dad4e-6cac-40d3-96bc-128105cb636f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fdbd3c19-745a-40ae-8122-30d3ed4199cc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4b71a1ea-142f-48ea-9626-04120613f50d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_935604fb-8e5a-4791-a234-c9d77d993879_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_be58d9e1-b550-4830-96d1-292b48424a77_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_44d06001-9eab-4066-910f-79f7995d2f45_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual height velocity at point in time</link:label>
    <link:label id="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_label_en-US" xlink:label="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Annual Height Velocity at Point in Time</link:label>
    <link:label id="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Annual Height Velocity at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:to="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_d35a3f49-3d36-4d1c-947d-6a223b925e82_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss on disposal of fixed assets and sales of equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_78fa18df-1f34-4c8a-8fa3-1d577aa07cff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption of 2033 Senior Notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_fe649dc9-d22f-46fd-ab87-1894544ef934_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a4e0c3f8-001f-4489-9a6e-172eba56e20f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c4b65897-c8ae-4bbe-a5d4-1e698c9df4ab_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_32506b34-14e3-4186-95a6-ffa82100c12f_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0014a5d-7c07-44bf-9b20-40b9d2f04d31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock_f243af00-44ae-48fd-9be8-4bdbe3f5b9e9_terseLabel_en-US" xlink:label="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Sales Allowances and Accruals</link:label>
    <link:label id="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock_label_en-US" xlink:label="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Product Sales Allowances And Accruals [Table Text Block]</link:label>
    <link:label id="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock_documentation_en-US" xlink:label="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Product Sales Allowances And Accruals [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:href="opk-20200630.xsd#opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:to="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6fa32cba-7d69-433c-95b2-498da4c77321_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_811b71b7-291b-4782-a99c-2e297f393486_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_StockOptionandWarrantInvestments_2a368a7a-2c0d-442e-a59b-b2dd8333bb8a_terseLabel_en-US" xlink:label="lab_opk_StockOptionandWarrantInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and options</link:label>
    <link:label id="lab_opk_StockOptionandWarrantInvestments_label_en-US" xlink:label="lab_opk_StockOptionandWarrantInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option and Warrant Investments</link:label>
    <link:label id="lab_opk_StockOptionandWarrantInvestments_documentation_en-US" xlink:label="lab_opk_StockOptionandWarrantInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option and Warrant Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockOptionandWarrantInvestments" xlink:href="opk-20200630.xsd#opk_StockOptionandWarrantInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_StockOptionandWarrantInvestments" xlink:to="lab_opk_StockOptionandWarrantInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentRollForward_55ca0b00-1a37-440b-ab17-c973b6af1ec8_terseLabel_en-US" xlink:label="lab_opk_DebtInstrumentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Roll Forward]</link:label>
    <link:label id="lab_opk_DebtInstrumentRollForward_label_en-US" xlink:label="lab_opk_DebtInstrumentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Roll Forward]</link:label>
    <link:label id="lab_opk_DebtInstrumentRollForward_documentation_en-US" xlink:label="lab_opk_DebtInstrumentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentRollForward" xlink:href="opk-20200630.xsd#opk_DebtInstrumentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentRollForward" xlink:to="lab_opk_DebtInstrumentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EirGenPharmaLimitedMember_3b2511ff-3aee-46e9-a238-1f218f84a4a4_verboseLabel_en-US" xlink:label="lab_opk_EirGenPharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rayaldee</link:label>
    <link:label id="lab_opk_EirGenPharmaLimitedMember_d38c9056-e3b9-4fd6-96f8-7d909a1cd50b_terseLabel_en-US" xlink:label="lab_opk_EirGenPharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EirGen Pharma Limited</link:label>
    <link:label id="lab_opk_EirGenPharmaLimitedMember_label_en-US" xlink:label="lab_opk_EirGenPharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EirGen Pharma Limited [Member]</link:label>
    <link:label id="lab_opk_EirGenPharmaLimitedMember_documentation_en-US" xlink:label="lab_opk_EirGenPharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EirGen Pharma Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EirGenPharmaLimitedMember" xlink:href="opk-20200630.xsd#opk_EirGenPharmaLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EirGenPharmaLimitedMember" xlink:to="lab_opk_EirGenPharmaLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_67aab9d7-81b7-4069-8232-24b30cd5b924_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_7dff3dba-1921-4220-82ed-ea806fe276a2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_9db66d27-4572-4aa2-912e-c624f2cc1e1a_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_4fb7906f-236e-4f7d-832b-c472f2f7a8c5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term line of credit, noncurrent</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_21116557-a3af-4b4c-93e4-e3823ac3406a_terseLabel_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:to="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_5372a84d-89ac-4e60-9293-5a834cd4c6d8_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_5ab3e3fb-a844-4d61-8261-3a6e8ed377ab_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_87838ad8-775f-4940-941c-60241dc816cc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PaymentsForLeases_cc09d134-dd49-4cf2-ba0a-25603645a131_totalLabel_en-US" xlink:label="lab_opk_PaymentsForLeases" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_opk_PaymentsForLeases_label_en-US" xlink:label="lab_opk_PaymentsForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Leases</link:label>
    <link:label id="lab_opk_PaymentsForLeases_documentation_en-US" xlink:label="lab_opk_PaymentsForLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PaymentsForLeases" xlink:href="opk-20200630.xsd#opk_PaymentsForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PaymentsForLeases" xlink:to="lab_opk_PaymentsForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BilbaoVizcayaBankMember_aaeee663-ced4-428f-b43d-a262d7cd0aed_verboseLabel_en-US" xlink:label="lab_opk_BilbaoVizcayaBankMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banco Bilbao Vizcaya</link:label>
    <link:label id="lab_opk_BilbaoVizcayaBankMember_label_en-US" xlink:label="lab_opk_BilbaoVizcayaBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bilbao Vizcaya Bank [Member]</link:label>
    <link:label id="lab_opk_BilbaoVizcayaBankMember_documentation_en-US" xlink:label="lab_opk_BilbaoVizcayaBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bilbao vizcaya bank.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BilbaoVizcayaBankMember" xlink:href="opk-20200630.xsd#opk_BilbaoVizcayaBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BilbaoVizcayaBankMember" xlink:to="lab_opk_BilbaoVizcayaBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_66bbcc8d-c0e8-4499-b00f-a8f28847547e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_cb0b5e63-fed1-4b71-b64b-8321e2bc5ca5_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_562ad08e-7d07-4007-bd48-ed74faf4b145_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SharesSurrenderedInLieuOfCashPayment_bd6d549e-36f1-4d64-9b40-e189b0708b3d_verboseLabel_en-US" xlink:label="lab_opk_SharesSurrenderedInLieuOfCashPayment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered in lieu of cash payment (in shares)</link:label>
    <link:label id="lab_opk_SharesSurrenderedInLieuOfCashPayment_label_en-US" xlink:label="lab_opk_SharesSurrenderedInLieuOfCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Surrendered in Lieu of Cash Payment</link:label>
    <link:label id="lab_opk_SharesSurrenderedInLieuOfCashPayment_documentation_en-US" xlink:label="lab_opk_SharesSurrenderedInLieuOfCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered in lieu of cash payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesSurrenderedInLieuOfCashPayment" xlink:href="opk-20200630.xsd#opk_SharesSurrenderedInLieuOfCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SharesSurrenderedInLieuOfCashPayment" xlink:to="lab_opk_SharesSurrenderedInLieuOfCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_country_MX_8116d366-aa51-4c3c-8f7c-2f5c20ca037f_verboseLabel_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico</link:label>
    <link:label id="lab_country_MX_label_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEXICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MX" xlink:to="lab_country_MX" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_37f2db3c-f59d-4187-bb1e-f94082d5a772_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1c7495d7-5863-4b3d-a5f3-8846698c8383_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from investments in investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1e3e329d-9d03-4321-9ec3-363f0b23f6a8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses from investments in investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_7932b8fd-bd1a-43f7-8e1e-c7d80326bdb2_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value changes of derivative instruments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_020c6c5c-3f8e-49a7-b1b2-87ec658ad72f_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_2f0567fd-d9aa-4435-8bf7-857afb7a27ac_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_64aa9830-3364-4863-8fd2-7438bef2ca35_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_53a47b89-4ed0-42a0-967b-15fcc8ce30b5_negatedLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses of equity method investees</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_f9067969-b6c2-44ca-a47d-48402eaa0b54_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9a115cc3-7f29-4dbd-b969-f94baf6d3bb3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes and investment losses</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_af297eda-05b7-4861-998b-b9d7a3f23bcc_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3ee59885-5ed2-4055-9443-76cd3bf5c6d4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SeriesBWarrantMember_35943826-8c84-4cb2-b573-00862121868a_terseLabel_en-US" xlink:label="lab_opk_SeriesBWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Warrant</link:label>
    <link:label id="lab_opk_SeriesBWarrantMember_label_en-US" xlink:label="lab_opk_SeriesBWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Warrant [Member]</link:label>
    <link:label id="lab_opk_SeriesBWarrantMember_documentation_en-US" xlink:label="lab_opk_SeriesBWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SeriesBWarrantMember" xlink:href="opk-20200630.xsd#opk_SeriesBWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SeriesBWarrantMember" xlink:to="lab_opk_SeriesBWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_cb3635f8-b5df-4c97-90b5-27ea2790f559_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity_db4da655-609e-40a6-8d95-d89d8f28fdaa_terseLabel_en-US" xlink:label="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity_label_en-US" xlink:label="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Excluding Variable Interest Entity</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity_documentation_en-US" xlink:label="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Excluding Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentExcludingVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:to="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_d12c5cf9-7dd4-4c3b-b1f3-45c59c99d493_terseLabel_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_label_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), First Twelve Months, Adjusted for Eurocurrency Liabilities [Member]</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_documentation_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), First Twelve Months, Adjusted for Eurocurrency Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:to="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_COVID19NumberOfTestsPerformed_096e7081-6bd0-41a0-9b9a-58f082ab12c2_terseLabel_en-US" xlink:label="lab_opk_COVID19NumberOfTestsPerformed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tests performed</link:label>
    <link:label id="lab_opk_COVID19NumberOfTestsPerformed_label_en-US" xlink:label="lab_opk_COVID19NumberOfTestsPerformed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Number of Tests Performed</link:label>
    <link:label id="lab_opk_COVID19NumberOfTestsPerformed_documentation_en-US" xlink:label="lab_opk_COVID19NumberOfTestsPerformed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Number of Tests Performed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19NumberOfTestsPerformed" xlink:href="opk-20200630.xsd#opk_COVID19NumberOfTestsPerformed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_COVID19NumberOfTestsPerformed" xlink:to="lab_opk_COVID19NumberOfTestsPerformed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_aaaa4735-3cc2-42bb-9f5a-fe9931878aa9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_7062cfde-1a8a-4e01-b086-ff61e71206f1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NewCreditAgreementMember_2f1a7e48-fe38-4645-ab14-1bd4454e3c50_terseLabel_en-US" xlink:label="lab_opk_NewCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Agreement</link:label>
    <link:label id="lab_opk_NewCreditAgreementMember_label_en-US" xlink:label="lab_opk_NewCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Agreement [Member]</link:label>
    <link:label id="lab_opk_NewCreditAgreementMember_documentation_en-US" xlink:label="lab_opk_NewCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NewCreditAgreementMember" xlink:href="opk-20200630.xsd#opk_NewCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NewCreditAgreementMember" xlink:to="lab_opk_NewCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_bac0340b-42a9-456c-8f3d-f9de5f41a973_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_614fa7ae-ba76-4b32-a5e9-2df359343a7c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation &#8211; employees and non-employees</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_27a015ab-3916-4ab1-bc7f-481a93fe9b1e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_f95d0a66-436c-4c09-8a7e-5c7680c34b0d_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_86bbd496-1178-4a6e-b18b-f196660f6976_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_InterestExpenseNonoperating_55328113-d790-4099-99f9-3a1c44191bb6_negatedLabel_en-US" xlink:label="lab_opk_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_opk_InterestExpenseNonoperating_label_en-US" xlink:label="lab_opk_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:label id="lab_opk_InterestExpenseNonoperating_documentation_en-US" xlink:label="lab_opk_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestExpenseNonoperating" xlink:href="opk-20200630.xsd#opk_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_InterestExpenseNonoperating" xlink:to="lab_opk_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_661eaaa3-2f9c-4d8c-8a67-f151ad9e3d31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DrFrostandMrPfennigerMember_b6e60f5b-00e3-42b0-8ad6-49704ccfda24_terseLabel_en-US" xlink:label="lab_opk_DrFrostandMrPfennigerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Frost and Mr Pfenniger</link:label>
    <link:label id="lab_opk_DrFrostandMrPfennigerMember_label_en-US" xlink:label="lab_opk_DrFrostandMrPfennigerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Frost and Mr Pfenniger [Member]</link:label>
    <link:label id="lab_opk_DrFrostandMrPfennigerMember_documentation_en-US" xlink:label="lab_opk_DrFrostandMrPfennigerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Frost and Mr Pfenniger [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DrFrostandMrPfennigerMember" xlink:href="opk-20200630.xsd#opk_DrFrostandMrPfennigerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DrFrostandMrPfennigerMember" xlink:to="lab_opk_DrFrostandMrPfennigerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_de014cd4-78ec-4398-804c-deaea96024ae_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82bacec5-2ff7-4e17-acbf-31a07a40d4ab_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_96744613-0ca7-4330-837d-f4654474cfd0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_f7b8c541-73f3-4d60-a676-722ec325f17f_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_3a6abc7e-9d5a-4e00-a650-7f95a27cf0c1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining principal</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_7f1a2d74-96ee-47d7-802a-697f1a4f600d_periodStartLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_2e0c2244-6754-4d26-bebc-e4dd471c38ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_a92398f8-6ddb-4ae3-a629-0e20ec8bc9c6_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_47fe8eec-8c13-4ecd-b0f8-f201ab229bd3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_513cc38a-53cf-4ccb-a55f-98023ff2d56d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a6e973fc-a900-49ae-bbca-bc4122ef1c47_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8ba704d1-1f0c-4747-989c-2ab4d19ecea7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ChromadexCorporationMember_d4b78479-ffb2-46e4-8012-80058a00ccc2_verboseLabel_en-US" xlink:label="lab_opk_ChromadexCorporationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChromaDex Corporation</link:label>
    <link:label id="lab_opk_ChromadexCorporationMember_label_en-US" xlink:label="lab_opk_ChromadexCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chromadex Corporation [Member]</link:label>
    <link:label id="lab_opk_ChromadexCorporationMember_documentation_en-US" xlink:label="lab_opk_ChromadexCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChromaDex corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromadexCorporationMember" xlink:href="opk-20200630.xsd#opk_ChromadexCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ChromadexCorporationMember" xlink:to="lab_opk_ChromadexCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_24596605-0e64-42e2-9213-2fffd48f4838_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_6ad47882-f46b-4e76-b27a-e16231c365e0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_286d23b0-a907-4d78-b39d-fd0690c8abff_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_e91aecd5-4afc-4eb8-8e49-95ce627343c3_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_aa03e2f3-c1cb-47f4-adb6-209354dd1220_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of Common Stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d55b5542-5789-434f-9c96-e78c1719fdaa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ff58568d-af6c-4207-9453-a17530c127d3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member_ff9aaf94-c1d2-4a4e-b693-3f9ee24c1ce7_terseLabel_en-US" xlink:label="lab_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS Accelerated and Advanced Payment Program, COVID-19</link:label>
    <link:label id="lab_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member_label_en-US" xlink:label="lab_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS Accelerated and Advanced Payment Program, COVID-19 [Member]</link:label>
    <link:label id="lab_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member_documentation_en-US" xlink:label="lab_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS Accelerated and Advanced Payment Program, COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member" xlink:href="opk-20200630.xsd#opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member" xlink:to="lab_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_adc5051f-df15-4694-bbd7-0e302f6c7e07_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeAgreementPeriodfromFirstCommercialSale_c36c7be0-aaa5-45c4-ba0f-bf427ba30ba8_terseLabel_en-US" xlink:label="lab_opk_CollaborativeAgreementPeriodfromFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period from first commercial sale</link:label>
    <link:label id="lab_opk_CollaborativeAgreementPeriodfromFirstCommercialSale_label_en-US" xlink:label="lab_opk_CollaborativeAgreementPeriodfromFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period from First Commercial Sale</link:label>
    <link:label id="lab_opk_CollaborativeAgreementPeriodfromFirstCommercialSale_documentation_en-US" xlink:label="lab_opk_CollaborativeAgreementPeriodfromFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period from First Commercial Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeAgreementPeriodfromFirstCommercialSale" xlink:href="opk-20200630.xsd#opk_CollaborativeAgreementPeriodfromFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeAgreementPeriodfromFirstCommercialSale" xlink:to="lab_opk_CollaborativeAgreementPeriodfromFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2f9775a4-9633-449c-b0ec-f267a1b243bf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RelatedPartyTransactionShares_26be5f18-d865-447a-8f87-bd8cabe65279_terseLabel_en-US" xlink:label="lab_opk_RelatedPartyTransactionShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received upon closing of transaction (in shares)</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionShares_label_en-US" xlink:label="lab_opk_RelatedPartyTransactionShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Shares</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionShares_documentation_en-US" xlink:label="lab_opk_RelatedPartyTransactionShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionShares" xlink:href="opk-20200630.xsd#opk_RelatedPartyTransactionShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RelatedPartyTransactionShares" xlink:to="lab_opk_RelatedPartyTransactionShares" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2721083c-eed5-4051-ade7-4c5182b1f69d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_fb21d029-5f46-420d-b3d7-82e6fa5a7e35_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b246c327-104d-4f23-8573-6c2d9785eb77_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f1939be1-0f51-4641-b9ef-a284641a24bb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_df93642a-8507-4eb1-9853-bc392301d0ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Instrument Losses and Gains Recorded</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OpkoChileMember_bb5f2f0a-e3b2-4d4f-b83b-5c17fcd518e9_terseLabel_en-US" xlink:label="lab_opk_OpkoChileMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Chile</link:label>
    <link:label id="lab_opk_OpkoChileMember_label_en-US" xlink:label="lab_opk_OpkoChileMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Chile [Member]</link:label>
    <link:label id="lab_opk_OpkoChileMember_documentation_en-US" xlink:label="lab_opk_OpkoChileMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opko Chile.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OpkoChileMember" xlink:href="opk-20200630.xsd#opk_OpkoChileMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OpkoChileMember" xlink:to="lab_opk_OpkoChileMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_f230b78d-7291-48c7-a11f-773dc445e0ad_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f6c52158-f722-429e-9df2-ae0a387ee951_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_e72262c6-657b-40e9-8d68-a1c148773806_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values and Presentation of Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_bba5dfb8-1d80-41a5-9a4b-bfe944de1ab6_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_de91176a-70ab-42f2-bf75-ac57fd9c3f9b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce159289-a537-46ce-8b45-155354d53082_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_94feb1dd-b323-4462-a7d0-0f72238f008f_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory received but not invoiced</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_d27fe39e-9b4a-4f29-a04f-6f90ddd94d28_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_6a8d9774-b637-4c2b-ac1a-9acb1af79593_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock ownership percentage</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_80e1a54e-9a6a-4ce0-86f4-bb12c40f81fd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ConvertibleSeniorNotesDue2025Member_11dc223d-0802-4f3e-b95b-4bb7d58f44a9_terseLabel_en-US" xlink:label="lab_opk_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025</link:label>
    <link:label id="lab_opk_ConvertibleSeniorNotesDue2025Member_label_en-US" xlink:label="lab_opk_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_opk_ConvertibleSeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_opk_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConvertibleSeniorNotesDue2025Member" xlink:href="opk-20200630.xsd#opk_ConvertibleSeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ConvertibleSeniorNotesDue2025Member" xlink:to="lab_opk_ConvertibleSeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_43a1ce58-5d07-4a15-aa28-590e842e5447_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption_074ebd9c-2f78-46a4-9540-b66cb3149009_terseLabel_en-US" xlink:label="lab_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities due to adoption of ASU No. 2016-02</link:label>
    <link:label id="lab_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption_label_en-US" xlink:label="lab_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability, Initial Recognition Upon Adoption</link:label>
    <link:label id="lab_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption_documentation_en-US" xlink:label="lab_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability, Initial Recognition Upon Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption" xlink:href="opk-20200630.xsd#opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption" xlink:to="lab_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_62b1a5ca-8c8a-4eda-b963-8604a8ce3d4d_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_635bf798-bf19-4306-8c96-063f9a1b2363_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement amount</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_45f32764-8dd6-4a27-aff7-e9f7ddb8777f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3459cd09-0d42-493f-8516-32f5430c11a9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e29d41bd-f6e0-4261-8fbc-f364473558a2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_64e820b2-2789-4448-a103-f32bce91cb0c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_e811d5b7-8113-4257-aa64-609b6054d6aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities and Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_96a116e5-de81-49a4-89ef-a3712cbe93a9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_082ed316-ba07-459e-8726-9505670c07f9_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_f4770c60-987b-4914-a03a-02ab1d9dcce5_verboseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Elimination</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e0c2c1c4-f930-446d-bd37-763a1567a7b8_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_72c7c2bb-04ef-42b3-9acb-9bb49db86a9a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_d6800222-f5fe-4557-ba48-d8f9a92b6bfd_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_f0c08a0d-fe70-4864-8d48-a021bc96ab7f_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_1477ad7d-c11a-42a6-8043-2a24be419a40_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_893f5cdd-a956-4adc-813a-536eccdf3b91_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9da533fc-8492-4b3c-b56e-d5c42ec4cc6c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a98676ef-9232-48be-8fb0-43e134d68309_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income and (expense), net:</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_d945a71f-ebde-4464-98a9-d23f36cefaac_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Difference between lease payments and discounted lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_HealthInsurersMember_9b0c01db-f7ec-4397-8116-1ec9e6d2b1ae_terseLabel_en-US" xlink:label="lab_opk_HealthInsurersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare insurers</link:label>
    <link:label id="lab_opk_HealthInsurersMember_label_en-US" xlink:label="lab_opk_HealthInsurersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurers [Member]</link:label>
    <link:label id="lab_opk_HealthInsurersMember_documentation_en-US" xlink:label="lab_opk_HealthInsurersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_HealthInsurersMember" xlink:href="opk-20200630.xsd#opk_HealthInsurersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_HealthInsurersMember" xlink:to="lab_opk_HealthInsurersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b7096a22-1983-4d46-9f9c-1a605ebc8d9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeAgreementAdditionalMilestonePayment_2da835c9-7091-4825-9af8-d0492572c99b_terseLabel_en-US" xlink:label="lab_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_opk_CollaborativeAgreementAdditionalMilestonePayment_label_en-US" xlink:label="lab_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Additional Milestone Payment</link:label>
    <link:label id="lab_opk_CollaborativeAgreementAdditionalMilestonePayment_documentation_en-US" xlink:label="lab_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Additional Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:href="opk-20200630.xsd#opk_CollaborativeAgreementAdditionalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:to="lab_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_62a2134e-0b78-4d44-bf6d-6a346bbd0f14_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_b70d3e57-e83c-4aca-9d58-8dc4683cf197_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_e1ce63db-fdd5-4108-8910-e217e0742893_verboseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_a333b664-1045-41d3-9f25-9e1bd4adbb37_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contracts</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_004d0c97-eec8-45d1-bce2-deb99c5b2de9_verboseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_21258fce-b3e8-4ccb-9934-b3a9928eb177_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_5165a7f5-579f-4b61-b3bf-5f2d1cc2c11f_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_034a7201-56e4-4e6b-bffb-7c6e3e6d1fda_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_45c1ee18-c871-4a08-8b1e-b32f3ef16194_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5dfd2af8-487e-4eb2-b939-bc974925e4cd_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_bd864520-4513-4237-9fa0-465f45e976c5_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished products</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d08d843c-a92e-478a-9831-1466003bdb3b_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3fe743b0-a6e8-4e57-9ca4-4beee3da720e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested_b8f6b95b-dae4-4672-9ad0-991fc6ceb0a4_terseLabel_en-US" xlink:label="lab_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment options, vested (in shares)</link:label>
    <link:label id="lab_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested_label_en-US" xlink:label="lab_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights, Vested</link:label>
    <link:label id="lab_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested_documentation_en-US" xlink:label="lab_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested" xlink:href="opk-20200630.xsd#opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested" xlink:to="lab_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_98edbab1-cdc8-427e-8050-6331fb5fab96_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_6fb58286-f067-492a-8bb7-b1eecf4716bc_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_608ef1f9-7a64-422d-9dfe-9b0c5d41825c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OPKOBiologicsMember_43a2019b-a19c-453a-a251-58a22fa70875_terseLabel_en-US" xlink:label="lab_opk_OPKOBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Biologics</link:label>
    <link:label id="lab_opk_OPKOBiologicsMember_label_en-US" xlink:label="lab_opk_OPKOBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Biologics [Member]</link:label>
    <link:label id="lab_opk_OPKOBiologicsMember_documentation_en-US" xlink:label="lab_opk_OPKOBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Biologics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOBiologicsMember" xlink:href="opk-20200630.xsd#opk_OPKOBiologicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OPKOBiologicsMember" xlink:to="lab_opk_OPKOBiologicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquityMethodInvestmentVariableInterestEntity_535b2f85-8e4a-41b4-92b0-4fd31c6c4386_terseLabel_en-US" xlink:label="lab_opk_EquityMethodInvestmentVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest entity, equity method</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentVariableInterestEntity_label_en-US" xlink:label="lab_opk_EquityMethodInvestmentVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Variable Interest Entity</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentVariableInterestEntity_documentation_en-US" xlink:label="lab_opk_EquityMethodInvestmentVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentVariableInterestEntity" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquityMethodInvestmentVariableInterestEntity" xlink:to="lab_opk_EquityMethodInvestmentVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_bbfee798-928b-4853-b01f-62a51ea5078f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5361466c-766c-49b2-9744-a6e2d76f3068_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption period two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ContingentConsiderationMember_aa181b9a-1a7f-4da9-8219-b8218cb5148b_terseLabel_en-US" xlink:label="lab_opk_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_opk_ContingentConsiderationMember_label_en-US" xlink:label="lab_opk_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_opk_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_opk_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ContingentConsiderationMember" xlink:href="opk-20200630.xsd#opk_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ContingentConsiderationMember" xlink:to="lab_opk_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AccruedClinicalTrialsCurrent_c22d24f1-f04d-4235-b9a3-53af5c4b6484_verboseLabel_en-US" xlink:label="lab_opk_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_opk_AccruedClinicalTrialsCurrent_label_en-US" xlink:label="lab_opk_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials, Current</link:label>
    <link:label id="lab_opk_AccruedClinicalTrialsCurrent_documentation_en-US" xlink:label="lab_opk_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trials.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedClinicalTrialsCurrent" xlink:href="opk-20200630.xsd#opk_AccruedClinicalTrialsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AccruedClinicalTrialsCurrent" xlink:to="lab_opk_AccruedClinicalTrialsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventorySupplies_7968fe40-9d38-4c4a-8131-8c5c126ed857_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable supplies</link:label>
    <link:label id="lab_us-gaap_OtherInventorySupplies_label_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Supplies, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventorySupplies" xlink:to="lab_us-gaap_OtherInventorySupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ProductRegistrationsMember_20f57982-de02-4bac-837a-450be1f48349_terseLabel_en-US" xlink:label="lab_opk_ProductRegistrationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product registrations</link:label>
    <link:label id="lab_opk_ProductRegistrationsMember_label_en-US" xlink:label="lab_opk_ProductRegistrationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Registrations [Member]</link:label>
    <link:label id="lab_opk_ProductRegistrationsMember_documentation_en-US" xlink:label="lab_opk_ProductRegistrationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Registrations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProductRegistrationsMember" xlink:href="opk-20200630.xsd#opk_ProductRegistrationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ProductRegistrationsMember" xlink:to="lab_opk_ProductRegistrationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_8fcef3a3-417f-4918-909f-37c3078c7857_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_58c946a9-e565-4fef-a14d-c88594fac036_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4a50f0c3-04fc-4570-bc5a-d462f33daff9_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_a3944982-0e4e-4763-9770-60832d3f3f9f_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SerologyAntibodyTestMember_632ea42a-467f-4163-a791-48b9bc4bc790_terseLabel_en-US" xlink:label="lab_opk_SerologyAntibodyTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serology Antibody Test</link:label>
    <link:label id="lab_opk_SerologyAntibodyTestMember_label_en-US" xlink:label="lab_opk_SerologyAntibodyTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serology Antibody Test [Member]</link:label>
    <link:label id="lab_opk_SerologyAntibodyTestMember_documentation_en-US" xlink:label="lab_opk_SerologyAntibodyTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serology Antibody Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SerologyAntibodyTestMember" xlink:href="opk-20200630.xsd#opk_SerologyAntibodyTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SerologyAntibodyTestMember" xlink:to="lab_opk_SerologyAntibodyTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6017f586-303f-4405-8ade-1578ec1db202_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementUpfrontPayment_5d130351-df31-43d5-9ba8-6086bc8a6a9d_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable and non-creditable upfront payment</link:label>
    <link:label id="lab_opk_CollaborativeArrangementUpfrontPayment_label_en-US" xlink:label="lab_opk_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment</link:label>
    <link:label id="lab_opk_CollaborativeArrangementUpfrontPayment_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementUpfrontPayment" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementUpfrontPayment" xlink:to="lab_opk_CollaborativeArrangementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_92983cd0-e707-44bd-a30b-a7757f6e5486_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b21f2056-fabe-4687-8b61-21e30428765d_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_217c1b78-21bb-406c-9d3a-2826542d18e7_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearOne_5b67cb02-2a26-435c-98b9-83ea0497b35d_terseLabel_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments per month in first year</link:label>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearOne_label_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Monthly Payments, Year One</link:label>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearOne_documentation_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Monthly Payments, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:href="opk-20200630.xsd#opk_OperatingLeasesMonthlyPaymentsYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:to="lab_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_ccb48633-aa6b-4d8b-af33-fa7906ff13fc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options/warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_a9e88375-8ed6-414d-b05c-3f578d292738_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DiagnosticMolecularTestMember_9407f524-59ea-4ed5-a2ae-dbed3fa8037d_terseLabel_en-US" xlink:label="lab_opk_DiagnosticMolecularTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Molecular Test</link:label>
    <link:label id="lab_opk_DiagnosticMolecularTestMember_label_en-US" xlink:label="lab_opk_DiagnosticMolecularTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Molecular Test [Member]</link:label>
    <link:label id="lab_opk_DiagnosticMolecularTestMember_documentation_en-US" xlink:label="lab_opk_DiagnosticMolecularTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Molecular Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticMolecularTestMember" xlink:href="opk-20200630.xsd#opk_DiagnosticMolecularTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DiagnosticMolecularTestMember" xlink:to="lab_opk_DiagnosticMolecularTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_e4b2ed22-8b28-463b-8720-3dc3669a6d82_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_26422bc7-17b1-4eb0-aff4-ba2275c40d36_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains and losses recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f54e25f1-4e8d-4cf1-8e4d-4ac9afe6418f_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_066430cd-4122-4801-bc42-bf1f2d5fdc45_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_2a296179-caea-42f6-a224-a13a18bed2d3_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_a7506f46-0a73-45a8-b9f6-2d58598dece4_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_dc6fa51a-eb16-4d96-ae0f-1cd755a3df8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1c3e47c7-f875-4027-8776-e9ea7186e48d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_21cb940c-ee43-4217-bdf3-faa4672d8352_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_af581913-0877-47fe-abe4-34e9de4f6474_verboseLabel_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock warrant and common stock options exercised (in shares)</link:label>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_label_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Options and Warrants Exercised</link:label>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_documentation_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock warrant and common stock options exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:href="opk-20200630.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:to="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_05fa034b-423c-4378-8c8a-499a634c476d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_042c37f8-8072-48d2-92da-5401253db5ef_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash financing:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_178f853b-cd01-49e2-bb3b-ebdcb4badd12_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_5543642b-0843-4888-ab74-55d5b5dec910_negatedLabel_en-US" xlink:label="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity securities and derivative instruments</link:label>
    <link:label id="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_label_en-US" xlink:label="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Equity Securities, FV-NI And Derivative Instruments</link:label>
    <link:label id="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_documentation_en-US" xlink:label="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Equity Securities, FV-NI And Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:href="opk-20200630.xsd#opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:to="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_d09cf966-2bbd-4af0-95c6-b6f3d0c412e9_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9f1210c0-55be-4cfc-a1e3-aa6706ecec0c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_23b91ca3-4b07-47f8-a514-0fa393ba627e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_MuseumofScienceIncMember_cf48b448-0c74-4137-aac3-2925d6bad6af_terseLabel_en-US" xlink:label="lab_opk_MuseumofScienceIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Museum of Science, Inc</link:label>
    <link:label id="lab_opk_MuseumofScienceIncMember_label_en-US" xlink:label="lab_opk_MuseumofScienceIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Museum of Science, Inc [Member]</link:label>
    <link:label id="lab_opk_MuseumofScienceIncMember_documentation_en-US" xlink:label="lab_opk_MuseumofScienceIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Museum of Science, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MuseumofScienceIncMember" xlink:href="opk-20200630.xsd#opk_MuseumofScienceIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_MuseumofScienceIncMember" xlink:to="lab_opk_MuseumofScienceIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_5d01c092-65ab-4b6b-8470-cf1c8c345a38_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SalesReturnsMember_ecd39959-a8d7-40ce-9a89-ab85e6a50f7f_terseLabel_en-US" xlink:label="lab_opk_SalesReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_opk_SalesReturnsMember_label_en-US" xlink:label="lab_opk_SalesReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns [Member]</link:label>
    <link:label id="lab_opk_SalesReturnsMember_documentation_en-US" xlink:label="lab_opk_SalesReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesReturnsMember" xlink:href="opk-20200630.xsd#opk_SalesReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SalesReturnsMember" xlink:to="lab_opk_SalesReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_5c17e8f3-6e43-4f65-8a78-e2057c30cadc_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_A5ConvertibleNotesMember_bfcd8bb2-4aa4-4db3-b5d9-6e44d823e93c_terseLabel_en-US" xlink:label="lab_opk_A5ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5% Convertible Notes</link:label>
    <link:label id="lab_opk_A5ConvertibleNotesMember_label_en-US" xlink:label="lab_opk_A5ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5% Convertible Notes [Member]</link:label>
    <link:label id="lab_opk_A5ConvertibleNotesMember_documentation_en-US" xlink:label="lab_opk_A5ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5% Convertible Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A5ConvertibleNotesMember" xlink:href="opk-20200630.xsd#opk_A5ConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_A5ConvertibleNotesMember" xlink:to="lab_opk_A5ConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_95ea2794-2ac2-480f-9f17-86549621079c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_de43f0c4-c296-4379-8ee3-c027e9afba4c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_74d2ab7a-17b0-4f68-aaab-ea4f37618b71_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_31a35472-518b-43e3-a6f0-4de64de33ce5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_5f77e581-5391-4776-b8a3-d6d18e79fffe_terseLabel_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_documentation_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:href="opk-20200630.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BiceBankMember_2af9d16a-b45c-447c-994d-d2c3e40a543e_verboseLabel_en-US" xlink:label="lab_opk_BiceBankMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BICE Bank</link:label>
    <link:label id="lab_opk_BiceBankMember_label_en-US" xlink:label="lab_opk_BiceBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bice Bank [Member]</link:label>
    <link:label id="lab_opk_BiceBankMember_documentation_en-US" xlink:label="lab_opk_BiceBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BICE Bank.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BiceBankMember" xlink:href="opk-20200630.xsd#opk_BiceBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BiceBankMember" xlink:to="lab_opk_BiceBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_50fd6c29-6e3a-48c7-89e0-165857c0bd54_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_926d5341-140b-4230-bfa6-2b521a6b61f4_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_WeightedAverageRemainingLeaseTermAbstract_2ad35c5f-0e60-4cfd-b2ad-d6426fff3ac7_terseLabel_en-US" xlink:label="lab_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_opk_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_opk_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:href="opk-20200630.xsd#opk_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_2949f891-fa3d-4f69-b2dd-4645288e5ebd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenue, initial payment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_33a513fe-1c94-4ff3-b9d7-56cae07a16eb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BioReferenceMember_38910acd-8d0a-4eb7-b67b-40f23ccea164_terseLabel_en-US" xlink:label="lab_opk_BioReferenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioReference</link:label>
    <link:label id="lab_opk_BioReferenceMember_label_en-US" xlink:label="lab_opk_BioReferenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bio-Reference [Member]</link:label>
    <link:label id="lab_opk_BioReferenceMember_documentation_en-US" xlink:label="lab_opk_BioReferenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bio-Reference [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember" xlink:href="opk-20200630.xsd#opk_BioReferenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BioReferenceMember" xlink:to="lab_opk_BioReferenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a73f645c-7c5a-4fe4-987f-5bf82e0b0385_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract_a10e1d40-48e1-40c5-bcc6-f158d80018f4_terseLabel_en-US" xlink:label="lab_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon the conversion of:</link:label>
    <link:label id="lab_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract_label_en-US" xlink:label="lab_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued in the Conversion of Stock and Debt Instruments [Abstract]</link:label>
    <link:label id="lab_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract_documentation_en-US" xlink:label="lab_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued in the Conversion of Stock and Debt Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract" xlink:href="opk-20200630.xsd#opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract" xlink:to="lab_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ChargebacksDiscountsRebatesAndFeesMember_a412b824-fbd9-45bc-b760-a9220ae87704_terseLabel_en-US" xlink:label="lab_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, discounts, rebates and fees</link:label>
    <link:label id="lab_opk_ChargebacksDiscountsRebatesAndFeesMember_label_en-US" xlink:label="lab_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts, Rebates And Fees [Member]</link:label>
    <link:label id="lab_opk_ChargebacksDiscountsRebatesAndFeesMember_documentation_en-US" xlink:label="lab_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts, Rebates And Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:href="opk-20200630.xsd#opk_ChargebacksDiscountsRebatesAndFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:to="lab_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4c14229b-c52f-4a8a-a95b-04afe57ba247_totalLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_a4f4d2b4-be6a-4f86-abb2-ab74a1deac96_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_be15983a-610d-44c0-adda-9a9092503260_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_34447c48-2a8f-4b74-8eac-8575d5d8103b_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: inventory reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_b00bac16-9349-4d7b-8392-f0e358317033_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_84a3683b-65f4-4218-ad0f-b3b098774a21_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_WeightedAverageDiscountRateAbstract_5508bbcd-a1da-48d1-aa46-6bc8e35ee017_terseLabel_en-US" xlink:label="lab_opk_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_opk_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_opk_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_opk_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_opk_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_WeightedAverageDiscountRateAbstract" xlink:href="opk-20200630.xsd#opk_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_WeightedAverageDiscountRateAbstract" xlink:to="lab_opk_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_b8c4f3f2-b145-4178-9c24-57d357781b55_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_803f8649-9d1a-43ea-9dad-df13cf874e3b_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_005af3e0-117f-4786-8b06-7a75e4640bb6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock - $0.01 par value, 1,000,000,000 shares authorized; 670,378,701 and 670,378,701 shares issued at June 30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_61458fa9-0bd4-4d61-aa21-0560b2d0c6bc_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_82ccea89-ba8b-4895-80a7-26c05e8658f1_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying value of investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_COVID19TestsPerformedPerDay_02d108ff-7b6f-40fb-84ff-022b1bf1b348_terseLabel_en-US" xlink:label="lab_opk_COVID19TestsPerformedPerDay" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tests performed per day</link:label>
    <link:label id="lab_opk_COVID19TestsPerformedPerDay_label_en-US" xlink:label="lab_opk_COVID19TestsPerformedPerDay" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Tests Performed Per Day</link:label>
    <link:label id="lab_opk_COVID19TestsPerformedPerDay_documentation_en-US" xlink:label="lab_opk_COVID19TestsPerformedPerDay" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19, Tests Performed Per Day</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestsPerformedPerDay" xlink:href="opk-20200630.xsd#opk_COVID19TestsPerformedPerDay"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_COVID19TestsPerformedPerDay" xlink:to="lab_opk_COVID19TestsPerformedPerDay" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage_2a374393-1e3e-4cf9-bcaf-042562e0cab8_terseLabel_en-US" xlink:label="lab_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total revolving commitment</link:label>
    <link:label id="lab_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage_label_en-US" xlink:label="lab_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Terms, Total Revolving Commitment, Percentage</link:label>
    <link:label id="lab_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage_documentation_en-US" xlink:label="lab_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Terms, Total Revolving Commitment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage" xlink:href="opk-20200630.xsd#opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage" xlink:to="lab_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EstadoBankMember_2bf09ed8-94fe-40c0-923c-778a3aa791e6_verboseLabel_en-US" xlink:label="lab_opk_EstadoBankMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estado Bank</link:label>
    <link:label id="lab_opk_EstadoBankMember_label_en-US" xlink:label="lab_opk_EstadoBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estado Bank [Member]</link:label>
    <link:label id="lab_opk_EstadoBankMember_documentation_en-US" xlink:label="lab_opk_EstadoBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estado bank.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EstadoBankMember" xlink:href="opk-20200630.xsd#opk_EstadoBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EstadoBankMember" xlink:to="lab_opk_EstadoBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_22322b8a-c8c2-4acd-bf29-89558d6f3acb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_ce22e634-ed5f-41c1-ae94-535048b061bd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_d8594ff6-ae16-4560-8923-7478a6bdf20a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_43876162-f15a-4cc6-830b-3a42450594e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Included in results of operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_4ff19776-7d69-4bef-b9bb-7324031bd21c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_InterestIncomeNonoperating_8c3aeaec-b919-4443-a73f-5454d6d118e6_verboseLabel_en-US" xlink:label="lab_opk_InterestIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_opk_InterestIncomeNonoperating_label_en-US" xlink:label="lab_opk_InterestIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Nonoperating</link:label>
    <link:label id="lab_opk_InterestIncomeNonoperating_documentation_en-US" xlink:label="lab_opk_InterestIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestIncomeNonoperating" xlink:href="opk-20200630.xsd#opk_InterestIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_InterestIncomeNonoperating" xlink:to="lab_opk_InterestIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_3d496528-876b-4885-84c4-a60589418b22_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0a61f065-75bd-40e8-b812-364a003b646e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FrostRealEstateHoldingsLLCMember_b818702d-06cd-4ee2-91e8-97bcd4ecb3f1_verboseLabel_en-US" xlink:label="lab_opk_FrostRealEstateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frost Real Estate Holdings LLC</link:label>
    <link:label id="lab_opk_FrostRealEstateHoldingsLLCMember_label_en-US" xlink:label="lab_opk_FrostRealEstateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frost Real Estate Holdings LLC [Member]</link:label>
    <link:label id="lab_opk_FrostRealEstateHoldingsLLCMember_documentation_en-US" xlink:label="lab_opk_FrostRealEstateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frost real estate holdings LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FrostRealEstateHoldingsLLCMember" xlink:href="opk-20200630.xsd#opk_FrostRealEstateHoldingsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FrostRealEstateHoldingsLLCMember" xlink:to="lab_opk_FrostRealEstateHoldingsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_63c17597-4a12-4625-bb52-3a1b3090ad09_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_213d8c55-3a36-45d2-abcb-be9c06fd7213_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_85b71f23-c081-45df-ac32-6d9d59f97f66_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net:</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement_99f31e76-9018-4794-8422-9dd9628f0d81_terseLabel_en-US" xlink:label="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency measurement</link:label>
    <link:label id="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement_label_en-US" xlink:label="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Foreign Currency Measurement</link:label>
    <link:label id="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement_documentation_en-US" xlink:label="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Foreign Currency Measurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:href="opk-20200630.xsd#opk_IncreaseDecreaseinForeignCurrencyMeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:to="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2ff45094-c454-47f1-aeb2-edd6b5ffe30e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_InCellDxIncMember_fb9803e9-0c74-4cbd-bb4f-4e5782e968f8_terseLabel_en-US" xlink:label="lab_opk_InCellDxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InCellDx, Inc</link:label>
    <link:label id="lab_opk_InCellDxIncMember_label_en-US" xlink:label="lab_opk_InCellDxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InCellDx, Inc [Member]</link:label>
    <link:label id="lab_opk_InCellDxIncMember_documentation_en-US" xlink:label="lab_opk_InCellDxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InCellDx, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InCellDxIncMember" xlink:href="opk-20200630.xsd#opk_InCellDxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_InCellDxIncMember" xlink:to="lab_opk_InCellDxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BancoDeSabadellMember_5f792967-1282-48ca-98f4-25f0f8be5f96_terseLabel_en-US" xlink:label="lab_opk_BancoDeSabadellMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banco De Sabadell</link:label>
    <link:label id="lab_opk_BancoDeSabadellMember_label_en-US" xlink:label="lab_opk_BancoDeSabadellMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banco De Sabadell [Member]</link:label>
    <link:label id="lab_opk_BancoDeSabadellMember_documentation_en-US" xlink:label="lab_opk_BancoDeSabadellMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banco De Sabadell [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BancoDeSabadellMember" xlink:href="opk-20200630.xsd#opk_BancoDeSabadellMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BancoDeSabadellMember" xlink:to="lab_opk_BancoDeSabadellMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ef8c007-3b78-4d26-953e-eb97ada570d7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d128bdf6-36f8-4ff7-8b09-f8e113b64ab8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d509581c-b19e-436b-846c-fb5288b30e5a_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived_ccd4856c-4cf2-4a5e-903c-777ec3d098b1_verboseLabel_en-US" xlink:label="lab_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payments to be received</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Estimated Milestone Payments To Be Received</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated milestone payment to be received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived" xlink:to="lab_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_eea68ebd-4d59-41d8-bf8d-e1877f68e116_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ac1187ba-c5ad-4404-9628-39bcb7d7b579_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember_0a0d45c0-db37-4334-b21c-ddd2f7834381_terseLabel_en-US" xlink:label="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable and Other Long-Term Liabilities</link:label>
    <link:label id="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember_label_en-US" xlink:label="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable And Other Long-Term Liabilities [Member]</link:label>
    <link:label id="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember_documentation_en-US" xlink:label="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable And Other Long-Term Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:href="opk-20200630.xsd#opk_NotesPayableAndOtherLongTermLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:to="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_b580a1e0-8ea7-424c-b59b-5ba9b1b7eb45_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4be47b16-6428-4b39-80a7-e37f1b78ede4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgages and other debts payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_f89cce7c-f97c-4312-90b6-5bfd068d0e23_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock_5036dfe3-d655-43f7-956d-8c9d4839ef66_terseLabel_en-US" xlink:label="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Assets and Liabilities</link:label>
    <link:label id="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="opk-20200630.xsd#opk_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ffb1d3bf-1e2c-41e4-a04e-ed8359e4c370_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_445f3e55-b24e-4d0b-bb87-ea959886fcd0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a231860b-6cbd-4896-b9f9-41589016be3b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e14bc855-7c6e-436e-95d3-8ef1f230d72e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_cca20833-f6c5-4c69-92da-3f49eca4fc5a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b1934cab-22f8-41b7-a473-5a11f88945c6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTextBlock_13e78283-3beb-4c35-acd3-2f5ddfe3e7c0_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7387f156-b224-4be8-9a4b-f33ff4897199_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_a1ed8b6d-030e-49f6-9421-c9bdb8f95ff9_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_e0b68886-6b93-4a1f-aa02-f7f72ab249f5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c164264e-c543-4cd2-92ad-263cbde8233c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_93e96958-6eab-4734-af09-ebc134b4d0a6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_ab9b6aa6-c278-42e6-96c2-eac79f7b3c59_terseLabel_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable under debt agreement (in shares)</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_label_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Maximum Shares Issuable</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_documentation_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Maximum Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:to="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_MembersofSeniorManagementMember_59579882-0b91-4ca8-ab3d-854ed7129bff_terseLabel_en-US" xlink:label="lab_opk_MembersofSeniorManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Members of Senior Management</link:label>
    <link:label id="lab_opk_MembersofSeniorManagementMember_label_en-US" xlink:label="lab_opk_MembersofSeniorManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Members of Senior Management [Member]</link:label>
    <link:label id="lab_opk_MembersofSeniorManagementMember_documentation_en-US" xlink:label="lab_opk_MembersofSeniorManagementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Members of Senior Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MembersofSeniorManagementMember" xlink:href="opk-20200630.xsd#opk_MembersofSeniorManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_MembersofSeniorManagementMember" xlink:to="lab_opk_MembersofSeniorManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_0ead8a4b-009c-4807-b014-a3f5df13e29c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_4d168710-db2a-4afd-8d53-14dcb1c45e62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6265e757-174f-4b28-be73-fbb0b21b8cbf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_d6ee91c7-499c-4704-b2bd-ff03ee71b795_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_5783bf0f-117b-455a-9ecc-5a7384230b6e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_ac06f4c1-5d76-4f29-b56f-3139ecdb9530_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ccfea47d-773f-46ae-9af3-b525a37fe195_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7891938d-5554-4c31-8530-f0a31004eedb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, estimated useful lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6f81ca81-dd5c-4bf7-ab9e-b6f777fb6df7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_f0f7352f-24bd-4d8a-89e6-aa10a952cd46_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest&#160;rate&#160;on borrowings at June 30, 2020</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_9ac730be-addf-4931-baf7-2406ad6f41ee_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_469dc210-ca9d-47e1-8e92-9392d6fbd673_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a6edf820-c162-49ce-8c81-104d37c0a312_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NIMSMember_7641b205-be20-4777-987f-891690f87531_terseLabel_en-US" xlink:label="lab_opk_NIMSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIMS</link:label>
    <link:label id="lab_opk_NIMSMember_label_en-US" xlink:label="lab_opk_NIMSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIMS [Member]</link:label>
    <link:label id="lab_opk_NIMSMember_documentation_en-US" xlink:label="lab_opk_NIMSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIMS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NIMSMember" xlink:href="opk-20200630.xsd#opk_NIMSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NIMSMember" xlink:to="lab_opk_NIMSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_aede06b4-7af7-4631-bdd0-fab7be0c4bb3_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_b03af787-2384-449b-8716-efb6cf4dd601_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_73a42800-8443-47b0-b399-43df19f21482_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition and shipping and handling costs</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SecurityMember_00df0961-7970-49cf-a77c-69b86a50b259_terseLabel_en-US" xlink:label="lab_opk_SecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Bank</link:label>
    <link:label id="lab_opk_SecurityMember_label_en-US" xlink:label="lab_opk_SecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security [Member]</link:label>
    <link:label id="lab_opk_SecurityMember_documentation_en-US" xlink:label="lab_opk_SecurityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SecurityMember" xlink:href="opk-20200630.xsd#opk_SecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SecurityMember" xlink:to="lab_opk_SecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_934df3ba-bd02-44d9-bc51-c1c714c04ae6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_96ca96fa-ebd0-4aec-bf65-1f93a2c59b71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_b509373f-59fc-4c20-8902-8d394d12942e_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases long-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_8c971531-290d-4289-b5a9-358a6ef25b84_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6a4553c-bc52-448f-b382-5ffebb0a9059_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_179a49d6-327c-4d3b-b242-2c2622eae66f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 1, 2020 through December 31, 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_3ab30d01-f96b-40ba-9f24-894c5012a3d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_d7301502-b652-417c-a6c4-dbb86780b68e_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_ad477843-7599-43cc-8ddb-1f33a60349e5_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_bb72da3e-cef8-4c38-90a6-038aefeab7e8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_983b0572-4bb4-4f42-83f6-5d88db8cc0a2_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_bb87369d-072c-43ea-b5e8-dcfa713af5d2_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributionTerm_c124aee8-b72b-40d9-ba5f-c2ffb61c572d_terseLabel_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party future contribution term</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributionTerm_label_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Future Contribution, Term</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributionTerm_documentation_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Future Contribution, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributionTerm" xlink:href="opk-20200630.xsd#opk_RelatedPartyTransactionFutureContributionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RelatedPartyTransactionFutureContributionTerm" xlink:to="lab_opk_RelatedPartyTransactionFutureContributionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_a374f802-20d4-4188-b275-b4fefb7248d0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8fef3ce2-75e5-4c3b-bd70-82d01934c0bf_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2ab23e4b-254e-408a-9713-bc616f5e69e6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4a834d59-da52-4713-bbb6-6da99281be76_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) per share, basic and diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock_0c9a8e7e-9b7d-4b5c-a6c7-22830503f976_verboseLabel_en-US" xlink:label="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of Certain Financial Statement Captions</link:label>
    <link:label id="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock_label_en-US" xlink:label="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of Certain Financial Statement Captions [Table Text Block]</link:label>
    <link:label id="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock_documentation_en-US" xlink:label="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of certain financial statement captions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:href="opk-20200630.xsd#opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:to="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_2b31b00d-23ca-432c-90ac-cdeda312c3ee_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SalesRevenueMember_5aff1bd9-892c-4eff-9d1f-db6db7e3663b_terseLabel_en-US" xlink:label="lab_opk_SalesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue</link:label>
    <link:label id="lab_opk_SalesRevenueMember_label_en-US" xlink:label="lab_opk_SalesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue [Member]</link:label>
    <link:label id="lab_opk_SalesRevenueMember_documentation_en-US" xlink:label="lab_opk_SalesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesRevenueMember" xlink:href="opk-20200630.xsd#opk_SalesRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SalesRevenueMember" xlink:to="lab_opk_SalesRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e3f69e93-f90d-4be9-820c-5e5f73dc2354_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PharmsynthezMember_e9c1d133-3338-4235-8f4b-eca78d1ca61b_terseLabel_en-US" xlink:label="lab_opk_PharmsynthezMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmsynthez</link:label>
    <link:label id="lab_opk_PharmsynthezMember_label_en-US" xlink:label="lab_opk_PharmsynthezMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmsynthez [Member]</link:label>
    <link:label id="lab_opk_PharmsynthezMember_documentation_en-US" xlink:label="lab_opk_PharmsynthezMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmsynthez [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember" xlink:href="opk-20200630.xsd#opk_PharmsynthezMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PharmsynthezMember" xlink:to="lab_opk_PharmsynthezMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f08c59c2-8167-4575-980d-c0f68719e457_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RegulatoryMilestonesMember_9e54c44a-9550-43d9-9d93-ec66f1919b0d_terseLabel_en-US" xlink:label="lab_opk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_opk_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_opk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_opk_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_opk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryMilestonesMember" xlink:href="opk-20200630.xsd#opk_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RegulatoryMilestonesMember" xlink:to="lab_opk_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0d2cccaa-b042-423e-99fc-9abb9bff2a2f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_63bb2706-1ff6-4bc5-b7a4-b34a4d82ce37_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares into which warrants may be converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2a1de55c-c538-4c21-b91a-38aacf46fa6d_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares into which warrants may be converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_753329d9-defe-47d3-8da9-0e129571a6b4_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tecnology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_dd526d54-5e01-4606-9923-ae4a9214b770_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_96304acb-f9e9-45ce-8107-551452f0b4e9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ChiefTechnicalOfficerMember_6e0bb437-c22f-4f65-9ded-d251d49f74a8_terseLabel_en-US" xlink:label="lab_opk_ChiefTechnicalOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jan Hsiao</link:label>
    <link:label id="lab_opk_ChiefTechnicalOfficerMember_label_en-US" xlink:label="lab_opk_ChiefTechnicalOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Technical Officer [Member]</link:label>
    <link:label id="lab_opk_ChiefTechnicalOfficerMember_documentation_en-US" xlink:label="lab_opk_ChiefTechnicalOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Technical Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChiefTechnicalOfficerMember" xlink:href="opk-20200630.xsd#opk_ChiefTechnicalOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ChiefTechnicalOfficerMember" xlink:to="lab_opk_ChiefTechnicalOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_c12c4884-0205-4d26-9c8e-154ac554a775_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesTable_28741e9b-665b-42e3-a540-948b62bcaa0e_terseLabel_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:href="opk-20200630.xsd#opk_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_fde16e80-6da5-45c5-be1b-e62938a37b13_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_50d402ae-d81b-4eb4-b30a-5b7b23440a23_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_f7901109-3a5d-423d-b58e-02796d88cad3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_885dcb66-4371-430b-b02e-03cb5743e56e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL INFORMATION:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_87aac507-4d30-46a2-84cd-396852118c17_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contracts Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contracts Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:to="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearThree_eb4046c7-b48a-46b1-ac96-e247ce7e8957_terseLabel_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments per month in third year</link:label>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearThree_label_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Monthly Payments, Year Three</link:label>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearThree_documentation_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Monthly Payments, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearThree" xlink:href="opk-20200630.xsd#opk_OperatingLeasesMonthlyPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OperatingLeasesMonthlyPaymentsYearThree" xlink:to="lab_opk_OperatingLeasesMonthlyPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9098973c-c4a1-4188-a2a2-7dd9176dbf7b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_93b2edc7-b83f-4c1d-b288-cac652302dc4_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equivalent redemption price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BankOfChileMember_876bb04d-68b9-42cc-9580-69d8024e7d12_verboseLabel_en-US" xlink:label="lab_opk_BankOfChileMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank of Chile</link:label>
    <link:label id="lab_opk_BankOfChileMember_label_en-US" xlink:label="lab_opk_BankOfChileMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank of Chile [Member]</link:label>
    <link:label id="lab_opk_BankOfChileMember_documentation_en-US" xlink:label="lab_opk_BankOfChileMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank of Chile.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BankOfChileMember" xlink:href="opk-20200630.xsd#opk_BankOfChileMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BankOfChileMember" xlink:to="lab_opk_BankOfChileMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NeovascMember_ff8e6f75-1eda-418a-ad6e-7c0b951af6a3_terseLabel_en-US" xlink:label="lab_opk_NeovascMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neovasc</link:label>
    <link:label id="lab_opk_NeovascMember_label_en-US" xlink:label="lab_opk_NeovascMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neovasc [Member]</link:label>
    <link:label id="lab_opk_NeovascMember_documentation_en-US" xlink:label="lab_opk_NeovascMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neovasc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NeovascMember" xlink:href="opk-20200630.xsd#opk_NeovascMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NeovascMember" xlink:to="lab_opk_NeovascMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5fd178ba-df7a-44e4-9525-7b0892f1fb7e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_0d54f0fb-b03f-428d-abec-da27fb568777_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e446d9a0-c57c-4d3c-b326-eb5a4f8a80d0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4092a2e-c8fa-4683-b871-5f73882486c9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_TesaroMember_261733e7-3cd0-47fe-b539-c84598cb5271_terseLabel_en-US" xlink:label="lab_opk_TesaroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tesaro</link:label>
    <link:label id="lab_opk_TesaroMember_label_en-US" xlink:label="lab_opk_TesaroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tesaro [Member]</link:label>
    <link:label id="lab_opk_TesaroMember_documentation_en-US" xlink:label="lab_opk_TesaroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tesaro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TesaroMember" xlink:href="opk-20200630.xsd#opk_TesaroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_TesaroMember" xlink:to="lab_opk_TesaroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_67726ee8-3184-429e-9968-d9ffe3e9d171_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_c3406bfe-2c3c-4062-baa1-865aceae80e6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_3561ac98-14b3-411e-898a-1ab6518106d0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_84cfe85b-dae2-4abd-8982-b954496e7530_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technologies</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_b43c7f2e-0d95-4c17-a948-a6848e4ffb57_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_7338a7d3-2360-4c2f-aa3d-6344c032b5e4_totalLabel_en-US" xlink:label="lab_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) before investment losses</link:label>
    <link:label id="lab_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_label_en-US" xlink:label="lab_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Before Investments in Investees, Extraordinary Items, Noncontrolling Interest, Net of Tax</link:label>
    <link:label id="lab_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_documentation_en-US" xlink:label="lab_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from continuing operations before investment losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" xlink:href="opk-20200630.xsd#opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" xlink:to="lab_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e95ac5ed-acef-4260-b495-c58904150de5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a1784418-8280-4747-9699-eadf19c947df_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_a338dca4-a397-4ba7-8c40-c055bd8bf465_terseLabel_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum conversion notice</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_label_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Notice Threshold, Maximum</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_documentation_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Notice Threshold, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:to="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OPKOHealthEuropeMember_13a88020-e0c0-419b-bcad-f917518cca02_terseLabel_en-US" xlink:label="lab_opk_OPKOHealthEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Health Europe</link:label>
    <link:label id="lab_opk_OPKOHealthEuropeMember_60bf49e7-c156-4387-ad6d-b8fa00bbd456_verboseLabel_en-US" xlink:label="lab_opk_OPKOHealthEuropeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Health Europe</link:label>
    <link:label id="lab_opk_OPKOHealthEuropeMember_label_en-US" xlink:label="lab_opk_OPKOHealthEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Health Europe [Member]</link:label>
    <link:label id="lab_opk_OPKOHealthEuropeMember_documentation_en-US" xlink:label="lab_opk_OPKOHealthEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Health Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOHealthEuropeMember" xlink:href="opk-20200630.xsd#opk_OPKOHealthEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OPKOHealthEuropeMember" xlink:to="lab_opk_OPKOHealthEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd93f463-83f4-4a62-8625-90eb4c11f750_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on notes payable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3b6b766a-7286-4bbb-ac0b-b351ccd3981f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on credit facility</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_201018d0-0a1a-4a9f-9d51-c2807c89e427_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_82f28e69-0856-4c3f-9a2a-bddcaa405aa4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 convertible notes including share lending arrangement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_2caeda20-9878-4b5a-87a1-78a259df47d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to current period sales</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SalesMilestonesMember_232c96b8-95b0-4396-802e-143362f621c8_terseLabel_en-US" xlink:label="lab_opk_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones</link:label>
    <link:label id="lab_opk_SalesMilestonesMember_label_en-US" xlink:label="lab_opk_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:label id="lab_opk_SalesMilestonesMember_documentation_en-US" xlink:label="lab_opk_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesMilestonesMember" xlink:href="opk-20200630.xsd#opk_SalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SalesMilestonesMember" xlink:to="lab_opk_SalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems_36fe0ed3-4e1f-44b1-8180-c2db90b2bc7f_terseLabel_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="opk-20200630.xsd#opk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_6a370f70-f154-44b5-9e0a-e4c28cf8d120_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentsAbstract" xlink:to="lab_us-gaap_DebtInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b79ae35-cbc8-456c-8646-78a6cc8413ba_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of Common Stock options and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_ec0f21c8-2c4e-43ef-849d-555bae41294f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior period performance obligation revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_198a270f-aae1-4546-ad63-583fe7541c87_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9e5dc4d-7b98-4262-aca0-a7bcc0a4837c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_53003473-1cf6-4e98-b6c5-a6f72f4d0692_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income and (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_d94b7d49-83f5-44fe-a95c-db0514fecc36_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquityMethodInvestmentSharesPurchasedInPeriod_e5fda02e-7f37-449d-8e3d-76618f98eedf_terseLabel_en-US" xlink:label="lab_opk_EquityMethodInvestmentSharesPurchasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, additional investment in period (in shares)</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentSharesPurchasedInPeriod_label_en-US" xlink:label="lab_opk_EquityMethodInvestmentSharesPurchasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Shares Purchased In Period</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentSharesPurchasedInPeriod_documentation_en-US" xlink:label="lab_opk_EquityMethodInvestmentSharesPurchasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Shares Purchased In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentSharesPurchasedInPeriod" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentSharesPurchasedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquityMethodInvestmentSharesPurchasedInPeriod" xlink:to="lab_opk_EquityMethodInvestmentSharesPurchasedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3006d7fd-532c-4d4e-a4e0-febdfc90a862_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_57c731e9-b27a-4f16-bc25-0d91f0f12418_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_74359927-0416-4f90-b56b-be035ff19964_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b10eff82-a043-43c9-99a4-42aca789b02a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_586de396-37b6-4c07-a505-702af91f6105_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_TaxesRecoverableCurrent_5260e2ae-1fde-4624-9eaf-148e429b37ac_terseLabel_en-US" xlink:label="lab_opk_TaxesRecoverableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes recoverable</link:label>
    <link:label id="lab_opk_TaxesRecoverableCurrent_label_en-US" xlink:label="lab_opk_TaxesRecoverableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Recoverable, Current</link:label>
    <link:label id="lab_opk_TaxesRecoverableCurrent_documentation_en-US" xlink:label="lab_opk_TaxesRecoverableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Recoverable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TaxesRecoverableCurrent" xlink:href="opk-20200630.xsd#opk_TaxesRecoverableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_TaxesRecoverableCurrent" xlink:to="lab_opk_TaxesRecoverableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d35ffde7-1706-41c3-8707-d467978ab495_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation and other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_bf7c1fbf-afed-4c95-b4bc-b08d1627d3e8_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_64b93f26-bc0b-4fbb-ae44-d4d559792d0d_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_35768093-9d47-41a5-846c-63a7e1ce079f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_67d2e907-af1d-4656-a9c8-ae702a97af67_terseLabel_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock issued for stock warrant and stock options exercised (in shares)</link:label>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_label_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Options and Warrants Exercised, Net of Shares Surrendered in Lieu of Cash Payment</link:label>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_documentation_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock issued for stock warrant and stock options exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:href="opk-20200630.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:to="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_InProcessResearchandDevelopment_5aee5c0d-d61e-468e-929b-a602d43e7cc2_terseLabel_en-US" xlink:label="lab_opk_InProcessResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_opk_InProcessResearchandDevelopment_label_en-US" xlink:label="lab_opk_InProcessResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_opk_InProcessResearchandDevelopment_documentation_en-US" xlink:label="lab_opk_InProcessResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InProcessResearchandDevelopment" xlink:href="opk-20200630.xsd#opk_InProcessResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_InProcessResearchandDevelopment" xlink:to="lab_opk_InProcessResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_762b6bfa-1fb6-4508-98f2-3fa0e1571270_terseLabel_en-US" xlink:label="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, in-process research and development and other intangible assets acquired</link:label>
    <link:label id="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_label_en-US" xlink:label="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets</link:label>
    <link:label id="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_documentation_en-US" xlink:label="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:href="opk-20200630.xsd#opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:to="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_43fea0d3-0cfd-4f52-a1f2-91ccb95748e5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_ad1aa6a7-5d99-473c-a722-9748faa3088f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage, equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_96c53736-28da-41e0-878b-10dd3eb8add3_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_3768e4cc-461a-469a-a626-4628a985beac_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_StrategicAlliancesTextBlock_b4397b59-22e4-450f-8766-6cd67be59171_terseLabel_en-US" xlink:label="lab_opk_StrategicAlliancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STRATEGIC ALLIANCES</link:label>
    <link:label id="lab_opk_StrategicAlliancesTextBlock_label_en-US" xlink:label="lab_opk_StrategicAlliancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances [Text Block]</link:label>
    <link:label id="lab_opk_StrategicAlliancesTextBlock_documentation_en-US" xlink:label="lab_opk_StrategicAlliancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StrategicAlliancesTextBlock" xlink:href="opk-20200630.xsd#opk_StrategicAlliancesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_StrategicAlliancesTextBlock" xlink:to="lab_opk_StrategicAlliancesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_213f0f2c-9adf-4e17-9476-b8ea86a2cd11_verboseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock options/warrants</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_aa9731e5-7a5c-4637-a31a-00e93c37e0f4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with no readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_93878ad6-ef6f-40fa-a222-43cacf597646_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8a6b1519-9ada-4077-a2f8-f4f56c216389_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94532de0-e1fe-4844-a386-bd959c6b7e10_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_92cce7d2-e7d8-4466-a930-6158222be9b6_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS AND ORGANIZATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b7c9f84f-0516-467c-b77a-532e005a9dc5_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets due to adoption of ASU No. 2016-02</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_605e14dd-ac44-473d-9db9-e3faffc465d0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 1, 2020 through December 31, 2020</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_0ce409b7-1153-44b7-ac9f-1a192fdd7865_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Method, Carrying Value and Underlying Equity in Net Assets of Unconsolidated Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTableTextBlock" xlink:to="lab_us-gaap_InvestmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a5d67979-0671-4815-b4f4-080f0851582b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_93029144-b5d3-4b12-be78-5ebf20c1724d_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inter-segment sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_24566e67-3769-4b77-b70a-be94717d59b9_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_07c97164-7347-4bcf-bdfd-7a0f18f52ad9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_5c70480d-39c1-4a05-92de-f0aac5b30bbf_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cb34f851-3c61-45a5-919c-a1c31dd38953_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_d5882a3d-5fa5-4887-ba7d-d0d77aaa258b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid (received), net of refunds</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c8335a9a-5fe9-4cbd-bcc4-ed1bf6523aac_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14dbeca3-51fc-4d8c-b734-9640623df2c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4b7c6b23-e2ef-4246-a291-26bbf839b489_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_39b0a5d0-7a7d-4aba-975d-ab8903ae5420_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DistributionToHealthcareProvidersCOVID19Member_940e6aea-35cb-42fb-ab5f-abca84b790bf_terseLabel_en-US" xlink:label="lab_opk_DistributionToHealthcareProvidersCOVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to Healthcare Providers, COVID-19</link:label>
    <link:label id="lab_opk_DistributionToHealthcareProvidersCOVID19Member_label_en-US" xlink:label="lab_opk_DistributionToHealthcareProvidersCOVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to Healthcare Providers, COVID-19 [Member]</link:label>
    <link:label id="lab_opk_DistributionToHealthcareProvidersCOVID19Member_documentation_en-US" xlink:label="lab_opk_DistributionToHealthcareProvidersCOVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to Healthcare Providers, COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DistributionToHealthcareProvidersCOVID19Member" xlink:href="opk-20200630.xsd#opk_DistributionToHealthcareProvidersCOVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DistributionToHealthcareProvidersCOVID19Member" xlink:to="lab_opk_DistributionToHealthcareProvidersCOVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f87b0af9-17ef-4f87-9b4e-8713a7d24622_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e43b25fe-8476-4b52-86b8-2cfd5bd0ea61_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a8de0f7d-5480-42b4-8f69-5cc4d671364b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_db391c64-9409-4165-9f6a-d2723bb06418_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases short-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_795b1fc5-d255-4c58-85ce-5817e6de0c25_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5d3800ad-67f9-41e4-98ff-c17cf88c7212_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_4f314e60-380a-43a1-910a-eb200fcd7cb8_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_91e98a6b-de6d-4eec-89fb-659539f80b2f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ScotiabankMember_4643483d-8d01-41e0-bee9-880ca5a47586_terseLabel_en-US" xlink:label="lab_opk_ScotiabankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scotiabank</link:label>
    <link:label id="lab_opk_ScotiabankMember_label_en-US" xlink:label="lab_opk_ScotiabankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scotiabank [Member]</link:label>
    <link:label id="lab_opk_ScotiabankMember_documentation_en-US" xlink:label="lab_opk_ScotiabankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scotiabank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ScotiabankMember" xlink:href="opk-20200630.xsd#opk_ScotiabankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ScotiabankMember" xlink:to="lab_opk_ScotiabankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_98749982-855a-4452-b0a5-05f057570f72_terseLabel_en-US" xlink:label="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:label id="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="opk-20200630.xsd#opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays_f2b29067-3515-4c29-9eb0-f1b6e004fb46_terseLabel_en-US" xlink:label="lab_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive days</link:label>
    <link:label id="lab_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays_label_en-US" xlink:label="lab_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Total Revolving Commitment, Threshold Consecutive Days</link:label>
    <link:label id="lab_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays_documentation_en-US" xlink:label="lab_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Total Revolving Commitment, Threshold Consecutive Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays" xlink:href="opk-20200630.xsd#opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays" xlink:to="lab_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e473d81f-73d6-4504-ac3c-22248b4bada9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Beginning and Ending Balances of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_dd22606f-a9c9-43ce-8867-5b76981927ad_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_718c9ac6-c9b7-48b8-944c-94b8a8aaee70_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_c656807c-84c4-4cfb-aad4-b53665364129_periodStartLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_657586b4-0a5d-4b32-a65b-65507bcd2f38_periodEndLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c5507052-71e6-4666-8a89-14285742a9b4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_VBIVaccinesIncMember_77c39c41-bfcd-4d4b-a98c-a35052632fe2_terseLabel_en-US" xlink:label="lab_opk_VBIVaccinesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VBI Vaccines Inc</link:label>
    <link:label id="lab_opk_VBIVaccinesIncMember_label_en-US" xlink:label="lab_opk_VBIVaccinesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VBI Vaccines Inc [Member]</link:label>
    <link:label id="lab_opk_VBIVaccinesIncMember_documentation_en-US" xlink:label="lab_opk_VBIVaccinesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VBI Vaccines Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_VBIVaccinesIncMember" xlink:href="opk-20200630.xsd#opk_VBIVaccinesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_VBIVaccinesIncMember" xlink:to="lab_opk_VBIVaccinesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f9b01f08-5b4e-428a-939b-7444aacab7b9_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_731b1e8a-35ab-4be2-a171-c32661906280_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants not to compete</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_25639f4e-e48f-472a-b87a-7897b3f9e4ae_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_1de23ab2-31a8-4bbc-ab0b-d299594fe54b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f319edb1-e9b4-413b-a41f-84f53250f8b9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_57196b6a-024d-46d6-87d8-56dd9ace0e4d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of Common Stock options and warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ed83ff6e-1d2f-48d2-a3e6-017545efaef7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net intangible assets other than goodwill</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_d0bb9b61-e44e-4385-9d91-1d0ff3fde76d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days applicable conversion price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_656a5b4a-a5a9-424b-83f4-2abd58546558_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_2b7c001e-d09c-4aa4-8af6-9e615e2fa3f7_terseLabel_en-US" xlink:label="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses.</link:label>
    <link:label id="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_label_en-US" xlink:label="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets (Accrued Expenses) [Member]</link:label>
    <link:label id="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_documentation_en-US" xlink:label="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets (Accrued Expenses) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:href="opk-20200630.xsd#opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:to="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment_5eb6b139-a049-4c91-8d21-8a02f0b6adeb_terseLabel_en-US" xlink:label="lab_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment under license agreements</link:label>
    <link:label id="lab_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment_label_en-US" xlink:label="lab_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements Proceeds as Up Front Payment</link:label>
    <link:label id="lab_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment_documentation_en-US" xlink:label="lab_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements Proceeds as Up Front Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment" xlink:href="opk-20200630.xsd#opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment" xlink:to="lab_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0449cb8c-e4ec-4c74-9c71-14c90ab8b6c8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit&#160;line capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_80e47163-f5c2-441a-a626-b7bd52da5479_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses:</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5f5ae726-e6d6-40b8-97f0-3d91809cee10_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a6c2191e-79ac-443d-9b36-daf9f4a481f5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_f9b57b15-a311-425e-816b-ce8d4b1307b1_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_57721fc4-fa16-4884-8956-8a3ef1b6a1d1_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_107d3ff8-7c31-4c90-8fd4-f6f3b4c73119_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_9348faf9-25c9-4e7a-a2ba-dbdabdd09b2a_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from investment in investees</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember_74ba31b6-1d68-4db9-936c-9606842ebf08_terseLabel_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR, Thereafter, Adjusted for Eurocurrency Liabilities</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember_label_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), Thereafter, Adjusted for Eurocurrency Liabilities [Member]</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember_documentation_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), Thereafter, Adjusted for Eurocurrency Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember" xlink:to="lab_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SharesReceivedAsGift_d5ab3146-127f-4544-a792-3428b778e8e8_terseLabel_en-US" xlink:label="lab_opk_SharesReceivedAsGift" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received as a gift (in shares)</link:label>
    <link:label id="lab_opk_SharesReceivedAsGift_label_en-US" xlink:label="lab_opk_SharesReceivedAsGift" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received As Gift</link:label>
    <link:label id="lab_opk_SharesReceivedAsGift_documentation_en-US" xlink:label="lab_opk_SharesReceivedAsGift" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received As Gift</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedAsGift" xlink:href="opk-20200630.xsd#opk_SharesReceivedAsGift"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SharesReceivedAsGift" xlink:to="lab_opk_SharesReceivedAsGift" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ea7ff541-9aed-4940-a567-54d31e518c6d_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eaa090df-bdf2-42e3-9757-519180ebc76c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2ed834cf-334a-4240-871a-9f0f7c4bc361_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f2a532dc-d786-4eee-a7ba-90f4672ca38a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_d616ebfd-515d-4e03-b009-9ec1b5602abe_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in investees</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_cb7f0eda-72af-4a0f-8f78-77c4c2e55eb7_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_d2d3c776-73a1-4dc9-ad96-136779b94ddb_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_MabVaxTherapeuticsHoldingsInc.Member_22a12487-4cb5-4df3-8c36-0e6f24f855bb_verboseLabel_en-US" xlink:label="lab_opk_MabVaxTherapeuticsHoldingsInc.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MabVax Therapeutics Holdings, Inc.</link:label>
    <link:label id="lab_opk_MabVaxTherapeuticsHoldingsInc.Member_26de9a29-3902-4647-9eed-1533d93b4ccd_terseLabel_en-US" xlink:label="lab_opk_MabVaxTherapeuticsHoldingsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MabVax</link:label>
    <link:label id="lab_opk_MabVaxTherapeuticsHoldingsInc.Member_label_en-US" xlink:label="lab_opk_MabVaxTherapeuticsHoldingsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MabVax Therapeutics Holdings, Inc. [Member]</link:label>
    <link:label id="lab_opk_MabVaxTherapeuticsHoldingsInc.Member_documentation_en-US" xlink:label="lab_opk_MabVaxTherapeuticsHoldingsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MabVax Therapeutics Holdings, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MabVaxTherapeuticsHoldingsInc.Member" xlink:href="opk-20200630.xsd#opk_MabVaxTherapeuticsHoldingsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_MabVaxTherapeuticsHoldingsInc.Member" xlink:to="lab_opk_MabVaxTherapeuticsHoldingsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_09ee3d41-5dde-4c3d-9012-0a46c47919d1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_13d3075e-aa31-44eb-a941-99470b476937_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DevelopmentandLicenseAgreementMember_c31eba80-6430-47d1-8d68-01c20a681d1c_terseLabel_en-US" xlink:label="lab_opk_DevelopmentandLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and License Agreement</link:label>
    <link:label id="lab_opk_DevelopmentandLicenseAgreementMember_label_en-US" xlink:label="lab_opk_DevelopmentandLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and License Agreement [Member]</link:label>
    <link:label id="lab_opk_DevelopmentandLicenseAgreementMember_documentation_en-US" xlink:label="lab_opk_DevelopmentandLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and License Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DevelopmentandLicenseAgreementMember" xlink:href="opk-20200630.xsd#opk_DevelopmentandLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DevelopmentandLicenseAgreementMember" xlink:to="lab_opk_DevelopmentandLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAbstract_e99a385a-05b0-426d-b021-410a24166dde_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Unclassified [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAbstract" xlink:to="lab_us-gaap_LongTermDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_104f7a56-1e5e-45c1-a019-d545dd01d335_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_3ee0fece-9361-40d6-8d67-e4908fdfb448_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_46d4754f-3db5-44c9-817d-0f86ec58ed37_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_e60c9dd9-bcbe-46e8-947a-94c059794005_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock - 549,907 shares at June 30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_89995240-05a9-46c3-9cba-93cfbdba05e2_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_355bc583-ae2a-4f84-ac5d-41871cc6660f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt repurchase amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_4541e668-beef-47a5-8772-f8e2a73ea4a9_terseLabel_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_label_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Warrants and Options, and Variable Interest Entities [Line Items]</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_documentation_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Warrants and Options, and Variable Interest Entities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:to="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aeea9aec-a212-4b2c-9f55-e611d14252c3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_70fd607c-0786-49f5-87c9-39a5abf89449_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8431db5e-be1e-4fcf-832c-a49a4a47d676_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_MilestoneDomain_c7e36987-2aff-44be-9520-e14e3d6f827f_terseLabel_en-US" xlink:label="lab_opk_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_opk_MilestoneDomain_label_en-US" xlink:label="lab_opk_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_opk_MilestoneDomain_documentation_en-US" xlink:label="lab_opk_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneDomain" xlink:href="opk-20200630.xsd#opk_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_MilestoneDomain" xlink:to="lab_opk_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_3904e7df-2c58-4d26-af40-b3902053d53f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetAbstract_6bf46505-d3e5-42d9-b17c-94e31388ad70_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net:</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract" xlink:to="lab_us-gaap_AccountsReceivableNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_5e865f47-047a-452d-93ee-900ca4ea931a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AutomobilesandAircraftMember_e49a4e21-b539-4a18-9ca4-0c5f21f36646_terseLabel_en-US" xlink:label="lab_opk_AutomobilesandAircraftMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automobiles and Aircraft</link:label>
    <link:label id="lab_opk_AutomobilesandAircraftMember_label_en-US" xlink:label="lab_opk_AutomobilesandAircraftMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automobiles and Aircraft [Member]</link:label>
    <link:label id="lab_opk_AutomobilesandAircraftMember_documentation_en-US" xlink:label="lab_opk_AutomobilesandAircraftMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automobiles and Aircraft [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AutomobilesandAircraftMember" xlink:href="opk-20200630.xsd#opk_AutomobilesandAircraftMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AutomobilesandAircraftMember" xlink:to="lab_opk_AutomobilesandAircraftMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_1c31704e-a1b1-40e9-80c5-e12a51dbf4ea_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_20d787eb-f89b-4447-80b7-ee14dbb7655d_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f6b15948-9895-4131-8a57-9e2578a22c2c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently adopted accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_be5140a4-e51b-437e-a12e-91343872cd6e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a04e9961-f879-4a6f-8a0f-9851d6f81bf4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>opk-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:58648600-8b9a-4bda-ba8d-a94f5b914ae0,g:b952a604-1bee-438c-aa3f-da7449f6ab9c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.opko.com/role/COVERPAGE" xlink:type="simple" xlink:href="opk-20200630.xsd#COVERPAGE"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/COVERPAGE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2706e4a2-be5b-48ea-8294-888d3bbfbc76" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_DocumentType_2706e4a2-be5b-48ea-8294-888d3bbfbc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_58b51c91-7006-4f53-8890-db831e8c1085" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_DocumentQuarterlyReport_58b51c91-7006-4f53-8890-db831e8c1085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cc33b190-e4ca-4560-9db6-968a5b09c83e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_DocumentPeriodEndDate_cc33b190-e4ca-4560-9db6-968a5b09c83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_142ec0a2-3fa1-4665-9ea5-76b0fe05b4da" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_DocumentTransitionReport_142ec0a2-3fa1-4665-9ea5-76b0fe05b4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_96598146-7623-4e62-80a3-0795d2321c25" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityFileNumber_96598146-7623-4e62-80a3-0795d2321c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8c16505c-4c5f-47c7-a816-f939032ab3c6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityRegistrantName_8c16505c-4c5f-47c7-a816-f939032ab3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4be23cfe-8e31-40db-a564-46f913adbc7a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4be23cfe-8e31-40db-a564-46f913adbc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_250f2450-74ff-4450-a012-5dd584678725" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityTaxIdentificationNumber_250f2450-74ff-4450-a012-5dd584678725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e3941f15-062d-42a8-84eb-50e1dee43e31" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityAddressAddressLine1_e3941f15-062d-42a8-84eb-50e1dee43e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f1b7021e-b09f-4cce-b8b4-be71cf3ad4a7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityAddressCityOrTown_f1b7021e-b09f-4cce-b8b4-be71cf3ad4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_53f12b91-cd5f-4e34-8c4b-78988f44642b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityAddressStateOrProvince_53f12b91-cd5f-4e34-8c4b-78988f44642b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_469c4023-a3cd-48e3-9c9c-9922e543800a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityAddressPostalZipCode_469c4023-a3cd-48e3-9c9c-9922e543800a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d0b3872f-1949-4ed2-84e3-5c39a0a5d68c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_CityAreaCode_d0b3872f-1949-4ed2-84e3-5c39a0a5d68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_483c5e1c-6449-4fb4-b285-7f80dba97b84" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_LocalPhoneNumber_483c5e1c-6449-4fb4-b285-7f80dba97b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c5c2fa8d-ad90-4e02-8246-bbdd3f3bc603" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_Security12bTitle_c5c2fa8d-ad90-4e02-8246-bbdd3f3bc603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e765e36b-5e65-40e4-b230-1b6001bc681c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_TradingSymbol_e765e36b-5e65-40e4-b230-1b6001bc681c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e0df1d19-85b4-407d-b887-51c6ceb34047" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_SecurityExchangeName_e0df1d19-85b4-407d-b887-51c6ceb34047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d324f37b-1011-4380-acea-0ddd12fbca5d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityCurrentReportingStatus_d324f37b-1011-4380-acea-0ddd12fbca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fdc21dd5-5821-4be9-ab73-cca91865a0f0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityInteractiveDataCurrent_fdc21dd5-5821-4be9-ab73-cca91865a0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_54af52a2-83cf-47f7-a4c3-737a189a7df8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityFilerCategory_54af52a2-83cf-47f7-a4c3-737a189a7df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_92d17c4d-876f-4c20-89d1-c33c5cbcae28" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntitySmallBusiness_92d17c4d-876f-4c20-89d1-c33c5cbcae28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4890328d-34ff-4604-b79f-2c307a565b0e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityEmergingGrowthCompany_4890328d-34ff-4604-b79f-2c307a565b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2d45d20e-bfa0-496b-9e82-20e49dd8a5c8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityShellCompany_2d45d20e-bfa0-496b-9e82-20e49dd8a5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8caa7081-0244-4539-b76a-8333b216f4ef" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8caa7081-0244-4539-b76a-8333b216f4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_487d1ea7-4651-47b0-a756-307a8cc0cb2e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_EntityCentralIndexKey_487d1ea7-4651-47b0-a756-307a8cc0cb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9a47893a-27ae-4d55-b23b-b48b99ce2a06" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_AmendmentFlag_9a47893a-27ae-4d55-b23b-b48b99ce2a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1b45d1a8-07fd-461d-b281-0031629c9404" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_DocumentFiscalYearFocus_1b45d1a8-07fd-461d-b281-0031629c9404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_44c46dc6-8715-49d7-8591-3ba65fed839f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_DocumentFiscalPeriodFocus_44c46dc6-8715-49d7-8591-3ba65fed839f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5858f1e2-ed11-4b20-bd7e-d932de86f408" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e96a0556-000f-4977-8dbe-78a43158b834" xlink:to="loc_dei_CurrentFiscalYearEndDate_5858f1e2-ed11-4b20-bd7e-d932de86f408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_923274d7-67ac-45b5-a158-b82227f5d961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b2cd045b-31fb-4699-9fad-7be20741c7c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_923274d7-67ac-45b5-a158-b82227f5d961" xlink:to="loc_us-gaap_AssetsAbstract_b2cd045b-31fb-4699-9fad-7be20741c7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c54eef52-664f-497f-8da6-a723b522d778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2cd045b-31fb-4699-9fad-7be20741c7c4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c54eef52-664f-497f-8da6-a723b522d778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e74497d5-bad6-49b0-9cb2-d226cf6df9ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c54eef52-664f-497f-8da6-a723b522d778" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e74497d5-bad6-49b0-9cb2-d226cf6df9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a1e5eb39-c421-4dcc-ab4c-f7b150261b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c54eef52-664f-497f-8da6-a723b522d778" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a1e5eb39-c421-4dcc-ab4c-f7b150261b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d7ba7fb4-8a56-4065-b2c7-413e80edb9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c54eef52-664f-497f-8da6-a723b522d778" xlink:to="loc_us-gaap_InventoryNet_d7ba7fb4-8a56-4065-b2c7-413e80edb9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7b7f5da1-6fc2-4fda-88ff-e0cbc33bd6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c54eef52-664f-497f-8da6-a723b522d778" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7b7f5da1-6fc2-4fda-88ff-e0cbc33bd6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_12c69537-ce2b-4c0a-9c4d-5d46c0186f29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c54eef52-664f-497f-8da6-a723b522d778" xlink:to="loc_us-gaap_AssetsCurrent_12c69537-ce2b-4c0a-9c4d-5d46c0186f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fca6cd29-52e5-419d-b63b-e83ca31619c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2cd045b-31fb-4699-9fad-7be20741c7c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fca6cd29-52e5-419d-b63b-e83ca31619c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_970a3458-5f8c-4bc0-979f-a17b43869c02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2cd045b-31fb-4699-9fad-7be20741c7c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_970a3458-5f8c-4bc0-979f-a17b43869c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InProcessResearchandDevelopment_1985d224-8af4-45ec-9ad2-69d5a1673bd4" xlink:href="opk-20200630.xsd#opk_InProcessResearchandDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2cd045b-31fb-4699-9fad-7be20741c7c4" xlink:to="loc_opk_InProcessResearchandDevelopment_1985d224-8af4-45ec-9ad2-69d5a1673bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_01ffe894-7525-4d4d-9e22-b928f7e3dd0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2cd045b-31fb-4699-9fad-7be20741c7c4" xlink:to="loc_us-gaap_Goodwill_01ffe894-7525-4d4d-9e22-b928f7e3dd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_0af42baa-bdb8-4554-bb7e-03e443ce6340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2cd045b-31fb-4699-9fad-7be20741c7c4" xlink:to="loc_us-gaap_LongTermInvestments_0af42baa-bdb8-4554-bb7e-03e443ce6340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d96a2783-6cfe-42a1-ba5b-2c6009098d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2cd045b-31fb-4699-9fad-7be20741c7c4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d96a2783-6cfe-42a1-ba5b-2c6009098d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6315374b-a343-4a9b-ad83-f1c004818aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2cd045b-31fb-4699-9fad-7be20741c7c4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6315374b-a343-4a9b-ad83-f1c004818aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2b54dab7-c0be-4a1e-8d6d-78cb874e6128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2cd045b-31fb-4699-9fad-7be20741c7c4" xlink:to="loc_us-gaap_Assets_2b54dab7-c0be-4a1e-8d6d-78cb874e6128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe1ab834-befc-4e2a-a8c9-96892af3e4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_923274d7-67ac-45b5-a158-b82227f5d961" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe1ab834-befc-4e2a-a8c9-96892af3e4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_131b3130-5fc4-4c75-b2d2-4036dade6734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe1ab834-befc-4e2a-a8c9-96892af3e4c2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_131b3130-5fc4-4c75-b2d2-4036dade6734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_042005f5-99aa-49c3-bbc5-5e2d607587d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_131b3130-5fc4-4c75-b2d2-4036dade6734" xlink:to="loc_us-gaap_AccountsPayableCurrent_042005f5-99aa-49c3-bbc5-5e2d607587d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2b327a74-c4a7-4282-8109-98ff4ac49841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_131b3130-5fc4-4c75-b2d2-4036dade6734" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2b327a74-c4a7-4282-8109-98ff4ac49841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_28d38610-8618-49dc-b3ea-7e0669ff9426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_131b3130-5fc4-4c75-b2d2-4036dade6734" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_28d38610-8618-49dc-b3ea-7e0669ff9426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_1cc12c54-ed43-481f-b64e-763bba4c16d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_131b3130-5fc4-4c75-b2d2-4036dade6734" xlink:to="loc_us-gaap_LinesOfCreditCurrent_1cc12c54-ed43-481f-b64e-763bba4c16d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f71d4292-5f10-464e-b75f-0d8703bf509d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_131b3130-5fc4-4c75-b2d2-4036dade6734" xlink:to="loc_us-gaap_LiabilitiesCurrent_f71d4292-5f10-464e-b75f-0d8703bf509d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32b8d097-5ab6-442a-b8db-985709c727fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe1ab834-befc-4e2a-a8c9-96892af3e4c2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32b8d097-5ab6-442a-b8db-985709c727fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_db41dd1d-0c5d-4761-84dc-cafd81158a90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe1ab834-befc-4e2a-a8c9-96892af3e4c2" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_db41dd1d-0c5d-4761-84dc-cafd81158a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3253f29d-4779-48a6-ad31-1e10364d6277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe1ab834-befc-4e2a-a8c9-96892af3e4c2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3253f29d-4779-48a6-ad31-1e10364d6277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e71a4854-dd0b-49a8-ab3a-15be8b320ce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe1ab834-befc-4e2a-a8c9-96892af3e4c2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e71a4854-dd0b-49a8-ab3a-15be8b320ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_4623a06a-3193-46db-8044-e83c010aa0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe1ab834-befc-4e2a-a8c9-96892af3e4c2" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_4623a06a-3193-46db-8044-e83c010aa0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5af4b206-92d9-4410-87ff-802cbbbeb5ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe1ab834-befc-4e2a-a8c9-96892af3e4c2" xlink:to="loc_us-gaap_Liabilities_5af4b206-92d9-4410-87ff-802cbbbeb5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a6c7f78c-75e3-45c8-a597-bc5a28850633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe1ab834-befc-4e2a-a8c9-96892af3e4c2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a6c7f78c-75e3-45c8-a597-bc5a28850633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_36911626-4c6e-4a0d-97d9-416a8608fd05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6c7f78c-75e3-45c8-a597-bc5a28850633" xlink:to="loc_us-gaap_CommonStockValue_36911626-4c6e-4a0d-97d9-416a8608fd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e076e9ed-0ef5-40e3-9635-ed5113278034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6c7f78c-75e3-45c8-a597-bc5a28850633" xlink:to="loc_us-gaap_TreasuryStockValue_e076e9ed-0ef5-40e3-9635-ed5113278034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_33541f5e-8224-4646-a5c6-cc12fecfe051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6c7f78c-75e3-45c8-a597-bc5a28850633" xlink:to="loc_us-gaap_AdditionalPaidInCapital_33541f5e-8224-4646-a5c6-cc12fecfe051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d9bfbf0-d32f-4db8-964c-455bed1aa057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6c7f78c-75e3-45c8-a597-bc5a28850633" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d9bfbf0-d32f-4db8-964c-455bed1aa057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_225b5ee5-bba9-48a8-8235-14ec4ee67c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6c7f78c-75e3-45c8-a597-bc5a28850633" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_225b5ee5-bba9-48a8-8235-14ec4ee67c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b3b4a949-14d9-47dd-9a26-d0e747de8bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6c7f78c-75e3-45c8-a597-bc5a28850633" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b3b4a949-14d9-47dd-9a26-d0e747de8bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e54010ff-5471-46ed-87ee-74f446b4a1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe1ab834-befc-4e2a-a8c9-96892af3e4c2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e54010ff-5471-46ed-87ee-74f446b4a1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1f15919a-ca57-4cee-9ef9-fc01cdf7e845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9f1a93cc-22cc-4cee-b091-ef001e2b80e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f15919a-ca57-4cee-9ef9-fc01cdf7e845" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9f1a93cc-22cc-4cee-b091-ef001e2b80e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_53f047e4-710b-45dd-8a7b-41c51ddc9440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f15919a-ca57-4cee-9ef9-fc01cdf7e845" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_53f047e4-710b-45dd-8a7b-41c51ddc9440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_892387ac-1e61-4c33-aade-dc77cfba29b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f15919a-ca57-4cee-9ef9-fc01cdf7e845" xlink:to="loc_us-gaap_CommonStockSharesIssued_892387ac-1e61-4c33-aade-dc77cfba29b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_481ad8e7-3516-49af-bf2c-9c44f4bfbb16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f15919a-ca57-4cee-9ef9-fc01cdf7e845" xlink:to="loc_us-gaap_TreasuryStockShares_481ad8e7-3516-49af-bf2c-9c44f4bfbb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fd023be2-c947-4709-8f01-7de9cecbc856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7ec50802-0b44-467e-8b23-d589e152c729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fd023be2-c947-4709-8f01-7de9cecbc856" xlink:to="loc_us-gaap_StatementTable_7ec50802-0b44-467e-8b23-d589e152c729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5fdb3f61-0b78-4678-a8ac-6d139145f7a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7ec50802-0b44-467e-8b23-d589e152c729" xlink:to="loc_srt_ProductOrServiceAxis_5fdb3f61-0b78-4678-a8ac-6d139145f7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_44c3c00f-c69e-4f04-ac9a-905e6c09ecbb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5fdb3f61-0b78-4678-a8ac-6d139145f7a0" xlink:to="loc_srt_ProductsAndServicesDomain_44c3c00f-c69e-4f04-ac9a-905e6c09ecbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_fe4c0408-f9b7-41d1-b4d1-b4590a4249b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_44c3c00f-c69e-4f04-ac9a-905e6c09ecbb" xlink:to="loc_us-gaap_ServiceMember_fe4c0408-f9b7-41d1-b4d1-b4590a4249b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3de89032-5582-49d2-a0d3-a6b984b646b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_44c3c00f-c69e-4f04-ac9a-905e6c09ecbb" xlink:to="loc_us-gaap_ProductMember_3de89032-5582-49d2-a0d3-a6b984b646b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_86432e3b-34be-4741-a919-d67f163ef608" xlink:href="opk-20200630.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_44c3c00f-c69e-4f04-ac9a-905e6c09ecbb" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_86432e3b-34be-4741-a919-d67f163ef608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7ec50802-0b44-467e-8b23-d589e152c729" xlink:to="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c4c8a360-6601-4ad1-8f2b-6078a80dc903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_RevenuesAbstract_c4c8a360-6601-4ad1-8f2b-6078a80dc903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_809748fb-a90f-4075-92b6-8a102eff5baf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c4c8a360-6601-4ad1-8f2b-6078a80dc903" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_809748fb-a90f-4075-92b6-8a102eff5baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0dec4383-f25c-4844-9157-c86b92041ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0dec4383-f25c-4844-9157-c86b92041ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b8310a55-1ba3-4224-8da4-c60168021a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b8310a55-1ba3-4224-8da4-c60168021a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7c885534-56ee-4826-9ea4-8e1928954e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7c885534-56ee-4826-9ea4-8e1928954e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_714ed1e8-1d20-4080-870e-367cb4a7e506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_714ed1e8-1d20-4080-870e-367cb4a7e506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9706d438-4ea6-440d-9e68-063060490ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9706d438-4ea6-440d-9e68-063060490ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4b84cfff-94d3-406e-835b-4bfaa7795f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_AssetImpairmentCharges_4b84cfff-94d3-406e-835b-4bfaa7795f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_694219e2-3d22-4b4a-94c0-8fe91c85cced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_01898fef-6659-46aa-ab9a-f1a2f6c5ae84" xlink:to="loc_us-gaap_OperatingExpenses_694219e2-3d22-4b4a-94c0-8fe91c85cced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c73dcd41-7a1d-4b59-aa6c-2a6fc7eb687d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_OperatingIncomeLoss_c73dcd41-7a1d-4b59-aa6c-2a6fc7eb687d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestIncomeNonoperating_abdbac11-e55c-46ae-a438-54337228c37b" xlink:href="opk-20200630.xsd#opk_InterestIncomeNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:to="loc_opk_InterestIncomeNonoperating_abdbac11-e55c-46ae-a438-54337228c37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestExpenseNonoperating_23061984-5a33-4d84-aa0a-feb55c13c8f0" xlink:href="opk-20200630.xsd#opk_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:to="loc_opk_InterestExpenseNonoperating_23061984-5a33-4d84-aa0a-feb55c13c8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_7635d446-a3bb-48ae-be7f-82bbe26f7e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_7635d446-a3bb-48ae-be7f-82bbe26f7e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_31d6df2d-e269-45ec-81eb-00b833cc00ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_31d6df2d-e269-45ec-81eb-00b833cc00ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bb68cb87-c76f-4e7a-bc62-df3cdf8cf8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b4bb900c-6636-48ec-beb1-3c0be8603b40" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bb68cb87-c76f-4e7a-bc62-df3cdf8cf8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c6949fa8-79ca-4920-9cf0-0052e82d6da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c6949fa8-79ca-4920-9cf0-0052e82d6da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_25189acb-9ef7-4d0f-a0e7-f25fd8263092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_25189acb-9ef7-4d0f-a0e7-f25fd8263092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_37e10be6-b1d9-4d79-a89e-ee5efb99fbab" xlink:href="opk-20200630.xsd#opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax_37e10be6-b1d9-4d79-a89e-ee5efb99fbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dc98842d-b233-4726-b920-cfae6866d441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dc98842d-b233-4726-b920-cfae6866d441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b24de358-fbdd-4c02-8dd6-31af5f6fffcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_ProfitLoss_b24de358-fbdd-4c02-8dd6-31af5f6fffcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6e849435-eb0e-4ab9-9b22-948f388cdf79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_EarningsPerShareAbstract_6e849435-eb0e-4ab9-9b22-948f388cdf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_745a0ec6-bdd0-4856-8391-d621ee79126c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6e849435-eb0e-4ab9-9b22-948f388cdf79" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_745a0ec6-bdd0-4856-8391-d621ee79126c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_abb12d92-5805-4a1a-8a45-dd4a373309d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13456f57-3aeb-4125-9de0-13e5264bf1fe" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_abb12d92-5805-4a1a-8a45-dd4a373309d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_20dd8726-5135-45b8-a2da-52fa9f67641b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e6f39c50-7d58-4286-9faf-e441f2d943da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_20dd8726-5135-45b8-a2da-52fa9f67641b" xlink:to="loc_us-gaap_ProfitLoss_e6f39c50-7d58-4286-9faf-e441f2d943da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_22decd29-5438-4a76-8f60-b25cd81acb93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_20dd8726-5135-45b8-a2da-52fa9f67641b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_22decd29-5438-4a76-8f60-b25cd81acb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2257c889-67c0-428e-a1b1-33365137b3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_22decd29-5438-4a76-8f60-b25cd81acb93" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2257c889-67c0-428e-a1b1-33365137b3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5e8741c0-3239-4235-ac5d-09057dae181c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_20dd8726-5135-45b8-a2da-52fa9f67641b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5e8741c0-3239-4235-ac5d-09057dae181c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="opk-20200630.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2fab32c6-6d83-4909-b1e6-35d2549e9bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_80ed3686-794a-41aa-9df3-6359d6285e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2fab32c6-6d83-4909-b1e6-35d2549e9bc1" xlink:to="loc_us-gaap_StatementTable_80ed3686-794a-41aa-9df3-6359d6285e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c748737e-1d64-41cb-ae73-054309352750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_80ed3686-794a-41aa-9df3-6359d6285e61" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c748737e-1d64-41cb-ae73-054309352750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c748737e-1d64-41cb-ae73-054309352750" xlink:to="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ee979a79-93fc-420e-af3d-020db10ea247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:to="loc_us-gaap_CommonStockMember_ee979a79-93fc-420e-af3d-020db10ea247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_16c9fc55-7cd5-4662-ad8c-2e3db0e68355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:to="loc_us-gaap_TreasuryStockMember_16c9fc55-7cd5-4662-ad8c-2e3db0e68355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d24a8ab2-228e-4013-9e69-ae2d7f28586a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d24a8ab2-228e-4013-9e69-ae2d7f28586a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_393235e1-4554-4a03-84a6-15e7349a9d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_393235e1-4554-4a03-84a6-15e7349a9d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2f65bbb4-2739-40b0-9d9a-bc0a6a5282f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f93dc36-ef70-48ad-907b-0a99c7ed0dcd" xlink:to="loc_us-gaap_RetainedEarningsMember_2f65bbb4-2739-40b0-9d9a-bc0a6a5282f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d81dbe2-0fc7-4013-88ea-a9bd2d439bec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_80ed3686-794a-41aa-9df3-6359d6285e61" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d81dbe2-0fc7-4013-88ea-a9bd2d439bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77905d76-b170-4e31-9cc3-7730283d9787" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d81dbe2-0fc7-4013-88ea-a9bd2d439bec" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77905d76-b170-4e31-9cc3-7730283d9787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1de22fd9-7f43-4355-ae73-d60f095fc84b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77905d76-b170-4e31-9cc3-7730283d9787" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1de22fd9-7f43-4355-ae73-d60f095fc84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d12c23df-d400-4d57-ace1-2468af8da8d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_80ed3686-794a-41aa-9df3-6359d6285e61" xlink:to="loc_us-gaap_StatementLineItems_d12c23df-d400-4d57-ace1-2468af8da8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d12c23df-d400-4d57-ace1-2468af8da8d4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_929738b5-56ee-48fa-8f24-c2c13c5815a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_SharesIssued_929738b5-56ee-48fa-8f24-c2c13c5815a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20a61e72-a74a-4165-a6cd-ff2079b20277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20a61e72-a74a-4165-a6cd-ff2079b20277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a3045994-5b82-4309-9dc7-b7597e8cc9a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a3045994-5b82-4309-9dc7-b7597e8cc9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b14b098-583c-4bab-b341-79abe53427b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b14b098-583c-4bab-b341-79abe53427b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6c38b8b0-bd03-459e-843c-9d58a50789cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6c38b8b0-bd03-459e-843c-9d58a50789cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1d2af96e-4b86-4568-ac53-28359cbd620f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1d2af96e-4b86-4568-ac53-28359cbd620f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b7c28cb0-9e5e-40cc-97b3-ee5f33c26565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b7c28cb0-9e5e-40cc-97b3-ee5f33c26565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b09d78ed-4831-4b3e-b489-c49db8c81cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_NetIncomeLoss_b09d78ed-4831-4b3e-b489-c49db8c81cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59ddda71-2504-422a-b027-9fe547a12fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59ddda71-2504-422a-b027-9fe547a12fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_d72c2613-7d1c-4b4e-a6cb-787d1bcdd0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_SharesIssued_d72c2613-7d1c-4b4e-a6cb-787d1bcdd0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ce9c52ab-2bf2-44ec-95ec-79df0ce62cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1dcbcb66-3de4-4013-8bae-88a4538fd0e8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ce9c52ab-2bf2-44ec-95ec-79df0ce62cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_4a850f44-53c6-4acd-b68f-c8bbc24f0e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d12c23df-d400-4d57-ace1-2468af8da8d4" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_4a850f44-53c6-4acd-b68f-c8bbc24f0e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="opk-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c0de6b87-d359-46fc-b846-af59c49fe353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7db2df33-82a4-424e-8437-f600625b074c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c0de6b87-d359-46fc-b846-af59c49fe353" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7db2df33-82a4-424e-8437-f600625b074c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9deccfbd-bd67-4f81-beba-f8182e6148fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7db2df33-82a4-424e-8437-f600625b074c" xlink:to="loc_us-gaap_ProfitLoss_9deccfbd-bd67-4f81-beba-f8182e6148fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7db2df33-82a4-424e-8437-f600625b074c" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_82739f33-cc30-4d00-b185-fa8499498139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_82739f33-cc30-4d00-b185-fa8499498139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_7cd1b6f0-8891-4a5d-85a9-e56955902846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:to="loc_us-gaap_PaidInKindInterest_7cd1b6f0-8891-4a5d-85a9-e56955902846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0b391bd0-d1a2-43b6-a38d-927afc04235a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0b391bd0-d1a2-43b6-a38d-927afc04235a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_552793d2-6eb2-4725-94f5-c0d4312ae85c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_552793d2-6eb2-4725-94f5-c0d4312ae85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_88dc3172-d3de-4011-a636-48d9a691c24d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:to="loc_us-gaap_ShareBasedCompensation_88dc3172-d3de-4011-a636-48d9a691c24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_77014c9a-a76f-4165-a48b-846d0ecd5fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_77014c9a-a76f-4165-a48b-846d0ecd5fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_4d527e55-ce79-4f63-943e-71cf2c16d101" xlink:href="opk-20200630.xsd#opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:to="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_4d527e55-ce79-4f63-943e-71cf2c16d101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_174f9838-5db3-4321-b70e-6db193660fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_174f9838-5db3-4321-b70e-6db193660fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_43b01cce-e895-4fef-97df-5854659298f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:to="loc_us-gaap_AssetImpairmentCharges_43b01cce-e895-4fef-97df-5854659298f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_86e75ebd-7dda-4496-95fc-6a2c34aa2df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_86e75ebd-7dda-4496-95fc-6a2c34aa2df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36130a41-9b87-4034-9966-258c74d89e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1223956f-878d-4a71-9489-adef92ec414b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36130a41-9b87-4034-9966-258c74d89e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8fc267e9-a767-4eb7-97f1-cbccfecea091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36130a41-9b87-4034-9966-258c74d89e18" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8fc267e9-a767-4eb7-97f1-cbccfecea091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6ed7cfa8-20d5-4199-885a-5367ca943a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36130a41-9b87-4034-9966-258c74d89e18" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6ed7cfa8-20d5-4199-885a-5367ca943a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4af5475d-fae9-44e5-a284-8f411a7236f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36130a41-9b87-4034-9966-258c74d89e18" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4af5475d-fae9-44e5-a284-8f411a7236f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a8673830-e405-4ff1-9dc9-bb4be83725e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36130a41-9b87-4034-9966-258c74d89e18" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a8673830-e405-4ff1-9dc9-bb4be83725e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bc88c956-ccaf-43b1-b69c-3b9853dc07ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36130a41-9b87-4034-9966-258c74d89e18" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bc88c956-ccaf-43b1-b69c-3b9853dc07ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement_36729799-0199-4fa4-94fa-82a5794c3fc4" xlink:href="opk-20200630.xsd#opk_IncreaseDecreaseinForeignCurrencyMeasurement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36130a41-9b87-4034-9966-258c74d89e18" xlink:to="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement_36729799-0199-4fa4-94fa-82a5794c3fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_dccc815d-ecfe-46f5-8b9c-54617bb6ab6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36130a41-9b87-4034-9966-258c74d89e18" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_dccc815d-ecfe-46f5-8b9c-54617bb6ab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_37eb8395-ec57-4ba9-8da8-c24b758f407e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36130a41-9b87-4034-9966-258c74d89e18" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_37eb8395-ec57-4ba9-8da8-c24b758f407e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8d824be3-b4a0-4c5b-8f32-c9b0543ec6b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7db2df33-82a4-424e-8437-f600625b074c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8d824be3-b4a0-4c5b-8f32-c9b0543ec6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9dd81175-23fb-4026-9ba3-c1cce1dc44dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c0de6b87-d359-46fc-b846-af59c49fe353" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9dd81175-23fb-4026-9ba3-c1cce1dc44dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_005905fe-3ad3-487c-a16e-34487c21b45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9dd81175-23fb-4026-9ba3-c1cce1dc44dc" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_005905fe-3ad3-487c-a16e-34487c21b45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_83fe44eb-2576-4e96-8cd4-5ba3417b3c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9dd81175-23fb-4026-9ba3-c1cce1dc44dc" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_83fe44eb-2576-4e96-8cd4-5ba3417b3c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_9e1f4df2-c1fc-4d63-b160-8dccf5f91241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9dd81175-23fb-4026-9ba3-c1cce1dc44dc" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_9e1f4df2-c1fc-4d63-b160-8dccf5f91241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7e92dad8-1af2-4b75-b761-4e765ededf06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9dd81175-23fb-4026-9ba3-c1cce1dc44dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7e92dad8-1af2-4b75-b761-4e765ededf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c53407c7-2c3c-4b7a-baf9-8341e89c01a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c0de6b87-d359-46fc-b846-af59c49fe353" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c53407c7-2c3c-4b7a-baf9-8341e89c01a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_9335a83a-9bf1-4dda-a4e6-d64e4c6c1265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c53407c7-2c3c-4b7a-baf9-8341e89c01a4" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_9335a83a-9bf1-4dda-a4e6-d64e4c6c1265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e8b5b108-53fc-4555-b2d1-01046afd8871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c53407c7-2c3c-4b7a-baf9-8341e89c01a4" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e8b5b108-53fc-4555-b2d1-01046afd8871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_440af37a-2db2-4772-b916-e0190ff76504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c53407c7-2c3c-4b7a-baf9-8341e89c01a4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_440af37a-2db2-4772-b916-e0190ff76504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_b07b19b5-1acd-47d0-8a40-88a07e232e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c53407c7-2c3c-4b7a-baf9-8341e89c01a4" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_b07b19b5-1acd-47d0-8a40-88a07e232e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_dd333b63-6869-4084-9ae1-794aa96be2e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c53407c7-2c3c-4b7a-baf9-8341e89c01a4" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_dd333b63-6869-4084-9ae1-794aa96be2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_fa48ac6f-5848-4432-86d6-0ec40077c59e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c53407c7-2c3c-4b7a-baf9-8341e89c01a4" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_fa48ac6f-5848-4432-86d6-0ec40077c59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bd843c3-44df-47e3-bdbd-2ffdc005dc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c53407c7-2c3c-4b7a-baf9-8341e89c01a4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bd843c3-44df-47e3-bdbd-2ffdc005dc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f81092a-ba59-4bc0-9c65-ea0ba5c48cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c53407c7-2c3c-4b7a-baf9-8341e89c01a4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f81092a-ba59-4bc0-9c65-ea0ba5c48cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f5e5528f-c5f5-493a-94b3-20ba5a2a1251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c0de6b87-d359-46fc-b846-af59c49fe353" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f5e5528f-c5f5-493a-94b3-20ba5a2a1251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e6a3759a-313a-4d46-87b2-ce35439f9453" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c0de6b87-d359-46fc-b846-af59c49fe353" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e6a3759a-313a-4d46-87b2-ce35439f9453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_259b2039-f18d-4713-8b69-5cc47d4fc955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c0de6b87-d359-46fc-b846-af59c49fe353" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_259b2039-f18d-4713-8b69-5cc47d4fc955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_13f713fe-6b1d-4fc0-a7b0-5c92c777a23a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c0de6b87-d359-46fc-b846-af59c49fe353" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_13f713fe-6b1d-4fc0-a7b0-5c92c777a23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_1afded8e-e814-4e9a-8234-c386f6c3305e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_13f713fe-6b1d-4fc0-a7b0-5c92c777a23a" xlink:to="loc_us-gaap_InterestPaidNet_1afded8e-e814-4e9a-8234-c386f6c3305e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_0687f916-e3fd-44d3-880d-9ce7e7cf2046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_13f713fe-6b1d-4fc0-a7b0-5c92c777a23a" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_0687f916-e3fd-44d3-880d-9ce7e7cf2046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9a5703c5-21b7-4d74-a156-1e9c7e7a95be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_13f713fe-6b1d-4fc0-a7b0-5c92c777a23a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9a5703c5-21b7-4d74-a156-1e9c7e7a95be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption_5fe5c20d-dd3d-4a2a-9908-2a710a940b58" xlink:href="opk-20200630.xsd#opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_13f713fe-6b1d-4fc0-a7b0-5c92c777a23a" xlink:to="loc_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption_5fe5c20d-dd3d-4a2a-9908-2a710a940b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3c382977-8100-44fb-ad75-9fc08afbee37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_13f713fe-6b1d-4fc0-a7b0-5c92c777a23a" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3c382977-8100-44fb-ad75-9fc08afbee37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract_1d1023c4-c448-4cb2-a61d-c4c4beba1406" xlink:href="opk-20200630.xsd#opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3c382977-8100-44fb-ad75-9fc08afbee37" xlink:to="loc_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract_1d1023c4-c448-4cb2-a61d-c4c4beba1406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CommonStockWarrantsNetExercised_a705f90d-33d1-471d-b0a3-9be8cf9e8552" xlink:href="opk-20200630.xsd#opk_CommonStockWarrantsNetExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract_1d1023c4-c448-4cb2-a61d-c4c4beba1406" xlink:to="loc_opk_CommonStockWarrantsNetExercised_a705f90d-33d1-471d-b0a3-9be8cf9e8552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/BusinessandOrganization" xlink:type="simple" xlink:href="opk-20200630.xsd#BusinessandOrganization"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/BusinessandOrganization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d026e64-8646-4103-bada-d77539d3a0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_635896b8-0054-444f-8e1c-3b9a8da89b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d026e64-8646-4103-bada-d77539d3a0a5" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_635896b8-0054-444f-8e1c-3b9a8da89b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/BusinessandOrganizationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#BusinessandOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/BusinessandOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_511243e3-5bb7-4b99-9393-a1e6fbb24b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NumberofSalesEmployees_02a03690-ee69-4a25-bae9-1331786839fe" xlink:href="opk-20200630.xsd#opk_NumberofSalesEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_511243e3-5bb7-4b99-9393-a1e6fbb24b88" xlink:to="loc_opk_NumberofSalesEmployees_02a03690-ee69-4a25-bae9-1331786839fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="opk-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_69a5e7d3-12e4-4dfc-8a64-c9eda711a208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b9fe0252-647c-42cd-b250-bff7507e84ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69a5e7d3-12e4-4dfc-8a64-c9eda711a208" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b9fe0252-647c-42cd-b250-bff7507e84ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="opk-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2ce89d2a-e898-43f6-adb6-40fe5cc7bd93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2ce89d2a-e898-43f6-adb6-40fe5cc7bd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_956314c1-205f-4bcd-8039-0b131ce8fac4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_956314c1-205f-4bcd-8039-0b131ce8fac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_2fc0a85d-34af-48da-81a6-94ee224168af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_UseOfEstimates_2fc0a85d-34af-48da-81a6-94ee224168af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c3cf2e7d-fe6b-4aba-bdf8-b93fc3b8a64c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c3cf2e7d-fe6b-4aba-bdf8-b93fc3b8a64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_ad6fd856-83ee-4586-bdd9-4219cb97f81b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_ad6fd856-83ee-4586-bdd9-4219cb97f81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_249844ff-f30a-4859-ac81-772425cae995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_249844ff-f30a-4859-ac81-772425cae995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_58dc3a20-5c4e-46cd-8c38-f1db4e5c6de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_58dc3a20-5c4e-46cd-8c38-f1db4e5c6de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_9ca17d9f-c903-4a69-8911-5555663969bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_9ca17d9f-c903-4a69-8911-5555663969bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_015a9de2-870c-4a05-aa0d-efa6f4618ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_015a9de2-870c-4a05-aa0d-efa6f4618ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_34dffcc7-b3bb-4858-b20c-44522081899f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_34dffcc7-b3bb-4858-b20c-44522081899f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5e10e471-67d0-43d7-8efa-b3e74638dfd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5e10e471-67d0-43d7-8efa-b3e74638dfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_111d6468-3f6a-4c06-9e23-4c680d922017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_111d6468-3f6a-4c06-9e23-4c680d922017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6b507b06-f5e5-487d-8bfc-bb7cc3a486aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6b507b06-f5e5-487d-8bfc-bb7cc3a486aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2366b003-f771-46e2-9282-87c7109465ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2366b003-f771-46e2-9282-87c7109465ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_a6f84a6a-ac0a-4503-917f-5e2919698d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_a6f84a6a-ac0a-4503-917f-5e2919698d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_4ac271b3-bdd8-4f30-bf33-3028471d1e68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_4ac271b3-bdd8-4f30-bf33-3028471d1e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_475db2a1-66f8-4c41-9a01-9800d1dce123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_475db2a1-66f8-4c41-9a01-9800d1dce123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_820faa99-2e8f-4e15-963f-3a4a8c505a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_820faa99-2e8f-4e15-963f-3a4a8c505a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_75f83d16-cda4-41bb-8495-c5de264911a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_75f83d16-cda4-41bb-8495-c5de264911a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_f769d124-43ec-4de2-ab8b-c526946ff115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_f769d124-43ec-4de2-ab8b-c526946ff115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_28e819e0-423d-4695-828f-32f05b9c8287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_28e819e0-423d-4695-828f-32f05b9c8287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70c8b5ce-456c-4deb-8f1c-e925f1c6f46c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d53f99ae-533f-4d21-91b9-0be308fffaf8" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70c8b5ce-456c-4deb-8f1c-e925f1c6f46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_15b316ea-0143-4d08-b468-47f0a7427051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:href="opk-20200630.xsd#opk_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15b316ea-0143-4d08-b468-47f0a7427051" xlink:to="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8fd47cf5-0add-4a7f-b703-14519433b1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8fd47cf5-0add-4a7f-b703-14519433b1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11028392-e943-4f23-91e7-33bb49130212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8fd47cf5-0add-4a7f-b703-14519433b1f6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11028392-e943-4f23-91e7-33bb49130212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5fe0c718-81f0-4fd4-aa59-1ccea07a9512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_11028392-e943-4f23-91e7-33bb49130212" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5fe0c718-81f0-4fd4-aa59-1ccea07a9512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_478ef007-185f-4631-9bcb-655a31b43cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_478ef007-185f-4631-9bcb-655a31b43cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_478ef007-185f-4631-9bcb-655a31b43cb6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_07095143-4472-493a-8b34-2ce47550a66e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_07095143-4472-493a-8b34-2ce47550a66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_0b9b93d2-b6f3-4cb3-b77d-c93515222a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_0b9b93d2-b6f3-4cb3-b77d-c93515222a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3b07bb48-ee46-4c9e-8b78-144f3fd89616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3b07bb48-ee46-4c9e-8b78-144f3fd89616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_c19f696f-e329-4e56-b3c1-4de8c68d4ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_c19f696f-e329-4e56-b3c1-4de8c68d4ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AutomobilesandAircraftMember_23ae3a29-9016-4d9a-a2ff-89d45d4aad0d" xlink:href="opk-20200630.xsd#opk_AutomobilesandAircraftMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60e5ce87-eeda-44e3-bbb0-040977f6c766" xlink:to="loc_opk_AutomobilesandAircraftMember_23ae3a29-9016-4d9a-a2ff-89d45d4aad0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_77c05984-a3f7-43be-a1b1-d4adb24424ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_77c05984-a3f7-43be-a1b1-d4adb24424ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d475fa2f-30b7-479b-95cc-0a936d0f2002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_77c05984-a3f7-43be-a1b1-d4adb24424ac" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d475fa2f-30b7-479b-95cc-0a936d0f2002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_c520d437-2613-4560-92b0-c138e7a3a412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d475fa2f-30b7-479b-95cc-0a936d0f2002" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_c520d437-2613-4560-92b0-c138e7a3a412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_213bbf98-2544-4057-839d-8e2517c29c62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d475fa2f-30b7-479b-95cc-0a936d0f2002" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_213bbf98-2544-4057-839d-8e2517c29c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2635bc3f-6955-4c04-a552-c64f201e7602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d475fa2f-30b7-479b-95cc-0a936d0f2002" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2635bc3f-6955-4c04-a552-c64f201e7602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6a9d878b-c415-447a-9b7a-69de82af3e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6a9d878b-c415-447a-9b7a-69de82af3e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0d1e6156-028e-41f2-88fc-633b91ff5df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6a9d878b-c415-447a-9b7a-69de82af3e6b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0d1e6156-028e-41f2-88fc-633b91ff5df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b662b676-afa2-4d59-89a8-0c0d5ecc258d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0d1e6156-028e-41f2-88fc-633b91ff5df3" xlink:to="loc_us-gaap_AccountsReceivableMember_b662b676-afa2-4d59-89a8-0c0d5ecc258d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f5c59a12-b2c9-4910-8eda-1466c2e5f0d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_srt_RangeAxis_f5c59a12-b2c9-4910-8eda-1466c2e5f0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b44db8d-f1f9-421b-9a1c-979d24ae10fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f5c59a12-b2c9-4910-8eda-1466c2e5f0d3" xlink:to="loc_srt_RangeMember_1b44db8d-f1f9-421b-9a1c-979d24ae10fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_461c3ff0-d633-4ff7-b3eb-f8f2a9281499" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b44db8d-f1f9-421b-9a1c-979d24ae10fc" xlink:to="loc_srt_MinimumMember_461c3ff0-d633-4ff7-b3eb-f8f2a9281499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4d1a9c9-cc05-4ee5-a294-b926cf5550b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b44db8d-f1f9-421b-9a1c-979d24ae10fc" xlink:to="loc_srt_MaximumMember_a4d1a9c9-cc05-4ee5-a294-b926cf5550b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestTypeAxis_09e5b85d-379b-4d5e-960b-21b4857932cf" xlink:href="opk-20200630.xsd#opk_COVID19TestTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_opk_COVID19TestTypeAxis_09e5b85d-379b-4d5e-960b-21b4857932cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestTypeDomain_b3831f01-262d-45ed-976e-7a1a1f605703" xlink:href="opk-20200630.xsd#opk_COVID19TestTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_COVID19TestTypeAxis_09e5b85d-379b-4d5e-960b-21b4857932cf" xlink:to="loc_opk_COVID19TestTypeDomain_b3831f01-262d-45ed-976e-7a1a1f605703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SerologyAntibodyTestMember_7a4ddcd5-1c97-4e12-8c2d-5fa3b9674604" xlink:href="opk-20200630.xsd#opk_SerologyAntibodyTestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_COVID19TestTypeDomain_b3831f01-262d-45ed-976e-7a1a1f605703" xlink:to="loc_opk_SerologyAntibodyTestMember_7a4ddcd5-1c97-4e12-8c2d-5fa3b9674604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticMolecularTestMember_b8345b19-edb0-4912-90d0-02bfc161e063" xlink:href="opk-20200630.xsd#opk_DiagnosticMolecularTestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_COVID19TestTypeDomain_b3831f01-262d-45ed-976e-7a1a1f605703" xlink:to="loc_opk_DiagnosticMolecularTestMember_b8345b19-edb0-4912-90d0-02bfc161e063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3ffb0585-c73e-4e08-90e4-b7ee0de5c004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3ffb0585-c73e-4e08-90e4-b7ee0de5c004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b899cfb0-0d4d-432e-890a-09f206dfcf18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3ffb0585-c73e-4e08-90e4-b7ee0de5c004" xlink:to="loc_us-gaap_SegmentDomain_b899cfb0-0d4d-432e-890a-09f206dfcf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember_07b594d0-6206-49d8-b6de-cd24fca5a4db" xlink:href="opk-20200630.xsd#opk_DiagnosticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b899cfb0-0d4d-432e-890a-09f206dfcf18" xlink:to="loc_opk_DiagnosticsMember_07b594d0-6206-49d8-b6de-cd24fca5a4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_edb7f0f9-ad34-4144-a894-ac4f75c5dc45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_srt_ProductOrServiceAxis_edb7f0f9-ad34-4144-a894-ac4f75c5dc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2507f82c-3a9c-4799-b5d8-68987ccd15e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_edb7f0f9-ad34-4144-a894-ac4f75c5dc45" xlink:to="loc_srt_ProductsAndServicesDomain_2507f82c-3a9c-4799-b5d8-68987ccd15e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_4588edd7-3a12-4536-97f6-974e4d1a8177" xlink:href="opk-20200630.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2507f82c-3a9c-4799-b5d8-68987ccd15e7" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_4588edd7-3a12-4536-97f6-974e4d1a8177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_95c854d6-f689-45ef-95cf-c81dd8b57abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_us-gaap_DebtInstrumentAxis_95c854d6-f689-45ef-95cf-c81dd8b57abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_16b2c628-02f4-427c-a04d-83fa90bc727a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_95c854d6-f689-45ef-95cf-c81dd8b57abf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_16b2c628-02f4-427c-a04d-83fa90bc727a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member_c68d1130-3ecc-492a-88c3-e825eee359c4" xlink:href="opk-20200630.xsd#opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_16b2c628-02f4-427c-a04d-83fa90bc727a" xlink:to="loc_opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member_c68d1130-3ecc-492a-88c3-e825eee359c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DistributionToHealthcareProvidersCOVID19Member_0b965b49-043e-45de-bf38-38fef5c6b99e" xlink:href="opk-20200630.xsd#opk_DistributionToHealthcareProvidersCOVID19Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_16b2c628-02f4-427c-a04d-83fa90bc727a" xlink:to="loc_opk_DistributionToHealthcareProvidersCOVID19Member_0b965b49-043e-45de-bf38-38fef5c6b99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:href="opk-20200630.xsd#opk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_5e8b9f31-6195-4efd-9721-07bff6662caf" xlink:to="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19NumberOfTestsPerformed_89901fce-7e31-4ded-a144-45d2d9c3bb63" xlink:href="opk-20200630.xsd#opk_COVID19NumberOfTestsPerformed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_opk_COVID19NumberOfTestsPerformed_89901fce-7e31-4ded-a144-45d2d9c3bb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19PercentOfTotalTestVolume_d23fcde4-622f-4b20-b0eb-504ad8f889d6" xlink:href="opk-20200630.xsd#opk_COVID19PercentOfTotalTestVolume"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_opk_COVID19PercentOfTotalTestVolume_d23fcde4-622f-4b20-b0eb-504ad8f889d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestsPerformedPerDay_1892d211-3a54-40fd-a4c2-fdb9d3828366" xlink:href="opk-20200630.xsd#opk_COVID19TestsPerformedPerDay"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_opk_COVID19TestsPerformedPerDay_1892d211-3a54-40fd-a4c2-fdb9d3828366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChangeInTestingVolumePercent_17802d8d-ace7-40c5-bfec-653e990c1374" xlink:href="opk-20200630.xsd#opk_ChangeInTestingVolumePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_opk_ChangeInTestingVolumePercent_17802d8d-ace7-40c5-bfec-653e990c1374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_838fb405-50b9-45d8-99ef-95f760611f25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_838fb405-50b9-45d8-99ef-95f760611f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed535878-e51a-45a3-8469-2c7d220ead0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed535878-e51a-45a3-8469-2c7d220ead0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_0102e3e1-9fb9-4bce-8650-0db14d6b3cb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_InventoryWriteDown_0102e3e1-9fb9-4bce-8650-0db14d6b3cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_232e18a6-e9dd-412b-a78b-8d5a826a41bb" xlink:href="opk-20200630.xsd#opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_232e18a6-e9dd-412b-a78b-8d5a826a41bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ea23ed4a-5646-4f7e-a134-c4eee4163c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_Goodwill_ea23ed4a-5646-4f7e-a134-c4eee4163c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8a073c40-ac1c-43cc-b08e-83e675120352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8a073c40-ac1c-43cc-b08e-83e675120352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d1e7f3ba-fbe9-4e7e-9dcc-f27ca15ab14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d1e7f3ba-fbe9-4e7e-9dcc-f27ca15ab14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d95a448b-5dcc-44ae-a570-0478f8b6c4de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d95a448b-5dcc-44ae-a570-0478f8b6c4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_643bd5fb-5c3d-467c-8f14-068fa539a539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_643bd5fb-5c3d-467c-8f14-068fa539a539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f6d78fc7-03d5-46bf-8f98-5967c7b59722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_Depreciation_f6d78fc7-03d5-46bf-8f98-5967c7b59722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6b56651f-b59d-4cdf-8283-955818f30b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6b56651f-b59d-4cdf-8283-955818f30b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_baa1d90b-7361-4cec-b5dd-db8309f90e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_baa1d90b-7361-4cec-b5dd-db8309f90e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_28b16a42-50f0-4228-9334-5bbb39acc6d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_28b16a42-50f0-4228-9334-5bbb39acc6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5320bc4a-85d5-47cc-84ea-562988ef80f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5320bc4a-85d5-47cc-84ea-562988ef80f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b03bfaf2-9c99-4d9d-afe2-cd1ddd749c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_4c8762b1-1ea2-491e-8097-341c6b581c0c" xlink:to="loc_us-gaap_NumberOfReportableSegments_b03bfaf2-9c99-4d9d-afe2-cd1ddd749c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="opk-20200630.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b4ea087c-47e0-4135-b755-e9e46028e832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_56388473-1f8c-4e79-b3a2-3d5fad542ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b4ea087c-47e0-4135-b755-e9e46028e832" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_56388473-1f8c-4e79-b3a2-3d5fad542ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/EarningsLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#EarningsLossPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/EarningsLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_42ba84bd-df6a-485a-8851-34c689f59d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_25ce60ff-9a8d-4617-9222-5f919de566a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_42ba84bd-df6a-485a-8851-34c689f59d5c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_25ce60ff-9a8d-4617-9222-5f919de566a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_511765d9-7212-44f4-a518-8f989d93421c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_25ce60ff-9a8d-4617-9222-5f919de566a0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_511765d9-7212-44f4-a518-8f989d93421c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fe5746e1-3214-4a42-9630-7296086854ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_511765d9-7212-44f4-a518-8f989d93421c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fe5746e1-3214-4a42-9630-7296086854ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7852446c-1863-45c3-b06b-9c742e5e8c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fe5746e1-3214-4a42-9630-7296086854ff" xlink:to="loc_us-gaap_CommonStockMember_7852446c-1863-45c3-b06b-9c742e5e8c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_25ce60ff-9a8d-4617-9222-5f919de566a0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bea510a0-7e37-4b69-8905-a7829501b043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bea510a0-7e37-4b69-8905-a7829501b043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d4918c57-1acb-46db-bf4e-77a293f92e44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d4918c57-1acb-46db-bf4e-77a293f92e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_8af523dc-7f9d-4112-9739-c746175f7866" xlink:href="opk-20200630.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:to="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_8af523dc-7f9d-4112-9739-c746175f7866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_b6468fdc-8a72-4ff9-980e-d69b0e591a1d" xlink:href="opk-20200630.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:to="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_b6468fdc-8a72-4ff9-980e-d69b0e591a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesSurrenderedInLieuOfCashPayment_186d1931-801d-4d4d-923e-0c5e8042fd51" xlink:href="opk-20200630.xsd#opk_SharesSurrenderedInLieuOfCashPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1628b42-7458-454e-baba-05c539b4055a" xlink:to="loc_opk_SharesSurrenderedInLieuOfCashPayment_186d1931-801d-4d4d-923e-0c5e8042fd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptions"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50391c61-abf0-4877-9234-4c34c21adac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b486f687-5df9-4f55-962e-da01c93044f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50391c61-abf0-4877-9234-4c34c21adac8" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b486f687-5df9-4f55-962e-da01c93044f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_feefe6d1-ef78-414b-ad0e-f2f99b545c75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock_c56881cc-0da9-4978-8232-c3b6e2af43ce" xlink:href="opk-20200630.xsd#opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_feefe6d1-ef78-414b-ad0e-f2f99b545c75" xlink:to="loc_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock_c56881cc-0da9-4978-8232-c3b6e2af43ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_e5c10702-f35e-461a-9203-0627e5b3d0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_feefe6d1-ef78-414b-ad0e-f2f99b545c75" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_e5c10702-f35e-461a-9203-0627e5b3d0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_898ebe3e-bd7b-42e4-bba2-ab2e2d9c36e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_85d51f30-d417-403e-a400-cebf51980e96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_898ebe3e-bd7b-42e4-bba2-ab2e2d9c36e0" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_85d51f30-d417-403e-a400-cebf51980e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0ef80fe-2768-48dd-954f-d9611ff2d722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_85d51f30-d417-403e-a400-cebf51980e96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0ef80fe-2768-48dd-954f-d9611ff2d722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0ef80fe-2768-48dd-954f-d9611ff2d722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_9e480e42-8ad3-4abc-b956-c305d5edda24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_9e480e42-8ad3-4abc-b956-c305d5edda24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d25db772-a732-4844-b4fe-6e8c1ad5bc5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d25db772-a732-4844-b4fe-6e8c1ad5bc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_66ec89db-a65a-4f24-a269-79f72d7168e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_TradeNamesMember_66ec89db-a65a-4f24-a269-79f72d7168e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_6133320a-6415-46ea-89d5-7533e571f7b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_6133320a-6415-46ea-89d5-7533e571f7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_44a73cae-3955-42a4-b666-b1295e41373f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_LicensingAgreementsMember_44a73cae-3955-42a4-b666-b1295e41373f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProductRegistrationsMember_e722d300-82da-4d5b-8921-333c27a97ff7" xlink:href="opk-20200630.xsd#opk_ProductRegistrationsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_opk_ProductRegistrationsMember_e722d300-82da-4d5b-8921-333c27a97ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1982953a-efa6-4c0e-b58b-d3c2a05fbe3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd4ed2d-148c-4f3f-b03f-abebc1d2516b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1982953a-efa6-4c0e-b58b-d3c2a05fbe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_85d51f30-d417-403e-a400-cebf51980e96" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetAbstract_aa85f27c-5593-4e3e-8cbc-436658457c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_AccountsReceivableNetAbstract_aa85f27c-5593-4e3e-8cbc-436658457c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_74d284c3-d587-427c-b091-3c285b525c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_aa85f27c-5593-4e3e-8cbc-436658457c8e" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_74d284c3-d587-427c-b091-3c285b525c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3a82703e-fbea-4295-929f-c6d7d8db976f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_aa85f27c-5593-4e3e-8cbc-436658457c8e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3a82703e-fbea-4295-929f-c6d7d8db976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_07ccae87-a15c-4e2d-87fc-afee53b34684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_aa85f27c-5593-4e3e-8cbc-436658457c8e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_07ccae87-a15c-4e2d-87fc-afee53b34684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_e204bd85-ad20-428c-8231-eabfe5451190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_OtherInventorySupplies_e204bd85-ad20-428c-8231-eabfe5451190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_e8e0f2a3-1094-44ed-a149-388e7264938d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_InventoryFinishedGoods_e8e0f2a3-1094-44ed-a149-388e7264938d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_b20e151f-b7df-415e-aac3-26ef3907026c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_InventoryWorkInProcess_b20e151f-b7df-415e-aac3-26ef3907026c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_8aa31d3c-5194-4cd5-bfa8-7b32e06054ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_InventoryRawMaterials_8aa31d3c-5194-4cd5-bfa8-7b32e06054ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_03d9ec7c-9ed4-49b0-bf54-247260d9a22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_InventoryValuationReserves_03d9ec7c-9ed4-49b0-bf54-247260d9a22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_711681b8-be9b-48c9-a48f-9110fa6d6421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_5cd8f9c3-a8b1-4723-8d1c-659e963577e2" xlink:to="loc_us-gaap_InventoryNet_711681b8-be9b-48c9-a48f-9110fa6d6421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TaxesRecoverableCurrent_37401a36-657a-4698-bab3-a40817cf16d8" xlink:href="opk-20200630.xsd#opk_TaxesRecoverableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_opk_TaxesRecoverableCurrent_37401a36-657a-4698-bab3-a40817cf16d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_cdab3529-50d3-458d-8fdd-1324759bb3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_us-gaap_Supplies_cdab3529-50d3-458d-8fdd-1324759bb3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_ec0a057c-f109-43ba-941e-a1774ef9a5be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_us-gaap_PrepaidInsurance_ec0a057c-f109-43ba-941e-a1774ef9a5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_8ab70079-d175-41e6-9591-f7d2b19951ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_8ab70079-d175-41e6-9591-f7d2b19951ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_66d99dc3-3cad-400a-86ae-62b4a56522a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_us-gaap_OtherAssetsCurrent_66d99dc3-3cad-400a-86ae-62b4a56522a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2af4ca3c-c627-4dff-a4aa-fdfbc5d071d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0be8b0dc-1e4e-4321-b6a7-cc71595a232a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2af4ca3c-c627-4dff-a4aa-fdfbc5d071d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b1491579-dfaa-4d1e-85d1-3d8c9910fb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b1491579-dfaa-4d1e-85d1-3d8c9910fb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_de4edd9c-07b2-4cde-8bbf-68bd56a1885d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b1491579-dfaa-4d1e-85d1-3d8c9910fb1a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_de4edd9c-07b2-4cde-8bbf-68bd56a1885d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_546d4727-ea66-4134-bfe9-19e7eb7227b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b1491579-dfaa-4d1e-85d1-3d8c9910fb1a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_546d4727-ea66-4134-bfe9-19e7eb7227b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f83e7965-b704-45b2-8467-b73aea16dfa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b1491579-dfaa-4d1e-85d1-3d8c9910fb1a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f83e7965-b704-45b2-8467-b73aea16dfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InventoryReceivedNotInvoicedCurrent_329d6f3b-88e1-477e-a578-b73244c5b356" xlink:href="opk-20200630.xsd#opk_InventoryReceivedNotInvoicedCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_opk_InventoryReceivedNotInvoicedCurrent_329d6f3b-88e1-477e-a578-b73244c5b356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedCommitmentsandContingenciesCurrent_9c6e0b09-d206-4e36-860b-247efe48ae40" xlink:href="opk-20200630.xsd#opk_AccruedCommitmentsandContingenciesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_opk_AccruedCommitmentsandContingenciesCurrent_9c6e0b09-d206-4e36-860b-247efe48ae40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_556ec7cf-e60a-4489-a8d4-a1f52a610d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_556ec7cf-e60a-4489-a8d4-a1f52a610d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_91dcd91b-3b9f-412a-a415-71797ef6de5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_91dcd91b-3b9f-412a-a415-71797ef6de5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedClinicalTrialsCurrent_f7cb12a9-d3b3-4bd6-9508-693580c64def" xlink:href="opk-20200630.xsd#opk_AccruedClinicalTrialsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_opk_AccruedClinicalTrialsCurrent_f7cb12a9-d3b3-4bd6-9508-693580c64def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_3cee56da-fc3a-49f7-85fc-ab72d5a55a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_3cee56da-fc3a-49f7-85fc-ab72d5a55a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_241fd4a9-0692-40b6-8638-05517e4f2ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_241fd4a9-0692-40b6-8638-05517e4f2ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f2c4e251-2186-4187-91fe-9ae6c64185cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f2c4e251-2186-4187-91fe-9ae6c64185cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_05b70946-b636-41af-9631-29213d83cafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_05b70946-b636-41af-9631-29213d83cafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_52231c4e-3d85-4bf2-b1cd-4d335f4695a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_de46a88b-054d-44a5-9dc2-b908d1b8521e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_52231c4e-3d85-4bf2-b1cd-4d335f4695a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_3174b38e-731b-44b8-902c-2370927f72dc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_abcfec9d-a9d3-4ddc-9cc0-b4fd320cb3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_LongTermLineOfCredit_abcfec9d-a9d3-4ddc-9cc0-b4fd320cb3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4da6c87f-4a98-443b-aba4-846d405157a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4da6c87f-4a98-443b-aba4-846d405157a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c38ee701-9c23-42ca-9a37-4ca71133b3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c38ee701-9c23-42ca-9a37-4ca71133b3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_28e4cac7-cf44-420a-8840-3f9026431b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_28e4cac7-cf44-420a-8840-3f9026431b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5efc3fe5-99e1-4067-9cba-dd186f0c34f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5efc3fe5-99e1-4067-9cba-dd186f0c34f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_fde6a189-d6c8-4a58-9fbc-5e6a856a633c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_fde6a189-d6c8-4a58-9fbc-5e6a856a633c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_27ba1bbf-1d68-41e0-b1f7-f16a7f0e6660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_200e4313-4328-46ff-89a9-8646603047ce" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_27ba1bbf-1d68-41e0-b1f7-f16a7f0e6660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a04f1155-38ca-49f5-90ff-b66785a7583e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_3e8d11d0-55fc-4a9e-920d-929fda7adf5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a04f1155-38ca-49f5-90ff-b66785a7583e" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_3e8d11d0-55fc-4a9e-920d-929fda7adf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_58194d7f-e963-4cb5-9d24-ab8d6d41ff02" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_3e8d11d0-55fc-4a9e-920d-929fda7adf5e" xlink:to="loc_srt_RangeAxis_58194d7f-e963-4cb5-9d24-ab8d6d41ff02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7332ac46-9e50-437b-b4ff-da6894bef4d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_58194d7f-e963-4cb5-9d24-ab8d6d41ff02" xlink:to="loc_srt_RangeMember_7332ac46-9e50-437b-b4ff-da6894bef4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7c350da1-164c-421b-99da-28d117e1c510" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7332ac46-9e50-437b-b4ff-da6894bef4d2" xlink:to="loc_srt_MinimumMember_7c350da1-164c-421b-99da-28d117e1c510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ffd921b-26ed-4915-8d8e-7b978168d1f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7332ac46-9e50-437b-b4ff-da6894bef4d2" xlink:to="loc_srt_MaximumMember_7ffd921b-26ed-4915-8d8e-7b978168d1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bc995521-23e5-47c2-9a96-44934c38716f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_3e8d11d0-55fc-4a9e-920d-929fda7adf5e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bc995521-23e5-47c2-9a96-44934c38716f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bc995521-23e5-47c2-9a96-44934c38716f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_38056fad-31c2-41a5-8477-6f1c87c5f427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_38056fad-31c2-41a5-8477-6f1c87c5f427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_a8b040c7-828a-4a88-ab04-2c0b3351fc97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_us-gaap_CustomerRelationshipsMember_a8b040c7-828a-4a88-ab04-2c0b3351fc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_97ab0d3b-a95e-4478-a4b1-8bd0db733e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_us-gaap_ProductMember_97ab0d3b-a95e-4478-a4b1-8bd0db733e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CovenantsNotToCompeteMember_1acffc4f-cc21-47d6-a827-13abe6130808" xlink:href="opk-20200630.xsd#opk_CovenantsNotToCompeteMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_opk_CovenantsNotToCompeteMember_1acffc4f-cc21-47d6-a827-13abe6130808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_2e058d6b-b476-44ab-b875-b2855eb16c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_us-gaap_TradeNamesMember_2e058d6b-b476-44ab-b875-b2855eb16c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_2a483d1e-fde8-4228-b61a-20ebc8d7d01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7514c808-890b-4e3d-8ac1-b20acc0c5dd6" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_2a483d1e-fde8-4228-b61a-20ebc8d7d01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_db99a4f4-c277-4c67-8d7b-e909c13e590c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_3e8d11d0-55fc-4a9e-920d-929fda7adf5e" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_db99a4f4-c277-4c67-8d7b-e909c13e590c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8915bf82-3969-4bb8-8bfd-1536779b22b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_db99a4f4-c277-4c67-8d7b-e909c13e590c" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8915bf82-3969-4bb8-8bfd-1536779b22b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b50a699c-fc7b-479e-a1a3-660e4c3898e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_004225c8-f042-4a95-9c58-d02e217bc5a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b50a699c-fc7b-479e-a1a3-660e4c3898e3" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_004225c8-f042-4a95-9c58-d02e217bc5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_35749cbb-d831-4cd4-b0d4-5b574ebce1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_004225c8-f042-4a95-9c58-d02e217bc5a6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_35749cbb-d831-4cd4-b0d4-5b574ebce1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d5f63a24-114a-4aa6-80e3-3b999490ff5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_35749cbb-d831-4cd4-b0d4-5b574ebce1dc" xlink:to="loc_us-gaap_SegmentDomain_d5f63a24-114a-4aa6-80e3-3b999490ff5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmaceuticalMember_983b0046-73c4-4c78-b902-d13525578ff9" xlink:href="opk-20200630.xsd#opk_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d5f63a24-114a-4aa6-80e3-3b999490ff5d" xlink:to="loc_opk_PharmaceuticalMember_983b0046-73c4-4c78-b902-d13525578ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember_1e9be080-3c1b-4a7b-a52a-125703d97dca" xlink:href="opk-20200630.xsd#opk_DiagnosticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d5f63a24-114a-4aa6-80e3-3b999490ff5d" xlink:to="loc_opk_DiagnosticsMember_1e9be080-3c1b-4a7b-a52a-125703d97dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_96c66614-0fe4-4cdd-9b39-c1f00d5c90b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_004225c8-f042-4a95-9c58-d02e217bc5a6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_96c66614-0fe4-4cdd-9b39-c1f00d5c90b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_96c66614-0fe4-4cdd-9b39-c1f00d5c90b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EirGenPharmaLimitedMember_f973aecc-9724-4ad1-b772-d43c43a4a88f" xlink:href="opk-20200630.xsd#opk_EirGenPharmaLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:to="loc_opk_EirGenPharmaLimitedMember_f973aecc-9724-4ad1-b772-d43c43a4a88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OpkoChileMember_43f52597-b35e-4fbb-af18-5a8cfff494a2" xlink:href="opk-20200630.xsd#opk_OpkoChileMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:to="loc_opk_OpkoChileMember_43f52597-b35e-4fbb-af18-5a8cfff494a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOBiologicsMember_ca0fbd42-4ac9-4448-8eee-7f675687ef95" xlink:href="opk-20200630.xsd#opk_OPKOBiologicsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:to="loc_opk_OPKOBiologicsMember_ca0fbd42-4ac9-4448-8eee-7f675687ef95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOHealthEuropeMember_c9c886f0-5f02-4367-8b0f-5ab0c562a2b7" xlink:href="opk-20200630.xsd#opk_OPKOHealthEuropeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:to="loc_opk_OPKOHealthEuropeMember_c9c886f0-5f02-4367-8b0f-5ab0c562a2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember_9c4226b1-f454-418f-9f86-b925cd45fe73" xlink:href="opk-20200630.xsd#opk_BioReferenceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4baf418-a740-4bcf-9659-fc2ffa6f9710" xlink:to="loc_opk_BioReferenceMember_9c4226b1-f454-418f-9f86-b925cd45fe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_88146fce-829f-46c6-80eb-43ad537feae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_004225c8-f042-4a95-9c58-d02e217bc5a6" xlink:to="loc_us-gaap_GoodwillLineItems_88146fce-829f-46c6-80eb-43ad537feae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_64d004a8-5aa8-4d87-857c-786a19272731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_88146fce-829f-46c6-80eb-43ad537feae1" xlink:to="loc_us-gaap_GoodwillRollForward_64d004a8-5aa8-4d87-857c-786a19272731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f4b05bda-9b9b-4773-94f9-90a2666b51fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_64d004a8-5aa8-4d87-857c-786a19272731" xlink:to="loc_us-gaap_Goodwill_f4b05bda-9b9b-4773-94f9-90a2666b51fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_b55a775e-e421-4ee6-9d73-3cf20763449a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_64d004a8-5aa8-4d87-857c-786a19272731" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_b55a775e-e421-4ee6-9d73-3cf20763449a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_65a154f1-da52-475f-ae75-e08dff7731c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_64d004a8-5aa8-4d87-857c-786a19272731" xlink:to="loc_us-gaap_Goodwill_65a154f1-da52-475f-ae75-e08dff7731c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/Investments" xlink:type="simple" xlink:href="opk-20200630.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_21c472e8-b8c7-4aa8-9892-4d1a9a8dc5fc" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock_b4558e51-2de9-4400-8d7c-6e462409ba8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_21c472e8-b8c7-4aa8-9892-4d1a9a8dc5fc" xlink:to="loc_us-gaap_InvestmentTextBlock_b4558e51-2de9-4400-8d7c-6e462409ba8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_8ca9b0b2-d82e-46c9-b13e-1946d34559b2" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock_7e6b8ef5-6309-4ac5-9270-fa1436920fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_8ca9b0b2-d82e-46c9-b13e-1946d34559b2" xlink:to="loc_us-gaap_InvestmentTableTextBlock_7e6b8ef5-6309-4ac5-9270-fa1436920fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_77fe1257-4e28-4d24-b5e5-d243c4c80a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_8ca9b0b2-d82e-46c9-b13e-1946d34559b2" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_77fe1257-4e28-4d24-b5e5-d243c4c80a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_88d67068-4029-4190-be1b-4142df3800b2" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity_18d7ce76-d981-4725-8d39-a8a56eb1c46f" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentExcludingVariableInterestEntity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_88d67068-4029-4190-be1b-4142df3800b2" xlink:to="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity_18d7ce76-d981-4725-8d39-a8a56eb1c46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentVariableInterestEntity_ce722906-e062-4982-8169-9881f7c2b1f9" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentVariableInterestEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_88d67068-4029-4190-be1b-4142df3800b2" xlink:to="loc_opk_EquityMethodInvestmentVariableInterestEntity_ce722906-e062-4982-8169-9881f7c2b1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_b9519a1b-7054-4aa1-9f31-4a5618919331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_88d67068-4029-4190-be1b-4142df3800b2" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_b9519a1b-7054-4aa1-9f31-4a5618919331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c990ea05-e828-4dab-a546-128c01dbd34c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_88d67068-4029-4190-be1b-4142df3800b2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c990ea05-e828-4dab-a546-128c01dbd34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockOptionandWarrantInvestments_b01be12e-3e4d-40e8-be7f-8df8bfd5b76a" xlink:href="opk-20200630.xsd#opk_StockOptionandWarrantInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_88d67068-4029-4190-be1b-4142df3800b2" xlink:to="loc_opk_StockOptionandWarrantInvestments_b01be12e-3e4d-40e8-be7f-8df8bfd5b76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_6e1d9558-571e-4654-b3a2-115753ae1dad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_88d67068-4029-4190-be1b-4142df3800b2" xlink:to="loc_us-gaap_LongTermInvestments_6e1d9558-571e-4654-b3a2-115753ae1dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_18ca9cb0-99f9-40cc-b4cc-afc121b35ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_88d67068-4029-4190-be1b-4142df3800b2" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_18ca9cb0-99f9-40cc-b4cc-afc121b35ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_8f524396-1cba-49dd-9b59-2e6716176616" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae3245df-6223-4c83-b75d-c8002a2af7d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_8f524396-1cba-49dd-9b59-2e6716176616" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae3245df-6223-4c83-b75d-c8002a2af7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8a916ddc-2cf2-4760-983e-d4dc9a7e4315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae3245df-6223-4c83-b75d-c8002a2af7d9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8a916ddc-2cf2-4760-983e-d4dc9a7e4315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d0e6a4bb-fa15-4a0e-9395-ebe5f9427d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8a916ddc-2cf2-4760-983e-d4dc9a7e4315" xlink:to="loc_us-gaap_ClassOfStockDomain_d0e6a4bb-fa15-4a0e-9395-ebe5f9427d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_0be583de-c177-4817-8269-4e8cd0a5634d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d0e6a4bb-fa15-4a0e-9395-ebe5f9427d75" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_0be583de-c177-4817-8269-4e8cd0a5634d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_526a7f10-279e-406b-8e96-3cc019de5518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d0e6a4bb-fa15-4a0e-9395-ebe5f9427d75" xlink:to="loc_us-gaap_RestrictedStockMember_526a7f10-279e-406b-8e96-3cc019de5518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e1a80245-e1cb-4b6d-a9c1-8bcda4e083fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae3245df-6223-4c83-b75d-c8002a2af7d9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e1a80245-e1cb-4b6d-a9c1-8bcda4e083fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e1a80245-e1cb-4b6d-a9c1-8bcda4e083fa" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember_f63ffec2-119a-4fff-9874-afd0adca2d02" xlink:href="opk-20200630.xsd#opk_PharmsynthezMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_PharmsynthezMember_f63ffec2-119a-4fff-9874-afd0adca2d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CocrystalMember_870b83da-0a5f-4cc8-bb50-8dc35acb8cf3" xlink:href="opk-20200630.xsd#opk_CocrystalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_CocrystalMember_870b83da-0a5f-4cc8-bb50-8dc35acb8cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NonInvasiveMonitoringSystemsInc.Member_8e1e23fd-ba3a-4347-83ca-9d49067a0326" xlink:href="opk-20200630.xsd#opk_NonInvasiveMonitoringSystemsInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_NonInvasiveMonitoringSystemsInc.Member_8e1e23fd-ba3a-4347-83ca-9d49067a0326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NeovascMember_2d31d299-1987-4a97-b270-cac4cbf5716a" xlink:href="opk-20200630.xsd#opk_NeovascMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_NeovascMember_2d31d299-1987-4a97-b270-cac4cbf5716a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InCellDxIncMember_8ab3e2d7-7f82-4528-9246-1754325a570b" xlink:href="opk-20200630.xsd#opk_InCellDxIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_InCellDxIncMember_8ab3e2d7-7f82-4528-9246-1754325a570b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_f8b0ed40-43ed-4696-8579-22881c3528e5" xlink:href="opk-20200630.xsd#opk_BioCardiaInc.Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_BioCardiaInc.Member_f8b0ed40-43ed-4696-8579-22881c3528e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_XeneticBiosciencesInc.Member_db84220c-4f0b-4dbf-8b0a-ec925f003ecf" xlink:href="opk-20200630.xsd#opk_XeneticBiosciencesInc.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_XeneticBiosciencesInc.Member_db84220c-4f0b-4dbf-8b0a-ec925f003ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhioPharmaceuticalsMember_e9bd82a9-195e-4007-ad6c-f1a609d88283" xlink:href="opk-20200630.xsd#opk_PhioPharmaceuticalsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_PhioPharmaceuticalsMember_e9bd82a9-195e-4007-ad6c-f1a609d88283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_VBIVaccinesIncMember_bdb49acc-e884-4c83-91f2-27acc727fc56" xlink:href="opk-20200630.xsd#opk_VBIVaccinesIncMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_VBIVaccinesIncMember_bdb49acc-e884-4c83-91f2-27acc727fc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromaDexMember_e2f4f73e-929b-482e-a685-ea8ff885eb54" xlink:href="opk-20200630.xsd#opk_ChromaDexMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_ChromaDexMember_e2f4f73e-929b-482e-a685-ea8ff885eb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MabVaxTherapeuticsHoldingsInc.Member_aa725fc3-87ea-4216-9624-1742cb68c136" xlink:href="opk-20200630.xsd#opk_MabVaxTherapeuticsHoldingsInc.Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_MabVaxTherapeuticsHoldingsInc.Member_aa725fc3-87ea-4216-9624-1742cb68c136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EloxxPharmaceuticalsMember_2434212b-e6fc-44a5-8b80-f3f08c402871" xlink:href="opk-20200630.xsd#opk_EloxxPharmaceuticalsMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_EloxxPharmaceuticalsMember_2434212b-e6fc-44a5-8b80-f3f08c402871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ZebraMember_81b34bf9-75e4-4db7-8af4-ab4f6f547cb5" xlink:href="opk-20200630.xsd#opk_ZebraMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ce43ff13-efaf-4d96-9bd4-273056fcafb8" xlink:to="loc_opk_ZebraMember_81b34bf9-75e4-4db7-8af4-ab4f6f547cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_cd4577cb-b396-46d8-852a-9017b3602381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae3245df-6223-4c83-b75d-c8002a2af7d9" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_cd4577cb-b396-46d8-852a-9017b3602381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_584f4e5d-c2ff-4de7-98ab-855bef4f5780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_cd4577cb-b396-46d8-852a-9017b3602381" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_584f4e5d-c2ff-4de7-98ab-855bef4f5780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_f9d55af7-f14a-4aaa-8604-fcb41128601f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_584f4e5d-c2ff-4de7-98ab-855bef4f5780" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_f9d55af7-f14a-4aaa-8604-fcb41128601f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae3245df-6223-4c83-b75d-c8002a2af7d9" xlink:to="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3db4e6bc-0431-4ecd-b769-bd1fb123b11b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3db4e6bc-0431-4ecd-b769-bd1fb123b11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9db798df-4bfe-4742-bcd9-c5d94b704e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_Assets_9db798df-4bfe-4742-bcd9-c5d94b704e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_190a7744-036b-4cd1-8b11-cf91a93ece7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_Liabilities_190a7744-036b-4cd1-8b11-cf91a93ece7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7abfaa7c-8951-4bde-8c8e-9e5813898297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_ProfitLoss_7abfaa7c-8951-4bde-8c8e-9e5813898297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_f4d9b4d3-a23f-45e0-b2c2-8d3bd44ac946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_f4d9b4d3-a23f-45e0-b2c2-8d3bd44ac946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquitySecurityFVNIOwnershipPercent_89f78c71-4ce9-4ff4-aef3-6642c0ead85e" xlink:href="opk-20200630.xsd#opk_EquitySecurityFVNIOwnershipPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_opk_EquitySecurityFVNIOwnershipPercent_89f78c71-4ce9-4ff4-aef3-6642c0ead85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4f798f5d-bdec-4532-b15e-4dddd98a07a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4f798f5d-bdec-4532-b15e-4dddd98a07a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested_3cc226e3-34a2-401c-bc15-75bc39e1d6b7" xlink:href="opk-20200630.xsd#opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested_3cc226e3-34a2-401c-bc15-75bc39e1d6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_b12dda57-b04a-4e61-a1c4-b326f15c7064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_b12dda57-b04a-4e61-a1c4-b326f15c7064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedAsGift_607bcee2-218f-413c-9272-421c15bfc162" xlink:href="opk-20200630.xsd#opk_SharesReceivedAsGift"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_eeea6369-f428-4013-8ddc-d57b0badb0ce" xlink:to="loc_opk_SharesReceivedAsGift_607bcee2-218f-413c-9272-421c15bfc162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_acb3c82c-39e5-410d-bd3c-b1716ebb6a06" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ec0f0195-8e1d-418f-a76b-604a09944517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_acb3c82c-39e5-410d-bd3c-b1716ebb6a06" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ec0f0195-8e1d-418f-a76b-604a09944517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_99ac9a1f-3dc3-4e01-adac-614a7ffa6f78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_acb3c82c-39e5-410d-bd3c-b1716ebb6a06" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_99ac9a1f-3dc3-4e01-adac-614a7ffa6f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_65878f05-0112-43b5-be94-643082dfcc96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_acb3c82c-39e5-410d-bd3c-b1716ebb6a06" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_65878f05-0112-43b5-be94-643082dfcc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/Debt" xlink:type="simple" xlink:href="opk-20200630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_24a2dde6-5257-40f4-a5db-b9526e84447e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_52e10ddc-2289-429e-a16d-8d6d35658433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_24a2dde6-5257-40f4-a5db-b9526e84447e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_52e10ddc-2289-429e-a16d-8d6d35658433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtTables" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f7b08c41-676c-4b09-abce-0793a44e2a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_32a36a5b-590f-49b0-99b5-0aa2e89cf1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f7b08c41-676c-4b09-abce-0793a44e2a8d" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_32a36a5b-590f-49b0-99b5-0aa2e89cf1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_197386a5-ecec-4325-97a9-25e57470bad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f7b08c41-676c-4b09-abce-0793a44e2a8d" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_197386a5-ecec-4325-97a9-25e57470bad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_02858067-f899-4ef9-bea3-052cebe85eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_02858067-f899-4ef9-bea3-052cebe85eb3" xlink:to="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2ae734b-fc32-4801-82f2-28b6c8defbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2ae734b-fc32-4801-82f2-28b6c8defbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8be75901-60a6-4839-bb74-bbc2d15fbbf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2ae734b-fc32-4801-82f2-28b6c8defbf6" xlink:to="loc_us-gaap_RelatedPartyDomain_8be75901-60a6-4839-bb74-bbc2d15fbbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DrFrostMember_2ee0f819-802c-4a81-91c2-8c7470492eda" xlink:href="opk-20200630.xsd#opk_DrFrostMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8be75901-60a6-4839-bb74-bbc2d15fbbf8" xlink:to="loc_opk_DrFrostMember_2ee0f819-802c-4a81-91c2-8c7470492eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_17ff36d6-7165-41f8-a8eb-8e5e242d5c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_StatementClassOfStockAxis_17ff36d6-7165-41f8-a8eb-8e5e242d5c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3ff7557a-44a6-4e78-af96-2b726f73a2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17ff36d6-7165-41f8-a8eb-8e5e242d5c8d" xlink:to="loc_us-gaap_ClassOfStockDomain_3ff7557a-44a6-4e78-af96-2b726f73a2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_01a97d68-46c4-401e-8baf-80282cc449ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3ff7557a-44a6-4e78-af96-2b726f73a2d3" xlink:to="loc_us-gaap_CommonStockMember_01a97d68-46c4-401e-8baf-80282cc449ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6c0e0897-d6af-4609-a07f-a2664d427196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_VariableRateAxis_6c0e0897-d6af-4609-a07f-a2664d427196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_6c0e0897-d6af-4609-a07f-a2664d427196" xlink:to="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_4728d3ec-007d-4c08-add1-4cb8a6758506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_4728d3ec-007d-4c08-add1-4cb8a6758506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_fb858177-8194-411f-8138-0a50b6f6d08a" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_fb858177-8194-411f-8138-0a50b6f6d08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORThereafterMember_bee286f5-1156-455a-9ce4-40b28d3b0004" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORThereafterMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORThereafterMember_bee286f5-1156-455a-9ce4-40b28d3b0004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_f295ab27-ef15-479f-bf7a-1fe4e4ba6e58" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_f295ab27-ef15-479f-bf7a-1fe4e4ba6e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember_8075721d-925f-4b11-8785-524e357a3a7c" xlink:href="opk-20200630.xsd#opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0ce74706-eb6c-48df-be96-d9296bdadaf5" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember_8075721d-925f-4b11-8785-524e357a3a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c2838c37-bf5d-44a1-82c3-467669a72abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_CreditFacilityAxis_c2838c37-bf5d-44a1-82c3-467669a72abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_c2838c37-bf5d-44a1-82c3-467669a72abe" xlink:to="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_fd5c6e91-7a88-4b43-aec1-58080e2e2eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:to="loc_us-gaap_LineOfCreditMember_fd5c6e91-7a88-4b43-aec1-58080e2e2eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2d40b3f5-1652-430c-bba0-9cb67657c97f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2d40b3f5-1652-430c-bba0-9cb67657c97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_fae6c95a-cd49-4b99-9130-c1fb345fea4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:to="loc_us-gaap_BridgeLoanMember_fae6c95a-cd49-4b99-9130-c1fb345fea4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_39d6bf3c-f4bd-4be2-a7c7-c1dfd011ec26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0e6510ed-cb99-4371-8344-b34061495472" xlink:to="loc_us-gaap_LetterOfCreditMember_39d6bf3c-f4bd-4be2-a7c7-c1dfd011ec26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_77d91a73-4c80-4fef-baeb-7e27f55a9c06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_77d91a73-4c80-4fef-baeb-7e27f55a9c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77d91a73-4c80-4fef-baeb-7e27f55a9c06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_6e64bdf9-1378-453c-8014-9024a5d65a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:to="loc_us-gaap_UnsecuredDebtMember_6e64bdf9-1378-453c-8014-9024a5d65a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_4a9f9895-24eb-4388-b389-24c2e6559ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:to="loc_us-gaap_LineOfCreditMember_4a9f9895-24eb-4388-b389-24c2e6559ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d3025166-d7a5-4087-b157-e1c9cbebd869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:to="loc_us-gaap_ConvertibleDebtMember_d3025166-d7a5-4087-b157-e1c9cbebd869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_c5159c6f-8cf4-4f54-b854-7405a80b6b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:to="loc_us-gaap_SeniorNotesMember_c5159c6f-8cf4-4f54-b854-7405a80b6b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_cd407291-f343-40f1-84fc-e3aafff9c51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_683f9911-c75b-499c-998d-4c6029af76b9" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_cd407291-f343-40f1-84fc-e3aafff9c51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1c5f825-a624-4d1e-9675-bf1f1063c220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1c5f825-a624-4d1e-9675-bf1f1063c220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1c5f825-a624-4d1e-9675-bf1f1063c220" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NewCreditAgreementMember_2ad8f7d6-80ea-4ba7-b68a-e44ee27c83cf" xlink:href="opk-20200630.xsd#opk_NewCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:to="loc_opk_NewCreditAgreementMember_2ad8f7d6-80ea-4ba7-b68a-e44ee27c83cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConvertibleSeniorNotesDue2025Member_201e9b84-c318-458e-885e-69e3a780b96b" xlink:href="opk-20200630.xsd#opk_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:to="loc_opk_ConvertibleSeniorNotesDue2025Member_201e9b84-c318-458e-885e-69e3a780b96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A5ConvertibleNotesMember_a13fe50b-dcae-4f4f-a422-c82ecb973d5e" xlink:href="opk-20200630.xsd#opk_A5ConvertibleNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:to="loc_opk_A5ConvertibleNotesMember_a13fe50b-dcae-4f4f-a422-c82ecb973d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesDueFebruary12033Member_e166bffd-baa2-42ec-9b0c-caef3e672109" xlink:href="opk-20200630.xsd#opk_NotesDueFebruary12033Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52d7181c-cb15-4931-a07b-7156a503fced" xlink:to="loc_opk_NotesDueFebruary12033Member_e166bffd-baa2-42ec-9b0c-caef3e672109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e80651f7-54c9-4457-8403-d15768ea3aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e80651f7-54c9-4457-8403-d15768ea3aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_483e35b1-ae74-46c4-b67b-e98bfa4353ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e80651f7-54c9-4457-8403-d15768ea3aa5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_483e35b1-ae74-46c4-b67b-e98bfa4353ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_02fc58d5-68fc-4493-8b50-9328ac60b5fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_483e35b1-ae74-46c4-b67b-e98bfa4353ab" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_02fc58d5-68fc-4493-8b50-9328ac60b5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_3e8ad7d0-5551-45e1-a447-ef3fd60ff9b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_483e35b1-ae74-46c4-b67b-e98bfa4353ab" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_3e8ad7d0-5551-45e1-a447-ef3fd60ff9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_62d9c7b8-49e1-46a7-9379-e9eb1f37baf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_483e35b1-ae74-46c4-b67b-e98bfa4353ab" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_62d9c7b8-49e1-46a7-9379-e9eb1f37baf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8dfab7a0-43d6-4857-b527-da89451ae521" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_srt_RangeAxis_8dfab7a0-43d6-4857-b527-da89451ae521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d57a8b0-8328-4994-a430-8e9f36fb0338" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8dfab7a0-43d6-4857-b527-da89451ae521" xlink:to="loc_srt_RangeMember_0d57a8b0-8328-4994-a430-8e9f36fb0338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f6c26e06-8f30-4e44-b19b-e15476b760d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d57a8b0-8328-4994-a430-8e9f36fb0338" xlink:to="loc_srt_MinimumMember_f6c26e06-8f30-4e44-b19b-e15476b760d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c812369-e76e-4554-b470-52b63a8b61a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d57a8b0-8328-4994-a430-8e9f36fb0338" xlink:to="loc_srt_MaximumMember_5c812369-e76e-4554-b470-52b63a8b61a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e6e6b2a0-99c2-44c5-aa4f-fee661e3a51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e6e6b2a0-99c2-44c5-aa4f-fee661e3a51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4317df3e-e13c-471a-b4ca-1de93bdd2f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6e6b2a0-99c2-44c5-aa4f-fee661e3a51f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4317df3e-e13c-471a-b4ca-1de93bdd2f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember_86866d7b-5081-4108-82f7-9e188efad247" xlink:href="opk-20200630.xsd#opk_BioReferenceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4317df3e-e13c-471a-b4ca-1de93bdd2f84" xlink:to="loc_opk_BioReferenceMember_86866d7b-5081-4108-82f7-9e188efad247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOHealthEuropeMember_66b44902-2815-4f07-9ce7-0920de8daf18" xlink:href="opk-20200630.xsd#opk_OPKOHealthEuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4317df3e-e13c-471a-b4ca-1de93bdd2f84" xlink:to="loc_opk_OPKOHealthEuropeMember_66b44902-2815-4f07-9ce7-0920de8daf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_18b07422-b2a0-4496-b204-cbd2c7f62591" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_45408dcc-d54d-40bf-9cf3-163bd4cc7d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_45408dcc-d54d-40bf-9cf3-163bd4cc7d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e0a28b21-0636-4dff-a1ac-ebbda329803e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e0a28b21-0636-4dff-a1ac-ebbda329803e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d128ba73-e318-4c1b-970f-dd3e41ff89df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d128ba73-e318-4c1b-970f-dd3e41ff89df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_06b4c43f-ee86-43db-825b-7206a176e41e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_06b4c43f-ee86-43db-825b-7206a176e41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6a1c2ad1-20a0-4674-bc14-d7dd6c64d59e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6a1c2ad1-20a0-4674-bc14-d7dd6c64d59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_ab2cc3c0-5f43-49bf-8a8c-421bda4b3abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_ab2cc3c0-5f43-49bf-8a8c-421bda4b3abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_b344394e-e158-4d56-b17a-29f74910a5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_b344394e-e158-4d56-b17a-29f74910a5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_cf42c9bc-33d0-45bf-9c30-a9853f2ae249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_cf42c9bc-33d0-45bf-9c30-a9853f2ae249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3c5f6cbf-b8da-413e-97aa-ae3efff6c5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3c5f6cbf-b8da-413e-97aa-ae3efff6c5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f31beb34-bff8-4485-9472-1c891229f9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f31beb34-bff8-4485-9472-1c891229f9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_abbcb2f1-0302-4ab5-a7cc-7636e9e8fb71" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_abbcb2f1-0302-4ab5-a7cc-7636e9e8fb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b602e607-f728-4fd8-8067-4070d9921ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b602e607-f728-4fd8-8067-4070d9921ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromConvertibleDebtConversionFee_346abce0-2a75-47cd-81c0-70a0f382b7f0" xlink:href="opk-20200630.xsd#opk_ProceedsFromConvertibleDebtConversionFee"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_ProceedsFromConvertibleDebtConversionFee_346abce0-2a75-47cd-81c0-70a0f382b7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_80ca9190-cf62-44ed-ba50-c16f7f8b77a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_80ca9190-cf62-44ed-ba50-c16f7f8b77a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9db37a6a-1c4a-4642-8632-913f570bfcec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9db37a6a-1c4a-4642-8632-913f570bfcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_29ee6974-9f51-4560-84a7-9b3523af55e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_29ee6974-9f51-4560-84a7-9b3523af55e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_ad5d9723-03f9-4aa5-8749-ca0710cfe183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentTerm_ad5d9723-03f9-4aa5-8749-ca0710cfe183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_f2c6a187-4d4f-4950-a0f0-bdf70c5cd1e7" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_f2c6a187-4d4f-4950-a0f0-bdf70c5cd1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_ba389e46-83ec-4a16-a28a-88a0e75be825" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_ba389e46-83ec-4a16-a28a-88a0e75be825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2139d68d-88d4-4b89-91ce-44bfb40b278e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2139d68d-88d4-4b89-91ce-44bfb40b278e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_f28f2617-ec8f-4df8-b2ad-479ec12788e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_f28f2617-ec8f-4df8-b2ad-479ec12788e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e47af8e1-e5e8-4294-83f3-7083c07752b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LongTermDebt_e47af8e1-e5e8-4294-83f3-7083c07752b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_02e2118e-39f1-42ad-b1ee-c3045ddc1454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_02e2118e-39f1-42ad-b1ee-c3045ddc1454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ce124920-d0e5-4608-8f3f-9a5bd91967cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ce124920-d0e5-4608-8f3f-9a5bd91967cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_272da164-9787-4803-bb4a-8b674e7ff74e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_272da164-9787-4803-bb4a-8b674e7ff74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage_5c555273-1378-4a4c-be7b-4bb5502eb283" xlink:href="opk-20200630.xsd#opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage_5c555273-1378-4a4c-be7b-4bb5502eb283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays_d077a6bc-da01-47da-808b-4bfcadb08c79" xlink:href="opk-20200630.xsd#opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays_d077a6bc-da01-47da-808b-4bfcadb08c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_d3e76148-d4ab-472e-a49c-4d713262b3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LongTermLineOfCredit_d3e76148-d4ab-472e-a49c-4d713262b3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0d975cb-81e5-434a-9ec7-e1785325a7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_StockholdersEquity_a0d975cb-81e5-434a-9ec7-e1785325a7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_53f6ce74-1488-4171-a62c-3f29a8f321df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_Goodwill_53f6ce74-1488-4171-a62c-3f29a8f321df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd0fc65d-a982-484f-8745-14d7a30df19c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd0fc65d-a982-484f-8745-14d7a30df19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentsNumberofFinancialInstitutions_500a842b-79bd-4d8e-9ade-26e921a1dcef" xlink:href="opk-20200630.xsd#opk_DebtInstrumentsNumberofFinancialInstitutions"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_opk_DebtInstrumentsNumberofFinancialInstitutions_500a842b-79bd-4d8e-9ade-26e921a1dcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_0f1c5490-db18-4bd8-a2a0-4741c242f76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_0f1c5490-db18-4bd8-a2a0-4741c242f76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_744a861f-c4d5-4ecb-9839-634102f1d013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4baccb7-ed85-4e2c-8530-bf38aaa4fa03" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_744a861f-c4d5-4ecb-9839-634102f1d013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtScheduleofNotesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_125af0d7-c414-484a-8032-a8b436b5538c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6f1ef4c7-65c3-4598-890e-ea5f641121a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_125af0d7-c414-484a-8032-a8b436b5538c" xlink:to="loc_us-gaap_DebtInstrumentTable_6f1ef4c7-65c3-4598-890e-ea5f641121a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4601e748-1133-4a0d-b439-13560da85545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1ef4c7-65c3-4598-890e-ea5f641121a8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4601e748-1133-4a0d-b439-13560da85545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e52d4003-79f2-42c0-ad87-8b89d182fc26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4601e748-1133-4a0d-b439-13560da85545" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e52d4003-79f2-42c0-ad87-8b89d182fc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7aeea4cd-3237-4c9c-bf2e-005aa60b6059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e52d4003-79f2-42c0-ad87-8b89d182fc26" xlink:to="loc_us-gaap_SeniorNotesMember_7aeea4cd-3237-4c9c-bf2e-005aa60b6059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8da5a301-46f4-4100-a0ad-decbb268ddaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6f1ef4c7-65c3-4598-890e-ea5f641121a8" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8da5a301-46f4-4100-a0ad-decbb268ddaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:href="opk-20200630.xsd#opk_DebtInstrumentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8da5a301-46f4-4100-a0ad-decbb268ddaa" xlink:to="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_91ec706c-9404-4387-aea4-ef4524e72a00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_91ec706c-9404-4387-aea4-ef4524e72a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0df5bc12-2d2e-4523-b9fa-f5f1877ae789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_91ec706c-9404-4387-aea4-ef4524e72a00" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0df5bc12-2d2e-4523-b9fa-f5f1877ae789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8c6d5fb0-ea1f-4459-bcd1-26496c452750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_91ec706c-9404-4387-aea4-ef4524e72a00" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8c6d5fb0-ea1f-4459-bcd1-26496c452750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_871b14c4-ad5e-4d99-835a-649cafd57244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_871b14c4-ad5e-4d99-835a-649cafd57244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3137d77c-fd14-4438-860e-ec77f10b06d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_871b14c4-ad5e-4d99-835a-649cafd57244" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3137d77c-fd14-4438-860e-ec77f10b06d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_f1a4a234-4228-4e76-8fcc-dd18c7c8b2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_871b14c4-ad5e-4d99-835a-649cafd57244" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_f1a4a234-4228-4e76-8fcc-dd18c7c8b2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a059c2e7-be92-45e0-913c-7ba7215622c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_871b14c4-ad5e-4d99-835a-649cafd57244" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a059c2e7-be92-45e0-913c-7ba7215622c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract_c353f31d-f0f1-437a-a7ca-bbbba92dbffa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:to="loc_us-gaap_DeferredFinanceCostsNetAbstract_c353f31d-f0f1-437a-a7ca-bbbba92dbffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c5daa0f4-5415-4177-b99f-7e5a3ea9d7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_c353f31d-f0f1-437a-a7ca-bbbba92dbffa" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c5daa0f4-5415-4177-b99f-7e5a3ea9d7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7c98713b-686f-4c09-8bbe-63bdb28bb331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_c353f31d-f0f1-437a-a7ca-bbbba92dbffa" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7c98713b-686f-4c09-8bbe-63bdb28bb331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cb2d903b-3b95-4c72-8c4c-16ca555b0b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_c353f31d-f0f1-437a-a7ca-bbbba92dbffa" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_cb2d903b-3b95-4c72-8c4c-16ca555b0b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAbstract_ea2a45af-1e36-4d40-9e5f-c85ba7c58698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_DebtInstrumentRollForward_95954c62-2a25-4994-8e0f-1eb6b5a367de" xlink:to="loc_us-gaap_LongTermDebtAbstract_ea2a45af-1e36-4d40-9e5f-c85ba7c58698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0b455962-5646-4d2b-8892-0ae0aa126331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_ea2a45af-1e36-4d40-9e5f-c85ba7c58698" xlink:to="loc_us-gaap_LongTermDebt_0b455962-5646-4d2b-8892-0ae0aa126331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_051343ba-0e78-42e4-a40b-2ab00b04e841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_ea2a45af-1e36-4d40-9e5f-c85ba7c58698" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_051343ba-0e78-42e4-a40b-2ab00b04e841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0406a719-8033-4e24-9b7c-755eba0a0987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_ea2a45af-1e36-4d40-9e5f-c85ba7c58698" xlink:to="loc_us-gaap_LongTermDebt_0406a719-8033-4e24-9b7c-755eba0a0987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtLinesofCreditDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtLinesofCreditDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DebtLinesofCreditDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fd5dd998-97a3-453c-8df3-f0f31e9b48b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_62a67fd0-4607-4360-98c9-e081a9811338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd5dd998-97a3-453c-8df3-f0f31e9b48b2" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_62a67fd0-4607-4360-98c9-e081a9811338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_911821e0-2a18-412e-bb2f-8acbf2ad3ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_62a67fd0-4607-4360-98c9-e081a9811338" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_911821e0-2a18-412e-bb2f-8acbf2ad3ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_911821e0-2a18-412e-bb2f-8acbf2ad3ab4" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_JPMorganChaseMember_613a2b44-a1e7-40a9-8645-83b6a3b385c7" xlink:href="opk-20200630.xsd#opk_JPMorganChaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_JPMorganChaseMember_613a2b44-a1e7-40a9-8645-83b6a3b385c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ItauBankMember_9be43a17-49f0-4161-a4b4-84a037852ea5" xlink:href="opk-20200630.xsd#opk_ItauBankMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_ItauBankMember_9be43a17-49f0-4161-a4b4-84a037852ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BankOfChileMember_4e649d8d-0f54-4ae7-a255-1542b2f4fadb" xlink:href="opk-20200630.xsd#opk_BankOfChileMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_BankOfChileMember_4e649d8d-0f54-4ae7-a255-1542b2f4fadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BiceBankMember_6114bf09-93d3-4bed-ab6a-fedbb2a01323" xlink:href="opk-20200630.xsd#opk_BiceBankMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_BiceBankMember_6114bf09-93d3-4bed-ab6a-fedbb2a01323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BbvaBankMember_5f7854ba-423a-4620-af89-e81b591c8633" xlink:href="opk-20200630.xsd#opk_BbvaBankMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_BbvaBankMember_5f7854ba-423a-4620-af89-e81b591c8633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SecurityMember_c5bc91ae-407d-4b79-add3-4f22161ecc0b" xlink:href="opk-20200630.xsd#opk_SecurityMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_SecurityMember_c5bc91ae-407d-4b79-add3-4f22161ecc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EstadoBankMember_d464f8ef-7941-4f59-89ab-d635f48cfc93" xlink:href="opk-20200630.xsd#opk_EstadoBankMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_EstadoBankMember_d464f8ef-7941-4f59-89ab-d635f48cfc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBankMember_efbb02aa-e670-48b3-98fa-dfccc9a2cb28" xlink:href="opk-20200630.xsd#opk_SantanderBankMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_SantanderBankMember_efbb02aa-e670-48b3-98fa-dfccc9a2cb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ScotiabankMember_a88ca397-a1b7-4bba-8413-67b4ab9d39c6" xlink:href="opk-20200630.xsd#opk_ScotiabankMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_ScotiabankMember_a88ca397-a1b7-4bba-8413-67b4ab9d39c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_Corpbanca1Member_d155f400-b13f-43a1-9f8c-e63e0ae5d4b8" xlink:href="opk-20200630.xsd#opk_Corpbanca1Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_Corpbanca1Member_d155f400-b13f-43a1-9f8c-e63e0ae5d4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BancoDeSabadellMember_109a7e75-56ea-4aee-b5c4-fd71d89b17b3" xlink:href="opk-20200630.xsd#opk_BancoDeSabadellMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_BancoDeSabadellMember_109a7e75-56ea-4aee-b5c4-fd71d89b17b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BilbaoVizcayaBankMember_09285760-ca6c-470b-a555-f0bbd752698e" xlink:href="opk-20200630.xsd#opk_BilbaoVizcayaBankMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_BilbaoVizcayaBankMember_09285760-ca6c-470b-a555-f0bbd752698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBank2MemberMember_2bc95c68-baa0-44fa-b88e-48fe16ec7e37" xlink:href="opk-20200630.xsd#opk_SantanderBank2MemberMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5f2ab706-5f65-4530-a5a4-baf8c16c5af3" xlink:to="loc_opk_SantanderBank2MemberMember_2bc95c68-baa0-44fa-b88e-48fe16ec7e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_a8b6a613-2316-4bb5-a5de-b164d484f777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_62a67fd0-4607-4360-98c9-e081a9811338" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_a8b6a613-2316-4bb5-a5de-b164d484f777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_eb7248cc-31c6-43dc-9427-bcb870bbb144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a8b6a613-2316-4bb5-a5de-b164d484f777" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_eb7248cc-31c6-43dc-9427-bcb870bbb144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e06deba3-69e9-4e77-a196-1357a0a36e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a8b6a613-2316-4bb5-a5de-b164d484f777" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e06deba3-69e9-4e77-a196-1357a0a36e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_24ce9d47-d019-473f-93ca-d60de63c8bec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a8b6a613-2316-4bb5-a5de-b164d484f777" xlink:to="loc_us-gaap_LineOfCredit_24ce9d47-d019-473f-93ca-d60de63c8bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DebtNotesPayableandOtherDebtDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8bd673e6-a7f5-4ddf-b8dd-905a4e8fc52a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bd1bab92-8e80-4d6e-852d-1775bc5488ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8bd673e6-a7f5-4ddf-b8dd-905a4e8fc52a" xlink:to="loc_us-gaap_DebtInstrumentTable_bd1bab92-8e80-4d6e-852d-1775bc5488ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_38e057be-e286-4bd9-85de-4174d3059628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bd1bab92-8e80-4d6e-852d-1775bc5488ed" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_38e057be-e286-4bd9-85de-4174d3059628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_96d35fe3-92e5-46ac-9ab5-88de3c892012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38e057be-e286-4bd9-85de-4174d3059628" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_96d35fe3-92e5-46ac-9ab5-88de3c892012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember_76089745-dc62-456a-9a7d-296220229f27" xlink:href="opk-20200630.xsd#opk_NotesPayableAndOtherLongTermLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_96d35fe3-92e5-46ac-9ab5-88de3c892012" xlink:to="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember_76089745-dc62-456a-9a7d-296220229f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_192a74ef-0a79-43cb-9f73-66871ab11357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bd1bab92-8e80-4d6e-852d-1775bc5488ed" xlink:to="loc_us-gaap_DebtInstrumentLineItems_192a74ef-0a79-43cb-9f73-66871ab11357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_143fe5c5-228b-44ce-ac79-d0f8ed2f55a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_192a74ef-0a79-43cb-9f73-66871ab11357" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_143fe5c5-228b-44ce-ac79-d0f8ed2f55a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9eaeb635-38f8-4cf2-aece-10c877a327e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_143fe5c5-228b-44ce-ac79-d0f8ed2f55a4" xlink:to="loc_us-gaap_LongTermDebtCurrent_9eaeb635-38f8-4cf2-aece-10c877a327e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_eec52490-19ab-43eb-8196-d1c8908c250e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_143fe5c5-228b-44ce-ac79-d0f8ed2f55a4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_eec52490-19ab-43eb-8196-d1c8908c250e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6ed809c6-3f50-4720-84ca-195cc3a31655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_143fe5c5-228b-44ce-ac79-d0f8ed2f55a4" xlink:to="loc_us-gaap_LongTermDebt_6ed809c6-3f50-4720-84ca-195cc3a31655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="simple" xlink:href="opk-20200630.xsd#AccumulatedOtherComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_55955967-d275-4ad5-8b62-62f656f4572b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_aa12edff-46f3-4628-8205-f68b47dd8735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_55955967-d275-4ad5-8b62-62f656f4572b" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_aa12edff-46f3-4628-8205-f68b47dd8735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="simple" xlink:href="opk-20200630.xsd#AccumulatedOtherComprehensiveLossTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dd23773d-3dc8-46ad-91f2-1b8597679696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3e3b070d-25a3-4d56-a541-a529e95a45a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd23773d-3dc8-46ad-91f2-1b8597679696" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3e3b070d-25a3-4d56-a541-a529e95a45a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#AccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_810b69bd-08cf-42a8-b627-b78bb32ea46d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e8750519-9574-430c-a686-41acabe7b477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_810b69bd-08cf-42a8-b627-b78bb32ea46d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e8750519-9574-430c-a686-41acabe7b477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a705dfdd-4c89-4602-b844-ea44748e50a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e8750519-9574-430c-a686-41acabe7b477" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a705dfdd-4c89-4602-b844-ea44748e50a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_333159c9-9d86-499b-84c6-974ed1896f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a705dfdd-4c89-4602-b844-ea44748e50a3" xlink:to="loc_us-gaap_EquityComponentDomain_333159c9-9d86-499b-84c6-974ed1896f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5c7a23b0-2bdd-4a61-973b-4a34273ff7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_333159c9-9d86-499b-84c6-974ed1896f23" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5c7a23b0-2bdd-4a61-973b-4a34273ff7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0ebfb0b4-9632-42a2-9cdf-42ac392a3c16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e8750519-9574-430c-a686-41acabe7b477" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0ebfb0b4-9632-42a2-9cdf-42ac392a3c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_289a6d5b-9782-409f-88ec-753ee21813ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0ebfb0b4-9632-42a2-9cdf-42ac392a3c16" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_289a6d5b-9782-409f-88ec-753ee21813ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c15ae0c5-e6df-4641-bf19-dfb94d02fb7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_289a6d5b-9782-409f-88ec-753ee21813ea" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c15ae0c5-e6df-4641-bf19-dfb94d02fb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_9d4ba352-d11a-4bfe-9ce9-be1ccb714b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_289a6d5b-9782-409f-88ec-753ee21813ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_9d4ba352-d11a-4bfe-9ce9-be1ccb714b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b4abd3af-982d-4e80-9765-dd14180fea49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_289a6d5b-9782-409f-88ec-753ee21813ea" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b4abd3af-982d-4e80-9765-dd14180fea49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e306bd20-ea73-4d03-aa11-3ac0c8ae1b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6d1502a6-9105-48b9-a50f-27ad6deedb2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e306bd20-ea73-4d03-aa11-3ac0c8ae1b79" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6d1502a6-9105-48b9-a50f-27ad6deedb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2f5e938e-8804-45ac-9f3c-ca33ddd7bf48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2cd76e9d-d3d4-4466-a18f-7d786a221d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2f5e938e-8804-45ac-9f3c-ca33ddd7bf48" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2cd76e9d-d3d4-4466-a18f-7d786a221d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a24e20f0-4769-4696-9bd2-b6cdc150d238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2f5e938e-8804-45ac-9f3c-ca33ddd7bf48" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a24e20f0-4769-4696-9bd2-b6cdc150d238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_70791925-b2e5-4ef4-8493-cb2b50ca5de2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2f5e938e-8804-45ac-9f3c-ca33ddd7bf48" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_70791925-b2e5-4ef4-8493-cb2b50ca5de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ca11ed58-fc60-48ec-9c6c-4aaa2074c7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cabd462-602f-4ae8-b16d-1cb87c72d232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ca11ed58-fc60-48ec-9c6c-4aaa2074c7fc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cabd462-602f-4ae8-b16d-1cb87c72d232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c8697f81-011f-47e0-bfff-1eb30e95fb1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cabd462-602f-4ae8-b16d-1cb87c72d232" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c8697f81-011f-47e0-bfff-1eb30e95fb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3dd39407-ce14-4526-a0ab-9d6ebc52212e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c8697f81-011f-47e0-bfff-1eb30e95fb1f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3dd39407-ce14-4526-a0ab-9d6ebc52212e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_da1be0bb-7ef3-4afa-8147-81d26cd3b393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3dd39407-ce14-4526-a0ab-9d6ebc52212e" xlink:to="loc_us-gaap_ForwardContractsMember_da1be0bb-7ef3-4afa-8147-81d26cd3b393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_72021263-8fec-4454-b1b1-aee643bff1bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cabd462-602f-4ae8-b16d-1cb87c72d232" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_72021263-8fec-4454-b1b1-aee643bff1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_362aeb2d-8b7c-443b-be5f-e6ffa9b51d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_72021263-8fec-4454-b1b1-aee643bff1bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_362aeb2d-8b7c-443b-be5f-e6ffa9b51d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7067a4c0-5015-4837-bf29-3c4934b7056f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_362aeb2d-8b7c-443b-be5f-e6ffa9b51d3b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7067a4c0-5015-4837-bf29-3c4934b7056f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f04620b0-f6f3-471b-8966-a33b93b81515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_362aeb2d-8b7c-443b-be5f-e6ffa9b51d3b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f04620b0-f6f3-471b-8966-a33b93b81515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0e165bc0-b6a6-4b90-b6b5-ffd7bc31188f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_362aeb2d-8b7c-443b-be5f-e6ffa9b51d3b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0e165bc0-b6a6-4b90-b6b5-ffd7bc31188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dc68236-3fc1-48f3-8922-0b1f47fae060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cabd462-602f-4ae8-b16d-1cb87c72d232" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dc68236-3fc1-48f3-8922-0b1f47fae060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dc68236-3fc1-48f3-8922-0b1f47fae060" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c5bb0679-7d45-458a-948e-8154bf1f07e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c5bb0679-7d45-458a-948e-8154bf1f07e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_700fac7d-5344-48f8-bddb-5e80212ea460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_700fac7d-5344-48f8-bddb-5e80212ea460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_46717f11-2390-4f74-8c99-dfe5badaec69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:to="loc_us-gaap_DerivativeAssets_46717f11-2390-4f74-8c99-dfe5badaec69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2bec454a-1436-4a52-ab0e-6cead7ac43f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_db67743f-f240-40a7-bdf0-95a0fa46f3cd" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2bec454a-1436-4a52-ab0e-6cead7ac43f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6e9f715d-1237-4bd6-9a6a-1324f7666393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dc68236-3fc1-48f3-8922-0b1f47fae060" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6e9f715d-1237-4bd6-9a6a-1324f7666393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a880fe0d-809c-454c-b4c8-0c8f4dd0ffe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6e9f715d-1237-4bd6-9a6a-1324f7666393" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a880fe0d-809c-454c-b4c8-0c8f4dd0ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_170eb3b0-649d-431f-9a1e-67affc2c1eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6e9f715d-1237-4bd6-9a6a-1324f7666393" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_170eb3b0-649d-431f-9a1e-67affc2c1eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsLevel3ReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2b7b6504-b184-46fa-9070-6cae55848087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_3305c0ca-e8cd-4dfe-b108-fddf34094ad8" xlink:href="opk-20200630.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2b7b6504-b184-46fa-9070-6cae55848087" xlink:to="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_3305c0ca-e8cd-4dfe-b108-fddf34094ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_56348b2b-a727-433c-8fd0-2d11a7f0e2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_3305c0ca-e8cd-4dfe-b108-fddf34094ad8" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_56348b2b-a727-433c-8fd0-2d11a7f0e2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a7120ca6-4f0e-46ab-9570-66096f517461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_56348b2b-a727-433c-8fd0-2d11a7f0e2ad" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a7120ca6-4f0e-46ab-9570-66096f517461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ContingentConsiderationMember_5c007013-1b45-4e82-a695-2f79df0acc3f" xlink:href="opk-20200630.xsd#opk_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a7120ca6-4f0e-46ab-9570-66096f517461" xlink:to="loc_opk_ContingentConsiderationMember_5c007013-1b45-4e82-a695-2f79df0acc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_0a083107-ec9c-40fa-b9d5-38926a777bda" xlink:href="opk-20200630.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_3305c0ca-e8cd-4dfe-b108-fddf34094ad8" xlink:to="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_0a083107-ec9c-40fa-b9d5-38926a777bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db95081a-b4da-48ba-a6bc-110c3acdf409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_0a083107-ec9c-40fa-b9d5-38926a777bda" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db95081a-b4da-48ba-a6bc-110c3acdf409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_68e0921d-e31b-4ce4-817f-de08bf2dd104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db95081a-b4da-48ba-a6bc-110c3acdf409" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_68e0921d-e31b-4ce4-817f-de08bf2dd104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b1e3d3df-0cec-4d71-86d5-2ac1efbead77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db95081a-b4da-48ba-a6bc-110c3acdf409" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b1e3d3df-0cec-4d71-86d5-2ac1efbead77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6518c874-da69-44d1-8433-343f8ebd1946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db95081a-b4da-48ba-a6bc-110c3acdf409" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6518c874-da69-44d1-8433-343f8ebd1946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0bf893c4-92c1-44fb-9cc1-f33c945ccb4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4445c607-2a71-486b-9868-14a7ce783098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0bf893c4-92c1-44fb-9cc1-f33c945ccb4f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4445c607-2a71-486b-9868-14a7ce783098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2d086b5f-3845-4bd8-a301-7e8e19aae496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4445c607-2a71-486b-9868-14a7ce783098" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2d086b5f-3845-4bd8-a301-7e8e19aae496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4e0f42b0-9fb5-455c-9ae3-bce70f38802e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2d086b5f-3845-4bd8-a301-7e8e19aae496" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4e0f42b0-9fb5-455c-9ae3-bce70f38802e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_caffdeae-97f8-4c36-bdc7-d6941ca1e20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4e0f42b0-9fb5-455c-9ae3-bce70f38802e" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_caffdeae-97f8-4c36-bdc7-d6941ca1e20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0990b35f-c87e-4477-8dfe-253245ef2c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4e0f42b0-9fb5-455c-9ae3-bce70f38802e" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0990b35f-c87e-4477-8dfe-253245ef2c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f45023a-ddf9-45cf-bef0-d4259bbdc023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4445c607-2a71-486b-9868-14a7ce783098" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f45023a-ddf9-45cf-bef0-d4259bbdc023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e2c64d74-7e78-41d0-90ac-f11070868786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f45023a-ddf9-45cf-bef0-d4259bbdc023" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e2c64d74-7e78-41d0-90ac-f11070868786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContracts" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContracts"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DerivativeContracts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a3d9d92-8b1e-4f12-9d82-d30e772979aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_294864a4-4b29-487d-ab05-08255a15129f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a3d9d92-8b1e-4f12-9d82-d30e772979aa" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_294864a4-4b29-487d-ab05-08255a15129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContractsTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DerivativeContractsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_37702fbb-e21d-4930-b205-fec024e05b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0167280c-872d-4d4e-975a-d82f11856c55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_37702fbb-e21d-4930-b205-fec024e05b5d" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0167280c-872d-4d4e-975a-d82f11856c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_480c714a-2acb-4c4f-bc0c-d19ab528acd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_37702fbb-e21d-4930-b205-fec024e05b5d" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_480c714a-2acb-4c4f-bc0c-d19ab528acd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContractsBalanceSheetComponentDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d419aa2b-9a08-4007-bae7-158ab7988e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_f53b7810-eb4a-442b-983c-679708a31929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d419aa2b-9a08-4007-bae7-158ab7988e14" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_f53b7810-eb4a-442b-983c-679708a31929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_741c8bc1-a4c7-43bc-8391-826592644340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_f53b7810-eb4a-442b-983c-679708a31929" xlink:to="loc_us-gaap_HedgingDesignationAxis_741c8bc1-a4c7-43bc-8391-826592644340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_cec7aaa8-a906-4e3d-ad8b-868dc0d0a148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_741c8bc1-a4c7-43bc-8391-826592644340" xlink:to="loc_us-gaap_HedgingDesignationDomain_cec7aaa8-a906-4e3d-ad8b-868dc0d0a148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_19a6449a-1e32-46fa-bb98-1fd3033b80e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_cec7aaa8-a906-4e3d-ad8b-868dc0d0a148" xlink:to="loc_us-gaap_NondesignatedMember_19a6449a-1e32-46fa-bb98-1fd3033b80e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_685be12b-a065-4f31-b1b9-5af84fd9f5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_f53b7810-eb4a-442b-983c-679708a31929" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_685be12b-a065-4f31-b1b9-5af84fd9f5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_11e18bf2-f293-4c3a-b31d-bb2dadfa47e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_685be12b-a065-4f31-b1b9-5af84fd9f5bc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_11e18bf2-f293-4c3a-b31d-bb2dadfa47e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_8033c738-e15e-4a86-81fc-b93620d03011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_11e18bf2-f293-4c3a-b31d-bb2dadfa47e4" xlink:to="loc_us-gaap_StockOptionMember_8033c738-e15e-4a86-81fc-b93620d03011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_d9d13fad-09bd-4c88-a41e-0bad29b76dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_11e18bf2-f293-4c3a-b31d-bb2dadfa47e4" xlink:to="loc_us-gaap_ForwardContractsMember_d9d13fad-09bd-4c88-a41e-0bad29b76dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6a3e4a0f-bc89-4052-ad64-5bfed67f5f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_f53b7810-eb4a-442b-983c-679708a31929" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6a3e4a0f-bc89-4052-ad64-5bfed67f5f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_693fe8ea-43f0-4eee-b81c-1608f7f6b304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6a3e4a0f-bc89-4052-ad64-5bfed67f5f6e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_693fe8ea-43f0-4eee-b81c-1608f7f6b304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_de5a009c-f0d6-4d69-a099-24725c2e52e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_693fe8ea-43f0-4eee-b81c-1608f7f6b304" xlink:to="loc_us-gaap_InvestmentsMember_de5a009c-f0d6-4d69-a099-24725c2e52e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_8bb3b5f8-694c-45df-b1d1-1fdf45faad94" xlink:href="opk-20200630.xsd#opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_693fe8ea-43f0-4eee-b81c-1608f7f6b304" xlink:to="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_8bb3b5f8-694c-45df-b1d1-1fdf45faad94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_83d4a57e-6bbe-4b71-bb28-79569e95ffa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_f53b7810-eb4a-442b-983c-679708a31929" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_83d4a57e-6bbe-4b71-bb28-79569e95ffa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_be9b153c-5b57-4f1c-a1dd-f436d165335d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_83d4a57e-6bbe-4b71-bb28-79569e95ffa7" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_be9b153c-5b57-4f1c-a1dd-f436d165335d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#DerivativeContractsDerivativeGainsLossesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ea51b9bd-5a0c-4cba-808c-93fdd4de0a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2906601b-d9fe-4cd7-9fb2-7ce193066acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ea51b9bd-5a0c-4cba-808c-93fdd4de0a76" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2906601b-d9fe-4cd7-9fb2-7ce193066acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e294f261-92c8-4a79-9d63-8af2e736ffa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2906601b-d9fe-4cd7-9fb2-7ce193066acf" xlink:to="loc_us-gaap_HedgingDesignationAxis_e294f261-92c8-4a79-9d63-8af2e736ffa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8ace32bb-06d8-4844-bfe3-ba6f3443df47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_e294f261-92c8-4a79-9d63-8af2e736ffa0" xlink:to="loc_us-gaap_HedgingDesignationDomain_8ace32bb-06d8-4844-bfe3-ba6f3443df47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_50abe0ac-73a6-47da-83f0-9b3452e43046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8ace32bb-06d8-4844-bfe3-ba6f3443df47" xlink:to="loc_us-gaap_NondesignatedMember_50abe0ac-73a6-47da-83f0-9b3452e43046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_aedfbaff-7cfc-4ab3-9cda-2340e88722d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2906601b-d9fe-4cd7-9fb2-7ce193066acf" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_aedfbaff-7cfc-4ab3-9cda-2340e88722d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_da1554ed-966c-4af7-a79a-2a4039ed8f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_aedfbaff-7cfc-4ab3-9cda-2340e88722d2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_da1554ed-966c-4af7-a79a-2a4039ed8f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_e673959b-ea6b-4b56-9c7a-f26169f69216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_da1554ed-966c-4af7-a79a-2a4039ed8f2e" xlink:to="loc_us-gaap_StockOptionMember_e673959b-ea6b-4b56-9c7a-f26169f69216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_8a6e62a2-308c-48b0-9304-791a93ee41f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_da1554ed-966c-4af7-a79a-2a4039ed8f2e" xlink:to="loc_us-gaap_ForwardContractsMember_8a6e62a2-308c-48b0-9304-791a93ee41f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aa78034a-6de5-435e-8ec8-4ed660e3ad60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2906601b-d9fe-4cd7-9fb2-7ce193066acf" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aa78034a-6de5-435e-8ec8-4ed660e3ad60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_8eb9ec0d-4982-403f-9560-fc625099bddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_aa78034a-6de5-435e-8ec8-4ed660e3ad60" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_8eb9ec0d-4982-403f-9560-fc625099bddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="opk-20200630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6c64b3c9-5103-4f8f-8d5d-ad36275571d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_98e8128b-65cf-4da8-abc3-11fac2eca7fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6c64b3c9-5103-4f8f-8d5d-ad36275571d1" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_98e8128b-65cf-4da8-abc3-11fac2eca7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_20440b76-8a51-46a4-945a-fd80ce872c0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_20440b76-8a51-46a4-945a-fd80ce872c0d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0d1689fd-c643-4a57-84f3-b27a4f63e4c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_srt_CounterpartyNameAxis_0d1689fd-c643-4a57-84f3-b27a4f63e4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a92313ee-7ad6-471a-ad16-ede041492501" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0d1689fd-c643-4a57-84f3-b27a4f63e4c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a92313ee-7ad6-471a-ad16-ede041492501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MembersofSeniorManagementMember_4ca10ee4-bbe7-4c27-bf16-9b3d5d46b37a" xlink:href="opk-20200630.xsd#opk_MembersofSeniorManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a92313ee-7ad6-471a-ad16-ede041492501" xlink:to="loc_opk_MembersofSeniorManagementMember_4ca10ee4-bbe7-4c27-bf16-9b3d5d46b37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dd7c9114-2616-4aee-9025-10f3574d1204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dd7c9114-2616-4aee-9025-10f3574d1204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c7d0468-b53d-4f13-9b66-949127f62bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd7c9114-2616-4aee-9025-10f3574d1204" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c7d0468-b53d-4f13-9b66-949127f62bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_8c8ca818-76e8-49c7-950e-cc98e462e2f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c7d0468-b53d-4f13-9b66-949127f62bf2" xlink:to="loc_us-gaap_IPOMember_8c8ca818-76e8-49c7-950e-cc98e462e2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_86fb6fd6-cc93-4f05-862b-c91ae0848179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c7d0468-b53d-4f13-9b66-949127f62bf2" xlink:to="loc_us-gaap_OverAllotmentOptionMember_86fb6fd6-cc93-4f05-862b-c91ae0848179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_35b4284e-20e1-47f7-b7b9-d460a58eebb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_CreditFacilityAxis_35b4284e-20e1-47f7-b7b9-d460a58eebb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_447da1aa-d578-4b7b-9af2-804219c11627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_35b4284e-20e1-47f7-b7b9-d460a58eebb3" xlink:to="loc_us-gaap_CreditFacilityDomain_447da1aa-d578-4b7b-9af2-804219c11627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_cf41db91-45f7-437d-8b5d-1a2ae0048bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_447da1aa-d578-4b7b-9af2-804219c11627" xlink:to="loc_us-gaap_LineOfCreditMember_cf41db91-45f7-437d-8b5d-1a2ae0048bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c4dbedf5-4621-466b-90d8-321ae3efbebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_447da1aa-d578-4b7b-9af2-804219c11627" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c4dbedf5-4621-466b-90d8-321ae3efbebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d6488d21-0efc-4c8d-be1a-dae11582cfb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d6488d21-0efc-4c8d-be1a-dae11582cfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_af4bb51f-cfd3-4aaf-ada6-258c948a492f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d6488d21-0efc-4c8d-be1a-dae11582cfb3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_af4bb51f-cfd3-4aaf-ada6-258c948a492f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SeriesAWarrantMember_617be38a-b66f-4612-aefd-c065c34f9216" xlink:href="opk-20200630.xsd#opk_SeriesAWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_af4bb51f-cfd3-4aaf-ada6-258c948a492f" xlink:to="loc_opk_SeriesAWarrantMember_617be38a-b66f-4612-aefd-c065c34f9216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SeriesBWarrantMember_a8466718-4002-4b53-a64a-1ff9e627aec3" xlink:href="opk-20200630.xsd#opk_SeriesBWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_af4bb51f-cfd3-4aaf-ada6-258c948a492f" xlink:to="loc_opk_SeriesBWarrantMember_a8466718-4002-4b53-a64a-1ff9e627aec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SeriesCWarrantMember_311e6cba-5951-4fa8-b5fa-4c8d766f2e10" xlink:href="opk-20200630.xsd#opk_SeriesCWarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_af4bb51f-cfd3-4aaf-ada6-258c948a492f" xlink:to="loc_opk_SeriesCWarrantMember_311e6cba-5951-4fa8-b5fa-4c8d766f2e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7dbabda6-28df-42be-8172-2d7d048b58a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_DebtInstrumentAxis_7dbabda6-28df-42be-8172-2d7d048b58a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5c8c3ae6-3bc7-435d-9713-7bed1e806862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7dbabda6-28df-42be-8172-2d7d048b58a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5c8c3ae6-3bc7-435d-9713-7bed1e806862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NewCreditAgreementMember_6aecae40-e6d6-40f6-a26d-a8a8c7d8fb02" xlink:href="opk-20200630.xsd#opk_NewCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c8c3ae6-3bc7-435d-9713-7bed1e806862" xlink:to="loc_opk_NewCreditAgreementMember_6aecae40-e6d6-40f6-a26d-a8a8c7d8fb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A5ConvertibleNotesMember_78b0c2c4-2a55-4d1b-a191-7edac55a542a" xlink:href="opk-20200630.xsd#opk_A5ConvertibleNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c8c3ae6-3bc7-435d-9713-7bed1e806862" xlink:to="loc_opk_A5ConvertibleNotesMember_78b0c2c4-2a55-4d1b-a191-7edac55a542a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_991f3de5-7274-4a52-8855-b4e0eb862b13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_991f3de5-7274-4a52-8855-b4e0eb862b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c121e020-e953-446c-b3ef-90cbb1017031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_991f3de5-7274-4a52-8855-b4e0eb862b13" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c121e020-e953-446c-b3ef-90cbb1017031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_459cb703-0856-4ddf-9515-c3197817356a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c121e020-e953-446c-b3ef-90cbb1017031" xlink:to="loc_us-gaap_UnsecuredDebtMember_459cb703-0856-4ddf-9515-c3197817356a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_bbcb682e-a616-44db-a8ed-43877428a670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c121e020-e953-446c-b3ef-90cbb1017031" xlink:to="loc_us-gaap_LineOfCreditMember_bbcb682e-a616-44db-a8ed-43877428a670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1b44e2fa-6f5c-4249-bbbf-05789df14244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c121e020-e953-446c-b3ef-90cbb1017031" xlink:to="loc_us-gaap_ConvertibleDebtMember_1b44e2fa-6f5c-4249-bbbf-05789df14244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c063daf6-2a12-4382-8591-3045f89417cc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_dei_LegalEntityAxis_c063daf6-2a12-4382-8591-3045f89417cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b4e32946-93c4-4f3a-be74-c85ba61e0f26" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c063daf6-2a12-4382-8591-3045f89417cc" xlink:to="loc_dei_EntityDomain_b4e32946-93c4-4f3a-be74-c85ba61e0f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_XeneticBiosciencesInc.Member_2dea9503-60ec-4528-9bb1-46bbbfbe8026" xlink:href="opk-20200630.xsd#opk_XeneticBiosciencesInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b4e32946-93c4-4f3a-be74-c85ba61e0f26" xlink:to="loc_opk_XeneticBiosciencesInc.Member_2dea9503-60ec-4528-9bb1-46bbbfbe8026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MuseumofScienceIncMember_59618a60-0782-48d2-acc3-317f3b0eb309" xlink:href="opk-20200630.xsd#opk_MuseumofScienceIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b4e32946-93c4-4f3a-be74-c85ba61e0f26" xlink:to="loc_opk_MuseumofScienceIncMember_59618a60-0782-48d2-acc3-317f3b0eb309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_49508327-0545-472f-9f6d-6d05d7f208dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_StatementClassOfStockAxis_49508327-0545-472f-9f6d-6d05d7f208dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fea2d099-d115-479e-92d7-21fd921e1de3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_49508327-0545-472f-9f6d-6d05d7f208dd" xlink:to="loc_us-gaap_ClassOfStockDomain_fea2d099-d115-479e-92d7-21fd921e1de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7f8e75c2-3c5c-4193-90ef-4b2ad0c78629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fea2d099-d115-479e-92d7-21fd921e1de3" xlink:to="loc_us-gaap_CommonStockMember_7f8e75c2-3c5c-4193-90ef-4b2ad0c78629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_718ee82e-cdc9-4b4f-b5b3-cfca2f7f5753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_718ee82e-cdc9-4b4f-b5b3-cfca2f7f5753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1d851abb-cb33-451e-9a58-f963f580076a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_718ee82e-cdc9-4b4f-b5b3-cfca2f7f5753" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1d851abb-cb33-451e-9a58-f963f580076a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOTransactionSharesMember_035ec9e0-7763-4ac7-a9b8-3b08e8fd0d9d" xlink:href="opk-20200630.xsd#opk_OPKOTransactionSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1d851abb-cb33-451e-9a58-f963f580076a" xlink:to="loc_opk_OPKOTransactionSharesMember_035ec9e0-7763-4ac7-a9b8-3b08e8fd0d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_8982208b-2236-4b4d-b7e2-a99ea66e5382" xlink:href="opk-20200630.xsd#opk_SharesReceivedUponClosingofXeneticTransactionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1d851abb-cb33-451e-9a58-f963f580076a" xlink:to="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_8982208b-2236-4b4d-b7e2-a99ea66e5382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FederalTradeCommissionFilingFeesMember_cb9a7f56-f865-4338-b600-4215119b2bd3" xlink:href="opk-20200630.xsd#opk_FederalTradeCommissionFilingFeesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1d851abb-cb33-451e-9a58-f963f580076a" xlink:to="loc_opk_FederalTradeCommissionFilingFeesMember_cb9a7f56-f865-4338-b600-4215119b2bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dcd81428-dcee-4082-abd1-39f86c849683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dcd81428-dcee-4082-abd1-39f86c849683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dcd81428-dcee-4082-abd1-39f86c849683" xlink:to="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_5133677d-1124-47be-9d35-65f8c6639bae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_srt_AffiliatedEntityMember_5133677d-1124-47be-9d35-65f8c6639bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c042d27b-8de3-41b3-944a-0fa695215a51" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_srt_DirectorMember_c042d27b-8de3-41b3-944a-0fa695215a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_a8c9b7a9-3164-4534-a247-91be49e26cd1" xlink:href="opk-20200630.xsd#opk_SharesReceivedUponClosingofXeneticTransactionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_a8c9b7a9-3164-4534-a247-91be49e26cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChiefTechnicalOfficerMember_8e0cebd7-fd15-477b-84f3-653ecf07c17e" xlink:href="opk-20200630.xsd#opk_ChiefTechnicalOfficerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_opk_ChiefTechnicalOfficerMember_8e0cebd7-fd15-477b-84f3-653ecf07c17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_3e04dbb2-ed12-46c3-967e-ed7e00579b15" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_srt_ChiefExecutiveOfficerMember_3e04dbb2-ed12-46c3-967e-ed7e00579b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_515ec82f-151c-474e-b02b-a85c481cb766" xlink:href="opk-20200630.xsd#opk_BioCardiaInc.Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_opk_BioCardiaInc.Member_515ec82f-151c-474e-b02b-a85c481cb766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DrFrostandMrPfennigerMember_2919351a-18ad-4582-89c8-d012c15c2520" xlink:href="opk-20200630.xsd#opk_DrFrostandMrPfennigerMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_opk_DrFrostandMrPfennigerMember_2919351a-18ad-4582-89c8-d012c15c2520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FrostRealEstateHoldingsLLCMember_495cd339-c062-46cd-b0f4-5e73ae9a43cb" xlink:href="opk-20200630.xsd#opk_FrostRealEstateHoldingsLLCMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c88c3c90-c78b-4000-ae6d-93452495b29e" xlink:to="loc_opk_FrostRealEstateHoldingsLLCMember_495cd339-c062-46cd-b0f4-5e73ae9a43cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1663b917-c037-4a38-94bf-d066596f4595" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1663b917-c037-4a38-94bf-d066596f4595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1663b917-c037-4a38-94bf-d066596f4595" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember_63d7ff0c-bf06-46e2-bfe3-6031de28bb50" xlink:href="opk-20200630.xsd#opk_PharmsynthezMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_PharmsynthezMember_63d7ff0c-bf06-46e2-bfe3-6031de28bb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ZebraMember_b7ef4c8a-2f44-4c03-a3df-12115bd4aacf" xlink:href="opk-20200630.xsd#opk_ZebraMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_ZebraMember_b7ef4c8a-2f44-4c03-a3df-12115bd4aacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NeovascMember_52092066-70af-41a3-aeb6-3f9b770945b2" xlink:href="opk-20200630.xsd#opk_NeovascMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_NeovascMember_52092066-70af-41a3-aeb6-3f9b770945b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromadexCorporationMember_c16d723e-b6a0-4667-a64e-15e80dcdf9e7" xlink:href="opk-20200630.xsd#opk_ChromadexCorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_ChromadexCorporationMember_c16d723e-b6a0-4667-a64e-15e80dcdf9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MabVaxTherapeuticsHoldingsInc.Member_ca8b507c-0d99-4c49-823f-ed0314893f81" xlink:href="opk-20200630.xsd#opk_MabVaxTherapeuticsHoldingsInc.Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_MabVaxTherapeuticsHoldingsInc.Member_ca8b507c-0d99-4c49-823f-ed0314893f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CocrystalMember_ee02f5df-8baf-4a4b-915b-57b8fad1a52e" xlink:href="opk-20200630.xsd#opk_CocrystalMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_CocrystalMember_ee02f5df-8baf-4a4b-915b-57b8fad1a52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NIMSMember_bd0faea3-32db-4045-8b10-77b8b7d3168c" xlink:href="opk-20200630.xsd#opk_NIMSMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_NIMSMember_bd0faea3-32db-4045-8b10-77b8b7d3168c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EloxxPharmaceuticalsMember_55df64c5-e892-4390-9e76-21820d1c9916" xlink:href="opk-20200630.xsd#opk_EloxxPharmaceuticalsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_EloxxPharmaceuticalsMember_55df64c5-e892-4390-9e76-21820d1c9916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_fffc65b0-cd5f-4815-bc71-d0154228c08b" xlink:href="opk-20200630.xsd#opk_BioCardiaInc.Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_BioCardiaInc.Member_fffc65b0-cd5f-4815-bc71-d0154228c08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InCellDxIncMember_8bbb2d29-71a6-47e7-b585-3e1c87d0c9c9" xlink:href="opk-20200630.xsd#opk_InCellDxIncMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52322252-2da4-4003-ab57-9db3318947fe" xlink:to="loc_opk_InCellDxIncMember_8bbb2d29-71a6-47e7-b585-3e1c87d0c9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_98337015-f38e-4461-ac0c-dc36f5a12c60" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1f8c0e1d-6fc3-4fc8-9d49-76b0e933ba1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1f8c0e1d-6fc3-4fc8-9d49-76b0e933ba1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5242f476-fdb5-4322-bb1c-de55c7d2596a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5242f476-fdb5-4322-bb1c-de55c7d2596a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_7933ce52-8367-4b65-a968-6544bcb07006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_7933ce52-8367-4b65-a968-6544bcb07006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ac226c23-f1eb-41ee-9ba4-c3a274229657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ac226c23-f1eb-41ee-9ba4-c3a274229657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_81998f8e-6739-49ff-aefe-5fe0a59b24f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_81998f8e-6739-49ff-aefe-5fe0a59b24f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5665064f-5c20-469f-87ed-5a4255fb7c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5665064f-5c20-469f-87ed-5a4255fb7c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_137a65ef-7205-44aa-9466-6ef765f80199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_SharesIssued_137a65ef-7205-44aa-9466-6ef765f80199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a1abc1a4-1428-40c2-932a-995d61080398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a1abc1a4-1428-40c2-932a-995d61080398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionShares_6c477af9-01bd-4631-bd1c-1552547eb9ee" xlink:href="opk-20200630.xsd#opk_RelatedPartyTransactionShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_RelatedPartyTransactionShares_6c477af9-01bd-4631-bd1c-1552547eb9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_50d612b3-7212-4dd1-ab41-6b1b642dfbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_50d612b3-7212-4dd1-ab41-6b1b642dfbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_27dfacf4-b671-41c8-8e80-62c4eccdaa2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_27dfacf4-b671-41c8-8e80-62c4eccdaa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ab7ea324-657e-4253-999d-f17cbe57797c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ab7ea324-657e-4253-999d-f17cbe57797c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_67702ee4-49a3-4428-918c-abce51063020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_67702ee4-49a3-4428-918c-abce51063020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquitySecurityFVNIOwnershipPercent_7ff87fc6-1070-4b64-a3b8-14d2fb4cb2d7" xlink:href="opk-20200630.xsd#opk_EquitySecurityFVNIOwnershipPercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_EquitySecurityFVNIOwnershipPercent_7ff87fc6-1070-4b64-a3b8-14d2fb4cb2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ccd593a5-8c84-4255-8529-1b93d4c0f15c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ccd593a5-8c84-4255-8529-1b93d4c0f15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleSharesIssued_9b507908-8438-4adc-a239-0f98542f6488" xlink:href="opk-20200630.xsd#opk_DebtInstrumentConvertibleSharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_DebtInstrumentConvertibleSharesIssued_9b507908-8438-4adc-a239-0f98542f6488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentSharesPurchasedInPeriod_714a7d93-c799-45dc-835b-41cdaac7e5c3" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentSharesPurchasedInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_EquityMethodInvestmentSharesPurchasedInPeriod_714a7d93-c799-45dc-835b-41cdaac7e5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_61e52f5e-9836-46f2-b368-cef6710f13af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_61e52f5e-9836-46f2-b368-cef6710f13af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2bf66dda-0c0f-4bf4-9c10-6fd305e7dc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2bf66dda-0c0f-4bf4-9c10-6fd305e7dc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived_4a97a66e-dc54-43a9-89da-448ad9a8df4d" xlink:href="opk-20200630.xsd#opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived_4a97a66e-dc54-43a9-89da-448ad9a8df4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_6ba04ef2-fac7-4a19-bbeb-e120b2385ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_6ba04ef2-fac7-4a19-bbeb-e120b2385ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributions_2b4cd8bf-1435-489a-b94e-958ea9b5d039" xlink:href="opk-20200630.xsd#opk_RelatedPartyTransactionFutureContributions"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_RelatedPartyTransactionFutureContributions_2b4cd8bf-1435-489a-b94e-958ea9b5d039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributionTerm_12272936-b4db-44a9-b94b-2a42c6f3c9d2" xlink:href="opk-20200630.xsd#opk_RelatedPartyTransactionFutureContributionTerm"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_RelatedPartyTransactionFutureContributionTerm_12272936-b4db-44a9-b94b-2a42c6f3c9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_5c44eaa8-0f8f-4c53-aa21-5be22c75bec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_5c44eaa8-0f8f-4c53-aa21-5be22c75bec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearOne_be90c4eb-f457-4724-90de-ee7c3f18c4f2" xlink:href="opk-20200630.xsd#opk_OperatingLeasesMonthlyPaymentsYearOne"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_OperatingLeasesMonthlyPaymentsYearOne_be90c4eb-f457-4724-90de-ee7c3f18c4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearThree_f266a121-67fd-473a-8eda-514b1ed1343e" xlink:href="opk-20200630.xsd#opk_OperatingLeasesMonthlyPaymentsYearThree"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_opk_OperatingLeasesMonthlyPaymentsYearThree_f266a121-67fd-473a-8eda-514b1ed1343e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_2b2c175c-5eef-461f-917f-e17d57d6c52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_335004ea-ccf9-4a4f-9453-f8a65f8d2b49" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_2b2c175c-5eef-461f-917f-e17d57d6c52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="opk-20200630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af0927b5-832b-493b-8d0f-9e01a7be41d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_03c6da69-8981-4bf5-8c55-cb7d4ed81db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af0927b5-832b-493b-8d0f-9e01a7be41d1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_03c6da69-8981-4bf5-8c55-cb7d4ed81db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db9391b2-7f7f-474d-91b9-02afb6719a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8985ac0c-a472-42b2-a927-d377135ce16d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db9391b2-7f7f-474d-91b9-02afb6719a3c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8985ac0c-a472-42b2-a927-d377135ce16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7b434124-091c-4b8a-b314-06eb8551f953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8985ac0c-a472-42b2-a927-d377135ce16d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7b434124-091c-4b8a-b314-06eb8551f953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7a1ea16d-2d66-45ce-9e3a-412d37f6a3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7b434124-091c-4b8a-b314-06eb8551f953" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7a1ea16d-2d66-45ce-9e3a-412d37f6a3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_2472a375-4fdb-44ba-b916-907321067322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7a1ea16d-2d66-45ce-9e3a-412d37f6a3ec" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_2472a375-4fdb-44ba-b916-907321067322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4db3b49d-da85-425e-b40a-6b816f2d0e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7a1ea16d-2d66-45ce-9e3a-412d37f6a3ec" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4db3b49d-da85-425e-b40a-6b816f2d0e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_aea5028c-b300-47f6-9c60-3ca2aa5f5c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8985ac0c-a472-42b2-a927-d377135ce16d" xlink:to="loc_us-gaap_LitigationStatusAxis_aea5028c-b300-47f6-9c60-3ca2aa5f5c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_d80e84d2-9da6-4539-aeb1-45d491ea0f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_aea5028c-b300-47f6-9c60-3ca2aa5f5c24" xlink:to="loc_us-gaap_LitigationStatusDomain_d80e84d2-9da6-4539-aeb1-45d491ea0f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_c5dd24c0-28f7-43cd-a13e-96a335d5c3be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_d80e84d2-9da6-4539-aeb1-45d491ea0f18" xlink:to="loc_us-gaap_SettledLitigationMember_c5dd24c0-28f7-43cd-a13e-96a335d5c3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8985ac0c-a472-42b2-a927-d377135ce16d" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9a0df51e-9201-419c-a5ef-7521a684aa8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9a0df51e-9201-419c-a5ef-7521a684aa8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NumberOfClassActionLawsuits_55233a50-c1cf-428b-901e-8e6169e7aa13" xlink:href="opk-20200630.xsd#opk_NumberOfClassActionLawsuits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_opk_NumberOfClassActionLawsuits_55233a50-c1cf-428b-901e-8e6169e7aa13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_7f8d6ec2-7a1d-4312-863a-978edd10ee49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_7f8d6ec2-7a1d-4312-863a-978edd10ee49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_98e37e4f-4cba-455d-84ef-0ab2870df46e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_98e37e4f-4cba-455d-84ef-0ab2870df46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NumberOfDerivativeLawsuits_cea79c2f-e41b-4797-a929-87edd2c7979a" xlink:href="opk-20200630.xsd#opk_NumberOfDerivativeLawsuits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_opk_NumberOfDerivativeLawsuits_cea79c2f-e41b-4797-a929-87edd2c7979a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_255998b2-b95b-40c0-a422-bcac71012e98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ecf079b4-44ef-4bb8-896a-fe32e0776c36" xlink:to="loc_us-gaap_PurchaseObligation_255998b2-b95b-40c0-a422-bcac71012e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognition" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2f5438b3-98cd-4650-8614-b9617d969d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2f2de8d8-befc-4f53-96cc-8efa81924bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2f5438b3-98cd-4650-8614-b9617d969d19" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2f2de8d8-befc-4f53-96cc-8efa81924bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3cd4bc8a-c3d4-493d-ad56-5c18459e34d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1b37d2e6-aabe-414e-ad32-7dd1674429b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3cd4bc8a-c3d4-493d-ad56-5c18459e34d3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1b37d2e6-aabe-414e-ad32-7dd1674429b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock_04c7c7e1-e577-4479-8707-9052acd490f8" xlink:href="opk-20200630.xsd#opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3cd4bc8a-c3d4-493d-ad56-5c18459e34d3" xlink:to="loc_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock_04c7c7e1-e577-4479-8707-9052acd490f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_84b1a6ab-6742-4104-abd9-6511b72cfaad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7aad485f-db36-49b9-a330-cb10c97eb7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_84b1a6ab-6742-4104-abd9-6511b72cfaad" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7aad485f-db36-49b9-a330-cb10c97eb7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b946e318-5a0a-4157-bf2e-4c99327ab44c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7aad485f-db36-49b9-a330-cb10c97eb7a8" xlink:to="loc_srt_CounterpartyNameAxis_b946e318-5a0a-4157-bf2e-4c99327ab44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ca0d9d4-8f46-4fea-ac5c-af0dcd898825" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b946e318-5a0a-4157-bf2e-4c99327ab44c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ca0d9d4-8f46-4fea-ac5c-af0dcd898825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember_686d648c-aacd-4565-867c-aeedf3a50e53" xlink:href="opk-20200630.xsd#opk_PfizerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ca0d9d4-8f46-4fea-ac5c-af0dcd898825" xlink:to="loc_opk_PfizerMember_686d648c-aacd-4565-867c-aeedf3a50e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember_a93c1a57-c86e-4829-9d78-137322484ab3" xlink:href="opk-20200630.xsd#opk_BioReferenceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ca0d9d4-8f46-4fea-ac5c-af0dcd898825" xlink:to="loc_opk_BioReferenceMember_a93c1a57-c86e-4829-9d78-137322484ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_aff71a83-b688-4ce5-80dd-aa1e5486a5e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7aad485f-db36-49b9-a330-cb10c97eb7a8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_aff71a83-b688-4ce5-80dd-aa1e5486a5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcf2a5ab-61be-4c22-8b72-552c3c7cd986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_aff71a83-b688-4ce5-80dd-aa1e5486a5e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcf2a5ab-61be-4c22-8b72-552c3c7cd986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b0c3baed-ecab-4626-9cdd-7eab5fc1f1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcf2a5ab-61be-4c22-8b72-552c3c7cd986" xlink:to="loc_us-gaap_ProductMember_b0c3baed-ecab-4626-9cdd-7eab5fc1f1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4877da9-85eb-4f99-9b0a-33d6c3a7ec88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7aad485f-db36-49b9-a330-cb10c97eb7a8" xlink:to="loc_srt_ProductOrServiceAxis_a4877da9-85eb-4f99-9b0a-33d6c3a7ec88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4a927d4b-bc16-40e2-9f2e-5af63d68b2f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a4877da9-85eb-4f99-9b0a-33d6c3a7ec88" xlink:to="loc_srt_ProductsAndServicesDomain_4a927d4b-bc16-40e2-9f2e-5af63d68b2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RayaldeeMember_7fc9cb78-8d38-42ae-bb6a-97c9dfcece7b" xlink:href="opk-20200630.xsd#opk_RayaldeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4a927d4b-bc16-40e2-9f2e-5af63d68b2f1" xlink:to="loc_opk_RayaldeeMember_7fc9cb78-8d38-42ae-bb6a-97c9dfcece7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_9648e8e2-5a4d-41f0-b425-814099bafc91" xlink:href="opk-20200630.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4a927d4b-bc16-40e2-9f2e-5af63d68b2f1" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_9648e8e2-5a4d-41f0-b425-814099bafc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7aad485f-db36-49b9-a330-cb10c97eb7a8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_8580d6c7-75d8-460f-946b-3bc02398a4ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_8580d6c7-75d8-460f-946b-3bc02398a4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability_dcb80fcb-5d84-446d-9298-6a198715cfc7" xlink:href="opk-20200630.xsd#opk_AccruedExpensePayorOverpaymentReimbursementLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:to="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability_dcb80fcb-5d84-446d-9298-6a198715cfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_389ba4b1-b145-42d0-a584-dc6df5192c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_389ba4b1-b145-42d0-a584-dc6df5192c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c2ebb08-ed03-4f0e-a8b8-fa42a051e48c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c2ebb08-ed03-4f0e-a8b8-fa42a051e48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d5ea2ad2-5635-49d2-b885-2f5ab03b9e66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_81e99aea-5afb-4501-b416-66c2cbfb64dd" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d5ea2ad2-5635-49d2-b885-2f5ab03b9e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionScheduleofDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_399c38b3-d0ef-4421-b0d8-46adb66b7e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b1e24cf8-3a82-460e-85f8-7a5c8618ea62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_399c38b3-d0ef-4421-b0d8-46adb66b7e47" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b1e24cf8-3a82-460e-85f8-7a5c8618ea62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cfcca94f-0401-46a5-b123-177cf6b3e8c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b1e24cf8-3a82-460e-85f8-7a5c8618ea62" xlink:to="loc_srt_ProductOrServiceAxis_cfcca94f-0401-46a5-b123-177cf6b3e8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cc6396a4-1f9b-41c5-ba64-52dac0e19d6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cfcca94f-0401-46a5-b123-177cf6b3e8c1" xlink:to="loc_srt_ProductsAndServicesDomain_cc6396a4-1f9b-41c5-ba64-52dac0e19d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cc6396a4-1f9b-41c5-ba64-52dac0e19d6d" xlink:to="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_HealthInsurersMember_7f2d3b37-8ba7-4cc6-bd2f-8c4e558791b8" xlink:href="opk-20200630.xsd#opk_HealthInsurersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:to="loc_opk_HealthInsurersMember_7f2d3b37-8ba7-4cc6-bd2f-8c4e558791b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentPayersMember_3fd1bc2e-e457-4990-81cd-0169e49d68a8" xlink:href="opk-20200630.xsd#opk_GovernmentPayersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:to="loc_opk_GovernmentPayersMember_3fd1bc2e-e457-4990-81cd-0169e49d68a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClientPayersMember_2bf58d58-b41a-498c-bed0-bf4c83059dc0" xlink:href="opk-20200630.xsd#opk_ClientPayersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:to="loc_opk_ClientPayersMember_2bf58d58-b41a-498c-bed0-bf4c83059dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PatientsMember_ca2cf938-bbb9-49dd-aaac-ce3cd34f70e4" xlink:href="opk-20200630.xsd#opk_PatientsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServiceMember_b460b4ce-7ade-4b3e-a01f-9e6c5901cd14" xlink:to="loc_opk_PatientsMember_ca2cf938-bbb9-49dd-aaac-ce3cd34f70e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a7b19381-ba16-4d08-9ff7-814f3efd4779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b1e24cf8-3a82-460e-85f8-7a5c8618ea62" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a7b19381-ba16-4d08-9ff7-814f3efd4779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4ba22c27-065e-45ed-85cc-8e95e8cc9546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a7b19381-ba16-4d08-9ff7-814f3efd4779" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4ba22c27-065e-45ed-85cc-8e95e8cc9546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0eac1af7-6361-4d3f-9640-aa44cba8f233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d21bc2d1-af83-4b92-b183-4aaad6973572" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0eac1af7-6361-4d3f-9640-aa44cba8f233" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d21bc2d1-af83-4b92-b183-4aaad6973572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6dd63245-863c-41d3-94a7-130e13ff013e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d21bc2d1-af83-4b92-b183-4aaad6973572" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6dd63245-863c-41d3-94a7-130e13ff013e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa32c265-3cce-48b3-af59-6929b1a23337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6dd63245-863c-41d3-94a7-130e13ff013e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa32c265-3cce-48b3-af59-6929b1a23337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChargebacksDiscountsRebatesAndFeesMember_a36b7ab9-ead1-4d72-847a-9d4313d9c120" xlink:href="opk-20200630.xsd#opk_ChargebacksDiscountsRebatesAndFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa32c265-3cce-48b3-af59-6929b1a23337" xlink:to="loc_opk_ChargebacksDiscountsRebatesAndFeesMember_a36b7ab9-ead1-4d72-847a-9d4313d9c120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentalMember_13cd24c5-c561-4554-bd58-fce748b62a1e" xlink:href="opk-20200630.xsd#opk_GovernmentalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa32c265-3cce-48b3-af59-6929b1a23337" xlink:to="loc_opk_GovernmentalMember_13cd24c5-c561-4554-bd58-fce748b62a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesReturnsMember_be96cd66-2332-4f0a-8fba-69a5b9b90e10" xlink:href="opk-20200630.xsd#opk_SalesReturnsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fa32c265-3cce-48b3-af59-6929b1a23337" xlink:to="loc_opk_SalesReturnsMember_be96cd66-2332-4f0a-8fba-69a5b9b90e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8d5a9f81-196e-4322-ab39-7eee414f4037" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d21bc2d1-af83-4b92-b183-4aaad6973572" xlink:to="loc_srt_ProductOrServiceAxis_8d5a9f81-196e-4322-ab39-7eee414f4037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b15b185-8cf1-49e5-b174-e26b626f84c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8d5a9f81-196e-4322-ab39-7eee414f4037" xlink:to="loc_srt_ProductsAndServicesDomain_2b15b185-8cf1-49e5-b174-e26b626f84c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RayaldeeMember_7f476d21-e321-447c-9b58-382f53a369f7" xlink:href="opk-20200630.xsd#opk_RayaldeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2b15b185-8cf1-49e5-b174-e26b626f84c0" xlink:to="loc_opk_RayaldeeMember_7f476d21-e321-447c-9b58-382f53a369f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_73c51042-b0ed-4253-ad61-4c40a7f7634d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d21bc2d1-af83-4b92-b183-4aaad6973572" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_73c51042-b0ed-4253-ad61-4c40a7f7634d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9fe0696c-af6d-4e5b-9bc8-1d938af3e4fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_73c51042-b0ed-4253-ad61-4c40a7f7634d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9fe0696c-af6d-4e5b-9bc8-1d938af3e4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_be1b0dac-c912-4bad-b101-aafae81e837e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9fe0696c-af6d-4e5b-9bc8-1d938af3e4fa" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_be1b0dac-c912-4bad-b101-aafae81e837e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fafed431-20e9-4728-994c-6a3831ed3077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9fe0696c-af6d-4e5b-9bc8-1d938af3e4fa" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fafed431-20e9-4728-994c-6a3831ed3077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_d13d59ef-fdab-459d-9301-ee9833392348" xlink:href="opk-20200630.xsd#opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9fe0696c-af6d-4e5b-9bc8-1d938af3e4fa" xlink:to="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_d13d59ef-fdab-459d-9301-ee9833392348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_71f1bb1c-0c06-4268-a804-0758071a579e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9fe0696c-af6d-4e5b-9bc8-1d938af3e4fa" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_71f1bb1c-0c06-4268-a804-0758071a579e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c3ffc959-7c8c-4e66-aa62-08eb04a07e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_73c51042-b0ed-4253-ad61-4c40a7f7634d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c3ffc959-7c8c-4e66-aa62-08eb04a07e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_980beefd-f0a0-4891-bb51-27c80d289174" xlink:href="opk-20200630.xsd#opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_73c51042-b0ed-4253-ad61-4c40a7f7634d" xlink:to="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_980beefd-f0a0-4891-bb51-27c80d289174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/StrategicAlliances" xlink:type="simple" xlink:href="opk-20200630.xsd#StrategicAlliances"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/StrategicAlliances" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_254e3613-cb6d-4c37-a433-e50b6265917b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StrategicAlliancesTextBlock_d9ad8b28-a8bd-4bdb-8a64-05735fefee6a" xlink:href="opk-20200630.xsd#opk_StrategicAlliancesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_254e3613-cb6d-4c37-a433-e50b6265917b" xlink:to="loc_opk_StrategicAlliancesTextBlock_d9ad8b28-a8bd-4bdb-8a64-05735fefee6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/StrategicAlliancesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#StrategicAlliancesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/StrategicAlliancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df8aed7f-6018-4629-836b-2215b04ce87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df8aed7f-6018-4629-836b-2215b04ce87c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d8d2538-a24a-4af0-b1fa-10c5df0e97d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_srt_ProductOrServiceAxis_4d8d2538-a24a-4af0-b1fa-10c5df0e97d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_759dcc88-61c1-496d-a5bf-c23ee8c6165e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4d8d2538-a24a-4af0-b1fa-10c5df0e97d2" xlink:to="loc_srt_ProductsAndServicesDomain_759dcc88-61c1-496d-a5bf-c23ee8c6165e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryMilestonesMember_cdcf4aa2-106a-4038-997a-fef61e9088c5" xlink:href="opk-20200630.xsd#opk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_759dcc88-61c1-496d-a5bf-c23ee8c6165e" xlink:to="loc_opk_RegulatoryMilestonesMember_cdcf4aa2-106a-4038-997a-fef61e9088c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesMilestonesMember_f41810b5-7a87-4b3b-b647-e8017ebcf8a4" xlink:href="opk-20200630.xsd#opk_SalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_759dcc88-61c1-496d-a5bf-c23ee8c6165e" xlink:to="loc_opk_SalesMilestonesMember_f41810b5-7a87-4b3b-b647-e8017ebcf8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneAxis_ad970937-cc7e-4e26-b97f-134e6a68341a" xlink:href="opk-20200630.xsd#opk_MilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_opk_MilestoneAxis_ad970937-cc7e-4e26-b97f-134e6a68341a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneDomain_98c65a37-d9cb-4805-b8d5-0c1b05dee16f" xlink:href="opk-20200630.xsd#opk_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_MilestoneAxis_ad970937-cc7e-4e26-b97f-134e6a68341a" xlink:to="loc_opk_MilestoneDomain_98c65a37-d9cb-4805-b8d5-0c1b05dee16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhaseTwoInitiationMember_1c7d97cc-c15f-470a-8800-86f1aa0264fe" xlink:href="opk-20200630.xsd#opk_PhaseTwoInitiationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_MilestoneDomain_98c65a37-d9cb-4805-b8d5-0c1b05dee16f" xlink:to="loc_opk_PhaseTwoInitiationMember_1c7d97cc-c15f-470a-8800-86f1aa0264fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryAndDevelopmentMember_98abeac8-8883-4fe3-b6cc-653f2ea52874" xlink:href="opk-20200630.xsd#opk_RegulatoryAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_MilestoneDomain_98c65a37-d9cb-4805-b8d5-0c1b05dee16f" xlink:to="loc_opk_RegulatoryAndDevelopmentMember_98abeac8-8883-4fe3-b6cc-653f2ea52874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesRevenueMember_1be9688d-d56b-4817-b751-10c7ff6a8db3" xlink:href="opk-20200630.xsd#opk_SalesRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_MilestoneDomain_98c65a37-d9cb-4805-b8d5-0c1b05dee16f" xlink:to="loc_opk_SalesRevenueMember_1be9688d-d56b-4817-b751-10c7ff6a8db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fa433b8-954f-4ac4-82fb-79a6e830d3cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fa433b8-954f-4ac4-82fb-79a6e830d3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b9e764ff-b23e-45b2-9e72-a32468b6be2f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fa433b8-954f-4ac4-82fb-79a6e830d3cc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b9e764ff-b23e-45b2-9e72-a32468b6be2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember_00104da2-8ed1-4a7e-a71e-815e82cbfe84" xlink:href="opk-20200630.xsd#opk_PharmsynthezMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9e764ff-b23e-45b2-9e72-a32468b6be2f" xlink:to="loc_opk_PharmsynthezMember_00104da2-8ed1-4a7e-a71e-815e82cbfe84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhioPharmaceuticalsMember_15bf02e6-15b2-4ce1-bd05-daa594fbd17c" xlink:href="opk-20200630.xsd#opk_PhioPharmaceuticalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9e764ff-b23e-45b2-9e72-a32468b6be2f" xlink:to="loc_opk_PhioPharmaceuticalsMember_15bf02e6-15b2-4ce1-bd05-daa594fbd17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fe5a9a7f-9739-442d-bdfa-d089e3cf1c10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_srt_RangeAxis_fe5a9a7f-9739-442d-bdfa-d089e3cf1c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7813c88c-165a-40ad-a587-46c71af806f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fe5a9a7f-9739-442d-bdfa-d089e3cf1c10" xlink:to="loc_srt_RangeMember_7813c88c-165a-40ad-a587-46c71af806f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff4ee2d4-f306-4b97-9325-81889fb0f11c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7813c88c-165a-40ad-a587-46c71af806f1" xlink:to="loc_srt_MinimumMember_ff4ee2d4-f306-4b97-9325-81889fb0f11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_46e88c5e-a5f1-442e-b7ce-8f78d9ead7ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7813c88c-165a-40ad-a587-46c71af806f1" xlink:to="loc_srt_MaximumMember_46e88c5e-a5f1-442e-b7ce-8f78d9ead7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_161c6c32-4195-4cba-a4ba-8d0b6124fa78" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_srt_CounterpartyNameAxis_161c6c32-4195-4cba-a4ba-8d0b6124fa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_161c6c32-4195-4cba-a4ba-8d0b6124fa78" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_faa07aae-9baa-4070-96a0-b9b72544048c" xlink:href="opk-20200630.xsd#opk_ViforFreseniusMedicalCarePharmaLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:to="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_faa07aae-9baa-4070-96a0-b9b72544048c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EirGenPharmaLimitedMember_d2dc4e4a-a4bb-4583-9694-89a613b1614b" xlink:href="opk-20200630.xsd#opk_EirGenPharmaLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:to="loc_opk_EirGenPharmaLimitedMember_d2dc4e4a-a4bb-4583-9694-89a613b1614b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember_0778a6e1-b7b8-4760-8770-4ad71688ab85" xlink:href="opk-20200630.xsd#opk_PfizerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:to="loc_opk_PfizerMember_0778a6e1-b7b8-4760-8770-4ad71688ab85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TesaroMember_43a38393-7793-43c6-9111-7875e9dd12ca" xlink:href="opk-20200630.xsd#opk_TesaroMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff2ad8e4-bf7f-424c-86f9-cab241bbaf9a" xlink:to="loc_opk_TesaroMember_43a38393-7793-43c6-9111-7875e9dd12ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cb1a1b2c-9623-4759-a447-c4ea1124727b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cb1a1b2c-9623-4759-a447-c4ea1124727b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cb1a1b2c-9623-4759-a447-c4ea1124727b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DevelopmentandLicenseAgreementMember_dc25cba8-93cc-42ab-af05-1bc90e4086b8" xlink:href="opk-20200630.xsd#opk_DevelopmentandLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:to="loc_opk_DevelopmentandLicenseAgreementMember_dc25cba8-93cc-42ab-af05-1bc90e4086b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryMilestonesMember_51bbd392-6270-4c79-8f43-6632691891b9" xlink:href="opk-20200630.xsd#opk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:to="loc_opk_RegulatoryMilestonesMember_51bbd392-6270-4c79-8f43-6632691891b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ExclusiveOptionMember_39f351f8-7982-4462-bc53-1c8a2e1cefd4" xlink:href="opk-20200630.xsd#opk_ExclusiveOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:to="loc_opk_ExclusiveOptionMember_39f351f8-7982-4462-bc53-1c8a2e1cefd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a232c504-4cd7-42a1-978a-84597daa85ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b802ed1a-2cb7-4816-b838-f486315b373a" xlink:to="loc_us-gaap_ProductMember_a232c504-4cd7-42a1-978a-84597daa85ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0310967-203d-4fc9-94cb-60985ce7d6bb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_ad3edd5a-7d02-4b37-aa53-53ec1474dbe5" xlink:href="opk-20200630.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_ad3edd5a-7d02-4b37-aa53-53ec1474dbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_90abf4c6-02df-482a-bd74-896d3536846f" xlink:href="opk-20200630.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_90abf4c6-02df-482a-bd74-896d3536846f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b66cd5d4-194d-4253-b897-3c80f24048d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b66cd5d4-194d-4253-b897-3c80f24048d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMaximumMilestonePayments_44db65db-78c8-4dad-8f93-aa9a7a907575" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementMaximumMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementMaximumMilestonePayments_44db65db-78c8-4dad-8f93-aa9a7a907575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_55df449a-2378-4115-82c8-441d9dc7ef41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_55df449a-2378-4115-82c8-441d9dc7ef41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeAgreementAdditionalMilestonePayment_1f6b3f87-396e-41c3-847f-89d9369a585a" xlink:href="opk-20200630.xsd#opk_CollaborativeAgreementAdditionalMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeAgreementAdditionalMilestonePayment_1f6b3f87-396e-41c3-847f-89d9369a585a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangement.MaximumMilestonePayments_09eef97e-b924-4e18-9707-a521195cb393" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangement.MaximumMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangement.MaximumMilestonePayments_09eef97e-b924-4e18-9707-a521195cb393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_b0edf185-d9ec-49af-a3a8-c7c57f29e3bf" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_b0edf185-d9ec-49af-a3a8-c7c57f29e3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementUpfrontPayment_890babfe-c07b-4164-8d28-d98a02b59492" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementUpfrontPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementUpfrontPayment_890babfe-c07b-4164-8d28-d98a02b59492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMilestonePayment_08a30f31-fe8c-41f7-8a1f-9c5904da1551" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementMilestonePayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementMilestonePayment_08a30f31-fe8c-41f7-8a1f-9c5904da1551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment_46a292f9-d468-44bf-9341-95bc949f80cf" xlink:href="opk-20200630.xsd#opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment_46a292f9-d468-44bf-9341-95bc949f80cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMilestonePaymentReceived_805b2e9d-569f-4f13-a562-a017099a44ef" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementMilestonePaymentReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementMilestonePaymentReceived_805b2e9d-569f-4f13-a562-a017099a44ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeAgreementPeriodfromFirstCommercialSale_00442b3e-61c0-41a8-910a-8abded34b081" xlink:href="opk-20200630.xsd#opk_CollaborativeAgreementPeriodfromFirstCommercialSale"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeAgreementPeriodfromFirstCommercialSale_00442b3e-61c0-41a8-910a-8abded34b081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold_d69f76f7-4e56-4aa1-befe-cc0f003cdc29" xlink:href="opk-20200630.xsd#opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold_d69f76f7-4e56-4aa1-befe-cc0f003cdc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_07cde8fa-adff-46e1-854b-be28b4d1083d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_07cde8fa-adff-46e1-854b-be28b4d1083d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived_25b95d26-0142-4c17-b283-3f7226205171" xlink:href="opk-20200630.xsd#opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b030d64e-1119-4cdb-a66d-3a7cae594e3c" xlink:to="loc_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived_25b95d26-0142-4c17-b283-3f7226205171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/Segments" xlink:type="simple" xlink:href="opk-20200630.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fe505908-ee2e-4478-a4fd-197ca4991e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_fe90ece6-5501-4810-a45b-fe05c3d273d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fe505908-ee2e-4478-a4fd-197ca4991e3c" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_fe90ece6-5501-4810-a45b-fe05c3d273d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsTables" xlink:type="simple" xlink:href="opk-20200630.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4a730e07-43bf-4e95-b8d0-71e664ca123b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1b9b0fde-72a4-4568-85d1-de9a2d32fefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4a730e07-43bf-4e95-b8d0-71e664ca123b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1b9b0fde-72a4-4568-85d1-de9a2d32fefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SegmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SegmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d9794460-ef98-457f-a571-36a2aa0654b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aec87e04-de7f-4e5d-b507-a4ef3866ef84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d9794460-ef98-457f-a571-36a2aa0654b6" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aec87e04-de7f-4e5d-b507-a4ef3866ef84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_761fa174-d2d4-4461-a211-d361dac6c23b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aec87e04-de7f-4e5d-b507-a4ef3866ef84" xlink:to="loc_srt_ConsolidationItemsAxis_761fa174-d2d4-4461-a211-d361dac6c23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_306c5ac9-8997-44fa-b4f8-73dda8716125" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_761fa174-d2d4-4461-a211-d361dac6c23b" xlink:to="loc_srt_ConsolidationItemsDomain_306c5ac9-8997-44fa-b4f8-73dda8716125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_4b85c3c9-6507-470e-80a3-6ba4fa9d3ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_306c5ac9-8997-44fa-b4f8-73dda8716125" xlink:to="loc_us-gaap_IntersegmentEliminationMember_4b85c3c9-6507-470e-80a3-6ba4fa9d3ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d0dc4109-7e8e-4417-b674-9f7d40390c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aec87e04-de7f-4e5d-b507-a4ef3866ef84" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d0dc4109-7e8e-4417-b674-9f7d40390c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_a204b35e-32de-4e8d-965a-fe73fdae93a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d0dc4109-7e8e-4417-b674-9f7d40390c76" xlink:to="loc_us-gaap_NumberOfReportableSegments_a204b35e-32de-4e8d-965a-fe73fdae93a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0b4cc35e-b477-47b5-ada1-da42cd151278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d0dc4109-7e8e-4417-b674-9f7d40390c76" xlink:to="loc_us-gaap_Revenues_0b4cc35e-b477-47b5-ada1-da42cd151278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a7565853-ddd4-4268-8c00-c29e8f61082f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d0dc4109-7e8e-4417-b674-9f7d40390c76" xlink:to="loc_us-gaap_InterestExpense_a7565853-ddd4-4268-8c00-c29e8f61082f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SegmentsOperationsandAssetsInformationDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0614fd28-f81c-4ff5-b0f9-a9bf966da605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0614fd28-f81c-4ff5-b0f9-a9bf966da605" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_06477713-0d9a-4c38-9176-ec7c17a948eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:to="loc_srt_ProductOrServiceAxis_06477713-0d9a-4c38-9176-ec7c17a948eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5d17559-62ed-4d62-b8ec-032f58683383" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_06477713-0d9a-4c38-9176-ec7c17a948eb" xlink:to="loc_srt_ProductsAndServicesDomain_a5d17559-62ed-4d62-b8ec-032f58683383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_54811510-68dd-4d55-be84-9cbdbac705ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5d17559-62ed-4d62-b8ec-032f58683383" xlink:to="loc_us-gaap_ServiceMember_54811510-68dd-4d55-be84-9cbdbac705ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_197c5ae6-ea33-4a70-ae6e-657ad6a7154b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5d17559-62ed-4d62-b8ec-032f58683383" xlink:to="loc_us-gaap_ProductMember_197c5ae6-ea33-4a70-ae6e-657ad6a7154b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_441d85a4-c519-4e8a-a39a-1ce3b1b6d498" xlink:href="opk-20200630.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5d17559-62ed-4d62-b8ec-032f58683383" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_441d85a4-c519-4e8a-a39a-1ce3b1b6d498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4948aa6c-f77a-400b-b00f-16f6f95b348c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4948aa6c-f77a-400b-b00f-16f6f95b348c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5a80b4be-3d58-4423-b0fd-508c486f40f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4948aa6c-f77a-400b-b00f-16f6f95b348c" xlink:to="loc_us-gaap_SegmentDomain_5a80b4be-3d58-4423-b0fd-508c486f40f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmaceuticalMember_79c019fd-eeba-48da-955f-97d9a1d47d70" xlink:href="opk-20200630.xsd#opk_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5a80b4be-3d58-4423-b0fd-508c486f40f5" xlink:to="loc_opk_PharmaceuticalMember_79c019fd-eeba-48da-955f-97d9a1d47d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember_cd4dfa83-a14b-440b-afc5-d85d12c1d056" xlink:href="opk-20200630.xsd#opk_DiagnosticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5a80b4be-3d58-4423-b0fd-508c486f40f5" xlink:to="loc_opk_DiagnosticsMember_cd4dfa83-a14b-440b-afc5-d85d12c1d056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_571bc078-b5b0-4509-970a-8004e4019294" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:to="loc_srt_ConsolidationItemsAxis_571bc078-b5b0-4509-970a-8004e4019294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9b768047-49a0-4296-8503-f12e7487cff3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_571bc078-b5b0-4509-970a-8004e4019294" xlink:to="loc_srt_ConsolidationItemsDomain_9b768047-49a0-4296-8503-f12e7487cff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_183a445e-586e-4e03-a0df-1e3bd90bec37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_9b768047-49a0-4296-8503-f12e7487cff3" xlink:to="loc_us-gaap_OperatingSegmentsMember_183a445e-586e-4e03-a0df-1e3bd90bec37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_dc050b70-86b4-4d73-b92f-ef7e7a3827b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_9b768047-49a0-4296-8503-f12e7487cff3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_dc050b70-86b4-4d73-b92f-ef7e7a3827b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8d0e3ed4-25d1-4c69-a32a-c9c74ffd0c98" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:to="loc_srt_StatementGeographicalAxis_8d0e3ed4-25d1-4c69-a32a-c9c74ffd0c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8d0e3ed4-25d1-4c69-a32a-c9c74ffd0c98" xlink:to="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b83f0704-f11a-479f-a3dc-6df25d45fa3d" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_US_b83f0704-f11a-479f-a3dc-6df25d45fa3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_1c392acb-ff68-4849-9fd0-41984d072d8e" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_IE_1c392acb-ff68-4849-9fd0-41984d072d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CL_22502600-1821-4d61-8413-0ba4b39735c1" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CL"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_CL_22502600-1821-4d61-8413-0ba4b39735c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_b8f05e4d-0944-4c0b-8b58-b695a2266e48" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_ES"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_ES_b8f05e4d-0944-4c0b-8b58-b695a2266e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IL_3bc54086-5c77-4c51-8422-2e15c58e97fb" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_IL_3bc54086-5c77-4c51-8422-2e15c58e97fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_67d06557-5f64-494f-ada7-d1e1d2eb757f" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_country_MX_67d06557-5f64-494f-ada7-d1e1d2eb757f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OtherCountriesMember_5fdbaf91-2ba4-4e67-9e3c-d1e306186694" xlink:href="opk-20200630.xsd#opk_OtherCountriesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4d2ca882-47ef-4277-beae-0623b081e1ed" xlink:to="loc_opk_OtherCountriesMember_5fdbaf91-2ba4-4e67-9e3c-d1e306186694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a313d260-82c7-40f8-b59b-80898cb7d68c" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f49eeda2-6d91-4c1c-8ae3-c03ada670c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f49eeda2-6d91-4c1c-8ae3-c03ada670c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_06578a75-3dee-44d9-ac3f-63e60dc5d3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_OperatingIncomeLoss_06578a75-3dee-44d9-ac3f-63e60dc5d3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_80011476-40e2-4a40-9856-ae31c22b689a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_80011476-40e2-4a40-9856-ae31c22b689a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_c864e754-8779-4de0-a661-89fa8270618e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_GainLossOnInvestments_c864e754-8779-4de0-a661-89fa8270618e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0e561a77-2720-4865-8375-b2cdb358f8c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_Assets_0e561a77-2720-4865-8375-b2cdb358f8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_211e2f1a-bc66-48bc-86c5-64754d5cddee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a0762b00-9bdf-43ec-9137-e605bd108409" xlink:to="loc_us-gaap_Goodwill_211e2f1a-bc66-48bc-86c5-64754d5cddee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/Leases" xlink:type="simple" xlink:href="opk-20200630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1c83d058-d9e5-4a7a-a6cb-692d5e2f1ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_c5fb8c16-167a-4696-9ef4-80523ab83b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c83d058-d9e5-4a7a-a6cb-692d5e2f1ef7" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_c5fb8c16-167a-4696-9ef4-80523ab83b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesTables" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1b7183de-f056-4e7f-938a-856f21f8e66e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AssetsAndLiabilitiesLesseeTableTextBlock_1c0602c5-9d12-49d4-a568-b2b43b148b4a" xlink:href="opk-20200630.xsd#opk_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b7183de-f056-4e7f-938a-856f21f8e66e" xlink:to="loc_opk_AssetsAndLiabilitiesLesseeTableTextBlock_1c0602c5-9d12-49d4-a568-b2b43b148b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2b01e6ec-55ef-4db1-ae3c-52c42da62753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b7183de-f056-4e7f-938a-856f21f8e66e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2b01e6ec-55ef-4db1-ae3c-52c42da62753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_4178ec40-dcf5-444e-bdfb-e51c2ad73fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b7183de-f056-4e7f-938a-856f21f8e66e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_4178ec40-dcf5-444e-bdfb-e51c2ad73fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_eab91300-0bb1-4ad0-9305-c54c14d6ed37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b7183de-f056-4e7f-938a-856f21f8e66e" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_eab91300-0bb1-4ad0-9305-c54c14d6ed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_239624c8-a366-46bc-8144-257755f930b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_af672c77-16a0-48ab-bf5b-809a7995c34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_239624c8-a366-46bc-8144-257755f930b0" xlink:to="loc_us-gaap_AssetsAbstract_af672c77-16a0-48ab-bf5b-809a7995c34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_821c0672-be40-406f-b37f-fdd501117c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af672c77-16a0-48ab-bf5b-809a7995c34a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_821c0672-be40-406f-b37f-fdd501117c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_6e3a3b6f-6f32-43c0-ac0e-9283c6c6a92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af672c77-16a0-48ab-bf5b-809a7995c34a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_6e3a3b6f-6f32-43c0-ac0e-9283c6c6a92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_94e58d2e-cb0e-40d7-8081-ce92b6f3aaf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_239624c8-a366-46bc-8144-257755f930b0" xlink:to="loc_us-gaap_LiabilitiesAbstract_94e58d2e-cb0e-40d7-8081-ce92b6f3aaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c5df47e5-2d43-4865-89ed-43873c9dfd21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_94e58d2e-cb0e-40d7-8081-ce92b6f3aaf6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c5df47e5-2d43-4865-89ed-43873c9dfd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4ab091ce-0f32-45f2-a244-c53f6947b4d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c5df47e5-2d43-4865-89ed-43873c9dfd21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4ab091ce-0f32-45f2-a244-c53f6947b4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_314c317b-a8bb-4108-9a21-24b582a09b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c5df47e5-2d43-4865-89ed-43873c9dfd21" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_314c317b-a8bb-4108-9a21-24b582a09b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_226e296f-1cb6-4e36-9cbd-3a86d5baa0c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_94e58d2e-cb0e-40d7-8081-ce92b6f3aaf6" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_226e296f-1cb6-4e36-9cbd-3a86d5baa0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c45a75dc-469d-4deb-9c75-d3fe831234b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_226e296f-1cb6-4e36-9cbd-3a86d5baa0c0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c45a75dc-469d-4deb-9c75-d3fe831234b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c8ef7531-bb6f-4d2e-a634-87061adf6e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_226e296f-1cb6-4e36-9cbd-3a86d5baa0c0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c8ef7531-bb6f-4d2e-a634-87061adf6e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_WeightedAverageRemainingLeaseTermAbstract_87981bb0-a836-40ab-85cb-1981570f4456" xlink:href="opk-20200630.xsd#opk_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_239624c8-a366-46bc-8144-257755f930b0" xlink:to="loc_opk_WeightedAverageRemainingLeaseTermAbstract_87981bb0-a836-40ab-85cb-1981570f4456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dd1dd4a0-a405-40b6-9259-7903a14807a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_WeightedAverageRemainingLeaseTermAbstract_87981bb0-a836-40ab-85cb-1981570f4456" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dd1dd4a0-a405-40b6-9259-7903a14807a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_7c447923-4451-46e1-be2d-d24ee068b608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_WeightedAverageRemainingLeaseTermAbstract_87981bb0-a836-40ab-85cb-1981570f4456" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_7c447923-4451-46e1-be2d-d24ee068b608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_WeightedAverageDiscountRateAbstract_3805740b-d357-4e6f-a220-16d277fecb4a" xlink:href="opk-20200630.xsd#opk_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_239624c8-a366-46bc-8144-257755f930b0" xlink:to="loc_opk_WeightedAverageDiscountRateAbstract_3805740b-d357-4e6f-a220-16d277fecb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_460c5b6d-24a1-4ec3-a2c9-5310e5bdc005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_WeightedAverageDiscountRateAbstract_3805740b-d357-4e6f-a220-16d277fecb4a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_460c5b6d-24a1-4ec3-a2c9-5310e5bdc005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_9d843e6e-3fc0-47bb-8520-97a89337d6cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_WeightedAverageDiscountRateAbstract_3805740b-d357-4e6f-a220-16d277fecb4a" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_9d843e6e-3fc0-47bb-8520-97a89337d6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_93731eb8-db2e-437d-896b-912b84df1bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_239624c8-a366-46bc-8144-257755f930b0" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_93731eb8-db2e-437d-896b-912b84df1bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesLeaseLiabilityMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_904f1f47-ff49-410d-943e-01db68d2ce4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8e6f929-f950-41c1-9309-ad9fb3abfdba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_904f1f47-ff49-410d-943e-01db68d2ce4f" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8e6f929-f950-41c1-9309-ad9fb3abfdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_692c4a09-f3bd-42e7-b9dd-0962e99a3add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8e6f929-f950-41c1-9309-ad9fb3abfdba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_692c4a09-f3bd-42e7-b9dd-0962e99a3add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a850f996-cdc0-4297-abb8-cf5ca7a38e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8e6f929-f950-41c1-9309-ad9fb3abfdba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a850f996-cdc0-4297-abb8-cf5ca7a38e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fe9b9630-4070-49f6-a3da-06405f3c99cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8e6f929-f950-41c1-9309-ad9fb3abfdba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fe9b9630-4070-49f6-a3da-06405f3c99cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5ee6a39c-987e-46d9-aab0-e7131c053951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8e6f929-f950-41c1-9309-ad9fb3abfdba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5ee6a39c-987e-46d9-aab0-e7131c053951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d2748718-df58-444b-8ace-8fe811cc7a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8e6f929-f950-41c1-9309-ad9fb3abfdba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d2748718-df58-444b-8ace-8fe811cc7a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_cfcf43df-35d4-446a-b421-213d1de471cb" xlink:href="opk-20200630.xsd#opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8e6f929-f950-41c1-9309-ad9fb3abfdba" xlink:to="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_cfcf43df-35d4-446a-b421-213d1de471cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_33102743-a64f-44fa-a2df-5aca924297fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8e6f929-f950-41c1-9309-ad9fb3abfdba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_33102743-a64f-44fa-a2df-5aca924297fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_31ca6dde-20ce-4bff-883a-b479c87a43a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8e6f929-f950-41c1-9309-ad9fb3abfdba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_31ca6dde-20ce-4bff-883a-b479c87a43a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a127242f-0ce4-4b1e-bbff-8ad3a1bdff1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8e6f929-f950-41c1-9309-ad9fb3abfdba" xlink:to="loc_us-gaap_OperatingLeaseLiability_a127242f-0ce4-4b1e-bbff-8ad3a1bdff1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_89fb8b5b-25db-432b-b111-e5aa37fd57d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_904f1f47-ff49-410d-943e-01db68d2ce4f" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_89fb8b5b-25db-432b-b111-e5aa37fd57d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_3c9d272f-2075-4bd7-af7a-f87198562ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_89fb8b5b-25db-432b-b111-e5aa37fd57d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_3c9d272f-2075-4bd7-af7a-f87198562ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c9d06ff0-2568-4dcd-bb46-84411d5c520a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_89fb8b5b-25db-432b-b111-e5aa37fd57d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c9d06ff0-2568-4dcd-bb46-84411d5c520a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2df84fd6-bc85-4e07-9051-e4113413d257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_89fb8b5b-25db-432b-b111-e5aa37fd57d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2df84fd6-bc85-4e07-9051-e4113413d257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_01d0bcad-8477-42ee-842c-2eec95dc6882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_89fb8b5b-25db-432b-b111-e5aa37fd57d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_01d0bcad-8477-42ee-842c-2eec95dc6882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_602a9f03-f0c4-4617-a6b3-c864966742b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_89fb8b5b-25db-432b-b111-e5aa37fd57d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_602a9f03-f0c4-4617-a6b3-c864966742b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_530182c4-327c-45dc-a617-ed0c3b95774e" xlink:href="opk-20200630.xsd#opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_89fb8b5b-25db-432b-b111-e5aa37fd57d2" xlink:to="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_530182c4-327c-45dc-a617-ed0c3b95774e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f6087c85-a450-4625-b2e4-6fcc8f8693fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_89fb8b5b-25db-432b-b111-e5aa37fd57d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f6087c85-a450-4625-b2e4-6fcc8f8693fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3203483d-eaa8-4198-9438-62950537a7da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_89fb8b5b-25db-432b-b111-e5aa37fd57d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3203483d-eaa8-4198-9438-62950537a7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_e9f1f647-b0dc-4876-8c58-b8990deaadac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_89fb8b5b-25db-432b-b111-e5aa37fd57d2" xlink:to="loc_us-gaap_FinanceLeaseLiability_e9f1f647-b0dc-4876-8c58-b8990deaadac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesLeaseLiabilityMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b3415cad-1652-4099-8787-fedc215082e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3cb07464-36e7-4da8-b9ec-d066577859d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b3415cad-1652-4099-8787-fedc215082e0" xlink:to="loc_us-gaap_OperatingLeaseCost_3cb07464-36e7-4da8-b9ec-d066577859d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_a57e87ff-bbf2-4c74-9506-b561299ba6fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b3415cad-1652-4099-8787-fedc215082e0" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_a57e87ff-bbf2-4c74-9506-b561299ba6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_c4b2e8dc-7f87-4cf8-97ea-d73c344997f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b3415cad-1652-4099-8787-fedc215082e0" xlink:to="loc_us-gaap_VariableLeaseCost_c4b2e8dc-7f87-4cf8-97ea-d73c344997f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#LeasesLeaseCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9de9daf0-38ad-47fe-b77d-c3633cbe82df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9818e903-b272-40fd-9014-97a83e42516c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9de9daf0-38ad-47fe-b77d-c3633cbe82df" xlink:to="loc_us-gaap_OperatingLeasePayments_9818e903-b272-40fd-9014-97a83e42516c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_d236434a-2d3b-4e22-9014-e8f26b0d6557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9de9daf0-38ad-47fe-b77d-c3633cbe82df" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_d236434a-2d3b-4e22-9014-e8f26b0d6557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_c6540a81-6090-4266-8ea4-e72c3b6dfdb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9de9daf0-38ad-47fe-b77d-c3633cbe82df" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_c6540a81-6090-4266-8ea4-e72c3b6dfdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PaymentsForLeases_cff25ddb-9567-48f1-8efe-c4d4b6f9edbb" xlink:href="opk-20200630.xsd#opk_PaymentsForLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9de9daf0-38ad-47fe-b77d-c3633cbe82df" xlink:to="loc_opk_PaymentsForLeases_cff25ddb-9567-48f1-8efe-c4d4b6f9edbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SubsequentEvents" xlink:type="simple" xlink:href="opk-20200630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_44218609-aa89-49ea-a02e-b7a1cd7c9d42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_41cfbbbb-75c4-4e2b-8a67-e8579d8d48d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_44218609-aa89-49ea-a02e-b7a1cd7c9d42" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_41cfbbbb-75c4-4e2b-8a67-e8579d8d48d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="opk-20200630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_12c32a32-ac8e-473d-b486-ebd275d3b6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b90b4917-5c23-4b11-9730-3c9cae881f28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_12c32a32-ac8e-473d-b486-ebd275d3b6b5" xlink:to="loc_us-gaap_SubsequentEventTable_b90b4917-5c23-4b11-9730-3c9cae881f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8e988bb-8975-4b91-a1f6-fac9b307a2aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b90b4917-5c23-4b11-9730-3c9cae881f28" xlink:to="loc_srt_ProductOrServiceAxis_b8e988bb-8975-4b91-a1f6-fac9b307a2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31c9973a-7bb7-4aa5-a09f-b393efd5ba76" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b8e988bb-8975-4b91-a1f6-fac9b307a2aa" xlink:to="loc_srt_ProductsAndServicesDomain_31c9973a-7bb7-4aa5-a09f-b393efd5ba76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_eb2e25af-afb9-4c32-8888-882c1f86e678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_31c9973a-7bb7-4aa5-a09f-b393efd5ba76" xlink:to="loc_us-gaap_ServiceMember_eb2e25af-afb9-4c32-8888-882c1f86e678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_808a46d2-12e1-4e61-89e6-03b4ffc45a0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b90b4917-5c23-4b11-9730-3c9cae881f28" xlink:to="loc_srt_LitigationCaseAxis_808a46d2-12e1-4e61-89e6-03b4ffc45a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4113b958-7ce8-4bd1-a3a0-1c8c9becefe7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_808a46d2-12e1-4e61-89e6-03b4ffc45a0a" xlink:to="loc_srt_LitigationCaseTypeDomain_4113b958-7ce8-4bd1-a3a0-1c8c9becefe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A4KscoreMember_ba6b607c-6768-4144-b71a-8a665ec8dd24" xlink:href="opk-20200630.xsd#opk_A4KscoreMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4113b958-7ce8-4bd1-a3a0-1c8c9becefe7" xlink:to="loc_opk_A4KscoreMember_ba6b607c-6768-4144-b71a-8a665ec8dd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ac0f3b4c-4503-40ca-9764-6e1dac52c0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b90b4917-5c23-4b11-9730-3c9cae881f28" xlink:to="loc_us-gaap_SubsequentEventLineItems_ac0f3b4c-4503-40ca-9764-6e1dac52c0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a12a921c-539f-43b4-be0c-3c223d88939a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_ac0f3b4c-4503-40ca-9764-6e1dac52c0f6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a12a921c-539f-43b4-be0c-3c223d88939a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>opk-20200630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:opk="http://www.opko.com/20200630"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="opk-20200630.xsd" xlink:type="simple"/>
    <context id="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic45ce08a007f4d38ae03538fab205183_I20200720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2020-07-20</instant>
        </period>
    </context>
    <context id="i5698d6f1fc1940309b63ded417c158e4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5492a302d8ca4a85901a3a7b73505049_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2b0d7b56e4e464a9d12b6d4962aea9f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6e422d827f1b4988be46200738452fe0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i717fe99763b443568a4e4ea66cbaafd2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia322ccb5ede0412f84ec2408b2552856_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i440a8d7180944369aae265f885c6d28a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2e6c1f5b817d47bf874e9f6b12b917c4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic3ee6bb1db084cdfb8f79401b5096546_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia8c4c5128c354e2dade223d90ca95718_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3dca3ea038b14e008a2d1981f1feded6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifd98b19d90454faca4fb220c3e3f056a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7395bc7d5fc44e6cb1075481b8adb1cf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i92dec2859b504d4dbeb247bd54453c0e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8173ffa4f57449388f4402918c710024_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2a60d3075b9948199e8195d7f913ac6c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id895905b1a694b509baac821f4b07cc9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i25b81bddf69248d2a9dca49367b845fb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i43dc309a84a34c9da443f4b8fb4f46d6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2b6ee414e2b14aa2b7779dae646fa43d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if81665549a744db4b9e3cbd8460e29b6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3a5a9e0119604e449787b4ccd42bbfe0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4af5a56db0c24f5d8ef4a585500444b2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i143f61f3bd52487bbac948c8fad1648c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9d1df47745364a0b99f41d53769dcdec_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i936bc210908045ebb32428a797e622c9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i64a03ce9a44446aba8fd3973415e1804_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4e72a60ac3204f79a58324d7ac06d70b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5fd219acb38f4ebd979473ebe1345577_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i52609be761ba4470bb6b72bcdc9ed16e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e9d6032dccc43d39b3c75fc3e207e87_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i21eeb8671f80463cbbd4d25c43812904_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3925554062df4071b663e93f01c6d247_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie00bd5bfbe0747e98efecb5d0d36c2eb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9409bbd3d79a4f199dc0914b6a6a6232_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic8a18f692161417a9aeed6b519fbe23c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i14e0f7cf90b845618c2da998b2ec9256_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if1ca894201f24ceb996ca85bc139745f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0cc1ebc6dac04ccbb4e43babd6ec58f5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5051d9d5fe094597bf4e37ba100c22fd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i73abe1462fc54ccca6f449fcd66ad85f_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i1cdf44d9233e47f7b9bf249aff94b19c_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i89218e50948c4507b1df814b142d514e_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ib353496e520042c2b547d13887f30ff4_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i077eb15fd51d4b74985ebd93f8f78daa_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9acb0e76a853407e8a654c3be8ff1fee_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i67bbc9625fd1467492f28cf2d894d765_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iec5715c6fc274f75937803500c320ab9_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4cc58805b460451388796d3179b73858_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i47c7b4841e944d8c8219ea505de34c81_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6096decc24534d73b84d8382fa7cfddd_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i44cab2f05311498cb261057427e71187_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7a7adf54fa64417e87f3555d5bf0773d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if62bbfa990154581b6b8060ab7f25983_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic97107d2cf63436bbd19e901d052161a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i5fb67fadb72846cdba88dedab4956840_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1d4687ed998d4bc89b441e1a77865855_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i280cba37fbf24b4683f965f0f7b346d8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic493611ea31741d8bb485d6a0d53db9f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i00f0723faaa34d11aa00d312f4c86b4e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaf70df459fcd4df1abd8e73dbfafd943_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ida9ba4776d674e048a8f35590863e24a_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1c9c6b69f3bc46868fad995b8c409262_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic3ca2bc91b8f4fdfb88ca44ddd58ce7d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iee436d2fd7ff45f3915d1e32dcd70904_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibd4ae6fdd629444197cc9a625cdcfc9f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9dfc05b578db438c821384cc836c5a4c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5497d158e29a4207b882cb978b473faa_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i00d185d0856f4299a62fe26f4513d5f8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id7248978ab134af9bb5051c652bb74f7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="opk:COVID19TestTypeAxis">opk:SerologyAntibodyTestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i137e26f6947848af8470ae5fd8e6bab1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="opk:COVID19TestTypeAxis">opk:DiagnosticMolecularTestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id2fe9bfd426d4e56a5b3bcbcaf3b2286_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib5e57cbd6ab542d79a08167f6ec07985_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i52f6774dfd1f4573beee75bf01ef821c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:DistributionToHealthcareProvidersCOVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i998e2997494745b2998bd29dda7de21f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:DistributionToHealthcareProvidersCOVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8b70e317a90e423daaa6fcc619c8eb46_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:DistributionToHealthcareProvidersCOVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i34113ca72899471b80fa537db298faf5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia5f22aa17f4f4f80a5186830a870ac40_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a9fcdf9701e4978a7f6f9fdbae12895_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic8597cb5f4cd4e56a0b43a5aaa79edf0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2c925c357ef94419a653f6179d8cd427_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id483c700016445cf875194cf5a6fd62b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7bf9292e3f244c65ab4a6e78952c669e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i287a64693aa543c9b39361bdcfae9f34_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4ecb6c47f6db44edbbe0ea91612ccfd1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic3ec9c63dd2d444eba263c0dabc7144b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if6a40facfada4fc5a367a7dcaf4f0135_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibf92eadea438478cb1b5f0aa51c40f56_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">opk:AutomobilesandAircraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i542ee96b497e4c8e81ce12f68616f43a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">opk:AutomobilesandAircraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i16be18cc629345ec9ee57120942f2250_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i741090abba6940d68c835c82f65dc928_D20191231-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic59039c688094e9385f6da64420c81a7_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iede87b24ecb34c16881dd3d454c04ad4_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8c116f9b15604e95aba107054937c166_D20191231-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2cf990d401b84d509ca83830387dfec4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i703dda2862bf49c082b5e9c7749b1af2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9ae1d925ca624ccfa017da2775100740_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4825a57053b245fdb80ca8d81b3e823e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i94c6cd428f6b456c8d5b3acae79fbf66_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i94eb82a852ec42fbb84bb7e84f189cd8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f1de219854f4356843dae3ee1cd6115_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3d2610a4d4b94c94af040534c9ec37b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaca125106e0d4865a167a745ed415e38_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i00247b06c5ee4f84af09a0224926e806_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a3ad80fd03a4bd898db95dcf64037d2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i57b9d57f64db42caaea9671412bed643_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ccef43c91b649af897f72ba0ca5d9aa_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i64d57f02fcfa4a818269328b1928521f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie8cd1bd900ad44d581af60988c19e099_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:ProductRegistrationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic3e7a27b8c6642a990135286515905fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:ProductRegistrationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i04069b5f0be245a5b667f48793383f5c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i135e6bd0ecae45b790948a4ae8040c83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i230b30ca3eb04af49f4ca4734faacd44_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i882f8261760b4d6aa3a96e6fa3284bfb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ied7d8e97b2b945238ba32720ff6e8c0f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9ecfd46843994ca2aa33b2267b51858d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1497918852414fb6ac3b2f71effa85a6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0da706af1baa4c159c9bbb8d4c1030fd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i11f6b9bd556843b1aafd7e182d59c3cb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:CovenantsNotToCompeteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8408841c1a734a08b778637e70249682_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5adb35b4c9f34a37aeb9549a65e96e46_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4f61b01165e24fc98421d859fadcd8b2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i179802b429d44dda9f21192ac337df1a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic18db37a30a74d9c9ee748531acedbae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4ea760e341c847f4a25f3b37d6b09d32_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i52b56c73c8d84a5e8fb1fa551b3eddd3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i483bd6c64a9c49c2b324993790f590ee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i798edede7d9340b38166a915bb9c5868_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4b2f66f652b94502a75f85a54c4c3ef4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0cd4a728fcd14faf998c1ab9c30b3b83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33fff5e9ff6341f0bb92ec8ca48cb6e0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idd9cb4e1c5bf46f7811c43a8af57ec52_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i94fa7a9bd57a4f9bb8aa3d9c5b228336_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i771f4bcba7074c7bbbdffdd2ad65b477_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9f6803f62e7447adadce391b33061cba_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i79658e603527497182db4f569fcc87f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i986492897965401d95c6a703c55c6e77_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i93c9c6bb19df4ae99dc27947a8f03121_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib4fc9634e3a348bab19da19df297d2c9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:PharmsynthezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i40c56be3936e42218c130b6171df7087_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4b1d2bd1b0014409b092ff4aa9f8efb5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NonInvasiveMonitoringSystemsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia1aa8cc835a1411f9161a88fefd51afb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iecfe4462c2ee470cb896cbcb8858c7f9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:InCellDxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie5822595b03740f291e2481860949888_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:BioCardiaInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i323d8d5a5c3f438bb251f37e63e4c809_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:XeneticBiosciencesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7d3ef7c1241144ff931d3374e709b07e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9f4e2d31d1d5424882ae14d6cb9c371c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibe9c0975275d45f6898ff7d4f683e8e3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:PhioPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i09cc35711f9348d9b1b3f52011a7e368_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:VBIVaccinesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i79df6dd0e9984686893d9cfc9fe6d27f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ChromaDexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if01ceaf264f64e64b9647bf4a84dac24_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:MabVaxTherapeuticsHoldingsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i94995994c21b4facabf08492a51c559a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:EloxxPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i84662a74a01c4b2d941452c7e6b5ee4a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i90446d4596a146d88429e4a98be0564f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if6747d466c09424e9a50661e16dd7503_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7f02e4f9fd574e05a785e3c62f223eb4_I20200225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-25</instant>
        </period>
    </context>
    <context id="i7c119d6e22ac4137a2e112127278f9af_D20200225-20200225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-25</startDate>
            <endDate>2020-02-25</endDate>
        </period>
    </context>
    <context id="i8195e9a3e7ae435da153c7711a07ccb8_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i628701cad23a4cacaed112b486d72676_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i3d0c8459b0d1480baa745356d20f4dc6_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i9c0022ff1fff4fa7ba8b28cb480d9e7b_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i7c71fc44fe84471c8a385354d7db5b4d_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i888c9ebcddbc498c8ab5222fdd77b5af_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i81c329c54b3b47abb5e4773dc4152952_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i34d8ef11ad99488aa65782d224ee68dd_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="ifd9c15a8bce54e078a65dfcda71e2b93_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="ib386889486af4a37ada3615b1c1421e7_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="id8a7a241ec2b494485438af91f368462_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i870ca847a91146ff97990a7c7cdd8e63_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8d2d51166e124a23a7ecda07a40b9b8c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if6c32717a26d40d88eae1ea4982913d6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a737d9667b94ccdbd7e9b723c6dcf66_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8c8df4da0e504a6a9b34701d6f7d3cd7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i45d70386f33c4ae487d8d292158b179c_I20181108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-08</instant>
        </period>
    </context>
    <context id="i268d6c6d9d5e407ea296ba2214d356e1_D20190220-20190220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-20</startDate>
            <endDate>2019-02-20</endDate>
        </period>
    </context>
    <context id="iac1e5f5cb1464cb9905c5e33a1c7fede_I20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="i41911bac43624dd190e89f282a2ee86a_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i640328d25f104a07a644f3c84408a24d_I20130130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-30</instant>
        </period>
    </context>
    <context id="i612e5c755b184a3585408a4ff760d866_D20130130-20130130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-30</startDate>
            <endDate>2013-01-30</endDate>
        </period>
    </context>
    <context id="i4631f4b114e54a1fbc1288a82a9c2663_D20130101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i21d898ee3d254a1aa7701dbf13c49fa2_D20130101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i3d496a3b69364f4b9c89244789d4e32d_I20190201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-01</instant>
        </period>
    </context>
    <context id="ie7f7c5a48e684b00b4e6a9dad87deb6f_D20130101-20130131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-01-31</endDate>
        </period>
    </context>
    <context id="i6e81f5b8d06047b19aa7e48cbf98af16_I20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="i743fcf96590e44c695952271c01375ce_I20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="i9fbb22c04f364ad5afd2e52f45a360e6_I20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="ie499e8a5b1e1470ab749b6aa2325157c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie73fdab1754844eeac2a5f34832d8a31_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="i4a682eabf2f34c8a9917e7ba7e3c88ff_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="i3d6e118592a94347b7f4c1050e6a8489_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="ie9339ecd27304a0184566aff4167b7d7_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="i034c1dc338af428faed94254148230d8_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="i24807c0e885b473087a1ad68767cb2f9_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="i047b3aa3c79c430db33cc3494843fe01_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idd1f11282fee4ec6b1d277f48503edb2_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i764a079c978a4ea0b66bc026841d4844_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8dbeb3eb23de47a1b6f04ae8eeb9574b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:JPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifc44f46b59e54e81a86a9fb4fb093caf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:JPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6559fae108574d0aa1c9714fb3e24788_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ItauBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib8b5e2d07aba47b7a77c8a56814325cd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ItauBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i48c73acda48c4111a5af1047ccf8cc87_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BankOfChileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i779d609c655f49bd9d3e70d6c46b21fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BankOfChileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76e8733ec84b470fb842fdfb15d41f7c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BiceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i10ec51989518476483634a001fbac0a7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BiceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icee7b550c55b456e9633769b30d100c7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BbvaBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia45c0ca28d4645e1bf8bb43d0dd8fabe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BbvaBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide21bf3a408f483c9f82c34a363accc8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i63a721c51927453b93d7de9c83a24c60_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c7a5f9bb26d4ad3b5047c54208133b5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:EstadoBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2f8f740cc35344458b1021626127aa9e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:EstadoBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3ae1a5c41df24314a8823e0cba821c20_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i57693f69122442efb5a7d809f56b6b3c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id04e2700b7f6495590aab83734460c88_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ScotiabankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9c490f5f8dd9456c9a903914580ff1b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ScotiabankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0c00ea5e5ee42868078230022479853_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:Corpbanca1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iac4d242acca94e6b92d84518bdbd23d7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:Corpbanca1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i846f414c67b44a778a4b2f8c9669725b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BancoDeSabadellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id0b422715f43443c9f03f43e7a9abfff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BancoDeSabadellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id96b2ea0a8c14dadb89a084344dce841_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BilbaoVizcayaBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6906c76a48dc48c48a3dfb34cdf030b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BilbaoVizcayaBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic444558faa604456a69c0ea677b33c92_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBank2MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i83f9b1ef620641e998c7c8c1895e255a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBank2MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8a9e82eefe34a719b632c3dd6b4c0bb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i05425f68234a4c09943873aa2d16cc00_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i95fecc4a436340768768e918eea21ff8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">opk:NotesPayableAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icf8f60d813964c65a753ded4929b4ce1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">opk:NotesPayableAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifbc9ba99b84443e38237727e48a82f23_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9b21a3e7a57d4609b0d409b6ba20c32c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i45a19ae7054d4411b573ae861b1aadf1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib6281d7b057a416cab5bb28eeef12716_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8cf69adbd58647c68a8b7b7475028534_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i350765d31f054cb4a900a05635ea70c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idef84b903bff4b0ea60e0666075a8447_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1c611772672a47c8984d0140e9dff6e2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic564593128ce4e4b84460058baeb14cf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i531ede9f4ddd48268654c99511a06679_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i432215f275164d1b94ffc495a44a8c93_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2ff069d8c2354606be4fd434fa345d89_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if458b89b3f2b4390bb62734646f1a224_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic8c6bc5e253b4fe2a84e3f5d4fb9d30e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f5503e95ced4126b68fbce3f56c2973_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i889906dfb28744f396261bd2650c45b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie329f1da30bf41b49d879864c1d2d60b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if7e565fc549d442ca4eb00695a5c82db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c5e6af0a8a040aaa94190167dea56ab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i466da00a6f1e4da59279c84d5c12fe30_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76725fac2d244963b0e9b87c1b59c414_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i156c35b6196a4d9cba4e041a0cb57b3b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8680556422af45dd8dfa9ce4d3edc1ba_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3a53eb2f2d054cc998864517435338b1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia730eb3f2de947f1ae2828ca66e4a318_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icdc50b58341940828f8595408b7a269e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e0ac6f1d4cb4c66b971c20cf8aeca20_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if667381c8f554ff082c1a91219f79181_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0aca251d226f472f9def2eed58862fb1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7aaa36a9c3b240c480e7a180e04210a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i80bdef2e23504d6fb04d750584ece882_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib9b681e985234321b995bee7faf1aa60_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iee03a450fc9448c1b8e2ea08fdc41417_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5c1ec4036db94ff8ab2eaaeed0d02080_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifc1b1f708d7d402caa5805034a48ad80_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia293f36717934081b9f1213686122a51_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3f3753e96f434c02990e62a093e23382_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib875afce9dcb4394b143601b365f6f9f_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iccf1d6fe84ba4e54b2f9cc386683e187_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i69d3efc364ab4dcb8a44ddd5b86d234d_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie55e61c7727f4127be76e9ba93be973f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2d3673e8cc554f419eeaf0ebe4a24185_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i03aeaa43340c459c8da023f93e0228ea_D20191029-20191029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-29</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="i3dbdeb0b817643be9cbd2dfa9e9606f9_I20191029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-29</instant>
        </period>
    </context>
    <context id="iec908835f0b2426ca21f5664f890c7b2_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="id3cfd08ad6df4811a785c595816354c4_D20191029-20191029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:MembersofSeniorManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-29</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="i39377d350ed8459c9f4a6c8173298ce4_I20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">opk:OPKOTransactionSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:XeneticBiosciencesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="ia9973ed8023248deb54e5d88777adf34_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">opk:SharesReceivedUponClosingofXeneticTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if0f5d9e5d0c94731921acdcd9d79d299_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">opk:FederalTradeCommissionFilingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:ChiefTechnicalOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i043083dceb38404bb2b35a4fd84c56dc_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">opk:FederalTradeCommissionFilingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i1bfdb219056b42969ad222d49e930c2e_I20181108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-08</instant>
        </period>
    </context>
    <context id="i6302ffbd2069456f9a5cc3c3c7a1e7a5_D20190220-20190220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-20</startDate>
            <endDate>2019-02-20</endDate>
        </period>
    </context>
    <context id="i5e3a3664d4aa4479ab2f7ff77d256120_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i65bd6c4d55ac4253a96252cdeb1cebf6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ChromadexCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i651485904eaf48cf9b0d0e4ae12aa57c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NIMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib51423d67fdf443e92d5bbdd0177b903_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="ia1752740ed5f481c9bd06120be92363d_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ie8fff2811a6f4c0c9d1e13125eac0f56_D20170401-20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="ia0bd41509ea64c85ab834813ae267e3d_D20170401-20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="i0a7333b8434e44f483b8888bb05796ca_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i04269715161949f5a492269ba0ca5d33_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i69978c473ccc4f789665ee256ad80248_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="i7c13820530324de6a22fce865f5cabb2_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="i513914a206464308b0f07a3fdec68ace_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesCWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="i3ad66425a0b64ba89a7212677580e0de_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ib0abeab516404b459edcdfb5578edb3c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i397e015eed2e471682652c5cde1df638_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">opk:SeriesCWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i202231196f75401e854be2d8baec5847_I20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostandMrPfennigerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MuseumofScienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="i6c3cb92761b94bb7b621e130359abbc8_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostandMrPfennigerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MuseumofScienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i1996c6025aa74093ba775cca607f2ad3_I20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:FrostRealEstateHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="i45906ae2d8ff43e28d1650b504a4b3c5_D20181227-20181227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2018-12-27</startDate>
            <endDate>2018-12-27</endDate>
        </period>
    </context>
    <context id="if4107320ea8b40a4941b1ec675d93864_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="icded229365d849a8885db0145859da11_D20180907-20180907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2018-09-07</startDate>
            <endDate>2018-09-07</endDate>
        </period>
    </context>
    <context id="i287de0999fc24a5cb5546c28ae66980f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibd5de3ee3106459b8b1aaab7a6b137d4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie2f7c56771ab4b20b7d3fa3715695ba7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2e55f87c472d4233942a0970f859291b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8fb7acf8a79143cfb95180991f377710_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia071dd1966f14fa29801b16850ffc8ea_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6668a10b9952410e9af8b9a573c3e502_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7313b7ad75404a70aedcc5983ef98116_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic8d2333fa91a41edb9d18575c207b357_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic673a0ad279b49569adc8053d136c9ed_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i357cf1c7f87349e9a4ad4f30e32145c1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2604b5fdeede46d09d8201be1e143102_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i98c6c923d99b4f72ba76f4043d93e5b7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iafbe4baeeb164e489598f3e93202ba13_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib7fba9e8f0b849fca41dd97146435305_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibd71af6f0ead42e3977e6816580c5b93_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0c056955493c4da89ecda0e8ec4dfeba_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i089a4e13e63742a3bf748b525008d6b6_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia7a45f8733e649d5a143646e955ce1f8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icbef2a22641441ef8b13514f0f8eebc1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic702ce3d60b840edaa4bec0798d18d2e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic01e46e792ea463fb3ad976ee43f07a4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i387d466a792a4a228b1f3c6bc7fc4238_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id67bcee65e014a2a88bd297922d60030_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i66ba957ba45c4cb99119dded44d3d424_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7922e995a9b44dc296c267b40bfec5f5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic0a4001228bb4c458e9d188609ce4c92_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaa95a3813d3b4948b9efc4c7b0d46611_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8fdb6f9b86ce4bbb9158e2c6d20fc489_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0f98c06a3c1e4ad896eadb86f6436385_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2327c5e5ccd74c11bba8c2252aa98414_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6569a37c094481dbbbf19ebad7e7881_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic15d90a4230749868f5b5c698ace3ce2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3e3522057538446ea1d251088ff7d6f5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8fa68b3c3ee24bd292852c6f5f85587c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0ac0c06819a046cfa71bf39ddbd390fc_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie3e2e61832ff4501874806792daa7e45_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia335908fb412465eaee57977f0412a4d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5d636303815c49c8a2406f9aaa62f932_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:BioReferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6b958666966849daa4cbbd1cef96fbf6_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia2fe40f321844ae6bf4ae91cb7dc8144_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i85584120b6ae40969ed88e8fc454cbac_D20171012-20171012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2017-10-12</startDate>
            <endDate>2017-10-12</endDate>
        </period>
    </context>
    <context id="i12ba1de7824543edbdd98ac438e809ef_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="opk:MilestoneAxis">opk:PhaseTwoInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i96d78de3ebc6453598709f12f3820f35_D20171012-20171012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="opk:MilestoneAxis">opk:RegulatoryAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-12</startDate>
            <endDate>2017-10-12</endDate>
        </period>
    </context>
    <context id="ie228af85f95c497a87274c2e14523168_D20171012-20171012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="opk:MilestoneAxis">opk:SalesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-12</startDate>
            <endDate>2017-10-12</endDate>
        </period>
    </context>
    <context id="i7eed0ec839c8449599c9e800686ae3ce_D20171012-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2017-10-12</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i61fa984d891a47d58311053b2676c0d2_D20200505-20200505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-05</startDate>
            <endDate>2020-05-05</endDate>
        </period>
    </context>
    <context id="i27932b492e774f8db8526aebe560cf2c_D20200505-20200505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-05</startDate>
            <endDate>2020-05-05</endDate>
        </period>
    </context>
    <context id="i36465446b239476682a20c709bd20264_D20160501-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:ViforFreseniusMedicalCarePharmaLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">opk:DevelopmentandLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="i80e8caee7a4340afab2963d15be9c425_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:ViforFreseniusMedicalCarePharmaLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">opk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i1aca0bd3383748acb9d44a211a37ecaf_D20160501-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:ViforFreseniusMedicalCarePharmaLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">opk:ExclusiveOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="i40db44cde7914640bc267bc5d3ca1d33_D20191021-20191021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-21</startDate>
            <endDate>2019-10-21</endDate>
        </period>
    </context>
    <context id="i0bb57ae1dccc4112800dea209c9b6318_D20150101-20150131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-31</endDate>
        </period>
    </context>
    <context id="ic54c6d599fea4f00a596b9e77dc46c21_D20150101-20150131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-31</endDate>
        </period>
    </context>
    <context id="i090a78b5b12948a8bc788af6634489b5_D20150101-20150131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-31</endDate>
        </period>
    </context>
    <context id="i4935e51954e74cb4802f926d08c79c4e_D20150101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if7a4105b8a0d43d798aa66064542811f_D20101201-20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:TesaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-12-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="if83c5551238f479bbacf93c87bc5c2a9_D20101201-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:TesaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-12-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i080c53c4c6124f38aaee94f9fcbb0577_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:TesaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5b1c90b9bdb34bb583bd46dc1902301f_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:TesaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i284f86e01b904662b657fa1db96fa2a3_I20130331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:PhioPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-03-31</instant>
        </period>
    </context>
    <context id="ic884ff99f6fc4caabe0eb0adf1366e62_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i851a20819c20437db63c3ed7b80d94a3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2d2c67981041400a9c26389895519dc2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i81434e108329422e88ec3e2303f45ee8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i44f0b42571364216bc7c04e7377e706e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5ba6b13bf7a9415ab5f66ca96f8d16e1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i68fb7f858bc4413a97b4525dd5797a6f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iafd6856e572145f7aa974629ed727822_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i08298c5ab2f84fd5ae3f88f51ad3bb30_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i62426df8ac264ca2861d073dca037333_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id8519b57ec414786acb984d55ce68d04_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9de6620da22b4ec5be9f72a4e769a2c8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8b15741ac49b49afb0e5f05f9ae67e48_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idc753fb5d2a648f29daaac8bb88bc64f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8b1215e9556046579114216aeac09f0a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4f46c52a8ad4493da6d40440badaf26c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if4e1eb15dab448d6b2ea94c22565bff4_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i53552ab0d0f048c0902d204716895bdd_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i285f40a66d974262a93473c2fc344b4e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifba1e15ab2b34df19c53cd26a28891e9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i22026731d58f47f6bd0ff0c6f70fcf10_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iecdbfdd262384e3da2176a1036fa1472_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2db64897d6404c58a431674a58d3c3b4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i127c96f883e447a49aa692832a21189b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7935d8cd6d2c4a9eb100d80e225fb6b1_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i77b768751f6a4284aa23055c0a54e8e7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8a6eba59724c47faa438965d96def811_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ieb999c735a4342efba32032318fe7b05_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i23194842f3d84a37bd807bed4100a22e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9dd9f71d8ea54fb3b4a6d84cc0903e51_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i89565ed2865e40509a73fa94d9ac6df0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1fc09bfbf0b54937b5e5c7c9ad9f5556_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i536a503a71bf40b38d8e2df97401bda3_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ief7ca9e930b14261a5d0126d1359cce0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i467d69f1593b4e59aeba2ae8185b03a5_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i95137661f82444ed8ade5d61a8c2693c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i78ab453f6db84127938a7075db98d34c_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iaccfccfe524e46b09fdc3bb72135977e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i70a53a1a90634b7198030c3447c9898c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i176405a326bc43a0a55b9bc8ac1d8bf2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibf8ef541025e44ee8cf8686ede2517a7_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i254cd6a34e0a4624a06cd9c4a34e9913_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1e8982b6568f486980128a9f7513ec32_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i63bb2b62077c41bc8668fc1ce4d89ec0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i198a3844c0c0490abcbc066a7dd24dc8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id56bcff9a57b427f8621c4e8187ca9c3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6e68ebe729e346baaedc4e909e8155d6_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie634e2306c8a4bebb90dffbe2e414e0e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibccc990af11146938643e532d4826cb5_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7027219b6b1045408436c1bb1b2f5a53_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0871f5c7e8b94f5781f08a92001c6cea_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia0460fea90284226bde4999b97d0ed81_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4da1a32fe2164419974b9faaefa37a49_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i62a29626ff724abb9ad4cee99f7898d9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9e418fb903dd4587b64cfae8429ade02_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if216b4c1ff0547679dcc2abcaf82d5dd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i914a917d0c624130b4baa7ce8b4d021d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i66aa17bc991b4212b0639a733b595a8a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1af19639eaec49a2970b68e53aa71655_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i06a58a1bdfc547f5961d72ff32ddb242_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6d16a24c094b4ab6964f823f0e7ca361_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i15f1fa750fa04018a4f1850d6bf7a8bd_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iba985ea2bc4348dcabba2e4c00d34207_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie9f619314d9249319d7a90de7f3e4587_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibcc2adb4a7c142589c1a8c280a393746_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7b6d1653ea794637b798906498b50d0e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7da3b5d4af3d4ef9b385a90d5a8722bc_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i309155533c28422e82b808d1dc76e743_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4a9bcd23670e4f6185473829764ef0a9_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9cfb0c9e22cd4f7eb6a00d4ace862685_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6a15f6d7c0e345db8249158f70fc4ed4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i31c3c30dd034436bb8769e07c7ddefc9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3e6d29b56e2343b0a824d97674db5c75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e4767da5b9c440090362640bac1a2e0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icfcc5f95aa934dfa95991eb13af1680d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i50b1c18c29b2480badccb24aa75ca3bd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:A4KscoreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i56d3de83d9ad4ba99bcdfa4b49b82318_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:A4KscoreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>opk:employee</measure>
    </unit>
    <unit id="test">
        <measure>opk:test</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>opk:segment</measure>
    </unit>
    <unit id="day">
        <measure>opk:day</measure>
    </unit>
    <unit id="institution">
        <measure>opk:institution</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="lawsuit">
        <measure>opk:lawsuit</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180L2ZyYWc6ZmI2ZjUyNjgwNjRkNGZkOTkxMjFhNTdiY2QxZDc5MzYvdGFibGU6OTc1MTYyYjYyODhiNDdlY2IwYTE3NjMwOGM1ZDE2MzYvdGFibGVyYW5nZTo5NzUxNjJiNjI4OGI0N2VjYjBhMTc2MzA4YzVkMTYzNl8yLTEtMS0xLTA_f5398f5e-36fa-4b42-abc7-400b6537d2c8">0000944809</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180L2ZyYWc6ZmI2ZjUyNjgwNjRkNGZkOTkxMjFhNTdiY2QxZDc5MzYvdGFibGU6OTc1MTYyYjYyODhiNDdlY2IwYTE3NjMwOGM1ZDE2MzYvdGFibGVyYW5nZTo5NzUxNjJiNjI4OGI0N2VjYjBhMTc2MzA4YzVkMTYzNl8zLTEtMS0xLTA_8fd300d5-3815-42bf-8806-b4cbb91e5cab">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180L2ZyYWc6ZmI2ZjUyNjgwNjRkNGZkOTkxMjFhNTdiY2QxZDc5MzYvdGFibGU6OTc1MTYyYjYyODhiNDdlY2IwYTE3NjMwOGM1ZDE2MzYvdGFibGVyYW5nZTo5NzUxNjJiNjI4OGI0N2VjYjBhMTc2MzA4YzVkMTYzNl80LTEtMS0xLTA_892c355d-b408-4867-b400-1c8d28efb4fb">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180L2ZyYWc6ZmI2ZjUyNjgwNjRkNGZkOTkxMjFhNTdiY2QxZDc5MzYvdGFibGU6OTc1MTYyYjYyODhiNDdlY2IwYTE3NjMwOGM1ZDE2MzYvdGFibGVyYW5nZTo5NzUxNjJiNjI4OGI0N2VjYjBhMTc2MzA4YzVkMTYzNl81LTEtMS0xLTA_8d313225-1f10-4747-831e-bee87e7d8437">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180L2ZyYWc6ZmI2ZjUyNjgwNjRkNGZkOTkxMjFhNTdiY2QxZDc5MzYvdGFibGU6OTc1MTYyYjYyODhiNDdlY2IwYTE3NjMwOGM1ZDE2MzYvdGFibGVyYW5nZTo5NzUxNjJiNjI4OGI0N2VjYjBhMTc2MzA4YzVkMTYzNl82LTEtMS0xLTA_cd1b40c6-2db6-4987-b38c-c9a26e3fe59c">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ic8a18f692161417a9aeed6b519fbe23c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfNS0wLTEtMS0xOTcx_2a78596e-2e9b-4170-8b5c-be1bf9f61bd7">us-gaap:AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ic3ca2bc91b8f4fdfb88ca44ddd58ce7d_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNS0wLTEtMS0xOTc1_d0d7ef42-df32-41f0-99db-db4b4d4334f1">us-gaap:AccountingStandardsUpdate201807Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i8cf69adbd58647c68a8b7b7475028534_D20190201-20190228"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182Ny9mcmFnOmMyZGJmZDdkYTQ1MDRkMDdhM2I4MDEyOGU0N2E3ZTM1L3RhYmxlOmIzMzJlNDY0NGQ3YTQyMzE4ZTFjZTlkMTMwM2Y4M2JjL3RhYmxlcmFuZ2U6YjMzMmU0NjQ0ZDdhNDIzMThlMWNlOWQxMzAzZjgzYmNfMy0xLTEtMS0w_7ac067cb-0597-4b5d-95c3-d100bb116a4d"
      unitRef="number">0.2367424</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ic3ca2bc91b8f4fdfb88ca44ddd58ce7d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184Mi9mcmFnOmNlMmExOGExZGViNzRkMDE4MWJkYmU3MTgyM2RjMTkyL3RhYmxlOmQwNmZmMGNjMzJjZDRlNzA5N2EyMTQ0YjNlODdmMDQyL3RhYmxlcmFuZ2U6ZDA2ZmYwY2MzMmNkNGU3MDk3YTIxNDRiM2U4N2YwNDJfMS0xLTEtMS0w_4c9b00ee-47c4-4d5c-a1c9-da2a9efd9090"
      unitRef="number">0.01</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <opk:NumberOfDerivativeLawsuits
      contextRef="icded229365d849a8885db0145859da11_D20180907-20180907"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184OC9mcmFnOjU1MDFiODg0OGU3MDQzNDM5MGExZmNkZjJiZTg1N2E4L3RleHRyZWdpb246NTUwMWI4ODQ4ZTcwNDM0MzkwYTFmY2RmMmJlODU3YThfMTI3_68047e18-4c2a-4abd-8547-5f1643e77d90"
      unitRef="lawsuit">12</opk:NumberOfDerivativeLawsuits>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMzM2L2ZyYWc6ZmRiYWRlNzhkMDAxNGFiZTkzMWRhZDg3NzI0YmM1OTgvdGFibGU6NmFhMmM3NDkzODllNGE3MWI5MjJlYTBmODYzODI5ZjIvdGFibGVyYW5nZTo2YWEyYzc0OTM4OWU0YTcxYjkyMmVhMGY4NjM4MjlmMl8wLTMtMS0xLTE5ODc_623da3fb-fb6b-40af-a46b-7882ab84721d">us-gaap:PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODcx_794c93cb-0831-4b1d-9264-7639c53865a7">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6NmFiMDdjZGJiYzYzNDBkOWI1NjZhODNjN2U3YTU5ZTEvdGFibGVyYW5nZTo2YWIwN2NkYmJjNjM0MGQ5YjU2NmE4M2M3ZTdhNTllMV8wLTAtMS0xLTA_6222afff-cb77-423d-9bee-6493264c3bae">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xMzQ_0612012e-2da5-48f4-804a-dbf29f3daeaf">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MGI1NmU3M2M4MjJiNDdhZDgzZTU3NjllMzMwZjg3MDUvdGFibGVyYW5nZTowYjU2ZTczYzgyMmI0N2FkODNlNTc2OWUzMzBmODcwNV8wLTAtMS0xLTA_bff69622-9886-437f-a39e-da41e413cfdb">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODcy_3ab6961e-fe44-4d10-abae-857a17bf062e">001-33528</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODcz_42937110-fa96-4b2b-8bdc-be2d2fb3462f">OPKO Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MGNlZmJiYTI4NjQ1NGQxMGI2YTYwZThhYmZjOWRjNGYvdGFibGVyYW5nZTowY2VmYmJhMjg2NDU0ZDEwYjZhNjBlOGFiZmM5ZGM0Zl8wLTAtMS0xLTA_2a041ec6-e61f-4db5-8d66-2b19ffe356a8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MGNlZmJiYTI4NjQ1NGQxMGI2YTYwZThhYmZjOWRjNGYvdGFibGVyYW5nZTowY2VmYmJhMjg2NDU0ZDEwYjZhNjBlOGFiZmM5ZGM0Zl8wLTItMS0xLTA_cbc5acde-45df-486e-93ac-c51008df9355">75-2402409</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV8wLTAtMS0xLTA_3d217c5c-e6d7-4ee2-b00d-efb5f67015a2">4400 Biscayne Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV8xLTAtMS0xLTA_e0d8856a-3aa1-4a9d-a6e2-a51284398450">Miami</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV8xLTEtMS0xLTA_17785b8b-1f65-4b12-ac2c-ac4ea7a28639">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV8xLTItMS0xLTA_3d25f682-7f33-485e-832d-c67fa2317887">33137</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV80LTAtMS0xLTA_e7a933b0-b2d6-40f5-a3a3-ee1529c847e5">(305)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6MjI3YTE4OTViMDY5NDVlNGI3ZjhmOWVjMGQ4MGM4NTUvdGFibGVyYW5nZToyMjdhMTg5NWIwNjk0NWU0YjdmOGY5ZWMwZDgwYzg1NV80LTEtMS0xLTA_28654c9b-f6ad-45f8-bc59-c5f893b1b69a">575-4100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6OWY3OTVjZDU4NjBhNDA3YThiZGIwZDIyOTNkZTRkZDMvdGFibGVyYW5nZTo5Zjc5NWNkNTg2MGE0MDdhOGJkYjBkMjI5M2RlNGRkM18xLTAtMS0xLTA_369c362f-2442-49bb-9820-ff9f1cb16f71">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6OWY3OTVjZDU4NjBhNDA3YThiZGIwZDIyOTNkZTRkZDMvdGFibGVyYW5nZTo5Zjc5NWNkNTg2MGE0MDdhOGJkYjBkMjI5M2RlNGRkM18xLTEtMS0xLTA_a1b5871f-da33-47c6-b8f0-aa0d9b022178">OPK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6OWY3OTVjZDU4NjBhNDA3YThiZGIwZDIyOTNkZTRkZDMvdGFibGVyYW5nZTo5Zjc5NWNkNTg2MGE0MDdhOGJkYjBkMjI5M2RlNGRkM18xLTItMS0xLTA_ba7bcf67-278e-46f4-89b0-d7dac2015c67">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODc0_7bd67c5b-60a0-4a67-88b5-0ff0400c513a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODY5_2291d305-98b4-4ef6-8d7c-59e70ae68656">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6NTYxYTcxOGQ2MzIyNDkzYmIwN2M5MTc3Y2FhNGEyOWUvdGFibGVyYW5nZTo1NjFhNzE4ZDYzMjI0OTNiYjA3YzkxNzdjYWE0YTI5ZV8wLTAtMS0xLTA_36ae4f0c-a8b2-494d-9943-b611e6afcf10">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6NTYxYTcxOGQ2MzIyNDkzYmIwN2M5MTc3Y2FhNGEyOWUvdGFibGVyYW5nZTo1NjFhNzE4ZDYzMjI0OTNiYjA3YzkxNzdjYWE0YTI5ZV8xLTMtMS0xLTA_15b6894a-a31e-4f2e-ba2e-852f9191804f">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGFibGU6NTYxYTcxOGQ2MzIyNDkzYmIwN2M5MTc3Y2FhNGEyOWUvdGFibGVyYW5nZTo1NjFhNzE4ZDYzMjI0OTNiYjA3YzkxNzdjYWE0YTI5ZV8yLTMtMS0xLTA_83d92366-1d55-4c22-b38b-3aba32dfc410">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODcw_890f99a2-622b-4ba4-818f-3c6e822aff3c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic45ce08a007f4d38ae03538fab205183_I20200720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xL2ZyYWc6YTgxYzIxMWE5MTg5NGMyZGI3Nzk0YTYyMGE0NzMwZDcvdGV4dHJlZ2lvbjphODFjMjExYTkxODk0YzJkYjc3OTRhNjIwYTQ3MzBkN18xODMy_865f64ba-a689-4a2c-95aa-795c8760144b"
      unitRef="shares">669831024</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMy0xLTEtMS0w_6bfccb24-d879-4074-b895-4b6555365970"
      unitRef="usd">21612000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMy0zLTEtMS0w_e436bca4-f2f7-440d-bc31-945f543d9a61"
      unitRef="usd">85452000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNS0xLTEtMS0w_f3507350-b74b-4d2f-b830-fd4ea7942bad"
      unitRef="usd">214352000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNS0zLTEtMS0w_57de302c-ef6d-4cc8-92d1-a4c49bfd1290"
      unitRef="usd">134617000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNi0xLTEtMS0w_5377de72-c5a4-475c-87d0-82a2b879be0a"
      unitRef="usd">72965000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNi0zLTEtMS0w_57131b63-0d75-4e4e-be1d-4817e07852e4"
      unitRef="usd">53434000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNy0xLTEtMS0w_c3007a7a-236c-49ad-bfc6-e0d3bb08c484"
      unitRef="usd">51125000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNy0zLTEtMS0w_9a85a18c-bdfa-4953-8436-e65feada7886"
      unitRef="usd">50542000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfOC0xLTEtMS0w_7438ffa1-3a79-462e-bf4a-8597dd1e0c93"
      unitRef="usd">360054000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfOC0zLTEtMS0w_a43e5966-6750-4a32-9696-023704aae313"
      unitRef="usd">324045000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfOS0xLTEtMS0w_03cf8f50-694c-42a6-89a3-3cc0f6e15dae"
      unitRef="usd">130540000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfOS0zLTEtMS0w_30ba4a39-6db0-4514-b84e-ca36994fbfe6"
      unitRef="usd">127111000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTAtMS0xLTEtMA_a6d05044-024b-47a5-965f-e6258ed192da"
      unitRef="usd">499125000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTAtMy0xLTEtMA_d33f01a5-17aa-4263-877d-9e34851cb697"
      unitRef="usd">528962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <opk:InProcessResearchandDevelopment
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTEtMS0xLTEtMA_f2e7e847-0cbc-4dca-b66a-63812cde1191"
      unitRef="usd">590200000</opk:InProcessResearchandDevelopment>
    <opk:InProcessResearchandDevelopment
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTEtMy0xLTEtMA_a7b3db14-7302-4319-a593-c2950026ac25"
      unitRef="usd">590200000</opk:InProcessResearchandDevelopment>
    <us-gaap:Goodwill
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTItMS0xLTEtMA_31f6efbf-9d09-4661-ac78-bf70e93e2eec"
      unitRef="usd">671599000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTItMy0xLTEtMA_2336b767-9933-4c73-b1ac-2cf7f0bb65ca"
      unitRef="usd">671940000</us-gaap:Goodwill>
    <us-gaap:LongTermInvestments
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTMtMS0xLTEtMA_32039d9e-d5fc-4f59-a4a6-4cc569dc8ce4"
      unitRef="usd">26260000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTMtMy0xLTEtMA_d2e5c8c6-4f63-439c-85ac-d893f3f65f59"
      unitRef="usd">20746000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTQtMS0xLTEtMA_9f988151-4755-49f1-9ecc-430cc72e73c0"
      unitRef="usd">38469000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTQtMy0xLTEtMA_68706dd1-6318-4ab3-b3c9-8812280bc994"
      unitRef="usd">39380000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTUtMS0xLTEtMA_946b4b6d-a100-4f3a-ac4e-d7268d99c851"
      unitRef="usd">7487000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTUtMy0xLTEtMA_019943fd-562b-4f08-9923-bd6a028930f9"
      unitRef="usd">6888000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTYtMS0xLTEtMA_775861b8-3587-43e4-998f-4181dbb60816"
      unitRef="usd">2323734000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTYtMy0xLTEtMA_00ff467f-cc99-49e6-b396-e4833be3b3f0"
      unitRef="usd">2309272000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTktMS0xLTEtMA_460ffa72-0d98-49da-b3db-527b7b715509"
      unitRef="usd">44671000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMTktMy0xLTEtMA_1e9671aa-ff7e-49d1-8fbe-dbc21d82b56d"
      unitRef="usd">62537000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjAtMS0xLTEtMA_539a3b26-11f8-407a-9123-8fd233113020"
      unitRef="usd">210111000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjAtMy0xLTEtMA_1b5c42a3-b057-40dd-a458-749fab1c117b"
      unitRef="usd">164925000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjEtMS0xLTEtMA_2dc8f983-6711-4e8d-92b9-6f50730eb54a"
      unitRef="usd">10298000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjEtMy0xLTEtMA_a3a5b900-548d-49e8-821f-6be3d600a301"
      unitRef="usd">12038000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjMtMS0xLTEtMA_761d3200-8443-4475-bfd4-79bd8b1ffeaa"
      unitRef="usd">14463000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjMtMy0xLTEtMA_8efe2425-6fdd-4e45-8bcb-67f77cf81614"
      unitRef="usd">9619000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjQtMS0xLTEtMA_8a3c9624-c336-4ac6-b7bc-3235cfa63fed"
      unitRef="usd">279543000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjQtMy0xLTEtMA_e93c653e-775e-4719-b50e-f7b044c2ba58"
      unitRef="usd">249119000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjUtMS0xLTEtMA_f545a34c-1115-4e65-a192-0fb57fa4d6c3"
      unitRef="usd">28759000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjUtMy0xLTEtMA_4a616054-02f9-496b-bc83-8f66fad5e73b"
      unitRef="usd">27665000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjYtMS0xLTEtMA_e5942124-afea-44b0-9352-3bcdf7500ca4"
      unitRef="usd">216457000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjYtMy0xLTEtMA_34c7ef95-6db6-487d-a988-02788ab85420"
      unitRef="usd">211208000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjctMS0xLTEtMA_fccadba5-3e86-448c-8852-002cdc69c85d"
      unitRef="usd">118979000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjctMy0xLTEtMA_8834df18-78f2-400c-8b5c-fbcbc8372646"
      unitRef="usd">118717000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjgtMS0xLTEtMA_83299a99-5e44-4a47-b9f4-231865fc9ff3"
      unitRef="usd">91653000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjgtMy0xLTEtMA_a2c42889-c01e-4788-83cb-13e9ab9c5e98"
      unitRef="usd">87804000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjktMS0xLTEtMA_80d5c2d9-f3ce-4997-a8c5-296c1337e5ff"
      unitRef="usd">455848000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMjktMy0xLTEtMA_7ceb7e90-1343-4f06-9d2d-411b9c18d9aa"
      unitRef="usd">445394000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzAtMS0xLTEtMA_4a179842-4c2f-4a48-b7b3-1b1c48bd9b70"
      unitRef="usd">735391000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzAtMy0xLTEtMA_9e3176c5-68fb-40f5-a018-9c2255815927"
      unitRef="usd">694513000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3MTk_43ef1d72-023e-4503-a6db-827aee7abe97"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3MTk_b9f1ee86-488a-460c-8d47-2dfa75621994"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3MzU_400c70a8-f0e1-49b3-9335-7829ef9f6751"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3MzU_fb20e6fa-5cca-4820-b63b-4f76df010ed3"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3NDg_b084ee6a-a238-497a-a0f1-06309753e965"
      unitRef="shares">670378701</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjQzZWMxOGE1NTdlNzQwNzE4YjRkNGZmNjk1NDc0YjViXzIxOTkwMjMyNTU3NjE_14d24c0a-d31b-461b-a3cf-e36b9bc7f19f"
      unitRef="shares">670378701</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMS0xLTEtMA_822bf45a-3489-40f5-87cb-c2418e9b1b6a"
      unitRef="usd">6704000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzYtMy0xLTEtMA_20d4b527-09ab-465b-bbf5-9befcaf4c1ec"
      unitRef="usd">6704000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmRjZWJhOWFkM2RiYTQ3MTJhZmFmYzljMzkxMTFlYTlhXzIxOTkwMjMyNTU2NDc_5e21263a-46a5-42fd-b686-75791a05d5ee"
      unitRef="shares">549907</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmRjZWJhOWFkM2RiYTQ3MTJhZmFmYzljMzkxMTFlYTlhXzIxOTkwMjMyNTU2NDc_e0d63b81-2235-44d8-9126-afa011c4ade5"
      unitRef="shares">549907</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzctMS0xLTEtMA_6c7f592e-e4e6-42ff-9f4c-89ed81a83a62"
      unitRef="usd">1791000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzctMy0xLTEtMA_fe1c207a-2ad0-412c-b6cd-0fd414a21f67"
      unitRef="usd">1791000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzgtMS0xLTEtMA_9b49ad17-0133-4a9b-b2a5-43890d4527c5"
      unitRef="usd">3147030000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzgtMy0xLTEtMA_b0569b22-e4f9-4fa7-92b0-8bbe2e91dbf2"
      unitRef="usd">3142993000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzktMS0xLTEtMA_04c0853f-89d5-4bc6-addb-25b32e618152"
      unitRef="usd">-25752000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfMzktMy0xLTEtMA_71f808b0-e325-4378-870c-04e056ac2da1"
      unitRef="usd">-22070000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDAtMS0xLTEtMA_4132b7c4-2043-45dc-991f-ca04999340d3"
      unitRef="usd">-1537848000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDAtMy0xLTEtMA_e74ae5b5-79cc-4c99-99b2-301d352d38db"
      unitRef="usd">-1511077000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDMtMS0xLTEtMA_68eaa09e-12e6-40f8-adb2-d6dec1dacdbc"
      unitRef="usd">1588343000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDMtMy0xLTEtMA_a58e5357-954e-4e78-9151-785d2b2e8ac8"
      unitRef="usd">1614759000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDQtMS0xLTEtMA_17f6c183-e828-4189-a3ff-569e39d3d093"
      unitRef="usd">2323734000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xOS9mcmFnOjE2ZTNjMGNjYTZkOTQ4YThhNjlkMTk2MjI0OWM1OGI4L3RhYmxlOmI4NGQxOWVlOTAzZjQwMzQ5ZGM5ZDk3MzBjZTQ3MDc4L3RhYmxlcmFuZ2U6Yjg0ZDE5ZWU5MDNmNDAzNDlkYzlkOTczMGNlNDcwNzhfNDQtMy0xLTEtMA_6feb6927-6cc6-45dc-bb76-1c01f5d6c832"
      unitRef="usd">2309272000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b0d7b56e4e464a9d12b6d4962aea9f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMy0xLTEtMS0w_5cee1a8b-3aca-4bef-9a3c-f2bef9f4f3b7"
      unitRef="usd">250971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e422d827f1b4988be46200738452fe0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMy0zLTEtMS0w_ba369b00-036b-4bcc-aed5-e5ac5720b67a"
      unitRef="usd">178458000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i717fe99763b443568a4e4ea66cbaafd2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMy01LTEtMS0w_792b3c7b-86a8-44c3-b329-439c6a94919c"
      unitRef="usd">421811000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia322ccb5ede0412f84ec2408b2552856_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMy03LTEtMS0w_aa027de1-4379-4441-9663-d34e2ff463ad"
      unitRef="usd">357349000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i440a8d7180944369aae265f885c6d28a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNC0xLTEtMS0w_c9f0989e-df43-4ba2-af26-17d1fe2eaa5b"
      unitRef="usd">29356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e6c1f5b817d47bf874e9f6b12b917c4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNC0zLTEtMS0w_1f101bfa-4c4a-47ef-a3ad-7590c09e5b8e"
      unitRef="usd">28680000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3ee6bb1db084cdfb8f79401b5096546_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNC01LTEtMS0w_1b042f1c-ea07-4430-a287-e2a50c41a896"
      unitRef="usd">60430000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8c4c5128c354e2dade223d90ca95718_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNC03LTEtMS0w_54359ca6-e3ca-48cf-8a83-34d57aef0e3f"
      unitRef="usd">53981000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dca3ea038b14e008a2d1981f1feded6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNS0xLTEtMS0w_63a3abfe-e947-479b-a062-dd6841bd42cc"
      unitRef="usd">20880000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd98b19d90454faca4fb220c3e3f056a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNS0zLTEtMS0w_ae0c2e27-c321-4078-96d8-82f0e49ca441"
      unitRef="usd">19230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7395bc7d5fc44e6cb1075481b8adb1cf_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNS01LTEtMS0w_ca20f210-eab3-4fa8-9d39-7cecc4e0cc3c"
      unitRef="usd">30433000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92dec2859b504d4dbeb247bd54453c0e_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNS03LTEtMS0w_df74d2ae-1eec-4c6c-be76-0bc8073f4fc4"
      unitRef="usd">37490000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNi0xLTEtMS0w_9fe6d97e-c27d-4d76-818e-d41e56e80bce"
      unitRef="usd">301207000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNi0zLTEtMS0w_14ec141f-a9b8-4104-9801-343cd3627be7"
      unitRef="usd">226368000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNi01LTEtMS0w_744d9b48-6570-4484-8bca-1d09c68240cf"
      unitRef="usd">512674000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNi03LTEtMS0w_2a636e80-8fcb-4a25-b46c-5952727e4c11"
      unitRef="usd">448820000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia2b0d7b56e4e464a9d12b6d4962aea9f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOC0xLTEtMS0w_ee6c7c43-1b15-4ec8-a24e-cf4dfb628525"
      unitRef="usd">144794000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6e422d827f1b4988be46200738452fe0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOC0zLTEtMS0w_9a0bf0b0-cad1-4e3c-848b-62684138f6b6"
      unitRef="usd">130078000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i717fe99763b443568a4e4ea66cbaafd2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOC01LTEtMS0w_8942a1f6-e63e-41f0-a7ad-605c631a102d"
      unitRef="usd">267680000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia322ccb5ede0412f84ec2408b2552856_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOC03LTEtMS0w_5614ad4f-ba40-4d59-a139-885c23148444"
      unitRef="usd">259981000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i440a8d7180944369aae265f885c6d28a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOS0xLTEtMS0w_c21a1ea5-b1c5-46a1-8625-bd9fcacc3fa5"
      unitRef="usd">17857000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2e6c1f5b817d47bf874e9f6b12b917c4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOS0zLTEtMS0w_8464bf57-55a8-4803-b960-89a29d4690fa"
      unitRef="usd">14145000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic3ee6bb1db084cdfb8f79401b5096546_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOS01LTEtMS0w_6ba3c255-9e12-42a7-9e51-86cfd322c82f"
      unitRef="usd">35229000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia8c4c5128c354e2dade223d90ca95718_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfOS03LTEtMS0w_ea24ed7d-595d-4672-a8ce-7ef1fceca0e0"
      unitRef="usd">28300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTEtMS0xLTEtMA_516ae421-619d-418e-9f72-feffe21a3730"
      unitRef="usd">77721000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTEtMy0xLTEtMA_2251ff68-fe02-4165-a082-1aa3fdb2f49c"
      unitRef="usd">88475000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTEtNS0xLTEtMA_80622c4f-f1f5-4859-8b96-8eb3e379feda"
      unitRef="usd">153852000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTEtNy0xLTEtMA_ea81ea53-dd3f-472e-8bf0-4f8bf0f6ff65"
      unitRef="usd">183633000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTItMS0xLTEtMA_d75bd3ef-f16e-4012-b9e7-f81e632abc59"
      unitRef="usd">17608000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTItMy0xLTEtMA_339a31fb-9510-4186-ba0d-f24c368a8a47"
      unitRef="usd">28286000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTItNS0xLTEtMA_9d3d54cb-651a-4346-9be0-f05ff6bc6c25"
      unitRef="usd">39369000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTItNy0xLTEtMA_fa68c3e0-c837-4d34-9783-312a0155bca2"
      unitRef="usd">64816000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTQtMS0xLTEtMA_058af295-8fc3-4228-a1f6-a76780194260"
      unitRef="usd">1111000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTQtMy0xLTEtMA_f561ceeb-ed9b-4a2c-8b01-99428e675c6b"
      unitRef="usd">-3775000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTQtNS0xLTEtMA_c587e228-f8c9-452b-987d-35bb26568120"
      unitRef="usd">251000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTQtNy0xLTEtMA_e384fd93-5172-48f1-ba7c-42d718ed0f80"
      unitRef="usd">1031000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTUtMS0xLTEtMA_7bb10a31-0abb-4e6f-ade2-1204006f7234"
      unitRef="usd">14937000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTUtMy0xLTEtMA_9d20767a-d982-4543-90fa-0149bdf2e2cc"
      unitRef="usd">16419000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTUtNS0xLTEtMA_d618217f-95ec-4d71-8b9d-932ca31d60c8"
      unitRef="usd">29874000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTUtNy0xLTEtMA_fb422219-f02b-47a8-a2bc-ff1834cd6218"
      unitRef="usd">32981000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTYtMS0xLTEtMA_f6943955-16ce-4fc0-98f3-5d3630680e7b"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTYtMy0xLTEtMA_70804a7a-8c26-403c-8d16-e90408691822"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTYtNS0xLTEtMA_91d33715-c8ea-41bc-8e73-d6e2ba1786cc"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTYtNy0xLTEtMA_656e62d3-4023-4c72-9789-dd78393f33c3"
      unitRef="usd">655000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingExpenses
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTctMS0xLTEtMA_824e228b-0465-4cff-b73f-d747be42550b"
      unitRef="usd">274028000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTctMy0xLTEtMA_f6317fbc-f9d6-433a-abc1-1a6d565ab216"
      unitRef="usd">273628000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTctNS0xLTEtMA_de2c18bc-364e-42aa-b4ba-a45c0b1a937b"
      unitRef="usd">526255000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTctNy0xLTEtMA_d5f56c35-b71d-47f8-8389-747186bb2c44"
      unitRef="usd">571397000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTgtMS0xLTEtMA_e1aa3c25-8794-4374-96ba-686a5eb1acd2"
      unitRef="usd">27179000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTgtMy0xLTEtMA_5452eded-23c9-4ad9-881c-bf2c5496431f"
      unitRef="usd">-47260000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTgtNS0xLTEtMA_90516898-4da8-4d4a-83b9-3bb9e7be9a05"
      unitRef="usd">-13581000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMTgtNy0xLTEtMA_7d633e88-87a6-4861-868a-1ed1cbfa113c"
      unitRef="usd">-122577000</us-gaap:OperatingIncomeLoss>
    <opk:InterestIncomeNonoperating
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjAtMS0xLTEtMA_f200c7ee-ef81-4969-a809-d649c6629bb7"
      unitRef="usd">5000</opk:InterestIncomeNonoperating>
    <opk:InterestIncomeNonoperating
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjAtMy0xLTEtMA_0804351e-e212-410e-85b3-be9e83cfb1d9"
      unitRef="usd">572000</opk:InterestIncomeNonoperating>
    <opk:InterestIncomeNonoperating
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjAtNS0xLTEtMA_b1d474de-fdaf-4857-8841-54ab3441d5d4"
      unitRef="usd">147000</opk:InterestIncomeNonoperating>
    <opk:InterestIncomeNonoperating
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjAtNy0xLTEtMA_1e7448cb-6f0e-44a8-9946-9376eb63e589"
      unitRef="usd">1127000</opk:InterestIncomeNonoperating>
    <opk:InterestExpenseNonoperating
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjEtMS0xLTEtMA_a729a27e-4ea8-4352-9f41-28e6fa557a42"
      unitRef="usd">5474000</opk:InterestExpenseNonoperating>
    <opk:InterestExpenseNonoperating
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjEtMy0xLTEtMA_f65f61d2-95bc-4012-82c4-9f6e37e12d8a"
      unitRef="usd">5501000</opk:InterestExpenseNonoperating>
    <opk:InterestExpenseNonoperating
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjEtNS0xLTEtMA_29833e97-8969-4b66-b886-230458b868d1"
      unitRef="usd">10970000</opk:InterestExpenseNonoperating>
    <opk:InterestExpenseNonoperating
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjEtNy0xLTEtMA_7f1c8182-5a62-41f2-942a-c185d3d56c77"
      unitRef="usd">10257000</opk:InterestExpenseNonoperating>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjItMS0xLTEtMA_cb51c65b-0f39-44b7-bcff-1c10f8385e48"
      unitRef="usd">-13000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjItMy0xLTEtMA_0771eed3-798c-4c12-aa6d-6551f419e9b6"
      unitRef="usd">-388000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjItNS0xLTEtMA_c53ca282-f3c8-4532-bb99-d3904a59f701"
      unitRef="usd">608000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjItNy0xLTEtMA_6f414b2d-e602-49c1-8773-05cd52f3c6cf"
      unitRef="usd">27000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjMtMS0xLTEtMA_3bf3fab7-666d-4073-ade5-8b1905c80236"
      unitRef="usd">18223000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjMtMy0xLTEtMA_b7e7ec19-9194-4976-8dfc-50b7cbd1785f"
      unitRef="usd">-5874000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjMtNS0xLTEtMA_1bdaa63c-0678-4398-904b-72f909072c3e"
      unitRef="usd">5890000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjMtNy0xLTEtMA_893cb547-d3c1-470f-996c-80c1b68934aa"
      unitRef="usd">-4897000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjQtMS0xLTEtMA_f89d2cf3-34a6-48b8-8175-ce2d4535e309"
      unitRef="usd">12741000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjQtMy0xLTEtMA_39e4d445-fc1e-4f3f-a1a0-63f6d617e2be"
      unitRef="usd">-11191000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjQtNS0xLTEtMA_cec3dd1e-fd9f-4fe1-8b2c-983e1b63cb2e"
      unitRef="usd">-4325000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjQtNy0xLTEtMA_79b85590-02ca-4664-8d9b-7d0eb2f8009b"
      unitRef="usd">-14000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjUtMS0xLTEtMA_06f403b0-adb3-410b-8190-05e20f896ba7"
      unitRef="usd">39920000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjUtMy0xLTEtMA_59f452ef-cfcc-4da3-9726-56f90cbd23b6"
      unitRef="usd">-58451000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjUtNS0xLTEtMA_aeae1bce-9eef-42d0-8e96-2bff89162f3d"
      unitRef="usd">-17906000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjUtNy0xLTEtMA_104b7730-88e7-4a06-85f1-ebff0082aae1"
      unitRef="usd">-136577000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjYtMS0xLTEtMA_96e37877-8815-4a29-943f-23742e5f1691"
      unitRef="usd">6028000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjYtMy0xLTEtMA_b2209e94-508b-40db-95cf-07e39073461e"
      unitRef="usd">1084000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjYtNS0xLTEtMA_c957074b-7331-4bc6-9097-55406c327092"
      unitRef="usd">7200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjYtNy0xLTEtMA_ea50c39e-3402-4e86-8f1a-3ad1ab52c02c"
      unitRef="usd">1866000</us-gaap:IncomeTaxExpenseBenefit>
    <opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjctMS0xLTEtMA_aade9bd3-2819-439c-bb30-cb94d9a17159"
      unitRef="usd">33892000</opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax>
    <opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjctMy0xLTEtMA_9f0aca5c-7850-43a6-a9c6-a436bd1eba70"
      unitRef="usd">-59535000</opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax>
    <opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjctNS0xLTEtMA_b992ecca-3cac-47f9-a53d-89ec9ee71f04"
      unitRef="usd">-25106000</opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax>
    <opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjctNy0xLTEtMA_362eb43a-a8e6-4d07-b85d-153d86f6b63c"
      unitRef="usd">-138443000</opk:IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjgtMS0xLTEtMA_020cfc87-9f1d-4398-b335-790c20f6678f"
      unitRef="usd">-189000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjgtMy0xLTEtMA_e8bedaea-ee95-40b9-83be-e03a14ce87e2"
      unitRef="usd">-271000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjgtNS0xLTEtMA_b7ce60e2-4cc9-441c-bc77-91f1f7c95ff4"
      unitRef="usd">-323000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjgtNy0xLTEtMA_a3b1b46e-7999-4419-ba13-862a0c3c7403"
      unitRef="usd">-2125000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjktMS0xLTEtMA_a7258ebd-9691-43a3-a94a-911f98f7d82f"
      unitRef="usd">33703000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjktMy0xLTEtMA_71211027-62eb-4849-bd81-3870079b69f7"
      unitRef="usd">-59806000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjktNS0xLTEtMA_daac8ccd-f771-4cce-991c-18cbd6376121"
      unitRef="usd">-25429000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMjktNy0xLTEtMA_9e1a32b4-af6f-452c-8a83-9a68857753f3"
      unitRef="usd">-140568000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMzktMS0xLTEtMA_242e6bd8-2277-4db1-bc07-97a8a1fb17bd"
      unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMzktMy0xLTEtMA_c2f85fe3-f401-4943-b9d0-5259710f5638"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMzktNS0xLTEtMA_5671ee78-0513-4609-ab63-e9c464bd20f4"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfMzktNy0xLTEtMA_baa621af-a327-41a4-861b-134e7a78aae1"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNDEtMS0xLTEtMA_9a3e7171-04ed-4203-9272-7e772acf6b6f"
      unitRef="shares">640578794</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNDEtMy0xLTEtMA_3e778f66-b0f0-4cae-914c-c7a7c748262a"
      unitRef="shares">586351045</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNDEtNS0xLTEtMA_aedf7632-d2de-496e-8f97-3f0873399c22"
      unitRef="shares">640578794</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yNS9mcmFnOjE0MGE2MTQ1ZmUyYzQxNzNhYmZkZjU4M2I5Y2IxODNmL3RhYmxlOmM4MzgwODg5NjZjNjRmMGZhZTY5YjE4MGM1MmI4YTdiL3RhYmxlcmFuZ2U6YzgzODA4ODk2NmM2NGYwZmFlNjliMTgwYzUyYjhhN2JfNDEtNy0xLTEtMA_bd158ef7-5f9f-4f73-a658-ccb68433c737"
      unitRef="shares">586347645</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfMi0xLTEtMS0w_32672c85-5769-4793-86ea-611eaade2689"
      unitRef="usd">33703000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfMi0zLTEtMS0w_f7c96cf6-a525-4fc0-a7fe-0dce9704bf9c"
      unitRef="usd">-59806000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfMi01LTEtMS0w_2b72c4e1-33e1-49b5-87a5-ff8a129b5be9"
      unitRef="usd">-25429000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfMi03LTEtMS0w_4f9e12f6-b6a1-460d-be10-01bae0d05e65"
      unitRef="usd">-140568000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfNC0xLTEtMS0w_5b324f50-41b4-4c82-8ae3-35484d43b28c"
      unitRef="usd">4435000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfNC0zLTEtMS0w_6e3c526c-821d-423b-9d97-fe332f5c74b2"
      unitRef="usd">2878000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfNC01LTEtMS0w_fb1c6177-0479-4290-8042-0c2e94b7b8ef"
      unitRef="usd">-3682000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfNC03LTEtMS0w_a6c78f00-1a1d-4352-9989-69e9f029888e"
      unitRef="usd">-220000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfOS0xLTEtMS0w_d6fbfbdd-ff27-4cf9-9164-b5ce20d402dc"
      unitRef="usd">38138000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfOS0zLTEtMS0w_8fb46d4e-4fea-4410-93c5-d0037adc97b2"
      unitRef="usd">-56928000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfOS01LTEtMS0w_2652d88b-3050-4871-9b9e-ecf6b3a6a507"
      unitRef="usd">-29111000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18yOC9mcmFnOmEwOTQwNTg5MTBkZDRiYTY5Y2E2ZGYxZjBiNzlhZTU0L3RhYmxlOjZjYjk5MzkwZTRkYzQzZDk4MzY3YmZlZmVlZDkxYzQyL3RhYmxlcmFuZ2U6NmNiOTkzOTBlNGRjNDNkOTgzNjdiZmVmZWVkOTFjNDJfOS03LTEtMS0w_d8fb012f-987d-4648-8d03-ef4b47f778f2"
      unitRef="usd">-140788000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i2a60d3075b9948199e8195d7f913ac6c_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi01LTEtMS0yNzM_a0ae4cfc-13ff-4d13-af5c-6142625d1b43"
      unitRef="shares">670378701</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a60d3075b9948199e8195d7f913ac6c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi03LTEtMS0yNzM_e0435d7b-e088-41f2-9ce2-58acdf14d30d"
      unitRef="usd">6704000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="id895905b1a694b509baac821f4b07cc9_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi05LTEtMS0yNzM_a76051c2-5fcb-48e3-89cb-2b7a9f104124"
      unitRef="shares">549907</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id895905b1a694b509baac821f4b07cc9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi0xMS0xLTEtMjcz_71ace562-565c-4c66-a9c5-7f84b9015ce5"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25b81bddf69248d2a9dca49367b845fb_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi0xMy0xLTEtMjcz_7aa5e1cd-d530-4397-8253-41d3a8b473ba"
      unitRef="usd">3145444000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43dc309a84a34c9da443f4b8fb4f46d6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi0xNS0xLTEtMjcz_52ca3c30-8b26-4583-b949-0a48a9795e3d"
      unitRef="usd">-30187000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b6ee414e2b14aa2b7779dae646fa43d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi0xNy0xLTEtMjcz_b810707d-ee06-46f8-bb1f-eae2a051ae63"
      unitRef="usd">-1571551000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if81665549a744db4b9e3cbd8460e29b6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMi0yMS0xLTEtMjcz_ca2e908e-c36b-4b02-8a72-a814164fd739"
      unitRef="usd">1548619000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3a5a9e0119604e449787b4ccd42bbfe0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMy0xMy0xLTEtMjcz_2457200f-2325-40b5-ada0-3bcc8e93c494"
      unitRef="usd">1586000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfMy0yMS0xLTEtMjcz_942a337d-ce4a-4a00-9197-74dd05611d1a"
      unitRef="usd">1586000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i4af5a56db0c24f5d8ef4a585500444b2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfNy0xNy0xLTEtMjcz_e76c22f8-f1af-40a7-b74a-2c37bb3b131d"
      unitRef="usd">33703000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfNy0yMS0xLTEtMjcz_19ebd750-9510-4c00-80f5-9c9029ccd2ab"
      unitRef="usd">33703000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i143f61f3bd52487bbac948c8fad1648c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOC0xNS0xLTEtMjcz_7da30dae-c053-42a1-a553-e9cd6c110f2a"
      unitRef="usd">4435000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOC0yMS0xLTEtMjcz_4f7b9f5b-8760-43c8-b9ea-67ced3b3ba33"
      unitRef="usd">4435000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="i9d1df47745364a0b99f41d53769dcdec_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS01LTEtMS0yNzM_920e25e4-2e1c-4518-a788-5d29b1cdf56b"
      unitRef="shares">670378701</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d1df47745364a0b99f41d53769dcdec_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS03LTEtMS0yNzM_4c8a9e54-0f8a-4af4-9ad1-351f364c3be9"
      unitRef="usd">6704000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i936bc210908045ebb32428a797e622c9_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS05LTEtMS0yNzM_cb3a6386-8646-4db6-8793-6858d692810f"
      unitRef="shares">549907</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i936bc210908045ebb32428a797e622c9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS0xMS0xLTEtMjcz_b9e17360-06a2-4f07-a2bb-715229bc1427"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64a03ce9a44446aba8fd3973415e1804_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS0xMy0xLTEtMjcz_5192cc4d-1018-4eee-93d9-d2668e97f1ed"
      unitRef="usd">3147030000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e72a60ac3204f79a58324d7ac06d70b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS0xNS0xLTEtMjcz_2ecc24e5-45be-4714-979d-86e9e346c35e"
      unitRef="usd">-25752000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5fd219acb38f4ebd979473ebe1345577_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS0xNy0xLTEtMjcz_19b233fa-af51-43ff-bcfc-a01b90f891cf"
      unitRef="usd">-1537848000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjNlODg2NWExYWJlZDRjNjc4ZjZmYWJhODMzN2M1ODg1L3RhYmxlcmFuZ2U6M2U4ODY1YTFhYmVkNGM2NzhmNmZhYmE4MzM3YzU4ODVfOS0yMS0xLTEtMjcz_829d7df2-cebe-47a1-9834-6b8aee0de021"
      unitRef="usd">1588343000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i52609be761ba4470bb6b72bcdc9ed16e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi01LTEtMS0w_50df40eb-cd15-4859-b65b-96bd27772ffe"
      unitRef="shares">670378701</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52609be761ba4470bb6b72bcdc9ed16e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi03LTEtMS0w_db88ea6c-ee71-4712-910e-a9a448fad599"
      unitRef="usd">6704000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i7e9d6032dccc43d39b3c75fc3e207e87_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi05LTEtMS0w_1f69b42b-2c28-4a2b-8e50-215bfc3b6cc1"
      unitRef="shares">549907</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e9d6032dccc43d39b3c75fc3e207e87_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi0xMS0xLTEtMA_ee3d86f8-e8a4-423f-8ea6-56d92fcd7494"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21eeb8671f80463cbbd4d25c43812904_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi0xMy0xLTEtMA_bb75305d-c2a7-45a1-a03a-127010551262"
      unitRef="usd">3142993000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3925554062df4071b663e93f01c6d247_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi0xNS0xLTEtMA_3d161e92-ee7c-414c-86a0-f06d71f2e39e"
      unitRef="usd">-22070000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie00bd5bfbe0747e98efecb5d0d36c2eb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi0xNy0xLTEtMA_1d596aa2-5235-44f9-941d-be90edeec31f"
      unitRef="usd">-1511077000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMi0yMS0xLTEtMA_d11fcb82-a9f0-4c69-99cb-c6e901d831c8"
      unitRef="usd">1614759000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9409bbd3d79a4f199dc0914b6a6a6232_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMy0xMy0xLTEtMA_9e330a79-8fd9-44ee-a1fc-d096d4ef5df6"
      unitRef="usd">4037000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfMy0yMS0xLTEtMA_4f2102e6-ab19-4e71-82f8-41cb735ab777"
      unitRef="usd">4037000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14e0f7cf90b845618c2da998b2ec9256_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfNS0xNy0xLTEtMA_b0c3fe19-c865-448d-9467-295d8b70a888"
      unitRef="usd">-1342000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1ca894201f24ceb996ca85bc139745f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfNS0yMS0xLTEtMA_2a303b0f-c58e-439d-92ce-6f3937dc3e08"
      unitRef="usd">-1342000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0cc1ebc6dac04ccbb4e43babd6ec58f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfNy0xNy0xLTEtMA_095dd9bc-ec71-4536-bdff-b3245eaf3b5f"
      unitRef="usd">-25429000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfNy0yMS0xLTEtMA_f81611cd-a9fa-44b5-9cc2-14130ce715f8"
      unitRef="usd">-25429000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5051d9d5fe094597bf4e37ba100c22fd_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOC0xNS0xLTEtMA_72eb4b56-24a1-4d8e-8972-d8f52147d14a"
      unitRef="usd">-3682000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOC0yMS0xLTEtMA_ab094556-dc48-443f-bf08-ca771aea8b8a"
      unitRef="usd">-3682000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="i9d1df47745364a0b99f41d53769dcdec_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS01LTEtMS0w_292cfdf7-4312-40ca-8e7c-4e81f3e10660"
      unitRef="shares">670378701</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d1df47745364a0b99f41d53769dcdec_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS03LTEtMS0w_b746dd04-9432-4f6f-b339-6a4e06956b01"
      unitRef="usd">6704000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i936bc210908045ebb32428a797e622c9_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS05LTEtMS0w_1a8c5eee-00fc-42e9-a618-5b491c1c92d7"
      unitRef="shares">549907</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i936bc210908045ebb32428a797e622c9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS0xMS0xLTEtMA_fae09d0a-9ec2-410c-9264-5d836faaff78"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64a03ce9a44446aba8fd3973415e1804_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS0xMy0xLTEtMA_a375f187-d116-45e9-b90b-c8cf2c2802a3"
      unitRef="usd">3147030000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e72a60ac3204f79a58324d7ac06d70b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS0xNS0xLTEtMA_400aaa93-be72-48fb-97ca-d07adaf0c38b"
      unitRef="usd">-25752000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5fd219acb38f4ebd979473ebe1345577_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS0xNy0xLTEtMA_7486c5c3-f3ea-4e50-a3f5-4539a5fb4593"
      unitRef="usd">-1537848000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOmY0YTYyZjM5NDNhNDQ1MzQ4NDYzYzBkZTk1MzQ1MDU2L3RhYmxlcmFuZ2U6ZjRhNjJmMzk0M2E0NDUzNDg0NjNjMGRlOTUzNDUwNTZfOS0yMS0xLTEtMA_56ce07b5-41db-4d9d-b504-21a602a7afc8"
      unitRef="usd">1588343000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i73abe1462fc54ccca6f449fcd66ad85f_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi01LTEtMS0yODM_091fda67-3769-4f49-88d6-ec955d84261e"
      unitRef="shares">616150952</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i73abe1462fc54ccca6f449fcd66ad85f_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi03LTEtMS0yODM_7537be58-b4e8-4533-ae49-348b5a96a68c"
      unitRef="usd">6162000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i1cdf44d9233e47f7b9bf249aff94b19c_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi05LTEtMS0yODM_9b47ab9b-4099-4772-aa82-848525fdc8b4"
      unitRef="shares">549907</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cdf44d9233e47f7b9bf249aff94b19c_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi0xMS0xLTEtMjgz_7aad77b8-95b8-4907-a6dc-afa40744cc17"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89218e50948c4507b1df814b142d514e_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi0xMy0xLTEtMjgz_e8e003a5-3893-44f7-bc30-e0869fa7594c"
      unitRef="usd">3058509000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib353496e520042c2b547d13887f30ff4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi0xNS0xLTEtMjgz_a4a2da4f-7439-41e4-a3d1-6582ef53c8ab"
      unitRef="usd">-23229000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i077eb15fd51d4b74985ebd93f8f78daa_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi0xNy0xLTEtMjgz_f578e62c-33f9-44d6-a6e8-80251ece9daa"
      unitRef="usd">-1276914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9acb0e76a853407e8a654c3be8ff1fee_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMi0yMS0xLTEtMjgz_5e474e71-8e6f-4856-870c-5547a4a68ff3"
      unitRef="usd">1762737000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i67bbc9625fd1467492f28cf2d894d765_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMy0xMy0xLTEtMjgz_0334b1cd-da39-49b0-9461-74023eb84cd2"
      unitRef="usd">3122000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfMy0yMS0xLTEtMjgz_9b2c8d0c-a016-4aa3-98c3-0440b5637293"
      unitRef="usd">3122000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="iec5715c6fc274f75937803500c320ab9_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfNy0xNy0xLTEtMjgz_1dcc347f-09b5-4945-a293-3fd450153a7c"
      unitRef="usd">-59806000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfNy0yMS0xLTEtMjgz_33f0a5cb-68be-46ae-a11f-10a47f5fbbe7"
      unitRef="usd">-59806000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4cc58805b460451388796d3179b73858_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOC0xNS0xLTEtMjgz_949bc2b6-0cf3-4f2b-8999-2078615b618d"
      unitRef="usd">2878000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOC0yMS0xLTEtMjgz_f3ed3f07-4382-40d5-be23-20b568202bf9"
      unitRef="usd">2878000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="i47c7b4841e944d8c8219ea505de34c81_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS01LTEtMS0yODM_3407ebf9-a9cb-4adf-b16a-996931f3b847"
      unitRef="shares">616150952</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47c7b4841e944d8c8219ea505de34c81_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS03LTEtMS0yODM_b713efe4-74ad-41e2-8be5-46ca44f43429"
      unitRef="usd">6162000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i6096decc24534d73b84d8382fa7cfddd_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS05LTEtMS0yODM_29240266-97d3-4cdb-9aba-80477a1fb99e"
      unitRef="shares">549907</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6096decc24534d73b84d8382fa7cfddd_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS0xMS0xLTEtMjgz_8a3748dc-66f5-4564-9a94-8a0a57d7dcde"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44cab2f05311498cb261057427e71187_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS0xMy0xLTEtMjgz_974f5779-b430-498b-bf62-1d369a918647"
      unitRef="usd">3061631000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a7adf54fa64417e87f3555d5bf0773d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS0xNS0xLTEtMjgz_593e6a40-9cc2-47ce-9e08-8d085394b0c8"
      unitRef="usd">-20351000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if62bbfa990154581b6b8060ab7f25983_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS0xNy0xLTEtMjgz_b1b5646f-c738-4f81-b659-f32dd5d992c3"
      unitRef="usd">-1336720000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic97107d2cf63436bbd19e901d052161a_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgzOWNkMDgyNTAxZTQxY2JiMDczMDE2ZmY5OGY0ZmM4L3RhYmxlcmFuZ2U6ODM5Y2QwODI1MDFlNDFjYmIwNzMwMTZmZjk4ZjRmYzhfOS0yMS0xLTEtMjgz_5d330f26-2d6b-43c6-bec6-02e247b58cac"
      unitRef="usd">1708931000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i5fb67fadb72846cdba88dedab4956840_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi01LTEtMS0w_4b2840fa-254e-4eef-a9d0-68bbdd7ab8fb"
      unitRef="shares">586881720</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5fb67fadb72846cdba88dedab4956840_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi03LTEtMS0w_4a49d1b1-a9cd-4e4c-832b-4b549c14ec72"
      unitRef="usd">5869000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i1d4687ed998d4bc89b441e1a77865855_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi05LTEtMS0w_96c96957-c550-4ef2-9218-9d551bf9a445"
      unitRef="shares">549907</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d4687ed998d4bc89b441e1a77865855_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi0xMS0xLTEtMA_f7563e43-73cb-44f6-9f3e-62dfafdf76fe"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i280cba37fbf24b4683f965f0f7b346d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi0xMy0xLTEtMA_c4281bf9-3f9f-4ca7-b519-c19e2cbadf21"
      unitRef="usd">3004422000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic493611ea31741d8bb485d6a0d53db9f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi0xNS0xLTEtMA_de81ab3c-810b-4499-a125-0fa781d720e2"
      unitRef="usd">-20131000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00f0723faaa34d11aa00d312f4c86b4e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi0xNy0xLTEtMA_6eeb17b9-9970-475a-ad53-ab244acf2719"
      unitRef="usd">-1197078000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf70df459fcd4df1abd8e73dbfafd943_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMi0yMS0xLTEtMA_0c064413-2ba2-4c49-aa89-77fa27bb5c4b"
      unitRef="usd">1791291000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ida9ba4776d674e048a8f35590863e24a_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMy0xMy0xLTEtMA_880e250d-fd5c-4b6b-895c-91858ccfa586"
      unitRef="usd">7579000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfMy0yMS0xLTEtMA_5961bd36-32a1-4cd4-9972-2b3102c834d4"
      unitRef="usd">7579000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1c9c6b69f3bc46868fad995b8c409262_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNC01LTEtMS0w_86b5da38-17b1-44c3-9bfa-1a5a3f6964af"
      unitRef="shares">19232</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ida9ba4776d674e048a8f35590863e24a_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNC0xMy0xLTEtMA_958cb6bc-ca57-4ee5-bf04-0e85914143ac"
      unitRef="usd">-3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNC0yMS0xLTEtMA_833224f9-92f2-4049-b673-2b60d0b519d6"
      unitRef="usd">-3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee436d2fd7ff45f3915d1e32dcd70904_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNS0xMy0xLTEtMA_f03faa82-7793-4bc1-96e6-de80822444a2"
      unitRef="usd">-926000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd4ae6fdd629444197cc9a625cdcfc9f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNS0xNy0xLTEtMA_c38f0c5b-9562-40b3-8cb9-55cf8e2060d8"
      unitRef="usd">926000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9dfc05b578db438c821384cc836c5a4c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNS0yMS0xLTEtMA_165680dc-2730-49b6-a151-02a20c93a167"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1c9c6b69f3bc46868fad995b8c409262_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNi01LTEtMS0w_87edb908-a2d8-4a11-9d81-4eb4eaa0720a"
      unitRef="shares">29250000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i1c9c6b69f3bc46868fad995b8c409262_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNi03LTEtMS0w_7793b50e-2005-4138-b2c5-4ba280d72619"
      unitRef="usd">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ida9ba4776d674e048a8f35590863e24a_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNi0xMy0xLTEtMA_91bfd227-1895-4b88-a0a5-11fb2bb8fe1e"
      unitRef="usd">50559000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNi0yMS0xLTEtMA_f1d3caa6-f9d6-43b3-8147-ba6e4350d7af"
      unitRef="usd">50852000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:NetIncomeLoss
      contextRef="i5497d158e29a4207b882cb978b473faa_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNy0xNy0xLTEtMA_f0332cf8-8e69-4774-ba77-5e2ac2721d4d"
      unitRef="usd">-140568000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfNy0yMS0xLTEtMA_b8192a96-a59a-4d33-9d5f-97a284e56850"
      unitRef="usd">-140568000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i00d185d0856f4299a62fe26f4513d5f8_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOC0xNS0xLTEtMA_84ba104f-89a7-4d60-a43f-a6104c455bb1"
      unitRef="usd">-220000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOC0yMS0xLTEtMA_c1250f7f-ca53-49fb-a8a6-7c27ae923952"
      unitRef="usd">-220000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="i47c7b4841e944d8c8219ea505de34c81_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS01LTEtMS0w_11767ebb-ff47-478f-87b6-9b88c4b22c10"
      unitRef="shares">616150952</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47c7b4841e944d8c8219ea505de34c81_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS03LTEtMS0w_0bc191d4-0b48-4411-bc09-0d9740fac658"
      unitRef="usd">6162000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i6096decc24534d73b84d8382fa7cfddd_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS05LTEtMS0w_950534c9-2d8f-4159-ad39-7b5b613c4b36"
      unitRef="shares">549907</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6096decc24534d73b84d8382fa7cfddd_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS0xMS0xLTEtMA_5842036e-f2fb-4e5e-bbeb-0cc8b04cf108"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44cab2f05311498cb261057427e71187_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS0xMy0xLTEtMA_9ceb1b0d-e30f-4c65-b83a-bb288173edf6"
      unitRef="usd">3061631000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a7adf54fa64417e87f3555d5bf0773d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS0xNS0xLTEtMA_4fc1a639-3f83-4d7e-b89c-abe24507c0b6"
      unitRef="usd">-20351000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if62bbfa990154581b6b8060ab7f25983_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS0xNy0xLTEtMA_388cf84a-bdf8-4c75-b0bf-00d03fb6ea66"
      unitRef="usd">-1336720000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic97107d2cf63436bbd19e901d052161a_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zMS9mcmFnOjM3YTlmZTgzNzYwMTQ3MzM4MmY3MDQ2ZGE4MjhhNTczL3RhYmxlOjgwNGQ4MTYyZTJhNzQwYmJhMmI4ODM0YWM2YzQ1YWMwL3RhYmxlcmFuZ2U6ODA0ZDgxNjJlMmE3NDBiYmEyYjg4MzRhYzZjNDVhYzBfOS0yMS0xLTEtMA_ee12f75f-8d48-4d47-abf6-b7b67b55380b"
      unitRef="usd">1708931000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMy0xLTEtMS0w_b86600e1-9f1e-4b5e-8d0f-87eb7e27a060"
      unitRef="usd">-25429000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMy0zLTEtMS0w_88801fe1-1a99-4687-947a-1d55e815738b"
      unitRef="usd">-140568000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNi0xLTEtMS0w_9baa15e7-c5f7-4df5-8b34-ba0473e4700e"
      unitRef="usd">44318000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNi0zLTEtMS0w_237cddb8-22ea-4129-9c8e-a20f55407c3c"
      unitRef="usd">47477000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaidInKindInterest
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNy0xLTEtMS0w_87fed4b4-5c29-438f-bfbf-a97ff806257e"
      unitRef="usd">5022000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNy0zLTEtMS0w_8fa70bc8-318e-4ec7-ae66-f0fa36ebeca8"
      unitRef="usd">2868000</us-gaap:PaidInKindInterest>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfOC0xLTEtMS0w_ff20b8b0-d89d-4851-a60d-64bdbc99933a"
      unitRef="usd">411000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfOC0zLTEtMS0w_729f9a08-533e-49e1-9898-883a3a067072"
      unitRef="usd">308000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTAtMS0xLTEtMA_690def50-0c62-43af-810c-6b36a624839b"
      unitRef="usd">-323000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTAtMy0xLTEtMA_faede164-a9a2-4d9a-b04f-da2ed1047282"
      unitRef="usd">-2125000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTEtMS0xLTEtMA_c0576a83-13d9-4bc8-9e79-63ab1fdd7a41"
      unitRef="usd">4037000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTEtMy0xLTEtMA_3f719ccf-1648-4e4d-a314-965be708e457"
      unitRef="usd">7579000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTUtMS0xLTEtMA_4a8d8aea-b93b-4e00-b850-bcf0c0231702"
      unitRef="usd">-156000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTUtMy0xLTEtMA_ae7220b9-e094-447f-b41f-aba2f4189718"
      unitRef="usd">-220000</us-gaap:GainLossOnDispositionOfAssets1>
    <opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTgtMS0xLTEtMA_e85439de-17fc-420c-822c-0bd0410ecd65"
      unitRef="usd">6515000</opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments>
    <opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMTgtMy0xLTEtMA_36af5c21-4702-4fd3-97c9-f517d461c67c"
      unitRef="usd">-5431000</opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjAtMS0xLTEtMA_16be821e-3c8c-4c46-9134-4454b9bc59d6"
      unitRef="usd">251000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjAtMy0xLTEtMA_8869d320-9ad6-43cf-9c8d-76357ddaab18"
      unitRef="usd">1031000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AssetImpairmentCharges
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjMtMS0xLTEtMA_f31a5812-9e33-4cfc-a97f-ad9103f76b7b"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjMtMy0xLTEtMA_1d24ecd0-b80a-4cc5-a80b-86add0e0d4e5"
      unitRef="usd">655000</us-gaap:AssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjQtMS0xLTEtMA_f7119b61-ddea-44de-9240-4a316aefdc58"
      unitRef="usd">1028000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjQtMy0xLTEtMA_61eb132c-27af-499d-9568-622f5dd861dd"
      unitRef="usd">168000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjYtMS0xLTEtMA_d1a64508-a637-4890-b5e1-e573f33c37f0"
      unitRef="usd">81539000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjYtMy0xLTEtMA_13dbffbd-7167-4a4f-a0e7-0b281b85345d"
      unitRef="usd">4398000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjctMS0xLTEtMA_74cc4124-f595-4d75-a77b-82beb308818c"
      unitRef="usd">21905000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjctMy0xLTEtMA_b0571a97-6986-453c-a1bb-2f5cf36c3910"
      unitRef="usd">6225000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjgtMS0xLTEtMA_d7367001-b1d6-43fd-aa1a-a15b562a7c3d"
      unitRef="usd">2619000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjgtMy0xLTEtMA_b323219e-17a6-465b-88c9-3d92d4de3b54"
      unitRef="usd">-2476000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjktMS0xLTEtMA_dbe46d7b-5254-4881-a5cb-007c166fc0fa"
      unitRef="usd">61000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMjktMy0xLTEtMA_bbb2c033-038e-4d97-9035-c1d7720699e2"
      unitRef="usd">-136000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzAtMS0xLTEtMA_4f0b75d1-54c6-4015-8d21-fbc16d46f23f"
      unitRef="usd">-16753000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzAtMy0xLTEtMA_b36c5e1b-0472-4c4d-ab23-a237510069f8"
      unitRef="usd">12887000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <opk:IncreaseDecreaseinForeignCurrencyMeasurement
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzEtMS0xLTEtMA_e8d93d01-bd1c-4880-b49e-2973809397df"
      unitRef="usd">-2077000</opk:IncreaseDecreaseinForeignCurrencyMeasurement>
    <opk:IncreaseDecreaseinForeignCurrencyMeasurement
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzEtMy0xLTEtMA_41543b7d-f56d-4944-837d-b145e8d18469"
      unitRef="usd">131000</opk:IncreaseDecreaseinForeignCurrencyMeasurement>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzItMS0xLTEtMA_1ece1936-1412-4cc3-8dcf-a349b43568cc"
      unitRef="usd">-4026000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzItMy0xLTEtMA_994b0d90-97f1-42d6-9c25-509b6ca114ba"
      unitRef="usd">-37015000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzMtMS0xLTEtMA_95530a4b-43d6-4da4-bfa0-afed52f0534a"
      unitRef="usd">47585000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzMtMy0xLTEtMA_c29febe9-0b29-437e-aea8-9fcc9e59c2b0"
      unitRef="usd">2095000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzYtMS0xLTEtMA_16950523-d443-4dbc-ab37-8f3a6d582ad7"
      unitRef="usd">-57793000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzYtMy0xLTEtMA_35be3eb7-9f61-4577-bfcf-0f4477f7ab4e"
      unitRef="usd">-102619000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzgtMS0xLTEtMA_6fefe7c1-dcd5-467c-9ac6-0822dc51ce45"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfMzgtMy0xLTEtMA_71f3466f-e274-441b-a665-0e3fb2103a43"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDMtMS0xLTEtMA_387a064c-1871-41f5-a118-98c2afc73454"
      unitRef="usd">65000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDMtMy0xLTEtMA_2b852d23-e797-4b2e-b5a9-d4ff84595c0b"
      unitRef="usd">309000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDUtMS0xLTEtMA_17fed21b-acc6-4e7e-89bd-81b70f385880"
      unitRef="usd">17149000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDUtMy0xLTEtMA_d37b7f94-a036-4b89-8ad0-8084b0173869"
      unitRef="usd">6432000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDYtMS0xLTEtMA_0d1d5d85-bcbb-47a5-b40e-53568825911f"
      unitRef="usd">-17084000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDYtMy0xLTEtMA_88c4c075-61fd-40c5-b789-5220ac44fd23"
      unitRef="usd">-7323000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDgtMS0xLTEtMA_0905e6e4-e58a-482d-be51-ef663f08fb75"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDgtMy0xLTEtMA_052d5d36-8d43-4203-8e65-b6b4c2831c7f"
      unitRef="usd">200293000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDktMS0xLTEtMA_96701ed6-83f6-4d01-a562-865f330446b8"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNDktMy0xLTEtMA_fdfc41cf-0577-4d78-b68b-774807164cbd"
      unitRef="usd">7762000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTEtMS0xLTEtMA_30c96c72-c0d2-45b2-93e0-1078f15cc510"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTEtMy0xLTEtMA_d149f55f-ceee-4bf1-9ad5-9b5afe82fe97"
      unitRef="usd">-3000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTQtMS0xLTEtMA_dc2c1e7f-cd6b-4762-bfe5-5bc1194c6a1a"
      unitRef="usd">393651000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTQtMy0xLTEtMA_f775cd85-80a4-4481-99ec-587eea39fe28"
      unitRef="usd">39695000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTUtMS0xLTEtMA_359fd982-9240-4204-a99f-29aafd495247"
      unitRef="usd">382374000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTUtMy0xLTEtMA_6f9efd1b-c8db-4b6c-af07-a05b1bb8f8c2"
      unitRef="usd">78824000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTgtMS0xLTEtMA_27093993-5467-4c2a-a57c-c08d1c4fdb48"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTgtMy0xLTEtMA_fd6b62c3-e68e-4d11-8154-34135051a299"
      unitRef="usd">28800000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTktMS0xLTEtMA_60d9c0a2-4a2f-4367-a493-8c87e89184d5"
      unitRef="usd">11277000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNTktMy0xLTEtMA_ef7e23f6-e55b-453d-b1be-c5cf187544bd"
      unitRef="usd">124599000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjAtMS0xLTEtMA_e5ec5201-942d-4a92-861b-15156b8deed1"
      unitRef="usd">-240000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjAtMy0xLTEtMA_c012895b-cefc-4765-894a-b9d529421727"
      unitRef="usd">-15000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjEtMS0xLTEtMA_57b00bf4-5587-4f09-9523-4e195f7fa4bc"
      unitRef="usd">-63840000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjEtMy0xLTEtMA_57a55e31-ad53-43ec-b7ce-bdd120dc6355"
      unitRef="usd">14642000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjItMS0xLTEtMA_b32b52e0-6c0d-41c6-aaf3-d127a8dd318c"
      unitRef="usd">85452000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaf70df459fcd4df1abd8e73dbfafd943_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjItMy0xLTEtMA_08d54877-d1bc-4f94-bea2-4d2d0ffdbc3e"
      unitRef="usd">96473000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjMtMS0xLTEtMA_c675e793-0930-4880-b607-1c17b8862e8a"
      unitRef="usd">21612000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic97107d2cf63436bbd19e901d052161a_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjMtMy0xLTEtMA_9f67399b-1690-43bf-84d3-576de2063bcb"
      unitRef="usd">111115000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjUtMS0xLTEtMA_573ad887-1cd8-49f7-846b-11caa5b4dac1"
      unitRef="usd">5578000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjUtMy0xLTEtMA_331c14fb-7662-4b4a-b7af-8cda00b284e0"
      unitRef="usd">5411000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjYtMS0xLTEtMA_f3ba26d4-b2f1-43e4-8263-96cb706e3108"
      unitRef="usd">-208000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjYtMy0xLTEtMA_accffb0d-a301-41e6-8bd4-5163cc8d6fed"
      unitRef="usd">2132000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjctMS0xLTEtMA_a0a0f68b-27b9-41f9-a769-39319228c2a1"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjctMy0xLTEtMA_d85f2adf-c637-4f6e-b52a-75ed0e867dc4"
      unitRef="usd">29640000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <opk:OperatingLeaseLiabilityInitialRecognitionUponAdoption
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjgtMS0xLTEtMA_9574f7e0-83c0-4277-980e-320a2d0b7cfd"
      unitRef="usd">0</opk:OperatingLeaseLiabilityInitialRecognitionUponAdoption>
    <opk:OperatingLeaseLiabilityInitialRecognitionUponAdoption
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNjgtMy0xLTEtMA_cd8f170f-04af-41e9-a513-31b66fe1cc99"
      unitRef="usd">30049000</opk:OperatingLeaseLiabilityInitialRecognitionUponAdoption>
    <opk:CommonStockWarrantsNetExercised
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNzQtMS0xLTEtMA_5bf023e7-8709-436f-8381-56b78957bfc3"
      unitRef="usd">0</opk:CommonStockWarrantsNetExercised>
    <opk:CommonStockWarrantsNetExercised
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18zNC9mcmFnOjgzM2NkZjg3ODY2ZjRhY2JiZGYyMDc2YTdhOGY2MDU3L3RhYmxlOjMxOWY0NmI0ODAxNzQwMTNhYTVkZWYzMTYzMTcxOWY2L3RhYmxlcmFuZ2U6MzE5ZjQ2YjQ4MDE3NDAxM2FhNWRlZjMxNjMxNzE5ZjZfNzQtMy0xLTEtMA_6d779613-c0d6-483c-9c3a-375a6cc0e62f"
      unitRef="usd">20000</opk:CommonStockWarrantsNetExercised>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180MC9mcmFnOjFiYTRiZmQ2MjQ5YTRmODI5NzQzNjJmYTkyYzRhOTViL3RleHRyZWdpb246MWJhNGJmZDYyNDlhNGY4Mjk3NDM2MmZhOTJjNGE5NWJfMjkxMQ_a402ef2f-2e8e-4fd0-8307-a0b025f69ea8">BUSINESS AND ORGANIZATION&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets.  Our diagnostics business includes BioReference Laboratories, Inc. (&#x201c;BioReference&#x201d;), one of the nation&#x2019;s largest full service laboratories with a core genetic testing business and an almost 300-person sales and marketing team focused on driving growth and leveraging new products, including the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;4Kscore&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; test.  Our pharmaceutical business features &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, an FDA-approved treatment for secondary hyperparathyroidism (&#x201c;SHPT&#x201d;) in adults with stage 3 or 4 chronic kidney disease (&#x201c;CKD&#x201d;) and vitamin D insufficiency (launched in November 2016); OPK88004, a selective androgen receptor modulator which we are exploring for various potential indications; and OPK88003, a once weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists (phase 2b).  Our pharmaceutical business also features hGH-CTP, a once-weekly human growth hormone that recently successfully completed a phase 3 trial and for which we have partnered with Pfizer Inc. (&#x201c;Pfizer&#x201d;).  We are incorporated in Delaware, and our principal executive offices are located in leased offices in Miami, Florida.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Through BioReference, we provide laboratory testing services, primarily to customers in the larger metropolitan areas across New York, New Jersey, Florida, Texas, Maryland, California, Pennsylvania, Delaware, Washington, DC, Illinois and Massachusetts, as well as to customers in a number of other states.  We offer a comprehensive test menu of clinical diagnostics for blood, urine and tissue analysis.  This includes hematology, clinical chemistry, immunoassay, infectious&#160;diseases, serology, hormones, and toxicology assays, as well as Pap smear, anatomic pathology (biopsies) and other types of tissue analysis.  We market our laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We operate established pharmaceutical platforms in Ireland, Chile, Spain, and Mexico, which are generating revenue and from which we expect to generate positive cash flow and facilitate future market entry for our products currently in development.  In addition, we have a development and commercial supply pharmaceutical company and a global supply chain operation and holding company in Ireland.  We own a specialty active pharmaceutical ingredients (&#x201c;APIs&#x201d;) manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our research and development activities are primarily performed at facilities in Woburn, MA, Waterford, Ireland, Kiryat Gat, Israel, and Barcelona, Spain.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <opk:NumberofSalesEmployees
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180MC9mcmFnOjFiYTRiZmQ2MjQ5YTRmODI5NzQzNjJmYTkyYzRhOTViL3RleHRyZWdpb246MWJhNGJmZDYyNDlhNGY4Mjk3NDM2MmZhOTJjNGE5NWJfMzY1_f7dac456-9dac-48e2-a4d0-929f7dabd234"
      unitRef="employee">300</opk:NumberofSalesEmployees>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0MTY_38fbd8d7-6098-47eb-a08f-a2641762d806">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Basis of presentation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;) and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all information and notes required by GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company&#x2019;s results of operations, financial position and cash flows have been made.  The results of operations and cash flows for the three and six months ended June 30, 2020 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2020 or any other future periods.  The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Principles of consolidation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and of our wholly owned subsidiaries.  All intercompany accounts and transactions are eliminated in consolidation.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Use of estimates&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Impact of COVID-19&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.   As the disease caused by SARS-CoV-2, a novel strain of coronavirus, COVID-19 continues to spread and severely impact the economy of the United States and other countries around the world, we are committed to being a part of the coordinated public and private sector response to this unprecedented challenge. In response to the COVID-19 pandemic, BioReference Laboratories is accepting specimens for two types of COVID-19 testing, diagnostic molecular testing and serology antibody testing, from healthcare providers, clinics and health and hospital systems throughout&#160;the U.S., to promote earlier diagnosis of the coronavirus, assess a patient&#x2019;s immune response to the virus and aid in limiting spread of infection. In addition to its robust nationwide COVID-19 testing offering, BioReference has partnerships with the&#160;New York State&#160;Department of Health, the New York City Health and Hospital Corporation (NYC&#160;Health + Hospitals), the&#160;State of New Jersey, the&#160;State of Florida&#160;and the cities of&#160;Detroit&#160;and&#160;Miami, among others,&#160;to provide COVID-19 testing. BioReference performed approximately 331.6&#160;thousand serology antibody tests and 2.2&#160;million diagnostic molecular tests for COVID-19 during the three months ended June 30, 2020, which represented 28.1% of BioReference&#x2019;s total test volume during the second quarter of 2020. For serologic antibody testing, BioReference has partnered with the State of New York, New York City and a number of employers and government agencies with the capacity to perform up to 400,000 tests per day and for diagnostic molecular tests, BioReference has the capacity to perform more than 50,000 tests per day. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have put preparedness plans in place at our facilities to maintain continuity of operations, while also taking steps to keep colleagues and customers healthy and safe. In line with recommendations to reduce large gatherings and increase social distancing, we have, where practical, transitioned many office-based colleagues to a remote work environment.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Beginning in March 2020, BioReference experienced, and continues to experience, a decline in routine clinical and genomics testing volumes due to the COVID-19 pandemic. Excluding COVID-19 test volumes, for the three months ended June 30, 2020, volumes in our diagnostics segment were down 46.5% as compared to volumes in the second quarter of 2019. Additionally, sales of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; have not increased in accordance with its expected growth trajectory as a result of challenges in onboarding new patients due to the COVID-19 pandemic. Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, a significant reduction in physician office visits, the cancellation of elective medical procedures, customers closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home or shelter-in-place policies, all of which have had, and may continue to have, an adverse impact on our operating results, cash flows and financial condition, including continued declines in testing volumes. It is also possible that we will experience an adverse impact on cash collections as a result of the impact of the COVID-19 pandemic.&#160;As stay at home orders and other restrictions have been lifted, we have seen our routine clinical and genomic testing volumes trending towards normalization with prior periods, however should stay at home orders or other restrictions be reenacted, we could see our routine testing levels decline. We also continue to see a substantial need for COVID-19 testing by our existing clients and expect new clients as infection rates for the virus continue to increase across the country.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, in response to the COVID-19 pandemic, the CARES Act was signed into law. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding the prior and future utilization of net operating losses, temporary changes to the prior and future limitations on interest deductions, temporary&#160;suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property, and the creation of certain payroll tax credits associated with the retention of employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have received, or expect to receive a number of benefits under The CARES Act including, but not limited to:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;We received approximately $14&#160;million under The Centers for Medicare &amp;amp; Medicaid Services (CMS) Accelerated and Advance Payment Program, which provides accelerated payments to Medicare providers/suppliers working to provide treatment to patients and combat the COVID-19 pandemic, and the amounts advanced are loans which will be offset against future claims and must be repaid. These loans are initially recorded as contract liabilities included in Accrued expenses and are recognized in Revenue from services when earned;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;We are eligible to defer depositing the employer&#x2019;s share of Social Security taxes for payments due from March 27, 2020 through December 31, 2020, interest-free and penalty-free;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;We received approximately $6.2&#160;million during the three months ended June 30, 2020 from the initial tranche of funds that was distributed to healthcare providers for related expenses or lost revenues that are attributable to the COVID-19 pandemic. We recognized the $6.2&#160;million grant in other revenues for the three and six months ended June 30, 2020;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;U.S. Department of Health and Human Services (HHS), will provide claims reimbursement to healthcare providers generally at Medicare rates for testing uninsured patients; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Clinical laboratories are provided a one-year reprieve from the reporting requirements under the Protecting Access to Medicare Act (&#x201c;PAMA&#x201d;) as well as a one-year delay of reimbursement rate reductions for clinical laboratory services provided under Medicare that were scheduled to take place in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Since the pandemic began in the U.S., we have invested, and expect to continue to invest, in testing capabilities and infrastructure to meet demand for our molecular and antibody testing for COVID-19. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase.  We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents.  These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Inventories&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Inventories are valued at the lower of cost and net realizable value.  Cost is determined by the first-in, first-out method.  We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value.  Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which is used in our testing laboratories.  Inventory obsolescence expense for the six months ended June&#160;30, 2020 and 2019 was $1.7 million and $1.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Pre-launch inventories&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  We may accumulate commercial quantities of certain product candidates prior to the date we anticipate that such products will receive final U.S. FDA approval.  The accumulation of such pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever.  This risk notwithstanding, we may accumulate pre-launch inventories of certain products when such action is appropriate in relation to the commercial value of the product launch opportunity.  In accordance with our policy, this pre-launch inventory is expensed.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Goodwill and intangible assets&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting.  Refer to Note 4.  Goodwill, in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) and other intangible assets acquired in business combinations, licensing and other transactions was $1.8 billion at both at June&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values.  Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill.  At acquisition, we generally determine the fair value of intangible assets, including IPR&amp;amp;D, using the &#x201c;income method.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill was $671.6&#160;million and $671.9 million respectively, at June&#160;30, 2020 and December&#160;31, 2019. Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.  We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing.  Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net intangible assets other than goodwill were $1.1 billion, including IPR&amp;amp;D of $590.2 million, at both June&#160;30, 2020 and December&#160;31, 2019.  Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products and IPR&amp;amp;D.  Considering the high risk nature of research and development and the industry&#x2019;s success rate of bringing developmental compounds to market, IPR&amp;amp;D impairment charges may occur in future periods.  Estimating the fair value of IPR&amp;amp;D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon obtaining regulatory approval, IPR&amp;amp;D assets are then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.  If the project is abandoned, the IPR&amp;amp;D asset is charged to expense.  Finite lived intangible assets are tested for impairment when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.  The testing includes a comparison of the carrying amount of the asset to its estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We believe that our estimates and assumptions are reasonable and otherwise consistent with assumptions that marketplace participants would use in their estimates of fair value.&#160; However, if future results are not consistent with our estimates and assumptions, including as a result of the COVID-19 global pandemic, then we may be exposed to an impairment charge, which could be material.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years.  We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up.  Amortization expense was $29.9 million and $33.0 million for the six months ended June 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair value measurements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments.  Investments that are considered equity securities as of June&#160;30, 2020 and December&#160;31, 2019 are predominately carried at fair value.  Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest applicable to such debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates.  The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts.  Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.  Refer to Note 8.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Contingent consideration&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense.  Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability.  Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions.  The assumptions used in estimating fair value require significant judgment.  The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Derivative financial instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges.  For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At June&#160;30, 2020 and December&#160;31, 2019, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognize all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations.  Refer to Note 9.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Property, plant and equipment are recorded at cost or fair value if acquired in a business combination.  Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases.  The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years.  Expenditures for repairs and maintenance are charged to expense as incurred.  Depreciation expense was $14.4 million and $14.5 million for the six months ended June 30, 2020 and 2019, respectively.  Assets held under finance leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheet and are amortized over the shorter of their useful lives or the expected term of their related leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Impairment of long-lived assets.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income taxes.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income taxes are accounted for under the asset-and-liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.  We periodically evaluate the realizability of our&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;net deferred tax assets.  Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;adjustment.  Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We operate in various countries and tax jurisdictions globally.&#160; For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.&#160; For the three and six months ended June 30, 2020, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue recognition&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;Topic 606&#x201d;).  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.  At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct.  We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.  For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 12.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Concentration of credit risk and allowance for credit losses&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable.  Substantially all of our accounts receivable are with either companies in the healthcare industry or patients.  However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.   At June&#160;30, 2020 and December&#160;31, 2019, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 11% and 6%, respectively, of our consolidated Accounts receivable, net. At June&#160;30, 2020, receivable balances (net of explicit and implicit price concessions) due directly from states, cities and other municipalities, specifically related to our real-time reverse-transcription polymerase chain reaction (real-time RT-PCR) assay to detect the 2019 novel coronavirus disease (COVID-19), were 37.6% of our consolidated Accounts receivable, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk.  At June&#160;30, 2020 and December&#160;31, 2019, receivables due from patients represented approximately 2.0% and 2.5%, respectively, of our consolidated Accounts receivable, net.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer&#x2019;s ability to pay.  Actual results could differ from those estimates.  The allowance for credit losses was $1.6 million and $1.9 million at June&#160;30, 2020 and December&#160;31, 2019, respectively.  The credit loss expense for the six months ended June 30, 2020 and 2019 was $0.2 million and $0.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Equity-based compensation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award.  We record excess tax benefits realized from the exercise of stock options as cash flows from operations.  For the six months ended June 30, 2020 and 2019, we recorded $4.0 million and $7.6 million, respectively, of equity-based compensation expense.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Research and development expenses.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development expenses include external and internal expenses.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  Research and development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;employee-related expenses include salaries, benefits and equity-based compensation expense.  Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.  We expense these costs in the period in which they are incurred.  We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received.  As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility and which have no alternative future use.  For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed.  Once the development process has been completed the asset will be amortized over its remaining estimated useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Segment reporting&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Our chief operating decision-maker (&#x201c;CODM&#x201d;) is Phillip Frost, M.D., our Chairman and Chief Executive Officer.  Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis.  We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of clinical laboratory operations through BioReference and point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense or income taxes.  Refer to Note 14.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Shipping and handling costs.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We do not charge customers for shipping and handling costs.  Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Foreign currency translation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  The financial statements of certain of our foreign operations are measured using the local currency as the functional currency.  The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods.  Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Variable interest entities&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  The consolidation of a variable interest entity (&#x201c;VIE&#x201d;) is required when an enterprise has a controlling financial interest.  A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.  Refer to Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Investments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  We have made strategic investments in development stage and emerging companies.  We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees.  For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations.  Refer to Note 5.  For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value.  Refer to Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#x201d; which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables.  This may result in the earlier recognition of allowances for losses.  The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2019, with early adoption permitted.  The adoption of ASU 2016-13 on January 1, 2020, did not have a significant impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQzNjg_08ba94b7-b061-462e-893b-eff6ab0388b7">Basis of presentation.  The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;) and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all information and notes required by GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company&#x2019;s results of operations, financial position and cash flows have been made.  The results of operations and cash flows for the three and six months ended June 30, 2020 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2020 or any other future periods.  The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQzNzM_9a836212-8117-4a94-9c81-d4eb2fcaad7a">Principles of consolidation.  The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and of our wholly owned subsidiaries.  All intercompany accounts and transactions are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODc1OA_5d6063ad-60de-4f78-9fd5-4863f57cace8">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Use of estimates&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from these estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <opk:COVID19NumberOfTestsPerformed
      contextRef="id7248978ab134af9bb5051c652bb74f7_D20200401-20200630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODc2MQ_f7a650e8-f88f-4934-9fe7-4c12b08f48cc"
      unitRef="test">331600</opk:COVID19NumberOfTestsPerformed>
    <opk:COVID19NumberOfTestsPerformed
      contextRef="i137e26f6947848af8470ae5fd8e6bab1_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODc3Nw_18173e2d-d4ae-49fd-b4fe-01416c3b1871"
      unitRef="test">2200000</opk:COVID19NumberOfTestsPerformed>
    <opk:COVID19PercentOfTotalTestVolume
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODc5MA_36491a4e-3299-4b88-a6c4-cb6173a05e7a"
      unitRef="number">0.281</opk:COVID19PercentOfTotalTestVolume>
    <opk:COVID19TestsPerformedPerDay
      contextRef="id7248978ab134af9bb5051c652bb74f7_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODc5Nw_855db79a-a441-48d6-9903-d87202783bac"
      unitRef="test">400000</opk:COVID19TestsPerformedPerDay>
    <opk:COVID19TestsPerformedPerDay
      contextRef="i137e26f6947848af8470ae5fd8e6bab1_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODgwNg_e612f196-9539-4e6c-a91f-3156d3e21bdf"
      unitRef="test">50000</opk:COVID19TestsPerformedPerDay>
    <opk:ChangeInTestingVolumePercent
      contextRef="id2fe9bfd426d4e56a5b3bcbcaf3b2286_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODgxNA_f870254a-c7e4-477b-9a40-9c1a3e8a819f"
      unitRef="number">-0.465</opk:ChangeInTestingVolumePercent>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ib5e57cbd6ab542d79a08167f6ec07985_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODgyMQ_6d90f4e9-3eeb-47bb-8cba-d95156382441"
      unitRef="usd">14000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i52f6774dfd1f4573beee75bf01ef821c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODgzNA_22af2b0f-d514-441c-9564-4ceb9dae3a4c"
      unitRef="usd">6200000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i998e2997494745b2998bd29dda7de21f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODg0OA_5cd0518c-af51-4d43-9faa-3514ff627296"
      unitRef="usd">6200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b70e317a90e423daaa6fcc619c8eb46_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjE5OTAyMzI4ODg0OA_7aee46fd-185c-4069-b1d5-fdc478055613"
      unitRef="usd">6200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NDI_e56f6da5-6b38-4840-8cce-9354745d9151">Cash and cash equivalents.  Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase.  We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents.  These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NDM_c395b13b-0491-427d-8458-d72b4037adc3">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Inventories&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Inventories are valued at the lower of cost and net realizable value.  Cost is determined by the first-in, first-out method.  We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value.  Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which is used in our testing laboratories.  Inventory obsolescence expense for the six months ended June&#160;30, 2020 and 2019 was $1.7 million and $1.3 million, respectively.&lt;/span&gt;Pre-launch inventories.  We may accumulate commercial quantities of certain product candidates prior to the date we anticipate that such products will receive final U.S. FDA approval.  The accumulation of such pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever.  This risk notwithstanding, we may accumulate pre-launch inventories of certain products when such action is appropriate in relation to the commercial value of the product launch opportunity.  In accordance with our policy, this pre-launch inventory is expensed.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjg2OQ_6641f582-1af1-4f80-a964-4e9eca1a0246"
      unitRef="usd">1700000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjg3Ng_4b773b47-78fa-459d-9280-b1531986f736"
      unitRef="usd">1300000</us-gaap:InventoryWriteDown>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NzA_5ede7702-9257-4ae8-ab77-0d2d9ca96e0b">&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Goodwill and intangible assets&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting.  Refer to Note 4.  Goodwill, in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) and other intangible assets acquired in business combinations, licensing and other transactions was $1.8 billion at both at June&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values.  Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill.  At acquisition, we generally determine the fair value of intangible assets, including IPR&amp;amp;D, using the &#x201c;income method.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill was $671.6&#160;million and $671.9 million respectively, at June&#160;30, 2020 and December&#160;31, 2019. Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.  We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing.  Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net intangible assets other than goodwill were $1.1 billion, including IPR&amp;amp;D of $590.2 million, at both June&#160;30, 2020 and December&#160;31, 2019.  Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products and IPR&amp;amp;D.  Considering the high risk nature of research and development and the industry&#x2019;s success rate of bringing developmental compounds to market, IPR&amp;amp;D impairment charges may occur in future periods.  Estimating the fair value of IPR&amp;amp;D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon obtaining regulatory approval, IPR&amp;amp;D assets are then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.  If the project is abandoned, the IPR&amp;amp;D asset is charged to expense.  Finite lived intangible assets are tested for impairment when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.  The testing includes a comparison of the carrying amount of the asset to its estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.&lt;/span&gt;&lt;/div&gt;We believe that our estimates and assumptions are reasonable and otherwise consistent with assumptions that marketplace participants would use in their estimates of fair value.&#160; However, if future results are not consistent with our estimates and assumptions, including as a result of the COVID-19 global pandemic, then we may be exposed to an impairment charge, which could be material.&#160; We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years.  We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMzg4Mw_27fae88e-4c6a-4a89-b653-2d473e6ddc79"
      unitRef="usd">1800000000</opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets>
    <opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMzg4Mw_61955bef-14ad-414f-987f-d561e48facc0"
      unitRef="usd">1800000000</opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTY0OTI2NzQ3NTAzMg_ad9da6e4-722a-4e56-97b5-7d32c60f0eca"
      unitRef="usd">671600000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfNDY0NA_d1e144be-bdbf-4712-a44d-24e7eae58009"
      unitRef="usd">671900000</us-gaap:Goodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfNTI3NA_784c143d-1622-4966-983f-0d127a78471c"
      unitRef="usd">1100000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfNTI3NA_d3b58c6a-9c75-4ff7-bf56-e86ebd400c3d"
      unitRef="usd">1100000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i34113ca72899471b80fa537db298faf5_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfNTI5Nw_2409e55a-4027-4e77-9108-1a9b5b266f85"
      unitRef="usd">590200000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia5f22aa17f4f4f80a5186830a870ac40_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfNTI5Nw_3d19217c-4996-421c-91bc-e6731d1978ff"
      unitRef="usd">590200000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0a9fcdf9701e4978a7f6f9fdbae12895_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfODA3NQ_a44c927a-c529-4fef-a0c0-f67b7c14a9f9">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic8597cb5f4cd4e56a0b43a5aaa79edf0_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfODA4MQ_a79fa8a2-1690-4a7c-aac1-0e6eaa52218b">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfODMwMg_befd390c-3e58-41cd-a6a1-06b7cb35efab"
      unitRef="usd">29900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfODMwOQ_185444cf-1ed2-43db-9cb4-a24c2a29f0aa"
      unitRef="usd">33000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0ODI_46a31dc0-3837-4824-a510-d05567810dc7">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair value measurements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments.  Investments that are considered equity securities as of June&#160;30, 2020 and December&#160;31, 2019 are predominately carried at fair value.  Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest applicable to such debt.&lt;/span&gt;In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates.  The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts.  Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NDU_2329c62b-c49a-4460-83ba-f5830ba0c825">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Contingent consideration&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense.  Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability.  Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions.  The assumptions used in estimating fair value require significant judgment.  The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.&lt;/span&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ1MDA_42a026fb-7329-40be-aca9-42ab9f620c2e">Derivative financial instruments.  We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges.  For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At June&#160;30, 2020 and December&#160;31, 2019, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognize all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NDg_50d2521d-1301-4713-8fcf-60d523dcd63c">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Property, plant and equipment are recorded at cost or fair value if acquired in a business combination.  Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases.  The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years.  Expenditures for repairs and maintenance are charged to expense as incurred.  Depreciation expense was $14.4 million and $14.5 million for the six months ended June 30, 2020 and 2019, respectively.  Assets held under finance leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheet and are amortized over the shorter of their useful lives or the expected term of their related leases.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2c925c357ef94419a653f6179d8cd427_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE2MDY_cd3cbcb4-9a57-43a7-ba56-622f931ed9ee">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id483c700016445cf875194cf5a6fd62b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE2NTc_ec2b4c8d-a5c0-4749-a64e-de5f27011f3c">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7bf9292e3f244c65ab4a6e78952c669e_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE2NjA_e07800bc-7c7e-43b0-83b1-4efe67bddbab">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i287a64693aa543c9b39361bdcfae9f34_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE2OTU_3604818e-ae40-4b8d-b032-30d0033661a1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4ecb6c47f6db44edbbe0ea91612ccfd1_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE2OTg_ec213c38-5896-4cb7-b612-7d7ba3bebf5c">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic3ec9c63dd2d444eba263c0dabc7144b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE4MTM_6f26875c-4125-4ce0-a90e-db06feedfdc0">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if6a40facfada4fc5a367a7dcaf4f0135_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE4MTY_d8c1c616-c204-4609-b262-eee596315f0b">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibf92eadea438478cb1b5f0aa51c40f56_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE4NDQ_9f4e2c8f-6143-438e-b133-f93c9a9d2e20">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i542ee96b497e4c8e81ce12f68616f43a_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE4NDc_47f7d5cd-2052-489e-8201-7cbb6f9a59c7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE5NjE_43a56985-de47-40f0-bf55-0032e73dc79f"
      unitRef="usd">14400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTE5Njg_e0fc45ff-758c-4c5d-b06e-e8bf42554854"
      unitRef="usd">14500000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NTk_ce86143a-3a7b-450f-9fa4-e47b83648ea9">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Impairment of long-lived assets.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0MTI_b4cd1190-823b-4ae5-951a-a360f6517a61">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income taxes.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income taxes are accounted for under the asset-and-liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those &lt;/span&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.  We periodically evaluate the realizability of our&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;net deferred tax assets.  Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;adjustment.  Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We operate in various countries and tax jurisdictions globally.&#160; For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.&#160; For the three and six months ended June 30, 2020, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQzNzE_c62b0197-068a-49d3-8f15-6e9ef45bd554">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue recognition&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;Topic 606&#x201d;).  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.  &lt;/span&gt;We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.  At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct.  We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Shipping and handling costs.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We do not charge customers for shipping and handling costs.  Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.&lt;/span&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0MDU_16d9796f-94da-4c86-a78a-db669ff6629e">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Concentration of credit risk and allowance for credit losses&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable.  Substantially all of our accounts receivable are with either companies in the healthcare industry or patients.  However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.&lt;/span&gt;While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i16be18cc629345ec9ee57120942f2250_D20200630-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTY5ODk_4b8c77a0-1187-488d-a44a-54bdc319104d"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i741090abba6940d68c835c82f65dc928_D20191231-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTY5OTY_574a9d83-4f9a-4e52-8d13-0c2ecb5aa1c9"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic59039c688094e9385f6da64420c81a7_D20200630-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTczNjQ_0c722028-2757-4821-8de6-082aa1cb83e2"
      unitRef="number">0.376</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iede87b24ecb34c16881dd3d454c04ad4_D20200630-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTc1OTk_c10735b0-d4ef-4338-9bca-f803e4676e30"
      unitRef="number">0.020</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8c116f9b15604e95aba107054937c166_D20191231-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTc2MDY_43144d35-a30d-4e93-9e89-1a6c9ee8bb0e"
      unitRef="number">0.025</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0Nzk_7dcab28c-5440-4da9-bb13-8a20df3cac37">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer&#x2019;s ability to pay.  Actual results could differ from those estimates.</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTgwNjI_9651c058-eb51-489c-90d5-05bb75d537e1"
      unitRef="usd">1600000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTgwNjk_2b5ae3d8-d777-4348-ba91-6c89ea325b64"
      unitRef="usd">1900000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTgxNDk_6dedfa4d-cef5-403e-9ee5-c8c833523093"
      unitRef="usd">200000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTgxNTY_f0a88957-71fc-40e0-8eea-6c2a272f880f"
      unitRef="usd">200000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQzNzk_ba3f9a08-c5a5-43aa-a24b-5ca8985a5ae0">Equity-based compensation.  We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award.  We record excess tax benefits realized from the exercise of stock options as cash flows from operations.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTg2NTg_01fdb479-80df-4e0c-975f-1e8b8a90c6ff"
      unitRef="usd">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMTg2NjU_45d6594f-ac2f-4b3e-925f-ca7d8997a863"
      unitRef="usd">7600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0Mjc_e70d831f-06db-41cf-bb2d-002b1a4bc996">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Research and development expenses.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development expenses include external and internal expenses.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  Research and development &lt;/span&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;employee-related expenses include salaries, benefits and equity-based compensation expense.  Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.  We expense these costs in the period in which they are incurred.  We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received.  As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility and which have no alternative future use.  For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed.  Once the development process has been completed the asset will be amortized over its remaining estimated useful life.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NzM_7389613c-e86c-41ea-b4a0-aa94607ec8e7">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Segment reporting&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Our chief operating decision-maker (&#x201c;CODM&#x201d;) is Phillip Frost, M.D., our Chairman and Chief Executive Officer.  Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis.  We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt; product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of clinical laboratory operations through BioReference and point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense or income taxes.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjA2ODg_1d6b79b5-d47e-4c6a-888c-36163887a94b"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0MzM_4ad59a4b-b74e-4472-a1be-5e31b7e54d72">Foreign currency translation.  The financial statements of certain of our foreign operations are measured using the local currency as the functional currency.  The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods.  Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss).</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0MDc_fff3dae5-fa9d-4adc-84bf-d5960c72fa7e">Variable interest entities.  The consolidation of a variable interest entity (&#x201c;VIE&#x201d;) is required when an enterprise has a controlling financial interest.  A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQ0NTU_a79b16f9-f423-4c06-b955-0e85cc6809dd">Investments.  We have made strategic investments in development stage and emerging companies.  We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees.  For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations.  Refer to Note 5.  For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180My9mcmFnOjdkY2M1NTkwODMzMzQxMmFhZTEwMWJiMzc2NWQwNjMyL3RleHRyZWdpb246N2RjYzU1OTA4MzMzNDEyYWFlMTAxYmIzNzY1ZDA2MzJfMjQzODU_0ee4483d-31f7-4d34-98b2-fd52cb1ad78c">&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#x201d; which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables.  This may result in the earlier recognition of allowances for losses.  The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2019, with early adoption permitted.  The adoption of ASU 2016-13 on January 1, 2020, did not have a significant impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfODI0NjMzNzIxMzE0Mw_c10b2735-49a8-44f1-9f9d-948a5bf43030">EARNINGS (LOSS) PER SHARE&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic income (loss) per share is computed by dividing our net income (loss) by the weighted average number of shares of our common stock par value $0.01 per share (&#x201c;Common Stock&#x201d;) outstanding during the period.  Shares of Common Stock outstanding under the&#160;share lending&#160;arrangement entered into in conjunction with the 2025 Notes (as defined in Note 6) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.  Refer to Note 6.  For diluted earnings per share, the dilutive impact of stock options and warrants is determined by applying the &#x201c;treasury stock&#x201d; method.  The dilutive impact of the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes (each, as defined herein and as discussed in Note 6) has been considered using the &#x201c;if converted&#x201d; method.  For periods in which their effect would be antidilutive, no effect is given to outstanding options, warrants or the potentially dilutive shares issuable pursuant to the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes in the dilutive computation.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A total of 69,505,513 and 68,933,402 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the three months ended June 30, 2020, and 2019, respectively, because their inclusion would be antidilutive. A total of 69,347,867 and 61,760,134 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the six months ended June 30, 2020, and 2019, respectively, because their inclusion would be antidilutive.  A full presentation of diluted earnings per share has not been provided because the required adjustments to the numerator and denominator resulted in diluted earnings per share equivalent to basic earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended June 30, 2020, and 2019, no Common Stock options or Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of no shares of Common Stock.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June 30, 2020, no Common Stock options or Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of no shares of Common Stock.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June 30, 2019, 24,877 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 19,232 shares of Common Stock.  Of the 24,877 Common Stock options and Common Stock warrants exercised, 5,645 shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTY3_10a35126-c6b7-4c49-8671-bf797e9744d1"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2cf990d401b84d509ca83830387dfec4_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTIwOA_7c7e79f3-94ea-41fb-a985-c995328504fe"
      unitRef="shares">69505513</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i703dda2862bf49c082b5e9c7749b1af2_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTIxNQ_728098a4-8b7d-4041-afaa-02fa8664d9c7"
      unitRef="shares">68933402</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9ae1d925ca624ccfa017da2775100740_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMjU4Ng_53318939-1e90-49fb-90f4-a5e14fb6564b"
      unitRef="shares">69347867</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4825a57053b245fdb80ca8d81b3e823e_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMjU3MA_cc04c328-f4d8-4bb7-bc5a-96b239951b6e"
      unitRef="shares">61760134</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA0Nw_7f963648-5a5d-4974-98e1-ee47915cbf35"
      unitRef="shares">0</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA0Nw_bb4ecfbe-6da0-4c00-a09e-73e3884c779b"
      unitRef="shares">0</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA3Nw_3661093c-1ea8-4e0d-923e-2cd052c561f9"
      unitRef="shares">0</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA3Nw_3aef9b82-753f-463d-908b-2ddc62b95e14"
      unitRef="shares">0</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA1OA_a901f3db-789b-4276-8b39-f7baa6dea840"
      unitRef="shares">0</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMzg0ODI5MDcwMjA4OA_3d4c853d-a647-44a6-9239-fa6513a593af"
      unitRef="shares">0</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMTIwOQ_83b5bc4d-5ef3-417c-afc5-a1ab459ba54e"
      unitRef="shares">24877</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMTIxNw_a25aad8e-7f6a-4eff-9b5c-01dec65c4001"
      unitRef="shares">19232</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMTIzMg_51495de9-1807-4716-8cbf-10d21f4c5875"
      unitRef="shares">24877</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised>
    <opk:SharesSurrenderedInLieuOfCashPayment
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM180OS9mcmFnOmUxZWIwN2Q1YmFiMzQyZjk4YTg3MGUwODgyMTYxZjUzL3RleHRyZWdpb246ZTFlYjA3ZDViYWIzNDJmOThhODcwZTA4ODIxNjFmNTNfMTA5OTUxMTYzMTIyNQ_b29b696b-6112-43f4-9986-147fbb1dee93"
      unitRef="shares">5645</opk:SharesSurrenderedInLieuOfCashPayment>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMTEwOA_d63919ba-1e3d-4224-977d-eac3b9d260eb">COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.935%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.667%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: allowance for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;214,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;134,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Inventories, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consumable supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets and prepaid expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Taxes recoverable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;445,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;445,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;296,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;296,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Covenants not to compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Product registrations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(327,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(298,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;499,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;528,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Inventory received but not invoiced&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance leases short-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;210,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;164,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.935%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.667%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Line of credit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mortgages and other debts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance leases long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our intangible assets and goodwill relate principally to our completed acquisitions of OPKO Renal, OPKO Biologics, EirGen Pharma Limited (&#x201c;EirGen&#x201d;) and BioReference.  We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives.  The estimated useful lives by asset class are as follows:  technologies - 7-17 years, customer relationships - 7-20 years, product registrations - 7-10 years, covenants not to compete - 5 years, trade names - 5-10 years, other 9-13 years.  We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred.  Our goodwill is not tax deductible for income tax purposes in any jurisdiction in which we operate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The changes in value of the intangible assets and goodwill during the six months ended June 30, 2020 were primarily due to foreign currency fluctuations between the Chilean Peso, the Euro and the Shekel against the U.S. dollar.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the changes in Goodwill by reporting unit during the six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.537%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.667%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30th&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rayaldee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;OPKO Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;OPKO Biologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;OPKO Health Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;BioReference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;434,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;434,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;671,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;671,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMTA4OA_cd5f1f19-e069-47d2-b6c4-967f010b5c3e">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.935%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.667%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: allowance for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;214,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;134,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Inventories, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consumable supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets and prepaid expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Taxes recoverable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;445,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;445,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;296,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;296,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Covenants not to compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Product registrations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(327,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(298,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;499,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;528,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Inventory received but not invoiced&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance leases short-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;210,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;164,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.935%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.667%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Line of credit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mortgages and other debts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance leases long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMi0xLTEtMS0w_8207e639-14f8-4750-8c43-e50dc7ca1142"
      unitRef="usd">215925000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMi0zLTEtMS0w_00e19fe8-75c5-41d8-9357-9f970ec4d076"
      unitRef="usd">136551000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMy0xLTEtMS0w_e54f5383-1c07-4d55-8f85-d4927328568a"
      unitRef="usd">1573000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMy0zLTEtMS0w_7e152999-ea48-4c88-9ca4-220fdfc0b706"
      unitRef="usd">1934000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNC0xLTEtMS0w_72a509d3-9b71-40d7-be96-412d54b0a212"
      unitRef="usd">214352000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNC0zLTEtMS0w_77d0f427-ea53-45c2-94ab-66af6f46a099"
      unitRef="usd">134617000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherInventorySupplies
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNi0xLTEtMS0w_1cc52a48-cf52-4ea4-9766-631590cc665a"
      unitRef="usd">41298000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNi0zLTEtMS0w_4ec405d7-ce2b-4d00-ad37-8b93c4098a68"
      unitRef="usd">23005000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryFinishedGoods
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNy0xLTEtMS0w_17d88d02-3bde-4c6d-a4cd-df7a32b5cdd8"
      unitRef="usd">24259000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNy0zLTEtMS0w_84221811-233e-4f62-b4ca-ad250801aa9d"
      unitRef="usd">25142000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfOC0xLTEtMS0w_231231f4-7797-4bb4-9952-78c730aea072"
      unitRef="usd">4711000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfOC0zLTEtMS0w_b2ecad33-dd22-40b8-99ea-eb87c1f67386"
      unitRef="usd">3238000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfOS0xLTEtMS0w_7b1f019e-ec45-4619-908e-8b743eee3dc1"
      unitRef="usd">5826000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfOS0zLTEtMS0w_c5078fa1-1861-49a6-8612-d9e879ac862b"
      unitRef="usd">4586000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryValuationReserves
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTAtMS0xLTEtMA_8c73a595-829e-4fee-95a1-4f47c56884fd"
      unitRef="usd">3129000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTAtMy0xLTEtMA_09b57170-bf54-42d8-a96c-e332416fbfa4"
      unitRef="usd">2537000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTEtMS0xLTEtMA_8f8ab59f-5d94-4760-978a-bc08f472b95c"
      unitRef="usd">72965000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTEtMy0xLTEtMA_8da62643-a274-4b90-9cae-d20382b02851"
      unitRef="usd">53434000</us-gaap:InventoryNet>
    <opk:TaxesRecoverableCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTMtMS0xLTEtMA_02e943f9-0d47-48bd-841b-1f7662957e06"
      unitRef="usd">12135000</opk:TaxesRecoverableCurrent>
    <opk:TaxesRecoverableCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTMtMy0xLTEtMA_8dd64c9c-2d6e-492c-abab-55e09808669b"
      unitRef="usd">19808000</opk:TaxesRecoverableCurrent>
    <us-gaap:Supplies
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTQtMS0xLTEtMA_62204d6e-6931-498e-a77e-c5d1c025f159"
      unitRef="usd">12999000</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTQtMy0xLTEtMA_f7af0c93-d054-4784-8211-344741542602"
      unitRef="usd">8147000</us-gaap:Supplies>
    <us-gaap:PrepaidInsurance
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTgtMS0xLTEtMA_80f94b18-d580-43e4-a208-fb9148be56b1"
      unitRef="usd">6274000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTgtMy0xLTEtMA_9b584065-32ef-4e51-a06c-ff0b5e5bacc5"
      unitRef="usd">3486000</us-gaap:PrepaidInsurance>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTktMS0xLTEtMA_ce145e09-c653-41fe-9ad0-e1c05909a164"
      unitRef="usd">661000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMTktMy0xLTEtMA_50ffe29d-7d9b-40a9-9f87-703b7020a253"
      unitRef="usd">3262000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjAtMS0xLTEtMA_ab2a44b8-6267-44cd-a3c4-bfb087e0ea3a"
      unitRef="usd">19056000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjAtMy0xLTEtMA_8129a711-2d88-427c-89f8-2f1bcb5619c5"
      unitRef="usd">15839000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjEtMS0xLTEtMA_3313f26f-054e-4970-ab5a-391231eded57"
      unitRef="usd">51125000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjEtMy0xLTEtMA_02920415-3e33-473c-bdf3-c96ccb09313a"
      unitRef="usd">50542000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i94c6cd428f6b456c8d5b3acae79fbf66_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjMtMS0xLTEtMA_a99e4a2b-8535-4c2d-be07-ab8be3ef5d34"
      unitRef="usd">445144000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i94eb82a852ec42fbb84bb7e84f189cd8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjMtMy0xLTEtMA_fcf28d5c-5837-4cd5-b51d-71b47cd9c514"
      unitRef="usd">445408000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5f1de219854f4356843dae3ee1cd6115_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjQtMS0xLTEtMA_75390492-1454-4e68-87ab-6e6b7b6bdc56"
      unitRef="usd">296251000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3d2610a4d4b94c94af040534c9ec37b2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjQtMy0xLTEtMA_1907161e-9670-4fc2-9409-74a9f483aa5c"
      unitRef="usd">296246000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaca125106e0d4865a167a745ed415e38_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjUtMS0xLTEtMA_b0f7d8f5-4567-4936-aa54-f6b5899856a1"
      unitRef="usd">49771000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i00247b06c5ee4f84af09a0224926e806_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjUtMy0xLTEtMA_8b469284-0142-443f-9843-c08d5d4c6c57"
      unitRef="usd">49786000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0a3ad80fd03a4bd898db95dcf64037d2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjctMS0xLTEtMA_99bf6b9c-f06a-4c00-b582-955caa807710"
      unitRef="usd">16318000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i57b9d57f64db42caaea9671412bed643_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjctMy0xLTEtMA_59c698b2-e077-4df3-bae1-578599f3ee4b"
      unitRef="usd">16318000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1ccef43c91b649af897f72ba0ca5d9aa_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjgtMS0xLTEtMA_f848133b-44df-44c9-8c7b-63c9bedaf00d"
      unitRef="usd">5766000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i64d57f02fcfa4a818269328b1928521f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjgtMy0xLTEtMA_14318670-c803-4fd8-8932-d87d9b09e194"
      unitRef="usd">5766000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie8cd1bd900ad44d581af60988c19e099_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjktMS0xLTEtMA_65d796e4-3620-4687-8da2-55921d66207d"
      unitRef="usd">7109000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic3e7a27b8c6642a990135286515905fa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMjktMy0xLTEtMA_a9b97b71-a5cc-4607-a88b-521e5a9269e7"
      unitRef="usd">7578000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i04069b5f0be245a5b667f48793383f5c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzAtMS0xLTEtMA_0e69a5ee-f9a2-44ba-a500-31466b72dc0e"
      unitRef="usd">6100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i135e6bd0ecae45b790948a4ae8040c83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzAtMy0xLTEtMA_7fc980b9-2856-434d-8c7c-e00055f9ad07"
      unitRef="usd">6094000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzEtMS0xLTEtMA_c342367f-71a0-4179-98c4-695577cef303"
      unitRef="usd">327334000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzEtMy0xLTEtMA_66e2156f-8f8f-49be-bdf4-344305b20e83"
      unitRef="usd">298234000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzItMS0xLTEtMA_bb844b44-13b9-4d68-8802-0b99a80989ec"
      unitRef="usd">499125000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzItMy0xLTEtMA_896c030d-0712-4438-95ad-1a99d5145dfe"
      unitRef="usd">528962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <opk:InventoryReceivedNotInvoicedCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzQtMS0xLTEtMzU2Mg_e3f63970-55b5-4c2c-95e9-d417d0858391"
      unitRef="usd">49005000</opk:InventoryReceivedNotInvoicedCurrent>
    <opk:InventoryReceivedNotInvoicedCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzQtMy0xLTEtMzU2Mg_89e6db37-a81a-4997-a383-8b270bec5886"
      unitRef="usd">13751000</opk:InventoryReceivedNotInvoicedCurrent>
    <opk:AccruedCommitmentsandContingenciesCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzQtMS0xLTEtMzU0MA_5978ba02-139e-4c21-b929-2691c5e8d6ab"
      unitRef="usd">38668000</opk:AccruedCommitmentsandContingenciesCurrent>
    <opk:AccruedCommitmentsandContingenciesCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzQtMy0xLTEtMzU0MA_1807199f-08ae-4a00-88df-0346d76e8c92"
      unitRef="usd">38635000</opk:AccruedCommitmentsandContingenciesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzUtMS0xLTEtMA_aeb3b67c-b2f1-4519-9eff-925f0af6ee13"
      unitRef="usd">34086000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzUtMy0xLTEtMA_b9505fac-466f-4602-91f9-e1c51fee3b0b"
      unitRef="usd">33671000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzctMS0xLTEtMzU1Mg_02addf7f-e9d4-4189-b5db-df4da3dd123c"
      unitRef="usd">16570000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzctMy0xLTEtMzU1Mg_c76ae447-806a-4ffa-aa4a-1e749eeb723d"
      unitRef="usd">19196000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <opk:AccruedClinicalTrialsCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzctMS0xLTEtMA_5fd1635c-2167-4989-954c-ac1ec4bcbee4"
      unitRef="usd">6079000</opk:AccruedClinicalTrialsCurrent>
    <opk:AccruedClinicalTrialsCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzctMy0xLTEtMA_7f8ac80f-1655-47f5-8194-e55cb8147edb"
      unitRef="usd">8122000</opk:AccruedClinicalTrialsCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzktMS0xLTEtMA_a8afe25f-b333-4695-8429-1edd59bbc72d"
      unitRef="usd">2375000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfMzktMy0xLTEtMA_c13ba25b-0af6-4632-b7f0-bbf1b43eab4b"
      unitRef="usd">2375000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDAtMS0xLTEtMA_9d75a96f-3bbb-46fa-97e7-a017b35149d3"
      unitRef="usd">2435000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDAtMy0xLTEtMA_3cd0ed13-2146-49a0-89e9-efe042736264"
      unitRef="usd">2743000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDItMS0xLTEtMA_62dae26e-ecaf-4685-859b-fa636c8d6825"
      unitRef="usd">4009000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDItMy0xLTEtMA_d6f7c3df-6720-42e4-a603-865d4808c0e2"
      unitRef="usd">1333000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDQtMS0xLTEtMA_0b882250-1ada-46e7-ad24-01dee0bb9218"
      unitRef="usd">56884000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDQtMy0xLTEtMA_d30251cb-d9f9-458e-afaa-1d06b8a0fc19"
      unitRef="usd">45099000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDUtMS0xLTEtMA_11e752eb-8c75-4505-b3e5-8c55187edc44"
      unitRef="usd">210111000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDUtMy0xLTEtMA_69f54ac1-fa4a-4163-93b2-627fd8d1b48c"
      unitRef="usd">164925000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDktMS0xLTEtMA_92e4b5bf-e1ce-401d-866a-d2130c8d6e61"
      unitRef="usd">51489000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNDktMy0xLTEtMA_e37b128c-fa6b-47da-b362-d3faa7cb769b"
      unitRef="usd">44749000</us-gaap:LongTermLineOfCredit>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTAtMS0xLTEtMA_19ad2b0e-59c4-4b26-83ac-b931803e1c3e"
      unitRef="usd">7559000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTAtMy0xLTEtMA_0f012fef-7ff1-4a6b-b050-8b9e5611e053"
      unitRef="usd">7308000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTItMS0xLTEtMA_2d72a1ce-3df1-483f-897c-746d367f82a9"
      unitRef="usd">4201000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTItMy0xLTEtMA_f0dfba9d-a3f1-470d-8714-3c0c5770f8f3"
      unitRef="usd">3906000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTMtMS0xLTEtMA_054ea014-902f-4cce-a676-7db48df902f5"
      unitRef="usd">2960000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTMtMy0xLTEtMA_cecd9d6e-93ac-4a2f-95e2-78e1a488ccc9"
      unitRef="usd">4046000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTQtMS0xLTEtMA_82d3799a-4401-4609-be39-ce61f9cb2f94"
      unitRef="usd">1170000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTQtMy0xLTEtMA_16313edf-8c96-448b-bb79-820a03615192"
      unitRef="usd">2571000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTUtMS0xLTEtMA_f2494799-db86-46c2-9bf3-ad6d25c8aa98"
      unitRef="usd">24274000</us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent>
    <us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTUtMy0xLTEtMA_5c123ed6-8e90-402e-9049-11241581e771"
      unitRef="usd">25224000</us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTYtMS0xLTEtMA_3f71d8c2-21cc-41f2-bca6-bb74f9aac5fe"
      unitRef="usd">91653000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOmE2ZDRlNThiNGI3MDQ1ZDNiNWI0NTg5NDZiOWQzMTc0L3RhYmxlcmFuZ2U6YTZkNGU1OGI0YjcwNDVkM2I1YjQ1ODk0NmI5ZDMxNzRfNTYtMy0xLTEtMA_5887ef32-614a-4ecb-af75-5ac186a2922c"
      unitRef="usd">87804000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i230b30ca3eb04af49f4ca4734faacd44_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1NjcyMQ_a337f835-270d-4d37-ba64-4b495333683f">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i882f8261760b4d6aa3a96e6fa3284bfb_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1NjcyNw_d0fe2183-e1e9-4c66-aa59-3c85d572e14d">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ied7d8e97b2b945238ba32720ff6e8c0f_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1NjczMw_9dfdba16-e927-482e-8f91-74f8eb4bee0f">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i9ecfd46843994ca2aa33b2267b51858d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1NjczOA_464db8ef-9d4b-45c3-b9d8-6f6262306091">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1497918852414fb6ac3b2f71effa85a6_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc0NA_64af5312-15e0-4d53-9b89-149f0e12f4ac">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i0da706af1baa4c159c9bbb8d4c1030fd_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc0OQ_c5025749-3c06-4994-b7d3-9343f0cfa797">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i11f6b9bd556843b1aafd7e182d59c3cb_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc1NQ_86a26781-d0b0-4ba1-aca9-e7f5c97bff61">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8408841c1a734a08b778637e70249682_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc2MA_ef469664-14bb-44dd-9aca-6af9c0734fd9">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i5adb35b4c9f34a37aeb9549a65e96e46_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc2NQ_3f1ebfbf-8a38-4278-8ed0-d1d1a0272802">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4f61b01165e24fc98421d859fadcd8b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc3MQ_1362bf04-4184-4409-831a-fff0499c8ac7">P9Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i179802b429d44dda9f21192ac337df1a_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMjE5OTAyMzI1Njc3Ng_926a35e4-f6ad-4212-a942-cd4e34018f81">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RleHRyZWdpb246NDhjMDk3YjlmYzRmNGRkM2I5NWFlZjJlZTFmYTJiODJfMTEwMQ_62915faa-1f94-44c5-8fb7-76f5fa075999">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the changes in Goodwill by reporting unit during the six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.537%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.667%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30th&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rayaldee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;OPKO Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;OPKO Biologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;OPKO Health Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;BioReference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;434,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;434,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;671,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;671,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ic18db37a30a74d9c9ee748531acedbae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNC0xLTEtMS0w_adb4ac57-36d3-463a-8199-21754eec5016"
      unitRef="usd">85605000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4ea760e341c847f4a25f3b37d6b09d32_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNC01LTEtMS0w_749a9368-5a8f-4ec8-a193-038ea1530e40"
      unitRef="usd">100000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i52b56c73c8d84a5e8fb1fa551b3eddd3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNC03LTEtMS0w_3eda7bdd-a5e5-4672-8412-9476a6e37a07"
      unitRef="usd">85705000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i483bd6c64a9c49c2b324993790f590ee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNi0xLTEtMS0w_d430a7cd-32c6-4527-95a5-64f0d73f402a"
      unitRef="usd">4348000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i798edede7d9340b38166a915bb9c5868_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNi01LTEtMS0w_59d5ba1d-729d-4d91-bf44-ec7d391dc6de"
      unitRef="usd">-450000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i4b2f66f652b94502a75f85a54c4c3ef4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNi03LTEtMS0w_383ce595-c3ae-4977-8a76-cf5a9794854c"
      unitRef="usd">3898000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0cd4a728fcd14faf998c1ab9c30b3b83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNy0xLTEtMS0w_d1f184bc-5514-4ddd-828a-23b9a629fc7d"
      unitRef="usd">139784000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i33fff5e9ff6341f0bb92ec8ca48cb6e0_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNy01LTEtMS0w_89479d64-68e2-47bc-995c-e57085969525"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="idd9cb4e1c5bf46f7811c43a8af57ec52_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfNy03LTEtMS0w_5bd11f6e-e7ea-4f6a-9001-cd2a0d33e2c6"
      unitRef="usd">139784000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i94fa7a9bd57a4f9bb8aa3d9c5b228336_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfOC0xLTEtMS0w_62c5dfb4-31be-414e-b75a-2a046381c1d2"
      unitRef="usd">7394000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i771f4bcba7074c7bbbdffdd2ad65b477_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfOC01LTEtMS0w_a43f397b-dff8-444a-b3f3-c2591e2a26a4"
      unitRef="usd">9000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i9f6803f62e7447adadce391b33061cba_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfOC03LTEtMS0w_ee1c822a-c9c5-480b-babd-66ed36ddf11e"
      unitRef="usd">7403000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i79658e603527497182db4f569fcc87f7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTQtMS0xLTEtMA_1d54bede-ec5e-4aa2-9ddc-28eaf16ea36b"
      unitRef="usd">434809000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i986492897965401d95c6a703c55c6e77_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTQtNS0xLTEtMA_5d5581cb-ab48-4a8b-a87e-64b31d0c2ce1"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i93c9c6bb19df4ae99dc27947a8f03121_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTQtNy0xLTEtMA_7b99b53b-2863-4f54-9984-f0245364d1bf"
      unitRef="usd">434809000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTctMS0xLTEtMA_74ddae7a-df7a-4ecb-864c-8287fc7796aa"
      unitRef="usd">671940000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTctNS0xLTEtMA_9590ead7-817f-4f30-a12b-120b91facfac"
      unitRef="usd">-341000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM181NS9mcmFnOjQ4YzA5N2I5ZmM0ZjRkZDNiOTVhZWYyZWUxZmEyYjgyL3RhYmxlOjc3YmRhOTc5YTY2ZjQ1ZTY5ZWYzYTFiODFkNWMwZDFlL3RhYmxlcmFuZ2U6NzdiZGE5NzlhNjZmNDVlNjllZjNhMWI4MWQ1YzBkMWVfMTctNy0xLTEtMA_48ba26cb-1903-4229-8eb3-9f0d4515ce4f"
      unitRef="usd">671599000</us-gaap:Goodwill>
    <us-gaap:InvestmentTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDc4OQ_f6732116-86e9-4a9f-9b45-c6e618c10a7c">INVESTMENTS&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.460%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.533%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.535%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Underlying Equity in Net Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable interest entity, equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity securities with no readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total carrying value of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;"&gt;Equity method investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our equity method investments consist of investments in Pharmsynthez (ownership 9%), Cocrystal Pharma, Inc. (&#x201c;COCP&#x201d;) (5%), Non-Invasive Monitoring Systems, Inc. (&#x201c;NIMS&#x201d;) (1%), Neovasc, Inc. (&#x201c;Neovasc&#x201d;) (2%), InCellDx, Inc. (&#x201c;InCellDx&#x201d;) (29%), BioCardia, Inc. (&#x201c;BioCardia&#x201d;) (2%), and Xenetic Biosciences, Inc. (&#x201c;Xenetic&#x201d;) (3%).  The aggregate total assets, liabilities, and net losses of our equity method investees as of and for the six months ended June 30, 2020 were $79.7 million, $32.4 million, and $26.6 million, respectively.  We have determined that we and/or our related parties can significantly influence control of our equity method investments through our board representation and/or voting power.  Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Condensed Consolidated Statement of Operations.  The aggregate value of our equity method investments based on the quoted market prices of their respective shares of common stock and the number of shares held by us as of June&#160;30, 2020 was $7.9 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our equity securities consist of investments in Phio Pharmaceuticals (&#x201c;Phio&#x201d;) (ownership 0.02%), VBI Vaccines Inc. (&#x201c;VBI&#x201d;) (3%), ChromaDex Corporation (&#x201c;ChromaDex&#x201d;) (0.1%), MabVax Therapeutics Holdings, Inc. (&#x201c;MabVax&#x201d;) (1%), and Eloxx Pharmaceuticals, Inc. (&#x201c;Eloxx&#x201d;) (3%).  We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of these investments.  Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have readily determinable fair value. Equity securities without a readily determinable fair value are adjusted to fair value when there is an observable price change. Net gains and losses on our equity securities for the six months ended June 30, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.592%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.706%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net gains and losses recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Net gains and losses realized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized net gains recognized during the period on equity securities still held at the reporting date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Sales of investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statement of Operations.  We did not have significant sales activity during the six months ended June 30, 2020 and 2019.  The cost of securities sold is based on the specific identification method.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Warrants and options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to our equity method investments and equity securities, we hold options to purchase 47 thousand additional shares of BioCardia, 33 thousand of which were vested as of June&#160;30, 2020, and 33 thousand, 0.7 million, 40 thousand and 404 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;warrants to purchase shares of COCP, InCellDx, Inc., Xenetic, and Phio, respectively.  We recorded the changes in the fair value of the options and warrants in Fair value changes of derivative instruments, net in our Condensed Consolidated Statement of Operations.  We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheet.  See further discussion of the Company&#x2019;s options and warrants in Note 8 and Note 9.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Investments in variable interest entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have determined that we hold variable interests in Zebra Biologics, Inc. (&#x201c;Zebra&#x201d;) based on our assessment that Zebra does not have sufficient resources to carry out its principal activities without additional financial support.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We own 1,260,000 shares of Zebra Series A-2 Preferred Stock and 900,000 shares of Zebra restricted common stock (ownership 29% at June&#160;30, 2020).  Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs.  Dr. Richard Lerner, M.D., a member of our Board of Directors, is a founder of Zebra and, along with Dr. Frost, serves as a member of Zebra&#x2019;s Board of Directors.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related parties&#x2019; investment, as well as our investment combined with the related parties&#x2019; investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra.  Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebra&#x2019;s economic performance and have no obligation to fund expected losses.  We determined, however, that we can significantly influence control of Zebra through our board representation and voting power.  Therefore, we have the ability to exercise significant influence over Zebra&#x2019;s operations and account for our investment in Zebra under the equity method.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:InvestmentTableTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDgxNw_38dd2f91-f4c7-4f64-98fc-d6444b5071b4">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.460%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.533%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.535%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Underlying Equity in Net Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable interest entity, equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity securities with no readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total carrying value of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentTableTextBlock>
    <opk:EquityMethodInvestmentExcludingVariableInterestEntity
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfMi0yLTEtMS0w_07590cf4-9dc2-4650-89c5-383b581d16a1"
      unitRef="usd">561000</opk:EquityMethodInvestmentExcludingVariableInterestEntity>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfMi00LTEtMS0w_f34de138-757e-4eda-9e52-d2c86dd9cfa2"
      unitRef="usd">2370000</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <opk:EquityMethodInvestmentVariableInterestEntity
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfMy0yLTEtMS0w_e043e614-429a-4d90-8d16-db994e01de69"
      unitRef="usd">836000</opk:EquityMethodInvestmentVariableInterestEntity>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfNC0yLTEtMS0w_36272ade-d2b2-42e1-87c3-2c68af681230"
      unitRef="usd">24777000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfNS0yLTEtMS0w_561bed32-ccab-4c6c-bcc1-727787c9d5fd"
      unitRef="usd">35000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <opk:StockOptionandWarrantInvestments
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfNi0yLTEtMS0w_534d6356-9f8f-479b-a268-6e0dbc08514c"
      unitRef="usd">51000</opk:StockOptionandWarrantInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjY1N2I3MDc4NmQyYjRkMTY5Yzg4OTYwN2EzNjA1NjA4L3RhYmxlcmFuZ2U6NjU3YjcwNzg2ZDJiNGQxNjljODg5NjA3YTM2MDU2MDhfNy0yLTEtMS0w_e2abf96e-0e1d-447a-b521-c8ab09bdf750"
      unitRef="usd">26260000</us-gaap:LongTermInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib4fc9634e3a348bab19da19df297d2c9_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjkx_740cdd31-f996-483a-a209-6faa23fe4014"
      unitRef="number">0.09</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i40c56be3936e42218c130b6171df7087_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMzI5_0cd1fdbd-e734-413b-8c68-5ebd7b85ab3b"
      unitRef="number">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4b1d2bd1b0014409b092ff4aa9f8efb5_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMzgy_c67e1dd9-fa6a-4c74-b76f-305e169fc3e5"
      unitRef="number">0.01</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia1aa8cc835a1411f9161a88fefd51afb_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDE0_06b2a5bc-d09e-439c-8ed2-47f75d54dc61"
      unitRef="number">0.02</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iecfe4462c2ee470cb896cbcb8858c7f9_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDQ4_a71314fe-23c9-45b5-9682-b54cee5a2c65"
      unitRef="number">0.29</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie5822595b03740f291e2481860949888_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDg0_90c44e03-3211-4ca2-abab-ae37a34ab699"
      unitRef="number">0.02</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i323d8d5a5c3f438bb251f37e63e4c809_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNTMy_632131d4-6ef5-4e49-930b-01fbb6e46131"
      unitRef="number">0.03</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:Assets
      contextRef="i7d3ef7c1241144ff931d3374e709b07e_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNjUx_8fe99f24-8228-4a7e-a760-dbf31c65e757"
      unitRef="usd">79700000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i7d3ef7c1241144ff931d3374e709b07e_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNjU1_28fd09fb-5d86-4a32-8a58-e1302334f087"
      unitRef="usd">32400000</us-gaap:Liabilities>
    <us-gaap:ProfitLoss
      contextRef="i9f4e2d31d1d5424882ae14d6cb9c371c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNjYz_da4ff28c-e7a8-4e99-96f2-63177a9fcd6f"
      unitRef="usd">-26600000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTI2OQ_951342b2-4290-413a-8603-81b151a95d8b"
      unitRef="usd">7900000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="ibe9c0975275d45f6898ff7d4f683e8e3_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTM4Mg_852752fe-9cde-49f9-a2cf-9526d9f862a9"
      unitRef="number">0.0002</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="i09cc35711f9348d9b1b3f52011a7e368_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTQxNA_b45c523a-bd96-4369-88cf-e6cfa4d900c1"
      unitRef="number">0.03</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="i79df6dd0e9984686893d9cfc9fe6d27f_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTQ1Ng_f62a0db4-5848-47d7-b7c5-de0976afa064"
      unitRef="number">0.001</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="if01ceaf264f64e64b9647bf4a84dac24_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTUwOA_83b19f60-56d6-4de1-926a-b8b87b039725"
      unitRef="number">0.01</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="i94995994c21b4facabf08492a51c559a_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMTU1Ng_1583bd52-2fe0-486d-86ff-cd64a3390772"
      unitRef="number">0.03</opk:EquitySecurityFVNIOwnershipPercent>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfNDgxOA_bf1f7950-efbe-41ee-8834-78d836795bce">Net gains and losses on our equity securities for the six months ended June 30, 2020 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.592%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.706%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net gains and losses recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Net gains and losses realized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized net gains recognized during the period on equity securities still held at the reporting date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjkxNmJhYmU2NTMwYjQwYmVhODkxOGFhZjQzYzUxODIwL3RhYmxlcmFuZ2U6OTE2YmFiZTY1MzBiNDBiZWE4OTE4YWFmNDNjNTE4MjBfMi0yLTEtMS0w_57a9419c-a2a0-4df4-8739-aa44a6e16337"
      unitRef="usd">5907000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjkxNmJhYmU2NTMwYjQwYmVhODkxOGFhZjQzYzUxODIwL3RhYmxlcmFuZ2U6OTE2YmFiZTY1MzBiNDBiZWE4OTE4YWFmNDNjNTE4MjBfMy0yLTEtMS0w_b3a71732-ca77-4585-a274-0f0ce1eef5da"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RhYmxlOjkxNmJhYmU2NTMwYjQwYmVhODkxOGFhZjQzYzUxODIwL3RhYmxlcmFuZ2U6OTE2YmFiZTY1MzBiNDBiZWE4OTE4YWFmNDNjNTE4MjBfNC0yLTEtMS0w_7381bd79-10a0-43d4-b009-b7aacadd3786"
      unitRef="usd">5907000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie5822595b03740f291e2481860949888_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjYyNg_66cb8140-bc43-49ab-bff2-3058c589a888"
      unitRef="shares">47000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <opk:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested
      contextRef="ie5822595b03740f291e2481860949888_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjY2MQ_8c82ea08-de5c-41a3-b6c5-f59dc694e694"
      unitRef="shares">33000</opk:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i40c56be3936e42218c130b6171df7087_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjY5OQ_75963950-7967-4018-bf93-d2e72859e279"
      unitRef="shares">33000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="iecfe4462c2ee470cb896cbcb8858c7f9_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjcwMw_57a40e39-694e-4744-a4d2-37b87326febd"
      unitRef="shares">700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i323d8d5a5c3f438bb251f37e63e4c809_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjcwNw_2f02f019-9cb0-4e1e-a4fc-199486df25a0"
      unitRef="shares">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ibe9c0975275d45f6898ff7d4f683e8e3_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMjcxNA_3da1b462-1bf2-4f83-9024-73a0428c7c3a"
      unitRef="shares">404</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i84662a74a01c4b2d941452c7e6b5ee4a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMzQ3Ng_d436ca9d-5d3b-4c74-8391-e1fea5e6895d"
      unitRef="shares">1260000</us-gaap:InvestmentOwnedBalanceShares>
    <opk:SharesReceivedAsGift
      contextRef="i90446d4596a146d88429e4a98be0564f_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMzUyNg_d8b1c489-94f8-4e94-a103-2d006847c9d4"
      unitRef="shares">900000</opk:SharesReceivedAsGift>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="if6747d466c09424e9a50661e16dd7503_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182MS9mcmFnOmI5OGE5MzNhNDc4MDQ4M2JiNWI2MDhhYTFiOGViODcwL3RleHRyZWdpb246Yjk4YTkzM2E0NzgwNDgzYmI1YjYwOGFhMWI4ZWI4NzBfMzU4MA_c05acf9c-4f2b-45fa-860a-d8ef16b2c2e4"
      unitRef="number">0.29</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTY0NTA_78b96ca1-517c-4ab3-9428-7d0ef3c1fccf">DEBT&#160;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $100 million.  Borrowings under the line of credit will bear interest at a rate of 11% per annum and may be repaid and reborrowed at any time.  The credit agreement includes various customary remedies for the lender following an event of default, including the acceleration of repayment of outstanding amounts under line of credit.  The line of credit matures on February 25, 2025. The line of credit also calls for a commitment fee equal to 0.25% per annum of the unused portion of the line. As of June 30, 2020, no funds were borrowed under the line of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2019, we issued $200.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the &#x201c;2025 Notes&#x201d;) in an underwritten public offering.  The 2025 Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on February&#160;15 and August&#160;15 of each year.  The notes mature on February&#160;15, 2025, unless earlier repurchased, redeemed or converted.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Holders may convert their 2025 Notes into shares of Common Stock at their option at any time prior to the close of business on the business day immediately preceding November&#160;15, 2024 only under the following circumstances:  (1)&#160;during any calendar quarter commencing after the calendar quarter ended March&#160;31, 2019 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2)&#160;during the five business day period after any five consecutive trading day period (the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our Common Stock and the conversion rate on each such trading day; (3)&#160;if we call any or all of the 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4)&#160;upon the occurrence of specified corporate events set forth in the indenture governing the 2025 Notes.  On or after November&#160;15, 2024, until the close of business on the business day immediately preceding the maturity date, holders of the 2025 Notes may convert their notes at any time, regardless of the foregoing conditions.  Upon conversion, we will pay or deliver, as the case may be, cash, shares of our Common Stock, or a combination of cash and shares of our Common Stock, at our election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The initial and current conversion rate for the 2025 Notes is 236.7424 shares of Common Stock per $1,000 principal amount of 2025 Notes (equivalent to a conversion price of approximately $4.22 per share of Common Stock).  The conversion rate for the 2025 Notes is subject to adjustment in certain events, but will not be adjusted for any accrued and unpaid interest.  In addition, following certain corporate events that occur prior to the maturity date of the 2025 Notes or if we deliver a notice of redemption, in certain circumstances the indenture governing the 2025 Notes requires an increase in the conversion rate of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;2025 Notes for a holder who elects to convert its notes in connection with such a corporate event or notice of redemption, as the case may be.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We may not redeem the 2025 Notes prior to February&#160;15, 2022.  We may redeem for cash any or all of the 2025 Notes, at our option, on or after February&#160;15, 2022, if the last reported sale price of our Common Stock has been at least 130% of the then current conversion price for the notes for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide a notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.  No sinking fund is provided for the 2025 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If we undergo a fundamental change, as defined in the indenture governing the 2025 Notes, prior to the maturity date of the 2025 Notes, holders may require us to repurchase for cash all or any portion of their notes at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.  The 2025 Notes are our senior unsecured obligations and rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2025 Notes; equal in right of payment to any of our existing and future liabilities that are not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In conjunction with the issuance of the 2025 Notes, we agreed to loan up to 30,000,000 shares of our Common Stock to affiliates of the underwriter in order to assist investors in the 2025 Notes to hedge their position. As of&#160;June&#160;30, 2020, a total of&#160;29,250,000 shares were issued under the&#160;share lending&#160;arrangement. We will not receive any of the proceeds from the sale of the borrowed shares, but we received a one-time nominal fee of $0.3 million for the newly issued shares. Shares of our Common Stock outstanding under the&#160;share lending&#160;arrangement are excluded from the calculation of basic and diluted earnings per share. See Note 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As required by ASC 470-20, &#x201c;Debt with Conversion and Other Options,&#x201d; we calculated the equity component of the 2025 Notes, taking into account both the fair value of the conversion option and the fair value of the&#160;share lending arrangement. The equity component was valued at&#160;$52.6 million&#160;at issue date and this amount was recorded as Additional paid-in capital, which resulted in a discount on the 2025 Notes. The discount is being amortized to Interest expense over the term of the 2025 Notes, which results in an effective interest rate on the 2025 Notes of 11.2%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth information related to the 2025 Notes which is included in our Condensed Consolidated Balance Sheet as of June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.985%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Debt Issuance Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(46,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(43,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 8, 2018, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the aggregate principal amount of $60 million.  The credit agreement was terminated on or around February 20, 2019 and we repaid the $28.8 million outstanding thereunder from the proceeds of the 2025 Notes offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2018, we issued a series of 5% Convertible Promissory Notes (the &#x201c;2023 Convertible Notes&#x201d;) in the aggregate principal amount of $55.0 million.  The 2023 Convertible Notes mature five years following the date of issuance.  Each holder of a 2023 Convertible Note has the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock at a conversion price of $5.00 per share.  We may redeem all or any part of the then issued and outstanding 2023 Convertible Notes, together with accrued and unpaid interest thereon, pro rata among the holders, upon no fewer than 30 days, and no more than 60 days, notice to the holders.  The 2023 Convertible Notes contain customary events of default and representations and warranties of OPKO.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Purchasers of the 2023 Convertible Notes included an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2013, we entered into note purchase agreements with respect to the issuance and sale of our 3.0% Senior Notes due 2033 (the &#x201c;2033 Senior Notes&#x201d;) in a private placement exempt from registration under the Securities Act.  We issued the 2033 Senior Notes on January&#160;30, 2013.  The 2033 Senior Notes, which totaled $175.0 million in original principal amount, bear interest at the rate of 3.0%&#160;per year, payable semiannually on February&#160;1 and August&#160;1 of each year.  The 2033 Senior Notes mature on February&#160;1, 2033, unless earlier repurchased, redeemed or converted.  Upon a fundamental change, as defined in the indenture governing the 2033 Senior Notes, subject to certain exceptions, the holders may require us to repurchase all or any portion of their 2033 Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the 2033 Senior Notes being repurchased, plus any accrued and unpaid interest to, but not including, the related fundamental change repurchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From 2013 to 2016, holders of the 2033 Senior Notes converted $143.2 million in aggregate principal amount into an aggregate of 21,539,873 shares of Common Stock. On February 1, 2019, approximately $28.8 million aggregate principal amount of 2033 Senior Notes were tendered by holders pursuant to such holders&#x2019; option to require us to repurchase the 2033 Senior Notes as set forth in the indenture, following which repurchase only $3.0 million aggregate principal amount of the 2033 Senior Notes remained outstanding.  Holders of the remaining $3.0 million principal amount of the 2033 Senior Notes may require us to repurchase such notes for 100% of their principal amount, plus accrued and unpaid interest, on February 1, 2023, on February 1, 2028, or following the occurrence of a fundamental change as described above.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The terms of the 2033 Senior Notes, include, among others: (i) rights to convert the notes into shares of our Common Stock, including upon a fundamental change; and (ii) a coupon make-whole payment in the event of a conversion by the holders of the 2033 Senior Notes on or after February 1, 2017 but prior to February 1, 2019.  We determined that these specific terms were embedded derivatives.  Embedded derivatives are required to be separated from the host contract, the 2033 Senior Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument.  We concluded that the embedded derivatives within the 2033 Senior Notes met these criteria and, as such, were valued separate and apart from the 2033 Senior Notes and recorded at fair value each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For accounting and financial reporting purposes, we combined these embedded derivatives and valued them together as one unit of accounting. In 2017, certain terms of the embedded derivatives expired pursuant to the original agreement and the embedded derivatives no longer met the criteria to be separated from the host contract and, as a result, the embedded derivatives were no longer required to be valued separate and apart from the 2033 Senior Notes and were reclassified to additional paid in capital. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2015, BioReference and certain of its subsidiaries entered into a credit agreement with JPMorgan Chase Bank, N.A. (&#x201c;CB&#x201d;), as lender and administrative agent, as amended (the &#x201c;Credit Agreement&#x201d;).  The Credit Agreement provides for a $75.0 million secured revolving credit facility and includes a $20.0 million sub-facility for swingline loans and a $20.0 million sub-facility for the issuance of letters of credit. The Credit Agreement matures on November 5, 2021 and is guaranteed by all of BioReference&#x2019;s domestic subsidiaries.  The Credit Agreement is also secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference.  Availability under the Credit Agreement is based on a borrowing base composed of eligible accounts receivables of BioReference and certain of its subsidiaries, as specified therein.  As of June&#160;30, 2020, $15.3 million remained available for borrowing under the Credit Agreement. Principal under the Credit Agreement is due upon maturity on November 5, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At BioReference&#x2019;s option, borrowings under the Credit Agreement (other than swingline loans) will bear interest at (i) the CB floating rate (defined as the higher of (a) the prime rate and (b) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) for an interest period of one month plus 2.50%) plus an applicable margin of 0.35% for the first 12 months and 0.50% thereafter or (ii) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) plus an applicable margin of 1.35% for the first 12 months and 1.50% thereafter.  Swingline loans will bear interest at the CB floating rate plus the applicable margin.  The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee of 0.25% of the lending commitments.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On February 25, 2020, BioReference and certain of its subsidiaries entered into Amendment No. 11 to the Credit Agreement, which amended the Credit Agreement to provide that the fixed charge coverage ratio requirement set forth in the Credit Agreement would not be tested for the quarter ended December 31, 2019, with respect to availability calculated on January 29, 2020 and January 30, 2020, subject, in the case of testing for the quarter ended December 31, 2019, to (i) there having been no event of default occurring and (ii) availability under the revolving facility exceeding 10% of the total revolving commitment, for at least 30 consecutive days for the period ended December 31, 2019, excluding December 18, 2019. The other terms of the Credit Agreement remain unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of June 30, 2020, $51.5 million outstanding under the Credit Agreement was included within Other long-term liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Credit Agreement contains customary covenants and restrictions, including, without limitation, covenants that require BioReference and its subsidiaries to maintain a minimum fixed charge coverage ratio if availability under the new credit facility falls below a specified amount and to comply with laws and restrictions on the ability of BioReference and its subsidiaries to incur additional indebtedness or to pay dividends and make certain other distributions to the Company, subject to certain exceptions as specified therein.  Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of BioReference to meet its debt service obligations.  The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement and execution upon the collateral securing obligations under the Credit Agreement.  Substantially all the assets of BioReference and its subsidiaries are restricted from sale, transfer, lease, disposal or distributions to the Company, subject to certain exceptions. As of June&#160;30, 2020, BioReference and its subsidiaries had net assets of approximately $913.2 million, which included goodwill of $434.8 million and intangible assets of $345.9 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to the Credit Agreement with CB, we had line of credit agreements with eleven other financial institutions as of both June&#160;30, 2020 and December&#160;31, 2019 in the U.S., Chile and Spain.  These lines of credit are used primarily as a source of working capital for inventory purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.675%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.096%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.096%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.096%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.101%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(Dollars in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Balance Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lender&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest&#160;rate&#160;on&lt;br/&gt;borrowings at &lt;br/&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Credit&#160;line&lt;br/&gt;capacity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;JPMorgan Chase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.67%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Itau Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Bank of Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;BICE Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;BBVA Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Security Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estado Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Santander Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Scotiabank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corpbanca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Banco De Sabadell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Banco Bilbao Vizcaya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Banco Santander&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;52,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At June&#160;30, 2020 and December&#160;31, 2019, the weighted average interest rate on our lines of credit was approximately 4.2% and 4.0%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At June&#160;30, 2020 and December&#160;31, 2019, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the Credit Agreement and amounts outstanding under lines of credit described above) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.263%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.501%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.503%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The notes and other debt mature at various dates ranging from 2020 through 2024, bearing variable interest rates from 0.7% up to 3.8%.  The weighted average interest rate on the notes and other debt was 2.6% and 2.7% on June&#160;30, 2020 and December&#160;31, 2019. The notes are partially secured by our office space in Barcelona.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7f02e4f9fd574e05a785e3c62f223eb4_I20200225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMjEw_f3e01ee0-f303-4df8-9f2b-7e5980d0982f"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7f02e4f9fd574e05a785e3c62f223eb4_I20200225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMjgz_9ec6b80c-adb4-431b-b1cf-8b1c8ece123b"
      unitRef="number">0.11</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i7c119d6e22ac4137a2e112127278f9af_D20200225-20200225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNjQx_d8a00a10-2f84-4392-82c8-5cd2f0e85a7f"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8195e9a3e7ae435da153c7711a07ccb8_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzg4_d706506a-696e-409e-b6f5-94cf2af40ed5"
      unitRef="usd">200000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i628701cad23a4cacaed112b486d72676_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTUz_6a674beb-1e43-4b60-8943-f97f0a94237e"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i3d0c8459b0d1480baa745356d20f4dc6_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU1Ng_615631b4-2768-44c6-993c-79b8b8adde84"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i9c0022ff1fff4fa7ba8b28cb480d9e7b_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTYyMA_90288559-4ad3-4f45-8ce7-55fcd8b22bee"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i7c71fc44fe84471c8a385354d7db5b4d_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTc1Mw_cd02f455-b200-4290-be48-1780b841df1f"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i888c9ebcddbc498c8ab5222fdd77b5af_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTgyNw_0756921b-a287-4ee5-8dcc-86a6932de2a6"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i81c329c54b3b47abb5e4773dc4152952_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTg2MA_efd9a04b-c91e-4ab0-aa6b-7139acb09000"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i34d8ef11ad99488aa65782d224ee68dd_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMjA1MQ_ad998d88-b18e-4a47-a327-9881255ec9ff"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i8195e9a3e7ae435da153c7711a07ccb8_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMzAyNw_866494b6-f879-44ac-9018-165e49bb0056"
      unitRef="usdPerShare">4.22</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ifd9c15a8bce54e078a65dfcda71e2b93_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMzgzOQ_a2b25524-ea99-40d0-b114-5cd835057688"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ib386889486af4a37ada3615b1c1421e7_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMzkwNg_d8e1e497-519b-47a3-9b34-f97acdc61ba3"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="id8a7a241ec2b494485438af91f368462_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMzk2Mg_229708ca-6f75-4e4d-a3c0-1954780010c7"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ifd9c15a8bce54e078a65dfcda71e2b93_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNDE5MQ_a4fb6789-de71-4e13-97ed-2381adc8a764"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i7c71fc44fe84471c8a385354d7db5b4d_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNDYxNg_6315f2d0-cb21-4bbd-9634-111ce7692258"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <opk:DebtInstrumentConvertibleDebtMaximumSharesIssuable
      contextRef="i8195e9a3e7ae435da153c7711a07ccb8_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNTQwNg_249f0d1c-9661-4a61-8292-f67ba64b2855"
      unitRef="shares">30000000</opk:DebtInstrumentConvertibleDebtMaximumSharesIssuable>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i870ca847a91146ff97990a7c7cdd8e63_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNTU2Mg_22403393-0a7d-43d0-90de-154b67ac5dc4"
      unitRef="shares">29250000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <opk:ProceedsFromConvertibleDebtConversionFee
      contextRef="i870ca847a91146ff97990a7c7cdd8e63_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNTc0MQ_de1b9393-df34-47cc-80c8-2722a855ebef"
      unitRef="usd">300000</opk:ProceedsFromConvertibleDebtConversionFee>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i8195e9a3e7ae435da153c7711a07ccb8_I20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNjIxMQ_e426c05a-ce44-4089-8e4e-870b5fdb7ee0"
      unitRef="usd">52600000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8d2d51166e124a23a7ecda07a40b9b8c_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNjQ4Ng_6d530c43-d749-45ba-bf53-75046fb4c3ad"
      unitRef="number">0.112</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTY0NjI_6dd8a311-5fb2-49e6-9926-9e058df53b21">&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth information related to the 2025 Notes which is included in our Condensed Consolidated Balance Sheet as of June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.985%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Debt Issuance Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(46,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(43,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At June&#160;30, 2020 and December&#160;31, 2019, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the Credit Agreement and amounts outstanding under lines of credit described above) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.263%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.501%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.503%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if6c32717a26d40d88eae1ea4982913d6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMS0xLTEtMS0w_8b1a6957-faa1-479c-9df1-efece6b3f253"
      unitRef="usd">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="if6c32717a26d40d88eae1ea4982913d6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMS0zLTEtMS0w_6e85e988-21f1-4549-91ce-61207643b63d"
      unitRef="usd">46774000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if6c32717a26d40d88eae1ea4982913d6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMS01LTEtMS0w_38dca37b-a985-4a55-b074-f64d7a5d297e"
      unitRef="usd">5086000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="if6c32717a26d40d88eae1ea4982913d6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMS03LTEtMS0w_569ee474-f0ae-4cf8-a542-83a3b099d2d6"
      unitRef="usd">148140000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i8a737d9667b94ccdbd7e9b723c6dcf66_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMy0zLTEtMS0w_c8ee39f1-6247-4015-ba93-04c529865371"
      unitRef="usd">3497000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i8a737d9667b94ccdbd7e9b723c6dcf66_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMy01LTEtMS0w_b8b81cf9-195b-410f-8dea-73c288a7ec97"
      unitRef="usd">381000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i8a737d9667b94ccdbd7e9b723c6dcf66_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfMy03LTEtMS0w_1cd769cf-ea5b-4795-8cac-7773f0615d89"
      unitRef="usd">3878000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8c8df4da0e504a6a9b34701d6f7d3cd7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfNS0xLTEtMS0w_ce470814-9df7-4ebc-96cc-1eea9ad51e95"
      unitRef="usd">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i8c8df4da0e504a6a9b34701d6f7d3cd7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfNS0zLTEtMS0w_29fb4f6f-826f-433e-8a18-e91fa8778e98"
      unitRef="usd">43277000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i8c8df4da0e504a6a9b34701d6f7d3cd7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfNS01LTEtMS0w_145b35d2-f13e-4309-9562-99c31954de72"
      unitRef="usd">4705000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i8c8df4da0e504a6a9b34701d6f7d3cd7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjMxNzA0NmU4ZWM1ZDQxY2ZhYWNmN2ZjOGQ0MjkxZTAyL3RhYmxlcmFuZ2U6MzE3MDQ2ZThlYzVkNDFjZmFhY2Y3ZmM4ZDQyOTFlMDJfNS03LTEtMS0w_fafb82f2-9f26-4437-a848-f8a6d7af1465"
      unitRef="usd">152018000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i45d70386f33c4ae487d8d292158b179c_I20181108"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNjg0NA_86b15262-04e2-46cf-a133-1598c8ffc9f1"
      unitRef="usd">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i268d6c6d9d5e407ea296ba2214d356e1_D20190220-20190220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNjkzNA_c03ce600-a600-4a06-96d8-24b60c8775d9"
      unitRef="usd">28800000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iac1e5f5cb1464cb9905c5e33a1c7fede_I20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzA0Nw_2dd9e151-debd-4d1d-a3de-1694b8c83a96"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iac1e5f5cb1464cb9905c5e33a1c7fede_I20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzE0Nw_595ea9d6-1f8d-4bb7-babf-510e1af84071"
      unitRef="usd">55000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i41911bac43624dd190e89f282a2ee86a_D20180201-20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMjE5OTAyMzI3MjA2NA_2573cbed-50fc-42f1-9008-dfe70089267f">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="iac1e5f5cb1464cb9905c5e33a1c7fede_I20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzUxMA_879029f9-80b0-45d4-90f2-f6baead8ca79"
      unitRef="usdPerShare">5.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <opk:DebtInstrumentConvertibleConversionNoticeThresholdMinimum
      contextRef="i41911bac43624dd190e89f282a2ee86a_D20180201-20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzcxMg_810e8530-e616-4704-acf4-13a225abe2a4">P30D</opk:DebtInstrumentConvertibleConversionNoticeThresholdMinimum>
    <opk:DebtInstrumentConvertibleConversionNoticeThresholdMaximum
      contextRef="i41911bac43624dd190e89f282a2ee86a_D20180201-20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfNzczOA_07cfcaf9-81e0-4895-9828-248c12e51096">P60D</opk:DebtInstrumentConvertibleConversionNoticeThresholdMaximum>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i640328d25f104a07a644f3c84408a24d_I20130130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfODE5OQ_96ecc9c4-7733-4476-8750-042df8e26d0a"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i640328d25f104a07a644f3c84408a24d_I20130130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfODQxNg_ed7cdb63-0c2b-458f-a4e1-764ff2da672b"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i640328d25f104a07a644f3c84408a24d_I20130130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfODQ3OA_8956db83-a951-45a2-b491-e3205905d33e"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i612e5c755b184a3585408a4ff760d866_D20130130-20130130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfODkwMg_334a9365-e82c-47a2-a640-170eea0b4f54"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i4631f4b114e54a1fbc1288a82a9c2663_D20130101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTE0Mw_861ad359-439c-4fb5-9a2e-5c5b3a26653b"
      unitRef="usd">143200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i21d898ee3d254a1aa7701dbf13c49fa2_D20130101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTE5Nw_62642ba8-290a-4810-9dcd-87906c3af3a8"
      unitRef="shares">21539873</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i3d496a3b69364f4b9c89244789d4e32d_I20190201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTI1OQ_200b6c6e-379b-485d-9a03-5858f6db2be7"
      unitRef="usd">28800000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:LongTermDebt
      contextRef="i3d496a3b69364f4b9c89244789d4e32d_I20190201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTQ4MQ_c24d85e8-9073-4ddf-821e-ebedbece9b11"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3d496a3b69364f4b9c89244789d4e32d_I20190201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTU4NA_1120650d-3eff-4481-b57e-879e573ee390"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ie7f7c5a48e684b00b4e6a9dad87deb6f_D20130101-20130131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfOTY3Mw_31ae1d5e-255c-4672-8394-76e2414a2acc"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6e81f5b8d06047b19aa7e48cbf98af16_I20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTE2MDk_f64de7e2-887d-4e9e-83d5-42737edae46a"
      unitRef="usd">75000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i743fcf96590e44c695952271c01375ce_I20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTE2NjE_b519a662-9508-435a-9d5d-efc7c62ac9ba"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9fbb22c04f364ad5afd2e52f45a360e6_I20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTE3MDM_a86a0f25-b186-460c-916f-a35eadffb0d5"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="ie499e8a5b1e1470ab749b6aa2325157c_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTIyNTk_436e3e95-8328-49f1-84a8-83c54e2fe05e"
      unitRef="usd">15300000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie73fdab1754844eeac2a5f34832d8a31_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTI3Mjc_20ee8a0d-6e3a-4afe-a8e1-8d38b791be80"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4a682eabf2f34c8a9917e7ba7e3c88ff_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTI3NjA_98c9e4c8-a311-4176-ac41-8a4b5e511aa6"
      unitRef="number">0.0035</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3d6e118592a94347b7f4c1050e6a8489_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTI3OTE_1e87627d-9bd9-4031-817b-f6fea624f463"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie9339ecd27304a0184566aff4167b7d7_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTI5MzI_16ba851b-ce1a-448e-862d-72749798b151"
      unitRef="number">0.0135</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i034c1dc338af428faed94254148230d8_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTI5NjM_f7a6d31d-f270-4f05-a17a-3233456e5357"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i24807c0e885b473087a1ad68767cb2f9_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTMxNzU_33ad8e7f-c6c3-4b97-840d-fa6d8317f3ca"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <opk:LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage
      contextRef="i047b3aa3c79c430db33cc3494843fe01_D20191001-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTM3OTI_f0f69783-b737-465f-8de3-686f4db58424"
      unitRef="number">0.10</opk:LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage>
    <opk:LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays
      contextRef="idd1f11282fee4ec6b1d277f48503edb2_D20191001-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTM4NDM_9a3e2040-7d5b-4eca-8db9-6ffb7422384d">P30D</opk:LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays>
    <us-gaap:LongTermLineOfCredit
      contextRef="ie499e8a5b1e1470ab749b6aa2325157c_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTQwMTQ_ddee10df-ef50-43d3-a111-e7877588d9f4"
      unitRef="usd">51500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:StockholdersEquity
      contextRef="i764a079c978a4ea0b66bc026841d4844_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTUzNzA_f81c89c9-327d-4240-b874-147cf209ae41"
      unitRef="usd">913200000</us-gaap:StockholdersEquity>
    <us-gaap:Goodwill
      contextRef="i764a079c978a4ea0b66bc026841d4844_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU0MDE_287b5b79-c2a2-48b6-bc62-330b3d6da7b0"
      unitRef="usd">434800000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i764a079c978a4ea0b66bc026841d4844_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU0Mjk_49370c12-7c3b-41d1-93ea-8adb54d7e664"
      unitRef="usd">345900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <opk:DebtInstrumentsNumberofFinancialInstitutions
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU1MTY_2c94def4-3e0d-4943-88a9-2800061dc1a1"
      unitRef="institution">11</opk:DebtInstrumentsNumberofFinancialInstitutions>
    <opk:DebtInstrumentsNumberofFinancialInstitutions
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU1MTY_38cb1654-5045-4841-ad6e-340c43252666"
      unitRef="institution">11</opk:DebtInstrumentsNumberofFinancialInstitutions>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTY0NjQ_bb2157f6-3d2b-4615-873a-254b3bd58439">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.675%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.096%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.096%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.096%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.101%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(Dollars in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Balance Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lender&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest&#160;rate&#160;on&lt;br/&gt;borrowings at &lt;br/&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Credit&#160;line&lt;br/&gt;capacity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;JPMorgan Chase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.67%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Itau Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Bank of Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;BICE Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;BBVA Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Security Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estado Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Santander Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Scotiabank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corpbanca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Banco De Sabadell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Banco Bilbao Vizcaya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Banco Santander&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;52,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i8dbeb3eb23de47a1b6f04ae8eeb9574b_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMi0yLTEtMS0w_c025e021-dd28-48b1-8014-b4139e6fcf21"
      unitRef="number">0.0367</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8dbeb3eb23de47a1b6f04ae8eeb9574b_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMi00LTEtMS0w_1224e89a-8c36-4820-bdbb-d7f6cffe0f10"
      unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i8dbeb3eb23de47a1b6f04ae8eeb9574b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMi02LTEtMS0w_4baee7fc-9dcb-4623-85cf-c589cd214977"
      unitRef="usd">51489000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ifc44f46b59e54e81a86a9fb4fb093caf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMi04LTEtMS0w_69a0d46f-f214-4c67-9db9-94eb07ce876e"
      unitRef="usd">44750000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i6559fae108574d0aa1c9714fb3e24788_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMy0yLTEtMS0w_5fb21f8d-5a8f-4896-9c16-962f989560df"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6559fae108574d0aa1c9714fb3e24788_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMy00LTEtMS0w_5ded93cb-f5cc-4939-adc0-8487270cd5c5"
      unitRef="usd">1810000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i6559fae108574d0aa1c9714fb3e24788_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMy02LTEtMS0w_63a51379-7552-4aa2-841f-e3d447951e3a"
      unitRef="usd">530000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ib8b5e2d07aba47b7a77c8a56814325cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMy04LTEtMS0w_54f4c291-d8a4-4570-9ab3-7e52c0725584"
      unitRef="usd">472000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i48c73acda48c4111a5af1047ccf8cc87_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNC0yLTEtMS0w_76eae41f-b283-48a2-916e-3816b8d0416d"
      unitRef="number">0.0660</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i48c73acda48c4111a5af1047ccf8cc87_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNC00LTEtMS0w_211ad0c5-588e-492e-84b2-e04fdf0b2ad0"
      unitRef="usd">3800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i48c73acda48c4111a5af1047ccf8cc87_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNC02LTEtMS0w_ce80aa98-cb0f-4769-af1e-d4f41fb33445"
      unitRef="usd">865000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i779d609c655f49bd9d3e70d6c46b21fe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNC04LTEtMS0w_6a8e89e3-8966-4903-ac7f-a0f901991757"
      unitRef="usd">851000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i76e8733ec84b470fb842fdfb15d41f7c_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNS0yLTEtMS0w_4af42e52-3970-4855-a6ad-94a593fcd151"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i76e8733ec84b470fb842fdfb15d41f7c_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNS00LTEtMS0w_0e59535a-492c-4ba5-90a2-c20994f834e2"
      unitRef="usd">2500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i76e8733ec84b470fb842fdfb15d41f7c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNS02LTEtMS0w_672df65e-7f24-439f-ab9e-a5e8ecbf85f1"
      unitRef="usd">1019000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i10ec51989518476483634a001fbac0a7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNS04LTEtMS0w_80e02f6b-3028-4d33-bbc9-82270eb6c4fc"
      unitRef="usd">1429000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="icee7b550c55b456e9633769b30d100c7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNi0yLTEtMS0w_57c4bf9a-8c8d-49f8-9511-885ad8252777"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icee7b550c55b456e9633769b30d100c7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNi00LTEtMS0w_90eada39-4015-4e63-be96-68b54a2650e7"
      unitRef="usd">3250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="icee7b550c55b456e9633769b30d100c7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNi02LTEtMS0w_72b25906-ddae-455a-87f5-f9fc9b065f92"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ia45c0ca28d4645e1bf8bb43d0dd8fabe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNi04LTEtMS0w_259a4ac6-f985-4c0f-8a1e-f33b36024237"
      unitRef="usd">11000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="ide21bf3a408f483c9f82c34a363accc8_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNy0yLTEtMS0w_2ca5763c-a95e-433b-b3ec-8b860b58fe4e"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ide21bf3a408f483c9f82c34a363accc8_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNy00LTEtMS0w_ed1db3e5-6939-4da7-8ab1-aa33c5bcda53"
      unitRef="usd">0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="ide21bf3a408f483c9f82c34a363accc8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNy02LTEtMS0w_2e6c1cae-c3bb-4fc2-a06b-e093b13e6831"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i63a721c51927453b93d7de9c83a24c60_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfNy04LTEtMS0w_abb862a9-40c9-403c-b707-cee79d199191"
      unitRef="usd">588000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i3c7a5f9bb26d4ad3b5047c54208133b5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOC0yLTEtMS0w_606e5b75-2f01-4b93-84e3-de3693f474a8"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3c7a5f9bb26d4ad3b5047c54208133b5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOC00LTEtMS0w_797a8e53-c684-4160-8166-cbc38fa5f0d6"
      unitRef="usd">3500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i3c7a5f9bb26d4ad3b5047c54208133b5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOC02LTEtMS0w_29537078-9544-498d-8490-e8fd8f831dec"
      unitRef="usd">1974000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i2f8f740cc35344458b1021626127aa9e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOC04LTEtMS0w_9e65345b-885c-4f34-a7c7-b5a683987600"
      unitRef="usd">1365000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i3ae1a5c41df24314a8823e0cba821c20_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOS0yLTEtMS0w_bb225838-ecca-4c9d-93a9-ae75ae997436"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3ae1a5c41df24314a8823e0cba821c20_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOS00LTEtMS0w_3c0c3569-d408-4952-ac52-0f4b4b4f4ce2"
      unitRef="usd">4500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i3ae1a5c41df24314a8823e0cba821c20_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOS02LTEtMS0w_1a96b3b5-2199-4512-aa8c-ad0577204e88"
      unitRef="usd">2648000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i57693f69122442efb5a7d809f56b6b3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfOS04LTEtMS0w_123d9caf-a699-4991-9fcb-e420b4a5e34e"
      unitRef="usd">1943000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="id04e2700b7f6495590aab83734460c88_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTAtMi0xLTEtMA_a9a01dde-5081-4210-9b44-a4c380855927"
      unitRef="number">0.0500</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id04e2700b7f6495590aab83734460c88_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTAtNC0xLTEtMA_98336b87-e466-4442-b983-1148a1dbf9ec"
      unitRef="usd">1800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="id04e2700b7f6495590aab83734460c88_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTAtNi0xLTEtMA_1887fc7b-bfcf-417d-9efb-cabd17c03669"
      unitRef="usd">1095000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i9c490f5f8dd9456c9a903914580ff1b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTAtOC0xLTEtMA_5a32b681-9266-4699-a561-1075055b9b26"
      unitRef="usd">668000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="ic0c00ea5e5ee42868078230022479853_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTEtMi0xLTEtMA_5cd63307-8c93-4f1a-a661-60fa22b30bd7"
      unitRef="number">0.0500</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic0c00ea5e5ee42868078230022479853_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTEtNC0xLTEtMA_421cc1e3-b8e0-4ca5-8a13-036d0b40d88d"
      unitRef="usd">3917000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="ic0c00ea5e5ee42868078230022479853_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTEtNi0xLTEtMA_40c1b689-b28b-4f91-a86b-ce04b986fa08"
      unitRef="usd">3917000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="iac4d242acca94e6b92d84518bdbd23d7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTEtOC0xLTEtMA_768ad890-5341-47ea-a4ab-b8598c6eadec"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i846f414c67b44a778a4b2f8c9669725b_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTItMi0xLTEtMA_b9e347fb-f4f9-4d0f-8993-3144c9f26955"
      unitRef="number">0.0130</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i846f414c67b44a778a4b2f8c9669725b_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTItNC0xLTEtMA_c624c8f4-6557-4d9d-9585-33d3f858add2"
      unitRef="usd">337000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i846f414c67b44a778a4b2f8c9669725b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTItNi0xLTEtMA_500321ea-5758-4fb7-840e-ef89688a1659"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="id0b422715f43443c9f03f43e7a9abfff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTItOC0xLTEtMA_e3995dee-d966-43d3-9035-dc399a84f585"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="id96b2ea0a8c14dadb89a084344dce841_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTMtMi0xLTEtMA_33d63ae3-6a85-4da7-8576-e929c54afa60"
      unitRef="number">0.0170</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id96b2ea0a8c14dadb89a084344dce841_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTMtNC0xLTEtMA_c28a94ad-a4bc-4eb4-9515-d4abdeb12b14"
      unitRef="usd">337000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="id96b2ea0a8c14dadb89a084344dce841_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTMtNi0xLTEtMA_af02964b-2f2f-4386-b564-aa60587b3b9f"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i6906c76a48dc48c48a3dfb34cdf030b1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTMtOC0xLTEtMA_085ef4b8-2bae-48d9-8e9f-438cf8757b54"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="ic444558faa604456a69c0ea677b33c92_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTQtMi0xLTEtMA_dc148102-65d9-4604-a582-7a3924d7c425"
      unitRef="number">0.0182</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic444558faa604456a69c0ea677b33c92_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTQtNC0xLTEtMA_d05e18b2-259d-4014-aa9c-c21cd151d089"
      unitRef="usd">561000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="ic444558faa604456a69c0ea677b33c92_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTQtNi0xLTEtMA_8900a97c-8722-47ae-83d9-4da764638f9c"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i83f9b1ef620641e998c7c8c1895e255a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTQtOC0xLTEtMA_640e4a61-ea20-4dc0-b43a-1d7a1759e88d"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTUtNC0xLTEtMA_6b5a494c-5cfb-466c-b54b-db524ca87876"
      unitRef="usd">101312000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTUtNi0xLTEtMA_32235ca2-d31b-4da2-869d-fdade49f9589"
      unitRef="usd">63537000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjFlYWJkOGJiNTE4ZjRiODg4MzJmYmM0ZmE1YjNiZDllL3RhYmxlcmFuZ2U6MWVhYmQ4YmI1MThmNGI4ODgzMmZiYzRmYTViM2JkOWVfMTUtOC0xLTEtMA_0e1ad276-640e-415a-8c02-19c2996ea3af"
      unitRef="usd">52077000</us-gaap:LineOfCredit>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="id8a9e82eefe34a719b632c3dd6b4c0bb_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU5MDU_11340d07-0e74-467c-bf17-66d0d77a8690"
      unitRef="number">0.042</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i05425f68234a4c09943873aa2d16cc00_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTU5MTI_7a18561c-559f-49d7-9d24-8e3e79ee6780"
      unitRef="number">0.040</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:LongTermDebtCurrent
      contextRef="i95fecc4a436340768768e918eea21ff8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMS0xLTEtMS0w_ccbd5f2c-4316-417d-a5fa-df9571fe867a"
      unitRef="usd">2415000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="icf8f60d813964c65a753ded4929b4ce1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMS0zLTEtMS0w_dfa7ca13-4615-42ba-aa8e-b6c2ce6a0a68"
      unitRef="usd">2494000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i95fecc4a436340768768e918eea21ff8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMi0xLTEtMS0w_6a6ab215-47d4-4827-b602-71461da98187"
      unitRef="usd">4936000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icf8f60d813964c65a753ded4929b4ce1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMi0zLTEtMS0w_6463b916-01b6-4fdf-91e6-bd484a3b5315"
      unitRef="usd">4723000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="i95fecc4a436340768768e918eea21ff8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMy0xLTEtMS0w_903fab77-a3df-4f3a-8683-02d6373d1a06"
      unitRef="usd">7351000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icf8f60d813964c65a753ded4929b4ce1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RhYmxlOjk3YTdlYzk5M2QxOTQ5OGFhZGIyMjFhZDRiYTI5Y2MyL3RhYmxlcmFuZ2U6OTdhN2VjOTkzZDE5NDk4YWFkYjIyMWFkNGJhMjljYzJfMy0zLTEtMS0w_83274e5c-a6e6-4cf0-9589-82a4d0df7ca6"
      unitRef="usd">7217000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="ifbc9ba99b84443e38237727e48a82f23_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTYyNzA_ef9938b3-48c2-4d76-9b8b-45e9e70ebdcf"
      unitRef="number">0.007</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="i9b21a3e7a57d4609b0d409b6ba20c32c_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTYyNzk_e568f2e1-7d51-498f-8775-c289e169d14d"
      unitRef="number">0.038</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i45a19ae7054d4411b573ae861b1aadf1_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTYzNTI_23c88cae-10d5-4166-b65d-5af1ea7e56d3"
      unitRef="number">0.026</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ib6281d7b057a416cab5bb28eeef12716_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM182NC9mcmFnOjUwOTEyMmZkOTAxMjQzYjZiM2JmZWJkOGFiZGYxM2U1L3RleHRyZWdpb246NTA5MTIyZmQ5MDEyNDNiNmIzYmZlYmQ4YWJkZjEzZTVfMTYzNTI_564140af-02aa-484c-a629-48942bdd637a"
      unitRef="number">0.026</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183MC9mcmFnOjIzZTM3YzdjMWVlYTQ4MTVhOWM0MmEyOGM3MTI2MzhlL3RleHRyZWdpb246MjNlMzdjN2MxZWVhNDgxNWE5YzQyYTI4YzcxMjYzOGVfMTY0_cea5b9e6-fbea-4435-8a03-1494d2e551f9">ACCUMULATED OTHER COMPREHENSIVE LOSS&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the six months ended June 30, 2020, changes in Accumulated other comprehensive loss, net of tax, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.530%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.470%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:20.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183MC9mcmFnOjIzZTM3YzdjMWVlYTQ4MTVhOWM0MmEyOGM3MTI2MzhlL3RleHRyZWdpb246MjNlMzdjN2MxZWVhNDgxNWE5YzQyYTI4YzcxMjYzOGVfMTcw_bb9294b2-e89e-421f-8ae0-3e9c7ef1ebe6">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the six months ended June 30, 2020, changes in Accumulated other comprehensive loss, net of tax, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.530%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.470%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:20.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i350765d31f054cb4a900a05635ea70c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183MC9mcmFnOjIzZTM3YzdjMWVlYTQ4MTVhOWM0MmEyOGM3MTI2MzhlL3RhYmxlOmY3MDE3ZDkzOWZkMzQ2NTJhYzVmNTk3ZjE5OTFjMWM3L3RhYmxlcmFuZ2U6ZjcwMTdkOTM5ZmQzNDY1MmFjNWY1OTdmMTk5MWMxYzdfMS0xLTEtMS0w_eaa32baf-2c6c-47f9-8e58-b9f5f4122795"
      unitRef="usd">-22070000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="idef84b903bff4b0ea60e0666075a8447_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183MC9mcmFnOjIzZTM3YzdjMWVlYTQ4MTVhOWM0MmEyOGM3MTI2MzhlL3RhYmxlOmY3MDE3ZDkzOWZkMzQ2NTJhYzVmNTk3ZjE5OTFjMWM3L3RhYmxlcmFuZ2U6ZjcwMTdkOTM5ZmQzNDY1MmFjNWY1OTdmMTk5MWMxYzdfMi0xLTEtMS0w_8f86d5c0-da60-4168-8657-a55992906cc3"
      unitRef="usd">-3682000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c611772672a47c8984d0140e9dff6e2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183MC9mcmFnOjIzZTM3YzdjMWVlYTQ4MTVhOWM0MmEyOGM3MTI2MzhlL3RhYmxlOmY3MDE3ZDkzOWZkMzQ2NTJhYzVmNTk3ZjE5OTFjMWM3L3RhYmxlcmFuZ2U6ZjcwMTdkOTM5ZmQzNDY1MmFjNWY1OTdmMTk5MWMxYzdfNS0xLTEtMS0w_5ef8243e-5a7f-488d-aebd-b0f1165b364f"
      unitRef="usd">-25752000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjc3Mw_12301279-a664-413d-98f2-f1444daafdfd">FAIR VALUE MEASUREMENTS&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We record fair values at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.  We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, we had equity securities (refer to Note 5), forward foreign currency exchange contracts for inventory purchases (refer to Note 9) and contingent consideration related to the acquisitions of CURNA, OPKO Diagnostics and OPKO Renal that are required to be measured at fair value on a recurring basis.  In addition, in connection with our investment and our consulting agreement with BioCardia, we record the related BioCardia options at fair value as well as the warrants from COCP, InCellDx, Xenetic and Phio.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our financial assets and liabilities measured at fair value on a recurring basis are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value measurements as of June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&lt;br/&gt;prices in&lt;br/&gt;active&lt;br/&gt;markets for&lt;br/&gt;identical&lt;br/&gt;assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value measurements as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&lt;br/&gt;prices in&lt;br/&gt;active&lt;br/&gt;markets for&lt;br/&gt;identical&lt;br/&gt;assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There have been no transfers between Level 1 and Level 2 and no transfers to or from Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020 and December&#160;31, 2019, the carrying value of our other financial instrument assets approximates their fair value due to their short-term nature or variable rate of interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.498%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent&lt;br/&gt;consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Included in results of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The estimated fair values of our financial instruments have been determined by using available market information and what we believe to be appropriate valuation methodologies.  We use the following methods and assumptions in estimating fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Contingent consideration&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2013; We estimate the fair value of the contingent consideration utilizing a discounted cash flow model for the expected payments based on estimated timing and expected revenues.  We use several discount rates depending on each type of contingent consideration related to OPKO Diagnostics, CURNA and OPKO Renal transactions. As of June&#160;30, 2020, of the $9.9 million of contingent consideration, $2.4 million was recorded in Accrued expenses and $7.6 million was recorded in Other long-term liabilities.  As of December&#160;31, 2019, of the $9.7 million of contingent consideration, $2.4 million was recorded in Accrued expenses and $7.3 million was recorded in Other long-term liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjc1Mg_a0bcb422-184c-4c92-bc49-ba048b328e8e">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our financial assets and liabilities measured at fair value on a recurring basis are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value measurements as of June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&lt;br/&gt;prices in&lt;br/&gt;active&lt;br/&gt;markets for&lt;br/&gt;identical&lt;br/&gt;assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value measurements as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&lt;br/&gt;prices in&lt;br/&gt;active&lt;br/&gt;markets for&lt;br/&gt;identical&lt;br/&gt;assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNS0xLTEtMS0w_bea683b7-ef39-4d96-a07f-a733a9ef4383"
      unitRef="usd">24777000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic564593128ce4e4b84460058baeb14cf_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNS0zLTEtMS0w_59838927-3bde-4550-972f-17e26f7d9c15"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i531ede9f4ddd48268654c99511a06679_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNS01LTEtMS0w_45ce8db4-64df-426f-82a1-7175964556b9"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNS03LTEtMS0w_f312f1f7-5be7-498a-afcf-417846709f8d"
      unitRef="usd">24777000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNi0xLTEtMS0w_c06f03db-fdec-4f9c-b985-5398096fb7fa"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic564593128ce4e4b84460058baeb14cf_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNi0zLTEtMS0w_3d60bd80-6299-4efe-a11e-5647730ec877"
      unitRef="usd">51000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i531ede9f4ddd48268654c99511a06679_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNi01LTEtMS0w_4eb16e7f-59b9-46a0-82f4-38af07ffb8ec"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNi03LTEtMS0w_cabc4e03-3fd1-411e-ac65-4b857339fc24"
      unitRef="usd">51000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssets
      contextRef="i432215f275164d1b94ffc495a44a8c93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNy0xLTEtMS0w_bb5eb861-78f9-44e0-acf4-6af9bbacbde9"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2ff069d8c2354606be4fd434fa345d89_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNy0zLTEtMS0w_6d508376-3832-4b9a-b89e-e38ecc75d1ff"
      unitRef="usd">215000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if458b89b3f2b4390bb62734646f1a224_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNy01LTEtMS0w_7af85c2f-3cc5-44fd-86b3-ac434568a1d7"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ic8c6bc5e253b4fe2a84e3f5d4fb9d30e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfNy03LTEtMS0w_ee1578ad-c0f5-472f-8aea-c92d6e19b271"
      unitRef="usd">215000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfOC0xLTEtMS0w_257c4f7b-3012-446f-a515-73e3d52d0102"
      unitRef="usd">24777000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic564593128ce4e4b84460058baeb14cf_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfOC0zLTEtMS0w_c612675f-c27e-476b-9249-fe7a9fb96c5d"
      unitRef="usd">266000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i531ede9f4ddd48268654c99511a06679_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfOC01LTEtMS0w_5d5083c6-af43-41f5-b641-24bad94fe083"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfOC03LTEtMS0w_fa6198c4-da79-4982-a614-ade9941942c3"
      unitRef="usd">25043000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTMtMS0xLTEtMA_f68e28e1-5167-4553-9b57-9fabb8f4dc3c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic564593128ce4e4b84460058baeb14cf_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTMtMy0xLTEtMA_185e4171-49cb-419f-b144-20e40158ef4f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i531ede9f4ddd48268654c99511a06679_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTMtNS0xLTEtMA_c9847e3a-dfe4-4060-894c-22a846753aca"
      unitRef="usd">9934000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTMtNy0xLTEtMA_cc658e31-9e94-4f53-9acf-e4159dddf809"
      unitRef="usd">9934000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib39f65ed13ce48db8f11ed672ed5fdba_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTQtMS0xLTEtMA_b7e3f534-6db3-4623-887b-8915fe7d9159"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic564593128ce4e4b84460058baeb14cf_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTQtMy0xLTEtMA_0e6e3b6f-7bfb-4b29-ab66-e37d39969030"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i531ede9f4ddd48268654c99511a06679_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTQtNS0xLTEtMA_aa0f0dce-936b-4896-9a56-8bdfb023b99b"
      unitRef="usd">9934000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjRhN2Q2ODUwMjBjNTQ1ZTJiNzNkMTliZjdmY2YxYzUwL3RhYmxlcmFuZ2U6NGE3ZDY4NTAyMGM1NDVlMmI3M2QxOWJmN2ZjZjFjNTBfMTQtNy0xLTEtMA_da049013-2966-4d69-8c49-9e9976cacde4"
      unitRef="usd">9934000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNi0xLTEtMS0w_200571e0-362f-4d0a-8dff-77e4076dcf9b"
      unitRef="usd">18870000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNi0zLTEtMS0w_31e6c977-0876-4f35-8bfb-a49cca3a7f21"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8f5503e95ced4126b68fbce3f56c2973_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNi01LTEtMS0w_1b43a3e8-a332-43e1-bebf-203414b4137e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNi03LTEtMS0w_da187b0d-e80a-47bf-a77b-7f5c2bfe7924"
      unitRef="usd">18870000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNy0xLTEtMS0w_9a6b10cd-0da8-4577-a151-2b2505a14c5a"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNy0zLTEtMS0w_81d9ff59-7ec9-4762-a58a-f0341873acc5"
      unitRef="usd">120000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8f5503e95ced4126b68fbce3f56c2973_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNy01LTEtMS0w_3ba52d26-62e3-46c3-8a78-2d4aad67779c"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfNy03LTEtMS0w_352e5c8c-b8cd-4909-b05c-d0346257bfff"
      unitRef="usd">120000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssets
      contextRef="i889906dfb28744f396261bd2650c45b2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOC0xLTEtMS0w_1d9cb264-0bba-48fb-8553-cdf70dd7046a"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie329f1da30bf41b49d879864c1d2d60b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOC0zLTEtMS0w_0dff7f49-a7f0-44ea-a7f8-dcbdb4af83b4"
      unitRef="usd">133000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if7e565fc549d442ca4eb00695a5c82db_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOC01LTEtMS0w_bcd6d4fd-531e-4084-880d-137084eddfa3"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5c5e6af0a8a040aaa94190167dea56ab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOC03LTEtMS0w_0889733b-b6d3-4f37-aa72-e455cfcfa4c5"
      unitRef="usd">133000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOS0xLTEtMS0w_a1572b95-7cca-4ad7-a8dc-fa3bcbc5fecf"
      unitRef="usd">18870000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOS0zLTEtMS0w_0bea9d26-179b-4ba4-8e7e-2d2a538d99df"
      unitRef="usd">253000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8f5503e95ced4126b68fbce3f56c2973_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOS01LTEtMS0w_c76f49fb-f6e9-4747-8745-46591a7620b7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfOS03LTEtMS0w_1ed743fe-99a7-46fd-b9c8-d4fc18d0df64"
      unitRef="usd">19123000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTQtMS0xLTEtMA_9ed1a0fe-37c3-46a8-9de6-0886fec3c9b7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTQtMy0xLTEtMA_62c2bafc-40fd-4864-b5da-33e0131ebe19"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8f5503e95ced4126b68fbce3f56c2973_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTQtNS0xLTEtMA_53d72810-cd1c-4c3a-abe0-2364571c41c8"
      unitRef="usd">9683000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTQtNy0xLTEtMA_7299cbd1-1c51-40be-bab4-3b4c7698e7a7"
      unitRef="usd">9683000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4a620c9bbe50476fb2f6bae7aae3eecd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTUtMS0xLTEtMA_5e4d125a-39e1-4e59-b6bb-54f103d603fa"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1f3aab5ab5e94f46a1988a120e4d41e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTUtMy0xLTEtMA_a668efbf-a9db-4e91-83d5-e9b9232dd53d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8f5503e95ced4126b68fbce3f56c2973_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTUtNS0xLTEtMA_86333679-3b13-4a80-952e-30ffb87efe1b"
      unitRef="usd">9683000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOjU3NDE3MzU4ODI1MTRjNmFiM2M1YmM3YWQ1NDI1YjBlL3RhYmxlcmFuZ2U6NTc0MTczNTg4MjUxNGM2YWIzYzViYzdhZDU0MjViMGVfMTUtNy0xLTEtMA_b5cf1f6d-6be0-4bb0-be34-c319080b2d26"
      unitRef="usd">9683000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjc2Nw_51cc3f6d-482d-49af-b89e-a9a99a7ed054">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of June&#160;30, 2020:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.498%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent&lt;br/&gt;consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Included in results of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjc3MA_70d563a3-d11f-4219-acc1-e01bb7eee8a1">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of June&#160;30, 2020:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.498%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent&lt;br/&gt;consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Included in results of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i466da00a6f1e4da59279c84d5c12fe30_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOmYwNzljZWVkZTAxNjRjZDY5ZDI5MDNhNzFmZTcyYWYxL3RhYmxlcmFuZ2U6ZjA3OWNlZWRlMDE2NGNkNjlkMjkwM2E3MWZlNzJhZjFfMi0xLTEtMS0w_758326fe-2bec-4bd6-bac6-efa9d581b150"
      unitRef="usd">9683000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i76725fac2d244963b0e9b87c1b59c414_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOmYwNzljZWVkZTAxNjRjZDY5ZDI5MDNhNzFmZTcyYWYxL3RhYmxlcmFuZ2U6ZjA3OWNlZWRlMDE2NGNkNjlkMjkwM2E3MWZlNzJhZjFfNS0xLTEtMS0w_dabeb3a9-e31c-4e1f-a43d-0971bc90cca8"
      unitRef="usd">251000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i156c35b6196a4d9cba4e041a0cb57b3b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RhYmxlOmYwNzljZWVkZTAxNjRjZDY5ZDI5MDNhNzFmZTcyYWYxL3RhYmxlcmFuZ2U6ZjA3OWNlZWRlMDE2NGNkNjlkMjkwM2E3MWZlNzJhZjFfOS0xLTEtMS0w_761b61f4-b627-4745-84a3-6abecc9a7de1"
      unitRef="usd">9934000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjQ5MA_0da6ab40-a4b3-43ba-bfd1-a2463e47c432"
      unitRef="usd">9900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8680556422af45dd8dfa9ce4d3edc1ba_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjUyMg_af4daa63-ffc2-4c01-8452-b34ec9e062dc"
      unitRef="usd">2400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3a53eb2f2d054cc998864517435338b1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjU2Mg_5b46ae76-78b3-4f56-a8e0-a4097758e5d2"
      unitRef="usd">7600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjYyOA_678cec40-5362-43b9-b836-d0e471d8aa1f"
      unitRef="usd">9700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia730eb3f2de947f1ae2828ca66e4a318_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjY2MA_f1b069e5-a017-4793-8680-7bbff147f78d"
      unitRef="usd">2400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icdc50b58341940828f8595408b7a269e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183My9mcmFnOjYzNzRiMTA3YTE5YTRkYWQ4MTY0NWY1MjZiZjM2MWE1L3RleHRyZWdpb246NjM3NGIxMDdhMTlhNGRhZDgxNjQ1ZjUyNmJmMzYxYTVfMjcwMA_87486a0c-fcc8-4aa4-8de1-664af38b310d"
      unitRef="usd">7300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RleHRyZWdpb246MjA3NDcxYmIxZjcyNGUwNWIyZDQ4OWFiY2NmYTUwNDVfMTE4Mw_fd9ca6ff-56c5-417d-bf92-36ba28e0ce86">DERIVATIVE CONTRACTS&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair values and the presentation of our derivative assets (liabilities) in the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.591%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.722%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common Stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses.  Unrealized (losses) on forward contracts are recorded in Accrued expenses.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We enter into foreign currency forward exchange contracts in an effort to mitigate the effects of exchange rate differences arising from inventory purchases on letters of credit.  Under these forward contracts, for any rate above or below the fixed rate, we receive or pay the difference between the spot rate and the fixed rate for the given amount at the settlement date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;To qualify the derivative instrument as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At June&#160;30, 2020 and December&#160;31, 2019, our derivative financial instruments did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognize the changes in Fair value of derivative instruments, net in our Condensed Consolidated Statement of Operations.  The following table summarizes the losses and gains recorded for the three and six months ended June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.508%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.261%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative gain (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common Stock options/warrants &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RleHRyZWdpb246MjA3NDcxYmIxZjcyNGUwNWIyZDQ4OWFiY2NmYTUwNDVfMTE5Mg_94a16682-ff6e-4d37-9e1a-e02062893b33">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair values and the presentation of our derivative assets (liabilities) in the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.591%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.722%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common Stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses.  Unrealized (losses) on forward contracts are recorded in Accrued expenses.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i1e0ac6f1d4cb4c66b971c20cf8aeca20_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjFhNGY5MWFkOWI5NzQ1MDJhNjI3ZjI3YjJhYmVlNjg5L3RhYmxlcmFuZ2U6MWE0ZjkxYWQ5Yjk3NDUwMmE2MjdmMjdiMmFiZWU2ODlfMy0zLTEtMS0w_b73cd2d9-6d25-4319-af1b-3b4bc03b3dec"
      unitRef="usd">51000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="if667381c8f554ff082c1a91219f79181_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjFhNGY5MWFkOWI5NzQ1MDJhNjI3ZjI3YjJhYmVlNjg5L3RhYmxlcmFuZ2U6MWE0ZjkxYWQ5Yjk3NDUwMmE2MjdmMjdiMmFiZWU2ODlfMy01LTEtMS0w_77061015-85e5-425d-b620-c03912eabb86"
      unitRef="usd">120000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i0aca251d226f472f9def2eed58862fb1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjFhNGY5MWFkOWI5NzQ1MDJhNjI3ZjI3YjJhYmVlNjg5L3RhYmxlcmFuZ2U6MWE0ZjkxYWQ5Yjk3NDUwMmE2MjdmMjdiMmFiZWU2ODlfNS0zLTEtMS0w_27368bef-0e45-4797-af6c-41f92f3794cd"
      unitRef="usd">215000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i7aaa36a9c3b240c480e7a180e04210a9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjFhNGY5MWFkOWI5NzQ1MDJhNjI3ZjI3YjJhYmVlNjg5L3RhYmxlcmFuZ2U6MWE0ZjkxYWQ5Yjk3NDUwMmE2MjdmMjdiMmFiZWU2ODlfNS01LTEtMS0w_3215eeff-379e-4827-8210-569c20a5cdf4"
      unitRef="usd">133000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RleHRyZWdpb246MjA3NDcxYmIxZjcyNGUwNWIyZDQ4OWFiY2NmYTUwNDVfMTIwMA_856bb133-860d-46dd-8429-bcefd16122f6">The following table summarizes the losses and gains recorded for the three and six months ended June 30, 2020 and 2019:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.508%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.261%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative gain (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common Stock options/warrants &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i80bdef2e23504d6fb04d750584ece882_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNC0xLTEtMS0w_ea677c85-9d2d-4255-b46e-a90ed61c7cf9"
      unitRef="usd">-7000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib9b681e985234321b995bee7faf1aa60_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNC0zLTEtMS0w_af039d97-c2c9-4a42-bb5d-fab21826acad"
      unitRef="usd">-392000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="iee03a450fc9448c1b8e2ea08fdc41417_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNC01LTEtMS0w_6ff678ac-e433-4d36-8d49-292328142c2a"
      unitRef="usd">-69000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i5c1ec4036db94ff8ab2eaaeed0d02080_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNC03LTEtMS0w_59270cb4-6aa7-47c3-b99c-6829983d6c9a"
      unitRef="usd">-24000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ifc1b1f708d7d402caa5805034a48ad80_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNi0xLTEtMS0w_84a32433-3218-4be1-9d52-61138142d0f9"
      unitRef="usd">-6000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ia293f36717934081b9f1213686122a51_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNi0zLTEtMS0w_db8f1823-e24b-4e90-b4dc-4f8300ebf71c"
      unitRef="usd">4000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i3f3753e96f434c02990e62a093e23382_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNi01LTEtMS0w_f165f329-dbdb-466e-a8c3-8b73ec564d78"
      unitRef="usd">677000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib875afce9dcb4394b143601b365f6f9f_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNi03LTEtMS0w_35741cb6-02f9-4a54-b2cc-aaf1a5f64439"
      unitRef="usd">51000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="iccf1d6fe84ba4e54b2f9cc386683e187_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNy0xLTEtMS0w_e04a3d1b-f31b-49b1-90b8-6780627dd13a"
      unitRef="usd">-13000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i69d3efc364ab4dcb8a44ddd5b86d234d_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNy0zLTEtMS0w_c0f84f52-5a84-498f-be4b-359582dd14e4"
      unitRef="usd">-388000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ie55e61c7727f4127be76e9ba93be973f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNy01LTEtMS0w_c8c0e814-d9ed-4d2a-a94f-7beec9ade86b"
      unitRef="usd">608000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i2d3673e8cc554f419eeaf0ebe4a24185_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183Ni9mcmFnOjIwNzQ3MWJiMWY3MjRlMDViMmQ0ODlhYmNjZmE1MDQ1L3RhYmxlOjY5OGYzMzEwNTc1MDRlOTRhYzI0ZWYyOTc1N2IwZTM4L3RhYmxlcmFuZ2U6Njk4ZjMzMTA1NzUwNGU5NGFjMjRlZjI5NzU3YjBlMzhfNy03LTEtMS0w_5e50a1d3-4787-4f99-b25b-eab9641f1bd1"
      unitRef="usd">27000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjE5OTAyMzI2NDI2OA_92909887-7f62-4d9a-a531-9e25382e9100">RELATED PARTY TRANSACTIONS&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $100 million.  Borrowings under the line of credit will bear interest at a rate of 11% per annum and may be repaid and reborrowed at any time.  The credit agreement includes various customary remedies for the lender following an event of default, including the acceleration of repayment of outstanding amounts under line of credit.  The line of credit matures on February 25, 2025.  The line of credit also calls for a commitment fee equal to 0.25% per annum of the unused portion of the line.  As of June 30, 2020, no funds were borrowed under the line of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On October 29, 2019, we issued 50 million shares of our Common Stock at a price of $1.50 per share in an underwritten public offering (the &#x201c;Offering&#x201d;), resulting in net proceeds to the Company of approximately $70 million, after deducting underwriting commissions and offering expenses.  In November 2019, pursuant to an option the Company granted the underwriters, we issued an additional 4,227,749 shares at the public offering price, less underwriting discounts and commissions, resulting in net proceeds to the Company of approximately $6 million. Drs. Frost and Hsiao and Mr. Steven Rubin, members of OPKO&#x2019;s senior management purchased an aggregate of 2,415,000 shares of Common Stock in the Offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On March 1, 2019, OPKO Pharmaceuticals, LLC entered into an assignment agreement with Xenetic Biosciences, Inc., as amended from time to time (the &#x201c;Assignment Agreement&#x201d;), pursuant to which Xenetic acquired all of OPKO Pharmaceuticals&#x2019; right, title and interest in and to that certain Intellectual Property License Agreement (the &#x201c;IP License Agreement&#x201d;), entered into between The Scripps Research Institute and OPKO Pharmaceuticals, regarding certain patents for novel CAR T platform technology and through which the Scripps Research Institute granted an exclusive royalty-bearing license in exchange for royalties, subject to the terms of the IP License Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Assignment Agreement and the IP License Agreement, Xenetic issued to OPKO Pharmaceuticals 164,062 shares of Xenetic common stock (the &#x201c;OPKO Transaction Shares&#x201d;). In connection with the Assignment Agreement, OPKO Pharmaceuticals entered into a voting agreement pursuant to which OPKO Pharmaceuticals agreed, among other things, to vote &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;its shares in Xenetic in favor of the transactions contemplated by the Assignment Agreement, and a lock-up agreement with Xenetic which restricts OPKO Pharmaceuticals&#x2019; sale or transfer of any of the OPKO Transaction Shares as provided therein and as otherwise required by law. The Assignment Agreement and the obligations thereunder took effect on July 19, 2019, after Xenetic satisfied certain closing conditions, including obtaining stockholder approval and securing certain financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company owns approximately 9% of Pharmsynthez and Pharmsynthez is Xenetic&#x2019;s largest and controlling stockholder. Dr. Richard Lerner, a director of the Company, is a co-inventor of Xenetic&#x2019;s technology and received 31,240 shares of Xenetic upon the closing of the Xenetic transactions described above.  Adam Logal, our Senior Vice President and Chief Financial Officer, is a director of Xenetic.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2019, we paid the $125,000 filing fee to the Federal Trade Commission (the &#x201c;FTC&#x201d;) in connection with filings made by us and Dr. Jane Hsiao, our Vice Chairman and Chief Technical Officer, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (&#x201c;HSR Act&#x201d;) relating to her purchases of Common Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2019, Dr. Phillip Frost, our Chairman and Chief Executive Officer, paid a filing fee of $280,000 to the FTC under the HSR Act in connection with filings made by us and Dr. Frost, relating to his purchases of Common Stock.&#160; We reimbursed Dr. Frost for the HSR filing fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 8, 2018, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $60 million.  Borrowings under the line of credit bore interest at a rate of 10% per annum and could have been repaid and reborrowed at any time.  The credit agreement included various customary remedies for the lender following an event of default, including the acceleration of repayment of outstanding amounts under line of credit.  The line of credit would have matured on November 8, 2023.  We repaid approximately $28.8 million that was borrowed in 2019 and terminated the line of credit on or around February 20, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2018, we issued the 2023 Convertible Notes in the aggregate principal amount of $55.0 million.  Refer to Note 6. Purchasers of the 2023 Convertible Notes included Dr. Hsiao and an affiliate of Dr. Frost.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We hold investments in Zebra (ownership 29%), Neovasc (2%), ChromaDex Corporation (0.1%), MabVax (1%), COCP (5%), NIMS (1%), Eloxx (3%), and BioCardia (2%).  These investments were considered related party transactions as a result of our executive management&#x2019;s ownership interests and/or board representation in these entities.  See further discussion of our investments in Note 5.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2018, we invested an additional $1.0 million in COCP for a convertible note, which was converted into 538,544 shares of its common stock in May 2018. In April 2017, we invested an additional $1.0 million in COCP for 138,889 shares of its common stock.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2017, we invested an additional $3.0 million in Neovasc for 20,547 shares of its common stock, 20,547 Series A warrants, 20,547 Series B warrants and 8,221 Series C warrants, after adjusting for a 1-for-100 reverse stock split in 2018. In April 2018, we exercised the Series B warrants in a cashless exercise and received 10,690 shares of Neovasc common stock. In the first quarter of 2019, we exercised the Series C warrants for $1.2 million and exchanged the Series A warrants and received a total of 22,660 additional shares of Neovasc common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2016, we entered into a Pledge Agreement with the Museum of Science, Inc. and the Museum of Science Endowment Fund, Inc. pursuant to which we agreed to contribute an aggregate of $1.0 million over a four-year period for constructing, equipping and the general operation of the Frost Science Museum.  Dr. Frost and Mr. Richard Pfenniger serve on the Board of Trustees of the Frost Science Museum and Mr. Pfenniger is the Vice Chairman of the Board of Trustees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We lease office space from Frost Real Estate Holdings, LLC (&#x201c;Frost Holdings&#x201d;) in Miami, Florida, where our principal executive offices are located.  Effective August 1, 2019, we entered into an amendment to our lease agreement with Frost Holdings.  The lease, as amended, is for approximately 29,500 square feet of space.  The lease provides for payments of approximately $89 thousand per month in the first year increasing annually to $101 thousand per month in the fifth year, plus applicable sales tax.  The rent is inclusive of operating expenses, property taxes and parking.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;BioReference purchases and uses certain products acquired from InCellDx, a company in which we hold a 29% minority interest.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We reimburse Dr.&#160;Frost for Company-related use by Dr.&#160;Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr.&#160;Frost.  We reimburse Dr. Frost for out-of-pocket operating costs for the use of the airplane by Dr. Frost or Company executives for Company-related business.  We do not reimburse Dr.&#160;Frost for personal use of the airplane by Dr.&#160;Frost or any other executive.  For the three and six months ended June 30, 2020, we reimbursed approximately $0 thousand and $94 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO &lt;/span&gt;&lt;/div&gt;executives. For the three and six months ended June 30, 2019, we reimbursed approximately $122&#160;thousand and $160&#160;thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7f02e4f9fd574e05a785e3c62f223eb4_I20200225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjMy_f3e01ee0-f303-4df8-9f2b-7e5980d0982f"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7f02e4f9fd574e05a785e3c62f223eb4_I20200225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMzA1_9ec6b80c-adb4-431b-b1cf-8b1c8ece123b"
      unitRef="number">0.11</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i7c119d6e22ac4137a2e112127278f9af_D20200225-20200225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjY0_d8a00a10-2f84-4392-82c8-5cd2f0e85a7f"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i03aeaa43340c459c8da023f93e0228ea_D20191029-20191029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfODE1_856b010b-38fb-414f-af0b-c88085f8646d"
      unitRef="shares">50000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i3dbdeb0b817643be9cbd2dfa9e9606f9_I20191029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfODU5_89961562-e086-492b-bae6-3ee7baee131e"
      unitRef="usdPerShare">1.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i03aeaa43340c459c8da023f93e0228ea_D20191029-20191029"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfOTgz_71dd9ba8-ccea-46cd-9833-f6fd228ec338"
      unitRef="usd">70000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iec908835f0b2426ca21f5664f890c7b2_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMTE1NA_78697797-632a-4d53-a858-1842a1e304c9"
      unitRef="shares">4227749</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iec908835f0b2426ca21f5664f890c7b2_D20191101-20191130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMTI5Nw_1270c83a-1324-45d8-b3ae-5a90fe64ce10"
      unitRef="usd">6000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id3cfd08ad6df4811a785c595816354c4_D20191029-20191029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMTQwNg_ebcbd69b-acda-460b-afb0-7ff6d2e61990"
      unitRef="shares">2415000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssued
      contextRef="i39377d350ed8459c9f4a6c8173298ce4_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjIxOA_24351297-3f1b-4d3a-8044-dd3558c37aea"
      unitRef="shares">164062</us-gaap:SharesIssued>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib4fc9634e3a348bab19da19df297d2c9_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjk3Nw_f8463704-fe41-427f-9dd7-63664679fe1c"
      unitRef="number">0.09</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <opk:RelatedPartyTransactionShares
      contextRef="ia9973ed8023248deb54e5d88777adf34_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMzE2NA_8a2f4e51-4b1e-4b9e-bd17-5907e9ea9cd8"
      unitRef="shares">31240</opk:RelatedPartyTransactionShares>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="if0f5d9e5d0c94731921acdcd9d79d299_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMzM3MA_11b26942-0ef4-4248-99e9-1f1bd239c643"
      unitRef="usd">125000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i043083dceb38404bb2b35a4fd84c56dc_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMzc1MQ_11d84d61-16c7-44e0-bdf9-4214f970177c"
      unitRef="usd">280000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i1bfdb219056b42969ad222d49e930c2e_I20181108"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNDU5OQ_97c43608-675b-4915-9767-cb8fde5e2040"
      unitRef="usd">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1bfdb219056b42969ad222d49e930c2e_I20181108"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNDY2Nw_55e40123-004b-4532-98ed-3a97556d546d"
      unitRef="number">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i6302ffbd2069456f9a5cc3c3c7a1e7a5_D20190220-20190220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTAwOQ_2f5dbe28-64f9-4ceb-9637-2af4a9db9728"
      unitRef="usd">28800000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iac1e5f5cb1464cb9905c5e33a1c7fede_I20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTE5Ng_595ea9d6-1f8d-4bb7-babf-510e1af84071"
      unitRef="usd">55000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i5e3a3664d4aa4479ab2f7ff77d256120_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTM1MQ_1f6b21be-1bdf-4f52-8d8c-9a26a518b96c"
      unitRef="number">0.29</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia1aa8cc835a1411f9161a88fefd51afb_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTM2NQ_424c6b79-a107-457f-8c40-831c39dc9771"
      unitRef="number">0.02</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="i65bd6c4d55ac4253a96252cdeb1cebf6_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTM5Mw_109f25bf-956f-4da0-a094-2b0a3243bedf"
      unitRef="number">0.001</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="if01ceaf264f64e64b9647bf4a84dac24_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTQwNg_83b19f60-56d6-4de1-926a-b8b87b039725"
      unitRef="number">0.01</opk:EquitySecurityFVNIOwnershipPercent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i40c56be3936e42218c130b6171df7087_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTQxNw_0cd1fdbd-e734-413b-8c68-5ebd7b85ab3b"
      unitRef="number">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="i651485904eaf48cf9b0d0e4ae12aa57c_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTQyOA_6f0e3bac-946f-4ee9-929f-93bdd561d41f"
      unitRef="number">0.01</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="i94995994c21b4facabf08492a51c559a_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTQ0MA_1ea5a234-77a3-4f7e-9d53-b0e22f158b93"
      unitRef="number">0.03</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="ie5822595b03740f291e2481860949888_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTQ2MA_4919ed37-7c73-4754-b40b-04c49d9238d5"
      unitRef="number">0.02</opk:EquitySecurityFVNIOwnershipPercent>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ib51423d67fdf443e92d5bbdd0177b903_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTczNg_bdcf17c7-fc3a-47f9-a312-feefdfd7fb91"
      unitRef="usd">1000000.0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <opk:DebtInstrumentConvertibleSharesIssued
      contextRef="ia1752740ed5f481c9bd06120be92363d_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTc5Ng_75a3062f-797f-4977-a697-5d2a039f28db"
      unitRef="shares">538544</opk:DebtInstrumentConvertibleSharesIssued>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ie8fff2811a6f4c0c9d1e13125eac0f56_D20170401-20170430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTg4MA_99caee7b-7f33-4eb7-8a8e-6371bcd48334"
      unitRef="usd">1000000.0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <opk:EquityMethodInvestmentSharesPurchasedInPeriod
      contextRef="ia0bd41509ea64c85ab834813ae267e3d_D20170401-20170430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTg5NQ_669f2085-f28e-4fad-9815-649062b09016"
      unitRef="shares">138889</opk:EquityMethodInvestmentSharesPurchasedInPeriod>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i0a7333b8434e44f483b8888bb05796ca_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTk3Mg_dcfa1618-d097-4f3c-bfdc-fa06443dbb99"
      unitRef="usd">3000000.0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <opk:EquityMethodInvestmentSharesPurchasedInPeriod
      contextRef="i04269715161949f5a492269ba0ca5d33_D20171101-20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNTk5MA_8edeb0cb-8fee-4118-b242-e86c85973c71"
      unitRef="shares">20547</opk:EquityMethodInvestmentSharesPurchasedInPeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i69978c473ccc4f789665ee256ad80248_I20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjAyMQ_ec2401f3-e7c9-4f92-8a98-d7b26a2a2930"
      unitRef="shares">20547</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7c13820530324de6a22fce865f5cabb2_I20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjA0Mw_3e9da12e-2dbb-450d-96f4-95bbbc27cafa"
      unitRef="shares">20547</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i513914a206464308b0f07a3fdec68ace_I20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjA2OA_11306243-d394-41be-beff-2e59e34d1f10"
      unitRef="shares">8221</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <opk:ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived
      contextRef="i3ad66425a0b64ba89a7212677580e0de_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjIzNw_728ed83c-725a-469d-93d6-beb043f01e51"
      unitRef="shares">10690</opk:ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ib0abeab516404b459edcdfb5578edb3c_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjM0MQ_96e81a2e-c4cf-42cc-937d-9b00eca93973"
      unitRef="usd">1200000</us-gaap:ProceedsFromWarrantExercises>
    <opk:ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived
      contextRef="i397e015eed2e471682652c5cde1df638_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjQwNA_34139627-e2c9-4ea0-999e-a484cc65b394"
      unitRef="shares">22660</opk:ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived>
    <opk:RelatedPartyTransactionFutureContributions
      contextRef="i202231196f75401e854be2d8baec5847_I20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNjY0MQ_3e9d82a4-5580-4a3c-8dea-32497890df8c"
      unitRef="usd">1000000.0</opk:RelatedPartyTransactionFutureContributions>
    <opk:RelatedPartyTransactionFutureContributionTerm
      contextRef="i6c3cb92761b94bb7b621e130359abbc8_D20161101-20161130"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMzg0ODI5MDcwNzAyNA_0896059f-c64f-4e09-a169-bd0ab9d92b87">P4Y</opk:RelatedPartyTransactionFutureContributionTerm>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i1996c6025aa74093ba775cca607f2ad3_I20190801"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNzIwMw_155e57a3-08be-4da2-8751-313362dc6ceb"
      unitRef="sqft">29500</us-gaap:AreaOfRealEstateProperty>
    <opk:OperatingLeasesMonthlyPaymentsYearOne
      contextRef="i1996c6025aa74093ba775cca607f2ad3_I20190801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNzI3OA_c5ecabf7-d344-4253-8d31-0d207b72e9d9"
      unitRef="usd">89000</opk:OperatingLeasesMonthlyPaymentsYearOne>
    <opk:OperatingLeasesMonthlyPaymentsYearThree
      contextRef="i1996c6025aa74093ba775cca607f2ad3_I20190801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNzMzMg_342baff2-c857-43dd-af5a-0846aa6ada58"
      unitRef="usd">101000</opk:OperatingLeasesMonthlyPaymentsYearThree>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iecfe4462c2ee470cb896cbcb8858c7f9_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfNzU3MA_a71314fe-23c9-45b5-9682-b54cee5a2c65"
      unitRef="number">0.29</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMTY0OTI2NzQ0OTg3NQ_ed8ac9f5-2a1e-44b3-b410-06738a9e7d87"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfODA1OQ_50b5a76d-3fd2-4a0c-b4b0-070738ce2aae"
      unitRef="usd">94000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjE5OTAyMzI2NDI4MA_bc8b0179-9520-40c8-9e4a-2b491e0bc295"
      unitRef="usd">122000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM183OS9mcmFnOmQ4YmIzMjRhNjIwMzQyYjU5YmVhN2ViMjc3NDc2NDg4L3RleHRyZWdpb246ZDhiYjMyNGE2MjAzNDJiNTliZWE3ZWIyNzc0NzY0ODhfMjE5OTAyMzI2NDI5NQ_22bbdb65-8725-4075-8969-069f05333851"
      unitRef="usd">160000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfODk3OA_db7141fc-8dcf-4e1b-84ce-f3f906b53915">COMMITMENTS AND CONTINGENCIES&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with our acquisitions of CURNA, OPKO Diagnostics and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events.  As a result, as of June 30, 2020, we recorded $9.9 million as contingent consideration, with $2.4 million recorded within Accrued expenses and $7.6 million recorded within Other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets.  Refer to Note 4.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On June 3, 2019, BioReference reported that Retrieval-Masters Creditors Bureau, Inc. d/b/a American Medical Collection Agency (&#x201c;AMCA&#x201d;), had notified BioReference about a data security incident involving AMCA (the &#x201c;AMCA Incident&#x201d;).  AMCA informed BioReference that an unauthorized user had access to AMCA&#x2019;s system between August 1, 2018 and March 30, 2019.  AMCA advised that AMCA&#x2019;s affected system may have included patient name, date of birth, address, phone, date of service, provider, and balance information, as well as credit card information, bank account information (but no passwords or security questions) and email addresses that were provided by the consumer to AMCA.  AMCA  advised BioReference that no Social Security Numbers were compromised, and BioReference provided no laboratory results or diagnostic information to AMCA.  BioReference notified patients and provided notice to the Office of Civil Rights of the AMCA Incident. BioReference had been named in at least two class action lawsuits against AMCA and other defendants in connection with the AMCA Incident. In April 2020, the class action lawsuits against BioReference were dismissed without prejudice. The Office of Inspector General and Office for Civil Rights (&#x201c;OCR&#x201d;) of the Department of Health and Human Services, as well as the attorney generals&#x2019; offices from certain states have contacted BioReference to request additional information relating to the AMCA Incident.  It is not possible at this time to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to whether the class action lawsuits or other lawsuits will be filed or refiled, and/or the lack of resolution of significant factual and legal issues.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As previously disclosed, on September 7, 2018, the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) filed a lawsuit in the Southern District of New York (the &#x201c;SEC Complaint&#x201d;) against a number of individuals and entities (the &#x201c;Defendants&#x201d;), including the Company and its CEO and Chairman, Dr. Phillip Frost.  The SEC alleged, among other things, that the Company (i) aided and abetted an illegal &#x201c;pump and dump&#x201d; scheme perpetrated by a number of the Defendants, and (ii) failed to file required Schedules 13D or 13G with the SEC.  On December 27, 2018, the Company announced that the Company and Dr. Frost entered into settlement agreements with the SEC, which upon approval of the court would resolve the SEC Complaint against each of them.  The settlement was approved by the court in January 2019.  Pursuant to the settlement, and without admitting or denying any of the allegations of the Complaint, the Company is enjoined from violating Section 13(d) of the Exchange Act and paid a $100,000 penalty.  Liability under Section 13(d) can be established without any showing of wrongful intent or negligence.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Following the SEC&#x2019;s announcement of the SEC Complaint, we were named in several class action lawsuits, more than a dozen derivative suits, and other litigation relating to the allegations in the SEC Complaint among other matters.  On June 26, 2020, The Amitim Funds, the lead plaintiff in the class action lawsuits  filed a Stipulation of Settlement  in the Southern District of Florida of behalf of itself and the remainder of the class, which, if approved, will provide for the settlement of and release of the class action claims against the Company and Dr. Frost for $16.5&#160;million. We reached agreement with our insurance carriers with respect to claims made in the class action and derivative lawsuits and we expect insurance coverage for a significant portion of the settlement amounts.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The settlement remains subject to certain terms and conditions including court approval. The Company is also in advanced negotiations to settle the derivative suits. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2017, the Civil Division of the United States Attorney&#x2019;s Office for the Southern District of New York (the &#x201c;SDNY&#x201d;) informed BioReference that it believes that, from 2008 to 2012, BioReference had, in violation of the False Claims Act, improperly billed Medicare and TRICARE (both are federal government healthcare programs) for clinical laboratory services provided to hospital inpatient beneficiaries at certain hospitals.  In April 2019, the SDNY also informed BioReference that it believes that BioReference provided physicians subsidies for electronic health record systems prior to 2012 that violated regulations adopted by HHS in 2006 which allowed laboratories to provide these donations under certain conditions.  BioReference and the SDNY are in negotiations to resolve the matter.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On October&#160;11, 2019, GeneDx received a letter from the Centers for&#160;Medicare&#160;and Medicaid Services (&#x201c;CMS&#x201d;), notifying GeneDx of CMS&#x2019; determination to suspend Medicare payments to GeneDx, which suspension became effective on September&#160;27, 2019 (the &#x201c;CMS Letter&#x201d;).  The CMS Letter specifically stated that the foregoing suspension may last for up to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;180 days from the effective date and may be extended under certain circumstances.  CMS advised that it suspended payments due to possible overpayments to GeneDx in connection with reimbursement claims for genetic testing services based on a diagnosis of family history of cancer, which testing CMS has alleged is not covered by Medicare under the applicable provisions of the Social Security Act on the basis that such testing is not reasonable and necessary for the diagnosis or treatment of illness or injury.  On or around February 3, 2020, we were notified that CMS was lifting the payment suspension.  CMS noted, however, that the decision to lift the payment suspension should not be construed as a positive determination regarding GeneDx&#x2019;s Medicare billing.  There can be no assurance that CMS and other governmental payor programs will not seek to recoup payments from us, suspend reimbursement or seek overpayment damages from GeneDx.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, we may receive inquiries, document requests, Civil Investigative Demands (&#x201c;CIDs&#x201d;) or subpoenas from the Department of Justice, OCR, CMS, various payors and fiscal intermediaries, and other state and federal regulators regarding investigations, audits and reviews.  In addition to the matters discussed in this note, we are currently responding to CIDs, subpoenas, payor audits, and document requests for various matters relating to our laboratory operations.  Some pending or threatened proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material.  Settlements of suits involving the types of issues that we routinely confront may require monetary payments as well as corporate integrity agreements.  Additionally, qui tam or &#x201c;whistleblower&#x201d; actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act&#x2019;s requirements for filing such suits.  Also, from time to time, we may detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians, among other things.  We may avail ourselves of various mechanisms to address these issues, including participation in voluntary disclosure protocols.  Participating in voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action.  The Company generally has cooperated, and intends to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are a party to other litigation in the ordinary course of business.  While we cannot predict the ultimate outcome of legal matters, we accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss.  It&#x2019;s reasonably possible the ultimate liability could exceed amounts currently estimated and we review established accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information.  To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.  Because of the high degree of judgment involved in establishing loss estimates, the ultimate outcome of such matters will differ from our estimates and such differences may be material to our business, financial condition, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At June&#160;30, 2020, we were committed to make future purchases for inventory and other items in 2020 that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating approximately $154.2 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMjQ1_de34d844-42e7-473a-aa74-f9bd38f29189"
      unitRef="usd">9900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8680556422af45dd8dfa9ce4d3edc1ba_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMjgy_662c9c0d-ed35-48fd-be31-e01f08f43b95"
      unitRef="usd">2400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3a53eb2f2d054cc998864517435338b1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMzIy_4c44bf64-05a9-46b5-b645-30e4d06f8250"
      unitRef="usd">7600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <opk:NumberOfClassActionLawsuits
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMTQzOQ_3fd587b4-b637-495e-bce6-6fa5274e1b71"
      unitRef="lawsuit">2</opk:NumberOfClassActionLawsuits>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i45906ae2d8ff43e28d1650b504a4b3c5_D20181227-20181227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMzQwMQ_2f420352-4974-4941-a9db-557b9c616107"
      unitRef="usd">100000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="if4107320ea8b40a4941b1ec675d93864_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfMjE5OTAyMzI2Njg0Mw_947bd67e-80f1-468f-a572-9d68381ed2bd"
      unitRef="usd">16500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:PurchaseObligation
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM184NS9mcmFnOjhiZTUyZjgwNjA0YTQwYzk5MDY4NzM0ODliMjFkYjExL3RleHRyZWdpb246OGJlNTJmODA2MDRhNDBjOTkwNjg3MzQ4OWIyMWRiMTFfODk3NA_e6852a3f-2428-4db1-8ae2-90fd8b84251f"
      unitRef="usd">154200000</us-gaap:PurchaseObligation>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTUzMDc_d2762e2d-af52-41f0-b9ea-fcd7ad2ef182">REVENUE RECOGNITION&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We generate revenues from services, products and intellectual property as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance obligations are satisfied.  Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs.  Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following are descriptions of our payors for laboratory services:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Healthcare Insurers.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules.  Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the third-party payors, are recorded upon settlement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Government Payors.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Reimbursements from government payors are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid.  Revenues consist of amounts billed, net of contractual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the government payors, are recorded upon settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Client Payors.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Client payors include physicians, hospitals, employers, and other institutions for which services are performed on a wholesale basis, and are billed and recognized as revenue based on negotiated fee schedules.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Patients.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients.  Insured patients (including amounts for coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers.  Collection of billings from patients is subject to credit risk and ability of the patients to pay.  Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions.  Implicit price concessions represent differences between amounts billed and the estimated consideration that we expect to receive from patients, which considers historical collection experience and other factors including current market conditions.  Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered.  Actual amounts are adjusted in the period those adjustments become known. For the six months ended June 30, 2020 and 2019, revenue increases (reductions) due to changes in estimates of implicit price concessions for performance obligations satisfied in prior periods of $0.2 million and $(14.3) million, respectively, were recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Third-party payors, including government programs, may decide to deny payment or recoup payments for testing they contend were improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received.  Our revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payors in interpretations, requirements, and &#x201c;conditions of participation&#x201d; in various programs.  We have processed requests for recoupment from third-party payors in the ordinary course of our business, and it is likely that we will continue to do so in the future.  If a third-party payer denies payment for testing or recoups money from us in a later period, reimbursement for our testing could decline.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As an integral part of our billing compliance program, we periodically assess our billing and coding practices, respond to payor audits on a routine basis, and investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements, as well as overpayment claims which may arise from time to time without fault on the part of the Company.  We may have an obligation to reimburse Medicare, Medicaid,&#160;and third-party payors for overpayments&#160;regardless of fault.  We have periodically identified and reported&#160;overpayments, reimbursed payors for&#160;overpayments&#160;and taken appropriate corrective action.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are also considered variable consideration and are included in the determination of the estimated transaction price for providing services.  These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and our historical settlement activity, including an assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved.  Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. As of June&#160;30, 2020 and December&#160;31, 2019, we had liabilities of approximately $21.4 million and $27.3 million, respectively, within Accrued expenses and Other long-term liabilities related to reimbursements for payor overpayments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The composition of Revenue from services by payor for the six months ended June 30, 2020 and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:10pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.039%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;183,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;211,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Client payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;421,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;357,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Client payers include cities and states for which BioReference provides COVID-19 testing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from products&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize revenue from product sales when a customer obtains control of promised goods or services.  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns.  Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, &#x201c;Sales Deductions&#x201d;) as well as estimated product returns which are all elements of variable consideration.  Allowances are recorded as a reduction of revenue at the time product revenues are recognized.  The actual amounts of consideration ultimately received may differ from our estimates.  If actual results in the future vary from our estimates, we will adjust these estimates, which would affect Revenue from products in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; is distributed in the U.S. principally through the retail pharmacy channel, which initiates with the largest wholesalers in the U.S. (collectively, &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Customers&#x201d;).  In addition to distribution agreements with &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Customers, we have entered into arrangements with many healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize revenue for shipments of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; at the time of delivery to customers after estimating Sales Deductions and product returns as elements of variable consideration utilizing historical information and market research projections. For the three and six months ended June 30, 2020, we recognized $8.6 million and $18.6&#160;million, respectively, in net product revenue from sales of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  For the three and six months ended June 30, 2019, we recognized $5.7 million and $11.5&#160;million, respectively, in net product revenue from sales of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents an analysis of product sales allowances and accruals for the three and six months ended June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:47.558%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.617%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.593%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Chargebacks, discounts, rebates and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Governmental &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Credits or payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total gross &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Provision for &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales allowances and accruals as a percentage of gross &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:47.558%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.617%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.593%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Chargebacks, discounts, rebates and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Governmental &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Credits or payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total gross &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Provision for &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales allowances and accruals as a percentage of gross &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from intellectual property&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements.  The terms of these agreements typically include payment to us for one or more of the following:  non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products.  Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For research, development and/or commercialization agreements that result in revenues, we identify all material performance obligations, which may include a license to intellectual property and know-how, and research and development activities.  In order to determine the transaction price, in addition to any upfront payment, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract.  We constrain (reduce) our estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract.  When determining if variable consideration should be constrained, we consider whether there are factors outside of our control that could result in a significant reversal of revenue.  In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue.  These estimates are re-assessed each reporting period as required.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upfront License Fees:  If a license to our intellectual property is determined to be functional intellectual property distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement.  The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.  If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Development and Regulatory Milestone Payments:  Depending on facts and circumstances, we may conclude that it is appropriate to include the milestone in the estimated transaction price or that it is appropriate to fully constrain the milestone.  A milestone payment is included in the transaction price in the reporting period that we conclude that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods.  We may record revenues from certain milestones in a reporting period before the milestone is achieved if we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We record a corresponding contract asset when this conclusion is reached.  Milestone payments that have been fully constrained are not included in the transaction price to date.  These milestones remain fully constrained until we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period.  We adjust our estimate of the overall transaction price, including the amount of revenue recorded, if necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and Development Activities:  If we are entitled to reimbursement from our customers for specified research and development expenses, we account for them as separate performance obligations if distinct.  We also determine whether the research and development funding would result in revenues or an offset to research and development expenses in accordance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;with provisions of gross or net revenue presentation.  The corresponding revenues or offset to research and development expenses are recognized as the related performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sales-based Milestone and Royalty Payments:  Our customers may be required to pay us sales-based milestone payments or royalties on future sales of commercial products.  We recognize revenues related to sales-based milestone and royalty payments upon the later to occur of (i) achievement of the customer&#x2019;s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to our intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other Potential Products and Services:  Arrangements may include an option for license rights, future supply of drug substance or drug product for either clinical development or commercial supply at the licensee&#x2019;s election.  We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the inception of the contract and revenue is recognized only if the option is exercised and products or services are subsequently delivered or when the rights expire.  If the promise is based on market terms and not considered a material right, the option is accounted for if and when exercised.  If we are entitled to additional payments when the licensee exercises these options, any additional payments are generally recorded in license or other revenues when the licensee obtains control of the goods, which is upon delivery.&lt;/span&gt;&lt;/div&gt;For the three and six months ended June 30, 2020, revenue from transfer of intellectual property principally reflects $13.9 million and $22.7 million of revenue, respectively, related to the Pfizer Transaction (as defined below).   In addition, revenue from the transfer of intellectual property and other for the three and six months ended June 30, 2020 includes a $6.2&#160;million grant received by BioReference from the CARES Act. For the three and six months ended June 30, 2019, revenue from the transfer of intellectual property principally reflects $18.2 million and $35.6 million of revenue, respectively, related to the Pfizer Transaction.  Refer to Note 13 for discussion of the Pfizer Transaction. Total contract liabilities included in Accrued expenses and Other long-term liabilities was $17.7 million and $21.8 million at June&#160;30, 2020 and December&#160;31, 2019, respectively.  The contract liability balance at June&#160;30, 2020 related primarily to accelerated payments received as part of the COVID-19 Aid, Relief, and Economic Security (CARES) Act.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMzY2NQ_fcc9bba1-ae22-4651-a6de-82d965214d29"
      unitRef="usd">200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMzY3Mg_143851a2-8c9e-4673-97ec-5e2cb91a6808"
      unitRef="usd">-14300000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <opk:AccruedExpensePayorOverpaymentReimbursementLiability
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfNjE5OQ_9fa07b17-16f9-44c5-a2a1-e60ea5f19b30"
      unitRef="usd">21400000</opk:AccruedExpensePayorOverpaymentReimbursementLiability>
    <opk:AccruedExpensePayorOverpaymentReimbursementLiability
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfNjIwNg_aaeaa075-1fc4-42cf-b343-259f00ead834"
      unitRef="usd">27300000</opk:AccruedExpensePayorOverpaymentReimbursementLiability>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMjE5OTAyMzI3MzUxNw_eb473d58-9455-4c5c-8648-d774e158f639">The composition of Revenue from services by payor for the six months ended June 30, 2020 and 2019 was as follows:&lt;div style="text-align:center;margin-top:14pt;margin-bottom:10pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.039%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;183,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;211,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Client payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;421,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;357,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Client payers include cities and states for which BioReference provides COVID-19 testing services.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i287de0999fc24a5cb5546c28ae66980f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMi0xLTEtMS0w_8fb7619d-7003-4aff-9f5b-99d8e57b5031"
      unitRef="usd">84082000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd5de3ee3106459b8b1aaab7a6b137d4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMi0zLTEtMS0w_28b4b406-dc08-40e3-a967-2e720eb6f833"
      unitRef="usd">106278000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2f7c56771ab4b20b7d3fa3715695ba7_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMi01LTEtMS0w_ecba4ca4-e31e-4709-8aba-dc3f9b4ab0bf"
      unitRef="usd">183232000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e55f87c472d4233942a0970f859291b_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMi03LTEtMS0w_16356cdb-a7c0-4cb3-aa2f-68f2e2ed4192"
      unitRef="usd">211207000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fb7acf8a79143cfb95180991f377710_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMy0xLTEtMS0w_334fea8b-8576-409d-9f63-0c24213a7508"
      unitRef="usd">15886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia071dd1966f14fa29801b16850ffc8ea_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMy0zLTEtMS0w_7ad4a716-aa40-472e-acea-f5db8d652ea7"
      unitRef="usd">28634000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6668a10b9952410e9af8b9a573c3e502_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMy01LTEtMS0w_655dd318-2d82-4d57-9996-1b17c398faa8"
      unitRef="usd">42784000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7313b7ad75404a70aedcc5983ef98116_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfMy03LTEtMS0w_30f855dd-dd09-42db-aaa3-84e848c0c58e"
      unitRef="usd">59037000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8d2333fa91a41edb9d18575c207b357_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNC0xLTEtMS0w_657d1cf8-a6c2-4e22-8646-101cd17302e7"
      unitRef="usd">141090000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic673a0ad279b49569adc8053d136c9ed_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNC0zLTEtMS0w_334abf97-ce02-478b-a9e8-917948944380"
      unitRef="usd">38101000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i357cf1c7f87349e9a4ad4f30e32145c1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNC01LTEtMS0w_86087644-00d6-4267-9327-f09b1235898d"
      unitRef="usd">180191000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2604b5fdeede46d09d8201be1e143102_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNC03LTEtMS0w_c984225b-2e59-4532-a8e3-11be482efb23"
      unitRef="usd">76559000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98c6c923d99b4f72ba76f4043d93e5b7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNS0xLTEtMS0w_e3f68f6f-6d0f-4819-ac08-6346a10f26dc"
      unitRef="usd">9913000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafbe4baeeb164e489598f3e93202ba13_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNS0zLTEtMS0w_c9c9c529-783c-48bb-8cb9-d4c90ad17ca0"
      unitRef="usd">5445000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7fba9e8f0b849fca41dd97146435305_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNS01LTEtMS0w_6c006596-19c9-4b5e-ba46-4afc53df5e6a"
      unitRef="usd">15604000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd71af6f0ead42e3977e6816580c5b93_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNS03LTEtMS0w_ad71ce9c-c871-42d6-ac7d-5326d1d0ffa7"
      unitRef="usd">10546000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b0d7b56e4e464a9d12b6d4962aea9f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNi0xLTEtMS0w_313291fe-d5a6-4370-a006-0174614bbdc4"
      unitRef="usd">250971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e422d827f1b4988be46200738452fe0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNi0zLTEtMS0w_2c46b322-49c4-4c2e-8c60-d27bc97dbb2b"
      unitRef="usd">178458000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i717fe99763b443568a4e4ea66cbaafd2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNi01LTEtMS0w_0c59e9a2-3e16-465e-a78d-135f8f7f602a"
      unitRef="usd">421811000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia322ccb5ede0412f84ec2408b2552856_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjVlMjNiZTBkOGJjNjRiODRiNDg2M2E3YmQ5OGE2ZTQ5L3RhYmxlcmFuZ2U6NWUyM2JlMGQ4YmM2NGI4NGI0ODYzYTdiZDk4YTZlNDlfNi03LTEtMS0w_ec93acdb-0783-4f27-93bb-767c95215049"
      unitRef="usd">357349000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfODI5Nw_645c2a0c-71ae-4b95-8a22-4e585698e13b"
      unitRef="usd">8600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTY0OTI2NzQ1NzA3OQ_b30c03f5-ca06-4ff2-a4e5-22e83720bdbd"
      unitRef="usd">18600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i0c056955493c4da89ecda0e8ec4dfeba_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfODMwNA_5b7ed3f8-bfc3-496b-b2bf-ce68a4e7b493"
      unitRef="usd">5700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i089a4e13e63742a3bf748b525008d6b6_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTY0OTI2NzQ1NzE1Nw_dc6a7534-dc4f-4a7e-bc24-1f7864f9f736"
      unitRef="usd">11500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <opk:ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTUzMDU_a6fb5e9e-a27c-4fac-a28a-8e7f0c55a3b8">&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents an analysis of product sales allowances and accruals for the three and six months ended June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:47.558%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.617%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.593%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Chargebacks, discounts, rebates and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Governmental &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Credits or payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total gross &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Provision for &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales allowances and accruals as a percentage of gross &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:47.558%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.617%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.593%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Chargebacks, discounts, rebates and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Governmental &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Credits or payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total gross &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Provision for &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales allowances and accruals as a percentage of gross &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;</opk:ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia7a45f8733e649d5a143646e955ce1f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMS0yLTEtMS0zMTgx_07d6dc86-4c14-47da-bac4-259b00ef33c3"
      unitRef="usd">2863000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="icbef2a22641441ef8b13514f0f8eebc1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMS00LTEtMS0zMTgx_dd18ca10-50be-4659-8cb5-5127d7ced814"
      unitRef="usd">6199000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ic702ce3d60b840edaa4bec0798d18d2e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMS02LTEtMS0zMTgx_f12a3b0c-4297-4034-aeaf-80805323244c"
      unitRef="usd">3332000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ic01e46e792ea463fb3ad976ee43f07a4_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMS04LTEtMS0zMTgx_2f97152f-36f9-41a2-a422-9f9d115fe72a"
      unitRef="usd">12394000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i387d466a792a4a228b1f3c6bc7fc4238_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMi0yLTEtMS0zMTgx_1c839d02-e9a7-4016-bb74-21b3cbc2072f"
      unitRef="usd">4468000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="id67bcee65e014a2a88bd297922d60030_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMi00LTEtMS0zMTgx_ca71f2b2-e30f-4b4a-895f-687b7d823e7a"
      unitRef="usd">9073000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i66ba957ba45c4cb99119dded44d3d424_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMi02LTEtMS0zMTgx_87d5b1d6-3a8e-4f0c-88f7-2e2927498948"
      unitRef="usd">686000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfMi04LTEtMS0zMTgx_1790ebd0-a802-4218-a649-a22852109581"
      unitRef="usd">14227000</us-gaap:ProvisionForDoubtfulAccounts>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="i387d466a792a4a228b1f3c6bc7fc4238_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNC0yLTEtMS0zMTgx_52c9bb08-66b1-4a15-a2eb-48127cc50c84"
      unitRef="usd">4441000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="id67bcee65e014a2a88bd297922d60030_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNC00LTEtMS0zMTgx_40a0e60a-7fe9-42bf-a44f-05ba9f7addc3"
      unitRef="usd">8273000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="i66ba957ba45c4cb99119dded44d3d424_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNC02LTEtMS0zMTgx_2831bfdc-f2ae-4180-8785-5a3443feba52"
      unitRef="usd">188000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNC04LTEtMS0zMTgx_7437e0c3-e5de-47f9-8704-eda0cc22f9c4"
      unitRef="usd">12902000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i7922e995a9b44dc296c267b40bfec5f5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNS0yLTEtMS0zMTgx_6a9599c5-b316-43bd-b962-90e38436bfaf"
      unitRef="usd">2890000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ic0a4001228bb4c458e9d188609ce4c92_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNS00LTEtMS0zMTgx_0a0d3f8f-9b61-4d6d-a87c-d6297272483b"
      unitRef="usd">6999000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="iaa95a3813d3b4948b9efc4c7b0d46611_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNS02LTEtMS0zMTgx_ffc1aeca-872b-40d4-a58e-d9752cc78ad8"
      unitRef="usd">3830000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i8fdb6f9b86ce4bbb9158e2c6d20fc489_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNS04LTEtMS0zMTgx_86799839-70c2-40b8-b3fb-60305ad87790"
      unitRef="usd">13719000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfNy04LTEtMS0zMTgx_1e778853-c018-4320-a658-7fa06c661287"
      unitRef="usd">22876000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales
      contextRef="i1d7d1bd2cbbb4e969f5b19be66afada8_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOjI3OGNiMDgxNjFjMzQ5YzlhN2M1OTI5MDEyYmY5ZDdiL3RhYmxlcmFuZ2U6Mjc4Y2IwODE2MWMzNDljOWE3YzU5MjkwMTJiZjlkN2JfOC04LTEtMS0zMTgx_26ef282b-80e9-4b90-bd91-b9d5db91c0c2"
      unitRef="number">0.62</opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i0f98c06a3c1e4ad896eadb86f6436385_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMS0yLTEtMS0w_40437988-f161-4982-a504-749ca93f4ed1"
      unitRef="usd">3194000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i2327c5e5ccd74c11bba8c2252aa98414_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMS00LTEtMS0w_320c935f-4945-4d5a-b5ac-923091df437b"
      unitRef="usd">5841000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id6569a37c094481dbbbf19ebad7e7881_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMS02LTEtMS0w_9733fb22-8bca-49cb-882c-659ebc7be601"
      unitRef="usd">2751000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ic15d90a4230749868f5b5c698ace3ce2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMS04LTEtMS0w_aae966bf-a2b2-45dd-b6bd-146b1de79c7e"
      unitRef="usd">11786000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i3e3522057538446ea1d251088ff7d6f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMi0yLTEtMS0w_bb9c1e2f-42a7-4daa-a8bd-e725f4ac0241"
      unitRef="usd">9293000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i8fa68b3c3ee24bd292852c6f5f85587c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMi00LTEtMS0w_104e006b-8459-40cd-9316-77855676de51"
      unitRef="usd">16281000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i0ac0c06819a046cfa71bf39ddbd390fc_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMi02LTEtMS0w_e1a16c93-a982-46ca-bb40-193401cba9f3"
      unitRef="usd">1389000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfMi04LTEtMS0w_ae608ea6-4f7f-43de-b25f-3ca17bf9db3b"
      unitRef="usd">26963000</us-gaap:ProvisionForDoubtfulAccounts>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="i3e3522057538446ea1d251088ff7d6f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNC0yLTEtMS0w_a2a1ee7c-0025-4919-957f-a11b2ae2484c"
      unitRef="usd">9597000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="i8fa68b3c3ee24bd292852c6f5f85587c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNC00LTEtMS0w_a772ec59-9a06-4bd1-b7b9-94a024ab777d"
      unitRef="usd">15123000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="i0ac0c06819a046cfa71bf39ddbd390fc_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNC02LTEtMS0w_7f7de239-6403-44ca-8ed6-6811207e3bcd"
      unitRef="usd">310000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNC04LTEtMS0w_775abadb-ee8c-44e3-b23b-340393a75540"
      unitRef="usd">25030000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i7922e995a9b44dc296c267b40bfec5f5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNS0yLTEtMS0w_174a85aa-b621-4a82-a949-7d4d8d08dbca"
      unitRef="usd">2890000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ic0a4001228bb4c458e9d188609ce4c92_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNS00LTEtMS0w_caf7b807-c399-4b1f-966a-1300e583c0d1"
      unitRef="usd">6999000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="iaa95a3813d3b4948b9efc4c7b0d46611_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNS02LTEtMS0w_f428d769-2bc5-4a60-a26b-3f19c3002fc9"
      unitRef="usd">3830000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i8fdb6f9b86ce4bbb9158e2c6d20fc489_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNS04LTEtMS0w_8c6fc0ef-0799-4beb-8f25-c81c8bee0cf9"
      unitRef="usd">13719000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfNy04LTEtMS0w_e12f8158-c46e-4ba0-95c1-164f1fdaf0db"
      unitRef="usd">45559000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales
      contextRef="ie398aed45822410ea39c6dd45698fc47_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RhYmxlOmVjMzJhYWQ3MjFhNjQ0M2Q4MzIzZTNhZTQ1NjFhMTZhL3RhYmxlcmFuZ2U6ZWMzMmFhZDcyMWE2NDQzZDgzMjNlM2FlNDU2MWExNmFfOC04LTEtMS0w_bbce13a5-f155-4abb-b8a0-100f1fb40034"
      unitRef="number">0.59</opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3e2e61832ff4501874806792daa7e45_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTQ5NzU_d307dce7-710c-4e67-bd42-ea326ef6ad34"
      unitRef="usd">13900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia335908fb412465eaee57977f0412a4d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTY0OTI2NzQ1NzMwOA_76399cb3-caf7-4943-9b44-5ec6e9d02068"
      unitRef="usd">22700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d636303815c49c8a2406f9aaa62f932_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMjE5OTAyMzI3MzM2OQ_99be7ece-31c9-4a61-a039-196b29f90656"
      unitRef="usd">6200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b958666966849daa4cbbd1cef96fbf6_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTQ5ODI_c22c4715-9ac2-47f3-9085-259478d3c6e0"
      unitRef="usd">18200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2fe40f321844ae6bf4ae91cb7dc8144_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTY0OTI2NzQ1NzU0Ng_e9e4906b-cd58-4711-bd72-e9c38f5a22d2"
      unitRef="usd">35600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTUxNzY_677c0260-3479-4747-94ad-a2028a8d9a97"
      unitRef="usd">17700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185MS9mcmFnOjU0NDRmZWIzYzBkNDRmY2I4Y2E5NjljN2ZiMTM4ODI3L3RleHRyZWdpb246NTQ0NGZlYjNjMGQ0NGZjYjhjYTk2OWM3ZmIxMzg4MjdfMTUxODM_97f4d72e-81a0-4021-b8a4-ae929420dc9a"
      unitRef="usd">21800000</us-gaap:ContractWithCustomerLiability>
    <opk:StrategicAlliancesTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTU0Nzk_4ce44a7f-567f-4333-8817-783b543721ad">STRATEGIC ALLIANCES&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Japan Tobacco Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On October 12, 2017, EirGen, our wholly owned subsidiary, and Japan Tobacco Inc. (&#x201c;JT&#x201d;) entered into a Development and License Agreement (the &#x201c;JT Agreement&#x201d;) granting JT the exclusive rights for the development and commercialization of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in Japan (the &#x201c;JT Territory&#x201d;).  The license grant to JT covers the therapeutic and preventative use of the product for (i)&#160;SHPT in non-dialysis and dialysis patients with CKD, (ii)&#160;rickets, and (iii)&#160;osteomalacia (the &#x201c;JT Initial Indications&#x201d;), as well as such additional indications as may be added to the scope of the license subject to the terms of the JT Agreement (the JT Additional Indications&#x201d; and together with the JT Initial Indications, the &#x201c;JT Field&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the license, OPKO received an initial upfront payment of $6 million and received another $6 million upon the initiation of OPKO&#x2019;s phase 2 study for &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in dialysis patients in the U.S. in September 2018 (the &#x201c;Initial Consideration&#x201d;). OPKO is also eligible to receive up to an additional aggregate amount of $31 million upon the achievement of certain regulatory and development milestones by JT for &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in the JT Territory, and $75 million upon the achievement of certain sales based milestones by JT in the JT Territory.  OPKO is also entitled to receive tiered, double digit royalty payments at percentages ranging from low double digits to mid-teens on net sales of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;within the JT Territory.  JT will, at its sole cost and expense, be responsible for performing all development activities necessary to obtain all regulatory approvals for &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in Japan and for all commercial activities pertaining to &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The JT Agreement provides for the following:  (1) an exclusive license in the JT Territory in the JT Field for the development and commercialization of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;; and (2) at JT&#x2019;s option, EirGen will supply products to support the development, sale and commercialization of the products to JT in the JT Territory.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Initial Consideration will be recognized over the performance period through 2021, when we anticipate completing the transfer of license materials specified in the JT Agreement and our performance obligation is complete.  Payments received for regulatory, development and sales milestones are non-refundable.  The milestones are payable if and when the associated milestone is achieved and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, no revenue has been recognized related to these milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Vifor Fresenius Medical Care Renal Pharma Ltd&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2016, EirGen and Vifor Fresenius Medical Care Renal Pharma Ltd (&#x201c;VFMCRP&#x201d;), entered into a Development and License Agreement (the &#x201c;VFMCRP Agreement&#x201d;) for the development and commercialization of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (the &#x201c;Product&#x201d;) worldwide, except for (i) the U.S., (ii) any country in Central America or South America (excluding Mexico), (iii) Russia, (iv) China, (v) Japan, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, and (x) Taiwan (the &#x201c;VFMCRP Territory&#x201d;).  The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the &#x201c;VFMCRP Field&#x201d;), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with CKD and vitamin D insufficiency/deficiency (the &#x201c;VFMCRP Initial Indication&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Effective May 5, 2020, we entered into an amendment to the VFMCRP Agreement (the &#x201c;VFMCRP Amendment&#x201d;), pursuant to which the parties agreed to exclude Mexico, South Korea, the Middle East and all of the countries of Africa from the VFMCRP Territory. In addition, the parties agreed to certain amendments to the milestone structure and to reduce minimum royalties payable. As revised, EirGen is eligible to receive up to $20&#160;million in Regulatory Milestones and $210&#160;million in Sales Milestones tied to launch, pricing and sales of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the VFMCRP Agreement, as amended, EirGen granted to VFMCRP an exclusive license in the VFMCRP Territory in the VFMCRP Field to use certain EirGen patents and technology to make, have made, use, sell, offer for sale, and import Products and to develop, commercialize, have commercialized, and otherwise exploit the Product.  EirGen received a non-refundable and non-creditable initial payment of $50 million, which was recognized in Revenue from the transfer of intellectual property and other in our Consolidated Statement of Operations in 2016.  EirGen also received a $2.0 million payment triggered by the approval of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in Canada for the treatment of SHPT in adults with stage 3 or 4 CKD and vitamin D insufficiency in July 2018. EirGen is also eligible to receive up to an additional $20&#160;million in regulatory milestones (&#x201c;Regulatory Milestones&#x201d;) and $210&#160;million in Sales Milestones tied to launch, pricing and sales of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;Sales Milestones&#x201d;), and will receive tiered royalties on sales of the product at percentage rates that range from the mid-teens to the mid-twenties or a minimum royalty, whichever is greater, upon the commencement of sales of the Product within the VFMCRP Territory and in the VFMCRP Field.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We plan to share responsibility with VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan.  EirGen will lead the manufacturing activities within and outside the VFMCRP Territory and the commercialization activities outside the VFMCRP Territory and outside the VFMCRP Field in the VFMCRP Territory and VFMCRP will lead the commercialization activities in the VFMCRP Territory and the VFMCRP Field.  For the initial development plan, the companies have agreed to certain cost sharing arrangements.  VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in the VFMCRP Territory in the VFMCRP Field except as otherwise provided in the VFMCRP Agreement.  The first of the clinical studies provided for in the development activities commenced in September 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted to VFMCRP an exclusive option (the &#x201c;Option&#x201d;) to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the U.S. solely for the treatment of SHPT in dialysis patients with CKD and vitamin D insufficiency (the &#x201c;Dialysis Indication&#x201d;).  Upon exercise of the Option, VFMCRP will reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the U.S.  VFMCRP would also pay EirGen up to an additional aggregate amount of $555 million of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the U.S. for the Dialysis Indication.  To date, VFMCRP has not exercised its option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payments received for Regulatory Milestones and Sales Milestones are non-refundable.  The Regulatory Milestones are payable if and when VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  We account for the Sales Milestones as royalties and Sales Milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2014, we entered into an exclusive worldwide agreement (the &#x201c;Pfizer Agreement&#x201d;) with Pfizer for the development and commercialization of our long-acting hGH-CTP (Somatrogon) for the treatment of growth hormone deficiency (&#x201c;GHD&#x201d;) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (the &#x201c;Pfizer Transaction&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2020, we entered into an Amended and Restated Development and Commercialization License Agreement (the &#x201c;Restated Agreement&#x201d;) with Pfizer, effective January 1, 2020, pursuant to which the parties agreed, among other things, to share all costs for Manufacturing Activities, as defined in the Restated Agreement, for developing a licensed product for the three indications included in the Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On October 21, 2019, we and Pfizer announced that the global phase 3 trial evaluating Somatrogon (hGH-CTP) dosed once-weekly in prepubertal children with GHD met its primary endpoint of non-inferiority to daily Genotropin&#xae; (somatropin) for injection, as measured by annual height velocity at 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the Pfizer Transaction, as restated, we received non-refundable and non-creditable upfront payments of $295.0 million and are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones.  Pfizer received the exclusive license to commercialize hGH-CTP worldwide.  In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of hGH-CTP for adult GHD with percentage rates ranging from the high teens to mid-twenties.  Upon the launch of hGH-CTP for pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both hGH-CTP and Pfizer&#x2019;s Genotropin&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The agreement with Pfizer will remain in effect until the last sale of the licensed product, unless earlier terminated as permitted under the Pfizer Agreement.  In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Pfizer Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period.  If the Pfizer Agreement is terminated by us for Pfizer&#x2019;s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions.     &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognized the non-refundable $295.0 million upfront payments as revenue as the research and development services were completed and as of June 30, 2020, we had no contract liabilities related to the Pfizer Transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Pfizer Transaction includes milestone payments of $275.0 million upon the achievement of certain milestones.  The milestones range from $20.0 million to $90.0 million each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets.  The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  To date, no revenue has been recognized related to the achievement of the milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;TESARO&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2009, we entered into an asset purchase agreement (the &#x201c;NK-1 Agreement&#x201d;) under which we acquired VARUBI&#x2122; (rolapitant) and other neurokinin-1 (&#x201c;NK-1&#x201d;) assets from Merck.  In December 2010, we entered into an exclusive license agreement with TESARO, Inc. (&#x201c;TESARO&#x201d;), in which we out-licensed the development, manufacture, commercialization and distribution of our lead NK-1 candidate, VARUBI&#x2122; (the &#x201c;TESARO License&#x201d;).  Under the terms of the license, we received a $6.0 million upfront payment from TESARO and we received $30 million of milestone payments from TESARO upon achievement of certain regulatory and commercial sale milestones and we are eligible to receive additional commercial milestone payments of up to $85 million if specified levels of annual net sales are achieved.  The sales based milestone payments will be recognized as revenue in full in the period in which the associated sales occur. For the six months ended June 30, 2020 and 2019, no revenue was recognized related to the achievement of the milestones under the TESARO License. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the TESARO License, TESARO was also obligated to pay us tiered royalties on annual net sales achieved in the U.S. and Europe at percentage rates that range from the low double digits to the low twenties, and outside of the U.S. and Europe at low double-digit percentage rates until the later of the date that all of the patent rights licensed from us and covering VARUBI&#x2122; expire, are invalidated or are not enforceable and 12 years from the first commercial sale of the product.  TESARO announced in 2018 that it had elected to suspend further distribution of Varubi IV.  In June 2018, TESARO assigned its rights and obligations under the agreement to TerSera Therapeutics LLC (&#x201c;TerSera&#x201d;) pursuant to an asset purchase agreement.  Under the asset purchase agreement, TerSera is responsible for VARUBI in the U.S. and Canada and TESARO was permitted to continue to commercialize VARUBY&#xae; in Europe and the rest of the world though a sublicense with TerSera.  In September 2019, TESARO informed us and TerSera that it intends to stop selling VARUBY&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in the TESARO Territory and that it intends to withdraw its marketing authorization for VARUBY&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The term of the license with TerSera will remain in force until the expiration of the royalty term in each country, unless we terminate the license earlier for material breach of the license or bankruptcy.  TerSera has a right to terminate the license at any time during the term for any reason on three months&#x2019; written notice.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Pharmsynthez &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2013, we entered into a series of concurrent transactions with Pharmsynthez, a Russian pharmaceutical company traded on the Moscow Stock Exchange, pursuant to which we acquired an equity method investment in Pharmsynthez (ownership 9%).  We also granted rights to certain technologies in the Russian Federation, Ukraine, Belarus, Azerbaijan and Kazakhstan (the &#x201c;Pharmsynthez Territories&#x201d;) to Pharmsynthez and agreed to perform certain development activities.  We will receive from Pharmsynthez royalties on net sales of products incorporating the technologies in the Pharmsynthez Territories, as well as a percentage of any sublicense income from third parties for the technologies in the Pharmsynthez Territories.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Phio Pharmaceuticals Corp.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2013, we completed the sale to RXi Pharmaceuticals Corporation (now known as Phio Pharmaceuticals Corp.) of substantially all of our assets in the field of RNA interference (the &#x201c;RNAi Assets&#x201d;) (collectively, the &#x201c;Asset Purchase Agreement&#x201d;).  Pursuant to the Asset Purchase Agreement, Phio will be required to pay us up to $50.0 million in milestone payments upon the successful development and commercialization of each drug developed by Phio, certain of its affiliates or any of its or their licensees or sublicensees utilizing patents included within the RNAi Assets (each, a &#x201c;Qualified Drug&#x201d;).  In addition, Phio will also be required to pay us royalties equal to: (a)&#160;a mid single-digit percentage of &#x201c;Net Sales&#x201d; (as defined in the Asset Purchase Agreement) with respect to each Qualified Drug sold for an ophthalmologic use during the applicable &#x201c;Royalty Period&#x201d; (as defined in the Asset Purchase Agreement); and (b)&#160;a low single-digit percentage of net sales with respect to each Qualified Drug sold for a non-ophthalmologic use during the applicable Royalty Period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have completed strategic deals with numerous institutions and commercial partners.  In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements.  At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products.&lt;/span&gt;&lt;/div&gt;</opk:StrategicAlliancesTextBlock>
    <opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment
      contextRef="i85584120b6ae40969ed88e8fc454cbac_D20171012-20171012"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfODM5_a382e991-a609-45e8-8b96-dcdac31d7588"
      unitRef="usd">6000000</opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment>
    <opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment
      contextRef="i12ba1de7824543edbdd98ac438e809ef_D20180901-20180930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfODYz_a6d37a0f-1b6e-4a9e-b743-d9d9ecf70d03"
      unitRef="usd">6000000</opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment>
    <opk:ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment
      contextRef="i96d78de3ebc6453598709f12f3820f35_D20171012-20171012"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTA3OA_77d04e9b-af20-424a-bcbe-e608a268b9ee"
      unitRef="usd">31000000</opk:ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment>
    <opk:ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment
      contextRef="ie228af85f95c497a87274c2e14523168_D20171012-20171012"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTE5NQ_483de098-af07-4240-b662-d212cded3939"
      unitRef="usd">75000000</opk:ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i7eed0ec839c8449599c9e800686ae3ce_D20171012-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMjU1Nw_9378d8a5-d728-4490-a802-690fb253b32d"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <opk:CollaborativeArrangementMaximumMilestonePayments
      contextRef="i61fa984d891a47d58311053b2676c0d2_D20200505-20200505"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMjE5OTAyMzI3MjA0Nw_83ad256d-2d7a-46ab-a1c9-d97fa8753ee5"
      unitRef="usd">20000000</opk:CollaborativeArrangementMaximumMilestonePayments>
    <opk:CollaborativeArrangementMaximumMilestonePayments
      contextRef="i27932b492e774f8db8526aebe560cf2c_D20200505-20200505"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMjE5OTAyMzI3MjA2MA_1a477170-58ec-4a97-ad2b-5ed17a90519a"
      unitRef="usd">210000000</opk:CollaborativeArrangementMaximumMilestonePayments>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="i36465446b239476682a20c709bd20264_D20160501-20160531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMzg5MA_13ccdbcb-13b6-4c02-a5b5-56adc57758d8"
      unitRef="usd">50000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <opk:CollaborativeAgreementAdditionalMilestonePayment
      contextRef="i80e8caee7a4340afab2963d15be9c425_D20180701-20180731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfNDA1Ng_7720e27d-f52a-4f90-814f-16f34feb8446"
      unitRef="usd">2000000.0</opk:CollaborativeAgreementAdditionalMilestonePayment>
    <opk:CollaborativeArrangementMaximumMilestonePayments
      contextRef="i61fa984d891a47d58311053b2676c0d2_D20200505-20200505"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfNjU5NzA2OTc4MzU2NA_83ad256d-2d7a-46ab-a1c9-d97fa8753ee5"
      unitRef="usd">20000000</opk:CollaborativeArrangementMaximumMilestonePayments>
    <opk:CollaborativeArrangementMaximumMilestonePayments
      contextRef="i27932b492e774f8db8526aebe560cf2c_D20200505-20200505"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfNjU5NzA2OTc4MzYwNA_1a477170-58ec-4a97-ad2b-5ed17a90519a"
      unitRef="usd">210000000</opk:CollaborativeArrangementMaximumMilestonePayments>
    <opk:CollaborativeArrangement.MaximumMilestonePayments
      contextRef="i1aca0bd3383748acb9d44a211a37ecaf_D20160501-20160531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfNjg0OQ_24d717f6-7d92-4b25-a861-b2c6811abc5b"
      unitRef="usd">555000000</opk:CollaborativeArrangement.MaximumMilestonePayments>
    <opk:CollaborativeArrangementAnnualHeightVelocityatPointinTime
      contextRef="i40db44cde7914640bc267bc5d3ca1d33_D20191021-20191021"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfODQyNQ_86becc3d-2b41-4b14-964a-8bc404b3be65">P12M</opk:CollaborativeArrangementAnnualHeightVelocityatPointinTime>
    <opk:CollaborativeArrangementUpfrontPayment
      contextRef="i0bb57ae1dccc4112800dea209c9b6318_D20150101-20150131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfODU4Ng_7a15805c-4a93-4be5-aaf9-84af0108120e"
      unitRef="usd">295000000.0</opk:CollaborativeArrangementUpfrontPayment>
    <opk:CollaborativeArrangement.MaximumMilestonePayments
      contextRef="i0bb57ae1dccc4112800dea209c9b6318_D20150101-20150131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfODYzNw_8598c98c-e16a-4b42-ae48-f5afe029d4fc"
      unitRef="usd">275000000.0</opk:CollaborativeArrangement.MaximumMilestonePayments>
    <opk:CollaborativeArrangementUpfrontPayment
      contextRef="i0bb57ae1dccc4112800dea209c9b6318_D20150101-20150131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfOTk0Mg_cafc2c91-3d8f-4adc-91ba-8b97d13dc752"
      unitRef="usd">295000000.0</opk:CollaborativeArrangementUpfrontPayment>
    <opk:CollaborativeArrangement.MaximumMilestonePayments
      contextRef="i0bb57ae1dccc4112800dea209c9b6318_D20150101-20150131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTAyMDE_834f110e-ca4b-4aa4-b4d0-b2da2e80f1f4"
      unitRef="usd">275000000.0</opk:CollaborativeArrangement.MaximumMilestonePayments>
    <opk:CollaborativeArrangementMilestonePayment
      contextRef="ic54c6d599fea4f00a596b9e77dc46c21_D20150101-20150131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTAyNzU_e1e6b27d-155f-4253-acb7-3fef69d6c88d"
      unitRef="usd">20000000.0</opk:CollaborativeArrangementMilestonePayment>
    <opk:CollaborativeArrangementMilestonePayment
      contextRef="i090a78b5b12948a8bc788af6634489b5_D20150101-20150131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTAyODE_d4a52348-156c-424d-9c78-466db5fe969e"
      unitRef="usd">90000000.0</opk:CollaborativeArrangementMilestonePayment>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i4935e51954e74cb4802f926d08c79c4e_D20150101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTA2MDI_0a43837d-97b1-4f05-865f-32fb2af3922b"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <opk:LicenseandCollaborationAgreementsProceedsasUpFrontPayment
      contextRef="if7a4105b8a0d43d798aa66064542811f_D20101201-20101231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTExNjA_0825da0b-fc1d-4dae-adee-77c5ad95e179"
      unitRef="usd">6000000.0</opk:LicenseandCollaborationAgreementsProceedsasUpFrontPayment>
    <opk:CollaborativeArrangementMilestonePaymentReceived
      contextRef="if83c5551238f479bbacf93c87bc5c2a9_D20101201-20180930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTEyMDc_ade390cc-76c9-4e3c-8091-b663ef74205e"
      unitRef="usd">30000000</opk:CollaborativeArrangementMilestonePaymentReceived>
    <opk:CollaborativeAgreementAdditionalMilestonePayment
      contextRef="if7a4105b8a0d43d798aa66064542811f_D20101201-20101231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTEzOTU_55fe5214-8dfd-489e-9bab-71301a97e87a"
      unitRef="usd">85000000</opk:CollaborativeAgreementAdditionalMilestonePayment>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i080c53c4c6124f38aaee94f9fcbb0577_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTE1OTg_45db6fa7-4c0b-4a62-808a-8fe3bb7da810"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i5b1c90b9bdb34bb583bd46dc1902301f_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTE1OTg_c03440e8-dac9-44a7-8252-8df9fb222e0e"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <opk:CollaborativeAgreementPeriodfromFirstCommercialSale
      contextRef="if7a4105b8a0d43d798aa66064542811f_D20101201-20101231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTIxMjU_76fa8ba2-cbc8-49b3-953f-35334f5fca09">P12Y</opk:CollaborativeAgreementPeriodfromFirstCommercialSale>
    <opk:CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTMxNTQ_8aefad29-8b4b-4d1d-943c-1aaa01900f48">P3M</opk:CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib4fc9634e3a348bab19da19df297d2c9_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTM0Mzg_740cdd31-f996-483a-a209-6faa23fe4014"
      unitRef="number">0.09</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <opk:EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived
      contextRef="i284f86e01b904662b657fa1db96fa2a3_I20130331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM185NC9mcmFnOmZjYzJiZDZiYTkzOTQ5OGI5NTExNThiNjkwNjg1MjVmL3RleHRyZWdpb246ZmNjMmJkNmJhOTM5NDk4Yjk1MTE1OGI2OTA2ODUyNWZfMTQyODE_acdab066-68dd-4213-bead-3cc752af3875"
      unitRef="usd">50000000.0</opk:EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90ZXh0cmVnaW9uOmYwOTQ4OWJhY2RiNzQ3MGRhMDRkNTQwMjQ1ZjBhZDUxXzEwMDU_069b7b12-2fb8-4759-a8af-d3073901c971">SEGMENTS&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Rayaldee&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of our clinical laboratory operations through BioReference and our point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense and income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.039%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;421,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;357,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;421,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;357,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from transfer of intellectual property and other: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(38,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(61,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(47,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,581)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(122,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Depreciation and amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss from investment in investees:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;265,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;184,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;446,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;369,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;301,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;226,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;512,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;448,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.114%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,148,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,174,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,121,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,035,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,323,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,309,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;237,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;434,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;434,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;671,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;671,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;No customer represented more than 10% of our total consolidated revenue during the six months ended June 30, 2020 and 2019. As of June&#160;30, 2020 and December&#160;31, 2019, no customer represented more than 10% of our accounts receivable balance.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90ZXh0cmVnaW9uOmYwOTQ4OWJhY2RiNzQ3MGRhMDRkNTQwMjQ1ZjBhZDUxXzUw_450e2493-567b-4a6c-8516-d93a68d42f52"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:Revenues
      contextRef="ic884ff99f6fc4caabe0eb0adf1366e62_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90ZXh0cmVnaW9uOmYwOTQ4OWJhY2RiNzQ3MGRhMDRkNTQwMjQ1ZjBhZDUxXzQ0MQ_c58b8db2-887e-4bc5-957e-71da9482afe6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:InterestExpense
      contextRef="ic884ff99f6fc4caabe0eb0adf1366e62_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90ZXh0cmVnaW9uOmYwOTQ4OWJhY2RiNzQ3MGRhMDRkNTQwMjQ1ZjBhZDUxXzU2Nw_96cd310b-2d65-411a-8389-fd27026cceb9"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90ZXh0cmVnaW9uOmYwOTQ4OWJhY2RiNzQ3MGRhMDRkNTQwMjQ1ZjBhZDUxXzk5OA_356ad894-c398-4f81-9fcf-d0e5f8dab984">Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.039%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;421,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;357,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;421,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;357,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from transfer of intellectual property and other: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(38,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(61,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(47,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,581)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(122,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Depreciation and amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss from investment in investees:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;265,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;184,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;446,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;369,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;301,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;226,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;512,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;448,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.114%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,148,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,174,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,121,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,035,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,323,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,309,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;237,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;434,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;434,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;671,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;671,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i851a20819c20437db63c3ed7b80d94a3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMtMS0xLTEtMA_bbcb8d36-46c7-46b5-a1c5-e73c8be25a48"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d2c67981041400a9c26389895519dc2_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMtMy0xLTEtMA_880035f6-2bd7-48c5-8caa-9e2b1f7b765f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81434e108329422e88ec3e2303f45ee8_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMtNS0xLTEtMA_3fdac6fc-bd0f-481d-bd0e-7fd46eafa91e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44f0b42571364216bc7c04e7377e706e_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMtNy0xLTEtMA_74f8571b-043c-4651-a894-7d1c003aba93"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ba6b13bf7a9415ab5f66ca96f8d16e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQtMS0xLTEtMA_50e77dd0-9f73-4984-b31d-4f961d452561"
      unitRef="usd">250971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68fb7f858bc4413a97b4525dd5797a6f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQtMy0xLTEtMA_02ea13f3-cf4c-4858-946d-2689b28caa6e"
      unitRef="usd">178458000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafd6856e572145f7aa974629ed727822_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQtNS0xLTEtMA_4e745f04-8f20-4bcd-a0cc-4feebaa34479"
      unitRef="usd">421811000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08298c5ab2f84fd5ae3f88f51ad3bb30_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQtNy0xLTEtMA_43750b06-dd4f-4bd9-8084-c1ccafa15b61"
      unitRef="usd">357349000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62426df8ac264ca2861d073dca037333_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzUtMS0xLTEtMA_e9bf4c98-2b00-46ee-a011-a86002b55be8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8519b57ec414786acb984d55ce68d04_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzUtMy0xLTEtMA_5edde8e4-94c1-4be8-8663-8b457a2da5a4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9de6620da22b4ec5be9f72a4e769a2c8_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzUtNS0xLTEtMA_ba3a6e67-a6c7-4ad0-a944-70a4ec242c62"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b15741ac49b49afb0e5f05f9ae67e48_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzUtNy0xLTEtMA_2f5bc1ae-95e4-431c-a56e-e7545adca286"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b0d7b56e4e464a9d12b6d4962aea9f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzYtMS0xLTEtMA_82238f6b-f5a5-455f-b05e-9168454b8f66"
      unitRef="usd">250971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e422d827f1b4988be46200738452fe0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzYtMy0xLTEtMA_0ec7273a-5b4b-4423-96d0-6f234df450db"
      unitRef="usd">178458000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i717fe99763b443568a4e4ea66cbaafd2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzYtNS0xLTEtMA_f162eb93-2d1f-4c96-9a4c-206702e88f23"
      unitRef="usd">421811000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia322ccb5ede0412f84ec2408b2552856_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzYtNy0xLTEtMA_461cfa9d-8ec5-42a3-aed8-76795743824d"
      unitRef="usd">357349000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc753fb5d2a648f29daaac8bb88bc64f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzgtMS0xLTEtMA_73c4e6de-75d3-434e-babe-197bc1901adc"
      unitRef="usd">29356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b1215e9556046579114216aeac09f0a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzgtMy0xLTEtMA_fec05f62-d41b-46db-8a06-4939f8beaad6"
      unitRef="usd">28680000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f46c52a8ad4493da6d40440badaf26c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzgtNS0xLTEtMA_7b6990ed-9cc8-4360-93a9-d792be4fde86"
      unitRef="usd">60430000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4e1eb15dab448d6b2ea94c22565bff4_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzgtNy0xLTEtMA_1462152f-110d-41be-b623-cf069ff397ad"
      unitRef="usd">53981000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i440a8d7180944369aae265f885c6d28a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzExLTEtMS0xLTA_a3958ca4-b403-4930-9cbf-5b486cebfd28"
      unitRef="usd">29356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e6c1f5b817d47bf874e9f6b12b917c4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzExLTMtMS0xLTA_5ce2055e-ddfb-4a8a-8481-b90058b83bb2"
      unitRef="usd">28680000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3ee6bb1db084cdfb8f79401b5096546_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzExLTUtMS0xLTA_4a7572a4-c336-47aa-9574-75cd5e9cd2aa"
      unitRef="usd">60430000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8c4c5128c354e2dade223d90ca95718_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzExLTctMS0xLTA_335bf5be-9185-438b-b759-69c69e94004d"
      unitRef="usd">53981000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53552ab0d0f048c0902d204716895bdd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzEzLTEtMS0xLTA_3a100af8-9903-41be-9e05-caa96c2a1c62"
      unitRef="usd">14686000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i285f40a66d974262a93473c2fc344b4e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzEzLTMtMS0xLTA_ac335591-878d-4b3b-9b9d-6dfc0eb782d3"
      unitRef="usd">19230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifba1e15ab2b34df19c53cd26a28891e9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzEzLTUtMS0xLTA_2967d093-0c6d-408b-9ad9-265160e89091"
      unitRef="usd">24239000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22026731d58f47f6bd0ff0c6f70fcf10_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzEzLTctMS0xLTA_5a3b457c-24d1-43b3-83a6-8dd6e22b12c2"
      unitRef="usd">37490000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecdbfdd262384e3da2176a1036fa1472_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE0LTEtMS0xLTA_88c8233e-8ec5-42f8-957f-99be248e48b7"
      unitRef="usd">6194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2db64897d6404c58a431674a58d3c3b4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE0LTMtMS0xLTA_30a1bb87-71ca-40bf-9ff7-a90eed8a63d3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i127c96f883e447a49aa692832a21189b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE0LTUtMS0xLTA_2f924f8c-5613-4efe-b42e-172ac14e57f2"
      unitRef="usd">6194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7935d8cd6d2c4a9eb100d80e225fb6b1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE0LTctMS0xLTA_3fd1c7f7-052a-42ab-b7b2-06ef89ff96aa"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77b768751f6a4284aa23055c0a54e8e7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE1LTEtMS0xLTA_9a6d916d-98df-411e-9669-81329195f754"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a6eba59724c47faa438965d96def811_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE1LTMtMS0xLTA_b171960f-3eb8-47b2-9244-8070487df846"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb999c735a4342efba32032318fe7b05_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE1LTUtMS0xLTA_765b5dd6-18a3-4612-8be5-48dfa30f2a8c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23194842f3d84a37bd807bed4100a22e_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE1LTctMS0xLTA_fd31b0ef-13d1-4fde-85b3-168570438861"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dca3ea038b14e008a2d1981f1feded6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE2LTEtMS0xLTA_7b21a68c-d539-4731-bab7-4bab8c3b6c94"
      unitRef="usd">20880000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd98b19d90454faca4fb220c3e3f056a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE2LTMtMS0xLTA_328f8edb-5680-47d9-8ce8-63dd2b69b8d1"
      unitRef="usd">19230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7395bc7d5fc44e6cb1075481b8adb1cf_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE2LTUtMS0xLTA_7d76165a-c7e3-4ebe-a0e9-3f5ee6efe5fc"
      unitRef="usd">30433000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92dec2859b504d4dbeb247bd54453c0e_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE2LTctMS0xLTA_c242e509-cea2-4e83-8faa-f884b4fc5487"
      unitRef="usd">37490000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9dd9f71d8ea54fb3b4a6d84cc0903e51_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE4LTEtMS0xLTA_61221bfe-8e6d-4426-abdb-65ab1011221b"
      unitRef="usd">-5996000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i89565ed2865e40509a73fa94d9ac6df0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE4LTMtMS0xLTA_1f88c06c-497a-4e8a-9249-423e45c6f0b8"
      unitRef="usd">-8556000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1fc09bfbf0b54937b5e5c7c9ad9f5556_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE4LTUtMS0xLTA_6d1dea82-cb03-453c-8ad7-cf0bb20c95ae"
      unitRef="usd">-20121000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i536a503a71bf40b38d8e2df97401bda3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE4LTctMS0xLTA_321bdaa9-92d2-4a8f-83ae-a59f85c06297"
      unitRef="usd">-38033000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ief7ca9e930b14261a5d0126d1359cce0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE5LTEtMS0xLTA_70d2547d-e354-40a3-a73c-97d137b95ff4"
      unitRef="usd">40935000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i467d69f1593b4e59aeba2ae8185b03a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE5LTMtMS0xLTA_74656f7f-1152-4373-b79c-49f9867e13f3"
      unitRef="usd">-28013000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i95137661f82444ed8ade5d61a8c2693c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE5LTUtMS0xLTA_544751df-cb3d-409e-a1d1-177ec3cde080"
      unitRef="usd">22803000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i78ab453f6db84127938a7075db98d34c_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzE5LTctMS0xLTA_8a3cd9ab-4ac0-4f98-a5e3-dd7efc305341"
      unitRef="usd">-61582000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaccfccfe524e46b09fdc3bb72135977e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIwLTEtMS0xLTA_a9978980-87d8-41f4-b405-39366c973f35"
      unitRef="usd">-7760000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i70a53a1a90634b7198030c3447c9898c_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIwLTMtMS0xLTA_64f27e7c-6677-420c-82ed-ec5e0a6d6936"
      unitRef="usd">-10691000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i176405a326bc43a0a55b9bc8ac1d8bf2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIwLTUtMS0xLTA_86a5e6d5-2e9d-485b-8370-e5d0d6bb0e2e"
      unitRef="usd">-16263000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibf8ef541025e44ee8cf8686ede2517a7_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIwLTctMS0xLTA_ed742626-472d-4528-af55-7580e9428766"
      unitRef="usd">-22962000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIyLTEtMS0xLTA_4ee32f13-ff99-4f05-8c0d-376be9f8ac8b"
      unitRef="usd">27179000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIyLTMtMS0xLTA_83f0ac6a-6cae-4d69-b9f0-9dc44e46e781"
      unitRef="usd">-47260000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIyLTUtMS0xLTA_d4a6eb1f-b708-4bc8-9c11-7e2365244fd1"
      unitRef="usd">-13581000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzIyLTctMS0xLTA_6d762f17-1a75-4f2d-8281-ff227cd8b9b7"
      unitRef="usd">-122577000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9dd9f71d8ea54fb3b4a6d84cc0903e51_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI0LTEtMS0xLTA_535638bd-dd1a-4480-92a2-94641b8950b1"
      unitRef="usd">7119000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i89565ed2865e40509a73fa94d9ac6df0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI0LTMtMS0xLTA_5d6cbc04-8c03-4972-be05-6678bf77f3aa"
      unitRef="usd">7382000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1fc09bfbf0b54937b5e5c7c9ad9f5556_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI0LTUtMS0xLTA_c602f9e4-56e3-4d48-bf3e-4c1c64eca438"
      unitRef="usd">14240000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i536a503a71bf40b38d8e2df97401bda3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI0LTctMS0xLTA_a27ab96e-9316-4f47-9f35-3186fc4782eb"
      unitRef="usd">14908000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ief7ca9e930b14261a5d0126d1359cce0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI1LTEtMS0xLTA_190ee9eb-1160-46a0-ae0e-8246667eca16"
      unitRef="usd">15147000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i467d69f1593b4e59aeba2ae8185b03a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI1LTMtMS0xLTA_8f0b893e-887f-4ed9-b93e-fa8974226194"
      unitRef="usd">16260000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i95137661f82444ed8ade5d61a8c2693c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI1LTUtMS0xLTA_ede72d9e-7131-4f3d-bb52-23de26c208cf"
      unitRef="usd">30019000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i78ab453f6db84127938a7075db98d34c_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI1LTctMS0xLTA_b1486135-9701-4719-98a6-ab7daca3c5d9"
      unitRef="usd">32530000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iaccfccfe524e46b09fdc3bb72135977e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI2LTEtMS0xLTA_72fdfd3d-5b64-4398-82ad-c1ac4117ea87"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i70a53a1a90634b7198030c3447c9898c_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI2LTMtMS0xLTA_0fd477f4-e740-47b0-93c5-9167e1592e94"
      unitRef="usd">19000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i176405a326bc43a0a55b9bc8ac1d8bf2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI2LTUtMS0xLTA_1bfcf6ff-e314-4118-8d99-b87666e61f08"
      unitRef="usd">59000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibf8ef541025e44ee8cf8686ede2517a7_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI2LTctMS0xLTA_2873f147-2c45-4d7b-82a8-84d15457677d"
      unitRef="usd">39000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI3LTEtMS0xLTA_694921e3-c527-43b8-a0d8-8ea6b90d3826"
      unitRef="usd">22266000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI3LTMtMS0xLTA_7533fb01-3591-4043-ad89-1919195c25d1"
      unitRef="usd">23661000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI3LTUtMS0xLTA_009f3e77-b250-4d42-a430-aff525f564f1"
      unitRef="usd">44318000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI3LTctMS0xLTA_9331eda8-6c12-4ff4-a398-9bbe24fc946c"
      unitRef="usd">47477000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnInvestments
      contextRef="i9dd9f71d8ea54fb3b4a6d84cc0903e51_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI5LTEtMS0xLTA_4e84622e-8682-4f35-9baa-a6abfd954f36"
      unitRef="usd">-189000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i89565ed2865e40509a73fa94d9ac6df0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI5LTMtMS0xLTA_535b7ecf-348c-4b95-8528-7b96bc3338e3"
      unitRef="usd">-271000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i1fc09bfbf0b54937b5e5c7c9ad9f5556_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI5LTUtMS0xLTA_7fecc4ce-6d3b-4cbc-8159-4914fb2b093d"
      unitRef="usd">-323000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i536a503a71bf40b38d8e2df97401bda3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzI5LTctMS0xLTA_598be7a7-ef3d-4b81-aabb-ff0faa660c72"
      unitRef="usd">-2125000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ief7ca9e930b14261a5d0126d1359cce0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMwLTEtMS0xLTA_6cf8fc22-dd55-4a30-9d2f-ca67c3dddf87"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i467d69f1593b4e59aeba2ae8185b03a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMwLTMtMS0xLTA_b86d905c-e940-4877-bbf8-2652880541b2"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i95137661f82444ed8ade5d61a8c2693c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMwLTUtMS0xLTA_37b89727-1758-4d1c-81e6-14354d798ed2"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i78ab453f6db84127938a7075db98d34c_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMwLTctMS0xLTA_c19f2e37-9770-4c45-9b49-7e53cc207ddd"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="iaccfccfe524e46b09fdc3bb72135977e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMxLTEtMS0xLTA_7e3ec725-3cc5-4eb6-8707-5bc563346d97"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i70a53a1a90634b7198030c3447c9898c_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMxLTMtMS0xLTA_d1b8bb8c-3265-4ef7-b2c8-be0a9d95d128"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i176405a326bc43a0a55b9bc8ac1d8bf2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMxLTUtMS0xLTA_4adb6c78-ef0d-41c0-b356-71513063ea03"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ibf8ef541025e44ee8cf8686ede2517a7_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMxLTctMS0xLTA_1382c2a8-503c-44d8-9b9f-51dc8263f9ca"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMyLTEtMS0xLTA_1bb2f258-f09c-4b21-af46-f01ed7b3ebeb"
      unitRef="usd">-189000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMyLTMtMS0xLTA_088390b2-276c-4d98-8bab-59b16eb9a7b0"
      unitRef="usd">-271000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMyLTUtMS0xLTA_e29279f9-d446-4b46-99c1-2af51b235e39"
      unitRef="usd">-323000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzMyLTctMS0xLTA_c1ca37cc-ce81-474b-993b-549c4110e391"
      unitRef="usd">-2125000</us-gaap:GainLossOnInvestments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i254cd6a34e0a4624a06cd9c4a34e9913_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM0LTEtMS0xLTA_ed487868-0e03-4b7b-84c8-86ea3c21038c"
      unitRef="usd">265890000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e8982b6568f486980128a9f7513ec32_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM0LTMtMS0xLTA_032b63cb-686e-4853-9c72-31b78a46f7bc"
      unitRef="usd">184310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63bb2b62077c41bc8668fc1ce4d89ec0_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM0LTUtMS0xLTA_3564c779-c141-4d99-bab6-d728090743ec"
      unitRef="usd">446761000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i198a3844c0c0490abcbc066a7dd24dc8_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM0LTctMS0xLTA_7d27e205-a0e9-4b06-aadb-3c780586aad1"
      unitRef="usd">369203000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id56bcff9a57b427f8621c4e8187ca9c3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM1LTEtMS0xLTA_caedd6f2-2e50-4ab5-87c4-d54c242e3c65"
      unitRef="usd">16847000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e68ebe729e346baaedc4e909e8155d6_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM1LTMtMS0xLTA_fb492ecc-3085-4739-8466-7c12475208e3"
      unitRef="usd">22174000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie634e2306c8a4bebb90dffbe2e414e0e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM1LTUtMS0xLTA_cffaea35-ff1f-4cec-817e-a429d6a2f8c0"
      unitRef="usd">28749000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibccc990af11146938643e532d4826cb5_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM1LTctMS0xLTA_3e426c18-69a6-4c64-bdf4-0eaf0c9777f2"
      unitRef="usd">42707000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7027219b6b1045408436c1bb1b2f5a53_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM2LTEtMS0xLTA_fd91e759-96c3-4ac2-8c9a-b3a7aa193813"
      unitRef="usd">11152000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0871f5c7e8b94f5781f08a92001c6cea_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM2LTMtMS0xLTA_b854bf7f-5121-4e4c-9ed0-8db3e7ba4c63"
      unitRef="usd">9051000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0460fea90284226bde4999b97d0ed81_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM2LTUtMS0xLTA_98c11730-433c-464f-8c34-b0f3dde08ae9"
      unitRef="usd">22002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4da1a32fe2164419974b9faaefa37a49_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM2LTctMS0xLTA_047c02e8-ee9f-4a17-b83a-39cc44141a30"
      unitRef="usd">16915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62a29626ff724abb9ad4cee99f7898d9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM3LTEtMS0xLTA_0e9b7a2b-5922-448e-bd17-fdb871844125"
      unitRef="usd">4136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e418fb903dd4587b64cfae8429ade02_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM3LTMtMS0xLTA_0079bb2c-c750-4528-b3b1-da29b8af4462"
      unitRef="usd">4876000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if216b4c1ff0547679dcc2abcaf82d5dd_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM3LTUtMS0xLTA_1181fba6-fd17-4558-9cf5-46e9df1f6a6a"
      unitRef="usd">8292000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i914a917d0c624130b4baa7ce8b4d021d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM3LTctMS0xLTA_303bccf7-169a-4644-9754-fb1a42b81763"
      unitRef="usd">9294000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66aa17bc991b4212b0639a733b595a8a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM4LTEtMS0xLTA_9d8a9b0b-0ede-4d0e-9d98-067ff9abef07"
      unitRef="usd">1183000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1af19639eaec49a2970b68e53aa71655_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM4LTMtMS0xLTA_e0a50261-4716-492e-b15a-ec7df3ca25cb"
      unitRef="usd">3768000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06a58a1bdfc547f5961d72ff32ddb242_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM4LTUtMS0xLTA_43eb2280-d855-4ff5-a388-363e0248548d"
      unitRef="usd">2890000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d16a24c094b4ab6964f823f0e7ca361_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM4LTctMS0xLTA_7ca47ac7-e21e-4ade-95cb-82005a67a5e1"
      unitRef="usd">6884000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15f1fa750fa04018a4f1850d6bf7a8bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM5LTEtMS0xLTA_2182760b-7f42-48ce-a4b7-7dee4f0291cd"
      unitRef="usd">1866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba985ea2bc4348dcabba2e4c00d34207_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM5LTMtMS0xLTA_b1c23eeb-5352-40d0-86e0-285943aad916"
      unitRef="usd">2058000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9f619314d9249319d7a90de7f3e4587_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM5LTUtMS0xLTA_fab79f4d-8c43-47e1-8d9f-d5db15751d40"
      unitRef="usd">3708000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcc2adb4a7c142589c1a8c280a393746_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzM5LTctMS0xLTA_9ab8586b-ff5a-4d88-8497-47ccaae5e78c"
      unitRef="usd">3589000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b6d1653ea794637b798906498b50d0e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQwLTEtMS0xLTA_bc9b1b90-0fa5-4393-ad15-fc0fd96f9227"
      unitRef="usd">133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7da3b5d4af3d4ef9b385a90d5a8722bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQwLTMtMS0xLTA_b6541094-9ef9-48aa-97dd-5b57ab6876e0"
      unitRef="usd">131000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i309155533c28422e82b808d1dc76e743_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQwLTUtMS0xLTA_ea4c0308-ad99-4db4-b64f-6c3179554f56"
      unitRef="usd">272000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a9bcd23670e4f6185473829764ef0a9_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQwLTctMS0xLTA_246624b2-e6c2-4585-9685-84b5fc76bc87"
      unitRef="usd">228000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQxLTEtMS0xLTA_1b587317-137a-4bcf-aefb-768bf1532079"
      unitRef="usd">301207000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e968a6d253c4091b8de039bf89f65dc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQxLTMtMS0xLTA_60b7b881-3e93-40a3-8c28-cb12fc337e27"
      unitRef="usd">226368000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQxLTUtMS0xLTA_e403ea7f-04d6-45e4-aaa1-733b61ddd7ad"
      unitRef="usd">512674000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZToyNmRhZjVmOGRiZWI0YjdlOWU5Mzk3MzUwZDE1Zjg1MC90YWJsZXJhbmdlOjI2ZGFmNWY4ZGJlYjRiN2U5ZTkzOTczNTBkMTVmODUwXzQxLTctMS0xLTA_e3fc0e8d-1867-4113-aca4-083fde7aec82"
      unitRef="usd">448820000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Assets
      contextRef="i9cfb0c9e22cd4f7eb6a00d4ace862685_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzItMS0xLTEtMA_97b0db5e-b66c-4101-aa65-aa9015059320"
      unitRef="usd">1148151000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6a15f6d7c0e345db8249158f70fc4ed4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzItMy0xLTEtMA_6731f5a3-779f-46fa-8ddb-3e4f24974043"
      unitRef="usd">1174639000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i31c3c30dd034436bb8769e07c7ddefc9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzMtMS0xLTEtMA_a697b2f8-301d-4180-ad33-19ebd67f06bc"
      unitRef="usd">1121202000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3e6d29b56e2343b0a824d97674db5c75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzMtMy0xLTEtMA_c5505cc8-8664-4d53-9de1-8fadf7cd98a4"
      unitRef="usd">1035112000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7e4767da5b9c440090362640bac1a2e0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzQtMS0xLTEtMA_0e213a9c-1ee6-4cd5-9de0-42e64df99595"
      unitRef="usd">54381000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="icfcc5f95aa934dfa95991eb13af1680d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzQtMy0xLTEtMA_37f25105-822b-4bbe-8c48-51e728842b37"
      unitRef="usd">99521000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzUtMS0xLTEtMA_45ba8d1b-3d2d-4aa2-a24c-db78280921a6"
      unitRef="usd">2323734000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzUtMy0xLTEtMA_23c3f890-2e1b-4a93-b742-58bb00a875e7"
      unitRef="usd">2309272000</us-gaap:Assets>
    <us-gaap:Goodwill
      contextRef="i9cfb0c9e22cd4f7eb6a00d4ace862685_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzctMS0xLTEtMA_c6ae6625-2f62-4f0e-afac-8d8dae459966"
      unitRef="usd">236790000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6a15f6d7c0e345db8249158f70fc4ed4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzctMy0xLTEtMA_ed19c44c-eb29-4e3f-8f17-7f8079167f0e"
      unitRef="usd">237131000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i31c3c30dd034436bb8769e07c7ddefc9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzgtMS0xLTEtMA_be256663-1e36-4e71-ac90-d74ce4d02202"
      unitRef="usd">434809000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3e6d29b56e2343b0a824d97674db5c75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzgtMy0xLTEtMA_65123c39-42ac-4e2c-96b6-972bc255d9a1"
      unitRef="usd">434809000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7e4767da5b9c440090362640bac1a2e0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzktMS0xLTEtMA_a02eb0b0-3b16-4f18-a572-12be142e2779"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icfcc5f95aa934dfa95991eb13af1680d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzktMy0xLTEtMA_ec81aaf7-eff5-415a-9629-a1dbccd7222e"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzEwLTEtMS0xLTA_6f81049c-0d91-4d27-9f1f-4fda1c89ecd7"
      unitRef="usd">671599000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDAvZnJhZzpmMDk0ODliYWNkYjc0NzBkYTA0ZDU0MDI0NWYwYWQ1MS90YWJsZTphM2E4MjFkZDM3NGE0ZjljOWI2NjM3OWM3ZWUwNTY4Ni90YWJsZXJhbmdlOmEzYTgyMWRkMzc0YTRmOWM5YjY2Mzc5YzdlZTA1Njg2XzEwLTMtMS0xLTA_bf1e7cca-5ffe-4530-bbb2-db65d9991f16"
      unitRef="usd">671940000</us-gaap:Goodwill>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzIwODg_2f352f84-4d68-40fa-918d-41fd78bedb31">LEASES&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have operating leases for office space, laboratory operations, research and development facilities, manufacturing locations, warehouses and certain equipment.  We determine if a contract contains a lease at inception or modification of a contract.  Our leases generally do not provide an implicit interest rate, and we therefore use our incremental borrowing rate as the discount rate when measuring operating lease liabilities.  The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment.  We used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.  Many of our leases contain rental escalation, renewal options and/or termination options that are factored into our determination of lease payments as appropriate.  Variable lease payment amounts that cannot be determined at the commencement of the lease are not included in the right-to-use assets or liabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.431%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.938%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.982%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.450%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classification on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current maturities of operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current maturities of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;July 1, 2020 through December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Difference between lease payments and discounted lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expense under operating leases and finance leases was $9.7 million and $1.2 million, respectively, for the six months ended June 30, 2020, which includes $1.6 million of variable lease costs. Expense under operating leases and finance leases was $9.8 million and $2.0 million, respectively, for the six months ended June 30, 2019, which includes $1.7 million of variable lease costs. Operating lease costs and finance lease costs are included within Operating loss in the Condensed Consolidated Statement of Operations. Short-term lease costs were not material.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Supplemental cash flow information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.700%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.931%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <opk:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzIwODQ_e2096ca8-6100-4129-a2a8-2f70529b0b1a">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.431%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.938%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.982%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.450%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classification on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current maturities of operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current maturities of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</opk:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzItNC0xLTEtMA_32aa088c-dc10-4684-bb20-8e47bb87d448"
      unitRef="usd">38469000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzItNi0xLTEtMA_2b1d9ead-06c5-4f4a-8751-babe3da5488a"
      unitRef="usd">39380000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzMtNC0xLTEtMA_b3d20e3f-c092-4144-a6e7-04445989a599"
      unitRef="usd">5395000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzMtNi0xLTEtMA_f52f6d68-3039-426b-bc03-550f0776c120"
      unitRef="usd">6789000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzctNC0xLTEtMA_cf7f1521-ae99-4e72-9be6-a56ac37ccd1b"
      unitRef="usd">10298000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzctNi0xLTEtMA_c949e409-8e45-4eb3-ba3a-37352a3ca7f3"
      unitRef="usd">12038000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzgtNC0xLTEtMA_1b6cb47e-450b-4a93-b402-c942036c7d20"
      unitRef="usd">2435000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzgtNi0xLTEtMA_1627d0df-80c5-4efc-8526-fb1ce721c987"
      unitRef="usd">2743000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzEwLTQtMS0xLTA_2e097eb4-060d-4139-adda-c37e753b8972"
      unitRef="usd">28759000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzEwLTYtMS0xLTA_aeea2e47-45a7-4bbc-9667-4206862057d9"
      unitRef="usd">27665000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzExLTQtMS0xLTA_0e6c2382-671d-4d6c-99ea-4f1c4fde613e"
      unitRef="usd">2960000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzExLTYtMS0xLTA_40dbd547-93d1-42a4-8164-82ec71eda2ea"
      unitRef="usd">4046000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE0LTQtMS0xLTA_ae1806d0-1326-4125-adba-f6ff4139c671">P5Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE0LTYtMS0xLTA_bb7e931c-a8fb-4e78-af57-3d2f2e5299ef">P5Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE1LTQtMS0xLTA_f39d815c-d35a-4eec-83d9-cea1b9f0ce0d">P2Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE1LTYtMS0xLTA_65e08b56-43ec-4a2f-9bf5-ea7500da786c">P2Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE3LTQtMS0xLTA_2d9af1c9-4005-4a24-a507-85c0fa120394"
      unitRef="number">0.064</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE3LTYtMS0xLTA_d66dba2b-557e-4e85-9eb0-17447330696b"
      unitRef="number">0.063</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE4LTQtMS0xLTA_3bfedb68-7f53-4d92-a0ba-ad3b98e3df4f"
      unitRef="number">0.039</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i5492a302d8ca4a85901a3a7b73505049_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTpkMzU4MmU3ZTcwODA0ZDVjYWEwNGY0NDcyODJmNGJkMy90YWJsZXJhbmdlOmQzNTgyZTdlNzA4MDRkNWNhYTA0ZjQ0NzI4MmY0YmQzXzE4LTYtMS0xLTA_82b5fb1b-5a89-4167-ae75-f5a32723d9eb"
      unitRef="number">0.030</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzIwODE_b01099d6-5858-404b-94c0-73427f91682a">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;July 1, 2020 through December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Difference between lease payments and discounted lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzIwODY_d14a4567-df0c-416d-ba9a-f6402e327183">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;July 1, 2020 through December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Difference between lease payments and discounted lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzEtMS0xLTEtMA_e14d5483-440b-4a67-908b-a664b5a04c0a"
      unitRef="usd">6604000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzEtMy0xLTEtMA_bd670897-3e81-4d72-bce9-ae5b9ad18659"
      unitRef="usd">1404000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzItMS0xLTEtMA_ea86c1f3-0010-49e2-be92-e6ebc030a41f"
      unitRef="usd">7479000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzItMy0xLTEtMA_5c867825-f54e-41af-ae10-5f411b23c31f"
      unitRef="usd">2186000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzMtMS0xLTEtMA_a9754ec7-392c-4b5d-8602-b603bf25adc7"
      unitRef="usd">6506000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzMtMy0xLTEtMA_a0df7854-3ceb-49bd-b269-068cc6009fa1"
      unitRef="usd">1175000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzQtMS0xLTEtMA_b5ede7d1-4ee1-4663-8ddd-0463c9cd6cf3"
      unitRef="usd">5845000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzQtMy0xLTEtMA_9f23b295-61b5-4713-9181-52179aa6994a"
      unitRef="usd">590000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzUtMS0xLTEtMA_d3755230-6cc1-4385-b950-e2acf4599e41"
      unitRef="usd">4671000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzUtMy0xLTEtMA_3427558d-1bd3-46e1-b122-41886ae40fce"
      unitRef="usd">249000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <opk:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzYtMS0xLTEtMA_1e3b1e02-4054-46c8-b415-6a9cc7d21f4b"
      unitRef="usd">17374000</opk:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <opk:FinanceLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzYtMy0xLTEtMA_f82d1c80-c950-4fe7-90ae-7fc7829b0060"
      unitRef="usd">0</opk:FinanceLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzctMS0xLTEtMA_fd40f229-103a-49d1-ad07-6cf34732da84"
      unitRef="usd">48479000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzctMy0xLTEtMA_e0f8b597-815b-44de-8c5c-ac1fcb4e3c36"
      unitRef="usd">5604000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzgtMS0xLTEtMA_9648f476-3ce8-470e-ba18-91ca3747f301"
      unitRef="usd">9422000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzgtMy0xLTEtMA_77eaa1df-9c36-4737-a427-4f55efa41ec0"
      unitRef="usd">209000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzktMS0xLTEtMA_e050da19-91e7-4820-9d6e-92c5a796c5e8"
      unitRef="usd">39057000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i5698d6f1fc1940309b63ded417c158e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTo2MmY0ODhhMzkzZGI0NjQyYjlhZWViNWJkM2YzNzllNC90YWJsZXJhbmdlOjYyZjQ4OGEzOTNkYjQ2NDJiOWFlZWI1YmQzZjM3OWU0XzktMy0xLTEtMA_6d2c673c-2fba-4354-b358-617b259ac1ea"
      unitRef="usd">5395000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE2Mjg_6a59082e-420a-47f1-bbf6-02aface6340d"
      unitRef="usd">9700000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE2MzU_7cda103b-b19a-4aca-962b-879bae9510cc"
      unitRef="usd">1200000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE2ODA_b6d7750a-bf55-46d6-bfba-128987f9aa31"
      unitRef="usd">1600000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE3NjI_bb63592b-dc00-43ff-8c64-b0d03e93a86d"
      unitRef="usd">9800000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE3Njk_f3c48ff3-ed6f-48bf-9d42-afbb4c850ceb"
      unitRef="usd">2000000.0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzE4MTQ_1a961622-43a7-4729-a7e2-2bcdb4375a36"
      unitRef="usd">1700000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90ZXh0cmVnaW9uOmZlOGMyYzgyOTNkMTQ1Mjc5YTk4MWE5NzE3YzhiZWEyXzIwNzk_392fda85-acbe-4d6a-98cb-bfd0d80cb5eb">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Supplemental cash flow information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.700%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.931%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzItMS0xLTEtMA_882fd0cc-7189-4cee-8b85-f0f8feec0325"
      unitRef="usd">9804000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzItMy0xLTEtMA_ae0aefea-a45e-4f2d-a90b-77996258e93f"
      unitRef="usd">10804000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzMtMS0xLTEtMA_15b69ceb-e789-41a1-a1fe-0869eba97151"
      unitRef="usd">86000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzMtMy0xLTEtMA_c784f547-97b5-4cfc-9e4e-f76ef204401f"
      unitRef="usd">234000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzQtMS0xLTEtMA_df9c24c0-3cba-41f4-a9c3-3b644566c031"
      unitRef="usd">1026000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzQtMy0xLTEtMA_6359a35a-39f4-4a42-b440-bf367dbe539b"
      unitRef="usd">1590000</us-gaap:FinanceLeasePrincipalPayments>
    <opk:PaymentsForLeases
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzUtMS0xLTEtMA_200d14cc-ba4f-4ce2-a2b7-cb0f62fc3a8a"
      unitRef="usd">10916000</opk:PaymentsForLeases>
    <opk:PaymentsForLeases
      contextRef="i8173ffa4f57449388f4402918c710024_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDMvZnJhZzpmZThjMmM4MjkzZDE0NTI3OWE5ODFhOTcxN2M4YmVhMi90YWJsZTozNDk5NTg4Njc1OTI0YzMzOWU0NDFmOTY0YTI0MWJhNC90YWJsZXJhbmdlOjM0OTk1ODg2NzU5MjRjMzM5ZTQ0MWY5NjRhMjQxYmE0XzUtMy0xLTEtMA_acb05852-0b5f-47ba-8c5e-b8f3e92466fa"
      unitRef="usd">12628000</opk:PaymentsForLeases>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDYvZnJhZzo5MDBhM2FlOWM4MGY0MGZhOGE4OGIwOTFmOTMzMzY5ZC90ZXh0cmVnaW9uOjkwMGEzYWU5YzgwZjQwZmE4YTg4YjA5MWY5MzMzNjlkXzEyMjY_333ddd31-0314-441b-a38d-2f9b0a35c770">SUBSEQUENT EVENTS&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered.  In July 2020, we received a favorable Medicare appeal decision from Novitas Solutions Inc. (&#x201c;Novitas&#x201d;) for previously denied Medicare claims for &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;4Kscore&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; tests we performed during 2019. As a result of the favorable appeal, Medicare will reimburse us for such &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;4Kscore&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; tests for patients who meet defined criteria. Due to a prior non-coverage determination by Novitas, no revenue was previously recognized for these &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;4Kscore&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; tests and therefore we recognized $10.9&#160;million for the previously denied &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;4Kscore&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; tests as a component of Revenue from services for the three and six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have reviewed all subsequent events and transactions that occurred after the date of our June&#160;30, 2020 Condensed Consolidated Balance Sheet, through the time of filing this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50b1c18c29b2480badccb24aa75ca3bd_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDYvZnJhZzo5MDBhM2FlOWM4MGY0MGZhOGE4OGIwOTFmOTMzMzY5ZC90ZXh0cmVnaW9uOjkwMGEzYWU5YzgwZjQwZmE4YTg4YjA5MWY5MzMzNjlkXzIxOTkwMjMyNjE0Mjc_4e238346-fd02-4b50-ba1e-54f7aa19c18f"
      unitRef="usd">10900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56d3de83d9ad4ba99bcdfa4b49b82318_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE5NjliNDViYTA5OTQ3ZTlhMDNjZTQyMWY3MDBmNWIzL3NlYzphOTY5YjQ1YmEwOTk0N2U5YTAzY2U0MjFmNzAwZjViM18xMDYvZnJhZzo5MDBhM2FlOWM4MGY0MGZhOGE4OGIwOTFmOTMzMzY5ZC90ZXh0cmVnaW9uOjkwMGEzYWU5YzgwZjQwZmE4YTg4YjA5MWY5MzMzNjlkXzIxOTkwMjMyNjE0Mjc_9c632883-a762-42f6-87cb-0ebfcb6a67a1"
      unitRef="usd">10900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501527514520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER PAGE - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jul. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OPKO Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">75-2402409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4400 Biscayne Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Miami<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">575-4100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OPK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">669,831,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000944809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501608336792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,612<span></span>
</td>
<td class="nump">$ 85,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">214,352<span></span>
</td>
<td class="nump">134,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">72,965<span></span>
</td>
<td class="nump">53,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">51,125<span></span>
</td>
<td class="nump">50,542<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">360,054<span></span>
</td>
<td class="nump">324,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">130,540<span></span>
</td>
<td class="nump">127,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">499,125<span></span>
</td>
<td class="nump">528,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InProcessResearchandDevelopment', window );">In-process research and development</a></td>
<td class="nump">590,200<span></span>
</td>
<td class="nump">590,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">671,599<span></span>
</td>
<td class="nump">671,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="nump">26,260<span></span>
</td>
<td class="nump">20,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">38,469<span></span>
</td>
<td class="nump">39,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">7,487<span></span>
</td>
<td class="nump">6,888<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,323,734<span></span>
</td>
<td class="nump">2,309,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">44,671<span></span>
</td>
<td class="nump">62,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">210,111<span></span>
</td>
<td class="nump">164,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating leases</a></td>
<td class="nump">10,298<span></span>
</td>
<td class="nump">12,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Current portion of lines of credit and notes payable</a></td>
<td class="nump">14,463<span></span>
</td>
<td class="nump">9,619<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">279,543<span></span>
</td>
<td class="nump">249,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">28,759<span></span>
</td>
<td class="nump">27,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes</a></td>
<td class="nump">216,457<span></span>
</td>
<td class="nump">211,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">118,979<span></span>
</td>
<td class="nump">118,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit</a></td>
<td class="nump">91,653<span></span>
</td>
<td class="nump">87,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">455,848<span></span>
</td>
<td class="nump">445,394<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">735,391<span></span>
</td>
<td class="nump">694,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock - $0.01 par value, 1,000,000,000 shares authorized; 670,378,701 and 670,378,701 shares issued at June 30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">6,704<span></span>
</td>
<td class="nump">6,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock - 549,907 shares at June 30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="num">(1,791)<span></span>
</td>
<td class="num">(1,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">3,147,030<span></span>
</td>
<td class="nump">3,142,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(25,752)<span></span>
</td>
<td class="num">(22,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,537,848)<span></span>
</td>
<td class="num">(1,511,077)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">1,588,343<span></span>
</td>
<td class="nump">1,614,759<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 2,323,734<span></span>
</td>
<td class="nump">$ 2,309,272<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_InProcessResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-Process Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_InProcessResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501528027912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">670,378,701<span></span>
</td>
<td class="nump">670,378,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">549,907<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501526369688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 301,207<span></span>
</td>
<td class="nump">$ 226,368<span></span>
</td>
<td class="nump">$ 512,674<span></span>
</td>
<td class="nump">$ 448,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">77,721<span></span>
</td>
<td class="nump">88,475<span></span>
</td>
<td class="nump">153,852<span></span>
</td>
<td class="nump">183,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,608<span></span>
</td>
<td class="nump">28,286<span></span>
</td>
<td class="nump">39,369<span></span>
</td>
<td class="nump">64,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="num">(3,775)<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">14,937<span></span>
</td>
<td class="nump">16,419<span></span>
</td>
<td class="nump">29,874<span></span>
</td>
<td class="nump">32,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">655<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">274,028<span></span>
</td>
<td class="nump">273,628<span></span>
</td>
<td class="nump">526,255<span></span>
</td>
<td class="nump">571,397<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">27,179<span></span>
</td>
<td class="num">(47,260)<span></span>
</td>
<td class="num">(13,581)<span></span>
</td>
<td class="num">(122,577)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income and (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InterestIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(5,474)<span></span>
</td>
<td class="num">(5,501)<span></span>
</td>
<td class="num">(10,970)<span></span>
</td>
<td class="num">(10,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Fair value changes of derivative instruments, net</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(388)<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">18,223<span></span>
</td>
<td class="num">(5,874)<span></span>
</td>
<td class="nump">5,890<span></span>
</td>
<td class="num">(4,897)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income and (expense), net</a></td>
<td class="nump">12,741<span></span>
</td>
<td class="num">(11,191)<span></span>
</td>
<td class="num">(4,325)<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes and investment losses</a></td>
<td class="nump">39,920<span></span>
</td>
<td class="num">(58,451)<span></span>
</td>
<td class="num">(17,906)<span></span>
</td>
<td class="num">(136,577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(6,028)<span></span>
</td>
<td class="num">(1,084)<span></span>
</td>
<td class="num">(7,200)<span></span>
</td>
<td class="num">(1,866)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax', window );">Net income (loss) before investment losses</a></td>
<td class="nump">33,892<span></span>
</td>
<td class="num">(59,535)<span></span>
</td>
<td class="num">(25,106)<span></span>
</td>
<td class="num">(138,443)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from investments in investees</a></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(271)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="num">(2,125)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (loss)</a></td>
<td class="nump">$ 33,703<span></span>
</td>
<td class="num">$ (59,806)<span></span>
</td>
<td class="num">$ (25,429)<span></span>
</td>
<td class="num">$ (140,568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Income (loss) per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per share (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">640,578,794<span></span>
</td>
<td class="nump">586,351,045<span></span>
</td>
<td class="nump">640,578,794<span></span>
</td>
<td class="nump">586,347,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 250,971<span></span>
</td>
<td class="nump">$ 178,458<span></span>
</td>
<td class="nump">$ 421,811<span></span>
</td>
<td class="nump">$ 357,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service revenue</a></td>
<td class="nump">144,794<span></span>
</td>
<td class="nump">130,078<span></span>
</td>
<td class="nump">267,680<span></span>
</td>
<td class="nump">259,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">29,356<span></span>
</td>
<td class="nump">28,680<span></span>
</td>
<td class="nump">60,430<span></span>
</td>
<td class="nump">53,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service revenue</a></td>
<td class="nump">17,857<span></span>
</td>
<td class="nump">14,145<span></span>
</td>
<td class="nump">35,229<span></span>
</td>
<td class="nump">28,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Revenue from transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 20,880<span></span>
</td>
<td class="nump">$ 19,230<span></span>
</td>
<td class="nump">$ 30,433<span></span>
</td>
<td class="nump">$ 37,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from continuing operations before investment losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Nonoperating</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_InterestIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Income, Nonoperating</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_InterestIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501527161896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 33,703<span></span>
</td>
<td class="num">$ (59,806)<span></span>
</td>
<td class="num">$ (25,429)<span></span>
</td>
<td class="num">$ (140,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in foreign currency translation and other comprehensive income (loss)</a></td>
<td class="nump">4,435<span></span>
</td>
<td class="nump">2,878<span></span>
</td>
<td class="num">(3,682)<span></span>
</td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 38,138<span></span>
</td>
<td class="num">$ (56,928)<span></span>
</td>
<td class="num">$ (29,111)<span></span>
</td>
<td class="num">$ (140,788)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501525411992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,881,720<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,791,291<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,869<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">$ 3,004,422<span></span>
</td>
<td class="num">$ (926)<span></span>
</td>
<td class="num">$ (20,131)<span></span>
</td>
<td class="num">$ (1,197,078)<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">7,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Common Stock options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of Common Stock options and warrants</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">2025 convertible notes including share lending arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">2025 convertible notes including share lending arrangement</a></td>
<td class="nump">50,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(140,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,150,952<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">1,708,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,162<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">3,061,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,351)<span></span>
</td>
<td class="num">(1,336,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,881,720<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">1,791,291<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,869<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">3,004,422<span></span>
</td>
<td class="num">$ (926)<span></span>
</td>
<td class="num">(20,131)<span></span>
</td>
<td class="num">(1,197,078)<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,378,701<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,614,759<span></span>
</td>
<td class="num">(1,342)<span></span>
</td>
<td class="nump">$ 6,704<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">3,142,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,070)<span></span>
</td>
<td class="num">(1,511,077)<span></span>
</td>
<td class="num">(1,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,150,952<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">$ 1,762,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,162<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">3,058,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,229)<span></span>
</td>
<td class="num">(1,276,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">3,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(59,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">2,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,150,952<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">1,708,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,162<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">3,061,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,351)<span></span>
</td>
<td class="num">(1,336,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,378,701<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">1,614,759<span></span>
</td>
<td class="num">$ (1,342)<span></span>
</td>
<td class="nump">$ 6,704<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">3,142,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,070)<span></span>
</td>
<td class="num">(1,511,077)<span></span>
</td>
<td class="num">$ (1,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">4,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(25,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(3,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,378,701<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">1,588,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,704<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">3,147,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,752)<span></span>
</td>
<td class="num">(1,537,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,378,701<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">1,548,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,704<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">3,145,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,187)<span></span>
</td>
<td class="num">(1,571,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">1,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">33,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">4,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,378,701<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 1,588,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,704<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">$ 3,147,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,752)<span></span>
</td>
<td class="num">$ (1,537,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501524887560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (25,429)<span></span>
</td>
<td class="num">$ (140,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">44,318<span></span>
</td>
<td class="nump">47,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest</a></td>
<td class="nump">5,022<span></span>
</td>
<td class="nump">2,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Losses from investments in investees</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation &#8211; employees and non-employees</a></td>
<td class="nump">4,037<span></span>
</td>
<td class="nump">7,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Realized loss on disposal of fixed assets and sales of equity securities</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments', window );">Change in fair value of equity securities and derivative instruments</a></td>
<td class="num">(6,515)<span></span>
</td>
<td class="nump">5,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax provision</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(81,539)<span></span>
</td>
<td class="num">(4,398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="num">(21,905)<span></span>
</td>
<td class="num">(6,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets and prepaid expenses</a></td>
<td class="num">(2,619)<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(16,753)<span></span>
</td>
<td class="nump">12,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_IncreaseDecreaseinForeignCurrencyMeasurement', window );">Foreign currency measurement</a></td>
<td class="num">(2,077)<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="num">(4,026)<span></span>
</td>
<td class="num">(37,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">47,585<span></span>
</td>
<td class="nump">2,095<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57,793)<span></span>
</td>
<td class="num">(102,619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Investments in investees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property, plant and equipment</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(17,149)<span></span>
</td>
<td class="num">(6,432)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(17,084)<span></span>
</td>
<td class="num">(7,323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Issuance of convertible notes, including to related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,762)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from the exercise of Common Stock options and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on lines of credit</a></td>
<td class="nump">393,651<span></span>
</td>
<td class="nump">39,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="num">(382,374)<span></span>
</td>
<td class="num">(78,824)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Redemption of 2033 Senior Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(28,800)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">11,277<span></span>
</td>
<td class="nump">124,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(63,840)<span></span>
</td>
<td class="nump">14,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">85,452<span></span>
</td>
<td class="nump">96,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">21,612<span></span>
</td>
<td class="nump">111,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">5,578<span></span>
</td>
<td class="nump">5,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid (received), net of refunds</a></td>
<td class="num">(208)<span></span>
</td>
<td class="nump">2,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets due to adoption of ASU No. 2016-02</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption', window );">Operating lease liabilities due to adoption of ASU No. 2016-02</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract', window );"><strong>Shares issued upon the conversion of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CommonStockWarrantsNetExercised', window );">Common Stock options and warrants, surrendered in net exercise</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CommonStockWarrantsNetExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants net exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CommonStockWarrantsNetExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Equity Securities, FV-NI And Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_IncreaseDecreaseinForeignCurrencyMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Foreign Currency Measurement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_IncreaseDecreaseinForeignCurrencyMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability, Initial Recognition Upon Adoption</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued in the Conversion of Stock and Debt Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520862312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Organization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">BUSINESS AND ORGANIZATION</a></td>
<td class="text">BUSINESS AND ORGANIZATION<div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets.  Our diagnostics business includes BioReference Laboratories, Inc. (&#8220;BioReference&#8221;), one of the nation&#8217;s largest full service laboratories with a core genetic testing business and an almost 300-person sales and marketing team focused on driving growth and leveraging new products, including the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> test.  Our pharmaceutical business features </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, an FDA-approved treatment for secondary hyperparathyroidism (&#8220;SHPT&#8221;) in adults with stage 3 or 4 chronic kidney disease (&#8220;CKD&#8221;) and vitamin D insufficiency (launched in November 2016); OPK88004, a selective androgen receptor modulator which we are exploring for various potential indications; and OPK88003, a once weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists (phase 2b).  Our pharmaceutical business also features hGH-CTP, a once-weekly human growth hormone that recently successfully completed a phase 3 trial and for which we have partnered with Pfizer Inc. (&#8220;Pfizer&#8221;).  We are incorporated in Delaware, and our principal executive offices are located in leased offices in Miami, Florida.   </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Through BioReference, we provide laboratory testing services, primarily to customers in the larger metropolitan areas across New York, New Jersey, Florida, Texas, Maryland, California, Pennsylvania, Delaware, Washington, DC, Illinois and Massachusetts, as well as to customers in a number of other states.  We offer a comprehensive test menu of clinical diagnostics for blood, urine and tissue analysis.  This includes hematology, clinical chemistry, immunoassay, infectious&#160;diseases, serology, hormones, and toxicology assays, as well as Pap smear, anatomic pathology (biopsies) and other types of tissue analysis.  We market our laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate established pharmaceutical platforms in Ireland, Chile, Spain, and Mexico, which are generating revenue and from which we expect to generate positive cash flow and facilitate future market entry for our products currently in development.  In addition, we have a development and commercial supply pharmaceutical company and a global supply chain operation and holding company in Ireland.  We own a specialty active pharmaceutical ingredients (&#8220;APIs&#8221;) manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development activities are primarily performed at facilities in Woburn, MA, Waterford, Ireland, Kiryat Gat, Israel, and Barcelona, Spain.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520838184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Basis of presentation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all information and notes required by GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company&#8217;s results of operations, financial position and cash flows have been made.  The results of operations and cash flows for the three and six months ended June 30, 2020 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2020 or any other future periods.  The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Principles of consolidation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and of our wholly owned subsidiaries.  All intercompany accounts and transactions are eliminated in consolidation.   </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of estimates</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from these estimates.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Impact of COVID-19</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.   As the disease caused by SARS-CoV-2, a novel strain of coronavirus, COVID-19 continues to spread and severely impact the economy of the United States and other countries around the world, we are committed to being a part of the coordinated public and private sector response to this unprecedented challenge. In response to the COVID-19 pandemic, BioReference Laboratories is accepting specimens for two types of COVID-19 testing, diagnostic molecular testing and serology antibody testing, from healthcare providers, clinics and health and hospital systems throughout&#160;the U.S., to promote earlier diagnosis of the coronavirus, assess a patient&#8217;s immune response to the virus and aid in limiting spread of infection. In addition to its robust nationwide COVID-19 testing offering, BioReference has partnerships with the&#160;New York State&#160;Department of Health, the New York City Health and Hospital Corporation (NYC&#160;Health + Hospitals), the&#160;State of New Jersey, the&#160;State of Florida&#160;and the cities of&#160;Detroit&#160;and&#160;Miami, among others,&#160;to provide COVID-19 testing. BioReference performed approximately 331.6&#160;thousand serology antibody tests and 2.2&#160;million diagnostic molecular tests for COVID-19 during the three months ended June 30, 2020, which represented 28.1% of BioReference&#8217;s total test volume during the second quarter of 2020. For serologic antibody testing, BioReference has partnered with the State of New York, New York City and a number of employers and government agencies with the capacity to perform up to 400,000 tests per day and for diagnostic molecular tests, BioReference has the capacity to perform more than 50,000 tests per day. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have put preparedness plans in place at our facilities to maintain continuity of operations, while also taking steps to keep colleagues and customers healthy and safe. In line with recommendations to reduce large gatherings and increase social distancing, we have, where practical, transitioned many office-based colleagues to a remote work environment.&#160;</span></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Beginning in March 2020, BioReference experienced, and continues to experience, a decline in routine clinical and genomics testing volumes due to the COVID-19 pandemic. Excluding COVID-19 test volumes, for the three months ended June 30, 2020, volumes in our diagnostics segment were down 46.5% as compared to volumes in the second quarter of 2019. Additionally, sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> have not increased in accordance with its expected growth trajectory as a result of challenges in onboarding new patients due to the COVID-19 pandemic. Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, a significant reduction in physician office visits, the cancellation of elective medical procedures, customers closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home or shelter-in-place policies, all of which have had, and may continue to have, an adverse impact on our operating results, cash flows and financial condition, including continued declines in testing volumes. It is also possible that we will experience an adverse impact on cash collections as a result of the impact of the COVID-19 pandemic.&#160;As stay at home orders and other restrictions have been lifted, we have seen our routine clinical and genomic testing volumes trending towards normalization with prior periods, however should stay at home orders or other restrictions be reenacted, we could see our routine testing levels decline. We also continue to see a substantial need for COVID-19 testing by our existing clients and expect new clients as infection rates for the virus continue to increase across the country.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, in response to the COVID-19 pandemic, the CARES Act was signed into law. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding the prior and future utilization of net operating losses, temporary changes to the prior and future limitations on interest deductions, temporary&#160;suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property, and the creation of certain payroll tax credits associated with the retention of employees.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have received, or expect to receive a number of benefits under The CARES Act including, but not limited to:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We received approximately $14&#160;million under The Centers for Medicare &amp; Medicaid Services (CMS) Accelerated and Advance Payment Program, which provides accelerated payments to Medicare providers/suppliers working to provide treatment to patients and combat the COVID-19 pandemic, and the amounts advanced are loans which will be offset against future claims and must be repaid. These loans are initially recorded as contract liabilities included in Accrued expenses and are recognized in Revenue from services when earned;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are eligible to defer depositing the employer&#8217;s share of Social Security taxes for payments due from March 27, 2020 through December 31, 2020, interest-free and penalty-free;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We received approximately $6.2&#160;million during the three months ended June 30, 2020 from the initial tranche of funds that was distributed to healthcare providers for related expenses or lost revenues that are attributable to the COVID-19 pandemic. We recognized the $6.2&#160;million grant in other revenues for the three and six months ended June 30, 2020;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">U.S. Department of Health and Human Services (HHS), will provide claims reimbursement to healthcare providers generally at Medicare rates for testing uninsured patients; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Clinical laboratories are provided a one-year reprieve from the reporting requirements under the Protecting Access to Medicare Act (&#8220;PAMA&#8221;) as well as a one-year delay of reimbursement rate reductions for clinical laboratory services provided under Medicare that were scheduled to take place in 2021.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the pandemic began in the U.S., we have invested, and expect to continue to invest, in testing capabilities and infrastructure to meet demand for our molecular and antibody testing for COVID-19. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash and cash equivalents</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase.  We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents.  These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Inventories</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Inventories are valued at the lower of cost and net realizable value.  Cost is determined by the first-in, first-out method.  We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value.  Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which is used in our testing laboratories.  Inventory obsolescence expense for the six months ended June&#160;30, 2020 and 2019 was $1.7 million and $1.3 million, respectively.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pre-launch inventories</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  We may accumulate commercial quantities of certain product candidates prior to the date we anticipate that such products will receive final U.S. FDA approval.  The accumulation of such pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever.  This risk notwithstanding, we may accumulate pre-launch inventories of certain products when such action is appropriate in relation to the commercial value of the product launch opportunity.  In accordance with our policy, this pre-launch inventory is expensed.&#160;&#160;</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill and intangible assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting.  Refer to Note 4.  Goodwill, in-process research and development (&#8220;IPR&amp;D&#8221;) and other intangible assets acquired in business combinations, licensing and other transactions was $1.8 billion at both at June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values.  Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill.  At acquisition, we generally determine the fair value of intangible assets, including IPR&amp;D, using the &#8220;income method.&#8221;</span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill was $671.6&#160;million and $671.9 million respectively, at June&#160;30, 2020 and December&#160;31, 2019. Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.  We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing.  Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net intangible assets other than goodwill were $1.1 billion, including IPR&amp;D of $590.2 million, at both June&#160;30, 2020 and December&#160;31, 2019.  Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products and IPR&amp;D.  Considering the high risk nature of research and development and the industry&#8217;s success rate of bringing developmental compounds to market, IPR&amp;D impairment charges may occur in future periods.  Estimating the fair value of IPR&amp;D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon obtaining regulatory approval, IPR&amp;D assets are then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.  If the project is abandoned, the IPR&amp;D asset is charged to expense.  Finite lived intangible assets are tested for impairment when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.  The testing includes a comparison of the carrying amount of the asset to its estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our estimates and assumptions are reasonable and otherwise consistent with assumptions that marketplace participants would use in their estimates of fair value.&#160; However, if future results are not consistent with our estimates and assumptions, including as a result of the COVID-19 global pandemic, then we may be exposed to an impairment charge, which could be material.&#160; </span></div><div style="text-indent:22.5pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years.  We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up.  Amortization expense was $29.9 million and $33.0 million for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair value measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments.  Investments that are considered equity securities as of June&#160;30, 2020 and December&#160;31, 2019 are predominately carried at fair value.  Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest applicable to such debt.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates.  The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts.  Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.  Refer to Note 8.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contingent consideration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense.  Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability.  Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions.  The assumptions used in estimating fair value require significant judgment.  The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Derivative financial instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges.  For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At June&#160;30, 2020 and December&#160;31, 2019, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognize all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations.  Refer to Note 9.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Property, plant and equipment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Property, plant and equipment are recorded at cost or fair value if acquired in a business combination.  Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases.  The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years.  Expenditures for repairs and maintenance are charged to expense as incurred.  Depreciation expense was $14.4 million and $14.5 million for the six months ended June 30, 2020 and 2019, respectively.  Assets held under finance leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheet and are amortized over the shorter of their useful lives or the expected term of their related leases.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Impairment of long-lived assets.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income taxes.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are accounted for under the asset-and-liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.  We periodically evaluate the realizability of our</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">net deferred tax assets.  Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">adjustment.  Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate in various countries and tax jurisdictions globally.&#160; For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.&#160; For the three and six months ended June 30, 2020, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue recognition</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;Topic 606&#8221;).  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.  At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct.  We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.  For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 12.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Concentration of credit risk and allowance for credit losses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable.  Substantially all of our accounts receivable are with either companies in the healthcare industry or patients.  However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.   At June&#160;30, 2020 and December&#160;31, 2019, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 11% and 6%, respectively, of our consolidated Accounts receivable, net. At June&#160;30, 2020, receivable balances (net of explicit and implicit price concessions) due directly from states, cities and other municipalities, specifically related to our real-time reverse-transcription polymerase chain reaction (real-time RT-PCR) assay to detect the 2019 novel coronavirus disease (COVID-19), were 37.6% of our consolidated Accounts receivable, net. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk.  At June&#160;30, 2020 and December&#160;31, 2019, receivables due from patients represented approximately 2.0% and 2.5%, respectively, of our consolidated Accounts receivable, net.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer&#8217;s ability to pay.  Actual results could differ from those estimates.  The allowance for credit losses was $1.6 million and $1.9 million at June&#160;30, 2020 and December&#160;31, 2019, respectively.  The credit loss expense for the six months ended June 30, 2020 and 2019 was $0.2 million and $0.2 million, respectively.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Equity-based compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award.  We record excess tax benefits realized from the exercise of stock options as cash flows from operations.  For the six months ended June 30, 2020 and 2019, we recorded $4.0 million and $7.6 million, respectively, of equity-based compensation expense.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expenses.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses include external and internal expenses.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  Research and development </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">employee-related expenses include salaries, benefits and equity-based compensation expense.  Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.  We expense these costs in the period in which they are incurred.  We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received.  As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility and which have no alternative future use.  For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed.  Once the development process has been completed the asset will be amortized over its remaining estimated useful life.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Segment reporting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Our chief operating decision-maker (&#8220;CODM&#8221;) is Phillip Frost, M.D., our Chairman and Chief Executive Officer.  Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis.  We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of clinical laboratory operations through BioReference and point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense or income taxes.  Refer to Note 14.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Shipping and handling costs.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not charge customers for shipping and handling costs.  Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Foreign currency translation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The financial statements of certain of our foreign operations are measured using the local currency as the functional currency.  The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods.  Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Variable interest entities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The consolidation of a variable interest entity (&#8220;VIE&#8221;) is required when an enterprise has a controlling financial interest.  A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.  Refer to Note 5.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  We have made strategic investments in development stage and emerging companies.  We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees.  For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations.  Refer to Note 5.  For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value.  Refer to Note 5.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently adopted accounting pronouncements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221; which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables.  This may result in the earlier recognition of allowances for losses.  The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2019, with early adoption permitted.  The adoption of ASU 2016-13 on January 1, 2020, did not have a significant impact on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522141304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic income (loss) per share is computed by dividing our net income (loss) by the weighted average number of shares of our common stock par value $0.01 per share (&#8220;Common Stock&#8221;) outstanding during the period.  Shares of Common Stock outstanding under the&#160;share lending&#160;arrangement entered into in conjunction with the 2025 Notes (as defined in Note 6) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.  Refer to Note 6.  For diluted earnings per share, the dilutive impact of stock options and warrants is determined by applying the &#8220;treasury stock&#8221; method.  The dilutive impact of the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes (each, as defined herein and as discussed in Note 6) has been considered using the &#8220;if converted&#8221; method.  For periods in which their effect would be antidilutive, no effect is given to outstanding options, warrants or the potentially dilutive shares issuable pursuant to the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes in the dilutive computation.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A total of 69,505,513 and 68,933,402 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the three months ended June 30, 2020, and 2019, respectively, because their inclusion would be antidilutive. A total of 69,347,867 and 61,760,134 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the six months ended June 30, 2020, and 2019, respectively, because their inclusion would be antidilutive.  A full presentation of diluted earnings per share has not been provided because the required adjustments to the numerator and denominator resulted in diluted earnings per share equivalent to basic earnings per share.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June 30, 2020, and 2019, no Common Stock options or Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of no shares of Common Stock.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2020, no Common Stock options or Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of no shares of Common Stock.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2019, 24,877 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 19,232 shares of Common Stock.  Of the 24,877 Common Stock options and Common Stock warrants exercised, 5,645 shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520838184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS</a></td>
<td class="text">COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:65.935%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.667%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215,925&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,551&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: allowance for credit losses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,573)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,934)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">134,617&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories, net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consumable supplies</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,005&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,142&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,711&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,238&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,586&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: inventory reserve</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,129)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,537)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets and prepaid expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes recoverable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,274&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,486&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other receivables</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,262&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,839&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,542&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Customer relationships</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">445,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">445,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Technologies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296,246&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade names</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,771&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Covenants not to compete</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Licenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product registrations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,109&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,578&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,094&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(327,334)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(298,234)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">499,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">528,962&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory received but not invoiced</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,005&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,751&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and Contingencies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,570&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,079&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,122&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,375&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,375&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases short-term</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,099&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">210,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">164,925&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:65.935%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.667%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Line of credit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,749&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgages and other debts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,201&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,906&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases long-term</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,170&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,274&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,653&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:22.5pt;margin-top:9pt;"><span><br/></span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our intangible assets and goodwill relate principally to our completed acquisitions of OPKO Renal, OPKO Biologics, EirGen Pharma Limited (&#8220;EirGen&#8221;) and BioReference.  We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives.  The estimated useful lives by asset class are as follows:  technologies - 7-17 years, customer relationships - 7-20 years, product registrations - 7-10 years, covenants not to compete - 5 years, trade names - 5-10 years, other 9-13 years.  We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred.  Our goodwill is not tax deductible for income tax purposes in any jurisdiction in which we operate.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in value of the intangible assets and goodwill during the six months ended June 30, 2020 were primarily due to foreign currency fluctuations between the Chilean Peso, the Euro and the Shekel against the U.S. dollar.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the changes in Goodwill by reporting unit during the six months ended June 30, 2020.</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:49.537%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:13.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.667%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign exchange and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30th</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceuticals</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rayaldee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,605&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,705&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPKO Chile</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(450)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,898&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPKO Biologics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPKO Health Europe</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,394&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,403&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BioReference</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434,809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434,809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">671,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(341)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">671,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522053144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract', window );"><strong>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">INVESTMENTS</a></td>
<td class="text">INVESTMENTS<div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June&#160;30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:51.460%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.533%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.535%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment type</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment Carrying Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Underlying Equity in Net Assets</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity method investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">561&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,370&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable interest entity, equity method</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">836&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants and options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total carrying value of investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,260&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;">Equity method investments</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our equity method investments consist of investments in Pharmsynthez (ownership 9%), Cocrystal Pharma, Inc. (&#8220;COCP&#8221;) (5%), Non-Invasive Monitoring Systems, Inc. (&#8220;NIMS&#8221;) (1%), Neovasc, Inc. (&#8220;Neovasc&#8221;) (2%), InCellDx, Inc. (&#8220;InCellDx&#8221;) (29%), BioCardia, Inc. (&#8220;BioCardia&#8221;) (2%), and Xenetic Biosciences, Inc. (&#8220;Xenetic&#8221;) (3%).  The aggregate total assets, liabilities, and net losses of our equity method investees as of and for the six months ended June 30, 2020 were $79.7 million, $32.4 million, and $26.6 million, respectively.  We have determined that we and/or our related parties can significantly influence control of our equity method investments through our board representation and/or voting power.  Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Condensed Consolidated Statement of Operations.  The aggregate value of our equity method investments based on the quoted market prices of their respective shares of common stock and the number of shares held by us as of June&#160;30, 2020 was $7.9 million.  </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Equity Securities</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our equity securities consist of investments in Phio Pharmaceuticals (&#8220;Phio&#8221;) (ownership 0.02%), VBI Vaccines Inc. (&#8220;VBI&#8221;) (3%), ChromaDex Corporation (&#8220;ChromaDex&#8221;) (0.1%), MabVax Therapeutics Holdings, Inc. (&#8220;MabVax&#8221;) (1%), and Eloxx Pharmaceuticals, Inc. (&#8220;Eloxx&#8221;) (3%).  We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of these investments.  Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have readily determinable fair value. Equity securities without a readily determinable fair value are adjusted to fair value when there is an observable price change. Net gains and losses on our equity securities for the six months ended June 30, 2020 were as follows:</span></div><div style="margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:76.592%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.706%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity Securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net gains and losses recognized during the period on equity securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,907&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Net gains and losses realized during the period on equity securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized net gains recognized during the period on equity securities still held at the reporting date</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,907&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sales of investments</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statement of Operations.  We did not have significant sales activity during the six months ended June 30, 2020 and 2019.  The cost of securities sold is based on the specific identification method.  </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Warrants and options</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to our equity method investments and equity securities, we hold options to purchase 47 thousand additional shares of BioCardia, 33 thousand of which were vested as of June&#160;30, 2020, and 33 thousand, 0.7 million, 40 thousand and 404 </span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">warrants to purchase shares of COCP, InCellDx, Inc., Xenetic, and Phio, respectively.  We recorded the changes in the fair value of the options and warrants in Fair value changes of derivative instruments, net in our Condensed Consolidated Statement of Operations.  We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheet.  See further discussion of the Company&#8217;s options and warrants in Note 8 and Note 9.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments in variable interest entities</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have determined that we hold variable interests in Zebra Biologics, Inc. (&#8220;Zebra&#8221;) based on our assessment that Zebra does not have sufficient resources to carry out its principal activities without additional financial support.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We own 1,260,000 shares of Zebra Series A-2 Preferred Stock and 900,000 shares of Zebra restricted common stock (ownership 29% at June&#160;30, 2020).  Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs.  Dr. Richard Lerner, M.D., a member of our Board of Directors, is a founder of Zebra and, along with Dr. Frost, serves as a member of Zebra&#8217;s Board of Directors.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related parties&#8217; investment, as well as our investment combined with the related parties&#8217; investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra.  Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebra&#8217;s economic performance and have no obligation to fund expected losses.  We determined, however, that we can significantly influence control of Zebra through our board representation and voting power.  Therefore, we have the ability to exercise significant influence over Zebra&#8217;s operations and account for our investment in Zebra under the equity method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522257784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT&#160;<div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $100 million.  Borrowings under the line of credit will bear interest at a rate of 11% per annum and may be repaid and reborrowed at any time.  The credit agreement includes various customary remedies for the lender following an event of default, including the acceleration of repayment of outstanding amounts under line of credit.  The line of credit matures on February 25, 2025. The line of credit also calls for a commitment fee equal to 0.25% per annum of the unused portion of the line. As of June 30, 2020, no funds were borrowed under the line of credit.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, we issued $200.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in an underwritten public offering.  The 2025 Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on February&#160;15 and August&#160;15 of each year.  The notes mature on February&#160;15, 2025, unless earlier repurchased, redeemed or converted.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders may convert their 2025 Notes into shares of Common Stock at their option at any time prior to the close of business on the business day immediately preceding November&#160;15, 2024 only under the following circumstances:  (1)&#160;during any calendar quarter commencing after the calendar quarter ended March&#160;31, 2019 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2)&#160;during the five business day period after any five consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our Common Stock and the conversion rate on each such trading day; (3)&#160;if we call any or all of the 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4)&#160;upon the occurrence of specified corporate events set forth in the indenture governing the 2025 Notes.  On or after November&#160;15, 2024, until the close of business on the business day immediately preceding the maturity date, holders of the 2025 Notes may convert their notes at any time, regardless of the foregoing conditions.  Upon conversion, we will pay or deliver, as the case may be, cash, shares of our Common Stock, or a combination of cash and shares of our Common Stock, at our election.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial and current conversion rate for the 2025 Notes is 236.7424 shares of Common Stock per $1,000 principal amount of 2025 Notes (equivalent to a conversion price of approximately $4.22 per share of Common Stock).  The conversion rate for the 2025 Notes is subject to adjustment in certain events, but will not be adjusted for any accrued and unpaid interest.  In addition, following certain corporate events that occur prior to the maturity date of the 2025 Notes or if we deliver a notice of redemption, in certain circumstances the indenture governing the 2025 Notes requires an increase in the conversion rate of the </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2025 Notes for a holder who elects to convert its notes in connection with such a corporate event or notice of redemption, as the case may be.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not redeem the 2025 Notes prior to February&#160;15, 2022.  We may redeem for cash any or all of the 2025 Notes, at our option, on or after February&#160;15, 2022, if the last reported sale price of our Common Stock has been at least 130% of the then current conversion price for the notes for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide a notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.  No sinking fund is provided for the 2025 Notes.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we undergo a fundamental change, as defined in the indenture governing the 2025 Notes, prior to the maturity date of the 2025 Notes, holders may require us to repurchase for cash all or any portion of their notes at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.  The 2025 Notes are our senior unsecured obligations and rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2025 Notes; equal in right of payment to any of our existing and future liabilities that are not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the issuance of the 2025 Notes, we agreed to loan up to 30,000,000 shares of our Common Stock to affiliates of the underwriter in order to assist investors in the 2025 Notes to hedge their position. As of&#160;June&#160;30, 2020, a total of&#160;29,250,000 shares were issued under the&#160;share lending&#160;arrangement. We will not receive any of the proceeds from the sale of the borrowed shares, but we received a one-time nominal fee of $0.3 million for the newly issued shares. Shares of our Common Stock outstanding under the&#160;share lending&#160;arrangement are excluded from the calculation of basic and diluted earnings per share. See Note 3.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As required by ASC 470-20, &#8220;Debt with Conversion and Other Options,&#8221; we calculated the equity component of the 2025 Notes, taking into account both the fair value of the conversion option and the fair value of the&#160;share lending arrangement. The equity component was valued at&#160;$52.6 million&#160;at issue date and this amount was recorded as Additional paid-in capital, which resulted in a discount on the 2025 Notes. The discount is being amortized to Interest expense over the term of the 2025 Notes, which results in an effective interest rate on the 2025 Notes of 11.2%.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth information related to the 2025 Notes which is included in our Condensed Consolidated Balance Sheet as of June&#160;30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:51.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.985%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 Senior Notes</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt Issuance Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">200,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(46,774)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,086)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148,140&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount and debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,497&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">381&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">200,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,277)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,705)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 8, 2018, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the aggregate principal amount of $60 million.  The credit agreement was terminated on or around February 20, 2019 and we repaid the $28.8 million outstanding thereunder from the proceeds of the 2025 Notes offering. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, we issued a series of 5% Convertible Promissory Notes (the &#8220;2023 Convertible Notes&#8221;) in the aggregate principal amount of $55.0 million.  The 2023 Convertible Notes mature five years following the date of issuance.  Each holder of a 2023 Convertible Note has the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock at a conversion price of $5.00 per share.  We may redeem all or any part of the then issued and outstanding 2023 Convertible Notes, together with accrued and unpaid interest thereon, pro rata among the holders, upon no fewer than 30 days, and no more than 60 days, notice to the holders.  The 2023 Convertible Notes contain customary events of default and representations and warranties of OPKO.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Purchasers of the 2023 Convertible Notes included an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2013, we entered into note purchase agreements with respect to the issuance and sale of our 3.0% Senior Notes due 2033 (the &#8220;2033 Senior Notes&#8221;) in a private placement exempt from registration under the Securities Act.  We issued the 2033 Senior Notes on January&#160;30, 2013.  The 2033 Senior Notes, which totaled $175.0 million in original principal amount, bear interest at the rate of 3.0%&#160;per year, payable semiannually on February&#160;1 and August&#160;1 of each year.  The 2033 Senior Notes mature on February&#160;1, 2033, unless earlier repurchased, redeemed or converted.  Upon a fundamental change, as defined in the indenture governing the 2033 Senior Notes, subject to certain exceptions, the holders may require us to repurchase all or any portion of their 2033 Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the 2033 Senior Notes being repurchased, plus any accrued and unpaid interest to, but not including, the related fundamental change repurchase date.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From 2013 to 2016, holders of the 2033 Senior Notes converted $143.2 million in aggregate principal amount into an aggregate of 21,539,873 shares of Common Stock. On February 1, 2019, approximately $28.8 million aggregate principal amount of 2033 Senior Notes were tendered by holders pursuant to such holders&#8217; option to require us to repurchase the 2033 Senior Notes as set forth in the indenture, following which repurchase only $3.0 million aggregate principal amount of the 2033 Senior Notes remained outstanding.  Holders of the remaining $3.0 million principal amount of the 2033 Senior Notes may require us to repurchase such notes for 100% of their principal amount, plus accrued and unpaid interest, on February 1, 2023, on February 1, 2028, or following the occurrence of a fundamental change as described above.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of the 2033 Senior Notes, include, among others: (i) rights to convert the notes into shares of our Common Stock, including upon a fundamental change; and (ii) a coupon make-whole payment in the event of a conversion by the holders of the 2033 Senior Notes on or after February 1, 2017 but prior to February 1, 2019.  We determined that these specific terms were embedded derivatives.  Embedded derivatives are required to be separated from the host contract, the 2033 Senior Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument.  We concluded that the embedded derivatives within the 2033 Senior Notes met these criteria and, as such, were valued separate and apart from the 2033 Senior Notes and recorded at fair value each reporting period.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For accounting and financial reporting purposes, we combined these embedded derivatives and valued them together as one unit of accounting. In 2017, certain terms of the embedded derivatives expired pursuant to the original agreement and the embedded derivatives no longer met the criteria to be separated from the host contract and, as a result, the embedded derivatives were no longer required to be valued separate and apart from the 2033 Senior Notes and were reclassified to additional paid in capital. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2015, BioReference and certain of its subsidiaries entered into a credit agreement with JPMorgan Chase Bank, N.A. (&#8220;CB&#8221;), as lender and administrative agent, as amended (the &#8220;Credit Agreement&#8221;).  The Credit Agreement provides for a $75.0 million secured revolving credit facility and includes a $20.0 million sub-facility for swingline loans and a $20.0 million sub-facility for the issuance of letters of credit. The Credit Agreement matures on November 5, 2021 and is guaranteed by all of BioReference&#8217;s domestic subsidiaries.  The Credit Agreement is also secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference.  Availability under the Credit Agreement is based on a borrowing base composed of eligible accounts receivables of BioReference and certain of its subsidiaries, as specified therein.  As of June&#160;30, 2020, $15.3 million remained available for borrowing under the Credit Agreement. Principal under the Credit Agreement is due upon maturity on November 5, 2021. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At BioReference&#8217;s option, borrowings under the Credit Agreement (other than swingline loans) will bear interest at (i) the CB floating rate (defined as the higher of (a) the prime rate and (b) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) for an interest period of one month plus 2.50%) plus an applicable margin of 0.35% for the first 12 months and 0.50% thereafter or (ii) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) plus an applicable margin of 1.35% for the first 12 months and 1.50% thereafter.  Swingline loans will bear interest at the CB floating rate plus the applicable margin.  The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee of 0.25% of the lending commitments.  </span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2020, BioReference and certain of its subsidiaries entered into Amendment No. 11 to the Credit Agreement, which amended the Credit Agreement to provide that the fixed charge coverage ratio requirement set forth in the Credit Agreement would not be tested for the quarter ended December 31, 2019, with respect to availability calculated on January 29, 2020 and January 30, 2020, subject, in the case of testing for the quarter ended December 31, 2019, to (i) there having been no event of default occurring and (ii) availability under the revolving facility exceeding 10% of the total revolving commitment, for at least 30 consecutive days for the period ended December 31, 2019, excluding December 18, 2019. The other terms of the Credit Agreement remain unchanged.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of June 30, 2020, $51.5 million outstanding under the Credit Agreement was included within Other long-term liabilities.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement contains customary covenants and restrictions, including, without limitation, covenants that require BioReference and its subsidiaries to maintain a minimum fixed charge coverage ratio if availability under the new credit facility falls below a specified amount and to comply with laws and restrictions on the ability of BioReference and its subsidiaries to incur additional indebtedness or to pay dividends and make certain other distributions to the Company, subject to certain exceptions as specified therein.  Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of BioReference to meet its debt service obligations.  The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement and execution upon the collateral securing obligations under the Credit Agreement.  Substantially all the assets of BioReference and its subsidiaries are restricted from sale, transfer, lease, disposal or distributions to the Company, subject to certain exceptions. As of June&#160;30, 2020, BioReference and its subsidiaries had net assets of approximately $913.2 million, which included goodwill of $434.8 million and intangible assets of $345.9 million.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the Credit Agreement with CB, we had line of credit agreements with eleven other financial institutions as of both June&#160;30, 2020 and December&#160;31, 2019 in the U.S., Chile and Spain.  These lines of credit are used primarily as a source of working capital for inventory purchases.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:38.675%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.096%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.096%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.096%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.101%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(Dollars in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance Outstanding</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lender</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest&#160;rate&#160;on<br/>borrowings at <br/>June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Credit&#160;line<br/>capacity</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">JPMorgan Chase</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.67%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Itau Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bank of Chile</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.60%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">865&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BICE Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BBVA Bank</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Security Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estado Bank</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,974&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Santander Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,648&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,943&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Scotiabank</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.00%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corpbanca</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.00%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Banco De Sabadell</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.30%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Banco Bilbao Vizcaya</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.70%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Banco Santander</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.82%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">561&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52,077&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020 and December&#160;31, 2019, the weighted average interest rate on our lines of credit was approximately 4.2% and 4.0%, respectively.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020 and December&#160;31, 2019, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the Credit Agreement and amounts outstanding under lines of credit described above) as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:58.263%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.501%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.503%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of notes payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,415&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,217&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>The notes and other debt mature at various dates ranging from 2020 through 2024, bearing variable interest rates from 0.7% up to 3.8%.  The weighted average interest rate on the notes and other debt was 2.6% and 2.7% on June&#160;30, 2020 and December&#160;31, 2019. The notes are partially secured by our office space in Barcelona.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520810168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the six months ended June 30, 2020, changes in Accumulated other comprehensive loss, net of tax, were as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:84.530%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.470%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,070)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other comprehensive loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,682)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,752)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501525045320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record fair values at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.  We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we had equity securities (refer to Note 5), forward foreign currency exchange contracts for inventory purchases (refer to Note 9) and contingent consideration related to the acquisitions of CURNA, OPKO Diagnostics and OPKO Renal that are required to be measured at fair value on a recurring basis.  In addition, in connection with our investment and our consulting agreement with BioCardia, we record the related BioCardia options at fair value as well as the warrants from COCP, InCellDx, Xenetic and Phio.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial assets and liabilities measured at fair value on a recurring basis are as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value measurements as of June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options/warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,043&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,934&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,934&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,934&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,934&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value measurements as of December&#160;31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options/warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">253&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no transfers between Level 1 and Level 2 and no transfers to or from Level 3 of the fair value hierarchy.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, the carrying value of our other financial instrument assets approximates their fair value due to their short-term nature or variable rate of interest.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of June&#160;30, 2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:78.498%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent<br/>consideration</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in results of operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,934&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair values of our financial instruments have been determined by using available market information and what we believe to be appropriate valuation methodologies.  We use the following methods and assumptions in estimating fair value:</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contingent consideration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; We estimate the fair value of the contingent consideration utilizing a discounted cash flow model for the expected payments based on estimated timing and expected revenues.  We use several discount rates depending on each type of contingent consideration related to OPKO Diagnostics, CURNA and OPKO Renal transactions. As of June&#160;30, 2020, of the $9.9 million of contingent consideration, $2.4 million was recorded in Accrued expenses and $7.6 million was recorded in Other long-term liabilities.  As of December&#160;31, 2019, of the $9.7 million of contingent consideration, $2.4 million was recorded in Accrued expenses and $7.3 million was recorded in Other long-term liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520823672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Contracts<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE CONTRACTS</a></td>
<td class="text">DERIVATIVE CONTRACTS<div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair values and the presentation of our derivative assets (liabilities) in the Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:35.591%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:37.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.722%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Component</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative financial instruments:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock options/warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses.  Unrealized (losses) on forward contracts are recorded in Accrued expenses.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We enter into foreign currency forward exchange contracts in an effort to mitigate the effects of exchange rate differences arising from inventory purchases on letters of credit.  Under these forward contracts, for any rate above or below the fixed rate, we receive or pay the difference between the spot rate and the fixed rate for the given amount at the settlement date.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To qualify the derivative instrument as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At June&#160;30, 2020 and December&#160;31, 2019, our derivative financial instruments did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognize the changes in Fair value of derivative instruments, net in our Condensed Consolidated Statement of Operations.  The following table summarizes the losses and gains recorded for the three and six months ended June 30, 2020 and 2019:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.508%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.257%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:9.257%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.261%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative gain (loss):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock options/warrants </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(392)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">677&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(388)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">608&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520803592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $100 million.  Borrowings under the line of credit will bear interest at a rate of 11% per annum and may be repaid and reborrowed at any time.  The credit agreement includes various customary remedies for the lender following an event of default, including the acceleration of repayment of outstanding amounts under line of credit.  The line of credit matures on February 25, 2025.  The line of credit also calls for a commitment fee equal to 0.25% per annum of the unused portion of the line.  As of June 30, 2020, no funds were borrowed under the line of credit.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 29, 2019, we issued 50 million shares of our Common Stock at a price of $1.50 per share in an underwritten public offering (the &#8220;Offering&#8221;), resulting in net proceeds to the Company of approximately $70 million, after deducting underwriting commissions and offering expenses.  In November 2019, pursuant to an option the Company granted the underwriters, we issued an additional 4,227,749 shares at the public offering price, less underwriting discounts and commissions, resulting in net proceeds to the Company of approximately $6 million. Drs. Frost and Hsiao and Mr. Steven Rubin, members of OPKO&#8217;s senior management purchased an aggregate of 2,415,000 shares of Common Stock in the Offering. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 1, 2019, OPKO Pharmaceuticals, LLC entered into an assignment agreement with Xenetic Biosciences, Inc., as amended from time to time (the &#8220;Assignment Agreement&#8221;), pursuant to which Xenetic acquired all of OPKO Pharmaceuticals&#8217; right, title and interest in and to that certain Intellectual Property License Agreement (the &#8220;IP License Agreement&#8221;), entered into between The Scripps Research Institute and OPKO Pharmaceuticals, regarding certain patents for novel CAR T platform technology and through which the Scripps Research Institute granted an exclusive royalty-bearing license in exchange for royalties, subject to the terms of the IP License Agreement.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Assignment Agreement and the IP License Agreement, Xenetic issued to OPKO Pharmaceuticals 164,062 shares of Xenetic common stock (the &#8220;OPKO Transaction Shares&#8221;). In connection with the Assignment Agreement, OPKO Pharmaceuticals entered into a voting agreement pursuant to which OPKO Pharmaceuticals agreed, among other things, to vote </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">its shares in Xenetic in favor of the transactions contemplated by the Assignment Agreement, and a lock-up agreement with Xenetic which restricts OPKO Pharmaceuticals&#8217; sale or transfer of any of the OPKO Transaction Shares as provided therein and as otherwise required by law. The Assignment Agreement and the obligations thereunder took effect on July 19, 2019, after Xenetic satisfied certain closing conditions, including obtaining stockholder approval and securing certain financing.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company owns approximately 9% of Pharmsynthez and Pharmsynthez is Xenetic&#8217;s largest and controlling stockholder. Dr. Richard Lerner, a director of the Company, is a co-inventor of Xenetic&#8217;s technology and received 31,240 shares of Xenetic upon the closing of the Xenetic transactions described above.  Adam Logal, our Senior Vice President and Chief Financial Officer, is a director of Xenetic.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, we paid the $125,000 filing fee to the Federal Trade Commission (the &#8220;FTC&#8221;) in connection with filings made by us and Dr. Jane Hsiao, our Vice Chairman and Chief Technical Officer, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (&#8220;HSR Act&#8221;) relating to her purchases of Common Stock.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, Dr. Phillip Frost, our Chairman and Chief Executive Officer, paid a filing fee of $280,000 to the FTC under the HSR Act in connection with filings made by us and Dr. Frost, relating to his purchases of Common Stock.&#160; We reimbursed Dr. Frost for the HSR filing fee.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 8, 2018, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $60 million.  Borrowings under the line of credit bore interest at a rate of 10% per annum and could have been repaid and reborrowed at any time.  The credit agreement included various customary remedies for the lender following an event of default, including the acceleration of repayment of outstanding amounts under line of credit.  The line of credit would have matured on November 8, 2023.  We repaid approximately $28.8 million that was borrowed in 2019 and terminated the line of credit on or around February 20, 2019.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, we issued the 2023 Convertible Notes in the aggregate principal amount of $55.0 million.  Refer to Note 6. Purchasers of the 2023 Convertible Notes included Dr. Hsiao and an affiliate of Dr. Frost.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We hold investments in Zebra (ownership 29%), Neovasc (2%), ChromaDex Corporation (0.1%), MabVax (1%), COCP (5%), NIMS (1%), Eloxx (3%), and BioCardia (2%).  These investments were considered related party transactions as a result of our executive management&#8217;s ownership interests and/or board representation in these entities.  See further discussion of our investments in Note 5.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, we invested an additional $1.0 million in COCP for a convertible note, which was converted into 538,544 shares of its common stock in May 2018. In April 2017, we invested an additional $1.0 million in COCP for 138,889 shares of its common stock.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017, we invested an additional $3.0 million in Neovasc for 20,547 shares of its common stock, 20,547 Series A warrants, 20,547 Series B warrants and 8,221 Series C warrants, after adjusting for a 1-for-100 reverse stock split in 2018. In April 2018, we exercised the Series B warrants in a cashless exercise and received 10,690 shares of Neovasc common stock. In the first quarter of 2019, we exercised the Series C warrants for $1.2 million and exchanged the Series A warrants and received a total of 22,660 additional shares of Neovasc common stock.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2016, we entered into a Pledge Agreement with the Museum of Science, Inc. and the Museum of Science Endowment Fund, Inc. pursuant to which we agreed to contribute an aggregate of $1.0 million over a four-year period for constructing, equipping and the general operation of the Frost Science Museum.  Dr. Frost and Mr. Richard Pfenniger serve on the Board of Trustees of the Frost Science Museum and Mr. Pfenniger is the Vice Chairman of the Board of Trustees.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We lease office space from Frost Real Estate Holdings, LLC (&#8220;Frost Holdings&#8221;) in Miami, Florida, where our principal executive offices are located.  Effective August 1, 2019, we entered into an amendment to our lease agreement with Frost Holdings.  The lease, as amended, is for approximately 29,500 square feet of space.  The lease provides for payments of approximately $89 thousand per month in the first year increasing annually to $101 thousand per month in the fifth year, plus applicable sales tax.  The rent is inclusive of operating expenses, property taxes and parking.   </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">BioReference purchases and uses certain products acquired from InCellDx, a company in which we hold a 29% minority interest.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We reimburse Dr.&#160;Frost for Company-related use by Dr.&#160;Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr.&#160;Frost.  We reimburse Dr. Frost for out-of-pocket operating costs for the use of the airplane by Dr. Frost or Company executives for Company-related business.  We do not reimburse Dr.&#160;Frost for personal use of the airplane by Dr.&#160;Frost or any other executive.  For the three and six months ended June 30, 2020, we reimbursed approximately $0 thousand and $94 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO </span></div>executives. For the three and six months ended June 30, 2019, we reimbursed approximately $122&#160;thousand and $160&#160;thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522220648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with our acquisitions of CURNA, OPKO Diagnostics and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events.  As a result, as of June 30, 2020, we recorded $9.9 million as contingent consideration, with $2.4 million recorded within Accrued expenses and $7.6 million recorded within Other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets.  Refer to Note 4.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 3, 2019, BioReference reported that Retrieval-Masters Creditors Bureau, Inc. d/b/a American Medical Collection Agency (&#8220;AMCA&#8221;), had notified BioReference about a data security incident involving AMCA (the &#8220;AMCA Incident&#8221;).  AMCA informed BioReference that an unauthorized user had access to AMCA&#8217;s system between August 1, 2018 and March 30, 2019.  AMCA advised that AMCA&#8217;s affected system may have included patient name, date of birth, address, phone, date of service, provider, and balance information, as well as credit card information, bank account information (but no passwords or security questions) and email addresses that were provided by the consumer to AMCA.  AMCA  advised BioReference that no Social Security Numbers were compromised, and BioReference provided no laboratory results or diagnostic information to AMCA.  BioReference notified patients and provided notice to the Office of Civil Rights of the AMCA Incident. BioReference had been named in at least two class action lawsuits against AMCA and other defendants in connection with the AMCA Incident. In April 2020, the class action lawsuits against BioReference were dismissed without prejudice. The Office of Inspector General and Office for Civil Rights (&#8220;OCR&#8221;) of the Department of Health and Human Services, as well as the attorney generals&#8217; offices from certain states have contacted BioReference to request additional information relating to the AMCA Incident.  It is not possible at this time to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to whether the class action lawsuits or other lawsuits will be filed or refiled, and/or the lack of resolution of significant factual and legal issues.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As previously disclosed, on September 7, 2018, the Securities and Exchange Commission (the &#8220;SEC&#8221;) filed a lawsuit in the Southern District of New York (the &#8220;SEC Complaint&#8221;) against a number of individuals and entities (the &#8220;Defendants&#8221;), including the Company and its CEO and Chairman, Dr. Phillip Frost.  The SEC alleged, among other things, that the Company (i) aided and abetted an illegal &#8220;pump and dump&#8221; scheme perpetrated by a number of the Defendants, and (ii) failed to file required Schedules 13D or 13G with the SEC.  On December 27, 2018, the Company announced that the Company and Dr. Frost entered into settlement agreements with the SEC, which upon approval of the court would resolve the SEC Complaint against each of them.  The settlement was approved by the court in January 2019.  Pursuant to the settlement, and without admitting or denying any of the allegations of the Complaint, the Company is enjoined from violating Section 13(d) of the Exchange Act and paid a $100,000 penalty.  Liability under Section 13(d) can be established without any showing of wrongful intent or negligence.  </span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Following the SEC&#8217;s announcement of the SEC Complaint, we were named in several class action lawsuits, more than a dozen derivative suits, and other litigation relating to the allegations in the SEC Complaint among other matters.  On June 26, 2020, The Amitim Funds, the lead plaintiff in the class action lawsuits  filed a Stipulation of Settlement  in the Southern District of Florida of behalf of itself and the remainder of the class, which, if approved, will provide for the settlement of and release of the class action claims against the Company and Dr. Frost for $16.5&#160;million. We reached agreement with our insurance carriers with respect to claims made in the class action and derivative lawsuits and we expect insurance coverage for a significant portion of the settlement amounts.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The settlement remains subject to certain terms and conditions including court approval. The Company is also in advanced negotiations to settle the derivative suits. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2017, the Civil Division of the United States Attorney&#8217;s Office for the Southern District of New York (the &#8220;SDNY&#8221;) informed BioReference that it believes that, from 2008 to 2012, BioReference had, in violation of the False Claims Act, improperly billed Medicare and TRICARE (both are federal government healthcare programs) for clinical laboratory services provided to hospital inpatient beneficiaries at certain hospitals.  In April 2019, the SDNY also informed BioReference that it believes that BioReference provided physicians subsidies for electronic health record systems prior to 2012 that violated regulations adopted by HHS in 2006 which allowed laboratories to provide these donations under certain conditions.  BioReference and the SDNY are in negotiations to resolve the matter.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October&#160;11, 2019, GeneDx received a letter from the Centers for&#160;Medicare&#160;and Medicaid Services (&#8220;CMS&#8221;), notifying GeneDx of CMS&#8217; determination to suspend Medicare payments to GeneDx, which suspension became effective on September&#160;27, 2019 (the &#8220;CMS Letter&#8221;).  The CMS Letter specifically stated that the foregoing suspension may last for up to </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">180 days from the effective date and may be extended under certain circumstances.  CMS advised that it suspended payments due to possible overpayments to GeneDx in connection with reimbursement claims for genetic testing services based on a diagnosis of family history of cancer, which testing CMS has alleged is not covered by Medicare under the applicable provisions of the Social Security Act on the basis that such testing is not reasonable and necessary for the diagnosis or treatment of illness or injury.  On or around February 3, 2020, we were notified that CMS was lifting the payment suspension.  CMS noted, however, that the decision to lift the payment suspension should not be construed as a positive determination regarding GeneDx&#8217;s Medicare billing.  There can be no assurance that CMS and other governmental payor programs will not seek to recoup payments from us, suspend reimbursement or seek overpayment damages from GeneDx.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may receive inquiries, document requests, Civil Investigative Demands (&#8220;CIDs&#8221;) or subpoenas from the Department of Justice, OCR, CMS, various payors and fiscal intermediaries, and other state and federal regulators regarding investigations, audits and reviews.  In addition to the matters discussed in this note, we are currently responding to CIDs, subpoenas, payor audits, and document requests for various matters relating to our laboratory operations.  Some pending or threatened proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material.  Settlements of suits involving the types of issues that we routinely confront may require monetary payments as well as corporate integrity agreements.  Additionally, qui tam or &#8220;whistleblower&#8221; actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act&#8217;s requirements for filing such suits.  Also, from time to time, we may detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians, among other things.  We may avail ourselves of various mechanisms to address these issues, including participation in voluntary disclosure protocols.  Participating in voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action.  The Company generally has cooperated, and intends to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to other litigation in the ordinary course of business.  While we cannot predict the ultimate outcome of legal matters, we accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss.  It&#8217;s reasonably possible the ultimate liability could exceed amounts currently estimated and we review established accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information.  To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.  Because of the high degree of judgment involved in establishing loss estimates, the ultimate outcome of such matters will differ from our estimates and such differences may be material to our business, financial condition, results of operations, and cash flows.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, we were committed to make future purchases for inventory and other items in 2020 that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating approximately $154.2 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501531683368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION<div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We generate revenues from services, products and intellectual property as follows:</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from services</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance obligations are satisfied.  Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs.  Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following are descriptions of our payors for laboratory services:</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Healthcare Insurers.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules.  Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the third-party payors, are recorded upon settlement.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Government Payors.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Reimbursements from government payors are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid.  Revenues consist of amounts billed, net of contractual </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the government payors, are recorded upon settlement.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Client Payors.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Client payors include physicians, hospitals, employers, and other institutions for which services are performed on a wholesale basis, and are billed and recognized as revenue based on negotiated fee schedules.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Patients.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients.  Insured patients (including amounts for coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers.  Collection of billings from patients is subject to credit risk and ability of the patients to pay.  Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions.  Implicit price concessions represent differences between amounts billed and the estimated consideration that we expect to receive from patients, which considers historical collection experience and other factors including current market conditions.  Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered.  Actual amounts are adjusted in the period those adjustments become known. For the six months ended June 30, 2020 and 2019, revenue increases (reductions) due to changes in estimates of implicit price concessions for performance obligations satisfied in prior periods of $0.2 million and $(14.3) million, respectively, were recognized.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third-party payors, including government programs, may decide to deny payment or recoup payments for testing they contend were improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received.  Our revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payors in interpretations, requirements, and &#8220;conditions of participation&#8221; in various programs.  We have processed requests for recoupment from third-party payors in the ordinary course of our business, and it is likely that we will continue to do so in the future.  If a third-party payer denies payment for testing or recoups money from us in a later period, reimbursement for our testing could decline.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As an integral part of our billing compliance program, we periodically assess our billing and coding practices, respond to payor audits on a routine basis, and investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements, as well as overpayment claims which may arise from time to time without fault on the part of the Company.  We may have an obligation to reimburse Medicare, Medicaid,&#160;and third-party payors for overpayments&#160;regardless of fault.  We have periodically identified and reported&#160;overpayments, reimbursed payors for&#160;overpayments&#160;and taken appropriate corrective action.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are also considered variable consideration and are included in the determination of the estimated transaction price for providing services.  These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and our historical settlement activity, including an assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved.  Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. As of June&#160;30, 2020 and December&#160;31, 2019, we had liabilities of approximately $21.4 million and $27.3 million, respectively, within Accrued expenses and Other long-term liabilities related to reimbursements for payor overpayments.</span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The composition of Revenue from services by payor for the six months ended June 30, 2020 and 2019 was as follows:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:10pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.666%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.039%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June&#160;30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June&#160;30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Healthcare insurers</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,082&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,278&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183,232&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">211,207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government payers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,634&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Client payers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141,090&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,101&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patients</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Client payers include cities and states for which BioReference provides COVID-19 testing services.</span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from products</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue from product sales when a customer obtains control of promised goods or services.  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns.  Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, &#8220;Sales Deductions&#8221;) as well as estimated product returns which are all elements of variable consideration.  Allowances are recorded as a reduction of revenue at the time product revenues are recognized.  The actual amounts of consideration ultimately received may differ from our estimates.  If actual results in the future vary from our estimates, we will adjust these estimates, which would affect Revenue from products in the period such variances become known.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is distributed in the U.S. principally through the retail pharmacy channel, which initiates with the largest wholesalers in the U.S. (collectively, &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Customers&#8221;).  In addition to distribution agreements with </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Customers, we have entered into arrangements with many healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue for shipments of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> at the time of delivery to customers after estimating Sales Deductions and product returns as elements of variable consideration utilizing historical information and market research projections. For the three and six months ended June 30, 2020, we recognized $8.6 million and $18.6&#160;million, respectively, in net product revenue from sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  For the three and six months ended June 30, 2019, we recognized $5.7 million and $11.5&#160;million, respectively, in net product revenue from sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents an analysis of product sales allowances and accruals for the three and six months ended June 30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:47.558%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.617%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.588%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.588%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.593%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Governmental </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,332&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,394&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,073&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">686&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,441)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,273)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(188)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,902)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,719&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Provision for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales allowances and accruals as a percentage of gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:47.558%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.617%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.588%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.588%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.593%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Governmental </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,841&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,751&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,293&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,963&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,597)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,123)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(310)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,030)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,719&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Provision for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales allowances and accruals as a percentage of gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues.</span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from intellectual property</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements.  The terms of these agreements typically include payment to us for one or more of the following:  non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products.  Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For research, development and/or commercialization agreements that result in revenues, we identify all material performance obligations, which may include a license to intellectual property and know-how, and research and development activities.  In order to determine the transaction price, in addition to any upfront payment, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract.  We constrain (reduce) our estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract.  When determining if variable consideration should be constrained, we consider whether there are factors outside of our control that could result in a significant reversal of revenue.  In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue.  These estimates are re-assessed each reporting period as required.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upfront License Fees:  If a license to our intellectual property is determined to be functional intellectual property distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement.  The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.  If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Development and Regulatory Milestone Payments:  Depending on facts and circumstances, we may conclude that it is appropriate to include the milestone in the estimated transaction price or that it is appropriate to fully constrain the milestone.  A milestone payment is included in the transaction price in the reporting period that we conclude that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods.  We may record revenues from certain milestones in a reporting period before the milestone is achieved if we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We record a corresponding contract asset when this conclusion is reached.  Milestone payments that have been fully constrained are not included in the transaction price to date.  These milestones remain fully constrained until we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period.  We adjust our estimate of the overall transaction price, including the amount of revenue recorded, if necessary.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and Development Activities:  If we are entitled to reimbursement from our customers for specified research and development expenses, we account for them as separate performance obligations if distinct.  We also determine whether the research and development funding would result in revenues or an offset to research and development expenses in accordance </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">with provisions of gross or net revenue presentation.  The corresponding revenues or offset to research and development expenses are recognized as the related performance obligations are satisfied.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales-based Milestone and Royalty Payments:  Our customers may be required to pay us sales-based milestone payments or royalties on future sales of commercial products.  We recognize revenues related to sales-based milestone and royalty payments upon the later to occur of (i) achievement of the customer&#8217;s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to our intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other Potential Products and Services:  Arrangements may include an option for license rights, future supply of drug substance or drug product for either clinical development or commercial supply at the licensee&#8217;s election.  We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the inception of the contract and revenue is recognized only if the option is exercised and products or services are subsequently delivered or when the rights expire.  If the promise is based on market terms and not considered a material right, the option is accounted for if and when exercised.  If we are entitled to additional payments when the licensee exercises these options, any additional payments are generally recorded in license or other revenues when the licensee obtains control of the goods, which is upon delivery.</span></div>For the three and six months ended June 30, 2020, revenue from transfer of intellectual property principally reflects $13.9 million and $22.7 million of revenue, respectively, related to the Pfizer Transaction (as defined below).   In addition, revenue from the transfer of intellectual property and other for the three and six months ended June 30, 2020 includes a $6.2&#160;million grant received by BioReference from the CARES Act. For the three and six months ended June 30, 2019, revenue from the transfer of intellectual property principally reflects $18.2 million and $35.6 million of revenue, respectively, related to the Pfizer Transaction.  Refer to Note 13 for discussion of the Pfizer Transaction. Total contract liabilities included in Accrued expenses and Other long-term liabilities was $17.7 million and $21.8 million at June&#160;30, 2020 and December&#160;31, 2019, respectively.  The contract liability balance at June&#160;30, 2020 related primarily to accelerated payments received as part of the COVID-19 Aid, Relief, and Economic Security (CARES) Act.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522248680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Alliances<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_StrategicAlliancesTextBlock', window );">STRATEGIC ALLIANCES</a></td>
<td class="text">STRATEGIC ALLIANCES<div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Japan Tobacco Inc.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 12, 2017, EirGen, our wholly owned subsidiary, and Japan Tobacco Inc. (&#8220;JT&#8221;) entered into a Development and License Agreement (the &#8220;JT Agreement&#8221;) granting JT the exclusive rights for the development and commercialization of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Japan (the &#8220;JT Territory&#8221;).  The license grant to JT covers the therapeutic and preventative use of the product for (i)&#160;SHPT in non-dialysis and dialysis patients with CKD, (ii)&#160;rickets, and (iii)&#160;osteomalacia (the &#8220;JT Initial Indications&#8221;), as well as such additional indications as may be added to the scope of the license subject to the terms of the JT Agreement (the JT Additional Indications&#8221; and together with the JT Initial Indications, the &#8220;JT Field&#8221;).  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the license, OPKO received an initial upfront payment of $6 million and received another $6 million upon the initiation of OPKO&#8217;s phase 2 study for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in dialysis patients in the U.S. in September 2018 (the &#8220;Initial Consideration&#8221;). OPKO is also eligible to receive up to an additional aggregate amount of $31 million upon the achievement of certain regulatory and development milestones by JT for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the JT Territory, and $75 million upon the achievement of certain sales based milestones by JT in the JT Territory.  OPKO is also entitled to receive tiered, double digit royalty payments at percentages ranging from low double digits to mid-teens on net sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">within the JT Territory.  JT will, at its sole cost and expense, be responsible for performing all development activities necessary to obtain all regulatory approvals for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Japan and for all commercial activities pertaining to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Japan.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The JT Agreement provides for the following:  (1) an exclusive license in the JT Territory in the JT Field for the development and commercialization of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">; and (2) at JT&#8217;s option, EirGen will supply products to support the development, sale and commercialization of the products to JT in the JT Territory.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Initial Consideration will be recognized over the performance period through 2021, when we anticipate completing the transfer of license materials specified in the JT Agreement and our performance obligation is complete.  Payments received for regulatory, development and sales milestones are non-refundable.  The milestones are payable if and when the associated milestone is achieved and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, no revenue has been recognized related to these milestones.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vifor Fresenius Medical Care Renal Pharma Ltd</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2016, EirGen and Vifor Fresenius Medical Care Renal Pharma Ltd (&#8220;VFMCRP&#8221;), entered into a Development and License Agreement (the &#8220;VFMCRP Agreement&#8221;) for the development and commercialization of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (the &#8220;Product&#8221;) worldwide, except for (i) the U.S., (ii) any country in Central America or South America (excluding Mexico), (iii) Russia, (iv) China, (v) Japan, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, and (x) Taiwan (the &#8220;VFMCRP Territory&#8221;).  The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the &#8220;VFMCRP Field&#8221;), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with CKD and vitamin D insufficiency/deficiency (the &#8220;VFMCRP Initial Indication&#8221;).</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective May 5, 2020, we entered into an amendment to the VFMCRP Agreement (the &#8220;VFMCRP Amendment&#8221;), pursuant to which the parties agreed to exclude Mexico, South Korea, the Middle East and all of the countries of Africa from the VFMCRP Territory. In addition, the parties agreed to certain amendments to the milestone structure and to reduce minimum royalties payable. As revised, EirGen is eligible to receive up to $20&#160;million in Regulatory Milestones and $210&#160;million in Sales Milestones tied to launch, pricing and sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the VFMCRP Agreement, as amended, EirGen granted to VFMCRP an exclusive license in the VFMCRP Territory in the VFMCRP Field to use certain EirGen patents and technology to make, have made, use, sell, offer for sale, and import Products and to develop, commercialize, have commercialized, and otherwise exploit the Product.  EirGen received a non-refundable and non-creditable initial payment of $50 million, which was recognized in Revenue from the transfer of intellectual property and other in our Consolidated Statement of Operations in 2016.  EirGen also received a $2.0 million payment triggered by the approval of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Canada for the treatment of SHPT in adults with stage 3 or 4 CKD and vitamin D insufficiency in July 2018. EirGen is also eligible to receive up to an additional $20&#160;million in regulatory milestones (&#8220;Regulatory Milestones&#8221;) and $210&#160;million in Sales Milestones tied to launch, pricing and sales of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;Sales Milestones&#8221;), and will receive tiered royalties on sales of the product at percentage rates that range from the mid-teens to the mid-twenties or a minimum royalty, whichever is greater, upon the commencement of sales of the Product within the VFMCRP Territory and in the VFMCRP Field.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We plan to share responsibility with VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan.  EirGen will lead the manufacturing activities within and outside the VFMCRP Territory and the commercialization activities outside the VFMCRP Territory and outside the VFMCRP Field in the VFMCRP Territory and VFMCRP will lead the commercialization activities in the VFMCRP Territory and the VFMCRP Field.  For the initial development plan, the companies have agreed to certain cost sharing arrangements.  VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in the VFMCRP Territory in the VFMCRP Field except as otherwise provided in the VFMCRP Agreement.  The first of the clinical studies provided for in the development activities commenced in September 2018.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted to VFMCRP an exclusive option (the &#8220;Option&#8221;) to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the U.S. solely for the treatment of SHPT in dialysis patients with CKD and vitamin D insufficiency (the &#8220;Dialysis Indication&#8221;).  Upon exercise of the Option, VFMCRP will reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the U.S.  VFMCRP would also pay EirGen up to an additional aggregate amount of $555 million of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the U.S. for the Dialysis Indication.  To date, VFMCRP has not exercised its option.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payments received for Regulatory Milestones and Sales Milestones are non-refundable.  The Regulatory Milestones are payable if and when VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  We account for the Sales Milestones as royalties and Sales Milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met.  </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pfizer Inc.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2014, we entered into an exclusive worldwide agreement (the &#8220;Pfizer Agreement&#8221;) with Pfizer for the development and commercialization of our long-acting hGH-CTP (Somatrogon) for the treatment of growth hormone deficiency (&#8220;GHD&#8221;) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (the &#8220;Pfizer Transaction&#8221;).  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2020, we entered into an Amended and Restated Development and Commercialization License Agreement (the &#8220;Restated Agreement&#8221;) with Pfizer, effective January 1, 2020, pursuant to which the parties agreed, among other things, to share all costs for Manufacturing Activities, as defined in the Restated Agreement, for developing a licensed product for the three indications included in the Agreement.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 21, 2019, we and Pfizer announced that the global phase 3 trial evaluating Somatrogon (hGH-CTP) dosed once-weekly in prepubertal children with GHD met its primary endpoint of non-inferiority to daily Genotropin&#174; (somatropin) for injection, as measured by annual height velocity at 12 months.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Pfizer Transaction, as restated, we received non-refundable and non-creditable upfront payments of $295.0 million and are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones.  Pfizer received the exclusive license to commercialize hGH-CTP worldwide.  In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of hGH-CTP for adult GHD with percentage rates ranging from the high teens to mid-twenties.  Upon the launch of hGH-CTP for pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both hGH-CTP and Pfizer&#8217;s Genotropin&#174;.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement with Pfizer will remain in effect until the last sale of the licensed product, unless earlier terminated as permitted under the Pfizer Agreement.  In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Pfizer Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period.  If the Pfizer Agreement is terminated by us for Pfizer&#8217;s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions.     </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized the non-refundable $295.0 million upfront payments as revenue as the research and development services were completed and as of June 30, 2020, we had no contract liabilities related to the Pfizer Transaction.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Pfizer Transaction includes milestone payments of $275.0 million upon the achievement of certain milestones.  The milestones range from $20.0 million to $90.0 million each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets.  The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  To date, no revenue has been recognized related to the achievement of the milestones.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">TESARO</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2009, we entered into an asset purchase agreement (the &#8220;NK-1 Agreement&#8221;) under which we acquired VARUBI&#8482; (rolapitant) and other neurokinin-1 (&#8220;NK-1&#8221;) assets from Merck.  In December 2010, we entered into an exclusive license agreement with TESARO, Inc. (&#8220;TESARO&#8221;), in which we out-licensed the development, manufacture, commercialization and distribution of our lead NK-1 candidate, VARUBI&#8482; (the &#8220;TESARO License&#8221;).  Under the terms of the license, we received a $6.0 million upfront payment from TESARO and we received $30 million of milestone payments from TESARO upon achievement of certain regulatory and commercial sale milestones and we are eligible to receive additional commercial milestone payments of up to $85 million if specified levels of annual net sales are achieved.  The sales based milestone payments will be recognized as revenue in full in the period in which the associated sales occur. For the six months ended June 30, 2020 and 2019, no revenue was recognized related to the achievement of the milestones under the TESARO License. </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the TESARO License, TESARO was also obligated to pay us tiered royalties on annual net sales achieved in the U.S. and Europe at percentage rates that range from the low double digits to the low twenties, and outside of the U.S. and Europe at low double-digit percentage rates until the later of the date that all of the patent rights licensed from us and covering VARUBI&#8482; expire, are invalidated or are not enforceable and 12 years from the first commercial sale of the product.  TESARO announced in 2018 that it had elected to suspend further distribution of Varubi IV.  In June 2018, TESARO assigned its rights and obligations under the agreement to TerSera Therapeutics LLC (&#8220;TerSera&#8221;) pursuant to an asset purchase agreement.  Under the asset purchase agreement, TerSera is responsible for VARUBI in the U.S. and Canada and TESARO was permitted to continue to commercialize VARUBY&#174; in Europe and the rest of the world though a sublicense with TerSera.  In September 2019, TESARO informed us and TerSera that it intends to stop selling VARUBY</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the TESARO Territory and that it intends to withdraw its marketing authorization for VARUBY</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Europe.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The term of the license with TerSera will remain in force until the expiration of the royalty term in each country, unless we terminate the license earlier for material breach of the license or bankruptcy.  TerSera has a right to terminate the license at any time during the term for any reason on three months&#8217; written notice.  </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pharmsynthez </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2013, we entered into a series of concurrent transactions with Pharmsynthez, a Russian pharmaceutical company traded on the Moscow Stock Exchange, pursuant to which we acquired an equity method investment in Pharmsynthez (ownership 9%).  We also granted rights to certain technologies in the Russian Federation, Ukraine, Belarus, Azerbaijan and Kazakhstan (the &#8220;Pharmsynthez Territories&#8221;) to Pharmsynthez and agreed to perform certain development activities.  We will receive from Pharmsynthez royalties on net sales of products incorporating the technologies in the Pharmsynthez Territories, as well as a percentage of any sublicense income from third parties for the technologies in the Pharmsynthez Territories.  </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Phio Pharmaceuticals Corp.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2013, we completed the sale to RXi Pharmaceuticals Corporation (now known as Phio Pharmaceuticals Corp.) of substantially all of our assets in the field of RNA interference (the &#8220;RNAi Assets&#8221;) (collectively, the &#8220;Asset Purchase Agreement&#8221;).  Pursuant to the Asset Purchase Agreement, Phio will be required to pay us up to $50.0 million in milestone payments upon the successful development and commercialization of each drug developed by Phio, certain of its affiliates or any of its or their licensees or sublicensees utilizing patents included within the RNAi Assets (each, a &#8220;Qualified Drug&#8221;).  In addition, Phio will also be required to pay us royalties equal to: (a)&#160;a mid single-digit percentage of &#8220;Net Sales&#8221; (as defined in the Asset Purchase Agreement) with respect to each Qualified Drug sold for an ophthalmologic use during the applicable &#8220;Royalty Period&#8221; (as defined in the Asset Purchase Agreement); and (b)&#160;a low single-digit percentage of net sales with respect to each Qualified Drug sold for a non-ophthalmologic use during the applicable Royalty Period.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have completed strategic deals with numerous institutions and commercial partners.  In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements.  At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_StrategicAlliancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic Alliances [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_StrategicAlliancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520809016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
<td class="text">SEGMENTS<div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of our clinical laboratory operations through BioReference and our point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense and income taxes.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.666%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.039%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from services:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from products:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from transfer of intellectual property and other: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,686&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating loss:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,996)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,556)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,121)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38,033)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,935&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28,013)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(61,582)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,760)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,691)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,263)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,962)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(47,260)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,581)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(122,577)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,240&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,908&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,260&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,266&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from investment in investees:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(189)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(271)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(323)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,125)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(189)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(271)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(323)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,125)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">265,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">184,310&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">446,761&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">369,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ireland</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,847&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,174&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,749&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chile</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,051&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,915&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spain</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,292&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,294&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Israel</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,183&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mexico</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">301,207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">226,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">512,674&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">448,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.114%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,148,151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,174,639&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,121,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,035,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,381&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,323,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,309,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">237,131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434,809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434,809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">671,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">671,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table>No customer represented more than 10% of our total consolidated revenue during the six months ended June 30, 2020 and 2019. As of June&#160;30, 2020 and December&#160;31, 2019, no customer represented more than 10% of our accounts receivable balance.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520568120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have operating leases for office space, laboratory operations, research and development facilities, manufacturing locations, warehouses and certain equipment.  We determine if a contract contains a lease at inception or modification of a contract.  Our leases generally do not provide an implicit interest rate, and we therefore use our incremental borrowing rate as the discount rate when measuring operating lease liabilities.  The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment.  We used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.  Many of our leases contain rental escalation, renewal options and/or termination options that are factored into our determination of lease payments as appropriate.  Variable lease payment amounts that cannot be determined at the commencement of the lease are not included in the right-to-use assets or liabilities.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of June 30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:31.431%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:28.938%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.982%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.450%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classification on the Balance Sheet</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,469&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,380&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current maturities of operating leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,038&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current maturities of finance leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,759&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.6 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average discount rate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of June 30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 1, 2020 through December 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,404&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,479&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,506&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted future minimum lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,479&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Difference between lease payments and discounted lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,422&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">209&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,057&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expense under operating leases and finance leases was $9.7 million and $1.2 million, respectively, for the six months ended June 30, 2020, which includes $1.6 million of variable lease costs. Expense under operating leases and finance leases was $9.8 million and $2.0 million, respectively, for the six months ended June 30, 2019, which includes $1.7 million of variable lease costs. Operating lease costs and finance lease costs are included within Operating loss in the Condensed Consolidated Statement of Operations. Short-term lease costs were not material.  </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental cash flow information is as follows:</span></div><div style="margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.700%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.931%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash out flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash out flows from finance leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">234&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing cash out flows from finance leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,026&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501528126360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered.  In July 2020, we received a favorable Medicare appeal decision from Novitas Solutions Inc. (&#8220;Novitas&#8221;) for previously denied Medicare claims for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> tests we performed during 2019. As a result of the favorable appeal, Medicare will reimburse us for such </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> tests for patients who meet defined criteria. Due to a prior non-coverage determination by Novitas, no revenue was previously recognized for these </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> tests and therefore we recognized $10.9&#160;million for the previously denied </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">4Kscore</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> tests as a component of Revenue from services for the three and six months ended June 30, 2020.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have reviewed all subsequent events and transactions that occurred after the date of our June&#160;30, 2020 Condensed Consolidated Balance Sheet, through the time of filing this Quarterly Report on Form 10-Q.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501527328536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">Basis of presentation.  The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all information and notes required by GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company&#8217;s results of operations, financial position and cash flows have been made.  The results of operations and cash flows for the three and six months ended June 30, 2020 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2020 or any other future periods.  The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">Principles of consolidation.  The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and of our wholly owned subsidiaries.  All intercompany accounts and transactions are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of estimates</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from these estimates.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">Cash and cash equivalents.  Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase.  We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents.  These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Inventories</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Inventories are valued at the lower of cost and net realizable value.  Cost is determined by the first-in, first-out method.  We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value.  Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which is used in our testing laboratories.  Inventory obsolescence expense for the six months ended June&#160;30, 2020 and 2019 was $1.7 million and $1.3 million, respectively.</span>Pre-launch inventories.  We may accumulate commercial quantities of certain product candidates prior to the date we anticipate that such products will receive final U.S. FDA approval.  The accumulation of such pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever.  This risk notwithstanding, we may accumulate pre-launch inventories of certain products when such action is appropriate in relation to the commercial value of the product launch opportunity.  In accordance with our policy, this pre-launch inventory is expensed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and intangible assets</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill and intangible assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting.  Refer to Note 4.  Goodwill, in-process research and development (&#8220;IPR&amp;D&#8221;) and other intangible assets acquired in business combinations, licensing and other transactions was $1.8 billion at both at June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values.  Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill.  At acquisition, we generally determine the fair value of intangible assets, including IPR&amp;D, using the &#8220;income method.&#8221;</span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill was $671.6&#160;million and $671.9 million respectively, at June&#160;30, 2020 and December&#160;31, 2019. Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.  We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing.  Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net intangible assets other than goodwill were $1.1 billion, including IPR&amp;D of $590.2 million, at both June&#160;30, 2020 and December&#160;31, 2019.  Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products and IPR&amp;D.  Considering the high risk nature of research and development and the industry&#8217;s success rate of bringing developmental compounds to market, IPR&amp;D impairment charges may occur in future periods.  Estimating the fair value of IPR&amp;D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon obtaining regulatory approval, IPR&amp;D assets are then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.  If the project is abandoned, the IPR&amp;D asset is charged to expense.  Finite lived intangible assets are tested for impairment when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.  The testing includes a comparison of the carrying amount of the asset to its estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span></div>We believe that our estimates and assumptions are reasonable and otherwise consistent with assumptions that marketplace participants would use in their estimates of fair value.&#160; However, if future results are not consistent with our estimates and assumptions, including as a result of the COVID-19 global pandemic, then we may be exposed to an impairment charge, which could be material.&#160; We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years.  We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair value measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments.  Investments that are considered equity securities as of June&#160;30, 2020 and December&#160;31, 2019 are predominately carried at fair value.  Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest applicable to such debt.</span>In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates.  The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts.  Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Contingent consideration</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contingent consideration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense.  Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability.  Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions.  The assumptions used in estimating fair value require significant judgment.  The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative financial instruments</a></td>
<td class="text">Derivative financial instruments.  We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges.  For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At June&#160;30, 2020 and December&#160;31, 2019, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognize all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Property, plant and equipment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Property, plant and equipment are recorded at cost or fair value if acquired in a business combination.  Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases.  The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years.  Expenditures for repairs and maintenance are charged to expense as incurred.  Depreciation expense was $14.4 million and $14.5 million for the six months ended June 30, 2020 and 2019, respectively.  Assets held under finance leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheet and are amortized over the shorter of their useful lives or the expected term of their related leases.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Impairment of long-lived assets.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income taxes.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are accounted for under the asset-and-liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those </span><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.  We periodically evaluate the realizability of our</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">net deferred tax assets.  Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">adjustment.  Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate in various countries and tax jurisdictions globally.&#160; For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.&#160; For the three and six months ended June 30, 2020, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition and shipping and handling costs</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue recognition</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;Topic 606&#8221;).  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.  </span>We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.  At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct.  We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Shipping and handling costs.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not charge customers for shipping and handling costs.  Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk and allowance for doubtful accounts</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Concentration of credit risk and allowance for credit losses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable.  Substantially all of our accounts receivable are with either companies in the healthcare industry or patients.  However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span>While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Allowance for doubtful accounts</a></td>
<td class="text">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer&#8217;s ability to pay.  Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Equity-based compensation</a></td>
<td class="text">Equity-based compensation.  We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award.  We record excess tax benefits realized from the exercise of stock options as cash flows from operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expenses.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses include external and internal expenses.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  Research and development </span><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">employee-related expenses include salaries, benefits and equity-based compensation expense.  Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.  We expense these costs in the period in which they are incurred.  We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received.  As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility and which have no alternative future use.  For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed.  Once the development process has been completed the asset will be amortized over its remaining estimated useful life.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Segment reporting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Our chief operating decision-maker (&#8220;CODM&#8221;) is Phillip Frost, M.D., our Chairman and Chief Executive Officer.  Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis.  We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rayaldee</span> product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of clinical laboratory operations through BioReference and point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense or income taxes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text">Foreign currency translation.  The financial statements of certain of our foreign operations are measured using the local currency as the functional currency.  The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods.  Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable interest entities</a></td>
<td class="text">Variable interest entities.  The consolidation of a variable interest entity (&#8220;VIE&#8221;) is required when an enterprise has a controlling financial interest.  A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">Investments.  We have made strategic investments in development stage and emerging companies.  We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees.  For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations.  Refer to Note 5.  For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently adopted accounting pronouncements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  </span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221; which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables.  This may result in the earlier recognition of allowances for losses.  The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2019, with early adoption permitted.  The adoption of ASU 2016-13 on January 1, 2020, did not have a significant impact on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522652648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock', window );">Composition of Certain Financial Statement Captions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:65.935%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.667%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215,925&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,551&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: allowance for credit losses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,573)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,934)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">134,617&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories, net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consumable supplies</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,005&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,142&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,711&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,238&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,586&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: inventory reserve</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,129)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,537)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets and prepaid expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes recoverable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,274&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,486&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other receivables</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,262&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,839&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,542&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Customer relationships</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">445,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">445,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Technologies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296,246&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade names</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,771&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Covenants not to compete</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Licenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product registrations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,109&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,578&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,094&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(327,334)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(298,234)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">499,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">528,962&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory received but not invoiced</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,005&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,751&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and Contingencies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,570&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,079&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,122&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,375&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,375&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases short-term</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,099&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">210,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">164,925&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:65.935%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.667%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Line of credit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,749&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgages and other debts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,201&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,906&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases long-term</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,170&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,274&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,653&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Changes in Goodwill</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the changes in Goodwill by reporting unit during the six months ended June 30, 2020.</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:49.537%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:13.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.667%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign exchange and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30th</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceuticals</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rayaldee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,605&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,705&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPKO Chile</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(450)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,898&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPKO Biologics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPKO Health Europe</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,394&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,403&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BioReference</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434,809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434,809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">671,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(341)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">671,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Composition of certain financial statement captions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522661832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract', window );"><strong>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Accounting Method, Carrying Value and Underlying Equity in Net Assets of Unconsolidated Investments</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June&#160;30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:51.460%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.533%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.535%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment type</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment Carrying Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Underlying Equity in Net Assets</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity method investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">561&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,370&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable interest entity, equity method</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">836&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants and options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total carrying value of investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,260&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Net Gains and Losses on Equity Securities</a></td>
<td class="text">Net gains and losses on our equity securities for the six months ended June 30, 2020 were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:76.592%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.706%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity Securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net gains and losses recognized during the period on equity securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,907&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Net gains and losses realized during the period on equity securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized net gains recognized during the period on equity securities still held at the reporting date</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,907&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522274408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth information related to the 2025 Notes which is included in our Condensed Consolidated Balance Sheet as of June&#160;30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:51.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.985%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 Senior Notes</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt Issuance Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">200,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(46,774)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,086)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148,140&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount and debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,497&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">381&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">200,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,277)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,705)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020 and December&#160;31, 2019, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the Credit Agreement and amounts outstanding under lines of credit described above) as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:58.263%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.501%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.503%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of notes payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,415&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,217&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Summary of Lines of Credit</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:38.675%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.096%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.096%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.096%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.101%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(Dollars in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance Outstanding</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lender</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest&#160;rate&#160;on<br/>borrowings at <br/>June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Credit&#160;line<br/>capacity</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">JPMorgan Chase</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.67%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Itau Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bank of Chile</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.60%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">865&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BICE Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BBVA Bank</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Security Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estado Bank</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,974&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Santander Bank</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,648&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,943&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Scotiabank</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.00%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corpbanca</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.00%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Banco De Sabadell</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.30%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Banco Bilbao Vizcaya</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.70%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Banco Santander</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.82%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">561&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52,077&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522174872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in Accumulated Other Comprehensive Loss, Net of Tax</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the six months ended June 30, 2020, changes in Accumulated other comprehensive loss, net of tax, were as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:84.530%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.470%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,070)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other comprehensive loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,682)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,752)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522335096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial assets and liabilities measured at fair value on a recurring basis are as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value measurements as of June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options/warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,043&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,934&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,934&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,934&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,934&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value measurements as of December&#160;31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options/warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">253&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of the Beginning and Ending Balances of Level 3 Assets</a></td>
<td class="text">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of June&#160;30, 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:78.498%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent<br/>consideration</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in results of operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,934&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of the Beginning and Ending Balances of Level 3 Liabilities</a></td>
<td class="text">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of June&#160;30, 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:78.498%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent<br/>consideration</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in results of operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,934&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501531797128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Contracts (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair Values and Presentation of Derivative Financial Instruments</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair values and the presentation of our derivative assets (liabilities) in the Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:35.591%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:37.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.722%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Component</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative financial instruments:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock options/warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses.  Unrealized (losses) on forward contracts are recorded in Accrued expenses.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Instrument Losses and Gains Recorded</a></td>
<td class="text">The following table summarizes the losses and gains recorded for the three and six months ended June 30, 2020 and 2019:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.508%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.257%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:9.257%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.261%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative gain (loss):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock options/warrants </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(392)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">677&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(388)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">608&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520649208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text">The composition of Revenue from services by payor for the six months ended June 30, 2020 and 2019 was as follows:<div style="text-align:center;margin-top:14pt;margin-bottom:10pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.666%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.039%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June&#160;30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June&#160;30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Healthcare insurers</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,082&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,278&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183,232&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">211,207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government payers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,634&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Client payers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141,090&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,101&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patients</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Client payers include cities and states for which BioReference provides COVID-19 testing services.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock', window );">Schedule of Product Sales Allowances and Accruals</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents an analysis of product sales allowances and accruals for the three and six months ended June 30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:47.558%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.617%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.588%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.588%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.593%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Governmental </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,332&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,394&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,073&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">686&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,441)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,273)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(188)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,902)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,719&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Provision for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales allowances and accruals as a percentage of gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:47.558%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.617%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.588%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.588%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.593%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Governmental </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,841&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,751&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,293&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,963&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,597)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,123)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(310)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,030)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,719&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Provision for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales allowances and accruals as a percentage of gross </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Rayaldee</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Product Sales Allowances And Accruals [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522012888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operations and Assets for Operating Segments and Geographic Information</a></td>
<td class="text">Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.666%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.039%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from services:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from products:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from transfer of intellectual property and other: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,686&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,880&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating loss:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,996)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,556)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,121)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38,033)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,935&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28,013)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(61,582)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,760)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,691)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,263)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,962)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(47,260)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,581)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(122,577)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,240&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,908&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,260&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,266&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from investment in investees:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(189)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(271)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(323)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,125)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(189)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(271)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(323)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,125)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">265,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">184,310&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">446,761&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">369,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ireland</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,847&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,174&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,749&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chile</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,051&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,915&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spain</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,292&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,294&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Israel</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,183&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mexico</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">301,207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">226,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">512,674&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">448,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.114%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,148,151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,174,639&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,121,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,035,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,381&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,323,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,309,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmaceutical</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">237,131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434,809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434,809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">671,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">671,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501527882104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Assets and Liabilities</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of June 30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:31.431%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:28.938%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.982%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.450%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classification on the Balance Sheet</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,469&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,380&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current maturities of operating leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,038&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current maturities of finance leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,759&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.6 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average discount rate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lease Liability Maturity</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of June 30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 1, 2020 through December 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,404&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,479&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,506&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted future minimum lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,479&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Difference between lease payments and discounted lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,422&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">209&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,057&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Lease Liability Maturity</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of June 30, 2020:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 1, 2020 through December 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,404&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,479&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,506&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted future minimum lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,479&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Difference between lease payments and discounted lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,422&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">209&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,057&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Cash Flows</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental cash flow information is as follows:</span></div><div style="margin-top:14pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.700%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.931%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">(in thousands)</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash out flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash out flows from finance leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">234&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing cash out flows from finance leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,026&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520774760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>employee</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_NumberofSalesEmployees', window );">Number of sales employees</a></td>
<td class="nump">300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_NumberofSalesEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Sales Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_NumberofSalesEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501527121560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>test</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_COVID19PercentOfTotalTestVolume', window );">Total test volume (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301,207<span></span>
</td>
<td class="nump">$ 226,368<span></span>
</td>
<td class="nump">$ 512,674<span></span>
</td>
<td class="nump">$ 448,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory obsolescence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets', window );">Goodwill, in-process research and development and other intangible assets acquired</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">671,599<span></span>
</td>
<td class="nump">671,940<span></span>
</td>
<td class="nump">671,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">671,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net intangible assets other than goodwill</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,937<span></span>
</td>
<td class="nump">16,419<span></span>
</td>
<td class="nump">29,874<span></span>
</td>
<td class="nump">32,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400<span></span>
</td>
<td class="nump">14,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts receivable</a></td>
<td class="num">$ (1,573)<span></span>
</td>
<td class="num">$ (1,934)<span></span>
</td>
<td class="num">(1,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member', window );">CMS Accelerated and Advanced Payment Program, COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=opk_DistributionToHealthcareProvidersCOVID19Member', window );">Distribution to Healthcare Providers, COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,880<span></span>
</td>
<td class="nump">$ 19,230<span></span>
</td>
<td class="nump">$ 30,433<span></span>
</td>
<td class="nump">$ 37,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | Distribution to Healthcare Providers, COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember', window );">Diagnostics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ChangeInTestingVolumePercent', window );">Change in testing volume (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_COVID19TestTypeAxis=opk_SerologyAntibodyTestMember', window );">Serology Antibody Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_COVID19NumberOfTestsPerformed', window );">Number of tests performed | test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_COVID19TestsPerformedPerDay', window );">Tests performed per day | test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_COVID19TestTypeAxis=opk_DiagnosticMolecularTestMember', window );">Diagnostic Molecular Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_COVID19NumberOfTestsPerformed', window );">Number of tests performed | test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_COVID19TestsPerformedPerDay', window );">Tests performed per day | test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember', window );">Government Contracts Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">37.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery, Medical and Other Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery, Medical and Other Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=opk_AutomobilesandAircraftMember', window );">Automobiles and Aircraft | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=opk_AutomobilesandAircraftMember', window );">Automobiles and Aircraft | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net intangible assets other than goodwill</a></td>
<td class="nump">$ 590,200<span></span>
</td>
<td class="nump">$ 590,200<span></span>
</td>
<td class="nump">$ 590,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_COVID19NumberOfTestsPerformed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COVID-19, Number of Tests Performed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_COVID19NumberOfTestsPerformed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_COVID19PercentOfTotalTestVolume">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COVID-19, Percent of Total Test Volume</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_COVID19PercentOfTotalTestVolume</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_COVID19TestsPerformedPerDay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COVID-19, Tests Performed Per Day</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_COVID19TestsPerformedPerDay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ChangeInTestingVolumePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Testing Volume, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ChangeInTestingVolumePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_DistributionToHealthcareProvidersCOVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_DistributionToHealthcareProvidersCOVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_COVID19TestTypeAxis=opk_SerologyAntibodyTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_COVID19TestTypeAxis=opk_SerologyAntibodyTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_COVID19TestTypeAxis=opk_DiagnosticMolecularTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_COVID19TestTypeAxis=opk_DiagnosticMolecularTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=opk_AutomobilesandAircraftMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=opk_AutomobilesandAircraftMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501533130072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised', window );">Number of common stock warrant and common stock options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment', window );">Number of common stock issued for stock warrant and stock options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SharesSurrenderedInLieuOfCashPayment', window );">Shares surrendered in lieu of cash payment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive potential shares (in shares)</a></td>
<td class="nump">69,505,513<span></span>
</td>
<td class="nump">68,933,402<span></span>
</td>
<td class="nump">69,347,867<span></span>
</td>
<td class="nump">61,760,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_SharesSurrenderedInLieuOfCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares surrendered in lieu of cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_SharesSurrenderedInLieuOfCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock warrant and common stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued for stock warrant and stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501527092680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts receivable, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 215,925<span></span>
</td>
<td class="nump">$ 136,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowance for credit losses</a></td>
<td class="num">(1,573)<span></span>
</td>
<td class="num">(1,934)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">214,352<span></span>
</td>
<td class="nump">134,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Consumable supplies</a></td>
<td class="nump">41,298<span></span>
</td>
<td class="nump">23,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">24,259<span></span>
</td>
<td class="nump">25,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in-process</a></td>
<td class="nump">4,711<span></span>
</td>
<td class="nump">3,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">5,826<span></span>
</td>
<td class="nump">4,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: inventory reserve</a></td>
<td class="num">(3,129)<span></span>
</td>
<td class="num">(2,537)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">72,965<span></span>
</td>
<td class="nump">53,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other current assets and prepaid expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_TaxesRecoverableCurrent', window );">Taxes recoverable</a></td>
<td class="nump">12,135<span></span>
</td>
<td class="nump">19,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Prepaid expenses</a></td>
<td class="nump">12,999<span></span>
</td>
<td class="nump">8,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">6,274<span></span>
</td>
<td class="nump">3,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">3,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">19,056<span></span>
</td>
<td class="nump">15,839<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">51,125<span></span>
</td>
<td class="nump">50,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(327,334)<span></span>
</td>
<td class="num">(298,234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">499,125<span></span>
</td>
<td class="nump">528,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InventoryReceivedNotInvoicedCurrent', window );">Inventory received but not invoiced</a></td>
<td class="nump">49,005<span></span>
</td>
<td class="nump">13,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AccruedCommitmentsandContingenciesCurrent', window );">Commitments and Contingencies</a></td>
<td class="nump">38,668<span></span>
</td>
<td class="nump">38,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee benefits</a></td>
<td class="nump">34,086<span></span>
</td>
<td class="nump">33,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">16,570<span></span>
</td>
<td class="nump">19,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AccruedClinicalTrialsCurrent', window );">Clinical trials</a></td>
<td class="nump">6,079<span></span>
</td>
<td class="nump">8,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases short-term</a></td>
<td class="nump">2,435<span></span>
</td>
<td class="nump">2,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">4,009<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">56,884<span></span>
</td>
<td class="nump">45,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">210,111<span></span>
</td>
<td class="nump">164,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Other long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Line of credit</a></td>
<td class="nump">51,489<span></span>
</td>
<td class="nump">44,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">7,559<span></span>
</td>
<td class="nump">7,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Mortgages and other debts payable</a></td>
<td class="nump">4,201<span></span>
</td>
<td class="nump">3,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance leases long-term</a></td>
<td class="nump">2,960<span></span>
</td>
<td class="nump">4,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities</a></td>
<td class="nump">1,170<span></span>
</td>
<td class="nump">2,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent', window );">Other</a></td>
<td class="nump">24,274<span></span>
</td>
<td class="nump">25,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">91,653<span></span>
</td>
<td class="nump">87,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">445,144<span></span>
</td>
<td class="nump">445,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">296,251<span></span>
</td>
<td class="nump">296,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">49,771<span></span>
</td>
<td class="nump">49,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Covenants not to compete</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">16,318<span></span>
</td>
<td class="nump">16,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">5,766<span></span>
</td>
<td class="nump">5,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_ProductRegistrationsMember', window );">Product registrations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">7,109<span></span>
</td>
<td class="nump">7,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="nump">$ 6,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AccruedClinicalTrialsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AccruedClinicalTrialsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AccruedCommitmentsandContingenciesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Commitments and Contingencies, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AccruedCommitmentsandContingenciesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_InventoryReceivedNotInvoicedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory Received, Not Invoiced, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_InventoryReceivedNotInvoicedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_TaxesRecoverableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Taxes Recoverable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_TaxesRecoverableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations and noncurrent portion of deferred revenue not separately disclosed in the balance sheet.  Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_ProductRegistrationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_ProductRegistrationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501525709816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_CovenantsNotToCompeteMember', window );">Covenants not to compete</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Tecnology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Products</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Tecnology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Products</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">13 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_CovenantsNotToCompeteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_CovenantsNotToCompeteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522806808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions - Changes in Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 671,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="num">(341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">671,599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember', window );">BioReference</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">434,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">85,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">85,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | OPKO Chile</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">4,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="num">(450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">3,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | OPKO Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">139,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">139,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | OPKO Health Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">7,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">7,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember', window );">Diagnostics | BioReference</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">434,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 434,809<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_EirGenPharmaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_EirGenPharmaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_OpkoChileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_OpkoChileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_OPKOBiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_OPKOBiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_OPKOHealthEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_OPKOHealthEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501531485480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract', window );"><strong>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentExcludingVariableInterestEntity', window );">Equity method investments</a></td>
<td class="nump">$ 561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentVariableInterestEntity', window );">Variable interest entity, equity method</a></td>
<td class="nump">836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">24,777<span></span>
</td>
<td class="nump">$ 18,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities with no readily determinable fair value</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_StockOptionandWarrantInvestments', window );">Warrants and options</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Total carrying value of investments</a></td>
<td class="nump">26,260<span></span>
</td>
<td class="nump">$ 20,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets', window );">Equity method investment, underlying equity in net assets</a></td>
<td class="nump">$ 2,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentExcludingVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Excluding Variable Interest Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentExcludingVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Variable Interest Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_StockOptionandWarrantInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Option and Warrant Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_StockOptionandWarrantInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522719784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets of equity method investees</a></td>
<td class="nump">$ 2,323,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,323,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,309,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total (liabilities) of equity method investees</a></td>
<td class="num">(735,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(735,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (694,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net losses of equity method investees</a></td>
<td class="num">(33,703)<span></span>
</td>
<td class="nump">$ 59,806<span></span>
</td>
<td class="nump">25,429<span></span>
</td>
<td class="nump">$ 140,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Market value</a></td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets of equity method investees</a></td>
<td class="nump">79,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total (liabilities) of equity method investees</a></td>
<td class="num">$ (32,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net losses of equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember', window );">Pharmsynthez</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage, equity method</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember', window );">Cocrystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage, equity method</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares)</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NonInvasiveMonitoringSystemsInc.Member', window );">Non-Invasive Monitoring Systems, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage, equity method</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember', window );">Neovasc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage, equity method</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember', window );">InCellDx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage, equity method</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares)</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member', window );">BioCardia, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage, equity method</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Ownership percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares)</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested', window );">Investment options, vested (in shares)</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_XeneticBiosciencesInc.Member', window );">Xenetic Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage, equity method</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PhioPharmaceuticalsMember', window );">Phio Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Ownership percentage</a></td>
<td class="nump">0.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares)</a></td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_VBIVaccinesIncMember', window );">VBI Vaccines Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Ownership percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromaDexMember', window );">ChromaDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Ownership percentage</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_MabVaxTherapeuticsHoldingsInc.Member', window );">MabVax Therapeutics Holdings, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Ownership percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember', window );">Eloxx Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Ownership percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember', window );">Zebra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage, equity method</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Zebra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="nump">1,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Zebra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SharesReceivedAsGift', window );">Shares received as a gift (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights, Vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquitySecurityFVNIOwnershipPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Security, FV-NI, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquitySecurityFVNIOwnershipPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_SharesReceivedAsGift">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Received As Gift</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_SharesReceivedAsGift</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NonInvasiveMonitoringSystemsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NonInvasiveMonitoringSystemsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_XeneticBiosciencesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_XeneticBiosciencesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PhioPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PhioPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_VBIVaccinesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_VBIVaccinesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromaDexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromaDexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_MabVaxTherapeuticsHoldingsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_MabVaxTherapeuticsHoldingsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520935080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Schedule of Net Gains and Losses on Equity Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract', window );"><strong>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net gains and losses recognized during the period on equity securities</a></td>
<td class="nump">$ 5,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Less: Net gains and losses realized during the period on equity securities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized net gains recognized during the period on equity securities still held at the reporting date</a></td>
<td class="nump">$ 5,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501511825464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">48 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 20, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2013</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>institution</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>institution </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 08, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,374,000<span></span>
</td>
<td class="nump">$ 78,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Long-term line of credit, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,749,000<span></span>
</td>
<td class="nump">51,489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 671,940,000<span></span>
</td>
<td class="nump">$ 671,599,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_DebtInstrumentsNumberofFinancialInstitutions', window );">Number of financial institutions | institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember', window );">BioReference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 913,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=opk_OPKOHealthEuropeMember', window );">OPKO Health Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays', window );">Consecutive days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | OPKO Health Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Variable interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage', window );">Percentage of total revolving commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | OPKO Health Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Variable interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2367424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable', window );">Shares issuable under debt agreement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued on converted debt (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ProceedsFromConvertibleDebtConversionFee', window );">Proceeds one-time nominal fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible debt, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Equivalent redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period one | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period one | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days applicable conversion price | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible debt, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period two | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days applicable conversion price | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible debt, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Equivalent redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period three | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period three | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days applicable conversion price | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 5% Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum', window );">Minimum conversion notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum', window );">Maximum conversion notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Notes Due February 1, 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Remaining principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,140,000<span></span>
</td>
<td class="nump">$ 152,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Notes Due February 1, 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Equivalent redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Notes | Notes Due February 1, 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Equivalent redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Remaining principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Long-term line of credit, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember', window );">Swingline | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR | Revolving Credit Facility | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember', window );">LIBOR, First 12 Months | Revolving Credit Facility | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORThereafterMember', window );">LIBOR Thereafter | Revolving Credit Facility | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember', window );">LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember', window );">LIBOR, Thereafter, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Convertible Debt | Notes Due February 1, 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued on converted debt (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,539,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_DrFrostMember', window );">Dr Frost | Line of Credit | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Notice Threshold, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Notice Threshold, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Maximum Shares Issuable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_DebtInstrumentsNumberofFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of financial institutions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_DebtInstrumentsNumberofFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Terms, Total Revolving Commitment, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit, Total Revolving Commitment, Threshold Consecutive Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ProceedsFromConvertibleDebtConversionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Convertible Debt, Conversion Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ProceedsFromConvertibleDebtConversionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_OPKOHealthEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_OPKOHealthEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_A5ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_A5ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_NotesDueFebruary12033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_NotesDueFebruary12033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_NewCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_NewCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_DrFrostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_DrFrostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501511792312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNetAbstract', window );"><strong>Debt Issuance Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>2025 Senior Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Beginning balance</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Ending balance</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountAbstract', window );"><strong>Discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Beginning balance</a></td>
<td class="num">(46,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">3,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Ending balance</a></td>
<td class="num">(43,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNetAbstract', window );"><strong>Debt Issuance Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Beginning balance</a></td>
<td class="num">(5,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Ending balance</a></td>
<td class="num">(4,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Beginning balance</a></td>
<td class="nump">148,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">3,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Ending balance</a></td>
<td class="nump">$ 152,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501608073816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Lines of Credit (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 101,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 63,537,000<span></span>
</td>
<td class="nump">$ 52,077,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_JPMorganChaseMember', window );">JPMorgan Chase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">3.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 51,489,000<span></span>
</td>
<td class="nump">44,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_ItauBankMember', window );">Itau Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 1,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 530,000<span></span>
</td>
<td class="nump">472,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_BankOfChileMember', window );">Bank of Chile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 865,000<span></span>
</td>
<td class="nump">851,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_BiceBankMember', window );">BICE Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 1,019,000<span></span>
</td>
<td class="nump">1,429,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_BbvaBankMember', window );">BBVA Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_SecurityMember', window );">Security Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">588,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_EstadoBankMember', window );">Estado Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 1,974,000<span></span>
</td>
<td class="nump">1,365,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_SantanderBankMember', window );">Santander Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 2,648,000<span></span>
</td>
<td class="nump">1,943,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_ScotiabankMember', window );">Scotiabank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 1,095,000<span></span>
</td>
<td class="nump">668,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_Corpbanca1Member', window );">Corpbanca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 3,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 3,917,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_BancoDeSabadellMember', window );">Banco De Sabadell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_BilbaoVizcayaBankMember', window );">Banco Bilbao Vizcaya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_SantanderBank2MemberMember', window );">Banco Santander</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at June 30, 2020</a></td>
<td class="nump">1.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_JPMorganChaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_JPMorganChaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_ItauBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_ItauBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_BankOfChileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_BankOfChileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_BiceBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_BiceBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_BbvaBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_BbvaBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_SecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_SecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_EstadoBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_EstadoBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_SantanderBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_SantanderBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_ScotiabankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_ScotiabankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_Corpbanca1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_Corpbanca1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_BancoDeSabadellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_BancoDeSabadellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_BilbaoVizcayaBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_BilbaoVizcayaBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_SantanderBank2MemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_SantanderBank2MemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501526548200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Notes Payable and Other Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Mortgage notes and other debt payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 91,653<span></span>
</td>
<td class="nump">$ 87,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=opk_NotesPayableAndOtherLongTermLiabilitiesMember', window );">Notes Payable and Other Long-Term Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Mortgage notes and other debt payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">4,936<span></span>
</td>
<td class="nump">4,723<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 7,351<span></span>
</td>
<td class="nump">$ 7,217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=opk_NotesPayableAndOtherLongTermLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=opk_NotesPayableAndOtherLongTermLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501531149496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 1,614,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">1,588,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(22,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(3,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">$ (25,752)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522495416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 24,777<span></span>
</td>
<td class="nump">$ 18,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Common stock options/warrants</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">25,043<span></span>
</td>
<td class="nump">19,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">9,934<span></span>
</td>
<td class="nump">9,683<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">9,934<span></span>
</td>
<td class="nump">9,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">24,777<span></span>
</td>
<td class="nump">18,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Common stock options/warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">24,777<span></span>
</td>
<td class="nump">18,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Common stock options/warrants</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Common stock options/warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">9,934<span></span>
</td>
<td class="nump">9,683<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">9,934<span></span>
</td>
<td class="nump">9,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Forward contracts</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts | Quoted prices in active markets for identical assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Forward contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts | Significant other observable inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Forward contracts</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts | Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Forward contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501531769640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Level 3 Reconciliation (Details) - Contingent consideration<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 9,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Included in results of operations</a></td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 9,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=opk_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=opk_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522611224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 9,934<span></span>
</td>
<td class="nump">$ 9,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501526655960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Contracts - Balance Sheet Component (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Common Stock options/warrants | Investments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Forward contracts | Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501607812392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Contracts - Derivative Gains (Losses) (Details) - Not Designated as Hedging Instrument - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative gain (loss)</a></td>
<td class="num">$ (13)<span></span>
</td>
<td class="num">$ (388)<span></span>
</td>
<td class="nump">$ 608<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Common Stock options/warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative gain (loss)</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative gain (loss)</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 677<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501508692888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 29, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 20, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 08, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,374,000<span></span>
</td>
<td class="nump">$ 78,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Reimbursement paid to related party for travel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember', window );">Pharmsynthez</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember', window );">Zebra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Stock ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember', window );">Neovasc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromadexCorporationMember', window );">ChromaDex Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_MabVaxTherapeuticsHoldingsInc.Member', window );">MabVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember', window );">COCP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NIMSMember', window );">NIMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember', window );">Eloxx Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member', window );">BioCardia, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember', window );">InCellDx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_FrostRealEstateHoldingsLLCMember', window );">Frost Real Estate Holdings LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_OperatingLeasesMonthlyPaymentsYearOne', window );">Lease payments per month in first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_OperatingLeasesMonthlyPaymentsYearThree', window );">Lease payments per month in third year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=opk_SharesReceivedUponClosingofXeneticTransactionMember', window );">Shares Received Upon Closing of Xenetic Transaction | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_RelatedPartyTransactionShares', window );">Shares received upon closing of transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=opk_FederalTradeCommissionFilingFeesMember', window );">Federal Trade Commission Filing Fees | Dr. Jan Hsiao</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=opk_FederalTradeCommissionFilingFeesMember', window );">Federal Trade Commission Filing Fees | Dr. Frost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Neovasc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentSharesPurchasedInPeriod', window );">Equity method investment, additional investment in period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | COCP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentSharesPurchasedInPeriod', window );">Equity method investment, additional investment in period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=opk_XeneticBiosciencesInc.Member', window );">Xenetic | OPKO Transaction Shares | Affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Issuance of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=opk_MuseumofScienceIncMember', window );">Museum of Science, Inc | Dr Frost and Mr Pfenniger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_RelatedPartyTransactionFutureContributions', window );">Related party future contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_RelatedPartyTransactionFutureContributionTerm', window );">Related party future contribution term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | COCP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Common Stock | COCP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_DebtInstrumentConvertibleSharesIssued', window );">Shares received after conversion (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=opk_A5ConvertibleNotesMember', window );">5% Convertible Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=opk_SeriesAWarrantMember', window );">Series A Warrant | Neovasc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=opk_SeriesBWarrantMember', window );">Series B Warrant | Neovasc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived', window );">Shares received upon exercise of warrant (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=opk_SeriesCWarrantMember', window );">Series C Warrant | Neovasc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived', window );">Shares received upon exercise of warrant (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on credit facility</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Unsecured Debt | Dr. Frost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | New Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,227,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_MembersofSeniorManagementMember', window );">Members of Senior Management | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Of Warrant, Number Of Securities Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_DebtInstrumentConvertibleSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_DebtInstrumentConvertibleSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentSharesPurchasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Shares Purchased In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentSharesPurchasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquitySecurityFVNIOwnershipPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Security, FV-NI, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquitySecurityFVNIOwnershipPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_OperatingLeasesMonthlyPaymentsYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Monthly Payments, Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_OperatingLeasesMonthlyPaymentsYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_OperatingLeasesMonthlyPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Monthly Payments, Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_OperatingLeasesMonthlyPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_RelatedPartyTransactionFutureContributionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Future Contribution, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_RelatedPartyTransactionFutureContributionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_RelatedPartyTransactionFutureContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Future Contributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_RelatedPartyTransactionFutureContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_RelatedPartyTransactionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_RelatedPartyTransactionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromadexCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromadexCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_MabVaxTherapeuticsHoldingsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_MabVaxTherapeuticsHoldingsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NIMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NIMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_FrostRealEstateHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_FrostRealEstateHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=opk_SharesReceivedUponClosingofXeneticTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=opk_SharesReceivedUponClosingofXeneticTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=opk_FederalTradeCommissionFilingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=opk_FederalTradeCommissionFilingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_ChiefTechnicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_ChiefTechnicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=opk_XeneticBiosciencesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=opk_XeneticBiosciencesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=opk_OPKOTransactionSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=opk_OPKOTransactionSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=opk_MuseumofScienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=opk_MuseumofScienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_DrFrostandMrPfennigerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_DrFrostandMrPfennigerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_A5ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_A5ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=opk_SeriesAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=opk_SeriesAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=opk_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=opk_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=opk_SeriesCWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=opk_SeriesCWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_NewCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_NewCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_MembersofSeniorManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_MembersofSeniorManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501531741160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 27, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 07, 2018 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,934,000<span></span>
</td>
<td class="nump">$ 9,683,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_NumberOfClassActionLawsuits', window );">Number of class action lawsuits (at least) | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_NumberOfDerivativeLawsuits', window );">Number of derivative lawsuits (at least) | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Inventory received but not invoiced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_NumberOfClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_NumberOfClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_NumberOfDerivativeLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Derivative Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_NumberOfDerivativeLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501527061816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">33 Months Ended</th>
<th class="th" colspan="1">66 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Prior period performance obligation revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="num">$ (14,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AccruedExpensePayorOverpaymentReimbursementLiability', window );">Overpayment reimbursement liability</a></td>
<td class="nump">$ 21,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400,000<span></span>
</td>
<td class="nump">$ 21,400,000<span></span>
</td>
<td class="nump">$ 27,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">301,207,000<span></span>
</td>
<td class="nump">$ 226,368,000<span></span>
</td>
<td class="nump">512,674,000<span></span>
</td>
<td class="nump">448,820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liability</a></td>
<td class="nump">17,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,700,000<span></span>
</td>
<td class="nump">17,700,000<span></span>
</td>
<td class="nump">$ 21,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_RayaldeeMember', window );">Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">8,600,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="nump">18,600,000<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">22,876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,559,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">20,880,000<span></span>
</td>
<td class="nump">19,230,000<span></span>
</td>
<td class="nump">30,433,000<span></span>
</td>
<td class="nump">37,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_PfizerMember', window );">Pfizer | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_PfizerMember', window );">Pfizer | Products | Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13,900,000<span></span>
</td>
<td class="nump">$ 18,200,000<span></span>
</td>
<td class="nump">$ 22,700,000<span></span>
</td>
<td class="nump">$ 35,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_BioReferenceMember', window );">BioReference | Products | Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AccruedExpensePayorOverpaymentReimbursementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expense, Payor Overpayment Reimbursement, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AccruedExpensePayorOverpaymentReimbursementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_RayaldeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_RayaldeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_BioReferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_BioReferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522487496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 301,207<span></span>
</td>
<td class="nump">$ 226,368<span></span>
</td>
<td class="nump">$ 512,674<span></span>
</td>
<td class="nump">$ 448,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">250,971<span></span>
</td>
<td class="nump">178,458<span></span>
</td>
<td class="nump">421,811<span></span>
</td>
<td class="nump">357,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_HealthInsurersMember', window );">Healthcare insurers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">84,082<span></span>
</td>
<td class="nump">106,278<span></span>
</td>
<td class="nump">183,232<span></span>
</td>
<td class="nump">211,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_GovernmentPayersMember', window );">Government payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,886<span></span>
</td>
<td class="nump">28,634<span></span>
</td>
<td class="nump">42,784<span></span>
</td>
<td class="nump">59,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_ClientPayersMember', window );">Client payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">141,090<span></span>
</td>
<td class="nump">38,101<span></span>
</td>
<td class="nump">180,191<span></span>
</td>
<td class="nump">76,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_PatientsMember', window );">Patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 9,913<span></span>
</td>
<td class="nump">$ 5,445<span></span>
</td>
<td class="nump">$ 15,604<span></span>
</td>
<td class="nump">$ 10,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_HealthInsurersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_HealthInsurersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_GovernmentPayersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_GovernmentPayersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_ClientPayersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_ClientPayersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_PatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_PatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501524322328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 301,207<span></span>
</td>
<td class="nump">$ 226,368<span></span>
</td>
<td class="nump">512,674<span></span>
</td>
<td class="nump">$ 448,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_RayaldeeMember', window );">Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">12,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="nump">14,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments', window );">Credits or payments made</a></td>
<td class="num">(12,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,030)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">13,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 22,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales', window );">Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales</a></td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_ChargebacksDiscountsRebatesAndFeesMember', window );">Chargebacks, discounts, rebates and fees | Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 2,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="nump">4,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments', window );">Credits or payments made</a></td>
<td class="num">(4,441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,597)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">2,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_GovernmentalMember', window );">Governmental | Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">6,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="nump">9,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments', window );">Credits or payments made</a></td>
<td class="num">(8,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">6,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_SalesReturnsMember', window );">Returns | Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">3,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="nump">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments', window );">Credits or payments made</a></td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 3,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance For Doubtful Accounts, Provision For Allowance As Percent Of Gross Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance For Doubtful Accounts Receivable, Decrease, Credits Or Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_RayaldeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_RayaldeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_ChargebacksDiscountsRebatesAndFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_ChargebacksDiscountsRebatesAndFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_GovernmentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_GovernmentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_SalesReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_SalesReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501526847752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Alliances (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">33 Months Ended</th>
<th class="th" colspan="1">66 Months Ended</th>
<th class="th" colspan="1">94 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 05, 2020</div></th>
<th class="th"><div>Oct. 21, 2019</div></th>
<th class="th"><div>Oct. 12, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment', window );">Upfront payment from development and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold', window );">Written termination threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCarePharmaLtdMember', window );">VFMCRP | Development and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License revenue, initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCarePharmaLtdMember', window );">VFMCRP | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeAgreementAdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCarePharmaLtdMember', window );">VFMCRP | Exclusive Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangement.MaximumMilestonePayments', window );">Additional milestone payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_PfizerMember', window );">Pfizer | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangement.MaximumMilestonePayments', window );">Additional milestone payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime', window );">Annual height velocity at point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementUpfrontPayment', window );">Non-refundable and non-creditable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_TesaroMember', window );">Tesaro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeAgreementAdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment', window );">Upfront payment under license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeAgreementPeriodfromFirstCommercialSale', window );">Period from first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Pfizer | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMilestonePayment', window );">Each milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Pfizer | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMilestonePayment', window );">Each milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember', window );">Pharmsynthez</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage, equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PhioPharmaceuticalsMember', window );">Phio Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived', window );">Maximum milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_MilestoneAxis=opk_PhaseTwoInitiationMember', window );">Phase Two Initiation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment', window );">Upfront payment from development and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_MilestoneAxis=opk_RegulatoryAndDevelopmentMember', window );">Regulatory and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment', window );">Milestone payment from development and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_MilestoneAxis=opk_SalesRevenueMember', window );">Sales Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment', window );">Milestone payment from development and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_RegulatoryMilestonesMember', window );">Regulatory Milestones | EirGen Pharma Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMaximumMilestonePayments', window );">Maximum milestone payments</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_SalesMilestonesMember', window );">Sales Milestones | EirGen Pharma Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMaximumMilestonePayments', window );">Maximum milestone payments</a></td>
<td class="nump">$ 210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeAgreementAdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Additional Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeAgreementAdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeAgreementPeriodfromFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period from First Commercial Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeAgreementPeriodfromFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangement.MaximumMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement. Maximum Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangement.MaximumMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Annual Height Velocity at Point in Time</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, License Termination, Written Notice Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementMaximumMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementMaximumMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated milestone payment to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and Collaboration Agreements Proceeds as Up Front Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Development And License Agreement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Development And License Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCarePharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCarePharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=opk_DevelopmentandLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=opk_DevelopmentandLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=opk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=opk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=opk_ExclusiveOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=opk_ExclusiveOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_TesaroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_TesaroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PhioPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PhioPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_MilestoneAxis=opk_PhaseTwoInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_MilestoneAxis=opk_PhaseTwoInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_MilestoneAxis=opk_RegulatoryAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_MilestoneAxis=opk_RegulatoryAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_MilestoneAxis=opk_SalesRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_MilestoneAxis=opk_SalesRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_EirGenPharmaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_EirGenPharmaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501526436712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Inter-segment sales</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Inter-segment allocation of interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501526761112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Operations and Assets Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 301,207<span></span>
</td>
<td class="nump">$ 226,368<span></span>
</td>
<td class="nump">$ 512,674<span></span>
</td>
<td class="nump">$ 448,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">27,179<span></span>
</td>
<td class="num">(47,260)<span></span>
</td>
<td class="num">(13,581)<span></span>
</td>
<td class="num">(122,577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">22,266<span></span>
</td>
<td class="nump">23,661<span></span>
</td>
<td class="nump">44,318<span></span>
</td>
<td class="nump">47,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net income (loss) from investment in investees</a></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(271)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="num">(2,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">2,323,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,323,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,309,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">671,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">671,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">671,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">265,890<span></span>
</td>
<td class="nump">184,310<span></span>
</td>
<td class="nump">446,761<span></span>
</td>
<td class="nump">369,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">16,847<span></span>
</td>
<td class="nump">22,174<span></span>
</td>
<td class="nump">28,749<span></span>
</td>
<td class="nump">42,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CL', window );">Chile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11,152<span></span>
</td>
<td class="nump">9,051<span></span>
</td>
<td class="nump">22,002<span></span>
</td>
<td class="nump">16,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,136<span></span>
</td>
<td class="nump">4,876<span></span>
</td>
<td class="nump">8,292<span></span>
</td>
<td class="nump">9,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">3,768<span></span>
</td>
<td class="nump">2,890<span></span>
</td>
<td class="nump">6,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,866<span></span>
</td>
<td class="nump">2,058<span></span>
</td>
<td class="nump">3,708<span></span>
</td>
<td class="nump">3,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=opk_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(7,760)<span></span>
</td>
<td class="num">(10,691)<span></span>
</td>
<td class="num">(16,263)<span></span>
</td>
<td class="num">(22,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net income (loss) from investment in investees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">54,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(5,996)<span></span>
</td>
<td class="num">(8,556)<span></span>
</td>
<td class="num">(20,121)<span></span>
</td>
<td class="num">(38,033)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,119<span></span>
</td>
<td class="nump">7,382<span></span>
</td>
<td class="nump">14,240<span></span>
</td>
<td class="nump">14,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net income (loss) from investment in investees</a></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(271)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="num">(2,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">1,148,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,148,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">236,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember', window );">Diagnostics | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">40,935<span></span>
</td>
<td class="num">(28,013)<span></span>
</td>
<td class="nump">22,803<span></span>
</td>
<td class="num">(61,582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">15,147<span></span>
</td>
<td class="nump">16,260<span></span>
</td>
<td class="nump">30,019<span></span>
</td>
<td class="nump">32,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net income (loss) from investment in investees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">1,121,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,121,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">434,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">250,971<span></span>
</td>
<td class="nump">178,458<span></span>
</td>
<td class="nump">421,811<span></span>
</td>
<td class="nump">357,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Pharmaceutical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Diagnostics | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">250,971<span></span>
</td>
<td class="nump">178,458<span></span>
</td>
<td class="nump">421,811<span></span>
</td>
<td class="nump">357,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">29,356<span></span>
</td>
<td class="nump">28,680<span></span>
</td>
<td class="nump">60,430<span></span>
</td>
<td class="nump">53,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products | Pharmaceutical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">29,356<span></span>
</td>
<td class="nump">28,680<span></span>
</td>
<td class="nump">60,430<span></span>
</td>
<td class="nump">53,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">20,880<span></span>
</td>
<td class="nump">19,230<span></span>
</td>
<td class="nump">30,433<span></span>
</td>
<td class="nump">37,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | Pharmaceutical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14,686<span></span>
</td>
<td class="nump">19,230<span></span>
</td>
<td class="nump">24,239<span></span>
</td>
<td class="nump">37,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | Diagnostics | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,194<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,194<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=opk_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=opk_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501615922760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 38,469<span></span>
</td>
<td class="nump">$ 39,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">5,395<span></span>
</td>
<td class="nump">6,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">10,298<span></span>
</td>
<td class="nump">12,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,435<span></span>
</td>
<td class="nump">2,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">28,759<span></span>
</td>
<td class="nump">27,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 2,960<span></span>
</td>
<td class="nump">$ 4,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:PropertyPlantAndEquipmentNet<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Discount Rate [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Lease Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501607928088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Liability Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">July 1, 2020 through December 31, 2020</a></td>
<td class="nump">$ 6,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">7,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">6,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">5,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">4,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">17,374<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted future minimum lease payments</a></td>
<td class="nump">48,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Difference between lease payments and discounted lease liabilities</a></td>
<td class="nump">9,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">39,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">July 1, 2020 through December 31, 2020</a></td>
<td class="nump">1,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">2,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total undiscounted future minimum lease payments</a></td>
<td class="nump">5,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Difference between lease payments and discounted lease liabilities</a></td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 5,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, Payments, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501527596920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease expense</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501520694664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash out flows from operating leases</a></td>
<td class="nump">$ 9,804<span></span>
</td>
<td class="nump">$ 10,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash out flows from finance leases</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash out flows from finance leases</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,590<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_PaymentsForLeases', window );">Total</a></td>
<td class="nump">$ 10,916<span></span>
</td>
<td class="nump">$ 12,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_PaymentsForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_PaymentsForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501528119656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 301,207<span></span>
</td>
<td class="nump">$ 226,368<span></span>
</td>
<td class="nump">$ 512,674<span></span>
</td>
<td class="nump">$ 448,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">250,971<span></span>
</td>
<td class="nump">$ 178,458<span></span>
</td>
<td class="nump">421,811<span></span>
</td>
<td class="nump">$ 357,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | 4Kscore</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=opk_A4KscoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=opk_A4KscoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140501522183208">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">us-gaap:AccountingStandardsUpdate201807Member<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "21O]0YGVM\D(%  !D%0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)6876_B.!2&KV=_A87VHB,5DCA Z8@B :4SW>D'+=U9S:[VPB2&1$WBC.-
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M/D4E5S::VY&" YH^#88\31BF?H@C.]&@(QHXB7XN-[!\0CZ/T@N,>2.2A,&
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M0X#6 E01L'"' *L%F") 6(< KP7XO@)6+6 I M3I$+!K 5L1<+H&[=0"CB+
MNBRXM8"KNM05):\6\!0!V^N:./PP<[C*H,V45_DR\0O_Z"!+[U!6XJ6^\J%*
MNDI>IDF4E.OCLLCD7R,I5QR=?/QP^?'=;')\-9V@RROYX_WTP]4E^GB*IG]<
MSZ[^1D-T?3E!+WY[B7Y#48*N%NDZ]Y,P/Q@5TGZI9134ML8;6[3#UE5:^#$@
M=F(6.UDOU[%?+B,TG<_ENGJ%+D06I2%*Y^@X3%?E0GLEG_Z1 9-+MP!,3'I,
MI,NE7*R711I\!:2G/>.2A2E?9S\ R5.SY'$81J7W?HPN_"@<SA)TXJ\B.$QO
MGZKK.0)XUF,\"#9&1(@^%@N1(1E26; 79265=M^E.90PL_VU3L0\"B+(M?-'
M*_G)@(SD&MLN-+I=:+1R@W>X,1:W49)$R:TLY[&?!.(5RA=^)G+T0JZJS>-+
MY!?2Q^ U8N05HIBX4"IO[%B5G;+]?3^R7-MUB4/QP>C[;MH"2.YYV-G"6B-A
MVY&PQXUD'Z_'&YWVCB_$\0CU2-OG$QVGC&JB(^3X/67H.FA8VFNC3G44PYAS
M2MNXMX VC]IMT!D DL%@BLT9Y!GQ'.RX;>"Y#MRUV9HZOITZ7@FQCJF;)4%9
MJP1Z(>>K>GI9UO2J[BW2.!19_CN:?EM'Q0_T^5,:QTB2D#L_"[\85H"U-6X9
M\V:C=UBRF1 %LCS(VN!7)$G<E\\"2AM+2V''<I3)/NT!M;RUM][:9F_O119$
M,E2R).RV![2I#CF2/1#)T&1^4K36,+1D;<U!XE%&80^=K8?.\WD(Q=;1O!HR
M);)&2,MK=^NU:_2:8FK)V4^^BZR(;F*!DK2013!*@G@=ED6E"B.*15*]5>[?
MBK((]P79U7RE'K6P_ =[[&T]]OXCCZ&@>WI-QJZE%)R)IZU]ZJES VFRK(ZT
M)[@AA-@XW ]R4R;'EBYEE8AEVX9B/:YUM!*#<&S92A&;[0%L^[E#7(G1SPW-
M"%HT(X9IQKA6U?*"JNWRK _5=K1I_,3<^:>;O.AI^^?K1#907#50#V2P>C>W
MB4TL[*G9,P6@IL9/FLY/S*V_/91]W![7&ENUS\&NI_;%"='[G1R?-K3]&CM@
ME6&I3K5Z!@!EUV:6VK4A'&',=CKSH^G)A/\B9E@;VH<:0E!3BC1-GIB[_-/8
M(=%;.$P/ :#*#VM(#T$$4& BZ?9@B@CITSDBH XDB1 .9HD LI,FDH;\D![V
MLU?-VIU6N&;IQ,=V,'-<!Q-U/G2H,2$;ED1Z:))6L_K<'M<:6YL5FW#'\M1L
M!/@185SMYH ^&0:N1D!'@1FIVV2$4T_E!V>0<[*=.5C--6@0%B'8<=1<ZQMN
M>XH:2DC<7[\M(0V_(V:"=QP$Z3HIRBRY+"1IEHIS=+T*_4*@S]/[HB07)>][
M%^7%%S!?S/K7^?#6]U=O&CM;,QLK,@]MPMZ+Y8W(3$<-#8>C9@ZW=TMY[V?F
M%4QU_M;%.@"H:073ANE1,],#6TJ?Y^-::?O$P:8.4[)Z @ !X@&@H-5)=0[)
ML.7*>"FK$P .Y9:0*K@9A"/4L3W".^*Z<R)%?_VRHPV9I#UD\BGG 10@=D1M
MQJ=]J+;'#5.C9J:VU]:(ZLQJ:'DNMM6)[<6UO6P8&#4SL,=LC*C.'JBK<HRS
M/E3;T89DT.<@&;T;(PJ0C*X2]3B201N201]+,GHW1E1OIO#&B +L :A/^[$'
MP"J\,0* X,8(PADW1K2A!=1\5/2DC1&<(OK94!</!:#&%&E8!C6S@-Z-$9PE
M^BD/3$6I?F0$45$ !E!14!F03+IS,!4%@" 5A7 P%>T=;OMJHV%.#/_ZGL@:
MJL/,5.=)/9'I%(%CE>:<]J':'C<D@IE/M_;JB4P_D!I2BVMDIQ_7]G+GRLK,
M-1[3$QEPU,-L5UE)9[VPMJL-R6!FDO'HKE@66KWD,9U>=)4\ &J\)VR8".NY
M\3%U1=#M,0,.@BS795PI*1.FG[< A0Q @?> P"F/++*8J4?$ % FJ*,2C1F$
M(Y:,/N]@3:QA3<S,FIZRM^M(D?U/9P"H,44:XL3,Q*EO;]>1)0!WLKAK$T_-
MDKU.7@ 4F"7@R8O%.5>S!+HVP\1UU"P!3UX<8NVPK'9<&^[$_H<C%=:0'68F
M.T_K8P#7L5Q;G84>5/MBO&G\_!FNO;A^Q,&87#+*O/;"VCXV[( _WY47!]H]
M9Y:2J7VHMJ,-*>#/?.4%%R@.7'EU%"@ :BI0O&$._">NO.#JQ(%O7< >!@"!
MZ@2@H.H$P. >!NF#>AAH%^QAHYWO#\NO:F7]EE4]1[&82U'\VI'3DFT^5-V\
M%.FJ^B3Q)BV*=%D]+H0OBU()D'^?IVGQ\%)^Y;C]7/CH7U!+ P04    " "2
M1O]0IV81D]((  "D(P  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;)U:
M;6_;.!+^*X1O<6B!NA9?)-F])$#JI-@LTB2(T]O/BD7'NDJBEZ+SLK_^AI0C
M.>*+T^V'1I*'Y#/#F7EF*!T]"?FS67.NT'-5ULWQ:*W4YLMDTBS7O,J:SV+#
M:_AE)625*;B5#Y-F(WF6FT%5.2%1E$RJK*A')T?FV8T\.1);518UOY&HV595
M)E^^\E(\'8_PZ/7!;?&P5OK!Y.1HDSWP!5<_-C<2[B;=+'E1\;HI1(TD7QV/
M3O&7.9OI 4;BOP5_:O:ND5;E7HB?^N8B/QY%&A$O^5+I*3+X\\CGO"SU3(#C
MK]VDHVY-/7#_^G7V;T9Y4.8^:_A<E'\6N5H?CZ8CE/-5MBW5K7CZG>\4BO5\
M2U$VYG_TU,JFR0@MMXT2U6XP(*B*NOV;/>\,L3< YG$/(+L!9#B >0;0W0!J
M%&V1&;7.,I6='$GQA*26AMGTA;&-&0W:%+7>QH62\&L!X]3)_/KJ[/QJ<7Z&
MX&IQ?7EQ=GH'-XL[^//]_.IN@:Z_H?GIXG?T[?+ZSP4:HQ^+,_3AMX_H-U34
MZ&XMMDU6Y\W11 $:/>=DN5OY:[LR\:R<H.^B5NL&G=<YS]^.GX 6G2KD596O
M)#CA']OZ,Z+1)T0B$CGPS-\]',\"<&AG66KFHS[+9LT:K2!,&K22HD(0>3)3
M1?W0NFZA"MY\":S#NG6868=YUKF"6"]%X]R!=F1B1NJ ?CP9DY@14.]QWS .
M,<RB.)EV<F^0Q1VR.&B!T_Q_X, 0\ZI!2D#0+T6]+$J.ZAUD_51?+[6IM@W/
MM4O]JIV2#DT2M-,9ASRW++(V>]0YRBHA5?&W>> R7CM=O&<5QBB>#FSGD$I9
MFKHMEW98T_">BGILC%+4BDO>*!>^U%HYC@@9P+.%R-2WK],.W32([G3/<$BL
M=-;D4L+NK8HZ@QV&K5N*1CD]<FJ;"^,!9EN&1A[(LP[R+ CY$KR-[P*QJ!_Y
MJUN"O[6WG#OASFPHA [@VC($D]B-%T=]7HZ"B,__VA;J9:PI*@=S5L#;36OQ
M?_]K2C#^#^+5IA0O -QX<PTNTSUQ9N/(-GU$TX$R#JDT3F<>;?98!@>UN>59
M6?P-FIBP!R7RHMF()BNU_ZR*9_@E@QU2K2[P'+2"7[@Q FKX<BM-(G JABW(
M.$Z&>ME"1+.$4RW2JT6":LW76?W M1>MLD*BQZS<<B=NHU;.9?&8Z;(%1C1*
M;HT/.E4B%MIQ$N-XJ)0M%D.*\FC5$Q>F_T@K2-\Z+P-H?=D4N4G4[N2Y6^*-
MO>-AH#N$<.3%WQ,B#C/B1;4!W-JX&G7K5TZ,S%H^&B*T19+8%]L]+^+X !7M
M$F910V1SI+)GM)'BL6A\UHP=AB)#*G))^7(][FD3)^$ZQGB#295[(5H6V7U1
M'B1GW#,>#E/>Z7(IMCHE TES")/[DG_2Q8'3'#:KC:<XIL.ZQB7'Z,QGDI[_
M<)@ +X R:B7DBQ^AS6%C@F>1%<$.N81XV:.G.QSFNVNUYA+Z!_ RB(*]?8,:
M"((C1_Q9$XHGH=J,-B8)MJSK(#Z6)F[HI"<^$B:^%KH_:HG-4.-DF%D<0ICZ
MH/4L1L(LUOGH)GO1#NJ$9Q/-&"=I/*P:''*83*>>PI'TE$3"E 3-+;2N]6[O
MER^HXEFSE5RG0R=>!]60*!W6!0XQ[,O4I&<:<H!I@%$DE/G[Z<0)TB:*,8O(
MD.1=8C2-L"><2,\H),PHL/%RR_NH,:$DC*,>0FX3"$OCZ3 /.,1(-//A[HF&
MA(GFZCW-E1.V327C.$UGEA<[Y("9]I/%6^@][9 #M#-HG]LR_?UM(>F9AX29
MY^(7^@%B,\JP9'"(C#&)/+4FZ4F'A$GG1HHEY_G.'.![IDS6%0Z4#K"M"MAH
M4V8ZW8-SZ@ITXXUYFW42RR-=79AO5WM>(F%>FF>;0D'5;P(I+Q0D)K>='12$
M4\R&'.222Q@E;IRT)R$:)B$K<%SNYP).'>R$TVC*!L!=<NE^;_D6>$]1%/]2
MV/0M^?O"AO9$0\-$<]$T6YCZM3-X! \L[O7ACE"\^:1+VW*;ZX7-T4^9*3#D
M)I->P]D$,XPLAPC$%9GYC+9W4A>FH3-^KU#QJH_W[(+:]&)!=#!0FB8^?^P)
MB(8)R Y^_LSELFB,^>>BJJ"G7BBQ_ DI7O=D+44]95)FGAZ3'NY^'")CG[%[
M3J)A3OHJ)(P!QS#G /I7T^HOH1\JG-F*VAQ#9S2QNDFG7.(C4=HS$0T?'-Y"
MQ?S2T@/@? ]@^TQP3*>$IE82< BFTREA'L@]I=$PI=WRG%>;U_,Y$E&*%KPN
MA$17.CJ=H \SFT-D#"6KC]IH3VTT3&U=MC5-< Z)XO[%F;F<P&VBPIA8!:Q+
MC+!XYJ$TVE,:#5/:^6K%E^:D@3\OVY,3*+$@C>SZ9M@#HYN.1W.AJ?D1J-L7
MEZ[NBUE[X2)(CZNSGO;88=J#Q"VA9>#H0\[;JX^: '])!^;JT>C4TL(AAUG"
M/.F2]2S(PHW:W <690K=\X>BKK5CZ=J)RT+D3AWL!FT:LWAXP.X0FR4L]:1)
MUM,K.W"T&%*!Z_8C"-Y!E3C!%GA'5Z?_^1RI9U06?OFU^'%S<VE>()Y>HHNK
M;]>WWT_O+JZO@B^\]MYX'3C@V[T50?HHPZF^35QQG [/RUQ2^V\CWJ+K"8Z%
M">ZB.]3CC4&(/K1G6CS_: Z,]-9)OMIZ7ILR1T]%(@N\+46PK_!E/=FQ,-E=
M=PUB:9* U*_!QV(UAD+X]1PIWW)=U&6YZ"CF=/$#J.6S?G>:C"/B5,LF.RL=
MV"($@LG#+ZRG0Q:FPZ%2>SW[/U7F,%LZ1&@4,0_?L)XLV30<6NM,ZN-8*%>!
M*+<;P*SKP;8$;UH5@F'6,QL[T*P=*BL_H<:<,N6\/<PVSOU:F#K--K/>-%MF
MLT6L]S23O>\=*BX?S&<@#3*'<^WW MW3[E.34_.!Q>#Y5_QEWGXPTD_3?K_R
M/9/ $@TXS JFC#ZGL(^R_22DO5%B8[ZJN!=*B<I<KGD&EM "\/M*0*6UN]$+
M=!_FG/P?4$L#!!0    ( ))&_U" ANT+FP<  /T/   8    >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&ULG5?O;^,V$OU7"!]0[ ).[#CI=M'\ )RDNYMNDQA)
M>HO>X3[0U,@B0I$J2=EQ__J^(27%V7:#0S\DEBAR.//FS>/P9./\8ZB(HGBJ
MC0VGHRK&YL?))*B*:AGV74,67TKG:QGQZE>3T'B215I4F\EL.GTWJ:6VH[.3
M-+;P9R>NC49;6G@1VKJ6?GM.QFU.1P>C?N!.KZK( Y.SDT:NZ)[BK\W"XVTR
M6"ET339H9X6G\G0T/_CQ_(CGIPG_UK0).\^"(UDZ]\@O5\7I:,H.D2$5V8+$
MSYHNR!@V!#=^[VR.ABUYX>YS;_U#BAVQ+&6@"V>^Z")6IZ/W(U%0*5L3[]SF
M$W7Q?,_VE#,A_1>;;NYT)%0;HJN[Q?"@UC;_RJ<.A_]GP:Q;,$M^YXV2EY<R
MRK,3[S;"\VQ8XX<4:EH-Y[3EI-Q'CZ\:Z^+9>1LP$H*0MA"W?B6M_D,R7B>3
M"/,\::(Z4^?9U.P;IMZ):V=C%<1/MJ#BY?H)W!I\F_6^G<]>-?AS:_?%X70L
M9M/9]!5[AT.LA\G>X3?L[88W%A?.!F=T(3,[$/["4R ;\X KQ0=MI55:&G&/
M00(58Q#_G2]#]"#3_U[QZ&CPZ"AY=/0M]'^]O[KYZ?Y>S&\NQ>W=Q_G-U7_F
M#U>W-W^'_C\T);Z0D!Y_H@#_?="EID)4)$VL%']0KFZDW8I8R2@"T6,0T0D*
M42Z-#I70M@ /_7;/H.BU78G&!<T8!7P21OH5)?B\;'1AMF(%$'A:3856  _%
M_DA0#G';>O@@5]:%J%40RYY[VBK3%A3$N79W5)(GJTC\(I?.R^B\IC 65U;M
MBS??_>O];#8]WIV7A@Z.WXZ%L\1IBQ4)FY+(GPY^. [9R1!%V1J#$/U:P[[9
ML8^JBQ4@4@Z K,@2'!012SB0Y6Z-2'#%U(@ S)SN-0 49 G24/Z<@^55D60M
M2H<:!MR84WB]YG&&A_?"9$-(B%SQJ(5^-=X5K8H(-@.2K""8H\\A^<7^9!2;
M2D*1%+4Q(3PX6)*,+5@L[N16FH)(C-GA#Y?S/=G _!JN1&AW9"[#.:@S*6<+
MR+&HM@BFD4"DVGJG"QWJ >_[3XN''F=.NBP@>AUHX D(<"A@[$BHRCL+Z!YU
M86F+; >"9 YV+CY?#F88@+6.$J(F+F$TM&6IE49*M^*-D:W%^5/P9C=PNUZ2
MAPP<O'M[+&X7G]^_GTZ/$)KHY'V=&.@=,H>30E&#K(H::!K.K]A46E5BD^N
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M\76)H 5G5]:2GI*D6TM'"#Q!_D)>8FN[#9)EO]E(>M>3I5H9P"E,I>@?2.I
M5KF':TR.-'&^3YJ12)5;&TLE.#JB<^0!R[B[F6;2&6.D<'XU)X_4*I+6DY=;
M=TKH&%P[L<^Z)UAT5N_EB&:,T'PVS0:4[XZB8%J@ <=[J\!&9+%BH(_$5W/>
MWT-ZS,5<>H@O$]4<5T'#+AT)NLL#V(A S1NPNXHAD"TX(8L)*_V7T\67P3+B
M&_K@B?]@QD&@H#_5'@EZ.Z],7P\/*V/F 'Y"OFJ_13V-Y!!MR]X/Q1.DAKS
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M,+[])B4BU_,/94#E5C!,6F]7V4*-<8!7BGOLBK/"&E1B86$G0S:'.HX^O^Y
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MI5)KV71*-V3DXFQR$9Q<QCS>#?BGDIMN[YTXDKG67_GCNCJ;^.R0K&5IV8+
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M.0P/0/]":[O]X 5V_SJ<_Q=02P,$%     @ DD;_4#&Z]*#1"0  1!L  !D
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M:K;F0AMD6:C7S:C'U\13H/ZI  (=T%X7:)4&:MV&<D6S=_3;7H]A*6<SJV8
MBL@YQAY*71$C(W7,">0/(9S%!K,USC9%4JD*9+0'Y9GA[?1"))Z4%9'R*@+%
M'$DO=HY/>L<H)G&,I.N*G=&P=]"\DK2=X5'OJ!D"4#+%Y3->]L0W)2*)<%;)
MC4/R2.:037O[4(14MBIF3LBD96@$,H5RLU1/-1[SF! \16[#A92.N47IVV*M
M3] \LJ:81;QJ8A D'(->Q&%2^B+O%7@T3'"9@;T]<0[*0SS360R<SVL*9)^1
MI.8$P?P$>9X62&]F0G;MJEKD)JM(,,O(K,F,)1THP [P8-1B'T!?!A/"/^))
M3*U)UG'7Q!0O)/#2X.#4P8.7;8H=PU#%JD+ZITQ9MMNM9UA-&]O]2?T,]&>C
MQ8_"T GHS;XC 3.K Y^ WH8F![QU/!68!,DFT*4$W]DC)"<MD@E<ANER8:3B
M4$R6HMA8%<0<@SO'O9,JWWH5K8T;8FW168MNM]&8-B5)!:H 'F7L:HC29(//
MAN,&O0$#_>'B!H4B")#:;A7<F%D!-B@1&9G(*[5 F"PRP*=AS8C5;+-KT&->
MNY63![F@J%F9L89._&EBRM)U1O%+UWB1G'T=F\5BW<JUS;QFC8R> S#E2NT-
M'!$;8(A+FI^>;@)V5X0&;DH-I8QYU*&B./.N%MQ;8#>/)9Y,G;UEECG5#N,O
MXA9)]21AO-OFJ@)N$,ETYB%'"K4*]":%:-DGC-+!2'PE=M4B(XCN"26#B*B(
M&(!X1UD-I,TCQ8*7WMTO- 6]9_H)W*2$?+&C(+Z1X7]Q8:!HFO94I096:&HW
MA)DX91]9 J.\]$./&ZH9+G*^*:E*4-HFD99R/U-RI"N[4O>D"7P*]@^O$[Q1
M6XHLLNXOK X+;C5(4AD0F/+4##2(W9/!L?BH')1[1JB,?T9DU3E^3>N=:2WW
MYS5T.8C1LRA@2*N;5*.J4)LPEK'GY7;6_L&G[GI3]BAWXR+D9AUI:U,B'%^1
M7+5[%5N.<\LCQF_;#((NV_A_5B]04JA#9A'&2ILZO%Y\?2?'M)SV0H)0!(>#
M_1-?' /C*T7;L2!<PL1*&:0R1T<+4!G(A)1@3O?EL[>Y<;]!ZQ&&FA<"?=NK
M+FW<P$W@I8@4JF1"3E988!,T='!<0Z8^""UD4XE;S>QHU*S%S#S2("=&(;<8
MX:8B[)FQM;.+:MCJ$0\&K?/Q[V!P@+I=.J*M:*,1W0;6>_)NU4#[\Z@0;^@N
MZURC<+S$T;6[F-HKE;#Z0[.RDH$=:.;TH^0V!K#(;5%^#OBUW$7=-:MJOU[/
ME:\2+ZMQ(6-)971,GWQZH$V<55A&9*A=4#C^7%:>>6F23*9+YJ/C=^Y9'>[0
M^8DW/,R/@,S-:N%[W'QQ)A1MN0]P/C_9R@+_I2964MK&9H;F9ZUMX=FZ;:GQ
M27ZA:Y-S_J,!'>,%U4V(IX]B"MQJ6H,#L8M:6:0I7ZL%550-+5#\TD!G=!7S
MY+)2<AN435%NL9#P5F1$O!QS=$IBGV[AW<%@T,I[K\\8>8;W\]^'XMZJJ;*6
M4ZCJDT\&F[>1>U"2*= KO76K2\7EE<K "GS1U/G]5.#)+J0XT%1VWAHA#:*4
M/+TDL902*,?(E8;U*'>H,UNR>J$"&$U693LDP'*J4' _PCXQX9([BKIUI4TD
M.48C'-IB!EA<X>;U&=1#M[2/RD)]=+V]*W" !"E65P2*Z 7?Y/!RI8&AW%AD
M QLR-?[V5;N'B:G5E](9'RR(O2NHI?%M7UM\G4><_D\/HCP7A%I+Z5%GL"_)
M5M-W:C$!95$VT7,EDME:$;X9E&O=*#/OTU:YU*.ULDOZSD&0S,FK0N#."8.I
M[,#5R^+(AK)JX7H]901*ST=\%68;V?3R4V"=]8RDA"KDVAT=R5*N!KNE)D%=
M1"+PCP'<S)?^Z(&76MD4R$S3)PXBV" OK.J*&657RBT+,J\IA#0LX8!)X>B^
MY=:N!8VWU^BE2X4-I"+%P\VU7V : OAUDU<S9Z/QI#Z?EJ+B3V(]DU7]GQ94
MXA=4UE351?HFIS:B"W*< V9 1<66K_Q$XJ'PFD\A:]]!Z+*IH+WRO4;E)__U
M:4EZJX6R@79JV]5MU3&M:'%OL/6*YC5_YHM*;],G]7[KEXU$V1G_?D,7?QSB
M?^2H1^N?B,[]+R/-<O_[TJVT,^J$8S7%5G0WAQUA_6\V_B4W&?].,C%Y;A)^
MC'#K4I868'YJP*/E"QU0_W!V]C]02P,$%     @ DD;_4&F%VI\>%P  2TD
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M>_?*GJ,KVR$D@K9KH41S6Y(+ZLE/:4:V"3*>1GLN:(#&6J6".C@<4O @(Z+
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MN?DS0Y^Y#$"EYR6V#L+9],3T+]V',M_RG\N!YT!4Q+^N%=2IH 5XOLR!O/U
M%]1_/^G=_P%02P,$%     @ DD;_4)R$#_&; @  C@4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,30N>&ULC53;;MI $/V5D=6'1$*Q,1!2!$A J)(J% 1)
M^E#U8;$';&4O9'<=R-]W=@TN40/JB[VS.W/FS+6[5?K%9(@6=H)+TPLR:S>=
M,#1)AH*9*[5!22\KI06S).IU:#8:6>J-! _C*+H.!<MET._ZNYGN=U5A>2YQ
MIL$40C#]/D2NMKV@'APNYODZL^XB['<W;(T+M$^;F28IK%#27* TN9*@<=4+
M!O7.L.GTO<)SCEMS= 87R5*I%R?<I[T@<H208V(= J/?&XZ0<P=$-%[WF$'E
MTAD>GP_HWWSL%,N2&1PI_C-/;=8+;@)(<<4*;N=J>X?[>%H.+U'<^"]L2]U&
M.X"D,%:)O3$Q$+DL_VRWS\.1P4UTPB#>&\2>=^G(L[QEEO6[6FU!.VU"<P<?
MJK<F<KET15E83:\YV=G^($D*47!F,86IS5##2 DJ;^;R_H;PH(SIAI8\.?TP
MV:,.2]3X!.HU3)2TF8&Q3#']:!\2PXIF?* YC,\"?B_D%32B&L11')W!:U1A
M-SQ>XP3>^+7([3O\&BR-U=09O\]@-BO,IL=LGDKE:/0T>7H8/(YO8?IX-Y[#
M:#J9S<=WXQ^+^^<Q/$P7B\]2>1;5#67';%B"O8#*8E"_8?!?KH"Z%JBB8/(=
MB+(<Z,H!E$RLDEF#)&-RC09R"<?=H'PW)!^Z@5,WU$#2KE KL&Q7@RUJ!&9@
MI3C-M^G Q;TDKZHP3*;FTI&@P9 P9)S)A%0MW&*"8DG8C;JC4/\*7^ BCFM1
M.[K<]^"_7N&B4;N^B2^/@3[$X4%:M7:+=#XK9G@T(P+UVF\"0YX*:<MQJ6ZK
M93,H9^RO>KFI)DRO<VF XXI,HZMV*P!=3G\I6+7Q$[=4EN;7'S-:F*B= KVO
ME+('P3FH5G#_#U!+ P04    " "21O]0@!VCGU@'  !U$P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-2YX;6RU6&UOVS@2_BN$MSAL =<OLO/:)("3IKC>
M-4TV:;L''/8#+=$648E422J.[]?O,R0ERTV<]HK=#XDI:3CSS#,O'.EDI<T7
MFPOAV$-9*'O:RYVKCH=#F^:BY':@*Z'P9*%-R1TNS7)H*R-XYC>5Q3 9C?:'
M)9>J=W;B[]V8LQ-=NT(J<6.8K<N2F_6Y*/3JM#?N-3=NY3)W=&-X=E+QI;@3
M[E-U8W U;+5DLA3*2JV8$8O3WFQ\?#XE>2_P68J5[:P9>3+7^@M=O,M.>R,"
M) J1.M+ \7,O+D11D"+ ^!IU]EJ3M+&[;K2_];[#ESFWXD(7O\O,Y:>]PQ[+
MQ(+7A;O5JW^*Z,\>Z4MU8?U_M@JRDVF/I;5UNHR;@:"4*OSRA\A#9\/A:,>&
M)&Y(/.Y@R*-\PQT_.S%ZQ0Q)0QLMO*M^-\!)14&Y<P9/)?:YL[=<&O:9%[5@
M5X+;V@@P[NS)T$$YB0S3J.@\*$IV*-IG5UJYW+)+E8EL>_\0H%ID28/L/'E6
MX;]J-6"349\EHV3TC+Y)Z^G$ZYM\W],WTJ:%)F<M^^]L;IU!<OSQC(UI:V/J
M;4QWV9B]NV6?9^\_7;*KR]G=I]O+J\L/'^^>8O.G%+'?!2HAU29C"W+GGMRQ
MC#O&%1,/TK'*R%3T(802M8BD5$OF<L%XJ6OEL(3L2M=%QN9>E4!-9,QIAD(I
M2 NW%JU &U9QZ1^ '&47PC#."LGGLI!NS:0B6> 0IE@'$1[*;"[<2@B%'#5?
MH*CBQLE45AQ)-6 SB^I/\WX'/9/ 'Z5?47UEK-PD(@K,"8.\Q^WP4'N(=5F1
M-1L<>L)6=+*V@K 2*\1$U[_6F0&Q6CNL_P>>H-$(\<I)>-Q!F>.:FS1?]]DJ
MEVE.*K61#GNL)UBJJH;9FC#"8O"!;&Z4#-C''$%AI!M.&W',WHM[4;!QGQJ)
M=Y);IN=6F'L^+UJEQ!D]^5IK!QD?8^MCX'M:]-^^CNJ2+751AP9(0W2I[ZD)
MG (>$])ORB02Q2'.8$VJS56+\S6(S:+QR9;Q6CWV!@8#A2#?X3:T*MW$,$,3
MHTRVSO:)5_1H;2A3O];2Q!!26B,'D9L9F=05D^3@:BLS?++I!4,;$6T;0? 0
M2IXQ4@<55J0U!1$T_ I+1)!F'\ .VWN))-5FQ:G4@$ N%=JQ,4*E:^!+P>-2
ML!0MCWJ')1DX=@]HVJQ952-5D*Z/U!Z]]%31/CA#"8ZEE2@C[L(Q5W 7"M)7
M;0J<5H94AS,7GVX_S/KL^N;?UVAB?*FT1<9;K]/?O!6*%YL !MJ"/M1[+*R,
M&D8GMZFDJ!? /6(8=29!WSO<S3)ONT\Q U 5C](5\H+I.GALG2]4@D"WR!^<
MB#Y42U22?^@WG$M] 3HE]U&(;8R\;)QN!9B.U;V-$_FT\ETJ5!QB8WRI+XPN
MV<7UQ4T?H.F ?_/09_\12H ;C^LFEWK KH$.B<E5*GD1^D!@KND$E ;_!T6>
M84ZA+S#:V&/V=B/?:6'6U_0WB<A^!;TNU[4% /N2_19*\@YI)A<RA5M;ZX_:
M ?+,0SYFEX^2]P5+IOV#@P,L_O'+83).7F^MXL,+799P!#-%^J6A>-BRV(CO
MC;O+M[$&-IG>/$S&>UOK@#'2V@&4[.]O@]GKCZ83]GY#^C&0[:B'9EOS>]0_
MFDSC_V"P&[RGO0_2S>_S07J#$[&<HV G8PK4^.@O#]3XL']X,-H!-3[\L4"-
MD4;=]>Y0C2>3K?4WH6HA)7N3;3A'_7'R\Z':/YS$_S\>*I)N?C]2^T>[QM$T
MIY%";881V\X9\03MG$")7V\)H_VA/_L^$4\I"C8UD:>.^">/#J_T47KX,XJE
M",V:^D)L%@O?"<.)N^DX4F'0K$.SC,VGJHQ^D'BW"$.$W!HY,OR%<P"W;*Z-
M>T6S$%/<(6O)H7MNI#]9$0)O5BI(H"/[22,V)C\!!BFT7$ IXL0R%TNI5#A3
M<2+B8/>=K0!<81LG&KIVM,LG6MOQ\YVNDS_GP1:UVL=UUR3!13AI<0!MJ#E&
MGT^+.@NC%AS&@1,05S$;+7)YW#6PC:EI!L02Z/(1V!ZIH_M/1<]V4K([GJXQ
M_'DV[[DL/.%QII$JO#S[MU 0N/)#.&DH).B-A[-/!LQD%$H"$>1+ >XR7>@E
MZ Z3*DV06]$-,B$XW=D8W$3GMN?0[Q7Q^#79:7CYMDQBX>P<8<(D[8G Y&A3
M>N\ /2FW.5L ,2MUAI2B@8GTB(<*4P6-HWP=V&WG_$UD\-OF:2-O0)VJ.Z18
MW#"(5&/45X5%B*J8VZ228^YTZ\J[\2-3V+>C5C_,8(\FKLT;T*[),_+VXFAP
MA!?YHB!#SX#HLQ?)8-I*KE!I860*23]+4U.+0(>B09, O3@8[._<<>W;4:'5
M,K213ADWB)]H;QO4!W\CZLE/H7[JA7W8^112"K/T'WPL\PD1OHJT=]MO2K/P
M*64C'CY(77&#!FE9(1;8.AH<[/68"1]YPH73E?^P,M?.Z=(O<\%!!0G@^4)C
M5H@79*#]TG;V)U!+ P04    " "21O]0W;\J#_@$  "-"P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6R-5EU/&SL0_2NCJ \@(9)L(% $2 %:E2OU
MMB*T?;BZ#\[N)+&Z:V]M;P+WU]\S]F8);:!]V5W;,V=FSGRLS]?6??=+YD /
M56G\16\90GW6[_M\R97RA[9F@Y.Y=94*6+I%W]>.51&5JK*?#0;C?J6TZ5V>
MQ[W/[O+<-J'4AC\[\DU5*?=XQ:5=7_2&O<W&G5XL@VST+\]KM> IAR_U9X=5
MOT,I=,7&:VO(\?RB-QF>71V)?!3XJGGMM[Y)(IE9^UT6M\5%;R .<<EY$ 2%
MUXJON2P%"&[\:#%[G4E1W/[>H+^/L2.6F?)\;<MON@C+B]YICPJ>JZ8,=W;]
M@=MXC@4OMZ6/3UHGV3&$\\8'6[7*\*#2)KW50\O#EL+IX 6%K%7(HM_)4/3R
M1@5U>>[LFIQ( TT^8JA1&\YI(TF9!H=3#;UP><-.KY0P0]?6! >6_'D_ %G.
M^WF+<I50LA=0QO01RDM/[TS!Q7/]/CSJW,HV;EUEKP+^U9A#&@T.*!MD@U?P
M1EV8HX@W^GV8M\8'UZ"N@B=E"OK Q4*;!4VD/G30[.E&^[RTOG%,_TQF/K+R
M[RM>''5>'$4OCE[RXMW=[=?)_>W7=W3]Z>_[N\GU_707V:^B2)N>^5KE?-%#
M'WIV*^[MA*;[)=/<EF@\"3"H6<EM]^G_$&:08Z4=K539<&)#]B*J"2JVC9V3
M;1P*O2-0><_@;J_4:J;+R-@^:1-544,%.I8+^?*VU(4*6%RI4IF<:2IUZL]H
M[U;$;>-A$LK/CJ%9U=;  4(5<*R"&\ZYFK&CT5 6G2MS;:"H50G[75;/!*&"
MZ]-@\^]D:XG#]]?*.25)OS4K]B&*'I"!P3=T/,1CF T(G0ZY@O)-+] 7@UE7
M@J^"%IAQG@ \_T5*H50<Y]:A_(6+3R##H7^=DSA:QH1?<%LK71 _U,*3/]PV
ML(>B\\+F']F8Y+EK>!OJ#67#8XED-*)O3# -)[0)5M PGTSK4?[8P?-#OE1F
MP5MV *T,\1PB@:!;(<4+I#$F&-LL0BB+3M7)8:%Q(MA22$Y[J;BYLQ7@5G#$
MND>J&P<->"KQE1S@703*'1<Z"!.H,K'B^=?P#V0+CCTF<VIFD7_LS.2_DDI9
M/X -.3V@=:2*=9*IU6.4>/(1:F'-G(K6US:TJ&T'/$%%J[*U !:(J6PC"0U)
M$3&4+)5$4N>'=&_I1X-DSEM[3Y7Z5)^H!E*TQ-1)?J:T_F@T6(AT2P] 6.<A
M2;6<BWWVJ8J$%4:7H* 9742%S2-V:MD6K1UQR55MD,6NHV4G80N:E*?W6YO/
M#=I8#]8LK.04OT"-O57*%"%6?H9X2).MQI7Q'6T\Z^!L,'Q[\/-8V=G+2%E!
M!NF)K$1.7PX5Y,V$=(]*CV,'3$>?T!IH%C0. B@?-]5A%P9=%T%3(<?2?]\-
M1 EK9P;;L0%A">&%D3>%AZDT /.I9A<=AB=_,)33&(B\I9G3M?VF&L/2<4J>
MUP]4I9\OR\]W!_="]QGLBLINT>F+(#]-ZH@I>%M?6_-8O$U3;/]W4_@-[9WL
MRW/T-HOO\=OXRH[V=TSAO?$^'='XY$1&];T-J!+(#D<)X?14WN/!J4S $]KU
MI^YO79$J=HMX$?2P@'9.MZ5NM[MK3M(5ZTD\750_*K>0I)0\A^K@\.2X1RY=
M_M(BV#I>N&8VX/H6/Y>X+[,3 9S/K0V;A1CH;N"7_P-02P,$%     @ DD;_
M4,,UAELW#0  J2,  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULU5K[
M<]LV$OY7,+[T)C=#RY)L^=$FF9&=>.)>G'ALM[W'W \0"4EH2((!2,NZO_Z^
M78 O2=:TUY\ZT\9\ (M][[=+O5D9^]4ME2K%<Y;F[NW!LBR+[X^.7+Q4F70#
M4Z@<;^;&9K+$K5T<N<(JF?"F+#T:#X>G1YG4^<&[-_SLSKY[8ZHRU;FZL\)5
M62;M^E*E9O7V8'10/[C7BV5)#X[>O2GD0CVH\J?BSN+NJ*&2Z$SE3IM<6#5_
M>S =?7]Y0NMYP<]:K5SG6I D,V.^TLU-\O9@2 RI5,4E49#X\Z2N5)H2(;#Q
M+= \:(ZDC=WKFOHURPY99M*I*Y/^HI-R^?;@_$ D:BZKM+PWJX\JR#,A>K%)
M'?\K5G[M,1;'E2M-%C:#@TSG_J]\#GKH;#@?OK!A'#:,F6]_$'/Y7I;RW1MK
M5L+2:E"C"Q:5=X,YG9-1'DJ+MQK[RG?W*I6E2L2=M.5:/%J9.\GZ<F^.2M"G
M54=QH'7I:8U?H'4J;DU>+IWXD"<JZ>\_ E\-<^.:N<OQ7H(_5OE ' \C,1Z.
MAWOH'3?"'C.]X]\MK/CW=.9*B[O_[#GGI#GGA,\Y>>F<#Y^FCQ_>B[OI_>,_
MQ>/]]//#].KQYLOGAUU*W4N+@O)[5\A8O3U U#EEG]3!G@/$EUQ<JYFM$&%B
M//&JB\1*"967RD)XG9=&2!'C6I="+JQ2"+(2?E<NA42<S.<ZU="3,'/QW@[$
MM36NC$1165=)+,3VU5+'2U$NE4@5;&U%;+),EZ1;O"VL>=*)$I5KB%:Y4W%%
MQY-\1#F<KW,F(S-3@32>OQH-AW#T-(59!N+26.A>YPL'$G00G]DGL<)B,5/2
MDF@0T4$J_"=LD&$T^DX4V"KSO,KP;X+X66,#<DHA=<)/K)KQ26"0]N9K42+U
M#,0CCMO2E,[CM$J4$T_2:@,I?9R2QBU6)!JOD"Z[^IF;-&4Y2!GJ27E90_:(
M D5ZS<J(8V0ML$]I"\N(SW46]B"QNA(L,RW66JV:OEH\[QNJ0A:#$9PPVTXR
MV;E!ILZ(6*:IET@&0S,S<P6G^E;)E&P^'(PG736#!(E2Y96#3@MC:V%J P[$
MU-$]8EPU,1Z)W(@YQ('GP)*B,<I+QA^0OW^)2S/#Z_$%41E=L+MKYRILG#3.
M)-Q2LNRD0RNN( @>/I0F_NK]I; Z5MX%!]A&LO 6\E%V8;"PLN3E.8)AENH8
MB^?*DB5>$VM__<OY>#S\X4MXR+>C'_X6P8 .9J9U()6CTB)"8J4@)31'.\%,
M04Z'PV6!E\\:EE+I6KPZ:_B/$)EP;SA-4L5,K.&(;M@PSG$R(X]N6%//*.!.
MN8&XR<5G\Z0RUA7KJ1O3$-$4;*4N1PLD20YK-F8X3UG7U3$EC03&P%XXPTDT
M'I]%9R<7M<*A7-J]J3)6=X0 <:XO2:)=[/V:Y.C(]8<4>=HFE??6A:S&)WQT
M6AJ^ND6V>R@I/,5]-=-0><;:8J?Y<O?W+V32T=D/3CB5:\1#)G,@%XX&J#)>
M2A?4L4"R6(3\,XY.1I-HB+36>F#/^T(.K/V&??I6@IP8U0Y-AXL[;,]0":I2
M(R2ACD^?KC;2.HZ&KA8YL[21V_^AH#%8X%(;%VN5QPHD;O)X ,^"KC/*5(F8
M6Y-Q\F.5TM^N;T];ZM.:>NOGVR6B/E/&WRI-;"*5U,K<E"<H5U@"4A'.+E/%
M9FG2.@=BXFT-KXJ5+0$[(0-,3#"/<M&=!6"E\OX)[@6_;_GL"7)SM[V@%:2G
MU)DJ5PHN0>GQ(;:Z*)RX1R5F"]WD#HQ6I>=TMYG(%2PG[)KC JY!#DXY-4=(
MIN)J>B\>10%\0D!;E"I>YB8UB[67>&E-M5AVZNX>1NJ0I4KSC+KB 'N%-6N9
MENM#JI/$21J$U[QH*?.%8F[\.DVNX:K9KU!J'5K02.;J#+Y+?0/Q4Y.E=_E)
MD&3WYJAQE9!4<.HN;8K1Z4DT/!UW8JG>&/N8<AQ3O81,=#IH3SSPWMK<G!AC
MD^>A4>!@>4F(W:&X":Z>#">I-@"W(V,G&=Z01%38L=V "5(GP9^(=H(L+ :_
M"<+#>(W6<C&73S!@,%#9!;<0KE19X<'O;+U'.#*1%"DT>%@5+R40+P!%)%(X
MN-D7S$XBB D+$3_(;YR9?8+FG+?;-)20 HIDE[$JA#Z>LU96VA%^"TD%(J5R
MY0',7L\S*$$+Z97"9 .N0-,H%-(OO!T\_%BA8(P:,.'+;BV\PW8WUSBU#N8X
M-<Y7X-P70=<%=&9&B^B*'7-I4CJ1B],3TA5QQM"XFQ[F.I=YS*7@L5O45E3;
M>V7MXCO2).O>K=%[J?\RQ=X#[6KFF_*52KM0H?R1<UC TPT6!XS][V%IY"[Q
M2=E<6>@"U=E"3:VC!>8B.H;@X:'."=[Z!9OG;J0U4%)(3HDX'D7CD^&.F*Z*
M@$=J)8=3Z_<]-P<D1U:<4>J;(:D"828R$Y_,0J818[X'7[5_)IQWAY/@7L$Y
MKI9:S<6UUSO,@EJ,139(U94YG,Q)PQ?I!G)R-T'<O1J-?<&G3@I,$U(.6?1:
M0;<X #Z?L/("N.DEK.O'JSHY46!OYB9/U0%]@ 1\O_)(B>SUHP0Z9D#C)691
MKY92(S;SCJ2/9 @*U%;2%F)_1'M\^!";LCR\-W!B(Z8Y:HM%ER-N,G)<CBHG
MIC&W)*.+LU/Q.O#^\>&>GC?\6^JYN;,Q@M)9C9.V8!!KM.U*6*DDTMV2<%M1
MMZ&,W;<%^O",(*(!3RN0;^ZZ-B!L/SX?LFEJ>SQ>=27WS/].I0?.>I+";_9(
M^@LE+YW-4!54AT;3-1(?+=\,"!OD?LYYZ?Q/U=.?_LZ6'GV?>JF;'VYV\V@6
MTD0L)6P_(YSV!]OZY,_7UJ]:#?@./Z$RUO>8\7%P.Z^<?G,T/A^<-WTR8^L5
M*FVC.QB4XM&74<! I,FZ)]S@A"2#;8!6L;03S+Z6;H7X>;>-)'+$)V(%)<26
M>@;H\!F0QS4>U;15:!Z1J LJH*V732:#CI_=JSF7=B8A3I%(0CS:!L6^>%IP
M!(J4MCM\,8Y8L50U!=4^5_KD")[_!5&E>(VZC4.7R&'CB^_077Q6*/TN%J_'
M='<%;)_)]^H9G-C"!/]X/1R,Z.VMG/TLG\5KOKGZ<G4G7D^8QLWM0WCZ(37/
M6'%,U\0G^KLKZC<D'\ .PT"_98UG*TAP5 #)66R8BQ8\%^W55.H,0]M=3TY4
MDVK;]K>I\*VL=?ARGCR"5\P,(0DX((TQ\]++Z2WK.)5IZCO0@2-3SRO+X)=F
M 94OD.'T#16S<2<O.1:OW9I0O!JU?D(T6*WU>*MUAARDHY 6*1S"NSK=3H[/
MH\G)20>T$#+O-2&:((+GASF<PFU3NCW[O]@;X<3S\XL])V[->/8?=-P_J/9+
M.@LA.SDYVW-45"]Y4)8RXQ0ZLM1YNLTWE\T;=L_S","@?G?5V>5QMDQ^1=KE
MRL<6&1WB[R$-A2T2+.IET*TK4E]JMK4;:N.SLK%V(;%L\T(=A8BE6_($JE[=
MQZ6C871ZT<6EM8JVE$YGS+5%M?H&'RQ]H],@PYV\M+*SJ##[N+$&<5'WY;U-
MT[XR&TXE,ETI>;8R'D>G*+@=0_\&_KM.<[H+6]RE*EETIRE-FWQ;.>4GO@]^
MK.2G2DW3M?6>O@^9%1.Y1IT(R[>QR$J%AI@><9NB9W[2TA^P]0(&<I#;S)$K
M#M?T40!@09N$54PI#S"6IZ<1S:YU4?CB[3E= -L3.*<)DNP.K#TZJ]GW @TZ
MN*T>'M;MTMU<Y;E>T 29/MB(T,1<<@8$S4?"TDJY??0;HBTQS5WK!J@/)+9H
M<U5*%0H>S5QI"W]&\@,^?^"]@K ?@#N@QX^H7W[00%/%&LW[=?6[;E-RJV6F
M(W&=&JL327F2B@IEZ+8VMY7"<P"?Q9K4Q%1M!N(#=]ST>EHMJ+D8=>;W6W--
MFD^RS^">CO&B;6#=/K\!+-'"[HR3NSK.+CT4-+Z()C2DI0!6A+NYXK'2.H1J
M).PI! 3G=@R<D:C+)6 DF9$ :T;?1FLDXU/%VG^T G:2SOMA7LD4FR'BJ]%P
MM)? '#=$ "@^K7@ND**AH\)%,Q=XBGSV;%L&MP'6.&^-VL4[WP<BDLR/3K%5
M^?P"1/"5YQ  %0RHV$';SH;65'313#:MH<\3KIWXLK_=Y/3A_?USY#\A\3@#
MJYLX9_0D"1_11VZX5+EN $2_7=KHEL+XX;"&,&"&NK-^:)*[^&%:XY'>8G K
M;8N4FF8"+CQ):AED( S%S9 6X+Z:3=.LZ\._E_@#KC\T\\,">9;\J=%Z;%S9
MMA,5!ZG'N#5#/2E:2;LB[%+ #";.4=&8J\00BGF1.7#CN$#\EO-Y M57(MX&
M <HEPM /L_2S]U0:BA*(WOC M^JUOALQ,VP]GOY_=7'2/."//X7/%^DZVBD[
MD"O-TK?MSVSSK''7U_VCSL\G,F47_",10CMH+/PO*9JGS>]0IO[G%^UR_R.6
M6VD7&K Y57-L'0[.)@?^>T9]4YJ"?XPQ,R5Z2[Y<*@D83@OP?FZ .L,-'=#\
M.N?=_P!02P,$%     @ DD;_4-Z(S8\P$0  X"H  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&ULI5IK<]LXLOTK*&]J*UNED67EO9.D2K&3B>>N[925
MV:VM6_L!(B$)"4EP %*R]M??T]T '[*=?=POMD210#]/GV[P[=[Y[V%K3*/N
MRJ(*[TZV35/_^?0T9%M3ZC!UM:GPR]KY4C?XZC>GH?9&Y_Q069S.9[.7IZ6V
MU<G[MWSMBW__UK5-82OSQ:O0EJ7VAP^F</MW)V<GZ<*MW6P;NG#Z_FVM-V9I
MFM_J+Q[?3KM5<EN:*EA7*6_6[TX69W_^\)SNYQO^:LT^##XKTF3EW'?Z<IF_
M.YF10*8P64,K:/S;F7-3%+00Q/@]KGG2;4D/#C^GU3^Q[M!EI8,Y=\7?;-YL
MWYV\/E&Y6>NV:&[=_K.)^KR@]3)7!/ZK]G+OB_F)RMK0N#(^# E*6\E_?1?M
M,'C@]>R1!^;Q@3G++1NQE!>ZT>_?>K=7GN[&:O2!5>6G(9RMR"G+QN-7B^>:
M]^>N+&T#*S=!Z2I7YZYJ;+4Q569->'O:8 NZ\32+RWV0Y>:/+/=276&!;5 ?
MJ]SDX^=/(5HGWSS)]V'^PP5_;:NI>C:;J/EL/OO!>L\Z?9_Q>L_^&WW5A0U9
MX4+KC?K?Q2HT'D'SCQ_L^KS;]3GO^ORQ76^NKBZ_7GV\_KI4B^L+=7YS_?7R
M^I>/U^>7'Y</6?G_L9RZK%3FJBJ&_=XV6^5:C_C_O;7!TL6@W%J=_W9[O9BH
MFR__<P.]]:9RH;&96(4OWII*%Q.U-TIOO#&Y:IRJ]4&MVX8,A#V"S8W7O U^
M:[9&(=T*XX-J:[J&"SK;6K,S9'#:-#.^ 5(H7(('IFJ!_9#; 3DT49KE@L=-
MYW'>WIO,>823>O)F^@9)4!2<SX%$$.<U8VDFHO63^?1Y=WNW"/T$"199YEM\
M-7? MV!$[R>OIB\??>(&^GA5N&KS4V-\J0JK5[: 0?&P3=IFKJQU=8!4%%HY
M+<U!%EQA<]W@RP==Z"HS:DDY"Q/<FC66A?VN76/4\ZFZJ:(-R 1G;R;J@W5\
MDZ''O*F=IW6:K6[P<.-A7UW\=*5#0Y8_]R:WC<.G#_"2;B>(AVRJ\M/5J5:+
MTGB;Z4I=X:9,%Y"L2/BXH"0XJ*=__,/K^7SV\^+J?,$?SW[^TT1M=:XJU]BU
M)0V&\N@5H!Y.A'(:[L]:;YL#[)'!&_"+K7:NV)$Y:$'UE*PTV(&$XQO35E.Y
MSU94;X[W8I4A?5OIMMDZ;_^).]H \Y%\,+X)@2R99#][]7-0X0##E&IEFKTQ
M4+/= %75&1OW-7O]2OML&T/N[$V40.<[&Y*91POJ]1HFPT]QY1(YL=4[0TH7
M+05,C2@DY2M=F@E9QE!@KZQOMHCR/$? AXFJMZX:_ PU=C;#A=J['87RA(5;
MQ7 1B\3P1NSOD6F< ^QOE6F?C^]9Z>H[!V3+;NA^44]7<%A%N1P"2F:.K/.]
MYWYO36",^!-O#PI@BR0S IW-L8<_DIB0\,"Q3QG8EA+*9*\C.]YW)$18NLPB
M"I=I\^NV7%$0\P:42MZ5]+288K1$MSV6*1"$R'SG#Q%+6*6\ [61^IUXH^6Z
MX(Z^$SP8;()E3$*YF_6:OA&(VAW,PU2&P8M^'<7UT384IRL*0PH-<IB"(0J#
MW%7-WJFL@$^8J4#00N]#:TF2#2 S--&>$,LQ$H%[F"K7)*N]#_D/2(+"L*@]
MY!5D9:?]<,.1Z.R3W 8X)$10I,P'%?S6 DS,5'T=F>:R"C4$@B-^,16 N9#*
M(K_#'6/;)=BY.;]-4)#L>6%J[9M403X;74 ]6NMS6P(,EI(W8905#,8--J_,
M06UD_Q S&*N0#$&M$5U=10H-\C!((E-=T9SBXZAU""_.#TH(KJ30:AA;WA2:
M*E(*E&,'(!$#Q9*J70AV59"0N!$7&S!=>HJ2KR1$8 U*3EYH#5+",>TUREVZ
M,%%V#4,<)I)/)5DR)H#HAMQ#-AD%!VV8\DR0YTU3F/AE#5Y!0$2%GLK8A+:0
MX,(RKFA9*7%#X)3+P .@GV0'L)W$W6CA%$2.$9M2"6%.$?3?>51B4:\"FYFP
M$)&#=,R41GE*ZVO&=KZ"?7)=8H?X:%M%-P)#Y+;]UK >CP=YIVIW98_"C^R$
M60I2A(S 'QE]3ITL5NCL.XDX-E"PFXH$1C:J-79J8[B3] B1$! US':0+COK
MVE <*)>(;-+ZCL*X1C$!^JE74II$LPB--A*4CW?9ED. >6S@UFA84Y<?S[OT
M$35TTB]QE"6R%FI71'9!'C*.KVNT3W]'^W2\&.U3%V38;MD$#EI5C-;TN*UR
M)',.K45,A)?(/%SNHL.KGE=(R>2,V;)21)XD0N"0\X\W0M*WVB+%4-0N_%1]
MV1)!J]4G#W 7U"%)8V!,*&NPGHONIY"+"3+<XJF%)@SMM($&.VCXL[*%^"P*
M7;=ES;?D^!#E5MP:(ZB-K\&_F-6A" X-(KB5])7R]=1BS[5FKR!"R3V,)Q85
M7"VQ9-X6,-G9LPN*O;-GO_1 #OV8%UZ83&)D/@J2WFZ5HU3([^M+ I#QV&CD
M'^.Y_D"0'A*$Z$MS--P;?'IK09&8U>N:JB(L%-4$P?"@!*XM<DF*G4G/]='3
M18U!0Q"?+,5W@^WWR%U9?D@K:'G$[J^Z:C4JO'"T+ZT/+65;UWBD5<38J3SI
M'.T>0S(Q B/,G P2I1\"3+S4"3TV+D#:5-\<(#,7=$4>1[1?QL)[]NQIWI6M
M+E4762-D O&&('ER-IM-9K-9A-W#5/TE-A('X!AXW]%R1-<!2H!+O2HL.OV!
M<A K;-V>U5NKO4?@KULJ20U72Z\JLRDL$7N4YT_@^G)O=$_/:&/<I!I[SWW<
MAC$!Z'A+0 M'1?U!<)VHTGFF>16U!NZ?8#S0S.XTS6!4O*>G,M1%;1XNH4,'
M)00;1]8@W5$YJ0GJ>ZCYR]1'4J@M$ NV5)]@YE@X0+W@&%[(KM=I@X<+1L+3
M96/KMM )^I=]_/X(83\5Z%=RS8V V>IBS;C9H&%>LR'H04]LFT,@Y18)$K-/
MJGW,CHD4J\A/F4Z-LX!6H&5A3K!+,UHP:88OMNS9WN-P0<L_.7LY?9%ZXZGZ
M&TFK";1ZT.AG#5BO]=RVH"]!@^HCG@ ?B!.2;^/FI<[-@V9GS.U#IN>FE-R&
MV_:L&6[D*!XW8@L]*LC4,/=$9H1W3+#"/2 21Z!W;%??DKR1)U+K+U* )>8V
M!68J8P)7"2-EX0&"H$ Z9OWY3C-0(T'16L3X[L"8Y3Q.F!&!/WL5T8E)] 7^
MAH&*OU66BM)2..TB$N$NWP<D_#]D!!?7?^^(P ]Z=+"-E2EH\",=XT00<SZ;
MO28E(?Y\<J\Q(C:00+57Y1-,!C4E6@"EN(O:0M1>4*@55>L\3C, ..26K[>7
MYXO;CVAS'?4)N+HV.4/5AD*D8@=ON8O@9[#8QNL2_2[9(RMLQ9.104\9._/0
MMX/08>M";1OF_ZG=7Z'/@&&M]DS7FBYFTKU'+GP3*1Z,F@+CW[;H(\UPO3T$
MDD!B-]B<)"&]> R.^@!.+;K'\58<8I!NUOGD'-E"?&$(1#81\*!6[NI(>#Y_
M7I++:/X?"8*F"H,?.^/1]C0VC#@ES4".ODD6DWJ7S-0GU%'7G/!1+.49,(X3
M9T@]I QP%;A!!TJ$Z>PL3=.H&[VX(_6-W0E!)O+G)40YIY@>B=U&H25?4,53
MS]FUK>=7RY[4\BR!B4;<BP8%<@.UG[DA#+%5-XX(+5"Q&H1QK0]"PO"C+)$8
MF-S*J;XR&6JQ,CR-(I 8-1&1(+X9I2^$4']A9?MQ&P-4=[WKO.#)@_3$ S()
M@\#JI-A #AI_%3I6B;8FF<]>S]"?'4)OTEY*'G>1,>DYXC5WX"H4ND>Q8'W6
MEA  _D<XD(2CB1SR(9J-9S;17GG+373775/"WS?F0^,2;VRY J<4_(_%B32B
MX0&-D!KJ5TGSY/JNW=5ITF290JXUBN1!H:EG\*"A-RGADPO30J32E@AO;&CC
M9(#KF.17%P]B&F9#=5W@&NG&.16&Q/5XFD;$,[;C$-9&X CM0(BX*4IY0%+R
M0**BHD235"+;J40,-,0%W-[-8X# E9'AA*V^M?[ :4<UV*.VYNJ367GF[<\&
M$WVADFGDQF*1.8C_%W;=)(X:73>(-HD$/$D4",R72.B@N\L1O"%F%2WTR"I$
MFJE=(=57,KEL^#" W$'18R541XF*T-<^[[.ZJZ:=FZ@:X7?.*9I?"G&O')9-
M+*53M>>^?56"[R K3)=*DI \DC(8\UU0#@2C[@.>$ZREN4[$D'$<\V 73P[R
M( U.Y%%1A7E>V<V@Z#^[B5(TXB2<2YTJ#XERA]04FL33,%P2&G+93W5VU/^B
M9<\'&'EY$?K9'AT,KVJ''F@ $^-1WZ\M#6\ARLWY[82L-E$[U%;7!K&3T+"U
M#9F6GH=JIU3?87/!*":W1B(0ZQFMT'OU>"2E0>@BWZ29C=E+]4Z3O]2?Q):#
MISDM3T:9S4IBB1DI-I"2J&5-P1/JF@J=M#ADE$EOBDF, -E<M+AG;L[*9(FT
M_[!O(@H^X"]$EG2LJTO'@PO9GY.;DME04SN:T<6>@#<XQ%,</.BHL;12', O
M ,_T+?'HXPFLX+"TMH2#%"03E7E+257PM)'Z\XIHI\3,#R:2 0D472- FG$.
MK]@%H,K$MOM>C$%1.H;^"(ID:@ZUX1]E*)<.-!30"N8S4 QP@("$O27\>4"#
M?A9E@&"L2[WA&8SS-1G;<!1N&'S[4<I4+;II<7&8*"RH&EV29C$S]E0L"K,B
M\I1*<^R#2'Q+/*>KD-PI<;H=4^-44I-[Z9P'O6W6/1K _,9S%6ILJ),^]/.>
MXU4[G(NFB, #Z=$0"Q=@8L(=R@(T-I+]!]&$()7:-K$]O%"YZB>6P#(^LA0I
M30<DG=H_FK<1-XA!'FLTPC -0O4]_*OI )^K=9S@(KZPCV4,B(QV:^O8G?;D
M^:$A(O>\I(/>T9&8HTV*G6C1):.AF8\-I8RJY=0LLE[1>3CR)*S#?K74%VI^
M7($THBC+^Q<1D):-H]<\INI+_P #UK]X@"L0'VA(,L;<9=\-^^/AU&!5=/-\
MZAIVIE*&NI(X')*@'+>U\7B%. _G@L!-.K3C650>)-+HN%XH6G=;/*OGCAD]
M""51!\^PM9SSROP[-O];4_T(K+M"!=P%7V2W,8%G>Q\8'X^'3G$ X:@2D#4S
M]B[/:MI D$3>W]+ =L]UG8]PZ. U$XK1%O'4!B"2$<+2"0V/D2,\2QW@5PZH
MX>@&?N0*N3$;O8C"2N*1V/-UG!=EA=M:&&O%=$V.Q <KD@_XA!%Q1C4GC]V3
MH!Q%1$?V#H^=-O%DS)'2E\/T[Q[K^/5(]UX&069S1^6DJPU]!4R[YFF8(_5U
M-.)D6Z7C!)U_:V5 50H)6E,W"VXKS<BP%3PZX?)M(0< U#QD [_0L3CR=T 3
M:%*VT^.S<@2Z5'GN4AKLM!^=]Q$?7A$F15VH\#)52+R[\U,,#$8+0:Y)-P:E
M@_40!3XZ4^O"8UB<9:X\B?]Y+"HO^,@;+</W4O:I1G8OL\101_)9Q]]28XD_
M8\)K93J'7AR=9MO/$+=V0[=2?:-+Z7 QD01>M',E^8</+Y/3TXG= QG#,B0^
MP]0WM^MUZLQ)Q6X1MK;(S+?0F""D^I?X0*)"*8<G _CO9@V3_I6!]8 I"7AE
M.J <H2Q3:6L>>#4IO:A APPR%RKU=Y->D:I;#Q^%.((AUU:":EW069Z]\!!E
M/I,L=5G&$]1_A4BQIG>,..X%K.-#XL$ISMK>$;U+-PP:1[W9>)ZNTZ$((? =
MFQ<Y^N3LQ?/IO)OW/O0.W.G@K</2^ V_6QDXLQIY ;&[VKV^N9"W%OO;Y=W/
M*^TW-&\MS!J/SJ:O7IPH+^]3RI?&U?P.(\"O<25_!#N _G0#?E\[5+?XA3;H
M7FI]_W]02P,$%     @ DD;_4*/V.>D$%@  !T4  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL[5Q;<]NXDOXK*&_.5EQ%R[K9EI-,JI),9B9;FTDJ
MEYF'K7V 2$CBA"(U(&E;Y]?OU]T ",J4DVR=O&SMBRU19*/O_74#TK/;RGZI
M-\8TZFY;E/5/)YNFV3TY/Z_3C=GJ>E3M3(E/5I7=Z@9O[?J\WEFC,WYH6YQ/
MQ^/+\ZW.RY/GS_C:>_O\6=4V15Z:]U;5[7:K[?ZE*:K;GTXF)_["AWR]:>C"
M^?-G.[TV'TWS>??>XMUYH)+E6U/6>54J:U8_G;R8/'DYI_OYAC]R<UM'KQ5)
MLJRJ+_3F3?;3R9@8,H5)&Z*@\>_&O#)%083 QM^.YDE8DAZ,7WOJO[#LD&6I
M:_.J*O[,LV;ST\GB1&5FI=NB^5#=_F:</!=$+ZV*FO^J6[EW?G6BTK9NJJU[
M&!QL\U+^ZSNGA^B!Q?C( U/WP)3YEH68RY]UHY\_L]6MLG0WJ-$+%I6?!G-Y
M24;YV%A\FN.YYOD'<V/*UJ@/)JW694Z:>G;>@#!]?)XZ(B^%R/0(D4OUMBJ;
M3:U>EYG)^L^?@Z' U=1S]7+Z(,'_:,N1FHT3-1U/QP_0FP4I9TQO]A4I5[;:
MJE?@U<(;H.EFHUZQCHU5__5B6?/U_WY@P7E8<,X+SH\M^/J/U[]_?JT^O'[U
M[M??WWQZ\^[W(;5^-Q'UIU%K4QJK&X.88*EJ$:LV]B9/39VHG:VR-FUJI<M,
MY64#ET<,M+J@3W;&-GNE\5!5("+K)ZJG'$^ENUI95>AEA14KN^\^SVNLSS[S
M3Y,IW:AF8U2#>%6-J1M\5B,NP((E/G>5;4R6J-M-GFZ4WH&/NQPA!3JW&U-V
M5.EV?'B39T04[!-5L,S9ITR-JI9%OM;DIG)SC=?U*C?92'T<)-)4:H=[3 EF
MTNK&6%Q;[M6-MGG5UJ"?V^QLITDI.[V'L'AR;?46$I9IT69YN0XW@P4DJDRE
MM (2H8;PPDM"&KV%HND_\?S69#G?1D+(FSP+M$?J95[ W.N:]=L37Y8U9#EO
M854B.U<KI<EBI 9Y+'6.3);-\CJM6@B9'-Z5Y:L5I.;W2]/<&NB;.-1;OE\M
MP8E3-@S'5@F,DDJ0@1M_<R(NM=T5>9HWN M<$QN@7;-)8K6W95[6+>D[&,#9
MG]0"52$U;_DR1",5ZV7!U&I0L*S7D?JT,<Y3R1#T9&;JU.8[<0$\6;56+%<?
M\]4GZC>CBV;#]GC#/%F8X(/)M\O6UHX)=O]-=V/N;N1%*?%G"E6D-.NJR5E'
M*V/.L.*96T91P<S:PC!I%YDL32W&Z^D[\3:-C?@-EANP&AFSLUQ/?W!)9>YV
MB'XR".+5H 2Z0&]A"=&;CTO_:*TVX+F"<<FQ3)D3:R61+GPQ):(V)]8""XVQ
MVV"0GE36ZG(M6AZI%]E?R+BB<O#$GAC$3CI%NX>9YYTW#Z]S&+'DE9QETLJ2
MZ[6[BC)*TXA[C=2O%/8E^_%[?F#8]NON-N=//<L?-3>M12FE>YZ$;IL-- B_
M!WM=)H%2,BZRN&4P1?R_[_Q(W[EGXJ^YSJLBC]W&O77NX3*UVFWV-?*AIC*P
MJ>I=#@? 2X,T6>V-=5FS @.6LDJ3-ZUD+S*4J*]? *7>.5EP1P4OTP7[8NZH
ML6MV=HQ+<1W*QI&L%6>J]RXUC]3G^^DZ6B20@K<@3^= G.'&/DT41KI0QXLR
MTNK41'269J.+%=D<>LEM6'3D,G3$QN,N?KP+2_ECAK5W)!@0J">G(@+TL2.'
M!/,<@J>#H@QR.5 !8/?.>\'P,M1N\JO )A!1W2[_<@&30@242)O77\1@S,O>
M"=P]Q?AD_RUA[Z,^E/JO5=N<(H$\FU7$TG&QK*AZF_HKM1R&.%[G >F@8[+]
MOR#1-!O Q^/9QLOS8*HYGE\D[E;("5W,DBNEK;4D 'K1+U LJ$IF'LXS'>_?
MEW$ZYA].-(1ST@H*-W?LL>(SVV6^;N5]YW<)R$35"^_6;>$A,:7:0N=;=@XV
M%ST0@=.>ZFMRF[^1*2#EPXB5%OV[S?%QRSKQ^A AJP:,4*JGN+2FL95TVTI'
MFM3$G@=]QS$?N2T1M5U'2C?[G.8^)1-7F;NQ8,/T<BA,FQ'6AS%=)7$^R1(R
M5P*Q>\2JNL_R$CR@H_E25K? HK] .+J]SN_45AI>6B53:%=-:%=9?]/QY#J)
M>$8V@*L@E5E)4A#X5&6B^'1#)8[#U6N5S?T S"8U'^N*0D=$!/&HW KYF.BC
M\6BJMN1(Y+7@]-'CR7PT._77$LZ=AJU7[!%RQIJHNI"CWH=?75#%!39XSE;O
MD9Q36)C$!2C8A[Z"W079;.>OB&S40C)<VI@]XP'H65B!4KB'+?8^N^#VLD(8
ML\<6N%X:TI.VX%ZO-15<5V*X_4,#!Q8(<.2E[]VH8H52S&LN#2K]C9$W&XU7
MG$9N<S@(4=E1;,1U"8[E>MZNI,%IE+&VLJ=2LY'B2!5+XV,IDURW:LNLDU\7
M-%S;^QP(E;]K;=?K.PI1I1F.MP&6P+M/@X@&<,TR]>Q'1:)J&U7D6Z"8AAU"
M,CQ]2K,$B\3?Z-!]N9SD,)[X0)MGH2A[Y^[A8]@%Z=EGN8"F#NF'G+,UH??\
M]W];3*?CIUVV)B;(&Q$I.WZ,[Y@\)7J^;^_:[C^-6-,E1Y/Q$O"VVJ4N\D5F
MT67P0V?W*0-I'/YCR3LI$7OLNFR1<$'8-<H-@8(B_X)0"E7N%AICG\Y+B?^L
M4G7EZ:[:!D4<M1?5_W!YE#%"U%";#Y\X5@+[-24GN"U+T H,4)0B?2(X+"!$
MA9CWE$"D(#B5TD *"93S-MD&2BQ8V4%<9WVN7#D;W>F:,H=;SH6EAKKKNO=8
MY#0[0OPROA+PYB8W-)'1\,VF%C!LX9W@*H;">7E#C*]E)":C)CAZ7D"1C$;K
MEC-:?)72+O&\%UBT,E1]I%,!O@6A" 8>5MN>2W:%5=*"V,658$DH%+%PQ-K!
M&9F15?+?QQM/D57ERI'3,+U^!2YUN6?/)4+LO3!'E_$E!3@60Q5/0@E/'/ZZ
MY\EL]HYI G5K;;."K;02EJ*(B6V)5 [_Y2(CW8?3>DPN\K+LZ)+,FOY"F)&&
M@BA7I'R )&M<0DME#O0Q8*5:3'9$H&/@P]5:<26NS#3?)^_HW"<,%=&^50&4
M@/LC0,7W8?'$CFS6*R_>D!V 1'-;UB*7*^TK&3L"RU,H>!S#H! FK2/1:;F.
M4H"?O1Y:7,C-[=;6B-\ZI1E15B(ZYD!CI!P!5@XY LZ(U AA=VS(5@J:F;AR
MP"<EPCVZ8V*V6OK&1P,W 42L0(S#"&Z II;'&.V6 >Q-&&G'_2SGRRH%7)=9
M,=%MP;)M4-M!5]JNFM)XV114-^NJX+KY.BCJ4(4Q )2,&S 2E<TC"% ]YAQ.
M>:<TMWA6]L1R[F;I-CQZ@PQ#KG+*J +$]D:[29(PP8"%WI:5*E"$C8UK.4]6
M#IST,,NY'H5M?1]Y_@S8L%V"ZFR2.!AZ2R&<H0YIWP]S<]E-X:&U1]/):-X'
MAM.KT>PH+(0W07<OTM2V$(E:KK)V]?P=-UPDVQGY9&]=C]7CG-7!/O&].$%T
MC5%5AU9@>,-BZ0?XJ^^#Z>I6U[W]D$\;Q,R1)S\>I?GX#;DFT ;H MOS$DR^
M>_7;P'#YD5K,D_%BBA>3\64RO5K0J\4LF<[HVG0R2:;CJWB$R4"@5I.+9+&X
M5--%<CF;J_DTN5K,U<5U,IY=16,JOG,^2<;78S5;))/Q!,3'R>1ZHJXNDXN+
MZS  4M?)]62F+I+Y_(*(7X[GX"BYF%^J3Q5--,',Q3BYOIH0@U>+9'Y!K,ZG
MDV0QH6NSBZMD-K\^6-S/R-*NJ^4"&P^_7N;5!^.&"'ZF4:M7[_YX\_,9U.9A
M29<7>PX0=KO^C-)&2"3Q+8J&:&['2;O-57AJM:1,4LO<L>*,A >V.>76=<5]
MD^TG9==,QFVIRPQ=AP]83P,)V0WZUGD'M8!W IF=&U-'.L $M01=L\A[2"P;
MRE]KW1P@F@AW@VP>/!!+468';D:@.BCM5'6$$-=JZN@:&O?%_95C@/4=-5)8
M8DV5T#@<0D7%W.BB#<61T@I5A=";L'H(Z_BVF40'&I77W/'34.T^LR/U/EQP
MW5)OZ.+F9UW]M&9)^DNH2[%KO$F_U$F\E9960!@,7:$MW9\H9:&35X_]]$F2
MH^M1/K)"?@ZWN<;D- :-O1VWGN*_?ZOL1=_>06S7"#HV8J>-=VUWQU37-?[&
MC[G\+$6V("+/!F+T!<6WK]+]<PLISE'%KBN-CA^>R99QKQ,B:?<##R:AE9)J
M[?K;^'-6X"WW,AK+0[;AO-$? G$%9A6[D68\ ?J@][K(4!T0Z7"3QN;+-IHC
M?1Y]'!&D*ZD7+;CG0[^RWK@Q%=(,@@VNMM7IGCOCTA2>T9Q&7;(C[I%:04X)
MT<(&0-=^\DK#;M<QZ8\V!,^CV3KT)9TSMYY>!B[Z'BLZ%N[3<5 "B<I0I\Z"
M$ZB.-FGDT2U:EKB%<DG=]AI^CG/W":>P;D!P!@*93%O+[)S1<7[#?G46S>N'
MPE=V L*$G+EQT,6/<G>MQ0/2LP<91T?*!V763;X+P1<>B&.'AO*F@!G@JM19
M>GW![ZCK=DY)->PP)X@^#G-N_0WQKF"T(O\G$8U2>8Q)B;0;;M.L7EO:M+/5
M7S(FK[MY9L. ATOS@Y")S1\A\T>+T64?,DZB*X>0,2\Y 1_D&0?B6"U]>WP?
M=P[GQMQ=C*X.N)N,+OY5W/7/)31L'[<EPN,27>IBCZH1ERFA$Y=E*JX$H=%P
M!MCZK=9X<@@Y7QTI8BY,F"1O>?T:;U1_<$XG(.^E+J3,->HM.XQT$4"P@'_)
MXG*&_Y> C]<$^)(98]3)-)E=SZGVWN3NK%X ^7Z3Q2=7UL \F5\N@#?'5S-U
M"0P[F2?3*5 K[Y@QT GS@:U&;GB,!^:34_5X 7P\P__)8D%_I\GU>'H:\]Q'
M^,SR]9A9OG8L+V;T?C)+KH L1>:UK>JZLZWPB&?Q\-5E)!89Z."N8[;DD@N9
M4]+QFA/$X"J74_6/'VS&>_T@JV$"@ST"V%_,)ZRFJPN&]1-T$9??8<GK9'H]
M4Q/T+0LT%LEL@78'NH:;'#?F=7)Q?47FNT@F4[+F;#+&W^D%6I?Q#[/F_$*Z
MG1]I3=#_A_JD[W@3ERLSC1PI@W05H=< #QW?<P.U^*/N/!]-?^[<L(D_\C<>
M]$3#A_Z&*EQ\L(;F4@33:.]ID( _>9@%8%. 933^<%20*RJNDPE++\>P7.X]
MY^WZ+320YKIPA^8BP"'Y-)Y@T49<AT>:_<Y/'OV9"S?@HIUO-U<LN5'85M;X
M\5-(T$]4695GLM-"J3I!'W0&P<O&2\ A]306PTVG#YE&_4 ]I\6\7S]51)9'
M\*NNTCJI>P1E;);30FSE"NXCXYBR*S*.H0 +(MOVSUS*'C+O]ND [?61?4$:
MCW@#6QG9AVY7<X<9-9@>*7FWE6+L14L.M?0UZPK2<UM1W:E&@9-NE+SG-H>@
MNZ5]Y".;FTDT4O>>H(,)F^K8:5<HFQ#\V::Z35R =68Z8B,&R]1!6=FUE)FN
MZ4(E'N$R@(B1-0'@=B<NYAR%Q>WMFW=CA&,39@&95=O4)@Q5_?DH97)N1#L@
MR'/F.[?704VVBXBZ\9M0;L6M0<')R) [XUS7-5W:GQM.<YNV6^EZ7=JB"87W
M#,<#PV;B&>^@ =G>-J?]7NT! ;G;DMD)CT]D8%RX><KQD?&.9J,HF=)H^HCP
MJ(W[0MH4EK&Q2U:TS\)M5;XRA[J$'#05\E;FS<[C3&^XJ5Q&DO/AYNX^FC&Q
M;>B/X;SMIQMD2VIXXL-N"$.65S;>ND Y+K^3E'UTJ[\XXU/2##/XNL^12 XG
MR#<4[-(<T/F*5IC1T2F.P94^]1ML-Q\XDP5I!JS3C=L)X@T]P0E\&DTVNT?J
MLPN(_W0!^XNAP[F\U1G%,*EE.(ZIZ_9QR"5T26.",G4'*H<?HAX7N:+I"IW,
M;XZ=GXCVMERS'?6W_2:CWR:@Q/0KS/T"T]^Q"4$EH4KM0XIN7$03>\FC-/_6
MMKO>,-)Q ;XZY%&*J1VL&6$'Q9/&QZ$L= N$V:@_NA4NX'Z)3ZJ[TJ8L@0I6
M>:1?1UNJAGOCBH!L?#0'1A&#?)\1).L9]5>;K3T2<%O,='NI>7H4PGR[9)\Y
M4AQ["3Z*W:\^F,?G;0B/NX& 59R^=A5\DB7 59YU_>^)LM1Z1WO6NK]=*MF<
M9-T:7;=6]M,KU-_:[:NT=E?5DHB],]!-W^N^G.W=]%8JF"QH7)<K*QY)!"52
M)')J?#HG3.YZ="*E2*DNW+2GMS4H,\^?#_#:!SD+1Z?_WP:@]MX!M2>X/:IW
M1VI=XL_IT($K1AA1?8K5SG##WV$B8.@\]J$=7^[UCU%=M81TNZK:HSY2+^YC
M4")RN M]?]%PL.[ -'X_8DC@?D&6F7+L.OWA:2B\7ZUA>7=*-$I/][9CP[D'
M6?F@:W&;P)T^W&&7>Q(NS8K:@@,S0?'IAHYY9>28]Q3@/HSWLWL/!]5(DG3J
M&3BR&/5\?2(_1EU.53K:X@^ GV C9<G&5X*\=E+7+O-8"E\JUF_O-3HB),]_
MEW3,]\!/31;2^]=]D3(NE.)A161!:^B[I /$(7U>_%\RTUDOE<9G)0B/]<5B
MH!PW*I'&>%A1[H, 06G-<"[FY5WRC8&Z5Q\?DX3(@UU.^";+X#:HWW3JIWKJ
M8*-^*T[:+T*_Q4#P5L R%7\^*W%X3J#;">I&*CRCETU$\T!GY\\H2!U->:SF
MAZY;PJFU <@B-1Q%AJN 6T2%=$QH&#<<Y<*/"FX/H'Y(;'SX!BI=49"R^%^1
M9^B8_\Z/N>IN6$7G9$TWV7;#ZNAK=OUT$3/T/=STMPW]UR&]:W[K5SEI&'(F
M8+G+0US@>6:RCVKZNYXS#!RPI1W<MI8!BZ-Y?XC#QR?C>8R+V#"6Z08<T6!F
M>*(6)9+A1;OAS[YC(.S,RU%-:H2X>\7:C_/3H33GI:;MO<G54SK,G]'):#XL
MH=U7<1[G>/C>E(B.8 ^:XG%]>I (:Z<$'G%P/DFU-)KMUB>";^_>S#9T;I+T
M3%;143G", WB$!^%TP/#VJO]R*DSES \<B>/WH<^]GW\1>B/X=N@+^+]RMXH
M"<KA+Y;*-TF=4):^V _QO4>TC,%IS\^V:SY[)D<#:-I'5_QV#]%P(QHZ2>N^
M$=>%3&]JYLGJ)E:H":;U/V,@B4?ZG-Q/2BOW;5B_F:J[01HS?]!/B@/BZ;I*
MY)0&'S.0E$B393FY]M5\Z'B%]LPN/NK8(8UNE'W0AU8ES7)=N=GYKL?<D3)J
M=ZHTC+T/OR'=.^[G-E[E7%UH;\5FE)5RVS5>[E@/+14:<;=#*K-G6I8*?73V
M\U"7R0'/?;7E*SGI3WP$:49'*IN?%_(1')<%#AMT$\C4?6,G',1#)&@9F=07
MQ3Y49(I>[]&4TMDO0\JZO^S J:AFX\XBA3,++FOYS>_1T"\GG$<_3@%G7_-/
M<!!=:$U^IR)<5?Y7/E[(CUMTM\M/A+S5=DT\%6:%1\>CJXL3,8I_TU0[_JF+
M9=4@,_++C=$P)-V SU<5<H-[0PN$WSYY_C]02P,$%     @ DD;_4!D.T?YU
M%0  ZT0  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULS5QI<QM'DOTK
M%1S-!!D!@8<D2[)E15"49,O6P24I>2<V]D.ANP"4V>C"5'<3@G_]OLPZNOH
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M?HQ_:11XWH))=V+$>Z5C7[4@Y[0)+^+F[@L1*CBL/]>VJB-N*R!]*O.H)\I
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M??IDST&4\ 70G/^<Q<S4M5GQQZ4"HK+T .[/C:G#%UH@_GV3E_\'4$L#!!0
M   ( ))&_U!WDY:;+@8  +8.   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;+576V_;-A3^*X07# G QB)U[Y( 3=MU'=:M2'9Y&/; R+1-3!8]DHZ3
M_?I]AY)5NW-2[&$OUB%Y+M^YTKS86O>G7VH=V,.J[?SE9!G"^N5TZINE7BE_
M;M>ZP\G<NI4*6+K%U*^=5K,HM&JG,DF*Z4J9;G)U$?<^NJL+NPFMZ?1'Q_QF
MM5+N\5JW=GLY$9/=QHU9+ -M3*\NUFJA;W7X9?W1834=M<S,2G?>V(XY/;^<
MO!(OKS/BCPR_&KWU>S0C3^ZL_9,6[V>7DX0 Z58W@30H?.[U:]VVI @P_AIT
M3D:3)+A/[[1_&WV'+W?*Z]>V_<W,PO)R4DW83,_5I@TW=ON='OS)25]C6Q]_
MV;;GE?6$-1L?[&H0!H*5Z?JO>ACBL"=0)4\(R$% 1MR]H8CRC0KJZL+9+7/$
M#6U$1%>C-,"9CI)R&QQ.#>3"U:U>(,3!7TP#M-'>M!DDKWM)^81DP3[8+BP]
M>]O-].Q0?@H4(Q2Y@W(MGU7X_:8[9VG"F4QD\HR^='0MC?K2YUUC-WIM73#=
M@OW^ZLX'AT+XXQGUV:@^B^JSI]2_???A[8\_WQZ+W+.2U&<O_5HU^G*"1O+:
MW>O)J([]II'?#@W![,8Q=)]35+^>F8Z%K44GD#OJKM7,#\GC;+U4*-%&;X)I
M5,M4-V,SHQ:=]=CPY^SGI?Z<9Q!F#70;'SRS\VCQ,[9# *^7IM6<?= /IK&<
MO7>ZA2T0WBG=V[U=8Q1P=J,>53O3,.OL;-,$YE6K?>0X8H7"H%RS[)'K>PR+
M-:'KD>^Y,L)>.X,I8MK'?SG0(-Y1::ON++!;][CO15@ZNUDLV;6Q-WJNG>X:
M_0F6-5UX8><O&N7TGE3$@1W:[2SS9M&9.8P " 2T>[&#%;T\IR3J>]5N5- P
MB"!H%P<HV0),K>#J3H2&"JQW.W,H5,1L;@*SCK76C\:-)]N']E3;VB9B)+WQ
M3/O ] .FMN_],EUC5X"A'@C9^ZZ?Y/U072@W(X.?E1J)*>\U@@KN_5/P[JHN
M<I%SFVY  3<:Z]84='V@SK,MYBY]%]HNG%HO30-<GY!07!49@Z*M?\DP<:-J
M) LEM.H'C:9!PS F=!P3.QYO'I[@.'V/EEG:C0=2?Q;G"GY$O4?=H-:ZC69S
M9U>,6M$T&O8_'I;G"?OZJTH*^<T7J#=[A2KSA->E8**L>)97+)."5T*P-"]Y
MFM7L]1BIG?13WY-1U\FH[634=S)J//!E:+MCOLB:IWE!1,6+*@%1)#Q+B<A3
M7E?BP(\OH?M/?GS1\H$/F-6=1XON2KNENWP#'^ <JBL\]GV+(G!'W!09;) Q
M47,9;<@,1$T1*WE6)P=N%ES4V0CU</6?7$QX%3T;K:;D8OK)ZD]C)U%S'P%^
MFO.Z+LZ(JGB>]Q3T"BDBF58\2=.S _@9"B3-P88S@3,I>96D[+00/*_DV9X+
MIR4OB^2,G8J$%[4@HN"R@,PIA.I"D@U9<E%2I$ZS$H=)M"M2Z.HA"+#F90D,
M&E=88X8NIK&QHLOV[[AQQ#?H%77\II7LDR2SI"?JI#KP2>1<9"6+\!(*(S5L
M"L,(Z[]3@K,<QZ0<X&01RRSE14$MDF4\%;%KD(.R9#\@\GV-F>X> S/.4MQO
M_4H?'0&GHJK[5)1#'F3:KY&9_.Q_:YHOV1U:!I!_Z0S-X-L Q9[<+W)>U3&Z
M%04@B9$HD/\X-@I4*&IDN,0ISA7"C>"),J,.+3%3,LG+I.SO?28$%[ED-4]R
M07Q)(DFJ%GE_Z[.,B[3 ;U46K.*R)EZ)1AK^'D"\2ED*^Q63$1E,5MGP=P+'
M%;(&M9AO8$KH-Z]J]A,U.!/H(9'";BEANXJ-)>! &1->\+2@O5Q(7@ ^.5KQ
M"F/^LTM@O!S>Z$:O[J X%9R]BI?=L2&"$JS@M>CI$C,%)790I=27P(%0H"U1
MLD+NI3='W#'6ZIKGDG1(CNSQ,LUZ.D%\X,\[:V=;T[;'AG6*?,4<2LP/"L!!
MVZ<(=E*/WZ?K"J.VQ"RHZX&JT77'_@5/]]X2*^T6\<7D<:]ONM _*\;=\5'V
MJG^+?&+O7W0?E%L87/^MGD,T.2_S"7/]*ZE?!+N.+Y,[&_#.B>02#TOMB 'G
M<VO#;D$&QJ?JU3]02P,$%     @ DD;_4)N9-3L2!P  ^Q$  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&ULK5A=;^,V%OTK%][LH@4TMBS+LITF 9+,
M#'8',YA!TVT?%GV@)=HB*HDJ2<7C_OJ>2TG^3+QM=U\LBN(]]]Q/DK[9:/.+
MS:5T]+4L*GL[R)VKKT<CF^:R%':H:UGARTJ;4CB\FO7(UD:*S N5Q2@*PV14
M"E4-[F[\W!=S=Z,;5ZA*?C%DF[(49OL@"[VY'8P'_<3W:IT[GAC=W=1B+9^D
M^W?]Q>!MM$/)5"DKJW1%1JYN!_?CZX>8U_L%/RJYL0=C8DN66O_"+__*;@<A
M$Y*%3!TC"#R>Y:,L"@8"C5\[S,%.)0L>CGOT]]YVV+(45C[JXB>5N?QV,!]0
M)E>B*=SW>O-/V=DS9;Q4%];_TJ9=.\;BM+%.EYTP&)2J:I_B:^>' X%Y^(I
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M^]'N_Z)E0T1@:6M/_Q9[?O;YLP=%V?G6;F4P4+ U#?^O;H01V8 7%V<&+&3
M@NCFA8C*UZI5/WSG[+YP^#3,AG_05FDT$&<:/)6KUL&O!L:U/USQ:11V55R9
M=6-6IE1-6UR6I>V:UC3KXH.M36FT+QZ&OQY]][B%I7&"QZ4L\Y*769Q9YGGQ
MHVW:C2_>-)6N^N,? \F1[D6@^^5B=,*_=LVL>'(Q*187BXN1^9Y$/CRA^9Z<
MF6]HP_]]N?2M [GYGY$%GL8%GM("3\\L\%)YXY'-H#Q>-ZU"H1QBY#VFF17%
MSQL-$E[:[4XU!]Q%UZBN,JVNBE<6>-YX_LO#YBJ%7[\UC6I*H^KB"F;1H&FM
M+S;J6A=+K1N<?Z<</&<:FMA5\+0&Z6PW]%F8M7,&)MG5P*ZU;K13=7W W_6N
MY;$M$/;+[&I6//S3'UXL%A??_OGR\@/].?_V4:&:BJ?$QTP#[.Y(6WW1V@+5
MKIA?3/^3'KMTK2EK#5_@]C_J=5?3YHNKZ7\! RZ)1B"I/DQPMD-1V:*Q+<Q:
MUET%W*EK^)OM&-D#F!-^!\*=_F=G<*O+0X'4%?!0@:RL=:N+5>23CWR"]=[Q
MUNS.-#@;D+15#=@Q_'U"BZGJ-]!?YNO#$O9D/+$,'K4-<*E!4FI8O>R<PQ_R
M 4!![R.LY?;&ZZ(ROJPMGB9\HTWSJ*"I*XT;:'2IO4=]!O:)A!0K91PLA]2^
M8OE ]L^_^A9W[L%ZD3R!G7?$&#_)MKRSWD1NE<IOBA78\5Q.MJK2(G^#LQV/
M1-XB*>W&:4T_>G-3;-DZ:+0.!>BVCKI=@!#2.8:]&=B+:2JP4VC/<;'VKFNW
M&]4"P0>@' ;LK$,9#00YC4X,^(AST,IX!LV!>5^LNK8#2F!N8RLO.[Z?DOF-
M[>J*B5"D)'"$OW4-^ZFH#MG4MTR(V\01/Y$XP]'?/D2T@E:WG2LNFZ:#)SX2
M5T ^H_+]+3+HH)63$WH-9[%=:O>G/\R?7WS[9(Y'-?]Z-F(FGT4S^6S4OGU(
M]@2.H8S[.&,L[SW9[V<R@WUI9;JN83%\_^%O[XN_:%6WFPE8BW)&QX3R">S>
M;RP:2KMO8%K?+4&!#8BV1L&Z)$/5:B>DI5GIG)UJO!(CB;JA:P-Q@1)SV]_D
MR($\CP?R?)2'OWC2,0VV"PRG]D.G\'DS%#-B/3L8ML7P\Y"9E0VAS3;M@36#
M#+18;)_97!3[K?JDLW607<I#O+D3EX+JKU8K" A%X\4$J&T\-7A>"Z=KHY:F
M!O,G4XGE12O TH36'%<^-X970=$)5FIPDT%[A\AQ^EHWG1"@;W8HE+ZH.O(7
M:1!Y8K),,W"$;4=NA0UB2;:F,K!M",93B ?2MW)VBY/XC&EC(O-5%)FO1@_\
M%5K<:'KQJ*Y5C5L=DIU[3@5Z<O:WJ))@:%T[!4W:3EBC8)O3)9@QY!='&WP$
M)%G6F36<3PUB!*:>SQ".X.L+.,(#>60P)"?'NNM<N8&T  CZ!P89WD:'3%'
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M$H4 MR3)USE_<7(B2 J30:QK>J>R&CA3DKRC2>#X:MX]3H!I49!8B5Y^TNV
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MDZ2N.::=4![:P!2$91K3TMBM\QH["2B:53=G6_B<'F*SG!0.Q,26ZKLEM;U
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M( W8MSK$R@[RY*%_)!?_XE%]"T\?/RX=2G0:>>U']"S,1D-A;+\++VM$Y+Y
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M)]?H['P4@&X:OUE8M?'-ME*66M=/"WHK43L#.L^5LON%"]"^OLD?4$L#!!0
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M-^3F-BP;]Z, ZPO<?F4,'0/?8/SUY'\ 4$L#!!0    ( ))&_U"U*F$DV0@
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M#7:UB@5=47'WRC37')=,;AJ0I&H%W)26<[$H,PFC*N4JE"68;)"<OZWEF-L
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MWYD:7)TG77.BG!(N&)F7U:25B^X7C#*Q2A##H%J4*6:\G^-U.G(G SL>ZM0
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MIE@ OV^U=H\GA8/F=<WR7U!+ P04    " "21O]08T4CL_ "   K"   &0
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M8SE0.X^5_/M2U/T"]R#D%"FJ3LS<1>CV .WM0;7!0U4,6&0[)[5'H9)QFL[
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M4=!=N<"(75]AUQ\$N[["KO^_P:[?Q&Y7,.DK[OI;<]?]><-;E9L@PRB@^H,
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M"17)0D/D^);.%RJ>A8-</ H5JT*85=M9^+-!6@\+*^B%<$!7-9VS^8)',UH
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M,7-BA^2PH#73UZ+Y")U#H<'+!%/V2YKV;!0Z)*N5%E5GC JJDK=_^M %8LO
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MT-0[FJ#;LNWF[42+E>V@=T)C/[;# E] D.8 [B^$T)N)(>C?U/0W4$L#!!0
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M<D\0S03C FU!/:+\432N= F(+V)6L8N*6I3;^5_];BMY_((G;V[/0]7JU-_
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M8CEGAU]I,2%7VUNR6&3_P:&0M0=@N1.2)86R0I!$:?Y+OA:!.%%0=LP*J%!
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MN7]+;O^E+K;M6UW?BKHN-NW'M4I6JFP ^O>'HJA?OC0G.+ZK>/,_4$L#!!0
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M235=S*38(VF?-FIVX%IUU28<X_9;N='2W&6F3B\NP;2DT&OD!NB2T14KF'Y
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MRS*S*GP-: 5Z#\!_280,3-!!_/INT8"(P3!H@E[F:61?X,'(!S#$O[&:OY<
M]Q*$TR!.1R)T,,/':?:6<6H6ZPC+< <S_*]HU@C_]+)&8SC#'<_P\X"&^T0C
M>#)"&=PA#3^/:;@/-8S3$=#@CFKX>5C# UR;!B-N'=?P\\"&^V0CT=AF[LB&
M_P1MN,^VL?XZL.%_3S;<1UL\^E^9=&0C_X]LI$\V$HQ\?:0#&_EK8&N4#D\R
M<3C]=7/X!T=.>WR_HG++N#(6F2D+3E/3@*Q/Q/5$BYT[A:Z$-F=:-\S-KPB0
M]@%S/Q-"/T[LP;;]7;+X 5!+ P04    " "21O]0IC*4AG$"  !;!@  &0
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M*(4I*7-YQU:?H184:+Z$Y<)\T:KR#3P+):60K*C!:@=%1JL_>:X3L0%0/.T
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M!9.SZTM*['"'!P=-&\^S,.@O530;_^S!A@2_OS4&]TZX6=./)/\#4$L#!!0
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MV_1O^6S\(]KB!5!+ 0(4 Q0    ( ))&_U '04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ DD;_4(DQ
M/GSO    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ DD;_4)E<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "21O]0YGVM\D(%  !D
M%0  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ DD;_4%?P47"^!@  8!H  !@              ("!A@T
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ))&_U"XJ2Z2
ME@(  ,P&   8              " @7H4  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " "21O]0B1Y"';H'   C(@  &
M@(%&%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ DD;_
M4 BJ:&,Q P  4 D  !@              ("!-A\  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( ))&_U!?7<'>,P@  #HL   8
M      " @9TB  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" "21O]0IV81D]((  "D(P  &               @($&*P  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ DD;_4("&[0N;!P  _0\  !@
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M970Q,BYX;6Q02P$"% ,4    " "21O]0:87:GQX7  !+20  &0
M    @(%Z>P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M ))&_U"<A _QFP(  (X%   9              " @<^2  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ DD;_4( =HY]8!P  =1,  !D
M             ("!H94  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " "21O]0W;\J#_@$  "-"P  &0              @($PG0  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ))&_U##-89;-PT
M *DC   9              " @5^B  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ DD;_4-Z(S8\P$0  X"H  !D              ("!
MS:\  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "21O]0
MH_8YZ006   '10  &0              @($TP0  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ))&_U 9#M'^=14  .M$   9
M      " @6_7  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ DD;_4'>3EILN!@  M@X  !D              ("!&^T  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "21O]0FYDU.Q('  #[$0
M&0              @(& \P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( ))&_U"-(01%+00  -P(   9              " @<GZ  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ DD;_4$9@'_2#
M&P  :UP  !D              ("!+?\  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " "21O]0Q*P32SX&   :#0  &0
M@('G&@$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ))&
M_U 6>WL'H0,  %0)   9              " @5PA 0!X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ DD;_4"[E8@_N!   &PL  !D
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M=#,Q+GAM;%!+ 0(4 Q0    ( ))&_U#==,'E1P4  )8,   9
M  " @?0Y 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MDD;_4/UV8]@)!0  Z@\  !D              ("!<C\! 'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " "21O]094'A42,"  "&!   &0
M            @(&R1 $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( ))&_U"U*F$DV0@  /LS   9              " @0Q' 0!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ DD;_4$<[K0Z+ P
M!0P  !D              ("!'% ! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " "21O]0!B\@%LD'   2)0  &0              @('>
M4P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ))&_U!'
M*P]2F0,  (H2   9              " @=Y; 0!X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ DD;_4/+V4??S P  NA$  !D
M     ("!KE\! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ))&_U"&943&1P,  &P,   9              "
M@4I] 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ DD;_
M4"41-BFX!0  (B@  !D              ("!R( ! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " "21O]0JN7F59,"  !&!P  &0
M        @(&WA@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( ))&_U!'"ZE*I0(  %\'   9              " @8&) 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ DD;_4!<^\PGK!   G!D
M !D              ("!78P! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " "21O]0T= !6I@"  #@!0  &0              @(%_D0$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ))&_U#IBJ>1
MG (  /$'   9              " @4Z4 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ DD;_4'1G.-SJ @  10@  !D
M ("!(9<! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "2
M1O]0$UE_6A #  !."@  &0              @(%"F@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( ))&_U"[7W>%_ L  "E+   9
M          " @8F= 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#
M%     @ DD;_4"CPM"%M P  @0P  !D              ("!O*D! 'AL+W=O
M<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "21O]07+DV788$  #-
M%   &0              @(%@K0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM
M;%!+ 0(4 Q0    ( ))&_U#._4%WO ,  !,/   9              " @1VR
M 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ DD;_4$Z,
MJGDV!0  7!<  !D              ("!$+8! 'AL+W=O<FMS:&5E=',O<VAE
M970U-RYX;6Q02P$"% ,4    " "21O]0MB4*P'L&  #E)   &0
M    @(%]NP$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M ))&_U GG0\G:P(  #\&   9              " @2_" 0!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ DD;_4/J01Q,3"0  MS@  !D
M             ("!T<0! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    " "21O]0GCB<.K@#  !'#0  &0              @($;S@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ))&_U!04 RE4@,
M *,,   9              " @0K2 0!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ DD;_4*8RE(9Q @  6P8  !D              ("!
MD]4! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " "21O]0
MR/S!>9D"   K!P  &0              @($[V $ >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    ( ))&_U .LK?EW0(  'D)   9
M      " @0O; 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @ DD;_4"N?@;7@ 0  5 0  !D              ("!']X! 'AL+W=O<FMS
M:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " "21O]0+)-V %<"  !$#
M#0              @ $VX $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ))&
M_U"7BKL<P    !,"   +              "  ;CB 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( ))&_U =_<EG804  (0K   /              "  :'C 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "21O]0'M^97AP"   ])P  &@
M            @ $OZ0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " "21O]0I7\.<>X!  "0)@  $P              @ &#ZP$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     2@!* #T4  "B[0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>446</ContextCount>
  <ElementCount>447</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>162</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - COVER PAGE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/COVERPAGE</Role>
      <ShortName>COVER PAGE</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Business and Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/BusinessandOrganization</Role>
      <ShortName>Business and Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - Composition of Certain Financial Statement Captions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions</Role>
      <ShortName>Composition of Certain Financial Statement Captions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Accumulated Other Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/AccumulatedOtherComprehensiveLoss</Role>
      <ShortName>Accumulated Other Comprehensive Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Derivative Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DerivativeContracts</Role>
      <ShortName>Derivative Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140112 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2145113 - Disclosure - Strategic Alliances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/StrategicAlliances</Role>
      <ShortName>Strategic Alliances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2147114 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2151115 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2157116 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.opko.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Composition of Certain Financial Statement Captions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables</Role>
      <ShortName>Composition of Certain Financial Statement Captions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/Investments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/Debt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/AccumulatedOtherComprehensiveLoss</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Derivative Contracts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DerivativeContractsTables</Role>
      <ShortName>Derivative Contracts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/DerivativeContracts</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2341307 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/RevenueRecognition</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2348308 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/Segments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2352309 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Business and Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/BusinessandOrganizationDetails</Role>
      <ShortName>Business and Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/BusinessandOrganization</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Earnings (Loss) Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/EarningsLossPerShareNarrativeDetails</Role>
      <ShortName>Earnings (Loss) Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/EarningsLossPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Composition of Certain Financial Statement Captions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails</Role>
      <ShortName>Composition of Certain Financial Statement Captions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Composition of Certain Financial Statement Captions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails</Role>
      <ShortName>Composition of Certain Financial Statement Captions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Composition of Certain Financial Statement Captions - Changes in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails</Role>
      <ShortName>Composition of Certain Financial Statement Captions - Changes in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Investments - Summary of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails</Role>
      <ShortName>Investments - Summary of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Investments - Schedule of Net Gains and Losses on Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails</Role>
      <ShortName>Investments - Schedule of Net Gains and Losses on Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Debt - Schedule of Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.opko.com/role/DebtScheduleofNotesDetails</Role>
      <ShortName>Debt - Schedule of Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Debt - Lines of Credit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DebtLinesofCreditDetails</Role>
      <ShortName>Debt - Lines of Credit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Debt - Notes Payable and Other Debt (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails</Role>
      <ShortName>Debt - Notes Payable and Other Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Fair Value Measurements - Level 3 Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails</Role>
      <ShortName>Fair Value Measurements - Level 3 Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Derivative Contracts - Balance Sheet Component (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails</Role>
      <ShortName>Derivative Contracts - Balance Sheet Component (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Derivative Contracts - Derivative Gains (Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails</Role>
      <ShortName>Derivative Contracts - Derivative Gains (Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/RelatedPartyTransactions</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/CommitmentsandContingencies</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Strategic Alliances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/StrategicAlliancesDetails</Role>
      <ShortName>Strategic Alliances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/StrategicAlliances</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2449426 - Disclosure - Segments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SegmentsNarrativeDetails</Role>
      <ShortName>Segments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2450427 - Disclosure - Segments - Operations and Assets Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails</Role>
      <ShortName>Segments - Operations and Assets Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2453428 - Disclosure - Leases - Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2454429 - Disclosure - Leases - Lease Liability Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails</Role>
      <ShortName>Leases - Lease Liability Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2455430 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2456431 - Disclosure - Leases - Lease Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails</Role>
      <ShortName>Leases - Lease Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2458432 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/SubsequentEvents</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="opk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - opk-20200630.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - opk-20200630.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="opk-20200630.htm">opk-20200630.htm</File>
    <File>a101viforlicagmtamend.htm</File>
    <File>a102pfizerlicagmtamend.htm</File>
    <File>opk-20200630.xsd</File>
    <File>opk-20200630_cal.xml</File>
    <File>opk-20200630_def.xml</File>
    <File>opk-20200630_lab.xml</File>
    <File>opk-20200630_pre.xml</File>
    <File>opk-6302020xex311.htm</File>
    <File>opk-6302020xex312.htm</File>
    <File>opk-6302020xex321.htm</File>
    <File>opk-6302020xex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "opk-20200630.htm": {
   "axisCustom": 2,
   "axisStandard": 39,
   "contextCount": 446,
   "dts": {
    "calculationLink": {
     "local": [
      "opk-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "opk-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "opk-20200630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "opk-20200630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "opk-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "opk-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 719,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 5,
    "http://www.opko.com/20200630": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 11
   },
   "keyCustom": 67,
   "keyStandard": 380,
   "memberCustom": 86,
   "memberStandard": 66,
   "nsprefix": "opk",
   "nsuri": "http://www.opko.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - COVER PAGE",
     "role": "http://www.opko.com/role/COVERPAGE",
     "shortName": "COVER PAGE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.opko.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - Composition of Certain Financial Statement Captions",
     "role": "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions",
     "shortName": "Composition of Certain Financial Statement Captions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Investments",
     "role": "http://www.opko.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Debt",
     "role": "http://www.opko.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Accumulated Other Comprehensive Loss",
     "role": "http://www.opko.com/role/AccumulatedOtherComprehensiveLoss",
     "shortName": "Accumulated Other Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Fair Value Measurements",
     "role": "http://www.opko.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Derivative Contracts",
     "role": "http://www.opko.com/role/DerivativeContracts",
     "shortName": "Derivative Contracts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Related Party Transactions",
     "role": "http://www.opko.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.opko.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140112 - Disclosure - Revenue Recognition",
     "role": "http://www.opko.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:StrategicAlliancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145113 - Disclosure - Strategic Alliances",
     "role": "http://www.opko.com/role/StrategicAlliances",
     "shortName": "Strategic Alliances",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:StrategicAlliancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147114 - Disclosure - Segments",
     "role": "http://www.opko.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151115 - Disclosure - Leases",
     "role": "http://www.opko.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157116 - Disclosure - Subsequent Events",
     "role": "http://www.opko.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Composition of Certain Financial Statement Captions (Tables)",
     "role": "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables",
     "shortName": "Composition of Certain Financial Statement Captions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Investments (Tables)",
     "role": "http://www.opko.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Debt (Tables)",
     "role": "http://www.opko.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - Accumulated Other Comprehensive Loss (Tables)",
     "role": "http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables",
     "shortName": "Accumulated Other Comprehensive Loss (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.opko.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Derivative Contracts (Tables)",
     "role": "http://www.opko.com/role/DerivativeContractsTables",
     "shortName": "Derivative Contracts (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341307 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://www.opko.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348308 - Disclosure - Segments (Tables)",
     "role": "http://www.opko.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352309 - Disclosure - Leases (Tables)",
     "role": "http://www.opko.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "opk:NumberofSalesEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Business and Organization (Details)",
     "role": "http://www.opko.com/role/BusinessandOrganizationDetails",
     "shortName": "Business and Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "opk:NumberofSalesEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "opk:COVID19PercentOfTotalTestVolume",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "opk:COVID19PercentOfTotalTestVolume",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Earnings (Loss) Per Share - Narrative (Details)",
     "role": "http://www.opko.com/role/EarningsLossPerShareNarrativeDetails",
     "shortName": "Earnings (Loss) Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Composition of Certain Financial Statement Captions (Details)",
     "role": "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
     "shortName": "Composition of Certain Financial Statement Captions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i11f6b9bd556843b1aafd7e182d59c3cb_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Composition of Certain Financial Statement Captions - Narrative (Details)",
     "role": "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
     "shortName": "Composition of Certain Financial Statement Captions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i11f6b9bd556843b1aafd7e182d59c3cb_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5492a302d8ca4a85901a3a7b73505049_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Composition of Certain Financial Statement Captions - Changes in Goodwill (Details)",
     "role": "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
     "shortName": "Composition of Certain Financial Statement Captions - Changes in Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "opk:EquityMethodInvestmentExcludingVariableInterestEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Investments - Summary of Investments (Details)",
     "role": "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails",
     "shortName": "Investments - Summary of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "opk:EquityMethodInvestmentExcludingVariableInterestEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Investments - Narrative (Details)",
     "role": "http://www.opko.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i9f4e2d31d1d5424882ae14d6cb9c371c_D20200101-20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Investments - Schedule of Net Gains and Losses on Equity Securities (Details)",
     "role": "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails",
     "shortName": "Investments - Schedule of Net Gains and Losses on Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.opko.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "opk:DebtInstrumentsNumberofFinancialInstitutions",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5492a302d8ca4a85901a3a7b73505049_I20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "opk:DebtInstrumentsNumberofFinancialInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "institution",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Debt - Schedule of Notes (Details)",
     "role": "http://www.opko.com/role/DebtScheduleofNotesDetails",
     "shortName": "Debt - Schedule of Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "if6c32717a26d40d88eae1ea4982913d6_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Debt - Lines of Credit (Details)",
     "role": "http://www.opko.com/role/DebtLinesofCreditDetails",
     "shortName": "Debt - Lines of Credit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Debt - Notes Payable and Other Debt (Details)",
     "role": "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
     "shortName": "Debt - Notes Payable and Other Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i95fecc4a436340768768e918eea21ff8_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5492a302d8ca4a85901a3a7b73505049_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails",
     "shortName": "Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i350765d31f054cb4a900a05635ea70c4_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details)",
     "role": "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
     "shortName": "Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i466da00a6f1e4da59279c84d5c12fe30_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Fair Value Measurements - Level 3 Reconciliation (Details)",
     "role": "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails",
     "shortName": "Fair Value Measurements - Level 3 Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i466da00a6f1e4da59279c84d5c12fe30_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Derivative Contracts - Balance Sheet Component (Details)",
     "role": "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
     "shortName": "Derivative Contracts - Balance Sheet Component (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i1e0ac6f1d4cb4c66b971c20cf8aeca20_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "iccf1d6fe84ba4e54b2f9cc386683e187_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Derivative Contracts - Derivative Gains (Losses) (Details)",
     "role": "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails",
     "shortName": "Derivative Contracts - Derivative Gains (Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "iccf1d6fe84ba4e54b2f9cc386683e187_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.opko.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.opko.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "opk:NumberOfClassActionLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Revenue Recognition - Narrative (Details)",
     "role": "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details)",
     "role": "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Schedule of Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i287de0999fc24a5cb5546c28ae66980f_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details)",
     "role": "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails",
     "shortName": "Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "opk:ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ic01e46e792ea463fb3ad976ee43f07a4_I20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i85584120b6ae40969ed88e8fc454cbac_D20171012-20171012",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Strategic Alliances (Details)",
     "role": "http://www.opko.com/role/StrategicAlliancesDetails",
     "shortName": "Strategic Alliances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i85584120b6ae40969ed88e8fc454cbac_D20171012-20171012",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449426 - Disclosure - Segments - Narrative (Details)",
     "role": "http://www.opko.com/role/SegmentsNarrativeDetails",
     "shortName": "Segments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ic884ff99f6fc4caabe0eb0adf1366e62_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5fb67fadb72846cdba88dedab4956840_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY",
     "role": "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i8173ffa4f57449388f4402918c710024_D20190101-20190630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450427 - Disclosure - Segments - Operations and Assets Information (Details)",
     "role": "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
     "shortName": "Segments - Operations and Assets Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "opk:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453428 - Disclosure - Leases - Lease Assets and Liabilities (Details)",
     "role": "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails",
     "shortName": "Leases - Lease Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "opk:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454429 - Disclosure - Leases - Lease Liability Maturity (Details)",
     "role": "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails",
     "shortName": "Leases - Lease Liability Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i5698d6f1fc1940309b63ded417c158e4_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455430 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.opko.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456431 - Disclosure - Leases - Lease Cash Flow Information (Details)",
     "role": "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails",
     "shortName": "Leases - Lease Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "ib11bb2b42a3e461ca645b2240e1ae5a1_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458432 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.opko.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "i56d3de83d9ad4ba99bcdfa4b49b82318_D20200401-20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaidInKindInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Business and Organization",
     "role": "http://www.opko.com/role/BusinessandOrganization",
     "shortName": "Business and Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.opko.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20200630.htm",
      "contextRef": "id0a9e8e9d71f4812be5a8e082a98beff_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": null,
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - opk-20200630.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - opk-20200630.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 162,
   "tag": {
    "country_CL": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CHILE",
        "verboseLabel": "Chile"
       }
      }
     },
     "localname": "CL",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SPAIN",
        "verboseLabel": "Spain"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ISRAEL",
        "verboseLabel": "Israel"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MEXICO",
        "verboseLabel": "Mexico"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "verboseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "opk_A4KscoreMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "4Kscore",
        "label": "4Kscore [Member]",
        "terseLabel": "4Kscore"
       }
      }
     },
     "localname": "A4KscoreMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_A5ConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "5% Convertible Notes [Member]",
        "label": "5% Convertible Notes [Member]",
        "terseLabel": "5% Convertible Notes"
       }
      }
     },
     "localname": "A5ConvertibleNotesMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_AccruedClinicalTrialsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued clinical trials.",
        "label": "Accrued Clinical Trials, Current",
        "verboseLabel": "Clinical trials"
       }
      }
     },
     "localname": "AccruedClinicalTrialsCurrent",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_AccruedCommitmentsandContingenciesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Commitments and Contingencies, Current",
        "label": "Accrued Commitments and Contingencies, Current",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "AccruedCommitmentsandContingenciesCurrent",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_AccruedExpensePayorOverpaymentReimbursementLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Expense, Payor Overpayment Reimbursement, Liability",
        "label": "Accrued Expense, Payor Overpayment Reimbursement, Liability",
        "terseLabel": "Overpayment reimbursement liability"
       }
      }
     },
     "localname": "AccruedExpensePayorOverpaymentReimbursementLiability",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Doubtful Accounts, Provision For Allowance As Percent Of Gross Sales",
        "label": "Allowance For Doubtful Accounts, Provision For Allowance As Percent Of Gross Sales",
        "terseLabel": "Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Doubtful Accounts Receivable, Decrease, Credits Or Payments",
        "label": "Allowance For Doubtful Accounts Receivable, Decrease, Credits Or Payments",
        "negatedTerseLabel": "Credits or payments made"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Assets and Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "opk_AutomobilesandAircraftMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Automobiles and Aircraft [Member]",
        "label": "Automobiles and Aircraft [Member]",
        "terseLabel": "Automobiles and Aircraft"
       }
      }
     },
     "localname": "AutomobilesandAircraftMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BancoDeSabadellMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Banco De Sabadell [Member]",
        "label": "Banco De Sabadell [Member]",
        "terseLabel": "Banco De Sabadell"
       }
      }
     },
     "localname": "BancoDeSabadellMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BankOfChileMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bank of Chile.",
        "label": "Bank of Chile [Member]",
        "verboseLabel": "Bank of Chile"
       }
      }
     },
     "localname": "BankOfChileMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BbvaBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BBVA bank.",
        "label": "BBVA Bank [Member]",
        "verboseLabel": "BBVA Bank"
       }
      }
     },
     "localname": "BbvaBankMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BiceBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BICE Bank.",
        "label": "Bice Bank [Member]",
        "verboseLabel": "BICE Bank"
       }
      }
     },
     "localname": "BiceBankMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BilbaoVizcayaBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bilbao vizcaya bank.",
        "label": "Bilbao Vizcaya Bank [Member]",
        "verboseLabel": "Banco Bilbao Vizcaya"
       }
      }
     },
     "localname": "BilbaoVizcayaBankMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BioCardiaInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BioCardia, Inc. [Member]",
        "label": "BioCardia, Inc. [Member]",
        "terseLabel": "BioCardia, Inc."
       }
      }
     },
     "localname": "BioCardiaInc.Member",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BioReferenceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bio-Reference [Member]",
        "label": "Bio-Reference [Member]",
        "terseLabel": "BioReference"
       }
      }
     },
     "localname": "BioReferenceMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets",
        "terseLabel": "Goodwill, in-process research and development and other intangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CMS Accelerated and Advanced Payment Program, COVID-19",
        "label": "CMS Accelerated and Advanced Payment Program, COVID-19 [Member]",
        "terseLabel": "CMS Accelerated and Advanced Payment Program, COVID-19"
       }
      }
     },
     "localname": "CMSAcceleratedAndAdvancedPaymentProgramCOVID19Member",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_COVID19NumberOfTestsPerformed": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "COVID-19, Number of Tests Performed",
        "label": "COVID-19, Number of Tests Performed",
        "terseLabel": "Number of tests performed"
       }
      }
     },
     "localname": "COVID19NumberOfTestsPerformed",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "opk_COVID19PercentOfTotalTestVolume": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "COVID-19, Percent of Total Test Volume",
        "label": "COVID-19, Percent of Total Test Volume",
        "terseLabel": "Total test volume (as a percent)"
       }
      }
     },
     "localname": "COVID19PercentOfTotalTestVolume",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "opk_COVID19TestTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "COVID-19, Test Type",
        "label": "COVID-19, Test Type [Axis]",
        "terseLabel": "COVID-19, Test Type [Axis]"
       }
      }
     },
     "localname": "COVID19TestTypeAxis",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_COVID19TestTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "COVID-19, Test Type",
        "label": "COVID-19, Test Type [Domain]",
        "terseLabel": "COVID-19, Test Type [Domain]"
       }
      }
     },
     "localname": "COVID19TestTypeDomain",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_COVID19TestsPerformedPerDay": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "COVID-19, Tests Performed Per Day",
        "label": "COVID-19, Tests Performed Per Day",
        "terseLabel": "Tests performed per day"
       }
      }
     },
     "localname": "COVID19TestsPerformedPerDay",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "opk_ChangeInTestingVolumePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in Testing Volume, Percent",
        "label": "Change in Testing Volume, Percent",
        "terseLabel": "Change in testing volume (as a percent)"
       }
      }
     },
     "localname": "ChangeInTestingVolumePercent",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "opk_ChargebacksDiscountsRebatesAndFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chargebacks, Discounts, Rebates And Fees [Member]",
        "label": "Chargebacks, Discounts, Rebates And Fees [Member]",
        "terseLabel": "Chargebacks, discounts, rebates and fees"
       }
      }
     },
     "localname": "ChargebacksDiscountsRebatesAndFeesMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ChiefTechnicalOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chief Technical Officer [Member]",
        "label": "Chief Technical Officer [Member]",
        "terseLabel": "Dr. Jan Hsiao"
       }
      }
     },
     "localname": "ChiefTechnicalOfficerMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ChromaDexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ChromaDex.",
        "label": "ChromaDex [Member]",
        "terseLabel": "ChromaDex"
       }
      }
     },
     "localname": "ChromaDexMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ChromadexCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ChromaDex corporation.",
        "label": "Chromadex Corporation [Member]",
        "verboseLabel": "ChromaDex Corporation"
       }
      }
     },
     "localname": "ChromadexCorporationMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Of Warrant, Number Of Securities Received",
        "label": "Class Of Warrant Or Right, Exercise Of Warrant, Number Of Securities Received",
        "terseLabel": "Shares received upon exercise of warrant (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExerciseOfWarrantNumberOfSecuritiesReceived",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights, Vested",
        "label": "Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights, Vested",
        "terseLabel": "Investment options, vested (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsVested",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_ClientPayersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Client Payers [Member]",
        "label": "Client Payers [Member]",
        "terseLabel": "Client payers"
       }
      }
     },
     "localname": "ClientPayersMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_CocrystalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cocrystal.",
        "label": "Cocrystal [Member]",
        "terseLabel": "Cocrystal",
        "verboseLabel": "COCP"
       }
      }
     },
     "localname": "CocrystalMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_CollaborativeAgreementAdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Additional Milestone Payment",
        "label": "Collaborative Agreement, Additional Milestone Payment",
        "terseLabel": "Additional milestone payment"
       }
      }
     },
     "localname": "CollaborativeAgreementAdditionalMilestonePayment",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CollaborativeAgreementPeriodfromFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Period from First Commercial Sale",
        "label": "Collaborative Agreement, Period from First Commercial Sale",
        "terseLabel": "Period from first commercial sale"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodfromFirstCommercialSale",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_CollaborativeArrangement.MaximumMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement. Maximum Milestone Payments",
        "label": "Collaborative Arrangement. Maximum Milestone Payments",
        "terseLabel": "Additional milestone payment to be received"
       }
      }
     },
     "localname": "CollaborativeArrangement.MaximumMilestonePayments",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Annual Height Velocity at Point in Time",
        "label": "Collaborative Arrangement, Annual Height Velocity at Point in Time",
        "terseLabel": "Annual height velocity at point in time"
       }
      }
     },
     "localname": "CollaborativeArrangementAnnualHeightVelocityatPointinTime",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, License Termination, Written Notice Threshold",
        "label": "Collaborative Arrangement, License Termination, Written Notice Threshold",
        "terseLabel": "Written termination threshold"
       }
      }
     },
     "localname": "CollaborativeArrangementLicenseTerminationWrittenNoticeThreshold",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_CollaborativeArrangementMaximumMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Milestone Payments",
        "label": "Collaborative Arrangement, Maximum Milestone Payments",
        "terseLabel": "Maximum milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumMilestonePayments",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CollaborativeArrangementMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment",
        "label": "Collaborative Arrangement, Milestone Payment",
        "terseLabel": "Each milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayment",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CollaborativeArrangementMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment Received",
        "label": "Collaborative Arrangement, Milestone Payment Received",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentReceived",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CollaborativeArrangementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Upfront Payment",
        "label": "Collaborative Arrangement, Upfront Payment",
        "terseLabel": "Non-refundable and non-creditable upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPayment",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CommonStockWarrantsNetExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock warrants net exercised.",
        "label": "Common Stock Warrants Net Exercised",
        "verboseLabel": "Common Stock options and warrants, surrendered in net exercise"
       }
      }
     },
     "localname": "CommonStockWarrantsNetExercised",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Composition of certain financial statement captions.",
        "label": "Composition of Certain Financial Statement Captions [Table Text Block]",
        "verboseLabel": "Composition of Certain Financial Statement Captions"
       }
      }
     },
     "localname": "CompositionOfCertainFinancialStatementCaptionsTableTextBlock",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "opk_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ConvertibleSeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2025 [Member]",
        "label": "Convertible Senior Notes Due 2025 [Member]",
        "terseLabel": "Convertible Senior Notes Due 2025"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2025Member",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_Corpbanca1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corpbanca1 [Member]",
        "label": "Corpbanca1 [Member]",
        "terseLabel": "Corpbanca"
       }
      }
     },
     "localname": "Corpbanca1Member",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_CovenantsNotToCompeteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Covenants not to compete.",
        "label": "Covenants Not to Compete [Member]",
        "terseLabel": "Covenants not to compete"
       }
      }
     },
     "localname": "CovenantsNotToCompeteMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Conversion Notice Threshold, Maximum",
        "label": "Debt Instrument, Convertible, Conversion Notice Threshold, Maximum",
        "terseLabel": "Maximum conversion notice"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionNoticeThresholdMaximum",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Conversion Notice Threshold, Minimum",
        "label": "Debt Instrument, Convertible, Conversion Notice Threshold, Minimum",
        "terseLabel": "Minimum conversion notice"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionNoticeThresholdMinimum",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Maximum Shares Issuable",
        "label": "Debt Instrument, Convertible Debt, Maximum Shares Issuable",
        "terseLabel": "Shares issuable under debt agreement (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtMaximumSharesIssuable",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_DebtInstrumentConvertibleSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Shares Issued",
        "label": "Debt Instrument, Convertible, Shares Issued",
        "terseLabel": "Shares received after conversion (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleSharesIssued",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_DebtInstrumentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument [Roll Forward]",
        "label": "Debt Instrument [Roll Forward]",
        "terseLabel": "Debt Instrument [Roll Forward]"
       }
      }
     },
     "localname": "DebtInstrumentRollForward",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_DebtInstrumentsNumberofFinancialInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of financial institutions.",
        "label": "Debt Instruments, Number of Financial Institutions",
        "verboseLabel": "Number of financial institutions"
       }
      }
     },
     "localname": "DebtInstrumentsNumberofFinancialInstitutions",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "opk_DevelopmentandLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development and License Agreement [Member]",
        "label": "Development and License Agreement [Member]",
        "terseLabel": "Development and License Agreement"
       }
      }
     },
     "localname": "DevelopmentandLicenseAgreementMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_DiagnosticMolecularTestMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Diagnostic Molecular Test",
        "label": "Diagnostic Molecular Test [Member]",
        "terseLabel": "Diagnostic Molecular Test"
       }
      }
     },
     "localname": "DiagnosticMolecularTestMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_DiagnosticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Diagnostics.",
        "label": "Diagnostics [Member]",
        "terseLabel": "Diagnostics",
        "verboseLabel": "Diagnostics"
       }
      }
     },
     "localname": "DiagnosticsMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_DistributionToHealthcareProvidersCOVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distribution to Healthcare Providers, COVID-19",
        "label": "Distribution to Healthcare Providers, COVID-19 [Member]",
        "terseLabel": "Distribution to Healthcare Providers, COVID-19"
       }
      }
     },
     "localname": "DistributionToHealthcareProvidersCOVID19Member",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_DrFrostMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dr Frost.",
        "label": "Dr Frost [Member]",
        "terseLabel": "Dr Frost"
       }
      }
     },
     "localname": "DrFrostMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_DrFrostandMrPfennigerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dr Frost and Mr Pfenniger [Member]",
        "label": "Dr Frost and Mr Pfenniger [Member]",
        "terseLabel": "Dr Frost and Mr Pfenniger"
       }
      }
     },
     "localname": "DrFrostandMrPfennigerMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_EirGenPharmaLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "EirGen Pharma Limited [Member]",
        "label": "EirGen Pharma Limited [Member]",
        "terseLabel": "EirGen Pharma Limited",
        "verboseLabel": "Rayaldee"
       }
      }
     },
     "localname": "EirGenPharmaLimitedMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_EloxxPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eloxx Pharmaceuticals [Member]",
        "label": "Eloxx Pharmaceuticals [Member]",
        "terseLabel": "Eloxx Pharmaceuticals"
       }
      }
     },
     "localname": "EloxxPharmaceuticalsMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated milestone payment to be received.",
        "label": "Equity Method Investment, Estimated Milestone Payments To Be Received",
        "verboseLabel": "Maximum milestone payments to be received"
       }
      }
     },
     "localname": "EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_EquityMethodInvestmentExcludingVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Excluding Variable Interest Entity",
        "label": "Equity Method Investment, Excluding Variable Interest Entity",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentExcludingVariableInterestEntity",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_EquityMethodInvestmentSharesPurchasedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Shares Purchased In Period",
        "label": "Equity Method Investment, Shares Purchased In Period",
        "terseLabel": "Equity method investment, additional investment in period (in shares)"
       }
      }
     },
     "localname": "EquityMethodInvestmentSharesPurchasedInPeriod",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_EquityMethodInvestmentVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Variable Interest Entity",
        "label": "Equity Method Investment, Variable Interest Entity",
        "terseLabel": "Variable interest entity, equity method"
       }
      }
     },
     "localname": "EquityMethodInvestmentVariableInterestEntity",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]",
        "label": "Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]",
        "terseLabel": "Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract",
     "nsuri": "http://www.opko.com/20200630",
     "xbrltype": "stringItemType"
    },
    "opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investments, Warrants and Options, and Variable Interest Entities [Line Items]",
        "label": "Equity Method Investments, Warrants and Options, and Variable Interest Entities [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_EquitySecurityFVNIOwnershipPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Security, FV-NI, Ownership Percentage",
        "label": "Equity Security, FV-NI, Ownership Percent",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquitySecurityFVNIOwnershipPercent",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "opk_EstadoBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estado bank.",
        "label": "Estado Bank [Member]",
        "verboseLabel": "Estado Bank"
       }
      }
     },
     "localname": "EstadoBankMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ExclusiveOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive Option [Member]",
        "label": "Exclusive Option [Member]",
        "terseLabel": "Exclusive Option"
       }
      }
     },
     "localname": "ExclusiveOptionMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_FederalTradeCommissionFilingFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Federal Trade Commission Filing Fees [Member]",
        "label": "Federal Trade Commission Filing Fees [Member]",
        "terseLabel": "Federal Trade Commission Filing Fees"
       }
      }
     },
     "localname": "FederalTradeCommissionFilingFeesMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Lease, Liability, Payments, Due after Year Four",
        "label": "Finance Lease, Liability, Payments, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_FrostRealEstateHoldingsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frost real estate holdings LLC.",
        "label": "Frost Real Estate Holdings LLC [Member]",
        "verboseLabel": "Frost Real Estate Holdings LLC"
       }
      }
     },
     "localname": "FrostRealEstateHoldingsLLCMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_GovernmentPayersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government Payers [Member]",
        "label": "Government Payers [Member]",
        "terseLabel": "Government payers"
       }
      }
     },
     "localname": "GovernmentPayersMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_GovernmentalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Governmental [Member]",
        "label": "Governmental [Member]",
        "terseLabel": "Governmental"
       }
      }
     },
     "localname": "GovernmentalMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_HealthInsurersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Health Insurers [Member]",
        "label": "Health Insurers [Member]",
        "terseLabel": "Healthcare insurers"
       }
      }
     },
     "localname": "HealthInsurersMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_InCellDxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "InCellDx, Inc [Member]",
        "label": "InCellDx, Inc [Member]",
        "terseLabel": "InCellDx, Inc"
       }
      }
     },
     "localname": "InCellDxIncMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_InProcessResearchandDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In-Process Research and Development",
        "label": "In-Process Research and Development",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchandDevelopment",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (loss) from continuing operations before investment losses.",
        "label": "Income (Loss) from Continuing Operations, Before Investments in Investees, Extraordinary Items, Noncontrolling Interest, Net of Tax",
        "totalLabel": "Net income (loss) before investment losses"
       }
      }
     },
     "localname": "IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Equity Securities, FV-NI And Derivative Instruments",
        "label": "Increase (Decrease) In Equity Securities, FV-NI And Derivative Instruments",
        "negatedLabel": "Change in fair value of equity securities and derivative instruments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_IncreaseDecreaseinForeignCurrencyMeasurement": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Foreign Currency Measurement",
        "label": "Increase (Decrease) in Foreign Currency Measurement",
        "terseLabel": "Foreign currency measurement"
       }
      }
     },
     "localname": "IncreaseDecreaseinForeignCurrencyMeasurement",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_InterestExpenseNonoperating": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest Expense, Nonoperating",
        "label": "Interest Expense, Nonoperating",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseNonoperating",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_InterestIncomeNonoperating": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest Income, Nonoperating",
        "label": "Interest Income, Nonoperating",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeNonoperating",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_InventoryReceivedNotInvoicedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory Received, Not Invoiced, Current",
        "label": "Inventory Received, Not Invoiced, Current",
        "terseLabel": "Inventory received but not invoiced"
       }
      }
     },
     "localname": "InventoryReceivedNotInvoicedCurrent",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_ItauBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Itau.",
        "label": "Itau Bank [Member]",
        "verboseLabel": "Itau Bank"
       }
      }
     },
     "localname": "ItauBankMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_JPMorganChaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "JP Morgan Chase [Member]",
        "label": "JP Morgan Chase [Member]",
        "terseLabel": "JPMorgan Chase"
       }
      }
     },
     "localname": "JPMorganChaseMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and Collaboration Agreements Proceeds as Up Front Payment",
        "label": "License and Collaboration Agreements Proceeds as Up Front Payment",
        "terseLabel": "Upfront payment under license agreements"
       }
      }
     },
     "localname": "LicenseandCollaborationAgreementsProceedsasUpFrontPayment",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line of Credit Facility, Covenant Terms, Total Revolving Commitment, Percentage",
        "label": "Line of Credit Facility, Covenant Terms, Total Revolving Commitment, Percentage",
        "terseLabel": "Percentage of total revolving commitment"
       }
      }
     },
     "localname": "LineofCreditFacilityCovenantTermsTotalRevolvingCommitmentPercentage",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "opk_LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line of Credit, Total Revolving Commitment, Threshold Consecutive Days",
        "label": "Line of Credit, Total Revolving Commitment, Threshold Consecutive Days",
        "terseLabel": "Consecutive days"
       }
      }
     },
     "localname": "LineofCreditTotalRevolvingCommitmentThresholdConsecutiveDays",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "London Interbank Offered Rate (LIBOR), First Twelve Months, Adjusted for Eurocurrency Liabilities [Member]",
        "label": "London Interbank Offered Rate (LIBOR), First Twelve Months, Adjusted for Eurocurrency Liabilities [Member]",
        "terseLabel": "LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "London Interbank Offered Rate (LIBOR), First Twelve Months [Member]",
        "label": "London Interbank Offered Rate (LIBOR), First Twelve Months [Member]",
        "terseLabel": "LIBOR, First 12 Months"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "London Interbank Offered Rate (LIBOR), Thereafter, Adjusted for Eurocurrency Liabilities [Member]",
        "label": "London Interbank Offered Rate (LIBOR), Thereafter, Adjusted for Eurocurrency Liabilities [Member]",
        "terseLabel": "LIBOR, Thereafter, Adjusted for Eurocurrency Liabilities"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORThereafterAdjustedforEurocurrencyLiabilitiesMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LondonInterbankOfferedRateLIBORThereafterMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "London Interbank Offered Rate (LIBOR), Thereafter [Member]",
        "label": "London Interbank Offered Rate (LIBOR), Thereafter [Member]",
        "terseLabel": "LIBOR Thereafter"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORThereafterMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_MabVaxTherapeuticsHoldingsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MabVax Therapeutics Holdings, Inc. [Member]",
        "label": "MabVax Therapeutics Holdings, Inc. [Member]",
        "terseLabel": "MabVax",
        "verboseLabel": "MabVax Therapeutics Holdings, Inc."
       }
      }
     },
     "localname": "MabVaxTherapeuticsHoldingsInc.Member",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_MembersofSeniorManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Members of Senior Management [Member]",
        "label": "Members of Senior Management [Member]",
        "terseLabel": "Members of Senior Management"
       }
      }
     },
     "localname": "MembersofSeniorManagementMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Milestone [Axis]",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_MuseumofScienceIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Museum of Science, Inc [Member]",
        "label": "Museum of Science, Inc [Member]",
        "terseLabel": "Museum of Science, Inc"
       }
      }
     },
     "localname": "MuseumofScienceIncMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NIMSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NIMS [Member]",
        "label": "NIMS [Member]",
        "terseLabel": "NIMS"
       }
      }
     },
     "localname": "NIMSMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NeovascMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Neovasc [Member]",
        "label": "Neovasc [Member]",
        "terseLabel": "Neovasc"
       }
      }
     },
     "localname": "NeovascMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NewCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New Credit Agreement [Member]",
        "label": "New Credit Agreement [Member]",
        "terseLabel": "New Credit Agreement"
       }
      }
     },
     "localname": "NewCreditAgreementMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NonInvasiveMonitoringSystemsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-Invasive Monitoring Systems, Inc. [Member]",
        "label": "Non-Invasive Monitoring Systems, Inc. [Member]",
        "terseLabel": "Non-Invasive Monitoring Systems, Inc."
       }
      }
     },
     "localname": "NonInvasiveMonitoringSystemsInc.Member",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NotesDueFebruary12033Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notes Due February 1, 2033 [Member]",
        "label": "Notes Due February 1, 2033 [Member]",
        "terseLabel": "Notes Due February 1, 2033"
       }
      }
     },
     "localname": "NotesDueFebruary12033Member",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NotesPayableAndOtherLongTermLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notes Payable And Other Long-Term Liabilities [Member]",
        "label": "Notes Payable And Other Long-Term Liabilities [Member]",
        "terseLabel": "Notes Payable and Other Long-Term Liabilities"
       }
      }
     },
     "localname": "NotesPayableAndOtherLongTermLiabilitiesMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NumberOfClassActionLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Class Action Lawsuits",
        "label": "Number Of Class Action Lawsuits",
        "terseLabel": "Number of class action lawsuits (at least)"
       }
      }
     },
     "localname": "NumberOfClassActionLawsuits",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "opk_NumberOfDerivativeLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Derivative Lawsuits",
        "label": "Number Of Derivative Lawsuits",
        "terseLabel": "Number of derivative lawsuits (at least)"
       }
      }
     },
     "localname": "NumberOfDerivativeLawsuits",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "opk_NumberofSalesEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Sales Employees",
        "label": "Number of Sales Employees",
        "terseLabel": "Number of sales employees"
       }
      }
     },
     "localname": "NumberofSalesEmployees",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "opk_OPKOBiologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "OPKO Biologics [Member]",
        "label": "OPKO Biologics [Member]",
        "terseLabel": "OPKO Biologics"
       }
      }
     },
     "localname": "OPKOBiologicsMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_OPKOHealthEuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "OPKO Health Europe [Member]",
        "label": "OPKO Health Europe [Member]",
        "terseLabel": "OPKO Health Europe",
        "verboseLabel": "OPKO Health Europe"
       }
      }
     },
     "localname": "OPKOHealthEuropeMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_OPKOTransactionSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "OPKO Transaction Shares [Member]",
        "label": "OPKO Transaction Shares [Member]",
        "terseLabel": "OPKO Transaction Shares"
       }
      }
     },
     "localname": "OPKOTransactionSharesMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_OperatingLeaseLiabilityInitialRecognitionUponAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease Liability, Initial Recognition Upon Adoption",
        "label": "Operating Lease Liability, Initial Recognition Upon Adoption",
        "terseLabel": "Operating lease liabilities due to adoption of ASU No. 2016-02"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityInitialRecognitionUponAdoption",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_OperatingLeasesMonthlyPaymentsYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Monthly Payments, Year One",
        "label": "Operating Leases, Monthly Payments, Year One",
        "terseLabel": "Lease payments per month in first year"
       }
      }
     },
     "localname": "OperatingLeasesMonthlyPaymentsYearOne",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_OperatingLeasesMonthlyPaymentsYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Monthly Payments, Year Three",
        "label": "Operating Leases, Monthly Payments, Year Three",
        "terseLabel": "Lease payments per month in third year"
       }
      }
     },
     "localname": "OperatingLeasesMonthlyPaymentsYearThree",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_OpkoChileMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Opko Chile.",
        "label": "OPKO Chile [Member]",
        "terseLabel": "OPKO Chile"
       }
      }
     },
     "localname": "OpkoChileMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PatientsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patients [Member]",
        "label": "Patients [Member]",
        "terseLabel": "Patients"
       }
      }
     },
     "localname": "PatientsMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PaymentsForLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For Leases",
        "label": "Payments For Leases",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PaymentsForLeases",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer [Member]",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pharmaceutical [Member]",
        "label": "Pharmaceutical [Member]",
        "terseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PharmsynthezMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pharmsynthez [Member]",
        "label": "Pharmsynthez [Member]",
        "terseLabel": "Pharmsynthez"
       }
      }
     },
     "localname": "PharmsynthezMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PhaseTwoInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase Two Initiation [Member]",
        "label": "Phase Two Initiation [Member]",
        "terseLabel": "Phase Two Initiation"
       }
      }
     },
     "localname": "PhaseTwoInitiationMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PhioPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phio Pharmaceuticals [Member]",
        "label": "Phio Pharmaceuticals [Member]",
        "terseLabel": "Phio Pharmaceuticals"
       }
      }
     },
     "localname": "PhioPharmaceuticalsMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets (Accrued Expenses) [Member]",
        "label": "Prepaid Expenses and Other Current Assets (Accrued Expenses) [Member]",
        "terseLabel": "Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses."
       }
      }
     },
     "localname": "PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ProceedsFromConvertibleDebtConversionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Convertible Debt, Conversion Fee",
        "label": "Proceeds From Convertible Debt, Conversion Fee",
        "terseLabel": "Proceeds one-time nominal fee"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebtConversionFee",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Development And License Agreement, Milestone Payment",
        "label": "Proceeds From Development And License Agreement, Milestone Payment",
        "terseLabel": "Milestone payment from development and license agreement"
       }
      }
     },
     "localname": "ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Development And License Agreement, Upfront Payment",
        "label": "Proceeds From Development And License Agreement, Upfront Payment",
        "terseLabel": "Upfront payment from development and license agreement"
       }
      }
     },
     "localname": "ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_ProductRegistrationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product Registrations [Member]",
        "label": "Product Registrations [Member]",
        "terseLabel": "Product registrations"
       }
      }
     },
     "localname": "ProductRegistrationsMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_RayaldeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rayaldee [Member]",
        "label": "Rayaldee [Member]",
        "terseLabel": "Rayaldee"
       }
      }
     },
     "localname": "RayaldeeMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_RegulatoryAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory And Development [Member]",
        "label": "Regulatory And Development [Member]",
        "terseLabel": "Regulatory and Development"
       }
      }
     },
     "localname": "RegulatoryAndDevelopmentMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_RelatedPartyTransactionFutureContributionTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transaction, Future Contribution, Term",
        "label": "Related Party Transaction, Future Contribution, Term",
        "terseLabel": "Related party future contribution term"
       }
      }
     },
     "localname": "RelatedPartyTransactionFutureContributionTerm",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_RelatedPartyTransactionFutureContributions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transaction, Future Contributions",
        "label": "Related Party Transaction, Future Contributions",
        "terseLabel": "Related party future contribution"
       }
      }
     },
     "localname": "RelatedPartyTransactionFutureContributions",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_RelatedPartyTransactionShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transaction, Shares",
        "label": "Related Party Transaction, Shares",
        "terseLabel": "Shares received upon closing of transaction (in shares)"
       }
      }
     },
     "localname": "RelatedPartyTransactionShares",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_SalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Milestones [Member]",
        "label": "Sales Milestones [Member]",
        "terseLabel": "Sales Milestones"
       }
      }
     },
     "localname": "SalesMilestonesMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SalesReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Returns [Member]",
        "label": "Sales Returns [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SalesRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Revenue [Member]",
        "label": "Sales Revenue [Member]",
        "terseLabel": "Sales Revenue"
       }
      }
     },
     "localname": "SalesRevenueMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SantanderBank2MemberMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Santander Bank2 [Member]",
        "label": "Santander Bank2 [Member] [Member]",
        "terseLabel": "Banco Santander"
       }
      }
     },
     "localname": "SantanderBank2MemberMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SantanderBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "santander Bank.",
        "label": "Santander Bank [Member]",
        "terseLabel": "Santander Bank"
       }
      }
     },
     "localname": "SantanderBankMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Product Sales Allowances And Accruals [Table Text Block]",
        "label": "Schedule Of Product Sales Allowances And Accruals [Table Text Block]",
        "terseLabel": "Schedule of Product Sales Allowances and Accruals"
       }
      }
     },
     "localname": "ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "opk_ScotiabankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Scotiabank [Member]",
        "label": "Scotiabank [Member]",
        "terseLabel": "Scotiabank"
       }
      }
     },
     "localname": "ScotiabankMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SecurityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security.",
        "label": "Security [Member]",
        "terseLabel": "Security Bank"
       }
      }
     },
     "localname": "SecurityMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SeriesAWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series A Warrant [Member]",
        "label": "Series A Warrant [Member]",
        "terseLabel": "Series A Warrant"
       }
      }
     },
     "localname": "SeriesAWarrantMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SeriesBWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series B Warrant [Member]",
        "label": "Series B Warrant [Member]",
        "terseLabel": "Series B Warrant"
       }
      }
     },
     "localname": "SeriesBWarrantMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SeriesCWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series C Warrant [Member]",
        "label": "Series C Warrant [Member]",
        "terseLabel": "Series C Warrant"
       }
      }
     },
     "localname": "SeriesCWarrantMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SerologyAntibodyTestMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Serology Antibody Test",
        "label": "Serology Antibody Test [Member]",
        "terseLabel": "Serology Antibody Test"
       }
      }
     },
     "localname": "SerologyAntibodyTestMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SharesIssuedintheConversionofStockandDebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares Issued in the Conversion of Stock and Debt Instruments [Abstract]",
        "label": "Shares Issued in the Conversion of Stock and Debt Instruments [Abstract]",
        "terseLabel": "Shares issued upon the conversion of:"
       }
      }
     },
     "localname": "SharesIssuedintheConversionofStockandDebtInstrumentsAbstract",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_SharesReceivedAsGift": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares Received As Gift",
        "label": "Shares Received As Gift",
        "terseLabel": "Shares received as a gift (in shares)"
       }
      }
     },
     "localname": "SharesReceivedAsGift",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_SharesReceivedUponClosingofXeneticTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares Received Upon Closing of Xenetic Transaction [Member]",
        "label": "Shares Received Upon Closing of Xenetic Transaction [Member]",
        "terseLabel": "Shares Received Upon Closing of Xenetic Transaction"
       }
      }
     },
     "localname": "SharesReceivedUponClosingofXeneticTransactionMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SharesSurrenderedInLieuOfCashPayment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares surrendered in lieu of cash payment.",
        "label": "Shares Surrendered in Lieu of Cash Payment",
        "verboseLabel": "Shares surrendered in lieu of cash payment (in shares)"
       }
      }
     },
     "localname": "SharesSurrenderedInLieuOfCashPayment",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common stock warrant and common stock options exercised.",
        "label": "Stock Issued During Period, Shares, Stock Options and Warrants Exercised",
        "verboseLabel": "Number of common stock warrant and common stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common stock issued for stock warrant and stock options exercised.",
        "label": "Stock Issued During Period, Shares, Stock Options and Warrants Exercised, Net of Shares Surrendered in Lieu of Cash Payment",
        "terseLabel": "Number of common stock issued for stock warrant and stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_StockOptionandWarrantInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Option and Warrant Investments",
        "label": "Stock Option and Warrant Investments",
        "terseLabel": "Warrants and options"
       }
      }
     },
     "localname": "StockOptionandWarrantInvestments",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_StrategicAlliancesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic Alliances [Text Block]",
        "label": "Strategic Alliances [Text Block]",
        "terseLabel": "STRATEGIC ALLIANCES"
       }
      }
     },
     "localname": "StrategicAlliancesTextBlock",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliances"
     ],
     "xbrltype": "textBlockItemType"
    },
    "opk_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of Significant Accounting Policies [Line Items]",
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of Significant Accounting Policies [Table]",
        "label": "Summary of Significant Accounting Policies [Table]",
        "terseLabel": "Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_TaxesRecoverableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Taxes Recoverable, Current",
        "label": "Taxes Recoverable, Current",
        "terseLabel": "Taxes recoverable"
       }
      }
     },
     "localname": "TaxesRecoverableCurrent",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_TesaroMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tesaro [Member]",
        "label": "Tesaro [Member]",
        "terseLabel": "Tesaro"
       }
      }
     },
     "localname": "TesaroMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_TransferOfIntellectualPropertyAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transfer Of Intellectual Property And Other [Member]",
        "label": "Transfer Of Intellectual Property And Other [Member]",
        "terseLabel": "Transfer of intellectual property and other",
        "verboseLabel": "Revenue from transfer of intellectual property and other"
       }
      }
     },
     "localname": "TransferOfIntellectualPropertyAndOtherMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_VBIVaccinesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VBI Vaccines Inc [Member]",
        "label": "VBI Vaccines Inc [Member]",
        "terseLabel": "VBI Vaccines Inc"
       }
      }
     },
     "localname": "VBIVaccinesIncMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ViforFreseniusMedicalCarePharmaLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vifor Fresenius Medical Care Pharma Ltd [Member]",
        "label": "Vifor Fresenius Medical Care Pharma Ltd [Member]",
        "terseLabel": "VFMCRP"
       }
      }
     },
     "localname": "ViforFreseniusMedicalCarePharmaLtdMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted Average Discount Rate [Abstract]",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted Average Remaining Lease Term [Abstract]",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_XeneticBiosciencesInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xenetic Biosciences, Inc. [Member]",
        "label": "Xenetic Biosciences, Inc. [Member]",
        "terseLabel": "Xenetic Biosciences, Inc.",
        "verboseLabel": "Xenetic"
       }
      }
     },
     "localname": "XeneticBiosciencesInc.Member",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ZebraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zebra [Member]",
        "label": "Zebra [Member]",
        "terseLabel": "Zebra"
       }
      }
     },
     "localname": "ZebraMember",
     "nsuri": "http://www.opko.com/20200630",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r373",
      "r518",
      "r519",
      "r521",
      "r636"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliate"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Dr. Frost"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "terseLabel": "Condensed Financial Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r192",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r218",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r192",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r218",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r68",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r147",
      "r154",
      "r256",
      "r389",
      "r390",
      "r391",
      "r407",
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r147",
      "r154",
      "r256",
      "r389",
      "r390",
      "r391",
      "r407",
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r147",
      "r154",
      "r256",
      "r389",
      "r390",
      "r391",
      "r407",
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r376",
      "r378",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r558",
      "r603",
      "r606"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r376",
      "r378",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r558",
      "r603",
      "r606"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r225",
      "r353",
      "r357",
      "r559",
      "r602",
      "r604"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r225",
      "r353",
      "r357",
      "r559",
      "r602",
      "r604"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r365",
      "r376",
      "r378",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r558",
      "r603",
      "r606"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r365",
      "r376",
      "r378",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r558",
      "r603",
      "r606"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r136",
      "r430"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "terseLabel": "Condensed Financial Statements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r226",
      "r227",
      "r353",
      "r358",
      "r605",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r226",
      "r227",
      "r353",
      "r358",
      "r605",
      "r623",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r407",
      "r408",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r232",
      "r233"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss [Abstract]",
        "verboseLabel": "Accounts receivable, net:"
       }
      }
     },
     "localname": "AccountsReceivableNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r28",
      "r232",
      "r233"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts receivable, net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r48"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued expenses",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued expenses:"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Liabilities",
        "verboseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r48"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r74",
      "r75",
      "r76",
      "r591",
      "r614",
      "r618"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r73",
      "r76",
      "r77",
      "r144",
      "r145",
      "r146",
      "r441",
      "r609",
      "r610"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r72",
      "r76",
      "r77",
      "r441",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r29",
      "r392"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "2025 convertible notes including share lending arrangement"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r379",
      "r381",
      "r394",
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r381",
      "r384",
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r234",
      "r259",
      "r261",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r35",
      "r234",
      "r259"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedLabel": "Less: allowance for credit losses",
        "negatedTerseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r97",
      "r116",
      "r494"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AmortizationOfFinancingCostsAndDiscounts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r92",
      "r116",
      "r496"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AmortizationOfFinancingCostsAndDiscounts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt discount and debt issuance costs",
        "verboseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r116",
      "r496"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "totalLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r116",
      "r286",
      "r295"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive potential shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of real estate property (in square feet)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r116",
      "r299"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges",
        "verboseLabel": "Impairment of assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r128",
      "r200",
      "r213",
      "r220",
      "r250",
      "r435",
      "r443",
      "r482",
      "r575",
      "r589"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Total assets of equity method investees"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r64",
      "r128",
      "r250",
      "r435",
      "r443",
      "r482"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails",
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r456",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails",
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BridgeLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.",
        "label": "Bridge Loan [Member]",
        "terseLabel": "Swingline"
       }
      }
     },
     "localname": "BridgeLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and Improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r375",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r375",
      "r377",
      "r415",
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r115",
      "r428"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r423",
      "r424",
      "r426"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails",
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r423",
      "r425"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r423",
      "r425"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r125",
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r39",
      "r118"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r18",
      "r119",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r110",
      "r118",
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r110",
      "r483"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Non-cash financing:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r127",
      "r128",
      "r159",
      "r160",
      "r161",
      "r163",
      "r165",
      "r172",
      "r173",
      "r174",
      "r250",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r332",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares into which warrants may be converted (in shares)",
        "verboseLabel": "Number of shares into which warrants may be converted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/EarningsLossPerShareNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.opko.com/role/EarningsLossPerShareNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common Stock - $0.01 par value, 1,000,000,000 shares authorized; 670,378,701 and 670,378,701 shares issued at June 30, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r124",
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "verboseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r80",
      "r82",
      "r90",
      "r433",
      "r450",
      "r582",
      "r598"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r89",
      "r99",
      "r581",
      "r597"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "verboseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r182",
      "r183",
      "r229",
      "r480",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r229",
      "r480",
      "r481",
      "r619"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r229",
      "r480",
      "r481",
      "r619"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r177",
      "r587"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risk and allowance for doubtful accounts"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r182",
      "r183",
      "r229",
      "r480",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r182",
      "r183",
      "r229",
      "r480",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r125",
      "r442",
      "r445",
      "r446"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "verboseLabel": "Variable interest entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r333",
      "r334",
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r333",
      "r334",
      "r354"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r333",
      "r334",
      "r354"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Milestone revenue recognized",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Prior period performance obligation revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r21",
      "r576",
      "r588",
      "r621"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Notes"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r222",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r93",
      "r559"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of service revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r180",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "verboseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Converted debt amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Shares issued on converted debt (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r576",
      "r577",
      "r588"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r23",
      "r317",
      "r577",
      "r588"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Equity component of convertible debt"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r51",
      "r323",
      "r324",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days applicable conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "verboseLabel": "Convertible debt, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Number of trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r495",
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Debt face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r50",
      "r320",
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on credit facility",
        "verboseLabel": "Interest rate on notes payable"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Redemption period one"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Redemption period three"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Redemption period two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "verboseLabel": "Equivalent redemption price"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Debt repurchase amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r52",
      "r132",
      "r323",
      "r325",
      "r326",
      "r327",
      "r494",
      "r495",
      "r497",
      "r586"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r494",
      "r497"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount [Abstract]",
        "terseLabel": "Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Instruments [Abstract]",
        "terseLabel": "2025 Senior Notes"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r43",
      "r496"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Issuance Costs, Net [Abstract]",
        "terseLabel": "Debt Issuance Cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r129",
      "r405",
      "r410",
      "r411",
      "r412"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r399",
      "r400"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r116",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r116",
      "r195"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r66",
      "r67",
      "r479"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Forward contracts"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract Type [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r65",
      "r69",
      "r459",
      "r540"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Common stock options/warrants",
        "verboseLabel": "Derivative asset"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "verboseLabel": "Derivative gain (loss)"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r457",
      "r460",
      "r463",
      "r465"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument Risk [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "DERIVATIVE CONTRACTS"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContracts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r454",
      "r457",
      "r463",
      "r465",
      "r466",
      "r468",
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r135",
      "r452",
      "r453",
      "r454",
      "r455",
      "r467"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "verboseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Tecnology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r353",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Income (loss) per share, basic and diluted:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r149",
      "r156",
      "r158",
      "r171",
      "r256",
      "r322",
      "r328",
      "r389",
      "r390",
      "r391",
      "r407",
      "r408",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r1",
      "r128",
      "r250",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r1",
      "r128",
      "r250",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
     "auth_ref": [
      "r1",
      "r128",
      "r250",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage, equity method",
        "verboseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.",
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Market value"
       }
      }
     },
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.",
        "label": "Equity Method Investment, Underlying Equity in Net Assets",
        "terseLabel": "Equity method investment, underlying equity in net assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r242",
      "r600"
     ],
     "calculation": {
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "totalLabel": "Net gains and losses recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r242",
      "r600"
     ],
     "calculation": {
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiRealizedGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized net gains recognized during the period on equity securities still held at the reporting date"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity securities with no readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r474",
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation of the Beginning and Ending Balances of Level 3 Assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r472",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r476",
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r366",
      "r367",
      "r372",
      "r374",
      "r472",
      "r530"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted prices in active markets for identical assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r366",
      "r367",
      "r372",
      "r374",
      "r472",
      "r531"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant other observable inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r472",
      "r532"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r474",
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of the Beginning and Ending Balances of Level 3 Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "verboseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Included in results of operations"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Measurements Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r456",
      "r462",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r501",
      "r505",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Finance lease expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r503",
      "r508"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails": {
       "order": 2.0,
       "parentTag": "opk_PaymentsForLeases",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash out flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r499",
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance leases short-term",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Lease Liability Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "verboseLabel": "Finance leases long-term"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total undiscounted future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "July 1, 2020 through December 31, 2020"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Difference between lease payments and discounted lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r502",
      "r508"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails": {
       "order": 3.0,
       "parentTag": "opk_PaymentsForLeases",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash out flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r511",
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r510",
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r238",
      "r239",
      "r260",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets, estimated useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r287",
      "r290",
      "r294",
      "r297",
      "r560",
      "r561"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r294",
      "r561"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r287",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r294",
      "r560"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Intangible assets, net:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r492"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forward contracts",
        "verboseLabel": "Forward Contracts"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails",
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Fair value changes of derivative instruments, net"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Realized loss on disposal of fixed assets and sales of equity securities"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r95",
      "r116",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Net income (loss) from investment in investees"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiRealizedGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "terseLabel": "Less: Net gains and losses realized during the period on equity securities"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r280",
      "r281",
      "r574"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r283",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GovernmentContractsConcentrationRiskMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City.",
        "label": "Government Contracts Concentration Risk [Member]",
        "terseLabel": "Government Contracts Concentration Risk"
       }
      }
     },
     "localname": "GovernmentContractsConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r454",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r298",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r134",
      "r200",
      "r212",
      "r216",
      "r219",
      "r222"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes and investment losses"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r87",
      "r116",
      "r197",
      "r244",
      "r579",
      "r595"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Losses from investments in investees",
        "verboseLabel": "Loss from investments in investees"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r129",
      "r157",
      "r158",
      "r198",
      "r401",
      "r409",
      "r413",
      "r601"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "opk_IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r125",
      "r397",
      "r398",
      "r402",
      "r403",
      "r404",
      "r406",
      "r624"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "verboseLabel": "Income taxes paid (received), net of refunds"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r289",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net intangible assets other than goodwill"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r289",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r285",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r85",
      "r194",
      "r493",
      "r496",
      "r583"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Inter-segment allocation of interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r108",
      "r112",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r192",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r218",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "verboseLabel": "Intersegment Elimination"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "verboseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r61"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Inventory, net",
        "verboseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Inventories, net:"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r62",
      "r125",
      "r170",
      "r272",
      "r274",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r61",
      "r142",
      "r275"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Less: inventory reserve"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "verboseLabel": "Work in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Provision for inventory obsolescence"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r620",
      "r622"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Investment owned (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r246",
      "r599"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTableTextBlock": {
     "auth_ref": [
      "r240",
      "r243",
      "r251",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment.",
        "label": "Investment [Table Text Block]",
        "verboseLabel": "Accounting Method, Carrying Value and Underlying Equity in Net Assets of Unconsolidated Investments"
       }
      }
     },
     "localname": "InvestmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r240",
      "r243",
      "r251",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]",
        "verboseLabel": "INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "verboseLabel": "Investments, net"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Cash Flows"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lease Liability Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "July 1, 2020 through December 31, 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Difference between lease payments and discounted lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r47",
      "r128",
      "r214",
      "r250",
      "r436",
      "r443",
      "r444",
      "r482"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "negatedLabel": "Total (liabilities) of equity method investees",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r128",
      "r250",
      "r482",
      "r578",
      "r593"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r49",
      "r128",
      "r250",
      "r436",
      "r443",
      "r444",
      "r482"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r23",
      "r24",
      "r128",
      "r250",
      "r436",
      "r443",
      "r444",
      "r482"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r23",
      "r577",
      "r588"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Balance Outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r45",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "verboseLabel": "Interest\u00a0rate\u00a0on borrowings at June 30, 2020"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit\u00a0line capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r45",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r21",
      "r576"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current",
        "terseLabel": "Current portion of lines of credit and notes payable"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement amount"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r23",
      "r318",
      "r577",
      "r590"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Remaining principal",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-term Debt, Unclassified [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-term Debt, by Current and Noncurrent [Abstract]",
        "verboseLabel": "Mortgage notes and other debt payables"
       }
      }
     },
     "localname": "LongTermDebtByCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Mortgages and other debts payable"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "verboseLabel": "Variable interest rates"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "totalLabel": "Total carrying value of investments",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r52",
      "r311",
      "r312"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "terseLabel": "Long-term line of credit, noncurrent",
        "verboseLabel": "Line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r52",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery, Medical and Other Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r110",
      "r114",
      "r117"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r78",
      "r81",
      "r88",
      "r117",
      "r128",
      "r148",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r162",
      "r200",
      "r212",
      "r216",
      "r219",
      "r222",
      "r250",
      "r482",
      "r580",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Covenants not to compete"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other income and (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r200",
      "r212",
      "r216",
      "r219",
      "r222"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating loss",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r506",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current maturities of operating leases",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r504",
      "r508"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails": {
       "order": 1.0,
       "parentTag": "opk_PaymentsForLeases",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash out flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r511",
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r510",
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "BUSINESS AND ORGANIZATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r48"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r76",
      "r84",
      "r484",
      "r486",
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Change in foreign currency translation and other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r79",
      "r82",
      "r433",
      "r434",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Supplies, Gross",
        "terseLabel": "Consumable supplies"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations and noncurrent portion of deferred revenue not separately disclosed in the balance sheet.  Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months.",
        "label": "Other Liabilities and Deferred Revenue, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesAndDeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other long-term liabilities",
        "verboseLabel": "Other long-term liabilities, principally contract liabilities, contingent consideration and line of credit"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Liabilities, Noncurrent [Abstract]",
        "verboseLabel": "Other long-term liabilities:"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income and (expense), net:"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "verboseLabel": "Non-cash interest"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Investments in investees"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r37",
      "r38"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Other current assets and prepaid expenses",
        "verboseLabel": "Other current assets and prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Other current assets and prepaid expenses:"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r6",
      "r9",
      "r277",
      "r279"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "verboseLabel": "Issuance of convertible notes, including to related parties"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "verboseLabel": "Proceeds from the exercise of Common Stock options and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "License revenue, initial payment"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r105",
      "r133"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "verboseLabel": "Borrowings on lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property, plant and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "verboseLabel": "Products"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r78",
      "r81",
      "r109",
      "r128",
      "r148",
      "r157",
      "r158",
      "r200",
      "r212",
      "r216",
      "r219",
      "r222",
      "r250",
      "r433",
      "r438",
      "r439",
      "r449",
      "r450",
      "r482",
      "r584"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Net losses of equity method investees",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net Income (loss)",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r19",
      "r20",
      "r302",
      "r594"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r41",
      "r125",
      "r302",
      "r625",
      "r626"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r19",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r91",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision related to current period sales"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Inventory received but not invoiced"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r36",
      "r125",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "verboseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net [Rollforward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r373",
      "r518",
      "r519"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r518",
      "r521"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related party transaction amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r373",
      "r518",
      "r519",
      "r521"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Reimbursement paid to related party for travel"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r373",
      "r518",
      "r521",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r516",
      "r517",
      "r519",
      "r522",
      "r523"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r106",
      "r133"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Repayments of lines of credit",
        "terseLabel": "Repayments of lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedTerseLabel": "Redemption of 2033 Senior Notes"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r396",
      "r637"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r125",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r328",
      "r392",
      "r592",
      "r613",
      "r618"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r149",
      "r156",
      "r158",
      "r256",
      "r389",
      "r390",
      "r391",
      "r407",
      "r408",
      "r609",
      "r611"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r191",
      "r192",
      "r211",
      "r217",
      "r218",
      "r225",
      "r226",
      "r229",
      "r352",
      "r353",
      "r559"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/SubsequentEventsDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r126",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition and shipping and handling costs"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r356",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r86",
      "r128",
      "r191",
      "r192",
      "r211",
      "r217",
      "r218",
      "r225",
      "r226",
      "r229",
      "r250",
      "r482",
      "r584"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "verboseLabel": "Inter-segment sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r509",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets due to adoption of ASU No. 2016-02"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r76",
      "r489",
      "r490"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Changes in Accumulated Other Comprehensive Loss, Net of Tax"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r52",
      "r132",
      "r323",
      "r325",
      "r326",
      "r327",
      "r494",
      "r495",
      "r497",
      "r586"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r457",
      "r463",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Derivative Instrument Losses and Gains Recorded"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Fair Values and Presentation of Derivative Financial Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r1",
      "r128",
      "r248",
      "r250",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r471",
      "r472"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r283",
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r283",
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Changes in Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r45",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "verboseLabel": "Summary of Lines of Credit"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r130",
      "r520",
      "r521"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r200",
      "r203",
      "r215",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r200",
      "r203",
      "r215",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Operations and Assets for Operating Segments and Geographic Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r187",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r229",
      "r602"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segment [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r187",
      "r189",
      "r190",
      "r200",
      "r204",
      "r216",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r228",
      "r229",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "SEGMENTS"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Segment reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Equity-based compensation \u2013 employees and non-employees"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance, shares (in shares)",
        "periodStartLabel": "Beginning balance, shares (in shares)",
        "terseLabel": "Issuance of shares (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r187",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r229",
      "r283",
      "r303",
      "r305",
      "r306",
      "r602"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r127",
      "r128",
      "r159",
      "r160",
      "r161",
      "r163",
      "r165",
      "r172",
      "r173",
      "r174",
      "r250",
      "r322",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r56",
      "r144",
      "r145",
      "r146",
      "r149",
      "r156",
      "r158",
      "r171",
      "r256",
      "r322",
      "r328",
      "r389",
      "r390",
      "r391",
      "r407",
      "r408",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r171",
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r55",
      "r322",
      "r323",
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "2025 convertible notes including share lending arrangement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r322",
      "r328",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercise of Common Stock options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r56",
      "r322",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of Common Stock options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "verboseLabel": "Common Stock options/warrants"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r32",
      "r33",
      "r128",
      "r236",
      "r250",
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "terseLabel": "Net assets"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r128",
      "r144",
      "r145",
      "r146",
      "r149",
      "r156",
      "r250",
      "r256",
      "r328",
      "r389",
      "r390",
      "r391",
      "r407",
      "r408",
      "r431",
      "r432",
      "r448",
      "r482",
      "r484",
      "r485",
      "r490",
      "r610",
      "r611"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r491",
      "r525"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r524",
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "verboseLabel": "COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Supplies": {
     "auth_ref": [
      "r7",
      "r9",
      "r278",
      "r279"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Supplies",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "Supplies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technologies"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade names"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r238",
      "r239",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r54",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "verboseLabel": "Treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r54",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "verboseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r54",
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury Stock - 549,907 shares at June 30, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Net Gains and Losses on Equity Securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r175",
      "r176",
      "r178",
      "r179",
      "r184",
      "r185",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Stock ownership percentage"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r507",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares outstanding, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "http://asc.fasb.org/topic&trid=75115024"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "http://asc.fasb.org/topic&trid=2197064"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759068-111685"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r638": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r639": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r641": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r642": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r643": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(7)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0000944809-20-000033-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000944809-20-000033-xbrl.zip
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M$ZD[DH=6 P]SS(Y#JX'_GCY-H6U :!OPGQ^9WK0-X/%4BCMJ5,]!'*G2>!F
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M"2R9_?KVM(?\-)0.]Y>?JME,Z!AT>[BK503O!B"0IHQCK:LL0)>NSS<<[X3
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M43P>'AX,C]H_F3[ZTIZ$TKL>LTT3IPHSQQK0-RQ4,K>4C3X? B,-$+MM/$G
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MBVFHG8<S_(4QE$E:]^N@S'*=-!)%T1-PAW54/,O$%U'5U;T3"66WV\QS=DX
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MFW/60!H+=CK10F#0KU74[]S2AWORV4@4<R$R1C,<N*(Z-5XIO=ZK:DN;BT"
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MOAKO>_@)!+"G:1*4O?C"O6?)/J#"HR"8>$R?\CC<B( MODA3N"2H<8G=C!L
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M8#:=5T#5"!Z&6<5U\2KJI-L4SJ_JJI7^N55I?##%- !X/12 U^'6E0P 7@'
M*P!X!0"O[ZC&AAJY_JJQK]^<MXK.+4M:%80IW2EXUZK$?FOM<*NFL9/6ZZKV
MQERF6'R")7[5-'-0!JG"+BEMJT(LO>&)^+T$?9(9$6OA2^9%EJB)R%1I5NH
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M;2B36,P%_%>K&5EREANJ\1A+FKDKE'CR N8PVJ.1,U78T:<B37!0> % 9KJ
M-;M3GT42L1*^@&?&@H]2@<^0V1UMB=$"Z$A$+$V%: @+JHNZ#OHU<$Z=(1?&
M=IEE,548QL1+T=TD:$$^E5H:8*U(6^26I!H4EKG,8,D$3_W3_6=7%2VMI5O
M'L)XJIK#][1"=)&=+)K @[B>L/B2@WV+K\W./>99+-(4)XM#)IK/@10^@OM4
MAM\FTM!;LO?P9"8+#,':?&R_'$1;<ZF**1R+">X^VB:-872U1'-IQ$J,%TO5
M_;NN]U&VM',<O*C;OQYBM/$Z)YIG1;U$]1ZY;VLP,\60M!W$AY,3W-2<-;B
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MFBV?\10^<HT]AW11%PC9: 0G2;[HG/E5,PRBOU4D?\7V<HBESFI&-<@Z(\E
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MX"-U:1P-G[1_+J[VH:J)PDHJ.KOV8%6;VM99X>G>O#.-<H'=Y<0DH3']FV5
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M>@RSC8D[6?QH/[-+D,\=_P2/A8B/?R:6M-6;<"BNB4S7&! 7* %!1G,JIR/
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MACD5^A2[+0$>LOVH-Z+EK2"^#9VL%=*NI,SQCN5>%<6I3!]9AFF/?_F/2@V
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M2I5/;T.<AV\@HN!^VOZC%PCCWP-R^N7TR^F7TS_9TR]Q09$.$A<<E?20N*#
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M1D*(=276U3VRKJ:G'HZ3"V(=G*EU<++7+^;#";F;A ;@;C0 3P>APD(#(#0
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M'%GXW_Y8\9F]UDE$A_=>:S^-A6Z_2H[3J!C^7L#Y5/"RX:TO=I8@PY]TGP%
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M AFY4#UIJLVN>9+")\UZ@JS=T2VUB!A[ 'Q58*-SY,7\J(1FDRYV#X49.IQ
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MXD4\84CDQ>J%MV>]@I>;3:G7,^-XK Z)C9'$]3P@C]5<VED;D\A7,?YQ.R8
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M0!)"<W;)?6JQCD2,!NMWQQD4)_Z+YL!SI 'DI*8G5?9J+F/B-4!T=P31_2E
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MHV21H*?C-X @;7;G(IF^(>5MP82ED\;C*N2VUQ)F\BV-$YQ@C_&T@W2>">W
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M:59@6>LZ=HP<SU2E-EZF#R.;7D7"U+UI=I/E\)\JPVX36#!OU;^+RH''*\8
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M&!Q3!FA$/]'.:)O%U6&"N$MA[$U%EW.4&LXC;'F->;/0>5#_TRJ;8E<BQF7
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MS--L12I'0D6S*IF3J< %8@1)(V4&PS ^-7H":VU#8]D#>[X#;06<F)\C3AA
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M?T7OWEZ<7[ZX/(?O_P5CQ7$A_ 0F03B5L\M7%\_'!4: OMT/^O9+@+X%Z%N
MOATR],VUD9X<<U#AUV T[70]X22]HG.$_[A\34?SL9GBOX8"CUWO*G#P]FJ<
MXT:X^,8#7  3]&$/B!_B4!9=LT)(JA!)08@)O.CPCE#?!(PV4&\L9OJ:8>B3
MB4H$O(A=1S)&*%R5:\(,$AR)NF@1Q@D;]4DN)RO PC?@YP1Y0.99$[V[1H
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M?RE2F[L@9P,GQHA?Q..$T<V#[NIZK(L&7''V"K;9I_V[.)K+F41"OQQI:T4
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ML17NLPYG* #ET"PF;A:S)%7ZIQQU.!-F2B;$N>M"V<$URSA\C*;$$*DVNLX
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MR :B&-Y9>7CZ*#JX4ZK?]I:Q @HY6.'<KA 5K!W<V6['$T'YO%2%R>L2V,+
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MCN6<DR6XQ/L*"*ZL=+E[R:J:0XE1P;G.X&>?:&(,<N7E6%PSE_@#^EM[BV'
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M:#FD0A^A7'^$\J^C/+FF_YE6L_3__B]02P,$%     @ DD;_4*#A;3#]:@,
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M$$;G[9FOSP"^OKSANRX.\[KCIYE_MT3\T,I<I^)GK,SU0[^E?)A.3DQ+ZUW
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M=02T+KJ&/]0:O*)X&>)>TF!KPX?5XL,-'?(!(SZE0SXX]%NZ\'G;NJ)H#>P
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M_%4ZV/.>WTR$BJE[5]F[1# &>YDUPC9X?. ?1UU18UU878SAT[]5W1(2&&S
M"+5$;<QB27VKKLQZ\LFLK"QEH/10+0&E2MKZ;*)QU%-N&%9"64HEL8I;"BF%
M6EGE,5^F,N))6U<^(.>I0RZ02*MT4!_+-79*TK@W$F?:^V6H_IBT]=G$Y!AA
M 5DUM-!#*H+UA]AB2'/$A63:VL1;'Z*M3UTDM5:*O*"42,$\A8IS*W.*.5:2
MT)P8[ VA5%.7*&U2Y*5@NUXKY&(F#]:$6H]D7)EE,5=8"(F<3&PW*?)2$&$<
M"\3E!%D6UX-ZK@/'\-!PGT-O/%JQF>FDR"O+D9VQVML P9@(ZHA5&.5<(4BX
M5XCFR[!?2MU2+)ZU%B]JS9#F5,C<<@JI84)1@GA.%1.6&**781H]:7&-M'@Q
M[!CAW,3D=D$<I;FB4BDNL2 X5GL44J\6.TY:O)K4.)>$66$LM]A0)9U&$%H!
M'<;,:Z[1:E'CI,6KR8OS7.=<Y QYKB@65"E,(&,&*D:=</D2\.+Y9+#408V7
MDJ,*Q9U63.:8&II[%3BJD)Q9R:WS J$EX*A)HVK%%YV64IJ<L%AG'CNO%<&0
M8(*$=[F&; GX8M*H6G&WH#N2"HH]L<'DD5P'XI9K9VG@< KC95D?GC2J-CQ*
M6BM]CJQP@3AY3315/.B6B;/QQ+$56\.]\H4 %D2=)./,62S"7PH9E"HG7DEJ
MI3+<>K@$U"DIT:+9$O(!<[37'FI&9;!MS#&3&ZD"0#'&^!*PI:1$BR9(C'#%
M(%$YTIY"340P;-AZF0?LT5:1)2!(28D6S8F<SXV23A*H$<4<*68APMPBPJ0Q
M#JX6)WKD"&G--&@QA(CRW'+I$9.!4#LFE=,**R>08#J@$ULM0K3:&K2@%<0,
MD9QSY 6FE#HKE'7,!BP2!G-)5FS=R6IKT(+F^832E!'/K184Q0UXA<IASJR6
MPA)J5HL*K;8&+88'*6-\^,\Q3!WE&DIO#=$ZQY$(Y;E; AY4RU7BB^$D.52,
M**3B2*<Z1U)  N,"A>!C"RG,$G"26DIS0=&2G%/(%,%<&TI4D"W34ANA#+)"
M^V6H$E=+:2[&5FLOG&<40<Q<8'M.&"^XX,XZS%"N\B6PU;64YH+V5F'46*X(
M=5!1CJF"W%AI:/Q%2K0LM<8N6=<;USONJ]-6##)5 C5QQYS^^8N/^ZME(Y$+
MEC#NA<.%IX('$XFP4-+GP1MSABS+W@8+E=QB["$/Q#0(#L,\-Q0%0\B#" TR
MCEHAG8%+8@\7/N:>WO8%(JJ(H-1  ZF$2AMM(.<JMQ93:Y:EZ-7"Q]P"ZDZQ
M0#Z]EXKEFN(\4!:,#(U1SA@_-RMDYW:V5\O.<<>%TR['TI'@V2OE;!"<A#((
MCS'+5\?.S4]R"\HI#,Y[W+Z&!U>/:J>UA-9[[;"C*/!-MSIV;KYC;@$^GC%&
M!OOF$4*42R(X)8X1;*G W&BV.G9NOF-N 6L-(,XQDG%Q#*2,0D$)-TAKI+%G
MBJV0G7OU=K7L'!0Y\LSD3FA)/<L%\C#X<Q$@#3=N&6H-+EQR"]H% U(.O5,2
M8D$QYMHZ*J74,K?068%6Q\[-=\PM8 \SJY BV#N,.*5(RIQJZ0/%](K$1;.K
M8^?F.^86L4>"PI)C[GV.J0K44EEJG)/2YT(**U?'SFVO6-Q2!O8O?/ %B+64
MB5QS:KQR 3F##!U<H;CE_"2WH(I;<9=':I#WD-&<Y](:@Y4VR@MLV64-Q!6P
M<_,=<T]OYR2B2J) 1PS'%!&HJ58J-X%J4@LQLJMCY^8[YA9@Y[A2*-?!&T>:
M8H1UD$U<LD(TDTP)M3IV;F?%_#FD/))!6$XY0V5@*SG47#A&PLA#G"U#7NW"
M);<8.P>Y8D(A;;T)=LXSR9'-L?<$6ZLQ799\E86/N:>W<]PBKC UH2=U\ JX
MY#1P$^*ARXTB?!GJQ2Q<<HNQ<XAYY%7.H%<1$H6B'@D&+8\[-@N]#/6U[RBY
MW?];+3NGE13,*1QS^ZBP)CCC"KLP!J$E%,-\=>S<_"2WH/DYZ3F2!%$K,0W_
M2ILK":W+/7'1,U\=.S??,;>0^3FL;#!QN4$4,R%-N=A&0$4DR2E?'3LWWS&W
M@/DY'3D*(T[EDG*2ZUR*(!\JA0[6#B[+.H4?2"ZN<"E+D+PJ15BXE5PUF5L5
M7'!+E2>6.B\U$2R"9_#)<QQLX?);O:>6XV)L(($2,<8(,>7<G1-8"R@LLB;G
M+J=D^6W@(L;C F;RE-3&8L)SZ&B@-2)X[D1@F?,P.J%:@9F\18S'!=1X,EY#
M(QW&QE*?.\U5<"2H,DYPS 7[O%/78?C<:V$4W: AX=SOA_7DR$,".@HQSVUN
MH".462V"HX*8*+?&H,[2J Y((DQ04H>ZJD- !X0!08^@#@098@BT%A)*"==:
MY%PZF)O<6N>-7 ET6+WEX7.!!N*XQ5(S[C"A1$,5L,$&>Y]3JYG)V4I PRKK
MPB/B0NYB/H)53$M#*8SU( -;B#O?&J2P@_7%A=HL19W+&(TU&9B73,5=!JU7
MDDD9-WTERB,NH*WO&*VA7!YQO#"HD4'"!/S$H<>TLL:$3TKES"BBER63Y\=;
MX(Y_? S<?%L,B^-2#5ZIP4PMWDWZGX'I]7_VC*7TJ!FWQ#I!;$RMU$I&_]HK
MJJD,+)P@L221RF>D(W..@OY1?'O1=X/>J&_<H/K:<LJ6C;?%UXU_AC_CA'C)
MI:9,*R@ES9U4D!A',0IN&_1,D\\1[J?7#(;G[: 3G:(+6JXX;@U?4+R>L]/A
MR[/"#ELO$(3_W\NUJ^>J_G$X?=@[?4'">>.ONC<<]CKE+^'TP:GJ3LX/1.#+
M<;\WZEI@>NU>_T7_6/^&&6M,_I_!=?C[R^K8/Z(6>O_2AS<'7G6*]OF+_W<0
MI#W(FNXL^]#KJ.[_:PQ4=P &H:_&)PZ*"_="A$>7W\ZJ%PDO_+(=N-WDQ1 .
MKQ*[$UAGHNT(ZO(B"\UR_7A:;+9:NC9GK;[S_UK[Q\_EGJ]M'"C==EG/9Z^B
M7@6*^<\_5%"&**P;=*)\K&H7Q]T7)ISL^B]G),^_DSRO)#\LGS'IQEX_M#1V
M85N=#MR+R8>7MAB<MM5YL*/EVY87O?SJ^J47/GYH^?SJYF-EE')=,%+JXS!H
M_M!.GC/6U?5*5_\8VN\/2K$.X0^.7[GXC_+VU2-"FV,'_6N-K$VN& LGZOH=
M%66F+]O.#Z^_ZO@MQ]T5^Q>=#K.2 &6E=@6U&!\<]_;WQT^5M<%[ /'^\?#E
M#_U*DRKQ3%_OC[+3)W*_G_0?992'-C]@Q* [#9FUC8_-G8/MK6S_8/,@YJ7>
M6<=K_EK[VZ\^?M@YV-G>SS:;6]GV_[WZ]V;SS7;V:F]W=V=_?V>ON03OBN_V
MKI\V]_^]TWQSL-=L9%NO,@P9E0]#*_8=6K%'1ZO>Z<1DLM!-<'S_FV%J9BQ^
M=Y2*RZMO ZKK0WEA2#4G,+JK6&7]8>CUWH?=[)^!KG5[W>:H$^YBLC&K^Q -
M=V&ADDXX:7/DJ4!8.Z:$@P(K*;3S_B9W,.NJ2.2M*UYL]<PHDM:#\U.W-BZW
M0?X^UUN]KV_QAZ^'9'=D3[:_'KV1)WN=;=8\:1?-K;^+PX--MG?PGAP=M%N[
M6\V3HX/WY[N?PME;?W::GW8NWI)F^_#BM+5W<,@.3]ZCP\[VV=[!%]C$'UFX
M]N(0?X2[)Z\[S8O-LZ.3OXM=)+Z]Q4?GAY\,/SPX_G9XL?-M]],VVSTX9LTW
MN^=';W9(\^(+/#PX/-]]LPV;%[MG1UOFJWWS-[7__JM]A-M?]4EXWM;KD]V3
M[6^'!U^^[6V%\R_^^G)X8LC>P8=6\V3G[#"T>??BSR_-\+R]+?/M<RZID<1H
M  5!@&ID@<2<@IR3N"F]X$P%XH,@>%^2YJD4-K($)<\#2A8$$/!N /';KNI_
MR?:Z[O=;]7%1VO<K=)N$2_D=V?;]>#Q>1Y0^#H^?:%+L67SZ[5*SQET;?WH<
M58]]>C<]GE75'S F>ETI-_N%:F<?NX7I69?M[E_1RJO*?,=7"HUY;+/E>_V.
M&H:K0V<-G D(T&MKU6[WAKKW[2:K]GZD^@%_V^<?W&FO/UQ* _>ZT&\^\F;G
M=;&[94^.WOQ5'%X<7C2W_ORR]VD'A98%H]<\"<\EAP<?V='!]OB:O\.S6/?H
MH(<//^V<-7'SRV'GKY/FR2[<??,^M/DC;G:VZ2[>#>]H6\V#=GOW;W'V]F!S
MN+L/OX5_/W.,L?+> Z/S'%!,@FW4S@%.)0DVTA"MW-K&__Y#YI2_O&X>+]%H
M/,A6:OCD]\'T!XZ>]Q\W/QQL?WA[F'W8?K?WX2![]_'#_L?-YD%VL)<%-^X@
M^&H9(MG>APRQW^SOV=[K[.#?V]F,AW?IW6V^.HB'D23TBEQ^@3O/*70W7V/Y
MNM?/ABV7_7>""UD5,,U<USK[^#Q[!K!>V#AA'.[8LNK\W*F^Z]Z$6._*]FQ7
M8=VEQ*N'$_+=B_>?(0^B0M@!;!4#5'@*!*0*6.VQ],0JI_S:QE^CKLL(;&2Q
MJZ\CS_K#B/E2*O3>A\3Z$NM+K.]J+"/NLEK$J8ZEIWV[;P+%ZWPD@:;1W9._
M0AMMZVCK^.+HX",);6[OQO-/CD/[/EZG?6>1XAT=F$ 6C\]W.SNAC:^_!*K8
M;AX8O/?IXT6 W<[>ECEK7J-]VGLN _<#4@@.*,D]4$0Z8!5%CB)BO-5CVD<3
M[7MLVG?P8;.YOU.2N\3['IOW#2^184+\?+_7N8SDU?<5?CCM_+__0!R^?/J_
M]>^VM8ULV$OB75WQ/B>N_ZK7Z12#F+24^2+0]NZH3&6:X^30=IG ]#H\K%D^
M:RF)U"]-$)U_)F4I$N2 =Y0":A$$2BL'!,MC<2</.78Q]PT!0A@6:9;HF<X2
MW3GK:4$H@^G=4&;N</+!'1>#2,2&S7#D^4'*Q6>*)<E1 !*O9'"P--9 :&N
M=MABKPGEV*]M[+W[SU[V;Z?:PU8CV^F:]5^!EIJ;MM^VORDSS*)"Q/3"J8ID
M:I#MGSH3DXAM5G2SG>$@>]4JH[>W3W@F:'U^T/JD8F4(K;,'BQ434:5(WTVL
M][SYO51FK@U?1!QUK!B/'0FZ"<?F'0F:>R!U$-<PGO9[7Z.)OCH=59GJ8'7&
MRZ2"TU&N>*SJ%YR_ZMGEM-R3J&JS?=3Y*[1KAS;#\YIOWG_;?;.#P_EG1P>M
MUF'GZ&3OTX>3YIO#[Z.J^._.8>>OUN[),6YN?81'6]MGAR='P=+_V=X+YQYU
M=MG1FUUXU+X:5<4*4N0,!XXC#^(Z5R LYP!K)+UWA'$EUC:V7%N=J;Y[0%CU
M43']'IB=!G<M!O?UL7N@ONV,EU^9<OPNL0O_U*-VYW+4&FV8,M8!RFP8M8([
M((DRP# $H;!>$L;6-G(&,(7A/_G#<5L?>WBO47[SJ+DI?WG>@^:WT@9EO7Y6
M%M/)_AKUBX$M3!G0[_E_ZOX?&U=L5GEJ_UAUBXOR^^\)1U=/*7;6/ZSOKV?;
MG=-V[]SU*RVX GU9L[?^^V--@#VIHX'QE'$_P'^$<([. )Z?$W//AM\(K'(1
M8ZA36!OD^2MC2*XB&]FTMN\&@_$_;X/FHV5F(B<[Y/!@F^X=A'MM';+0QG8S
M7'-TTNKL??K[9/?->[K[9I<V#[[+RCC?/;&M\CDQ*?<DM/'31WAX8CM[;P[9
MT:?XG..SPXMC=#TK@UB,<L-,\!]L#JAS&&@(+7!>,\]SB)C":QNQ@$KV9S$P
MZKSKLC_;7^UW8<,[F, )1H6KW$_LTXVG+H+HE"-K#B9ME8?CJ_!QKQ_H<3<-
MQI\-QF^S@]%!*T3PV %1"@&JI 6*AQ&I&,*"$BDH@VL;NT50D;HD2,V-\ZWR
M "G]C;W^NW[O:]$U2QWR>K)1LGTY2E">"Z:%!LAS%M=6A@%BL E_J%.YPH(3
MN;;Q^FU=AL@O^W'/;X"\ZPV&JGU4G"Y[1/C)AL?.+*,+S$U@D'M" !7, 4%P
MD"S/O<($Y4+D:QN$()+?/ZRT$.]G20?+;V-ECE//[_H!Z(M3U<ZVOSDS&A9?
M7;;G?6'<X/?LMZ#H6=3TN\21YDRBYS6;^\L1J]2PG\QOU\$Q2G&*ZV8M^D*;
M?:>2(;N+(8-7O*%<24(T!!I;#BCT#"BB"' .,2R-H+EC 64)9+]?-V17,XV_
M&[S\Z0E?&AG71\;;7NB==ZU@FY9_"O')1L?4"PIN#J-&:N"YLH R+X V3 (3
M/DFBD>92K6VP/'A("'ZWF/6A1".1PE\EA=,DQ/_]A\ H?SG(#ES;G<:!D%4C
MH<S+;(_B:V31=JPZ-WS$3+_4\-KF5IZ,!L/"GU\OE'9USA,M,)7]NX0=>DNM
MP^# ]8MA$6[9+P>SZSN;G8[Z@U%,+1[VLG!&.3^,\&_Z]^C^Q46"FV;XXF&I
MQ8@NS4)[M(X)F\=*^W!G(O#<[DR6; W_(UB_&]5][LN0BV%5ZM<IT\I,6PT&
M*Q:674RW]E7)%O;/.[K73CWZZSTZ63-2ZJG[9EJJ>QQ^Z&9GK2+\,@7^A:?B
MK5*OS]'='%OM\W!A"4)+[&[NA6<'5_/D:.LC;9[\V6IN;0;WLU6$Z\)Y.^=[
M!\TO1P<?OAQM[5YW-]G1B0FN9O-+\^ 8QWOO;MG6WINXLNS/+\&-9;OX0W!=
M/WPIVSB;)\*E(1Q[@"G%@$JM@108 N^E1T8C[G-4K24.8V1_V#-?&MFIZF=?
M57ODLO\)\D6Q-D(V:#TL#3T-G<4-G;%UJ8Q+&C=W&#?3,(U"FHG0[<"J.!N7
M&PZT\! H!:W4$&.4BW)19AH32S FKB]UBL3@^U5.$U.S/:8-2[L@^:F'S702
M6ZM<&\]S@'/A .6Q7E\8+L#F5AD,$3,\#R1M<W]K\WWVIMW3JAV\[G;PN[-8
MN-@-?SZU_0LQB[&6;Y0YX7?QZ7]\G[H&.G:Z-F:ZNTR?9Z;ES)>L$XM"G[5<
MN4PB!C7ZE]',%]EOZ/=JWJ6E!F4I$9NI=CN<$HNEQ5C)?T=%C)0,>YEVXQ/"
MG<?!DNI21.+:BJH U3AN,A-NF0RH&$N)AV,!JLR&H\'UB:>>]IUQI2.$<'6_
MLC+F(/LMW#2,W6PP"MQ]T.K%==Z34DW#EAI>>Y?L3%UM;UD8I;QX_#:_-S+5
MM=EO>.:5=8"!<)(^B5H8+BK/#U?&]HQO5FZ@6+:D;*X:##,)JSM8=3Y8?]J:
M.9]"RV)O#7Y13_[W'YB1>M7UN;6E,WTZ[URF5Z-^/\B[*A88^=-0#4>#I30$
MOU29 G[.M>6Y81IPJ""@*N"Z$)H!Z#T,DC(,$;6V<>@&-\_C+M]X0%PLW7AH
M[B5+5J%_!/. XYUB. SP7[**?J\;^7#[/'.!&Y]G.S%&KTR9Q[6EABJ+U:RN
MF[CI/68G!SZ,PID4LG%%DE&[6DNV#PYN,V79(UFQJCV7=LD-?D\&9Y4,SHQ2
M1IT<VY]G9W .V6>,);($,A!ZCP+J/ ?"Y@8PZ7*H'!><\61PDL&IB<$I!IG*
MVN$%7::,"08G[B!M2XSN1T?CQE^SH+;@A@.#3K!3X1G]">\,2-,)777>B*Y5
MN%GP0F)7'F>AP\Z&K<GA]>!IN;)EUOFB6Y:S+7.78YX*#F]Y2_O*P^CEY+2?
MGG![^R8G1L]J?/(M;1V?>:O^G/:J<KPO^BZ:UZ]N=MO8:QO*KMU\I=*#7GLT
M="_'T31X^\ZS-]9%2QN.+O&&H]7?5G\::3UV0/>=^@*4#P)^H=IGP5]?^R/M
M5IQV*TZ[%2?P^/ENQ1,>4W/B4G1+!W4<C<4:X$D<=C;X>GLBV\(J8I:E/>##
MU!J)=8+1/)++J%PG:"X)<1BOT_G<&:U+*E,^W(K,4):1@9*(1W_DN-<_OZDD
M8PQ?]5^-3UC*B,%X/\.#PV^'!^;;WIOW>/=BY[RY]>7BL!/W*=P-]S#D$+]N
M-=]LG^]]^FXE!FJ>A&,7V_1HZ_!B]V0'[ATTB\.337)X\>5;\\*>''[:#L_=
M84?72ZAPY:B'!BBA8VH,M2"P!P(T1\AQY8U'<&WC[<WNT[.?]K\Y!O+ X?3M
MV77?'#!I<ZJC%0T8*^HSZ]EY;&)VN;M5RAE]O$S=F\)@STY;'Q5&JWAR]NPZ
M<0[:N5]%.RL@O0QY5E_'P<QGU\VKM3UD1:!+.?\Y&@17=;"<.1Y/2J #<=Z=
M%G1BF@M)%5 $.4 ]=D K'/="PEXBB02D_FX[0_[$EM:K<$B]6K-:$#,')-^^
M>2HJH?<*H/=$MF]*T;ZJ))M0_&<H?CZ+XH)8B0GG %G& #48 TV$!D1I1;#U
MAL8PR)U1_-?3L^L:8M_Q/YB%;V3%S:D#A;\I3:U,3@M.3[=7YI:-!M4,?N@B
MU[4QZ^O[G6E[_?)9[?/X\+,B/#H\-NN&E^O%2?FOQ:!THKJJ:^) #ZY5W)PE
MGCP8JJY5?3O(XNXNA;UMU3OY3?U^TZS!>I;-:=/4^232K*#JW3\M9=!R[?9$
M.[/?@LZ5Z2'5MFEWF"KZ_<5395/]T##=OZ\6;9/V8\<OLRGZI:3QL\]"0B^E
MPH#CH%M4*PH$$AX0PYW 6'E/S$_M29T'X^R(.-S>7];4PV5,Q;U;ZN'W"1O/
M:/'79IG[]]>H?5YU&8:-+&)9XWL:8B>;1;\NLX\#!1AUBPHIR^7>@[6KZ&DH
M,P$L%82YIY8(Y2!A1'BE,61(D,\[)6CF.("F=:;HJ/;@7VL[S==7,/1%=]2Q
MO>'XA!N6WY1KT<NEZ/ME*_9&PY+!!*T/KEGPFL+I\-DAZ^[Y9\&9YP%0@>)"
M JJP 9(I!7+)C,@Y1)3JM0W.94,0U("83M!U(M^-:AG_H,J"FB[YSWK3+KY]
M"_64G)GRJWX].3.*N!RZ=\G9FV-"YV+2-*^7+KP1Q&N6IOG+;7[L-,WEW^#Z
M8///M]O9WNOLU5[S8+MYL+\$>U?_"CXBN)Z3?"Y);WB=T[FD '*\+OC#<_%^
M<)"MY_RN)?$64;CUET/4"X/7GX\_6#]\_?5&WQU@$5G;>+?YX2#;6<]>[S0W
MFZ]V-M]F@:+O?=C=/-C9:]Z MO.K6[L*^QTM9$[K7:!!RY^,=-W,%=VX3><+
M0-G,%>4M^ )7UOS<\5X&3+EWH^^!*7QM8V?H.N. \OH=(&0!A?R7U( E9?M>
MV5Y?3G*5&[)U;O$2'L48/9T+_JO[QBP!*;S>P/("+-<Q2_!>WQ$G8WW0:)KC
M!'/X5*IMF;+[IVJ'@>BR_99SPT&FRL!B.1)7OD?^&G7=\WC3C#R/]X3/XS6K
MV:"R5L.6,R[N6Y(1%']%,OMMU%4C6X2Q_?NJ.H*/[K7,;JN6;%A]%3^_1:.7
MG4Q=<9V1N.XZTSS1JSJK)F:WTJNI=Q-YU=ZIJQXT+40Z#$]QSX!PQ3Z*!FOP
M/%ZU>!ZO^>V9:.ZX"F25V/L\7OEY>$?Q39^)0,DS\([B>\YX1\DA2@[1DC7Z
M?KHNDD.45+.&JBGNZ!#%-19]UPKGQ6K>S\ ^B;@0R/0Z+OOM>;SMV][@.;A\
MX4U_?QZO>2UR4?KTQ;?LBH<4?8>,P,3$$A-[+N9.)B:65+-^JDG0'9G8]G]'
MQ? \@7L"]S2"OAM!""9T3[I90]VD=_6SU:"5O6[WSJ83CPG7$ZX_][&#<,+U
MI)LUU,VXP7)O&%HU[&6W /Q-&?0)K!-8+U&C[S<@$+T/6"^;%J:%<S5J]#VR
M4J&<73F'T\JYI&USUK9=U57'I;V/6S&B_.4@VRH&9C08Q/)/T6_;[*KV^: H
M/;\I38@\HBI'&<_YX :C]O6LU'EQAMKJ>2("M6CT/4< 98D)+)^05UTS<3[+
M!$AB DG;YJQM[V/YYV)8%O(KC7KXH3WY'CE!NS<8Q5J!F[HW&F:[JO_%#;,/
MQ>!+,O3)T"^!@G.2#/WR"7G5-9/ 64-/DZ%/VC9G;8MU-/M!ETHC_Z[?,\Y&
MNYZL>++B2Z"]_%Z!^R689:V)LJ7"F->5[;(RYLYZMG?P[^T/-2N+N:AMYQ)=
MKC&:UF%4SM4$I-J2-1+<<]"VM^Y8M2N>[*+P$E%.1'D9]):G>:VDF?73S"L9
M+F@S&?"D;G-6MSA%E;U69MCK)]N=;/<RJ"SGR78OGY!773,I3MFI]1'<<]"V
MC]UJ?U+7CXL05=O-KB[?=V;4+X:%JV:R/@[*7>+&CGJR],G2+X.&)TN?-+.&
MFLE2]FE]!/<<M&W+>54N(?EX&C>A=MVBUY^Q\,F:)VN^!%J<K'G2S!IJID@I
MIO41W'/0MMUP4?#7O0MN^LS2D63%DQ5? NWE]]H9:HG4\.H%(MGL^NHA0[,V
MFR6;G;1MSMJV-VRY?K;3];U^I[Q9LM;)6B^!WB9K77^1KKP>TEEKS9.U3MHV
M9VW;_M8J=#%,+G4RTLN@KO<STDNP:C,9Z7HT^CYZF*]M[ =9J^$\8Y$)8^NH
M)L]!M_F]]F^<MW+_ZJFIT:G1J=$U.#4U.C4Z-;H&IZ9&/VFC_Q@JW783(G49
M#MOXI^[_<8UES?J#O4%9%OM%W[7+TIDOSPH[;%5D;TS\*%[/V?>>Y.1*I0>]
M]FCH7H[] #A[BUL)NG'=H>M/&/I/6GGK=0\GR8'<SH4DX_*ER35:._,WOE9A
M_[5VEW+/:Y.+6OVI$W;L@.X[]04H'WKBA6J?J?/!VA]7.JQ3=,$UZ7TGE,7X
M1O(N'5@SU^B7VWQWSRCX10=Q'%?[@P=5[]X8,UV> ?)=R:MJ@+S:_!C+4FU^
M.,SV#S8/MG>WFP?9A^TWFQ^V=IIOLM=['SZ%C^#MWMY_XO?+<_9_C!'CE$],
M*YWOJ/YQ& DQ8"$?(]0U7] X:!6#6,6X'^37/L\^N-->?YCUNMGK7K^3(0C>
M!XO0':JB.\CB[@<XMJ9_IOH6M'N]+T7W.+S99#>D1GD&>IFI039LJ6$6;MK)
MP@.L\^'1ME+/<C.\=_WB:[AL=H':V_#/<:G'H1EQACW;-,.HDTA*EOTV?OJ[
M_;<?-L?/^;T1KX]7C)=;YIOQ_'C_F?M>WH601FR9ZE3;[_T6SQO?]>KIT]O'
M17-7'X&V;WC$]C?34MUC-_,L>NNS9D^>/&D]BQU^2[=F1=>T1];-_J3* M.]
M43]SWTY# ZOM)!J9=NW"^4'6ZX>KXDB./V=]=QQN'>\:KSCM]^PH--2ZKZ[=
M.XTWS)P//3Z,-Q@-@J@&X9._W,C"3#:R:(0[7>YBT;O<Q:(16A8^NN/8%[WR
M 8/8J'"@:GI\<NR!TU[9I'#+HG.JJKZ*O[_:^WMG"R"9A9%B7:<P40-C4R>M
M<>%6X^>%6XT;T<A,W&71E[LLA@O_"(^^H=&A;P][HW!N-]C ^'A?[KI[6V?K
M\[))/C:O4N*6&USI>]O+NKUA5K*7>*!?F&$8.\->%@;3L->/4<78#4$]^K%O
M.VH8!L(@M..#B@DDC1\]?GS7<+-8:MP4I^7>8[V)G,/G(+4XUK+0P.)KJ7^-
M;!@>9,N^GPA(#2:=:\O[M=QYIOHN-,:ZT)(_G5&C\%IW:LGX!:KN:*FOKGS_
M<Q?D9\J7M(WO>RD^K.B&UPW?0N\,1OK$Q2[M9?UB\*5:CSKJ&M>/X%*.HO+V
MIC=J!Q9:-BYJ0'C+4>C.R6N%RVWA?4"1T*B >:H=[NW[O4ZX7_@PBG'KRY-#
ME_6C\I3]%S0N# U[*=];7SSTSFYYLZH<QFTMFG;_;+??WK[XT)EKXNM?RFI&
MTD7WQTT[*/MYTK8),@Q;O?"K=0/3+W1\R3"PS\IGA/N-<2=.OF=H$\S6^I@
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M=+^&$5ZN(ILCB7V8[[>"0#Y_$GLIT(#?";CO ]S%#&EE) _0G6-@F** YLP
MD5L(!%98BUQJ!]7:1HX;DK,4.UF%T'F"NJ7CK GJ'@YULQP5$13L$( V9X Z
MZH!V*+!5@7('<\&PHVL;C#0HH0GJ:DE15SOBNE?MOG(EH6NRT?"I*FS<=R,N
ME?LN&2:%(9:.O;ZK1+I=272S:TOA;Y8R3]&(!R#];#Z((1#F*E< $VX E<H"
M[0T'#EJB-12&BHCTJ('P4Y#:50]&I$#LZB'@_$EM0L!'1\ IUY5!9@H) [3U
M*B @(T!0$A"0,^^45;D0/" @;#":IJ+JR74?'@(@O/Y<]Z W5.UK7+<>0=E?
M6<FRS(C_!&D'"=L?B.U[KV;8;4Z)\%XA$ RR!)1C%]@M52!8Z=Q:Y*"19&V#
M<-B K'Z!C#L-KYJ"5@KH)IA\@@R%!),/A\DI!5:4."8Y!SQG$%!%,)!<<@ Q
MR2%5RI%8!))@VH"T?E-;*P:3-0L&UY\?OQO7OF]DIVW5K>JEQ^60I[' 6<K#
M70U"/!'RNRCBS:[=G@@XS?/=$_AG\W A,5[X@/E<4@,H5AP(J0@@QD#/'6)6
MN9B+%H,?, 4_4O@W8=]"PK\)^QX+^Z:DET =!$8DX%8'TLM07 E-'3"*<"FI
MU][Q@'TX;R"$$O;5DM>N=+&FG>O[LJ1TW-7@LJ^+\'CWMOCJ[%3&52@C(?H]
M%S<?;$8TKQCMYF?%;32Z%$ <UY7EB@')F0>.XR [BR2V:FV#2OE$Z0RKGKCV
M;$.Z*XQ_\^>S"?\>%__.+_'/$N*#O!A N5+!G^<$B#RW0#I"!4-&<YFO;3 L
M&I*G^@[UY+0K':O=Z8+3?L_$36CZ;N!4WU0U[&S<XKQ7.K4I6+NT!+=W^N7%
M3O==)> /8_D&\6Y-I9O0_5[HOCW+;CUVN1,T!]!H Z@U"FC.%>!$(&RL0\$N
M!W27L!'DER(6*5J;P.\)V6T"OSF WY3:!B$1JQ$%>1 ?H 1)H)@DP&#)(,1<
M&<P2^-6;VJYTN/;->&/M%*!=6OXZ"5!,1)GP^EYXO3-+5@GRW'GM@;0PIMYR
M!)3)!= ^ATX2AYTS:QL\1PTF90I%I%!L0KH%A&(3TCT4Z:;,%!/"=<YS("4A
M@)J< (V4 =CXW$.M.3.J0CKY)$E4JXYT*>AZ[Z#K5S<8=F[:&R3%%Y:.G+[M
M=8\/7+\S(]6$WO="[]TK/!5#(JUTP#)O /5,@F!L>2S,&(1IC3"QU WF#<Q3
M6"'%5!/F+8*F)LQ[!,R;21/ C@5@"R#G>6"L1!H@6&"L5DCBB><LH&# /-C(
M*4^85TO"NM*AU+U3UU?#T,"L[=3 964S0<^#T<#5J@#""H/Z_(GLI93?1B%_
MB+VPYS\.JDRP!._W@O?WLY16>BD$8BC6J&6 2H^ =":06P*-R;'+B8%K&T0T
M*$^1UQ1Y3>BW"$J;T.]1T6]*;KG((;<6 4Z0 %1I C0Q$@1(Q%A ;:0,#CV1
M#2)2-+:>Y':EH[%5Z=KYLM@4FG@Z%CLMQ=CL=4TJ1?, _/YXA;U2KJGF%B@$
M(:">** ,=<#FF LKI1$,K6WD#2K2[C@I'IM ;R'D-8'>8X#>E+0&@4A*O 6,
M8QU #PH@)0[,U7(%L9 $>KFVP1M"B 1ZM>2LO^#=HW7,ZL];JS*T-_/6)^NX
M^Y52K%7_+7 #^GM4R%MFN_=497F3H;N7H3N<9?=YS@1'6@#"1 XH<308.N$!
M10)9K3D4B*]MX ;!I)'7<'.A%2LV68/8=;(=R78LWG8\5:WB9#ON:SMFG"3H
M/>6Y!\9(":AT'&@B.7!4$*(=T<3#TG9 V<!Y_>I;K)CM2)'_>_;AVYW-/W?>
M[ASL;.]GF\VM;/O]QYV#P_F'XV;TC@2]L[U1K"EWQP+TMP7K%ATLK%_OU"RJ
M4/_Q,*[;G[4+I8MV,2S<X$7=V.FS?G[-$'X)]B7=-":<-1QDI^I<!1R9;U3V
M/E*N53<]JC_S*]'J9799GB#<-=;F=Y4RIWU6'N+"?)D-?U$>?!B58P"M%,&%
ML0K$LB: X>!KZAPQ!N7:!J4-GJ>:TRLQNYT0/R'^$@6I$N(_"N)/@U;(R8#E
M2@'O<Q<1'P'AM0-6&XRLP)IQN[;!<8.1E,]4SZ#4+[A7R^&R]$?.9J[:73JM
MK%H)WAY%^G8:5TE _@ @/[FRMP C4A&-.4#(!^H.<P6BK0UH;C$A" 7#'&<?
M$'RB_6)6?6'!HH-?"?J6E, FZ'L<Z)OAL)H9&B0'-&1Y@#YK@:),@)Q*KS0R
M".5Z;0-QVI!I6Y6:DMC5CKM/II("2(SZY;#/>C[K7:TCD)9;+3^UO;IL=@+S
MYPGD'P+R5W87P-8(+P4!/$<(4"<LD%A+P#V#.8%.,ZH"R,,&EFD-PDJ$IA/\
M+1V]3?#WN/ WL[\ 44Q+" &C ?FH= ((C#S@VA'+(0R"17$[V 8D"?[F3G%M
M,3AMJ_/8R>XGZ3!/>&H*+C^4EY_V^B5Z!E+>+KH5.S=]9XMAN?U7MS=TM^;,
MI"C,TK'TMU'&>_Y5*>%DG!YBG*X4J<TYLB3(! A*": T9T![2T$NM14:>>]4
MY.:T03E)\9<4>DZ@MX@BM0GT'@'TIHQ<..\PQ0QP;P,C=Y0!H8T&//=Y;KQ
M'-&U#=G@*%4Q7+68,^'UY[95003S_2*&>H29[[?<=76 _BG8;9I<_"68OU*M
M5BAB),<4&$(XH,IPH'-M ,&$&:\X\<ZN;>!<-AA]"G([AU%64P!+4>F$ED]!
MBQ-:_BI:3DFQD\1P1AS(<^8 S9$$FD$'?*XAI09KQ41 2RH;Z$EH\;-&RYK%
M@^M/F:]O[/ $I'D.)1I6T PL+'$CE8]\H%6X4C/7,\H4H08@A!B@CC.@D,0
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MJL*"HIL9=5H,5;L>RU*7#,;KQ5FGPGT79+O3?55)-D'YO:#\2E5"J:E4%N4
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M0 4*#'(FH8'2!9&[ (ZBP<53[,R=P#&!8SUD=P]P-,0YKC6R&@IJK-?"YS)
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M]*H-'TU:.5,L=:J3<4I"$#Z9G%E.Z$5O*^>?W0AORP0:DF:D,'\F8*0B1M-
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MP;?2!*]\(,%)796HE\1G"H0F(RT#!L*%C2W1I/V/B'^(?TCP*. HX"C@3U'
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MP<-Z/3N,7DY/?>%G59_0?K@U804U$KEX5,;K>SXX3!T7JDJ:;G!69*$@HBL
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M&9^4K2JLJF8Q)B4]%NTV1.&/+&YR:^[LXA:/7/U>7/W="L!QFD74:.#JB46
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M#&SS A5U<=75WMS.8=>0\6VT=8X5NHLS,'P?4&J/]/7MZ.OT\O#TQ*0TMK0
MJN()\%>3*B(*:DE">:I!FE.I[;,7_'/(Z_DC+Z'PA6K+19< Y<KG+F;"%^##
M!S@QPA>S#+*X71RBG&/#X=9U@B?I6F+-)999^%J\A7CG+-Z%N7!WOS/F K&Y
M9D:<MJ[_OCK)6_+^;#?">L>%2^)WDJ$VKK9AKD67/ 4S7ZI0CS4Y%6CEP?/\
MN.5<U<Y%U%0N+*'+9N$[_73E$SA7XSP+2 5PD*8^CNK,<(,%VY@9XPKHB'35
M=(.Y8S=5S*=!%\(E2CTS!YN_<C+M^368T\\AHB]/1-]8>J,<Z>UG X=CCG2
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MF8%UJ4$H$Z\WM>ON$Z3Q'N>P<:MX)H)TPP3=5L+A\[TZ@G7D&A&53!MYJKP
MJ2[ZJE27^S =IOPZ8ZC+OT N$LI$>ZR8+@#:"D_/=E;E(RA<"Q?L0=WMH@)*
MP*BLRRVY-+[RLA?$ZR?K9N6TI#87;97\70I\%WQ<3]]>>=IID+RO4 T-2ZU;
MYX$G/!AT49?A,7VN]JRT"Z/[$MD&O\0U_)2J<$-36&!W*$=(U24<T"8DL@=D
M-W_P+^H2]C\D2V/1]B428IOYO&[R6'!Z<^XN1]K,A6KG[?-:8.(K\VZGB,A
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MDFI.K%8LRR/.4YJLYWYWL,-3;"7LHE/!5QVXT'U1348-:0.GNEY#<N!%ZVI
M?*6'@\SN+>%__O/MCU-O*;9V:3 ,:U.>RV7=='7+:X7> $1IT5O @UA"B$P
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M)X/LV"E%H"I(["WCL^??F[KMT^D> ^.A(8EE1+HMG;^VLK=,^>;2AOQ,-^G
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MAX 6%7!#2?X&-H&EPMJ@(U))6K A4T+&"8\P@>61P@,6YD;,IDW9@F/3"]7
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MVV$,\)W3/0!?S%_Z:]2-#8]FN-W*0OS\!@QR5F/RZ5*,2>R8[S;/.%F.QNB
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MME*C*<F/MRS0L\#!N@H)'/>ZC/?6FFGY6+*V_OI:>GNU2D(^K09-"WE6MCS
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M<:XG)G7SW?KN[Z*/H-'#QN#/*@U_8M'XD(]*@G:P)[5!!LS07'^5(TLP0S3
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MP<5IG.1JYZ!W.#K/)@,W-$:=^.T8%9\P[X/<N#7HC+K]SYF 2VY[=S2AV;#
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MYRW\I:FA*$GEK.2.:B&R.I0=RS^JF7?*$)=/ZZ3,PS0^89I+5MJ[S8IF 2H
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M=$V>B6PM\(P;3&OL5@T)YCJUC24AT]"TXP3\O#$K8)\M!B@'!#250U=;VSC
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M1G9_0M]?!X>]T,F&W6XZRN?<SD]O=G.SF?#:-O1HLI<+=ZV\J:6^!7PO3J@
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M.<C5QDA56$?04"L97[O*;M_FO*X?!#X$R;M-C[D08;KBDRMS ^CC^Y<:@%'
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ME5=PW(!4-D&YB\MZ4PHI#+!O"JI:RBBW#IY(O0$RQ4@CI37M*>2[4DBZ<W;
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M;Z?"W7@V3<8^.1V;]RB]M9AHQM5T7KMH%E2>6(VDF59\4#W4_*6[+[)J+30
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MO*--L(E>"?/"]4 /Q+#TT\;86.]=AR?6M(!M#$&./P(9\ ,N;<M'T=13U2(
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MK%4H'&%.L,O1#&IFR[98^8?2G=4:8Q,VTEC1:\-XTX0WFO!#.$C=2-0%)0D
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MV=;FEOC2W<@21+P2B]U&R7<T %*%HX2$9MN43#R:TS&P YS!/_,[ FY]YH[
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MZ* *C:5F2C-&%=K9I:H/J-)A2(<A'89T&/*%& *ZAHO8R:@D93IHPXQGD:)
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M4-_Y3*$-#;X#Y80@+CE5C(E@L"<<(Z5BE%Y$7J4)X6]1PZ"=*K0*91V W03
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M @CU6Z\'[*>8A B[D9A.OS<_+6#J\(1J#KT8PO3W]D3R 5L?-FQ-@$,Z:L8
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MG23>E"6MO34]O)SFL0%,MB&,5FD5AE3#U]7DF! %EJ61"EN;. DG9K#IZ;
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MDG5#:=MCN1(E,PRSU$'(+%(JUKROUS.M5IU VB[>@].VC[PL&IA[+6TVRN;
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MT\+&MZ=I)QT@4?(DI)"T\63-KYR,G&D XTEEIZWH<%J&/8WGLYXS*60E&Z=
M+5R$3P&1#9IB<FFJ\8)A3-M+![K"O)ST"M7.DQ,\N1Z6UR*/&FYJMK4UJ*J
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M*&M)U*$PC?*<ASZOLNI23XQDYUQ6>L.GTT'2I$W.G_MHZDJE*?XKYQK/ /F
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M>#RH**3AFE, [,GI-;7JNXI">SF?JT&A1>K6K'*QI^/QXG\'&]>F$HUZ#T8
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M84#N%9-TF8QGCD;C:8JUJH+Z5RZJ[BY[P$U+-$SDM7+9,K4]/AZD9EA[X=/
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M$6@PFCK A'%1'PL^%GR\ 1]YL,0RFB(EDG-BC.+.)&MCLDQ9;HH#==/P<>Y
MQ5QY3*-&,9H$YC51R&EF$3/>PUQSF'A<)R@9<KUJ4L''M7"@;G,2ZLLSV^V7
M%-1EIUA12XVD,B5%N77.V,!!-L8DI8T.ICA0-PKAV:(#%4?CE*6Y;C>EB',=
MD0L \RDXK8@&D*=B9X]W"),E0E8R" H\7H='$SG1R1D,)B,76CG)?;)1<PI
M&7$IX+!Q\+A0P $KXQSUR*N<H2^H1HXY@@(PHM,V<2YS!D%'JP*/!1X+/-X
MCXD2Z;@G*6'!E50F>$^M\S9I&D0(Q7^Z:? X]Y\2HDER5H*Z"#HC%T(CXY-
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MK?/S;()ILH)C.B4_:'7'= IFWPNSCQ=U<Q>ID%(R1"*3@-F*(.L-1D%Q'WG
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M'=+*.!N-(-C[G3VR>SUF,YWZ3@7R/(OPQ_>Q=]')TU*WFQUU/U2G@UP0N8H
M'.%R@]A.=7[2]2=5M^][DQ#7%R[^M,-N1OZ"%GG)'#U_^K>302D!0.&2$(C+
M(.$GT&((U4:K9*QEN5K=[O42GC.T&*3J?2O7ULWH0;*CW6KY5*.)8BE9GH3B
MW#"M$^>8&J*](AA3GM<.,>W:@1\*U3S4XF&';U_\[< X$08 )GB,0?%-"6DO
M0?O% ;-HF-6RIAK]<%2SRADO5/.IJ7_W=V*>ZY08BF"M(JY=0B9PBFQRCGLM
ML(]N9X_N7B_U\S540\Q74<TJ%T^AFH4EP^'SOXDUDLA\9IY9!8HI-<BJ2!%U
M/CC.E+ Y59%\3C'])-4<72:7YL_7&6;Z]V&<+J!0G7?')]W^XAT&HU%5=]^.
MU;-!MO5&\#7XJ3:.;4XY>SF&_^1DM#RB]DKX?+=Z>3(8CA% Q>FE!YX#=E3]
MP;B"M0-VF^WM5M7,*JUMT$LFYP,H2%?SI]I%^"J+[A7<^E^]@7_WS2W$%^>'
M']_]S0Q-P6J!K'=@)@4):K+VH#6G@(/&W@G KBK"=CW+)O]P$G>VS GP<G)V
MUJL7L.U5WHY.JM0;G,.B;^ M;[4N;),1P%T//A@]N;Q8%V2Q\-Z$S^70NHQ$
M(XK:VS*31>-4@G?MV;-1?#+]X8?0'9WU[,63;K\><7W13<7&SKMA?/+$@ 6+
M5>WI;=,!VOLW'Y/=Q@M\Q:/6?"CSM9_Y_+,7?_Y#T)29O.?%>)=\[D/!V#VO
M_=*0#;OMQ5N4XJQ7[H^LWPG4A4%#%T\:PR@O=ACE=S7C#";PD##ZQR>C;6:Y
MLO8QZ[E;(>V=O1^_I%'>(J8Y!24@YWAC2N07OOJ%#;,.29U+WKZ?75)?<^IJ
M[=9;UKY6'29_  &6!;&\!4%,R5[\*A'.S;):31U,QK6J"IKI<'!ZS:>XGDF-
M)>OC&V\-_[4ACOOG)DY/V6Y+>L?'P^?OQ.&K8W[XUI.C5R_PFX\''W-*QN'S
M'T]A'/@-_.W@]<\GU],[#C",C1P]/Z:''_\0!V]_?WOP\4# .\'WW\ [_WYR
M\/:W#_ .5UL :TU3P-XC1;1!'!8XTDX+E'#2*4:/&17Y+)0N1VQ+XF%AF,(P
MC\ P7QO9* RS>H99:!D7L8TI6F2YB(@G&I UV"&EC)%4@.; TLX>P85B-O.$
MV3=5Q>'S%MOEA(]2J6'3[) O9TBTA'#4W[K<\A51PZ4FRT0X:7(CT:BR\4$L
M09:DB+"6)CIK%!%D9T^OH,/RMW;2>.U,C0*.ZZY"%W!<!3C.]6:O-$P75\BH
MW&_.)X],Y!$E)6.B&.:/@-Y,6:G-O@E:\I9',AHX>%2]N+1>>@R/_"(/_#KL
MPAHXL[WB-KD7_%]JQ!R2\91[C)C/YRYA)I$UGB'F).="2H_KLPL=3%>@'F]_
M5Z9M58@+*CZ&%[F@XH.BXL)I=":,9<(B9@ 0N>44.9A&Y!*3*@#1,9-[%G56
MTH9Y^U&QN(L?H#S9*@VQ4MSED:W=4NIE=39(;GXU)=4?!\.:;0N[WHU=+S7!
MAGD(A'N/'*A).1F((DN=0M[A)&GRS&I;AVH-67>?_#=7^F7M#)A"<X7FMI[F
M5F%4%II[$)I;R$@"/A-:4(2= )I3SN:V,A$YG5@TE$N9,LW1CJ37BSL4FEMG
MB_1K3[0]RCFY,N@RZ,T<])=+#6:V[/8G]9G@>]89V/NG&WZ_=_V0?DU[UDCC
MN' 6&\-5-!8S'SDE26&<A&-_$RQWOG"TGZY130-U<TV#PZ-7^Q61U9)+:;R<
MN%'\OPG,R?[[K&ZL3S&--ZV2,1!PGY,#^F/OZ#4H&C^]P0<__75R]-,^/_KI
M!=PG*PV@!GQ\(_YZ=J68QMMWYP<_[7]\\QJ>\_$8[OW;^5^G^_P-*!]OWCX5
M66G(5\)[O/O/Q_V+@[=O_F:,A1 809@1CC@G#EFF Z+).&R9\$KA1B.$-1[#
MTZS&<:6C($;H)",W.%HKL..:,^Z%B2Y<+;[Q\H]_O=S_[8_]PU?5_I_P[\OK
M^^A*+97%/=7,RQ>?^>FM1W<WK\+'JY-<>^;TK!<_U.T>ZEHX]M1UCR?-[X-4
MN5Q5IW^<"S%U3]UD.&I*V@SC\:37%+2IK_(]VST=56?#0>X>4U]@<TF;7B__
M%R0]ZH9I!9QL",#FJ,:#ZB &4,:&L;Y'\PLH7G"7XZ$]'>6'_M^D"Q]/1OG;
M<33NYN(X]8']L\$8!M*UO;HHU#".AP-;UXFJ;'@[&8W;-G!Y>%7LS0KQS$H#
M71K3M)3/,/K!,9@I;1VA883M.XG33\] SH/0?K%7%_D!T;_O^MB4"QKFR@'#
M&':KZD6_^GG2NYA6/JSO'&%P(-\JV?>#83V&^>N?G45XDVRQC/*SZW2/P\'[
M[AA>X.6@-VD$]Z+O=ZOO<F=TBG]H/ZY_(S_\HQ;#&8RX.YB,X,FP++LQS!_1
MSE#^UG0G/.[:K!_\!%ZAU_6W6:W\?T=^,(SK,?C/#[4:QZ:B4UXRV3"%B0B3
M8<[KR>;K;O44%DPN;3;IU8LRKZCYJF@60V<^=>>P!^?[+V^&/(NCB3\I4[FB
MJ:PW%T!%#2KG)X/J-$:P V."*P#]AMVZ9-=N];S!-0L[L0N7 /W :X#-:8\C
M?#O7_.KV&\1Q%],-WH&OS: F5[=<V,4M('W,+>>;2B6P -9#;ML_Z9F40.+#
M"**/+8A/9^,N)05!B2">:$^-HUQC9X/W\).U2GC+7'C(ZK6_-^OH1R"09S"&
M/+K7W?'),V#$ >A!^Q]R13L HJ>C4>Z7&5[9#VM4='#5ZNF+#S"F\X.W!Q>'
M;_=A//YO'BG3C$N4 J:(.X%S4\N(!$_*6F)@'M,=FS4$%J)FP=C G37&^9 L
M=]PX31G1[>3S,OF//_G&2T:U9L@J"9-/DT1:>8=P=,D[::6R.5D0[UYOVO<)
M!^>T*.6T<.EU!6T]\/ ; /.L<F5K9]!O38%VMS3*]DR1G\[4^&08&[OD\W7-
M=S]9]G#S2T"^CM6)?9]Y[WTWGF?C!131T<RY4<7WLU[; #;]4;/TP58[L2!A
M[R?#8;XH@=Y3RS071LV2'TR&M1";/3*5Y*<*J?[+]NJT]Y<GH'-U\L0,)L<G
MS23!Z^8;IFXV4N%/W5'UV\0.X8&PPWZ/9X,A#*1?_0@(6A&,?KLR6[=WK7W.
MOO^49VV9][F/JV^]%UNS&&[_[_+D- M##4:U*^!);>V#]=Z6%26Y+F@[>$Z;
M!^S<?*5UHVR]QQ_:Z!%>O,4-[J1+U<_NL"QNNFY=)YJS*YMPX=^[.*3-S"%]
M,IQ'#H\C<L-HWZ$:=I[8WKF]&.U\?]EK#4OAROQ=FY:OE6%*]Y&AN8T(/ULC
M])]VX\9< =6"JOQ?7YYTM;-75Z?.F)\UW$P___S>[MVTH&Z.4IAK]8<W(6[Q
MXM7^045WJX.GAT]_VC_8/WR5W7Y$_?"R>O[BY;,_7KY\<718/3U\#O__])<W
M+U^\K(Y^K'Y\<?CT\-F+I[]4SXX.G[]X-?W.[_LO__CE5?V5HU_W?W^:/WAY
M@QYSRXU(Z,XUDEEO!OJ$E(_^W/_]SQ?[KS=:H[NK)O]F,*E&)X-)+X":9T.C
M0^5V\)-1[8H>#XYC=H+4-?!KI6O2MV!%CALU[2:%K3W%:'OS&OBU+[]QF?<'
MH)!W:J5Q4-\XS;Y^J;;XM/9^[(WB>?;"-&[X+VEX5P:<5<WI</WB(.=/'=UF
MD(M#RQJCK1U_,*+\@*=]T!][-XSF?V?FQ$6TP]9\>!Y]/'5QV&J_I&E:47V7
MO];Z]F?73[W[NU65HS5-J?6LZB[,4#N<;.*,)J=GM0K>F05+1HN2'@S/[3"@
MWF#P+M]D_N:-RM[MOQ_T<@2EZD_R".L82'?TKKG'!)3P87Y2C@UUV@EJU.[!
M*$Y'%$/;RZ=]E=_A^NI'L P&PU&G?9TLMU]A#JL7G>H%C*"1!'DZ]87/Q9>?
M._MR^^UJ^L4O+H4ZG@6K.8[\L.ORI&=3KS8:QH/FO^T,3E=B-B-&\Z7^,H(-
M,X^-[7_P)[9_G%L^G)YV:^DW$P.OW\C)UQO)VPG\I5YZ?IQ71N/JKX-8H9L2
M/&K:Y %&W@RJEJ$%V>9#3N-F;37NWD_/VBUMSTV,38+I60?&0%[OXW#43=E7
M<A)M;WS2A+/ DK?]BV;=CF)\-XT0@GK0'>7>+V$R&@\O4 ] +4MMJI+7;3MZ
M((O&N!_:LVZ 28!WK_?5:1UTZ<'\#-_%W#6D.H)I#%U[W!_ CO*CRDU&,-RZ
M_4?;7N9?W<'O$28U9BOU%^NRCC,8YD5S*6"W^+7ION[ @HW39=]$!EIF'S6#
M'(VK-,E6=^.?@#\NW+Y>I]FK 0(YCOT(XZN]'?E%9L.L-T$?3/=3>(&*88S.
M0*"P3T:VUZ[KYF7KK1SM:;U*ASF2FH62GP!?Z<4VBM&'"3X;#L+$CZ^ 0 E,
MK,:7U:[)LQ,+A.3CI,YGG,]WBG8\ <#9T-GXW5[87H@;,1U90:A^?/X4V3/8
M$CFZ/P8=JDX]:$*T8._T@QU>5"<7L.G.+.S<DXOAH M<>3K#A9?__O75+(H/
MX&1#S17UY@8\@SW'*K@9K_S)<-"'+?ZN&_KQ(A-NW3YH>I]G__M\=IN\97-P
M$2S=ZCG<=#1)"9@%H.>B^JYG@<I/&HHYA&'75 \ZB 0X.OKU?[7&F,.KP?![
ML4VIZ(<AJ%7].HWA#-"G.@4$Z&4<:GMMG3=X'3^<@>PS'N3WS\D6@\EH(5<#
M8!E6:ZNBY$&VSV/Y>8.,GUE?.L](=PZ@#L \^'#1!S,M/Z[;^M%!EA7-F.SB
M3+]Q$>#]8MKXJ_;UPO?SSH![V/ ^>Q #P-HDE]: 0=2N2'LZ:)$KHYKO@0*5
ML?BG7WY%I#KN3;P]'BR\<\A4GO_4S0[E[V #@O2I^\<7-J3MC0;S77GRT[_1
MLU>_3M\7M:]Y,H'E. 7<$]!@,B]T^V]C$V!*BX*N?;*PF,;]G&W2+)1?$RS<
M8>.OGOB<A)-IXZ+-[QG7B2?-@!DLJDFXR)/_='(,)-GF)%1;K4PT5>#C7$,
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MU%-$G(7VE*Q$AW_C7C#'1GW*S3O.S3/Z ^7FJ8CB^1C,M%0UOXHG*O/PNO7
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M'26B$ABQ)Z8,AB:)85&4S.8X<@13F+ 0#Q]Z0>S.\$>8([.G+DA,*M'C)$Y
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M/'S!,WJA:;?&<_&HO)C%&=KHGCO N/)*3<29I4](&D98IDO?$HYI(%N0RV"
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MXZ^!X7 =$!+&(QFF+'I>@V@&,827X=K%UJW9FV1R_/=G_W,_T@_!;B7A +(
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M?('?Y*P@#97)J Q)M0/KT2($"/6;Q?TGURI+$ZK5W&'F.RHHK\;9DG[79#<
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M5_%-%W64J2HL..+0<3#L[U/I %6EPF.?XPTZ&FI?K..@+U[@Q7H'='Z5/\X
M)RF&Z,&2X8.*9(_^NP302BRK7*[A_[>.]Z^Q;SX&B<8PAP?PG)RB8E.1IW1P
M&6M-R@S]=&,ZUN>B=?[*G'/3[^-5EKEQLC-:H+8\;_!@ <KK#'TAL (M:#9
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M'^Q=%&I6QE4@ZT(61<S>HQW8L:XR<1VS@@O@%:#8!&,(.I<V]MX!L%4DZ"2
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M+ZFIY3U=5_?T1(8&'/5W5K?-?@W'=;K(;^KA[7M0<[N'2YL]U$\J9]\[M7E
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M./& 6+ 8,>1SZ"6BF:]?R*N>R"X:V7VQ6)0E95EI8>]85-&J,A%J+?K8.JN
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MVV X=;$)&3:AV84$]@<B06^-M]B-N@:%8XRIA+:$6Y!$8@!:SFT\28)9%JV
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MCA?+(O,%7,H\XE;C\A IKD=9HHNA.0D@!:'1&:.$X$8VN1&P&[PA.?=UZ=+
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M_D8X0[I">B3*5+!+K7S'4FH<7L#JOZ^F*_J^AW@^[\1\^=N;5UW1B TG;R/
M=55QSHC)104<* D:-$Z:R1IA!(^W-]^VY2_V0+'G^^@_])1S9)O]<+4^/(X1
M$5,@64>+SAXMC\@Y1:@2-')N4<%-]B\&5.OC6*_ 'VFF'")SVCV??"NI+QH.
M3!A/5%(,%:<X\9::\@P0M5DKZUV3T[0'<.U"0_?'HF%-2]6,%VZM!'<+_HZ
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M[TLF-'Y&IO_\F/P,GI=SP6E93E\-T4K26T6SE$2)B!Z?CXD$;3.)-H3(9:;
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M0"#99NX=MTRZ-M5V6M%WZ\W'[:9VL.V;/@S7\T+YVG^Y <3+Q+Q#)<9(R[H
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M<7UUS7H?XG5_D"$@=VBZ-8@G@]$=M^M6&T5.CZ6%DU$&@E1"(3('=0*'$\"
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M%ME',=.F4FWHDU1$/XUGF.BO5Z8/US)+%YG/2):5('\Z: V,%[#!D/T#IMG
M@?NO_J[U>H 46U?I[^'M@$\A.@BD'$OT,THSD-JQ("+J@-*F+ ;X$M^=CWF
MTH\AZH:NQ7*^]:<QEM\Q?9J,$UR\I9THX8JP'GG"F!TK>7E]4ZE;AVE8HS 5
M[I)P0X;X/?**[UK3K437L!WK<BY*A?7Z3TR7"V+@?5@*N<XQ2H:Y9LS91%N0
M=4B_=<BY<2&*(0T=A@VCVH[CNU5[2_DV[*=6V?AR/'T%LSR&.PEQ1AA,7A8F
MC$C$0HTL<EGK#$S27J3H[) <P@V/_FXUV$)4#7ML5#@_S7Z>3><+F.1?9^\*
M3B;CCS>$DD$$900PX2'3R5!37$,B3X(+F81)TL@AG70>><5WK<E6HFM87;N,
M*%90MX.;_W-ZD<D F/_RRZM5O5<P*2L5:I^MY3Z1B6U%,X-. 0;0*L4A<=HG
MWO-=Z[:I$!L64]0SX#:.^/I_+I<>V^+3-+^9?,7YLF?_PS]%O)E1)LAWBT$X
MPJT<TZ \^0&Q$#&M-<$6;4*S0_@0H.<?I#VJ*C>X= ?%8K8!6]V&#(#6>J[D
MXY"./TSR>+J==M5+XRC>$PB-5%+2Z<AD!ETW;,4@&O)&<U1*^*!=:1;-.P5C
M'IDI^1P)LXLZ&H>-WGV"V>?YM\GB$_YSU:%(95<*[:NQ<$N'+DKZ"6O)C1(9
MI8_1##%('S[YN&,E6\I\VDQ@C3-+_E^,,UA5FSLL.GE@LFA:4:HK4IG<'2F$
MB5D#I#) ;W<>>18*VU=$S7NI3;_"_*802O(@:=-@CD-A6@ !P6B9*B$ZQX,F
MFWF KNX]]"RTM;^8FD=-:;F0\<]7T]F7Z0SNQ'*3L-E)A2Q:X'4 @ZN]>)$)
M@Y[GE$M -T!YV]]P%IIL),"&H=-E:2+$?\"?OW_"&7S!R\4XS5=>YYU(40)/
M6[9+C.<0:)O0@7FI"L-,.[KV014_Y%YDR+O.0M7-A=HX</IJFF;?Y@NXN(:"
MR&4QM._[6+<5T)$%VO^9<=$7R *,''3K<?^Q9Z'*0T35.&CZVYM?/ZS.[<P+
M(.W^2N8:8-*&\(B:RAM]=%D)Z].0X_+FB6>AJST%U#@2^OIB^N>?2ZL8TO+C
MAXM5/J4AXEB=#$,?:O>&P!GM[)9)X27/(H4P:&##]C><A1H;";!A_'/;#4HI
M)5D3.4O9T&;@A6$Q.5'C[49+Z1/W0V+:)[ULZJC(0T76L(:]PGDS>847%S_]
M>=M^@3S1*+,,S D@1]6A8]%XPQ2*Y%WF*:0AG2H>//@LM'>8N+96%OX?_[XF
ME%_HM\N_6/YY7?1[+/]2__?O[]_<".B//_[X-T(U_;<T_?SO2\DL\]:7(:HY
M3/*KZ61!!A9.TACG]T',QY^_7#QEOSSVM'^_A7<?]O4C[VGR *#XYP(G&?._
M_LLX_\>_CKTW&ATY #I(#>0$F+K'"56L3%X;/1J(N8E(?\(%C"\:2W;UT'X"
MW@A[3<Y")] &>):HM=,0G"\2@\  B%; 8W)>/?^P5..7E_/Q!.?S%XD^Y?ER
M]3=O6=!/\W$MU[@6"KY9X.?Y:)E3$R)]T7I9$!X]\\$"*Z@D<N=L4ANZ7QV>
MB[P'UD,SL5>O)#W$\00>?27$Y6C(42!]EF4]C*0U:!$2 T."<D;2YN4U@.^2
MJKT'UN-?6??FVWI&=V\%-@XB_W99Q?>V+-L[O%C>O_X"?\SIE)V3!2J5 D/V
MBTAUI(6OPT8)I:>=PI(M"K#>2WZSY[7]%>=+AY:R[5#P\0Z^+??XGZ>S9=N]
M#[A87"Q[NLQK(XYL,4GF0-1^M4(R;Q4P.BLP9\$1=9<F)X]@.E^>M%9(A]+$
M7VCU'Y=+O07UXO/TDG[]@UP>S+]/WRX^X6R9K3$*'I5#3>NOL\XT>;',5W%P
MB-([VN>T[7(8[83R_/G43VF-@_*K3?(GG(V_0LVYO=DC$X(+21:&6L3:7ZA6
M[9-+YAW17B;Z?1@RFF;[&\Z7!@TEVS >?[/97<[2)YCCVWAQ3=*1-"8$'R6+
MP=0@9N(,M*3?)DA.<$%.BN]RZ#R <KZD:"3^AJ'^ASF!&V0Q?_GM:<E<90GZ
MX,TR+1"TDW4(6^W>(!W+RCFA3$)A^[3R;(._(?7@XN+Y$.X4ZMUD-/]+%5=>
M_*]T,9UC_H]_7<PN\?8/Z<WXY^+UU5GY'_\ZQX_UAX,=>KB 2<(/GQ 7O]1_
M?=/**&JE:^DG#[4D(=8IS4K0;RU&;XPHH4]3N6V 3I\/?$1RK#OM+934P4W;
MA&O5U&P LIZ]&[9#.TT/AS8J',"+ ^1_9(: 0"#2,YFM):,^(0M(;B.AIF^B
M6%"X8?+']\>,)SHY')T8.XB] R%>I$2G6EX%%\<W#8XD;8N@G&&ZU#0!38Y>
M#,*RP)V2@EOZM<O@WFV 3F!G-U+:M(/$.W2T7?KWOTTGZ7(VHR/S(3Z=HXHZ
M9);!$TAID$7-@=GHA2TR<W2E!R.> G8VS&BJ@1X#(6^#1 M87,Z7VR(@&"Y]
MG8%5VY_1$EE(EC.50 *88I+L,B-L$Y@?V28]6#E]0\%+3-??R!!476?*;H1U
MHIFR!ZOM"1X<(/,C;"&KOF:>H]=9LI!K^HQ1H2;O"_HIZT ;*B^B2SCOF$QX
M:J;LD8BPBZA[S-597B_D6W"KE&^3L]2),^E+G;:>,@.AZ/"D$U.9;)**7>Z!
MMN YP;#)!NI:CZ,UD/560[-9LMI[_(J32_K':?KQZDE[9%)M>,B!F5-/P5K+
ME HQ6QZ#"=R")K//>U.L#I[.;2ND2:/'$1XBKJ7ML$_ZV=9'-1?=)HCKJ6;&
M9K0A."&E]D5$'V4@<ILLR.V.88, 'Z(]1(R_P6RVO/;:/Y]OP$.;B_9QV&M"
MYK%X%P.7LJ F6]-#*"E!A.RLPH@;A/S@^8?M_S^-Y_#QXPRO-J3:U&'YPMN+
M R\P!#KWF(%"7K"A+3MJ\H*M33+%$JWN,U[M*6 -)BPO9I 6_S5>?'IU.5],
M/^/L'<[*=/:Y^I*WEVL?Z-=Y&6-^,WDWPZ_CZ>6<_MUXFD?>>)YM<LR9[)FV
MO+"@;60J)BY5\* '-=;<632'0S_^<=J49QNF.!]3EXUS^*X#4*___$*F*;Z#
M;]/9VZ\X^W*54O0>QY_CY6R^O-:ZS3G,*7I>4F0$MU[JU98],GAF0=1#SJ22
MAA2R[O/N,R'/443?9:S90[+?@+M_7OP3\TCY$$&3A1I%G>DF,V=@"'=.MB:M
M!IETE[CQ;C#/A%-'T%&7X05+0#^3C#8!?_UGNKBL)<$OYG.D_\^_PY\CD23&
MR/VR!ICIPI&!CYX5T!*X$63.=+F=V@/KF7&KM[8:)@@.^AQ&V2!(()?:6$7L
M#_13)'>-R6(@<A4#KO?!/,(.=6:D::>!#OF$6U9^%8-W )E<H\)RK&-]0@P,
ME.(L1<%3<!@== E%/@;J6(E>72G13.JG3M5:MOVMJ='5<)LMOMVT_(IDP:,2
MGJ3#ZXV?<2P6B4RG$)1T$+4><D8-ZZ>\ <"IKK_::7;:4,*-V^2]QR_7>; O
M:*E7\XS7(%Z';(> ;-UK<3"ZX[==/%R1TV-IX624$0GJ3$'-?-'TD13:8:&.
M-892>QSYX+ULU@3VQ%1YI-_BB9BRB_!;MU0LY(^M6E1;;[,EPY@!I-JBVAKF
MK:/?(N92B_]P/<-W<S/%.\\\;K>%3B*?-I!7XQ#:R_'T/1:<X23A:FI'4$D
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M)S $5&N;<"N:$\QY;:.M:2]1M]X?MH+362;PM=&9P]KOV3D6$9!Q*U7D7J#
M(?>QSU'_CTUM/:+Z=Y%P0[6GVM][]FWT]P^CZ%7ACFLZWP00C%!H33DQFPNM
M4IM"OWNHX_E*S'-,__9Q^O7?KY]XI>?KWZRK^?:MQSWJ&XE_>I#L&MIV*P1O
M7H]$4D%"BJP4ZYGVFOP5XF$=C.)UYD[F34GX!VGOS>MST-Z.LNOP[;WZ922E
MX61-<":\%/5&6#"O:W9/!!U5<,JD#<,9#]+>JU_.07L[RJ[AA>4*P>OZ]1=N
M4&?&@ZXM(3G9@=&016B# 2FM1;W!>CY(>Z_/8N?<478-(Z$W7_\O(Q63J8V7
MF4FUCU8RE3]2,HG").,QN+(A#^FPG?,LOKT=9=?0:5DA^/5_CZS+W!KCF"F6
M^!-TJ5W0',L$/4N,SK@-;<<.TMZO__L<M+>C[!H6H-0;LF6FTG*XS&Q\VS"[
MY#HY1C!)6S?3:!VK@WHK'E7KV:Q=OY+:>(VXZ=G?L\::R&OK!)1F/39^09CO
MU7;W^C\\L"O&IM>OM;LP.L9(0LL906N+D$/@EHLLG$U!Z=%#)+LN?^_>P_?^
M\R:B&-!WV$J1>1W 8P-]_,%#*+X8I:)U20IA1MM0[2J6Y:]7I8W+V0@0QQ>T
M*)SOWW)EX(.;B'(W^&M"%A%U3"&I:)PNVH+B7$9TJ)4'Y\)H]Y7L)?[5([_]
M"HO+&?UO$]EO?6H[P0\#OOZM2P>>-MNH2.H!<AW?)Y6RQ0L=3;"C'=>PJ\@;
M=-G>\J F@MVIPW8=TRT5<3:9K)44H ,=8K%(#"I8@-'32/=B["N8?_KY8OI'
MDQ9-PY[;CK5#P3]HR124UYJC$D:C42%X54!;RXM '>1HYW7LT"7K,L[Q?RYK
M/Z^O^\X36'_$H;VN'H6T)KN /"F1/40.VD<9?089LBQ&<CK:XN@Q=/N+Z8"V
M85N>U%AH0WAG@TH6J^R(=]KJZ#T*K9)1Y),G#@]DUZCIU_VG_G);,9UX45&G
MFGJAF.8)6'#DI5BL+0J-I+_NTSA_"Z!3-/<"(2%(D1AM [5J/&IR%GAB*DFI
MLO>T^W;IP/-]-/=JP9P6#;UVT5*'O(XU.5Q=3\?P_Y=W[3H1PT"PYU\L^?UH
MD! EE/S KK.F/ G^7V)]NBO0<8=-'"M "A>1DJQGK(SC>&<EVJ3XRS[7XG:H
M:GT:(SDF5FZ*416]B>_^5\%,,V+88D"L1G>W[@H8*<6(*&(*CCN1E !5O"B0
M$QH90$/+R^7WN2NL9O0[^X0>9*?ESK<$]=_L$[J(:DJB_PG*TX: 43GQJ 81
ML)8_ W ")$L6FF2H+ ZAJ1;1'JGOM4\8SWP/N)O;)Q!JT@Z*@(*IND-H$?G@
M1F=5HB>_3=F=7=HG=#%STSZA!]:!,[W:O6>&[O7XA?]8EPF/>Y!D!.L7+90F
M55?_J_<?>2%YKE-*M@[D, &_?/R?D.^5J [<37 9S0M?<=X:V!#3:.V^%LQ\
MZ5Y+TE6^5R(\6+>OQF:5,IA<%"%3Y,&]L%89D+72+(L592K4DJ&Q0]9OJ/8,
MTGN '9SZ_&"?WO/A[2PL"!Z]#%GX4#>@*6L%!@4B@O>.<EP6W?+C^_-=Y^KO
M&)0/0R#JK2=Q.ET;Y.#O[SX 4$L#!!0    ( ))&_U"$78QZ=U ! !6Y#0 4
M    ;W!K+3(P,C P-C,P7VQA8BYX;6S4O7USY#AR/OB_/P5N''$W&R',\ 4D
M@3W;OU"KU;OZG5J26YI9^R8N*O JT5NJTA:I[I8__0%\J:+JA06P2#8=7O=T
M2R0S\P'Q,)%(9/[+__K^/ =?Y2I+EXM__<G_Q?L)R 5?BG3Q^*\__?;P">*?
M_M>__=,__<O_ >%_?/AR#3XN^>NS7.3@8B5I+@7XEN9/X&]"9G\':K5\!G];
MKOZ>?J40_EMQT\7RY6V5/C[E(/ ";_NWJS]'.$8X]CR(&:$0,4$AHUA 2I"*
M&/$1E=[9XY\9B0(:>PCZ3$J(0LPAI:&"@B8($1531GCQT'FZ^/N?S1^,9A)H
MXQ99\<]__>DISU_^_.NOW[Y]^^4[6\U_6:X>?PT\+_RUOOJGZO+O.]=_"XNK
M?4+(K\5OUY=FZ;X+]6/]7__C\_4]?Y+/%*:++*<+;@1DZ9^SXH?72T[S O.C
M>H&#5YA_P?HR:'X$_0"&_B_?,_'3O_T3 "4<J^5<?I$*F/_^]N7JH$CRJ[GB
MUX5\-"-[)U?I4MSG=)5?4R;G6OOB:?G;B_S7G[+T^64NZY\]K:3:_]CY:O7N
MJ49+8K3T8Z/E/Q\2]NL)ZO>D;[ZK:P_*%>;>]*5C&Z8WO:G[H/E!#J]P0\S)
M*I<OU.5"C/7NKD6=K/KP&O?U6BQS.A_AM=B(::@\-S^XUG^KQ)@'M9!I(:>B
M[H:J\GLN%T*6;/GNT2 5__J3_MOL-8./E+[,SO4'[U9]D71^J>D\EW>KY8M<
MY6^S6&*F"(X@(]+7WR8OTA\S;4W$O2 .D1>P.)[EZW=[)A?PM_M:C4*6G:"?
M'"S-#\S8E<R6KRN^^=8]S_=]P/2WRWSM\*\+^BRS%UK=H+4U;D%IP+\9/<%2
MOS1:4R +5<%+I2OX.5V [!^O="6!DC+_T[_\NC'W!*SGHR$X'P<\HR0HM02U
MF@>Q6O)W^LR-#[%<;0.QY-9 O)N;!0B*9JRPHGK$K\9M^U7.\ZS^"30_@9Y?
M^1G_?%36KSOC?;ZJ#:$K?F0PJBM^Y4OM0;WD\-VX&(_3S>)\Z?:JE$AK)7X"
MRY60*^TC[S%HYP7^\)JE"YEE%\MGEBX*3R^[6\Y3_C:C5"@NB8")T'XN8BR&
MA&@'F#&?^Q$+A/+03'OD;&E+&(>%N;SP39'#O?<7RT6NUQ9F!:%'-$LUI(7"
M;OS0 J\=0_0#V< <42L)FEJ"4DWP1_7?!_T) Q_T%/C[_]<?;QR'IT_F:)$V
M*G<<MWJ;/2SNZ,8?U^:QMTHOLD6:7[RN5GK"S*)(17H]+*",D'8T4( @"T()
MI4 1PGK!3 /IXFCL$S(U)Z-2"[PL5P9=\\F<&[7-7WBA.* + 1;+7/_LA;Y1
M-I=N7+(7:CL6.17 @?G#J&=P*O4[ Y6&_=%$F_U]$L1>.:-20YNEVZ30>JT;
M'2Q?_CZ[_,=KFK_=2_ZZTO_]]/O-U>VWA9YY3^F+7GER\[92_2IX4B4:-R^&
M2 @.61C%T/<#G\0Q%3X.;8C!3MS4*&*M'W@I%:2/EA1@"6\[&?0/VL"T4"H+
M:FW/P*??X<W5&=C@6.G<*XBB"AP7'\D1P7PG=P*@MKV<U@3L!E-)Q?J>@E^]
M./0*=K5\R"@\ZV90S;B.=W5SQ6[S)[FZ62[,NI":M<O5@B^?Y>7W%[G(Y"P6
M GL*8<A0%$#$/:*Y5T10^<0/HB"B5"5NR[EV@=-;TA7Z@K10$OPL2S7_= 86
MTI)!+)&V\\GZ0V]@&BYA:VH*KBH,*V4/!\V</34[5/KTV8Y('-5[L[-^VX^S
MO,O=H[MY?69R=:L^RE7Z53_YJYZAWS)-8]F,>[%(L @@C>(((H)C2/PXAHIA
MJL(8JYA8Q9+;Q4S-@RLU-4L5L=85S"MEP<\T!W-),]L@\A&(CWMS_0 W,'U4
MF-TJL%$3U'KV I2]Q]8/8"-Y:MV <W+-CN/1XI*UW#R:*W;<@*8+9G%U-]?K
M8OG\G.;FG<C.%V(=.N:IS#ZF&9\OL]>5- '0(OXY2P+/]RE"T(]-9!V'$:04
M!9#'',L *Q0AXN:*N2DP/=?LXO;SYZN'SY<W#_?@_.8CN+B]>;BZ^<OES<75
MY;V;<^8X%G;.VG#X#LR^#<6+^.,[U<%&=_#'(/'Y;KCUZ=XY:C"JN]<-G6WW
MK^-3NC'=%SDO4DGH*G][6-%%1GFQF?#AK?F;\^]I-O.1%WO"0Y!C*B'RE8)4
MKSUAHG^,HR ));,*]KF+GIK;6.D'"@7!'T;%PW/L5-CM"&T8, <F,R<<G;G*
M'9(^><I!^J@<Y8[*-C]U>$(W;KK7;IW,SN_TJ,C52HK[7//=9VE\OAE%'J4X
MBF$2H=#L/"#(5,A@$%#,P@@AJ9 +&;7(FAK[E*J"<[!6%A3:NC%0&[AVE-,3
M9 -SS"&TP!^EJCT2C@4@?3),F[A1*<7"[FT.L;FE&VF</YL-^_\NUO)F9<AR
MXS0M7Q>Y%O:<OC[/$DJ)7IT)&.$X@(AP"?6K(V 8JB1)B!*(^$YID\<D3HU
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M B@Y\2%**(?$]Q(8AE% <(BHPL3)[6B3-C5RJW7KM(':CJNE=](76H-[*W9
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MUEST](=WX_RZ?MJGY>I:KW[G]S+/Y[*LUZ<X"@,<2ZA8J)F<F5/%0GK03[R
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MUR5XSRJ.NQ@?!M^=9?E 8DX/REIY=\(D.& ?PS@R9^:2V+0S4#'T$N03)<-
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M!(0IJ*F,F#:2"60(2Z@2%"@DJ(@#R^+$%M*F%Z1N)GB!Y8M9YY2)\=\J]<]
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MA*R,!"MM)2C_GIG&MD6FIDDO*/XB-[:XK2*&&'"[A<,/'L:!/TN;$:SM \9
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M4)<&8 XZ3&VYM&Y"U;#A<!.J;LW 7(;(CO0'!GY@2G?#'/QA; "%$3VNEDZ
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MPU"$OBDAJ?\P9X*C!#+E*9@HG"!-%S[%5ELC^QX^M<]^H1\H% 2EAO:-0G>
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M;;QA&NES,/QPN;6!ZP?@MKYQ)TH8K]%</U"\ZTS7TR.[!03N5J8-6_YVIU_
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M!3P],TT$,D'UU]K4O[3PVM&Q!ZNXUJ;9;JFUUN?"[Z+^'RT6O+'%948H2JB
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M:0=Q/'O3CO#@NY81Z!]/;C^H U[GKMU[?)<8KP7PXY^N0>V9@TZ'^50@]]*
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M!0&=!Z0E(*CEY<&"@\XKL!LHY/%T1*3B0SD__L-,5$JYRMPA/K+NC*8:BJS
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M2<%QHK"5*R3+83#1QT8<IWHR[K9N%"]@7;-L%X(K]Q>-5[2! :QQJ/[VZ.C
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M1:Y I0I,64 @1LPBM?/%$-#W?5(:A7I,'$P,_ $1,CTOPU"Q,]U^!&&Q-1=
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M@&T'HW:BB-.[9Q+XX_.'NW=OP;>[Z[MWWR[_P@]U;$DM;1ZNO][F#_L?[LZ
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M75D#G_7JAB\?OBSFWTNEU9N7/Y9:?9AM8BRNI;56JIBAS9XG=9HS1!GD>59
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M!&;(Y-9"DFGJ=^L<-.O8..55]81=L?\;J 7W2<FY8!'\>*9S:'MFG$Y0#:]
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M:KO,G[C.-\K[!UO/;?)?4RGW?KDQ5\U2E/)$DQ02A1G$,<>0)G;R@Y8H%IG
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M-ON81^93B72:$YG0)$?$+R 3&O5Q0B][!0&S&@X M6MX."Q\@P>(=[B5JMT
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M%T%R]Z5"@#621]4/-"_'J@N-%O?JXJVC.5E=RA^Z6IW7]LP[JA,);JVV-K_
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MUP\\6P7M3,*JJ5S97DZN%@NV+O9_ZSD'S'U%7'EG )P')Z%7@U$/U&[^4"Y
MJ?E0HU(=L!IN=FJ;\!\X3-4!D_;IJBX/\(\K[QKO5GUXWRSE0:/_7Q2S_1"D
MV6O9TC+;#^TM*^;%K\O]\+YRYIGY9X.)N:O<F%6=IU*=YRHE,4P1C2&V;;<Y
M80C*3,9$Y51K[92%/:B64Z/(PQE_E:UEH>:!M: QUXYRW1D,2HMOP*'-U9!
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M>JZ,^V"/CJO[G$BMOBBMUK;[3AWD0,:CB)B0D,B(0:QX#GF6<X@CG2 AE"$
MIUC1^<=/[;T_U-#G2.8$-I?#J6O &/R :@5WVO4ZI#I!Q.>@ZAIDQCJL\D/(
M\^#J$@"MAU<G-XUX@'5)X>-#K(M7]7-9[IZ5+8&JMUJ=^[!XQG*D,WNZGHO4
MD)E6&%*2:YAR31(5\0@1KQ1D7P6F1G<[_:N@EV=/=F_XW=R>(4$=F#;W>);J
MW0"G:$TX9ZDO="'=*&\=1G6P^B+TVO7J_9P>S<#*H<O5,.;Y<O-XD/:\TN4L
M9F9'7!SF2!>[G0:+(Q5+'$%,5&S;AJ60"Y%!':=$DBB*B=M1W[6*3(WY*EO
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M\,>RM,2N3JVC'4Y7*GD#]BMW<)!5F03X2W-#L;LC8&.S0/B&_)I>J]*H']=
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M/,[7$KP8U=V/.%VA[SX^'@#0@=EJ/ZBM4OD&U$J#1NL;8/4&I>+A,74_,AX
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M/S6:J+4'B[(JPX\D/(%W8X_AX!R85AHD2\UO0*,[J)4'C?; JK]+R W'.?V
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M,Q ,&_5U:K"1 [G.Z'P8FW7NAOXNRZ6:GQ_["V;$$@^E'H<A9CY$Q(L@#KB
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M.'X]6]2&)#[CL4?E.%M$]NG,^OY^S-5J0;*MD;/+\YLK1O)(Q#V8Z/T_(I1
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MQ6_0 VIK(<8]K^Z+T<'Q=>\'.>F]=?.=+38Z_*Q)09@+GH92Q@+Z/) 0I3R
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MB@)!I6=T\N]$NJEQ4*F&3OEJ%)F!1A4=?0W:RMBWXW4SP=TL]N;3YIC]*MW
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MQZT?;(7&0=%@N[M[MJ(3ZVM2/'W6]<BXX.]_?"UT/'5U**B9DJVS;R6-SF5
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MJZ0&;;%!(_=,E^VVJ.1K!GK,!28!AB'V HABE"@37G#H1V'(L<X68D;-.5Q
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M"&C!@^G%;NPET2;VF_?3R?D7F%V6"'"^*&B>CRBBF ?O24C!(IR5)"$8(%2
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MC^X]Z"Q<5)28A)ZHY%83EWTF@"%)QL4F1:IRV/9"]_X8_99[1\@SOO]+Q-[
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M0\1?770P1^ERGYW&""-8C?QJ6RK:!>%6*!=#TIQ6F?MZ&-G#MD)K ,$UU-M
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MW<@;UH#UA)='A0+]:Z9-KVJWI5[=9AW;=@UEPY(2V3D/1 F1$9.<$<>"(S2
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MN;D2^9 /QEC24ELBLL:0)U)-''#T&:*V-#E<9JS*S9>G"-H-8C];4K\7\3<
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M-RWVWJ!@%^O5.,I&N\0X\B2@S(?%J,T'&Y QKC%FRYFQ.BU>=Z5PMY+?G^U
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M5)7:?^X498'*2E/Z?DA;BV:V-FB>-L>]:+ !4!XHUY/+<O P2M(Q&Y4AS,>
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M4JYKI3B1[%5&ED1M$.E%'150.S:B3YF#L4HW:IWT*$W3@NA8<3_HGC0.[SN
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MJSK0$X^/+!*N%&6S94[8&KLNGH''.NS#H-0RF]0F&''<B+"F+M*81\\XC.\
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MO_/F::S5T:1_,!,[,#E?7ZYF<URM7J7_NIRM9FN>KX,2%NWZU LA23KZDF$
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M;\_P6PZ=(9*[6B>!BIJ%J!76F>G!LBS(5. ^2<.Q!9H>)ZF?!A@-03621#K
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M%]2>4O"W5Z$<8XD\:A:LDM6TD"RDO#8RD@H25!)-_.I]"9WVFN9DYV93^76
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M4^$N1$V^83TYB]$S3\MC!95$[IQ-JDG'V1-H[=MK=@K6L;6 )X3AU\O/<;Z
M)Y=XY8Y^FP7@N1A!^U+RVF\D$'.W?=^,%&"]!O!-U.,)M':./EOCYQ&\MA)F
M][9I^SL1VQL4KZX*(N"W]>5\LYX9(Y4BCX8ED8AQTD>*NFE='JVP 1V &'+G
M](E7= XZGPE,8_)Y @IN7W[UXW+U%C_"Q97O<75UWQ6?+2;)*&K/Y&\(R;RE
M8#TXCSD+CMAF-LL3-/4UNL^ML,82S@1P=LM-OE[$54NE5[\!B2U_6&[S.U<%
M5,&C<JAKY7$$\IE-9KZRCT.4WI%&UK;1/)8CJ.S;U_VYL=A.@+TG5^^4^0^X
MFG^E!7[%:UV>$%Q(LC#4(C+M@JO.<=CV=\XRT>< 1]C,AV_HV[J]A\D\D\L3
MT&3[IA+OXL5N0\RD,2%X"IUBJ+TD.(7HH.M4F 3)"2XDMNF _)"4OEW9G]T^
MGB>**9;>OL>ON+BD'T[+CXLM!T\H1SOPD+/+S[Y'V$CE9KO7U!+K[0TW2)M:
M7OWZ<KU9?L;5=4&/+$8K'Q4+/M56Q>1P>RLTB=T*EX,-633Q30?2=_ZE@B=?
M<U.0*8O,Z+-G$4MBNM1^E#8E"C<*>!&DCKF)ZAE*8.^I=>.CZ>%E@0:B>AFJ
M:9M"/*5>]M%'-5!3AXA\9F6E4M8Q>6!)Y=JW4V4&V5AFDO#:!%0Z-ZF8>R9E
M]<-\#1\_KO#*!-?[I-O7;AE_ W\1E<L2+0-Z M-"(S%!4?Q*T:IU6LL0FVBJ
M0=2]##5U#(X>=#0>74B=X[:;$Y!?5LM\F39U;,_ZU<7%\K=:?5*K@K=U2'"Q
MOK=(KI-+#@6K_9K)[W0UUN".!6XD$(L#+T,Z.)Y,0.\IFNW ]GQR>1D&\N?:
M0:8&NZ=?+1GPT 9&\VG"G]E\>AT%6(B,-) DI<0U@Y@#LT:(Z&0J $WN24S
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MW=R8QV!3'9%+2Y:U3!.8+Q&($6!BB($4[A"M\?#)?7/G34%P)ANG47EQM\#
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MK6"?;P&3A3,F,"LQ,YUK*U"/B7$EB_'6*^75R!AZ2$6_/-3Y@GV(DC.Y/($
M;4?]OHVP]H)B!,ZLSY5X0VH9/;F4*>8(R7$#38I][U#1'2+G2O5!MNA4%D\
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M4AKZ%%&=;5L;5(TFA4E@ZA:3?EXNTCT^26E1!G+U1(HU%:;LMO\T4^!M-A&
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MB3U'KG;WC?HEDA;_7__M_P%02P,$%     @ DD;_4):);03]!P  ^2H  !4
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M* /[L 'A2Y-?C[)L+)B2MZ#* YT'_>M_>8F>&"I[NJL=[%NH_ V[6G_2+*I
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M* 69UT-;C_NDO9KX#2CND5IR@GNTU<NB0(T2$SC:8K62PI\>V"*R4DAN)$U
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MY!$&4>%@5#JL_>SKEN5GN/WI[Z&>_A=02P,$%     @ DD;_4 S>1\YT!
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MS79?Z^^\\#<>7DEB3+Y"LZ@*M/?B+P/5L_Q083^9C/\!4$L! A0#%     @
MDD;_4'N0FIF9$   BY8  !D              ( !     &$Q,#%V:69O<FQI
M8V%G;71A;65N9"YH=&U02P$"% ,4    " "21O]0N_&@9NR7 0#62Q, &@
M            @ '0$   83$P,G!F:7IE<FQI8V%G;71A;65N9"YH=&U02P$"
M% ,4    " "21O]0H.%M,/UJ P!862P $               @ 'TJ $ ;W!K
M+3(P,C P-C,P+FAT;5!+ 0(4 Q0    ( ))&_U"W%@V<"AD   41 0 0
M          "  1\4!0!O<&LM,C R,# V,S N>'-D4$L! A0#%     @ DD;_
M4+RGR^&Q*@  /[H! !0              ( !5RT% &]P:RTR,#(P,#8S,%]C
M86PN>&UL4$L! A0#%     @ DD;_4)7L1'<BG@  K'D& !0
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L &]P:RTV,S R,#(P>&5X,S(R+FAT;5!+!08     #  , !\#  !$+P@    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
